<SEC-DOCUMENT>0001144204-13-060509.txt : 20131112
<SEC-HEADER>0001144204-13-060509.hdr.sgml : 20131111
<ACCEPTANCE-DATETIME>20131112160716
ACCESSION NUMBER:		0001144204-13-060509
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20130930
FILED AS OF DATE:		20131112
DATE AS OF CHANGE:		20131112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVAVAX INC
		CENTRAL INDEX KEY:			0001000694
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				222816046
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26770
		FILM NUMBER:		131210213

	BUSINESS ADDRESS:	
		STREET 1:		9920 BELWARD CAMPUS DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-268-2000

	MAIL ADDRESS:	
		STREET 1:		9920 BELWARD CAMPUS DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v358320_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES SECURITIES AND EXCHANGE
COMMISSION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 10-Q</P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black"><B>QUARTERLY REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="text-align: justify; padding-bottom: 1pt"><B>For the quarterly period ended September 30, 2013</B></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OR</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><B>TRANSITION
                                                                                                                               REPORT
                                                                                                                               PURSUANT
                                                                                                                               TO
                                                                                                                               SECTION
                                                                                                                               13
                                                                                                                               OR
                                                                                                                               15(d)
                                                                                                                               OF
                                                                                                                               THE
                                                                                                                               SECURITIES
                                                                                                                               EXCHANGE
                                                                                                                               ACT
                                                                                                                               OF
                                                                                                                               1934</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B></B></TD><TD STYLE="text-align: justify"><B>For the
                                                                                    transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>to<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                                                                    </U>.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File No. 0-26770</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVAVAX, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B>&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 48%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>22-2816046</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9920 Belward Campus Drive, Rockville,
        MD</B></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>20850</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Zip code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(240) 268-2000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in"><FONT STYLE="color: black">Indicate
by check mark whether the </FONT>Registrant<FONT STYLE="color: black">: (1) has filed all reports required to be filed by Section
13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant
was required to file such reports), and (2) has been subject to such filing requi</FONT>rements for the past 90 days. Yes <FONT STYLE="font-family: Wingdings">x</FONT>
No <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">Indicate by check mark
whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&sect;232.405 of this chapter) during the preceding
12&nbsp;months (or for such shorter period that the registrant was required to submit and post such files). Yes <FONT STYLE="font-family: Wingdings">x</FONT>
No <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
in Rule 12b-2 of the Exchange Act. (Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt; color: black">Large accelerated filer </FONT><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 18%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt; color: black">Accelerated filer&nbsp;&nbsp;</FONT><FONT STYLE="font: 10pt Wingdings">x</FONT></TD>
    <TD STYLE="width: 38%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt; color: black">Non-accelerated filer&nbsp;&nbsp;</FONT><FONT STYLE="font: 10pt Wingdings">&uml;</FONT><BR>
<FONT STYLE="font-size: 10pt; color: black">(Do not check if a smaller reporting company)</FONT></TD>
    <TD STYLE="width: 23%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt; color: black">Smaller reporting company </FONT><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in"><FONT STYLE="color: black">Indicate
by check mark whether </FONT>the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <FONT STYLE="font-family: Wingdings">&uml;</FONT>
No <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">The number of shares outstanding<FONT STYLE="color: black">
of the Registrant&rsquo;s Common Stock, $0.01 par value, was 208,510,739 as of October 31, 2013.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>&#9;</U></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVAVAX, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>PART I. FINANCIAL INFORMATION</B></FONT></TD>
    <TD STYLE="padding: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page No.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 8%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 85%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 7%; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Item 1.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Consolidated Financial Statements</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Consolidated Balance Sheets as of September 30, 2013 (unaudited) and December 31, 2012</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Consolidated Statements of Operations and Statements of Comprehensive Loss for the three and nine months ended September 30, 2013 and 2012 (unaudited)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Consolidated Statements of Cash Flows for the nine months ended &nbsp;September 30, 2013 and 2012 (unaudited)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right"><FONT STYLE="font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Notes to the Consolidated Financial Statements (unaudited)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right"><FONT STYLE="font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Item 2.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right"><FONT STYLE="font-size: 10pt">16</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Item 3.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Quantitative and Qualitative Disclosures about Market Risk</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Item 4.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Controls and Procedures</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-weight: bold; text-indent: 0; font-style: italic">&nbsp;</TD>
    <TD STYLE="padding: 0; font-weight: bold; text-indent: 0; font-style: italic">&nbsp;</TD>
    <TD STYLE="padding: 0; font-weight: bold; text-indent: 0; font-style: italic; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; font-weight: bold; text-indent: 0; font-style: italic"><FONT STYLE="font-size: 10pt; font-style: normal">PART II. OTHER INFORMATION</FONT></TD>
    <TD STYLE="padding: 0; font-weight: bold; text-indent: 0; font-style: italic; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; font-weight: bold; text-indent: 0; font-style: italic">&nbsp;</TD>
    <TD STYLE="padding: 0; font-weight: bold; text-indent: 0; font-style: italic; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Item 1A.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right"><FONT STYLE="font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Item 6.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Exhibits</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right"><FONT STYLE="font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>SIGNATURES</B></FONT> </TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right">37</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I. FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1. Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVAVAX, INC.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(in thousands, except share and per
share information)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; color: black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: black; font-weight: bold; text-align: center">September 30,</TD><TD STYLE="font-size: 10pt; color: black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: black; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: black; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-size: 10pt; color: black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-size: 10pt; color: black; font-weight: bold; text-align: center">ASSETS</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Current assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Cash and cash equivalents</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">122,493</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">17,399</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-left: 0.125in; text-indent: 0">Short-term investments available-for-sale</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23,917</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">26,712</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Restricted cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">124</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">986</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0.125in">Accounts receivables</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,911</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,011</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0.125in">Unbilled receivables</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,194</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,570</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0.125in">Prepaid expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,016</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,559</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: 0">Other current assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">365</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">171</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Total current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">155,020</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,408</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">Investments available-for-sale</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,233</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Property and equipment, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13,969</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11,456</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Intangibles, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16,405</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">Goodwill</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">58,759</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">33,141</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Restricted cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">757</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">756</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0; text-indent: 0">Other non-current assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">164</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">351</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: 0">Total assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">245,074</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">102,345</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="9" STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-left: 1.75pt">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Current liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,339</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3,228</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Accrued expenses and other current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,553</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,275</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Deferred revenue</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">190</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">258</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Current portion of capital leases</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">115</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">58</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Current portion of notes payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">597</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">157</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Warrant liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">267</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: 0">Deferred rent</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">466</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">432</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: 0">Total current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">14,260</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11,675</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Deferred revenue</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Non-current portion of capital leases</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">222</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">237</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Non-current portion of notes payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,653</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">753</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Deferred rent</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,287</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,940</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: 0">Other non-current liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,578</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&#9;&#9;&#8213;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: 0">Total liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">28,500</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22,105</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 1pt">Commitments and contingences</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Stockholders&rsquo; equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Preferred stock, $0.01 par value, 2,000,000 shares authorized; no shares issued and outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Common stock, $0.01 par value, 300,000,000 shares authorized at September 30, 2013 and 200,000,000 shares authorized at December 31, 2012; and 208,965,169 shares issued and 208,509,739 shares outstanding at September 30, 2013 and 148,398,747 shares issued and 147,943,317 shares outstanding at December 31, 2012</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,090</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,484</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Additional paid-in capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">611,913</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">438,939</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Accumulated deficit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(396,092</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(358,163</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0.125in">Treasury stock, 455,430 shares, cost basis</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,450</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,450</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 0; padding-left: 0.125in">Accumulated other comprehensive income</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,113</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">430</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: 0">Total stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">216,574</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">80,240</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in; text-indent: 0">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">245,074</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">102,345</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOVAVAX, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED STATEMENTS OF OPERATIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(in thousands, except per share information)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the Three Months</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ended
                                                                                                                                                                                                                                           September
                                                                                                                                                                                                                                           30,&#9;</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the Nine Months</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ended
                                                                                                                                                                                                                                          September
                                                                                                                                                                                                                                          30,&#9;</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">Revenue:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Government contracts</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">4,268</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5,583</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">10,985</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">17,328</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: 0">Research and development collaborations</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">534</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">182</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,182</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">182</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: 0">Total revenue</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,802</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,765</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">12,167</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,510</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Costs and expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Cost of government contracts revenue</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,276</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,838</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,619</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,740</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Research and development</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13,948</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,642</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">33,989</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">17,270</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: 0">General and administrative</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,857</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,134</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,740</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,670</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: 0">Total costs and expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,081</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">12,614</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">50,348</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">37,680</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Loss from operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(15,279</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(6,849</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(38,181</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(20,170</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Other income (expense):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Interest income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">53</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">39</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">149</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">111</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Interest expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(64</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(6</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(132</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(12</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Other expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(10</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&#8213;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(10</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&#8213;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: 0">Change in fair value of warrant liability</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&#9;&#8213;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(401</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">267</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(401</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Loss from operations before income tax</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(15,300</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(7,217</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(37,907</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(20,472</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0; text-indent: 0">Income tax expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&#9;&#8213;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&#9;&#8213;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8213;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0; text-indent: 0">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(15,300</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,217</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(37,929</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(20,472</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0; text-indent: 0">Basic and diluted net loss per share</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.09</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.05</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.24</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.16</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">Basic and diluted weighted average number of common shares outstanding</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">168,537</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">134,178</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">156,555</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">127,246</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF COMPREHENSIVE
LOSS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(in thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the Three Months</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>Ended
                                                                                                                                                                                                                                           September
                                                                                                                                                                                                                                           30,&#9;</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the Nine Months</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ended
                                                                                                                                                                                                                                          September
                                                                                                                                                                                                                                          30,&#9;</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 44%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Net loss</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(15,300</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(7,217</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(37,929</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(20,472</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Other comprehensive income (loss):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in; text-indent: 0">Net unrealized gains (losses) on investments available-for-sale</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(33</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">96</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">174</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">204</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: 0">Foreign currency adjustment</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">509</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><P STYLE="margin: 0pt 0">&#8213;</P>


<FONT STYLE="font-size: 10pt"><U></U></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">509</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8213;<FONT STYLE="font-size: 10pt">&#9;<U></U></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 0; padding-left: 0">Other comprehensive income (loss)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">476</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">96</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">683</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">204</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0; text-indent: 0">Comprehensive loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(14,824</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(7,121</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(37,246</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(20,268</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOVAVAX, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED STATEMENTS OF CASH FLOWS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(in thousands)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the Nine Months</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ended
                                                                                                                                                                                                                                          September
                                                                                                                                                                                                                                          30,&#9;</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-indent: 0; padding-left: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0; text-indent: 0">Operating Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Net loss</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">$</FONT></TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><FONT STYLE="font-weight: normal; font-style: normal">(37,929</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">)</FONT></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(20,472</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0.125in">Reconciliation of net loss to net cash used in operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: 0">Change in fair value of warrant liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(267</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">401</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: 0">Depreciation and amortization</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,636</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,216</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: 0">Amortization of net premiums on investments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">326</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: 0">Gain on disposal of property and equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(37</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(26</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: 0">Deferred rent</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">678</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">436</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-left: 0.25in; text-indent: 0">Non-cash stock-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,784</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,668</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: 0">Restricted cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">862</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(838</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: 0">Accounts receivables</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(291</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(504</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: 0">Unbilled receivables</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,624</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">111</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: 0">Prepaid expenses and other assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">639</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(271</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: 0; padding-bottom: 1pt">Accounts payable and accrued expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">623</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(304</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: 0">Deferred revenue</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(199</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">803</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in; text-indent: 0">Lease incentives received</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">703</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,803</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: 0">Net cash used in operating activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(33,096</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(14,977</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0; text-indent: 0">Investing Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0.125in">Capital expenditures</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,762</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,202</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0.125in">Proceeds from disposal of property and equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">83</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">318</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0.125in">Net cash received from the Isconova AB acquisition</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,034</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0.125in">Proceeds from maturities of investments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23,630</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0; padding-left: 0.125in">Purchases of investments</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(14,754</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(15,763</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: 0">Net cash provided by (used in) investing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,231</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(15,147</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0; text-indent: 0">Financing Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Principal payments of capital leases</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(54</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(90</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0; padding-bottom: 1pt">Principal payments of notes payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(305</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(20</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Proceeds from notes payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,450</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">650</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0.125in">Restricted cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(756</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0.125in">Net proceeds from sales of common stock, net of offering costs of $6.1 million and $0.4 million, respectively</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">128,659</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">26,925</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: 0">Proceeds from the exercise of stock options</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,194</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">49</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: 0">Net cash provided by financing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">130,943</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">26,758</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Effect of exchange rate on cash and cash equivalents</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: 0">Net increase (decrease) in cash and cash equivalents</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">105,094</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,366</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in; text-indent: 0">Cash and cash equivalents at beginning of period</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,399</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">14,104</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: 0">Cash and cash equivalents at end of period</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">122,493</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">10,738</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0; text-indent: 0; padding-bottom: 1pt">Supplemental disclosure of non-cash activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: 0">Common stock issued in connection with the Isconova AB acquisition</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">41,942</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: 0">Property and equipment purchases included in accounts payable and accrued expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">407</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,365</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: 0">Deposit applied towards the purchase of laboratory equipment</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">500</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: 0">Equipment acquired under a capital lease</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">399</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0; text-indent: 0">&nbsp;<BR>Supplemental disclosure of cash flow information:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: 0">Cash payments of interest</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">120</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOVAVAX, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<BR>
September 30, 2013</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Note 1 &ndash; Organization</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Novavax, Inc. (&ldquo;Novavax,&rdquo;
and together with its subsidiary, &ldquo;Novavax AB,&rdquo; the &ldquo;Company&rdquo;) is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of recombinant protein nanoparticle vaccines and adjuvants. The Company&rsquo;s
product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for seasonal
influenza, pandemic influenza and respiratory syncytial virus (&ldquo;RSV&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Note 2 &ndash; Operations</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
vaccine candidates, some of which may include an adjuvant, currently under development will require significant additional research
and development efforts that include extensive pre-clinical and clinical testing, and regulatory approval prior to commercial use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a clinical-stage
biopharmaceutical company, the Company has primarily funded its operations from proceeds through the sale of its common stock in
equity offerings and revenue under its contract with the Department of Health and Human Services, Biomedical Advanced Research
and Development Authority (&ldquo;HHS BARDA&rdquo;). Management regularly reviews the Company&rsquo;s cash and cash equivalents
and investments against its operating budget to ensure the Company will have sufficient working capital, and will continue to draw
upon such available sources of capital to meet its product development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Note 3 &ndash; Summary
of Significant Accounting Policies</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B><I>Basis of Presentation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying unaudited
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&ldquo;U.S. GAAP&rdquo;) for interim financial information and the instructions to Form 10-Q and Article 10
of Regulation S-X. The consolidated balance sheet as of September 30, 2013, consolidated statements of operations and consolidated
statements of comprehensive loss for the three and nine months ended September 30, 2013 and 2012 and the consolidated statements
of cash flows for the nine months ended September 30, 2013 and 2012 are unaudited, but include all adjustments (consisting of normal
recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, operating results,
comprehensive loss and cash flows, respectively, for the periods presented. Although the Company believes that the disclosures
in these consolidated financial statements are adequate to make the information presented not misleading, certain information and
footnote information normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed
or omitted as permitted under the rules and regulations of the United States Securities and Exchange Commission (&ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As discussed in more
detail in Note 4, the Company acquired Swedish-based Isconova AB (&ldquo;Isconova&rdquo;) on July 31, 2013. Isconova was subsequently
renamed Novavax AB. The consolidated financial statements include the accounts of Novavax, Inc. and its subsidiary, Novavax AB.
All intercompany accounts and transactions have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements are presented in U.S. dollars. The translation of assets and liabilities to U.S. dollars is made at the exchange
rate in effect at the consolidated balance sheet date, while equity accounts are translated at historical rates. The translation
of statement of operations data is made at the average exchange rate in effect for the period. The translation of operating cash
flow data is made at the average exchange rate in effect for the period, and investing and financing cash flow data is translated
at the exchange rate in effect at the date of the underlying transaction. Translation gains and losses are recognized as a component
of accumulated other comprehensive income in the accompanying consolidated balance sheets. The foreign currency translation adjustment
balance included in accumulated other comprehensive income was $0.5 million at September 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying unaudited
consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the
Company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2012. Results for this or any interim period are not
necessarily indicative of results for any future interim period or for the entire year. The Company operates in one business segment:
developing recombinant vaccines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of
consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ
materially from these estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B><I>Fair Value Measurements
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company applies
Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 820, <I>Fair Value Measurements and Disclosures</I>, for financial
and non-financial assets and liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 820 discusses valuation
techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash
flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). The statement utilizes a fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following
is a brief description of those three levels:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets
or liabilities.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either
directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical
or similar assets or liabilities in markets that are not active.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 3: Unobservable inputs that reflect the reporting entity&rsquo;s own assumptions.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Investments</I></B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investments consist
of commercial paper, corporate notes and an investment in one auction rate security. Classification of marketable securities between
current and non-current is dependent upon the original maturity date at purchase. Those securities purchased with original maturities
greater than 90 days, but less than one year are classified as current and those with greater than one year are classified as non-current.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interest and dividend
income is recorded when earned and included in interest income. Premiums and discounts, if any, on investments are amortized or
accreted to maturity and included in interest income. The specific identification method is used in computing realized gains and
losses on the sale of the Company&rsquo;s securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has classified
its investments as available-for-sale since the Company may need to liquidate these securities within the next year. The available-for-sale
securities are carried at fair value and unrealized gains and losses on these securities, if determined to be temporary, are included
in accumulated other comprehensive income (loss) in stockholders&rsquo; equity. Investments are evaluated periodically to determine
whether a decline in value is &ldquo;other-than-temporary.&rdquo; The term &ldquo;other-than-temporary&rdquo; is not intended to
indicate a permanent decline in value. Rather, it means that the prospects for a near term recovery of value are not necessarily
favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security.
Management reviews criteria, such as the magnitude and duration of the decline, as well as the Company&rsquo;s ability to hold
the securities until market recovery, to predict whether the loss in value is other-than-temporary. If a decline in value is determined
to be other-than-temporary, the value of the security is reduced and the impairment is recorded in the statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Restricted Cash</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
restricted cash includes payments received under the PATH agreement (See Note 10) until such time as the Company has paid for the
work performed under the agreement. In addition, the Company&rsquo;s non-current restricted cash with respect to its manufacturing,
laboratory and office space in Gaithersburg, Maryland functions as collateral for letters of credit, which serve as security deposits
for the duration of the leases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: yellow"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B><I>Net Loss per Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net loss per share
is computed using the weighted average number of shares of common stock outstanding. All outstanding warrants, stock options and
unvested restricted stock awards totaling 12,157,634<B> </B>shares and 12,951,625 shares at September 30, 2013 and 2012, respectively,
are excluded from the computation, as their effect is antidilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B><I>Reclassifications</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Overhead expenses relating
to supply chain management of $0.2 million and $0.6 million for the three and nine months ended September 30, 2012, respectively,
have been reclassified from general and administrative expenses to research and development expenses. Also, within the September
30, 2012 statement of cash flows, restricted cash received of $0.8 million recorded in financing activities has been reclassified
and is included in operating activities. These reclassifications have been made to conform to current year presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 4 &ndash; Acquisition of Isconova AB </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: windowtext">On
July 31, 2013 (the &ldquo;acquisition date&rdquo;), Novavax announced the acquisition of Isconova (the &ldquo;Acquisition&rdquo;)
pursuant to its public tender offer to acquire all outstanding shares and warrants of the company directly from such holders and
its private offer for all of Isconova&rsquo;s outstanding stock options.</FONT> As a result of the public offer for shares and
warrants and private offer for stock options, Novavax issued approximately 15.6 million shares of its Common Stock valued at $41.9
million and paid cash of approximately $22,000 to acquire 99.5% of the outstanding shares and all of the outstanding stock options
and warrants of Is<FONT STYLE="color: windowtext">conova. On September 6, 2013, Isconova AB was renamed &ldquo;Nov</FONT>avax AB&rdquo;
and was delisted as a publicly traded company in Sweden. This transaction has been accounted for using the purchase method of accounting,
with Novavax as the acquirer. The results of Novavax AB&rsquo;s operations have been included in the consolidated financial statements
since the acquisition date.<FONT STYLE="color: windowtext"> For the three months ended September 30, 2013, the minority interest
in Novavax AB&rsquo;s net loss and stockholders&rsquo; equity is immaterial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; color: windowtext">Novavax
AB has focused its recent efforts on the development of saponin-based, immune-modulating adjuvants that work with different types
of vaccine antigens to enhance the immunogenic effect of the antigen. Novavax AB has collaborated with several vaccine companies
to allow its lead adjuvant, Matrix-M&trade;, to be tested with a number of antigens in development; the Company has recently begun
development work pairing the Novavax AB adjuvant with its own pandemic influenza VLP antigen. The Company believes that the Novavax
AB adjuvants can be powerful complements to certain of its recombinant vaccine programs and will enable future discovery efforts
and potentially reduce vaccine development timeframes and costs both by eliminating the need to in-license third-party adjuvants
and related costs and by harmonizing operating and regulatory processes.</FONT> <FONT STYLE="font-size: 10pt">The total purchase
price is summarized as follows (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 86%; font-size: 10pt; padding-left: 0">Value of shares of Novavax Common Stock issued</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">41,942</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0">Cash paid to Isconova warrant holders</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">22</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0">Total purchase price</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">41,964</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The value of Novavax
Common Stock issued is based on the closing price of Novavax&rsquo; Common Stock on the acquisition date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below summarizes
the preliminary allocation of the purchase price based upon the fair values of assets acquired and liabilities assumed at the acquisition
date. The preliminary allocation is based upon information that was available to management at the time the consolidated financial
statements were prepared. Accordingly, the allocation may change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">(in thousands)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 86%; font-size: 10pt; text-align: left; padding-left: 0">Cash and cash equivalents</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3,056</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0">Accounts receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">603</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0">Prepaid expenses and other assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,092</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0">Property and equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">165</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0">Intangible assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16,380</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0">Goodwill</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">25,298</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0">Accounts payable and other current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,784</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; padding-bottom: 1pt">Capital leases</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(94</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0">Notes payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(193</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0">Other non-current liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,559</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0">Total purchase price</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">41,964</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A substantial portion
of the assets acquired from Isconova consisted of intangible assets relating to its proprietary adjuvant technology and collaboration
agreements. The preliminary fair values of the proprietary technology and agreements were determined based on estimates of expected
future net cash flows. The present value of future net cash flows was then determined utilizing an estimate of the appropriate
discount rate, which is consistent with the uncertainties of the cash flows utilized. The fair value measurements are based on
significant unobservable inputs that were developed by the Company using publicly available information, market participant assumptions,
cost and development assumptions, expected synergies and other cost savings that a market participant would be expected to realize
as a result of the combination and certain other high-level assumptions. The proprietary technology is amortized over its estimated
remaining useful life based on the Company&rsquo;s expected future net cash flows. The agreements are amortized over the estimated
periods of expected future net cash flows. Amortization expense for intangible assets will be recorded on a straight-line basis
over the expected useful lives of the assets, ranging from seven to 20 years. The carrying value and expected lives of the intangible
assets may change based upon finalizing the purchase price allocation, and such intangibles will be periodically reviewed to determine
if the facts and circumstances suggest that a potential impairment may have occurred. Impairment charges, if any, will be recorded
in the period in which the impairment occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recorded
$25.3 million in goodwill related to the Acquisition representing the purchase price paid in the Acquisition that was in excess
of the fair value of the assets acquired and liabilities assumed, which is included in the Company&rsquo;s vaccine operations because
of the anticipated complementary use of Novavax AB adjuvants with its vaccine candidates discussed above. The goodwill generated
from the Acquisition is expected to be deductible for U.S. federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company incurred
approximately $1.3 million in transaction costs related to the Acquisition, which is included in general and administrative expenses
in the Company&rsquo;s consolidated statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From the acquisition
date to September 30, 2013, the Company has recognized revenue of $0.4 million and recorded a net loss of $1.5 million from the
operations of Novavax AB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following unaudited
consolidated pro forma financial information is presented as if the Acquisition occurred on January 1, 2012. The unaudited pro
forma financial information has been presented for comparative purposes only and is not necessarily indicative of results of operations
that would have been achieved had the Company completed the Acquisition during the periods presented, or the future consolidated
results of operations of the combined company. The unaudited pro forma financial information combines the historical results of
operations of Novavax and Isconova for the periods presented below and reflects the application of the following adjustments:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Elimination of the historical intangible
assets and amortization expense unrelated to the Acquisition;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amortization expense related to the fair
value of intangible assets acquired; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The exclusion of acquisition-related costs
incurred for the Acquisition.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; padding-left: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Three Months Ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>September
                                                                                                                                                                                                                              30,</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Nine Months Ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>September
                                                                                                                                                                                                                                        30,</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-size: 10pt; text-align: center">(in thousands)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 44%; font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0">Revenue</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,869</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,272</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">14,195</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">19,530</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0">Net loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(15,687</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(8,490</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(40,565</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(25,033</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0">Basic and diluted net loss per share</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.09</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.06</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.24</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.18</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Novavax AB has an operating
lease for its facility that expires in 2017. As of September 30, 2013, the aggregate remaining rental payments due under this operating
lease commitment was approximately $1.9 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 5 &ndash; Fair Value Measurements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">The
following table represents the Company&rsquo;s fair value hierarchy for its financial assets and liabilities measured at fair value
on a recurring basis (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value at September 30, 2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value at December 31, 2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-decoration: underline; padding-bottom: 1pt; padding-left: 0; text-align: left; text-indent: 0">Assets</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>&#9;Level
1</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Level
                                                                                                                2&#9;</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Level
                                                                                                                3<U></U></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Level
                                                                                                                  1</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Level
                                                                                                                  2</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Level
                                                                                                                  3</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 28%; font-size: 10pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Corporate debt securities and auction rate securities</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">23,917</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">32,945</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0; text-indent: 0">Total investments</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">23,917</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">32,945</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-decoration: underline; padding-left: 0; text-indent: 0">Liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0; text-indent: 0">Warrant liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">267</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">During
the nine months ended September 30, 2013, the Company did not have any transfers between levels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
provides a reconciliation of the beginning and ending balance of Level 3 assets and liabilities measured on a recurring basis for
the nine months ended September 30, 2013 (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; padding-left: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Fair&nbsp;Value&nbsp;Measurements&nbsp;of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrants&nbsp;Using Significant</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Unobservable&nbsp;Inputs&nbsp;</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Level&nbsp;3)<U></U></B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 77%; font-size: 10pt; padding-left: 0">Balance at December 31, 2012</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 20%; font-size: 10pt; text-align: right">267</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0">Change in fair value of Warrant liability</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(267</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0">Balance at September 30, 2013</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amounts in the
Company&rsquo;s consolidated balance sheet for accounts receivables, unbilled receivables and accounts payable approximate fair
value due to their short-term nature. Based on borrowing rates available to the Company, the fair value of capital leases and notes
payable approximates their carrying value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 6 &ndash; Investments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investments classified
as available-for-sale as of September 30, 2013 and December 31, 2012 were comprised of (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>September 30, 2013</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>December 31, 2012</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amortized Cost</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Gross Unrealized Gains</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Gross Unrealized Losses</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Fair Value</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amortized Cost</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Gross Unrealized Gains</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Gross Unrealized Losses</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Fair Value</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCFFCC">
    <TD STYLE="width: 20%; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Auction rate securities</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">1,175</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">601</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">1,776</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">1,175</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">409</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-size: 10pt">1,584</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Corporate debt securities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">22,137</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">4</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">22,141</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">31,340</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">21</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">31,361</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCFFCC">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">23,312</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">605</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&mdash; </FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">23,917</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">32,515</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">430</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">32,945</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 7 &ndash; Goodwill and Other Intangible Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B><I>Goodwill</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The changes in the carrying amounts of goodwill
for the nine months ended September 30, 2013 and 2012 were as following (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Nine Months Ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>September
                                                                                                                                                                                                                             30,</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Beginning balance</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">33,141</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">33,141</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Goodwill resulting from acquisition of business</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">25,298</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0; text-indent: 0">Currency translation</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">320</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; text-indent: 0; padding-left: 0">Ending balance</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">58,759</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">33,141</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B><I>Identifiable
Intangible Assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Identifiable intangible assets consisted
of the following as of September 30, 2013 (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Gross Carrying
    Amount</B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Accumulated
                                                                                                                                                                                         Amortization</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Intangible</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Assets,
                                                                                                                                                                                                           Net</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Finite-lived intangible assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 58%; font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0">Proprietary adjuvant technology</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">11,594</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(97</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">11,497</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0; text-indent: 0">Collaboration agreements</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,992</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(84</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,908</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0; text-indent: 0">Total identifiable intangible assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">16,586</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(181</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">16,405</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Amortization expense
for the nine months ended September 30, 2013 was $0.2 million.<B> </B>Estimated amortization expense for existing intangible assets
for the remainder of 2013 and for each of the five succeeding years ending December 31,will be as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; text-align: left; padding-left: 0">Year</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Amount</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 13%; font-size: 10pt; padding-left: 0; text-align: left">2013 (remainder)</TD><TD STYLE="width: 74%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">271</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0">2014</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,084</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0">2015</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,084</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0">2016</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right"><FONT STYLE="font-weight: normal; font-style: normal">1,084</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0">2017</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right"><FONT STYLE="font-weight: normal; font-style: normal">1,084</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0">2018</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right"><FONT STYLE="font-weight: normal; font-style: normal">1,084</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 8 &ndash; Stockholders&rsquo; Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 13, 2013, the
Company&rsquo;s stockholders of record as of April 16, 2013 approved the amendment of the Company&rsquo;s certificate of incorporation
to increase the total number of shares of Common Stock that the Company is authorized to issue from 200,000,000 shares to 300,000,000
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2012, the
Company entered into an At Market Issuance Sales Agreement (&ldquo;2012 Sales Agreement&rdquo;), under which the Board of Directors
of the Company (the &ldquo;Board&rdquo;) approved the Company&rsquo;s sale of up to an aggregate of $50 million in gross proceeds
of its common stock. The shares of common stock are being offered pursuant to a shelf registration statement filed with the SEC
in March 2013, which replaced the previous shelf registration statement filed in 2010. The Board&rsquo;s standing Finance Committee
(the &ldquo;Committee&rdquo;) assists with its responsibilities to monitor, provide advice to senior management of the Company
and approve all capital raising activities. The Committee has been authorized by the Board, absent any action by the Board to the
contrary, to take any additional actions necessary to carry out the Board&rsquo;s authorization of the issuance and sale of the
common stock sold pursuant to the 2012 Sales Agreement. In doing so, the Committee is authorized to set the amount of shares to
be sold, the period of time during which such sales may occur and the minimum sales price per share. During the nine months ended
September 30, 2013, the Company sold 12.6 million shares at sales prices ranging from $2.06 to $3.38 per share, resulting in $34.0
million in net proceeds. The most recent sales to occur under the 2012 Sales Agreement were on September 10, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2013,
the Company completed a public offering of 31,846,950 shares of its common stock, including 4,153,950 shares of common stock that
were issued upon the exercise in full of the over-allotment granted to the underwriters, at a price of $3.14 per share resulting
in net proceeds of approximately $94.7 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 9 &ndash; Stock-Based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><B><I>Stock Options</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has granted
equity awards under several plans, two of which remain active. Under the 2005 Stock Incentive Plan (the &ldquo;2005 Plan&rdquo;),
equity awards may be granted to officers, directors, employees, consultants and advisors to the Company and any present or future
subsidiary. The 2005 Plan, approved in May 2005 and amended in June 2007, June 2011, June 2012 and June 2013 by the Company&rsquo;s
stockholders, currently authorizes the grant of equity awards for up to 22,312,192 shares of common stock, which included, at the
time of approval of the 2005 Plan, a maximum 5,746,468 shares of common stock subject to stock options outstanding under the Company&rsquo;s
1995 Stock Option Plan (the &ldquo;1995 Plan&rdquo;) that may revert to and become issuable under the 2005 Plan if such options
expire or otherwise terminate unexercised. The Company received approval at its 2013 annual meeting of stockholders to increase
the number of shares of common stock available for issuance under the 2005 Plan by 4,000,000 shares. The term of the Company&rsquo;s
1995 Plan has expired and no new awards will be made under the 1995 Plan; however, outstanding stock options remain in existence
in accordance with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the 2005 Plan
and the 1995 Plan, incentive stock options, having a maximum term of 10 years, can be or were granted at no less than 100% of the
fair value of the Company&rsquo;s common stock at the time of grant and are generally exercisable over periods ranging from six
months to four years. There is no minimum exercise price for non-statutory stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in"><B><I>Stock Options Awards</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following is a summary of option activity
under the 2005 Plan and the 1995 Plan for the nine months ended September 30, 2013:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2005 Stock Incentive Plan</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">1995 Stock Option Plan</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Stock Options</B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Weighted-Average
    Exercise Price</B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Stock Options</B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Weighted-Average
    Exercise Price</B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 44%; font-size: 10pt; padding-left: 0; text-indent: 0">Outstanding at January 1, 2013</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">9,143,825</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1.87</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">211,900</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">4.94</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">Granted</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right"><FONT STYLE="font-weight: normal; font-style: normal">4,117,500</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">$</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right"><FONT STYLE="font-weight: normal; font-style: normal">1.92</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">Exercised</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right"><FONT STYLE="font-weight: normal; font-style: normal">(522,292</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">)</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2.29</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; padding-left: 0; text-indent: 0">Canceled</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(802,883</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1.74</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(23,750</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4.05</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0; text-indent: 0">Outstanding at September 30, 2013</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">11,936,150</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.88</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">188,150</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5.04</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; text-indent: 0; padding-left: 0">Shares exercisable at September 30, 2013</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,647,873</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2.12</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">188,150</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5.04</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 0; text-indent: 0">Shares available for grant at &#9;September 30, 2013</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><FONT STYLE="font-weight: normal; font-style: normal">6,461,494</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of stock
options granted was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Three Months Ended <BR>September 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended <BR>September 30,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 44%; font-size: 10pt; text-align: left">Weighted-average fair value of stock options granted</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: center">$1.41</TD><TD STYLE="width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: center">$1.09</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: center">$1.02</TD><TD STYLE="width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: center">$0.71</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Risk-free interest rate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">1.12%-1.36%</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0.55%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0.54%-1.36%</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0.55%-1.54%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Dividend yield</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0%</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0%</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Volatility</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">56.75%-62.51</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">76.60%-76.71%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">55.81%-73.72%</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">75.47%-80.48%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Expected term (in years)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">4.25</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">4.24</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">3.98-7.05</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">3.34-7.09</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Expected forfeiture rate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">23.15%</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">23.15%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0%-23.15%</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0%-23.15%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate intrinsic
value and weighted-average remaining contractual term of stock options outstanding as of September 30, 2013 was approximately $15.9
million and 7.6<B> </B>years, respectively. The aggregate intrinsic value and weighted-average remaining contractual term of stock
options exercisable as of September 30, 2013 was approximately $5.5 million and 5.9<B> </B>years, respectively. The aggregate intrinsic
value represents the total intrinsic value (the difference between the Company&rsquo;s closing stock price on the last trading
day of the period and the exercise price, multiplied by the number of in-the-money options) that would have been received by the
option holders had all option holders exercised their options on September 30, 2013. This amount is subject to change based on
changes to the fair value of the Company&rsquo;s common stock. The aggregate intrinsic value of options exercised for the nine
months ended September 30, 2013 and 2012 was $0.3 million and less than $0.1 million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B><I>Employee Stock Purchase Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company received
approval at its 2013 annual meeting of stockholders to adopt an Employee Stock Purchase Plan (the &ldquo;ESPP&rdquo;), which currently
authorizes an aggregate of 2,000,000 shares of Common Stock to be purchased. The ESPP allows employees to purchase shares of Common
Stock of the Company at each purchase date through payroll deductions of up to a maximum of 15% of their compensation, at 85% of
the lesser of the market price of the shares at the time of purchase or the market price on the beginning date of an option period
(or, if later, the date during the option period when the employee was first eligible to participate). The first option period
under the ESPP commenced on August 1, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ESPP is considered
compensatory for financial reporting purposes. As such, the fair value of ESPP shares was estimated at the date of grant using
the Black-Scholes option-pricing model with the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended <BR> September 30,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 65%; font-size: 10pt">Weighted-average fair value of ESPP shares granted</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 17%; font-size: 10pt; text-align: center">$0.78</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Risk-free interest rate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0.04%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Dividend yield</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Volatility</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">50.80%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Expected term (in years)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0.5</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Expected forfeiture rate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">5%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><B><I>Restricted
Stock Awards</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the 2005 Plan,
the Company has granted restricted stock awards subject to certain performance-based and/or time-based vesting conditions which,
if not met, would result in forfeiture of the shares and reversal of any previously recognized related stock-based compensation
expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a
summary of restricted stock awards activity for the nine months ended September 30, 2013:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>Number of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>Shares</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Per Share Weighted-Average Grant-Date</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Fair
                                                                                                                                                                                                                                                            Value</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0">Outstanding and Unvested at January 1, 2013</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">33,334</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1.39</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0">Restricted stock granted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0">Restricted stock vested</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0">Restricted stock forfeited</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0">Outstanding and Unvested at September 30, 2013</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">33,334</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.39</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company recorded stock-based compensation
expense in the consolidated statements of operations as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Three Months Ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>September
                                                                                                                                                                                                                              30,</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Nine Months Ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>September
                                                                                                                                                                                                                             30,</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 44%; font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Research and development</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">316</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">219</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">829</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">638</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0; text-indent: 0">General and administrative</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">347</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">274</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">955</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,030</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: 0; padding-left: 0; padding-bottom: 2.5pt">Total stock-based compensation expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">663</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">493</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">1,784</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">1,668</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30,
2013, there was approximately $4.7<B> </B>million of total unrecognized compensation expense (net of estimated forfeitures) related
to unvested options and restricted stock awards. This unrecognized compensation expense is expected to be recognized over a weighted-average
period of 1.5<B> </B>years. This estimate does not include the impact of other possible stock-based awards that may be made during
future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Note 10 &ndash;
U.S. Government Agreement, Joint Venture and Collaborations</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><B><I>HHS
BARDA Contract for Recombinant Influenza Vaccines</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2011, the
Company was awarded a contract from HHS BARDA valued at $97 million for the first three-year base-period, with an HHS BARDA option
for an additional two-year period valued at $82 million, for a total contract value of up to $179 million. The HHS BARDA contract
award provides significant funding for the Company&rsquo;s ongoing clinical development and product scale-up of both its seasonal
and pandemic influenza vaccine candidates. This is a cost-plus-fixed-fee contract in which HHS BARDA will reimburse the Company
for allowable direct contract costs incurred plus allowable indirect costs and a fixed-fee earned in the further development of
its multivalent seasonal and monovalent pandemic influenza vaccines. HHS BARDA originally directed the Company to develop its monovalent
pandemic influenza vaccines against the A(H5N1) strain. Recently, however, HHS BARDA has directed the Company to develop its monovalent
pandemic influenza vaccines against the A(H7N9) strain and is working with the Company to modify the contract in this respect;
nevertheless, the Company&rsquo;s H5N1 vaccine program remains a viable development opportunity under the contract. Billings under
the contract are based on approved provisional indirect billing rates, which permit recovery of fringe benefits, overhead and general
and administrative expenses not exceeding certain limits. These indirect rates are subject to audit by HHS BARDA on an annual basis.
An audit by the U.S. government of fiscal years 2011 and 2012 has been initiated, but has not been completed as of the date of
this filing. When the final determination of the allowable costs for any year has been made, revenue and billings may be adjusted
accordingly; however, management believes that revenue for periods subject to audit has been recorded in amounts that are expected
to be realized upon final audit and settlement. The Company recognized revenue of approximately $10.7 million in the nine months
ended September 30, 2013, and has recognized approximately $45 million in revenue since the inception of the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under certain circumstances,
HHS BARDA reimbursements may be delayed or even potentially withheld. In March 2012, the Company decided to conduct a Phase 2 clinical
trial of its quadrivalent seasonal influenza vaccine candidate (&ldquo;205 Trial&rdquo;) under its existing U.S. investigational
new drug application (&ldquo;IND&rdquo;) for its trivalent seasonal influenza vaccine candidate as opposed to waiting to conduct
this clinical trial under a new IND for its quadrivalent vaccine candidate (&ldquo;Quadrivalent IND&rdquo;). Based on the Company&rsquo;s
discussions with HHS BARDA in 2012, the outside clinical trial costs for the 205 Trial may only be submitted for reimbursement
to HHS BARDA and recorded as revenue by the Company after it submits the clinical trial data in a future Quadrivalent IND. The
submission of the Quadrivalent IND is expected shortly before the Company initiates the next Phase 2 dose-confirmatory clinical
trial, which is currently expected in the first quarter of 2014. The outside clinical trial costs of the 205 Trial conducted last
year total $2.9 million, which was incurred from the inception of the clinical trial through September 30, 2013. These costs have
been recorded as an expense and are included in cost of government contracts revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B><I>CPL Biologicals
Private Limited (&ldquo;CPLB&rdquo;) Joint Venture</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2009, the Company
formed a joint venture with Cadila Pharmaceuticals Limited (&ldquo;Cadila&rdquo;) named CPL Biologicals Private Limited (&ldquo;CPLB&rdquo;)
to develop and manufacture vaccines, biological therapeutics and diagnostics in India. CPLB is owned 20% by the Company and 80%
by Cadila. The Company accounts for its investment in CPLB using the equity method. Since the carrying value of the Company&rsquo;s
initial investment was nominal and there is no guarantee or commitment to provide future funding, the Company has not recorded
any losses related to this investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B><I>LG Life Sciences,
Ltd. (&ldquo;LGLS&rdquo;) License Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2011, the
Company entered into a license agreement with LGLS that allows LGLS to use the Company&rsquo;s technology to develop and commercially
sell influenza vaccines exclusively in South Korea and non-exclusively in certain other specified countries. At its own cost, LGLS
is responsible for funding both its clinical development of the influenza VLP vaccines and a manufacturing facility to produce
such vaccine in South Korea. Under the license agreement, the Company is obligated to provide LGLS with information and materials
related to the manufacture of the licensed products, provide on-going project management and regulatory support and conduct clinical
trials of its influenza vaccines in order to obtain FDA approval in the U.S. The term of the license agreement is expected to terminate
in 2027. Payments to the Company under the license agreement include an upfront payment of $2.5 million, reimbursements of certain
development and product costs, payments related to the achievement of certain milestones and royalty payments in the high single
digits from LGLS&rsquo;s future commercial sales of influenza VLP vaccines. The upfront payment has been deferred and will be recognized
when the previously mentioned obligations in the agreement are satisfied, which may not occur until the end of the term of the
agreement. Payments for milestones under the agreement will be recognized on a straight-line basis over the remaining term of the
research and development period upon achievement of such milestone. Any royalties under the agreement will be recognized as earned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B><I>PATH Vaccine
Solutions (&ldquo;PATH&rdquo;) Clinical Development Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2012, the Company
entered into a clinical development agreement with PATH to develop its vaccine candidate to protect against RSV through maternal
immunization in low-resource countries (the &ldquo;RSV Collaboration Program&rdquo;). The Company was awarded approximately $2.0
million by PATH for initial funding under the agreement to partially support its initial Phase 2 dose-ranging clinical trial in
women of childbearing age, which was launched in October 2012. The funding under the agreement was increased by $0.4 million and
the term extended to April 2014 to support the Company&rsquo;s reproductive toxicology studies, which are necessary before it conducts
clinical trials in pregnant women. The Company retains global rights to commercialize the product and has made a commitment to
make the vaccine affordable and available in low-resource countries. To the extent PATH elects to continue to fund 50% of the Company&rsquo;s
external clinical development costs for the RSV Collaboration Program, but the Company does not continue development, the Company
would then grant PATH a fully-paid license to its RSV vaccine technology for use in pregnant women in such low-resource countries.
The Company recognized revenue of approximately $0.7 million in the nine months ended September 30, 2013, and has recognized approximately
$2.0 million in revenue since the inception of the agreement. Revenue under this arrangement is being recognized under the proportional
performance method and earned in proportion to the contract costs incurred in performance of the work as compared to total estimated
contract costs. Costs incurred under this agreement represent a reasonable measurement of proportional performance of the services
being performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Note 11 &ndash;
Notes Payable</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2012,
the Company entered into a master security agreement with General Electric Capital Corporation (&ldquo;GE&rdquo;), whereby the
Company could borrow up to $2.0 million to finance the purchases of equipment through June 2013 (each, an &ldquo;Equipment Loan&rdquo;).
Each Equipment Loan bears interest at the three-year U.S. Government treasury rate plus 11.68%, provided that the rate shall not
be less than 12.1%, and is to be repaid over forty-two (42) months. GE will maintain a security interest in all equipment financed
under the Equipment Loan. During the nine months ended September 30, 2013, the Company financed $1.5 million at interest rates
of 12.1% with monthly principal payments totaling $34,529 (&ldquo;2013 Funding&rdquo;). Interest accrues on the outstanding balance
until paid in full. As of September 30, 2013, the Company has financed $2.0 million in total under the Equipment Loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Aggregate future minimum
principal payments on the GE notes payable, including the 2013 Funding, at September 30, 2013 are as follows (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; padding-left: 0; text-align: left">Year</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 13%; font-size: 10pt; padding-left: 0; text-align: left">2013 (remainder)</TD><TD STYLE="width: 74%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">143</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0">2014</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">571</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0">2015</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">571</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0">2016</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">396</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 0; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,681</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Note 12 &ndash;
Warrant Liability</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">In July 2008, the
Company completed a registered direct offering of 6,686,650 units, raising approximately $17.5 million in net proceeds. Each unit
consisted of one share of common stock and a warrant to purchase 0.5 shares of common stock (the &ldquo;Warrants&rdquo;) at a price
of $2.68 per unit. The Warrants represent the right to acquire an aggregate of 3,343,325 shares of common stock at an exercise
price of $3.62 per share and were exercisable between January 31, 2009 and July 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="color: black">During
the nine months ended September 30, 2013 and 2012, the Company recorded as other income (expense) </FONT>in its consolidated statements
of operations <FONT STYLE="color: black">a change in fair value of warrant liability of $0.3 million and ($0.4) million, respectively.
All Warrants expired unexercised on July 31, 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Note 13 &ndash;
Manufacturing, Laboratory and Office Facility</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company leases
its new manufacturing, laboratory and office space in Gaithersburg, Maryland with rent payments for such space to the landlord
commencing April 1, 2014. Under the terms of one lease agreement, the landlord provided the Company with a tenant improvement allowance
of $2.5 million and an additional tenant improvement allowance of $3 million, such additional tenant improvement allowance is to
be paid back to the landlord during the remainder of the term of such lease agreement through additional rent payments (collectively,
the &ldquo;Improvement Allowance&rdquo;). The Company has been funded $0.7 million in the nine months ended September 30, 2013,
and has been funded $5.0 million in total under the Improvement Allowance. The Improvement Allowance is being amortized on a straight-line
basis over the remaining term of the lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Note 14 <FONT STYLE="font-weight: normal">&ndash;
</FONT>Master Services Agreement with Cadila</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the JV with Cadila, the Company entered into a master services agreement, which the Company and Cadila amended in July 2011, and
subsequently in March 2013, in each case to extend the term by one year for which services can be provided by Cadila under this
agreement. Under the revised terms, if by March 2014, the amount of services provided by Cadila under the master services agreement
is less than $7.5 million, the Company will pay Cadila the portion of the shortfall amount that is less than or equal to $2.0 million
and 50% of the portion of the shortfall amount that exceeds $2.0 million. Through September 30, 2013, the Company has purchased
$2.4 million in services from Cadila pursuant to this agreement, which includes $0.8 million of services provided, since the beginning
of 2013, by CPLB to the Company on behalf of Cadila pursuant to an October 2013 amendment authorizing such CPLB services. The Company
plans to explore with Cadila ways to potentially address its remaining financial obligation and/or extend the time period during
which the Company could utilize such services. The Company can provide no assurance, however, that these efforts will be successful.
If the Company fails to negotiate a change in this arrangement, the Company expects that it will be obligated to spend a portion
of its available cash and cash equivalents to pay Cadila for its shortfall in services purchased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="background-color: yellow"><B></B></FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Item 2.&#9;Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any statements in the
discussion below and elsewhere in this report, about our expectations, beliefs, plans, objectives, assumptions or future events
or performance are not historical facts and are forward-looking statements. Such forward-looking statements include, without limitation,
statements regarding our expectations regarding future revenue and expense levels, the efficacy, safety and intended utilization
of our product candidates, the development of our clinical-stage product candidates and our recombinant vaccine and adjuvant technologies,
the future development of our product candidates by us, the conduct, timing and results of future clinical trials, plans regarding
regulatory filings, our available cash resources and the availability of financing generally, our plans regarding partnering activities
and business development initiatives, and other factors referenced herein. You can identify these forward-looking statements by
the use of words or phrases such as &ldquo;believe,&rdquo; &ldquo;may,&rdquo; &ldquo;could,&rdquo; &ldquo;will,&rdquo; &ldquo;possible,&rdquo;
&ldquo;can,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;ongoing,&rdquo; &ldquo;consider,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;intend,&rdquo; &ldquo;seek,&rdquo; &ldquo;plan,&rdquo; &ldquo;project,&rdquo; &ldquo;expect,&rdquo; &ldquo;should,&rdquo;
&ldquo;would,&rdquo; or &ldquo;assume&rdquo; or the negative of these terms, or other comparable terminology, although not all
forward-looking statements contain these words.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any or all of our forward-looking
statements in the Quarterly Report may turn out to be inaccurate. Among the factors that could cause actual results to differ materially
from those indicated in the forward-looking statements are risks and uncertainties inherent in our business including, without
limitation, the progress, timing or success of our clinical trials; difficulties or delays in development, testing, obtaining regulatory
approval for producing and marketing our product candidates; regulatory developments in the United States or in foreign countries;
the risks associated with our reliance on collaborations for the development and commercialization of our product candidates; unexpected
adverse side effects or inadequate efficacy of our product candidates that could delay or prevent product development or commercialization,
or that could result in recalls or product liability claims; our ability to attract and retain key scientific, management or operational
personnel; the size and growth potential of the markets for our product candidates and our ability to serve those markets; the
scope and validity of patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies;
our ability to establish and maintain strategic collaborations or to otherwise obtain additional financing to support our operations
on commercially reasonable terms; successful administration of our business and financial reporting capabilities; and other risks
detailed in this report, including those identified in Part II, Item 1A, &ldquo;Risk Factors&rdquo; of our Annual Report on Form
10-K for year ended December 31, 2012. In light of these risks and uncertainties, the forward-looking events and circumstances
discussed in this Quarterly Report may not occur as we contemplate, and actual results could differ materially from those anticipated
or implied by the forward-looking statements and we therefore caution readers not to place undue reliance on such forward-looking
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we believe
that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee future results, events, levels
of activity, performance or achievement. We undertake no obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise, unless required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Novavax, Inc. (Novavax,
and together with its subsidiary, Novavax AB, the Company, we or us) is a clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of recombinant protein nanoparticle vaccines and adjuvants. Our vaccine technology
platform is based on proprietary recombinant nanoparticle vaccine technology that includes virus-like particles (&ldquo;VLPs&rdquo;)
vaccines and recombinant protein micelle vaccines. These vaccine candidates are genetically engineered three-dimensional nanostructures
that incorporate immunologically important recombinant proteins. Our vaccine product pipeline targets a variety of infectious diseases
with candidates currently in clinical development for seasonal influenza, pandemic influenza and respiratory syncytial virus (&ldquo;RSV&rdquo;).
We operate in one business segment: developing recombinant vaccines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Through our Sweden-based
subsidiary, Novavax AB (formerly Isconova AB), we are also developing patented technology for the production of immune stimulating
saponin-based adjuvants that we expect to utilize in conjunction with our pandemic influenza vaccine candidates and potentially
with other vaccine candidates that may benefit from such an adjuvant. The Matrix&trade; technology utilizes selected Quillaja saponaria
fractions, which form separate matrix structures, to develop modern, multi-purpose immune-modulating adjuvant products for a broad
range of vaccine applications. We acquired the Matrix&trade; technology through our acquisition of Isconova AB in the third quarter
of 2013 because we believe this saponin-based adjuvant technology is a powerful complement to our recombinant vaccine programs.
Our lead adjuvant for human applications, Matrix-M&trade;, is in clinical trials with our partner Genocea Biosciences and is planned
for a clinical trial in combination with our H7N9 vaccine candidate in the first quarter of 2014 under our contract with the Department
of Health and Human Services, Biomedical Advanced Research and Development Authority (HHS BARDA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><SUP>&nbsp;</SUP>&#9;In
2009, we formed a joint venture with Cadila Pharmaceuticals Limited (&ldquo;Cadila&rdquo;) named CPL Biologicals Private Limited
(&ldquo;CPLB&rdquo;) to develop and manufacture vaccines, biological therapeutics and diagnostics in India. CPLB is owned 20% by
us and 80% by Cadila. CPLB operates a state-of-the-art manufacturing facility for the production of influenza vaccine and other
vaccine candidates. CPLB is actively developing a number of vaccine candidates that were genetically engineered by Novavax. CPLB&rsquo;s
rabies vaccine candidate is expected to begin a Phase 1 clinical trial in India in late 2013 or in early 2014. We continue to account
for our investment in CPLB using the equity method. Since the carrying value of our initial investment was nominal and there is
no guarantee or commitment to provide future funding, we have not recorded nor do we expect to record losses related to this investment
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Clinical Product Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A current summary of
our significant research and development programs and status of related products in development follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 32%; font-size: 10pt; font-weight: bold; text-align: justify; border-bottom: Black 1pt solid; background-color: White">Program</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt; background-color: White">&nbsp;</TD>
    <TD STYLE="width: 32%; font-size: 10pt; font-weight: bold; text-align: justify; border-bottom: Black 1pt solid; background-color: White">Development Phase</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt; background-color: White">&nbsp;</TD>
    <TD STYLE="width: 32%; font-size: 10pt; font-weight: bold; text-align: justify; border-bottom: Black 1pt solid; background-color: White">Collaborator</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">RSV</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Phase 2</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">PATH</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Seasonal Quadrivalent Influenza</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Phase 2</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">HHS BARDA/LGLS</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Pandemic (H5N1) Influenza</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Phase 1</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">HHS BARDA/LGLS<SUP>1</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Pandemic (H7N9) Influenza</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Phase 1</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">HHS BARDA/LGLS<SUP>1</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Seasonal Trivalent Influenza (India)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Phase 1</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">CPLB</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Pandemic (H1N1) Influenza (India)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Phase 1</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">CPLB</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Rabies</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Phase 1-ready</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">CPLB</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Respiratory Syncytial Virus (RSV)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">RSV is a widespread
disease that causes infections of the lower respiratory tract. While RSV affects persons of all ages, it acutely impacts infants,
the elderly, young children and others with compromised immune systems. Current estimates indicate that RSV is responsible for
over 30 million new acute lower respiratory infection episodes and between 150,000 and 200,000 deaths in children under five years
old<SUP>2</SUP>. In the U.S., nearly all children become infected with RSV before they are two years old; it has been associated
with 20% of hospitalizations and 15% of office visits for acute respiratory infection in young children. The World Health Organization
(WHO) estimates that the global disease burden for RSV is 64 million cases. Because there is no approved prophylactic vaccine,
the unmet medical need of an RSV vaccine has the potential to protect millions of patients from this far-reaching disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><SUP>1</SUP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">
<FONT STYLE="color: black">Although we initiated development of our pandemic influenza vaccine program under our contract with
HHS BARDA against the A(H5N1) strain, because of concern over the potential mutation and spread of the A(H7N9) influenza strain
in China, we independently initiated a second pandemic vaccine program in the first half of 2013 against A(H7N9). Recently, HHS
BARDA has directed us to shift our contracted development activities to our H7N9 program; however, the H5N1 vaccine program remains
a validated clinical asset and a viable potential development opportunity under the HHS BARDA contract.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><SUP>2</SUP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">
<FONT STYLE="color: black">Nair, H.,&nbsp;<I>et al.</I>, (2010) Lancet. 375:1545-1555</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing a
vaccine candidate to prevent RSV disease and are looking at susceptible target populations, including infants who may receive protection
through antibodies transferred from their mothers who would be immunized during the last trimester of pregnancy, the elderly and
young children.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Maternal Immunization Development Program
- Clinical Experience</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2013, we announced
top-line data from a Phase 2 dose-ranging clinical trial in women of childbearing age that were similar to, or exceeded, immune
responses seen in our first Phase 1 clinical trial. This randomized, blinded, placebo-controlled Phase 2 clinical trial evaluated
the safety and immunogenicity of two dose levels of our RSV vaccine candidate, with and without an aluminum phosphate adjuvant,
in 330 women of childbearing age. We further reported that the vaccine candidate was well-tolerated, the two-dose alum-adjuvanted
groups showed a 13 to 16-fold rise in anti-F IgG antibodies to the F protein compared to a 6 to 10-fold rise in the non-alum groups,
and Palivizumab-like antibody titers rose 8 to 9-fold with four-fold rises in &ge;92% of subjects in the two-dose alum-adjuvanted
groups.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August, 2013, in
advance of initiating a Phase 2 clinical trial in a small group of pregnant women expected in 2014 and in consultation with the
FDA, we initiated a reproductive toxicology study in rabbits to confirm the safety of our proposed formulation, which we expect
to complete in the first quarter of 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2013, we
initiated and completed enrollment in a Phase 2 dose-confirmation clinical trial in 720 women of childbearing age, which further
supports our maternal immunization program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Elderly Development
Program - Clinical Experience</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2012, we
initiated a Phase 1 dose-ranging clinical trial in the elderly, which supports our goals of developing a vaccine in elderly adults.
This clinical trial was a randomized, blinded, placebo-controlled Phase 1 clinical trial that evaluated the safety and immunogenicity
in 220 enrolled elderly adults, 60 years of age and older, who received a single intramuscular injection of our RSV vaccine candidate
(with and without alum) or placebo plus a single dose of licensed influenza vaccine or placebo at days 0 and 28. In July 2013,
we announced top-line data from the Phase 1 clinical trial in the elderly that further corroborated our previous clinical experiences
with our RSV vaccine candidate. We further reported that the vaccine candidate was well-tolerated, that the <FONT STYLE="color: black">higher
dose groups had better overall immune responses than the lower dose groups and that essentially undetectable Day 0 levels of antibodies
that compete with palivizumab increased to between 80% and 97% of active vaccine recipients by Day 28.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">Our
expected path forward in the elderly would include a dose-confirmation clinical trial, as we continue to assess the potential for
a combination RSV and influenza vaccine for the elderly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>PATH Vaccine
Solutions (PATH) Clinical Development Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2012, we entered
into a clinical development agreement with PATH to develop our vaccine candidate to protect against RSV through maternal immunization
in low-resource countries (RSV Collaboration Program). We were awarded approximately $2.0 million by PATH for initial funding under
the agreement to partially support our Phase 2 dose-ranging clinical trial in women of childbearing age as described above. Funding
under the agreement was increased by $0.4 million and the term extended to April 2014 to support our reproductive toxicology studies,
which are necessary before we conduct clinical trials in pregnant women. We retain global rights to commercialize the product and
have made a commitment to make the vaccine affordable and available in low-resource countries. To the extent PATH elects to continue
to fund 50% of our external clinical development costs for the RSV Collaboration Program, but we do not continue development, we
would then grant PATH a fully-paid license to our RSV vaccine technology for use in pregnant women in such low-resource countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Influenza</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Seasonal Influenza
Vaccine</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Developing and commercializing
a Novavax seasonal influenza vaccine remains an important strategic goal and viable opportunity for us. The Advisory Committee
for Immunization Practices of the Center for Disease Control and Prevention (CDC) recommends that a<FONT STYLE="color: black">ll
persons aged six months and older should be vaccinated annually</FONT> against seasonal influenza. In conjunction with these universal
recommendations, attention from the 2009 influenza H1N1 pandemic has increased public health awareness of the importance of seasonal
influenza vaccination, the market for which is expected to continue to grow worldwide in both developed and developing global markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently
four quadrivalent influenza vaccines licensed in the U.S., but in the coming years, additional seasonal influenza vaccines are
expected to be produced and licensed within and outside of the U.S. in a quadrivalent formulation (four influenza strains: two
influenza A strains and two influenza B strains), as opposed to the current trivalent formulation (three influenza strains: two
influenza A strains and one influenza B strain). With two distinct lineages of influenza B viruses circulating, governmental health
authorities have advocated for the addition of a second influenza B strain to provide additional protection. Current estimates
for seasonal influenza vaccines growth in the top seven markets (U.S., Japan, France, Germany, Italy, Spain and UK), show potential
growth from the current market of approximately $3.6 billion to $4.7 billion over the next ten years<SUP>3</SUP>. Recombinant
seasonal influenza vaccines, like the candidate we are developing, have an important advantage; once licensed for commercial sale,
large quantities of vaccines can be quickly and cost-effectively manufactured without the use of either the live influenza virus
or eggs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Top-line data from
our most recent Phase 2 clinical trial for our quadrivalent influenza vaccine candidate were announced in July 2012. In that clinical
trial, our quadrivalent VLP vaccine candidate demonstrated immunogenicity against all four viral strains based on HAI responses
at day 21, and was also well-tolerated, as evidenced by the absence of any observed vaccine-related serious adverse events (SAEs)
and an acceptable reactogenicity profile. Our vaccine candidate met the FDA accelerated approval seroprotection rates criterion
for all four viral strains. The potential to fulfill the seroconversion rates criterion was demonstrated for three of the four
viral strains. The fourth strain, B/Brisbane/60/08, despite fulfilling the seroprotection criterion, failed to demonstrate a satisfactory
seroconversion rate. Following our last Phase 2 clinical trial, o<FONT STYLE="color: black">ur seasonal influenza vaccine candidate
activities focused on locking the manufacturing process that will ensure consistent and enhanced immune responses in all strains.
We completed these activities in September 2013. In October 2013, we began manufacturing A and B strain influenza VLPs for the
next Phase 2 clinical trial with our quadrivalent vaccine candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Pandemic Influenza Vaccine</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the aftermath of
the 2009 H1N1 influenza pandemic, recognition of the potential devastation of a human influenza pandemic remains a key priority
with both governmental health authorities and influenza vaccine manufacturers. In the U.S. alone, the 2009 H1N1 pandemic led to
the production of approximately 126 million doses of monovalent (single strain) vaccine. Public health awareness and government
preparedness for the next potential influenza pandemic are driving development of vaccines that can be manufactured quickly against
a potentially threatening influenza strain. Until the spring of 2013, industry and health experts focused attention on developing
a monovalent H5N1 influenza vaccine as a potential key defense against a future pandemic threat; however, recent attention has
shifted to the potential development of an H7N9 influenza vaccine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><SUP>3</SUP><FONT STYLE="font: 10pt Times New Roman, Times, Serif">
Market Forecasts: Seasonal Influenza Vaccines. Datamonitor (2012)&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2012, we
reported positive results from two Phase 1 clinical trials of our pandemic (H5N1) vaccine candidate in combination with two different
adjuvants, both of which are designed to improve the immunogenicity of vaccines at lower doses and thus provide antigen dose-sparing.
The top-line data demonstrated safety and immunogenicity of varying dose-levels of the vaccine, with and without adjuvant, and
further demonstrated statistically significant robust adjuvant effects on immune response. <B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2013, we initiated
manufacturing of a new monovalent influenza vaccine candidate against the A/Anhui/1/13-like H7N9 strain of avian influenza (A(H7N9)).
This strain was first recognized by Chinese health authorities as a potential pandemic influenza threat in late March 2013. In
a three month period, we took the A(H7N9) viral gene sequence provided to vaccine manufacturers by the WHO, developed and purified
a VLP antigen, conducted multiple animal studies, and initiated a Phase 1 clinical trial in Australia on our own, independent from
our HHS BARDA contract. In September 2013, HHS BARDA directed us to focus our development of a monovalent pandemic influenza vaccine
on the A(H7N9) strain and notified us that they intend to fund a Phase 1 U.S. clinical trial with our H7N9 candidate and Matrix-M
adjuvant in the first half of 2014; <FONT STYLE="color: black">however, HHS BARDA has also indicated that our H5N1 vaccine program
remains a viable development opportunity under our contract</FONT>. The initiation and funding of any such study is contingent
on the completion of a contract modification with HHS BARDA that is currently underway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Potential Accelerated
Approval Pathway for Influenza</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the past, we have
referenced attainment of accelerated approval immunogenicity endpoints for seroprotection and seroconversion as a potential pathway
for licensure of our influenza vaccines. The criteria for granting such accelerated approval of a Biologics License Application
(BLA, the biologic equivalent to a New Drug Application or NDA) for new seasonal and pandemic influenza vaccines was published
by the U.S. Food and Drug Administration, Center for Biologics Evaluation and Research (FDA). Under FDA guidance, developers that
can demonstrate results that meet or exceed certain specified immunogenicity endpoint criteria in <FONT STYLE="color: black">their
clinical trials may, at the FDA&rsquo;s discretion, be granted a license to market a product prior to submission of traditional
clinical endpoint efficacy trial data. It should be noted that FDA licensure based on accelerated approval nevertheless requires
sponsors to conduct a post-licensure efficacy study to demonstrate the clinical benefit of the vaccine, which would thereby support
traditional approval of the vaccine. Because it is not possible to conduct a clinical endpoint efficacy study for a pandemic vaccine
in advance of a declared pandemic, FDA&rsquo;s pandemic guidance allows for submission of seasonal influenza clinical efficacy
data for the purpose of confirming clinical benefit of a pandemic vaccine manufactured by the same process. </FONT>Thus, the demonstration
of efficacy with a seasonal vaccine provides a key link between the seasonal and pandemic programs. Accelerated approval further
necessitates a shortage of influenza vaccine relative to the total population recommended to receive such vaccine, a situation
that persists with seasonal influenza vaccine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we have not
ruled out this accelerated approval approach, particularly for our pandemic program or certain subject populations within the seasonal
influenza program, we do not expect to pursue accelerated approval of our quadrivalent seasonal influenza vaccine, largely because
of the uncertainty as to whether the accelerated approval pathway will be available to us at the time of our BLA submissions and
the unknown ability of current and new influenza strains to meet such accelerated approval criteria. We are planning, therefore,
to pursue traditional licensure of our quadrivalent seasonal influenza vaccine by conducting a clinical endpoint efficacy study
for the purpose of submitting the data within the original BLA. These efficacy data will also support the requirement for clinical
efficacy data for our pandemic vaccine program. Novavax plans to discuss with the FDA our licensure pathways (both the traditional
pathway for seasonal and possible accelerated pathways for pandemic and certain subject populations within the seasonal program)
during future formal meetings. The likely impact of such an efficacy trial would be an additional year or more before the FDA grants
licensure to our seasonal influenza vaccine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>HHS BARDA Contract
for Recombinant Influenza Vaccines</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HHS BARDA awarded us
a contract in February 2011, which funds the development of both our seasonal and pandemic influenza vaccine candidates. The contract,
valued at $97 million for the first three-year base-period and $82 million for an HHS BARDA optional two-year period, is a cost-plus-fixed-fee
contract in which HHS BARDA reimburses us for allowable direct contract costs incurred plus allowable indirect costs and a fixed-fee
earned in the ongoing clinical development and product scale-up of our multivalent seasonal and monovalent pandemic influenza vaccines.
HHS BARDA originally directed us to develop our monovalent pandemic influenza vaccine against the A(H5N1) strain. Recently, however,
HHS BARDA has directed us to develop our monovalent pandemic influenza vaccine against the A(H7N9) strain and is working with us
to modify the HHS BARDA contract in this respect; nevertheless, our H5N1 vaccine program remains a viable development opportunity
under the contract. We recognized revenue of approximately $10.7 million in the nine months ended September 30, 2013, and have
recognized approximately $45 million in revenue since the inception of the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under certain circumstances,
HHS BARDA reimbursements may be delayed or even potentially withheld. In March 2012, we decided to conduct a Phase 2 clinical trial
of our quadrivalent seasonal influenza vaccine candidate (the 205 Trial) under our existing U.S. investigational new drug application
(IND) for our trivalent seasonal influenza vaccine candidate as opposed to waiting to conduct this clinical trial under a new IND
for our quadrivalent vaccine candidate (Quadrivalent IND). Based on our discussions with HHS BARDA in 2012, the outside clinical
trial costs for the 205 Trial may only be submitted for reimbursement to HHS BARDA and recorded as revenue by us after we submit
the clinical trial data in a future Quadrivalent IND. The submission of the Quadrivalent IND is expected shortly before we initiate
the next Phase 2 dose-confirmatory clinical trial, which is currently expected in the first quarter of 2014. The outside clinical
trial costs of the 205 Trial conducted last year total $2.9 million, which was incurred from the inception of the clinical trial
through June 30, 2013. These costs have been recorded as an expense and are included in cost of government contracts revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>LG Life Sciences,
Ltd. (LGLS) License Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2011, we
entered into a license agreement with LGLS that allows LGLS to use our technology to develop and commercially sell our influenza
vaccines in South Korea and certain other emerging-market countries. LGLS received an exclusive license to our influenza VLP technology
in South Korea and a non-exclusive license in the other specified countries. At its own cost, LGLS is responsible for funding both
its clinical development of the influenza VLP vaccines and a manufacturing facility to produce such vaccine in South Korea. We
received an upfront payment and may receive reimbursements of certain development and product costs, payments related to the achievement
of certain milestones and royalty payments in the high single digits from LGLS&rsquo;s future commercial sales of influenza VLP
vaccines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rabies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CPLB is currently developing
a rabies vaccine candidate that we genetically engineered and expects to initiate its Phase 1 clinical trial in India in late 2013
or early 2014. Our common objective is to develop a recombinant vaccine that can be administered as a pre-exposure prophylaxis
for residents of certain higher-risk geographies, as well as travelers to such locations, and with the potential to provide post-exposure
prophylaxis with fewer doses. Preliminary pre-clinical results have demonstrated that this vaccine candidate has the potential
to successfully prevent the rabies virus from entering the central nervous system, thus preventing death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Emerging Diseases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We pay close attention
to global reports of emerging diseases for which there do not appear to be immediate cures and where a vaccine protocol could offer
potential protection. In addition to our response to the A(H7N9) influenza strain (see discussion above), we have been monitoring
reports around the Middle East Respiratory Syndrome Coronavirus (MERS), a novel coronavirus first identified in September 2012
by an Egyptian virologist. MERS has become an emerging threat in 2013 with more than 50 confirmed cases of infection and 30 deaths.
The MERS virus is a part of the coronavirus family that includes the severe acute respiratory syndrome coronavirus (SARS). Because
of the public health priority given to MERS, within weeks of getting the virus&rsquo; sequence, Novavax successfully produced a
vaccine candidate designed to provide protection against MERS. This vaccine candidate, which was made using our recombinant nanoparticle
vaccine technology, is based on the major surface spike protein, which we had earlier identified as the antigen of choice in our
work with a SARS vaccine candidate. Although this currently remains a pre-clinical program, we believe that our MERS vaccine candidate
offers a viable option to interested global public health authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Sales of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2012, we
entered into an At Market Issuance Sales Agreement (2012 Sales Agreement), under which our Board of Directors (the Board) approved
the sale of up to an aggregate of $50 million in gross proceeds of our common stock. The shares of common stock are being offered
pursuant to a shelf registration statement filed with the SEC in March 2013, which replaced the previous shelf registration statement
filed in 2010. The Board&rsquo;s standing Finance Committee (the Committee) assists with its responsibilities to monitor, provide
advice to our senior management and approve all capital raising activities. The Committee has been authorized by the Board, absent
any action by the Board to the contrary, to take any additional actions necessary to carry out the Board&rsquo;s authorization
of the issuance and sale of the common stock sold pursuant to the 2012 Sales Agreement. In doing so, the Committee is authorized
to set the amount of shares to be sold, the period of time during which such sales may occur and the minimum sales price per share.
During the nine months ended September 30, 2013, we sold 12.6 million shares at sales prices ranging from $2.06 to $3.38 per share,
resulting in approximately $34.0 million in net proceeds. The most recent sales to occur under the 2012 Sales Agreement were on
September 10, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2013,
we completed a public offering of 31,846,950 shares of our common stock, including 4,153,950 shares of common stock that were issued
upon the exercise in full of the over-allotment granted to the underwriters, at a price of $3.14 per share resulting in net proceeds
of approximately $94.7 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Critical Accounting
Policies and Use of Estimates </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no material
changes to our critical accounting policies as described in Item&nbsp;7 of our Annual Report on Form 10-K for the fiscal year ended
December&nbsp;31, 2012, as filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Recent Accounting
Pronouncements Not Yet Adopted</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have considered
the applicability and impact of all Financial Accounting Standards Board&rsquo;s Accounting Standards Updates (ASUs). Recently
issued ASUs were evaluated and determined to be not applicable in this Quarterly Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a
discussion of our historical financial condition and results of operations, which includes Novavax AB&rsquo;s operations since
the acquisition date of July 31, 2013, and should be read in conjunction with the consolidated financial statements and notes thereto
set forth in this Quarterly Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Three Months Ended September 30, 2013
and 2012 </B>(amounts in tables are presented in thousands, except per share information)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Revenue:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Three Months Ended <BR>September 30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change 2012 to 2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; color: black; font-weight: bold">Revenue:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 58%; font-size: 10pt; text-align: left">Total revenue</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">4,802</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5,765</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(963</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenue for the three
months ended September 30, 2013 was $4.8 million as compared to $5.8 million for the same period in 2012, a decrease of $1.0 million
or 17%. Revenue for the three months ended September 30, 2013 and 2012 is primarily comprised of services performed under the HHS
BARDA contract and, to a much lesser extent in 2013, revenue of recently acquired Novavax AB. The decrease in revenue is primarily
due to the higher level of activity in the three months ended September 30, 2012 associated with our influenza clinical trials
under the HHS BARDA contract as compared to the same period in 2013 when no similar clinical trials were initiated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For 2013, we expect
a decrease in revenue due to fewer externally funded clinical trials in 2013 as compared to 2012, offset by increased product development
activities under the HHS BARDA contract to support the ultimate initiation of later-stage clinical trials of our seasonal influenza
and pandemic (H7N9) influenza vaccine candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Costs and Expenses:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Three Months Ended <BR>September 30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change 2012 to&nbsp;2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Costs and Expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 58%; font-size: 10pt; text-align: left">Cost of government contracts revenue</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">2,276</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3,838</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(1,562</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Research and development</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13,948</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,642</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,306</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,857</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,134</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,723</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total costs and expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">20,081</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">12,614</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,467</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Cost
of Government Contracts Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cost of government
contracts revenue includes direct costs of salaries, laboratory supplies, consultants and subcontractors and other direct costs
associated with our process development, manufacturing, clinical, regulatory and quality assurance activities under research contracts.
Cost of government contracts revenue decreased to $2.3 million for the three months ended September 30, 2013 from $3.8 million
for the same period in 2012, a decrease of $1.6 million, or 41%. The decrease in cost of government contracts revenue is primarily
related to the levels of activity associated with our influenza clinical trials previously mentioned, including the 205 Trial (see
discussion of the 205 Trial in <I>HHS BARDA Contract for Recombinant Influenza Vaccines </I>above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For 2013, we expect
the cost of government contracts revenue to decrease due to fewer externally funded clinical trials in 2013 as compared to 2012,
offset by increased product development activities under the HHS BARDA contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Research
and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 45.8pt">Research and development
expenses include salaries, laboratory supplies, consultants and subcontractors and other expenses associated with our process development,
manufacturing, clinical, regulatory and quality assurance activities for internally funded programs. In addition, indirect costs
such as fringe benefits and overhead expenses are also included in research and development expenses. Research and development
expenses increased to $13.9 million for the three months ended September 30, 2013 from $6.6 million for the same period in 2012,
an increase of $7.3 million, or 110%. Excluding the increase in research and development expenses of approximately $1.4 million
of recently acquired Novavax AB, the remaining increase in research and development expenses was primarily due to increased costs
relating to our RSV and pandemic (H7N9) influenza clinical trials (internally funded programs at this time) and higher employee-related
costs. For 2013, we expect a significant increase in research and development expenses primarily due to additional clinical trials
of our RSV and pandemic (H7N9) influenza vaccine candidates and employee-related costs to support product development of RSV and
other potential vaccine candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Costs and Expenses
by Functional Area</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We track our cost of
government contracts revenue and research and development expenses by the type of costs incurred in identifying, developing, manufacturing
and testing vaccine candidates. We evaluate and prioritize our activities according to functional area and therefore believe that
project-by-project information would not form a reasonable basis for disclosure to our investors. At September 30, 2013, we had
153 employees dedicated to our research and development programs versus 103<B> </B>employees as of September 30, 2012. Historically,
we did not account for internal research and development expenses by project, since our employees&rsquo; work time is spread across
multiple programs and our internal manufacturing clean-room facility produces multiple vaccine candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summarizes
our cost of government contracts revenue and research and development expenses by functional area for the three months ended September
30 (in millions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 68%; font-size: 10pt; color: black">Manufacturing</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">8.7</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">5.3</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Vaccine Discovery</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.5</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.9</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Clinical and Regulatory</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6.0</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4.3</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total cost of government contracts revenue and research and development expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16.2</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10.5</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not provide forward-looking
estimates of costs and time to complete our research programs due to the many uncertainties associated with vaccine development.
As we obtain data from pre-clinical studies and clinical trials, we may elect to discontinue or delay clinical trials in order
to focus our resources on more promising vaccine candidates. Completion of clinical trials may take several years or more, but
the length of time can vary substantially depending upon the phase, size of clinical trial, primary and secondary endpoints and
the intended use of the vaccine candidate. The cost of clinical trials may vary significantly over the life of a project as a result
of a variety of factors, including:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the number of patients who participate in the clinical trials and the specific patient population;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the number of sites included in the clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">if clinical trial locations are domestic, international or both;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the time to enroll patients;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the duration of treatment and follow-up;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the safety and efficacy profile of the vaccine candidate; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the cost and timing of, and the ability to secure, regulatory approvals.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.1pt"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of these
uncertainties, we are unable to determine with any significant degree of certainty the duration and completion costs of our research
and development projects or when, and to what extent, we will generate future cash flows from our research projects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>General</I></B></FONT><B><I>
and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">General
and administrative expenses increased to $3.9 million for the three months ended September 30, 2013 from $2.1 million for the same
period in 2012, an increase of $1.7 million, or 81%. Excluding the increase in general and administrative expenses of approximately
$0.6 million of recently acquired</FONT> <FONT STYLE="font-size: 10pt">Novavax AB, the remaining increase was primarily due to
higher professional fees, including those associated with our acquisition of Novavax AB. For 2013, we expect general and administrative
expenses to increase as a result of increased professional fees, including those associated with our acquisition of Novavax AB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Other Income (Expense):</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Three Months Ended <BR> September 30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: black; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; color: black; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; color: black">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: black; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; color: black; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; color: black">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; color: black; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; color: black; text-align: center; border-bottom: Black 1pt solid">Change 2012 to 2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; color: black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other Income (Expense):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 58%; font: 10pt Times New Roman, Times, Serif; color: black; text-align: left">Interest income</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">53</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">39</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">14</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: black; text-align: left">Interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(64</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(58</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: black; text-align: left">Other expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9;&#8213;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: black; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#8213;</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(401</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">401</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total other income (expense)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(21</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(368</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">347</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We had total other
expense of less than $0.1<B> </B>million for the three months ended September 30, 2013 compared to total other expense of $0.4
million for the same period in 2012. For the three months ended September 30, 2013, the change in fair value of the warrant liability
resulted in a $0.4 million decrease in total other expense as compared to the same period in 2012. The warrants expired unexercised
on July 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Net Loss:</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Three Months Ended <BR>September 30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change 2012 to&nbsp;2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Net Loss:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 58%; font-size: 10pt; text-align: left">Net loss</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(15,300</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(7,217</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(8,083</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt">Net loss per share</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.09</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.05</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.04</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Weighted shares outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">168,537</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">134,178</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">34,359</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net loss for the three
months ended September 30, 2013 was $15.3 million, or $0.09 per share, as compared to $7.2 million, or $0.05 per share, for the
same period in 2012, an increased net loss of $8.1 million. The increased net loss was primarily due to higher research and development
spending, including increased costs relating to our RSV and pandemic (H7N9) influenza clinical trials and higher employee-related
costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The increase in weighted
average shares outstanding for the three months ended September 30, 2013 is primarily a result of sales of our common stock in
2012 and 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Nine Months Ended September 30, 2013
and 2012 </B>(amounts in tables are presented in thousands, except per share information)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Revenue:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nine Months Ended </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September
                                                                                                                                                                                                                    30,</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: black"><B>Change
    2012 to 2013</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; color: black; font-weight: bold; padding-left: 0">Revenue:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 58%; font-size: 10pt; text-align: left; padding-left: 0">Total revenue</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">12,167</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">17,510</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(5,343</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenue for the nine
months ended September 30, 2013 was $12.2 million as compared to $17.5 million for the same period in 2012, a decrease of $5.3
million or 31%. Revenue for the nine months ended September 30, 2013 and 2012 is primarily comprised of services performed under
the HHS BARDA contract and, to a much lesser extent in 2013, the PATH clinical development agreement. The decrease in revenue is
primarily due to the higher level of activity in the nine months ended September 30, 2012 associated with our influenza clinical
trials under the HHS BARDA contract as compared to the same period in 2013 when no similar clinical trials were initiated, partially
offset by revenue under the PATH clinical development agreement in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Costs and Expenses:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended <BR>September 30,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Change
2012 to&nbsp;2013</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0">Costs and Expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 58%; font-size: 10pt; text-align: left; padding-left: 0">Cost of government contracts revenue</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5,619</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">12,740</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(7,121</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0">Research and development</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">33,989</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">17,270</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16,719</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0">General and administrative</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,740</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,670</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,070</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0">Total costs and expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">50,348</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">37,680</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">12,668</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Cost
of Government Contracts Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cost of government
contracts revenue includes direct costs of salaries, laboratory supplies, consultants and subcontractors and other direct costs
associated with our process development, manufacturing, clinical, regulatory and quality assurance activities under research contracts.
Cost of government contracts revenue decreased to $5.6 million for the nine months ended September 30, 2013 from $12.7 million
for the same period in 2012, a decrease of $7.1 million, or 56%. The decrease in cost of government contracts revenue is primarily
related to the levels of activity associated with our influenza clinical trials previously mentioned, including the 205 Trial (see
discussion of the 205 Trial in HHS BARDA Contract for Recombinant Influenza Vaccines above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><B><I>Research
and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expenses include salaries, laboratory supplies, consultants and subcontractors and other expenses associated with our process development,
manufacturing, clinical, regulatory and quality assurance activities for internally funded programs. In addition, indirect costs
such as fringe benefits and overhead expenses are also included in research and development expenses. Research and development
expenses increased to $34.0 million for the nine months ended September 30, 2013 from $17.3 million for the same period in 2012,
an increase of $16.7 million, or 97%. Excluding the increase in research and development expenses of approximately $1.4 million
of recently acquired Novavax AB, the remaining increase in research and development expenses was primarily due to increased costs
relating to our RSV and pandemic (H7N9) influenza clinical trials (internally funded programs at this time) and higher employee-related
costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Costs and Expenses
by Functional Area</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summarizes
our cost of government contracts revenue and research and development expenses by functional area for the nine months ended September
30 (in millions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; font-size: 10pt; color: black; padding-left: 0; text-indent: 0">Manufacturing</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">21.9</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">14.8</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0; text-indent: 0">Vaccine Discovery</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4.0</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.5</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0; text-indent: 0">Clinical and Regulatory</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">13.7</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">12.7</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: 0; padding-left: 0">Total cost of government contracts revenue and research and development expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">39.6</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30.0</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>General</I></B></FONT><B><I>
and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses increased to $10.7 million for the nine months ended September 30, 2013 from $7.7 million for the same period in 2012,
an increase of $3.1 million, or 40%. Excluding the increase in general and administrative expenses of approximately $0.6 million
of recently acquired Novavax AB, the remaining increase was primarily due to higher professional fees, including those associated
with our acquisition of Novavax AB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Other Income (Expense):</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Nine Months Ended </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>September
                                                                                                                                                                                                                    30,</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: black; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt; color: black"><B>Change
    2012 to 2013</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; color: black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0">Other Income (Expense):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 58%; font-size: 10pt; color: black; text-align: left; padding-left: 0">Interest income</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">149</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">111</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">38</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; color: black; text-align: left; padding-left: 0">Interest expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(132</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(12</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(120</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; color: black; text-align: left; padding-left: 0">Other expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(10</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&#9;&#8213;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(10</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; color: black; text-align: left; padding-bottom: 1pt; padding-left: 0">Change in fair value of warrant liability</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">267</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(401</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">668</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0">Total other income (expense)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">274</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(302</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">576</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We had total other
income of $0.3<B> </B>million for the nine months ended September 30, 2013 compared to total other expense of $0.3 million for
the same period in 2012. For the nine months ended September 30, 2013, the change in fair value of the warrant liability resulted
in a $0.7 million increase in total other income as compared to the same period in 2012. The warrants expired unexercised on July
31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Net Loss:</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; padding-left: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nine Months Ended </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September
                                                                                                                                                                                                                    30,</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Change
2012 to&nbsp;2013</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0">Net Loss:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 58%; font-size: 10pt; text-align: left; padding-left: 0">Net loss</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(37,929</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(20,472</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(17,457</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; padding-left: 0">Net loss per share</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.24</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.16</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.08</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0">Weighted shares outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">156,555</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">127,246</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">29,309</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net loss for the nine
months ended September 30, 2013 was $37.9 million, or $0.24 per share, as compared to $20.5 million, or $0.16 per share, for the
same period in 2012, an increased net loss of $17.5 million. The increased net loss was primarily due to higher research and development
spending, including increased costs relating to our RSV and pandemic (H7N9) influenza clinical trials and higher employee-related
costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The increase in weighted
average shares outstanding for the nine months ended September 30, 2013 is primarily a result of sales of our common stock in 2012
and 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Liquidity Matters
and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future capital
requirements depend on numerous factors including, but not limited to, the commitments and progress of our research and development
programs, the progress of pre-clinical and clinical testing, the time and costs involved in obtaining regulatory approvals, the
costs of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights and manufacturing costs.
We plan to continue to have multiple vaccines and products in various stages of development, and we believe our operating expenses
and capital requirements will fluctuate depending upon the timing of certain events, such as the scope, initiation, rate and progress
of our pre-clinical studies and clinical trials and other research and development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30,
2013, we had $146.4 million in cash and cash equivalents and investments as compared to $50.3 million as of December 31, 2012.
These amounts consisted of $122.5 million in cash and cash equivalents and $23.9 million in investments as of September 30, 2013
as compared to $17.4 million in cash and cash equivalents and $32.9 million in investments at December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
summarizes cash flows for the nine months ended September 30, 2013 and 2012 (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nine Months Ended </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 30,</B></P></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2013</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2012</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Change 2012 to<U> </U>2013</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black"><B>Summary of Cash Flows:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCFFCC">
    <TD STYLE="padding-left: 1.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Net cash (used in) provided by:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 61%; padding-left: 1.75pt; text-indent: 9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Operating activities</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">(33,096</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">(14,977</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">(18,119</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCFFCC">
    <TD STYLE="padding-left: 1.75pt; text-indent: 9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Investing activities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">7,231</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">(15,147</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">22,378</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 1.75pt; text-indent: 9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Financing activities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">130,943</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">26,758</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">104,185</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCFFCC">
    <TD STYLE="padding-left: 1.75pt; text-indent: 9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Effect of exchange rate on cash and cash equivalents</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">16</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">&#9;&#8213;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">16</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 1.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Net increase (decrease) in cash and cash equivalents</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">105,094</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">(3,366</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">108,460</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCFFCC">
    <TD STYLE="padding-left: 1.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Cash and cash equivalents at beginning of period</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">17,399</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">14,104</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">3,295</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 1.75pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Cash and cash equivalents at end of period</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">122,493</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">10,738</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">111,755</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities increased to $33.1<B> </B>million for the nine months ended September 30, 2013 as compared to $15.0 million for the
same period in 2012, respectively. The increase in cash usage was primarily due to increased costs relating to our RSV and pandemic
(H7N9) influenza clinical trials and higher employee-related costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the nine months
ended September 30, 2013 and 2012, our investing activities consisted of purchases and maturities of investments and capital expenditures.
In the nine months ended September 30, 2013, we primarily utilized our short-term investments to fund operations and increase our
cash balances. In the same period in 2012, we primarily purchased short-term investments to increase our rate of return on our
investments. Capital expenditures for the nine months ended September 30, 2013 and 2012 were $4.8 million and $2.2 million, respectively.
The increase in capital expenditures was primarily due to purchase of laboratory equipment and tenant improvements relating to
our new manufacturing facility. In late 2013, we expect our level of capital expenditures to decrease due to the expected completion
of the scale-up work on our new manufacturing facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our financing activities
consist primarily of sales of our common stock. In the nine months ended September 30, 2013, we received net proceeds of $94.7
million through our public offering at a sales price of $3.14 per share and $34.0 million through our At Market Issuance Sales
Agreements at an average sales price of $2.76 per share. In the same period in 2012, we received net proceeds of $14.8 million
through our At Market Issuance Sales Agreements at an average sales price of $1.70 per share and $12.1 million to two affiliates
of RA Capital Management, LLC at a sales price of $1.22.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November&nbsp;2011,
we entered into lease agreements under which we lease our new manufacturing, laboratory and office space in Gaithersburg, Maryland
with rent payments for such space to the landlord commencing April 1, 2014. Under the terms of the arrangement, the landlord provided
us with a tenant improvement allowance of $2.5 million and an additional tenant improvement allowance of $3 million (collectively,
the Improvement Allowance). The additional tenant improvement allowance is to be paid back to the landlord over the remaining term
of the lease agreement through additional rent payments. We were funded $0.7 million in the nine months ended September 30, 2013,
and have been funded $5.0 million in total under the Improvement Allowance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2012,
we entered into a master security agreement, whereby we could borrow up to $2.0 million to finance the purchases of equipment through
June 2013 (Equipment Loan). We financed $1.5 million in the nine months ended September 30, 2013, and have financed $2.0 million
in total under the Equipment Loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into
agreements with outside providers to support our clinical development. As of September 30, 2013, $8.0 million remains unpaid on
certain of these agreements in the event our outside providers complete their services in 2013. However, under the terms of the
agreements, we have the option to terminate for convenience pursuant to notification, but we would be obligated to pay the provider
for all costs incurred through the effective date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: silver"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have licensed certain
rights from Wyeth. The Wyeth license, which provides for an upfront payment (previously made), ongoing annual license fees, milestone
payments and royalties on any product sales, is a non-exclusive, worldwide license to a family of patent applications covering
VLP technology for use in human vaccines in certain fields, with expected patent expiration in early 2022. The license may be terminated
by Wyeth only for cause and may be terminated by us only after we have provided ninety (90) days notice that we have absolutely
and finally ceased activity, including through any affiliate or sublicense, related to the manufacturing, development, marketing
or sale of products covered by the license. Payments under the agreement to Wyeth from 2007 through September 30, 2013 totaled
$5.9&nbsp;million, of which $0.2 million was paid in the nine months ended September 30, 2013. We do not expect to make a milestone
payment to Wyeth in the next 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
CPLB, we entered into a master services agreement with Cadila, which we and Cadila amended in July 2011, and subsequently in March
2013, in each case to extend the term by one year for which services can be provided by Cadila under this agreement. Under the
revised terms, if, by March 2014, the amount of services provided by Cadila under the master services agreement is less than $7.5
million, we will pay Cadila the portion of the shortfall amount that is less than or equal to $2.0 million and 50% of the portion
of the shortfall amount that exceeds $2.0 million. Recently, the Company and Cadila agreed to an amendment that allows CPLB, as
of the beginning of 2013, to provide services on behalf of Cadila. Through September 30, 2013, we have purchased $2.4<B> </B>million
in services from Cadila pursuant to this agreement, including amounts in which CPLB provided the services on behalf of Cadila.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our September
30, 2013 cash and cash equivalents and investment balances and the anticipated revenue under the contract with HHS BARDA, we believe
we have adequate capital to fund our operating plans into 2016. Additional capital may be required in the future to develop our
vaccine candidates through clinical development, manufacturing and commercialization. Our ability to obtain such additional capital
will likely be subject to various factors, including our ability to perform and thus generate revenue under the HHS BARDA contract,
our overall business performance and market conditions.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any capital raised
by an equity offering will likely be substantially dilutive to the existing stockholders and any licensing or development arrangement
may require us to give up rights to a product or technology at less than its full potential value. We cannot provide any assurance
that new financing will be available on commercially acceptable terms, if at all. If we are unable to perform under the HHS BARDA
contract or obtain additional capital, we will assess our capital resources and may be required to delay, reduce the scope of,
or eliminate one or more of our product research and development programs, and/or downsize our organization, including our general
and administrative infrastructure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 3.&#9;Quantitative and Qualitative
Disclosures About Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The primary objective
of our investment activities is preservation of capital, with the secondary objective of maximizing income. As of September 30,
2013, we had cash and cash equivalents of $122.5 million, investments of $23.9 million, all of which are short-term, and working
capital of $140.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our exposure to market
risk is primarily confined to our investment portfolio. As of September 30, 2013, our investments were classified as available-for-sale.
We do not believe that a change in the market rates of interest would have any significant impact on the realizable value of our
investment portfolio. Changes in interest rates may affect the investment income we earn on our investments when they mature and
the proceeds are reinvested into new investments and, therefore, could impact our cash flows and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interest and dividend
income is recorded when earned and included in interest income. Premiums and discounts, if any, on investments are amortized or
accreted to maturity and included in interest income. The specific identification method is used in computing realized gains and
losses on the sale of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are headquartered
in the U.S. where we conduct the vast majority of our business activities. Accordingly, even with the acquisition of Novavax AB,
we have not had any material exposure to foreign currency rate fluctuations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have material
debt and, as such, do not believe that we are exposed to any material interest rate risk as a result of our borrowing activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item&nbsp;4. Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Evaluation of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, with
the assistance of our Chief Executive Officer and Chief Financial Officer, has reviewed and evaluated the effectiveness of our
disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended)
as of September 30, 2013. Management recognizes that any controls and procedures, no matter how well designed and operated, can
provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the
cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable
assurance of achieving their control objectives. Based on the evaluation of our disclosure controls and procedures as of September
30, 2013, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and
procedures were effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Changes in Internal Control over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, including
our Chief Executive Officer and Chief Financial Officer, has evaluated any changes in our internal control over financial reporting
that occurred during the third quarter of 2013, and has concluded that there was no change that occurred during the third quarter
of 2013 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the third quarter
of 2013, the Company acquired Novavax AB. The Company is currently in the process of integrating Novavax AB pursuant to the Sarbanes-Oxley
Act of 2002. The Company is evaluating changes to processes, information technology systems and other components of internal controls
over financial reporting as part of its ongoing integration activities, and as a result, controls will be changed as needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II. OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item&nbsp;1A. Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following risk
factors reflect material changes to the Company&rsquo;s risk factors as described in Part II, Item &nbsp;1A, &ldquo;Risk Factors&rdquo;
of the Company&rsquo;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RISKS RELATED TO OUR BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Even with the
HHS BARDA contract award, we may not be able to fully fund our influenza programs. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HHS BARDA contract
is a cost-plus-fixed-fee contract that only reimburses certain specified activities that have been previously authorized by HHS
BARDA. There is no guarantee that additional activities will not be needed and, if so, that HHS BARDA will reimburse us for these
activities. Additionally, we have limited experience meeting the significant requirements of a federal government contractor, which
includes having appropriate accounting, project tracking and earned-value management systems implemented and operational, and our
existing operations may not meet these requirements in a timely way or at all. Performance under the HHS BARDA contract requires
that we comply with appropriate regulations and operational mandates, with which we have minimal operational experience. Our ability
to be regularly and fully reimbursed for our activities will depend on our ability to comply and demonstrate compliance with such
requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We may not meet
the milestones of our contract with HHS BARDA during the contract period and HHS BARDA may elect not to extend the contract period
for us to meet these milestones. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HHS BARDA contract
anticipates that we file Biologics License Applications (BLA, the biologic equivalent to a New Drug Application or NDA) for licensure
of both a seasonal influenza vaccine and a pandemic influenza vaccine; however, the contract is for a base-period of three years
plus an option-period of two additional years, and there is no guarantee that we will successfully complete all of the tasks required
to file these BLAs during the anticipated contract period. For example, while we have made significant progress during the last
year in addressing our goal of consistent and enhanced immune responses in all strains of our influenza vaccine candidates, there
is no guarantee that we will ever be successful in having all the strains meet the immunogenicity criteria for accelerated approval
by the FDA. The inability to meet such goals could cause delays in our influenza vaccine candidate programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>HHS BARDA directed
activities under the contract may require us to change our plans such that other activities anticipated under the contract may
not occur during the contract period, which may necessitate that we fund such activities ourselves or not conduct them at all.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HHS BARDA has directed
us to focus on developing our pandemic influenza vaccine against the A(H7N9) strain; while we expect to be able to initiate a Phase
2 clinical trial for our pandemic (H7N9) influenza vaccine candidate, certain work that had been conducted on our pandemic (H5N1)
influenza vaccine candidate may need to be duplicated or re-conducted on our pandemic (H7N9) influenza vaccine candidate. To the
extent that such work is reimbursed by HHS BARDA under our contract, such funds may not be available for other development activities
that we had anticipated would be performed under the contract. In such cases, we will need to decide whether to conduct the activities
at our own expense or to determine that such activities are unnecessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our expectation
that our pandemic influenza vaccine candidate will be granted accelerated approval by the FDA is not guaranteed and if we don't
get accelerated approval, development of this vaccine will take longer and cost significantly more prior to BLA approval. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As is the case with
seasonal influenza, FDA has articulated the immunogenicity criteria for accelerated approval of vaccines that address potential
pandemic influenza strains. Because a controlled efficacy clinical trial of a pandemic vaccine candidate is not logistically or
ethically possible, accelerated approval will require evidence that a seasonal vaccine made by the same manufacturing process as
the pandemic vaccine is efficacious. There is no guarantee the FDA will grant accelerated approval of our pandemic vaccine before
we provide seasonal influenza efficacy data. If our seasonal influenza vaccine does not get accelerated approval from the FDA,
it is likely that we will need to conduct larger and more expensive efficacy clinical trials and that licensure of our seasonal
vaccine will be materially delayed for a year or more, assuming such licensure occurs at all, which may, in turn, delay the FDA
approval of our pandemic vaccine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Because of changes
to the influenza vaccine industry and regulatory environment, accelerated approval by the FDA of our seasonal influenza vaccine
candidate may not be available in which case development of this vaccine will take longer and cost significantly more prior to
BLA approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While FDA regulations
allow for the accelerated approval of a seasonal influenza vaccine based on surrogate endpoint criteria for products that treat
serious diseases and fill an unmet medical need, which can allow developers to obtain licensure well ahead of the timeline for
demonstrating clinical results in a traditional efficacy trial, the seasonal influenza vaccine industry has made significant steps
to provide sufficient supply to the recommended population in the U.S. Thus, the FDA may no longer view the development of our
seasonal influenza vaccine as meeting an unmet medical need. If our seasonal influenza vaccine does not receive accelerated approval
from the FDA, we will need to conduct larger and more expensive efficacy clinical trials and that licensure of our seasonal vaccine
will be materially delayed for a year or more, assuming such licensure occurs at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our recent acquisition
of Novavax AB, collaborations with regional partners, such as Cadila, LGLS, and PATH, as well as contracts with international providers,
expose us to additional risks associated with doing business outside the U.S., and any adverse event could have a material negative
impact on our operations. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We acquired Novavax
AB on July 31, 2013. We have also formed a joint venture with Cadila in India, entered into a license agreement with LGLS in South
Korea, a clinical development agreement with PATH and have entered into other agreements and arrangements with companies in other
countries. We plan to continue to enter into collaborations or partnerships with companies, non-profit organizations and local
governments in other parts of the world. Risks of conducting business outside the U.S. include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">multiple regulatory requirements could affect our ability to develop, manufacture and sell products
in such local markets;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">compliance with anti-bribery laws such as the United States Foreign Corrupt Practices Act and similar
anti-bribery laws in other jurisdictions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">trade protections measures and import and export licensing requirements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">different labor regulations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">changes in environmental, health and safety laws;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">exchange rates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">potentially negative consequences from changes in or interpretations of tax laws;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">political instability and actual or anticipated military or potential conflicts;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">economic instability, inflation, recession and interest rate fluctuations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">minimal or diminished protection of intellectual property in some countries; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify; padding-bottom: 1pt">possible nationalization and expropriation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These risks, individually
or in the aggregate, could have a material adverse effect on our business, financial conditions, results of operations and cash
flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our business
may be adversely affected if we do not successfully execute our business development initiatives.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate growing
through both internal development projects, as well as external opportunities, which include the acquisition, partnering and in-licensing
of products, technologies and companies or the entry into strategic alliances and collaborations. The availability of high quality
opportunities is limited, and we may fail to identify candidates that we and our stockholders consider suitable or complete transactions
on terms that prove advantageous. In order to pursue such opportunities, we may require significant additional financing, which
may not be available to us on favorable terms, if at all. Even if we are able to successfully identify and complete acquisitions,
like our business combination with Novavax AB, we may not be able to integrate the assets or take full advantage of the opportunities
and, consequently, may not realize the benefits that we expect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To effectively manage
our current and future potential growth, we will need to continue to enhance our operational, financial and management processes
and to effectively expand, train and manage our employee base. Supporting our growth initiatives will require significant expenditures
and management resources, including investments in research and development, manufacturing and other areas of our business. If
we do not successfully manage our growth and do not successfully execute our growth initiatives, then our business and financial
results may be adversely impacted, and we may incur asset impairment or restructuring charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RISKS RELATED TO OUR ACQUISITION OF
NOVAVAX AB</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We may not be
able to successfully integrate our business with the business of Novavax AB. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The acquisition of
Novavax AB involves the integration of two companies based in different countries that had been operating independently. This integration
will be a complex, costly and time-consuming process. We may encounter difficulties in integrating our operations, technology and
personnel with those of Novavax AB and this may continue for some time. Our management has limited experience integrating operations
as substantial and geographically diverse as those of Novavax AB. We may not successfully integrate our operations and Novavax
AB's operations in a timely manner, or at all. The failure to successfully integrate the businesses' operations could adversely
affect our business, financial condition and results of operations. The anticipated benefits relate to utilizing Novavax AB's proprietary
adjuvants, including Matrix-M, with one or more of Novavax' product candidates and retaining the full economics and developmental
control of these adjuvanted vaccines, as well as other opportunities resulting from Novavax' and Novavax AB's complementary product
candidates, industry specialties and technology platforms. However, these anticipated benefits are based on projections and assumptions,
not actual experience, and assume a successful integration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>As a result of
the combination with Novavax AB, we may face risks upon entering into certain specific areas of vaccine development for which we
have limited or no experience. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Novavax AB develops
adjuvants in veterinary vaccines. The development and improvement of vaccines for the global veterinary market is an area of vaccine
development for which we have limited or no experience. Although comprising a small part of our business, this lack of experience
may have a negative impact to operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Novavax AB adjuvants,
including Matrix-M, may prove to have limited or no benefit to our vaccine development programs. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot guarantee
that Matrix-M, or any other of Novavax AB's saponin-based adjuvants, will offer immunogenic benefits to any of our vaccine programs
until such adjuvants are tested in clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We may not be
able to achieve the anticipated strategic benefits of our recent combination with Novavax AB. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not able to
guarantee that anticipated strategic benefits from the completed acquisition of Novavax AB, including cost savings from operational
activities, will be realized within the time periods contemplated or that they will be realized at all. We are not able to guarantee
that the combination of Novavax and Novavax AB will result in the realization of the full benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Adjuvants, including
saponin-based adjuvants such as Matrix-M, are likely to face increased regulatory scrutiny and may prove to be unpopular with vaccine-using
consumers and advocacy groups. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory agencies,
including the FDA, have been cautious in approving adjuvants for use in commercial vaccines. Recent reports on adjuvants that contain
squalene, a commercially extracted adjuvant derived from shark liver oil, as an active ingredient, and links to neurological disorders
like narcolepsy may cause regulatory agencies to increase their scrutiny of all adjuvants, whether they contain squalene or not.
Although none of the adjuvants made by Novavax AB contain squalene, the impact of such regulatory scrutiny may be detrimental to
vaccine products containing non-squalene adjuvants. In addition, adjuvant usage has been unpopular with a small group of vaccine
advocacy and consumer groups who oppose the addition of further active ingredients in vaccines; their opposition may gain support
and have a detrimental impact on commercialization efforts and opportunities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>As a result of
the acquisition of Novavax AB, we will have revenue and expenses outside of the U.S., so we will be subject to fluctuations in
foreign currency rates, and if our management is unable to manage our exposure to foreign currencies successfully, our operating
results will suffer. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the acquisition
of Novavax AB, we will be exposed to risks associated with the translation of Novavax AB's Swedish Krona (SEK)-denominated financial
results and balance sheet into U.S. dollars. Our reporting currency will remain as the U.S. dollar. Any inability to successfully
manage fluctuations in foreign currency rates could have a material adverse effect on our results of operations and, as a result,
on the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The uncertainties
associated with our combination with Novavax AB may cause key personnel to leave. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our employees, including
the employees of Novavax AB, may perceive uncertainty about their future role with the combined business until strategies with
regard to the combined business are fully executed. Any uncertainty may affect either our ability to retain key scientific, management
or operational personnel. Novavax AB's technology is based, in part, on trade secret and know-how, so if we are not able to retain
key technical employees, we might have difficulties in continuing to develop and maintain Novavax AB's proprietary adjuvants, which
may impede the achievement of our objectives with this acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PRODUCT DEVELOPMENT RISKS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We have not completed
the development of vaccine products and we may not succeed in obtaining the FDA approval necessary to sell such vaccine products.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The development, manufacture
and marketing of our pharmaceutical and biological products are subject to government regulation in the U.S. and other countries,
including the European Medicines Agency and the Swedish Medical Products Agency with respect to our adjuvant product being developed
in Sweden. In the U.S. and most foreign countries, we must complete rigorous pre-clinical testing and extensive clinical trials
that demonstrate the safety and efficacy of a product in order to apply for regulatory approval to market the product. None of
our vaccine candidates have yet gained regulatory approval in the U.S. or elsewhere. We also have vaccine candidates in clinical
trials and pre-clinical laboratory or animal studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The steps required
by the FDA before our proposed investigational products may be marketed in the U.S. include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">performance of pre-clinical (animal and laboratory) tests;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">submissions to the FDA of an IND, which must become effective before clinical trials may commence;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">performance of adequate and well-controlled clinical trials to establish the safety and efficacy
of the investigational product in the intended target population;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">performance of a consistent and reproducible manufacturing process intended for commercial use,
including appropriate manufacturing data and regulatory inspections;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">submission to the FDA of a BLA or a NDA; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">FDA approval of the BLA or NDA before any commercial sale or shipment of the product.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The processes are expensive
and can take many years to complete, and we may not be able to demonstrate the safety and efficacy of our vaccine candidates to
the satisfaction of regulatory authorities. The start of clinical trials can be delayed or take longer than anticipated for many
and varied reasons, many of which are out of our control. Safety concerns may emerge that could lengthen the ongoing clinical trials
or require additional clinical trials to be conducted. Promising results in early clinical trials may not be replicated in subsequent
clinical trials. Regulatory authorities may also require additional testing, and we may be required to demonstrate that our proposed
products represent an improved form of treatment over existing therapies, which we may be unable to do without conducting further
clinical trials. Moreover, if the FDA or a foreign regulatory body grants regulatory approval of a product, the approval may be
limited to specific indications or limited with respect to its distribution. Expanded or additional indications for approved products
may not be approved, which could limit our revenue. Foreign regulatory authorities may apply similar limitations or may refuse
to grant any approval. Consequently, even if we believe that pre-clinical and clinical data are sufficient to support regulatory
approval for our vaccine candidates, the FDA and foreign regulatory authorities may not ultimately grant approval for commercial
sale in any jurisdiction. If our vaccine candidates are not approved, our ability to generate revenue will be limited and our business
will be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We may not be
able to secure sufficient supplies of a key component of our adjuvant technology. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because an important
component of our recently acquired adjuvant technology is extracted from trees (Quillaja saponins) grown in Chile, we need to establish
long term access to Quillaja extract with a consistent and sufficiently high quality. We will need to find partners and make investments
to secure the supply of raw material or the introduction of products may be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We expect to
continue to use all of our current manufacturing facility; however, if we choose not to do so, we may not be able to defray the
lease payments and operating expenses of that facility. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With our new late-stage
and commercial launch manufacturing facility in Gaithersburg, Maryland, we have the opportunity to continue to fully utilize our
current facility in Rockville, Maryland to develop early-stage clinical material and perform other pilot manufacturing activities.
Although we expect to utilize the entire Rockville facility, depending on our needs, we may decide to sublease a portion or all
of the Rockville facility prior to the end of our lease on January 31, 2017. Further, while we have structured our new facility
arrangement to limit our financial exposure over the next five months, the expenses of leasing two manufacturing facilities are
significant. If we decide to sublease a portion or all of the Rockville facility, such a sublease may prove difficult to obtain
and even if we are able to do so, the sublease payments may not cover our lease payments and operating expenses for the space that
we would sublet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item&nbsp;6. Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Exhibits marked with
a single asterisk (*) are filed herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding: 0; text-align: right; text-indent: 0"><FONT STYLE="font-size: 10pt; color: black">3.1</FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 90%; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt; color: black">Amended and Restated Certificate of Incorporation of Novavax, Inc., as amended by Certificates of Amendment dated December 18, 2000, July 8, 2004, May 13, 2009 and June 13, 2013 (Incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: right; text-indent: 0"><FONT STYLE="font-size: 10pt; color: black">3.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt; color: black">Amended and Restated By-Laws of the Company (Incorporated by reference to Exhibit 3.2 to the Company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2012)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: right; text-indent: 0"><FONT STYLE="font-size: 10pt; color: black">10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt; color: black">Amendment No. 3 to Master Services Agreement between Novavax, Inc. and Cadila Pharmaceuticals Ltd. Dated October 29, 2013 (Incorporated by reference to Exhibit 1.1 to the Company&rsquo;s Report on Form 8-K dated October 30, 2013)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: right; text-indent: 0"><FONT STYLE="font-size: 10pt; color: black">31.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt; color: black">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(e) of the Securities Exchange Act </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: right; text-indent: 0"><FONT STYLE="font-size: 10pt; color: black">31.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt; color: black">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(e) of the Securities Exchange Act&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: right; text-indent: 0"><FONT STYLE="font-size: 10pt; color: black">32.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt; color: black">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: right; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: right; text-indent: 0"><FONT STYLE="font-size: 10pt; color: black">32.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt; color: black">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 49%; padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>NOVAVAX, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Date: November 12, 2013</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">By: &nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/
    Stanley C. Erck</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">and Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Date: November 12, 2013</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/
    Barclay A. Phillips</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Senior Vice President, Chief Financial Officer and Treasurer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; text-align: justify; padding-top: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 39; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>v358320_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Stanley C. Erck, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&#9;I have reviewed this Quarterly Report
on Form 10-Q of Novavax, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&#9;Based on my knowledge, this report
does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&#9;Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&#9;The registrant&rsquo;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and we have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">a) designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">b) designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">c) evaluated the effectiveness of the
registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">d) disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most
recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.&#9;The registrant&rsquo;s other certifying
officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">a)&#9;all significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">b)&#9;
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Date: November 12, 2013</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Stanley C. Erck</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>v358320_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL
AND ACCOUNTING OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Barclay A. Phillips, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. I have reviewed this Quarterly Report
on Form 10-Q of Novavax, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. The registrant&rsquo;s other certifying
officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and we have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">a) designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">b) designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">c) evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">d) disclosed in this report any
change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or
is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. The registrant&rsquo;s other certifying
officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">a) all significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0; padding-left: 0; text-align: justify; padding-top: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Date: November 12, 2013</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-right: 0; padding-left: 0; text-align: justify; padding-top: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; padding-right: 0; padding-left: 0; text-align: justify; padding-top: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Barclay A. Phillips</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Senior Vice President, Chief Financial Officer and Treasurer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: -3in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>v358320_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO 18 UNITED STATES C. &sect;1350<BR>
(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Quarterly Report of Novavax, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the fiscal period ended September 30, 2013 as
filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Stanley C. Erck, President
and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to Section&nbsp;906
of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT>The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT>The information contained in the Report fairly presents, in all material respects, the financial condition and results of
operations of the Company for the dates and periods covered by this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0; padding-left: 0; text-align: justify; padding-top: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Date: November 12, 2013</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-right: 0; padding-left: 0; text-align: justify; padding-top: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; padding-right: 0; padding-left: 0; text-align: justify; padding-top: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/
    Stanley C. Erck</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; padding-top: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0; padding-left: 0; text-align: justify; padding-top: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>v358320_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL
AND ACCOUNTING OFFICER PURSUANT TO 18 UNITED STATES C. &sect;1350<BR>
(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Quarterly Report of Novavax, Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the fiscal period ended September 30, 2013 as
filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Barclay A. Phillips, Senior
Vice President, Chief Financial Officer and Treasurer, hereby certify, pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to
Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">1) The Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">2) The information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the
dates and periods covered by this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Date: November 12, 2013</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; padding: 0; text-indent: 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Barclay A. Phillips</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Senior Vice President, Chief Financial Officer and Treasurer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>nvax-20130930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-11-12 @ 6:50 AM-->
<xbrl xmlns:country="http://xbrl.sec.gov/country/2012-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nvax="http://www.novavax.com/20130930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="nvax-20130930.xsd" />
  <dei:AmendmentFlag id="AmendmentFlag.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="CurrentFiscalYearEndDate.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus id="DocumentFiscalPeriodFocus.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="DocumentFiscalYearFocus.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate id="DocumentPeriodEndDate.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">2013-09-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType id="DocumentType.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey id="EntityCentralIndexKey.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">0001000694</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding id="EntityCommonStockSharesOutstanding.3662.0.0.0.0.0.0" contextRef="as-of-2013-10-31.3662.0.0.0.0.0.0.0" unitRef="shares" decimals="0">208510739</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityFilerCategory id="EntityFilerCategory.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName id="EntityRegistrantName.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">NOVAVAX INC</dei:EntityRegistrantName>
  <dei:TradingSymbol id="TradingSymbol.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">NVAX</dei:TradingSymbol>
  <nvax:AcquisitionOfIsconovaAbTextBlock id="AcquisitionOfIsconovaAbTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Note 4 - Acquisition of Isconova AB&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &lt;font style="COLOR: windowtext"&gt;On July 31, 2013 (the "acquisition date"), Novavax announced the acquisition of Isconova (the "Acquisition") pursuant to its public tender offer to acquire all outstanding shares and warrants of the company directly from such holders and its private offer for all of Isconova&amp;#39;s outstanding stock options.&lt;/font&gt; As a result of the public offer for shares and warrants and private offer for stock options, Novavax issued approximately 15.6 million shares of its Common Stock valued at $41.9 million and paid cash of approximately $22,000 to acquire 99.5% of the outstanding shares and all of the outstanding stock options and warrants of Is&lt;font style="COLOR: windowtext"&gt;conova. On September 6, 2013, Isconova AB was renamed "Nov&lt;/font&gt;avax AB" and was delisted as a publicly traded company in Sweden. This transaction has been accounted for using the purchase method of accounting, with Novavax as the acquirer. The results of Novavax AB&amp;#39;s operations have been included in the consolidated financial statements since the acquisition date. &lt;font style="COLOR: windowtext"&gt;For the three months ended September 30, 2013, the minority interest in Novavax AB&amp;#39;s net loss and stockholders&amp;#39; equity is immaterial.&lt;/font&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt; COLOR: windowtext"&gt;Novavax AB has focused its recent efforts on the development of saponin-based, immune-modulating adjuvants that work with different types of vaccine antigens to enhance the immunogenic effect of the antigen. Novavax AB has collaborated with several vaccine companies to allow its lead adjuvant, Matrix-M&amp;trade;, to be tested with a number of antigens in development; the Company has recently begun development work pairing the Novavax AB adjuvant with its own pandemic influenza VLP antigen. The Company believes that the Novavax AB adjuvants can be powerful complements to certain of its recombinant vaccine programs and will enable future discovery efforts and potentially reduce vaccine development timeframes and costs both by eliminating the need to in-license third-party adjuvants and related costs and by harmonizing operating and regulatory processes.&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The total purchase price is summarized as follows (in thousands):&lt;/font&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; WIDTH: 86%"&gt;Value of shares of Novavax Common Stock issued&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 41,942&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Cash paid to Isconova warrant holders&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 22&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"&gt; Total purchase price&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 41,964&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The value of Novavax Common Stock issued is based on the closing price of Novavax&amp;#39; Common Stock on the acquisition date.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The table below summarizes the preliminary allocation of the purchase price based upon the fair values of assets acquired and liabilities assumed at the acquisition date. The preliminary allocation is based upon information that was available to management at the time the consolidated financial statements were prepared. Accordingly, the allocation may change.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;(in thousands)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 86%"&gt; Cash and cash equivalents&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 3,056&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Accounts receivable&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;603&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Prepaid expenses and other assets&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;1,092&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Property and equipment&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;165&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Intangible assets&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;16,380&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px"&gt;Goodwill&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;25,298&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Accounts payable and other current liabilities&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;(2,784&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Capital leases&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;(94&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Notes payable&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;(193&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Other non-current liabilities&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (1,559&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"&gt; Total purchase price&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 41,964&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; A substantial portion of the assets acquired from Isconova consisted of intangible assets relating to its proprietary adjuvant technology and collaboration agreements. The preliminary fair values of the proprietary technology and agreements were determined based on estimates of expected future net cash flows. The present value of future net cash flows was then determined utilizing an estimate of the appropriate discount rate, which is consistent with the uncertainties of the cash flows utilized. The fair value measurements are based on significant unobservable inputs that were developed by the Company using publicly available information, market participant assumptions, cost and development assumptions, expected synergies and other cost savings that a market participant would be expected to realize as a result of the combination and certain other high-level assumptions. The proprietary technology is amortized over its estimated remaining useful life based on the Company&amp;#39;s expected future net cash flows. The agreements are amortized over the estimated periods of expected future net cash flows. Amortization expense for intangible assets will be recorded on a straight-line basis over the expected useful lives of the assets, ranging from seven to 20 years. The carrying value and expected lives of the intangible assets may change based upon finalizing the purchase price allocation, and such intangibles will be periodically reviewed to determine if the facts and circumstances suggest that a potential impairment may have occurred. Impairment charges, if any, will be recorded in the period in which the impairment occurs.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The Company recorded $25.3 million in goodwill related to the Acquisition representing the purchase price paid in the Acquisition that was in excess of the fair value of the assets acquired and liabilities assumed, which is included in the Company&amp;#39;s vaccine operations because of the anticipated complementary use of Novavax AB adjuvants with its vaccine candidates discussed above. The goodwill generated from the Acquisition is expected to be deductible for U.S. federal income tax purposes.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The Company incurred approximately $1.3 million in transaction costs related to the Acquisition, which is included in general and administrative expenses in the Company&amp;#39;s consolidated statement of operations.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; From the acquisition date to September 30, 2013, the Company has recognized revenue of $0.4 million and recorded a net loss of $1.5 million from the operations of Novavax AB.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The following unaudited consolidated pro forma financial information is presented as if the Acquisition occurred on January 1, 2012. The unaudited pro forma financial information has been presented for comparative purposes only and is not necessarily indicative of results of operations that would have been achieved had the Company completed the Acquisition during the periods presented, or the future consolidated results of operations of the combined company. The unaudited pro forma financial information combines the historical results of operations of Novavax and Isconova for the periods presented below and reflects the application of the following adjustments:&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-FAMILY: Symbol; WIDTH: 0.25in"&gt;&amp;middot;&lt;/td&gt; &lt;td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"&gt; Elimination of the historical intangible assets and amortization expense unrelated to the Acquisition;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-FAMILY: Symbol; WIDTH: 0.25in"&gt;&amp;middot;&lt;/td&gt; &lt;td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"&gt; Amortization expense related to the fair value of intangible assets acquired; and&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-FAMILY: Symbol; WIDTH: 0.25in"&gt;&amp;middot;&lt;/td&gt; &lt;td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"&gt; The exclusion of acquisition-related costs incurred for the Acquisition.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Three Months Ended&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Nine Months Ended&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="14"&gt;(in thousands)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; WIDTH: 44%"&gt; Revenue&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; 4,869&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; 6,272&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; 14,195&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; 19,530&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Net loss&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; (15,687&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; (8,490&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; (40,565&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; (25,033&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Basic and diluted net loss per share&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"&gt; (0.09&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"&gt; )&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"&gt; (0.06&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"&gt; )&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"&gt; (0.24&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"&gt; )&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"&gt; (0.18&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"&gt; )&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Novavax AB has an operating lease for its facility that expires in 2017. As of September 30, 2013, the aggregate remaining rental payments due under this operating lease commitment was approximately $1.9 million.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</nvax:AcquisitionOfIsconovaAbTextBlock>
  <nvax:AcquisitionTransactionCosts id="AcquisitionTransactionCosts.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1300000</nvax:AcquisitionTransactionCosts>
  <nvax:AdditionalTenantImprovementAllowance id="AdditionalTenantImprovementAllowance.2675.0.0.0.0.0.0" contextRef="as-of-2011-11-30.2675.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3000000</nvax:AdditionalTenantImprovementAllowance>
  <nvax:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted id="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">-0.24</nvax:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted>
  <nvax:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted id="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">-0.18</nvax:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted>
  <nvax:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted id="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">-0.09</nvax:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted>
  <nvax:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted id="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">-0.06</nvax:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted>
  <nvax:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill id="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.3676.0.0.0.0.0.0" contextRef="as-of-2013-07-31.3676.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25298000</nvax:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill>
  <nvax:CapitalLeaseObligationEquipmentPurchased id="CapitalLeaseObligationEquipmentPurchased.2663.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <nvax:CapitalLeaseObligationEquipmentPurchased id="CapitalLeaseObligationEquipmentPurchased.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">399000</nvax:CapitalLeaseObligationEquipmentPurchased>
  <nvax:ClinicalTrialCostsIncurred id="ClinicalTrialCostsIncurred.2682.23929.5386.0.0.0.0" contextRef="from-2012-03-01-to-2013-09-30.2682.0.23929.5386.0.0.0.0" unitRef="USD" decimals="-3">2900000</nvax:ClinicalTrialCostsIncurred>
  <nvax:CommonSharesPerUnit id="CommonSharesPerUnit.2673.0.0.0.0.0.0" contextRef="as-of-2008-07-31.2673.0.0.0.0.0.0.0" unitRef="shares" decimals="0">1</nvax:CommonSharesPerUnit>
  <nvax:CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement id="CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement.2663.3373.4365.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.3373.4365.0.0.0.0" unitRef="USD" decimals="-3">50000000</nvax:CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement>
  <nvax:ContractTerm id="ContractTerm.2680.23929.5386.0.0.0.0" contextRef="from-2011-02-01-to-2011-02-28.2680.0.23929.5386.0.0.0.0">P3Y</nvax:ContractTerm>
  <nvax:ContractTerm id="ContractTerm.2680.23930.5386.0.0.0.0" contextRef="from-2011-02-01-to-2011-02-28.2680.0.23930.5386.0.0.0.0">P2Y</nvax:ContractTerm>
  <nvax:DepositsForAcquisitionOfPropertyAndEquipment id="DepositsForAcquisitionOfPropertyAndEquipment.2663.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <nvax:DepositsForAcquisitionOfPropertyAndEquipment id="DepositsForAcquisitionOfPropertyAndEquipment.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">500000</nvax:DepositsForAcquisitionOfPropertyAndEquipment>
  <nvax:HalfPaymentForPortionOfShortfallExceedingTwoMillion id="HalfPaymentForPortionOfShortfallExceedingTwoMillion.2663.31352.4540.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.31352.4540.0.0.0.0" unitRef="USD" decimals="-3">2000000</nvax:HalfPaymentForPortionOfShortfallExceedingTwoMillion>
  <nvax:JointVenturePercentageOwnedByOthers id="JointVenturePercentageOwnedByOthers.2664.23927.4820.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.23927.4820.0.0.0.0" unitRef="pure" decimals="1">0.8</nvax:JointVenturePercentageOwnedByOthers>
  <nvax:LoanAgreementFutureMinimumPaymentsDue id="LoanAgreementFutureMinimumPaymentsDue.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1681000</nvax:LoanAgreementFutureMinimumPaymentsDue>
  <nvax:LoanAgreementFutureMinimumPaymentsDueInYearThree id="LoanAgreementFutureMinimumPaymentsDueInYearThree.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">396000</nvax:LoanAgreementFutureMinimumPaymentsDueInYearThree>
  <nvax:LoanAgreementFutureMinimumPaymentsDueInYearTwo id="LoanAgreementFutureMinimumPaymentsDueInYearTwo.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">571000</nvax:LoanAgreementFutureMinimumPaymentsDueInYearTwo>
  <nvax:LoanAgreementFutureMinimumPaymentsNextTwelveMonths id="LoanAgreementFutureMinimumPaymentsNextTwelveMonths.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">571000</nvax:LoanAgreementFutureMinimumPaymentsNextTwelveMonths>
  <nvax:LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear id="LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">143000</nvax:LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear>
  <nvax:MasterServiceAgreement id="MasterServiceAgreement.4008.3373.4365.31352.4540.0.0" contextRef="from-2009-03-31-to-2013-09-30.4008.0.3373.4365.31352.4540.0.0" unitRef="USD" decimals="-3">7500000</nvax:MasterServiceAgreement>
  <nvax:MasterServicesAgreementWithCadilaTextBlock id="MasterServicesAgreementWithCadilaTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; Note 14 &lt;font style="FONT-WEIGHT: normal"&gt;-&lt;/font&gt; Master Services Agreement with Cadila&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; In connection with the JV with Cadila, the Company entered into a master services agreement, which the Company and Cadila amended in July 2011, and subsequently in March 2013, in each case to extend the term by one year for which services can be provided by Cadila under this agreement. Under the revised terms, if by March 2014, the amount of services provided by Cadila under the master services agreement is less than $7.5 million, the Company will pay Cadila the portion of the shortfall amount that is less than or equal to $2.0 million and 50% of the portion of the shortfall amount that exceeds $2.0 million. Through September 30, 2013, the Company has purchased $2.4 million in services from Cadila pursuant to this agreement, which includes $0.8 million of services provided, since the beginning of 2013, by CPLB to the Company on behalf of Cadila pursuant to an October 2013 amendment authorizing such CPLB services. The Company plans to explore with Cadila ways to potentially address its remaining financial obligation and/or extend the time period during which the Company could utilize such services. The Company can provide no assurance, however, that these efforts will be successful. If the Company fails to negotiate a change in this arrangement, the Company expects that it will be obligated to spend a portion of its available cash and cash equivalents to pay Cadila for its shortfall in services purchased.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</nvax:MasterServicesAgreementWithCadilaTextBlock>
  <nvax:NewFacilityLeaseDisclosureTextBlock id="NewFacilityLeaseDisclosureTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; Note 13 - Manufacturing, Laboratory and Office Facility&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The Company leases its new manufacturing, laboratory and office space in Gaithersburg, Maryland with rent payments for such space to the landlord commencing April 1, 2014. Under the terms of one lease agreement, the landlord provided the Company with a tenant improvement allowance of $2.5 million and an additional tenant improvement allowance of $3 million, such additional tenant improvement allowance is to be paid back to the landlord during the remainder of the term of such lease agreement through additional rent payments (collectively, the "Improvement Allowance"). The Company has been funded $0.7 million in the nine months ended September 30, 2013, and has been funded $5.0 million in total under the Improvement Allowance. The Improvement Allowance is being amortized on a straight-line basis over the remaining term of the lease.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</nvax:NewFacilityLeaseDisclosureTextBlock>
  <nvax:NovavaxSharesIssued id="NovavaxSharesIssued.2677.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-07-31.2677.0.0.0.0.0.0.0" unitRef="shares" decimals="0">15600000</nvax:NovavaxSharesIssued>
  <nvax:OperationsDisclosureTextBlock id="OperationsDisclosureTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; Note 2 - Operations&lt;/p&gt; &lt;p style="FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The Company&amp;#39;s vaccine candidates, some of which may include an adjuvant, currently under development will require significant additional research and development efforts that include extensive pre-clinical and clinical testing, and regulatory approval prior to commercial use.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; As a clinical-stage biopharmaceutical company, the Company has primarily funded its operations from proceeds through the sale of its common stock in equity offerings and revenue under its contract with the Department of Health and Human Services, Biomedical Advanced Research and Development Authority ("HHS BARDA"). Management regularly reviews the Company&amp;#39;s cash and cash equivalents and investments against its operating budget to ensure the Company will have sufficient working capital, and will continue to draw upon such available sources of capital to meet its product development activities.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</nvax:OperationsDisclosureTextBlock>
  <nvax:PaymentToRelatedPartyPortionOfShortfall id="PaymentToRelatedPartyPortionOfShortfall.2663.3373.4365.31352.4540.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.3373.4365.31352.4540.0.0" unitRef="USD" decimals="-3">2000000</nvax:PaymentToRelatedPartyPortionOfShortfall>
  <nvax:ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses id="ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">600000</nvax:ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses>
  <nvax:ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses id="ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">200000</nvax:ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses>
  <nvax:ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities id="ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">800000</nvax:ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities>
  <nvax:ResearchAndDevelopmentCollaboration id="ResearchAndDevelopmentCollaboration.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1182000</nvax:ResearchAndDevelopmentCollaboration>
  <nvax:ResearchAndDevelopmentCollaboration id="ResearchAndDevelopmentCollaboration.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">182000</nvax:ResearchAndDevelopmentCollaboration>
  <nvax:ResearchAndDevelopmentCollaboration id="ResearchAndDevelopmentCollaboration.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">534000</nvax:ResearchAndDevelopmentCollaboration>
  <nvax:ResearchAndDevelopmentCollaboration id="ResearchAndDevelopmentCollaboration.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">182000</nvax:ResearchAndDevelopmentCollaboration>
  <nvax:ResearchAndDevelopmentCollaboration id="ResearchAndDevelopmentCollaboration.2663.23945.5386.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23945.5386.0.0.0.0" unitRef="USD" decimals="-3">700000</nvax:ResearchAndDevelopmentCollaboration>
  <nvax:ResearchAndDevelopmentCollaboration id="ResearchAndDevelopmentCollaboration.2683.23945.5386.0.0.0.0" contextRef="from-2012-07-01-to-2012-07-31.2683.0.23945.5386.0.0.0.0" unitRef="USD" decimals="-3">2000000</nvax:ResearchAndDevelopmentCollaboration>
  <nvax:ResearchAndDevelopmentCollaboration id="ResearchAndDevelopmentCollaboration.2685.23945.5386.0.0.0.0" contextRef="from-2012-07-01-to-2013-09-30.2685.0.23945.5386.0.0.0.0" unitRef="USD" decimals="-3">2000000</nvax:ResearchAndDevelopmentCollaboration>
  <nvax:ResearchAndDevelopmentCollaborationIncrease id="ResearchAndDevelopmentCollaborationIncrease.2684.23945.5386.0.0.0.0" contextRef="as-of-2013-08-31.2684.0.23945.5386.0.0.0.0" unitRef="USD" decimals="-3">400000</nvax:ResearchAndDevelopmentCollaborationIncrease>
  <nvax:ScheduleOfPurchasePriceTableTextBlock id="ScheduleOfPurchasePriceTableTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The total purchase price is summarized as follows (in thousands):&lt;/font&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; WIDTH: 86%"&gt;Value of shares of Novavax Common Stock issued&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 41,942&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Cash paid to Isconova warrant holders&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 22&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"&gt; Total purchase price&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 41,964&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</nvax:ScheduleOfPurchasePriceTableTextBlock>
  <nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock id="ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The following is a summary of restricted stock awards activity for the nine months ended September 30, 2013:&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Per Share Weighted-Average Grant-Date&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Fair Value&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 72%"&gt; Outstanding and Unvested at January 1, 2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 33,334&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 1.39&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Restricted stock granted&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Restricted stock vested&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Restricted stock forfeited&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Outstanding and Unvested at September 30, 2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 33,334&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1.39&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</nvax:ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock>
  <nvax:ServicesProvidedDuringThePeriod id="ServicesProvidedDuringThePeriod.2663.31352.4540.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.31352.4540.0.0.0.0" unitRef="USD" decimals="-3">800000</nvax:ServicesProvidedDuringThePeriod>
  <nvax:ServicesPurchased id="ServicesPurchased.4008.31352.4540.0.0.0.0" contextRef="from-2009-03-31-to-2013-09-30.4008.0.31352.4540.0.0.0.0" unitRef="USD" decimals="-3">2400000</nvax:ServicesPurchased>
  <nvax:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate id="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="pure" decimals="4">0.2315</nvax:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
  <nvax:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate id="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="pure" decimals="4">0.2315</nvax:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
  <nvax:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate id="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.2663.3382.4365.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.3382.4365.0.0.0.0" unitRef="pure" decimals="0">0</nvax:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
  <nvax:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate id="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.2666.3382.4365.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.3382.4365.0.0.0.0" unitRef="pure" decimals="0">0</nvax:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
  <nvax:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate id="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.2663.3373.4365.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.3373.4365.0.0.0.0" unitRef="pure" decimals="4">0.2315</nvax:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
  <nvax:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate id="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.2666.3373.4365.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.3373.4365.0.0.0.0" unitRef="pure" decimals="4">0.2315</nvax:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
  <nvax:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate id="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.2667.1806.1391.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.1806.1391.0.0.0.0" unitRef="pure" decimals="2">0.05</nvax:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
  <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.2663.23962.4031.3382.4365.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23962.4031.3382.4365.0.0">P6M</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant>
  <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.2663.23962.4031.3373.4365.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23962.4031.3373.4365.0.0">P4Y</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant>
  <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.2663.23942.4031.3382.4365.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23942.4031.3382.4365.0.0">P6M</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant>
  <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.2663.23942.4031.3373.4365.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23942.4031.3373.4365.0.0">P4Y</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant>
  <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent.2664.23962.4031.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.23962.4031.0.0.0.0" unitRef="pure" decimals="0">1</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent>
  <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent.2664.23942.4031.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.23942.4031.0.0.0.0" unitRef="pure" decimals="0">1</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent>
  <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.2663.23962.4031.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23962.4031.0.0.0.0">P10Y</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm>
  <nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.2663.23942.4031.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23942.4031.0.0.0.0">P10Y</nvax:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm>
  <nvax:StockWarrantsTextBlock id="StockWarrantsTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; Note 12 - Warrant Liability&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.55in"&gt; In July 2008, the Company completed a registered direct offering of 6,686,650 units, raising approximately $17.5 million in net proceeds. Each unit consisted of one share of common stock and a warrant to purchase 0.5 shares of common stock (the "Warrants") at a price of $2.68 per unit. The Warrants represent the right to acquire an aggregate of 3,343,325 shares of common stock at an exercise price of $3.62 per share and were exercisable between January 31, 2009 and July 31, 2013.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.55in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.55in"&gt; &lt;font style="COLOR: black"&gt;During the nine months ended September 30, 2013 and 2012, the Company recorded as other income (expense)&lt;/font&gt; in its consolidated statements of operations &lt;font style="COLOR: black"&gt;a change in fair value of warrant liability of $0.3 million and ($0.4) million, respectively. All Warrants expired unexercised on July 31, 2013.&lt;/font&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.55in"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</nvax:StockWarrantsTextBlock>
  <nvax:TenantImprovementAllowance id="TenantImprovementAllowance.2675.0.0.0.0.0.0" contextRef="as-of-2011-11-30.2675.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2500000</nvax:TenantImprovementAllowance>
  <nvax:UpfrontLicensePayment id="UpfrontLicensePayment.2679.23933.5386.0.0.0.0" contextRef="as-of-2011-02-28.2679.0.23933.5386.0.0.0.0" unitRef="USD" decimals="-3">2500000</nvax:UpfrontLicensePayment>
  <us-gaap:AccountsPayableCurrent id="AccountsPayableCurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3339000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="AccountsPayableCurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3228000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1911000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1011000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="AccretionAmortizationOfDiscountsAndPremiumsInvestments.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-326000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="AccretionAmortizationOfDiscountsAndPremiumsInvestments.2666.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AccruedLiabilitiesCurrent id="AccruedLiabilitiesCurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">9553000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="AccruedLiabilitiesCurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7275000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="AccumulatedOtherComprehensiveIncomeLossNetOfTax.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1113000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="AccumulatedOtherComprehensiveIncomeLossNetOfTax.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">430000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife id="AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife.2663.3382.4365.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.3382.4365.0.0.0.0">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
  <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife id="AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife.2663.3373.4365.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.3373.4365.0.0.0.0">P20Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
  <us-gaap:AdditionalPaidInCapital id="AdditionalPaidInCapital.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">611913000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital id="AdditionalPaidInCapital.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">438939000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2663.4573.2652.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.4573.2652.0.0.0.0" unitRef="USD" decimals="-3">829000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2666.4573.2652.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.4573.2652.0.0.0.0" unitRef="USD" decimals="-3">638000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2667.4573.2652.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.4573.2652.0.0.0.0" unitRef="USD" decimals="-3">316000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2668.4573.2652.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.4573.2652.0.0.0.0" unitRef="USD" decimals="-3">219000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2663.2476.2652.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.2476.2652.0.0.0.0" unitRef="USD" decimals="-3">955000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2666.2476.2652.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.2476.2652.0.0.0.0" unitRef="USD" decimals="-3">1030000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2667.2476.2652.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.2476.2652.0.0.0.0" unitRef="USD" decimals="-3">347000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2668.2476.2652.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.2476.2652.0.0.0.0" unitRef="USD" decimals="-3">274000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1784000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1668000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">663000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">493000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfIntangibleAssets id="AmortizationOfIntangibleAssets.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">200000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets id="AmortizationOfIntangibleAssets.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="shares" decimals="0">12157634</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="shares" decimals="0">12951625</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets id="Assets.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">245074000</us-gaap:Assets>
  <us-gaap:Assets id="Assets.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">102345000</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="AssetsCurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">155020000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="AssetsCurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">50408000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecurities id="AvailableForSaleSecurities.2664.1234.3313.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.1234.3313.0.0.0.0" unitRef="USD" decimals="-3">22141000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="AvailableForSaleSecurities.2665.1234.3313.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.1234.3313.0.0.0.0" unitRef="USD" decimals="-3">31361000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="AvailableForSaleSecurities.2664.646.3313.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.646.3313.0.0.0.0" unitRef="USD" decimals="-3">1776000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="AvailableForSaleSecurities.2665.646.3313.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.646.3313.0.0.0.0" unitRef="USD" decimals="-3">1584000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="AvailableForSaleSecurities.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">23917000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="AvailableForSaleSecurities.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">32945000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="AvailableForSaleSecurities.2664.2138.1998.0.0.0.0" xsi:nil="true" contextRef="as-of-2013-09-30.2664.0.2138.1998.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AvailableForSaleSecurities id="AvailableForSaleSecurities.2665.2138.1998.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-12-31.2665.0.2138.1998.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AvailableForSaleSecurities id="AvailableForSaleSecurities.2664.2139.1998.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.2139.1998.0.0.0.0" unitRef="USD" decimals="-3">23917000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="AvailableForSaleSecurities.2665.2139.1998.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.2139.1998.0.0.0.0" unitRef="USD" decimals="-3">32945000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities id="AvailableForSaleSecurities.2664.2129.1998.0.0.0.0" xsi:nil="true" contextRef="as-of-2013-09-30.2664.0.2129.1998.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AvailableForSaleSecurities id="AvailableForSaleSecurities.2665.2129.1998.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-12-31.2665.0.2129.1998.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="AvailableForSaleSecuritiesAmortizedCost.2664.1234.3313.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.1234.3313.0.0.0.0" unitRef="USD" decimals="-3">22137000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="AvailableForSaleSecuritiesAmortizedCost.2665.1234.3313.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.1234.3313.0.0.0.0" unitRef="USD" decimals="-3">31340000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="AvailableForSaleSecuritiesAmortizedCost.2664.646.3313.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.646.3313.0.0.0.0" unitRef="USD" decimals="-3">1175000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="AvailableForSaleSecuritiesAmortizedCost.2665.646.3313.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.646.3313.0.0.0.0" unitRef="USD" decimals="-3">1175000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="AvailableForSaleSecuritiesAmortizedCost.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">23312000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesAmortizedCost id="AvailableForSaleSecuritiesAmortizedCost.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">32515000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
  <us-gaap:AvailableForSaleSecuritiesCurrent id="AvailableForSaleSecuritiesCurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">23917000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesCurrent id="AvailableForSaleSecuritiesCurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">26712000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains id="AvailableForSaleSecuritiesGrossUnrealizedGains.2663.1234.3313.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.1234.3313.0.0.0.0" unitRef="USD" decimals="-3">4000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains id="AvailableForSaleSecuritiesGrossUnrealizedGains.2671.1234.3313.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.2671.0.1234.3313.0.0.0.0" unitRef="USD" decimals="-3">21000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains id="AvailableForSaleSecuritiesGrossUnrealizedGains.2663.646.3313.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.646.3313.0.0.0.0" unitRef="USD" decimals="-3">601000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains id="AvailableForSaleSecuritiesGrossUnrealizedGains.2671.646.3313.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.2671.0.646.3313.0.0.0.0" unitRef="USD" decimals="-3">409000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains id="AvailableForSaleSecuritiesGrossUnrealizedGains.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">605000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains id="AvailableForSaleSecuritiesGrossUnrealizedGains.2671.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-12-31.2671.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">430000</us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains>
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss id="AvailableForSaleSecuritiesGrossUnrealizedLoss.2663.1234.3313.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2663.0.1234.3313.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss id="AvailableForSaleSecuritiesGrossUnrealizedLoss.2671.1234.3313.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-12-31.2671.0.1234.3313.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss id="AvailableForSaleSecuritiesGrossUnrealizedLoss.2663.646.3313.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2663.0.646.3313.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss id="AvailableForSaleSecuritiesGrossUnrealizedLoss.2671.646.3313.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-12-31.2671.0.646.3313.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss id="AvailableForSaleSecuritiesGrossUnrealizedLoss.2663.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss id="AvailableForSaleSecuritiesGrossUnrealizedLoss.2671.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-12-31.2671.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AvailableForSaleSecuritiesNoncurrent id="AvailableForSaleSecuritiesNoncurrent.2664.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AvailableForSaleSecuritiesNoncurrent id="AvailableForSaleSecuritiesNoncurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6233000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesTextBlock id="AvailableForSaleSecuritiesTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Investments classified as available-for-sale as of September 30, 2013 and December 31, 2012 were comprised of (in thousands):&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="14"&gt;&lt;strong&gt;September 30, 2013&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="14"&gt;&lt;strong&gt;December 31, 2012&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Amortized Cost&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Gross Unrealized Gains&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Gross Unrealized Losses&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Fair Value&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Amortized Cost&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Gross Unrealized Gains&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Gross Unrealized Losses&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Fair Value&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 9pt; TEXT-INDENT: -9pt; WIDTH: 20%"&gt; Auction rate securities&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"&gt; 1,175&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"&gt;601&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"&gt;-&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"&gt; 1,776&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"&gt; 1,175&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"&gt;409&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"&gt;-&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"&gt; 1,584&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 9pt; TEXT-INDENT: -9pt"&gt; Corporate debt securities&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 22,137&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 4&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 22,141&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 31,340&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 21&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 31,361&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;Total&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 23,312&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 605&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; TEXT-ALIGN: right"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;-&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 23,917&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 32,515&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 430&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 32,945&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="BasisOfAccountingPolicyPolicyTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &lt;strong&gt;&lt;em&gt;Basis of Presentation&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The consolidated balance sheet as of September 30, 2013, consolidated statements of operations and consolidated statements of comprehensive loss for the three and nine months ended September 30, 2013 and 2012 and the consolidated statements of cash flows for the nine months ended September 30, 2013 and 2012 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, operating results, comprehensive loss and cash flows, respectively, for the periods presented. Although the Company believes that the disclosures in these consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted under the rules and regulations of the United States Securities and Exchange Commission ("SEC").&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; As discussed in more detail in Note 4, the Company acquired Swedish-based Isconova AB ("Isconova") on July 31, 2013. Isconova was subsequently renamed Novavax AB. The consolidated financial statements include the accounts of Novavax, Inc. and its subsidiary, Novavax AB. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The accompanying consolidated financial statements are presented in U.S. dollars. The translation of assets and liabilities to U.S. dollars is made at the exchange rate in effect at the consolidated balance sheet date, while equity accounts are translated at historical rates. The translation of statement of operations data is made at the average exchange rate in effect for the period. The translation of operating cash flow data is made at the average exchange rate in effect for the period, and investing and financing cash flow data is translated at the exchange rate in effect at the date of the underlying transaction. Translation gains and losses are recognized as a component of accumulated other comprehensive income in the accompanying consolidated balance sheets. The foreign currency translation adjustment balance included in accumulated other comprehensive income was $0.5 million at September 30, 2013.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&amp;#39;s Annual Report on Form 10-K for the year ended December 31, 2012. Results for this or any interim period are not necessarily indicative of results for any future interim period or for the entire year. The Company operates in one business segment: developing recombinant vaccines.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; Note 3 - Summary of Significant Accounting Policies&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &lt;strong&gt;&lt;em&gt;Basis of Presentation&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The consolidated balance sheet as of September 30, 2013, consolidated statements of operations and consolidated statements of comprehensive loss for the three and nine months ended September 30, 2013 and 2012 and the consolidated statements of cash flows for the nine months ended September 30, 2013 and 2012 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, operating results, comprehensive loss and cash flows, respectively, for the periods presented. Although the Company believes that the disclosures in these consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted under the rules and regulations of the United States Securities and Exchange Commission ("SEC").&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; As discussed in more detail in Note 4, the Company acquired Swedish-based Isconova AB ("Isconova") on July 31, 2013. Isconova was subsequently renamed Novavax AB. The consolidated financial statements include the accounts of Novavax, Inc. and its subsidiary, Novavax AB. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The accompanying consolidated financial statements are presented in U.S. dollars. The translation of assets and liabilities to U.S. dollars is made at the exchange rate in effect at the consolidated balance sheet date, while equity accounts are translated at historical rates. The translation of statement of operations data is made at the average exchange rate in effect for the period. The translation of operating cash flow data is made at the average exchange rate in effect for the period, and investing and financing cash flow data is translated at the exchange rate in effect at the date of the underlying transaction. Translation gains and losses are recognized as a component of accumulated other comprehensive income in the accompanying consolidated balance sheets. The foreign currency translation adjustment balance included in accumulated other comprehensive income was $0.5 million at September 30, 2013.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&amp;#39;s Annual Report on Form 10-K for the year ended December 31, 2012. Results for this or any interim period are not necessarily indicative of results for any future interim period or for the entire year. The Company operates in one business segment: developing recombinant vaccines.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &lt;strong&gt;&lt;em&gt;Use of Estimates&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these estimates.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &lt;strong&gt;&lt;em&gt;Fair Value Measurements&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The Company applies Accounting Standards Codification ("ASC") Topic 820, &lt;em&gt;Fair Value Measurements and Disclosures&lt;/em&gt;, for financial and non-financial assets and liabilities.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; ASC 820 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). The statement utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-FAMILY: Symbol; WIDTH: 0.25in"&gt;&amp;middot;&lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt;Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-FAMILY: Symbol; WIDTH: 0.25in"&gt;&amp;middot;&lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt;Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-FAMILY: Symbol; WIDTH: 0.25in"&gt;&amp;middot;&lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt;Level 3: Unobservable inputs that reflect the reporting entity&amp;#39;s own assumptions.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &lt;strong&gt;&lt;em&gt;Investments&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold italic 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Investments consist of commercial paper, corporate notes and an investment in one auction rate security. Classification of marketable securities between current and non-current is dependent upon the original maturity date at purchase. Those securities purchased with original maturities greater than 90 days, but less than one year are classified as current and those with greater than one year are classified as non-current.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Interest and dividend income is recorded when earned and included in interest income. Premiums and discounts, if any, on investments are amortized or accreted to maturity and included in interest income. The specific identification method is used in computing realized gains and losses on the sale of the Company&amp;#39;s securities.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The Company has classified its investments as available-for-sale since the Company may need to liquidate these securities within the next year. The available-for-sale securities are carried at fair value and unrealized gains and losses on these securities, if determined to be temporary, are included in accumulated other comprehensive income (loss) in stockholders&amp;#39; equity. Investments are evaluated periodically to determine whether a decline in value is "other-than-temporary." The term "other-than-temporary" is not intended to indicate a permanent decline in value. Rather, it means that the prospects for a near term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. Management reviews criteria, such as the magnitude and duration of the decline, as well as the Company&amp;#39;s ability to hold the securities until market recovery, to predict whether the loss in value is other-than-temporary. If a decline in value is determined to be other-than-temporary, the value of the security is reduced and the impairment is recorded in the statement of operations.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold italic 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; Restricted Cash&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold italic 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The Company&amp;#39;s restricted cash includes payments received under the PATH agreement (See Note 10) until such time as the Company has paid for the work performed under the agreement. In addition, the Company&amp;#39;s non-current restricted cash with respect to its manufacturing, laboratory and office space in Gaithersburg, Maryland functions as collateral for letters of credit, which serve as security deposits for the duration of the leases.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &lt;strong&gt;&lt;em&gt;Net Loss per Share&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Net loss per share is computed using the weighted average number of shares of common stock outstanding. All outstanding warrants, stock options and unvested restricted stock awards totaling 12,157,634 shares and 12,951,625 shares at September 30, 2013 and 2012, respectively, are excluded from the computation, as their effect is antidilutive.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"&gt; &lt;strong&gt;&lt;em&gt;Reclassifications&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Overhead expenses relating to supply chain management of $0.2 million and $0.6 million for the three and nine months ended September 30, 2012, respectively, have been reclassified from general and administrative expenses to research and development expenses. Also, within the September 30, 2012 statement of cash flows, restricted cash received of $0.8 million recorded in financing activities has been reclassified and is included in operating activities. These reclassifications have been made to conform to current year presentation.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:BusinessAcquisitionProFormaInformationTextBlock id="BusinessAcquisitionProFormaInformationTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The unaudited pro forma financial information combines the historical results of operations of Novavax and Isconova for the periods presented below and reflects the application of the following adjustments:&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-FAMILY: Symbol; WIDTH: 0.25in"&gt;&amp;middot;&lt;/td&gt; &lt;td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"&gt; Elimination of the historical intangible assets and amortization expense unrelated to the Acquisition;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-FAMILY: Symbol; WIDTH: 0.25in"&gt;&amp;middot;&lt;/td&gt; &lt;td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"&gt; Amortization expense related to the fair value of intangible assets acquired; and&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-FAMILY: Symbol; WIDTH: 0.25in"&gt;&amp;middot;&lt;/td&gt; &lt;td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"&gt; The exclusion of acquisition-related costs incurred for the Acquisition.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Three Months Ended&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Nine Months Ended&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="14"&gt;(in thousands)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; WIDTH: 44%"&gt; Revenue&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; 4,869&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; 6,272&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; 14,195&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"&gt; 19,530&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Net loss&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; (15,687&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; (8,490&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; (40,565&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; (25,033&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Basic and diluted net loss per share&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"&gt; (0.09&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"&gt; )&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"&gt; (0.06&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"&gt; )&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"&gt; (0.24&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"&gt; )&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"&gt; (0.18&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"&gt; )&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss id="BusinessAcquisitionsProFormaNetIncomeLoss.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-40565000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss id="BusinessAcquisitionsProFormaNetIncomeLoss.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-25033000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss id="BusinessAcquisitionsProFormaNetIncomeLoss.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-15687000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss id="BusinessAcquisitionsProFormaNetIncomeLoss.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-8490000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaRevenue id="BusinessAcquisitionsProFormaRevenue.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">14195000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <us-gaap:BusinessAcquisitionsProFormaRevenue id="BusinessAcquisitionsProFormaRevenue.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">19530000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <us-gaap:BusinessAcquisitionsProFormaRevenue id="BusinessAcquisitionsProFormaRevenue.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4869000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <us-gaap:BusinessAcquisitionsProFormaRevenue id="BusinessAcquisitionsProFormaRevenue.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6272000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <us-gaap:BusinessCombinationConsiderationTransferred1 id="BusinessCombinationConsiderationTransferred1.2677.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-07-31.2677.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">41964000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable id="BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.2677.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-07-31.2677.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">41942000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation id="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation.3676.0.0.0.0.0.0" contextRef="as-of-2013-07-31.3676.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">94000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents id="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents.3676.0.0.0.0.0.0" contextRef="as-of-2013-07-31.3676.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3056000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets id="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets.3676.0.0.0.0.0.0" contextRef="as-of-2013-07-31.3676.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1092000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables id="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables.3676.0.0.0.0.0.0" contextRef="as-of-2013-07-31.3676.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">603000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable id="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable.3676.0.0.0.0.0.0" contextRef="as-of-2013-07-31.3676.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2784000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill id="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill.3676.0.0.0.0.0.0" contextRef="as-of-2013-07-31.3676.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">16380000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt id="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt.3676.0.0.0.0.0.0" contextRef="as-of-2013-07-31.3676.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">193000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther id="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther.3676.0.0.0.0.0.0" contextRef="as-of-2013-07-31.3676.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1559000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment id="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment.3676.0.0.0.0.0.0" contextRef="as-of-2013-07-31.3676.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">165000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet id="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.3676.0.0.0.0.0.0" contextRef="as-of-2013-07-31.3676.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">41964000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="CapitalExpendituresIncurredButNotYetPaid.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">407000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="CapitalExpendituresIncurredButNotYetPaid.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1365000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalLeaseObligationsCurrent id="CapitalLeaseObligationsCurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">115000</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:CapitalLeaseObligationsCurrent id="CapitalLeaseObligationsCurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">58000</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:CapitalLeaseObligationsNoncurrent id="CapitalLeaseObligationsNoncurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">222000</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:CapitalLeaseObligationsNoncurrent id="CapitalLeaseObligationsNoncurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">237000</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:CashAcquiredFromAcquisition id="CashAcquiredFromAcquisition.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3034000</us-gaap:CashAcquiredFromAcquisition>
  <us-gaap:CashAcquiredFromAcquisition id="CashAcquiredFromAcquisition.2666.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">122493000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">17399000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.2669.0.0.0.0.0.0" contextRef="as-of-2011-12-31.2669.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">14104000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.2670.0.0.0.0.0.0" contextRef="as-of-2012-09-30.2670.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">10738000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">105094000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-3366000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy id="CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold italic 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; Restricted Cash&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold italic 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The Company&amp;#39;s restricted cash includes payments received under the PATH agreement (See Note 10) until such time as the Company has paid for the work performed under the agreement. In addition, the Company&amp;#39;s non-current restricted cash with respect to its manufacturing, laboratory and office space in Gaithersburg, Maryland functions as collateral for letters of credit, which serve as security deposits for the duration of the leases.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights id="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights.2673.0.0.0.0.0.0" contextRef="as-of-2008-07-31.2673.0.0.0.0.0.0.0" unitRef="USD_per_Warrant" decimals="2">3.62</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight.2673.0.0.0.0.0.0" contextRef="as-of-2008-07-31.2673.0.0.0.0.0.0.0" unitRef="shares" decimals="1">0.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights.2673.0.0.0.0.0.0" contextRef="as-of-2008-07-31.2673.0.0.0.0.0.0.0" unitRef="shares" decimals="0">3343325</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock id="CollaborativeArrangementDisclosureTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; Note 10 - U.S. Government Agreement, Joint Venture and Collaborations&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; TEXT-INDENT: 0in"&gt; &lt;strong&gt;&lt;em&gt;HHS BARDA Contract for Recombinant Influenza Vaccines&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; In February 2011, the Company was awarded a contract from HHS BARDA valued at $97 million for the first three-year base-period, with an HHS BARDA option for an additional two-year period valued at $82 million, for a total contract value of up to $179 million. The HHS BARDA contract award provides significant funding for the Company&amp;#39;s ongoing clinical development and product scale-up of both its seasonal and pandemic influenza vaccine candidates. This is a cost-plus-fixed-fee contract in which HHS BARDA will reimburse the Company for allowable direct contract costs incurred plus allowable indirect costs and a fixed-fee earned in the further development of its multivalent seasonal and monovalent pandemic influenza vaccines. HHS BARDA originally directed the Company to develop its monovalent pandemic influenza vaccines against the A(H5N1) strain. Recently, however, HHS BARDA has directed the Company to develop its monovalent pandemic influenza vaccines against the A(H7N9) strain and is working with the Company to modify the contract in this respect; nevertheless, the Company&amp;#39;s H5N1 vaccine program remains a viable development opportunity under the contract. Billings under the contract are based on approved provisional indirect billing rates, which permit recovery of fringe benefits, overhead and general and administrative expenses not exceeding certain limits. These indirect rates are subject to audit by HHS BARDA on an annual basis. An audit by the U.S. government of fiscal years 2011 and 2012 has been initiated, but has not been completed as of the date of this filing. When the final determination of the allowable costs for any year has been made, revenue and billings may be adjusted accordingly; however, management believes that revenue for periods subject to audit has been recorded in amounts that are expected to be realized upon final audit and settlement. The Company recognized revenue of approximately $10.7 million in the nine months ended September 30, 2013, and has recognized approximately $45 million in revenue since the inception of the contract.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Under certain circumstances, HHS BARDA reimbursements may be delayed or even potentially withheld. In March 2012, the Company decided to conduct a Phase 2 clinical trial of its quadrivalent seasonal influenza vaccine candidate ("205 Trial") under its existing U.S. investigational new drug application ("IND") for its trivalent seasonal influenza vaccine candidate as opposed to waiting to conduct this clinical trial under a new IND for its quadrivalent vaccine candidate ("Quadrivalent IND"). Based on the Company&amp;#39;s discussions with HHS BARDA in 2012, the outside clinical trial costs for the 205 Trial may only be submitted for reimbursement to HHS BARDA and recorded as revenue by the Company after it submits the clinical trial data in a future Quadrivalent IND. The submission of the Quadrivalent IND is expected shortly before the Company initiates the next Phase 2 dose-confirmatory clinical trial, which is currently expected in the first quarter of 2014. The outside clinical trial costs of the 205 Trial conducted last year total $2.9 million, which was incurred from the inception of the clinical trial through September 30, 2013. These costs have been recorded as an expense and are included in cost of government contracts revenue.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"&gt; &lt;strong&gt;&lt;em&gt;CPL Biologicals Private Limited ("CPLB") Joint Venture&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; In 2009, the Company formed a joint venture with Cadila Pharmaceuticals Limited ("Cadila") named CPL Biologicals Private Limited ("CPLB") to develop and manufacture vaccines, biological therapeutics and diagnostics in India. CPLB is owned 20% by the Company and 80% by Cadila. The Company accounts for its investment in CPLB using the equity method. Since the carrying value of the Company&amp;#39;s initial investment was nominal and there is no guarantee or commitment to provide future funding, the Company has not recorded any losses related to this investment.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"&gt; &lt;strong&gt;&lt;em&gt;LG Life Sciences, Ltd. ("LGLS") License Agreement&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; In February 2011, the Company entered into a license agreement with LGLS that allows LGLS to use the Company&amp;#39;s technology to develop and commercially sell influenza vaccines exclusively in South Korea and non-exclusively in certain other specified countries. At its own cost, LGLS is responsible for funding both its clinical development of the influenza VLP vaccines and a manufacturing facility to produce such vaccine in South Korea. Under the license agreement, the Company is obligated to provide LGLS with information and materials related to the manufacture of the licensed products, provide on-going project management and regulatory support and conduct clinical trials of its influenza vaccines in order to obtain FDA approval in the U.S. The term of the license agreement is expected to terminate in 2027. Payments to the Company under the license agreement include an upfront payment of $2.5 million, reimbursements of certain development and product costs, payments related to the achievement of certain milestones and royalty payments in the high single digits from LGLS&amp;#39;s future commercial sales of influenza VLP vaccines. The upfront payment has been deferred and will be recognized when the previously mentioned obligations in the agreement are satisfied, which may not occur until the end of the term of the agreement. Payments for milestones under the agreement will be recognized on a straight-line basis over the remaining term of the research and development period upon achievement of such milestone. Any royalties under the agreement will be recognized as earned.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"&gt; &lt;strong&gt;&lt;em&gt;PATH Vaccine Solutions ("PATH") Clinical Development Agreement&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; In July 2012, the Company entered into a clinical development agreement with PATH to develop its vaccine candidate to protect against RSV through maternal immunization in low-resource countries (the "RSV Collaboration Program"). The Company was awarded approximately $2.0 million by PATH for initial funding under the agreement to partially support its initial Phase 2 dose-ranging clinical trial in women of childbearing age, which was launched in October 2012. The funding under the agreement was increased by $0.4 million and the term extended to April 2014 to support the Company&amp;#39;s reproductive toxicology studies, which are necessary before it conducts clinical trials in pregnant women. The Company retains global rights to commercialize the product and has made a commitment to make the vaccine affordable and available in low-resource countries. To the extent PATH elects to continue to fund 50% of the Company&amp;#39;s external clinical development costs for the RSV Collaboration Program, but the Company does not continue development, the Company would then grant PATH a fully-paid license to its RSV vaccine technology for use in pregnant women in such low-resource countries. The Company recognized revenue of approximately $0.7 million in the nine months ended September 30, 2013, and has recognized approximately $2.0 million in revenue since the inception of the agreement. Revenue under this arrangement is being recognized under the proportional performance method and earned in proportion to the contract costs incurred in performance of the work as compared to total estimated contract costs. Costs incurred under this agreement represent a reasonable measurement of proportional performance of the services being performed.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingencies id="CommitmentsAndContingencies.2664.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="CommitmentsAndContingencies.2665.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="shares" decimals="0">300000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="shares" decimals="0">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="CommonStockSharesIssued.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="shares" decimals="0">208965169</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="CommonStockSharesIssued.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="shares" decimals="0">148398747</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="CommonStockSharesOutstanding.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="shares" decimals="0">208509739</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="CommonStockSharesOutstanding.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="shares" decimals="0">147943317</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue id="CommonStockValue.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2090000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="CommonStockValue.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1484000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax id="ComprehensiveIncomeNetOfTax.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-37246000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="ComprehensiveIncomeNetOfTax.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-20268000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="ComprehensiveIncomeNetOfTax.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-14824000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="ComprehensiveIncomeNetOfTax.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-7121000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ContractRevenueCost id="ContractRevenueCost.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5619000</us-gaap:ContractRevenueCost>
  <us-gaap:ContractRevenueCost id="ContractRevenueCost.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">12740000</us-gaap:ContractRevenueCost>
  <us-gaap:ContractRevenueCost id="ContractRevenueCost.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2276000</us-gaap:ContractRevenueCost>
  <us-gaap:ContractRevenueCost id="ContractRevenueCost.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3838000</us-gaap:ContractRevenueCost>
  <us-gaap:ContractsRevenue id="ContractsRevenue.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">10985000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue id="ContractsRevenue.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">17328000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue id="ContractsRevenue.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4268000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue id="ContractsRevenue.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5583000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue id="ContractsRevenue.2663.23929.5386.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23929.5386.0.0.0.0" unitRef="USD" decimals="-3">10700000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue id="ContractsRevenue.2681.23929.5386.0.0.0.0" contextRef="from-2011-02-01-to-2013-09-30.2681.0.23929.5386.0.0.0.0" unitRef="USD" decimals="-3">45000000</us-gaap:ContractsRevenue>
  <us-gaap:ConversionOfStockAmountConverted1 id="ConversionOfStockAmountConverted1.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">41942000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:ConversionOfStockAmountConverted1 id="ConversionOfStockAmountConverted1.2666.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CostsAndExpenses id="CostsAndExpenses.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">50348000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses id="CostsAndExpenses.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">37680000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses id="CostsAndExpenses.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">20081000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses id="CostsAndExpenses.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">12614000</us-gaap:CostsAndExpenses>
  <us-gaap:DebtDisclosureTextBlock id="DebtDisclosureTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; Note 11 - Notes Payable&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; In September 2012, the Company entered into a master security agreement with General Electric Capital Corporation ("GE"), whereby the Company could borrow up to $2.0 million to finance the purchases of equipment through June 2013 (each, an "Equipment Loan"). Each Equipment Loan bears interest at the three-year U.S. Government treasury rate plus 11.68%, provided that the rate shall not be less than 12.1%, and is to be repaid over forty-two (42) months. GE will maintain a security interest in all equipment financed under the Equipment Loan. During the nine months ended September 30, 2013, the Company financed $1.5 million at interest rates of 12.1% with monthly principal payments totaling $34,529 ("2013 Funding"). Interest accrues on the outstanding balance until paid in full. As of September 30, 2013, the Company has financed $2.0 million in total under the Equipment Loan.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Aggregate future minimum principal payments on the GE notes payable, including the 2013 Funding, at September 30, 2013 are as follows (in thousands):&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Year&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold" colspan="2"&gt;Amount&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 13%"&gt; 2013 (remainder)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 74%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 2%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt;143&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; 2014&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;571&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; 2015&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;571&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; 2016&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 396&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,681&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="DebtInstrumentBasisSpreadOnVariableRate1.2678.0.0.0.0.0.0" contextRef="from-2012-09-01-to-2012-09-30.2678.0.0.0.0.0.0.0" unitRef="pure" decimals="4">0.1168</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:DebtInstrumentFaceAmount id="DebtInstrumentFaceAmount.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod id="DebtInstrumentInterestRateDuringPeriod.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="pure" decimals="3">0.121</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMinimum id="DebtInstrumentInterestRateStatedPercentageRateRangeMinimum.2678.0.0.0.0.0.0" contextRef="from-2012-09-01-to-2012-09-30.2678.0.0.0.0.0.0.0" unitRef="pure" decimals="3">0.121</us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMinimum>
  <us-gaap:DebtInstrumentPeriodicPayment id="DebtInstrumentPeriodicPayment.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="0">34529</us-gaap:DebtInstrumentPeriodicPayment>
  <us-gaap:DebtInstrumentTerm id="DebtInstrumentTerm.2678.0.0.0.0.0.0" contextRef="from-2012-09-01-to-2012-09-30.2678.0.0.0.0.0.0.0">P42M</us-gaap:DebtInstrumentTerm>
  <us-gaap:DeferredRentCreditCurrent id="DeferredRentCreditCurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">466000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditCurrent id="DeferredRentCreditCurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">432000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="DeferredRentCreditNoncurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">8287000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent id="DeferredRentCreditNoncurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6940000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRevenueCurrent id="DeferredRevenueCurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">190000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="DeferredRevenueCurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">258000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent id="DeferredRevenueNoncurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2500000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="DeferredRevenueNoncurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2500000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DepreciationAndAmortization id="DepreciationAndAmortization.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1636000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization id="DepreciationAndAmortization.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1216000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DerivativeLiabilitiesCurrent id="DerivativeLiabilitiesCurrent.2664.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:DerivativeLiabilitiesCurrent id="DerivativeLiabilitiesCurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">267000</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Note 9 - Stock-Based Compensation&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &lt;strong&gt;&lt;em&gt;Stock Options&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The Company has granted equity awards under several plans, two of which remain active. Under the 2005 Stock Incentive Plan (the "2005 Plan"), equity awards may be granted to officers, directors, employees, consultants and advisors to the Company and any present or future subsidiary. The 2005 Plan, approved in May 2005 and amended in June 2007, June 2011, June 2012 and June 2013 by the Company&amp;#39;s stockholders, currently authorizes the grant of equity awards for up to 22,312,192 shares of common stock, which included, at the time of approval of the 2005 Plan, a maximum 5,746,468 shares of common stock subject to stock options outstanding under the Company&amp;#39;s 1995 Stock Option Plan (the "1995 Plan") that may revert to and become issuable under the 2005 Plan if such options expire or otherwise terminate unexercised. The Company received approval at its 2013 annual meeting of stockholders to increase the number of shares of common stock available for issuance under the 2005 Plan by 4,000,000 shares. The term of the Company&amp;#39;s 1995 Plan has expired and no new awards will be made under the 1995 Plan; however, outstanding stock options remain in existence in accordance with their terms.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Under the 2005 Plan and the 1995 Plan, incentive stock options, having a maximum term of 10 years, can be or were granted at no less than 100% of the fair value of the Company&amp;#39;s common stock at the time of grant and are generally exercisable over periods ranging from six months to four years. There is no minimum exercise price for non-statutory stock options.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; TEXT-INDENT: 0in"&gt; &lt;strong&gt;&lt;em&gt;Stock Options Awards&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The following is a summary of option activity under the 2005 Plan and the 1995 Plan for the nine months ended September 30, 2013:&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6"&gt;2005 Stock Incentive Plan&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6"&gt;1995 Stock Option Plan&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Stock Options&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Weighted-Average Exercise Price&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Stock Options&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Weighted-Average Exercise Price&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; WIDTH: 44%; TEXT-INDENT: 0px"&gt; Outstanding at January 1, 2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 9,143,825&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 1.87&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 211,900&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 4.94&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Granted&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"&gt; 4,117,500&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"&gt; 1.92&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Exercised&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"&gt; (522,292&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;2.29&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Canceled&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (802,883&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1.74&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (23,750&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 4.05&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Outstanding at September 30, 2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 11,936,150&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1.88&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 188,150&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 5.04&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Shares exercisable at September 30, 2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4,647,873&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 2.12&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 188,150&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 5.04&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Shares available for grant at September 30, 2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"&gt; 6,461,494&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The fair value of stock options granted was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid" colspan="6"&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Three Months Ended&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid" colspan="6"&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Nine Months Ended&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;2012&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;2012&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 44%"&gt;Weighted-average fair value of stock options granted&lt;/td&gt; &lt;td style="WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 1.41&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 1.09&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 1.02&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 0.71&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Risk-free interest rate&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;1.12%-1.36&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0.55&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0.54%-1.36&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0.55%-1.54&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Dividend yield&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Volatility&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;56.75%-62.51&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;76.60%-76.71&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;55.81%-73.72&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;75.47%-80.48&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Expected term (in years)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;4.25&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;4.24&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;3.98-7.05&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;3.34-7.09&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Expected forfeiture rate&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;23.15&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;23.15&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0%-23.15&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0%-23.15&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The aggregate intrinsic value and weighted-average remaining contractual term of stock options outstanding as of September 30, 2013 was approximately $15.9 million and 7.6 years, respectively. The aggregate intrinsic value and weighted-average remaining contractual term of stock options exercisable as of September 30, 2013 was approximately $5.5 million and 5.9 years, respectively. The aggregate intrinsic value represents the total intrinsic value (the difference between the Company&amp;#39;s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on September 30, 2013. This amount is subject to change based on changes to the fair value of the Company&amp;#39;s common stock. The aggregate intrinsic value of options exercised for the nine months ended September 30, 2013 and 2012 was $0.3 million and less than $0.1 million, respectively.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &lt;strong&gt;&lt;em&gt;Employee Stock Purchase Plan&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The Company received approval at its 2013 annual meeting of stockholders to adopt an Employee Stock Purchase Plan (the "ESPP"), which currently authorizes an aggregate of 2,000,000 shares of Common Stock to be purchased. The ESPP allows employees to purchase shares of Common Stock of the Company at each purchase date through payroll deductions of up to a maximum of 15% of their compensation, at 85% of the lesser of the market price of the shares at the time of purchase or the market price on the beginning date of an option period (or, if later, the date during the option period when the employee was first eligible to participate). The first option period under the ESPP commenced on August 1, 2013.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The ESPP is considered compensatory for financial reporting purposes. As such, the fair value of ESPP shares was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 75%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center" colspan="3"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;Three Months Ended&lt;/strong&gt;&lt;/font&gt; &lt;br /&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;September 30,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center"&gt; &lt;strong&gt;2013&lt;/strong&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 77%"&gt;Weighted-average fair value of ESPP shares granted&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 20%"&gt; 0.78&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Risk-free interest rate&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0.04&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Dividend yield&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Volatility&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;50.80&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Expected term (in years)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0.5&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Expected forfeiture rate&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;5&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; TEXT-INDENT: 0in"&gt; &lt;strong&gt;&lt;em&gt;Restricted Stock Awards&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Under the 2005 Plan, the Company has granted restricted stock awards subject to certain performance-based and/or time-based vesting conditions which, if not met, would result in forfeiture of the shares and reversal of any previously recognized related stock-based compensation expense.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The following is a summary of restricted stock awards activity for the nine months ended September 30, 2013:&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Per Share Weighted-Average Grant-Date&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Fair Value&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 72%"&gt; Outstanding and Unvested at January 1, 2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 33,334&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 1.39&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Restricted stock granted&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Restricted stock vested&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Restricted stock forfeited&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Outstanding and Unvested at September 30, 2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 33,334&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1.39&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Three Months Ended&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Nine Months Ended&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 44%; TEXT-INDENT: 0px"&gt; Research and development&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt;316&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt;219&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt;829&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt;638&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; General and administrative&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 347&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 274&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 955&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1,030&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Total stock-based compensation expense&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 663&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 493&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,784&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,668&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; As of September 30, 2013, there was approximately $4.7 million of total unrecognized compensation expense (net of estimated forfeitures) related to unvested options and restricted stock awards. This unrecognized compensation expense is expected to be recognized over a weighted-average period of 1.5 years. This estimate does not include the impact of other possible stock-based awards that may be made during future periods.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">-0.09</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock id="EarningsPerSharePolicyTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &lt;strong&gt;&lt;em&gt;Net Loss per Share&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Net loss per share is computed using the weighted average number of shares of common stock outstanding. All outstanding warrants, stock options and unvested restricted stock awards totaling 12,157,634 shares and 12,951,625 shares at September 30, 2013 and 2012, respectively, are excluded from the computation, as their effect is antidilutive.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="EffectOfExchangeRateOnCashAndCashEquivalents.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">16000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="EffectOfExchangeRateOnCashAndCashEquivalents.2666.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EquityIssuancePerShareAmount id="EquityIssuancePerShareAmount.2672.0.0.0.0.0.0" contextRef="from-2008-07-01-to-2008-07-31.2672.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">2.68</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:EquityIssuancePerShareAmount id="EquityIssuancePerShareAmount.2663.3382.4365.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.3382.4365.0.0.0.0" unitRef="USD_per_share" decimals="2">2.06</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:EquityIssuancePerShareAmount id="EquityIssuancePerShareAmount.2663.3373.4365.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.3373.4365.0.0.0.0" unitRef="USD_per_share" decimals="2">3.38</us-gaap:EquityIssuancePerShareAmount>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage id="EquityMethodInvestmentOwnershipPercentage.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="pure" decimals="1">0.2</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:FairValueDisclosuresTextBlock id="FairValueDisclosuresTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Note 5 - Fair Value Measurements&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px; TEXT-ALIGN: justify; TEXT-INDENT: 0.5in"&gt; The following table represents the Company&amp;#39;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px; TEXT-ALIGN: justify; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="10"&gt;Fair Value at September 30, 2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="10"&gt;Fair Value at December 31, 2012&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-DECORATION: underline; TEXT-INDENT: 0px"&gt; Assets&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &lt;strong&gt;Level 1&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;Level 2&lt;/strong&gt;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &lt;strong&gt;Level 3&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &lt;strong&gt;Level 1&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &lt;strong&gt;Level 2&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &lt;strong&gt;Level 3&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.125in; WIDTH: 28%; TEXT-INDENT: -0.125in"&gt; Corporate debt securities and auction rate securities&lt;/td&gt; &lt;td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"&gt; 23,917&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"&gt; 32,945&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Total investments&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 23,917&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 32,945&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-LEFT: 0px; TEXT-DECORATION: underline; TEXT-INDENT: 0px"&gt; Liabilities&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Warrant liabilities&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 267&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px; TEXT-ALIGN: justify; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px; TEXT-ALIGN: justify; TEXT-INDENT: 0.5in"&gt; During the nine months ended September 30, 2013, the Company did not have any transfers between levels.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The following table provides a reconciliation of the beginning and ending balance of Level 3 assets and liabilities measured on a recurring basis for the nine months ended September 30, 2013 (in thousands):&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 75%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Fair&amp;nbsp;Value&amp;nbsp;Measurements&amp;nbsp;of&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Warrants&amp;nbsp;Using Significant&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Unobservable&amp;nbsp;Inputs&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;(Level&amp;nbsp;3)&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; WIDTH: 77%"&gt;Balance at December 31, 2012&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 20%"&gt;267&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Change in fair value of Warrant liability&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (267&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"&gt; Balance at September 30, 2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The amounts in the Company&amp;#39;s consolidated balance sheet for accounts receivables, unbilled receivables and accounts payable approximate fair value due to their short-term nature. Based on borrowing rates available to the Company, the fair value of capital leases and notes payable approximates their carrying value.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The following table provides a reconciliation of the beginning and ending balance of Level 3 assets and liabilities measured on a recurring basis for the nine months ended September 30, 2013 (in thousands):&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 75%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Fair&amp;nbsp;Value&amp;nbsp;Measurements&amp;nbsp;of&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Warrants&amp;nbsp;Using Significant&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Unobservable&amp;nbsp;Inputs&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;(Level&amp;nbsp;3)&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; WIDTH: 77%"&gt;Balance at December 31, 2012&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 20%"&gt;267&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Change in fair value of Warrant liability&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (267&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"&gt; Balance at September 30, 2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="FairValueMeasurementPolicyPolicyTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &lt;strong&gt;&lt;em&gt;Fair Value Measurements&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The Company applies Accounting Standards Codification ("ASC") Topic 820, &lt;em&gt;Fair Value Measurements and Disclosures&lt;/em&gt;, for financial and non-financial assets and liabilities.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; ASC 820 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). The statement utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-FAMILY: Symbol; WIDTH: 0.25in"&gt;&amp;middot;&lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt;Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-FAMILY: Symbol; WIDTH: 0.25in"&gt;&amp;middot;&lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt;Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-FAMILY: Symbol; WIDTH: 0.25in"&gt;&amp;middot;&lt;/td&gt; &lt;td style="TEXT-ALIGN: justify"&gt;Level 3: Unobservable inputs that reflect the reporting entity&amp;#39;s own assumptions.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease id="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease.2663.23966.4707.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23966.4707.0.0.0.0" unitRef="USD" decimals="-3">-267000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.2664.23966.4707.0.0.0.0" xsi:nil="true" contextRef="as-of-2013-09-30.2664.0.23966.4707.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.2665.23966.4707.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.23966.4707.0.0.0.0" unitRef="USD" decimals="-3">267000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="FiniteLivedIntangibleAssetsAccumulatedAmortization.2664.31339.2311.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.31339.2311.0.0.0.0" unitRef="USD" decimals="-3">84000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="FiniteLivedIntangibleAssetsAccumulatedAmortization.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">181000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="FiniteLivedIntangibleAssetsAccumulatedAmortization.2664.32669.2311.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.32669.2311.0.0.0.0" unitRef="USD" decimals="-3">97000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths id="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1084000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear id="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">271000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive id="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1084000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour id="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1084000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree id="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1084000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo id="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1084000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
  <us-gaap:FiniteLivedIntangibleAssetsGross id="FiniteLivedIntangibleAssetsGross.2664.32669.2311.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.32669.2311.0.0.0.0" unitRef="USD" decimals="-3">11594000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross id="FiniteLivedIntangibleAssetsGross.2664.31339.2311.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.31339.2311.0.0.0.0" unitRef="USD" decimals="-3">4992000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross id="FiniteLivedIntangibleAssetsGross.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">16586000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="FiniteLivedIntangibleAssetsNet.2664.32669.2311.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.32669.2311.0.0.0.0" unitRef="USD" decimals="-3">11497000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="FiniteLivedIntangibleAssetsNet.2664.31339.2311.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.31339.2311.0.0.0.0" unitRef="USD" decimals="-3">4908000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="FiniteLivedIntangibleAssetsNet.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">16405000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax id="GainLossOnDerivativeInstrumentsNetPretax.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">267000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax id="GainLossOnDerivativeInstrumentsNetPretax.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-401000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax id="GainLossOnDerivativeInstrumentsNetPretax.2667.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax id="GainLossOnDerivativeInstrumentsNetPretax.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-401000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="GainLossOnSaleOfPropertyPlantEquipment.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">37000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="GainLossOnSaleOfPropertyPlantEquipment.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">26000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">10740000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7670000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3857000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2134000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:Goodwill id="Goodwill.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">58759000</us-gaap:Goodwill>
  <us-gaap:Goodwill id="Goodwill.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">33141000</us-gaap:Goodwill>
  <us-gaap:Goodwill id="Goodwill.2669.0.0.0.0.0.0" contextRef="as-of-2011-12-31.2669.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">33141000</us-gaap:Goodwill>
  <us-gaap:Goodwill id="Goodwill.2670.0.0.0.0.0.0" contextRef="as-of-2012-09-30.2670.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">33141000</us-gaap:Goodwill>
  <us-gaap:GoodwillAcquiredDuringPeriod id="GoodwillAcquiredDuringPeriod.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25298000</us-gaap:GoodwillAcquiredDuringPeriod>
  <us-gaap:GoodwillAcquiredDuringPeriod id="GoodwillAcquiredDuringPeriod.2666.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock id="GoodwillAndIntangibleAssetsDisclosureTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Note 7 - Goodwill and Other Intangible Assets&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &lt;strong&gt;&lt;em&gt;Goodwill&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The changes in the carrying amounts of goodwill for the nine months ended September 30, 2013 and 2012 were as following (in thousands):&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Nine Months Ended&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 72%; TEXT-INDENT: 0px"&gt; Beginning balance&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 33,141&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 33,141&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Goodwill resulting from acquisition of business&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;25,298&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Currency translation&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 320&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Ending balance&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 58,759&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 33,141&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &lt;strong&gt;&lt;em&gt;Identifiable Intangible Assets&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Identifiable intangible assets consisted of the following as of September 30, 2013 (in thousands):&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Gross Carrying Amount&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Accumulated Amortization&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Intangible&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Assets, Net&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Finite-lived intangible assets:&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 58%; TEXT-INDENT: 0px"&gt; Proprietary adjuvant technology&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 11,594&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt;(97&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 11,497&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Collaboration agreements&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 4,992&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (84&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 4,908&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Total identifiable intangible assets&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 16,586&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; (181&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 16,405&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Amortization expense for the nine months ended September 30, 2013 was $0.2 million. Estimated amortization expense for existing intangible assets for the remainder of 2013 and for each of the five succeeding years ending December 31,will be as follows (in thousands):&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Year&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;Amount&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 13%"&gt; 2013 (remainder)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 74%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 2%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt;271&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; 2014&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;1,084&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; 2015&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;1,084&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; 2016&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"&gt; 1,084&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; 2017&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"&gt; 1,084&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; 2018&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"&gt; 1,084&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <us-gaap:GoodwillTranslationAdjustments id="GoodwillTranslationAdjustments.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">320000</us-gaap:GoodwillTranslationAdjustments>
  <us-gaap:GoodwillTranslationAdjustments id="GoodwillTranslationAdjustments.2666.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:GovernmentContractReceivable id="GovernmentContractReceivable.2679.23929.5386.0.0.0.0" contextRef="as-of-2011-02-28.2679.0.23929.5386.0.0.0.0" unitRef="USD" decimals="-3">97000000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable id="GovernmentContractReceivable.2679.23930.5386.0.0.0.0" contextRef="as-of-2011-02-28.2679.0.23930.5386.0.0.0.0" unitRef="USD" decimals="-3">82000000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivable id="GovernmentContractReceivable.2679.0.0.0.0.0.0" contextRef="as-of-2011-02-28.2679.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">179000000</us-gaap:GovernmentContractReceivable>
  <us-gaap:GovernmentContractReceivableUnbilledAmounts id="GovernmentContractReceivableUnbilledAmounts.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3194000</us-gaap:GovernmentContractReceivableUnbilledAmounts>
  <us-gaap:GovernmentContractReceivableUnbilledAmounts id="GovernmentContractReceivableUnbilledAmounts.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1570000</us-gaap:GovernmentContractReceivableUnbilledAmounts>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-37907000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-20472000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-15300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-7217000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit id="IncomeTaxExpenseBenefit.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">22000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="IncomeTaxExpenseBenefit.2666.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncomeTaxExpenseBenefit id="IncomeTaxExpenseBenefit.2667.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncomeTaxExpenseBenefit id="IncomeTaxExpenseBenefit.2668.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">623000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-304000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="IncreaseDecreaseInAccountsReceivable.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">291000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="IncreaseDecreaseInAccountsReceivable.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">504000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="IncreaseDecreaseInDeferredRevenue.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-199000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="IncreaseDecreaseInDeferredRevenue.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">803000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="IncreaseDecreaseInOtherNoncurrentLiabilities.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">703000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="IncreaseDecreaseInOtherNoncurrentLiabilities.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2803000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-639000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">271000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="IncreaseDecreaseInRestrictedCash.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-862000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="IncreaseDecreaseInRestrictedCash.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">838000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInUnbilledReceivables id="IncreaseDecreaseInUnbilledReceivables.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1624000</us-gaap:IncreaseDecreaseInUnbilledReceivables>
  <us-gaap:IncreaseDecreaseInUnbilledReceivables id="IncreaseDecreaseInUnbilledReceivables.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-111000</us-gaap:IncreaseDecreaseInUnbilledReceivables>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="IntangibleAssetsNetExcludingGoodwill.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">16405000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="IntangibleAssetsNetExcludingGoodwill.2665.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:InterestExpense id="InterestExpense.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">132000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="InterestExpense.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">12000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="InterestExpense.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">64000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="InterestExpense.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6000</us-gaap:InterestExpense>
  <us-gaap:InterestPaid id="InterestPaid.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">120000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid id="InterestPaid.2666.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:InvestmentIncomeNet id="InvestmentIncomeNet.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">149000</us-gaap:InvestmentIncomeNet>
  <us-gaap:InvestmentIncomeNet id="InvestmentIncomeNet.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">111000</us-gaap:InvestmentIncomeNet>
  <us-gaap:InvestmentIncomeNet id="InvestmentIncomeNet.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">53000</us-gaap:InvestmentIncomeNet>
  <us-gaap:InvestmentIncomeNet id="InvestmentIncomeNet.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">39000</us-gaap:InvestmentIncomeNet>
  <us-gaap:InvestmentPolicyTextBlock id="InvestmentPolicyTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &lt;strong&gt;&lt;em&gt;Investments&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold italic 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Investments consist of commercial paper, corporate notes and an investment in one auction rate security. Classification of marketable securities between current and non-current is dependent upon the original maturity date at purchase. Those securities purchased with original maturities greater than 90 days, but less than one year are classified as current and those with greater than one year are classified as non-current.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Interest and dividend income is recorded when earned and included in interest income. Premiums and discounts, if any, on investments are amortized or accreted to maturity and included in interest income. The specific identification method is used in computing realized gains and losses on the sale of the Company&amp;#39;s securities.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The Company has classified its investments as available-for-sale since the Company may need to liquidate these securities within the next year. The available-for-sale securities are carried at fair value and unrealized gains and losses on these securities, if determined to be temporary, are included in accumulated other comprehensive income (loss) in stockholders&amp;#39; equity. Investments are evaluated periodically to determine whether a decline in value is "other-than-temporary." The term "other-than-temporary" is not intended to indicate a permanent decline in value. Rather, it means that the prospects for a near term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. Management reviews criteria, such as the magnitude and duration of the decline, as well as the Company&amp;#39;s ability to hold the securities until market recovery, to predict whether the loss in value is other-than-temporary. If a decline in value is determined to be other-than-temporary, the value of the security is reduced and the impairment is recorded in the statement of operations.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
  <us-gaap:InvestmentsFairValueDisclosure id="InvestmentsFairValueDisclosure.2664.2138.1998.0.0.0.0" xsi:nil="true" contextRef="as-of-2013-09-30.2664.0.2138.1998.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:InvestmentsFairValueDisclosure id="InvestmentsFairValueDisclosure.2665.2138.1998.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-12-31.2665.0.2138.1998.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:InvestmentsFairValueDisclosure id="InvestmentsFairValueDisclosure.2664.2139.1998.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.2139.1998.0.0.0.0" unitRef="USD" decimals="-3">23917000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="InvestmentsFairValueDisclosure.2665.2139.1998.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.2139.1998.0.0.0.0" unitRef="USD" decimals="-3">32945000</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="InvestmentsFairValueDisclosure.2664.2129.1998.0.0.0.0" xsi:nil="true" contextRef="as-of-2013-09-30.2664.0.2129.1998.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:InvestmentsFairValueDisclosure id="InvestmentsFairValueDisclosure.2665.2129.1998.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-12-31.2665.0.2129.1998.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock id="InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Note 6 - Investments&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Investments classified as available-for-sale as of September 30, 2013 and December 31, 2012 were comprised of (in thousands):&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="14"&gt;&lt;strong&gt;September 30, 2013&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="14"&gt;&lt;strong&gt;December 31, 2012&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Amortized Cost&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Gross Unrealized Gains&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Gross Unrealized Losses&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Fair Value&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Amortized Cost&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Gross Unrealized Gains&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Gross Unrealized Losses&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Fair Value&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 9pt; TEXT-INDENT: -9pt; WIDTH: 20%"&gt; Auction rate securities&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"&gt; 1,175&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"&gt;601&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"&gt;-&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"&gt; 1,776&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"&gt; 1,175&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"&gt;409&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"&gt;-&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"&gt; 1,584&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 9pt; TEXT-INDENT: -9pt"&gt; Corporate debt securities&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 22,137&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 4&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 22,141&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 31,340&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 21&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 31,361&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;Total&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 23,312&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 605&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; TEXT-ALIGN: right"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;-&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 23,917&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 32,515&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 430&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt; 32,945&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
  <us-gaap:Liabilities id="Liabilities.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">28500000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="Liabilities.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">22105000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">245074000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">102345000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">14260000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">11675000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermNotesPayable id="LongTermNotesPayable.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1653000</us-gaap:LongTermNotesPayable>
  <us-gaap:LongTermNotesPayable id="LongTermNotesPayable.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">753000</us-gaap:LongTermNotesPayable>
  <us-gaap:NatureOfOperations id="NatureOfOperations.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; Note 1 - Organization&lt;/p&gt; &lt;p style="FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Novavax, Inc. ("Novavax," and together with its subsidiary, "Novavax AB," the "Company") is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant protein nanoparticle vaccines and adjuvants. The Company&amp;#39;s product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for seasonal influenza, pandemic influenza and respiratory syncytial virus ("RSV").&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">130943000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">26758000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7231000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-15147000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-33096000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-14977000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.3691.32703.750.0.0.0.0" contextRef="from-2013-09-01-to-2013-09-30.3691.0.32703.750.0.0.0.0" unitRef="USD" decimals="-3">-1500000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-37929000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-20472000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-15300000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-7217000</us-gaap:NetIncomeLoss>
  <us-gaap:NotesPayableCurrent id="NotesPayableCurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">597000</us-gaap:NotesPayableCurrent>
  <us-gaap:NotesPayableCurrent id="NotesPayableCurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">157000</us-gaap:NotesPayableCurrent>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-38181000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-20170000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-15279000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-6849000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsReceivable id="OperatingLeasesFutureMinimumPaymentsReceivable.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1900000</us-gaap:OperatingLeasesFutureMinimumPaymentsReceivable>
  <us-gaap:OtherAssetsCurrent id="OtherAssetsCurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">365000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent id="OtherAssetsCurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">171000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent id="OtherAssetsNoncurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">164000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="OtherAssetsNoncurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">351000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent id="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">509000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent id="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.2666.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent id="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">509000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent id="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.2668.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">683000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">204000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">476000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">96000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">174000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">204000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-33000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">96000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherLiabilitiesFairValueDisclosure id="OtherLiabilitiesFairValueDisclosure.2664.2138.1998.0.0.0.0" xsi:nil="true" contextRef="as-of-2013-09-30.2664.0.2138.1998.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:OtherLiabilitiesFairValueDisclosure id="OtherLiabilitiesFairValueDisclosure.2665.2138.1998.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-12-31.2665.0.2138.1998.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:OtherLiabilitiesFairValueDisclosure id="OtherLiabilitiesFairValueDisclosure.2664.2139.1998.0.0.0.0" xsi:nil="true" contextRef="as-of-2013-09-30.2664.0.2139.1998.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:OtherLiabilitiesFairValueDisclosure id="OtherLiabilitiesFairValueDisclosure.2665.2139.1998.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-12-31.2665.0.2139.1998.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:OtherLiabilitiesFairValueDisclosure id="OtherLiabilitiesFairValueDisclosure.2664.2129.1998.0.0.0.0" xsi:nil="true" contextRef="as-of-2013-09-30.2664.0.2129.1998.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:OtherLiabilitiesFairValueDisclosure id="OtherLiabilitiesFairValueDisclosure.2665.2129.1998.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.2129.1998.0.0.0.0" unitRef="USD" decimals="-3">267000</us-gaap:OtherLiabilitiesFairValueDisclosure>
  <us-gaap:OtherLiabilitiesNoncurrent id="OtherLiabilitiesNoncurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1578000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="OtherLiabilitiesNoncurrent.2665.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:OtherNoncashIncomeExpense id="OtherNoncashIncomeExpense.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-678000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:OtherNoncashIncomeExpense id="OtherNoncashIncomeExpense.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-436000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:OtherNonoperatingExpense id="OtherNonoperatingExpense.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">10000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense id="OtherNonoperatingExpense.2666.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:OtherNonoperatingExpense id="OtherNonoperatingExpense.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">10000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense id="OtherNonoperatingExpense.2668.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PaymentsForProceedsFromTenantAllowance id="PaymentsForProceedsFromTenantAllowance.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">700000</us-gaap:PaymentsForProceedsFromTenantAllowance>
  <us-gaap:PaymentsForProceedsFromTenantAllowance id="PaymentsForProceedsFromTenantAllowance.2676.0.0.0.0.0.0" contextRef="from-2011-11-01-to-2013-09-30.2676.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5000000</us-gaap:PaymentsForProceedsFromTenantAllowance>
  <us-gaap:PaymentsOfStockIssuanceCosts id="PaymentsOfStockIssuanceCosts.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6100000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts id="PaymentsOfStockIssuanceCosts.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">400000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities id="PaymentsToAcquireAvailableForSaleSecurities.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">14754000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities id="PaymentsToAcquireAvailableForSaleSecurities.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">15763000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquireBusinessesGross id="PaymentsToAcquireBusinessesGross.2677.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-07-31.2677.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">22000</us-gaap:PaymentsToAcquireBusinessesGross>
  <us-gaap:PaymentsToAcquireProductiveAssets id="PaymentsToAcquireProductiveAssets.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4762000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PaymentsToAcquireProductiveAssets id="PaymentsToAcquireProductiveAssets.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2202000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="PreferredStockParOrStatedValuePerShare.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="PreferredStockParOrStatedValuePerShare.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="PreferredStockSharesAuthorized.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="shares" decimals="0">2000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="PreferredStockSharesAuthorized.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="shares" decimals="0">2000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="PreferredStockSharesIssued.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="PreferredStockSharesIssued.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="PreferredStockSharesOutstanding.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="PreferredStockSharesOutstanding.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue id="PreferredStockValue.2664.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="PreferredStockValue.2665.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PrepaidExpenseCurrent id="PrepaidExpenseCurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3016000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent id="PrepaidExpenseCurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2559000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription id="PriorPeriodReclassificationAdjustmentDescription.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"&gt; &lt;strong&gt;&lt;em&gt;Reclassifications&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Overhead expenses relating to supply chain management of $0.2 million and $0.6 million for the three and nine months ended September 30, 2012, respectively, have been reclassified from general and administrative expenses to research and development expenses. Also, within the September 30, 2012 statement of cash flows, restricted cash received of $0.8 million recorded in financing activities has been reclassified and is included in operating activities. These reclassifications have been made to conform to current year presentation.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="ProceedsFromIssuanceOfCommonStock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">128659000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="ProceedsFromIssuanceOfCommonStock.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">26925000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfDebt id="ProceedsFromIssuanceOfDebt.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1500000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="ProceedsFromIssuanceOrSaleOfEquity.2672.0.0.0.0.0.0" contextRef="from-2008-07-01-to-2008-07-31.2672.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">17500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromNotesPayable id="ProceedsFromNotesPayable.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1450000</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:ProceedsFromNotesPayable id="ProceedsFromNotesPayable.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">650000</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:ProceedsFromRepaymentsOfNotesPayable id="ProceedsFromRepaymentsOfNotesPayable.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-305000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
  <us-gaap:ProceedsFromRepaymentsOfNotesPayable id="ProceedsFromRepaymentsOfNotesPayable.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-20000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
  <us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities id="ProceedsFromRepaymentsOfRestrictedCashFinancingActivities.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-1000</us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities>
  <us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities id="ProceedsFromRepaymentsOfRestrictedCashFinancingActivities.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-756000</us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities id="ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">23630000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities id="ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2500000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="ProceedsFromSaleOfPropertyPlantAndEquipment.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">83000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="ProceedsFromSaleOfPropertyPlantAndEquipment.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">318000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1194000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">49000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PropertyPlantAndEquipmentNet id="PropertyPlantAndEquipmentNet.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">13969000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="PropertyPlantAndEquipmentNet.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">11456000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="RepaymentsOfLongTermCapitalLeaseObligations.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">54000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations id="RepaymentsOfLongTermCapitalLeaseObligations.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">90000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">33989000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">17270000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">13948000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6642000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue id="RestrictedCashAndCashEquivalentsAtCarryingValue.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">124000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue id="RestrictedCashAndCashEquivalentsAtCarryingValue.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">986000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="RestrictedCashAndCashEquivalentsNoncurrent.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">757000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent id="RestrictedCashAndCashEquivalentsNoncurrent.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">756000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="RetainedEarningsAccumulatedDeficit.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-396092000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="RetainedEarningsAccumulatedDeficit.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-358163000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:Revenues id="Revenues.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">12167000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">17510000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4802000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5765000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.3691.32703.750.0.0.0.0" contextRef="from-2013-09-01-to-2013-09-30.3691.0.32703.750.0.0.0.0" unitRef="USD" decimals="-3">400000</us-gaap:Revenues>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="SaleOfStockNumberOfSharesIssuedInTransaction.3691.32671.5224.0.0.0.0" contextRef="from-2013-09-01-to-2013-09-30.3691.0.32671.5224.0.0.0.0" unitRef="shares" decimals="0">4153950</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockPricePerShare id="SaleOfStockPricePerShare.2664.32671.5224.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.32671.5224.0.0.0.0" unitRef="USD_per_share" decimals="2">3.14</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Three Months Ended&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Nine Months Ended&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 44%; TEXT-INDENT: 0px"&gt; Research and development&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt;316&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt;219&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt;829&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt;638&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; General and administrative&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 347&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 274&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 955&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1,030&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Total stock-based compensation expense&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 663&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 493&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,784&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,668&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock id="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px; TEXT-ALIGN: justify; TEXT-INDENT: 0.5in"&gt; The following table represents the Company&amp;#39;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px; TEXT-ALIGN: justify; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="10"&gt;Fair Value at September 30, 2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="10"&gt;Fair Value at December 31, 2012&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-DECORATION: underline; TEXT-INDENT: 0px"&gt; Assets&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &lt;strong&gt;Level 1&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;Level 2&lt;/strong&gt;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &lt;strong&gt;Level 3&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &lt;strong&gt;Level 1&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &lt;strong&gt;Level 2&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"&gt; &lt;strong&gt;Level 3&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.125in; WIDTH: 28%; TEXT-INDENT: -0.125in"&gt; Corporate debt securities and auction rate securities&lt;/td&gt; &lt;td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"&gt; 23,917&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"&gt; 32,945&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Total investments&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 23,917&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 32,945&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-LEFT: 0px; TEXT-DECORATION: underline; TEXT-INDENT: 0px"&gt; Liabilities&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Warrant liabilities&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 267&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock id="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Year&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;Amount&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 13%"&gt; 2013 (remainder)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 74%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 2%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt;271&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; 2014&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;1,084&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; 2015&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;1,084&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; 2016&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"&gt; 1,084&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; 2017&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"&gt; 1,084&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; 2018&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"&gt; 1,084&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock id="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Gross Carrying Amount&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Accumulated Amortization&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Intangible&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Assets, Net&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Finite-lived intangible assets:&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 58%; TEXT-INDENT: 0px"&gt; Proprietary adjuvant technology&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 11,594&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt;(97&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 11,497&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Collaboration agreements&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 4,992&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (84&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 4,908&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Total identifiable intangible assets&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 16,586&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; (181&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 16,405&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:ScheduleOfGoodwillTextBlock id="ScheduleOfGoodwillTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;Nine Months Ended&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"&gt; &lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2012&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 72%; TEXT-INDENT: 0px"&gt; Beginning balance&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 33,141&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 33,141&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Goodwill resulting from acquisition of business&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;25,298&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Currency translation&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 320&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Ending balance&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 58,759&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 33,141&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
  <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock id="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; Aggregate future minimum principal payments on the GE notes payable, including the 2013 Funding, at September 30, 2013 are as follows (in thousands):&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Year&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold" colspan="2"&gt;Amount&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 13%"&gt; 2013 (remainder)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 74%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 2%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt;143&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; 2014&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;571&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; 2015&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;571&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; 2016&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 396&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1,681&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock id="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;(in thousands)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 86%"&gt; Cash and cash equivalents&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 3,056&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Accounts receivable&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;603&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Prepaid expenses and other assets&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;1,092&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Property and equipment&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;165&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Intangible assets&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;16,380&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px"&gt;Goodwill&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;25,298&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Accounts payable and other current liabilities&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;(2,784&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Capital leases&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;(94&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Notes payable&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;(193&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"&gt; Other non-current liabilities&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (1,559&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"&gt; Total purchase price&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 41,964&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6"&gt;2005 Stock Incentive Plan&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6"&gt;1995 Stock Option Plan&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Stock Options&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Weighted-Average Exercise Price&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Stock Options&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;Weighted-Average Exercise Price&lt;/strong&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; WIDTH: 44%; TEXT-INDENT: 0px"&gt; Outstanding at January 1, 2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 9,143,825&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 1.87&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 211,900&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 4.94&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Granted&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"&gt; 4,117,500&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"&gt; 1.92&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Exercised&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"&gt; (522,292&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;2.29&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Canceled&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (802,883&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1.74&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; (23,750&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; )&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 4.05&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Outstanding at September 30, 2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 11,936,150&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 1.88&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 188,150&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 5.04&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Shares exercisable at September 30, 2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4,647,873&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 2.12&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 188,150&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 5.04&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif; PADDING-LEFT: 0px; TEXT-INDENT: 0px"&gt; Shares available for grant at September 30, 2013&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; &lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"&gt; 6,461,494&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &lt;font style="FONT-WEIGHT: normal; FONT-STYLE: normal"&gt;&amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The fair value of stock options granted was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid" colspan="6"&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Three Months Ended&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid" colspan="6"&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Nine Months Ended&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;2012&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;2013&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"&gt;&lt;strong&gt;2012&lt;/strong&gt;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 44%"&gt;Weighted-average fair value of stock options granted&lt;/td&gt; &lt;td style="WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 1.41&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 1.09&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 1.02&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 2%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"&gt; 0.71&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Risk-free interest rate&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;1.12%-1.36&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0.55&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0.54%-1.36&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0.55%-1.54&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Dividend yield&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Volatility&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;56.75%-62.51&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;76.60%-76.71&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;55.81%-73.72&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;75.47%-80.48&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Expected term (in years)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;4.25&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;4.24&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;3.98-7.05&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;3.34-7.09&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Expected forfeiture rate&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;23.15&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;23.15&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0%-23.15&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0%-23.15&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.2663.1806.1391.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.1806.1391.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The ESPP is considered compensatory for financial reporting purposes. As such, the fair value of ESPP shares was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 75%" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center" colspan="3"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;Three Months Ended&lt;/strong&gt;&lt;/font&gt; &lt;br /&gt; &lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;September 30,&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center"&gt; &lt;strong&gt;2013&lt;/strong&gt;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 77%"&gt;Weighted-average fair value of ESPP shares granted&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 20%"&gt; 0.78&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Risk-free interest rate&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0.04&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Dividend yield&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Volatility&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;50.80&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Expected term (in years)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;0.5&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="FONT-SIZE: 10pt"&gt;Expected forfeiture rate&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; TEXT-ALIGN: right"&gt;5&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1784000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1668000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.2663.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="shares" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue.2663.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD_per_share" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.2663.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="shares" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.2663.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD_per_share" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="shares" decimals="0">33334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="shares" decimals="0">33334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">1.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">1.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod.2663.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="shares" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue.2663.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD_per_share" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.2667.1806.1391.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.1806.1391.0.0.0.0" unitRef="pure" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0">P4Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0">P4Y2M27D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.2663.3373.4365.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.3373.4365.0.0.0.0">P7Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.2666.3373.4365.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.3373.4365.0.0.0.0">P7Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.2667.1806.1391.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.1806.1391.0.0.0.0">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.2663.3382.4365.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.3382.4365.0.0.0.0">P3Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.2666.3382.4365.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.3382.4365.0.0.0.0">P3Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.2667.1806.1391.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.1806.1391.0.0.0.0" unitRef="pure" decimals="3">0.508</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="pure" decimals="4">0.7372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="pure" decimals="4">0.8048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="pure" decimals="4">0.6251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="pure" decimals="4">0.7671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="pure" decimals="4">0.5581</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="pure" decimals="4">0.7547</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="pure" decimals="4">0.5675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="pure" decimals="3">0.766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.2667.1806.1391.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.1806.1391.0.0.0.0" unitRef="pure" decimals="4">0.0004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="pure" decimals="4">0.0055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="pure" decimals="4">0.0136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="pure" decimals="4">0.0154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="pure" decimals="4">0.0136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="pure" decimals="4">0.0054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="pure" decimals="4">0.0055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="pure" decimals="4">0.0112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized.2663.23962.4031.4759.5162.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23962.4031.4759.5162.0.0" unitRef="shares" decimals="0">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.2664.23962.4031.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.23962.4031.0.0.0.0" unitRef="shares" decimals="0">22312192</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.2664.23942.4031.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.23942.4031.0.0.0.0" unitRef="shares" decimals="0">5746468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.2664.27970.4031.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.27970.4031.0.0.0.0" unitRef="shares" decimals="0">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.2664.23962.4031.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.23962.4031.0.0.0.0" unitRef="shares" decimals="0">6461494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.2664.23962.4031.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.23962.4031.0.0.0.0" unitRef="shares" decimals="0">4647873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.2664.23942.4031.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.23942.4031.0.0.0.0" unitRef="shares" decimals="0">188150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.2664.23962.4031.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.23962.4031.0.0.0.0" unitRef="USD_per_share" decimals="2">2.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.2664.23942.4031.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.23942.4031.0.0.0.0" unitRef="USD_per_share" decimals="2">5.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod.2663.23942.4031.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23942.4031.0.0.0.0" unitRef="shares" decimals="0">23750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod.2663.23962.4031.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23962.4031.0.0.0.0" unitRef="shares" decimals="0">802883</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.2663.23962.4031.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23962.4031.0.0.0.0" unitRef="shares" decimals="0">4117500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.2663.23942.4031.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23942.4031.0.0.0.0" unitRef="shares" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.2667.1806.1391.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.1806.1391.0.0.0.0" unitRef="USD_per_share" decimals="2">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">1.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">15900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.2664.23962.4031.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.23962.4031.0.0.0.0" unitRef="shares" decimals="0">11936150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.2665.23962.4031.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.23962.4031.0.0.0.0" unitRef="shares" decimals="0">9143825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.2664.23942.4031.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.23942.4031.0.0.0.0" unitRef="shares" decimals="0">188150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.2665.23942.4031.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.23942.4031.0.0.0.0" unitRef="shares" decimals="0">211900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.2664.23962.4031.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.23962.4031.0.0.0.0" unitRef="USD_per_share" decimals="2">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.2665.23962.4031.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.23962.4031.0.0.0.0" unitRef="USD_per_share" decimals="2">1.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.2664.23942.4031.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.23942.4031.0.0.0.0" unitRef="USD_per_share" decimals="2">5.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.2665.23942.4031.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.23942.4031.0.0.0.0" unitRef="USD_per_share" decimals="2">4.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.2663.23962.4031.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23962.4031.0.0.0.0" unitRef="USD_per_share" decimals="2">2.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.2663.23942.4031.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23942.4031.0.0.0.0" unitRef="USD_per_share" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.2663.23962.4031.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23962.4031.0.0.0.0" unitRef="USD_per_share" decimals="2">1.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.2663.23942.4031.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23942.4031.0.0.0.0" unitRef="USD_per_share" decimals="2">4.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.2663.23962.4031.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23962.4031.0.0.0.0" unitRef="USD_per_share" decimals="2">1.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.2663.23942.4031.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23942.4031.0.0.0.0" unitRef="USD_per_share" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockholdersEquity id="StockholdersEquity.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">216574000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">80240000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="StockholdersEquityNoteDisclosureTextBlock.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &lt;strong&gt;Note 8 - Stockholders&amp;#39; Equity&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; On June 13, 2013, the Company&amp;#39;s stockholders of record as of April 16, 2013 approved the amendment of the Company&amp;#39;s certificate of incorporation to increase the total number of shares of Common Stock that the Company is authorized to issue from 200,000,000 shares to 300,000,000 shares.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; In October 2012, the Company entered into an At Market Issuance Sales Agreement ("2012 Sales Agreement"), under which the Board of Directors of the Company (the "Board") approved the Company&amp;#39;s sale of up to an aggregate of $50 million in gross proceeds of its common stock. The shares of common stock are being offered pursuant to a shelf registration statement filed with the SEC in March 2013, which replaced the previous shelf registration statement filed in 2010. The Board&amp;#39;s standing Finance Committee (the "Committee") assists with its responsibilities to monitor, provide advice to senior management of the Company and approve all capital raising activities. The Committee has been authorized by the Board, absent any action by the Board to the contrary, to take any additional actions necessary to carry out the Board&amp;#39;s authorization of the issuance and sale of the common stock sold pursuant to the 2012 Sales Agreement. In doing so, the Committee is authorized to set the amount of shares to be sold, the period of time during which such sales may occur and the minimum sales price per share. During the nine months ended September 30, 2013, the Company sold 12.6 million shares at sales prices ranging from $2.06 to $3.38 per share, resulting in $34.0 million in net proceeds. The most recent sales to occur under the 2012 Sales Agreement were on September 10, 2013.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; In September 2013, the Company completed a public offering of 31,846,950 shares of its common stock, including 4,153,950 shares of common stock that were issued upon the exercise in full of the over-allotment granted to the underwriters, at a price of $3.14 per share resulting in net proceeds of approximately $94.7 million.&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="StockIssuedDuringPeriodSharesNewIssues.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="shares" decimals="0">12600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="StockIssuedDuringPeriodSharesNewIssues.2672.0.0.0.0.0.0" contextRef="from-2008-07-01-to-2008-07-31.2672.0.0.0.0.0.0.0" unitRef="shares" decimals="0">6686650</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="StockIssuedDuringPeriodSharesNewIssues.3691.32671.5224.0.0.0.0" contextRef="from-2013-09-01-to-2013-09-30.3691.0.32671.5224.0.0.0.0" unitRef="shares" decimals="0">31846950</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.2663.23962.4031.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23962.4031.0.0.0.0" unitRef="shares" decimals="0">522292</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.2663.23942.4031.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-09-30.2663.0.23942.4031.0.0.0.0" unitRef="shares" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">34000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.3691.32671.5224.0.0.0.0" contextRef="from-2013-09-01-to-2013-09-30.3691.0.32671.5224.0.0.0.0" unitRef="USD" decimals="-3">94700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:TreasuryStockShares id="TreasuryStockShares.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="shares" decimals="0">455430</us-gaap:TreasuryStockShares>
  <us-gaap:TreasuryStockShares id="TreasuryStockShares.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="shares" decimals="0">455430</us-gaap:TreasuryStockShares>
  <us-gaap:TreasuryStockValue id="TreasuryStockValue.2664.0.0.0.0.0.0" contextRef="as-of-2013-09-30.2664.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2450000</us-gaap:TreasuryStockValue>
  <us-gaap:TreasuryStockValue id="TreasuryStockValue.2665.0.0.0.0.0.0" contextRef="as-of-2012-12-31.2665.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2450000</us-gaap:TreasuryStockValue>
  <us-gaap:UseOfEstimates id="UseOfEstimates.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &lt;strong&gt;&lt;em&gt;Use of Estimates&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"&gt; The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these estimates.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.2663.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0" unitRef="shares" decimals="0">156555</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.2666.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0" unitRef="shares" decimals="0">127246</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.2667.0.0.0.0.0.0" contextRef="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0" unitRef="shares" decimals="0">168537</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.2668.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0" unitRef="shares" decimals="0">134178</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USD_per_share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USD_per_Warrant">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>nvax:Warrant</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="from-2013-09-01-to-2013-09-30.3691.0.32703.750.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:NovavaxAbMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-09-01-to-2013-09-30.3691.0.32671.5224.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:SecondPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-09-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-07-01-to-2013-09-30.2667.0.4573.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-07-01-to-2013-09-30.2667.0.2476.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-07-01-to-2013-09-30.2667.0.1806.1391.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-07-01-to-2013-09-30.2667.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-07-01-to-2013-07-31.2677.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>
      <xbrli:endDate>2013-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.646.3313.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.4573.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.3382.4365.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.3373.4365.31352.4540.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:CadilaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.3373.4365.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.31352.4540.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:CadilaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.2476.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.23966.4707.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:WarrantsSettleableInCashMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.23962.4031.4759.5162.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:TwoZeroZeroFiveStockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.23962.4031.3382.4365.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:TwoZeroZeroFiveStockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.23962.4031.3373.4365.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:TwoZeroZeroFiveStockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.23962.4031.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:TwoZeroZeroFiveStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.23945.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:PathVaccineSolutionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.23942.4031.3382.4365.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:OneNineNineFiveStockOptionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.23942.4031.3373.4365.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:OneNineNineFiveStockOptionPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.23942.4031.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:OneNineNineFiveStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.23929.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:HhsBardaContractAwardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.1806.1391.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.1234.3313.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-09-30.2663.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-09-01-to-2012-09-30.2678.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-09-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2013-09-30.2685.0.23945.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:PathVaccineSolutionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.2668.0.4573.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.2668.0.2476.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.2668.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-07-31.2683.0.23945.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:PathVaccineSolutionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-03-01-to-2013-09-30.2682.0.23929.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:HhsBardaContractAwardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-03-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.2671.0.646.3313.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.2671.0.1234.3313.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-12-31.2671.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.2666.0.4573.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.2666.0.3382.4365.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.2666.0.3373.4365.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.2666.0.2476.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.2666.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-11-01-to-2013-09-30.2676.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-11-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-02-01-to-2013-09-30.2681.0.23929.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:HhsBardaContractAwardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-02-01</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-02-01-to-2011-02-28.2680.0.23930.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:HhsBardaOptionForAdditionalPeriodMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-02-01</xbrli:startDate>
      <xbrli:endDate>2011-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-02-01-to-2011-02-28.2680.0.23929.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:HhsBardaContractAwardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-02-01</xbrli:startDate>
      <xbrli:endDate>2011-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2009-03-31-to-2013-09-30.4008.0.3373.4365.31352.4540.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:CadilaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-03-31</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2009-03-31-to-2013-09-30.4008.0.31352.4540.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:CadilaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-03-31</xbrli:startDate>
      <xbrli:endDate>2013-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2008-07-01-to-2008-07-31.2672.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2008-07-01</xbrli:startDate>
      <xbrli:endDate>2008-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-10-31.3662.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2664.0.646.3313.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2664.0.32671.5224.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:SecondPublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2664.0.32669.2311.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:ProprietaryAdjuvantTechnologyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2664.0.31339.2311.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:CollaborationAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2664.0.27970.4031.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2664.0.23966.4707.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:WarrantsSettleableInCashMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2664.0.23962.4031.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:TwoZeroZeroFiveStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2664.0.23942.4031.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:OneNineNineFiveStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2664.0.23927.4820.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:EquityMethodInvesteeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2664.0.2139.1998.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2664.0.2138.1998.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2664.0.2129.1998.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2664.0.1234.3313.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-09-30.2664.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-08-31.2684.0.23945.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:PathVaccineSolutionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-07-31.3676.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.2665.0.646.3313.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AuctionRateSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.2665.0.23966.4707.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:WarrantsSettleableInCashMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.2665.0.23962.4031.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:TwoZeroZeroFiveStockIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.2665.0.23942.4031.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:OneNineNineFiveStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.2665.0.2139.1998.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.2665.0.2138.1998.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.2665.0.2129.1998.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.2665.0.1234.3313.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.2665.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-09-30.2670.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.2669.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-11-30.2675.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-02-28.2679.0.23933.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:LicenseAgreementWithLgLifeSciencesLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-02-28.2679.0.23930.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:HhsBardaOptionForAdditionalPeriodMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-02-28.2679.0.23929.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">nvax:HhsBardaContractAwardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-02-28.2679.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2008-07-31.2673.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2008-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>nvax-20130930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-11-12 @ 6:50 AM-->
<xsd:schema targetNamespace="http://www.novavax.com/20130930" elementFormDefault="qualified" xmlns:nvax="http://www.novavax.com/20130930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="nvax-20130930_cal.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="nvax-20130930_def.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="nvax-20130930_lab.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="nvax-20130930_pre.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:roleType roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAb" id="nvax-aoia" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>104 - Disclosure - Acquisition of Isconova AB</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbNarrativeDetails" id="nvax-aoiand" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40401 - Disclosure - Acquisition of Isconova AB (Narrative) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" id="nvax-aoiasoaaalad" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40403 - Disclosure - Acquisition of Isconova AB (Schedule of Assets Acquired and Liabilities Assumed) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbScheduleOfPurchasePriceDetails" id="nvax-aoiasoppd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40402 - Disclosure - Acquisition of Isconova AB (Schedule of Purchase Price) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbTables" id="nvax-aoiat" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>304 - Disclosure - Acquisition of Isconova AB (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbUnauditedProFormaFinancialInformationOfOperationsDetails" id="nvax-aoiaupffiood" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40404 - Disclosure - Acquisition of Isconova AB (Unaudited Pro Forma Financial Information of Operations) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/BalanceSheets" id="nvax-bs" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>002 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/BalanceSheetsParenthetical" id="nvax-bsp" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>003 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/DocumentAndEntityInformation" id="nvax-daei" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/FairValueMeasurements" id="nvax-fvm" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/FairValueMeasurementsFairValueHierarchyDetails" id="nvax-fvmfvhd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40501 - Disclosure - Fair Value Measurements (Fair Value Hierarchy) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/FairValueMeasurementsReconciliationOfLevelThreeAssetsAndLiabilitiesDetails" id="nvax-fvmrolaald" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40502 - Disclosure - Fair Value Measurements (Reconciliation of Level 3 Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/FairValueMeasurementsTables" id="nvax-fvmt" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>305 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssets" id="nvax-gaoia" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>107 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfEstimatedAmortizationExpenseDetails" id="nvax-gaoiasoeaed" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40703 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Estimated Amortization Expense) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails" id="nvax-gaoiasogd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40701 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIdentifiableIntangibleAssetsDetails" id="nvax-gaoiasoiiad" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40702 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Identifiable Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsTables" id="nvax-gaoiat" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>307 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/Investments" id="nvax-i" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>106 - Disclosure - Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/InvestmentsDetails" id="nvax-id" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40601 - Disclosure - Investments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/InvestmentsTables" id="nvax-it" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>306 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/ManufacturingLaboratoryAndOfficeFacility" id="nvax-mlaof" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>113 - Disclosure - Manufacturing, Laboratory and Office Facility</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/ManufacturingLaboratoryAndOfficeFacilityDetails" id="nvax-mlaofd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>41301 - Disclosure - Manufacturing, Laboratory and Office Facility (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/MasterServicesAgreementWithCadila" id="nvax-msawc" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>114 - Disclosure - Master Services Agreement with Cadila</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/MasterServicesAgreementWithCadilaDetails" id="nvax-msawcd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>41401 - Disclosure - Master Services Agreement with Cadila (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/NotesPayable" id="nvax-np" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>111 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/NotesPayableAggregateFutureMinimumPrincipalPaymentsOnEquipmentLoanDetails" id="nvax-npafmppoeld" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>41102 - Disclosure - Notes Payable (Aggregate Future Minimum Principal Payments on Equipment Loan) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/NotesPayableNarrativeDetails" id="nvax-npnd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>41101 - Disclosure - Notes Payable (Narrative) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/NotesPayableTables" id="nvax-npt" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>311 - Disclosure - Notes Payable (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/Organization" id="nvax-o" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/Operations" id="nvax-o1" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>102 - Disclosure - Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/StockbasedCompensation" id="nvax-sc" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>109 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/StockbasedCompensationAssumptionsUsedInEstimationOfFairValueOfStockOptionsGrantedDetails" id="nvax-scauieofvosogd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40903 - Disclosure - Stock-Based Compensation (Assumptions Used in Estimation of Fair Value of Stock Options Granted) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/StockbasedCompensationNarrativeDetails" id="nvax-scnd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40901 - Disclosure - Stock-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" id="nvax-scsced" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40905 - Disclosure - Stock-Based Compensation (Stock-Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/StockbasedCompensationSummaryOfOptionActivityDetails" id="nvax-scsooad" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40902 - Disclosure - Stock-Based Compensation (Summary of Option Activity) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/StockbasedCompensationSummaryOfRestrictedStockAwardsActivityDetails" id="nvax-scsorsaad" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40904 - Disclosure - Stock-Based Compensation (Summary of Restricted Stock Awards Activity) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/StockbasedCompensationTables" id="nvax-sct" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>309 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/StockholdersEquity" id="nvax-se" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>108 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/StockholdersEquityDetails" id="nvax-sed" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40801 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/StatementsOfCashFlows" id="nvax-socf" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>006 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/StatementsOfCashFlowsParenthetical" id="nvax-socfp" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>007 - Statement - STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/StatementsOfComprehensiveLoss" id="nvax-socl" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>005 - Statement - STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/StatementsOfOperations" id="nvax-soo" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>004 - Statement - STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/SummaryOfSignificantAccountingPolicies" id="nvax-sosap" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>103 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" id="nvax-sosapnd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40301 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/SummaryOfSignificantAccountingPoliciesPolicy" id="nvax-sosapp" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>203 - Disclosure - Summary of Significant Accounting Policies (Policy)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/UsGovernmentAgreementJointVentureAndCollaborations" id="nvax-ugajvac" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>110 - Disclosure - U.S. Government Agreement, Joint Venture and Collaborations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/UsGovernmentAgreementJointVentureAndCollaborationsDetails" id="nvax-ugajvacd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>41001 - Disclosure - U.S. Government Agreement, Joint Venture and Collaborations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/WarrantLiability" id="nvax-wl" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>112 - Disclosure - Warrant Liability</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.novavax.com/role/WarrantLiabilityDetails" id="nvax-wld" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>41201 - Disclosure - Warrant Liability (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:element name="AcquiredOutstandingShares" id="nvax_AcquiredOutstandingShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element name="AcquisitionOfIsconovaAbTextBlock" id="nvax_AcquisitionOfIsconovaAbTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="AcquisitionTransactionCosts" id="nvax_AcquisitionTransactionCosts" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="AdditionalTenantImprovementAllowance" id="nvax_AdditionalTenantImprovementAllowance" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="AggregateGrossProceedsSaleOfStock" id="nvax_AggregateGrossProceedsSaleOfStock" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" id="nvax_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType" />
  <xsd:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" id="nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="CadilaMember" id="nvax_CadilaMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="CapitalLeaseObligationEquipmentPurchased" id="nvax_CapitalLeaseObligationEquipmentPurchased" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ClinicalTrialCostsIncurred" id="nvax_ClinicalTrialCostsIncurred" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="CollaborationAgreementsMember" id="nvax_CollaborationAgreementsMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="CommonSharesPerUnit" id="nvax_CommonSharesPerUnit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element name="CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement" id="nvax_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ContractTerm" id="nvax_ContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element name="DepositsForAcquisitionOfPropertyAndEquipment" id="nvax_DepositsForAcquisitionOfPropertyAndEquipment" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="nvax_DocumentAndEntityInformationAbstract" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="EmployeeStockPurchasePlanMember" id="nvax_EmployeeStockPurchasePlanMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="EquityMethodInvesteeOneMember" id="nvax_EquityMethodInvesteeOneMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ExpectedClinicalTrialCosts" id="nvax_ExpectedClinicalTrialCosts" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="GovernmentContractReceivableIncrease" id="nvax_GovernmentContractReceivableIncrease" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="HalfPaymentForPortionOfShortfallExceedingTwoMillion" id="nvax_HalfPaymentForPortionOfShortfallExceedingTwoMillion" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="HhsBardaContractAwardMember" id="nvax_HhsBardaContractAwardMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="HhsBardaOptionForAdditionalPeriodMember" id="nvax_HhsBardaOptionForAdditionalPeriodMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="JointVenturePercentageOwnedByOthers" id="nvax_JointVenturePercentageOwnedByOthers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="LeasedFacilitySquareFootage" id="nvax_LeasedFacilitySquareFootage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element name="LicenseAgreementWithLgLifeSciencesLtdMember" id="nvax_LicenseAgreementWithLgLifeSciencesLtdMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="LoanAgreementFutureMinimumPaymentsDue" id="nvax_LoanAgreementFutureMinimumPaymentsDue" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="LoanAgreementFutureMinimumPaymentsDueInYearThree" id="nvax_LoanAgreementFutureMinimumPaymentsDueInYearThree" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="LoanAgreementFutureMinimumPaymentsDueInYearTwo" id="nvax_LoanAgreementFutureMinimumPaymentsDueInYearTwo" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="LoanAgreementFutureMinimumPaymentsNextTwelveMonths" id="nvax_LoanAgreementFutureMinimumPaymentsNextTwelveMonths" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear" id="nvax_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ManufacturingLaboratoryAndOfficeFacilityAbstract" id="nvax_ManufacturingLaboratoryAndOfficeFacilityAbstract" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="MasterServiceAgreement" id="nvax_MasterServiceAgreement" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="MasterServicesAgreementWithCadilaAbstract" id="nvax_MasterServicesAgreementWithCadilaAbstract" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="MasterServicesAgreementWithCadilaTextBlock" id="nvax_MasterServicesAgreementWithCadilaTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="NewFacilityLeaseDisclosureTextBlock" id="nvax_NewFacilityLeaseDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="NovavaxAbMember" id="nvax_NovavaxAbMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="NovavaxSharesIssued" id="nvax_NovavaxSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element name="NumberOfAuctionRateSecuritiesIncludedInInvestments" id="nvax_NumberOfAuctionRateSecuritiesIncludedInInvestments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element name="OneNineNineFiveStockOptionPlanMember" id="nvax_OneNineNineFiveStockOptionPlanMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="OperationsAbstract" id="nvax_OperationsAbstract" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="OperationsDisclosureTextBlock" id="nvax_OperationsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="PathVaccineSolutionsMember" id="nvax_PathVaccineSolutionsMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="PaymentToRelatedPartyPortionOfShortfall" id="nvax_PaymentToRelatedPartyPortionOfShortfall" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent" id="nvax_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="ProprietaryAdjuvantTechnologyMember" id="nvax_ProprietaryAdjuvantTechnologyMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ReclassificationFromAccountsPayableToLeaseIncentivesReceived" id="nvax_ReclassificationFromAccountsPayableToLeaseIncentivesReceived" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses" id="nvax_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities" id="nvax_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ResearchAndDevelopmentCollaboration" id="nvax_ResearchAndDevelopmentCollaboration" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ResearchAndDevelopmentCollaborationIncrease" id="nvax_ResearchAndDevelopmentCollaborationIncrease" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="RoyaltyPaymentsPercentOfFutureProductSales" id="nvax_RoyaltyPaymentsPercentOfFutureProductSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="ScheduleOfPurchasePriceTableTextBlock" id="nvax_ScheduleOfPurchasePriceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" id="nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="SecondPublicOfferingMember" id="nvax_SecondPublicOfferingMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ServicesProvidedDuringThePeriod" id="nvax_ServicesProvidedDuringThePeriod" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ServicesPurchased" id="nvax_ServicesPurchased" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" id="nvax_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant" id="nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" id="nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm" id="nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType" />
  <xsd:element name="StockWarrantsTextBlock" id="nvax_StockWarrantsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="TenantAllowanceInterestRate" id="nvax_TenantAllowanceInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="TenantImprovementAllowance" id="nvax_TenantImprovementAllowance" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="TwoZeroZeroFiveStockIncentivePlanMember" id="nvax_TwoZeroZeroFiveStockIncentivePlanMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="UpfrontLicensePayment" id="nvax_UpfrontLicensePayment" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="UsGovernmentAgreementAndCollaborationsAbstract" id="nvax_UsGovernmentAgreementAndCollaborationsAbstract" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="WarrantLiabilityAbstract" id="nvax_WarrantLiabilityAbstract" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="WarrantsSettleableInCashMember" id="nvax_WarrantsSettleableInCashMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>nvax-20130930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-11-12 @ 6:50 AM-->
<link:linkbase xmlns:nvax="http://www.novavax.com/20130930" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.novavax.com/role/BalanceSheets" xlink:href="nvax-20130930.xsd#nvax-bs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/BalanceSheetsParenthetical" xlink:href="nvax-20130930.xsd#nvax-bsp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StatementsOfCashFlows" xlink:href="nvax-20130930.xsd#nvax-socf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/DocumentAndEntityInformation" xlink:href="nvax-20130930.xsd#nvax-daei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurements" xlink:href="nvax-20130930.xsd#nvax-fvm" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsFairValueHierarchyDetails" xlink:href="nvax-20130930.xsd#nvax-fvmfvhd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsReconciliationOfLevelThreeAssetsAndLiabilitiesDetails" xlink:href="nvax-20130930.xsd#nvax-fvmrolaald" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsTables" xlink:href="nvax-20130930.xsd#nvax-fvmt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/Investments" xlink:href="nvax-20130930.xsd#nvax-i" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/InvestmentsDetails" xlink:href="nvax-20130930.xsd#nvax-id" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/InvestmentsTables" xlink:href="nvax-20130930.xsd#nvax-it" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/ManufacturingLaboratoryAndOfficeFacility" xlink:href="nvax-20130930.xsd#nvax-mlaof" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/ManufacturingLaboratoryAndOfficeFacilityDetails" xlink:href="nvax-20130930.xsd#nvax-mlaofd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/NotesPayable" xlink:href="nvax-20130930.xsd#nvax-np" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/NotesPayableAggregateFutureMinimumPrincipalPaymentsOnEquipmentLoanDetails" xlink:href="nvax-20130930.xsd#nvax-npafmppoeld" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/NotesPayableNarrativeDetails" xlink:href="nvax-20130930.xsd#nvax-npnd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/NotesPayableTables" xlink:href="nvax-20130930.xsd#nvax-npt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/Organization" xlink:href="nvax-20130930.xsd#nvax-o" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/Operations" xlink:href="nvax-20130930.xsd#nvax-o1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensation" xlink:href="nvax-20130930.xsd#nvax-sc" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationAssumptionsUsedInEstimationOfFairValueOfStockOptionsGrantedDetails" xlink:href="nvax-20130930.xsd#nvax-scauieofvosogd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationNarrativeDetails" xlink:href="nvax-20130930.xsd#nvax-scnd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:href="nvax-20130930.xsd#nvax-scsced" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationSummaryOfOptionActivityDetails" xlink:href="nvax-20130930.xsd#nvax-scsooad" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationSummaryOfRestrictedStockAwardsActivityDetails" xlink:href="nvax-20130930.xsd#nvax-scsorsaad" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationTables" xlink:href="nvax-20130930.xsd#nvax-sct" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StatementsOfComprehensiveLoss" xlink:href="nvax-20130930.xsd#nvax-socl" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StatementsOfOperations" xlink:href="nvax-20130930.xsd#nvax-soo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="nvax-20130930.xsd#nvax-sosap" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="nvax-20130930.xsd#nvax-sosapnd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryOfSignificantAccountingPoliciesPolicy" xlink:href="nvax-20130930.xsd#nvax-sosapp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StatementsOfCashFlowsParenthetical" xlink:href="nvax-20130930.xsd#nvax-socfp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/UsGovernmentAgreementJointVentureAndCollaborations" xlink:href="nvax-20130930.xsd#nvax-ugajvac" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/UsGovernmentAgreementJointVentureAndCollaborationsDetails" xlink:href="nvax-20130930.xsd#nvax-ugajvacd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/WarrantLiability" xlink:href="nvax-20130930.xsd#nvax-wl" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/WarrantLiabilityDetails" xlink:href="nvax-20130930.xsd#nvax-wld" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersEquity" xlink:href="nvax-20130930.xsd#nvax-se" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAb" xlink:href="nvax-20130930.xsd#nvax-aoia" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersEquityDetails" xlink:href="nvax-20130930.xsd#nvax-sed" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbNarrativeDetails" xlink:href="nvax-20130930.xsd#nvax-aoiand" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssets" xlink:href="nvax-20130930.xsd#nvax-gaoia" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/MasterServicesAgreementWithCadila" xlink:href="nvax-20130930.xsd#nvax-msawc" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsTables" xlink:href="nvax-20130930.xsd#nvax-gaoiat" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbTables" xlink:href="nvax-20130930.xsd#nvax-aoiat" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/MasterServicesAgreementWithCadilaDetails" xlink:href="nvax-20130930.xsd#nvax-msawcd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails" xlink:href="nvax-20130930.xsd#nvax-gaoiasogd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIdentifiableIntangibleAssetsDetails" xlink:href="nvax-20130930.xsd#nvax-gaoiasoiiad" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfEstimatedAmortizationExpenseDetails" xlink:href="nvax-20130930.xsd#nvax-gaoiasoeaed" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbScheduleOfPurchasePriceDetails" xlink:href="nvax-20130930.xsd#nvax-aoiasoppd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="nvax-20130930.xsd#nvax-aoiasoaaalad" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbUnauditedProFormaFinancialInformationOfOperationsDetails" xlink:href="nvax-20130930.xsd#nvax-aoiaupffiood" xlink:type="simple" />
  <link:calculationLink xlink:title="002 - Statement - BALANCE SHEETS" xlink:role="http://www.novavax.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:label="loc_Assets.6057.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.15211.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.6057.14.6" xlink:to="loc_PropertyPlantAndEquipmentNet.15211.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AssetsCurrent.6084.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.6057.14.6" xlink:to="loc_AssetsCurrent.6084.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_Goodwill.10732.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.6057.14.6" xlink:to="loc_Goodwill.10732.14.6" order="5.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_RestrictedCashAndCashEquivalentsNoncurrent.15932.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.6057.14.6" xlink:to="loc_RestrictedCashAndCashEquivalentsNoncurrent.15932.14.6" order="6.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherAssetsNoncurrent.13824.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.6057.14.6" xlink:to="loc_OtherAssetsNoncurrent.13824.14.6" order="7.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesNoncurrent.6236.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.6057.14.6" xlink:to="loc_AvailableForSaleSecuritiesNoncurrent.6236.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IntangibleAssetsNetExcludingGoodwill.11570.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.6057.14.6" xlink:to="loc_IntangibleAssetsNetExcludingGoodwill.11570.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PrepaidExpenseCurrent.14768.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.6084.14.6" xlink:to="loc_PrepaidExpenseCurrent.14768.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.6084.14.6" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6843.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesCurrent.6200.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.6084.14.6" xlink:to="loc_AvailableForSaleSecuritiesCurrent.6200.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GovernmentContractReceivableUnbilledAmounts.10756.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GovernmentContractReceivableUnbilledAmounts" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.6084.14.6" xlink:to="loc_GovernmentContractReceivableUnbilledAmounts.10756.14.6" order="5.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherAssetsCurrent.13853.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.6084.14.6" xlink:to="loc_OtherAssetsCurrent.13853.14.6" order="6.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_RestrictedCashAndCashEquivalentsAtCarryingValue.15928.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.6084.14.6" xlink:to="loc_RestrictedCashAndCashEquivalentsAtCarryingValue.15928.14.6" order="7.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5665.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.6084.14.6" xlink:to="loc_AccountsReceivableNetCurrent.5665.14.6" order="20.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesCurrent.12126.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:loc xlink:label="loc_NotesPayableCurrent.13431.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.12126.14.6" xlink:to="loc_NotesPayableCurrent.13431.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccruedLiabilitiesCurrent.5762.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.12126.14.6" xlink:to="loc_AccruedLiabilitiesCurrent.5762.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsPayableCurrent.5684.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.12126.14.6" xlink:to="loc_AccountsPayableCurrent.5684.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7937.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.12126.14.6" xlink:to="loc_DeferredRevenueCurrent.7937.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CapitalLeaseObligationsCurrent.6657.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.12126.14.6" xlink:to="loc_CapitalLeaseObligationsCurrent.6657.14.6" order="5.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredRentCreditCurrent.7951.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.12126.14.6" xlink:to="loc_DeferredRentCreditCurrent.7951.14.6" order="6.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DerivativeLiabilitiesCurrent.8440.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.12126.14.6" xlink:to="loc_DerivativeLiabilitiesCurrent.8440.14.6" order="20.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.12135.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.17302.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.12135.14.6" xlink:to="loc_StockholdersEquity.17302.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentsAndContingencies.7121.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.12135.14.6" xlink:to="loc_CommitmentsAndContingencies.7121.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_Liabilities.12166.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.12135.14.6" xlink:to="loc_Liabilities.12166.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_Liabilities.12166.14.6" xlink:to="loc_LiabilitiesCurrent.12126.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7950.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Liabilities.12166.14.6" xlink:to="loc_DeferredRevenueNoncurrent.7950.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CapitalLeaseObligationsNoncurrent.6668.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Liabilities.12166.14.6" xlink:to="loc_CapitalLeaseObligationsNoncurrent.6668.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LongTermNotesPayable.12765.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Liabilities.12166.14.6" xlink:to="loc_LongTermNotesPayable.12765.14.6" order="5.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredRentCreditNoncurrent.7913.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Liabilities.12166.14.6" xlink:to="loc_DeferredRentCreditNoncurrent.7913.14.6" order="6.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherLiabilitiesNoncurrent.14010.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Liabilities.12166.14.6" xlink:to="loc_OtherLiabilitiesNoncurrent.14010.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_RetainedEarningsAccumulatedDeficit.16058.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_StockholdersEquity.17302.14.6" xlink:to="loc_RetainedEarningsAccumulatedDeficit.16058.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AdditionalPaidInCapital.5816.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_StockholdersEquity.17302.14.6" xlink:to="loc_AdditionalPaidInCapital.5816.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CommonStockValue.7134.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_StockholdersEquity.17302.14.6" xlink:to="loc_CommonStockValue.7134.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PreferredStockValue.14687.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_StockholdersEquity.17302.14.6" xlink:to="loc_PreferredStockValue.14687.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax.5786.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_StockholdersEquity.17302.14.6" xlink:to="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax.5786.14.6" order="5.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_TreasuryStockValue.17716.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockValue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_StockholdersEquity.17302.14.6" xlink:to="loc_TreasuryStockValue.17716.14.6" order="6.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="006 - Statement - STATEMENTS OF CASH FLOWS" xlink:role="http://www.novavax.com/role/StatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.14.6" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.13246.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.14.6" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities.13246.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.13253.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.14.6" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities.13253.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.14.6" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsToAcquireAvailableForSaleSecurities.14334.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.13246.14.6" xlink:to="loc_PaymentsToAcquireAvailableForSaleSecurities.14334.14.6" order="1.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.15068.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.13246.14.6" xlink:to="loc_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.15068.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsToAcquireProductiveAssets.14309.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.13246.14.6" xlink:to="loc_PaymentsToAcquireProductiveAssets.14309.14.6" order="5.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.15098.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.13246.14.6" xlink:to="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.15098.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CashAcquiredFromAcquisition.6848.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.13246.14.6" xlink:to="loc_CashAcquiredFromAcquisition.6848.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStock.15031.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.13253.14.6" xlink:to="loc_ProceedsFromIssuanceOfCommonStock.15031.14.6" order="6.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.13253.14.6" xlink:to="loc_ProceedsFromStockOptionsExercised.15050.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities.14902.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.13253.14.6" xlink:to="loc_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities.14902.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromNotesPayable.15002.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.13253.14.6" xlink:to="loc_ProceedsFromNotesPayable.15002.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromRepaymentsOfNotesPayable.14920.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.13253.14.6" xlink:to="loc_ProceedsFromRepaymentsOfNotesPayable.14920.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_RepaymentsOfLongTermCapitalLeaseObligations.15819.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.13253.14.6" xlink:to="loc_RepaymentsOfLongTermCapitalLeaseObligations.15819.14.6" order="5.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_NetIncomeLoss.13265.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DepreciationAndAmortization.8349.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_DepreciationAndAmortization.8349.14.6" order="11.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensation.16900.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_ShareBasedCompensation.16900.14.6" order="12.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment.10640.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_GainLossOnSaleOfPropertyPlantEquipment.10640.14.6" order="13.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.14.6" order="14.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInUnbilledReceivables.11471.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_IncreaseDecreaseInUnbilledReceivables.11471.14.6" order="4.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.11432.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.11432.14.6" order="5.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.11341.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_IncreaseDecreaseInDeferredRevenue.11341.14.6" order="6.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInOtherNoncurrentLiabilities.11304.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_IncreaseDecreaseInOtherNoncurrentLiabilities.11304.14.6" order="7.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherNoncashIncomeExpense.13827.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_OtherNoncashIncomeExpense.13827.14.6" order="8.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccretionAmortizationOfDiscountsAndPremiumsInvestments.5696.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_AccretionAmortizationOfDiscountsAndPremiumsInvestments.5696.14.6" order="9.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GainLossOnDerivativeInstrumentsNetPretax.10572.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_GainLossOnDerivativeInstrumentsNetPretax.10572.14.6" order="10.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCash.11462.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_IncreaseDecreaseInRestrictedCash.11462.14.6" order="2.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.11237.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.14.6" xlink:to="loc_IncreaseDecreaseInAccountsReceivable.11237.14.6" order="3.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="41102 - Disclosure - Notes Payable (Aggregate Future Minimum Principal Payments on Equipment Loan) (Details)" xlink:role="http://www.novavax.com/role/NotesPayableAggregateFutureMinimumPrincipalPaymentsOnEquipmentLoanDetails" xlink:type="extended">
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsDue.23934.14.6" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsDue" xlink:type="locator" />
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear.23938.14.6" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsDue.23934.14.6" xlink:to="loc_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear.23938.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsDueInYearTwo.23937.14.6" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsDueInYearTwo" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsDue.23934.14.6" xlink:to="loc_LoanAgreementFutureMinimumPaymentsDueInYearTwo.23937.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsDueInYearThree.23936.14.6" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsDueInYearThree" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsDue.23934.14.6" xlink:to="loc_LoanAgreementFutureMinimumPaymentsDueInYearThree.23936.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsNextTwelveMonths.32695.14.6" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsNextTwelveMonths" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsDue.23934.14.6" xlink:to="loc_LoanAgreementFutureMinimumPaymentsNextTwelveMonths.32695.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="005 - Statement - STATEMENTS OF COMPREHENSIVE LOSS" xlink:role="http://www.novavax.com/role/StatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:label="loc_ComprehensiveIncomeNetOfTax.7190.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_ComprehensiveIncomeNetOfTax.7190.14.6" xlink:to="loc_NetIncomeLoss.13265.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.14111.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_ComprehensiveIncomeNetOfTax.7190.14.6" xlink:to="loc_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.14111.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.13897.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.14111.14.6" xlink:to="loc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.13897.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.14099.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.14111.14.6" xlink:to="loc_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.14099.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="004 - Statement - STATEMENTS OF OPERATIONS" xlink:role="http://www.novavax.com/role/StatementsOfOperations" xlink:type="extended">
    <link:loc xlink:label="loc_CostsAndExpenses.7476.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10699.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CostsAndExpenses.7476.14.6" xlink:to="loc_GeneralAndAdministrativeExpense.10699.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15880.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CostsAndExpenses.7476.14.6" xlink:to="loc_ResearchAndDevelopmentExpense.15880.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ContractRevenueCost.7296.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractRevenueCost" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CostsAndExpenses.7476.14.6" xlink:to="loc_ContractRevenueCost.7296.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.11075.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator" />
    <link:loc xlink:label="loc_OperatingIncomeLoss.13592.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.11075.14.6" xlink:to="loc_OperatingIncomeLoss.13592.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GainLossOnDerivativeInstrumentsNetPretax.10572.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.11075.14.6" xlink:to="loc_GainLossOnDerivativeInstrumentsNetPretax.10572.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InterestExpense.11654.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.11075.14.6" xlink:to="loc_InterestExpense.11654.14.6" order="4.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InvestmentIncomeNet.11894.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.11075.14.6" xlink:to="loc_InvestmentIncomeNet.11894.14.6" order="5.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherNonoperatingExpense.13989.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.11075.14.6" xlink:to="loc_OtherNonoperatingExpense.13989.14.6" order="2.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeTaxExpenseBenefit.11134.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetIncomeLoss.13265.14.6" xlink:to="loc_IncomeTaxExpenseBenefit.11134.14.6" order="2.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_NetIncomeLoss.13265.14.6" xlink:to="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.11075.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.13592.14.6" xlink:to="loc_CostsAndExpenses.7476.14.6" order="1.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_Revenues.16160.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.13592.14.6" xlink:to="loc_Revenues.16160.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ContractsRevenue.7301.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractsRevenue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Revenues.16160.14.6" xlink:to="loc_ContractsRevenue.7301.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentCollaboration.23950.14.6" xlink:href="nvax-20130930.xsd#nvax_ResearchAndDevelopmentCollaboration" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Revenues.16160.14.6" xlink:to="loc_ResearchAndDevelopmentCollaboration.23950.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="40702 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Identifiable Intangible Assets) (Details)" xlink:role="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsNet.10326.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsGross.10303.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_FiniteLivedIntangibleAssetsNet.10326.14.6" xlink:to="loc_FiniteLivedIntangibleAssetsGross.10303.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAccumulatedAmortization.10322.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_FiniteLivedIntangibleAssetsNet.10326.14.6" xlink:to="loc_FiniteLivedIntangibleAssetsAccumulatedAmortization.10322.14.6" order="2.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="40402 - Disclosure - Acquisition of Isconova AB (Schedule of Purchase Price) (Details)" xlink:role="http://www.novavax.com/role/AcquisitionOfIsconovaAbScheduleOfPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:label="loc_BusinessCombinationConsiderationTransferred1.6477.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" />
    <link:loc xlink:label="loc_PaymentsToAcquireBusinessesGross.14339.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_BusinessCombinationConsiderationTransferred1.6477.14.6" xlink:to="loc_PaymentsToAcquireBusinessesGross.14339.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.6397.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_BusinessCombinationConsiderationTransferred1.6477.14.6" xlink:to="loc_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.6397.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="40403 - Disclosure - Acquisition of Isconova AB (Schedule of Assets Acquired and Liabilities Assumed) (Details)" xlink:role="http://www.novavax.com/role/AcquisitionOfIsconovaAbScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.6620.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="locator" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents.6385.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.6620.14.6" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents.6385.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables.6361.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.6620.14.6" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables.6361.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment.6544.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.6620.14.6" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment.6544.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.31348.14.6" xlink:href="nvax-20130930.xsd#nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.6620.14.6" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.31348.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill.6432.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.6620.14.6" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill.6432.14.6" order="5.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets.6351.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.6620.14.6" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets.6351.14.6" order="6.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable.6359.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.6620.14.6" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable.6359.14.6" order="7.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation.6375.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.6620.14.6" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation.6375.14.6" order="8.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt.6429.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.6620.14.6" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt.6429.14.6" order="9.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther.6380.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.6620.14.6" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther.6380.14.6" order="10.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>nvax-20130930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-11-12 @ 6:50 AM-->
<link:linkbase xmlns:nvax="http://www.novavax.com/20130930" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.novavax.com/role/BalanceSheets" xlink:href="nvax-20130930.xsd#nvax-bs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/BalanceSheetsParenthetical" xlink:href="nvax-20130930.xsd#nvax-bsp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StatementsOfCashFlows" xlink:href="nvax-20130930.xsd#nvax-socf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/DocumentAndEntityInformation" xlink:href="nvax-20130930.xsd#nvax-daei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurements" xlink:href="nvax-20130930.xsd#nvax-fvm" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsFairValueHierarchyDetails" xlink:href="nvax-20130930.xsd#nvax-fvmfvhd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsReconciliationOfLevelThreeAssetsAndLiabilitiesDetails" xlink:href="nvax-20130930.xsd#nvax-fvmrolaald" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsTables" xlink:href="nvax-20130930.xsd#nvax-fvmt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/Investments" xlink:href="nvax-20130930.xsd#nvax-i" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/InvestmentsDetails" xlink:href="nvax-20130930.xsd#nvax-id" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/InvestmentsTables" xlink:href="nvax-20130930.xsd#nvax-it" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/ManufacturingLaboratoryAndOfficeFacility" xlink:href="nvax-20130930.xsd#nvax-mlaof" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/ManufacturingLaboratoryAndOfficeFacilityDetails" xlink:href="nvax-20130930.xsd#nvax-mlaofd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/NotesPayable" xlink:href="nvax-20130930.xsd#nvax-np" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/NotesPayableAggregateFutureMinimumPrincipalPaymentsOnEquipmentLoanDetails" xlink:href="nvax-20130930.xsd#nvax-npafmppoeld" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/NotesPayableNarrativeDetails" xlink:href="nvax-20130930.xsd#nvax-npnd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/NotesPayableTables" xlink:href="nvax-20130930.xsd#nvax-npt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/Organization" xlink:href="nvax-20130930.xsd#nvax-o" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/Operations" xlink:href="nvax-20130930.xsd#nvax-o1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensation" xlink:href="nvax-20130930.xsd#nvax-sc" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationAssumptionsUsedInEstimationOfFairValueOfStockOptionsGrantedDetails" xlink:href="nvax-20130930.xsd#nvax-scauieofvosogd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationNarrativeDetails" xlink:href="nvax-20130930.xsd#nvax-scnd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:href="nvax-20130930.xsd#nvax-scsced" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationSummaryOfOptionActivityDetails" xlink:href="nvax-20130930.xsd#nvax-scsooad" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationSummaryOfRestrictedStockAwardsActivityDetails" xlink:href="nvax-20130930.xsd#nvax-scsorsaad" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationTables" xlink:href="nvax-20130930.xsd#nvax-sct" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StatementsOfComprehensiveLoss" xlink:href="nvax-20130930.xsd#nvax-socl" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StatementsOfOperations" xlink:href="nvax-20130930.xsd#nvax-soo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="nvax-20130930.xsd#nvax-sosap" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="nvax-20130930.xsd#nvax-sosapnd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryOfSignificantAccountingPoliciesPolicy" xlink:href="nvax-20130930.xsd#nvax-sosapp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StatementsOfCashFlowsParenthetical" xlink:href="nvax-20130930.xsd#nvax-socfp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/UsGovernmentAgreementJointVentureAndCollaborations" xlink:href="nvax-20130930.xsd#nvax-ugajvac" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/UsGovernmentAgreementJointVentureAndCollaborationsDetails" xlink:href="nvax-20130930.xsd#nvax-ugajvacd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/WarrantLiability" xlink:href="nvax-20130930.xsd#nvax-wl" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/WarrantLiabilityDetails" xlink:href="nvax-20130930.xsd#nvax-wld" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersEquity" xlink:href="nvax-20130930.xsd#nvax-se" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAb" xlink:href="nvax-20130930.xsd#nvax-aoia" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersEquityDetails" xlink:href="nvax-20130930.xsd#nvax-sed" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbNarrativeDetails" xlink:href="nvax-20130930.xsd#nvax-aoiand" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssets" xlink:href="nvax-20130930.xsd#nvax-gaoia" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/MasterServicesAgreementWithCadila" xlink:href="nvax-20130930.xsd#nvax-msawc" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsTables" xlink:href="nvax-20130930.xsd#nvax-gaoiat" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbTables" xlink:href="nvax-20130930.xsd#nvax-aoiat" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/MasterServicesAgreementWithCadilaDetails" xlink:href="nvax-20130930.xsd#nvax-msawcd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails" xlink:href="nvax-20130930.xsd#nvax-gaoiasogd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIdentifiableIntangibleAssetsDetails" xlink:href="nvax-20130930.xsd#nvax-gaoiasoiiad" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfEstimatedAmortizationExpenseDetails" xlink:href="nvax-20130930.xsd#nvax-gaoiasoeaed" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbScheduleOfPurchasePriceDetails" xlink:href="nvax-20130930.xsd#nvax-aoiasoppd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="nvax-20130930.xsd#nvax-aoiasoaaalad" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbUnauditedProFormaFinancialInformationOfOperationsDetails" xlink:href="nvax-20130930.xsd#nvax-aoiaupffiood" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:definitionLink xlink:title="40501 - Disclosure - Fair Value Measurements (Fair Value Hierarchy) (Details)" xlink:role="http://www.novavax.com/role/FairValueMeasurementsFairValueHierarchyDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AssetsFairValueDisclosureAbstract.608.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InvestmentsFairValueDisclosure.11996.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AssetsFairValueDisclosureAbstract.608.7.6" xlink:to="loc_InvestmentsFairValueDisclosure.11996.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AvailableForSaleSecurities.6182.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AssetsFairValueDisclosureAbstract.608.7.6" xlink:to="loc_AvailableForSaleSecurities.6182.7.6" order="1.87500" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable.1996.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueByFairValueHierarchyLevelAxis.1998.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable.1996.5.6" xlink:to="loc_FairValueByFairValueHierarchyLevelAxis.1998.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueByFairValueHierarchyLevelAxis.1998.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueMeasurementsFairValueHierarchyDomain.2060.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FairValueByFairValueHierarchyLevelAxis.1998.6.6" xlink:to="loc_FairValueMeasurementsFairValueHierarchyDomain.2060.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueByFairValueHierarchyLevelAxis.1998.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueMeasurementsFairValueHierarchyDomain.2060.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FairValueByFairValueHierarchyLevelAxis.1998.8.6" xlink:to="loc_FairValueMeasurementsFairValueHierarchyDomain.2060.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems.2051.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable.1996.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems.2051.9.6" xlink:to="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable.1996.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems.2051.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems.2051.7.6" xlink:to="loc_AssetsFairValueDisclosureAbstract.608.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesFairValueDisclosureAbstract.3067.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems.2051.7.6" xlink:to="loc_LiabilitiesFairValueDisclosureAbstract.3067.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueMeasurementsFairValueHierarchyDomain.2060.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueInputsLevel1Member.2138.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FairValueMeasurementsFairValueHierarchyDomain.2060.7.6" xlink:to="loc_FairValueInputsLevel1Member.2138.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueInputsLevel2Member.2139.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FairValueMeasurementsFairValueHierarchyDomain.2060.7.6" xlink:to="loc_FairValueInputsLevel2Member.2139.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueInputsLevel3Member.2129.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FairValueMeasurementsFairValueHierarchyDomain.2060.7.6" xlink:to="loc_FairValueInputsLevel3Member.2129.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherLiabilitiesFairValueDisclosure.13881.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_LiabilitiesFairValueDisclosureAbstract.3067.7.6" xlink:to="loc_OtherLiabilitiesFairValueDisclosure.13881.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40502 - Disclosure - Fair Value Measurements (Reconciliation of Level 3 Assets and Liabilities) (Details)" xlink:role="http://www.novavax.com/role/FairValueMeasurementsReconciliationOfLevelThreeAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_FairValueByShareholdersEquityClassDomain.2057.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_WarrantsSettleableInCashMember.23966.7.6" xlink:href="nvax-20130930.xsd#nvax_WarrantsSettleableInCashMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FairValueByShareholdersEquityClassDomain.2057.7.6" xlink:to="loc_WarrantsSettleableInCashMember.23966.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable.2133.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareholdersEquityClassAxis.4707.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareholdersEquityClassAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable.2133.5.6" xlink:to="loc_ShareholdersEquityClassAxis.4707.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.2134.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable.2133.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.2134.9.6" xlink:to="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable.2133.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.2134.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.9648.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.2134.7.6" xlink:to="loc_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.9648.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease.9954.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.2134.7.6" xlink:to="loc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease.9954.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareholdersEquityClassAxis.4707.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareholdersEquityClassAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueByShareholdersEquityClassDomain.2057.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareholdersEquityClassAxis.4707.6.6" xlink:to="loc_FairValueByShareholdersEquityClassDomain.2057.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareholdersEquityClassAxis.4707.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareholdersEquityClassAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueByShareholdersEquityClassDomain.2057.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareholdersEquityClassAxis.4707.8.6" xlink:to="loc_FairValueByShareholdersEquityClassDomain.2057.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40601 - Disclosure - Investments (Details)" xlink:role="http://www.novavax.com/role/InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_MajorTypesOfDebtAndEquitySecuritiesAxis.3313.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_MajorTypesOfDebtAndEquitySecuritiesDomain.3315.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_MajorTypesOfDebtAndEquitySecuritiesAxis.3313.6.6" xlink:to="loc_MajorTypesOfDebtAndEquitySecuritiesDomain.3315.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_MajorTypesOfDebtAndEquitySecuritiesAxis.3313.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_MajorTypesOfDebtAndEquitySecuritiesDomain.3315.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_MajorTypesOfDebtAndEquitySecuritiesAxis.3313.8.6" xlink:to="loc_MajorTypesOfDebtAndEquitySecuritiesDomain.3315.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_MajorTypesOfDebtAndEquitySecuritiesDomain.3315.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CorporateDebtSecuritiesMember.1234.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_MajorTypesOfDebtAndEquitySecuritiesDomain.3315.7.6" xlink:to="loc_CorporateDebtSecuritiesMember.1234.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AuctionRateSecuritiesMember.646.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AuctionRateSecuritiesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_MajorTypesOfDebtAndEquitySecuritiesDomain.3315.7.6" xlink:to="loc_AuctionRateSecuritiesMember.646.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfAvailableForSaleSecuritiesTable.4765.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" />
    <link:loc xlink:label="loc_MajorTypesOfDebtAndEquitySecuritiesAxis.3313.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfAvailableForSaleSecuritiesTable.4765.5.6" xlink:to="loc_MajorTypesOfDebtAndEquitySecuritiesAxis.3313.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfAvailableForSaleSecuritiesLineItems.4805.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesAmortizedCost.6209.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfAvailableForSaleSecuritiesLineItems.4805.7.6" xlink:to="loc_AvailableForSaleSecuritiesAmortizedCost.6209.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfAvailableForSaleSecuritiesLineItems.4805.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfAvailableForSaleSecuritiesTable.4765.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfAvailableForSaleSecuritiesLineItems.4805.9.6" xlink:to="loc_ScheduleOfAvailableForSaleSecuritiesTable.4765.9.6" order="5.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_AvailableForSaleSecurities.6182.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfAvailableForSaleSecuritiesLineItems.4805.7.6" xlink:to="loc_AvailableForSaleSecurities.6182.7.6" order="5.75000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesGrossUnrealizedGains.6229.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfAvailableForSaleSecuritiesLineItems.4805.7.6" xlink:to="loc_AvailableForSaleSecuritiesGrossUnrealizedGains.6229.7.6" order="2.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesGrossUnrealizedLoss.6213.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfAvailableForSaleSecuritiesLineItems.4805.7.6" xlink:to="loc_AvailableForSaleSecuritiesGrossUnrealizedLoss.6213.7.6" order="4.37500" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40903 - Disclosure - Stock-Based Compensation (Assumptions Used in Estimation of Fair Value of Stock Options Granted) (Details)" xlink:role="http://www.novavax.com/role/StockbasedCompensationAssumptionsUsedInEstimationOfFairValueOfStockOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TypeOfDeferredCompensationDomain.5392.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfDeferredCompensationDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.8.6" xlink:to="loc_TypeOfDeferredCompensationDomain.5392.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TypeOfDeferredCompensationDomain.5392.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfDeferredCompensationDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.6.6" xlink:to="loc_TypeOfDeferredCompensationDomain.5392.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4365.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4365.8.6" xlink:to="loc_RangeMember.4366.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4365.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4365.6.6" xlink:to="loc_RangeMember.4366.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeMember.4366.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:loc xlink:label="loc_MinimumMember.3382.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4366.7.6" xlink:to="loc_MinimumMember.3382.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MaximumMember.3373.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4366.7.6" xlink:to="loc_MaximumMember.3373.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeAxis.4365.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.5.6" xlink:to="loc_RangeAxis.4365.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.5.6" xlink:to="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.5.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.9.6" xlink:to="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.16978.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.16978.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum.16941.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum.16941.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.16975.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.16975.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.16906.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.16906.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.16956.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.16956.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.16894.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.16894.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.16972.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.16972.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.16892.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.16892.7.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.16199.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.16199.7.6" order="10.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.23955.7.6" xlink:href="nvax-20130930.xsd#nvax_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.23955.7.6" order="11.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_TypeOfDeferredCompensationDomain.5392.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfDeferredCompensationDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeStockOptionMember.1806.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TypeOfDeferredCompensationDomain.5392.7.6" xlink:to="loc_EmployeeStockOptionMember.1806.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40901 - Disclosure - Stock-Based Compensation (Narrative) (Details)" xlink:role="http://www.novavax.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:label="loc_PlanNameDomain.4029.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_TwoZeroZeroFiveStockIncentivePlanMember.23962.7.6" xlink:href="nvax-20130930.xsd#nvax_TwoZeroZeroFiveStockIncentivePlanMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PlanNameDomain.4029.7.6" xlink:to="loc_TwoZeroZeroFiveStockIncentivePlanMember.23962.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OneNineNineFiveStockOptionPlanMember.23942.7.6" xlink:href="nvax-20130930.xsd#nvax_OneNineNineFiveStockOptionPlanMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PlanNameDomain.4029.7.6" xlink:to="loc_OneNineNineFiveStockOptionPlanMember.23942.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeStockPurchasePlanMember.27970.7.6" xlink:href="nvax-20130930.xsd#nvax_EmployeeStockPurchasePlanMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PlanNameDomain.4029.7.6" xlink:to="loc_EmployeeStockPurchasePlanMember.27970.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PlanNameAxis.4031.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_PlanNameDomain.4029.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PlanNameAxis.4031.8.6" xlink:to="loc_PlanNameDomain.4029.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_PlanNameAxis.4031.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_PlanNameDomain.4029.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PlanNameAxis.4031.6.6" xlink:to="loc_PlanNameDomain.4029.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4365.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4365.8.6" xlink:to="loc_RangeMember.4366.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4365.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4365.6.6" xlink:to="loc_RangeMember.4366.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeMember.4366.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:loc xlink:label="loc_MinimumMember.3382.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4366.7.6" xlink:to="loc_MinimumMember.3382.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MaximumMember.3373.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4366.7.6" xlink:to="loc_MaximumMember.3373.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4760.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioForecastMember.4759.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.7.6" xlink:to="loc_ScenarioForecastMember.4759.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:loc xlink:label="loc_PlanNameAxis.4031.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.5.6" xlink:to="loc_PlanNameAxis.4031.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4365.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.5.6" xlink:to="loc_RangeAxis.4365.5.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.5162.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.5.6" xlink:to="loc_StatementScenarioAxis.5162.5.6" order="1.75000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.9.6" xlink:to="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16973.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16973.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.23958.7.6" xlink:href="nvax-20130930.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.23958.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent.23957.7.6" xlink:href="nvax-20130930.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent.23957.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.23956.7.6" xlink:href="nvax-20130930.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.23956.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.17001.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.17001.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2.16219.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2.16219.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.16197.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.16197.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1.16217.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1.16217.7.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16970.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16970.7.6" order="10.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.9212.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.9212.7.6" order="11.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.9214.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.9214.7.6" order="12.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized.16895.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized.16895.7.6" order="13.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.5162.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4760.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementScenarioAxis.5162.6.6" xlink:to="loc_ScenarioUnspecifiedDomain.4760.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.5162.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4760.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementScenarioAxis.5162.8.6" xlink:to="loc_ScenarioUnspecifiedDomain.4760.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40905 - Disclosure - Stock-Based Compensation (Stock-Based Compensation Expense) (Details)" xlink:role="http://www.novavax.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.9.6" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5919.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.7.6" xlink:to="loc_AllocatedShareBasedCompensationExpense.5919.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeStatementLocationAxis.2652.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeStatementLocationAxis.2652.8.6" xlink:to="loc_IncomeStatementLocationDomain.2671.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeStatementLocationAxis.2652.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeStatementLocationAxis.2652.6.6" xlink:to="loc_IncomeStatementLocationDomain.2671.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4573.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeStatementLocationDomain.2671.7.6" xlink:to="loc_ResearchAndDevelopmentExpenseMember.4573.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2476.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeStatementLocationDomain.2671.7.6" xlink:to="loc_GeneralAndAdministrativeExpenseMember.2476.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeStatementLocationAxis.2652.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.5.6" xlink:to="loc_IncomeStatementLocationAxis.2652.5.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40902 - Disclosure - Stock-Based Compensation (Summary of Option Activity) (Details)" xlink:role="http://www.novavax.com/role/StockbasedCompensationSummaryOfOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:label="loc_PlanNameDomain.4029.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_TwoZeroZeroFiveStockIncentivePlanMember.23962.7.6" xlink:href="nvax-20130930.xsd#nvax_TwoZeroZeroFiveStockIncentivePlanMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PlanNameDomain.4029.7.6" xlink:to="loc_TwoZeroZeroFiveStockIncentivePlanMember.23962.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OneNineNineFiveStockOptionPlanMember.23942.7.6" xlink:href="nvax-20130930.xsd#nvax_OneNineNineFiveStockOptionPlanMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PlanNameDomain.4029.7.6" xlink:to="loc_OneNineNineFiveStockOptionPlanMember.23942.7.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PlanNameAxis.4031.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_PlanNameDomain.4029.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PlanNameAxis.4031.8.6" xlink:to="loc_PlanNameDomain.4029.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_PlanNameAxis.4031.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_PlanNameDomain.4029.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_PlanNameAxis.4031.6.6" xlink:to="loc_PlanNameDomain.4029.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:loc xlink:label="loc_PlanNameAxis.4031.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.5.6" xlink:to="loc_PlanNameAxis.4031.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16982.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16982.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.16885.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.7.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.16885.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16942.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.7.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16942.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.16889.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.7.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.16889.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16947.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16947.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.9.6" xlink:to="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16990.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16990.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16909.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16909.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod.16962.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod.16962.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16964.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16964.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.16969.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.16969.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="309 - Disclosure - Stock-Based Compensation (Tables)" xlink:role="http://www.novavax.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.1379.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.4832.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.1379.9.6" xlink:to="loc_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.4832.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.1379.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.16476.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.1379.7.6" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.16476.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.16335.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.1379.7.6" xlink:to="loc_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.16335.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.16360.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.1379.7.6" xlink:to="loc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.16360.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.23954.7.6" xlink:href="nvax-20130930.xsd#nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.1379.7.6" xlink:to="loc_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.23954.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TypeOfDeferredCompensationDomain.5392.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfDeferredCompensationDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.8.6" xlink:to="loc_TypeOfDeferredCompensationDomain.5392.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TypeOfDeferredCompensationDomain.5392.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfDeferredCompensationDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.6.6" xlink:to="loc_TypeOfDeferredCompensationDomain.5392.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.4832.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.4832.5.6" xlink:to="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_TypeOfDeferredCompensationDomain.5392.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfDeferredCompensationDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeStockOptionMember.1806.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TypeOfDeferredCompensationDomain.5392.7.6" xlink:to="loc_EmployeeStockOptionMember.1806.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="41001 - Disclosure - U.S. Government Agreement, Joint Venture and Collaborations (Details)" xlink:role="http://www.novavax.com/role/UsGovernmentAgreementJointVentureAndCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:loc xlink:label="loc_HhsBardaContractAwardMember.23929.7.6" xlink:href="nvax-20130930.xsd#nvax_HhsBardaContractAwardMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.7.6" xlink:to="loc_HhsBardaContractAwardMember.23929.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_HhsBardaOptionForAdditionalPeriodMember.23930.7.6" xlink:href="nvax-20130930.xsd#nvax_HhsBardaOptionForAdditionalPeriodMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.7.6" xlink:to="loc_HhsBardaOptionForAdditionalPeriodMember.23930.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_LicenseAgreementWithLgLifeSciencesLtdMember.23933.7.6" xlink:href="nvax-20130930.xsd#nvax_LicenseAgreementWithLgLifeSciencesLtdMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.7.6" xlink:to="loc_LicenseAgreementWithLgLifeSciencesLtdMember.23933.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PathVaccineSolutionsMember.23945.7.6" xlink:href="nvax-20130930.xsd#nvax_PathVaccineSolutionsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.7.6" xlink:to="loc_PathVaccineSolutionsMember.23945.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable.4810.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.9.6" xlink:to="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable.4810.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_GovernmentContractReceivable.10758.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.7.6" xlink:to="loc_GovernmentContractReceivable.10758.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ContractsRevenue.7301.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractsRevenue" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.7.6" xlink:to="loc_ContractsRevenue.7301.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ExpectedClinicalTrialCosts.23928.7.6" xlink:href="nvax-20130930.xsd#nvax_ExpectedClinicalTrialCosts" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.7.6" xlink:to="loc_ExpectedClinicalTrialCosts.23928.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_UpfrontLicensePayment.23963.7.6" xlink:href="nvax-20130930.xsd#nvax_UpfrontLicensePayment" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.7.6" xlink:to="loc_UpfrontLicensePayment.23963.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RoyaltyPaymentsPercentOfFutureProductSales.23951.7.6" xlink:href="nvax-20130930.xsd#nvax_RoyaltyPaymentsPercentOfFutureProductSales" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.7.6" xlink:to="loc_RoyaltyPaymentsPercentOfFutureProductSales.23951.7.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent.23946.7.6" xlink:href="nvax-20130930.xsd#nvax_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.7.6" xlink:to="loc_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent.23946.7.6" order="12.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ContractTerm.23923.7.6" xlink:href="nvax-20130930.xsd#nvax_ContractTerm" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.7.6" xlink:to="loc_ContractTerm.23923.7.6" order="11.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentCollaboration.23950.7.6" xlink:href="nvax-20130930.xsd#nvax_ResearchAndDevelopmentCollaboration" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.7.6" xlink:to="loc_ResearchAndDevelopmentCollaboration.23950.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ClinicalTrialCostsIncurred.23919.7.6" xlink:href="nvax-20130930.xsd#nvax_ClinicalTrialCostsIncurred" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.7.6" xlink:to="loc_ClinicalTrialCostsIncurred.23919.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EquityMethodInvestmentOwnershipPercentage.9324.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.7.6" xlink:to="loc_EquityMethodInvestmentOwnershipPercentage.9324.7.6" order="10.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_GovernmentContractReceivableIncrease.27086.7.6" xlink:href="nvax-20130930.xsd#nvax_GovernmentContractReceivableIncrease" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.7.6" xlink:to="loc_GovernmentContractReceivableIncrease.27086.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_JointVenturePercentageOwnedByOthers.23931.7.6" xlink:href="nvax-20130930.xsd#nvax_JointVenturePercentageOwnedByOthers" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.7.6" xlink:to="loc_JointVenturePercentageOwnedByOthers.23931.7.6" order="91.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentCollaborationIncrease.28056.7.6" xlink:href="nvax-20130930.xsd#nvax_ResearchAndDevelopmentCollaborationIncrease" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.7.6" xlink:to="loc_ResearchAndDevelopmentCollaborationIncrease.28056.7.6" order="2.62500" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EquityMethodInvesteeNameDomain.1871.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityMethodInvesteeOneMember.23927.7.6" xlink:href="nvax-20130930.xsd#nvax_EquityMethodInvesteeOneMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityMethodInvesteeNameDomain.1871.7.6" xlink:to="loc_EquityMethodInvesteeOneMember.23927.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4365.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4365.8.6" xlink:to="loc_RangeMember.4366.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4365.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4365.6.6" xlink:to="loc_RangeMember.4366.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeMember.4366.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:loc xlink:label="loc_MinimumMember.3382.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4366.7.6" xlink:to="loc_MinimumMember.3382.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MaximumMember.3373.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4366.7.6" xlink:to="loc_MaximumMember.3373.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable.4810.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeAxis.4365.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable.4810.5.6" xlink:to="loc_RangeAxis.4365.5.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_TypeOfArrangementAxis.5386.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable.4810.5.6" xlink:to="loc_TypeOfArrangementAxis.5386.5.6" order="1.25000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis.4820.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable.4810.5.6" xlink:to="loc_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis.4820.5.6" order="1.75000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis.4820.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityMethodInvesteeNameDomain.1871.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis.4820.8.6" xlink:to="loc_EquityMethodInvesteeNameDomain.1871.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis.4820.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityMethodInvesteeNameDomain.1871.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis.4820.6.6" xlink:to="loc_EquityMethodInvesteeNameDomain.1871.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_TypeOfArrangementAxis.5386.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TypeOfArrangementAxis.5386.8.6" xlink:to="loc_ArrangementsAndNonarrangementTransactionsMember.373.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_TypeOfArrangementAxis.5386.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TypeOfArrangementAxis.5386.6.6" xlink:to="loc_ArrangementsAndNonarrangementTransactionsMember.373.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40801 - Disclosure - Stockholders' Equity (Details)" xlink:role="http://www.novavax.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:label="loc_RangeAxis.4365.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4365.8.6" xlink:to="loc_RangeMember.4366.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4365.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4365.6.6" xlink:to="loc_RangeMember.4366.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeMember.4366.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:loc xlink:label="loc_MinimumMember.3382.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4366.7.6" xlink:to="loc_MinimumMember.3382.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MaximumMember.3373.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4366.7.6" xlink:to="loc_MaximumMember.3373.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SaleOfStockNameOfTransactionDomain.4737.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_IPOMember.2975.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SaleOfStockNameOfTransactionDomain.4737.7.6" xlink:to="loc_IPOMember.2975.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SecondPublicOfferingMember.32671.7.6" xlink:href="nvax-20130930.xsd#nvax_SecondPublicOfferingMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SaleOfStockNameOfTransactionDomain.4737.7.6" xlink:to="loc_SecondPublicOfferingMember.32671.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsidiarySaleOfStockAxis.5224.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_SaleOfStockNameOfTransactionDomain.4737.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsidiarySaleOfStockAxis.5224.8.6" xlink:to="loc_SaleOfStockNameOfTransactionDomain.4737.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsidiarySaleOfStockAxis.5224.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_SaleOfStockNameOfTransactionDomain.4737.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsidiarySaleOfStockAxis.5224.6.6" xlink:to="loc_SaleOfStockNameOfTransactionDomain.4737.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.5225.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeAxis.4365.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.5225.5.6" xlink:to="loc_RangeAxis.4365.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsidiarySaleOfStockAxis.5224.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.5225.5.6" xlink:to="loc_SubsidiarySaleOfStockAxis.5224.5.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsidiarySaleOfStockLineItems.5227.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.5225.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.9.6" xlink:to="loc_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.5225.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsidiarySaleOfStockLineItems.5227.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.7144.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.7.6" xlink:to="loc_CommonStockSharesAuthorized.7144.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SaleOfStockPricePerShare.16232.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.7.6" xlink:to="loc_SaleOfStockPricePerShare.16232.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.17271.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesNewIssues.17271.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.17285.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.7.6" xlink:to="loc_StockIssuedDuringPeriodValueNewIssues.17285.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SaleOfStockNumberOfSharesIssuedInTransaction.16262.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.7.6" xlink:to="loc_SaleOfStockNumberOfSharesIssuedInTransaction.16262.7.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AggregateGrossProceedsSaleOfStock.31357.7.6" xlink:href="nvax-20130930.xsd#nvax_AggregateGrossProceedsSaleOfStock" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.7.6" xlink:to="loc_AggregateGrossProceedsSaleOfStock.31357.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement.32670.7.6" xlink:href="nvax-20130930.xsd#nvax_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.7.6" xlink:to="loc_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement.32670.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EquityIssuancePerShareAmount.9323.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.7.6" xlink:to="loc_EquityIssuancePerShareAmount.9323.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40401 - Disclosure - Acquisition of Isconova AB (Narrative) (Details)" xlink:role="http://www.novavax.com/role/AcquisitionOfIsconovaAbNarrativeDetails" xlink:type="extended">
    <link:loc xlink:label="loc_BusinessAcquisitionAxis.750.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_BusinessAcquisitionAcquireeDomain.775.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_BusinessAcquisitionAxis.750.8.6" xlink:to="loc_BusinessAcquisitionAcquireeDomain.775.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_BusinessAcquisitionAxis.750.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_BusinessAcquisitionAcquireeDomain.775.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_BusinessAcquisitionAxis.750.6.6" xlink:to="loc_BusinessAcquisitionAcquireeDomain.775.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_BusinessAcquisitionLineItems.769.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfBusinessAcquisitionsByAcquisitionTable.4809.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_BusinessAcquisitionLineItems.769.9.6" xlink:to="loc_ScheduleOfBusinessAcquisitionsByAcquisitionTable.4809.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_BusinessAcquisitionLineItems.769.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AcquiredOutstandingShares.27087.7.6" xlink:href="nvax-20130930.xsd#nvax_AcquiredOutstandingShares" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_BusinessAcquisitionLineItems.769.7.6" xlink:to="loc_AcquiredOutstandingShares.27087.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_NovavaxSharesIssued.28072.7.6" xlink:href="nvax-20130930.xsd#nvax_NovavaxSharesIssued" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_BusinessAcquisitionLineItems.769.7.6" xlink:to="loc_NovavaxSharesIssued.28072.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_UnsolicitedTenderOfferCosts.17869.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnsolicitedTenderOfferCosts" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_BusinessAcquisitionLineItems.769.7.6" xlink:to="loc_UnsolicitedTenderOfferCosts.17869.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesAcquisitions.17221.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_BusinessAcquisitionLineItems.769.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesAcquisitions.17221.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.6397.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_BusinessAcquisitionLineItems.769.7.6" xlink:to="loc_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.6397.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsToAcquireBusinessesGross.14339.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_BusinessAcquisitionLineItems.769.7.6" xlink:to="loc_PaymentsToAcquireBusinessesGross.14339.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife.5803.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_BusinessAcquisitionLineItems.769.7.6" xlink:to="loc_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife.5803.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.31348.7.6" xlink:href="nvax-20130930.xsd#nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_BusinessAcquisitionLineItems.769.7.6" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.31348.7.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_Revenues.16160.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_BusinessAcquisitionLineItems.769.7.6" xlink:to="loc_Revenues.16160.7.6" order="10.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_BusinessAcquisitionLineItems.769.7.6" xlink:to="loc_NetIncomeLoss.13265.7.6" order="11.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AcquisitionCostsCumulative.5810.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AcquisitionCostsCumulative" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_BusinessAcquisitionLineItems.769.7.6" xlink:to="loc_AcquisitionCostsCumulative.5810.7.6" order="12.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AcquisitionTransactionCosts.32704.7.6" xlink:href="nvax-20130930.xsd#nvax_AcquisitionTransactionCosts" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_BusinessAcquisitionLineItems.769.7.6" xlink:to="loc_AcquisitionTransactionCosts.32704.7.6" order="13.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsReceivable.13573.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_BusinessAcquisitionLineItems.769.7.6" xlink:to="loc_OperatingLeasesFutureMinimumPaymentsReceivable.13573.7.6" order="14.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_BusinessAcquisitionAcquireeDomain.775.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_NovavaxAbMember.32703.7.6" xlink:href="nvax-20130930.xsd#nvax_NovavaxAbMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_BusinessAcquisitionAcquireeDomain.775.7.6" xlink:to="loc_NovavaxAbMember.32703.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4365.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4365.8.6" xlink:to="loc_RangeMember.4366.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4365.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4365.6.6" xlink:to="loc_RangeMember.4366.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeMember.4366.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:loc xlink:label="loc_MinimumMember.3382.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4366.7.6" xlink:to="loc_MinimumMember.3382.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MaximumMember.3373.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4366.7.6" xlink:to="loc_MaximumMember.3373.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfBusinessAcquisitionsByAcquisitionTable.4809.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeAxis.4365.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfBusinessAcquisitionsByAcquisitionTable.4809.5.6" xlink:to="loc_RangeAxis.4365.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_BusinessAcquisitionAxis.750.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfBusinessAcquisitionsByAcquisitionTable.4809.5.6" xlink:to="loc_BusinessAcquisitionAxis.750.5.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="41401 - Disclosure - Master Services Agreement with Cadila (Details)" xlink:role="http://www.novavax.com/role/MasterServicesAgreementWithCadilaDetails" xlink:type="extended">
    <link:loc xlink:label="loc_RangeAxis.4365.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4365.8.6" xlink:to="loc_RangeMember.4366.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4365.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeAxis.4365.6.6" xlink:to="loc_RangeMember.4366.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeMember.4366.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:loc xlink:label="loc_MaximumMember.3373.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RangeMember.4366.7.6" xlink:to="loc_MaximumMember.3373.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RelatedPartyTransactionLineItems.4538.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4873.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RelatedPartyTransactionLineItems.4538.9.6" xlink:to="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4873.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_RelatedPartyTransactionLineItems.4538.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_MasterServiceAgreement.31351.7.6" xlink:href="nvax-20130930.xsd#nvax_MasterServiceAgreement" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RelatedPartyTransactionLineItems.4538.7.6" xlink:to="loc_MasterServiceAgreement.31351.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentToRelatedPartyPortionOfShortfall.31353.7.6" xlink:href="nvax-20130930.xsd#nvax_PaymentToRelatedPartyPortionOfShortfall" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RelatedPartyTransactionLineItems.4538.7.6" xlink:to="loc_PaymentToRelatedPartyPortionOfShortfall.31353.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ServicesPurchased.31355.7.6" xlink:href="nvax-20130930.xsd#nvax_ServicesPurchased" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RelatedPartyTransactionLineItems.4538.7.6" xlink:to="loc_ServicesPurchased.31355.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_HalfPaymentForPortionOfShortfallExceedingTwoMillion.31354.7.6" xlink:href="nvax-20130930.xsd#nvax_HalfPaymentForPortionOfShortfallExceedingTwoMillion" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RelatedPartyTransactionLineItems.4538.7.6" xlink:to="loc_HalfPaymentForPortionOfShortfallExceedingTwoMillion.31354.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ServicesProvidedDuringThePeriod.31356.7.6" xlink:href="nvax-20130930.xsd#nvax_ServicesProvidedDuringThePeriod" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RelatedPartyTransactionLineItems.4538.7.6" xlink:to="loc_ServicesProvidedDuringThePeriod.31356.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RelatedPartyTransactionsByRelatedPartyAxis.4540.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RelatedPartyDomain.4542.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RelatedPartyTransactionsByRelatedPartyAxis.4540.8.6" xlink:to="loc_RelatedPartyDomain.4542.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_RelatedPartyTransactionsByRelatedPartyAxis.4540.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RelatedPartyDomain.4542.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RelatedPartyTransactionsByRelatedPartyAxis.4540.6.6" xlink:to="loc_RelatedPartyDomain.4542.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_RelatedPartyDomain.4542.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CadilaMember.31352.7.6" xlink:href="nvax-20130930.xsd#nvax_CadilaMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_RelatedPartyDomain.4542.7.6" xlink:to="loc_CadilaMember.31352.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4873.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" />
    <link:loc xlink:label="loc_RelatedPartyTransactionsByRelatedPartyAxis.4540.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4873.5.6" xlink:to="loc_RelatedPartyTransactionsByRelatedPartyAxis.4540.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4365.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4873.5.6" xlink:to="loc_RangeAxis.4365.5.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40702 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Identifiable Intangible Assets) (Details)" xlink:role="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AcquiredFiniteLivedIntangibleAssetsLineItems.478.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfFiniteLivedIntangibleAssetsTable.4785.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AcquiredFiniteLivedIntangibleAssetsLineItems.478.9.6" xlink:to="loc_ScheduleOfFiniteLivedIntangibleAssetsTable.4785.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_AcquiredFiniteLivedIntangibleAssetsLineItems.478.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsGross.10303.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AcquiredFiniteLivedIntangibleAssetsLineItems.478.7.6" xlink:to="loc_FiniteLivedIntangibleAssetsGross.10303.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAccumulatedAmortization.10322.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AcquiredFiniteLivedIntangibleAssetsLineItems.478.7.6" xlink:to="loc_FiniteLivedIntangibleAssetsAccumulatedAmortization.10322.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsNet.10326.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AcquiredFiniteLivedIntangibleAssetsLineItems.478.7.6" xlink:to="loc_FiniteLivedIntangibleAssetsNet.10326.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsMajorClassNameDomain.2309.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_TechnologyEquipmentMember.5302.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TechnologyEquipmentMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FiniteLivedIntangibleAssetsMajorClassNameDomain.2309.7.6" xlink:to="loc_TechnologyEquipmentMember.5302.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborationAgreementsMember.31339.7.6" xlink:href="nvax-20130930.xsd#nvax_CollaborationAgreementsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FiniteLivedIntangibleAssetsMajorClassNameDomain.2309.7.6" xlink:to="loc_CollaborationAgreementsMember.31339.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProprietaryAdjuvantTechnologyMember.32669.7.6" xlink:href="nvax-20130930.xsd#nvax_ProprietaryAdjuvantTechnologyMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FiniteLivedIntangibleAssetsMajorClassNameDomain.2309.7.6" xlink:to="loc_ProprietaryAdjuvantTechnologyMember.32669.7.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsByMajorClassAxis.2311.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsMajorClassNameDomain.2309.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FiniteLivedIntangibleAssetsByMajorClassAxis.2311.8.6" xlink:to="loc_FiniteLivedIntangibleAssetsMajorClassNameDomain.2309.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsByMajorClassAxis.2311.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsMajorClassNameDomain.2309.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_FiniteLivedIntangibleAssetsByMajorClassAxis.2311.6.6" xlink:to="loc_FiniteLivedIntangibleAssetsMajorClassNameDomain.2309.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfFiniteLivedIntangibleAssetsTable.4785.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsByMajorClassAxis.2311.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfFiniteLivedIntangibleAssetsTable.4785.5.6" xlink:to="loc_FiniteLivedIntangibleAssetsByMajorClassAxis.2311.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>nvax-20130930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-11-12 @ 6:50 AM-->
<link:linkbase xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-roles-2013-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/changeLabel2012" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-roles-2013-01-31.xsd#changeLabel2012" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/fragmentDocumentation" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-roles-2013-01-31.xsd#fragmentDocumentation" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/fragmentLabel" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-roles-2013-01-31.xsd#fragmentLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/changeLabel2013" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-roles-2013-01-31.xsd#changeLabel2013" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/deprecatedLabel" xlink:href="http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd#deprecatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/deprecatedDateLabel" xlink:href="http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd#deprecatedDateLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:label="loc_AccountsPayableCurrent.5684.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableCurrent.5684.11.7" xlink:to="lab_AccountsPayableCurrent.158268.208068" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableCurrent.158268.208068" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableCurrent.158268.208068">Accounts payable</link:label>
    <link:loc xlink:label="loc_AccountsPayableCurrent.5684.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableCurrent.5684.11.6" xlink:to="lab_AccountsPayableCurrent.421.208067" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableCurrent.421.208067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableCurrent.421.208067">Accounts Payable, Current</link:label>
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5665.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsReceivableNetCurrent.5665.11.7" xlink:to="lab_AccountsReceivableNetCurrent.174140.208070" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsReceivableNetCurrent.174140.208070" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsReceivableNetCurrent.174140.208070">Accounts receivables</link:label>
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5665.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsReceivableNetCurrent.5665.11.6" xlink:to="lab_AccountsReceivableNetCurrent.390.208069" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsReceivableNetCurrent.390.208069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsReceivableNetCurrent.390.208069">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:label="loc_AccruedLiabilitiesCurrent.5762.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccruedLiabilitiesCurrent.5762.11.7" xlink:to="lab_AccruedLiabilitiesCurrent.158269.208072" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccruedLiabilitiesCurrent.158269.208072" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccruedLiabilitiesCurrent.158269.208072">Accrued expenses and other current liabilities</link:label>
    <link:loc xlink:label="loc_AccruedLiabilitiesCurrent.5762.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccruedLiabilitiesCurrent.5762.11.6" xlink:to="lab_AccruedLiabilitiesCurrent.550.208071" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccruedLiabilitiesCurrent.550.208071" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccruedLiabilitiesCurrent.550.208071">Accrued Liabilities, Current</link:label>
    <link:loc xlink:label="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax.5786.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax.5786.11.7" xlink:to="lab_AccumulatedOtherComprehensiveIncomeLossNetOfTax.158522.208074" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccumulatedOtherComprehensiveIncomeLossNetOfTax.158522.208074" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccumulatedOtherComprehensiveIncomeLossNetOfTax.158522.208074">Accumulated other comprehensive income</link:label>
    <link:loc xlink:label="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax.5786.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax.5786.11.6" xlink:to="lab_AccumulatedOtherComprehensiveIncomeLossNetOfTax.632.208073" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccumulatedOtherComprehensiveIncomeLossNetOfTax.632.208073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccumulatedOtherComprehensiveIncomeLossNetOfTax.632.208073">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:label="loc_AdditionalPaidInCapital.5816.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalPaidInCapital.5816.11.7" xlink:to="lab_AdditionalPaidInCapital.158278.208076" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdditionalPaidInCapital.158278.208076" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdditionalPaidInCapital.158278.208076">Additional paid-in capital</link:label>
    <link:loc xlink:label="loc_AdditionalPaidInCapital.5816.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalPaidInCapital.5816.11.6" xlink:to="lab_AdditionalPaidInCapital.673.208075" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdditionalPaidInCapital.673.208075" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdditionalPaidInCapital.673.208075">Additional Paid in Capital</link:label>
    <link:loc xlink:label="loc_Assets.6057.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Assets.6057.11.6" xlink:to="lab_Assets.1134.208077" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Assets.1134.208077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Assets.1134.208077">Assets</link:label>
    <link:loc xlink:label="loc_Assets.6057.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Assets.6057.11.9" xlink:to="lab_Assets.158265.208078" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Assets.158265.208078" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_Assets.158265.208078">Total assets</link:label>
    <link:loc xlink:label="loc_AssetsAbstract.620.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsAbstract.620.11.6" xlink:to="lab_AssetsAbstract.1105.208079" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsAbstract.1105.208079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsAbstract.1105.208079">Assets [Abstract]</link:label>
    <link:loc xlink:label="loc_AssetsAbstract.620.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsAbstract.620.11.7" xlink:to="lab_AssetsAbstract.158253.208080" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsAbstract.158253.208080" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsAbstract.158253.208080">ASSETS</link:label>
    <link:loc xlink:label="loc_AssetsCurrent.6084.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrent.6084.11.6" xlink:to="lab_AssetsCurrent.1123.208081" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrent.1123.208081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrent.1123.208081">Assets, Current</link:label>
    <link:loc xlink:label="loc_AssetsCurrent.6084.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrent.6084.11.9" xlink:to="lab_AssetsCurrent.158259.208082" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrent.158259.208082" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrent.158259.208082">Total current assets</link:label>
    <link:loc xlink:label="loc_AssetsCurrentAbstract.616.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrentAbstract.616.11.6" xlink:to="lab_AssetsCurrentAbstract.1099.208083" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrentAbstract.1099.208083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrentAbstract.1099.208083">Assets, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_AssetsCurrentAbstract.616.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrentAbstract.616.11.7" xlink:to="lab_AssetsCurrentAbstract.158254.208084" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrentAbstract.158254.208084" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrentAbstract.158254.208084">Current assets:</link:label>
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesCurrent.6200.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AvailableForSaleSecuritiesCurrent.6200.11.6" xlink:to="lab_AvailableForSaleSecuritiesCurrent.1282.208085" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AvailableForSaleSecuritiesCurrent.1282.208085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AvailableForSaleSecuritiesCurrent.1282.208085">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesCurrent.6200.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AvailableForSaleSecuritiesCurrent.6200.11.7" xlink:to="lab_AvailableForSaleSecuritiesCurrent.158483.208086" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AvailableForSaleSecuritiesCurrent.158483.208086" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AvailableForSaleSecuritiesCurrent.158483.208086">Short-term investments available-for-sale</link:label>
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesNoncurrent.6236.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AvailableForSaleSecuritiesNoncurrent.6236.11.6" xlink:to="lab_AvailableForSaleSecuritiesNoncurrent.1354.208087" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AvailableForSaleSecuritiesNoncurrent.1354.208087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AvailableForSaleSecuritiesNoncurrent.1354.208087">Available-for-sale Securities, Noncurrent</link:label>
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesNoncurrent.6236.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AvailableForSaleSecuritiesNoncurrent.6236.11.7" xlink:to="lab_AvailableForSaleSecuritiesNoncurrent.495160.208088" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AvailableForSaleSecuritiesNoncurrent.495160.208088" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AvailableForSaleSecuritiesNoncurrent.495160.208088">Investments available-for-sale</link:label>
    <link:loc xlink:label="loc_CapitalLeaseObligationsCurrent.6657.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CapitalLeaseObligationsCurrent.6657.11.7" xlink:to="lab_CapitalLeaseObligationsCurrent.158512.208090" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CapitalLeaseObligationsCurrent.158512.208090" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CapitalLeaseObligationsCurrent.158512.208090">Current portion of capital leases</link:label>
    <link:loc xlink:label="loc_CapitalLeaseObligationsCurrent.6657.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CapitalLeaseObligationsCurrent.6657.11.6" xlink:to="lab_CapitalLeaseObligationsCurrent.1990.208089" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CapitalLeaseObligationsCurrent.1990.208089" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CapitalLeaseObligationsCurrent.1990.208089">Capital Lease Obligations, Current</link:label>
    <link:loc xlink:label="loc_CapitalLeaseObligationsNoncurrent.6668.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CapitalLeaseObligationsNoncurrent.6668.11.7" xlink:to="lab_CapitalLeaseObligationsNoncurrent.158516.208092" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CapitalLeaseObligationsNoncurrent.158516.208092" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CapitalLeaseObligationsNoncurrent.158516.208092">Non-current portion of capital leases</link:label>
    <link:loc xlink:label="loc_CapitalLeaseObligationsNoncurrent.6668.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CapitalLeaseObligationsNoncurrent.6668.11.6" xlink:to="lab_CapitalLeaseObligationsNoncurrent.1991.208091" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CapitalLeaseObligationsNoncurrent.1991.208091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CapitalLeaseObligationsNoncurrent.1991.208091">Capital Lease Obligations, Noncurrent</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.7" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.158255.208094" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.158255.208094" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.158255.208094">Cash and cash equivalents</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.6" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.2187.208093" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.2187.208093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.2187.208093">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingencies.7121.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingencies.7121.11.7" xlink:to="lab_CommitmentsAndContingencies.158274.208096" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingencies.158274.208096" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingencies.158274.208096">Commitments and contingencies</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingencies.7121.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingencies.7121.11.6" xlink:to="lab_CommitmentsAndContingencies.2677.208095" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingencies.2677.208095" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingencies.2677.208095">Commitments and Contingencies</link:label>
    <link:loc xlink:label="loc_CommonStockValue.7134.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockValue.7134.11.7" xlink:to="lab_CommonStockValue.158277.208098" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockValue.158277.208098" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockValue.158277.208098">Common stock, $0.01 par value, 300,000,000 shares authorized at September 30, 2013 and 200,000,000 shares authorized at December 31, 2012; and 208,965,169 shares issued and 208,509,739 shares outstanding at September 30, 2013 and 148,398,747 shares issued and 147,943,317 shares outstanding at December 31, 2012</link:label>
    <link:loc xlink:label="loc_CommonStockValue.7134.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockValue.7134.11.6" xlink:to="lab_CommonStockValue.2730.208097" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockValue.2730.208097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockValue.2730.208097">Common Stock, Value, Issued</link:label>
    <link:loc xlink:label="loc_DeferredRentCreditCurrent.7951.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRentCreditCurrent.7951.11.7" xlink:to="lab_DeferredRentCreditCurrent.138305.208100" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRentCreditCurrent.138305.208100" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRentCreditCurrent.138305.208100">Deferred rent</link:label>
    <link:loc xlink:label="loc_DeferredRentCreditCurrent.7951.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRentCreditCurrent.7951.11.6" xlink:to="lab_DeferredRentCreditCurrent.3858.208099" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRentCreditCurrent.3858.208099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRentCreditCurrent.3858.208099">Deferred Rent Credit, Current</link:label>
    <link:loc xlink:label="loc_DeferredRentCreditNoncurrent.7913.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRentCreditNoncurrent.7913.11.7" xlink:to="lab_DeferredRentCreditNoncurrent.158518.208102" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRentCreditNoncurrent.158518.208102" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRentCreditNoncurrent.158518.208102">Deferred rent</link:label>
    <link:loc xlink:label="loc_DeferredRentCreditNoncurrent.7913.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRentCreditNoncurrent.7913.11.6" xlink:to="lab_DeferredRentCreditNoncurrent.3813.208101" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRentCreditNoncurrent.3813.208101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRentCreditNoncurrent.3813.208101">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7937.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueCurrent.7937.11.7" xlink:to="lab_DeferredRevenueCurrent.158511.208104" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueCurrent.158511.208104" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueCurrent.158511.208104">Deferred revenue</link:label>
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7937.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueCurrent.7937.11.6" xlink:to="lab_DeferredRevenueCurrent.3980.208103" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueCurrent.3980.208103" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueCurrent.3980.208103">Deferred Revenue, Current</link:label>
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7950.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueNoncurrent.7950.11.7" xlink:to="lab_DeferredRevenueNoncurrent.160442.208106" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueNoncurrent.160442.208106" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueNoncurrent.160442.208106">Deferred revenue</link:label>
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7950.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueNoncurrent.7950.11.6" xlink:to="lab_DeferredRevenueNoncurrent.3963.208105" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueNoncurrent.3963.208105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueNoncurrent.3963.208105">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:label="loc_DerivativeLiabilitiesCurrent.8440.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DerivativeLiabilitiesCurrent.8440.11.7" xlink:to="lab_DerivativeLiabilitiesCurrent.171371.208108" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DerivativeLiabilitiesCurrent.171371.208108" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DerivativeLiabilitiesCurrent.171371.208108">Warrant liability</link:label>
    <link:loc xlink:label="loc_DerivativeLiabilitiesCurrent.8440.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DerivativeLiabilitiesCurrent.8440.11.6" xlink:to="lab_DerivativeLiabilitiesCurrent.4511.208107" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DerivativeLiabilitiesCurrent.4511.208107" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DerivativeLiabilitiesCurrent.4511.208107">Derivative Liabilities, Current</link:label>
    <link:loc xlink:label="loc_Goodwill.10732.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Goodwill.10732.11.7" xlink:to="lab_Goodwill.158505.208110" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Goodwill.158505.208110" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_Goodwill.158505.208110">Goodwill</link:label>
    <link:loc xlink:label="loc_Goodwill.10732.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Goodwill.10732.11.6" xlink:to="lab_Goodwill.7915.208109" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Goodwill.7915.208109" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Goodwill.7915.208109">Goodwill</link:label>
    <link:loc xlink:label="loc_GovernmentContractReceivableUnbilledAmounts.10756.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GovernmentContractReceivableUnbilledAmounts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GovernmentContractReceivableUnbilledAmounts.10756.11.7" xlink:to="lab_GovernmentContractReceivableUnbilledAmounts.158441.208112" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GovernmentContractReceivableUnbilledAmounts.158441.208112" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GovernmentContractReceivableUnbilledAmounts.158441.208112">Unbilled receivables</link:label>
    <link:loc xlink:label="loc_GovernmentContractReceivableUnbilledAmounts.10756.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GovernmentContractReceivableUnbilledAmounts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GovernmentContractReceivableUnbilledAmounts.10756.11.6" xlink:to="lab_GovernmentContractReceivableUnbilledAmounts.7956.208111" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GovernmentContractReceivableUnbilledAmounts.7956.208111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GovernmentContractReceivableUnbilledAmounts.7956.208111">Government Contract Receivable, Unbilled Amounts</link:label>
    <link:loc xlink:label="loc_IntangibleAssetsNetExcludingGoodwill.11570.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IntangibleAssetsNetExcludingGoodwill.11570.11.6" xlink:to="lab_IntangibleAssetsNetExcludingGoodwill.9591" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IntangibleAssetsNetExcludingGoodwill.9591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IntangibleAssetsNetExcludingGoodwill.9591">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:label="loc_IntangibleAssetsNetExcludingGoodwill.11570.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IntangibleAssetsNetExcludingGoodwill.11570.11.7" xlink:to="lab_IntangibleAssetsNetExcludingGoodwill.134349.272504" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IntangibleAssetsNetExcludingGoodwill.134349.272504" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IntangibleAssetsNetExcludingGoodwill.134349.272504">Intangibles, net</link:label>
    <link:loc xlink:label="loc_Liabilities.12166.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Liabilities.12166.11.6" xlink:to="lab_Liabilities.10148.208113" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Liabilities.10148.208113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Liabilities.10148.208113">Liabilities</link:label>
    <link:loc xlink:label="loc_Liabilities.12166.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Liabilities.12166.11.9" xlink:to="lab_Liabilities.158273.208114" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Liabilities.158273.208114" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_Liabilities.158273.208114">Total liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.12135.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquity.12135.11.6" xlink:to="lab_LiabilitiesAndStockholdersEquity.10196.208115" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquity.10196.208115" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquity.10196.208115">Liabilities and Equity</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.12135.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquity.12135.11.9" xlink:to="lab_LiabilitiesAndStockholdersEquity.158281.208116" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquity.158281.208116" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquity.158281.208116">Total liabilities and stockholders' equity</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.3066.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.11.6" xlink:to="lab_LiabilitiesAndStockholdersEquityAbstract.10173.208117" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquityAbstract.10173.208117" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquityAbstract.10173.208117">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.3066.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.11.7" xlink:to="lab_LiabilitiesAndStockholdersEquityAbstract.158266.208118" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquityAbstract.158266.208118" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquityAbstract.158266.208118">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrent.12126.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrent.12126.11.6" xlink:to="lab_LiabilitiesCurrent.10094.208119" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrent.10094.208119" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrent.10094.208119">Liabilities, Current</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrent.12126.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrent.12126.11.9" xlink:to="lab_LiabilitiesCurrent.158271.208120" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrent.158271.208120" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrent.158271.208120">Total current liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.3060.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.11.6" xlink:to="lab_LiabilitiesCurrentAbstract.10147.208121" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrentAbstract.10147.208121" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrentAbstract.10147.208121">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.3060.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.11.7" xlink:to="lab_LiabilitiesCurrentAbstract.158267.208122" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrentAbstract.158267.208122" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrentAbstract.158267.208122">Current liabilities:</link:label>
    <link:loc xlink:label="loc_LongTermNotesPayable.12765.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LongTermNotesPayable.12765.11.6" xlink:to="lab_LongTermNotesPayable.11006.208123" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LongTermNotesPayable.11006.208123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LongTermNotesPayable.11006.208123">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:label="loc_LongTermNotesPayable.12765.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LongTermNotesPayable.12765.11.7" xlink:to="lab_LongTermNotesPayable.158517.208124" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LongTermNotesPayable.158517.208124" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LongTermNotesPayable.158517.208124">Non-current portion of notes payable</link:label>
    <link:loc xlink:label="loc_NotesPayableCurrent.13431.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NotesPayableCurrent.13431.11.6" xlink:to="lab_NotesPayableCurrent.12132.208125" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NotesPayableCurrent.12132.208125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NotesPayableCurrent.12132.208125">Notes Payable, Current</link:label>
    <link:loc xlink:label="loc_NotesPayableCurrent.13431.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NotesPayableCurrent.13431.11.7" xlink:to="lab_NotesPayableCurrent.158270.208126" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NotesPayableCurrent.158270.208126" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NotesPayableCurrent.158270.208126">Current portion of notes payable</link:label>
    <link:loc xlink:label="loc_OtherAssetsCurrent.13853.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherAssetsCurrent.13853.11.6" xlink:to="lab_OtherAssetsCurrent.12521.208127" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherAssetsCurrent.12521.208127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherAssetsCurrent.12521.208127">Other Assets, Current</link:label>
    <link:loc xlink:label="loc_OtherAssetsCurrent.13853.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherAssetsCurrent.13853.11.7" xlink:to="lab_OtherAssetsCurrent.158486.208128" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherAssetsCurrent.158486.208128" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherAssetsCurrent.158486.208128">Other current assets</link:label>
    <link:loc xlink:label="loc_OtherAssetsNoncurrent.13824.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherAssetsNoncurrent.13824.11.6" xlink:to="lab_OtherAssetsNoncurrent.12607.208129" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherAssetsNoncurrent.12607.208129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherAssetsNoncurrent.12607.208129">Other Assets, Noncurrent</link:label>
    <link:loc xlink:label="loc_OtherAssetsNoncurrent.13824.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherAssetsNoncurrent.13824.11.7" xlink:to="lab_OtherAssetsNoncurrent.158504.208130" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherAssetsNoncurrent.158504.208130" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherAssetsNoncurrent.158504.208130">Other non-current assets</link:label>
    <link:loc xlink:label="loc_OtherLiabilitiesNoncurrent.14010.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherLiabilitiesNoncurrent.14010.11.6" xlink:to="lab_OtherLiabilitiesNoncurrent.13535" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherLiabilitiesNoncurrent.13535" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherLiabilitiesNoncurrent.13535">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:label="loc_OtherLiabilitiesNoncurrent.14010.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherLiabilitiesNoncurrent.14010.11.7" xlink:to="lab_OtherLiabilitiesNoncurrent.134353.272505" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherLiabilitiesNoncurrent.134353.272505" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherLiabilitiesNoncurrent.134353.272505">Other non-current liabilities</link:label>
    <link:loc xlink:label="loc_PreferredStockValue.14687.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PreferredStockValue.14687.11.6" xlink:to="lab_PreferredStockValue.14020.208131" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PreferredStockValue.14020.208131" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PreferredStockValue.14020.208131">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:label="loc_PreferredStockValue.14687.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PreferredStockValue.14687.11.7" xlink:to="lab_PreferredStockValue.158276.208132" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PreferredStockValue.158276.208132" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PreferredStockValue.158276.208132">Preferred stock, $0.01 par value, 2,000,000 shares authorized; no shares issued and outstanding</link:label>
    <link:loc xlink:label="loc_PrepaidExpenseCurrent.14768.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PrepaidExpenseCurrent.14768.11.6" xlink:to="lab_PrepaidExpenseCurrent.14227.208133" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PrepaidExpenseCurrent.14227.208133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PrepaidExpenseCurrent.14227.208133">Prepaid Expense, Current</link:label>
    <link:loc xlink:label="loc_PrepaidExpenseCurrent.14768.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PrepaidExpenseCurrent.14768.11.7" xlink:to="lab_PrepaidExpenseCurrent.158258.208134" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PrepaidExpenseCurrent.158258.208134" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PrepaidExpenseCurrent.158258.208134">Prepaid expenses</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.15211.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentNet.15211.11.6" xlink:to="lab_PropertyPlantAndEquipmentNet.14913.208135" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentNet.14913.208135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentNet.14913.208135">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.15211.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentNet.15211.11.7" xlink:to="lab_PropertyPlantAndEquipmentNet.158260.208136" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentNet.158260.208136" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentNet.158260.208136">Property and equipment, net</link:label>
    <link:loc xlink:label="loc_RestrictedCashAndCashEquivalentsAtCarryingValue.15928.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RestrictedCashAndCashEquivalentsAtCarryingValue.15928.11.7" xlink:to="lab_RestrictedCashAndCashEquivalentsAtCarryingValue.158485.208138" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RestrictedCashAndCashEquivalentsAtCarryingValue.158485.208138" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RestrictedCashAndCashEquivalentsAtCarryingValue.158485.208138">Restricted cash</link:label>
    <link:loc xlink:label="loc_RestrictedCashAndCashEquivalentsAtCarryingValue.15928.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RestrictedCashAndCashEquivalentsAtCarryingValue.15928.11.6" xlink:to="lab_RestrictedCashAndCashEquivalentsAtCarryingValue.15967.208137" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RestrictedCashAndCashEquivalentsAtCarryingValue.15967.208137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RestrictedCashAndCashEquivalentsAtCarryingValue.15967.208137">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:label="loc_RestrictedCashAndCashEquivalentsNoncurrent.15932.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RestrictedCashAndCashEquivalentsNoncurrent.15932.11.7" xlink:to="lab_RestrictedCashAndCashEquivalentsNoncurrent.158506.208140" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RestrictedCashAndCashEquivalentsNoncurrent.158506.208140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RestrictedCashAndCashEquivalentsNoncurrent.158506.208140">Restricted cash</link:label>
    <link:loc xlink:label="loc_RestrictedCashAndCashEquivalentsNoncurrent.15932.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RestrictedCashAndCashEquivalentsNoncurrent.15932.11.6" xlink:to="lab_RestrictedCashAndCashEquivalentsNoncurrent.15973.208139" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RestrictedCashAndCashEquivalentsNoncurrent.15973.208139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RestrictedCashAndCashEquivalentsNoncurrent.15973.208139">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:label="loc_RetainedEarningsAccumulatedDeficit.16058.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RetainedEarningsAccumulatedDeficit.16058.11.7" xlink:to="lab_RetainedEarningsAccumulatedDeficit.158279.208142" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RetainedEarningsAccumulatedDeficit.158279.208142" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RetainedEarningsAccumulatedDeficit.158279.208142">Accumulated deficit</link:label>
    <link:loc xlink:label="loc_RetainedEarningsAccumulatedDeficit.16058.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RetainedEarningsAccumulatedDeficit.16058.11.6" xlink:to="lab_RetainedEarningsAccumulatedDeficit.16146.208141" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RetainedEarningsAccumulatedDeficit.16146.208141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RetainedEarningsAccumulatedDeficit.16146.208141">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:label="loc_StatementOfFinancialPositionAbstract.5171.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.11.6" xlink:to="lab_StatementOfFinancialPositionAbstract.158252.208143" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfFinancialPositionAbstract.158252.208143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfFinancialPositionAbstract.158252.208143">BALANCE SHEETS [Abstract]</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.17302.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.17302.11.9" xlink:to="lab_StockholdersEquity.158280.208145" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.158280.208145" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.158280.208145">Total stockholders' equity</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.17302.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.17302.11.6" xlink:to="lab_StockholdersEquity.18029.208144" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.18029.208144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.18029.208144">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:label="loc_StockholdersEquityAbstract.5197.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityAbstract.5197.11.7" xlink:to="lab_StockholdersEquityAbstract.158275.208147" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityAbstract.158275.208147" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityAbstract.158275.208147">Stockholders' equity:</link:label>
    <link:loc xlink:label="loc_StockholdersEquityAbstract.5197.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityAbstract.5197.11.6" xlink:to="lab_StockholdersEquityAbstract.18017.208146" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityAbstract.18017.208146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityAbstract.18017.208146">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:label="loc_TreasuryStockValue.17716.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TreasuryStockValue.17716.11.6" xlink:to="lab_TreasuryStockValue.18646.208148" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TreasuryStockValue.18646.208148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TreasuryStockValue.18646.208148">Treasury Stock, Value</link:label>
    <link:loc xlink:label="loc_TreasuryStockValue.17716.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TreasuryStockValue.17716.11.52" xlink:to="lab_TreasuryStockValue42.158520.208149" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TreasuryStockValue42.158520.208149" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_TreasuryStockValue42.158520.208149">Treasury stock, 455,430 shares, cost basis</link:label>
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.7131.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.7131.11.6" xlink:to="lab_CommonStockParOrStatedValuePerShare.2741.208150" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare.2741.208150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare.2741.208150">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.7131.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.7131.11.7" xlink:to="lab_CommonStockParOrStatedValuePerShare7.158287.208151" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare7.158287.208151" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare7.158287.208151">Common stock, par value per share</link:label>
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.7144.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesAuthorized.7144.11.6" xlink:to="lab_CommonStockSharesAuthorized.2742.208152" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesAuthorized.2742.208152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesAuthorized.2742.208152">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.7144.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesAuthorized.7144.11.7" xlink:to="lab_CommonStockSharesAuthorized7.158288.208153" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesAuthorized7.158288.208153" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesAuthorized7.158288.208153">Common stock, shares authorized</link:label>
    <link:loc xlink:label="loc_CommonStockSharesIssued.7136.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesIssued.7136.11.6" xlink:to="lab_CommonStockSharesIssued.2734.208154" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesIssued.2734.208154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesIssued.2734.208154">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:label="loc_CommonStockSharesIssued.7136.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesIssued.7136.11.7" xlink:to="lab_CommonStockSharesIssued7.158289.208155" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesIssued7.158289.208155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesIssued7.158289.208155">Common stock, shares issued</link:label>
    <link:loc xlink:label="loc_CommonStockSharesOutstanding.7164.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesOutstanding.7164.11.7" xlink:to="lab_CommonStockSharesOutstanding.158290.208157" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesOutstanding.158290.208157" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesOutstanding.158290.208157">Common stock, shares outstanding</link:label>
    <link:loc xlink:label="loc_CommonStockSharesOutstanding.7164.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesOutstanding.7164.11.6" xlink:to="lab_CommonStockSharesOutstanding.2714.208156" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesOutstanding.2714.208156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesOutstanding.2714.208156">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:label="loc_PreferredStockParOrStatedValuePerShare.14668.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PreferredStockParOrStatedValuePerShare.14668.11.6" xlink:to="lab_PreferredStockParOrStatedValuePerShare.14088.208158" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PreferredStockParOrStatedValuePerShare.14088.208158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PreferredStockParOrStatedValuePerShare.14088.208158">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:label="loc_PreferredStockParOrStatedValuePerShare.14668.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PreferredStockParOrStatedValuePerShare.14668.11.7" xlink:to="lab_PreferredStockParOrStatedValuePerShare.158283.208159" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PreferredStockParOrStatedValuePerShare.158283.208159" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PreferredStockParOrStatedValuePerShare.158283.208159">Preferred stock, par or stated value per share</link:label>
    <link:loc xlink:label="loc_PreferredStockSharesAuthorized.14701.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PreferredStockSharesAuthorized.14701.11.6" xlink:to="lab_PreferredStockSharesAuthorized.14024.208160" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PreferredStockSharesAuthorized.14024.208160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PreferredStockSharesAuthorized.14024.208160">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:label="loc_PreferredStockSharesAuthorized.14701.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PreferredStockSharesAuthorized.14701.11.7" xlink:to="lab_PreferredStockSharesAuthorized.158284.208161" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PreferredStockSharesAuthorized.158284.208161" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PreferredStockSharesAuthorized.158284.208161">Preferred stock, shares authorized</link:label>
    <link:loc xlink:label="loc_PreferredStockSharesIssued.14694.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PreferredStockSharesIssued.14694.11.6" xlink:to="lab_PreferredStockSharesIssued.14076.208162" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PreferredStockSharesIssued.14076.208162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PreferredStockSharesIssued.14076.208162">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:label="loc_PreferredStockSharesIssued.14694.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PreferredStockSharesIssued.14694.11.7" xlink:to="lab_PreferredStockSharesIssued.158285.208163" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PreferredStockSharesIssued.158285.208163" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PreferredStockSharesIssued.158285.208163">Preferred stock, shares issued</link:label>
    <link:loc xlink:label="loc_PreferredStockSharesOutstanding.14710.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PreferredStockSharesOutstanding.14710.11.6" xlink:to="lab_PreferredStockSharesOutstanding.14104.208164" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PreferredStockSharesOutstanding.14104.208164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PreferredStockSharesOutstanding.14104.208164">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:label="loc_PreferredStockSharesOutstanding.14710.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PreferredStockSharesOutstanding.14710.11.7" xlink:to="lab_PreferredStockSharesOutstanding.158286.208165" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PreferredStockSharesOutstanding.158286.208165" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PreferredStockSharesOutstanding.158286.208165">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:label="loc_TreasuryStockShares.17707.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockShares" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TreasuryStockShares.17707.11.6" xlink:to="lab_TreasuryStockShares.18653.208166" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TreasuryStockShares.18653.208166" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TreasuryStockShares.18653.208166">Treasury Stock, Shares</link:label>
    <link:loc xlink:label="loc_TreasuryStockShares.17707.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockShares" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TreasuryStockShares.17707.11.7" xlink:to="lab_TreasuryStockShares7.158525.208167" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TreasuryStockShares7.158525.208167" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_TreasuryStockShares7.158525.208167">Treasury stock, shares</link:label>
    <link:loc xlink:label="loc_AccretionAmortizationOfDiscountsAndPremiumsInvestments.5696.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccretionAmortizationOfDiscountsAndPremiumsInvestments.5696.11.52" xlink:to="lab_AccretionAmortizationOfDiscountsAndPremiumsInvestments.158695.208212" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccretionAmortizationOfDiscountsAndPremiumsInvestments.158695.208212" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccretionAmortizationOfDiscountsAndPremiumsInvestments.158695.208212">Amortization of net premiums on investments</link:label>
    <link:loc xlink:label="loc_AccretionAmortizationOfDiscountsAndPremiumsInvestments.5696.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccretionAmortizationOfDiscountsAndPremiumsInvestments.5696.11.6" xlink:to="lab_AccretionAmortizationOfDiscountsAndPremiumsInvestments.448.208211" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccretionAmortizationOfDiscountsAndPremiumsInvestments.448.208211" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccretionAmortizationOfDiscountsAndPremiumsInvestments.448.208211">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.11.7" xlink:to="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.158335.208214" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.158335.208214" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.158335.208214">Reconciliation of net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.11.6" xlink:to="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726.208213" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726.208213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726.208213">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_CapitalExpendituresIncurredButNotYetPaid.6683.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CapitalExpendituresIncurredButNotYetPaid.6683.11.7" xlink:to="lab_CapitalExpendituresIncurredButNotYetPaid.158671.208216" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CapitalExpendituresIncurredButNotYetPaid.158671.208216" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CapitalExpendituresIncurredButNotYetPaid.158671.208216">Property and equipment purchases included in accounts payable and accrued expenses</link:label>
    <link:loc xlink:label="loc_CapitalExpendituresIncurredButNotYetPaid.6683.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CapitalExpendituresIncurredButNotYetPaid.6683.11.6" xlink:to="lab_CapitalExpendituresIncurredButNotYetPaid.1947.208215" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CapitalExpendituresIncurredButNotYetPaid.1947.208215" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CapitalExpendituresIncurredButNotYetPaid.1947.208215">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:label="loc_CapitalLeaseObligationEquipmentPurchased.29940.11.6" xlink:href="nvax-20130930.xsd#nvax_CapitalLeaseObligationEquipmentPurchased" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CapitalLeaseObligationEquipmentPurchased.29940.11.6" xlink:to="lab_CapitalLeaseObligationEquipmentPurchased.259675" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CapitalLeaseObligationEquipmentPurchased.259675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CapitalLeaseObligationEquipmentPurchased.259675">Capital Lease Obligation Equipment Purchased</link:label>
    <link:loc xlink:label="loc_CapitalLeaseObligationEquipmentPurchased.29940.11.12" xlink:href="nvax-20130930.xsd#nvax_CapitalLeaseObligationEquipmentPurchased" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CapitalLeaseObligationEquipmentPurchased.29940.11.12" xlink:to="lab_CapitalLeaseObligationEquipmentPurchased12.259676" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CapitalLeaseObligationEquipmentPurchased12.259676" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CapitalLeaseObligationEquipmentPurchased12.259676">Capital Lease Obligation Equipment Purchased</link:label>
    <link:loc xlink:label="loc_CapitalLeaseObligationEquipmentPurchased.29940.11.7" xlink:href="nvax-20130930.xsd#nvax_CapitalLeaseObligationEquipmentPurchased" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CapitalLeaseObligationEquipmentPurchased.29940.11.7" xlink:to="lab_CapitalLeaseObligationEquipmentPurchased7.259677" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CapitalLeaseObligationEquipmentPurchased7.259677" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CapitalLeaseObligationEquipmentPurchased7.259677">Equipment acquired under a capital lease</link:label>
    <link:loc xlink:label="loc_CashAcquiredFromAcquisition.6848.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAcquiredFromAcquisition.6848.11.6" xlink:to="lab_CashAcquiredFromAcquisition.2341" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAcquiredFromAcquisition.2341" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashAcquiredFromAcquisition.2341">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:label="loc_CashAcquiredFromAcquisition.6848.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAcquiredFromAcquisition.6848.11.7" xlink:to="lab_CashAcquiredFromAcquisition.280482" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAcquiredFromAcquisition.280482" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAcquiredFromAcquisition.280482">Net cash received from the Isconova AB acquisition</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.10" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.158342.208217" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.158342.208217" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.158342.208217">Cash and cash equivalents at beginning of period</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.11" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.158343.208218" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.158343.208218" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.158343.208218">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.11.9" xlink:to="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.158341.208220" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.158341.208220" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.158341.208220">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.11.6" xlink:to="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245.208219" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245.208219" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245.208219">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:label="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.944.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.944.11.7" xlink:to="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.158347.208222" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.158347.208222" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.158347.208222">Supplemental disclosure of non-cash activities:</link:label>
    <link:loc xlink:label="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.944.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.944.11.6" xlink:to="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.2287.208221" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.2287.208221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.2287.208221">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:label="loc_ConversionOfStockAmountConverted1.7336.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ConversionOfStockAmountConverted1.7336.11.6" xlink:to="lab_ConversionOfStockAmountConverted1.3188" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ConversionOfStockAmountConverted1.3188" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ConversionOfStockAmountConverted1.3188">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:label="loc_ConversionOfStockAmountConverted1.7336.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ConversionOfStockAmountConverted1.7336.11.7" xlink:to="lab_ConversionOfStockAmountConverted1.140209.272514" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ConversionOfStockAmountConverted1.140209.272514" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ConversionOfStockAmountConverted1.140209.272514">Common stock issued in connection with the Isconova AB acquisition</link:label>
    <link:loc xlink:label="loc_DepositsForAcquisitionOfPropertyAndEquipment.23925.11.6" xlink:href="nvax-20130930.xsd#nvax_DepositsForAcquisitionOfPropertyAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepositsForAcquisitionOfPropertyAndEquipment.23925.11.6" xlink:to="lab_DepositsForAcquisitionOfPropertyAndEquipment.158668.208223" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepositsForAcquisitionOfPropertyAndEquipment.158668.208223" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DepositsForAcquisitionOfPropertyAndEquipment.158668.208223">Deposits For Acquisition Of Property And Equipment</link:label>
    <link:loc xlink:label="loc_DepositsForAcquisitionOfPropertyAndEquipment.23925.11.12" xlink:href="nvax-20130930.xsd#nvax_DepositsForAcquisitionOfPropertyAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepositsForAcquisitionOfPropertyAndEquipment.23925.11.12" xlink:to="lab_DepositsForAcquisitionOfPropertyAndEquipment.158669.208225" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepositsForAcquisitionOfPropertyAndEquipment.158669.208225" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_DepositsForAcquisitionOfPropertyAndEquipment.158669.208225">Deposits For Acquisition Of Property And Equipment</link:label>
    <link:loc xlink:label="loc_DepositsForAcquisitionOfPropertyAndEquipment.23925.11.7" xlink:href="nvax-20130930.xsd#nvax_DepositsForAcquisitionOfPropertyAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepositsForAcquisitionOfPropertyAndEquipment.23925.11.7" xlink:to="lab_DepositsForAcquisitionOfPropertyAndEquipment.158670.208224" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepositsForAcquisitionOfPropertyAndEquipment.158670.208224" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DepositsForAcquisitionOfPropertyAndEquipment.158670.208224">Deposit applied towards the purchase of laboratory equipment</link:label>
    <link:loc xlink:label="loc_DepreciationAndAmortization.8349.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepreciationAndAmortization.8349.11.7" xlink:to="lab_DepreciationAndAmortization.158317.208227" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepreciationAndAmortization.158317.208227" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DepreciationAndAmortization.158317.208227">Depreciation and amortization</link:label>
    <link:loc xlink:label="loc_DepreciationAndAmortization.8349.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepreciationAndAmortization.8349.11.6" xlink:to="lab_DepreciationAndAmortization.4491.208226" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepreciationAndAmortization.4491.208226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DepreciationAndAmortization.4491.208226">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.11.6" xlink:to="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5755" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5755">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.11.7" xlink:to="lab_EffectOfExchangeRateOnCashAndCashEquivalents.134402.272513" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectOfExchangeRateOnCashAndCashEquivalents.134402.272513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EffectOfExchangeRateOnCashAndCashEquivalents.134402.272513">Effect of exchange rate on cash and cash equivalents</link:label>
    <link:loc xlink:label="loc_GainLossOnDerivativeInstrumentsNetPretax.10572.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GainLossOnDerivativeInstrumentsNetPretax.10572.11.52" xlink:to="lab_GainLossOnDerivativeInstrumentsNetPretax.158697.208229" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GainLossOnDerivativeInstrumentsNetPretax.158697.208229" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_GainLossOnDerivativeInstrumentsNetPretax.158697.208229">Change in fair value of warrant liability</link:label>
    <link:loc xlink:label="loc_GainLossOnDerivativeInstrumentsNetPretax.10572.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GainLossOnDerivativeInstrumentsNetPretax.10572.11.6" xlink:to="lab_GainLossOnDerivativeInstrumentsNetPretax.7662.208228" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GainLossOnDerivativeInstrumentsNetPretax.7662.208228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GainLossOnDerivativeInstrumentsNetPretax.7662.208228">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment.10640.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GainLossOnSaleOfPropertyPlantEquipment.10640.11.6" xlink:to="lab_GainLossOnSaleOfPropertyPlantEquipment.7730.208230" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GainLossOnSaleOfPropertyPlantEquipment.7730.208230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GainLossOnSaleOfPropertyPlantEquipment.7730.208230">Gain (Loss) on Sale of Property Plant Equipment</link:label>
    <link:loc xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment.10640.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GainLossOnSaleOfPropertyPlantEquipment.10640.11.52" xlink:to="lab_GainLossOnSaleOfPropertyPlantEquipment42.158319.208231" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GainLossOnSaleOfPropertyPlantEquipment42.158319.208231" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_GainLossOnSaleOfPropertyPlantEquipment42.158319.208231">Gain on disposal of property and equipment</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.11.7" xlink:to="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.158325.208233" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.158325.208233" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.158325.208233">Accounts payable and accrued expenses</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.11.6" xlink:to="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810.208232" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810.208232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810.208232">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.11237.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsReceivable.11237.11.6" xlink:to="lab_IncreaseDecreaseInAccountsReceivable.8785.208234" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsReceivable.8785.208234" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsReceivable.8785.208234">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.11237.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsReceivable.11237.11.52" xlink:to="lab_IncreaseDecreaseInAccountsReceivable42.158321.208235" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsReceivable42.158321.208235" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsReceivable42.158321.208235">Accounts receivables</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.11341.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInDeferredRevenue.11341.11.7" xlink:to="lab_IncreaseDecreaseInDeferredRevenue.158326.208237" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInDeferredRevenue.158326.208237" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInDeferredRevenue.158326.208237">Deferred revenue</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.11341.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInDeferredRevenue.11341.11.6" xlink:to="lab_IncreaseDecreaseInDeferredRevenue.8782.208236" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInDeferredRevenue.8782.208236" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInDeferredRevenue.8782.208236">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.11.7" xlink:to="lab_IncreaseDecreaseInOperatingCapitalAbstract.158320.208239" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOperatingCapitalAbstract.158320.208239" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOperatingCapitalAbstract.158320.208239">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.11.6" xlink:to="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850.208238" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850.208238" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850.208238">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOtherNoncurrentLiabilities.11304.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOtherNoncurrentLiabilities.11304.11.7" xlink:to="lab_IncreaseDecreaseInOtherNoncurrentLiabilities.158688.208241" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOtherNoncurrentLiabilities.158688.208241" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOtherNoncurrentLiabilities.158688.208241">Lease incentives received</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOtherNoncurrentLiabilities.11304.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOtherNoncurrentLiabilities.11304.11.6" xlink:to="lab_IncreaseDecreaseInOtherNoncurrentLiabilities.8781.208240" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOtherNoncurrentLiabilities.8781.208240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOtherNoncurrentLiabilities.8781.208240">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.11432.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.11432.11.6" xlink:to="lab_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.8897.208242" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.8897.208242" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.8897.208242">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.11432.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.11432.11.52" xlink:to="lab_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets42.158323.208243" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets42.158323.208243" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets42.158323.208243">Prepaid expenses and other assets</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCash.11462.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInRestrictedCash.11462.11.52" xlink:to="lab_IncreaseDecreaseInRestrictedCash.495168.208245" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInRestrictedCash.495168.208245" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInRestrictedCash.495168.208245">Restricted cash</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCash.11462.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInRestrictedCash.11462.11.6" xlink:to="lab_IncreaseDecreaseInRestrictedCash.9005.208244" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInRestrictedCash.9005.208244" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInRestrictedCash.9005.208244">Increase (Decrease) in Restricted Cash</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInUnbilledReceivables.11471.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInUnbilledReceivables.11471.11.52" xlink:to="lab_IncreaseDecreaseInUnbilledReceivables.158661.208247" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInUnbilledReceivables.158661.208247" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInUnbilledReceivables.158661.208247">Unbilled receivables</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInUnbilledReceivables.11471.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInUnbilledReceivables.11471.11.6" xlink:to="lab_IncreaseDecreaseInUnbilledReceivables.9010.208246" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInUnbilledReceivables.9010.208246" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInUnbilledReceivables.9010.208246">Increase (Decrease) in Unbilled Receivables</link:label>
    <link:loc xlink:label="loc_InterestPaid.11757.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InterestPaid.11757.11.7" xlink:to="lab_InterestPaid.158345.208249" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InterestPaid.158345.208249" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InterestPaid.158345.208249">Cash payments of interest</link:label>
    <link:loc xlink:label="loc_InterestPaid.11757.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InterestPaid.11757.11.6" xlink:to="lab_InterestPaid.9537.208248" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InterestPaid.9537.208248" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InterestPaid.9537.208248">Interest Paid</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.13253.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.13253.11.6" xlink:to="lab_NetCashProvidedByUsedInFinancingActivities.11796.208250" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivities.11796.208250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivities.11796.208250">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.13253.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.13253.11.9" xlink:to="lab_NetCashProvidedByUsedInFinancingActivities.158331.208251" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivities.158331.208251" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivities.158331.208251">Net cash provided by financing activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.11.6" xlink:to="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763.208252" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763.208252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763.208252">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.11.7" xlink:to="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.158339.208253" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.158339.208253" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.158339.208253">Financing Activities:</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.13246.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.13246.11.6" xlink:to="lab_NetCashProvidedByUsedInInvestingActivities.11776.208254" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivities.11776.208254" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivities.11776.208254">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.13246.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.13246.11.9" xlink:to="lab_NetCashProvidedByUsedInInvestingActivities.158334.208255" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivities.158334.208255" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivities.158334.208255">Net cash provided by (used in) investing activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.11.6" xlink:to="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840.208256" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840.208256" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840.208256">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.11.7" xlink:to="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.158338.208257" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.158338.208257" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.158338.208257">Investing Activities:</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.13262.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.11.6" xlink:to="lab_NetCashProvidedByUsedInOperatingActivities.11871.208258" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivities.11871.208258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivities.11871.208258">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.13262.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.13262.11.9" xlink:to="lab_NetCashProvidedByUsedInOperatingActivities.158336.208259" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivities.158336.208259" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivities.158336.208259">Net cash used in operating activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.11.6" xlink:to="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842.208260" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842.208260" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842.208260">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.11.7" xlink:to="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.158337.208261" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.158337.208261" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.158337.208261">Operating Activities:</link:label>
    <link:loc xlink:label="loc_OtherNoncashIncomeExpense.13827.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherNoncashIncomeExpense.13827.11.6" xlink:to="lab_OtherNoncashIncomeExpense.12505.208264" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherNoncashIncomeExpense.12505.208264" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherNoncashIncomeExpense.12505.208264">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:label="loc_OtherNoncashIncomeExpense.13827.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherNoncashIncomeExpense.13827.11.52" xlink:to="lab_OtherNoncashIncomeExpense.158692.208265" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherNoncashIncomeExpense.158692.208265" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherNoncashIncomeExpense.158692.208265">Deferred rent</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquireAvailableForSaleSecurities.14334.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquireAvailableForSaleSecurities.14334.11.6" xlink:to="lab_PaymentsToAcquireAvailableForSaleSecurities.13557.208266" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquireAvailableForSaleSecurities.13557.208266" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquireAvailableForSaleSecurities.13557.208266">Payments to Acquire Available-for-sale Securities</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquireAvailableForSaleSecurities.14334.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquireAvailableForSaleSecurities.14334.11.52" xlink:to="lab_PaymentsToAcquireAvailableForSaleSecurities42.158687.208267" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquireAvailableForSaleSecurities42.158687.208267" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquireAvailableForSaleSecurities42.158687.208267">Purchases of investments</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquireProductiveAssets.14309.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquireProductiveAssets.14309.11.6" xlink:to="lab_PaymentsToAcquireProductiveAssets.13554.208268" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquireProductiveAssets.13554.208268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquireProductiveAssets.13554.208268">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquireProductiveAssets.14309.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquireProductiveAssets.14309.11.52" xlink:to="lab_PaymentsToAcquireProductiveAssets42.158684.208269" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquireProductiveAssets42.158684.208269" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquireProductiveAssets42.158684.208269">Capital expenditures</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStock.15031.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStock.15031.11.6" xlink:to="lab_ProceedsFromIssuanceOfCommonStock.14546.208270" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStock.14546.208270" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStock.14546.208270">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStock.15031.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStock.15031.11.7" xlink:to="lab_ProceedsFromIssuanceOfCommonStock.158330.208271" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStock.158330.208271" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStock.158330.208271">Net proceeds from sales of common stock, net of offering costs of $6.1 million and $0.4 million, respectively</link:label>
    <link:loc xlink:label="loc_ProceedsFromNotesPayable.15002.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromNotesPayable.15002.11.6" xlink:to="lab_ProceedsFromNotesPayable.14515.208275" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromNotesPayable.14515.208275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromNotesPayable.14515.208275">Proceeds from Notes Payable</link:label>
    <link:loc xlink:label="loc_ProceedsFromNotesPayable.15002.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromNotesPayable.15002.11.7" xlink:to="lab_ProceedsFromNotesPayable.158880.208276" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromNotesPayable.158880.208276" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromNotesPayable.158880.208276">Proceeds from notes payable</link:label>
    <link:loc xlink:label="loc_ProceedsFromRepaymentsOfNotesPayable.14920.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromRepaymentsOfNotesPayable.14920.11.6" xlink:to="lab_ProceedsFromRepaymentsOfNotesPayable.14362.208277" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromRepaymentsOfNotesPayable.14362.208277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromRepaymentsOfNotesPayable.14362.208277">Proceeds from (Repayments of) Notes Payable</link:label>
    <link:loc xlink:label="loc_ProceedsFromRepaymentsOfNotesPayable.14920.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromRepaymentsOfNotesPayable.14920.11.7" xlink:to="lab_ProceedsFromRepaymentsOfNotesPayable.158677.208278" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromRepaymentsOfNotesPayable.158677.208278" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromRepaymentsOfNotesPayable.158677.208278">Principal payments of notes payable</link:label>
    <link:loc xlink:label="loc_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities.14902.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities.14902.11.6" xlink:to="lab_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities.14452.208279" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities.14452.208279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities.14452.208279">Proceeds from (Repayments of) Restricted Cash, Financing Activities</link:label>
    <link:loc xlink:label="loc_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities.14902.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities.14902.11.7" xlink:to="lab_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities.158675.208280" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities.158675.208280" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities.158675.208280">Restricted cash</link:label>
    <link:loc xlink:label="loc_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.15068.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.15068.11.6" xlink:to="lab_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.14549.208281" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.14549.208281" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.14549.208281">Proceeds from Sale and Maturity of Available-for-sale Securities</link:label>
    <link:loc xlink:label="loc_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.15068.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.15068.11.7" xlink:to="lab_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.158686.208282" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.158686.208282" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.158686.208282">Proceeds from maturities of investments</link:label>
    <link:loc xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.15098.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.15098.11.6" xlink:to="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.14631.208283" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.14631.208283" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.14631.208283">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.15098.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.15098.11.7" xlink:to="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.158333.208284" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.158333.208284" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.158333.208284">Proceeds from disposal of property and equipment</link:label>
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromStockOptionsExercised.15050.11.6" xlink:to="lab_ProceedsFromStockOptionsExercised.14691.208285" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromStockOptionsExercised.14691.208285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromStockOptionsExercised.14691.208285">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromStockOptionsExercised.15050.11.7" xlink:to="lab_ProceedsFromStockOptionsExercised.158674.208286" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromStockOptionsExercised.158674.208286" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromStockOptionsExercised.158674.208286">Proceeds from the exercise of stock options</link:label>
    <link:loc xlink:label="loc_RepaymentsOfLongTermCapitalLeaseObligations.15819.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RepaymentsOfLongTermCapitalLeaseObligations.15819.11.6" xlink:to="lab_RepaymentsOfLongTermCapitalLeaseObligations.15813.208287" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RepaymentsOfLongTermCapitalLeaseObligations.15813.208287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RepaymentsOfLongTermCapitalLeaseObligations.15813.208287">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:loc xlink:label="loc_RepaymentsOfLongTermCapitalLeaseObligations.15819.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RepaymentsOfLongTermCapitalLeaseObligations.15819.11.52" xlink:to="lab_RepaymentsOfLongTermCapitalLeaseObligations.158681.208288" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RepaymentsOfLongTermCapitalLeaseObligations.158681.208288" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_RepaymentsOfLongTermCapitalLeaseObligations.158681.208288">Principal payments of capital leases</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensation.16900.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensation.16900.11.6" xlink:to="lab_ShareBasedCompensation.17402.208289" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensation.17402.208289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensation.17402.208289">Share-based Compensation</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensation.16900.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensation.16900.11.7" xlink:to="lab_ShareBasedCompensation7.158318.208290" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensation7.158318.208290" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensation7.158318.208290">Non-cash stock-based compensation</link:label>
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.5168.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.11.6" xlink:to="lab_StatementOfCashFlowsAbstract.158316.208291" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfCashFlowsAbstract.158316.208291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfCashFlowsAbstract.158316.208291">STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:loc xlink:label="loc_SupplementalCashFlowInformationAbstract.5255.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalCashFlowInformationAbstract.5255.11.7" xlink:to="lab_SupplementalCashFlowInformationAbstract.158344.208293" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalCashFlowInformationAbstract.158344.208293" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalCashFlowInformationAbstract.158344.208293">Supplemental disclosure of cash flow information:</link:label>
    <link:loc xlink:label="loc_SupplementalCashFlowInformationAbstract.5255.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalCashFlowInformationAbstract.5255.11.6" xlink:to="lab_SupplementalCashFlowInformationAbstract.18204.208292" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalCashFlowInformationAbstract.18204.208292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalCashFlowInformationAbstract.18204.208292">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:label="loc_AmendmentFlag.144.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmendmentFlag.144.11.6" xlink:to="lab_AmendmentFlag.8.208055" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AmendmentFlag.8.208055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AmendmentFlag.8.208055">Amendment Flag</link:label>
    <link:loc xlink:label="loc_CurrentFiscalYearEndDate.155.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CurrentFiscalYearEndDate.155.11.6" xlink:to="lab_CurrentFiscalYearEndDate.20.208056" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CurrentFiscalYearEndDate.20.208056" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CurrentFiscalYearEndDate.20.208056">Current Fiscal Year End Date</link:label>
    <link:loc xlink:label="loc_DocumentAndEntityInformationAbstract.23926.11.6" xlink:href="nvax-20130930.xsd#nvax_DocumentAndEntityInformationAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentAndEntityInformationAbstract.23926.11.6" xlink:to="lab_DocumentAndEntityInformationAbstract.158197.208057" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentAndEntityInformationAbstract.158197.208057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentAndEntityInformationAbstract.158197.208057">Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:label="loc_DocumentFiscalPeriodFocus.206.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentFiscalPeriodFocus.206.11.6" xlink:to="lab_DocumentFiscalPeriodFocus.123.208058" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentFiscalPeriodFocus.123.208058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentFiscalPeriodFocus.123.208058">Document Fiscal Period Focus</link:label>
    <link:loc xlink:label="loc_DocumentFiscalYearFocus.205.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentFiscalYearFocus.205.11.6" xlink:to="lab_DocumentFiscalYearFocus.122.208059" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentFiscalYearFocus.122.208059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentFiscalYearFocus.122.208059">Document Fiscal Year Focus</link:label>
    <link:loc xlink:label="loc_DocumentPeriodEndDate.161.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentPeriodEndDate.161.11.6" xlink:to="lab_DocumentPeriodEndDate.30.208060" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentPeriodEndDate.30.208060" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentPeriodEndDate.30.208060">Document Period End Date</link:label>
    <link:loc xlink:label="loc_DocumentType.210.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentType.210.11.6" xlink:to="lab_DocumentType.32.208061" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentType.32.208061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentType.32.208061">Document Type</link:label>
    <link:loc xlink:label="loc_EntityCentralIndexKey.186.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityCentralIndexKey.186.11.6" xlink:to="lab_EntityCentralIndexKey.101.208062" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityCentralIndexKey.101.208062" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityCentralIndexKey.101.208062">Entity Central Index Key</link:label>
    <link:loc xlink:label="loc_EntityCommonStockSharesOutstanding.190.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityCommonStockSharesOutstanding.190.11.6" xlink:to="lab_EntityCommonStockSharesOutstanding.105.208063" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityCommonStockSharesOutstanding.105.208063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityCommonStockSharesOutstanding.105.208063">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:label="loc_EntityFilerCategory.183.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityFilerCategory.183.11.6" xlink:to="lab_EntityFilerCategory.98.208064" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityFilerCategory.98.208064" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityFilerCategory.98.208064">Entity Filer Category</link:label>
    <link:loc xlink:label="loc_EntityRegistrantName.185.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityRegistrantName.185.11.6" xlink:to="lab_EntityRegistrantName.100.208065" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityRegistrantName.100.208065" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityRegistrantName.100.208065">Entity Registrant Name</link:label>
    <link:loc xlink:label="loc_TradingSymbol.176.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TradingSymbol.176.11.6" xlink:to="lab_TradingSymbol.60.208066" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TradingSymbol.60.208066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TradingSymbol.60.208066">Trading Symbol</link:label>
    <link:loc xlink:label="loc_FairValueDisclosuresAbstract.2053.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueDisclosuresAbstract.2053.11.6" xlink:to="lab_FairValueDisclosuresAbstract.495117.208589" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueDisclosuresAbstract.495117.208589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueDisclosuresAbstract.495117.208589">Fair Value Measurements [Abstract]</link:label>
    <link:loc xlink:label="loc_FairValueDisclosuresTextBlock.9740.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueDisclosuresTextBlock.9740.11.6" xlink:to="lab_FairValueDisclosuresTextBlock.6346.208590" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueDisclosuresTextBlock.6346.208590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueDisclosuresTextBlock.6346.208590">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:label="loc_FairValueDisclosuresTextBlock.9740.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueDisclosuresTextBlock.9740.11.7" xlink:to="lab_FairValueDisclosuresTextBlock7.495118.208591" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueDisclosuresTextBlock7.495118.208591" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FairValueDisclosuresTextBlock7.495118.208591">Fair Value Measurements</link:label>
    <link:loc xlink:label="loc_FairValueInputsLevel1Member.2138.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueInputsLevel1Member.2138.11.7" xlink:to="FairValueInputsLevel1Member.141121.495124.208601" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="FairValueInputsLevel1Member.141121.495124.208601" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="FairValueInputsLevel1Member.141121.495124.208601">Level 1 [Member]</link:label>
    <link:loc xlink:label="loc_InvestmentsFairValueDisclosure.11996.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InvestmentsFairValueDisclosure.11996.11.7" xlink:to="InvestmentsFairValueDisclosure.495128.208602" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="InvestmentsFairValueDisclosure.495128.208602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="InvestmentsFairValueDisclosure.495128.208602">Total investments</link:label>
    <link:loc xlink:label="loc_AssetsFairValueDisclosureAbstract.608.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsFairValueDisclosureAbstract.608.11.6" xlink:to="lab_AssetsFairValueDisclosureAbstract.1139.208603" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsFairValueDisclosureAbstract.1139.208603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsFairValueDisclosureAbstract.1139.208603">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:label="loc_AssetsFairValueDisclosureAbstract.608.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsFairValueDisclosureAbstract.608.11.7" xlink:to="lab_AssetsFairValueDisclosureAbstract7.495129.208604" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsFairValueDisclosureAbstract7.495129.208604" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsFairValueDisclosureAbstract7.495129.208604">Assets</link:label>
    <link:loc xlink:label="loc_AvailableForSaleSecurities.6182.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AvailableForSaleSecurities.6182.11.6" xlink:to="lab_AvailableForSaleSecurities.1289" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AvailableForSaleSecurities.1289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AvailableForSaleSecurities.1289">Available-for-sale Securities</link:label>
    <link:loc xlink:label="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems.2051.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems.2051.11.6" xlink:to="lab_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems.6333.495127.208607" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems.6333.495127.208607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems.6333.495127.208607">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:label="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable.1996.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable.1996.11.6" xlink:to="lab_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable.6255.495121.208608" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable.6255.495121.208608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable.6255.495121.208608">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:label="loc_FairValueByFairValueHierarchyLevelAxis.1998.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueByFairValueHierarchyLevelAxis.1998.11.6" xlink:to="lab_FairValueByFairValueHierarchyLevelAxis.6113.495122.208609" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueByFairValueHierarchyLevelAxis.6113.495122.208609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueByFairValueHierarchyLevelAxis.6113.495122.208609">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:label="loc_FairValueInputsLevel1Member.2138.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueInputsLevel1Member.2138.11.6" xlink:to="lab_FairValueInputsLevel1Member.6601.208610" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueInputsLevel1Member.6601.208610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueInputsLevel1Member.6601.208610">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:label="loc_FairValueInputsLevel2Member.2139.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueInputsLevel2Member.2139.11.7" xlink:to="lab_FairValueInputsLevel2Member.138285.495125.208612" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueInputsLevel2Member.138285.495125.208612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FairValueInputsLevel2Member.138285.495125.208612">Level 2 [Member]</link:label>
    <link:loc xlink:label="loc_FairValueInputsLevel2Member.2139.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueInputsLevel2Member.2139.11.6" xlink:to="lab_FairValueInputsLevel2Member.6625.208611" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueInputsLevel2Member.6625.208611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueInputsLevel2Member.6625.208611">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:label="loc_FairValueInputsLevel3Member.2129.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueInputsLevel3Member.2129.11.7" xlink:to="lab_FairValueInputsLevel3Member.141122.495126.208614" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueInputsLevel3Member.141122.495126.208614" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FairValueInputsLevel3Member.141122.495126.208614">Level 3 [Member]</link:label>
    <link:loc xlink:label="loc_FairValueInputsLevel3Member.2129.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueInputsLevel3Member.2129.11.6" xlink:to="lab_FairValueInputsLevel3Member.6593.208613" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueInputsLevel3Member.6593.208613" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueInputsLevel3Member.6593.208613">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:label="loc_FairValueMeasurementsFairValueHierarchyDomain.2060.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueMeasurementsFairValueHierarchyDomain.2060.11.6" xlink:to="lab_FairValueMeasurementsFairValueHierarchyDomain.6292.495123.208615" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueMeasurementsFairValueHierarchyDomain.6292.495123.208615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueMeasurementsFairValueHierarchyDomain.6292.495123.208615">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:label="loc_InvestmentsFairValueDisclosure.11996.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InvestmentsFairValueDisclosure.11996.11.6" xlink:to="lab_InvestmentsFairValueDisclosure.9873.208616" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InvestmentsFairValueDisclosure.9873.208616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InvestmentsFairValueDisclosure.9873.208616">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:label="loc_LiabilitiesFairValueDisclosureAbstract.3067.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesFairValueDisclosureAbstract.3067.11.6" xlink:to="lab_LiabilitiesFairValueDisclosureAbstract.10189.208617" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesFairValueDisclosureAbstract.10189.208617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesFairValueDisclosureAbstract.10189.208617">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesFairValueDisclosureAbstract.3067.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesFairValueDisclosureAbstract.3067.11.7" xlink:to="lab_LiabilitiesFairValueDisclosureAbstract.139877.208618" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesFairValueDisclosureAbstract.139877.208618" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesFairValueDisclosureAbstract.139877.208618">Liabilities:</link:label>
    <link:loc xlink:label="loc_OtherLiabilitiesFairValueDisclosure.13881.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherLiabilitiesFairValueDisclosure.13881.11.6" xlink:to="lab_OtherLiabilitiesFairValueDisclosure.12701.208619" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherLiabilitiesFairValueDisclosure.12701.208619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherLiabilitiesFairValueDisclosure.12701.208619">Other Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:label="loc_OtherLiabilitiesFairValueDisclosure.13881.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherLiabilitiesFairValueDisclosure.13881.11.7" xlink:to="lab_OtherLiabilitiesFairValueDisclosure.495130.208620" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherLiabilitiesFairValueDisclosure.495130.208620" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherLiabilitiesFairValueDisclosure.495130.208620">Warrant liabilities</link:label>
    <link:loc xlink:label="loc_AvailableForSaleSecurities.6182.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AvailableForSaleSecurities.6182.11.7" xlink:to="us-gaap_AvailableForSaleSecurities_lbl.483991.208672" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_AvailableForSaleSecurities_lbl.483991.208672" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_AvailableForSaleSecurities_lbl.483991.208672">Corporate debt and auction rate securities</link:label>
    <link:loc xlink:label="loc_FairValueByShareholdersEquityClassDomain.2057.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueByShareholdersEquityClassDomain.2057.11.6" xlink:to="lab_FairValueByShareholdersEquityClassDomain.6355.208621" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueByShareholdersEquityClassDomain.6355.208621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueByShareholdersEquityClassDomain.6355.208621">Fair Value by Shareholders' Equity Class [Domain]</link:label>
    <link:loc xlink:label="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.2134.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.2134.11.6" xlink:to="lab_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.6675.208622" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.6675.208622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.6675.208622">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:label="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable.2133.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable.2133.11.6" xlink:to="lab_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable.6699.208623" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable.6699.208623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable.6699.208623">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:label="loc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease.9954.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease.9954.11.7" xlink:to="lab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease.158983.208625" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease.158983.208625" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease.158983.208625">Change in fair value of Warrant liability</link:label>
    <link:loc xlink:label="loc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease.9954.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease.9954.11.6" xlink:to="lab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease.6650.208624" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease.6650.208624" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease.6650.208624">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
    <link:loc xlink:label="loc_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.9648.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.9648.11.10" xlink:to="lab_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.158981.208627" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.158981.208627" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.158981.208627">Balance at December 31, 2012</link:label>
    <link:loc xlink:label="loc_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.9648.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.9648.11.11" xlink:to="lab_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.158984.208628" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.158984.208628" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.158984.208628">Balance at September 30, 2013</link:label>
    <link:loc xlink:label="loc_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.9648.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.9648.11.6" xlink:to="lab_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.6176.208626" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.6176.208626" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.6176.208626">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:label="loc_ShareholdersEquityClassAxis.4707.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareholdersEquityClassAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareholdersEquityClassAxis.4707.11.6" xlink:to="lab_ShareholdersEquityClassAxis.16351.208629" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareholdersEquityClassAxis.16351.208629" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareholdersEquityClassAxis.16351.208629">Shareholders' Equity Class [Axis]</link:label>
    <link:loc xlink:label="loc_WarrantsSettleableInCashMember.23966.11.6" xlink:href="nvax-20130930.xsd#nvax_WarrantsSettleableInCashMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WarrantsSettleableInCashMember.23966.11.6" xlink:to="lab_WarrantsSettleableInCashMember.495132.208630" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WarrantsSettleableInCashMember.495132.208630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_WarrantsSettleableInCashMember.495132.208630">Warrants Settleable In Cash [Member]</link:label>
    <link:loc xlink:label="loc_WarrantsSettleableInCashMember.23966.11.12" xlink:href="nvax-20130930.xsd#nvax_WarrantsSettleableInCashMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WarrantsSettleableInCashMember.23966.11.12" xlink:to="lab_WarrantsSettleableInCashMember.495133.208631" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WarrantsSettleableInCashMember.495133.208631" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_WarrantsSettleableInCashMember.495133.208631">Warrants Settleable In Cash Member.</link:label>
    <link:loc xlink:label="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock.9863.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock.9863.11.7" xlink:to="lab_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock.158811.208596" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock.158811.208596" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock.158811.208596">Reconciliation of Level 3 Assets and Liabilities</link:label>
    <link:loc xlink:label="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock.9863.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock.9863.11.6" xlink:to="lab_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock.6652.208595" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock.6652.208595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock.6652.208595">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock.16321.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock.16321.11.7" xlink:to="lab_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock.158809.208598" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock.158809.208598" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock.158809.208598">Fair Value Hierarchy</link:label>
    <link:loc xlink:label="loc_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock.16321.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock.16321.11.6" xlink:to="lab_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock.16543.208597" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock.16543.208597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock.16543.208597">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:label="loc_InvestmentsDebtAndEquitySecuritiesAbstract.2966.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InvestmentsDebtAndEquitySecuritiesAbstract.2966.11.6" xlink:to="lab_InvestmentsDebtAndEquitySecuritiesAbstract.495119.208592" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InvestmentsDebtAndEquitySecuritiesAbstract.495119.208592" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InvestmentsDebtAndEquitySecuritiesAbstract.495119.208592">Investments [Abstract]</link:label>
    <link:loc xlink:label="loc_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock.12012.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock.12012.11.6" xlink:to="lab_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock.9861.208593" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock.9861.208593" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock.9861.208593">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock.12012.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock.12012.11.7" xlink:to="lab_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock7.495120.208594" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock7.495120.208594" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock7.495120.208594">Investments</link:label>
    <link:loc xlink:label="loc_AuctionRateSecuritiesMember.646.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AuctionRateSecuritiesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AuctionRateSecuritiesMember.646.11.6" xlink:to="lab_AuctionRateSecuritiesMember.1205.495144.208632" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AuctionRateSecuritiesMember.1205.495144.208632" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AuctionRateSecuritiesMember.1205.495144.208632">Auction Rate Securities [Member]</link:label>
    <link:loc xlink:label="loc_AvailableForSaleSecurities.6182.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AvailableForSaleSecurities.6182.11.8" xlink:to="lab_AvailableForSaleSecurities8.208673" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AvailableForSaleSecurities8.208673" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AvailableForSaleSecurities8.208673">Fair Value</link:label>
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesAmortizedCost.6209.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AvailableForSaleSecuritiesAmortizedCost.6209.11.6" xlink:to="lab_AvailableForSaleSecuritiesAmortizedCost.1331.208633" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AvailableForSaleSecuritiesAmortizedCost.1331.208633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AvailableForSaleSecuritiesAmortizedCost.1331.208633">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesAmortizedCost.6209.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AvailableForSaleSecuritiesAmortizedCost.6209.11.7" xlink:to="lab_AvailableForSaleSecuritiesAmortizedCost.145893.495141.208634" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AvailableForSaleSecuritiesAmortizedCost.145893.495141.208634" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AvailableForSaleSecuritiesAmortizedCost.145893.495141.208634">Amortized Cost</link:label>
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesGrossUnrealizedGains.6229.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AvailableForSaleSecuritiesGrossUnrealizedGains.6229.11.6" xlink:to="lab_AvailableForSaleSecuritiesGrossUnrealizedGains.1369" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AvailableForSaleSecuritiesGrossUnrealizedGains.1369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AvailableForSaleSecuritiesGrossUnrealizedGains.1369">Available-for-sale Securities, Gross Unrealized Gain</link:label>
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesGrossUnrealizedGains.6229.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AvailableForSaleSecuritiesGrossUnrealizedGains.6229.11.7" xlink:to="lab_AvailableForSaleSecuritiesGrossUnrealizedGains.208674" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AvailableForSaleSecuritiesGrossUnrealizedGains.208674" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AvailableForSaleSecuritiesGrossUnrealizedGains.208674">Gross Unrealized Gains</link:label>
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesGrossUnrealizedLoss.6213.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AvailableForSaleSecuritiesGrossUnrealizedLoss.6213.11.6" xlink:to="lab_AvailableForSaleSecuritiesGrossUnrealizedLoss.1343" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AvailableForSaleSecuritiesGrossUnrealizedLoss.1343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AvailableForSaleSecuritiesGrossUnrealizedLoss.1343">Available-for-sale Securities, Gross Unrealized Loss</link:label>
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesGrossUnrealizedLoss.6213.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AvailableForSaleSecuritiesGrossUnrealizedLoss.6213.11.7" xlink:to="lab_AvailableForSaleSecuritiesGrossUnrealizedLoss.208675" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AvailableForSaleSecuritiesGrossUnrealizedLoss.208675" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AvailableForSaleSecuritiesGrossUnrealizedLoss.208675">Gross Unrealized Losses</link:label>
    <link:loc xlink:label="loc_CorporateDebtSecuritiesMember.1234.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CorporateDebtSecuritiesMember.1234.11.6" xlink:to="lab_CorporateDebtSecuritiesMember.3145.495143.208640" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CorporateDebtSecuritiesMember.3145.495143.208640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CorporateDebtSecuritiesMember.3145.495143.208640">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:label="loc_MajorTypesOfDebtAndEquitySecuritiesAxis.3313.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MajorTypesOfDebtAndEquitySecuritiesAxis.3313.11.6" xlink:to="lab_MajorTypesOfDebtAndEquitySecuritiesAxis.11217.495138.208641" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MajorTypesOfDebtAndEquitySecuritiesAxis.11217.495138.208641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MajorTypesOfDebtAndEquitySecuritiesAxis.11217.495138.208641">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:label="loc_MajorTypesOfDebtAndEquitySecuritiesDomain.3315.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MajorTypesOfDebtAndEquitySecuritiesDomain.3315.11.6" xlink:to="lab_MajorTypesOfDebtAndEquitySecuritiesDomain.11220.495139.208642" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MajorTypesOfDebtAndEquitySecuritiesDomain.11220.495139.208642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MajorTypesOfDebtAndEquitySecuritiesDomain.11220.495139.208642">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:label="loc_ScheduleOfAvailableForSaleSecuritiesLineItems.4805.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfAvailableForSaleSecuritiesLineItems.4805.11.6" xlink:to="lab_ScheduleOfAvailableForSaleSecuritiesLineItems.16695.495140.208643" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfAvailableForSaleSecuritiesLineItems.16695.495140.208643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfAvailableForSaleSecuritiesLineItems.16695.495140.208643">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:label="loc_ScheduleOfAvailableForSaleSecuritiesTable.4765.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfAvailableForSaleSecuritiesTable.4765.11.6" xlink:to="lab_ScheduleOfAvailableForSaleSecuritiesTable.16599.495137.208644" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfAvailableForSaleSecuritiesTable.16599.495137.208644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfAvailableForSaleSecuritiesTable.16599.495137.208644">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesTextBlock.6161.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AvailableForSaleSecuritiesTextBlock.6161.11.6" xlink:to="lab_AvailableForSaleSecuritiesTextBlock.1296.208599" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AvailableForSaleSecuritiesTextBlock.1296.208599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AvailableForSaleSecuritiesTextBlock.1296.208599">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesTextBlock.6161.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AvailableForSaleSecuritiesTextBlock.6161.11.7" xlink:to="lab_AvailableForSaleSecuritiesTextBlock.158813.208600" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AvailableForSaleSecuritiesTextBlock.158813.208600" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AvailableForSaleSecuritiesTextBlock.158813.208600">Investments Classified as Available-For-Sale</link:label>
    <link:loc xlink:label="loc_ManufacturingLaboratoryAndOfficeFacilityAbstract.23939.11.6" xlink:href="nvax-20130930.xsd#nvax_ManufacturingLaboratoryAndOfficeFacilityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ManufacturingLaboratoryAndOfficeFacilityAbstract.23939.11.6" xlink:to="lab_ManufacturingLaboratoryAndOfficeFacilityAbstract.158762.208341" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ManufacturingLaboratoryAndOfficeFacilityAbstract.158762.208341" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ManufacturingLaboratoryAndOfficeFacilityAbstract.158762.208341">Manufacturing Laboratory and Office Facility [Abstract]</link:label>
    <link:loc xlink:label="loc_ManufacturingLaboratoryAndOfficeFacilityAbstract.23939.11.12" xlink:href="nvax-20130930.xsd#nvax_ManufacturingLaboratoryAndOfficeFacilityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ManufacturingLaboratoryAndOfficeFacilityAbstract.23939.11.12" xlink:to="lab_NewFacilityLeaseDisclosureAbstract.158763.208342" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NewFacilityLeaseDisclosureAbstract.158763.208342" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_NewFacilityLeaseDisclosureAbstract.158763.208342">New Facility Lease Disclosure [Abstract]</link:label>
    <link:loc xlink:label="loc_NewFacilityLeaseDisclosureTextBlock.23940.11.6" xlink:href="nvax-20130930.xsd#nvax_NewFacilityLeaseDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NewFacilityLeaseDisclosureTextBlock.23940.11.6" xlink:to="lab_NewFacilityLeaseDisclosureTextBlock.158764.208343" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NewFacilityLeaseDisclosureTextBlock.158764.208343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NewFacilityLeaseDisclosureTextBlock.158764.208343">New Facility Lease Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_NewFacilityLeaseDisclosureTextBlock.23940.11.12" xlink:href="nvax-20130930.xsd#nvax_NewFacilityLeaseDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NewFacilityLeaseDisclosureTextBlock.23940.11.12" xlink:to="lab_NewFacilityLeaseDisclosureTextBlock.158765.208345" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NewFacilityLeaseDisclosureTextBlock.158765.208345" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_NewFacilityLeaseDisclosureTextBlock.158765.208345">New Facility Lease Disclosure</link:label>
    <link:loc xlink:label="loc_NewFacilityLeaseDisclosureTextBlock.23940.11.7" xlink:href="nvax-20130930.xsd#nvax_NewFacilityLeaseDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NewFacilityLeaseDisclosureTextBlock.23940.11.7" xlink:to="lab_NewFacilityLeaseDisclosureTextBlock.158766.208344" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NewFacilityLeaseDisclosureTextBlock.158766.208344" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NewFacilityLeaseDisclosureTextBlock.158766.208344">Manufacturing, Laboratory and Office Facility</link:label>
    <link:loc xlink:label="loc_AdditionalTenantImprovementAllowance.23916.11.6" xlink:href="nvax-20130930.xsd#nvax_AdditionalTenantImprovementAllowance" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalTenantImprovementAllowance.23916.11.6" xlink:to="lab_AdditionalTenantImprovementAllowance.159754.208576" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdditionalTenantImprovementAllowance.159754.208576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdditionalTenantImprovementAllowance.159754.208576">Additional Tenant Improvement Allowance</link:label>
    <link:loc xlink:label="loc_AdditionalTenantImprovementAllowance.23916.11.12" xlink:href="nvax-20130930.xsd#nvax_AdditionalTenantImprovementAllowance" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalTenantImprovementAllowance.23916.11.12" xlink:to="lab_AdditionalTenantImprovementAllowance.159755.208577" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdditionalTenantImprovementAllowance.159755.208577" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_AdditionalTenantImprovementAllowance.159755.208577">Additional tenant improvement allowance</link:label>
    <link:loc xlink:label="loc_AdditionalTenantImprovementAllowance.23916.11.7" xlink:href="nvax-20130930.xsd#nvax_AdditionalTenantImprovementAllowance" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalTenantImprovementAllowance.23916.11.7" xlink:to="lab_AdditionalTenantImprovementAllowance7.159756.208578" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdditionalTenantImprovementAllowance7.159756.208578" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdditionalTenantImprovementAllowance7.159756.208578">Additional tenant improvement allowance</link:label>
    <link:loc xlink:label="loc_LeasedFacilitySquareFootage.23932.11.6" xlink:href="nvax-20130930.xsd#nvax_LeasedFacilitySquareFootage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LeasedFacilitySquareFootage.23932.11.6" xlink:to="lab_LeasedFacilitySquareFootage.159747.208579" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LeasedFacilitySquareFootage.159747.208579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LeasedFacilitySquareFootage.159747.208579">Leased Facility Square Footage</link:label>
    <link:loc xlink:label="loc_LeasedFacilitySquareFootage.23932.11.12" xlink:href="nvax-20130930.xsd#nvax_LeasedFacilitySquareFootage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LeasedFacilitySquareFootage.23932.11.12" xlink:to="lab_LeasedFacilitySquareFootage.174157.208580" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LeasedFacilitySquareFootage.174157.208580" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_LeasedFacilitySquareFootage.174157.208580">Amount of square footage of leased facililty.</link:label>
    <link:loc xlink:label="loc_LeasedFacilitySquareFootage.23932.11.7" xlink:href="nvax-20130930.xsd#nvax_LeasedFacilitySquareFootage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LeasedFacilitySquareFootage.23932.11.7" xlink:to="lab_LeasedFacilitySquareFootage7.159753.208581" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LeasedFacilitySquareFootage7.159753.208581" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LeasedFacilitySquareFootage7.159753.208581">Leased facility square footage</link:label>
    <link:loc xlink:label="loc_PaymentsForProceedsFromTenantAllowance.14211.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsForProceedsFromTenantAllowance.14211.11.6" xlink:to="lab_PaymentsForProceedsFromTenantAllowance.13363.208582" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsForProceedsFromTenantAllowance.13363.208582" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsForProceedsFromTenantAllowance.13363.208582">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:loc xlink:label="loc_PaymentsForProceedsFromTenantAllowance.14211.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsForProceedsFromTenantAllowance.14211.11.7" xlink:to="lab_PaymentsForProceedsFromTenantAllowance.159758.208583" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsForProceedsFromTenantAllowance.159758.208583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsForProceedsFromTenantAllowance.159758.208583">Amount funded from tenant allowance</link:label>
    <link:loc xlink:label="loc_TenantAllowanceInterestRate.23960.11.6" xlink:href="nvax-20130930.xsd#nvax_TenantAllowanceInterestRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TenantAllowanceInterestRate.23960.11.6" xlink:to="lab_TenantAllowanceInterestRate.171384.208584" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TenantAllowanceInterestRate.171384.208584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TenantAllowanceInterestRate.171384.208584">Tenant Allowance Interest Rate</link:label>
    <link:loc xlink:label="loc_TenantAllowanceInterestRate.23960.11.12" xlink:href="nvax-20130930.xsd#nvax_TenantAllowanceInterestRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TenantAllowanceInterestRate.23960.11.12" xlink:to="lab_TenantAllowanceInterestRate.171385.208585" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TenantAllowanceInterestRate.171385.208585" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_TenantAllowanceInterestRate.171385.208585">Tenant Allowance Interest Rate</link:label>
    <link:loc xlink:label="loc_TenantImprovementAllowance.23961.11.6" xlink:href="nvax-20130930.xsd#nvax_TenantImprovementAllowance" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TenantImprovementAllowance.23961.11.6" xlink:to="lab_TenantImprovementAllowance.159750.208586" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TenantImprovementAllowance.159750.208586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TenantImprovementAllowance.159750.208586">Tenant Improvement Allowance</link:label>
    <link:loc xlink:label="loc_TenantImprovementAllowance.23961.11.12" xlink:href="nvax-20130930.xsd#nvax_TenantImprovementAllowance" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TenantImprovementAllowance.23961.11.12" xlink:to="lab_TenantImprovementAllowance.159751.208587" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TenantImprovementAllowance.159751.208587" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_TenantImprovementAllowance.159751.208587">Tenant Improvement Allowance</link:label>
    <link:loc xlink:label="loc_TenantImprovementAllowance.23961.11.7" xlink:href="nvax-20130930.xsd#nvax_TenantImprovementAllowance" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TenantImprovementAllowance.23961.11.7" xlink:to="lab_TenantImprovementAllowance7.159752.208588" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TenantImprovementAllowance7.159752.208588" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_TenantImprovementAllowance7.159752.208588">Tenant improvement allowance</link:label>
    <link:loc xlink:label="loc_DebtDisclosureAbstract.1355.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtDisclosureAbstract.1355.11.6" xlink:to="lab_DebtDisclosureAbstract.158743.208328" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtDisclosureAbstract.158743.208328" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtDisclosureAbstract.158743.208328">Notes Payable [Abstract]</link:label>
    <link:loc xlink:label="loc_DebtDisclosureTextBlock.7682.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtDisclosureTextBlock.7682.11.6" xlink:to="lab_DebtDisclosureTextBlock.3550.208329" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtDisclosureTextBlock.3550.208329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtDisclosureTextBlock.3550.208329">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_DebtDisclosureTextBlock.7682.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtDisclosureTextBlock.7682.11.7" xlink:to="lab_DebtDisclosureTextBlock7.158744.208330" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtDisclosureTextBlock7.158744.208330" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DebtDisclosureTextBlock7.158744.208330">Notes Payable</link:label>
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsDue.23934.11.9" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsDue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsDue.23934.11.9" xlink:to="lab_CapitalLeasesFutureMinimumPaymentsDue9.159292.208551" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CapitalLeasesFutureMinimumPaymentsDue9.159292.208551" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_CapitalLeasesFutureMinimumPaymentsDue9.159292.208551">Total</link:label>
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsDue.23934.11.6" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsDue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsDue.23934.11.6" xlink:to="lab_LoanAgreementFutureMinimumPaymentsDue.159285.208552" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LoanAgreementFutureMinimumPaymentsDue.159285.208552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LoanAgreementFutureMinimumPaymentsDue.159285.208552">Loan Agreement Future Minimum Payments Due</link:label>
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsDue.23934.11.12" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsDue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsDue.23934.11.12" xlink:to="lab_LoanAgreementFutureMinimumPaymentsDue.159290.208553" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LoanAgreementFutureMinimumPaymentsDue.159290.208553" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_LoanAgreementFutureMinimumPaymentsDue.159290.208553">Amount of minimum loan payments.</link:label>
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsDueInYearThree.23936.11.6" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsDueInYearThree" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsDueInYearThree.23936.11.6" xlink:to="lab_LoanAgreementFutureMinimumPaymentsDueInYearThree.208557" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LoanAgreementFutureMinimumPaymentsDueInYearThree.208557" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LoanAgreementFutureMinimumPaymentsDueInYearThree.208557">Loan Agreement Future Minimum Payments Due In Year Three</link:label>
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsDueInYearThree.23936.11.12" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsDueInYearThree" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsDueInYearThree.23936.11.12" xlink:to="lab_LoanAgreementFutureMinimumPaymentsDueInYearThree.159277.208558" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LoanAgreementFutureMinimumPaymentsDueInYearThree.159277.208558" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_LoanAgreementFutureMinimumPaymentsDueInYearThree.159277.208558">Amount of minimum loan payments maturing in the third fiscal year following the latest fiscal year.</link:label>
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsDueInYearThree.23936.11.7" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsDueInYearThree" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsDueInYearThree.23936.11.7" xlink:to="lab_LoanAgreementFutureMinimumPaymentsDueInYearThree7.159278.208559" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LoanAgreementFutureMinimumPaymentsDueInYearThree7.159278.208559" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LoanAgreementFutureMinimumPaymentsDueInYearThree7.159278.208559">2016</link:label>
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsDueInYearTwo.23937.11.6" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsDueInYearTwo" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsDueInYearTwo.23937.11.6" xlink:to="lab_LoanAgreementFutureMinimumPaymentsDueInYearTwo.208560" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LoanAgreementFutureMinimumPaymentsDueInYearTwo.208560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LoanAgreementFutureMinimumPaymentsDueInYearTwo.208560">Loan Agreement Future Minimum Payments Due In Year Two</link:label>
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsDueInYearTwo.23937.11.12" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsDueInYearTwo" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsDueInYearTwo.23937.11.12" xlink:to="lab_LoanAgreementFutureMinimumPaymentsDueInYearTwo.159274.208561" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LoanAgreementFutureMinimumPaymentsDueInYearTwo.159274.208561" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_LoanAgreementFutureMinimumPaymentsDueInYearTwo.159274.208561">Amount of minimum loan payments maturing in the second fiscal year following the latest fiscal year.</link:label>
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsDueInYearTwo.23937.11.7" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsDueInYearTwo" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsDueInYearTwo.23937.11.7" xlink:to="lab_LoanAgreementFutureMinimumPaymentsDueInYearTwo7.159275.208562" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LoanAgreementFutureMinimumPaymentsDueInYearTwo7.159275.208562" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LoanAgreementFutureMinimumPaymentsDueInYearTwo7.159275.208562">2015</link:label>
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsNextTwelveMonths.32695.11.6" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsNextTwelveMonths" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsNextTwelveMonths.32695.11.6" xlink:to="lab_LoanAgreementFutureMinimumPaymentsNextTwelveMonths.280685" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LoanAgreementFutureMinimumPaymentsNextTwelveMonths.280685" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LoanAgreementFutureMinimumPaymentsNextTwelveMonths.280685">Loan Agreement Future Minimum Payments Next Twelve Months</link:label>
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsNextTwelveMonths.32695.11.12" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsNextTwelveMonths" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsNextTwelveMonths.32695.11.12" xlink:to="lab_LoanAgreementFutureMinimumPaymentsNextTwelveMonths12.280686" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LoanAgreementFutureMinimumPaymentsNextTwelveMonths12.280686" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_LoanAgreementFutureMinimumPaymentsNextTwelveMonths12.280686">Amount of minimum loan payments maturing in the next fiscal year following the latest fiscal year.</link:label>
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsNextTwelveMonths.32695.11.7" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsNextTwelveMonths" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsNextTwelveMonths.32695.11.7" xlink:to="lab_LoanAgreementFutureMinimumPaymentsNextTwelveMonths7.280687" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LoanAgreementFutureMinimumPaymentsNextTwelveMonths7.280687" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LoanAgreementFutureMinimumPaymentsNextTwelveMonths7.280687">2014</link:label>
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear.23938.11.6" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear.23938.11.6" xlink:to="lab_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear.159258.208563" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear.159258.208563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear.159258.208563">Loan Agreement Future Minimum Payments Remainder Of Fiscal Year</link:label>
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear.23938.11.12" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear.23938.11.12" xlink:to="lab_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear.159264.208564" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear.159264.208564" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear.159264.208564">Amount of minimum loan payments maturing in the remainder of the fiscal year following the latest fiscal year ended.</link:label>
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear.23938.11.7" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear.23938.11.7" xlink:to="lab_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear7.159266.208565" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear7.159266.208565" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear7.159266.208565">2013 (remainder)</link:label>
    <link:loc xlink:label="loc_DebtInstrumentBasisSpreadOnVariableRate1.7653.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentBasisSpreadOnVariableRate1.7653.11.6" xlink:to="lab_DebtInstrumentBasisSpreadOnVariableRate1.3690" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentBasisSpreadOnVariableRate1.3690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentBasisSpreadOnVariableRate1.3690">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:label="loc_DebtInstrumentBasisSpreadOnVariableRate1.7653.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentBasisSpreadOnVariableRate1.7653.11.7" xlink:to="lab_DebtInstrumentBasisSpreadOnVariableRate1.208677" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentBasisSpreadOnVariableRate1.208677" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentBasisSpreadOnVariableRate1.208677">Interest rate in addition to three-year U.S. Government treasury rate</link:label>
    <link:loc xlink:label="loc_DebtInstrumentFaceAmount.7642.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentFaceAmount.7642.11.7" xlink:to="lab_DebtInstrumentFaceAmount.159637.208539" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentFaceAmount.159637.208539" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentFaceAmount.159637.208539">Borrowing limit of loan</link:label>
    <link:loc xlink:label="loc_DebtInstrumentFaceAmount.7642.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentFaceAmount.7642.11.6" xlink:to="lab_DebtInstrumentFaceAmount.3599.208538" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentFaceAmount.3599.208538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentFaceAmount.3599.208538">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:label="loc_DebtInstrumentInterestRateDuringPeriod.7760.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentInterestRateDuringPeriod.7760.11.7" xlink:to="lab_DebtInstrumentInterestRateDuringPeriod.159642.208543" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentInterestRateDuringPeriod.159642.208543" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentInterestRateDuringPeriod.159642.208543">Interest rate during period</link:label>
    <link:loc xlink:label="loc_DebtInstrumentInterestRateDuringPeriod.7760.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentInterestRateDuringPeriod.7760.11.6" xlink:to="lab_DebtInstrumentInterestRateDuringPeriod.3669.208542" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentInterestRateDuringPeriod.3669.208542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentInterestRateDuringPeriod.3669.208542">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:label="loc_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum.7766.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum.7766.11.7" xlink:to="lab_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum.159640.208545" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum.159640.208545" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum.159640.208545">Minimum interest rate</link:label>
    <link:loc xlink:label="loc_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum.7766.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum.7766.11.6" xlink:to="lab_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum.3627.208544" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum.3627.208544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum.3627.208544">Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum</link:label>
    <link:loc xlink:label="loc_DebtInstrumentPeriodicPayment.7731.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentPeriodicPayment.7731.11.7" xlink:to="lab_DebtInstrumentPeriodicPayment.159643.208547" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentPeriodicPayment.159643.208547" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentPeriodicPayment.159643.208547">Monthly principal payments</link:label>
    <link:loc xlink:label="loc_DebtInstrumentPeriodicPayment.7731.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentPeriodicPayment.7731.11.6" xlink:to="lab_DebtInstrumentPeriodicPayment.3635.208546" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentPeriodicPayment.3635.208546" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentPeriodicPayment.3635.208546">Debt Instrument, Periodic Payment</link:label>
    <link:loc xlink:label="loc_DebtInstrumentTerm.7687.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentTerm.7687.11.6" xlink:to="lab_DebtInstrumentTerm.3731" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentTerm.3731" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentTerm.3731">Debt Instrument, Term</link:label>
    <link:loc xlink:label="loc_DebtInstrumentTerm.7687.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtInstrumentTerm.7687.11.7" xlink:to="lab_DebtInstrumentTerm.208676" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtInstrumentTerm.208676" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DebtInstrumentTerm.208676">Repayment term</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfDebt.14860.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfDebt.14860.11.6" xlink:to="lab_ProceedsFromIssuanceOfDebt.14891" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfDebt.14891" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfDebt.14891">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfDebt.14860.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfDebt.14860.11.7" xlink:to="lab_ProceedsFromIssuanceOfDebt.182593.208678" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfDebt.182593.208678" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfDebt.182593.208678">Debt instrument, increase in borrowings</link:label>
    <link:loc xlink:label="loc_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock.16372.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock.16372.11.6" xlink:to="lab_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock.16605.208346" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock.16605.208346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock.16605.208346">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock.16372.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock.16372.11.7" xlink:to="lab_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock.495205.208347" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock.495205.208347" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock.495205.208347">Schedule of Future Minimum Principal Payments</link:label>
    <link:loc xlink:label="loc_NatureOfOperations.13195.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NatureOfOperations.13195.11.6" xlink:to="lab_NatureOfOperations.11734.208296" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NatureOfOperations.11734.208296" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NatureOfOperations.11734.208296">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:label="loc_NatureOfOperations.13195.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NatureOfOperations.13195.11.7" xlink:to="lab_NatureOfOperations7.158717.208297" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NatureOfOperations7.158717.208297" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NatureOfOperations7.158717.208297">Organization</link:label>
    <link:loc xlink:label="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract.3716.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract.3716.11.6" xlink:to="lab_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract.158715.208298" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract.158715.208298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract.158715.208298">Organization [Abstract]</link:label>
    <link:loc xlink:label="loc_OperationsAbstract.23943.11.6" xlink:href="nvax-20130930.xsd#nvax_OperationsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperationsAbstract.23943.11.6" xlink:to="lab_OperationsAbstract.158719.208299" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperationsAbstract.158719.208299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OperationsAbstract.158719.208299">Operations [Abstract]</link:label>
    <link:loc xlink:label="loc_OperationsAbstract.23943.11.12" xlink:href="nvax-20130930.xsd#nvax_OperationsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperationsAbstract.23943.11.12" xlink:to="lab_OperationsAbstract.158721.208300" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperationsAbstract.158721.208300" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_OperationsAbstract.158721.208300">Operations [Abstract]</link:label>
    <link:loc xlink:label="loc_OperationsDisclosureTextBlock.23944.11.6" xlink:href="nvax-20130930.xsd#nvax_OperationsDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperationsDisclosureTextBlock.23944.11.6" xlink:to="lab_OperationsDisclosureTextBlock.158726.208301" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperationsDisclosureTextBlock.158726.208301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OperationsDisclosureTextBlock.158726.208301">Operations Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_OperationsDisclosureTextBlock.23944.11.12" xlink:href="nvax-20130930.xsd#nvax_OperationsDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperationsDisclosureTextBlock.23944.11.12" xlink:to="lab_OperationsDisclosureTextBlock.158728.208303" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperationsDisclosureTextBlock.158728.208303" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_OperationsDisclosureTextBlock.158728.208303">Operations Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_OperationsDisclosureTextBlock.23944.11.7" xlink:href="nvax-20130930.xsd#nvax_OperationsDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperationsDisclosureTextBlock.23944.11.7" xlink:to="lab_OperationsDisclosureTextBlock.158730.208302" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperationsDisclosureTextBlock.158730.208302" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OperationsDisclosureTextBlock.158730.208302">Operations</link:label>
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1637.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1637.11.6" xlink:to="lab_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.158734.208321" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.158734.208321" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.158734.208321">Stock-Based Compensation [Abstract]</link:label>
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.8793.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.8793.11.6" xlink:to="lab_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.5017.208322" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.5017.208322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.5017.208322">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.8793.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.8793.11.7" xlink:to="lab_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock7.158735.208323" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock7.158735.208323" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock7.158735.208323">Stock-Based Compensation</link:label>
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.11.6" xlink:to="lab_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.3902" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.3902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.3902">Type of Deferred Compensation [Axis]</link:label>
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.11.7" xlink:to="lab_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.272587" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.272587" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.272587">Type of Deferred Compensation [Axis]</link:label>
    <link:loc xlink:label="loc_EmployeeStockOptionMember.1806.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeStockOptionMember.1806.11.6" xlink:to="lab_EmployeeStockOptionMember.5884" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeStockOptionMember.5884" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeStockOptionMember.5884">Employee Stock Option [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeStockOptionMember.1806.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeStockOptionMember.1806.11.8" xlink:to="lab_EmployeeStockOptionMember.272590" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeStockOptionMember.272590" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeStockOptionMember.272590">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:label="loc_MaximumMember.3373.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MaximumMember.3373.11.7" xlink:to="lab_MaximumMember.149646.208444" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MaximumMember.149646.208444" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_MaximumMember.149646.208444">Maximum [Member]</link:label>
    <link:loc xlink:label="loc_MinimumMember.3382.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MinimumMember.3382.11.7" xlink:to="lab_MinimumMember.147963.208446" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MinimumMember.147963.208446" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_MinimumMember.147963.208446">Minimum [Member]</link:label>
    <link:loc xlink:label="loc_RangeAxis.4365.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RangeAxis.4365.11.7" xlink:to="lab_RangeAxis.147959.208448" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RangeAxis.147959.208448" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RangeAxis.147959.208448">Range [Axis]</link:label>
    <link:loc xlink:label="loc_RangeMember.4366.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RangeMember.4366.11.7" xlink:to="lab_RangeMember.147960.208450" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RangeMember.147960.208450" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RangeMember.147960.208450">Range [Domain]</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.11.7" xlink:to="lab_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.154696.208453" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.154696.208453" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.154696.208453">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.11.6" xlink:to="lab_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.16890.208452" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.16890.208452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.16890.208452">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.16956.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.16956.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.134186.208455" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.134186.208455" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.134186.208455">Dividend yield</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.16956.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.16956.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.17508.208454" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.17508.208454" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.17508.208454">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.23955.11.6" xlink:href="nvax-20130930.xsd#nvax_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.23955.11.6" xlink:to="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.159127.208456" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.159127.208456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.159127.208456">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Forfeiture Rate</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.23955.11.12" xlink:href="nvax-20130930.xsd#nvax_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.23955.11.12" xlink:to="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.159135.208457" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.159135.208457" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.159135.208457">Estimated rate of forfeitures.</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.23955.11.7" xlink:href="nvax-20130930.xsd#nvax_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.23955.11.7" xlink:to="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate7.159138.208458" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate7.159138.208458" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate7.159138.208458">Expected forfeiture rate</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.16199.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.16199.11.6" xlink:to="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.16361.208459" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.16361.208459" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.16361.208459">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.16199.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.16199.11.7" xlink:to="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm17.159146.208460" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm17.159146.208460" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm17.159146.208460">Expected term (in years)</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.16972.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.16972.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.134184.208462" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.134184.208462" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.134184.208462">Volatility</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.16972.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.16972.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.17502.208461" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.17502.208461" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.17502.208461">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.16892.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.16892.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.141993.208464" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.141993.208464" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.141993.208464">Volatility, maximum</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.16892.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.16892.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.17412.208463" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.17412.208463" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.17412.208463">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.16894.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.16894.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.141992.208466" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.141992.208466" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.141992.208466">Volatility, minimum</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.16894.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.16894.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.17415.208465" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.17415.208465" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.17415.208465">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.16975.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.16975.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.159144.208468" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.159144.208468" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.159144.208468">Risk-free interest rate</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.16975.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.16975.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.17501.208467" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.17501.208467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.17501.208467">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.16906.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.16906.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.141988.208470" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.141988.208470" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.141988.208470">Risk-free interest rate, maximum</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.16906.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.16906.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.17444.208469" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.17444.208469" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.17444.208469">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum.16941.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum.16941.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum.141986.208472" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum.141986.208472" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum.141986.208472">Risk-free interest rate, minimum</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum.16941.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum.16941.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum.17486.208471" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum.17486.208471" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum.17486.208471">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.17450.208473" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.17450.208473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.17450.208473">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.16978.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.16978.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.159140.208475" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.159140.208475" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.159140.208475">Weighted-average fair value of stock options granted</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.16978.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.16978.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.17513.208474" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.17513.208474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.17513.208474">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:label="loc_TypeOfDeferredCompensationDomain.5392.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfDeferredCompensationDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TypeOfDeferredCompensationDomain.5392.11.6" xlink:to="lab_TypeOfDeferredCompensationDomain.19413" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TypeOfDeferredCompensationDomain.19413" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TypeOfDeferredCompensationDomain.19413">Type of Deferred Compensation, All Types [Domain]</link:label>
    <link:loc xlink:label="loc_TypeOfDeferredCompensationDomain.5392.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfDeferredCompensationDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TypeOfDeferredCompensationDomain.5392.11.7" xlink:to="lab_TypeOfDeferredCompensationDomain.272588" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TypeOfDeferredCompensationDomain.272588" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_TypeOfDeferredCompensationDomain.272588">Type of Deferred Compensation, All Types [Domain]</link:label>
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.9212.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.9212.11.7" xlink:to="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.160206.208369" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.160206.208369" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.160206.208369">Unrecognized compensation expense</link:label>
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.9212.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.9212.11.6" xlink:to="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.5607.208368" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.5607.208368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.5607.208368">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.9214.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.9214.11.7" xlink:to="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.160218.208371" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.160218.208371" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.160218.208371">Unrecognized compensation expense, recognition period</link:label>
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.9214.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.9214.11.6" xlink:to="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.5594.208370" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.5594.208370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.5594.208370">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:label="loc_EmployeeStockPurchasePlanMember.27970.11.6" xlink:href="nvax-20130930.xsd#nvax_EmployeeStockPurchasePlanMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeStockPurchasePlanMember.27970.11.6" xlink:to="lab_EmployeeStockPurchasePlanMember.244022" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeStockPurchasePlanMember.244022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeStockPurchasePlanMember.244022">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeStockPurchasePlanMember.27970.11.12" xlink:href="nvax-20130930.xsd#nvax_EmployeeStockPurchasePlanMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeStockPurchasePlanMember.27970.11.12" xlink:to="lab_EmployeeStockPurchasePlanMember12.244023" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeStockPurchasePlanMember12.244023" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeStockPurchasePlanMember12.244023">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:label="loc_OneNineNineFiveStockOptionPlanMember.23942.11.6" xlink:href="nvax-20130930.xsd#nvax_OneNineNineFiveStockOptionPlanMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OneNineNineFiveStockOptionPlanMember.23942.11.6" xlink:to="lab_OneNineNineFiveStockOptionPlanMember.159059.208372" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OneNineNineFiveStockOptionPlanMember.159059.208372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OneNineNineFiveStockOptionPlanMember.159059.208372">One Nine Nine Five Stock Option Plan [Member]</link:label>
    <link:loc xlink:label="loc_OneNineNineFiveStockOptionPlanMember.23942.11.12" xlink:href="nvax-20130930.xsd#nvax_OneNineNineFiveStockOptionPlanMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OneNineNineFiveStockOptionPlanMember.23942.11.12" xlink:to="lab_OneNineNineFiveStockOptionPlanMember.159062.208373" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OneNineNineFiveStockOptionPlanMember.159062.208373" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_OneNineNineFiveStockOptionPlanMember.159062.208373">1995 Stock Option Plan [Member]</link:label>
    <link:loc xlink:label="loc_OneNineNineFiveStockOptionPlanMember.23942.11.7" xlink:href="nvax-20130930.xsd#nvax_OneNineNineFiveStockOptionPlanMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OneNineNineFiveStockOptionPlanMember.23942.11.7" xlink:to="lab_OneNineNineFiveStockOptionPlanMember7.159063.208374" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OneNineNineFiveStockOptionPlanMember7.159063.208374" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OneNineNineFiveStockOptionPlanMember7.159063.208374">1995 Stock Option Plan [Member]</link:label>
    <link:loc xlink:label="loc_PlanNameAxis.4031.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PlanNameAxis.4031.11.6" xlink:to="lab_PlanNameAxis.13737.208375" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PlanNameAxis.13737.208375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PlanNameAxis.13737.208375">Plan Name [Axis]</link:label>
    <link:loc xlink:label="loc_PlanNameDomain.4029.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PlanNameDomain.4029.11.6" xlink:to="lab_PlanNameDomain.13729.208376" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PlanNameDomain.13729.208376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PlanNameDomain.13729.208376">Plan Name [Domain]</link:label>
    <link:loc xlink:label="loc_ScenarioForecastMember.4759.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioForecastMember.4759.11.6" xlink:to="lab_ScenarioForecastMember.16505.208377" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioForecastMember.16505.208377" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioForecastMember.16505.208377">Scenario, Forecast [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4760.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.11.6" xlink:to="lab_ScenarioUnspecifiedDomain.16504.208378" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioUnspecifiedDomain.16504.208378" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioUnspecifiedDomain.16504.208378">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized.16895.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized.16895.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized.17427.208379" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized.17427.208379" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized.17427.208379">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized.16895.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized.16895.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized7.508082.208380" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized7.508082.208380" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized7.508082.208380">Increase in shares available for issuance approved at the 2013 annual stockholders' meeting</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16973.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16973.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.135582.208382" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.135582.208382" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.135582.208382">Common stock reserved for issuance</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16973.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16973.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.17523.208381" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.17523.208381" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.17523.208381">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.16197.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.16197.11.6" xlink:to="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.16359.208383" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.16359.208383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.16359.208383">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1.16217.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1.16217.11.7" xlink:to="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1.159449.208385" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1.159449.208385" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1.159449.208385">Weighted-average remaining contractual term of stock options exercisable</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1.16217.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1.16217.11.6" xlink:to="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1.16365.208384" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1.16365.208384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1.16365.208384">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.23956.11.6" xlink:href="nvax-20130930.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.23956.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.159434.208386" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.159434.208386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.159434.208386">Share Based Compensation Arrangement By Share Based Payment Award Options Exercise Period From Date Of Grant</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.23956.11.12" xlink:href="nvax-20130930.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.23956.11.12" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.159442.208387" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.159442.208387" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.159442.208387">Period of time incentive stock options are exercisable, from the date of grant.</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.23956.11.7" xlink:href="nvax-20130930.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.23956.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant7.159443.208388" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant7.159443.208388" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant7.159443.208388">Exercise period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16970.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16970.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.159451.208390" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.159451.208390" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.159451.208390">Aggregate intrinsic value of stock options exercised</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16970.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16970.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.17514.208389" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.17514.208389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.17514.208389">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent.23957.11.6" xlink:href="nvax-20130930.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent.23957.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent.159413.208391" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent.159413.208391" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent.159413.208391">Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Exercise Price Minimum Percent</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent.23957.11.12" xlink:href="nvax-20130930.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent.23957.11.12" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateSalePriceMinimumPercent.159429.208392" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateSalePriceMinimumPercent.159429.208392" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateSalePriceMinimumPercent.159429.208392">The minimum grant-date exercise price of incentive stock options granted as a percent of the common stock share price.</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent.23957.11.7" xlink:href="nvax-20130930.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent.23957.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateSalePriceMinimumPercent7.159432.208393" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateSalePriceMinimumPercent7.159432.208393" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateSalePriceMinimumPercent7.159432.208393">Minimum grant price, percent of common stock fair value</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.23958.11.6" xlink:href="nvax-20130930.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.23958.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.159336.208394" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.159336.208394" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.159336.208394">Share Based Compensation Arrangement By Share Based Payment Award Options Maximum Term</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.23958.11.12" xlink:href="nvax-20130930.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.23958.11.12" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.159409.208395" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.159409.208395" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.159409.208395">Maximum term of incentive stock options.</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.23958.11.7" xlink:href="nvax-20130930.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.23958.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm7.159412.208396" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm7.159412.208396" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm7.159412.208396">Maximum term of options</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.17001.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.17001.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.159445.208398" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.159445.208398" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.159445.208398">Aggregate intrinsic value of stock options outstanding</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.17001.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.17001.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.17557.208397" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.17557.208397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.17557.208397">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2.16219.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2.16219.11.7" xlink:to="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2.159446.208400" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2.159446.208400" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2.159446.208400">Weighted-average remaining contractual term of stock options outstanding</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2.16219.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2.16219.11.6" xlink:to="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2.16368.208399" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2.16368.208399" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2.16368.208399">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:label="loc_StatementScenarioAxis.5162.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementScenarioAxis.5162.11.6" xlink:to="lab_StatementScenarioAxis.17868.208401" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementScenarioAxis.17868.208401" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementScenarioAxis.17868.208401">Scenario [Axis]</link:label>
    <link:loc xlink:label="loc_TwoZeroZeroFiveStockIncentivePlanMember.23962.11.6" xlink:href="nvax-20130930.xsd#nvax_TwoZeroZeroFiveStockIncentivePlanMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TwoZeroZeroFiveStockIncentivePlanMember.23962.11.6" xlink:to="lab_TwoZeroZeroFiveStockIncentivePlanMember.159049.208402" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TwoZeroZeroFiveStockIncentivePlanMember.159049.208402" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TwoZeroZeroFiveStockIncentivePlanMember.159049.208402">Two Zero Zero Five Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:label="loc_TwoZeroZeroFiveStockIncentivePlanMember.23962.11.12" xlink:href="nvax-20130930.xsd#nvax_TwoZeroZeroFiveStockIncentivePlanMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TwoZeroZeroFiveStockIncentivePlanMember.23962.11.12" xlink:to="lab_TwoZeroZeroFiveStockIncentivePlanMember.159055.208403" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TwoZeroZeroFiveStockIncentivePlanMember.159055.208403" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_TwoZeroZeroFiveStockIncentivePlanMember.159055.208403">2005 Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:label="loc_TwoZeroZeroFiveStockIncentivePlanMember.23962.11.7" xlink:href="nvax-20130930.xsd#nvax_TwoZeroZeroFiveStockIncentivePlanMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TwoZeroZeroFiveStockIncentivePlanMember.23962.11.7" xlink:to="lab_TwoZeroZeroFiveStockIncentivePlanMember7.159057.208404" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TwoZeroZeroFiveStockIncentivePlanMember7.159057.208404" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_TwoZeroZeroFiveStockIncentivePlanMember7.159057.208404">2005 Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.16197.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.16197.11.7" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.159447.208405" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.159447.208405" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.159447.208405">Aggregate intrinsic value of stock options exercisable</link:label>
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5919.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AllocatedShareBasedCompensationExpense.5919.11.6" xlink:to="lab_AllocatedShareBasedCompensationExpense.852.208406" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AllocatedShareBasedCompensationExpense.852.208406" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AllocatedShareBasedCompensationExpense.852.208406">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5919.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AllocatedShareBasedCompensationExpense.5919.11.7" xlink:to="lab_AllocatedShareBasedCompensationExpense7.159040.208407" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AllocatedShareBasedCompensationExpense7.159040.208407" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AllocatedShareBasedCompensationExpense7.159040.208407">Stock-based compensation expense</link:label>
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.11.6" xlink:to="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.5595.208408" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.5595.208408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.5595.208408">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2476.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpenseMember.2476.11.6" xlink:to="lab_GeneralAndAdministrativeExpenseMember.7876.208410" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpenseMember.7876.208410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpenseMember.7876.208410">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2476.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpenseMember.2476.11.7" xlink:to="lab_GeneralAndAdministrativeExpenseMember7.159042.208411" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpenseMember7.159042.208411" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpenseMember7.159042.208411">General and administrative [Member]</link:label>
    <link:loc xlink:label="loc_IncomeStatementLocationAxis.2652.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeStatementLocationAxis.2652.11.6" xlink:to="lab_IncomeStatementLocationAxis.8839" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeStatementLocationAxis.8839" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeStatementLocationAxis.8839">Income Statement Location [Axis]</link:label>
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeStatementLocationDomain.2671.11.6" xlink:to="lab_IncomeStatementLocationDomain.8906" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeStatementLocationDomain.8906" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeStatementLocationDomain.8906">Income Statement Location [Domain]</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4573.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpenseMember.4573.11.6" xlink:to="lab_ResearchAndDevelopmentExpenseMember.15885.208412" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpenseMember.15885.208412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpenseMember.15885.208412">Research and Development Expense [Member]</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4573.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpenseMember.4573.11.7" xlink:to="lab_ResearchAndDevelopmentExpenseMember7.159041.208413" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpenseMember7.159041.208413" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpenseMember7.159041.208413">Research and development [Member]</link:label>
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.11.6" xlink:to="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.16738.208415" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.16738.208415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.16738.208415">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.16969.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.16969.11.8" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.160437.208417" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.160437.208417" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.160437.208417">Shares available for grant at September 30, 2013</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.16969.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.16969.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.17518.208416" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.17518.208416" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.17518.208416">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16964.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16964.11.11" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.159097.208419" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.159097.208419" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.159097.208419">Shares exercisable at September 30, 2013</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16964.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16964.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.17517.208418" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.17517.208418" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.17517.208418">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16947.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16947.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.134209.208421" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.134209.208421" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.134209.208421">Options exercisable, September 30, 2013</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16947.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16947.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.17506.208420" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.17506.208420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.17506.208420">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod.16962.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod.16962.11.52" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod.159074.208423" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod.159074.208423" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod.159074.208423">Canceled</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod.16962.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod.16962.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod.17531.208422" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod.17531.208422" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod.17531.208422">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16909.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16909.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.134193.208425" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.134193.208425" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.134193.208425">Granted</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16909.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16909.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.17448.208424" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.17448.208424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.17448.208424">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16990.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16990.11.10" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.159077.208427" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.159077.208427" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.159077.208427">Outstanding at January 1, 2013</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16990.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16990.11.11" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.159082.208428" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.159082.208428" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.159082.208428">Outstanding at September 30, 2013</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16990.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16990.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.17577.208426" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.17577.208426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.17577.208426">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.17522.208429" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.17522.208429" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.17522.208429">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward7.495270.208430" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward7.495270.208430" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward7.495270.208430">Stock Options</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16982.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16982.11.10" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.159079.208432" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.159079.208432" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.159079.208432">Outstanding at January 1, 2013</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16982.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16982.11.11" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.159083.208433" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.159083.208433" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.159083.208433">Outstanding at September 30, 2013</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16982.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16982.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.17554.208431" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.17554.208431" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.17554.208431">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.173668.208435" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.173668.208435" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.173668.208435">Weighted-Average Exercise Price</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.17430.208434" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.17430.208434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.17430.208434">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16942.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16942.11.7" xlink:to="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.134206.208437" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.134206.208437" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.134206.208437">Exercised</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16942.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16942.11.6" xlink:to="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.17487.208436" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.17487.208436" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.17487.208436">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.16889.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.16889.11.7" xlink:to="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.159076.208439" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.159076.208439" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.159076.208439">Canceled</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.16889.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.16889.11.6" xlink:to="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.17409.208438" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.17409.208438" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.17409.208438">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.16885.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.16885.11.7" xlink:to="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.134205.208441" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.134205.208441" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.134205.208441">Granted</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.16885.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.16885.11.6" xlink:to="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.17479.208440" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.17479.208440" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.17479.208440">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.11.52" xlink:to="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.159072.208443" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.159072.208443" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.159072.208443">Exercised</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984.208442" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984.208442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984.208442">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16926.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16926.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.159176.208477" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.159176.208477" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.159176.208477">Restricted stock forfeited</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16926.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16926.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.17413.208476" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.17413.208476" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.17413.208476">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue.16925.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue.16925.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue.160309.208479" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue.160309.208479" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue.160309.208479">Restricted stock forfeited</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue.16925.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue.16925.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue.17469.208478" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue.17469.208478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue.17469.208478">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16881.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16881.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.159170.208481" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.159170.208481" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.159170.208481">Restricted stock granted</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16881.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16881.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.17481.208480" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.17481.208480" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.17481.208480">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.16884.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.16884.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.159171.208483" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.159171.208483" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.159171.208483">Restricted stock granted</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.16884.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.16884.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.17411.208482" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.17411.208482" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.17411.208482">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16890.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16890.11.10" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.159168.208486" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.159168.208486" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.159168.208486">Outstanding and Unvested at January 1, 2013</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16890.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16890.11.11" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.159177.208485" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.159177.208485" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.159177.208485">Outstanding and Unvested at September 30, 2013</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16890.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16890.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.17456.208484" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.17456.208484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.17456.208484">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward.5064.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward.5064.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward.17399.208487" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward.17399.208487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward.17399.208487">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward.5064.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward.5064.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward7.134167.208488" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward7.134167.208488" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward7.134167.208488">Number of Shares</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.16911.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.16911.11.10" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.159169.208490" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.159169.208490" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.159169.208490">Outstanding and Unvested at January 1, 2013</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.16911.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.16911.11.11" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.159178.208491" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.159178.208491" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.159178.208491">Outstanding and Unvested at September 30, 2013</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.16911.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.16911.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.17416.208489" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.17416.208489" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.17416.208489">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.5071.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.5071.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.159179.208493" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.159179.208493" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.159179.208493">Per Share Weighted-Average Grant-Date Fair Value</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.5071.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.5071.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.17446.208492" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.17446.208492" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.17446.208492">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod.16897.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod.16897.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod.159174.208495" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod.159174.208495" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod.159174.208495">Restricted stock vested</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod.16897.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod.16897.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod.17464.208494" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod.17464.208494" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod.17464.208494">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue.16963.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue.16963.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue.159173.208497" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue.159173.208497" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue.159173.208497">Restricted stock vested</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue.16963.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue.16963.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue.17512.208496" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue.17512.208496" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue.17512.208496">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.1379.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.1379.11.6" xlink:to="lab_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.3864" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.3864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.3864">Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</link:label>
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.1379.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.1379.11.7" xlink:to="lab_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.272589" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.272589" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.272589">Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</link:label>
    <link:loc xlink:label="loc_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.4832.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.4832.11.6" xlink:to="lab_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.17424" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.17424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.17424">Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]</link:label>
    <link:loc xlink:label="loc_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.4832.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.4832.11.7" xlink:to="lab_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.272586" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.272586" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.272586">Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]</link:label>
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.16476.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.16476.11.7" xlink:to="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.158815.208349" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.158815.208349" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.158815.208349">Stock-Based Compensation Expense</link:label>
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.16476.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.16476.11.6" xlink:to="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.16754.208348" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.16754.208348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.16754.208348">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.23954.11.6" xlink:href="nvax-20130930.xsd#nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.23954.11.6" xlink:to="lab_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.158819.208350" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.158819.208350" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.158819.208350">Schedule Of Share Based Compensation Restricted Stock Awards Activity [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.23954.11.12" xlink:href="nvax-20130930.xsd#nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.23954.11.12" xlink:to="lab_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.158820.208352" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.158820.208352" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.158820.208352">Schedule Of Share Based Compensation, Restricted Stock Awards, Activity</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.23954.11.7" xlink:href="nvax-20130930.xsd#nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.23954.11.7" xlink:to="lab_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.158822.208351" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.158822.208351" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.158822.208351">Summary of Restricted Stock Awards Activity</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.16335.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.16335.11.7" xlink:to="lab_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.158817.208354" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.158817.208354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.158817.208354">Summary of Option Activity</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.16335.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.16335.11.6" xlink:to="lab_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.16559.208353" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.16559.208353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.16559.208353">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.16360.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.16360.11.7" xlink:to="lab_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.158818.208356" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.158818.208356" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.158818.208356">Assumptions used to Estimate Grant Date Fair Value of Stock Options granted using Black-Scholes Option-Pricing Model</link:label>
    <link:loc xlink:label="loc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.16360.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.16360.11.6" xlink:to="lab_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.16593.208355" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.16593.208355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.16593.208355">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ComprehensiveIncomeNetOfTax.7190.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ComprehensiveIncomeNetOfTax.7190.11.9" xlink:to="lab_ComprehensiveIncomeNetOfTax.158315.208205" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ComprehensiveIncomeNetOfTax.158315.208205" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_ComprehensiveIncomeNetOfTax.158315.208205">Comprehensive loss</link:label>
    <link:loc xlink:label="loc_ComprehensiveIncomeNetOfTax.7190.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ComprehensiveIncomeNetOfTax.7190.11.6" xlink:to="lab_ComprehensiveIncomeNetOfTax.2818.208204" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ComprehensiveIncomeNetOfTax.2818.208204" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ComprehensiveIncomeNetOfTax.2818.208204">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:label="loc_ComprehensiveIncomeNetOfTaxAbstract.1128.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ComprehensiveIncomeNetOfTaxAbstract.1128.11.7" xlink:to="lab_ComprehensiveIncomeNetOfTaxAbstract.158535.208207" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ComprehensiveIncomeNetOfTaxAbstract.158535.208207" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ComprehensiveIncomeNetOfTaxAbstract.158535.208207">Other comprehensive income (loss):</link:label>
    <link:loc xlink:label="loc_ComprehensiveIncomeNetOfTaxAbstract.1128.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ComprehensiveIncomeNetOfTaxAbstract.1128.11.6" xlink:to="lab_ComprehensiveIncomeNetOfTaxAbstract.2817.208206" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ComprehensiveIncomeNetOfTaxAbstract.2817.208206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ComprehensiveIncomeNetOfTaxAbstract.2817.208206">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:label="loc_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.14099.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.14099.11.6" xlink:to="lab_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.13697" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.13697" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.13697">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:label="loc_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.14099.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.14099.11.7" xlink:to="lab_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.426630.513184.280481" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.426630.513184.280481" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.426630.513184.280481">Foreign currency adjustment</link:label>
    <link:loc xlink:label="loc_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.14111.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.14111.11.6" xlink:to="lab_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.13726" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.13726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.13726">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:label="loc_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.14111.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.14111.11.9" xlink:to="lab_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.272508" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.272508" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.272508">Other comprehensive income (loss)</link:label>
    <link:loc xlink:label="loc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.13897.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.13897.11.6" xlink:to="lab_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.12884.208208" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.12884.208208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.12884.208208">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:loc xlink:label="loc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.13897.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.13897.11.7" xlink:to="lab_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.158312.208209" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.158312.208209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.158312.208209">Net unrealized gains (losses) on investments available-for-sale</link:label>
    <link:loc xlink:label="loc_StatementOfIncomeAndComprehensiveIncomeAbstract.5170.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract.5170.11.6" xlink:to="lab_StatementOfIncomeAndComprehensiveIncomeAbstract.158310.208210" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfIncomeAndComprehensiveIncomeAbstract.158310.208210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfIncomeAndComprehensiveIncomeAbstract.158310.208210">STATEMENTS OF COMPREHENSIVE LOSS [Abstract]</link:label>
    <link:loc xlink:label="loc_ContractRevenueCost.7296.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractRevenueCost" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ContractRevenueCost.7296.11.7" xlink:to="lab_ContractRevenueCost.158877.208169" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ContractRevenueCost.158877.208169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ContractRevenueCost.158877.208169">Cost of government contracts revenue</link:label>
    <link:loc xlink:label="loc_ContractRevenueCost.7296.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractRevenueCost" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ContractRevenueCost.7296.11.6" xlink:to="lab_ContractRevenueCost.2994.208168" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ContractRevenueCost.2994.208168" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ContractRevenueCost.2994.208168">Contract Revenue Cost</link:label>
    <link:loc xlink:label="loc_ContractsRevenue.7301.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractsRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ContractsRevenue.7301.11.6" xlink:to="lab_ContractsRevenue.3006.208170" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ContractsRevenue.3006.208170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ContractsRevenue.3006.208170">Contracts Revenue</link:label>
    <link:loc xlink:label="loc_ContractsRevenue.7301.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractsRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ContractsRevenue.7301.11.7" xlink:to="lab_ContractsRevenue7.158875.208171" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ContractsRevenue7.158875.208171" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ContractsRevenue7.158875.208171">Government contracts</link:label>
    <link:loc xlink:label="loc_CostsAndExpenses.7476.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostsAndExpenses.7476.11.9" xlink:to="lab_CostsAndExpenses.158530.208173" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostsAndExpenses.158530.208173" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_CostsAndExpenses.158530.208173">Total costs and expenses</link:label>
    <link:loc xlink:label="loc_CostsAndExpenses.7476.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostsAndExpenses.7476.11.6" xlink:to="lab_CostsAndExpenses.3285.208172" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostsAndExpenses.3285.208172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CostsAndExpenses.3285.208172">Costs and Expenses</link:label>
    <link:loc xlink:label="loc_CostsAndExpensesAbstract.1259.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostsAndExpensesAbstract.1259.11.7" xlink:to="lab_CostsAndExpensesAbstract.158528.208175" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostsAndExpensesAbstract.158528.208175" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CostsAndExpensesAbstract.158528.208175">Costs and expenses:</link:label>
    <link:loc xlink:label="loc_CostsAndExpensesAbstract.1259.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostsAndExpensesAbstract.1259.11.6" xlink:to="lab_CostsAndExpensesAbstract.3279.208174" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostsAndExpensesAbstract.3279.208174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CostsAndExpensesAbstract.3279.208174">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.9078.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDiluted.9078.11.7" xlink:to="lab_EarningsPerShareBasicAndDiluted.158309.208177" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareBasicAndDiluted.158309.208177" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareBasicAndDiluted.158309.208177">Basic and diluted net loss per share</link:label>
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.9078.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDiluted.9078.11.6" xlink:to="lab_EarningsPerShareBasicAndDiluted.5415.208176" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareBasicAndDiluted.5415.208176" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareBasicAndDiluted.5415.208176">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:label="loc_GainLossOnDerivativeInstrumentsNetPretax.10572.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GainLossOnDerivativeInstrumentsNetPretax.10572.11.7" xlink:to="lab_GainLossOnDerivativeInstrumentsNetPretax.158533.208178" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GainLossOnDerivativeInstrumentsNetPretax.158533.208178" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GainLossOnDerivativeInstrumentsNetPretax.158533.208178">Change in fair value of warrant liability</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10699.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpense.10699.11.7" xlink:to="lab_GeneralAndAdministrativeExpense.158529.208180" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpense.158529.208180" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpense.158529.208180">General and administrative</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10699.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpense.10699.11.6" xlink:to="lab_GeneralAndAdministrativeExpense.7870.208179" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpense.7870.208179" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpense.7870.208179">General and Administrative Expense</link:label>
    <link:loc xlink:label="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.11075.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.11075.11.9" xlink:to="lab_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.158308.208182" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.158308.208182" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.158308.208182">Loss from operations before income tax</link:label>
    <link:loc xlink:label="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.11075.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.11075.11.6" xlink:to="lab_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.8488.208181" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.8488.208181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.8488.208181">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:loc xlink:label="loc_IncomeStatementAbstract.2649.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeStatementAbstract.2649.11.6" xlink:to="lab_IncomeStatementAbstract.158291.208183" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeStatementAbstract.158291.208183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeStatementAbstract.158291.208183">STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:loc xlink:label="loc_IncomeTaxExpenseBenefit.11134.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeTaxExpenseBenefit.11134.11.7" xlink:to="lab_IncomeTaxExpenseBenefit.158296.208185" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeTaxExpenseBenefit.158296.208185" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncomeTaxExpenseBenefit.158296.208185">Income tax expense</link:label>
    <link:loc xlink:label="loc_IncomeTaxExpenseBenefit.11134.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeTaxExpenseBenefit.11134.11.6" xlink:to="lab_IncomeTaxExpenseBenefit.8536.208184" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeTaxExpenseBenefit.8536.208184" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeTaxExpenseBenefit.8536.208184">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:label="loc_InterestExpense.11654.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InterestExpense.11654.11.52" xlink:to="lab_InterestExpense.158532.208187" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InterestExpense.158532.208187" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_InterestExpense.158532.208187">Interest expense</link:label>
    <link:loc xlink:label="loc_InterestExpense.11654.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InterestExpense.11654.11.6" xlink:to="lab_InterestExpense.9280.208186" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InterestExpense.9280.208186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InterestExpense.9280.208186">Interest Expense</link:label>
    <link:loc xlink:label="loc_InvestmentIncomeNet.11894.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InvestmentIncomeNet.11894.11.7" xlink:to="lab_InvestmentIncomeNet.134939.208189" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InvestmentIncomeNet.134939.208189" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InvestmentIncomeNet.134939.208189">Interest income</link:label>
    <link:loc xlink:label="loc_InvestmentIncomeNet.11894.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InvestmentIncomeNet.11894.11.6" xlink:to="lab_InvestmentIncomeNet.9715.208188" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InvestmentIncomeNet.9715.208188" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InvestmentIncomeNet.9715.208188">Investment Income, Net</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.13265.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.13265.11.9" xlink:to="lab_NetIncomeLoss.158297.208190" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.158297.208190" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.158297.208190">Net loss</link:label>
    <link:loc xlink:label="loc_NonoperatingIncomeExpenseAbstract.3592.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NonoperatingIncomeExpenseAbstract.3592.11.6" xlink:to="lab_NonoperatingIncomeExpenseAbstract.12067.208191" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NonoperatingIncomeExpenseAbstract.12067.208191" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NonoperatingIncomeExpenseAbstract.12067.208191">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:label="loc_NonoperatingIncomeExpenseAbstract.3592.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NonoperatingIncomeExpenseAbstract.3592.11.7" xlink:to="lab_NonoperatingIncomeExpenseAbstract.158304.208192" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NonoperatingIncomeExpenseAbstract.158304.208192" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NonoperatingIncomeExpenseAbstract.158304.208192">Other income (expense):</link:label>
    <link:loc xlink:label="loc_OperatingIncomeLoss.13592.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingIncomeLoss.13592.11.6" xlink:to="lab_OperatingIncomeLoss.12364.208193" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingIncomeLoss.12364.208193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OperatingIncomeLoss.12364.208193">Operating Income (Loss)</link:label>
    <link:loc xlink:label="loc_OperatingIncomeLoss.13592.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingIncomeLoss.13592.11.9" xlink:to="lab_OperatingIncomeLoss.158293.208194" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingIncomeLoss.158293.208194" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_OperatingIncomeLoss.158293.208194">Loss from operations</link:label>
    <link:loc xlink:label="loc_OtherNonoperatingExpense.13989.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherNonoperatingExpense.13989.11.6" xlink:to="lab_OtherNonoperatingExpense.13500" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherNonoperatingExpense.13500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherNonoperatingExpense.13500">Other Nonoperating Expense</link:label>
    <link:loc xlink:label="loc_OtherNonoperatingExpense.13989.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherNonoperatingExpense.13989.11.52" xlink:to="lab_OtherNonoperatingExpense42.171749.272572" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherNonoperatingExpense42.171749.272572" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherNonoperatingExpense42.171749.272572">Other expense</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentCollaboration.23950.11.6" xlink:href="nvax-20130930.xsd#nvax_ResearchAndDevelopmentCollaboration" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentCollaboration.23950.11.6" xlink:to="lab_ResearchAndDevelopmentCollaboration.171372.208195" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentCollaboration.171372.208195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentCollaboration.171372.208195">Research And Development Collaboration</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentCollaboration.23950.11.12" xlink:href="nvax-20130930.xsd#nvax_ResearchAndDevelopmentCollaboration" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentCollaboration.23950.11.12" xlink:to="lab_ResearchAndDevelopmentCollaboration.171373.208196" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentCollaboration.171373.208196" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentCollaboration.171373.208196">Research And Development Collaboration</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentCollaboration.23950.11.7" xlink:href="nvax-20130930.xsd#nvax_ResearchAndDevelopmentCollaboration" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentCollaboration.23950.11.7" xlink:to="lab_ResearchAndDevelopmentCollaboration7.171374.208197" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentCollaboration7.171374.208197" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentCollaboration7.171374.208197">Research and development collaborations</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15880.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpense.15880.11.7" xlink:to="lab_ResearchAndDevelopmentExpense.158534.208199" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpense.158534.208199" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpense.158534.208199">Research and development</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15880.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpense.15880.11.6" xlink:to="lab_ResearchAndDevelopmentExpense.15873.208198" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpense.15873.208198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpense.15873.208198">Research and Development Expense</link:label>
    <link:loc xlink:label="loc_Revenues.16160.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Revenues.16160.11.9" xlink:to="lab_Revenues.171375.208201" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Revenues.171375.208201" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_Revenues.171375.208201">Total revenue</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.11.7" xlink:to="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.158306.208203" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.158306.208203" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.158306.208203">Basic and diluted weighted average number of common shares outstanding</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.11.6" xlink:to="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243.208202" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243.208202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243.208202">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.414.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountingPoliciesAbstract.414.11.6" xlink:to="lab_AccountingPoliciesAbstract.158732.208304" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountingPoliciesAbstract.158732.208304" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountingPoliciesAbstract.158732.208304">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.11.6" xlink:to="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457.208305" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457.208305" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457.208305">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.11.7" xlink:to="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.158733.208306" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.158733.208306" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.158733.208306">Summary of Significant Accounting Policies</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.11.6" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005.208357" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005.208357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005.208357">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.11.7" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.159310.208358" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.159310.208358" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.159310.208358">Number of shares excluded from the computation of net loss per share</link:label>
    <link:loc xlink:label="loc_NumberOfAuctionRateSecuritiesIncludedInInvestments.23941.11.6" xlink:href="nvax-20130930.xsd#nvax_NumberOfAuctionRateSecuritiesIncludedInInvestments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfAuctionRateSecuritiesIncludedInInvestments.23941.11.6" xlink:to="lab_NumberOfAuctionRateSecuritiesIncludedInInvestments.159313.208359" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfAuctionRateSecuritiesIncludedInInvestments.159313.208359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfAuctionRateSecuritiesIncludedInInvestments.159313.208359">Number Of Auction Rate Securities Included In Investments</link:label>
    <link:loc xlink:label="loc_NumberOfAuctionRateSecuritiesIncludedInInvestments.23941.11.12" xlink:href="nvax-20130930.xsd#nvax_NumberOfAuctionRateSecuritiesIncludedInInvestments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfAuctionRateSecuritiesIncludedInInvestments.23941.11.12" xlink:to="lab_NumberOfAuctionRateSecuritiesIncludedInInvestments.159314.208360" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfAuctionRateSecuritiesIncludedInInvestments.159314.208360" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfAuctionRateSecuritiesIncludedInInvestments.159314.208360">Number of Auction Rate Securities Included In Investments</link:label>
    <link:loc xlink:label="loc_NumberOfAuctionRateSecuritiesIncludedInInvestments.23941.11.7" xlink:href="nvax-20130930.xsd#nvax_NumberOfAuctionRateSecuritiesIncludedInInvestments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfAuctionRateSecuritiesIncludedInInvestments.23941.11.7" xlink:to="lab_NumberOfAuctionRateSecuritiesIncludedInInvestments7.159315.208361" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfAuctionRateSecuritiesIncludedInInvestments7.159315.208361" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfAuctionRateSecuritiesIncludedInInvestments7.159315.208361">Number of auction rate securities</link:label>
    <link:loc xlink:label="loc_ReclassificationFromAccountsPayableToLeaseIncentivesReceived.23948.11.6" xlink:href="nvax-20130930.xsd#nvax_ReclassificationFromAccountsPayableToLeaseIncentivesReceived" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ReclassificationFromAccountsPayableToLeaseIncentivesReceived.23948.11.6" xlink:to="lab_ReclassificationFromAccountsPayableToLeaseIncentivesReceived.508057.208362" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ReclassificationFromAccountsPayableToLeaseIncentivesReceived.508057.208362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ReclassificationFromAccountsPayableToLeaseIncentivesReceived.508057.208362">Reclassification From Accounts Payable To Lease Incentives Received</link:label>
    <link:loc xlink:label="loc_ReclassificationFromAccountsPayableToLeaseIncentivesReceived.23948.11.12" xlink:href="nvax-20130930.xsd#nvax_ReclassificationFromAccountsPayableToLeaseIncentivesReceived" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ReclassificationFromAccountsPayableToLeaseIncentivesReceived.23948.11.12" xlink:to="lab_ReclassificationFromAccountsPayableToLeaseIncentivesReceived.508058.208364" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ReclassificationFromAccountsPayableToLeaseIncentivesReceived.508058.208364" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ReclassificationFromAccountsPayableToLeaseIncentivesReceived.508058.208364">Reclassification of additional lease incentives recorded in accounts payable and accrued expenses to lease incentives received.</link:label>
    <link:loc xlink:label="loc_ReclassificationFromAccountsPayableToLeaseIncentivesReceived.23948.11.7" xlink:href="nvax-20130930.xsd#nvax_ReclassificationFromAccountsPayableToLeaseIncentivesReceived" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ReclassificationFromAccountsPayableToLeaseIncentivesReceived.23948.11.7" xlink:to="lab_ReclassificationFromAccountsPayableToLeaseIncentivesReceived.508060.208363" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ReclassificationFromAccountsPayableToLeaseIncentivesReceived.508060.208363" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ReclassificationFromAccountsPayableToLeaseIncentivesReceived.508060.208363">Reclassification of additional lease incentives</link:label>
    <link:loc xlink:label="loc_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.23949.11.6" xlink:href="nvax-20130930.xsd#nvax_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.23949.11.6" xlink:to="lab_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.508053.208365" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.508053.208365" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.508053.208365">Reclassification From General Administrative Expenses To Research Development Expenses</link:label>
    <link:loc xlink:label="loc_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.23949.11.12" xlink:href="nvax-20130930.xsd#nvax_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.23949.11.12" xlink:to="lab_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.508055.208367" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.508055.208367" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.508055.208367">Reclassification of general and administrative expenses relating to supply chain management expenses to research and development expenses.</link:label>
    <link:loc xlink:label="loc_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.23949.11.7" xlink:href="nvax-20130930.xsd#nvax_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.23949.11.7" xlink:to="lab_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.508056.208366" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.508056.208366" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.508056.208366">Reclassification of general and administrative expenses</link:label>
    <link:loc xlink:label="loc_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities.32668.11.6" xlink:href="nvax-20130930.xsd#nvax_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities.32668.11.6" xlink:to="lab_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities.280473" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities.280473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities.280473">Reclassification Of Restricted Cash From Financing Activities To Operating Activities</link:label>
    <link:loc xlink:label="loc_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities.32668.11.12" xlink:href="nvax-20130930.xsd#nvax_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities.32668.11.12" xlink:to="lab_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities12.280474" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities12.280474" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities12.280474">"Reclassification of restricted cash from financing activities to operating activities</link:label>
    <link:loc xlink:label="loc_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities.32668.11.7" xlink:href="nvax-20130930.xsd#nvax_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities.32668.11.7" xlink:to="lab_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities7.280475" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities7.280475" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities7.280475">Reclassification of restricted cash</link:label>
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.11.6" xlink:to="lab_BasisOfAccountingPolicyPolicyTextBlock.1458.208307" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfAccountingPolicyPolicyTextBlock.1458.208307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfAccountingPolicyPolicyTextBlock.1458.208307">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.11.7" xlink:to="lab_BasisOfAccountingPolicyPolicyTextBlock7.158806.208308" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfAccountingPolicyPolicyTextBlock7.158806.208308" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfAccountingPolicyPolicyTextBlock7.158806.208308">Basis of Presentation</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy.6831.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy.6831.11.7" xlink:to="lab_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy.158802.208310" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy.158802.208310" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy.158802.208310">Restricted Cash</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy.6831.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy.6831.11.6" xlink:to="lab_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy.2199.208309" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy.2199.208309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy.2199.208309">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.9080.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerSharePolicyTextBlock.9080.11.7" xlink:to="lab_EarningsPerSharePolicyTextBlock.158800.208312" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerSharePolicyTextBlock.158800.208312" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerSharePolicyTextBlock.158800.208312">Net Loss per Share</link:label>
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.9080.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerSharePolicyTextBlock.9080.11.6" xlink:to="lab_EarningsPerSharePolicyTextBlock.5427.208311" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerSharePolicyTextBlock.5427.208311" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerSharePolicyTextBlock.5427.208311">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_FairValueMeasurementPolicyPolicyTextBlock.9608.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueMeasurementPolicyPolicyTextBlock.9608.11.7" xlink:to="lab_FairValueMeasurementPolicyPolicyTextBlock.158804.208314" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueMeasurementPolicyPolicyTextBlock.158804.208314" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FairValueMeasurementPolicyPolicyTextBlock.158804.208314">Fair Value Measurements</link:label>
    <link:loc xlink:label="loc_FairValueMeasurementPolicyPolicyTextBlock.9608.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueMeasurementPolicyPolicyTextBlock.9608.11.6" xlink:to="lab_FairValueMeasurementPolicyPolicyTextBlock.6214.208313" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueMeasurementPolicyPolicyTextBlock.6214.208313" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueMeasurementPolicyPolicyTextBlock.6214.208313">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_InvestmentPolicyTextBlock.11895.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InvestmentPolicyTextBlock.11895.11.7" xlink:to="lab_InvestmentPolicyTextBlock.495189.208316" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InvestmentPolicyTextBlock.495189.208316" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InvestmentPolicyTextBlock.495189.208316">Investments</link:label>
    <link:loc xlink:label="loc_InvestmentPolicyTextBlock.11895.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InvestmentPolicyTextBlock.11895.11.6" xlink:to="lab_InvestmentPolicyTextBlock.9729.208315" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InvestmentPolicyTextBlock.9729.208315" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InvestmentPolicyTextBlock.9729.208315">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_PriorPeriodReclassificationAdjustmentDescription.14858.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PriorPeriodReclassificationAdjustmentDescription.14858.11.6" xlink:to="lab_PriorPeriodReclassificationAdjustmentDescription.14343.208317" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PriorPeriodReclassificationAdjustmentDescription.14343.208317" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PriorPeriodReclassificationAdjustmentDescription.14343.208317">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_PriorPeriodReclassificationAdjustmentDescription.14858.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PriorPeriodReclassificationAdjustmentDescription.14858.11.7" xlink:to="lab_Reclassificationandpresentation.495198.208318" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Reclassificationandpresentation.495198.208318" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_Reclassificationandpresentation.495198.208318">Reclassifications</link:label>
    <link:loc xlink:label="loc_UseOfEstimates.17889.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" />
    <link:labelArc xlink:from="loc_UseOfEstimates.17889.11.7" xlink:to="lab_UseOfEstimates.158805.208320" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_UseOfEstimates.158805.208320" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_UseOfEstimates.158805.208320">Use of Estimates</link:label>
    <link:loc xlink:label="loc_UseOfEstimates.17889.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" />
    <link:labelArc xlink:from="loc_UseOfEstimates.17889.11.6" xlink:to="lab_UseOfEstimates.18953.208319" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_UseOfEstimates.18953.208319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_UseOfEstimates.18953.208319">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_PaymentsOfStockIssuanceCosts.14360.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsOfStockIssuanceCosts.14360.11.6" xlink:to="lab_PaymentsOfStockIssuanceCosts.13507.208294" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsOfStockIssuanceCosts.13507.208294" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsOfStockIssuanceCosts.13507.208294">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:label="loc_PaymentsOfStockIssuanceCosts.14360.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsOfStockIssuanceCosts.14360.11.7" xlink:to="lab_PaymentsOfStockIssuanceCosts.158712.208295" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsOfStockIssuanceCosts.158712.208295" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsOfStockIssuanceCosts.158712.208295">Net proceeds from sales of common stock, offering costs</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementDisclosureTextBlock.7097.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementDisclosureTextBlock.7097.11.7" xlink:to="lab_CollaborativeArrangementDisclosureTextBlock.158740.208325" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementDisclosureTextBlock.158740.208325" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementDisclosureTextBlock.158740.208325">U.S. Government Agreement, Joint Venture and Collaborations</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementDisclosureTextBlock.7097.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementDisclosureTextBlock.7097.11.6" xlink:to="lab_CollaborativeArrangementDisclosureTextBlock.2614.208324" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementDisclosureTextBlock.2614.208324" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementDisclosureTextBlock.2614.208324">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_UsGovernmentAgreementAndCollaborationsAbstract.23964.11.12" xlink:href="nvax-20130930.xsd#nvax_UsGovernmentAgreementAndCollaborationsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_UsGovernmentAgreementAndCollaborationsAbstract.23964.11.12" xlink:to="lab_CollaborativeArrangementsDisclosureAbstract.158739.208326" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementsDisclosureAbstract.158739.208326" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementsDisclosureAbstract.158739.208326">Collaborative Arrangements Disclosure [Abstract].</link:label>
    <link:loc xlink:label="loc_UsGovernmentAgreementAndCollaborationsAbstract.23964.11.6" xlink:href="nvax-20130930.xsd#nvax_UsGovernmentAgreementAndCollaborationsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_UsGovernmentAgreementAndCollaborationsAbstract.23964.11.6" xlink:to="lab_UsGovernmentAgreementAndCollaborationsAbstract.158738.208327" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_UsGovernmentAgreementAndCollaborationsAbstract.158738.208327" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_UsGovernmentAgreementAndCollaborationsAbstract.158738.208327">U.S. Government Agreement, Joint Venture and Collaborations [Abstract]</link:label>
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.11.6" xlink:to="lab_ArrangementsAndNonarrangementTransactionsMember.288" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ArrangementsAndNonarrangementTransactionsMember.288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ArrangementsAndNonarrangementTransactionsMember.288">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:label="loc_ClinicalTrialCostsIncurred.23919.11.6" xlink:href="nvax-20130930.xsd#nvax_ClinicalTrialCostsIncurred" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ClinicalTrialCostsIncurred.23919.11.6" xlink:to="lab_ClinicalTrialCostsIncurred.174154.208498" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ClinicalTrialCostsIncurred.174154.208498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ClinicalTrialCostsIncurred.174154.208498">Clinical Trial Costs Incurred</link:label>
    <link:loc xlink:label="loc_ClinicalTrialCostsIncurred.23919.11.12" xlink:href="nvax-20130930.xsd#nvax_ClinicalTrialCostsIncurred" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ClinicalTrialCostsIncurred.23919.11.12" xlink:to="lab_ClinicalTrialCostsIncurred.174663.208499" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ClinicalTrialCostsIncurred.174663.208499" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ClinicalTrialCostsIncurred.174663.208499">Total clinical trial costs incurred.</link:label>
    <link:loc xlink:label="loc_ClinicalTrialCostsIncurred.23919.11.7" xlink:href="nvax-20130930.xsd#nvax_ClinicalTrialCostsIncurred" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ClinicalTrialCostsIncurred.23919.11.7" xlink:to="lab_ClinicalTrialCostsIncurred7.174155.208500" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ClinicalTrialCostsIncurred7.174155.208500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ClinicalTrialCostsIncurred7.174155.208500">Trial costs incurred</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.11.6" xlink:to="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.2609.208502" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.2609.208502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.2609.208502">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:label="loc_ContractTerm.23923.11.6" xlink:href="nvax-20130930.xsd#nvax_ContractTerm" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ContractTerm.23923.11.6" xlink:to="lab_ContractTerm.208504" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ContractTerm.208504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ContractTerm.208504">Contract Term</link:label>
    <link:loc xlink:label="loc_ContractTerm.23923.11.12" xlink:href="nvax-20130930.xsd#nvax_ContractTerm" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ContractTerm.23923.11.12" xlink:to="lab_ContractTerm.160368.208505" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ContractTerm.160368.208505" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ContractTerm.160368.208505">Contract Term</link:label>
    <link:loc xlink:label="loc_ContractTerm.23923.11.7" xlink:href="nvax-20130930.xsd#nvax_ContractTerm" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ContractTerm.23923.11.7" xlink:to="lab_ContractTerm7.160369.208506" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ContractTerm7.160369.208506" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ContractTerm7.160369.208506">Contract term</link:label>
    <link:loc xlink:label="loc_EquityMethodInvesteeNameDomain.1871.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityMethodInvesteeNameDomain.1871.11.6" xlink:to="lab_EquityMethodInvesteeNameDomain.5832.208645" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityMethodInvesteeNameDomain.5832.208645" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EquityMethodInvesteeNameDomain.5832.208645">Equity Method Investee, Name [Domain]</link:label>
    <link:loc xlink:label="loc_EquityMethodInvesteeOneMember.23927.11.6" xlink:href="nvax-20130930.xsd#nvax_EquityMethodInvesteeOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityMethodInvesteeOneMember.23927.11.6" xlink:to="lab_EquityMethodInvesteeOneMember.508043.208646" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityMethodInvesteeOneMember.508043.208646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EquityMethodInvesteeOneMember.508043.208646">Equity Method Investee One [Member]</link:label>
    <link:loc xlink:label="loc_EquityMethodInvesteeOneMember.23927.11.12" xlink:href="nvax-20130930.xsd#nvax_EquityMethodInvesteeOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityMethodInvesteeOneMember.23927.11.12" xlink:to="lab_EquityMethodInvesteeOneMember.508044.208648" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityMethodInvesteeOneMember.508044.208648" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EquityMethodInvesteeOneMember.508044.208648">Equity Method Investee One Member.</link:label>
    <link:loc xlink:label="loc_EquityMethodInvesteeOneMember.23927.11.7" xlink:href="nvax-20130930.xsd#nvax_EquityMethodInvesteeOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityMethodInvesteeOneMember.23927.11.7" xlink:to="lab_EquityMethodInvesteeOneMember.508045.208647" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityMethodInvesteeOneMember.508045.208647" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EquityMethodInvesteeOneMember.508045.208647">Cadila [Member]</link:label>
    <link:loc xlink:label="loc_EquityMethodInvestmentOwnershipPercentage.9324.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityMethodInvestmentOwnershipPercentage.9324.11.6" xlink:to="lab_EquityMethodInvestmentOwnershipPercentage.6081" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityMethodInvestmentOwnershipPercentage.6081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EquityMethodInvestmentOwnershipPercentage.6081">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:label="loc_EquityMethodInvestmentOwnershipPercentage.9324.11.20" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityMethodInvestmentOwnershipPercentage.9324.11.20" xlink:to="lab_EquityMethodInvestmentOwnershipPercentage20.236064" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityMethodInvestmentOwnershipPercentage20.236064" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:type="resource" xml:lang="en-US" id="lab_EquityMethodInvestmentOwnershipPercentage20.236064">Ownership percentage</link:label>
    <link:loc xlink:label="loc_ExpectedClinicalTrialCosts.23928.11.6" xlink:href="nvax-20130930.xsd#nvax_ExpectedClinicalTrialCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ExpectedClinicalTrialCosts.23928.11.6" xlink:to="lab_ExpectedClinicalTrialCosts.159534.208507" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ExpectedClinicalTrialCosts.159534.208507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ExpectedClinicalTrialCosts.159534.208507">Expected Clinical Trial Costs</link:label>
    <link:loc xlink:label="loc_ExpectedClinicalTrialCosts.23928.11.12" xlink:href="nvax-20130930.xsd#nvax_ExpectedClinicalTrialCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ExpectedClinicalTrialCosts.23928.11.12" xlink:to="lab_ExpectedClinicalTrialCosts.159537.208508" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ExpectedClinicalTrialCosts.159537.208508" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ExpectedClinicalTrialCosts.159537.208508">Total expected clinical trial costs.</link:label>
    <link:loc xlink:label="loc_GovernmentContractReceivable.10758.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GovernmentContractReceivable.10758.11.6" xlink:to="lab_GovernmentContractReceivable.7961.208509" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GovernmentContractReceivable.7961.208509" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GovernmentContractReceivable.7961.208509">Government Contract Receivable</link:label>
    <link:loc xlink:label="loc_GovernmentContractReceivable.10758.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GovernmentContractReceivable.10758.11.7" xlink:to="lab_GovernmentContractReceivable7.159497.208510" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GovernmentContractReceivable7.159497.208510" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GovernmentContractReceivable7.159497.208510">Contract receivable</link:label>
    <link:loc xlink:label="loc_GovernmentContractReceivableIncrease.27086.11.6" xlink:href="nvax-20130930.xsd#nvax_GovernmentContractReceivableIncrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GovernmentContractReceivableIncrease.27086.11.6" xlink:to="lab_GovernmentContractReceivableIncrease.236866" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GovernmentContractReceivableIncrease.236866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GovernmentContractReceivableIncrease.236866">Government Contract Receivable Increase</link:label>
    <link:loc xlink:label="loc_GovernmentContractReceivableIncrease.27086.11.12" xlink:href="nvax-20130930.xsd#nvax_GovernmentContractReceivableIncrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GovernmentContractReceivableIncrease.27086.11.12" xlink:to="lab_GovernmentContractReceivableIncrease12.236867" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GovernmentContractReceivableIncrease12.236867" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_GovernmentContractReceivableIncrease12.236867">Government Contract Receivable Increase</link:label>
    <link:loc xlink:label="loc_GovernmentContractReceivableIncrease.27086.11.7" xlink:href="nvax-20130930.xsd#nvax_GovernmentContractReceivableIncrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GovernmentContractReceivableIncrease.27086.11.7" xlink:to="lab_GovernmentContractReceivableIncrease7.236868" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GovernmentContractReceivableIncrease7.236868" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GovernmentContractReceivableIncrease7.236868">Increase contract receivable</link:label>
    <link:loc xlink:label="loc_HhsBardaContractAwardMember.23929.11.6" xlink:href="nvax-20130930.xsd#nvax_HhsBardaContractAwardMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_HhsBardaContractAwardMember.23929.11.6" xlink:to="lab_HhsBardaContractAwardMember.159498.208511" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_HhsBardaContractAwardMember.159498.208511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_HhsBardaContractAwardMember.159498.208511">Hhs Barda Contract Award [Member]</link:label>
    <link:loc xlink:label="loc_HhsBardaContractAwardMember.23929.11.12" xlink:href="nvax-20130930.xsd#nvax_HhsBardaContractAwardMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_HhsBardaContractAwardMember.23929.11.12" xlink:to="lab_HhsBardaContractAwardMember.159499.208512" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_HhsBardaContractAwardMember.159499.208512" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_HhsBardaContractAwardMember.159499.208512">HHS BARDA Contract Award [Member]</link:label>
    <link:loc xlink:label="loc_HhsBardaContractAwardMember.23929.11.7" xlink:href="nvax-20130930.xsd#nvax_HhsBardaContractAwardMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_HhsBardaContractAwardMember.23929.11.7" xlink:to="lab_HhsBardaContractAwardMember7.159500.208513" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_HhsBardaContractAwardMember7.159500.208513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_HhsBardaContractAwardMember7.159500.208513">HHS BARDA Contract [Member]</link:label>
    <link:loc xlink:label="loc_HhsBardaOptionForAdditionalPeriodMember.23930.11.6" xlink:href="nvax-20130930.xsd#nvax_HhsBardaOptionForAdditionalPeriodMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_HhsBardaOptionForAdditionalPeriodMember.23930.11.6" xlink:to="lab_HhsBardaOptionForAdditionalPeriodMember.159501.208514" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_HhsBardaOptionForAdditionalPeriodMember.159501.208514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_HhsBardaOptionForAdditionalPeriodMember.159501.208514">Hhs Barda Option For Additional Period [Member]</link:label>
    <link:loc xlink:label="loc_HhsBardaOptionForAdditionalPeriodMember.23930.11.12" xlink:href="nvax-20130930.xsd#nvax_HhsBardaOptionForAdditionalPeriodMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_HhsBardaOptionForAdditionalPeriodMember.23930.11.12" xlink:to="lab_HhsBardaOptionForAdditionalPeriodMember.159504.208515" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_HhsBardaOptionForAdditionalPeriodMember.159504.208515" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_HhsBardaOptionForAdditionalPeriodMember.159504.208515">HHS Barda Option For Additional Period [Member]</link:label>
    <link:loc xlink:label="loc_HhsBardaOptionForAdditionalPeriodMember.23930.11.7" xlink:href="nvax-20130930.xsd#nvax_HhsBardaOptionForAdditionalPeriodMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_HhsBardaOptionForAdditionalPeriodMember.23930.11.7" xlink:to="lab_HhsBardaOptionForAdditionalPeriodMember7.159508.208516" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_HhsBardaOptionForAdditionalPeriodMember7.159508.208516" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_HhsBardaOptionForAdditionalPeriodMember7.159508.208516">HHS BARDA Option for Additional Period [Member]</link:label>
    <link:loc xlink:label="loc_JointVenturePercentageOwnedByOthers.23931.11.20" xlink:href="nvax-20130930.xsd#nvax_JointVenturePercentageOwnedByOthers" xlink:type="locator" />
    <link:labelArc xlink:from="loc_JointVenturePercentageOwnedByOthers.23931.11.20" xlink:to="lab_JointVenturePercentageOwnedByOthers.245105" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_JointVenturePercentageOwnedByOthers.245105" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:type="resource" xml:lang="en-US" id="lab_JointVenturePercentageOwnedByOthers.245105">Joint Venture Percentage Owned By Others</link:label>
    <link:loc xlink:label="loc_JointVenturePercentageOwnedByOthers.23931.11.6" xlink:href="nvax-20130930.xsd#nvax_JointVenturePercentageOwnedByOthers" xlink:type="locator" />
    <link:labelArc xlink:from="loc_JointVenturePercentageOwnedByOthers.23931.11.6" xlink:to="lab_JointVenturePercentageOwnedByOthers.158892.208649" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_JointVenturePercentageOwnedByOthers.158892.208649" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_JointVenturePercentageOwnedByOthers.158892.208649">Joint Venture Percentage Owned By Others</link:label>
    <link:loc xlink:label="loc_JointVenturePercentageOwnedByOthers.23931.11.12" xlink:href="nvax-20130930.xsd#nvax_JointVenturePercentageOwnedByOthers" xlink:type="locator" />
    <link:labelArc xlink:from="loc_JointVenturePercentageOwnedByOthers.23931.11.12" xlink:to="lab_JointVenturePercentageOwnedByOthers.158898.208651" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_JointVenturePercentageOwnedByOthers.158898.208651" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_JointVenturePercentageOwnedByOthers.158898.208651">The percentage of the joint venture owned by others.</link:label>
    <link:loc xlink:label="loc_LicenseAgreementWithLgLifeSciencesLtdMember.23933.11.6" xlink:href="nvax-20130930.xsd#nvax_LicenseAgreementWithLgLifeSciencesLtdMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LicenseAgreementWithLgLifeSciencesLtdMember.23933.11.6" xlink:to="lab_LicenseAgreementWithLgLifeSciencesLtdMember.159514.208517" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LicenseAgreementWithLgLifeSciencesLtdMember.159514.208517" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LicenseAgreementWithLgLifeSciencesLtdMember.159514.208517">License Agreement With Lg Life Sciences Ltd [Member]</link:label>
    <link:loc xlink:label="loc_LicenseAgreementWithLgLifeSciencesLtdMember.23933.11.12" xlink:href="nvax-20130930.xsd#nvax_LicenseAgreementWithLgLifeSciencesLtdMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LicenseAgreementWithLgLifeSciencesLtdMember.23933.11.12" xlink:to="lab_LicenseAgreementWithLgLifeSciencesLtdMember.159515.208518" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LicenseAgreementWithLgLifeSciencesLtdMember.159515.208518" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_LicenseAgreementWithLgLifeSciencesLtdMember.159515.208518">License Agreement with LG Life Sciences, Ltd. [Member]</link:label>
    <link:loc xlink:label="loc_LicenseAgreementWithLgLifeSciencesLtdMember.23933.11.7" xlink:href="nvax-20130930.xsd#nvax_LicenseAgreementWithLgLifeSciencesLtdMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LicenseAgreementWithLgLifeSciencesLtdMember.23933.11.7" xlink:to="lab_LicenseAgreementWithLgLifeSciencesLtdMember7.159516.208519" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LicenseAgreementWithLgLifeSciencesLtdMember7.159516.208519" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LicenseAgreementWithLgLifeSciencesLtdMember7.159516.208519">License Agreement with LG Life Sciences, Ltd. [Member]</link:label>
    <link:loc xlink:label="loc_RoyaltyPaymentsPercentOfFutureProductSales.23951.11.7" xlink:href="nvax-20130930.xsd#nvax_RoyaltyPaymentsPercentOfFutureProductSales" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RoyaltyPaymentsPercentOfFutureProductSales.23951.11.7" xlink:to="lab_MilestonesAndRoyaltyPaymentsPercentOfFutureProductSales7.159560.208520" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonesAndRoyaltyPaymentsPercentOfFutureProductSales7.159560.208520" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_MilestonesAndRoyaltyPaymentsPercentOfFutureProductSales7.159560.208520">Royalty payments, percent</link:label>
    <link:loc xlink:label="loc_PathVaccineSolutionsMember.23945.11.6" xlink:href="nvax-20130930.xsd#nvax_PathVaccineSolutionsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PathVaccineSolutionsMember.23945.11.6" xlink:to="lab_PathVaccineSolutionsMember.159517.208521" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PathVaccineSolutionsMember.159517.208521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PathVaccineSolutionsMember.159517.208521">Path Vaccine Solutions [Member]</link:label>
    <link:loc xlink:label="loc_PathVaccineSolutionsMember.23945.11.12" xlink:href="nvax-20130930.xsd#nvax_PathVaccineSolutionsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PathVaccineSolutionsMember.23945.11.12" xlink:to="lab_PathVaccineSolutionsMember.159520.208522" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PathVaccineSolutionsMember.159520.208522" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_PathVaccineSolutionsMember.159520.208522">PATH Vaccine Solutions [Member]</link:label>
    <link:loc xlink:label="loc_PathVaccineSolutionsMember.23945.11.7" xlink:href="nvax-20130930.xsd#nvax_PathVaccineSolutionsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PathVaccineSolutionsMember.23945.11.7" xlink:to="lab_PathVaccineSolutionsMember7.159521.208523" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PathVaccineSolutionsMember7.159521.208523" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PathVaccineSolutionsMember7.159521.208523">PATH Vaccine Solutions [Member]</link:label>
    <link:loc xlink:label="loc_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent.23946.11.6" xlink:href="nvax-20130930.xsd#nvax_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent.23946.11.6" xlink:to="lab_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent.159561.208524" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent.159561.208524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent.159561.208524">Potential Provided Funding Of External Clinical Development Costs Percent</link:label>
    <link:loc xlink:label="loc_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent.23946.11.12" xlink:href="nvax-20130930.xsd#nvax_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent.23946.11.12" xlink:to="lab_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent.174153.208525" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent.174153.208525" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent.174153.208525">The precentage of potential provided fuding of external clinical development costs.</link:label>
    <link:loc xlink:label="loc_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent.23946.11.7" xlink:href="nvax-20130930.xsd#nvax_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent.23946.11.7" xlink:to="lab_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent7.159566.208526" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent7.159566.208526" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent7.159566.208526">Potential funding of external clinical development costs</link:label>
    <link:loc xlink:label="loc_ExpectedClinicalTrialCosts.23928.11.7" xlink:href="nvax-20130930.xsd#nvax_ExpectedClinicalTrialCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ExpectedClinicalTrialCosts.23928.11.7" xlink:to="lab_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalExpectedCosts7.159540.208529" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalExpectedCosts7.159540.208529" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentArrangementWithFederalGovernmentTotalExpectedCosts7.159540.208529">Expected costs</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentCollaborationIncrease.28056.11.6" xlink:href="nvax-20130930.xsd#nvax_ResearchAndDevelopmentCollaborationIncrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentCollaborationIncrease.28056.11.6" xlink:to="lab_ResearchAndDevelopmentCollaborationIncrease.245106" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentCollaborationIncrease.245106" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentCollaborationIncrease.245106">Research And Development Collaboration Increase</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentCollaborationIncrease.28056.11.12" xlink:href="nvax-20130930.xsd#nvax_ResearchAndDevelopmentCollaborationIncrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentCollaborationIncrease.28056.11.12" xlink:to="lab_ResearchAndDevelopmentCollaborationIncrease12.245107" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentCollaborationIncrease12.245107" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentCollaborationIncrease12.245107">Research And Development Collaboration Increase</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentCollaborationIncrease.28056.11.7" xlink:href="nvax-20130930.xsd#nvax_ResearchAndDevelopmentCollaborationIncrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentCollaborationIncrease.28056.11.7" xlink:to="lab_ResearchAndDevelopmentCollaborationIncrease7.245108" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentCollaborationIncrease7.245108" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentCollaborationIncrease7.245108">Research and development collaboration increase</link:label>
    <link:loc xlink:label="loc_RoyaltyPaymentsPercentOfFutureProductSales.23951.11.6" xlink:href="nvax-20130930.xsd#nvax_RoyaltyPaymentsPercentOfFutureProductSales" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RoyaltyPaymentsPercentOfFutureProductSales.23951.11.6" xlink:to="lab_RoyaltyPaymentsPercentOfFutureProductSales.159552.208530" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RoyaltyPaymentsPercentOfFutureProductSales.159552.208530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RoyaltyPaymentsPercentOfFutureProductSales.159552.208530">Royalty Payments Percent Of Future Product Sales</link:label>
    <link:loc xlink:label="loc_RoyaltyPaymentsPercentOfFutureProductSales.23951.11.12" xlink:href="nvax-20130930.xsd#nvax_RoyaltyPaymentsPercentOfFutureProductSales" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RoyaltyPaymentsPercentOfFutureProductSales.23951.11.12" xlink:to="lab_RoyaltyPaymentsPercentOfFutureProductSales.159559.208531" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RoyaltyPaymentsPercentOfFutureProductSales.159559.208531" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_RoyaltyPaymentsPercentOfFutureProductSales.159559.208531">Royalty payments as a percent of future product sales.</link:label>
    <link:loc xlink:label="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable.4810.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable.4810.11.6" xlink:to="lab_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable.16712.208532" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable.16712.208532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable.16712.208532">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:label="loc_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis.4820.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis.4820.11.6" xlink:to="lab_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis.16777.208652" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis.16777.208652" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis.16777.208652">Equity Method Investee, Name [Axis]</link:label>
    <link:loc xlink:label="loc_TypeOfArrangementAxis.5386.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TypeOfArrangementAxis.5386.11.6" xlink:to="lab_TypeOfArrangementAxis.19407" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TypeOfArrangementAxis.19407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TypeOfArrangementAxis.19407">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:label="loc_UpfrontLicensePayment.23963.11.6" xlink:href="nvax-20130930.xsd#nvax_UpfrontLicensePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_UpfrontLicensePayment.23963.11.6" xlink:to="lab_UpfrontLicensePayment.159544.208533" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_UpfrontLicensePayment.159544.208533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_UpfrontLicensePayment.159544.208533">Upfront License Payment</link:label>
    <link:loc xlink:label="loc_UpfrontLicensePayment.23963.11.12" xlink:href="nvax-20130930.xsd#nvax_UpfrontLicensePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_UpfrontLicensePayment.23963.11.12" xlink:to="lab_UpfrontLicensePayment.159547.208534" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_UpfrontLicensePayment.159547.208534" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_UpfrontLicensePayment.159547.208534">Upfront License Payment</link:label>
    <link:loc xlink:label="loc_UpfrontLicensePayment.23963.11.7" xlink:href="nvax-20130930.xsd#nvax_UpfrontLicensePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_UpfrontLicensePayment.23963.11.7" xlink:to="lab_UpfrontLicensePayment7.159549.208535" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_UpfrontLicensePayment7.159549.208535" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_UpfrontLicensePayment7.159549.208535">Upfront license payment</link:label>
    <link:loc xlink:label="loc_StockWarrantsTextBlock.23959.11.6" xlink:href="nvax-20130930.xsd#nvax_StockWarrantsTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockWarrantsTextBlock.23959.11.6" xlink:to="lab_StockWarrantsTextBlock.158747.208331" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockWarrantsTextBlock.158747.208331" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockWarrantsTextBlock.158747.208331">Stock Warrants [Text Block]</link:label>
    <link:loc xlink:label="loc_StockWarrantsTextBlock.23959.11.12" xlink:href="nvax-20130930.xsd#nvax_StockWarrantsTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockWarrantsTextBlock.23959.11.12" xlink:to="lab_StockWarrantsTextBlock.158748.208333" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockWarrantsTextBlock.158748.208333" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_StockWarrantsTextBlock.158748.208333">Stock Warrant Disclosure</link:label>
    <link:loc xlink:label="loc_StockWarrantsTextBlock.23959.11.7" xlink:href="nvax-20130930.xsd#nvax_StockWarrantsTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockWarrantsTextBlock.23959.11.7" xlink:to="lab_StockWarrantsTextBlock.158749.208332" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockWarrantsTextBlock.158749.208332" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockWarrantsTextBlock.158749.208332">Warrant Liability</link:label>
    <link:loc xlink:label="loc_WarrantLiabilityAbstract.23965.11.6" xlink:href="nvax-20130930.xsd#nvax_WarrantLiabilityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WarrantLiabilityAbstract.23965.11.6" xlink:to="lab_WarrantLiabilityAbstract.158745.208334" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WarrantLiabilityAbstract.158745.208334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_WarrantLiabilityAbstract.158745.208334">Warrant Liability [Abstract]</link:label>
    <link:loc xlink:label="loc_WarrantLiabilityAbstract.23965.11.12" xlink:href="nvax-20130930.xsd#nvax_WarrantLiabilityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WarrantLiabilityAbstract.23965.11.12" xlink:to="lab_WarrantLiabilityAbstract.158746.208335" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WarrantLiabilityAbstract.158746.208335" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_WarrantLiabilityAbstract.158746.208335">Warrant Liability [Abstract]</link:label>
    <link:loc xlink:label="loc_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights.7037.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights.7037.11.7" xlink:to="lab_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights.159680.208567" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights.159680.208567" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights.159680.208567">Exercise price of warrants</link:label>
    <link:loc xlink:label="loc_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights.7037.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights.7037.11.6" xlink:to="lab_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights.2536.208566" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights.2536.208566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights.2536.208566">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:label="loc_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight.7038.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight.7038.11.6" xlink:to="lab_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight.2648" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight.2648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight.2648">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:label="loc_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight.7038.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight.7038.11.7" xlink:to="lab_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight.217381" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight.217381" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight.217381">Shares entitled per warrant</link:label>
    <link:loc xlink:label="loc_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights.7036.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights.7036.11.6" xlink:to="lab_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights.2538.208571" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights.2538.208571" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights.2538.208571">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:label="loc_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights.7036.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights.7036.11.7" xlink:to="lab_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights7.159678.208572" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights7.159678.208572" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights7.159678.208572">Aggregate shares common stock callable by warrants</link:label>
    <link:loc xlink:label="loc_CommonSharesPerUnit.23920.11.6" xlink:href="nvax-20130930.xsd#nvax_CommonSharesPerUnit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonSharesPerUnit.23920.11.6" xlink:to="lab_CommonSharesPerUnit.208573" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonSharesPerUnit.208573" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonSharesPerUnit.208573">Common Shares Per Unit</link:label>
    <link:loc xlink:label="loc_CommonSharesPerUnit.23920.11.12" xlink:href="nvax-20130930.xsd#nvax_CommonSharesPerUnit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonSharesPerUnit.23920.11.12" xlink:to="lab_CommonSharesPerUnit.159667.208574" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonSharesPerUnit.159667.208574" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CommonSharesPerUnit.159667.208574">Shares included in each equity unit.</link:label>
    <link:loc xlink:label="loc_CommonSharesPerUnit.23920.11.7" xlink:href="nvax-20130930.xsd#nvax_CommonSharesPerUnit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonSharesPerUnit.23920.11.7" xlink:to="lab_CommonSharesPerUnit7.159670.208575" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonSharesPerUnit7.159670.208575" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonSharesPerUnit7.159670.208575">Common shares per unit</link:label>
    <link:loc xlink:label="loc_EquityIssuancePerShareAmount.9323.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityIssuancePerShareAmount.9323.11.7" xlink:to="lab_EquityIssuancePerShareAmount7.159677.208665" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityIssuancePerShareAmount7.159677.208665" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EquityIssuancePerShareAmount7.159677.208665">Equity issuance, price per share</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOrSaleOfEquity.14962.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOrSaleOfEquity.14962.11.6" xlink:to="lab_ProceedsFromIssuanceOrSaleOfEquity.14589.208666" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOrSaleOfEquity.14589.208666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOrSaleOfEquity.14589.208666">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOrSaleOfEquity.14962.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOrSaleOfEquity.14962.11.7" xlink:to="lab_ProceedsFromIssuanceOrSaleOfEquity.159663.208667" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOrSaleOfEquity.159663.208667" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOrSaleOfEquity.159663.208667">Proceeds from direct offering</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.17271.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesNewIssues.17271.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesNewIssues.159661.208669" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues.159661.208669" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesNewIssues.159661.208669">Units issued in direct offering</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteAbstract.5200.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteAbstract.5200.11.6" xlink:to="lab_StockholdersEquityNoteAbstract.236058" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteAbstract.236058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteAbstract.236058">Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.17310.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteDisclosureTextBlock.17310.11.6" xlink:to="lab_StockholdersEquityNoteDisclosureTextBlock.18747" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteDisclosureTextBlock.18747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteDisclosureTextBlock.18747">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.17310.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteDisclosureTextBlock.17310.11.7" xlink:to="lab_StockholdersEquityNoteDisclosureTextBlock.546849.236059" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteDisclosureTextBlock.546849.236059" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteDisclosureTextBlock.546849.236059">Stockholders' Equity</link:label>
    <link:loc xlink:label="loc_AcquisitionOfIsconovaAbTextBlock.27967.11.6" xlink:href="nvax-20130930.xsd#nvax_AcquisitionOfIsconovaAbTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AcquisitionOfIsconovaAbTextBlock.27967.11.6" xlink:to="lab_AcquisitionOfIsconovaAbTextBlock.244009" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AcquisitionOfIsconovaAbTextBlock.244009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AcquisitionOfIsconovaAbTextBlock.244009">Acquisition Of Isconova Ab [Text Block]</link:label>
    <link:loc xlink:label="loc_AcquisitionOfIsconovaAbTextBlock.27967.11.12" xlink:href="nvax-20130930.xsd#nvax_AcquisitionOfIsconovaAbTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AcquisitionOfIsconovaAbTextBlock.27967.11.12" xlink:to="lab_AcquisitionOfIsconovaAbTextBlock12.244010" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AcquisitionOfIsconovaAbTextBlock12.244010" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_AcquisitionOfIsconovaAbTextBlock12.244010">Acquisition Of Isconova Ab [Text Block]</link:label>
    <link:loc xlink:label="loc_AcquisitionOfIsconovaAbTextBlock.27967.11.7" xlink:href="nvax-20130930.xsd#nvax_AcquisitionOfIsconovaAbTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AcquisitionOfIsconovaAbTextBlock.27967.11.7" xlink:to="lab_AcquisitionOfIsconovaAbTextBlock7.244011" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AcquisitionOfIsconovaAbTextBlock7.244011" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AcquisitionOfIsconovaAbTextBlock7.244011">Acquisition Of Isconova AB</link:label>
    <link:loc xlink:label="loc_BusinessCombinationsAbstract.782.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationsAbstract.782.11.6" xlink:to="lab_BusinessCombinationsAbstract.243990" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationsAbstract.243990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationsAbstract.243990">Acquisition Of Isconova AB [Abstract]</link:label>
    <link:loc xlink:label="loc_AggregateGrossProceedsSaleOfStock.31357.11.6" xlink:href="nvax-20130930.xsd#nvax_AggregateGrossProceedsSaleOfStock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AggregateGrossProceedsSaleOfStock.31357.11.6" xlink:to="lab_AggregateGrossProceedsSaleOfStock.272760" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AggregateGrossProceedsSaleOfStock.272760" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AggregateGrossProceedsSaleOfStock.272760">Aggregate Gross Proceeds Sale Of Stock</link:label>
    <link:loc xlink:label="loc_AggregateGrossProceedsSaleOfStock.31357.11.12" xlink:href="nvax-20130930.xsd#nvax_AggregateGrossProceedsSaleOfStock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AggregateGrossProceedsSaleOfStock.31357.11.12" xlink:to="lab_AggregateGrossProceedsSaleOfStock12.272761" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AggregateGrossProceedsSaleOfStock12.272761" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_AggregateGrossProceedsSaleOfStock12.272761">Aggregate Gross Proceeds Sale Of Stock</link:label>
    <link:loc xlink:label="loc_AggregateGrossProceedsSaleOfStock.31357.11.7" xlink:href="nvax-20130930.xsd#nvax_AggregateGrossProceedsSaleOfStock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AggregateGrossProceedsSaleOfStock.31357.11.7" xlink:to="lab_AggregateGrossProceedsSaleOfStock7.272762" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AggregateGrossProceedsSaleOfStock7.272762" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AggregateGrossProceedsSaleOfStock7.272762">Aggregate gross proceeds</link:label>
    <link:loc xlink:label="loc_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement.32670.11.6" xlink:href="nvax-20130930.xsd#nvax_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement.32670.11.6" xlink:to="lab_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement.280483" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement.280483" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement.280483">Common Stock Value Authorized Under Prior Shelf Registration Statement</link:label>
    <link:loc xlink:label="loc_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement.32670.11.12" xlink:href="nvax-20130930.xsd#nvax_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement.32670.11.12" xlink:to="lab_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement12.280484" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement12.280484" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement12.280484">Common stock authorized for issuance under prior shelf registration statement with SEC, dollar amount.</link:label>
    <link:loc xlink:label="loc_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement.32670.11.7" xlink:href="nvax-20130930.xsd#nvax_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement.32670.11.7" xlink:to="lab_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement7.280485" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement7.280485" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement7.280485">Common stock authorized for issuance under prior shelf registration statement with SEC, dollar amount</link:label>
    <link:loc xlink:label="loc_EquityIssuancePerShareAmount.9323.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityIssuancePerShareAmount.9323.11.6" xlink:to="lab_EquityIssuancePerShareAmount.5807.208664" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityIssuancePerShareAmount.5807.208664" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EquityIssuancePerShareAmount.5807.208664">Equity Issuance, Per Share Amount</link:label>
    <link:loc xlink:label="loc_EquityIssuancePerShareAmount.9323.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityIssuancePerShareAmount.9323.11.8" xlink:to="lab_EquityIssuancePerShareAmount8.525880.280731" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityIssuancePerShareAmount8.525880.280731" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EquityIssuancePerShareAmount8.525880.280731">Sales per share price range</link:label>
    <link:loc xlink:label="loc_IPOMember.2975.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IPOMember.2975.11.6" xlink:to="lab_IPOMember.10288" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IPOMember.10288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IPOMember.10288">IPO [Member]</link:label>
    <link:loc xlink:label="loc_IPOMember.2975.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IPOMember.2975.11.7" xlink:to="lab_IPOMember.272759" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IPOMember.272759" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IPOMember.272759">Public Offering [Member]</link:label>
    <link:loc xlink:label="loc_SaleOfStockNameOfTransactionDomain.4737.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SaleOfStockNameOfTransactionDomain.4737.11.6" xlink:to="lab_SaleOfStockNameOfTransactionDomain.17104" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SaleOfStockNameOfTransactionDomain.17104" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SaleOfStockNameOfTransactionDomain.17104">Sale of Stock, Name of Transaction [Domain]</link:label>
    <link:loc xlink:label="loc_SaleOfStockNameOfTransactionDomain.4737.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SaleOfStockNameOfTransactionDomain.4737.11.7" xlink:to="lab_SaleOfStockNameOfTransactionDomain.272758" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SaleOfStockNameOfTransactionDomain.272758" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SaleOfStockNameOfTransactionDomain.272758">Sale of Stock, Name of Transaction [Domain]</link:label>
    <link:loc xlink:label="loc_SaleOfStockNumberOfSharesIssuedInTransaction.16262.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SaleOfStockNumberOfSharesIssuedInTransaction.16262.11.6" xlink:to="lab_SaleOfStockNumberOfSharesIssuedInTransaction.17102" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SaleOfStockNumberOfSharesIssuedInTransaction.17102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SaleOfStockNumberOfSharesIssuedInTransaction.17102">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:label="loc_SaleOfStockNumberOfSharesIssuedInTransaction.16262.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SaleOfStockNumberOfSharesIssuedInTransaction.16262.11.8" xlink:to="lab_SaleOfStockNumberOfSharesIssuedInTransaction.272756" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SaleOfStockNumberOfSharesIssuedInTransaction.272756" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SaleOfStockNumberOfSharesIssuedInTransaction.272756">Common stock issued upon exercise in full over-allotment granted</link:label>
    <link:loc xlink:label="loc_SaleOfStockPricePerShare.16232.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SaleOfStockPricePerShare.16232.11.6" xlink:to="lab_SaleOfStockPricePerShare.17061" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SaleOfStockPricePerShare.17061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SaleOfStockPricePerShare.17061">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:label="loc_SaleOfStockPricePerShare.16232.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SaleOfStockPricePerShare.16232.11.8" xlink:to="lab_SaleOfStockPricePerShare.535555.272753" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SaleOfStockPricePerShare.535555.272753" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SaleOfStockPricePerShare.535555.272753">Sales per share price range</link:label>
    <link:loc xlink:label="loc_SecondPublicOfferingMember.32671.11.6" xlink:href="nvax-20130930.xsd#nvax_SecondPublicOfferingMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SecondPublicOfferingMember.32671.11.6" xlink:to="lab_SecondPublicOfferingMember.280486" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SecondPublicOfferingMember.280486" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SecondPublicOfferingMember.280486">Second Public Offering [Member]</link:label>
    <link:loc xlink:label="loc_SecondPublicOfferingMember.32671.11.12" xlink:href="nvax-20130930.xsd#nvax_SecondPublicOfferingMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SecondPublicOfferingMember.32671.11.12" xlink:to="lab_SecondPublicOfferingMember12.280487" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SecondPublicOfferingMember12.280487" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SecondPublicOfferingMember12.280487">Second Public Offering [Member]</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.17271.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesNewIssues.17271.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesNewIssues.17977.208668" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues.17977.208668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesNewIssues.17977.208668">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.17285.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueNewIssues.17285.11.6" xlink:to="lab_StockIssuedDuringPeriodValueNewIssues.18706" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueNewIssues.18706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueNewIssues.18706">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:label="loc_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.5225.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.5225.11.6" xlink:to="lab_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.18821" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.18821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.18821">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:label="loc_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.5225.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.5225.11.7" xlink:to="lab_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.272751" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.272751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.272751">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:label="loc_SubsidiarySaleOfStockAxis.5224.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsidiarySaleOfStockAxis.5224.11.6" xlink:to="lab_SubsidiarySaleOfStockAxis.18819" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsidiarySaleOfStockAxis.18819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsidiarySaleOfStockAxis.18819">Subsidiary, Sale of Stock [Axis]</link:label>
    <link:loc xlink:label="loc_SubsidiarySaleOfStockAxis.5224.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsidiarySaleOfStockAxis.5224.11.7" xlink:to="lab_SubsidiarySaleOfStockAxis.272757" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsidiarySaleOfStockAxis.272757" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SubsidiarySaleOfStockAxis.272757">Subsidiary, Sale of Stock [Axis]</link:label>
    <link:loc xlink:label="loc_SubsidiarySaleOfStockLineItems.5227.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.11.6" xlink:to="lab_SubsidiarySaleOfStockLineItems.18830" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsidiarySaleOfStockLineItems.18830" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsidiarySaleOfStockLineItems.18830">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:label="loc_SubsidiarySaleOfStockLineItems.5227.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.11.7" xlink:to="lab_SubsidiarySaleOfStockLineItems.272752" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsidiarySaleOfStockLineItems.272752" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SubsidiarySaleOfStockLineItems.272752">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.17271.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesNewIssues.17271.11.8" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues.390262.272754" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues.390262.272754" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues.390262.272754">Shares sold</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.17285.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueNewIssues.17285.11.8" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues.390260.272755" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues.390260.272755" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues.390260.272755">Proceeds from shares sold</link:label>
    <link:loc xlink:label="loc_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife.5803.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife.5803.11.6" xlink:to="lab_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife.641" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife.641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife.641">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:label="loc_AcquiredOutstandingShares.27087.11.6" xlink:href="nvax-20130930.xsd#nvax_AcquiredOutstandingShares" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AcquiredOutstandingShares.27087.11.6" xlink:to="lab_AcquiredOutstandingShares.236872" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AcquiredOutstandingShares.236872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AcquiredOutstandingShares.236872">Acquired Outstanding Shares</link:label>
    <link:loc xlink:label="loc_AcquiredOutstandingShares.27087.11.12" xlink:href="nvax-20130930.xsd#nvax_AcquiredOutstandingShares" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AcquiredOutstandingShares.27087.11.12" xlink:to="lab_AcquiredOutstandingShares12.236873" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AcquiredOutstandingShares12.236873" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_AcquiredOutstandingShares12.236873">Acquired Outstanding Shares</link:label>
    <link:loc xlink:label="loc_AcquiredOutstandingShares.27087.11.7" xlink:href="nvax-20130930.xsd#nvax_AcquiredOutstandingShares" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AcquiredOutstandingShares.27087.11.7" xlink:to="lab_AcquiredOutstandingShares7.236874" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AcquiredOutstandingShares7.236874" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AcquiredOutstandingShares7.236874">Expected outstanding Isconova AB shares acquired</link:label>
    <link:loc xlink:label="loc_AcquisitionCostsCumulative.5810.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AcquisitionCostsCumulative" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AcquisitionCostsCumulative.5810.11.6" xlink:to="lab_AcquisitionCostsCumulative.651" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AcquisitionCostsCumulative.651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AcquisitionCostsCumulative.651">Acquisition Costs, Cumulative</link:label>
    <link:loc xlink:label="loc_AcquisitionCostsCumulative.5810.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AcquisitionCostsCumulative" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AcquisitionCostsCumulative.5810.11.7" xlink:to="lab_AcquisitionCostsCumulative.272766" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AcquisitionCostsCumulative.272766" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AcquisitionCostsCumulative.272766">Transaction costs</link:label>
    <link:loc xlink:label="loc_AcquisitionTransactionCosts.32704.11.6" xlink:href="nvax-20130930.xsd#nvax_AcquisitionTransactionCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AcquisitionTransactionCosts.32704.11.6" xlink:to="lab_AcquisitionTransactionCosts.280735" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AcquisitionTransactionCosts.280735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AcquisitionTransactionCosts.280735">Acquisition Transaction Costs</link:label>
    <link:loc xlink:label="loc_AcquisitionTransactionCosts.32704.11.12" xlink:href="nvax-20130930.xsd#nvax_AcquisitionTransactionCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AcquisitionTransactionCosts.32704.11.12" xlink:to="lab_AcquisitionTransactionCosts12.280736" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AcquisitionTransactionCosts12.280736" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_AcquisitionTransactionCosts12.280736">Acquisition Transaction Costs</link:label>
    <link:loc xlink:label="loc_AcquisitionTransactionCosts.32704.11.7" xlink:href="nvax-20130930.xsd#nvax_AcquisitionTransactionCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AcquisitionTransactionCosts.32704.11.7" xlink:to="lab_AcquisitionTransactionCosts7.280737" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AcquisitionTransactionCosts7.280737" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AcquisitionTransactionCosts7.280737">Transaction costs</link:label>
    <link:loc xlink:label="loc_BusinessAcquisitionAcquireeDomain.775.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessAcquisitionAcquireeDomain.775.11.6" xlink:to="lab_BusinessAcquisitionAcquireeDomain.1717" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessAcquisitionAcquireeDomain.1717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessAcquisitionAcquireeDomain.1717">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:label="loc_BusinessAcquisitionAxis.750.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessAcquisitionAxis.750.11.6" xlink:to="lab_BusinessAcquisitionAxis.1595" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessAcquisitionAxis.1595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessAcquisitionAxis.1595">Business Acquisition [Axis]</link:label>
    <link:loc xlink:label="loc_BusinessAcquisitionLineItems.769.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessAcquisitionLineItems.769.11.6" xlink:to="lab_BusinessAcquisitionLineItems.1685" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessAcquisitionLineItems.1685" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessAcquisitionLineItems.1685">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:label="loc_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.6397.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.6397.11.6" xlink:to="lab_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.1631" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.1631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.1631">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:label="loc_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.6397.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.6397.11.8" xlink:to="lab_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.272730" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.272730" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.272730">Value of shares of Novavax Common Stock issued</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.31348.11.6" xlink:href="nvax-20130930.xsd#nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.31348.11.6" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.272704" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.272704" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.272704">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Goodwill</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.31348.11.12" xlink:href="nvax-20130930.xsd#nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.31348.11.12" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill12.272705" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill12.272705" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill12.272705">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Goodwill</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.31348.11.7" xlink:href="nvax-20130930.xsd#nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.31348.11.7" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill7.272706" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill7.272706" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill7.272706">Goodwill</link:label>
    <link:loc xlink:label="loc_MaximumMember.3373.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MaximumMember.3373.11.6" xlink:to="lab_MaximumMember.11410.508254.208445" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MaximumMember.11410.508254.208445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MaximumMember.11410.508254.208445">Maximum [Member]</link:label>
    <link:loc xlink:label="loc_MinimumMember.3382.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MinimumMember.3382.11.6" xlink:to="lab_MinimumMember.11450.508253.208447" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MinimumMember.11450.508253.208447" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MinimumMember.11450.508253.208447">Minimum [Member]</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.13265.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.13265.11.6" xlink:to="lab_NetIncomeLoss.11860.208262" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.11860.208262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.11860.208262">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.13265.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.13265.11.7" xlink:to="lab_NetIncomeLoss.158311.208263" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.158311.208263" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.158311.208263">Net loss</link:label>
    <link:loc xlink:label="loc_NovavaxAbMember.32703.11.6" xlink:href="nvax-20130930.xsd#nvax_NovavaxAbMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NovavaxAbMember.32703.11.6" xlink:to="lab_NovavaxAbMember.280732" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NovavaxAbMember.280732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NovavaxAbMember.280732">Novavax Ab [Member]</link:label>
    <link:loc xlink:label="loc_NovavaxAbMember.32703.11.12" xlink:href="nvax-20130930.xsd#nvax_NovavaxAbMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NovavaxAbMember.32703.11.12" xlink:to="lab_NovavaxAbMember12.280733" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NovavaxAbMember12.280733" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_NovavaxAbMember12.280733">Novavax AB [Member]</link:label>
    <link:loc xlink:label="loc_NovavaxAbMember.32703.11.7" xlink:href="nvax-20130930.xsd#nvax_NovavaxAbMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NovavaxAbMember.32703.11.7" xlink:to="lab_NovavaxAbMember7.280734" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NovavaxAbMember7.280734" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NovavaxAbMember7.280734">Novavax AB [Member]</link:label>
    <link:loc xlink:label="loc_NovavaxSharesIssued.28072.11.6" xlink:href="nvax-20130930.xsd#nvax_NovavaxSharesIssued" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NovavaxSharesIssued.28072.11.6" xlink:to="lab_NovavaxSharesIssued.245233" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NovavaxSharesIssued.245233" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NovavaxSharesIssued.245233">Novavax Shares Issued</link:label>
    <link:loc xlink:label="loc_NovavaxSharesIssued.28072.11.12" xlink:href="nvax-20130930.xsd#nvax_NovavaxSharesIssued" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NovavaxSharesIssued.28072.11.12" xlink:to="lab_NovavaxSharesIssued12.245234" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NovavaxSharesIssued12.245234" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_NovavaxSharesIssued12.245234">Novavax Shares Issued</link:label>
    <link:loc xlink:label="loc_NovavaxSharesIssued.28072.11.7" xlink:href="nvax-20130930.xsd#nvax_NovavaxSharesIssued" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NovavaxSharesIssued.28072.11.7" xlink:to="lab_NovavaxSharesIssued7.245235" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NovavaxSharesIssued7.245235" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NovavaxSharesIssued7.245235">Novavax shares issued for Isconova AB shares acquired</link:label>
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsReceivable.13573.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingLeasesFutureMinimumPaymentsReceivable.13573.11.6" xlink:to="lab_OperatingLeasesFutureMinimumPaymentsReceivable.12832" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingLeasesFutureMinimumPaymentsReceivable.12832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OperatingLeasesFutureMinimumPaymentsReceivable.12832">Operating Leases, Future Minimum Payments Receivable</link:label>
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsReceivable.13573.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingLeasesFutureMinimumPaymentsReceivable.13573.11.7" xlink:to="lab_OperatingLeasesFutureMinimumPaymentsReceivable.272767" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingLeasesFutureMinimumPaymentsReceivable.272767" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OperatingLeasesFutureMinimumPaymentsReceivable.272767">Aggregate remaining rental payments due under operating lease commitments</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquireBusinessesGross.14339.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquireBusinessesGross.14339.11.6" xlink:to="lab_PaymentsToAcquireBusinessesGross.14103" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquireBusinessesGross.14103" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquireBusinessesGross.14103">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquireBusinessesGross.14339.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquireBusinessesGross.14339.11.8" xlink:to="lab_PaymentsToAcquireBusinessesGross.272729" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquireBusinessesGross.272729" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquireBusinessesGross.272729">Cash paid to Isconova warrant holders</link:label>
    <link:loc xlink:label="loc_RangeAxis.4365.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RangeAxis.4365.11.6" xlink:to="lab_RangeAxis.15198.508251.208449" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RangeAxis.15198.508251.208449" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RangeAxis.15198.508251.208449">Range [Axis]</link:label>
    <link:loc xlink:label="loc_RangeMember.4366.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RangeMember.4366.11.6" xlink:to="lab_RangeMember.15199.508252.208451" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RangeMember.15199.508252.208451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RangeMember.15199.508252.208451">Range [Domain]</link:label>
    <link:loc xlink:label="loc_Revenues.16160.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Revenues.16160.11.6" xlink:to="lab_Revenues.16307.208200" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Revenues.16307.208200" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Revenues.16307.208200">Revenues</link:label>
    <link:loc xlink:label="loc_ScheduleOfBusinessAcquisitionsByAcquisitionTable.4809.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfBusinessAcquisitionsByAcquisitionTable.4809.11.6" xlink:to="lab_ScheduleOfBusinessAcquisitionsByAcquisitionTable.17364" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfBusinessAcquisitionsByAcquisitionTable.17364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfBusinessAcquisitionsByAcquisitionTable.17364">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesAcquisitions.17221.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesAcquisitions.17221.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesAcquisitions.18622" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesAcquisitions.18622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesAcquisitions.18622">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesAcquisitions.17221.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesAcquisitions.17221.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesAcquisitions.216257.236875" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesAcquisitions.216257.236875" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesAcquisitions.216257.236875">Shares issued for private offer</link:label>
    <link:loc xlink:label="loc_UnsolicitedTenderOfferCosts.17869.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnsolicitedTenderOfferCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_UnsolicitedTenderOfferCosts.17869.11.6" xlink:to="lab_UnsolicitedTenderOfferCosts.19637" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_UnsolicitedTenderOfferCosts.19637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_UnsolicitedTenderOfferCosts.19637">Unsolicited Tender Offer Costs</link:label>
    <link:loc xlink:label="loc_UnsolicitedTenderOfferCosts.17869.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnsolicitedTenderOfferCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_UnsolicitedTenderOfferCosts.17869.11.7" xlink:to="lab_UnsolicitedTenderOfferCosts7.236870" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_UnsolicitedTenderOfferCosts7.236870" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_UnsolicitedTenderOfferCosts7.236870">Offer to cash out warrants</link:label>
    <link:loc xlink:label="loc_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife.5803.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife.5803.11.8" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife.242430" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife.242430" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife.242430">Acquired finite-lived intangible assets, weighted-average useful life</link:label>
    <link:loc xlink:label="loc_BusinessAcquisitionAcquireeDomain.775.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessAcquisitionAcquireeDomain.775.11.8" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain.423143.513448.221657" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain.423143.513448.221657" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_us-gaap_BusinessAcquisitionAcquireeDomain.423143.513448.221657">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:label="loc_BusinessAcquisitionAxis.750.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessAcquisitionAxis.750.11.8" xlink:to="lab_us-gaap_BusinessAcquisitionAxis.423142.513449.221658" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_us-gaap_BusinessAcquisitionAxis.423142.513449.221658" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_us-gaap_BusinessAcquisitionAxis.423142.513449.221658">Business Acquisition [Axis]</link:label>
    <link:loc xlink:label="loc_BusinessAcquisitionLineItems.769.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessAcquisitionLineItems.769.11.8" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems.369535.513450.221659" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_us-gaap_BusinessAcquisitionLineItems.369535.513450.221659" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_us-gaap_BusinessAcquisitionLineItems.369535.513450.221659">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:label="loc_RangeAxis.4365.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RangeAxis.4365.11.8" xlink:to="lab_us-gaap_RangeAxis.423195.513509.221982" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_us-gaap_RangeAxis.423195.513509.221982" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_us-gaap_RangeAxis.423195.513509.221982">Range [Axis]</link:label>
    <link:loc xlink:label="loc_RangeMember.4366.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RangeMember.4366.11.8" xlink:to="lab_us-gaap_RangeMember.423196.513510.221983" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_us-gaap_RangeMember.423196.513510.221983" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_us-gaap_RangeMember.423196.513510.221983">Range [Domain]</link:label>
    <link:loc xlink:label="loc_MaximumMember.3373.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MaximumMember.3373.11.8" xlink:to="us-gaap_MaximumMember_lbl.458504.190478" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_MaximumMember_lbl.458504.190478" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_MaximumMember_lbl.458504.190478">Maximum [Member]</link:label>
    <link:loc xlink:label="loc_MinimumMember.3382.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MinimumMember.3382.11.8" xlink:to="us-gaap_MinimumMember_lbl.458503.190785" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_MinimumMember_lbl.458503.190785" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_MinimumMember_lbl.458503.190785">Minimum [Member]</link:label>
    <link:loc xlink:label="loc_Revenues.16160.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Revenues.16160.11.7" xlink:to="us-gaap_Revenues_lbl.185402" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_Revenues_lbl.185402" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_Revenues_lbl.185402">Revenue</link:label>
    <link:loc xlink:label="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.11.6" xlink:to="lab_GoodwillAndIntangibleAssetsDisclosureAbstract.272573" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GoodwillAndIntangibleAssetsDisclosureAbstract.272573" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GoodwillAndIntangibleAssetsDisclosureAbstract.272573">Goodwill and Other Intangible Assets [Abstract]</link:label>
    <link:loc xlink:label="loc_GoodwillAndIntangibleAssetsDisclosureTextBlock.10734.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureTextBlock.10734.11.6" xlink:to="lab_GoodwillAndIntangibleAssetsDisclosureTextBlock.8279" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GoodwillAndIntangibleAssetsDisclosureTextBlock.8279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GoodwillAndIntangibleAssetsDisclosureTextBlock.8279">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_GoodwillAndIntangibleAssetsDisclosureTextBlock.10734.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureTextBlock.10734.11.7" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl.272574" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl.272574" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl.272574">Goodwill and Other Intangible Assets</link:label>
    <link:loc xlink:label="loc_MasterServicesAgreementWithCadilaAbstract.31327.11.6" xlink:href="nvax-20130930.xsd#nvax_MasterServicesAgreementWithCadilaAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MasterServicesAgreementWithCadilaAbstract.31327.11.6" xlink:to="lab_MasterServicesAgreementWithCadilaAbstract.272575" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MasterServicesAgreementWithCadilaAbstract.272575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MasterServicesAgreementWithCadilaAbstract.272575">Master Services Agreement with Cadila [Abstract]</link:label>
    <link:loc xlink:label="loc_MasterServicesAgreementWithCadilaAbstract.31327.11.12" xlink:href="nvax-20130930.xsd#nvax_MasterServicesAgreementWithCadilaAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MasterServicesAgreementWithCadilaAbstract.31327.11.12" xlink:to="lab_MasterServicesAgreementWithCadilaAbstract12.272576" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MasterServicesAgreementWithCadilaAbstract12.272576" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_MasterServicesAgreementWithCadilaAbstract12.272576">Master Services Agreement With Cadila [Abstract]</link:label>
    <link:loc xlink:label="loc_MasterServicesAgreementWithCadilaTextBlock.31328.11.6" xlink:href="nvax-20130930.xsd#nvax_MasterServicesAgreementWithCadilaTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MasterServicesAgreementWithCadilaTextBlock.31328.11.6" xlink:to="lab_MasterServicesAgreementWithCadilaTextBlock.272577" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MasterServicesAgreementWithCadilaTextBlock.272577" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MasterServicesAgreementWithCadilaTextBlock.272577">Master Services Agreement With Cadila [Text Block]</link:label>
    <link:loc xlink:label="loc_MasterServicesAgreementWithCadilaTextBlock.31328.11.12" xlink:href="nvax-20130930.xsd#nvax_MasterServicesAgreementWithCadilaTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MasterServicesAgreementWithCadilaTextBlock.31328.11.12" xlink:to="lab_MasterServicesAgreementWithCadilaTextBlock12.272578" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MasterServicesAgreementWithCadilaTextBlock12.272578" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_MasterServicesAgreementWithCadilaTextBlock12.272578">Master Services Agreement With Cadila [Text Block]</link:label>
    <link:loc xlink:label="loc_MasterServicesAgreementWithCadilaTextBlock.31328.11.7" xlink:href="nvax-20130930.xsd#nvax_MasterServicesAgreementWithCadilaTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MasterServicesAgreementWithCadilaTextBlock.31328.11.7" xlink:to="lab_MasterServicesAgreementWithCadilaTextBlock7.272579" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MasterServicesAgreementWithCadilaTextBlock7.272579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_MasterServicesAgreementWithCadilaTextBlock7.272579">Master Services Agreement with Cadila</link:label>
    <link:loc xlink:label="loc_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock.16221.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock.16221.11.6" xlink:to="lab_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock.17034" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock.17034" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock.17034">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock.16221.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock.16221.11.7" xlink:to="lab_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock.134446.272585" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock.134446.272585" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock.134446.272585">Schedule of Estimated Amortization Expense</link:label>
    <link:loc xlink:label="loc_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock.16433.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock.16433.11.6" xlink:to="lab_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock.17348" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock.17348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock.17348">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock.16433.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock.16433.11.7" xlink:to="lab_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock7.134447.272584" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock7.134447.272584" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock7.134447.272584">Schedule of Identifiable Intangible Assets</link:label>
    <link:loc xlink:label="loc_ScheduleOfGoodwillTextBlock.16511.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfGoodwillTextBlock.16511.11.6" xlink:to="lab_ScheduleOfGoodwillTextBlock.17476" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfGoodwillTextBlock.17476" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfGoodwillTextBlock.17476">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfGoodwillTextBlock.16511.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfGoodwillTextBlock.16511.11.7" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl.185436" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl.185436" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_ScheduleOfGoodwillTextBlock_lbl.185436">Schedule of Goodwill</link:label>
    <link:loc xlink:label="loc_BusinessAcquisitionProFormaInformationTextBlock.6390.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessAcquisitionProFormaInformationTextBlock.6390.11.6" xlink:to="lab_BusinessAcquisitionProFormaInformationTextBlock.1621" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessAcquisitionProFormaInformationTextBlock.1621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessAcquisitionProFormaInformationTextBlock.1621">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:label="loc_BusinessAcquisitionProFormaInformationTextBlock.6390.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessAcquisitionProFormaInformationTextBlock.6390.11.7" xlink:to="lab_BusinessAcquisitionProFormaInformationTextBlock.142145.272580" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessAcquisitionProFormaInformationTextBlock.142145.272580" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BusinessAcquisitionProFormaInformationTextBlock.142145.272580">Unaudited Pro Forma Financial Information of Operations</link:label>
    <link:loc xlink:label="loc_ScheduleOfPurchasePriceTableTextBlock.31329.11.6" xlink:href="nvax-20130930.xsd#nvax_ScheduleOfPurchasePriceTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfPurchasePriceTableTextBlock.31329.11.6" xlink:to="lab_ScheduleOfPurchasePriceTableTextBlock.272581" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfPurchasePriceTableTextBlock.272581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfPurchasePriceTableTextBlock.272581">Schedule Of Purchase Price [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfPurchasePriceTableTextBlock.31329.11.12" xlink:href="nvax-20130930.xsd#nvax_ScheduleOfPurchasePriceTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfPurchasePriceTableTextBlock.31329.11.12" xlink:to="lab_ScheduleOfPurchasePriceTableTextBlock12.272582" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfPurchasePriceTableTextBlock12.272582" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfPurchasePriceTableTextBlock12.272582">Schedule Of Purchase Price [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfPurchasePriceTableTextBlock.31329.11.7" xlink:href="nvax-20130930.xsd#nvax_ScheduleOfPurchasePriceTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfPurchasePriceTableTextBlock.31329.11.7" xlink:to="lab_ScheduleOfPurchasePriceTableTextBlock7.272583" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfPurchasePriceTableTextBlock7.272583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfPurchasePriceTableTextBlock7.272583">Schedule of Purchase Price</link:label>
    <link:loc xlink:label="loc_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock.16301.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock.16301.11.6" xlink:to="lab_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock.17174" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock.17174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock.17174">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock.16301.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock.16301.11.7" xlink:to="lab_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock.186263" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock.186263" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock.186263">Schedule of Assets Acquired and Liabilities Assumed</link:label>
    <link:loc xlink:label="loc_CadilaMember.31352.11.6" xlink:href="nvax-20130930.xsd#nvax_CadilaMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CadilaMember.31352.11.6" xlink:to="lab_CadilaMember.272736" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CadilaMember.272736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CadilaMember.272736">Cadila [Member]</link:label>
    <link:loc xlink:label="loc_CadilaMember.31352.11.12" xlink:href="nvax-20130930.xsd#nvax_CadilaMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CadilaMember.31352.11.12" xlink:to="lab_CadilaMember12.272737" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CadilaMember12.272737" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CadilaMember12.272737">Cadila [Member]</link:label>
    <link:loc xlink:label="loc_HalfPaymentForPortionOfShortfallExceedingTwoMillion.31354.11.6" xlink:href="nvax-20130930.xsd#nvax_HalfPaymentForPortionOfShortfallExceedingTwoMillion" xlink:type="locator" />
    <link:labelArc xlink:from="loc_HalfPaymentForPortionOfShortfallExceedingTwoMillion.31354.11.6" xlink:to="lab_HalfPaymentForPortionOfShortfallExceedingTwoMillion.272742" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_HalfPaymentForPortionOfShortfallExceedingTwoMillion.272742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_HalfPaymentForPortionOfShortfallExceedingTwoMillion.272742">Half Payment For Portion Of Shortfall Exceeding Two Million</link:label>
    <link:loc xlink:label="loc_HalfPaymentForPortionOfShortfallExceedingTwoMillion.31354.11.12" xlink:href="nvax-20130930.xsd#nvax_HalfPaymentForPortionOfShortfallExceedingTwoMillion" xlink:type="locator" />
    <link:labelArc xlink:from="loc_HalfPaymentForPortionOfShortfallExceedingTwoMillion.31354.11.12" xlink:to="lab_HalfPaymentForPortionOfShortfallExceedingTwoMillion12.272743" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_HalfPaymentForPortionOfShortfallExceedingTwoMillion12.272743" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_HalfPaymentForPortionOfShortfallExceedingTwoMillion12.272743">Half Payment For Portion Of Shortfall Exceeding Two Million</link:label>
    <link:loc xlink:label="loc_HalfPaymentForPortionOfShortfallExceedingTwoMillion.31354.11.7" xlink:href="nvax-20130930.xsd#nvax_HalfPaymentForPortionOfShortfallExceedingTwoMillion" xlink:type="locator" />
    <link:labelArc xlink:from="loc_HalfPaymentForPortionOfShortfallExceedingTwoMillion.31354.11.7" xlink:to="lab_HalfPaymentForPortionOfShortfallExceedingTwoMillion7.272744" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_HalfPaymentForPortionOfShortfallExceedingTwoMillion7.272744" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_HalfPaymentForPortionOfShortfallExceedingTwoMillion7.272744">Basis limit for 50% payment of the portion of the shortfall</link:label>
    <link:loc xlink:label="loc_MasterServiceAgreement.31351.11.6" xlink:href="nvax-20130930.xsd#nvax_MasterServiceAgreement" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MasterServiceAgreement.31351.11.6" xlink:to="lab_MasterServiceAgreement.272733" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MasterServiceAgreement.272733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MasterServiceAgreement.272733">Master Service Agreement</link:label>
    <link:loc xlink:label="loc_MasterServiceAgreement.31351.11.12" xlink:href="nvax-20130930.xsd#nvax_MasterServiceAgreement" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MasterServiceAgreement.31351.11.12" xlink:to="lab_MasterServiceAgreement12.272734" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MasterServiceAgreement12.272734" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_MasterServiceAgreement12.272734">Master Service Agreement</link:label>
    <link:loc xlink:label="loc_MasterServiceAgreement.31351.11.7" xlink:href="nvax-20130930.xsd#nvax_MasterServiceAgreement" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MasterServiceAgreement.31351.11.7" xlink:to="lab_MasterServiceAgreement7.272735" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MasterServiceAgreement7.272735" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_MasterServiceAgreement7.272735">Total amount of services to be provided</link:label>
    <link:loc xlink:label="loc_PaymentToRelatedPartyPortionOfShortfall.31353.11.6" xlink:href="nvax-20130930.xsd#nvax_PaymentToRelatedPartyPortionOfShortfall" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentToRelatedPartyPortionOfShortfall.31353.11.6" xlink:to="lab_PaymentToRelatedPartyPortionOfShortfall.272739" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentToRelatedPartyPortionOfShortfall.272739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentToRelatedPartyPortionOfShortfall.272739">Payment To Related Party Portion Of Shortfall</link:label>
    <link:loc xlink:label="loc_PaymentToRelatedPartyPortionOfShortfall.31353.11.12" xlink:href="nvax-20130930.xsd#nvax_PaymentToRelatedPartyPortionOfShortfall" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentToRelatedPartyPortionOfShortfall.31353.11.12" xlink:to="lab_PaymentToRelatedPartyPortionOfShortfall12.272740" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentToRelatedPartyPortionOfShortfall12.272740" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_PaymentToRelatedPartyPortionOfShortfall12.272740">Payment To Related Party Portion Of Shortfall</link:label>
    <link:loc xlink:label="loc_PaymentToRelatedPartyPortionOfShortfall.31353.11.7" xlink:href="nvax-20130930.xsd#nvax_PaymentToRelatedPartyPortionOfShortfall" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentToRelatedPartyPortionOfShortfall.31353.11.7" xlink:to="lab_PaymentToRelatedPartyPortionOfShortfall7.272741" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentToRelatedPartyPortionOfShortfall7.272741" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentToRelatedPartyPortionOfShortfall7.272741">Payment for portion of shortfall</link:label>
    <link:loc xlink:label="loc_RelatedPartyDomain.4542.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RelatedPartyDomain.4542.11.6" xlink:to="lab_RelatedPartyDomain.16366" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RelatedPartyDomain.16366" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RelatedPartyDomain.16366">Related Party [Domain]</link:label>
    <link:loc xlink:label="loc_RelatedPartyTransactionLineItems.4538.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RelatedPartyTransactionLineItems.4538.11.6" xlink:to="lab_RelatedPartyTransactionLineItems.16345" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RelatedPartyTransactionLineItems.16345" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RelatedPartyTransactionLineItems.16345">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:label="loc_RelatedPartyTransactionsByRelatedPartyAxis.4540.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RelatedPartyTransactionsByRelatedPartyAxis.4540.11.6" xlink:to="lab_RelatedPartyTransactionsByRelatedPartyAxis.16359" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RelatedPartyTransactionsByRelatedPartyAxis.16359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RelatedPartyTransactionsByRelatedPartyAxis.16359">Related Party [Axis]</link:label>
    <link:loc xlink:label="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4873.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4873.11.6" xlink:to="lab_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.17511" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.17511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.17511">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:label="loc_ServicesProvidedDuringThePeriod.31356.11.6" xlink:href="nvax-20130930.xsd#nvax_ServicesProvidedDuringThePeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ServicesProvidedDuringThePeriod.31356.11.6" xlink:to="lab_ServicesProvidedDuringThePeriod.272748" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ServicesProvidedDuringThePeriod.272748" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ServicesProvidedDuringThePeriod.272748">Services Provided During The Period</link:label>
    <link:loc xlink:label="loc_ServicesProvidedDuringThePeriod.31356.11.12" xlink:href="nvax-20130930.xsd#nvax_ServicesProvidedDuringThePeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ServicesProvidedDuringThePeriod.31356.11.12" xlink:to="lab_ServicesProvidedDuringThePeriod12.272749" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ServicesProvidedDuringThePeriod12.272749" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ServicesProvidedDuringThePeriod12.272749">Services Provided During The Period</link:label>
    <link:loc xlink:label="loc_ServicesProvidedDuringThePeriod.31356.11.7" xlink:href="nvax-20130930.xsd#nvax_ServicesProvidedDuringThePeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ServicesProvidedDuringThePeriod.31356.11.7" xlink:to="lab_ServicesProvidedDuringThePeriod7.272750" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ServicesProvidedDuringThePeriod7.272750" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ServicesProvidedDuringThePeriod7.272750">Services provided by CPLB on behalf of Cadila</link:label>
    <link:loc xlink:label="loc_ServicesPurchased.31355.11.6" xlink:href="nvax-20130930.xsd#nvax_ServicesPurchased" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ServicesPurchased.31355.11.6" xlink:to="lab_ServicesPurchased.272745" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ServicesPurchased.272745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ServicesPurchased.272745">Services Purchased</link:label>
    <link:loc xlink:label="loc_ServicesPurchased.31355.11.12" xlink:href="nvax-20130930.xsd#nvax_ServicesPurchased" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ServicesPurchased.31355.11.12" xlink:to="lab_ServicesPurchased12.272746" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ServicesPurchased12.272746" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ServicesPurchased12.272746">Services Purchased</link:label>
    <link:loc xlink:label="loc_ServicesPurchased.31355.11.7" xlink:href="nvax-20130930.xsd#nvax_ServicesPurchased" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ServicesPurchased.31355.11.7" xlink:to="lab_ServicesPurchased7.272747" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ServicesPurchased7.272747" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ServicesPurchased7.272747">Services purchased</link:label>
    <link:loc xlink:label="loc_Goodwill.10732.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Goodwill.10732.11.10" xlink:to="lab_Goodwill.272591" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Goodwill.272591" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_Goodwill.272591">Beginning balance</link:label>
    <link:loc xlink:label="loc_Goodwill.10732.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Goodwill.10732.11.11" xlink:to="lab_Goodwill.272592" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Goodwill.272592" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_Goodwill.272592">Ending balance</link:label>
    <link:loc xlink:label="loc_GoodwillAcquiredDuringPeriod.10749.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GoodwillAcquiredDuringPeriod.10749.11.6" xlink:to="lab_GoodwillAcquiredDuringPeriod.8301" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GoodwillAcquiredDuringPeriod.8301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GoodwillAcquiredDuringPeriod.8301">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:label="loc_GoodwillAcquiredDuringPeriod.10749.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GoodwillAcquiredDuringPeriod.10749.11.7" xlink:to="lab_GoodwillAcquiredDuringPeriod7.272593" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GoodwillAcquiredDuringPeriod7.272593" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GoodwillAcquiredDuringPeriod7.272593">Goodwill resulting from acquisition of business</link:label>
    <link:loc xlink:label="loc_GoodwillTranslationAdjustments.10736.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillTranslationAdjustments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GoodwillTranslationAdjustments.10736.11.6" xlink:to="lab_GoodwillTranslationAdjustments.8281" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GoodwillTranslationAdjustments.8281" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GoodwillTranslationAdjustments.8281">Goodwill, Translation Adjustments</link:label>
    <link:loc xlink:label="loc_GoodwillTranslationAdjustments.10736.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillTranslationAdjustments" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GoodwillTranslationAdjustments.10736.11.8" xlink:to="lab_GoodwillTranslationAdjustments8.272594" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GoodwillTranslationAdjustments8.272594" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GoodwillTranslationAdjustments8.272594">Currency translation</link:label>
    <link:loc xlink:label="loc_AcquiredFiniteLivedIntangibleAssetsLineItems.478.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AcquiredFiniteLivedIntangibleAssetsLineItems.478.11.6" xlink:to="lab_AcquiredFiniteLivedIntangibleAssetsLineItems.647" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AcquiredFiniteLivedIntangibleAssetsLineItems.647" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AcquiredFiniteLivedIntangibleAssetsLineItems.647">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:label="loc_CollaborationAgreementsMember.31339.11.6" xlink:href="nvax-20130930.xsd#nvax_CollaborationAgreementsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborationAgreementsMember.31339.11.6" xlink:to="lab_CollaborationAgreementsMember.272633" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborationAgreementsMember.272633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborationAgreementsMember.272633">Collaboration Agreements [Member]</link:label>
    <link:loc xlink:label="loc_CollaborationAgreementsMember.31339.11.12" xlink:href="nvax-20130930.xsd#nvax_CollaborationAgreementsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborationAgreementsMember.31339.11.12" xlink:to="lab_CollaborationAgreementsMember12.272634" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborationAgreementsMember12.272634" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CollaborationAgreementsMember12.272634">Collaboration Agreements [Member]</link:label>
    <link:loc xlink:label="loc_CollaborationAgreementsMember.31339.11.7" xlink:href="nvax-20130930.xsd#nvax_CollaborationAgreementsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborationAgreementsMember.31339.11.7" xlink:to="lab_CollaborationAgreementsMember7.272635" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborationAgreementsMember7.272635" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CollaborationAgreementsMember7.272635">Collaboration agreements [Member]</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAccumulatedAmortization.10322.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsAccumulatedAmortization.10322.11.6" xlink:to="lab_FiniteLivedIntangibleAssetsAccumulatedAmortization.7624" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsAccumulatedAmortization.7624" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsAccumulatedAmortization.7624">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAccumulatedAmortization.10322.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsAccumulatedAmortization.10322.11.52" xlink:to="lab_FiniteLivedIntangibleAssetsAccumulatedAmortization42.145173.182831" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsAccumulatedAmortization42.145173.182831" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsAccumulatedAmortization42.145173.182831">Accumulated Amortization</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsByMajorClassAxis.2311.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsByMajorClassAxis.2311.11.6" xlink:to="lab_FiniteLivedIntangibleAssetsByMajorClassAxis.7635" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsByMajorClassAxis.7635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsByMajorClassAxis.7635">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsGross.10303.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsGross.10303.11.6" xlink:to="lab_FiniteLivedIntangibleAssetsGross.7599" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsGross.7599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsGross.7599">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsGross.10303.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsGross.10303.11.7" xlink:to="lab_FiniteLivedIntangibleAssetsGross7.134076.272630" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsGross7.134076.272630" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsGross7.134076.272630">Gross Carrying Amount</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsMajorClassNameDomain.2309.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsMajorClassNameDomain.2309.11.6" xlink:to="lab_FiniteLivedIntangibleAssetsMajorClassNameDomain.7632" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsMajorClassNameDomain.7632" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsMajorClassNameDomain.7632">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsNet.10326.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsNet.10326.11.6" xlink:to="lab_FiniteLivedIntangibleAssetsNet.7628" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsNet.7628" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsNet.7628">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsNet.10326.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsNet.10326.11.9" xlink:to="lab_FiniteLivedIntangibleAssetsNet.272631" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsNet.272631" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsNet.272631">Intangible Assets, Net</link:label>
    <link:loc xlink:label="loc_ProprietaryAdjuvantTechnologyMember.32669.11.6" xlink:href="nvax-20130930.xsd#nvax_ProprietaryAdjuvantTechnologyMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProprietaryAdjuvantTechnologyMember.32669.11.6" xlink:to="lab_ProprietaryAdjuvantTechnologyMember.280477" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProprietaryAdjuvantTechnologyMember.280477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProprietaryAdjuvantTechnologyMember.280477">Proprietary Adjuvant Technology [Member]</link:label>
    <link:loc xlink:label="loc_ProprietaryAdjuvantTechnologyMember.32669.11.12" xlink:href="nvax-20130930.xsd#nvax_ProprietaryAdjuvantTechnologyMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProprietaryAdjuvantTechnologyMember.32669.11.12" xlink:to="lab_ProprietaryAdjuvantTechnologyMember12.280478" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProprietaryAdjuvantTechnologyMember12.280478" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ProprietaryAdjuvantTechnologyMember12.280478">Proprietary Adjuvant Technology [Member]</link:label>
    <link:loc xlink:label="loc_ProprietaryAdjuvantTechnologyMember.32669.11.7" xlink:href="nvax-20130930.xsd#nvax_ProprietaryAdjuvantTechnologyMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProprietaryAdjuvantTechnologyMember.32669.11.7" xlink:to="lab_ProprietaryAdjuvantTechnologyMember7.280479" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProprietaryAdjuvantTechnologyMember7.280479" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProprietaryAdjuvantTechnologyMember7.280479">Proprietary adjuvant technology [Member]</link:label>
    <link:loc xlink:label="loc_ScheduleOfFiniteLivedIntangibleAssetsTable.4785.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfFiniteLivedIntangibleAssetsTable.4785.11.6" xlink:to="lab_ScheduleOfFiniteLivedIntangibleAssetsTable.17287" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfFiniteLivedIntangibleAssetsTable.17287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfFiniteLivedIntangibleAssetsTable.17287">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:label="loc_TechnologyEquipmentMember.5302.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TechnologyEquipmentMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TechnologyEquipmentMember.5302.11.6" xlink:to="lab_TechnologyEquipmentMember.19035" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TechnologyEquipmentMember.19035" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TechnologyEquipmentMember.19035">Technology Equipment [Member]</link:label>
    <link:loc xlink:label="loc_TechnologyEquipmentMember.5302.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TechnologyEquipmentMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TechnologyEquipmentMember.5302.11.8" xlink:to="lab_TechnologyEquipmentMember8.272632" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TechnologyEquipmentMember8.272632" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_TechnologyEquipmentMember8.272632">Proprietary adjuvant technology [Member]</link:label>
    <link:loc xlink:label="loc_AmortizationOfIntangibleAssets.5980.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmortizationOfIntangibleAssets.5980.11.6" xlink:to="lab_AmortizationOfIntangibleAssets.949" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AmortizationOfIntangibleAssets.949" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AmortizationOfIntangibleAssets.949">Amortization of Intangible Assets</link:label>
    <link:loc xlink:label="loc_AmortizationOfIntangibleAssets.5980.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmortizationOfIntangibleAssets.5980.11.7" xlink:to="lab_AmortizationOfIntangibleAssets7.134092.182873" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AmortizationOfIntangibleAssets7.134092.182873" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AmortizationOfIntangibleAssets7.134092.182873">Amortization expense related to intangible assets</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths.10340.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths.10340.11.6" xlink:to="lab_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths.7653" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths.7653" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths.7653">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.10353.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.10353.11.6" xlink:to="lab_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.7668" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.7668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.7668">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.10353.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.10353.11.7" xlink:to="lab_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.134083.272595" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.134083.272595" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.134083.272595">2013 (remainder)</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.10308.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.10308.11.6" xlink:to="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.7606" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.7606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.7606">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.10308.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.10308.11.7" xlink:to="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.144112.272600" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.144112.272600" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.144112.272600">2018</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.10342.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.10342.11.6" xlink:to="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.7655" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.7655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.7655">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.10342.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.10342.11.7" xlink:to="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.488992.272599" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.488992.272599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.488992.272599">2017</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.10316.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.10316.11.6" xlink:to="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.7615" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.7615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.7615">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.10316.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.10316.11.7" xlink:to="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.488989.272598" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.488989.272598" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.488989.272598">2016</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.10343.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.10343.11.6" xlink:to="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.7656" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.7656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.7656">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.10343.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.10343.11.7" xlink:to="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.488988.272597" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.488988.272597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.488988.272597">2015</link:label>
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths.10340.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths.10340.11.7" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl.484552.272596" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl.484552.272596" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl.484552.272596">2014</link:label>
    <link:loc xlink:label="loc_BusinessCombinationConsiderationTransferred1.6477.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationConsiderationTransferred1.6477.11.6" xlink:to="lab_BusinessCombinationConsiderationTransferred1.1748" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationConsiderationTransferred1.1748" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationConsiderationTransferred1.1748">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:label="loc_BusinessCombinationConsiderationTransferred1.6477.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationConsiderationTransferred1.6477.11.9" xlink:to="lab_BusinessCombinationConsiderationTransferred1.280476" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationConsiderationTransferred1.280476" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationConsiderationTransferred1.280476">Total purchase price</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation.6375.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation.6375.11.6" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation.1600" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation.1600" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation.1600">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Capital Lease Obligation</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation.6375.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation.6375.11.52" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation.272699" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation.272699" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation.272699">Capital leases</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents.6385.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents.6385.11.6" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents.1615" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents.1615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents.1615">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents.6385.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents.6385.11.7" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents.272694" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents.272694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents.272694">Cash and cash equivalents</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets.6351.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets.6351.11.6" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets.1567" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets.1567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets.1567">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets.6351.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets.6351.11.7" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets.272695" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets.272695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets.272695">Prepaid expenses and other assets</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables.6361.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables.6361.11.6" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables.1579" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables.1579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables.1579">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables.6361.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables.6361.11.7" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables.271875" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables.271875" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables.271875">Accounts receivable</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable.6359.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable.6359.11.6" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable.1576" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable.1576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable.1576">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable.6359.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable.6359.11.52" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable52.272698" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable52.272698" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable52.272698">Accounts payable and other current liabilities</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill.6432.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill.6432.11.6" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill.1680" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill.1680" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill.1680">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill.6432.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill.6432.11.7" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill.272696" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill.272696" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill.272696">Intangible assets</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt.6429.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt.6429.11.6" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt.1676" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt.1676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt.1676">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt.6429.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt.6429.11.52" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt.272700" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt.272700" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt.272700">Notes payable</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther.6380.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther.6380.11.6" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther.1605" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther.1605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther.1605">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther.6380.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther.6380.11.52" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther.272701" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther.272701" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther.272701">Other non-current liabilities</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment.6544.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment.6544.11.6" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment.1838" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment.1838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment.1838">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment.6544.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment.6544.11.7" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment.186285" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment.186285" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment.186285">Property and equipment</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.6620.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.6620.11.6" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.1943" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.1943" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.1943">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.6620.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.6620.11.9" xlink:to="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.272703" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.272703" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.272703">Total purchase price</link:label>
    <link:loc xlink:label="loc_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted.31350.11.6" xlink:href="nvax-20130930.xsd#nvax_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted.31350.11.6" xlink:to="lab_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted.272724" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted.272724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted.272724">Business Acquisition Pro Forma Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:label="loc_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted.31350.11.12" xlink:href="nvax-20130930.xsd#nvax_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted.31350.11.12" xlink:to="lab_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted12.272725" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted12.272725" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted12.272725">The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</link:label>
    <link:loc xlink:label="loc_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted.31350.11.7" xlink:href="nvax-20130930.xsd#nvax_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted.31350.11.7" xlink:to="lab_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted7.272726" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted7.272726" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted7.272726">Basic and diluted net loss per share</link:label>
    <link:loc xlink:label="loc_BusinessAcquisitionsProFormaNetIncomeLoss.6465.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessAcquisitionsProFormaNetIncomeLoss.6465.11.6" xlink:to="lab_BusinessAcquisitionsProFormaNetIncomeLoss.1726" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessAcquisitionsProFormaNetIncomeLoss.1726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessAcquisitionsProFormaNetIncomeLoss.1726">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:label="loc_BusinessAcquisitionsProFormaNetIncomeLoss.6465.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessAcquisitionsProFormaNetIncomeLoss.6465.11.7" xlink:to="lab_BusinessAcquisitionsProFormaNetIncomeLoss.156125.272723" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessAcquisitionsProFormaNetIncomeLoss.156125.272723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BusinessAcquisitionsProFormaNetIncomeLoss.156125.272723">Net loss</link:label>
    <link:loc xlink:label="loc_BusinessAcquisitionsProFormaRevenue.6457.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessAcquisitionsProFormaRevenue.6457.11.6" xlink:to="lab_BusinessAcquisitionsProFormaRevenue.1715" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessAcquisitionsProFormaRevenue.1715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BusinessAcquisitionsProFormaRevenue.1715">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:label="loc_BusinessAcquisitionsProFormaRevenue.6457.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BusinessAcquisitionsProFormaRevenue.6457.11.7" xlink:to="lab_BusinessAcquisitionsProFormaRevenue.135782.272722" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BusinessAcquisitionsProFormaRevenue.135782.272722" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BusinessAcquisitionsProFormaRevenue.135782.272722">Revenue</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>nvax-20130930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-11-12 @ 6:50 AM-->
<link:linkbase xmlns:nvax="http://www.novavax.com/20130930" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.novavax.com/role/BalanceSheets" xlink:href="nvax-20130930.xsd#nvax-bs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/BalanceSheetsParenthetical" xlink:href="nvax-20130930.xsd#nvax-bsp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StatementsOfCashFlows" xlink:href="nvax-20130930.xsd#nvax-socf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/DocumentAndEntityInformation" xlink:href="nvax-20130930.xsd#nvax-daei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurements" xlink:href="nvax-20130930.xsd#nvax-fvm" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsFairValueHierarchyDetails" xlink:href="nvax-20130930.xsd#nvax-fvmfvhd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsReconciliationOfLevelThreeAssetsAndLiabilitiesDetails" xlink:href="nvax-20130930.xsd#nvax-fvmrolaald" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/FairValueMeasurementsTables" xlink:href="nvax-20130930.xsd#nvax-fvmt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/Investments" xlink:href="nvax-20130930.xsd#nvax-i" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/InvestmentsDetails" xlink:href="nvax-20130930.xsd#nvax-id" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/InvestmentsTables" xlink:href="nvax-20130930.xsd#nvax-it" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/ManufacturingLaboratoryAndOfficeFacility" xlink:href="nvax-20130930.xsd#nvax-mlaof" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/ManufacturingLaboratoryAndOfficeFacilityDetails" xlink:href="nvax-20130930.xsd#nvax-mlaofd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/NotesPayable" xlink:href="nvax-20130930.xsd#nvax-np" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/NotesPayableAggregateFutureMinimumPrincipalPaymentsOnEquipmentLoanDetails" xlink:href="nvax-20130930.xsd#nvax-npafmppoeld" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/NotesPayableNarrativeDetails" xlink:href="nvax-20130930.xsd#nvax-npnd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/NotesPayableTables" xlink:href="nvax-20130930.xsd#nvax-npt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/Organization" xlink:href="nvax-20130930.xsd#nvax-o" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/Operations" xlink:href="nvax-20130930.xsd#nvax-o1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensation" xlink:href="nvax-20130930.xsd#nvax-sc" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationAssumptionsUsedInEstimationOfFairValueOfStockOptionsGrantedDetails" xlink:href="nvax-20130930.xsd#nvax-scauieofvosogd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationNarrativeDetails" xlink:href="nvax-20130930.xsd#nvax-scnd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:href="nvax-20130930.xsd#nvax-scsced" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationSummaryOfOptionActivityDetails" xlink:href="nvax-20130930.xsd#nvax-scsooad" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationSummaryOfRestrictedStockAwardsActivityDetails" xlink:href="nvax-20130930.xsd#nvax-scsorsaad" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockbasedCompensationTables" xlink:href="nvax-20130930.xsd#nvax-sct" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StatementsOfComprehensiveLoss" xlink:href="nvax-20130930.xsd#nvax-socl" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StatementsOfOperations" xlink:href="nvax-20130930.xsd#nvax-soo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="nvax-20130930.xsd#nvax-sosap" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="nvax-20130930.xsd#nvax-sosapnd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/SummaryOfSignificantAccountingPoliciesPolicy" xlink:href="nvax-20130930.xsd#nvax-sosapp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StatementsOfCashFlowsParenthetical" xlink:href="nvax-20130930.xsd#nvax-socfp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/UsGovernmentAgreementJointVentureAndCollaborations" xlink:href="nvax-20130930.xsd#nvax-ugajvac" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/UsGovernmentAgreementJointVentureAndCollaborationsDetails" xlink:href="nvax-20130930.xsd#nvax-ugajvacd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/WarrantLiability" xlink:href="nvax-20130930.xsd#nvax-wl" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/WarrantLiabilityDetails" xlink:href="nvax-20130930.xsd#nvax-wld" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersEquity" xlink:href="nvax-20130930.xsd#nvax-se" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAb" xlink:href="nvax-20130930.xsd#nvax-aoia" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/StockholdersEquityDetails" xlink:href="nvax-20130930.xsd#nvax-sed" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbNarrativeDetails" xlink:href="nvax-20130930.xsd#nvax-aoiand" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssets" xlink:href="nvax-20130930.xsd#nvax-gaoia" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/MasterServicesAgreementWithCadila" xlink:href="nvax-20130930.xsd#nvax-msawc" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsTables" xlink:href="nvax-20130930.xsd#nvax-gaoiat" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbTables" xlink:href="nvax-20130930.xsd#nvax-aoiat" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/MasterServicesAgreementWithCadilaDetails" xlink:href="nvax-20130930.xsd#nvax-msawcd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails" xlink:href="nvax-20130930.xsd#nvax-gaoiasogd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIdentifiableIntangibleAssetsDetails" xlink:href="nvax-20130930.xsd#nvax-gaoiasoiiad" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfEstimatedAmortizationExpenseDetails" xlink:href="nvax-20130930.xsd#nvax-gaoiasoeaed" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbScheduleOfPurchasePriceDetails" xlink:href="nvax-20130930.xsd#nvax-aoiasoppd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="nvax-20130930.xsd#nvax-aoiasoaaalad" xlink:type="simple" />
  <link:roleRef roleURI="http://www.novavax.com/role/AcquisitionOfIsconovaAbUnauditedProFormaFinancialInformationOfOperationsDetails" xlink:href="nvax-20130930.xsd#nvax-aoiaupffiood" xlink:type="simple" />
  <link:presentationLink xlink:title="002 - Statement - BALANCE SHEETS" xlink:role="http://www.novavax.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:label="loc_AssetsCurrentAbstract.616.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.616.12.7" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PrepaidExpenseCurrent.14768.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.616.12.7" xlink:to="loc_PrepaidExpenseCurrent.14768.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsCurrentAbstract.616.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AssetsCurrent.6084.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.616.12.9" xlink:to="loc_AssetsCurrent.6084.12.9" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesCurrent.6200.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.616.12.7" xlink:to="loc_AvailableForSaleSecuritiesCurrent.6200.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_GovernmentContractReceivableUnbilledAmounts.10756.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GovernmentContractReceivableUnbilledAmounts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.616.12.7" xlink:to="loc_GovernmentContractReceivableUnbilledAmounts.10756.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherAssetsCurrent.13853.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.616.12.7" xlink:to="loc_OtherAssetsCurrent.13853.12.7" order="4.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_RestrictedCashAndCashEquivalentsAtCarryingValue.15928.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.616.12.7" xlink:to="loc_RestrictedCashAndCashEquivalentsAtCarryingValue.15928.12.7" order="1.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5665.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.616.12.7" xlink:to="loc_AccountsReceivableNetCurrent.5665.12.7" order="2.25000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsAbstract.620.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.7" xlink:to="loc_AssetsCurrentAbstract.616.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.15211.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.7" xlink:to="loc_PropertyPlantAndEquipmentNet.15211.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsAbstract.620.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_Assets.6057.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.9" xlink:to="loc_Assets.6057.12.9" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_Goodwill.10732.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.7" xlink:to="loc_Goodwill.10732.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_RestrictedCashAndCashEquivalentsNoncurrent.15932.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.7" xlink:to="loc_RestrictedCashAndCashEquivalentsNoncurrent.15932.12.7" order="2.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherAssetsNoncurrent.13824.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.7" xlink:to="loc_OtherAssetsNoncurrent.13824.12.7" order="2.88000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesNoncurrent.6236.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.7" xlink:to="loc_AvailableForSaleSecuritiesNoncurrent.6236.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IntangibleAssetsNetExcludingGoodwill.11570.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.7" xlink:to="loc_IntangibleAssetsNetExcludingGoodwill.11570.12.7" order="2.25000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.3060.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableCurrent.5684.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.12.7" xlink:to="loc_AccountsPayableCurrent.5684.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccruedLiabilitiesCurrent.5762.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.12.7" xlink:to="loc_AccruedLiabilitiesCurrent.5762.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NotesPayableCurrent.13431.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.12.7" xlink:to="loc_NotesPayableCurrent.13431.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.3060.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LiabilitiesCurrent.12126.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.12.9" xlink:to="loc_LiabilitiesCurrent.12126.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_DeferredRentCreditCurrent.7951.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.12.7" xlink:to="loc_DeferredRentCreditCurrent.7951.12.7" order="3.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CapitalLeaseObligationsCurrent.6657.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.12.7" xlink:to="loc_CapitalLeaseObligationsCurrent.6657.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7937.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.12.7" xlink:to="loc_DeferredRevenueCurrent.7937.12.7" order="2.25000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DerivativeLiabilitiesCurrent.8440.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.12.7" xlink:to="loc_DerivativeLiabilitiesCurrent.8440.12.7" order="3.25000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:to="loc_LiabilitiesCurrentAbstract.3060.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_Liabilities.12166.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.9" xlink:to="loc_Liabilities.12166.12.9" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_CommitmentsAndContingencies.7121.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:to="loc_CommitmentsAndContingencies.7121.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockholdersEquityAbstract.5197.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:to="loc_StockholdersEquityAbstract.5197.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.12135.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.9" xlink:to="loc_LiabilitiesAndStockholdersEquity.12135.12.9" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7950.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:to="loc_DeferredRevenueNoncurrent.7950.12.7" order="1.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LongTermNotesPayable.12765.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:to="loc_LongTermNotesPayable.12765.12.7" order="2.38000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DeferredRentCreditNoncurrent.7913.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:to="loc_DeferredRentCreditNoncurrent.7913.12.7" order="2.69000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CapitalLeaseObligationsNoncurrent.6668.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:to="loc_CapitalLeaseObligationsNoncurrent.6668.12.7" order="2.06000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherLiabilitiesNoncurrent.14010.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:to="loc_OtherLiabilitiesNoncurrent.14010.12.7" order="2.84500" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:to="loc_AssetsAbstract.620.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PreferredStockValue.14687.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityAbstract.5197.12.7" xlink:to="loc_PreferredStockValue.14687.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockValue.7134.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityAbstract.5197.12.7" xlink:to="loc_CommonStockValue.7134.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdditionalPaidInCapital.5816.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityAbstract.5197.12.7" xlink:to="loc_AdditionalPaidInCapital.5816.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_RetainedEarningsAccumulatedDeficit.16058.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityAbstract.5197.12.7" xlink:to="loc_RetainedEarningsAccumulatedDeficit.16058.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockholdersEquityAbstract.5197.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.17302.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityAbstract.5197.12.9" xlink:to="loc_StockholdersEquity.17302.12.9" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_StockholdersEquityAbstract.5197.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_TreasuryStockValue.17716.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityAbstract.5197.12.52" xlink:to="loc_TreasuryStockValue.17716.12.52" order="4.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax.5786.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityAbstract.5197.12.7" xlink:to="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax.5786.12.7" order="4.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="003 - Statement - BALANCE SHEETS (Parenthetical)" xlink:role="http://www.novavax.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_PreferredStockParOrStatedValuePerShare.14668.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:to="loc_PreferredStockParOrStatedValuePerShare.14668.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PreferredStockSharesAuthorized.14701.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:to="loc_PreferredStockSharesAuthorized.14701.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PreferredStockSharesIssued.14694.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:to="loc_PreferredStockSharesIssued.14694.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PreferredStockSharesOutstanding.14710.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:to="loc_PreferredStockSharesOutstanding.14710.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.7131.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:to="loc_CommonStockParOrStatedValuePerShare.7131.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.7144.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:to="loc_CommonStockSharesAuthorized.7144.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockSharesIssued.7136.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:to="loc_CommonStockSharesIssued.7136.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockSharesOutstanding.7164.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:to="loc_CommonStockSharesOutstanding.7164.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_TreasuryStockShares.17707.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockShares" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:to="loc_TreasuryStockShares.17707.12.7" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="006 - Statement - STATEMENTS OF CASH FLOWS" xlink:role="http://www.novavax.com/role/StatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DepreciationAndAmortization.8349.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.7" xlink:to="loc_DepreciationAndAmortization.8349.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensation.16900.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.7" xlink:to="loc_ShareBasedCompensation.16900.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment.10640.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.52" xlink:to="loc_GainLossOnSaleOfPropertyPlantEquipment.10640.12.52" order="3.63000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.7" xlink:to="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_GainLossOnDerivativeInstrumentsNetPretax.10572.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.52" xlink:to="loc_GainLossOnDerivativeInstrumentsNetPretax.10572.12.52" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_AccretionAmortizationOfDiscountsAndPremiumsInvestments.5696.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.52" xlink:to="loc_AccretionAmortizationOfDiscountsAndPremiumsInvestments.5696.12.52" order="3.25000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_OtherNoncashIncomeExpense.13827.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.52" xlink:to="loc_OtherNoncashIncomeExpense.13827.12.52" order="3.81000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.944.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DepositsForAcquisitionOfPropertyAndEquipment.23925.12.7" xlink:href="nvax-20130930.xsd#nvax_DepositsForAcquisitionOfPropertyAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.944.12.7" xlink:to="loc_DepositsForAcquisitionOfPropertyAndEquipment.23925.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CapitalExpendituresIncurredButNotYetPaid.6683.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.944.12.7" xlink:to="loc_CapitalExpendituresIncurredButNotYetPaid.6683.12.7" order="4.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CapitalLeaseObligationEquipmentPurchased.29940.12.7" xlink:href="nvax-20130930.xsd#nvax_CapitalLeaseObligationEquipmentPurchased" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.944.12.7" xlink:to="loc_CapitalLeaseObligationEquipmentPurchased.29940.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ConversionOfStockAmountConverted1.7336.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.944.12.7" xlink:to="loc_ConversionOfStockAmountConverted1.7336.12.7" order="4.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.11237.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.52" xlink:to="loc_IncreaseDecreaseInAccountsReceivable.11237.12.52" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.7" xlink:to="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.12.7" order="2.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInUnbilledReceivables.11471.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.52" xlink:to="loc_IncreaseDecreaseInUnbilledReceivables.11471.12.52" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.11432.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.52" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.11432.12.52" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInOtherNoncurrentLiabilities.11304.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.7" xlink:to="loc_IncreaseDecreaseInOtherNoncurrentLiabilities.11304.12.7" order="2.94000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.11341.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.7" xlink:to="loc_IncreaseDecreaseInDeferredRevenue.11341.12.7" order="2.84000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCash.11462.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.52" xlink:to="loc_IncreaseDecreaseInRestrictedCash.11462.12.52" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStock.15031.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.7" xlink:to="loc_ProceedsFromIssuanceOfCommonStock.15031.12.7" order="5.88000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.13253.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.9" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities.13253.12.9" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_ProceedsFromRepaymentsOfNotesPayable.14920.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.7" xlink:to="loc_ProceedsFromRepaymentsOfNotesPayable.14920.12.7" order="5.38000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromNotesPayable.15002.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.7" xlink:to="loc_ProceedsFromNotesPayable.15002.12.7" order="5.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities.14902.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.7" xlink:to="loc_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities.14902.12.7" order="5.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.7" xlink:to="loc_ProceedsFromStockOptionsExercised.15050.12.7" order="5.94000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_RepaymentsOfLongTermCapitalLeaseObligations.15819.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.52" xlink:to="loc_RepaymentsOfLongTermCapitalLeaseObligations.15819.12.52" order="5.25000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.13246.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.9" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities.13246.12.9" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_PaymentsToAcquireProductiveAssets.14309.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.52" xlink:to="loc_PaymentsToAcquireProductiveAssets.14309.12.52" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.15068.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.7" xlink:to="loc_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.15068.12.7" order="5.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PaymentsToAcquireAvailableForSaleSecurities.14334.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.52" xlink:to="loc_PaymentsToAcquireAvailableForSaleSecurities.14334.12.52" order="5.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.15098.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.7" xlink:to="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.15098.12.7" order="4.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CashAcquiredFromAcquisition.6848.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.7" xlink:to="loc_CashAcquiredFromAcquisition.6848.12.7" order="5.31250" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.12.7" xlink:to="loc_NetIncomeLoss.13265.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.12.7" xlink:to="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.13262.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.12.9" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities.13262.12.9" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.5168.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.9" xlink:to="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.12.9" order="5.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.5168.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.10" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.10" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_SupplementalCashFlowInformationAbstract.5255.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_SupplementalCashFlowInformationAbstract.5255.12.7" order="9.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.5168.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.11" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.11" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.944.12.7" order="8.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.12.7" order="5.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InterestPaid.11757.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalCashFlowInformationAbstract.5255.12.7" xlink:to="loc_InterestPaid.11757.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="001 - Document - Document and Entity Information" xlink:role="http://www.novavax.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:label="loc_DocumentAndEntityInformationAbstract.23926.12.6" xlink:href="nvax-20130930.xsd#nvax_DocumentAndEntityInformationAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DocumentType.210.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23926.12.6" xlink:to="loc_DocumentType.210.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AmendmentFlag.144.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23926.12.6" xlink:to="loc_AmendmentFlag.144.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentPeriodEndDate.161.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23926.12.6" xlink:to="loc_DocumentPeriodEndDate.161.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityRegistrantName.185.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23926.12.6" xlink:to="loc_EntityRegistrantName.185.12.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityCentralIndexKey.186.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23926.12.6" xlink:to="loc_EntityCentralIndexKey.186.12.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CurrentFiscalYearEndDate.155.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23926.12.6" xlink:to="loc_CurrentFiscalYearEndDate.155.12.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentFiscalYearFocus.205.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23926.12.6" xlink:to="loc_DocumentFiscalYearFocus.205.12.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentFiscalPeriodFocus.206.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23926.12.6" xlink:to="loc_DocumentFiscalPeriodFocus.206.12.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityFilerCategory.183.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23926.12.6" xlink:to="loc_EntityFilerCategory.183.12.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityCommonStockSharesOutstanding.190.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23926.12.6" xlink:to="loc_EntityCommonStockSharesOutstanding.190.12.6" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_TradingSymbol.176.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23926.12.6" xlink:to="loc_TradingSymbol.176.12.6" order="5.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="105 - Disclosure - Fair Value Measurements" xlink:role="http://www.novavax.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:label="loc_FairValueDisclosuresAbstract.2053.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueDisclosuresTextBlock.9740.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueDisclosuresAbstract.2053.12.7" xlink:to="loc_FairValueDisclosuresTextBlock.9740.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40501 - Disclosure - Fair Value Measurements (Fair Value Hierarchy) (Details)" xlink:role="http://www.novavax.com/role/FairValueMeasurementsFairValueHierarchyDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AssetsFairValueDisclosureAbstract.608.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InvestmentsFairValueDisclosure.11996.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsFairValueDisclosureAbstract.608.12.7" xlink:to="loc_InvestmentsFairValueDisclosure.11996.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AvailableForSaleSecurities.6182.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsFairValueDisclosureAbstract.608.12.7" xlink:to="loc_AvailableForSaleSecurities.6182.12.7" order="1.87500" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable.1996.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueByFairValueHierarchyLevelAxis.1998.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable.1996.12.6" xlink:to="loc_FairValueByFairValueHierarchyLevelAxis.1998.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems.2051.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable.1996.12.6" xlink:to="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems.2051.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueMeasurementsFairValueHierarchyDomain.2060.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueByFairValueHierarchyLevelAxis.1998.12.6" xlink:to="loc_FairValueMeasurementsFairValueHierarchyDomain.2060.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems.2051.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems.2051.12.7" xlink:to="loc_AssetsFairValueDisclosureAbstract.608.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesFairValueDisclosureAbstract.3067.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems.2051.12.7" xlink:to="loc_LiabilitiesFairValueDisclosureAbstract.3067.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_FairValueDisclosuresAbstract.2053.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueDisclosuresAbstract.2053.12.6" xlink:to="loc_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable.1996.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueMeasurementsFairValueHierarchyDomain.2060.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueInputsLevel1Member.2138.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueMeasurementsFairValueHierarchyDomain.2060.12.7" xlink:to="loc_FairValueInputsLevel1Member.2138.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_FairValueInputsLevel2Member.2139.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueMeasurementsFairValueHierarchyDomain.2060.12.7" xlink:to="loc_FairValueInputsLevel2Member.2139.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_FairValueInputsLevel3Member.2129.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueMeasurementsFairValueHierarchyDomain.2060.12.7" xlink:to="loc_FairValueInputsLevel3Member.2129.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherLiabilitiesFairValueDisclosure.13881.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesFairValueDisclosureAbstract.3067.12.7" xlink:to="loc_OtherLiabilitiesFairValueDisclosure.13881.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40502 - Disclosure - Fair Value Measurements (Reconciliation of Level 3 Assets and Liabilities) (Details)" xlink:role="http://www.novavax.com/role/FairValueMeasurementsReconciliationOfLevelThreeAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_FairValueDisclosuresAbstract.2053.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable.2133.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueDisclosuresAbstract.2053.12.6" xlink:to="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable.2133.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueByShareholdersEquityClassDomain.2057.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_WarrantsSettleableInCashMember.23966.12.6" xlink:href="nvax-20130930.xsd#nvax_WarrantsSettleableInCashMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueByShareholdersEquityClassDomain.2057.12.6" xlink:to="loc_WarrantsSettleableInCashMember.23966.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareholdersEquityClassAxis.4707.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareholdersEquityClassAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable.2133.12.6" xlink:to="loc_ShareholdersEquityClassAxis.4707.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.2134.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable.2133.12.6" xlink:to="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.2134.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.2134.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.9648.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.2134.12.10" xlink:to="loc_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.9648.12.10" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.2134.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease.9954.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.2134.12.7" xlink:to="loc_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease.9954.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.2134.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.9648.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems.2134.12.11" xlink:to="loc_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.9648.12.11" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:from="loc_ShareholdersEquityClassAxis.4707.12.6" xlink:to="loc_FairValueByShareholdersEquityClassDomain.2057.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="305 - Disclosure - Fair Value Measurements (Tables)" xlink:role="http://www.novavax.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:label="loc_FairValueDisclosuresAbstract.2053.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock.16321.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueDisclosuresAbstract.2053.12.7" xlink:to="loc_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock.16321.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock.9863.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueDisclosuresAbstract.2053.12.7" xlink:to="loc_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock.9863.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="106 - Disclosure - Investments" xlink:role="http://www.novavax.com/role/Investments" xlink:type="extended">
    <link:loc xlink:label="loc_InvestmentsDebtAndEquitySecuritiesAbstract.2966.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock.12012.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InvestmentsDebtAndEquitySecuritiesAbstract.2966.12.7" xlink:to="loc_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock.12012.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40601 - Disclosure - Investments (Details)" xlink:role="http://www.novavax.com/role/InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_InvestmentsDebtAndEquitySecuritiesAbstract.2966.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfAvailableForSaleSecuritiesTable.4765.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InvestmentsDebtAndEquitySecuritiesAbstract.2966.12.6" xlink:to="loc_ScheduleOfAvailableForSaleSecuritiesTable.4765.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MajorTypesOfDebtAndEquitySecuritiesAxis.3313.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_MajorTypesOfDebtAndEquitySecuritiesDomain.3315.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_MajorTypesOfDebtAndEquitySecuritiesAxis.3313.12.6" xlink:to="loc_MajorTypesOfDebtAndEquitySecuritiesDomain.3315.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CorporateDebtSecuritiesMember.1234.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_MajorTypesOfDebtAndEquitySecuritiesDomain.3315.12.6" xlink:to="loc_CorporateDebtSecuritiesMember.1234.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AuctionRateSecuritiesMember.646.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AuctionRateSecuritiesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_MajorTypesOfDebtAndEquitySecuritiesDomain.3315.12.6" xlink:to="loc_AuctionRateSecuritiesMember.646.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfAvailableForSaleSecuritiesTable.4765.12.6" xlink:to="loc_MajorTypesOfDebtAndEquitySecuritiesAxis.3313.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfAvailableForSaleSecuritiesLineItems.4805.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfAvailableForSaleSecuritiesTable.4765.12.6" xlink:to="loc_ScheduleOfAvailableForSaleSecuritiesLineItems.4805.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfAvailableForSaleSecuritiesLineItems.4805.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesAmortizedCost.6209.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfAvailableForSaleSecuritiesLineItems.4805.12.7" xlink:to="loc_AvailableForSaleSecuritiesAmortizedCost.6209.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfAvailableForSaleSecuritiesLineItems.4805.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AvailableForSaleSecurities.6182.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfAvailableForSaleSecuritiesLineItems.4805.12.8" xlink:to="loc_AvailableForSaleSecurities.6182.12.8" order="5.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesGrossUnrealizedGains.6229.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfAvailableForSaleSecuritiesLineItems.4805.12.7" xlink:to="loc_AvailableForSaleSecuritiesGrossUnrealizedGains.6229.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesGrossUnrealizedLoss.6213.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfAvailableForSaleSecuritiesLineItems.4805.12.7" xlink:to="loc_AvailableForSaleSecuritiesGrossUnrealizedLoss.6213.12.7" order="4.37500" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="306 - Disclosure - Investments (Tables)" xlink:role="http://www.novavax.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:label="loc_InvestmentsDebtAndEquitySecuritiesAbstract.2966.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AvailableForSaleSecuritiesTextBlock.6161.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InvestmentsDebtAndEquitySecuritiesAbstract.2966.12.7" xlink:to="loc_AvailableForSaleSecuritiesTextBlock.6161.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="113 - Disclosure - Manufacturing, Laboratory and Office Facility" xlink:role="http://www.novavax.com/role/ManufacturingLaboratoryAndOfficeFacility" xlink:type="extended">
    <link:loc xlink:label="loc_ManufacturingLaboratoryAndOfficeFacilityAbstract.23939.12.7" xlink:href="nvax-20130930.xsd#nvax_ManufacturingLaboratoryAndOfficeFacilityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NewFacilityLeaseDisclosureTextBlock.23940.12.7" xlink:href="nvax-20130930.xsd#nvax_NewFacilityLeaseDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ManufacturingLaboratoryAndOfficeFacilityAbstract.23939.12.7" xlink:to="loc_NewFacilityLeaseDisclosureTextBlock.23940.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="41301 - Disclosure - Manufacturing, Laboratory and Office Facility (Details)" xlink:role="http://www.novavax.com/role/ManufacturingLaboratoryAndOfficeFacilityDetails" xlink:type="extended">
    <link:loc xlink:label="loc_ManufacturingLaboratoryAndOfficeFacilityAbstract.23939.12.7" xlink:href="nvax-20130930.xsd#nvax_ManufacturingLaboratoryAndOfficeFacilityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LeasedFacilitySquareFootage.23932.12.7" xlink:href="nvax-20130930.xsd#nvax_LeasedFacilitySquareFootage" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ManufacturingLaboratoryAndOfficeFacilityAbstract.23939.12.7" xlink:to="loc_LeasedFacilitySquareFootage.23932.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_TenantImprovementAllowance.23961.12.7" xlink:href="nvax-20130930.xsd#nvax_TenantImprovementAllowance" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ManufacturingLaboratoryAndOfficeFacilityAbstract.23939.12.7" xlink:to="loc_TenantImprovementAllowance.23961.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdditionalTenantImprovementAllowance.23916.12.7" xlink:href="nvax-20130930.xsd#nvax_AdditionalTenantImprovementAllowance" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ManufacturingLaboratoryAndOfficeFacilityAbstract.23939.12.7" xlink:to="loc_AdditionalTenantImprovementAllowance.23916.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PaymentsForProceedsFromTenantAllowance.14211.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ManufacturingLaboratoryAndOfficeFacilityAbstract.23939.12.7" xlink:to="loc_PaymentsForProceedsFromTenantAllowance.14211.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ManufacturingLaboratoryAndOfficeFacilityAbstract.23939.12.6" xlink:href="nvax-20130930.xsd#nvax_ManufacturingLaboratoryAndOfficeFacilityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_TenantAllowanceInterestRate.23960.12.6" xlink:href="nvax-20130930.xsd#nvax_TenantAllowanceInterestRate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ManufacturingLaboratoryAndOfficeFacilityAbstract.23939.12.6" xlink:to="loc_TenantAllowanceInterestRate.23960.12.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="111 - Disclosure - Notes Payable" xlink:role="http://www.novavax.com/role/NotesPayable" xlink:type="extended">
    <link:loc xlink:label="loc_DebtDisclosureAbstract.1355.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DebtDisclosureTextBlock.7682.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_DebtDisclosureTextBlock.7682.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="41102 - Disclosure - Notes Payable (Aggregate Future Minimum Principal Payments on Equipment Loan) (Details)" xlink:role="http://www.novavax.com/role/NotesPayableAggregateFutureMinimumPrincipalPaymentsOnEquipmentLoanDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DebtDisclosureAbstract.1355.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear.23938.12.7" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear.23938.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsDueInYearTwo.23937.12.7" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsDueInYearTwo" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_LoanAgreementFutureMinimumPaymentsDueInYearTwo.23937.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsDueInYearThree.23936.12.7" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsDueInYearThree" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_LoanAgreementFutureMinimumPaymentsDueInYearThree.23936.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DebtDisclosureAbstract.1355.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsDue.23934.12.9" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsDue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.9" xlink:to="loc_LoanAgreementFutureMinimumPaymentsDue.23934.12.9" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_LoanAgreementFutureMinimumPaymentsNextTwelveMonths.32695.12.7" xlink:href="nvax-20130930.xsd#nvax_LoanAgreementFutureMinimumPaymentsNextTwelveMonths" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_LoanAgreementFutureMinimumPaymentsNextTwelveMonths.32695.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="41101 - Disclosure - Notes Payable (Narrative) (Details)" xlink:role="http://www.novavax.com/role/NotesPayableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DebtDisclosureAbstract.1355.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DebtInstrumentFaceAmount.7642.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_DebtInstrumentFaceAmount.7642.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum.7766.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum.7766.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DebtInstrumentInterestRateDuringPeriod.7760.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_DebtInstrumentInterestRateDuringPeriod.7760.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DebtInstrumentPeriodicPayment.7731.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_DebtInstrumentPeriodicPayment.7731.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DebtInstrumentTerm.7687.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_DebtInstrumentTerm.7687.12.7" order="3.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DebtInstrumentBasisSpreadOnVariableRate1.7653.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_DebtInstrumentBasisSpreadOnVariableRate1.7653.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfDebt.14860.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_ProceedsFromIssuanceOfDebt.14860.12.7" order="5.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="311 - Disclosure - Notes Payable (Tables)" xlink:role="http://www.novavax.com/role/NotesPayableTables" xlink:type="extended">
    <link:loc xlink:label="loc_DebtDisclosureAbstract.1355.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock.16372.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DebtDisclosureAbstract.1355.12.7" xlink:to="loc_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock.16372.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="101 - Disclosure - Organization" xlink:role="http://www.novavax.com/role/Organization" xlink:type="extended">
    <link:loc xlink:label="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract.3716.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NatureOfOperations.13195.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract.3716.12.7" xlink:to="loc_NatureOfOperations.13195.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="102 - Disclosure - Operations" xlink:role="http://www.novavax.com/role/Operations" xlink:type="extended">
    <link:loc xlink:label="loc_OperationsAbstract.23943.12.7" xlink:href="nvax-20130930.xsd#nvax_OperationsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_OperationsDisclosureTextBlock.23944.12.7" xlink:href="nvax-20130930.xsd#nvax_OperationsDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_OperationsAbstract.23943.12.7" xlink:to="loc_OperationsDisclosureTextBlock.23944.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="109 - Disclosure - Stock-Based Compensation" xlink:role="http://www.novavax.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1637.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.8793.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1637.12.7" xlink:to="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock.8793.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40903 - Disclosure - Stock-Based Compensation (Assumptions Used in Estimation of Fair Value of Stock Options Granted) (Details)" xlink:role="http://www.novavax.com/role/StockbasedCompensationAssumptionsUsedInEstimationOfFairValueOfStockOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TypeOfDeferredCompensationDomain.5392.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfDeferredCompensationDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.12.7" xlink:to="loc_TypeOfDeferredCompensationDomain.5392.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1637.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1637.12.7" xlink:to="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.12.7" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_RangeAxis.4365.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeAxis.4365.12.7" xlink:to="loc_RangeMember.4366.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_MinimumMember.3382.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4366.12.7" xlink:to="loc_MinimumMember.3382.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_MaximumMember.3373.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4366.12.7" xlink:to="loc_MaximumMember.3373.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.12.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.12.7" xlink:to="loc_RangeAxis.4365.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.12.7" xlink:to="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.16978.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.16978.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum.16941.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum.16941.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.16975.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate.16975.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.16906.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum.16906.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.16956.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate.16956.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.16894.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum.16894.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.16972.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate.16972.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.16892.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum.16892.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.16199.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1.16199.12.7" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.23955.12.7" xlink:href="nvax-20130930.xsd#nvax_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate.23955.12.7" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_TypeOfDeferredCompensationDomain.5392.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfDeferredCompensationDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeStockOptionMember.1806.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_TypeOfDeferredCompensationDomain.5392.12.8" xlink:to="loc_EmployeeStockOptionMember.1806.12.8" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40901 - Disclosure - Stock-Based Compensation (Narrative) (Details)" xlink:role="http://www.novavax.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1637.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1637.12.6" xlink:to="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_PlanNameDomain.4029.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_TwoZeroZeroFiveStockIncentivePlanMember.23962.12.7" xlink:href="nvax-20130930.xsd#nvax_TwoZeroZeroFiveStockIncentivePlanMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PlanNameDomain.4029.12.7" xlink:to="loc_TwoZeroZeroFiveStockIncentivePlanMember.23962.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OneNineNineFiveStockOptionPlanMember.23942.12.7" xlink:href="nvax-20130930.xsd#nvax_OneNineNineFiveStockOptionPlanMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PlanNameDomain.4029.12.7" xlink:to="loc_OneNineNineFiveStockOptionPlanMember.23942.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PlanNameDomain.4029.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeStockPurchasePlanMember.27970.12.6" xlink:href="nvax-20130930.xsd#nvax_EmployeeStockPurchasePlanMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PlanNameDomain.4029.12.6" xlink:to="loc_EmployeeStockPurchasePlanMember.27970.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_PlanNameAxis.4031.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PlanNameAxis.4031.12.6" xlink:to="loc_PlanNameDomain.4029.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4365.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeAxis.4365.12.6" xlink:to="loc_RangeMember.4366.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MinimumMember.3382.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4366.12.6" xlink:to="loc_MinimumMember.3382.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MaximumMember.3373.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4366.12.6" xlink:to="loc_MaximumMember.3373.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4760.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioForecastMember.4759.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.12.6" xlink:to="loc_ScenarioForecastMember.4759.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.12.6" xlink:to="loc_PlanNameAxis.4031.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.12.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.12.6" xlink:to="loc_RangeAxis.4365.12.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.5162.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.12.6" xlink:to="loc_StatementScenarioAxis.5162.12.6" order="1.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16973.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16973.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.23958.12.7" xlink:href="nvax-20130930.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm.23958.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent.23957.12.7" xlink:href="nvax-20130930.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent.23957.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.23956.12.7" xlink:href="nvax-20130930.xsd#nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant.23956.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.17001.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.17001.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2.16219.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2.16219.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1.16217.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1.16217.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.16197.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.16197.12.7" order="6.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16970.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue.16970.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.9212.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.9212.12.7" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.9214.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1.9214.12.7" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized.16895.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized.16895.12.7" order="12.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementScenarioAxis.5162.12.6" xlink:to="loc_ScenarioUnspecifiedDomain.4760.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40905 - Disclosure - Stock-Based Compensation (Stock-Based Compensation Expense) (Details)" xlink:role="http://www.novavax.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1637.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1637.12.6" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5919.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.12.7" xlink:to="loc_AllocatedShareBasedCompensationExpense.5919.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeStatementLocationAxis.2652.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementLocationAxis.2652.12.6" xlink:to="loc_IncomeStatementLocationDomain.2671.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4573.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementLocationDomain.2671.12.7" xlink:to="loc_ResearchAndDevelopmentExpenseMember.4573.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2476.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementLocationDomain.2671.12.7" xlink:to="loc_GeneralAndAdministrativeExpenseMember.2476.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.12.6" xlink:to="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.12.6" xlink:to="loc_IncomeStatementLocationAxis.2652.12.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40902 - Disclosure - Stock-Based Compensation (Summary of Option Activity) (Details)" xlink:role="http://www.novavax.com/role/StockbasedCompensationSummaryOfOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1637.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1637.12.6" xlink:to="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_PlanNameDomain.4029.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_TwoZeroZeroFiveStockIncentivePlanMember.23962.12.7" xlink:href="nvax-20130930.xsd#nvax_TwoZeroZeroFiveStockIncentivePlanMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PlanNameDomain.4029.12.7" xlink:to="loc_TwoZeroZeroFiveStockIncentivePlanMember.23962.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OneNineNineFiveStockOptionPlanMember.23942.12.7" xlink:href="nvax-20130930.xsd#nvax_OneNineNineFiveStockOptionPlanMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PlanNameDomain.4029.12.7" xlink:to="loc_OneNineNineFiveStockOptionPlanMember.23942.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PlanNameAxis.4031.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_PlanNameDomain.4029.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_PlanNameAxis.4031.12.6" xlink:to="loc_PlanNameDomain.4029.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.12.6" xlink:to="loc_PlanNameAxis.4031.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable.4883.12.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16982.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.12.10" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16982.12.10" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16982.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.12.11" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.16982.12.11" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.16885.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.12.7" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.16885.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16942.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.12.7" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.16942.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.16889.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.12.7" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.16889.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16947.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.16947.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems.5072.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward.5065.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16990.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.12.10" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16990.12.10" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16990.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.12.11" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.16990.12.11" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16909.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross.16909.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.12.52" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.12.52" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod.16962.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.12.52" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod.16962.12.52" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16964.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.12.11" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.16964.12.11" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.16969.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward.5085.12.8" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant.16969.12.8" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40904 - Disclosure - Stock-Based Compensation (Summary of Restricted Stock Awards Activity) (Details)" xlink:role="http://www.novavax.com/role/StockbasedCompensationSummaryOfRestrictedStockAwardsActivityDetails" xlink:type="extended">
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1637.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward.5064.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1637.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward.5064.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.5071.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1637.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.5071.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward.5064.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16890.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward.5064.12.11" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16890.12.11" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward.5064.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16890.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward.5064.12.10" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.16890.12.10" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16881.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward.5064.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16881.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod.16897.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward.5064.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod.16897.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16926.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward.5064.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod.16926.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.5071.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.16911.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.5071.12.10" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.16911.12.10" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.5071.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.16911.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.5071.12.11" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.16911.12.11" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.16884.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.5071.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.16884.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue.16963.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.5071.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue.16963.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue.16925.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward.5071.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue.16925.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="309 - Disclosure - Stock-Based Compensation (Tables)" xlink:role="http://www.novavax.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.1379.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.16476.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.1379.12.7" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock.16476.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.16335.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.1379.12.7" xlink:to="loc_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock.16335.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.16360.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.1379.12.7" xlink:to="loc_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock.16360.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.23954.12.7" xlink:href="nvax-20130930.xsd#nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.1379.12.7" xlink:to="loc_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock.23954.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TypeOfDeferredCompensationDomain.5392.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfDeferredCompensationDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.12.7" xlink:to="loc_TypeOfDeferredCompensationDomain.5392.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1637.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.4832.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract.1637.12.7" xlink:to="loc_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.4832.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.4832.12.7" xlink:to="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis.1391.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable.4832.12.7" xlink:to="loc_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems.1379.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_TypeOfDeferredCompensationDomain.5392.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfDeferredCompensationDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeStockOptionMember.1806.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_TypeOfDeferredCompensationDomain.5392.12.8" xlink:to="loc_EmployeeStockOptionMember.1806.12.8" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="005 - Statement - STATEMENTS OF COMPREHENSIVE LOSS" xlink:role="http://www.novavax.com/role/StatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:label="loc_ComprehensiveIncomeNetOfTaxAbstract.1128.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.13897.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ComprehensiveIncomeNetOfTaxAbstract.1128.12.7" xlink:to="loc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.13897.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ComprehensiveIncomeNetOfTaxAbstract.1128.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.14111.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ComprehensiveIncomeNetOfTaxAbstract.1128.12.9" xlink:to="loc_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.14111.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.14099.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ComprehensiveIncomeNetOfTaxAbstract.1128.12.7" xlink:to="loc_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.14099.12.7" order="3.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfIncomeAndComprehensiveIncomeAbstract.5170.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract.5170.12.7" xlink:to="loc_NetIncomeLoss.13265.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfIncomeAndComprehensiveIncomeAbstract.5170.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ComprehensiveIncomeNetOfTax.7190.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract.5170.12.9" xlink:to="loc_ComprehensiveIncomeNetOfTax.7190.12.9" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract.5170.12.7" xlink:to="loc_ComprehensiveIncomeNetOfTaxAbstract.1128.12.7" order="3.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="004 - Statement - STATEMENTS OF OPERATIONS" xlink:role="http://www.novavax.com/role/StatementsOfOperations" xlink:type="extended">
    <link:loc xlink:label="loc_CostsAndExpensesAbstract.1259.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ContractRevenueCost.7296.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractRevenueCost" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CostsAndExpensesAbstract.1259.12.7" xlink:to="loc_ContractRevenueCost.7296.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15880.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CostsAndExpensesAbstract.1259.12.7" xlink:to="loc_ResearchAndDevelopmentExpense.15880.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10699.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CostsAndExpensesAbstract.1259.12.7" xlink:to="loc_GeneralAndAdministrativeExpense.10699.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CostsAndExpensesAbstract.1259.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CostsAndExpenses.7476.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpenses" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CostsAndExpensesAbstract.1259.12.9" xlink:to="loc_CostsAndExpenses.7476.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2649.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_OperatingIncomeLoss.13592.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.9" xlink:to="loc_OperatingIncomeLoss.13592.12.9" order="12.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2649.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeTaxExpenseBenefit.11134.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_IncomeTaxExpenseBenefit.11134.12.7" order="16.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.9" xlink:to="loc_NetIncomeLoss.13265.12.9" order="17.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_NonoperatingIncomeExpenseAbstract.3592.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_NonoperatingIncomeExpenseAbstract.3592.12.7" order="12.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.12.7" order="20.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.11075.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.9" xlink:to="loc_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.11075.12.9" order="15.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.9078.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_EarningsPerShareBasicAndDiluted.9078.12.7" order="19.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ContractsRevenue.7301.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractsRevenue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_ContractsRevenue.7301.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_CostsAndExpensesAbstract.1259.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentCollaboration.23950.12.7" xlink:href="nvax-20130930.xsd#nvax_ResearchAndDevelopmentCollaboration" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_ResearchAndDevelopmentCollaboration.23950.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_Revenues.16160.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.9" xlink:to="loc_Revenues.16160.12.9" order="2.25000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_NonoperatingIncomeExpenseAbstract.3592.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InterestExpense.11654.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NonoperatingIncomeExpenseAbstract.3592.12.52" xlink:to="loc_InterestExpense.11654.12.52" order="1.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_GainLossOnDerivativeInstrumentsNetPretax.10572.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NonoperatingIncomeExpenseAbstract.3592.12.7" xlink:to="loc_GainLossOnDerivativeInstrumentsNetPretax.10572.12.7" order="1.88000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InvestmentIncomeNet.11894.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NonoperatingIncomeExpenseAbstract.3592.12.7" xlink:to="loc_InvestmentIncomeNet.11894.12.7" order="1.63000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherNonoperatingExpense.13989.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NonoperatingIncomeExpenseAbstract.3592.12.52" xlink:to="loc_OtherNonoperatingExpense.13989.12.52" order="1.81500" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="103 - Disclosure - Summary of Significant Accounting Policies" xlink:role="http://www.novavax.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.414.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40301 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)" xlink:role="http://www.novavax.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.414.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NumberOfAuctionRateSecuritiesIncludedInInvestments.23941.12.7" xlink:href="nvax-20130930.xsd#nvax_NumberOfAuctionRateSecuritiesIncludedInInvestments" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_NumberOfAuctionRateSecuritiesIncludedInInvestments.23941.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.23949.12.7" xlink:href="nvax-20130930.xsd#nvax_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses.23949.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ReclassificationFromAccountsPayableToLeaseIncentivesReceived.23948.12.7" xlink:href="nvax-20130930.xsd#nvax_ReclassificationFromAccountsPayableToLeaseIncentivesReceived" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_ReclassificationFromAccountsPayableToLeaseIncentivesReceived.23948.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities.32668.12.7" xlink:href="nvax-20130930.xsd#nvax_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities.32668.12.7" order="4.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.14099.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent.14099.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="203 - Disclosure - Summary of Significant Accounting Policies (Policy)" xlink:role="http://www.novavax.com/role/SummaryOfSignificantAccountingPoliciesPolicy" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.414.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_UseOfEstimates.17889.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_UseOfEstimates.17889.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_FairValueMeasurementPolicyPolicyTextBlock.9608.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_FairValueMeasurementPolicyPolicyTextBlock.9608.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy.6831.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy.6831.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.9080.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_EarningsPerSharePolicyTextBlock.9080.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InvestmentPolicyTextBlock.11895.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_InvestmentPolicyTextBlock.11895.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PriorPeriodReclassificationAdjustmentDescription.14858.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_PriorPeriodReclassificationAdjustmentDescription.14858.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="007 - Statement - STATEMENTS OF CASH FLOWS (Parenthetical)" xlink:role="http://www.novavax.com/role/StatementsOfCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_PaymentsOfStockIssuanceCosts.14360.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_PaymentsOfStockIssuanceCosts.14360.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="110 - Disclosure - U.S. Government Agreement, Joint Venture and Collaborations" xlink:role="http://www.novavax.com/role/UsGovernmentAgreementJointVentureAndCollaborations" xlink:type="extended">
    <link:loc xlink:label="loc_UsGovernmentAgreementAndCollaborationsAbstract.23964.12.7" xlink:href="nvax-20130930.xsd#nvax_UsGovernmentAgreementAndCollaborationsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborativeArrangementDisclosureTextBlock.7097.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_UsGovernmentAgreementAndCollaborationsAbstract.23964.12.7" xlink:to="loc_CollaborativeArrangementDisclosureTextBlock.7097.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="41001 - Disclosure - U.S. Government Agreement, Joint Venture and Collaborations (Details)" xlink:role="http://www.novavax.com/role/UsGovernmentAgreementJointVentureAndCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:loc xlink:label="loc_HhsBardaContractAwardMember.23929.12.7" xlink:href="nvax-20130930.xsd#nvax_HhsBardaContractAwardMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.7" xlink:to="loc_HhsBardaContractAwardMember.23929.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_HhsBardaOptionForAdditionalPeriodMember.23930.12.7" xlink:href="nvax-20130930.xsd#nvax_HhsBardaOptionForAdditionalPeriodMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.7" xlink:to="loc_HhsBardaOptionForAdditionalPeriodMember.23930.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LicenseAgreementWithLgLifeSciencesLtdMember.23933.12.7" xlink:href="nvax-20130930.xsd#nvax_LicenseAgreementWithLgLifeSciencesLtdMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.7" xlink:to="loc_LicenseAgreementWithLgLifeSciencesLtdMember.23933.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PathVaccineSolutionsMember.23945.12.7" xlink:href="nvax-20130930.xsd#nvax_PathVaccineSolutionsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.7" xlink:to="loc_PathVaccineSolutionsMember.23945.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_GovernmentContractReceivable.10758.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.12.7" xlink:to="loc_GovernmentContractReceivable.10758.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ExpectedClinicalTrialCosts.23928.12.7" xlink:href="nvax-20130930.xsd#nvax_ExpectedClinicalTrialCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.12.7" xlink:to="loc_ExpectedClinicalTrialCosts.23928.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ContractsRevenue.7301.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractsRevenue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.12.7" xlink:to="loc_ContractsRevenue.7301.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_UpfrontLicensePayment.23963.12.7" xlink:href="nvax-20130930.xsd#nvax_UpfrontLicensePayment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.12.7" xlink:to="loc_UpfrontLicensePayment.23963.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_RoyaltyPaymentsPercentOfFutureProductSales.23951.12.7" xlink:href="nvax-20130930.xsd#nvax_RoyaltyPaymentsPercentOfFutureProductSales" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.12.7" xlink:to="loc_RoyaltyPaymentsPercentOfFutureProductSales.23951.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent.23946.12.7" xlink:href="nvax-20130930.xsd#nvax_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.12.7" xlink:to="loc_PotentialProvidedFundingOfExternalClinicalDevelopmentCostsPercent.23946.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ContractTerm.23923.12.7" xlink:href="nvax-20130930.xsd#nvax_ContractTerm" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.12.7" xlink:to="loc_ContractTerm.23923.12.7" order="1.25000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentCollaboration.23950.12.7" xlink:href="nvax-20130930.xsd#nvax_ResearchAndDevelopmentCollaboration" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.12.7" xlink:to="loc_ResearchAndDevelopmentCollaboration.23950.12.7" order="2.25000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ClinicalTrialCostsIncurred.23919.12.7" xlink:href="nvax-20130930.xsd#nvax_ClinicalTrialCostsIncurred" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.12.7" xlink:to="loc_ClinicalTrialCostsIncurred.23919.12.7" order="3.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.12.20" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityMethodInvestmentOwnershipPercentage.9324.12.20" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.12.20" xlink:to="loc_EquityMethodInvestmentOwnershipPercentage.9324.12.20" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:loc xlink:label="loc_GovernmentContractReceivableIncrease.27086.12.7" xlink:href="nvax-20130930.xsd#nvax_GovernmentContractReceivableIncrease" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.12.7" xlink:to="loc_GovernmentContractReceivableIncrease.27086.12.7" order="1.12500" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_JointVenturePercentageOwnedByOthers.23931.12.20" xlink:href="nvax-20130930.xsd#nvax_JointVenturePercentageOwnedByOthers" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.12.20" xlink:to="loc_JointVenturePercentageOwnedByOthers.23931.12.20" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentCollaborationIncrease.28056.12.7" xlink:href="nvax-20130930.xsd#nvax_ResearchAndDevelopmentCollaborationIncrease" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.12.7" xlink:to="loc_ResearchAndDevelopmentCollaborationIncrease.28056.12.7" order="2.62500" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EquityMethodInvesteeNameDomain.1871.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityMethodInvesteeOneMember.23927.12.7" xlink:href="nvax-20130930.xsd#nvax_EquityMethodInvesteeOneMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityMethodInvesteeNameDomain.1871.12.7" xlink:to="loc_EquityMethodInvesteeOneMember.23927.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_RangeAxis.4365.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeAxis.4365.12.6" xlink:to="loc_RangeMember.4366.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MinimumMember.3382.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4366.12.6" xlink:to="loc_MinimumMember.3382.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MaximumMember.3373.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4366.12.6" xlink:to="loc_MaximumMember.3373.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable.4810.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable.4810.12.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems.1044.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable.4810.12.6" xlink:to="loc_RangeAxis.4365.12.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_TypeOfArrangementAxis.5386.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable.4810.12.6" xlink:to="loc_TypeOfArrangementAxis.5386.12.6" order="1.25000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis.4820.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable.4810.12.6" xlink:to="loc_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis.4820.12.6" order="1.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EquityMethodInvesteeNameDomain.1871.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis.4820.12.6" xlink:to="loc_EquityMethodInvesteeNameDomain.1871.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_TypeOfArrangementAxis.5386.12.6" xlink:to="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_UsGovernmentAgreementAndCollaborationsAbstract.23964.12.6" xlink:href="nvax-20130930.xsd#nvax_UsGovernmentAgreementAndCollaborationsAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_UsGovernmentAgreementAndCollaborationsAbstract.23964.12.6" xlink:to="loc_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable.4810.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="112 - Disclosure - Warrant Liability" xlink:role="http://www.novavax.com/role/WarrantLiability" xlink:type="extended">
    <link:loc xlink:label="loc_WarrantLiabilityAbstract.23965.12.7" xlink:href="nvax-20130930.xsd#nvax_WarrantLiabilityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_StockWarrantsTextBlock.23959.12.7" xlink:href="nvax-20130930.xsd#nvax_StockWarrantsTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_WarrantLiabilityAbstract.23965.12.7" xlink:to="loc_StockWarrantsTextBlock.23959.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="41201 - Disclosure - Warrant Liability (Details)" xlink:role="http://www.novavax.com/role/WarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:label="loc_WarrantLiabilityAbstract.23965.12.7" xlink:href="nvax-20130930.xsd#nvax_WarrantLiabilityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOrSaleOfEquity.14962.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_WarrantLiabilityAbstract.23965.12.7" xlink:to="loc_ProceedsFromIssuanceOrSaleOfEquity.14962.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.17271.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_WarrantLiabilityAbstract.23965.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesNewIssues.17271.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonSharesPerUnit.23920.12.7" xlink:href="nvax-20130930.xsd#nvax_CommonSharesPerUnit" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_WarrantLiabilityAbstract.23965.12.7" xlink:to="loc_CommonSharesPerUnit.23920.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights.7036.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_WarrantLiabilityAbstract.23965.12.7" xlink:to="loc_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights.7036.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights.7037.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_WarrantLiabilityAbstract.23965.12.7" xlink:to="loc_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights.7037.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_GainLossOnDerivativeInstrumentsNetPretax.10572.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_WarrantLiabilityAbstract.23965.12.7" xlink:to="loc_GainLossOnDerivativeInstrumentsNetPretax.10572.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight.7038.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_WarrantLiabilityAbstract.23965.12.7" xlink:to="loc_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight.7038.12.7" order="4.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EquityIssuancePerShareAmount.9323.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_WarrantLiabilityAbstract.23965.12.7" xlink:to="loc_EquityIssuancePerShareAmount.9323.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="108 - Disclosure - Stockholders' Equity" xlink:role="http://www.novavax.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:label="loc_StockholdersEquityNoteAbstract.5200.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.17310.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityNoteAbstract.5200.12.7" xlink:to="loc_StockholdersEquityNoteDisclosureTextBlock.17310.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="104 - Disclosure - Acquisition of Isconova AB" xlink:role="http://www.novavax.com/role/AcquisitionOfIsconovaAb" xlink:type="extended">
    <link:loc xlink:label="loc_BusinessCombinationsAbstract.782.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AcquisitionOfIsconovaAbTextBlock.27967.12.7" xlink:href="nvax-20130930.xsd#nvax_AcquisitionOfIsconovaAbTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.7" xlink:to="loc_AcquisitionOfIsconovaAbTextBlock.27967.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40801 - Disclosure - Stockholders' Equity (Details)" xlink:role="http://www.novavax.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:label="loc_RangeAxis.4365.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeAxis.4365.12.7" xlink:to="loc_RangeMember.4366.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_MinimumMember.3382.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4366.12.7" xlink:to="loc_MinimumMember.3382.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_MaximumMember.3373.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4366.12.7" xlink:to="loc_MaximumMember.3373.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SaleOfStockNameOfTransactionDomain.4737.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_IPOMember.2975.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SaleOfStockNameOfTransactionDomain.4737.12.7" xlink:to="loc_IPOMember.2975.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SaleOfStockNameOfTransactionDomain.4737.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_SecondPublicOfferingMember.32671.12.6" xlink:href="nvax-20130930.xsd#nvax_SecondPublicOfferingMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SaleOfStockNameOfTransactionDomain.4737.12.6" xlink:to="loc_SecondPublicOfferingMember.32671.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StockholdersEquityNoteAbstract.5200.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.5225.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityNoteAbstract.5200.12.7" xlink:to="loc_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.5225.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SubsidiarySaleOfStockAxis.5224.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsidiarySaleOfStockAxis.5224.12.7" xlink:to="loc_SaleOfStockNameOfTransactionDomain.4737.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.5225.12.7" xlink:to="loc_RangeAxis.4365.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SubsidiarySaleOfStockLineItems.5227.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.5225.12.7" xlink:to="loc_SubsidiarySaleOfStockLineItems.5227.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable.5225.12.7" xlink:to="loc_SubsidiarySaleOfStockAxis.5224.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.7144.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.12.7" xlink:to="loc_CommonStockSharesAuthorized.7144.12.7" order="1.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SubsidiarySaleOfStockLineItems.5227.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_SaleOfStockPricePerShare.16232.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.12.8" xlink:to="loc_SaleOfStockPricePerShare.16232.12.8" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.17271.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.12.8" xlink:to="loc_StockIssuedDuringPeriodSharesNewIssues.17271.12.8" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.17285.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.12.8" xlink:to="loc_StockIssuedDuringPeriodValueNewIssues.17285.12.8" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_SaleOfStockNumberOfSharesIssuedInTransaction.16262.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.12.8" xlink:to="loc_SaleOfStockNumberOfSharesIssuedInTransaction.16262.12.8" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_AggregateGrossProceedsSaleOfStock.31357.12.7" xlink:href="nvax-20130930.xsd#nvax_AggregateGrossProceedsSaleOfStock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.12.7" xlink:to="loc_AggregateGrossProceedsSaleOfStock.31357.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement.32670.12.7" xlink:href="nvax-20130930.xsd#nvax_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.12.7" xlink:to="loc_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement.32670.12.7" order="1.62500" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EquityIssuancePerShareAmount.9323.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsidiarySaleOfStockLineItems.5227.12.8" xlink:to="loc_EquityIssuancePerShareAmount.9323.12.8" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40401 - Disclosure - Acquisition of Isconova AB (Narrative) (Details)" xlink:role="http://www.novavax.com/role/AcquisitionOfIsconovaAbNarrativeDetails" xlink:type="extended">
    <link:loc xlink:label="loc_BusinessAcquisitionAxis.750.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_BusinessAcquisitionAcquireeDomain.775.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessAcquisitionAxis.750.12.8" xlink:to="loc_BusinessAcquisitionAcquireeDomain.775.12.8" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_BusinessAcquisitionLineItems.769.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_UnsolicitedTenderOfferCosts.17869.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UnsolicitedTenderOfferCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessAcquisitionLineItems.769.12.7" xlink:to="loc_UnsolicitedTenderOfferCosts.17869.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AcquiredOutstandingShares.27087.12.7" xlink:href="nvax-20130930.xsd#nvax_AcquiredOutstandingShares" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessAcquisitionLineItems.769.12.7" xlink:to="loc_AcquiredOutstandingShares.27087.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesAcquisitions.17221.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessAcquisitionLineItems.769.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesAcquisitions.17221.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NovavaxSharesIssued.28072.12.7" xlink:href="nvax-20130930.xsd#nvax_NovavaxSharesIssued" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessAcquisitionLineItems.769.12.7" xlink:to="loc_NovavaxSharesIssued.28072.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_BusinessAcquisitionLineItems.769.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.6397.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessAcquisitionLineItems.769.12.8" xlink:to="loc_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.6397.12.8" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_PaymentsToAcquireBusinessesGross.14339.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessAcquisitionLineItems.769.12.8" xlink:to="loc_PaymentsToAcquireBusinessesGross.14339.12.8" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife.5803.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessAcquisitionLineItems.769.12.8" xlink:to="loc_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife.5803.12.8" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.31348.12.7" xlink:href="nvax-20130930.xsd#nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessAcquisitionLineItems.769.12.7" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.31348.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AcquisitionCostsCumulative.5810.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AcquisitionCostsCumulative" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessAcquisitionLineItems.769.12.7" xlink:to="loc_AcquisitionCostsCumulative.5810.12.7" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OperatingLeasesFutureMinimumPaymentsReceivable.13573.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessAcquisitionLineItems.769.12.7" xlink:to="loc_OperatingLeasesFutureMinimumPaymentsReceivable.13573.12.7" order="13.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_Revenues.16160.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessAcquisitionLineItems.769.12.7" xlink:to="loc_Revenues.16160.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessAcquisitionLineItems.769.12.7" xlink:to="loc_NetIncomeLoss.13265.12.7" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AcquisitionTransactionCosts.32704.12.7" xlink:href="nvax-20130930.xsd#nvax_AcquisitionTransactionCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessAcquisitionLineItems.769.12.7" xlink:to="loc_AcquisitionTransactionCosts.32704.12.7" order="12.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_BusinessAcquisitionAcquireeDomain.775.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_NovavaxAbMember.32703.12.7" xlink:href="nvax-20130930.xsd#nvax_NovavaxAbMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessAcquisitionAcquireeDomain.775.12.7" xlink:to="loc_NovavaxAbMember.32703.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_BusinessCombinationsAbstract.782.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfBusinessAcquisitionsByAcquisitionTable.4809.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.6" xlink:to="loc_ScheduleOfBusinessAcquisitionsByAcquisitionTable.4809.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_RangeAxis.4365.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeAxis.4365.12.8" xlink:to="loc_RangeMember.4366.12.8" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_MinimumMember.3382.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4366.12.8" xlink:to="loc_MinimumMember.3382.12.8" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_MaximumMember.3373.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4366.12.8" xlink:to="loc_MaximumMember.3373.12.8" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_ScheduleOfBusinessAcquisitionsByAcquisitionTable.4809.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfBusinessAcquisitionsByAcquisitionTable.4809.12.8" xlink:to="loc_RangeAxis.4365.12.8" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:from="loc_ScheduleOfBusinessAcquisitionsByAcquisitionTable.4809.12.8" xlink:to="loc_BusinessAcquisitionAxis.750.12.8" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:from="loc_ScheduleOfBusinessAcquisitionsByAcquisitionTable.4809.12.8" xlink:to="loc_BusinessAcquisitionLineItems.769.12.8" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="107 - Disclosure - Goodwill and Other Intangible Assets" xlink:role="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:label="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_GoodwillAndIntangibleAssetsDisclosureTextBlock.10734.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.7" xlink:to="loc_GoodwillAndIntangibleAssetsDisclosureTextBlock.10734.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="114 - Disclosure - Master Services Agreement with Cadila" xlink:role="http://www.novavax.com/role/MasterServicesAgreementWithCadila" xlink:type="extended">
    <link:loc xlink:label="loc_MasterServicesAgreementWithCadilaAbstract.31327.12.7" xlink:href="nvax-20130930.xsd#nvax_MasterServicesAgreementWithCadilaAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_MasterServicesAgreementWithCadilaTextBlock.31328.12.7" xlink:href="nvax-20130930.xsd#nvax_MasterServicesAgreementWithCadilaTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_MasterServicesAgreementWithCadilaAbstract.31327.12.7" xlink:to="loc_MasterServicesAgreementWithCadilaTextBlock.31328.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="307 - Disclosure - Goodwill and Other Intangible Assets (Tables)" xlink:role="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:label="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfGoodwillTextBlock.16511.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.7" xlink:to="loc_ScheduleOfGoodwillTextBlock.16511.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock.16433.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.7" xlink:to="loc_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock.16433.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock.16221.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.7" xlink:to="loc_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock.16221.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="304 - Disclosure - Acquisition of Isconova AB (Tables)" xlink:role="http://www.novavax.com/role/AcquisitionOfIsconovaAbTables" xlink:type="extended">
    <link:loc xlink:label="loc_BusinessCombinationsAbstract.782.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock.16301.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.7" xlink:to="loc_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock.16301.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_BusinessAcquisitionProFormaInformationTextBlock.6390.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.7" xlink:to="loc_BusinessAcquisitionProFormaInformationTextBlock.6390.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfPurchasePriceTableTextBlock.31329.12.7" xlink:href="nvax-20130930.xsd#nvax_ScheduleOfPurchasePriceTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.7" xlink:to="loc_ScheduleOfPurchasePriceTableTextBlock.31329.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="41401 - Disclosure - Master Services Agreement with Cadila (Details)" xlink:role="http://www.novavax.com/role/MasterServicesAgreementWithCadilaDetails" xlink:type="extended">
    <link:loc xlink:label="loc_RangeAxis.4365.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RangeMember.4366.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeAxis.4365.12.6" xlink:to="loc_RangeMember.4366.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MaximumMember.3373.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RangeMember.4366.12.6" xlink:to="loc_MaximumMember.3373.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_RelatedPartyTransactionLineItems.4538.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_MasterServiceAgreement.31351.12.7" xlink:href="nvax-20130930.xsd#nvax_MasterServiceAgreement" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RelatedPartyTransactionLineItems.4538.12.7" xlink:to="loc_MasterServiceAgreement.31351.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PaymentToRelatedPartyPortionOfShortfall.31353.12.7" xlink:href="nvax-20130930.xsd#nvax_PaymentToRelatedPartyPortionOfShortfall" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RelatedPartyTransactionLineItems.4538.12.7" xlink:to="loc_PaymentToRelatedPartyPortionOfShortfall.31353.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_HalfPaymentForPortionOfShortfallExceedingTwoMillion.31354.12.7" xlink:href="nvax-20130930.xsd#nvax_HalfPaymentForPortionOfShortfallExceedingTwoMillion" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RelatedPartyTransactionLineItems.4538.12.7" xlink:to="loc_HalfPaymentForPortionOfShortfallExceedingTwoMillion.31354.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ServicesPurchased.31355.12.7" xlink:href="nvax-20130930.xsd#nvax_ServicesPurchased" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RelatedPartyTransactionLineItems.4538.12.7" xlink:to="loc_ServicesPurchased.31355.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ServicesProvidedDuringThePeriod.31356.12.7" xlink:href="nvax-20130930.xsd#nvax_ServicesProvidedDuringThePeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RelatedPartyTransactionLineItems.4538.12.7" xlink:to="loc_ServicesProvidedDuringThePeriod.31356.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_RelatedPartyTransactionsByRelatedPartyAxis.4540.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_RelatedPartyDomain.4542.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RelatedPartyTransactionsByRelatedPartyAxis.4540.12.6" xlink:to="loc_RelatedPartyDomain.4542.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CadilaMember.31352.12.6" xlink:href="nvax-20130930.xsd#nvax_CadilaMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_RelatedPartyDomain.4542.12.6" xlink:to="loc_CadilaMember.31352.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4873.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4873.12.6" xlink:to="loc_RelatedPartyTransactionsByRelatedPartyAxis.4540.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4873.12.6" xlink:to="loc_RangeAxis.4365.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_RelatedPartyTransactionLineItems.4538.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4873.12.6" xlink:to="loc_RelatedPartyTransactionLineItems.4538.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MasterServicesAgreementWithCadilaAbstract.31327.12.6" xlink:href="nvax-20130930.xsd#nvax_MasterServicesAgreementWithCadilaAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_MasterServicesAgreementWithCadilaAbstract.31327.12.6" xlink:to="loc_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable.4873.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40701 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill) (Details)" xlink:role="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails" xlink:type="extended">
    <link:loc xlink:label="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_Goodwill.10732.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.10" xlink:to="loc_Goodwill.10732.12.10" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_GoodwillAcquiredDuringPeriod.10749.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.7" xlink:to="loc_GoodwillAcquiredDuringPeriod.10749.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_GoodwillTranslationAdjustments.10736.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillTranslationAdjustments" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.8" xlink:to="loc_GoodwillTranslationAdjustments.10736.12.8" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_Goodwill.10732.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.11" xlink:to="loc_Goodwill.10732.12.11" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40702 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Identifiable Intangible Assets) (Details)" xlink:role="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AcquiredFiniteLivedIntangibleAssetsLineItems.478.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsGross.10303.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AcquiredFiniteLivedIntangibleAssetsLineItems.478.12.7" xlink:to="loc_FiniteLivedIntangibleAssetsGross.10303.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AcquiredFiniteLivedIntangibleAssetsLineItems.478.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAccumulatedAmortization.10322.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AcquiredFiniteLivedIntangibleAssetsLineItems.478.12.52" xlink:to="loc_FiniteLivedIntangibleAssetsAccumulatedAmortization.10322.12.52" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_AcquiredFiniteLivedIntangibleAssetsLineItems.478.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsNet.10326.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AcquiredFiniteLivedIntangibleAssetsLineItems.478.12.9" xlink:to="loc_FiniteLivedIntangibleAssetsNet.10326.12.9" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsMajorClassNameDomain.2309.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_TechnologyEquipmentMember.5302.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TechnologyEquipmentMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FiniteLivedIntangibleAssetsMajorClassNameDomain.2309.12.8" xlink:to="loc_TechnologyEquipmentMember.5302.12.8" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsMajorClassNameDomain.2309.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborationAgreementsMember.31339.12.7" xlink:href="nvax-20130930.xsd#nvax_CollaborationAgreementsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FiniteLivedIntangibleAssetsMajorClassNameDomain.2309.12.7" xlink:to="loc_CollaborationAgreementsMember.31339.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProprietaryAdjuvantTechnologyMember.32669.12.7" xlink:href="nvax-20130930.xsd#nvax_ProprietaryAdjuvantTechnologyMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FiniteLivedIntangibleAssetsMajorClassNameDomain.2309.12.7" xlink:to="loc_ProprietaryAdjuvantTechnologyMember.32669.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsByMajorClassAxis.2311.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsMajorClassNameDomain.2309.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FiniteLivedIntangibleAssetsByMajorClassAxis.2311.12.6" xlink:to="loc_FiniteLivedIntangibleAssetsMajorClassNameDomain.2309.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfFiniteLivedIntangibleAssetsTable.4785.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.6" xlink:to="loc_ScheduleOfFiniteLivedIntangibleAssetsTable.4785.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfFiniteLivedIntangibleAssetsTable.4785.12.6" xlink:to="loc_FiniteLivedIntangibleAssetsByMajorClassAxis.2311.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AcquiredFiniteLivedIntangibleAssetsLineItems.478.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfFiniteLivedIntangibleAssetsTable.4785.12.6" xlink:to="loc_AcquiredFiniteLivedIntangibleAssetsLineItems.478.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40703 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Estimated Amortization Expense) (Details)" xlink:role="http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfEstimatedAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:label="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.10353.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.7" xlink:to="loc_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.10353.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths.10340.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.7" xlink:to="loc_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths.10340.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.10343.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.7" xlink:to="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo.10343.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.10316.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.7" xlink:to="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree.10316.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.10342.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.7" xlink:to="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.10342.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.10308.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.7" xlink:to="loc_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.10308.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AmortizationOfIntangibleAssets.5980.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_GoodwillAndIntangibleAssetsDisclosureAbstract.2496.12.7" xlink:to="loc_AmortizationOfIntangibleAssets.5980.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40402 - Disclosure - Acquisition of Isconova AB (Schedule of Purchase Price) (Details)" xlink:role="http://www.novavax.com/role/AcquisitionOfIsconovaAbScheduleOfPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:label="loc_BusinessCombinationsAbstract.782.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_PaymentsToAcquireBusinessesGross.14339.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.8" xlink:to="loc_PaymentsToAcquireBusinessesGross.14339.12.8" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.6397.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.8" xlink:to="loc_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable.6397.12.8" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_BusinessCombinationsAbstract.782.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_BusinessCombinationConsiderationTransferred1.6477.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.9" xlink:to="loc_BusinessCombinationConsiderationTransferred1.6477.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40403 - Disclosure - Acquisition of Isconova AB (Schedule of Assets Acquired and Liabilities Assumed) (Details)" xlink:role="http://www.novavax.com/role/AcquisitionOfIsconovaAbScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:label="loc_BusinessCombinationsAbstract.782.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents.6385.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.7" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents.6385.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables.6361.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.7" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables.6361.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets.6351.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.7" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets.6351.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment.6544.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.7" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment.6544.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill.6432.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.7" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill.6432.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_BusinessCombinationsAbstract.782.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable.6359.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.52" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable.6359.12.52" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation.6375.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.52" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation.6375.12.52" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt.6429.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.52" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt.6429.12.52" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther.6380.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.52" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther.6380.12.52" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_BusinessCombinationsAbstract.782.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.6620.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.9" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet.6620.12.9" order="12.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.31348.12.7" xlink:href="nvax-20130930.xsd#nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.7" xlink:to="loc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill.31348.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40404 - Disclosure - Acquisition of Isconova AB (Unaudited Pro Forma Financial Information of Operations) (Details)" xlink:role="http://www.novavax.com/role/AcquisitionOfIsconovaAbUnauditedProFormaFinancialInformationOfOperationsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_BusinessCombinationsAbstract.782.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_BusinessAcquisitionsProFormaRevenue.6457.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.7" xlink:to="loc_BusinessAcquisitionsProFormaRevenue.6457.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_BusinessAcquisitionsProFormaNetIncomeLoss.6465.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.7" xlink:to="loc_BusinessAcquisitionsProFormaNetIncomeLoss.6465.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted.31350.12.7" xlink:href="nvax-20130930.xsd#nvax_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_BusinessCombinationsAbstract.782.12.7" xlink:to="loc_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted.31350.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>U.S. Government Agreement, Joint Venture and Collaborations<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_UsGovernmentAgreementAndCollaborationsAbstract', window );"><strong>U.S. Government Agreement, Joint Venture and Collaborations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">U.S. Government Agreement, Joint Venture and Collaborations</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> Note 10 - U.S. Government Agreement, Joint Venture and Collaborations</p> <p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; TEXT-INDENT: 0in"> <strong><em>HHS BARDA Contract for Recombinant Influenza Vaccines</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; TEXT-INDENT: 0in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In February 2011, the Company was awarded a contract from HHS BARDA valued at $97 million for the first three-year base-period, with an HHS BARDA option for an additional two-year period valued at $82 million, for a total contract value of up to $179 million. The HHS BARDA contract award provides significant funding for the Company&#39;s ongoing clinical development and product scale-up of both its seasonal and pandemic influenza vaccine candidates. This is a cost-plus-fixed-fee contract in which HHS BARDA will reimburse the Company for allowable direct contract costs incurred plus allowable indirect costs and a fixed-fee earned in the further development of its multivalent seasonal and monovalent pandemic influenza vaccines. HHS BARDA originally directed the Company to develop its monovalent pandemic influenza vaccines against the A(H5N1) strain. Recently, however, HHS BARDA has directed the Company to develop its monovalent pandemic influenza vaccines against the A(H7N9) strain and is working with the Company to modify the contract in this respect; nevertheless, the Company&#39;s H5N1 vaccine program remains a viable development opportunity under the contract. Billings under the contract are based on approved provisional indirect billing rates, which permit recovery of fringe benefits, overhead and general and administrative expenses not exceeding certain limits. These indirect rates are subject to audit by HHS BARDA on an annual basis. An audit by the U.S. government of fiscal years 2011 and 2012 has been initiated, but has not been completed as of the date of this filing. When the final determination of the allowable costs for any year has been made, revenue and billings may be adjusted accordingly; however, management believes that revenue for periods subject to audit has been recorded in amounts that are expected to be realized upon final audit and settlement. The Company recognized revenue of approximately $10.7 million in the nine months ended September 30, 2013, and has recognized approximately $45 million in revenue since the inception of the contract.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Under certain circumstances, HHS BARDA reimbursements may be delayed or even potentially withheld. In March 2012, the Company decided to conduct a Phase 2 clinical trial of its quadrivalent seasonal influenza vaccine candidate ("205 Trial") under its existing U.S. investigational new drug application ("IND") for its trivalent seasonal influenza vaccine candidate as opposed to waiting to conduct this clinical trial under a new IND for its quadrivalent vaccine candidate ("Quadrivalent IND"). Based on the Company&#39;s discussions with HHS BARDA in 2012, the outside clinical trial costs for the 205 Trial may only be submitted for reimbursement to HHS BARDA and recorded as revenue by the Company after it submits the clinical trial data in a future Quadrivalent IND. The submission of the Quadrivalent IND is expected shortly before the Company initiates the next Phase 2 dose-confirmatory clinical trial, which is currently expected in the first quarter of 2014. The outside clinical trial costs of the 205 Trial conducted last year total $2.9 million, which was incurred from the inception of the clinical trial through September 30, 2013. These costs have been recorded as an expense and are included in cost of government contracts revenue.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> <strong><em>CPL Biologicals Private Limited ("CPLB") Joint Venture</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In 2009, the Company formed a joint venture with Cadila Pharmaceuticals Limited ("Cadila") named CPL Biologicals Private Limited ("CPLB") to develop and manufacture vaccines, biological therapeutics and diagnostics in India. CPLB is owned 20% by the Company and 80% by Cadila. The Company accounts for its investment in CPLB using the equity method. Since the carrying value of the Company&#39;s initial investment was nominal and there is no guarantee or commitment to provide future funding, the Company has not recorded any losses related to this investment.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> <strong><em>LG Life Sciences, Ltd. ("LGLS") License Agreement</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In February 2011, the Company entered into a license agreement with LGLS that allows LGLS to use the Company&#39;s technology to develop and commercially sell influenza vaccines exclusively in South Korea and non-exclusively in certain other specified countries. At its own cost, LGLS is responsible for funding both its clinical development of the influenza VLP vaccines and a manufacturing facility to produce such vaccine in South Korea. Under the license agreement, the Company is obligated to provide LGLS with information and materials related to the manufacture of the licensed products, provide on-going project management and regulatory support and conduct clinical trials of its influenza vaccines in order to obtain FDA approval in the U.S. The term of the license agreement is expected to terminate in 2027. Payments to the Company under the license agreement include an upfront payment of $2.5 million, reimbursements of certain development and product costs, payments related to the achievement of certain milestones and royalty payments in the high single digits from LGLS&#39;s future commercial sales of influenza VLP vaccines. The upfront payment has been deferred and will be recognized when the previously mentioned obligations in the agreement are satisfied, which may not occur until the end of the term of the agreement. Payments for milestones under the agreement will be recognized on a straight-line basis over the remaining term of the research and development period upon achievement of such milestone. Any royalties under the agreement will be recognized as earned.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> <strong><em>PATH Vaccine Solutions ("PATH") Clinical Development Agreement</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In July 2012, the Company entered into a clinical development agreement with PATH to develop its vaccine candidate to protect against RSV through maternal immunization in low-resource countries (the "RSV Collaboration Program"). The Company was awarded approximately $2.0 million by PATH for initial funding under the agreement to partially support its initial Phase 2 dose-ranging clinical trial in women of childbearing age, which was launched in October 2012. The funding under the agreement was increased by $0.4 million and the term extended to April 2014 to support the Company&#39;s reproductive toxicology studies, which are necessary before it conducts clinical trials in pregnant women. The Company retains global rights to commercialize the product and has made a commitment to make the vaccine affordable and available in low-resource countries. To the extent PATH elects to continue to fund 50% of the Company&#39;s external clinical development costs for the RSV Collaboration Program, but the Company does not continue development, the Company would then grant PATH a fully-paid license to its RSV vaccine technology for use in pregnant women in such low-resource countries. The Company recognized revenue of approximately $0.7 million in the nine months ended September 30, 2013, and has recognized approximately $2.0 million in revenue since the inception of the agreement. Revenue under this arrangement is being recognized under the proportional performance method and earned in proportion to the contract costs incurred in performance of the work as compared to total estimated contract costs. Costs incurred under this agreement represent a reasonable measurement of proportional performance of the services being performed.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_UsGovernmentAgreementAndCollaborationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_UsGovernmentAgreementAndCollaborationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 808<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CollaborativeArrangementDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0`)X\5<$@(``$H?```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F4MNVS`41><%N@>!T\*B
M^7&:!+8SZ&?8!FBZ`%9ZM@1+)$$RJ;W[4G(2!('KP*B!WHD%2^2[1QR<@>[\
M9MMWQ0.%V#J[8**<LH)LY>K6KA?LY]W7R24K8C*V-IVSM&`[BNQF^?[=_&[G
M*19YMXT+UJ3DKSF/54.]B:7S9/.3E0N]2?EO6'-OJHU9$Y?3Z06OG$UDTR0-
M,]AR_IE6YKY+Q9=MOKTG"=1%5GS:+QRR%LQXW[6529F4/]CZ5<KD,:',.\<U
ML6E]_)`Q&#^8,#SY>\#CON_Y:$);4W%K0OIF^HS!MQW_[<+FEW.;\OB0`Y1N
MM6HKJEUUW^<3**,/9.K8$*6^*\=KV9O6/G$?R1\71SY>Q)E!AO<;!Y_((4$X
M%`B'!N&8@7!<@'!\!.&X!.&X`N$04Q00%*,*%*4*%*<*%*D*%*L*%*T*%*\*
M%+$*%+-*%+-*%+-*%+-*%+-*%+-*%+-*%+-*%+-*%+-*%+,J%+,J%+,J%+,J
M%+,J%+,J%+,J%+,J%+,J%+,J%+-J%+-J%+-J%+-J%+-J%+-J%+-J%+-J%+-J
M%+-J%+/.4,PZ^U]F3;FI)#[^_CO"..:-JBRF74?QS)^W]T/?2FY,H/I'"KG3
M/3O`R]G'.'+C>1N<C[G[#73Z*3R5N\/NB<^#**26GNO=0S7I<V+NC4\/?-73
MTM!,UU0?R.9C$[[\`P``__\#`%!+`P04``8`"````"$`M54P(_4```!,`@``
M"P`(`E]R96QS+RYR96QS(*($`BB@``(`````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````````(R2ST[#
M,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?VA`."2F/;T?;GSS];
MWN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:CAQA5]W>;%]XI)2;
M8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4<IA:-&3&:AEW)3E/8:_'E`M/-7!
M:@@'>P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_;J)I"RTF#%?.<
MTQ')^R)C`YXFVEQ/]/^V.'$B2XG02.#S/-^*<T#KZX$NGVBI^+W./.*GA.%-
M9/AAP<4/5%\```#__P,`4$L#!!0`!@`(````(0`V*V)W/0(``)L>```:``@!
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**```0``````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````"\F4]KVT`0Q>^%?@>Q]UJ>F963E,BYE$*N
M;?H!A+6V3&Q):+=__.V[N$5QH'F]F'<QK(1W'\.;W^R,[A]^'0_%CS#%_=#7
M3A9+5X1^,[3[?E>[;T^?/]RZ(J:F;YO#T(?:G4)T#^OW[^Z_A$.3\I]BMQ]C
MD7?I8^VZE,:/91DW73@V<3&,H<]OML-T;%)>3KMR;#;/S2Z4NERNRNER#[=^
MM6?QV-9N>FS%7/%T&O/1_]]\V&[WF_!IV'P_AC[]XXSRYS`]QRZ$E#=MIEU(
MM9L?Q?+\1FR1-;OR#3DY'EPYMTB.KLAR=(7DV!U9CMTA.2ID.2I(CGFR'/-(
MCE>R'*]0S@U;S@V24V424A.]6B(Y[.#`V+"-`WTC;`0*1*"R$:@0@<)&H$`$
M*AN!"A%H;"<;M+*QL]Q@FGLV`CU$H*_(1/85(G)UU8MI3*=#OEK/M](_:W@^
M.1HP&,*VBD"K"!O"`B%L;`@;A+!G0]A#"%=7A7#*K6=XR:/SLCS_XIB0LPE&
MA.U>:%YANT5@;/2J;IF;_Q?'S(_^S@,4EFQEEVR%)=O8'#;(86.7;(-5RE^U
M9,]&>=L['LZ2/'N6Y.$LB:T&BJG8);."Y8%M'.@;82-0(`*%C4"!"%0V<Q0R
MQ^C6@=XQ=I8;3'//'MYX/+QAET^%Y=.S(>@A!*NKW@1CUTRA_9JF_*GILO&]
M?(SZ7W9L8&C8-H8N%C8!!1)0V0142$!E$U`A`8UM'8/>\>S>T\_-9_GJD_+Z
M-P```/__`P!02P,$%``&``@````A`&W6WC-]!```?`\```\```!X;"]W;W)K
M8F]O:RYX;6R4E\%RHS@0AN];M>_@XKYC&["=I)),D0R9>,JQ4\%)CBH%9%L5
MD+R2L.-]^FU@PC3(9F=/CB#]T^K^_A9<?OW(TMZ.*<VEN'*&7P9.CXE8)ERL
MKYSGY=U?9TY/&RH2FDK!KIP#T\[7ZS__N-Q+]?XFY7L/!(2^<C;&;"_Z?1UO
M6$;U%[EE`NZLI,JH@:5:]_56,9KH#6,F2_ON8##N9Y0+IU*X4+^C(5<K'K-O
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M+.[(XC%\"I;3Q1PGX:-XOYU#,_YV\?#X%-Z'\VCZ$I+9`F4!-:X+,/H/E2"Z
M)W>SQ2O.8HSBR\Z?WL5M'5_5!&4Q02J3=A8+M::"_U-"C6)&N(!G5M"6J<H&
M.`37[+P=$N591M6!R!6)^%IPL!85A@1Q+'-AL`PNVG#0U@GBOW.N>>'!0FNJ
M8RGDCI+@!FO@P@TM].XH5^2%ICDC#XSJ7('-A-%8`-=L:$$X%3MPLQ4$XZMN
M]]"B[KN4R9ZG:6F;!3"KP#4P[=;\+64$/_P<Z]CT&1F_;V2:P-@A(53#'%#P
M&)S_*PD;NB+XAFJ6D%N9P=S4[<Z/&ZZUJ'N.R'<),UP4NR?!6K&R>.2'Y+#&
MB6`;#RWNYM(P#:@>*.P>AV'PAA9YKU2I@IL9IV\\;6T=`SBT"'R@(E_1V.0*
MSALRHV\2&):`9#'&L&O'F$"8I*W!]0"3'7H7,;6#XT&C&NRYV>"M8`I=B\)N
M1T`7ZF$VQC2Z%HVG+4&6]`WK8$!="]`3MBA$4CB)43X84-<"%+G#CIU@/EV+
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MYWYI//A"@^^?&#X=BY_BVZM\2O_SP_GZ7P```/__`P!02P,$%``&``@````A
M``]MC":=!0``@18``!@```!X;"]W;W)K<VAE971S+W-H965T-"YX;6R<6%N/
M\C80?:_4_Q#E'1([5Q#PZ<MEVT]JI:KJY3D;#$1+"$JRR^Z_[S@.P3-9+ML7
M=F&.3WQ\QIZ)%]_>R[WQ)NJFJ`Y+DTUMTQ"'O%H7A^W2_/NOITEH&DV;'=;9
MOCJ(I?DA&O/;ZN>?%J>J?FEV0K0&,!R:I;EKV^/<LII\)\JLF59'<8#(IJK+
MK(6O]=9JCK7(UMV@<F]QV_:M,BL.IF*8UX]P5)M-D8NDRE]+<6@522WV60OS
M;W;%L3FSE?DC=&56O[P>)WE5'H'BN=@7[4=':AIE/O^Q/51U]KP'W>_,S?(S
M=_=E1%\6>5TUU::=`IVE)CK6/+-F%C"M%NL"%,AE-VJQ69K?V3SEW+16BVZ!
M_BG$J='^-YI==?JE+M:_%0<!JPT^20>>J^I%0G^LY4\PV!J-?NH<^*,VUF*3
MO>[;/ZO3KZ+8[EJPVP-%4MA\_9&()H<5!9HI]R137NUA`O!IE(5,#5B1[+W[
M>RK6[6YI.O[4"VR'`=QX%DW[5$A*T\A?F[8J_U4@UE,I$MZ3P(B>A/$I#SWF
M^?=9+#6C3F"2M=EJ45<G`[(&GMD<,YF#;`[,9V5J'H/6:U)!HR3Y+EDZ+E#1
M@#]OJV"VL-Y@2?,>$BE(8!H#)&08$I\A<@$E;7+^X3*&#$G/".D>*!IDP6)1
M60[8_KEA9Q5R$%81VGB*T1C",2(>(T("2<80@DC'"(T$"77^CU`Y"')0]\+!
M,B(%<36(AQ'Q741R%Y'>0B"9,!'=S]L^2O#2A#6\I)J+)Q\I2-BEJLO]$(=C
M/>QY(5F<1`\S>Q:2I4E1/'#XA1Z)@OVFBY)[[WZ2RD%$''E\I"!N)\YSB/18
MCS(MK=264U&_&\M&X?3:8*3+Q[INFR7!1(^/W8@41,W)#6VR66(][`4^68U$
M#S/._`"SIR@>>.RRY9$H.+ETLVZ+DF"RP<AC(P6!3!F2E$P\OHM([B+26P@D
M3[8J6AVX+4^"B6>7%._R*%(0Y1GG`;$TUL-.Z)#1B1[V?$9J2:J'&0_<*Y;-
MOJ))@HDF\MA(0?J]X<Q<,NM8C_N^2_(TT<..,PL)?:K'6<"#*ZH8U+''K>K0
M6-?L0JR\ZC%*F!-Z)%5C%.>,GB@)BC-;]Z-[0(H`@7]5F:SF#R<A4[5?/^9G
MI#V(>DR?AK8];CD42>\I]QDY+1/$X-D.-3U%`"?PM98!;3`F:_KCXE0'@,21
M?(HZQJ6IYCYA'J<]5XP1?NB2E$LPP`D97:`4([C-KIHG:_GC^E3EA\_A^)N1
M*ANQ6]U!EUCQ?4AR'Y+>A&`3965_7*3J`Y"))+\BIC#G8HUK4XRBSL@]?2RC
MYJ9H,&.7O8$ER9+^N"35`"!)I&Y%\LT(CE(E:>(3Q3$)8\4)CC*')'U*XI<P
M%B6+^N.B5`N`1)&"%3&%Z45I34*?B.?P)9_'=ITQ\OUH0BG2X0F?4F!YLJP_
M+D\U`4@>.>(C-FX4Z/SC`=/-W[4O"=6M08+B?-1GH?!$'XZUR>*N:7NL*V:J
M)4`:27F.>LQP7CHV*80Q1@2<D65*,,`)9C9!I!C!;3>XEJ*RW&LZ;W=<3#4'
M2!\Y#J(>`X?"<*:./50\MS#)P"-]YI?I][7\)@.RDG^I4^G0N%-AU*&H!ZD7
M-ZAY8P\QXA,/,0`\Y&0A4XRXX2'_4L/2H:E`LHFB'C3K7L`F]M0FDXM'`'+\
M)A3`R0&<4@"[G'78/L@V/4,?VXEP#T<;:49?V:(>U+==?N@Y9!_%&.&X+"#;
M.<$(S_<\LA+R2E!.Y=S<!=RE2M6-G[H0*T6]%;'8[QLCKU[E;1X'$X9?U4UC
MQ.9P306W3>3W!&X@N]^M(0`7@,=L*W[/ZFUQ:(R]V`"E/0V@.M;J"E%]::MC
M=^GT7+5P]=?]NX.K7@$78/84P)NJ:L]?Y#77<'F\^@\``/__`P!02P,$%``&
M``@````A`%!:5\H3`P``?0D``!D```!X;"]W;W)K<VAE971S+W-H965T,SDN
M>&ULE)9=;YLP%(;O)^T_6+XO7PE)&H543:INE39IFO9Q[8`)5@$CVVG:?[]S
M<$*`;(S>D.#S^N4YQS:'U=UKD9,7KK20941]QZ.$E[%,1+F/Z,\?CS<+2K1A
M9<)R6?*(OG%-[]8?/ZR.4CWKC'-#P*'4$<V,J9:NJ^.,%TP[LN(E1%*I"F;@
M5NU=72G.DGI2D;N!Y\W<@HF26H>E&N,ATU3$_$'&AX*7QIHHGC,#_#H3E3Z[
M%?$8NX*IYT-U$\NB`HN=R(5YJTTI*>+ET[Z4BNURR/O5G[+X[%W?7-D7(E92
MR]0X8.=:T.N<;]U;%YS6JT1`!EAVHG@:T7M_N?4]ZJY7=8%^"7[4K?]$9_+X
M28GDBR@Y5!O6"5=@)^4S2I\2'(+)[M7LQWH%OBF2\)0=<O-='C]SL<\,+'<(
M&6%BR^3M@>L8*@HV3A"B4RQS`(`K*01N#:@(>ZU_CR(Q640G,R><>Q,?Y&3'
MM7D4:$E)?-!&%K^MR#]969/@9#(!^E,\<()%Z(>S_[NXEJA.\($9MEXI>22P
M:^"9NF*X!_TE.&-F$ZB/Y6AR_5>JD".:W*-+1.>4P'0-Z_.RGH;!RGV!FL8G
MS>9:XW<5V[,"EP+P&D;(O,WX]ZJ?45",*+@*R+:Q`^#=L/7(MM>*Q472(8$*
MM4G.U1HFPDE0U3;`;-Y-?6,UTY8F["JV0XH.(YBT&8?94!Q1*,"E.+=>]\D;
MJUG4RQK,?<_K";96`-?&Y`+?08/-/AX-Q8B&NRGP_&F/RH9G==CW%M-K+*L8
M@35[#Q:*6UB73.UNL^$A+*L8@07':7RU4-S"FO6J9<-#6%8Q`@N;6NN-,;R_
M4-S"ZF][&Q["LHH16+?OP4)Q"VO1JY8-#V%9Q0@L:$N=<HU[9=2S$/!RI*;A
MI$=Y$IT.)NS_JX/945Q.K3V3MMO99E!PM>=;GN>:Q/*`G0S/73/:=-G[`-^K
MO?$-=E\<=YL`-+^*[?E7IO:BU"3G*5AZSAR.I++MT]X86=4M:"<-M+WZ;P:?
M.1S>VYX#XE1*<[[!!S0?3NL_````__\#`%!+`P04``8`"````"$`2:*STEP$
M```G$0``&0```'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6R4F&^OHC@4QM]O
MLM^!\'Y`D"(:=3+(GYUD-MEL=G9?(U8E%ZBA>+WWV^\I!:3%H<H+D?KCX9RG
MIZ5U_?6CR+5W7-&,E!O=,F:ZALN4'++RM-%__A-]\72-UDEY2')2XHW^B:G^
M=?O[;^L;J=[H&>-:`X62;O1S75]6IDG3,RX2:I`++N&7(ZF*I(;+ZF322X63
M0W-3D9OV;.::19*5.E=85<]HD.,Q2W%`TFN!RYJ+5#A/:HB?GK,+[=2*]!FY
M(JG>KI<O*2DN(+'/\JS^;$1UK4A7WT\EJ9)]#GE_6$Z2=MK-Q4B^R-**4'*L
M#9`S>:#CG)?FT@2E[?J000;,=JW"QXW^S5K%EJ6;VW5CT+\9OM'!=XV>R2VN
MLL./K,3@-O03ZX$](6\,_7Y@37"S.;H[:GK@KTH[X&-RS>N_R>T/G)W.-70W
M@HQ88JO#9X!I"HZ"C&$CII22'`*`3ZW(6&F`(\E'<[YEA_J\T>>N@1:SN06X
MML>TCC(FJ6OIE=:D^(]#34:]B-V*S"'Z]G=D.#9:>*^H.*T*G#L5V[`]9"'W
MA5@@ZB8A.'<)6:_'XK8J<.YB6;YLRZ(5@?-=Q$/(<;V%TER3=U33[T%2)]MU
M16X:#";H"GI)V-"T5J#<=3COGKX$?E4!T/5,Y!M3:;2@<RF4[?O60<[:?(=2
M2UO&?\!8KLCLQHPE$D%'L-ICCPZ[!NW^:%DVX@RDUS.2;-P1;'"`,[T]4(NR
M/7,858_'0^<&NTETPYN):?@<&4;D("0RNS%CBT3P@/!$)!S'(HE$2B*>(@2W
M8,0.W9IVB<',I:XG?=ZPZ!MV<D,@-X2=QKUC'2355/2`L9:B2_$#QKYWF9`C
MS"?/Y\A@F`,'A>>@A?ALGS/PV1>G7`A*(E`2H9*(E$0\10@>P70T](A-*@ZT
M3=<#NVFC0ZWU/CA(JF:?,Q!'S\A>*8E`281*(E(2,2>\9BY$,SCZ7A><@C?"
MT*EIAQ@L.K20TO<Y,F40)]PFL#D+C!U]<,V<&@P96('Q0V1"Y9,B)1%/$8)-
M,%$^;Q.#19L<)`UXGS-3/BF)0$F$G%ARKPU+>B-&2H%XBA`,8@OPP6M\NHX8
M+!GD2B7@<X:7B>MZKHLD8C<D+-MMBD2LD8`C$RZ'0Y&YY3GN4GY.I!2)IPC!
MI>4K+C%8=DE:-OB<F4APQPD^#\P=,$FR2*D0#A66SD)6B)0*\10A^&/!TF98
M1FSB5B]WFKMDIZ15AM]"4U:ID4"-A"W"*]>QT'Q<46J5>!(1/6-+QZ>''FS>
M1E4UFIQ:B,\;MN%*;\%=^_N$EX$:"=5()`4RDY96;"O*LNDFN/D]4&X1WV?R
M_4:!JQ/>X3RG6DJN;`_IP+S8M_+];<3VMVP!*+7[]@J6A^/VG;V"5>*X/;!7
ML%B$=K,7@FWJ)3GA/Y/JE)54R_$10I@9;.M4\8TNOZC)I5F[[TD-&]3FZQG^
MD,"PUY@9`!\)J;L+]H#^+X[M_P```/__`P!02P,$%``&``@````A`#5WC*/!
M!0``#QP``!D```!X;"]W;W)K<VAE971S+W-H965T-#$N>&ULG%G;CJ,X$'U?
M:?\!\3XA7!)(E&0TT.K=D7:DU6HOSS1Q$M0A1$!W>OY^RRXGP84QI/LAE^:X
M.#Y5KF/BU=>/XFB]LZK.R]/:=B=3VV*GK-SFI_W:_N?OYR^1;=5->MJFQ_+$
MUO9/5MM?-[_^LKJ4U6M]8*RQ(,*I7MN'ICDO':?.#JQ(ZTEY9B>XLBNK(FW@
M:[5WZG/%TJT85!P=;SJ=.T6:GVR,L*S&Q"AWNSQC3V7V5K!3@T$J=DP;X%\?
M\G-]C59D8\(5:?7Z=OZ2E<490KSDQ[SY*8+:5I$MO^]/996^'&'>'VZ09M?8
MXDLG?)%G55F7NV8"X1PDVIWSPEDX$&FSVN8P`RZ[5;'=VO[F+A,_LIW-2@CT
M;\XN=>NS51_*RV]5OOTC/S%0&_+$,_!2EJ\<^GW+_P6#G<[H9Y&!/RMKRW;I
MV['YJ[S\SO+]H8%TSV!&?&++[<\G5F>@*(29>#,>*2N/0`!>K2+GI0&*I!_B
M_9)OF\/:]N>363CU78!;+ZQNGG,>TK:RM[HIB_\0Y,I0&,230>!=!O&"2>#-
MPNB1*+Z,`N\RBNM-O&CFSN;#7!R<EY#I*6W2S:HJ+Q;4'C"OSRFO9'<)D:_Z
MX&QNBO4)!DKQ(-]X%!$+M*@AR^^;8.ZOG'?(3"8Q,6)"V[IA7!617!$\H4#O
MQA%THQQ]J`1]#J^4^""54C15[Q=W(9Z*2+J(Z`Y1.()VE&/06V=7CGP05%1+
MDF`>J!1BQ`0MS$Q%)":$PA&"4([#.O)!:QN$N*4MF!,&,6(BD7AWMI@2H1.\
M#J^W&/<("D-0C#(<5I$/H@SGJD8Q8MH,@GFH8I(NIH?EO,MR6$<^B+*,5`8Q
M8N9"Q]FL(R->;D^BAR`LLL=EY(,HP04AB)@V@R"DR>YB>EARCR6M9UA&/HBP
M#$D?B1$3"!G]CHKMJV[KJE*("Y6;N=5P,.5T;Q.B0\:(P24"FE'1\');V![1
M7&A\CZLF1E&*G0;-0Z_M-HD@).THD9':H#ZFQ%K,&KK8_)4^$]XCHX@2I+^Y
M@"1&B))BES=W4G_#S4:,&NK9$F3DB=:BAZ@\>7]O\1S0$=U`U9%V0Q=!V&@\
M#S8S[H(4;"(Q8P@"Y@&"'$U+D;3BV$50^^9!2+IEH@'="T:54.,KPZV&[Q,[
M3&E'E*!PBN:G]LM$7FW/HX_BITS%U;A*9YLC07H2<M6,MA;W4]XB1@VN&I-S
M2)XFB)IRC;N,6-T:>XFHO;@(PM433,4?S?O59`9W/"YQ&KX!'U&:&LMI[4QE
MMS29BM33!%'T]#2^,ZRG&#64=PDRU:<1HO)\R'4\C>M$U!<EJ,TOB*@O:D`]
M*]W3^,YPQL4HTC:C^QTPXQ+49DH@B1&B*DE\AU?FB(RCM<#K;:_??:;Q$&3D
M:8*H/"',>/OQ.)KJV,DX@MK\@HB8:"(CM4%WL56&Q'[,#LX?YCL,J4%*D/[F
MN+:-$)6?QGM&9!H]8R#3)F.1/$T0E2?QG@$=T2O,.R$/0?*1*X12G=-MAH3H
MI5;Y$<\9X*?QFK"3YZZ1=#="7A?45XF?<AM/XS8AW0A)4,]&2%X=(2)OA>WE
M/,X0Q2BZK$DF8PG2D\!B-$*49/O$:,:U1S%JR!`ER,@3C4L/47D2NS$7I<_1
M5$?:'B6H??.N(6I`/47I\U;?>L`9F7$T"&5Y1[0H16CUD?9.0F9\M-'X,&'*
M<[A-BE&#&>>A!WB:(&K&'[(;7V<WG8PC2,TX-409J0VZBZTRU!@.7WD#M8E&
MH61\VEGC)C>1&3=!5)[$<$:N<?04LS'Z"-*+)7F:("K/AXP'SELZ:SPDR8PE
M2/Y$H'W(D1#]%)`?GLO@@4/!JCU+V/%86UGYQL]<7'AFOOT7SX-B.`\2AR?.
M[0(<QYS3/?N15OO\5%M'MH.ATTD()5GA@0Y^:<JS^+W_I6S@($9\/,#!&X/S
MB>D$P+NR;*Y?^`G#[2AO\S\```#__P,`4$L#!!0`!@`(````(0"NI"_*K`0`
M`(43```9````>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;)1878^K-A!]K]3_
M@'A?P`8"1$FN=KO:]DJM5%6]M\^$.`E:P!&0S>Z_[]ACODS8A3PD@1S/F3/V
M'!-OOKWGF?'&RBKEQ=8DEF,:K$CX(2U.6_/'OR\/H6E4=5P<XHP7;&M^L,K\
MMOOUE\V-EZ_5F;':@`A%M37/=7U9VW:5G%D>5Q:_L`)^.?(RCVNX+$]V=2E9
M?)"#\LRFCK.R\S@M3(RP+N?$X,=CFK!GGEQS5M08I&197$/^U3F]5$VT/)D3
M+H_+U^OE(>'Y!4+LTRRM/V10T\B3]?=3P<MXGX'N=^+%21-;7HS"YVE2\HH?
M:PO"V9CH6'-D1S9$VFT.*2@093=*=MR:CV3]Y+JFO=O(`OU,V:WJ?3>J,[_]
M7J:'/]."0;5AGL0,[#E_%=#O!W$+!MNCT2]R!OXNC0,[QM>L_H??_F#IZ5S#
M=/N@2`A;'SZ>695`12&,17T1*>$9)`#O1IZ*I0$5B=_EYRT]U.>MZ:XL/W!<
M`G!CSZKZ)14A32.Y5C7/_T,04:$P"%5!X%,%(;[E43\(9T2Q,2,I\#FNX]VF
MY#<#5@UP5I=8K$&RALB-,LRCU3HE%32*((\BRM8,3`-45#`_;SLO<C;V&]0T
M49@GQ,![BR$MPH9LVI0@C7Y*]XO<,`NP8!9%%ZD\X8T^#;U/XRZA$>"M";';
MY+W`;^,B,V*\'J9##`0"9+Y``8;UTHOJ.GII$3.#&5;;?&8!'FIVG5#3C)B5
MG/*(>&Y()S2OEC`+L,X<:<R(06:/D,#O5650;5B5\S4+L,9,]&HC!ID??$II
M-+'"A/WW>NOSA2S`.G,7%U<88A1SZ-`P=-NJ##1'2Y@%6&?N9A&9$8/,A$3N
MBOA=60;4!-RUKUHXB@OW/E<O1^E)K%IQF(0"J3E?>4$83.@GPFQZI9^9!%I4
MO\M=$NA)(`B36'DKXD5>"QE60EA1+XDO*H#&-6ST$3F"9G0Z$6XTGQR]:Z!\
MU.LRY-:,9+,3*^R2&\H6;C2?&;UKR*SW.D%0PSS5;V)+7L!\Q]]&O2Y#-IJI
M1;O,AIH7V1NYXV]$[W4%:C0'4XMLD;V1>_ZF][H"-<QAY_E#S9J]S>RQL<]Y
M4?<@H!H=09@!M7JU&6:PR.;(V.>\WAI6S`B:T6!4\[G/NUNBO]K&%6@.N>9O
M7Y#?\;51=].^KU'P^*G]E`H/FMW?$JT9N]-U$59=@?K"W0XSF'.ZR-<D6F,?
M];@"S6('T`+M`JVSZWU.$:0V=>K"@\S][43\55C`?<_=]$Z7(;>FVM;#<')3
MIYJ_S>MU.4K7KV_J"C0CAT5.1]'I/M].%:@_\UV)ALM.,[LO&FYL<N-'9]HW
M.<^*/*?_FK![NLCR)%J;@''SC2UOJOG$<]S\)2C1&ONH^12H/P63[(M,S[UC
M>KV-!(U'@7"C\2QG8O;=198GT;KN+K)B%B&;!PO?<B;F&TXU!A6?UWARU#"#
M\2:K0*C]3@9X&H*'!3DK3^PWEF65D?"K..D@\!38WFU/81ZI/$=I?X!#D$M\
M8G_%Y2DM*B-C1QCJ6`&84XG'*'A1\XL\BMCS&HX_Y-<S''<Q^$/O6``^<EXW
M%^*@ICU`V_T/``#__P,`4$L#!!0`!@`(````(0!K;KPB5P,``!X+```9````
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;)Q676^B0!1]WV3_`^&]PB"@&+6I
MVW2WR6ZRV>S'\PBC3@H,F1EK^^_WSEQ$P%JU+R)P[CGWBSMW>OM2Y,XSDXJ+
M<N:2@>\ZK$Q%QLOUS/WS^^%F[#I*TS*CN2C9S'UERKV=?_XTW0GYI#:,:0<8
M2C5S-UI7$\]3Z8855`U$Q4IXLQ*RH!INY=I3E60TLT9%[@6^'WL%Y:6+#!-Y
M"8=8K7C*[D6Z+5BID42RG&KP7VUXI?9L17H)74'ET[:Z2451`<62YUR_6E+7
M*=+)X[H4DBYSB/N%A#3=<]N;(_J"IU(HL=(#H//0T>.8$R_Q@&D^S3A$8-+N
M2+::N7=DLB"QZ\VG-D%_.=NIUG]';<3NJ^39=UXRR#;4R51@*<23@3YFYA$8
M>T?6#[8"/Z63L17=YOJ7V'UC?+W14.X((C*!3;+7>Z92R"C0#(+(,*4B!P?@
MURFX:0W("'VQUQW/]&;F#N-!-/*'!.#.DBG]P`VEZZ1;I47Q#T&DID*2H":!
M:TU"@D$PCD@4GV?QT",;X#W5=#Z58N=`UX"FJJCI03(!9A-9>#(R",G8W!DC
M:PIH!>5XGH?A:.H]0PK3&K-`S,AU&DS0(#P0;SP`U;X'0ZC0V[G=>V",NAX$
M?0<0,K*%;>L-/Z)GC*!JK6C"<-S$8[.R0$S8PD0-HA,Q0-H1OQ^I`<]<".:0
MQU'<\*(R8L:V$B2.QH?W'5VHZ^6Z!MS7[:<8,:'5O2%CTKC5D8VOD37@KFP8
M)@TOAHN8N`XW]$^D&7JO':YI[?.-98QZ^I'?TT?,!84V\[_W<9WWP!B=:S7$
M7.!!TO7@_58SX&[LP5&K(:;./8F2L,E-I^8$ON!VZ.\+6W1?N=]L-:CNMN3P
MNBO<&VAGA'%*M;^NXW8C"-K'')Z4-A.G5>XSTCB?.M+1X0O"3B<(NJ#0Y$-C
MS5J=:[8:=(D3@+DB`P;=K_IA=-490!`F/TR2$X>(.8VO4+YDN%E*.`UQNHU/
M-?I5TPV6E'[(;_0;@G"<AXE_.&>PTW%-P5.\8'+-OK`\5TXJMF8%(>!O\Q37
MHP6L1X$]!YL7L)U4=,U^4+GFI7)RM@)3?S""Q$C<;_!&B\H>LTNA82^Q?S>P
MAS+8`OP!@%="Z/V-V:":S7;^'P``__\#`%!+`P04``8`"````"$`C21H<=H"
M``"[!P``&0```'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6R455MOVR`8?9^T
M_X!XKZ]Q;DI2-:ZZ5=JD:=KEF6!LH]K&`M*T_WX?D+BVTZ;=2V+,X7"^<^#S
MZOJIKM`CDXJ+9HU#+\"(-51DO"G6^/>ONZLY1DJ3)B.5:-@:/S.%KS>?/ZT.
M0CZHDC&-@*%1:UQJW2Y]7]&2U41YHF4-S.1"UD3#4!:^:B4CF5U45WX4!%._
M)KS!CF$I/\(A\IQ3=BOHOF:-=B22542#?E7R5IW8:OH1NIK(AWU[147=`L6.
M5UP_6U*,:KJ\+QHAR:Z"NI_"":$G;CLXHZ\YE4*)7'M`YSNAYS4O_(4/3)M5
MQJ$"8SN2+%_CFW"9SK"_65E__G!V4+UGI$IQ^")Y]HTW#,R&F$P`.R$>#/0^
M,Z]@L7^V^LX&\$.BC.5D7^F?XO"5\:+4D'8"!9FZEMGS+5,4#`4:+TH,$Q45
M"(!?5'-S,L`0\F3_#SS3Y1K'4R^9!7$(<+1C2M]Q0XD1W2LMZK\.%!ZI'$ET
M)(E!_7$^\J)Y$B;3]UE\I\@6>$LTV:RD."`X-+"G:HDY@N$2F$^5.1U=K6^5
M"C4:DAO#8KF@"@7Q/&XFD^G*?P1/Z1&S=9@91ATF'"+2$\)$`?(ZC5#Y6&,,
M&;[N_DF26324%,V&^VU?@0P1Z3EB'G60@4;P[O\UFD5P%GJ61-.Q2(>9]#!)
MI\":GUY"##0"25_C9?\,>(W!@"ZN:!8,=]XZS-P&'L?A9!SHV_,#77`'^KK,
M&7P_7[-HK&^T_]9AIE9?E$2+^5!_ZN9!95=CO.@@`XG3H<3+UAGP6-K+L;&A
M;1UFXJR+1L:FI]GWA<%]ZGMW69@!CX7%7<%.F,.X3)/Y+'DQQ)VV_OPP<V>8
M:Z*NQ]1,%BQE5:40%7O3($,HN'OK>O<6>K?M='XW`;VS)07[3F3!&X4JEL/2
MP)M!7M)U7S?0HK57?"<T=$W[6,)'DD%+"CP`YT+HT\`TE>ZSN_D'``#__P,`
M4$L#!!0`!@`(````(0`0V<!VZ@,``!P/```9````>&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;)176X^;.!A]K[3_`?'>@+GEHB15PVAV*[525>VVSPXX"1K`
M"'LF,_]^/_.1@,V4PLL0QL>'\]WM[:?7(K=>6"TR7NYLLG!MBY4)3[/RO+/_
M^_?QX\JVA*1E2G->LIW]QH3]:?_7A^V5UT_BPIBT@*$4._LB9;5Q')%<6$'%
M@E>LA)43KPLJX;4^.Z*J&4V;347N>*X;.07-2AL9-O44#GXZ90E[X,ESP4J)
M)#7+J03]XI)5XL96)%/H"EH_/5<?$UY40'',\DR^-:2V522;+^>2U_28@]VO
M)*#)C;MY&=`765)SP4]R`70."AW:O';6#C#MMVD&%BBW6S4[[>S/9!.3M>WL
MMXV#?F;L*GJ_+7'AU[_K+/V:E0R\#7%2$3AR_J2@7U+U+]CL#'8_-A'X7ELI
M.]'G7/[@UW]8=KY("'<(%BG#-NG;`Q,)>!1H%EZHF!*>@P#X:Q692@WP"'UM
MGM<LE9>=[4>+<.GZ!.#6D0GYF"E*VTJ>A>3%+P21E@I)O)8$GBT)"1>!%RY7
M<UC\E@6>-Y9H,HN#=C5N>J"2[K<UOUJ0>Z!<5%1E,MD`\_M^`8<H[&<%;K:`
MR0*"^;(/`K)U7B``28LY##$&(AXB@L"[LS@@[*X./-97IZ+G0PZ,JU2;=)7>
M\D[?&')X!Z(CXG<0JSM$TPA>FZ]1;0);;*OG2?_.CR(1$_0PH8Z(QQ":1B#I
M:QSWGP+O;'#`79L7KO4O'Q"S:G+`\Z$:]/6XO^Y[(>F4:[J@AJ;K4F!#5^3J
MWST@)FAT16[WU<:C<7\U\+N]FJ9HCB8%-C49^7Y`#'CD[D_?<&<\"M'4+>>H
M4V!3G1&I`V*B-I)K8I1*W%_WO770^533I0;FY#ZBP+JN(`B,2"*F[[7NRQC-
M,82F;:UKF]9%U*8_52ABQC2.(32-!-K:=`<V:-V#PQIM01A:0I:F_WZ_KBN;
M-R*PNVO=8U"E!$&W,C4*)M:6`[<K%EV7:M&34XY@0]=U&1\^M*!^0`>E.H[1
M%:K^/%TA=G-=H5FM!$%M3)?+2*^:6%\/5UU5Z<K`Q!G*%%K/MJ#7!W!:$03U
M?3=(N#&(KL\8#--*5AWL_EBS+6A4YVU.=!V[,T77.6M8D'>FQ6"RMJ"V(7O$
M-QNR!O")'_QFCI%9HZ)!ZS'VAG6+PP#KMDLM;,<M`RYZ76GI#ILU)\AP4'A1
MQ]PFWG`.#(MV%*,K-*;%^%D)[BYF:7C1H&@1U)Z6/&*>F=4-2+$@`$+:LQ&U
MX?T&#^X5/;-OM#YGI;!R=H)#A;M80L;6>+O!%\FKY@A\Y!)N)<W/"]Q"&9SB
MW06`3YS+VXNZ/]WOM?O_`0``__\#`%!+`P04``8`"````"$`5KY-:$P#```%
M"@``&0```'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6R45EV/VC`0?*_4_Q#E
M'1*')!`$G.YZNK92*U55/YY-XH!U21S9YKC[]UU[0TC"0>$%")F=V=FUUU[<
MO9:%\\*DXJ):NF3LNPZK4I'Q:K-T?_]Z&LU<1VE:9;00%5NZ;TRY=ZN/'Q9[
M(9_5EC'M`$.EENY6ZWKN>2K=LI*JL:A9!6]R(4NJX5%N/%5+1C,;5!9>X/NQ
M5U)>N<@PE]=PB#SG*7L4Z:YDE482R0JJ(7^UY;4ZL)7I-70EE<^[>I2*L@:*
M-2^X?K.DKE.F\Z^;2DBZ+L#W*PEI>N"V#R?T)4^E4"+78Z#S,-%3SXF7>,"T
M6F0<')BR.Y+E2_>>S!](Z'JKA2W0'\[VJO/;45NQ_RQY]HU7#*H-?3(=6`OQ
M;*!?,_,7!'LGT4^V`S^DD[&<[@K]4^R_,+[9:FAW!(Z,L7GV]LA4"A4%FG$0
M&:94%)``?#HE-TL#*D)?[?>>9WJ[="?Q.)KZ$P)P9\V4?N*&TG72G=*B_(L@
MTE`A2="0P'=#0L@X#*+I[`H6#S.R!A^IIJN%%'L'5@UHJIJ:-4CFP&R<A6>=
M@243<V^";"B@%;3C914&R<)[@1*F#>8!,5/7.6+(M,5X(-_F`+K#'";0H_>K
M>\C!!/5S"([T-LT'A$QM:[MZD[[>91T#AGYU?)#94`@Q80<3O>\4(%VGEY4-
M>.F"B;:"$[^E18<(F=D63/PH;E_WZ@O]O%[5@/NJ)!GV%C&AE8W]R?NJ\2VJ
M!CQ0);.6%\TB)K:JQ$^"]G7/+*RXZ\T:<%\6)FO+B[*(0;,D/M-8,^D[V^AR
M8PUXJ$H&JHAIS,:3V3&KGMOD%ET#[NN&QR*B682@;!`%R;$'/5D"V[/KUXR-
M_V]9&]5/(/"'&30@3&$43&=A6YE^"H/)=;GD!,=1=S,%_K&7:+X!8:M'R3EA
M,U:N[C7!(=07'LZ/!M0(D^3,CB(W#2Z+[E>[,R`:QSBYFF*3*#KN]'ZQ;QI<
M<!0/%QI)3HK=G5TA2>)AN?$TQL.J9'+#/K&B4$XJ=N:D)3`&VG_Q%O``MX#`
M#OOV!1S"-=VP[U1N>*6<@N40ZH^G,,`D'N/XH$5MSY*UT'#\VI];N&XQ..S\
M,8!S(?3AP5P4V@O<ZA\```#__P,`4$L#!!0`!@`(````(0!QR]Z'"`,``*8(
M```9````>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;)2676_:,!2&[R?M/UB^
M)U^0$!!0%4*W2ITT3?NX-HE#K"9Q9)O2_OL=QR1+S-9V-RWQ>?URGG.<8U8W
MSU6)GJB0C-=K[#L>1K1.><;JXQK_^'XWB3&2BM09*7E-U_B%2GRS^?AA=>;B
M41:4*@0.M5SC0JEFZ;HR+6A%I,,;6D,DYZ(B"A[%T96-H"1K-U6E&WA>Y%:$
MU=@X+,5[/'B>LY0F/#U5M%;&1-"2*,A?%JR1G5N5OL>N(N+QU$Q27C5@<6`E
M4R^M*495NKP_UER00PG<S_Z,I)UW^W!E7[%4<,ESY8"=:Q*]9EZX"Q><-JN,
M`8$N.Q(T7^-;?[F/L+M9M?7YR>A9#CXC6?#S)\&R!U93*#:T23?@P/FCEMYG
M>@DVNU>[[]H&?!4HHSDYE>H;/W^F[%@HZ'8(0)IKF;TD5*904+!Q@E`[I;R$
M!.`OJI@^&5`0\MS^/[-,%6L\C9QP[DU]D*,#E>J.:4N,TI-4O/IE1/[%RI@$
M%Q/8<3'Q`R>(0S^,WG9Q348M8$(4V:P$/R,X-/"=LB'Z"/I+<.[(3!X]Z[]0
M@5&;W&J7U@LH)+3G:3.;>BOW"6J:7C1;HYECU&MB?RS9=1)=0>V;=`M_]EA;
M]IU"MP^0>BZHELTUA;[_O6,=AMYD8UA?N+W6!!;%M2*V),FUQ%+LKQ4#DQ'I
M=$SZ.J$6P^D;-,&/Y^/\MT8S&VC"L6+WIB)Y4[%_33'B@T2&G7R=3XO7&(K7
M'[(@L#MH-+$YIG&TL."&X2B86XU)AF%_YB^LVNQ'\44X>`U&5/"NO9]*B\=4
MOF>_7D9CJ"8P$^RV[D:">+:P#))1?.:%D4TV$@2A-YWVE1NA1?^#IL4VFMTP
MHUFT#9MXCF=WS(Y'?5YFBECQ8#:.P\VA<^C]_;B/&RYS+YBQ65%QI#M:EA*E
M_*1G?@!Y]:OF.MKZ2YAE,)*L]02NJ7;=[0-P333D2+\0<62U1"7-P=)SYE!L
M82X:\Z!XTTZF`U=P0;0?"_@]0&%*>@Z(<\Y5]Z!G8?\+8_,;``#__P,`4$L#
M!!0`!@`(````(0!GH?\`#P0``",1```9````>&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;)28;6_:,!#'WT_:=XCR?@0G`0H"II&JVZ1-FJ8]O#:)@:A)',6F
MM-]^9SM-_<`,O&E)\O/E?W>^.\SRXW-=!4^D8R5M5B$:C<.`-#DMRF:_"G__
M>OAP%P:,XZ;`%6W(*GPA+/RX?O]N>:+=(SL0P@.PT+!5>."\7401RP^DQFQ$
M6]+`DQWM:LSALMM'K.T(+N2BNHKB\7@:U;AL0F5AT5UC@^YV94[N:7ZL2<.5
MD8Y4F(-^=BA;]FJMSJ\Q5^/N\=A^R&G=@HEM697\11H-@SI??-TWM,/;"OQ^
M1BG.7VW+"\=\7>8=973'1V`N4D)=G^?1/`)+ZV51@@<B[$%'=JOP$UID<1Q&
MZZ4,T)^2G)CV.6`'>OK<E<6WLB$0;<B3R,"6TD>!?BW$+5@<.:L?9`9^=$%!
M=OA8\9_T](64^P.'=$_`(^'8HGBY)RR'B(*943P1EG):@0#X&]2EV!H0$?PL
M_Y_*@A]683(=36;C!`$>;`GC#Z4P&0;YD7%:_U40ZDTI(W%O)`'U_?-X%-]-
MT&1ZV4JD%$D'[S''ZV5'3P'L&G@G:['8@V@!EH5G"<3GO&?@DECS22R22X%F
MD(ZG=9K$R^@)0ICWS$8QLS`8&(O(SA!W@Y$(]`TBP?7;18I%ILAX-IB7?FP4
M,I-A%HYEV@U#`$1&%^"/CH`ABKKGR=1ZLV)2C9F81.8C#&U@1-=V70;%HE4(
M[@[929/$5+!1S)W,;YS,D16]3'^>Q//TS0-#'^QP79\_=@*V=:66+L7`VP?M
M;V^6><U\A*%M>HLV`5_*JV)\VGR$H0U*1X_;=7D5B^SXV7E5C*XQF9LASKR(
MH5*,.*U_^+,K8%-=G%I=8:,8KSHO8JB;WZ).P&9^T\3:61O%Z.HL(O,1AC8$
M;?;ZT$G:CIU=&3VDRW-2ZV=,A=9P\"<7J7YN]A2[[_60KM`.H!<Q]8EV??7F
M0ZJY^_MR#WGU*3OG$5.?Z.&:ONM*&*G.;\;1KN$>FOZW.1N`ISLC\$/7>"''
M@K9WH5W!TN0J]&A35A3@TW;3Z!!?R"[6;P^=3YX:'E[$S.]-XP.ISJ_G-4Z=
M"G;'@UO!7L94:`V1"]D]-SVLJ;]![FQP*MB'F/IN&A](-?X+%>Q.!T>?#S'U
M60/DR@I6,T#/M/OM"KF#PLVTES&4QC=-$TE?JN,>TFO%4>AG3(4W39-831,]
MU^XT[B%=H9UK+V+J$WU=Z];^6H'CIML)[6KN(5V?&T%EJ/^:/7TK-R5.G4G5
MD:TFW9YDI*I8D-.C.&_&T/^'N^HLO$&+C3P*6_<S<4:6I]SA`1Q16[PGWW&W
M+QL65&0')L>C&3323AURU06GK3Q(;2F'PZG\>(`?(PB<F,8C@'>4\M<+<8P>
M?MY8_P,``/__`P!02P,$%``&``@````A`*067&M]`@``CP8``!D```!X;"]W
M;W)K<VAE971S+W-H965T,S4N>&ULE%5;;]HP%'Z?M/]@^;UQ$A*@B%"UJM@J
M;=(T[?)L'(=8C>/(-K=_OV,;4BYM1U](`M_Y+N><F.G=5C9HS;41JBUP$L48
M\9:I4K3+`O_^-;\98V0L;4O:J)87>,<-OIM]_C3=*/UL:LXM`H;6%+BVMIL0
M8EC-)361ZG@+OU1*2VKA42^)Z32GI2^2#4GC>$@D%2T.#!-]#8>J*L'XHV(K
MR5L;2#1OJ`7_IA:=.;!)=@V=I/IYU=TP)3N@6(A&V)TGQ4BRR=.R59HN&LB]
M33+*#MS^X8)>"J:5496-@(X$HY>9;\DM`:;9M!20P+4=:5X5^#Z9/(PPF4U]
M?_X(OC%']\C4:O-%B_*;:#DT&\;D!K!0ZME!GTKW%123B^JY'\`/C4I>T55C
M?ZK-5RZ6M85IYQ#(Y9J4NT=N&#04:*(T=TQ,-6``/I$4;C.@(73KKQM1VKK`
M@V&4C^)!`G"TX,;.A:/$B*V,5?)O`"5[JD"2[DG@NB=)\BA+\]'X"A82'/F`
MC]32V52K#8*E`4W34;>"R0287;(A].?U9!#)U=R[(E\*:`/36,^RP7A*UM!"
MML<\7&*2'D%`O'<`JN<.!O]UX(I.':2CGMZ;?'@%TB-.#`Q.#;P?W8$+#-Q'
MT6][WJ`<,-D1)N\1)\H`.8^>O;E6A^:[(EB@(_8LBWO^X"!@KG``:L<.WL_N
MP*?9T_QEJ$$Y8,9^*=+ARTQ.<@\_HNK`YZKI6=Z`R;SJS9NRHX_(.O"Y;'8F
M&S#';1Z\[$)(',Z4\,IU=,F_4[T4K4$-KV"#XF@$#=/A1`D/5G5^L1?*PDG@
M;VLX^#F\=W$$X$HI>WAP9U;_5S+[!P``__\#`%!+`P04``8`"````"$`0'+?
MS#P&``!*'@``&0```'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6R4F5UOHS@4
MAN]7VO^`N"_A,X2HZ6C`[NY(L])JM1_7E)`$-80(Z'3FW^\Q-M3'9&S2BR:!
MQV_\GG,,)_CQT_?Z;'TKVZYJ+CO;<US;*B]%LZ\NQYW]S]_/#QO;ZOK\LL_/
MS:7<V3_*SO[T].LOC^]-^]J=RK*W0.'2[>Q3WU^WJU57G,HZ[YSF6E[@S*%I
MZ[R'C^UQU5W;,M\/@^KSRG?=]:K.JXO-%;;M$HWF<*B*DC3%6UU>>B[2EN>\
MA_EWI^K:C6IUL42NSMO7M^M#T=17D'BISE7_8Q"UK;K8?CE>FC9_.8/O[UZ8
M%Z/V\&$F7U=%VW3-H7=`;L4G.O><K)(5*#T][BMPP,)NM>5A9W_VMM3?V*NG
MQR%`_U;E>R>]M[I3\_Y;6^V_5I<2H@UY8AEX:9I7AG[9LT,P>#4;_3QDX,_6
MVI>'_.W<_]6\_UY6QU,/Z8[`$3.VW?\@95=`1$'&\2.F5#1GF`#\M^J*E09$
M)/\^O+Y7^_ZTLX.U$\5NX`%NO91=_UPQ2=LJWKJ^J?_CD">DN(@O1.!5B'AK
MQ]]$7K2^0R40*O`J5/S`"?THWMPSEU"HP.NH$MZO`MZ'L,#KJ.(O5EGQ&`\I
M(WF?/SVVS;L%ZP"BV%USMJJ\+2BS7(7PRB,[9>]GR8.L,9'/3&5GQ[8%PSNH
MN&]/8>(_KKY!E12"2>?,QL-(-B*L)I@N&0]\Z"I#Z$BP@@1+DR_(N^SK=NV-
MTV<PF_[XO2D_`-J3'\5--B<V"D+FB$+0.2&)(#M0@+*=,4UZ6VP0+![)1;@.
M<<A3SD!E3DXC3&1&@A@)JB.03YB(ZC.`"Y#>)QNTLR&8DX?`=[&+E#/)4)N>
M$RIEE.'3;N+*?PI,%%C-JGS:=>*/T<@I+#+9J=XA@['#,`D4AYR)76'1\^F#
M,K.,(S"_*5!*L@D2B9Q0#H/K!O1!^5:J#DC07RP/0/;7]]AG,+8?^!]A'2X5
M*6<TWC).B`"!-S33!$V57WV,DE1'(+MP:5R>;09CNV&BKEO.3-D.(NQFGGL^
M0!,?<J\D509$H?RMR#YK[:2[C+[8&8SM!_Y:*7;."/O*6L]T)XGN)/W)2>0E
MN<<+@[&7,%'67,J9T8L3K6.%R!0B7J_1NE26`E'P*-IX,J^4$E7P.`KCVS@*
M@P>7Y>4Y'6@U$&I2!31%`CHU%Y4U+H),Y>.U=+$5#02;)=S:^541KL9![,F2
M,9:DJN3&#6.9_Y@R#@9K0Q87N,>;%G3#"I1K=2H@><&&B3+=[":TP9[(#4@I
M,*I%L%/6LRQWRCL<[%3Y\M3CT)0C/_`BN0"5\L[NY(G@Y4@J4Z!:!/MGK8SD
MGW5BY@[%XPV0'(?05?*4"D@SS\R,$#-"M0AV"Y-1W;*?!_H+N,=&F1I/`6G=
M<AT-0LPJ5(M@MZR9N3^WO`62<SMO/]GO7P@)[S_A,J3D/A/GM5:YA`:A6A5L
ME74NDE5#0GF?@RTJRS+U."26<>C(2QC>0SNJW'@R,4+CB)@1JD6P:=:P+#?-
MVQML^N/ZS[M.#_5`:B,BSFH-<@$-0K4JV"#K7Y8;Y-T.-JC<85(/MT1.Y&Y0
M8I4JR`2O\4/,"-4BV#+K7I9;YKT.LCR_\W)(MA!N9K4[AY2;"O&,"-4BR*=_
M5[LUT+C="@)E?JF`IONNJP"9`.1`*`@Q(U2+8(]W=5'^O(L*O03W/JF`-!8R
M,T+,"-4BV"54GURQRY[E^&R4Z9XJ(*U;KJ-!B%F%:A'L5NF7]#<:?]XG!;/U
M*2"-A<R,D!L(/!'`Y4-O0-":3A!V"A.2\VIPRFCC"N60UJD1(3Y'QG4^S7ZX
M@]&?G<7>E,[(X&W>$86S!W+L*3P$0.O-B!"S"M4BV*72%"U<F;SO@<J=GJK-
M'[/Z'-*Z-2+$K$*U"'9[5S?DW^B&YBO3V,QD0D<3"'(+<94^@]Z$/GY#8Z=W
MM46P-;9@97)(8R,3.AJ$"&1<F8[AER_;M6-36\!S_WR+CN_WU&5[++/R?.ZL
MHGECVV\!/"F>CDY;@Y]]M@VB'$^]+6S.S(\3V$H<CJ^F`;"3=\V/Y1]Y>ZPN
MG74N#_!5\(L'UG++]P+YA[ZY#KM/+TT/>WC#VQ/LV9:P[>,Z`!^:IA\_L,T=
MM@<Y;%\]_0\``/__`P!02P,$%``&``@````A`&.E'T`@`P``20H``!D```!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&ULG%9=;YLP%'V?M/]@^;V`0TB:**1J
M5W6KM$K3M(]G!TRP"AC93M/^^UW;A!#2I&1Y(`&.S[GWW!M?+VY>RP*],*FX
MJ&),O``C5B4BY=4ZQK]_/5Q=8Z0TK5):B(K%^(TI?+/\_&FQ%?)9Y8QI!`R5
MBG&N=3WW?97DK*3*$S6KX$TF9$DUW,JUKVK):&H7E84_"H*)7U)>8<<PET,X
M1);QA-V+9%.R2CL2R0JJ(7Z5\UKMV,ID"%U)Y?.FODI$60/%BA=<OUE2C,ID
M_KBNA*2K`O)^)6.:[+CMS1%]R1,IE,BT!W2^"_0XYYD_\X%IN4@Y9&!L1Y)E
M,;XE\SLRQOYR80WZP]E6=7XCE8OM5\G3[[QBX#;4R51@)<2S@3ZFYA$L]H]6
M/]@*_)`H91G=%/JGV'YC?)UK*'<$&9G$YNG;/5,).`HTWB@R3(DH(`"XHI*;
MU@!'Z*O]WO)4YS$.)UXT#4("<+1B2C]P0XE1LE%:E'\=B#14CF34D,!W0T(B
M;SR*IM<#6'P7D4WPGFJZ7$BQ1=`UH*EJ:GJ0S('99!:"/RZ.-M=3J4*.AN36
ML,1XBA$L5U"?EV44A`O_!3Q-&LR=P\"UQ9`6X4,T;4@01C>D]TW>*1NP43:F
MFU#NW(.NS.A]F?`2&0,&9SK!1\&XY77*#C/N8EK$08(`Z2:X\_Q\HF91C"&[
MUKYP?-WRNP@<9F(+$,)G'^&!/O1<5_^\K@'W=6<]78?I9A[N(0?2DTND#;@G
M'04]:8<9(@W=.3QK`^Y+[]O5N>TP0Z3-''CG3W;>>+.H'\*^E5T(#O-AP6?_
MHV\6]5L^ZKGO,%T+]HB#NA/84RZWP*[J>7#4]`UH9KN>>*<ZCYC]IU.$\^9;
M=%]YW]/._0;43?^D^D6;&G&;V,&?_:CS&]`@]8OV.N(VLD/U?O,WH$'J`.HZ
M/VR_@WG^<?\WH).U=Q/=#;R2R37[PHI"H41LS+0FT#+MT_8D<3NR9X'V!0SR
MFJ[9$Y5K7BE4L`R6!MX4-CWIC@+N1HO:CM.5T##"[<\<CFP,AE+@`3@30N]N
MS&&C/00N_P$``/__`P!02P,$%``&``@````A`*F]9C%[`P``+@P``!D```!X
M;"]W;W)K<VAE971S+W-H965T-#4N>&ULE)9=;YLP%(;O)^T_(.X;O@(A49*J
M"72KM$G3M(]K!TQB%3"RG:;]]SO&(<'00G;3!LYS7OOU.7'.\OZUR(T7S#BA
MY<IT)K9IX#*A*2GW*_/WK\>[T#2X0&6*<EKBE?F&N7F__OQI>:+LF1\P%@8H
ME'QE'H2H%I;%DP,N$)_0"I<0R2@KD(!'MK=XQ3!*ZZ0BMUS;#JP"D=)4"@MV
MBP;-,I+@B";'`I="B3"<(P'[YP=2\4:M2&Z1*Q![/E9W"2TJD-B1G(BW6M0T
MBF3QM"\I0[L<?+\Z4Y0TVO5#3[X@":.<9F("<I;::-_SW)I;H+1>I@0<R&,W
M&,Y6YH.SB!W;M-;+^H#^$'SBK<\&/]#3%T;2;Z3$<-I0)UF!':7/$GU*Y2M(
MMGK9CW4%?C`CQ1DZYN(G/7W%9'\04&X?'$ECB_0MPCR!$P69B>M+I83FL`'X
M:Q1$M@:<"'JM_Y](*@XKTPLF_LSV',"-'>;BD4A)TTB.7-#BKX*<LY02<<\B
MD'$6<=R)&_J.'XRK6&I'M<$(";1>,GHRH&M@35XAV8/.`I0;9VH?%Z\?606/
M4N1!JM1:X()#?5[6OATLK1<XT^3,;!0S,XT+$SHZLFT0>8)2-VI>7',Z*7%#
MR/*!I8LO.*VN+P_J_G[%&ALR2;?ASO0M;MY!=&+;)T)71Z(^TB'B/M$2T8QZ
M?:/3#UNS,2J3H`E;M?#MKE/%3-N,;F,[2D2C1#Q$:#YA(^V"#A=2PBL3#O'2
M:[X=ZKO?*":LNS4(/#VZ;4>G\TXT:D>=63C5DV,M'`37E35'4*7;'4FXZVBN
M+[M1#"Q^=:T3VU$B&B7B(4+S%^C^Y-4RWIDR::PS%3/D<Y2(1HEXB-!\PI5V
M>QTEW*WCM3_J6V^CF&G=F9[3N4>W[:CK='H@:D=#MQ.-V]'`NZZK^9%32^LG
M8?B;)N&.'\?6NVZCF*%ZC1+1*!$/$9J_N>[OMKZ426-]J9@AGZ-$-$K$0X3F
M$R:B_RAD37<JV;LSSY"Z-+UIYR=CJX7=6>=:C+3PW/?U-I$3G#QC)>[8WK6-
ME"TUGJGII<!LC[<XS[F1T*,<O5SXNES>JK%PXRQ@I(#)H/,^DN-B/?!=`C"M
M56B/OR.V)R4W<IR!I#V9P67'U+RG'@2MZ@%A1P7,:?7'`\SE&(85>P)P1JEH
M'N1(<IGTU_\```#__P,`4$L#!!0`!@`(````(0`BY'#N/PP``*-O```-````
M>&PO<W1Y;&5S+GAM;.Q=;8_BR!'^'BG_P?(F44[*+&#,`'/#G!9VG*RTV9SN
M)DJD7!09,#.^]0LQ9G?FHOSW5+7?JC'&;;NAYT,.W0X8NNJI>JJKJ]MM^_:[
M9]_3OCC1S@V#F3YXV]<U)UB%:S=XG.E_?;"N)KJVB^U@;7MAX,ST%V>G?W?W
MZU_=[N(7S_GQR7%B#40$NYG^%,?;FUYOMWIR?'OW-MPZ`7RS"2/?CN%C]-C;
M;2/'7N^PD>_UC'[_NN?;;J`G$F[\E8@0WXX^[[=7J]#?VK&[=#TW?F&R=,U?
MW7QX#,+(7GH`]7E@VJM,-OM0$N^[JRC<A9OX+8CKA9N-NW+***>]:0\DW=T&
M>]_RXYVV"O=!/-.-_)"6?/-A/=.O=2TQ>1&N`<3O_KT/XV]_D_QY\X<W;_K_
M^N;;?_S@K/_YT^_+W_WTC=[+U!"9P,%IF6_[)\7"UXGD7FK!W>TF#(@A(W`3
M>NOF<Q!^#2S\#H(!S,.?W=WN?M&^V!X<&2"\5>B%D18#RV`?.Q+8OI/\8F%[
M[C)R\6<;VW>]E^2P@0=88*2_\UV@"0_V$@V7U;-$-)E-$X3!V33$(]0F'TRR
M\>!IF^R?C]C$Z1K5Z^KB/TX7L^*T7=)TE>.BY,,NNG*NB)[H<3G3+0MRR*#?
M1[=2PLZD;+KH@[Z+*;L>7<RRH36TQE(MXV*QS!LJ'%HR75FCT'HW?G\Q=\I7
M5F5=FH8OU0.PP\GUH@M=]T3_'EOXND2<7'A`D\H8%QU,,I?X6?<K\N.#ZSL[
M[9/S5?LA].T`G4L'-O;KX^.R?-&(G`L!^2K.+#X/W@-&&WL97;&GO4&^*WBL
M28SD`VFY9S<P@<7+#@+)];R\0!Z.L(2$(W>W4*O'3A18\$%+WS^\;*&`#&!:
M@1'82WY7\^O'R'X9&*R,$FNP"SUWC2@>%ZQL3:U=7-];BWNFER`315$AU+(6
MXS,(O9]/%_*1+J93V4(-"UZ2A;X;X4NR4`O^6TCS:3IPF+)`YO*TV,5I9O_M
M>#J=3@;7D\ED:@X'ILF<O$PCV@W6SK.#,T]I;BHC&`&"Z7`RO38`2-^<,%47
M13`$`./1:#(:3`T3_F>CU/D1R/8IS+05LTH0*&*5(%#$*IOI]"1D_K2GP**/
M8E8)`D6L$@2*6!U+SL!CY:P2!(I8)0@4L<K6YR3V55A,5=Q7"0)%K!($BEB5
M5GRF&7BJG%6"0!&K!,&E6<VF58NLL"Y79M+JXU07%O$66QEJHHO-&F&>N@RC
M-9SURD[E#(8P1TR.W=UZSB:&&6GD/C[AWSC<PK_+,([A'-'=[=JU'\/`]N!M
M+VN1_3W1$LZBP0FSF1X_N:O/H"R9?.>5=B(-59Q+0Y[U3)Q-F&.S/S9'QG4R
M84NLZZS:=];NWB];E^L^&I?@1C'#B0^#7$D:#L5"80]92.D3;,&H9DP+-H"8
MR$)"L(4,&XM%<U$;20LQ&TD#01M)"U$;(=B/=:[,D^MP#R=P#PFVK$F_GZQ-
MBNHY+9``/Q(QQT&0-F5_UC8YXM':-DUMA?Q2ZAMS`U^L.CYB:4V+LITU#8Y8
M6=-"U$8^;C)V.>%<0CV"Y,#?W,_;P0!02<,,ST$23/,3KJXF9TZ$TQUO;DG/
M@2FR]`B;<<2[G4Q/1U,8G%>.Y_V(P^7?-_D(#8M>=[?/&[(K`K:JX+8!W'2!
M;V%E.7V;C,;)!_!:52.CLI%F;[?>RZ>]OW0BB^U?82K845S!+C[-61E1?'[G
MN8^![[!E.ST1\WT4QLXJ9OMKV(I^%9YA!9Y!*D@$3Q?]9H5^\).P/[KHAV6A
MHR2"7Y3JA^`2UB\S'G`G41K40`$-ZE-X9"*`R7^&`$A0@0!W/J4^@/!4@0`F
M51D""-`"`<`Y$15=^L&`9#.(@4(EZ#^72L@QF96<RC-:695^0?\)*RTN_79R
M,\FW$.B%F^'#"0"=5%:E6%4IAM`./:UP`7PXX0(+1ETY0]Z@*N<K<PA)NH"A
M\`BD@5,>D1>5).>"S@+`:8_,)=8A)"@P%:F&`'"40"!$#!2-OP.*0=$(3*-!
MT1!,(7!C\`7[!&6"&R$580`\2GI%42<,N!'C@FX@$%1E2!(-AJH423&HRI$%
M%8:J%$D@J,J0E`E5*9)B4)4C"16J4B2!`!Y1DB$I$ZI2),6@*D<65`Q5I4@"
M056&)$P,SYPB>W39-%E$)>NG8[R<JVKI$0C*IO^'7#UO:A=2!U63)I"5-4]F
M3\G,$;A@<RDRE49P=K9VJCV%D?L+3#+QFK,5+*8ZD8[7*,;NBA[Y&MG;!^<9
MIJ+)6:'G32<#:S`5^F'=6]>:*)?NGPY8!)BN<42MY6Q27[LP?Q`9_.)V;834
M@L#%'=48T-<I!NDA(*F+8,]5[288))5CH%0AGG3-&0YS-42K;%8;JU0YC-92
ME=,X^7F_B]W-2[/DA>"$O%&9S3MD*YQCBFFW((IQ(*A)7IW=@=.]UX5H(#MD
MNO`E&\M1OEX3P":=6SAT*KM2$VW2X^(H%XT0_;\WLSTXIPI5Z:PU(HATW^'A
M:LJIL<]BYS]JL^]KPD*C&3=%"8R*I*:D--5XZGAERX]7@OZCF-FV+`'0%<7%
M\'"A2@*]%)Z@2R^(KG7P<9[",V+BKIJGI^5J>\:Y7'<!N%T#D<LS<(>95^)>
MH<Y>AMN\M[>*D8Y.AR#N/J^A,9NMTLCI9(WZ6&6Q1/&)^JN*=2X'E.`U)UTJ
M:,"33:`;C$NJ1Z#7$8/G+$E;=8HJ0'69O%4::860%HE<ORAGPU,QU@JPS++B
M`G!%TXY0#WZE>*L"MI0E^6`0RH"MXK,*T.OI094(X0S1J>*R59>1ZL.VI#:I
M"W`KP>M:8C.P+$@706MF>WR0MYC7M<AP))S.C:YK,/'XZGHD[[[+17_E"%<3
M_CQ>H0Q7IEO#&[HDB]EP\4JOM%@D5**6/=N\1FWE[Q8C'M>[N()"CKN;Y)Y+
MUL_-J0=_;+(3BI4Q6J;^5$X2)EF.%\]4P]2"H^>D*T\JE3TGTFF$/4CGHZWR
M**4<LL"2+2[A[HPR<"F44\#E8#V:G*HB]-)P1=.06#(M+4J)Q`4_&+2*DJY6
MU'C]E5E!8X>4-'!8/-);N;E;;)\?7ZMD03S(%UV`]]0<@P_;EC5,76Y`JKMM
M*J"YJ8U_JA"44VFKD&H#B=8>7%#5,-:2H[S.3&X,4*HST4-IL7'630_EWM<`
M68.QG!\2A5FM+2VHGZ!Z%8MK'HP0@^*[=S"&,^KPK5!/.SX85"([YA:V`16V
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M3<'X3J043($\8I$)7XA;E',TY+UK"GIW;J^SK,L'#(XS(C#@43NKO0>/0`KQ
M`4KL*@U<72$&X4*ZD*0G9_596\!-=W)!?'_`851$T/WSUK,#.PZC%PVOS,C%
M\:2/!,7],0QS'_$2#/@H`NA/\+@I>)*5!GY)/,3',.[*;R(F[PN\>_`R[29B
MH'6"AH\_K&6;B('6B1@^J6+])"+F0[#=YPSQN12';A$1']W@L[/F(X?WL`$@
M121]<O9Q9.?QQW<I0]`QG_!63;D,/D4DSU+([BN5UI^?X,Y,F1-QA9#T':RA
M18#_91\3-V(K(L00S$L/;@SWN\LZ,2<"88G@>`CA:JE<Q$%&$93Q-SL*L+=P
M7?<@1BLL*JX]@^I__5S<MHOY/<8'LK$;>N7S`7#4VMG8>R]^R+^<Z<7[/[,[
M24(PI;_ZWOT2QDS$3"_>?\1;=$(OAO4&2#<?=W#;1_BK[2-WIO_G?CZ>OK^W
MC*M)?SZY,H?.Z&HZFK^_&IF+^?OWUK1O]!?_!9?AT^MNX/%G'9X.QYYB!U>?
M#<R;G0?/D(M28U/P/Q;'9CKYD,!G>X(!-ISLR8SH[?*GZ]W]#P``__\#`%!+
M`P04``8`"````"$`I#"_20Q+``"G[P``%````'AL+W-H87)E9%-T<FEN9W,N
M>&ULS)WK;AQ'EN>_+[#OD"!DB`)(FE>)]&U0IB1;W;+$$6GU#!;[H5B5)*M=
MK&+7113]>1[$V)?8[WZ4?9+]_<^)B(R\%$E[IK$+3'O$RLB($^=^B\AO_N7S
M];CX5,[FH^GDV[6=K>VUHIP,IL/1Y/+;M9_/7F\>KA7S17\R[(^GD_+;M;MR
MOO8OW_WW__;-?+XH>'<R_W;M:K&X^>K++^>#J_*Z/]^:WI03GEQ,9]?]!7_.
M+K^<W\S*_G!^59:+Z_&7N]O;S[^\[H\F:\5@NIPLOEW;W=UEX>5D](]E>>P_
M'3P_6/ONF_GHNV\6W[V<#I;7Y611`$?Q:K(8+>Z*-Q-?`+B_^7+QW3=?:J@/
M/RI^FDX65W.&#LMA\^EI>;-5[&UO%+O;.WO-A^\'"Q[N=#]\`(SB?_3.YXM9
M?[#XG\UIGS9_2%.=W=V4S8=/=[8W_[7Y8P\$#`T)K\?]R^;3IQ?]\;PU45KE
MI)R-ID+=L'C97[3&!91^*"]'V@"(?M>_;HUZ^N[]Q]['WK\5;]X=-]</,QQ#
MI%E_#'&&Y>?BK^5=<]S3[>WM'?[W_&B_^>ALUA?7%:=WU^?3<?/ITW>LW/SQ
M>#F;L6+Q>C0?L.J_E_W9RCT^W=S<V=W<VVG.D7"43_(:AILW1S[M8ICFZP'3
MW1/\:XO?`MY>C\;EK#B&-)?361MIO<&@9`"/A^R5?S5!B^B?7E]/)\7I8CKX
M9:,XO>K/RGGQ?KDP`0:WS=>^[[WMO3M^59S^^.K5V6FQ_O/IR^+)L^:H-Y/B
M[&JZG"-\\PV$=%S.Y\5T<57.;D?SLIC?E(/1Q:@M:"_+09*EW>:DD73]^;Q<
MS+]J/>[/KTS:!_I'^8_EZ%-_#*E;1#F]FLX6FXMR=EV,)I_*^4(B,B_ZG_JC
M<?]\7&ZB)3;GO-M<X0-C9Z.!4*HUFH]!N?30O)B5@Y+%F:JU]L^3\]%XS`3W
MC#F9E3?]T;`H/Z,5Y^TYW@N/Q2`PLF.C"<O9=`%WWS_FS1_:_-/??_O]M^8R
M)S,T]PS5*BTKE-\(EQO%I%PTA[Z98!(N1T)*Y_,?IM/A+;AION>[G4PGF_?O
MQG?<C8W(.>-1'_2/%J.RS3Z)>C?].Y&N"0?/9TL(%ZEB6S:63FC.IF^^_;*\
M*%$\HONG<K)LS1XAO($U,4_%]`(6NQF)B..RW\$$'2],I@MD=P7X?^O/3$M'
M&%L:(X-PTB)>G9WB'*"QN<]W&9T>O9<5+]V[GS9;W`.5@W_/@&.TX"CJ`5AY
M@#.`\L.MZ=BCZ<JKZ7B("_34N'YQU])&"'&@^-Q5ZY/MK>T=J#,K4$O+$G=A
M`Z.F_Q5SU[K]Y0+--/JU''Y=3*;QU]%\+K:3@$U7JV5M`+99M=:>K]2]6M%?
M%'@XB_+Z'+T2W1Q;$;=K-91Z#X4=7G,':/?K\-[AQM'S@XV=YT<=^]C=/MPX
MV#[:>+&7GF9;NP><G?W#C;VCPXT7^R\ZIMW9?[%QM+^WL;>3GC:F;4';9-_>
M<(AVF$X0.ZG@S=$DBF%KY`#_<CDV^SHL+T:#45MH<&#GR]E=I,K^P<'&_EXD
M]P9,AC]\WI^/6E*$KDF3!Q4SO;Z9E5?8@]&G$K,UF+:=+>=R8X$&=S:!;\F#
M$>TQ;S;-_PG^`GYSN1CA33U;Y0XTWEKM]+:D1O(RG2F<D-4UR2FP.$[]YK9:
M;[<$Z[%ON-`]=G3&9<U7ZG*9I'_U'NHO/+B!SN'=T'<.O0?TLP;[.BS-#9Z>
M]<Y>_?3J';[@^]?%^Y-7'WIG;]Z_>Z1G6'X>H'C<[2R&_47_CSB+>X^.V5JN
MY$JH5[/F#U-"WHE%4[(.BME:<HN#2#PQ<#=TB*4?3\TA0M3'N)93W'&42^LU
M%\=5G@%:`N=4_E7P!UNVYEB*!(_AL@/$8L6TJT!MTO>'<D(4,38`^L/KT<3"
MO05:J#G2=R&E5@>W.>[ME%C@8C:]+N0[=F/$K;NKN6(];/Q9:^/XE"7QRF*%
M0DR/PP1-2'R5%0^/KW!7I6J+B_XH&&TA^?8A1ZIK?\5Y25`1%7>QZ']NPO+&
M5+J>1#HW1[PK%\48W#5__QX+,C#Z#$?CI=0DWK>-7*UEVN_<EJ/+*[W<A\W[
M;'RR-'=`CFCP+=Q+N4=CU*7J^/U/)Q]>_?CJW>F;CZ^*M^]/5^J$!]];+95.
M0B!L6<=B7<AJ\XS0N)R@V\;RM(I+<DIS'UO.GQ7X4'\L)GP-64>7N`D6C@V(
MA(9_7WI(V234@[`V7T!C9]OJHGT#<[W3'XO7;]__;26FW[O$D3+I#9#A[DCH
M0XF"&Q`GF6R*YQ-#+:;V;XNPEW/0AW@$*69.5.*J.5^6[&009I0RZU\KTOG5
MEFCNNY<]B\OS^O5H>4T6H4:AYJL_0$X-&8[F-U-B>+U^TQFD-M^T($29`W.#
M-O'+V)X8"Y^K$TI7$/,&"BPW8=*8A1LMQ772"/'MA:G%]=T1;#,Z=7W<"$F;
M6WJKR!'X!KAH*.R8F&BG7203#]*T.;NG#Y1^NX>7CD,0:TH6WWJ)NFY.1!)A
M4);#8!3^!.4B])Y3@6QF7<!F\68.*T\_]8O>]W`G^8FYN??W0T`*>CDST1#W
M9.J@]=H26P^*8<I[QR7TPHF?1D,`/+\KUH/\/`LK")&5`#67>CV:])')^Y%]
M,H/6HQL+7NX\J05@]^<1NM^9W)=*J-/KWJ':.9O.R*N\FN$K6A6/CJ5A@'5Z
M0="L7;H;P2]/GF_M%-?DA905D>(@CMZ//VP4L!.Y1''WN)71J,,I=B@_E[.!
M$I!,;&*.\NKTR#HI=I%HL)I.K]C`P+:":^L>A'*P4DDF8-J!_>.>_*06AY!R
MO\MB?5CZO\0GCY_C6)JL:S%%U^<D[2<3H1D\8!'(\S?Y[=[WJ2JL?O-T>7,S
M+L5]\"'"/,!N(?5ZP9)X!MAJ0X'-2XF,(N0^M/'I9"(Z@\?;T>*J^&/"S1Z;
M.<KB)@DON!XO)96LTX\YW)!&>Y2>Q;A-42Q%GYV3U"X64YQ$])F`C,MH_R$$
M(%U?Y4J;B'\5DZBNKY0R7%(9F17]NB`WW[L'[<9O%^/I+1M,!;"623**L^ND
M-T;!N6ZM5(OXCC.?XW')@)4^RVHO[]%JI*X_FI"_GUWV)RM\COS9/56Y=RC&
M8J?8+/+QS77>87$^]3]O4-.BG+&^%O]>,VY:3"]+.&/FC#PB6IHOS^>CX:@_
MN]LHXF`LUL::<=":W,#^Y&X-#4!D50S&!&%D6S9)BN"GGX^F-WCFU_U!N;0L
MC#DMC"\N5)&"?Y`9<:)D40$BB^2AJ2D)A$Z:43YQ<OJPIM/K<^D\T^&+$O'@
MCRE)#-89EV1C!E@DM+FFD-O[B:'S+2H_91%@?DH^>C8=+E&)-Z.;$LA+0IP9
M"-!./O5GHQ+!1#3@3!/OY5QP6L;;\1,6@?DGPQ$9`I9S5WLQOC.-&+!1VQ-<
M7F@22^0Q-?G6R:_D%D#C$#=RH.7\-X-=1F2$FI9@SN\F@[L%F"@^C69`L[[V
MX?3CVK.M)HV#)]T1S5=/'N*C7?'1RABXCL8V'C:*.4E`(>_V:D3.X;HOA)@J
M8U>)(.09O5($OER3Y-17Q04CBM)!1<\)9"C+@6IT694)!3W=68WR`D1#R<45
M1B4N77Y>A"PE+OMF9%;#<_H#*BJ]OA&P?ZD\JI"/`L5#DO^"39JA1\7+@3,+
M>+E%A=X?$8@-$X/`F06.FY:YA@?!S(50@P5@-R&>@;+N1R;_97$UFRXOW?;(
MC3&^Y07!B(RY0X&0")O&U>[+N'R$-$P@@=;!I%D6J3)HV!%DRU),4/5'0E0L
MG83KQ^4U%#TM9Y]&`Y7/OA]!^:&40-$;(G4#0/^04^EEEGOJ>5D!B-;7?OSQ
MM/B^]^%E#XXN?NI/4""VW*P4#68@`CA'Y:W;KH`JA-A,B""Q?V2^BX&7N<A%
MWP)JV*'")'[&^7*(S(N@\(:\`2FD2`GCP2OR#BC""V72\1V*V^GL%W,$/8!P
M5K&1PMN($IIF&\[ZM\7R1MA?*NT62[B(!N8=70$>H__+\&N:20RRJ)1R4:B<
MNA:;G2ZOX1-35*>9C(2@3&">3,<"O!7;//[-AY3%'LKB\;,UU942/H:-$TDS
MOIE<J>8@:1PY0&9NM*OEI+\D:(.[0/J<+4H!$UZY(PSW65[>/08CX'E93I`J
M\;&DR?VIV5`<ZFP>_"M-CO`I6E$X0*%-24;8C^>J1-F[XI&?)[;\*0`[->EI
MH03?AY=_WCK=*G[H]4XPC%+XYJ^,KC/H,G?'^%03DNU9S+!'RL.*@U[3<E2H
M><9&]()IV]D6Y]#<(LTDI_-T\]_<L-40<=X?V]:L2ZE`H?!2NY*F2D^&O0QG
M#,^TC<G7ZI&B2U4"4C;(MJU-H9E*2(=\XM67!=I(K4RXZ2"R#8\-I#%E-R'E
M'OB2\UBM]@?70-H3'VV@"9#`:*6P/56Z#%LK.,@OBSM`S43=8+).,F#Z+1O[
MS(V.-A_5B+VLFBPI*D1_+H$57_0]@0ON$N-K=KU:,;(Y\!!Z(Q*$Y7AA.5Z@
M;CLPGW2A_&J&,#;%H1N)+AY;R<[8VN5PJ^BATY,5B:"?XQFAL8,E%615X&0)
M)GXB%JR1J8(]8RC$#BRAGQ5S2N'U?W%=FXM"@@8,+PBEYW08#,$O&R5.4@(M
M'ZV=7DRG"\9*>L`H^1&)A),'F0WD-)E]&$167ZD=DDACG3$'IDV8<8C1@).A
MY90JO;2#;#?]._Z'>S7"VFPI;2*(W:"YE`=BUU7)J;C*DSP:_RI&ZY`$C*BU
M$15S^NJXP_7#Z1!YEJ3Z;,]D*R%8">;&X*)X)T3MUYT-RSU))9[>8K?G5R&]
MF*>GUM?B7^@S5O_+$M3&ML*M*I-UR]X5,$!D]+A9[`F==T/6M:B#P*%#4W5R
M2Y1#H2XH9E-A,5[Q^$7H:48I^5H]I-ATK\1$<4>:2F_BXI`_#?JVHBH,3RW)
MK`DHJ[@&O+>L[UD`+YFE:CC;[MR9Y*!B<U8PSAJJ"C<+$8H!%K0['.)I5^.=
M+'$K&<I?501VC8`IBR*LU9,\K(-+3!P3']<`K1L+6=(->>[XD<%AK/`&]!$\
M=LA:5VA%6D/D\"F=U+V%I`>DWC*[PE+])N"QRK-J`U*<VJ!K,&>H"))DHUH!
M19ELA)5P_W-+N:/G'J7I?'@HD+ASI0B4X^D1-!'BH_XWS3&^TSHVC_,INQ73
M!M[P`I%86297Z@7J*#8F5E(!"7$D)H?UZ77&;Q4K/:I[0ZI"X(KJW9Q=8YA`
M<NA2+S?%_8LHE7VDK<0]DUPW/Q(N*1B2K`<QR2K^:SL1#TMI,OJ9>*^2USDV
M<4Q:7)CM1T/R]^7$]$85('7+.J21<;*8958BL?FFA6)TNA03<4QO,EDB0Q](
MV,V@U22Y?W]--OM.'<'N.K7:A;9XTWR",%HN-0X&.B\ZGRXOQB,RKM$348@Y
M(H$QP'1BV&"2X%S81):L6:HVTIR'V:,DPER*T06>BV/859!TM@]#P8-X6'-E
M9;`2Y:5<\Z]B:D1LGB=U8OZF1<J?/4/^"D\,6]\.:LZD&,R,NR?`=FJ:KI-,
M0,<@N0\*CBV)6YG[D(&0<DTQ:71?E"LP,$PYHZ>7UYZT1WQ@S;YK7-$9D""K
M9/+:&W$EC)T%.9NJ\K%$$("3XRD97O6.Z_Q<@3R\;;.!*V"+.0&-"5T(N!:X
M)=)'Z1W]%=5P;[`0_T;FH=\8J1F.5#4!=31#D+B"U6+]"SHF[+6H_%IM#1_5
MBUC\1*X,[K-`[IO:R8@99RET9N.K^0T)QF_7(/N<-$2Y]IV8(+*@)[X1+W39
MTM!(0SF[LBSX,2=#E%0RIW%]K7>*3U6<36](PQWN<J;"%V0A_=\)_QE]R:F,
M7]7LQ>F2[37^HGW&[=$U(.SHE]EKR.5#SD;7,/^[\K;X,(5]]/2B3\7H+LR@
M'[ZTB1??K=BSL<-+?#JO580H/@/IGP2.1PJ5N(@15"3)?NEDWT!+`,R.L(!8
M(33YIG/MGT!`EF%1#J[LI`RABF=*/,-#5N,74B*6=^N30"$"0U7.U/\,/]DS
MPG2BJ6?NSZ)9E7.LQAL_."7@(\3H(NHQ&PC5DG/PS+`LOK;&QVH.^Q-I1WS'
M,)FQOIB,=96\Z=-:::F7/A9.Z)#.#6,M>:7W26>)(2L7B%RX&CQDG+/^G:L1
M>0:*MG>N.RS-2!"@<0)L-+FAQ59.7Q?JE('$H54:R<0EGQC]/V4*A>'GLRDF
M;*P,7#+:8Z)$R3$&H\^`47F!4IX/9B/39,(;42'2ZC/XNZT*S>__NRZ;B^_>
M:I%BYZOB/?'`S$X<Q#U$*O]CB6D<*MFB=-@Z1MGZ4\KA,]D+RWE%4GN$3WT:
M"9:G&=0@V,X\XI8:<1AVOR)8,.1Y%P.J>5+4UW9MC0F;5L!&XY;H&E>B2%%2
MYT.M#;%Z`\4YP"$3ZG\9N4%8#&'J2VG:.0$&WG[W+CKV+MEKSU)AXS%3NLB(
MEV28V*I\`,?Q"KSM?46**T-(Y$!-0`?Y6,&$.---FUA(U%G(EYG>FCQ$:]A:
MP/LS.G3ZXKOLD5ENH@LW@2G9?M/'Y"CS,<.DRF-F)Q(FD`1AJX2O$"FGH^\I
M-8M.<#PLMK[;*H['4+;2_O"YH\@43!A&UA3';W&KU*$R/6:!@R*,?R,WP_)&
M7AFZQO*]0@H1$85L.!73IV#^3O&'Q6:QZBHVD5QE2\5'0_=!FG,(FDN<4&RI
MR#@ICM"H_3OTIC)7I!>,NKYI<Q5%YD'8IER/5)\*ZD[+F[=3FU4X6_&Z5<D=
M#QTT!2Y,NLT]I-D*A,A=-F4+DN3>S93UNZ55O,!5G`@D'Y)JW.:K:A)_;ZLX
MB;U5&BFOR+RGC6*$^S1!$C$@%<5A`G8<VK>8';D@L,#OYM_2C9$4#ZYZ)GWM
M!\$&A<M9<A.NJ9!R^)`=F<XUW_$:]2(!:+3N:9T0F<G0:=)0F]&_CY/K7[%`
M"ZN")`RTLE!&3B4^:GMG^['(D,Z)H6N4X,[6`PUW./^.DC%'5"USKA%U9A1C
ML#F].:%PEGGW7:MD*2LQ'8VHZC9`4V063NAHM3>V<%2#P@A-_DH)-?$+5#QG
M-R4A+<82^HO@0=%:;/;(0-(;,'G32V.-,PFDM/+S9RQ1NM$%`G=W9830^X"3
M@!-?@RPE=>F+L7(RT^L]()P7:V9\-B6WG.\+\&^MF6N@[74/6-.KTM02#,N9
MLV2(UN!TRS3V+;AOKDD\V!<X8)!$:DG2`%)"#]&3$I.EA-VJ]J$OQLB`D)"J
M#B^5ZZ!'4Y&'BQ?]3Z`?1PSY,U5DTXH2\B%PE'[1^U3K4`%B/@X,T7FCL+;B
M!FH`I(+'/+1)<@WD_IQXR-(?#H?Y(4E;HK]K)4(O#.*TL(L1U?3H8FBWUWW2
M(0NZ:%PS+;$9(4VDIP%O<-*\N"V5]1>BDM!AS/Q<GA%;?&)/*XF%HW'G6,0\
MTH@_MC!5'$I83;TP,(:FM=I(SA>=;%&\0;U%T,2EB8T2NT59Z'K?$=B)-Y$(
ML)8JRTKT!-,(OWHT,W_5G@8]S;)Z6OFMD*!*W;4TU0?4-IZ<=.TQC51-?_"L
MAE,9BC#8G/`@PJ3.8Y</F.2@*I,M87M/^)WTSGZDB(LC:["NG^+1OE-&>V?[
M62"#T9V8'%K7R.@E=9U<C6Z=BK@2'_Y6AKI:)2T@+4#>RD]=.4HKE9U90O!9
MWXR95'Y4U45\($5-]+>\P-VR"'HC;[<2%>@-4D1A@:S(3:LPJ)_-SY<S2A\_
MH>E(F0%[R#K!DZK1DS&&W9$A[6E<4GV@P`21L'@`;1E<XB:+B?5"X%D\$7(1
M](1553/B^II,^+'.%H75ZO16M3W05IRJY;Y)9(TP#M>(N4:(W_``L(]",L;(
MTP?WM/3;:[Z/O'DAZ^U7I6J<GSB,!Q_PA&JMD\;A2U/EK)Z1R4?U0RN<SB,+
ML)W=C9V#%QO/]_;C"3XAG5^/#G8VGN\>I%^[DHZVEBJ7S8*;D$`JVUV<F/T(
M.#&LF^J!W*0\0HI>:A2M8F<FD($6(3Y@7W+GM57:?X\.OU*V,J5N9B7,8MAW
M98SQH@<45LNR6K`.R=7=*KG*[OGA>?HARLX?JNFV$%)56I#QRCLUU(1JNR&S
M?J2GV@H2!2DQ6>JJ`,2\42+N5RPRQ[)D3DPK3[Q;5VTI&0`79:QB/R=EY"@Z
M3!CA@3NU8#)D1F`D"ZN\@*=6'JL5UO8JL"%R[K@$S5I[.T:2U;N>JIIG-4@K
M^8"2D,"4OHF1B3GQ-\)5:*IH,5*OZCN7XHA5/NIT3<G.1[ZOC;RG.63U2\WI
M38WOTT:2OW(?1.27%M^];Y0BBW49K+5^MBM%76MDB&)5L#^9$$'(^FEH/C)?
MS>?)8"$M2'`V7ZK]+&CTF^4Y?36X36:?K+M3CVQ*1![_L*:B@EH3Y<,Q+=-Q
M@D+Z47GVF$#P'*F9LN"8&I]+8Y,K^:0XTI>3/-HZ%4$4?%='L>OJ,)#_GYX[
M[$[*%CTYAW`CC0MB-NT\X+#:31>6A++VOFN*OJ)O:,NV#-YGR\VCZ78.,B56
MV1<A%(NN!KE3M?J[EV51RY/]G:VC).4&@9P'4P;`7I_^R:Z=E\^I?W2T=?!%
MW&6-('Y233,&R@D/M1$&2FC^-\+G_/+FH03PG\P^HSZHT6\5B%2E*)_[Q4$T
M"Q-WZSF*`>Z5!^EU?74$NRC_/V(J0M'/`+46\*14S)B,$>(-E(1')J,*U+B-
MAQ^CI*&MU>U03J1A4<19A=4\1=/8A))*-O":Y*SR76*6AJC*,@'BAU1<<)-3
MJ1OW0H-2"-4QEP$3_ZB6>M]+</&:S"/(]7MN(UQ99/U:53(^>>GX>;SB$7^N
MWJ0(M]H%C7KUX$\RSVN+`K6FDLP/M'BY)TTX3WJ+M%B6\4E8,VQ,HB\I63%I
M;T3I9D%I?K20;UPIMU1W,!M18=@H&QO/)?NRZNCSV"H<4C2Y.P%IY_V;*5UE
MWA5#,'U]O9R4F]<TC@>'2DEKZRYG^\37%E=8!."U+ZVPX%8L(W?LE)9WAZL#
M<ZCKE)1`()C-3@\^3?31%PR:,KRQE>'(]E.=WH9/;=DYB7<%!7$MYWGE#F6=
ME.VW@$2-55:5%^R*,8C'/F_^]'_^XW]9['JN+(L)DDU*CB"=N4W`(T49LKXV
MC8X^-5LFO\?QB_1QJ&=9&^M84M09`X*,3!&AOAT12NED9FWVQW]\>X+<&R;-
M4TJ)LG;/6L?TZAR>*)MT,[TE#%R.33OX\2##U2!TG$&!P"WIS$'$+8F4RUF?
MDY_B4>L`1C&J0!5*39:PM'Q*9#(-O"%F!6QHH9YFQ>*)6!D^"X6Q%\P.Y?26
M'SL[)][7$;W8I!3Q%Q-Z<"I>B9K2(,=H-MRD9(:419SZ5!8,F#J,!^*940<U
MX/1?-6/FC+)R:%A3%[PUG*O5I!(W:7Z51NN:Y+^J++K"ESC#:"[L'JFDC:V,
M))U`$9YL3&R`N2!,I@VR6(=;4==^[U<\>@W825LLOOMHN3K)O!MI_A7YIN8F
M=-]A\:3ITQ[K.)G=EH7@)0L:C'D1E%GS);^IH+ZIUA@VGY([]T`H9/A9X:#:
M5$,6>1U5U?:>UMV@,+IE/;K@6!B[(W"HE81X-WHWL)EUTL$WTCNAS,ZR[OKY
M`=4`C,.9RB=YGI`70KDOF%'T%EP9RW'2;#Q?*HL3\ILMR"W+N@*>A"1;/.\B
M=7TN1R*FU:5"LX`Y+&?YIL?99C1-[$^QCEO\AIGZ6\>DLC5#AB>EZ0>8ALMV
M_%_GY299>NZ,N/[UN]Z:0TX>=>S\3;H6+1"@.4U:*3^1:`G)%(-F5&J^O;Z[
M\>)PO_EKZ[Z^XWOO&EMOW[SXSLJ!`:3F].L[1WOMWS8.#HZ:O_;@9R[`E('!
MFBI[G66-FPQIR8LDXVJ]<2\4WL7!"9?+138V]6N*VW.#*%4DDB9="4KP)K"^
MM$706W+);Z;]LUM:JB3HW`U?SMH-T3%9RQ9HS)NRG<I^PYM9?CFI#OR`T.7$
M=I1AL21O,'%RTZK420)'.8=*276.M4@"\.09X,-Y@<=[(X0<C'-<.`92%G:!
M*D7`L19H9=V8ZT26(^Y9WCP7[5\!OW6/ZW:].%D%=!$:,FB!/V-TA<#836&%
M:BLU)9SDY]&6JZKD`:-VUP[:"2,K:**+Y!%%"E$J)9/IH(U86)`9YQ3/#>SH
MVL[[S%0&CR57-5R$.WU,'\81B6*<'RQGEZ8OX:@@IWI]WO\$QJ6UT6C]KB5O
M8P]DF@Q-&*J=P-,*['$ZS]5#;:V?8M_H2X&`&2W#EU>;UDF2[R7R3B4,&:]"
MV:RNBTME/EED$/DHNH%7?$-55L[<>'1!OTM?;3'!G@6\$VBE373RI<.1"88R
MN(W%1<=J<>(VSJD;9STT=2^_/T2#Y:DIOFRK"?,G\4]QHSW'R#[Z1$*SOJ[#
MP<U30Z6?G1(^#*0HG`D).KD1+*[K+)*;4D<@RG26H@4<HRG7!UN%-RB41O%-
M&BCM;$Q*.DW:!KNR6P']9E<5J=+TI'4%:-W!R<P>R7#6LMQ7-36Z26=!P85C
M.E1?_3P@!`;\I$+4&:`55&R!9\1[H]F`VUG0PFHSFB\O+Z%<Y/7DB^=5,&W!
MLM13VJ5U-2:EH*I&AE'FE#!9XMB#$(%+A#)7,P(+9=5+3[):8&6U-IL\.M+5
M=<]GC(HJ(LWX9/=@:R_EHYCQ,EQ)"G>,48>&`\W?RW*?-.9X\G<%ULTW#;#F
M[R6_AV=4+M17$E@H4XTUIHI9SY6>6::@FPF-2BQC5)7E0<[+01]>CNO+&$L)
M:L.H&`[H237+;H9!T1O6G2HI+C<[H!`N+I`=V)89\=,RW(%&J<4L0$*NER,L
M!:1+P9H(1BDEJ8`'X<^APKF%;I(UH;8NX@L230K(V;@:%'6-%NQ/"2Y%4=W$
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M'+P<7RUZ)VK96F5COFY%35W^3>/]NA7I@$0V#*MK]_4V%S@#`59.MW.08"33
M))MQ(=>#28%&I&<RUB';REW_Y,>37ZG5JKER33TU'[Z3-W;?VQ_D:+4OUU[?
M.=AX?OBB.=WZX<;^T7;KU_WM#3XDT?IY]V!C>Z\=UG*K<RNJ7>?'YZT)J/JW
M`G%&[APV1U;*T;0Q,5H0-/PZZQHQLR=;B_^EZ\P5\A!4P$M05!5O?:?B!>5Y
M\REJ*+4O6(0TR"5=/I<*\RJ_7LVW"L1C@]"0OKK8M8/":L*!N(9KLRW.;%3L
MLNI>BQ->=Q\^N:?._4Y-2`=4KU>\VL2B>+@28D^A)6?-Q?[8\^@$*YFT5$<$
MQ-&&Y61B,BG.<BXQ@D6T\^8[&1;58N5@R)1Y&%%/*[442K8Y)FN3KKG+^OB7
M%%O\$N]@R9K#>Z:&FK^&8P3=/[?NSO71+4DX3JWBP_*<<#=K5I72Z^@/)TAN
M+KG9_,%3M5D';G/`V^I*_^:COS5N:NU8[Z6UBIG"?\RM!G57B?N(S(2;'59O
M@7F)%VH0B_WL%G]WAQ]-WL3)4"^GA_E8W-H%G+)(%'C"K6VR7W1$.%/Y.4]T
M=*!+;FHZF;23+:/V?@P6NM/\F?^);/_^FR7Z?_\M/UKV^V_3BQ5$FO_^V\^6
M-L_N5VD.S0]*_/Z;'S=I?Y)BW?#P^V][K23G]^%,+(+UH*`<6U)8JC13#2"Y
MR5-W32#7=Y^W#$VV\,,2+;V%B[#4AT3NCP?.:[>/B(*A1)YGI0FAEQW?'#$?
M*`U/J>4;N-`[.O)]RPH0.L"$M,]Q5#=^/87<$Z<&MXKO8P:(&ZYG?M`)MU>L
M_"E\4B6\'F-NEZ,Z9N,U/=X7:?!-\B1S'J&9^@:6>@:E963R!O-[+I>387F.
M8<F&-ZF:/6H<]DA;K$X#$&_`*6U*VYY:G.<I82PI.5=+I%T\)%\]=__PLH])
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M0K.\*TV(]:RCDGK\T<-H<@`Z]%"ZBR`!T10T]82O'P9R5'.J4N:G4BWKK:2Q
MGW-5'@=/AQ\PG];>$UM@JM:L>6I<84*Z>4)?JX7@&>A*\%5?=+)9]24G5ZP=
MWU5BV?97FCI<FH+O34[UH2;9@GI`@@ZEO&SJ@2ZT2=%;Z%B+#OB_86EK@#NU
MZ[=[U?F>-3,IC9_5S+VTENNJJ/+]E-L<A/.7=@1[ZL=@\@U[0[>-HY7;D@&1
M%A7JX^',Y8U0`I#]E(9@[B<'V[4"C/DR^*1^@3@#%(\/LB,KGF"L2)(_\V(R
MU];J-CG",C!#&C;UEU/FNRK'8BC_A*4ECJL<^P4W,X5N/VV2J\#DCH-/Y%LR
M%=/\X28"Y[D;E<OH?WK,U)ZFV?8=&-9(1*B"9KH"?6\$$X_IFC-N`A<8:^EO
MH9BSU6HN2[47S/>-VB+B1^Z$8O6;<7<4E]]Z@$G-QFY6X!']`[IF-6NVJ4N*
M*;5`1Y4/\;=O[)-T5$<M6*O.8/@N$G"6N/(&7[]]5#<EA=*\;942)+<`J,YN
M%X89[O/G@ES[Q9;C5.@0JG[0;7;V0G4YK4!@RU0@5$-3$I^!YG2IX=OFB+B-
MTEC+\ZK/S!`M]RHRIZ^<W>I*$:;./!K1)3EVGFTX%<_I:(R&54AI:01=9J$A
M??,G)%R!D]D#A2ZMZG-X)EL#K`\J).]=.*V.*\AU`(Y#I2JG&N4T,PT?H^OE
MM>W,3C8,+"WNZVP5_ZG\AR%E9[?=]D^`[?"@G:%*O1C^9)?DJ(CT9&]K[]".
MN=FF[4`0QQ;<\/)T?ZNF"U1BBIK`N>U:;168`[&1K\>LOGU77JN(Y"&7-'?Z
MZMU.^+AOE\*M1KG<!Z+>B!,'5B!5@24VPKNN<:6C^_L.]Y]SMBU^]4TD;.HP
MBMQV(:;>V>=TW%YC/&O(S)@AA%W`KD4`X11&:N=+'S=0TF*IDS'N_>JL\:9Z
MWOQF87IIK=\>7&DCAJE;.]-+JH"YV8>HIK>AT,Y^12%PK7,E@4`Y/32XD?P]
MVM]Z$55Y"ZGF%VQZV@#Q4(-&IZ>\:MQ#OL=1]#T>NP;7<)L::3HG9RZ_1FI5
M^2+RXHU]-)H.N:/`3&7L"><2FPFH7-S"C/%N;G>_R,^H&+A%="[7T=ES^R`X
M$&]HG2`(PF4\88:@[G$4#NQOF>3ZJA)VE$0$2;QO)UQG+.ZGG+#1O$0%?WI7
MJI="@1$$A/ZX)DK*8@GF,N2!%T0*4Z]Z!G-CS4Q'8R-");"ZJ=Y%,($'Z]S(
MP"`(9B7OT(Y`;JO(#_/?S='CP8L-]_F0)Q+5X==P'VW\:R_:BP"5&4<.$`57
ME=U8U*F;8:)B1]4(IX81X;Z.+WGG[G5PE&A/YU"/.)V8G+E<RJ)M=[DL4<((
MAJ8V[1N9G?9@K9+(*+(Q$BU,"@V=>\!W*I]O[#\_7+&*>A__3I^?T._"'0\D
MY4>5G+FT2(6(G:.CR#7.N#G+V$/!@H=@VD*,HCH^5P.PDDAR3H&?+@FS?6JC
MJ-9(!%7)W"Q+A,FK2[J+P)K:[#O.N)L8&)60\.`_^[=50H-?`-;TL\6LSA^@
M#%1*`TJ7`HS=QZ=[N8/&-$0$&@O<FBO>Y83G=,L2CJ)VLNU=^\/;V&]\V]1Y
M6IN*=&V@W`13>L"1(2E1"0#G@Z*RZX(8RMF1T6K=1)2O:4J_%3$HLJ\Z0PC2
MU&@G2;)8U"YXX`_E:_/+M&$*DJ""MUUB^+FN8@QR02M&2L"8Y0E*I\:!&SAP
MGT21BILC6K@:V^)8!!`MA0("T6:/HB*"OJ"DNBF';[=_$?%93_G6F;I.R+J\
MN4B;-IDAX.FZ\,!TEC:2G4LE_WK_W>AS/#`%1UUP-7S6AL=\UHJ17*7(R,$.
MBI%T$8$B@Z5_(B(_/-AMVZ(]*7K&%5UFI<K>R2U$UM(5\RYQ;BQ4W*VXJ)+.
M%BE3:N(Q%9Q6NL@F-FM+@C4W0TW(NS5/<]3?PL<$-WO01!\I>164`U<-X5LT
MA[_/!`'NJ7?CM`J-/[@#TYPD+M%J*5@_0-_O'K7JF,=R^XGQFA.M'V[O;AP>
MMM9=W]W;>''0ZA=H`%\YB[&_JCG_J9N<G'79]*/?2P4'HW@0C,>\W_7]]C.T
M05TF:VH@.1?*HU6MN(`KT;7+MC"`#D-U=O-[74ZS>3I`BV.1G9LWY51*H7"H
MKQQ77>.5%!#,QJO,6NR9^"E>6_P(F)MH_S":_[)YH?X3TGHD`Q0[8+F:PW:V
M=G:_V*3]K]7`\45S*'?D[G</Y<F!GASL-]]Y&>_LNAN5XQ;K?9R.\8/5T=%\
M[^#YU@NF?+Z[==!*D[YXOO5\^XM-_M^+UK.#@ZW#'9[M;;UH"<"+@ZW]%U]L
M'O)!M58/RJO8Y&QJ7]EQ4_JM[.'>UM'AYHNM[5:_#,'=OAX<-7>29D:Q7G#'
M'Q7$3D*PHUWBC];$8MDJ9P0M::[0!U#]L);T8KSW9#-RBYM3<9^G$_P2U6C0
MZAR?&V7/,;8EL[/9Y6"K?I;]!7%Q,)1*R^#GX0:-0T?</W$#-;VRJMPA>6X$
M;`=9UZ:PJ/W\"?@;+38+.S_8I)*ELN+176+-V"[1<`C"23HG4(A*_;ZD<1_Q
M)3%DJ3*NYXO^1<B31.L8<$'*0V:'<QX*7VGUJY)1E4?)H4Z6Y]#QI&0Z#P>#
M`]ULMU3.P7S:D+$*!CMZK6K"5+:L\7,$QGPP_+:PAMJ$VBPF5U1^@2>&^%<6
M*PR\-X%^(O;!V_YWBN+JNK&!TBR5X-[N:DY$LT<0*]#E#6G*QW@9YAU;DDSL
M1OMPU5PO`E4>(H_2-Q[K-_NTO*M7(9H-,?-)^(B?Q3]-37,&G/]584A_""[8
M4'$?`"%F?W5ZPC=I8@S9&:8V\]YVMX6BD2Q4!/2LNF`)0=+7$!NR.^VTD!WK
MN,4ZQS!?05,<MVJV$+5&Y&#/2Y6MTFMFV;EHP#Y40G/(C%I@;+M7LI7W0_X^
M!;O\M)-NXU!K1I;6L?#Y,#TURN.K!R@X1ZP219!OCZ?G[B,%1R-&W0F^P(3U
M-UTS5%U2T3T!UT$2@W985S:<\!9;JS!,[&QC0U95?]=?L,LT]7-$LAF`B]$,
M)<3QVTL[BB"TQ_-CB_*94\C'U&>KW'FC'X@B03)P4>XM+^DU#GWH>RWN%T?;
M2R@$JW(/K:J1<*W3XY+0JBD>=:Q#E9@^D.?'(=06JLC>=U[7%C9Y0/[_WSY?
M#JDYH&U'_@,^'GI?R5D/;;J#L8Y(V5$3Q2-/_,EO#'.Z60IA?ZZ>PS$\N`U:
M4%P9E.%S+VB]+\6ZW#D0?N&0EQ$'8OH5>!1S=(S)^'/"\0"N/T&1V,%`EL9\
M*2F0>4Y!AJ*\H%8MTT,Z7.(5DGA6DB)/IM)I.M<A[J?BH5@V`)/82%50,APZ
M-M?)@I73W@Q=5Z$G%(J<.R5)C[$?K3#@7;P>HZGI3TU=-'\]0<?8DR+%#S$>
MM1AR\V6'_U\+YT#GS_%F.W31`X%IQF_.&P_SI8\3%]S+OCXLD+T]\CZ8VZY%
M$TU2*I'5Q2%V?_!#?"$V%!VEA=H'E,Q"9*=#,/_.,P_V-7CKR$.K-[>`1H/;
MVULU.2:^Z'!WL_*$&2+S4W4*(XE(ES@4ZRI[L);D5K?BV+U%(8R9/T/"7*PP
M!NE*1-?^^'(FG)WJ0\8"47IX>09),$VGL<:Y'UP-,FT)L'X[_`EF#ZAU,LM\
M^K!@W$4QG!*I3^P*7+M$T6BK8Y0#VZT?8\9\4%HF79R3)^B_E&@&)$M]!F,:
MZ@8.0D>6TK[A)\`G.F18I,8$J@(441?%1WY5A"CD'><=2:W6<?^8R)^:ZJ%R
M$BG/3?\,U`]_:OXFNZ:O<+*E\`U06>T/RLKK1#?[?I,^4/N1K"_G7EK[?</'
M:\KSF9U;\SJ*Y#$*LG&\<H]PJ#Y/%)?1T<!J>8N9&;`HGARE:IUY$)K+G1>[
M;VI37&-'C3>=E!@E?88;WZJ:+;@YVHK\VZI&3RG,)PB<F"U[F%JS_%L8?=Q7
MG4!)$'M8#^^ZP_EDYT4*L\7$9;9^>L=X$H<R--3GUPCH.Z_RA@1DAB^*2]/)
MI97MTT=J\VN"Q'[,9Q\RG@^HM6\"#D#934&J9J2O#=M(_M/XS/`GIZ)RYN$S
MQD$$S8+J*-7FS7@YY\L?G\OAY@59JK0;-*T7^BM,6Y&!#T%=<W=MZ%**A#?L
MZS8>RXE[';":JW%F2TMZ`&&CX^<5&!_O+-(!RP@1+*"C?4'S7RQG()#O,U#,
MB%<B@!$AP\)L"">)KB&&>(8+[NSWFY4XFF]E-(W7\^.]^%X`(*.;@IT`@*_\
MJ`7('U%>408!_NFM_WCP;N<92HVN%NZJ0PJ!6W?%I$)-A7BY@O\\.%Z\.XIP
MF,*#-^)G<-,U&Y'.;)Q4ZNB"?A<VD3,+5U+I`("EG+ZF-(5R98BB[9I;"\MK
MX^F\-NR-OW+-FZH]P19\`-MY*">PW3"^I*,H+TO$U3D)P!4"B%<LB==`TPT/
M*6>1JL4FI3IFB-`G_J-_R2X+ME,$,9!&>=`)94XL6[*4SX4.5BE]-"DO8#Q*
M:CRQ.WDEAH\Y<2V;I^/WWJ`9;]#0J<[P)7/$*X$5#C6PC\S=MR_DJE9=<0GN
MLQ2@US;9\@B6[O'#$A\_5K7-7%U6Y@31N>"8/%@P`ZWRZ(XQ@250Q'?63J4N
M8%W-0DE:WZ/0[]J"/<-ZW'!#M32^^4/"?@R"C2EH:0-?6\7?=!^,GBI.5&"O
M5*CJN'+\`42/U##B.L25@6OU.X.NZNZ2J5?&QHY=&KB!=-Z+A#/@IV<%4W4-
M4U8#S7K/S@FEF4@U?`Q2G%/K!N^AC?6$EN2WHIP\9Q:F$=.U/"9=D@%$U9T9
M@31B&EJR%G[C@9N7*&^98QA!`U.-'.K.=M7T$O7D8R(=$B0LK=UDRS3FWC^(
M[32:.<)`&Q[Y4Q%,_["L9:1@DLJF^^$!;^3UVLT=&QD7)_LBSRS1D^I-_P[D
M0191O7;/GI04FD8W>62=DKLUM0.W#3CFAA:WZY3-HO:+$_9.0QUG:V!P"0%!
M-O\-]H1O&`QU)V_=H'"##Y]]F/R*HFH:5S[=NDOWR9DFH0O",RZR3*FUV\3/
MCQ6..`/K^D=E_.%L2=4[.P_.=UG?O602,:*F`+(_`HE$$:6I5"T[ON7.>;D?
MV>9-,AO[=H!UK<)MP>II[1HBNG;]KSFF#.[L=):X)+`SRC]<RL'.0P-II;_@
M+VD=IYL*(A"L29I**VC:A&V<?S2S[CA`]M&2UKOJE[O6^$D8J!84]R<1-BEP
MA1+RZU$&^Q<H*H@0)I:(M^!"X?&Q4[1`;%EJHL3%VD#SS_P&A=<<IZZ`I#GL
MT)MM"C9P>8M`18WLT-A77"(W#R'[)F*((TVLJ.1<G<[1LK%2E25.:[()[<^]
M<"C/EPWC<8-]W\2]I`G;JB@#()(V&-&J)^;1N[--2V9RJB-,"B!0*7XY2KK%
MHZUDZ@(;<\;M4-P@1L:=;ZJK*W*R8S2U>YWR$$=(=[-@^FZ17I5*R*QFU'%2
MG,8RK7S5\<E;O!+=\2:],E<#@EWN_58F'ERLKS'B>^2[%F\V52;ZC!:)H[HF
M@Q7L/L3B[Q:JLKZ%JN:J'5.:&IM>@_2#DLO/;/5L51O`NG[)\Z/!1&ZBPRL<
M83_#)R_2_:9S7(.T8;'0C&]Y"0!/00Q'?*H%3.IO6.P-\0A74@L)XGAN@04I
MN]M?1#\ELKD6._2??6]U\RCKOI29B&K2=:L%]:QBTU<=`J$QS^]VWBI.Q58N
MS/&$%2J6LQ*!ARNEY<(F3U$Y,YM=C#KAN^#R9`2D-@S?Z,?B$JE1MZLU*0U(
MM(_\'9`8HL.H)4)<6"=P]*XJ'J4I4I_>P$G),CVFP2N(6BSX]H?BK2Y*.QV,
ME.B'/F\7V,CUM;<_O#V%`]Y2FQ3/I^1'!_?=$^K#=E8%(%U"=Q]WLOELZ6XU
MC]2U%KC!LS+/;E[X#^2I6%EZID+RHKH5L<%M0J&Z_)CB#D^)HE#+"$MI(K)S
M*W:+P4[14E?%7U&;?:./>JD:0Z(KXFDF!2X<SH$-C:6XM%'NLS<-ZI)BJ0%0
MJ/U`904ZF+!T&U0,\%-DGE1N(U#5GBOH=<UQ,*@N)FI\BZ(EBWV1KMHPWD&3
MRKY1-(MFN+[5O,>W19$ZETGJ^,J!;N(P'R%RINW0E`E@JI!@[KD+/12'"`TN
M5.8M@IQD)RR>TA=P7UP`0GC*@Q^L#S5SQK4,!V.68[=;\=-2^CG8D88MLXA#
M_E&%TX1/4*.L,AD7>I3/%X27Q>N7O=`QC-CRMZAA/MD9_V!WJ0.SA;R:769"
M#5;L(FJBN':Y]^0D7E^BQQ5K!S]0OW3,ZH8&%B4NP-Z1N@BWH$@+82&3^ZUX
M)V1>W#/F>>3@G,>$*S!K'JY9/3`?`:MI#ZR=W]]D^BR;C0]8HN5H2'"6G$WO
M^F,"[S1+P)MN>M2%])>D9H=4(Z6%E><3`^'HI4N<HNR&PQ(L5-$JYW_7[$TL
MI%AK6%Z4NJ_/I#FVNV9Q2ZJ6WF"3=1@*7:&=X6GR4F!U<SL#_)6FDL7728"Y
MQ#]Z(O(H%>/&DQWZ$IAH6()?]J!_Y@R39LOX0$8I0Z:[UWHQ#49)HLW.Z_ET
M>9&6%EIU%6356)1#@$HB589J$`?D'!'2GQ9W-DANJB2!J'0!Y3JCMZX2?23`
M6$+/T;5,T(F^ZO4QA$FGTS'N@/S^]34]P`0=1S?N)6Y4S.;UXBG!#GOTER54
MK8*$8#R@"8B`RL$6=>K>'.=8!@,MLS-BWZA34[94F@-9PC)AOT+R[L/I1XCO
M/0HJQ<SD`=CE_J-?75?"7R0QN+!J3LLO^CK9D]"HH1EJ106\0TN"K87R?=Q6
M+9M^`R#IJR<ZS93B<L(5VXWY0):HX;-AT$[VHXN$VI1:!MR<AJ_WN0Y5EF><
MPF(+)&)+<T*JQ\AL\I9F?DO<H$;&PW-X0"O2=QM%2/"/^]S0>V6TJ1TA=6F_
M#TR]C8=F)V+M%-__)>[<>JLXDCC^54;61G8D0_`%0AX2R0$[ZP@;A,WN0[0/
M&!O""K#E8Y*UM!]^?_^JKNZ>GC-SQB2[&RF2.=/3TUU=7??+H!)@OH/TL+RP
M9`^VYKFYX,BN3B\XB(8644/18D8A$1<8]:_W;[P:\X)6@B!^K%]TH23XG5T`
M8,C]3;`BU*?`7X.)E@NZ7+PS5XI!IR^MTJW4;)SO/EQ2$:&CC>RO8!VK+`(.
M%B(C+6E]=I=%`LVY)8]*+4Q^5&*B=A:(2U-Z1>K+628B4&)V1U&2!3JS,A#>
M.")AM56!55L8!)329OI;9]4]?/!54+\"3KUKUR##HR8_KGH).;744>1WRV)U
M3L4[*'7+5E%-VQ=F/%2!EZF>*M';]R%E')'QGA5##=[+3H3K6D>`K9(\M4R)
MIH.3U"]&+9=?[?:@LSLW+&:PC,:R]E\TVM74@77'&B:L=IDZRA/A5I`@'0B*
M5M'JG;=FY)]GEMQ<\=X8JHC'2XO\,<,ZC`=X(MY!!%-#':&E,PL'<8P6@NGL
M0[/F#_F"N/]N"M!Y5+,E!FP-6;@=7`LH&D1&LY@C+US,)C?B8H&`VXRHG/V)
M8^G:93`>`,8U7L!5X,2B/^Q&=RHU8`]Y:72O:74+;R8?\$KK)XJN96S'5G`(
M\5%?F7RXTF6\A<MX<KK#.NQS)2?]2,`K`G1N+UE`9!K"3YX1T^V+8!"?1'?0
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M9QB)9J>$'K`1=T#F-6P:F@[['$9,N.RNQE$F<IH3I(1@R1[.#>[[7JX]D90D
M-$E+W5P"@+09CAO,87-`1E1BD_7+1"G0:+/<Y`P4D&E98HX9-K6+J:XYI=3+
MWU,9PZAT.,@-&0Q829RV(4Z#MUIZ!X%*4OZ#Q_TC$)5/CD:HLJIGF-"?@@VL
MUH;``6X]HNXJ_Y/^+I\Q\ERN'-&7HJE6FO5K(42=7)[HA"805RI-/]`G/<!9
M7Y)`QA%9:)++7#A;KDT$X2H'O>K(S*F"HGLO>7V-!)8%2A&'5R?#4^C`RQ5H
M)2YFQ."*3QF5D3PI"F+ULQ!5(7\ESI[%[FSN[/)_Z78[V`"?EC%<QC:$(-`1
MSLT@,O(?;5<9^2)6EGR9AAIWC&R*"%>D"`%H^>`[`XL=J?^RU0886R^WIW<K
MB6F3#ME7,9ERJ8$);ANOS+Z1+/PIDTB-K?X?O:W`,0F?PJ?5X8M^,U8L]?K=
MV?=K!P?$\//?VC=LZD!&)`S9WZ^=$O&[H*K7[]W+2Z0P/7W[&FW_UA]OZ8=O
MK,'7S0_H%B.U)P.?HZJGA4`,TBHVI)W!GA1"<?E)QJHZ^6@/+I2QEJ-0"6CN
M9F`:%I6FW6NBF6R^:N)UE.V,W'-LL5XG3`XN(>1S;[1]D"RF+5WIO;SBW964
M;`=*UIOPKJLYA68_D=0JT[YJ/B%\@!CRO')2?[R=N(EG*JM<6*E4&]-@O!4Y
M=$)$@X3]\P\HC4;)\!.(@KH*[;5\\?F]RCG=$%P:XD$01`.])G26")U6Y^D0
MCE575D)0V:FMBE@[.NFQ,@(]5;K!1#C$%.(^).>)W%1F3SM:$;(JKF_5ZSL%
M#6W#<]_-\I<)"&>DDXJ:]J"4XDOUFUOASJ$Q+%D_"#KZV]5$*^25H<,`-QE5
M:^D?SP8V"(G1YL%P8*[1F21#B"OD$&JM1-E"*@4=@',12U"EA!.6=K=H$`OK
MB=D>5I8FS98BEK5OS;QTB<ZFECZ2D.OZ(P$S&*$4$</E_R*+IV'@0+HZ<IWE
M)+2OO:S6&?JY&W%('4S1F7YIE"Q`IFZ6=S,\5I573%&S:#GP_'CQ_9K1Y2\D
MXZF2=<4TSB#R_]/^C7>`?Y^\'\K)]@F#FWF<[+"$83__S;4$/[B^2-@8?K.Z
M>JU:8Y5&'Q8]S1=D5SPC^<NM9A^("'Z'A1GJIP$$;"Q0G_@.7)/'=2$V_FGY
M:W0;,P.96R$+*4#7%9VTB`<1WU0W*_`RU;'(A)+A:3FA2-0VB9H,R\%AD3TB
MQV@"!`3?EI7M.HBJXE[QQ8E/8=P(5;^%G6YLE319B<S]LS!7!NI)[$*P3K:@
MH)`6S_)6*FE:G6G(O?F!$_!&!83R]JS<.HW*^CAK9@^Q)`FTTM=$FYP4SU'Y
M0H*'K&[?WPV^(DS(UAUS>J638W@N]&?^^<P``@-=;0,W(=./\WSB&NTI;5;=
MGDMZ(2.EZV$M!="*GD@<*K`:6GIV@:4!'OTV3J)>%:RTJN2XPT%<I'*54<Y(
M$H"Q,)L^EM4W<%[!Y\U8@2R']$"JB\+R$Q!^?WUKSW+_+:X.;`^)T(6<XKYR
MA5HNA^*?T[53NEI]FY!C4S1FEQBPWZ7Z.KLI"0^3HBR3H)-`VE^[[EVZ"0K6
M4`$(]#7E:>?(ZS#<<*^CN6\XZH`,E&6!Z0#+@_/]`#TYC?C&.8]/%^\N<:1`
M^6NIVO%!NJ%;4ONW1_J)&=UE,T+EC._U?/2(U-P"M$-Q3DZ:(Y;46.S\UOA0
M-\7^X"*EH$$_CW(W18[T9KF0-49GI!_PUI-2+J:JF$]G,O-Q"7->H-<0<(*3
MS_ZZ'91NJ!JU:/VY>PYMO39.I4@N!J]0TX/>6QA@&?\BY2(KHFI8TN44FN,2
M2NPA*;'0&"]U8P+'?"M(_>D]*Y/L;=C"$1W6$>V8YY^)S&I%BU>YE]0+VD<=
MR"#>'9A14XA_6`59L+WG6(G-BSA(O-'6YO>&>N,=D3AW7B,RGS!`"W#E$I+-
MZ3)\_I3@&MU?A#SY3(0FFH"1U@3QBM?%<C'9_LD=C0Y&&K.,H40U_J_O`1E^
M[X&!ZB6)3?U^%M&K(IVD]EH=8'MPASG:"VP>0<UZS!,"'!<>0@2"[?V6FA#<
MX\COG1!%W,Z?RY]K'<^!\[5LF=%0-JUQ[,,U8L9$[0?J,;WBY8//3+VY3]">
MYQSNU0V@]CUD<O"F9?8.:RR.0O!IQ'6(C$9%QFZOT$GG+0H81*%$,MCT[-J4
M/8S71`KDHOOEF=HT'=Y<?%S\8["H0K:>>[#ZGA2M)05O[`Y[%0[Y`5%?+W/M
M[L[2=SNE[];=@+@\)U::RZ<NU1H]\+!?ELC'W!/Q$K4\4EFBP6K'0#@&\K*[
MES@OF%HWU->TA_7F'&0<V>YD68E?CJRKSP":Q[6[:O1<:^0[\(9N1\G,S>Z3
MG3].;P""LJ65?.98]E:IS5]W&T_E8?]`1NS&JY.GW5\&G"2G<H<UUD("I37G
M6&,HY]7G&X_DX&AE$E;L9;%^MFN%S*2+7UJYS<@!FC,-Y#:.4PR]?66*E=X%
M*EO@(1Z81;<O`T+[%32B^ZHH:W)G^S#8!MQ[#%WBU$>?I[J58\]_U#V2[%AO
M=^JVQYIPN`%`U!?JGWLN0&9L+#<]3;;RP:[M8^+RR*@3'1`0ZZ/H7)1]@FP@
M'1+K]W9`\=>_]32K%HKKT:&W?7"*M+C`>2UAS_S7[8#B2BI2]7@WM?%&:@-Q
MHP8VUZ"&W$9]M?ORV(PK.'?BQ/_R.33,.J2M/_C%+Q3.9GSU\!.*)F&(K'M!
M.5R2_:CD\P(>?R*T5(;<:U6[-\W:7!56VC1'(;<'70D\=6^K;J-ZD"6A&<L+
M#STK4=\T07=FLS07HK9&[WLE40U*:?B[V^/O*@ZPVQE]7FVV#X6[RGH]"&7/
MQ(EEX9DWB^-[`LG-*]GLEG.4.>^.GR5N`[)=57I/"D3:DAE$V1"1+Y(1D*7>
M@T%U&S+D1'@4D3H]`7>*)M9RZDHN24GD*8907_\BY:(KW%L@Y5(/@Y7[AJ96
M%)V<7DJ<JM\9D3H*PCX5PLYX(\1B0^Y1^;K>3;S1PX[EYQY#YT\^+8'/^&0F
MA6B/8DG/D'G.EZ@,4U`?2/Z;R[K^H*CB^T66NI;EYI^??Y.[IHJ2&V/5_:C6
M;/M".!\YU+M#<5H;F0/%6HF1U44Y,%5@_/NB@J'.7=P,.*,)UJGHWKJ%>A`<
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MT#4]"!PR)K,^VR4W\494$F`6&OA6-D?+^&RG6;W5[M_D51*'`*'<E$WW`OW\
M9A00A]'82U;V5&/RM^A16L,C):<!);P`LKQ:7%\JZ6%W.3.>U+S@BY8>8!IC
M,/LY`LP,O^TWUK\<18!;G/'8Q]=WERO)RVO`C\)\Q7`M))FCQA8R8X85IHMQ
M]E$Y4MPDF$UT,T08?T,IKQ:HY_&@0V]F>VSCJZFMGJ]D]01/DZ"5W$R5XI6%
MC5B&F44OSF<L?*08.A62_2C:%8^/=\"WXTLA\]$I>T.6SQ((B![JM+[]3!Y`
M%3'G:=O?+F4&ZSN.RAU%=6+DSO1(?,QIRN7CD@6IVWJ\XKG/0W&39=QV'!4J
MQ%QE3)YQX,7>:K+-@.L7>TB6/X:U,BMC>WL2$_M8842?L?AB''<_<D\^J^6X
MS4[!6<7Z*[T\%4=D@WC.4M+)E'3N._%"57-8/H=#RL*2;,\Q:A:Y&F;I.=>%
M4XZI[.:C)+3-><B15*O+)*Y6B+:^FS0R[$S;(+8>3KY-W8+[W3;QX_#/07."
M%*8P!JA2'^9)$GQ'`52&)B(N7KY7(A73Z8]]Z1GB2:\"@[NZ1@HWC,U2:99;
M@V8++Y9GX([-12'H<5M_I=V#-)6'C@@$M-=C$OO?2!?T[KW](11%RI;L:5]=
M!CHR%>7NQ=S:6Y^'2$QL'P;-'?R^O5RL&+U(U5ZPON.QLDS4=MI3JQC5SU9K
MQ[Q*F?V1@DB0E'R6[;#G%$&Y7OSZ_BHD5E)IVS&]<C$R)TNR5:L;O7S>_7CK
MCN0!H3WN^^SNHKW^>'E]??F[[!%6GTYB]`<RJ=J585GRW"F(BN5/1J2K1RC1
M`<6+<;9$I9=(U4X:(AJ:;9F\'?3R(@'4(G#;I^N[P:7;)V9'5$'&:\(V/E'<
M(\Y8XH_GI+'K`2C[&TWQ2%=+!>4CL?*EB4WM6H[[YU.TX96N4T7/]O.-9K"V
M9+7.UN?;U?3Z%3;'[$P#0$W:3;NAT/U<VP$\EHK3CNH;=E9,Z2)$QU&]IU8>
M52Z8%/<VA&5PE0K\DKK54_S>$(%H1GYL+FF"P2D7%4A*I)!^="115E@`PX2F
M_#^]H=79Q]L]WREO8/6Y;.],<D*<H5!T;S,ZX(2G:+!C@?CMLBNV-A6_/WC-
M6XFD:'+WLOM7.00/:&]?F15`7`.F8>ACKIJ'NY.0>IF*:+^@-L)MS:\FK6_F
MG4F44=Q?(:I!CD`:BYXJT7KZ9XZY:_=]DB-`4XS;P`Y:1D1V!1AL89H0@3;L
MLYW^U"+W7Y>>O_$Y0ES.P-<T9?M:&"*UN2KN<,DNOEDL;G[XCP````#__P,`
M4$L#!!0`!@`(````(0#%]M$%%0,``-$)```8````>&PO=V]R:W-H965T<R]S
M:&5E=#,N>&ULE)9;;]HP%,??)^T[1'EO+N1&$%`U5-TJ;=(T[?)L$H=83>+(
M=DO[[7=L<XD-990'2/#??__.\8E/YK>O7>N\8,8)[1=NZ`6N@_N25J3?+-S?
MOQYNIJ[#!>HKU-(>+]PWS-W;Y>=/\RUE3[S!6#C@T/.%VP@QS'R?EPWN$/?H
M@'L8J2GKD(!;MO'YP#"JU*2N]2=!D/H=(KVK'6;L&@]:UZ3$][1\[G`OM`G#
M+1+`SQLR\+U;5UYCUR'V]#S<E+0;P&)-6B+>E*GK=.7L<=-3AM8MQ/T:QJC<
M>ZN;$_N.E(QR6@L/['P->AIS[N<^."WG%8$(9-H=ANN%>Q?.5F'H^LNY2M`?
M@K=\=.WPAFZ_,%)](SV&;,,^R1U84_HDI8^5_`LF^R>S']0._&!.A6OTW(J?
M=/L5DTTC8+L3B$@&-JO>[C$O(:-@XTT2Z532%@#@V^F(+`W("'I5OUM2B6;A
M1JF79$$4@MQ98RX>B+1TG?*9"]K]U2(5T<%DLC.)@'XW/O$FTR1,TO^[^)I(
M!7B/!%K.&=TZ4#6P)A^0K,%P!LXRL@CR<SXR"$G.N9.3U%10<]B.EV4ZG?LO
MD,%R)RE.)1-3L3JC.)KX@'=@A,C'C)?9I!AB<)TC6VZN7&A)/)(DIF)U26&@
MP3ICM.O2)R<M7%CC@)@%)D"A);G*;>`%H3F\>G?8@(,(QW"7\R;%%I2U:J$E
MJ8*"$TA^+*Y+"@,-ROYZ-"FVT*QB*K0DUOFRH,Z/&3CI1W"DV,*)S"4++3F/
M<W[,P,D^@B/%%DYLX6C)N]7T[K`!)9O9Z*2X7$U2;$%9SUBA);J:(EU-)_4T
MUNPJ;J0Q\/*/X$FQA9=:.=.2?;%/\S0)4^L@68TU83R-\FD69P<?`R^$0_7Z
M]"FU!7@T5H=PL=,<"),@SR*;T!"%<9;'410>G4Q$JQ=<WF'HMR<Y/)[?.T2M
MT8AQDL21?6#L7,XJ-)QNRKIG#6B#OR.V(3UW6ES#\1EX&3S>3+=D?2/HH'K3
MF@IHI>JR@5<G#(TK\$!<4RKV-[+I'U[&EO\```#__P,`4$L#!!0`!@`(````
M(0#?EWCGL08``'L=```8````>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULE%G;
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MF^-_`!+H"IQ(=*(,>[3+A5PE(DE_[F4)C(8%?BS[\N&^;5X"4S7FGMVYM#4H
M[HSGMU=DEF*Q'RQXN,20[4P:OCW(]'[YS41N@Q`-D"P,'(0BBC<0JPMD:6A=
MN)D5^]QLU)7)W6V.]B+&,;NX'Y:A`9(-T;7K*KP?"`$3$)_`[1M;L"'HKSQG
M-P9([$$2BBAN(0@UXV0Z-0M>AV:5EZ2HB-Y8`V0U)%5(&>>*`@H"R%3NUD9X
MF7KV>4W+F;V(\1/T]AH@*12=R@7+:4'L:2;DY7I"+Z7T;F?4@ADMYQ9*"2`Q
MABV^W'2P%KXU7[E6(91,K_@1NTW)@ADEEB@-$(B4R`4+9$',D6<FI.SDFBP+
M%LQ(L4AH@``I)7)F+GRS,,)XB2,AE<\A9<&,%&LV#1`D%0F7'\B>;Y9)<J7@
MA5&DZ:$:T(P6NZ]&#!252AGK@IA%YO)+8B7F"3N(,E$(UF%Z\+@.L;"2))(N
M31`P@DBB.+JBZ\+J[>3J&M`L9,XQM"%BC$8YA7/Y0G:@\L`_E<KU#0V<E>#I
MY$"P_<#%+"Q:``8#I_)TQ(P`1)RXBJ#4K`9/IP:*3:BY8L&X`0:II7$T*C8`
MF,^W`DO9,>F_+61V^\3Z,^;BBAA@EZPRKP4QI;[J*R5BMSY*;9;LBPFZCQCH
MT2QAO5(P\[5\SI)^,=;^V-4PYA,P.(]2+K/H`I4EN1:M6>(OQNH?L_MJQ$`B
M99Q$&4,4!"$BJ6)7B325LX:```TW_74I7\\QQ@PP?HF[>V.=W8(0>G+6-!C0
M5-IB5RM`#S$0.Z44%P]JE]))(R7&YL&TC9D<SX68U;I&#!#,DX359$'LF<Q<
M<"G!64-!@I@3<7,KQ\@!!ILA9[)<H`LPR\1=36E9;9ZLN1*4G-!B"=.(05K"
MA0-JC9BOLK*R/)T5B+C/*F'1T!(PP"K)69(+8C8[M+<W:/8Y=`:M\0CP)`ES
M"!B_.<<=\(J!!])KW&;-`#F>`0D?3XB!D,4I:]R"FI6[FM;7K!D@QS.`]YM&
M#/2CB&7*4EU0@$BO=N2L.2#?F`.NIS";@,$YD$0C9E?M-&:S9H`$\2;5S\:/
M1@QJ@72YPIY\U?^APM25"K/O)J97_X"FVI\P+="(P52F/-4%VH%VYIE)N!23
M_ML;LP'->+%X:,0`KY5<N8!`O(@]S;T=,25F!7JRBBF+9L18SVG$8,"2C!5@
M@?8K<D+)S1)^-19^3R2A^A&#U;\:ES\%2.'MQBDUJ]73XP;*3NJ?Q44KP%R)
M"R;U)H82G#4'%.BWB>!ED\9W^AHQ/D'6+,5-"*7'1H'="\6&Q$\:8SP2N+1J
M!1B?YFA<W<90HFPX6*+"KO,G3,=3(G5[?2Q&P&`Q1J/=D?+M(EXYQ:0,9\T(
M-9X1Z4A;_!F0"O,&BV\HT0M0C]4J]T),R<V:$VH\)U)V:XT8N/4[\R@?Y8Q_
MP2#)2GA>"+V8S8MI6_+A*BJ#_#E/(P9IV@>NRWX->OD&@%)DHV,BQ?%3`W^+
MI6/``$4A1DE&.VZNO-?5E-^L"1*/)PC?M6G$`"\ITF3TJ$H0JTA>FV[F0(JH
M],38C0=)RL:K'CRO0WA9_^;C-$&\^3@-9UUP%'2LVJ>JJ`Z'+M@TS_8<2YH7
MVI=?X8Q-BSLM[9$)^[TP9V_#[\N+P1Q]G<NGZDO9/M6G+CA4.^,R6F1&N%HX
M/(,O?7,>3FH>F]X<>@W_[LTA9V6.9**%`>^:IG_]8H_G+L>F#_\#``#__P,`
M4$L#!!0`!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q
M+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]
M&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_
MW^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$CO
MVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,<Q-N(BP@E<15,8"'P'=
MB%76JM5F)<(T]E",(R![>S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T
M0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I
M@O%TS?`4P2AG6NO76U=V<OH&P-0RKM?K=7NUG)X!8-\'3:TL19KU_D:MD]$L
M@.SC,NUNM5&MN_@"_?4EF5N=3J?12F6Q1`W(/M:7\!O59GU[S<$;D,4WEO#U
MSG:WVW3P!F3QS25\_TJK67?Q!A0R&D^7T-JA_7Y*/8=,.-LMA6\`?*.:PA<H
MB(8\NC2+"8_5JEB+\'TN^@#00(85C9&:)V2"?8CB+HY&@F+-`&\27)BQ0[Y<
M&M*\D/0%353;^S#!D!$+>J^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$N
MCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+
MKS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2<C<;X5PQ!39P4.@78)Z9X*
M'>"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX
M.(N#<N9B5L0=8'Q8QKN+8\>UO5D"53,+2L?VW9`X8NXS'"L<D)@HI.?XE)`2
M[>Y1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-Z
MAQRZ2$@(S$J$'Q+FF/$ZGBD<E9$<XH@5#7X3J[!,R,%<^$5<3RKP=$`81[TQ
MD;)LS6T!^A:<?@-#O2IU^QZ;1RY2*#HMHWD3<UY$[O!I-\114H8=T#@L8C^0
M4PA1C/:Y*H/O<3=#]#OX`<<KW7V7$L?=IQ>".S1P1%H$B)Z9B1)?7B?<B=_!
MG$TP,54&2KI3J2,:_UW99A3JMN7PKFRWO6W8Q,J29_=$L5Z%^P^6Z!T\B_<)
M9,7R%O6N0K^KT-Y;7Z%7Y?+%U^5%*88JK1L2VVN;SCM:V7A/*&,#-6?DIC2]
MMX0-:-R'0;W.'#I)?A!+0GC4F0P,'%P@L%F#!%<?414.0IQ`WU[S-)%`IJ0#
MB1(NX;QHADMI:SST_LJ>-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@
MK,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)
MQW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q<J2(EH/&PSZ['B*
MU0K<6IKL&W`[BY.*[.HKV&7>>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)Q
MTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2
M(=4.EJ$-#3.5A@"+-2<K_UH#S'I1"I14H[-)L;X!P?"O20%V=%U+)A/BJZ*S
M"R/:=O8U+:5\IH@8A.,C-&(S<8#!_3I409\QE7#C82J"?H'K.6UM,^46YS3I
MBI=B!F?',4M"G)9;G:)9)ENX*4BY#.:M(![H5BJ[4>[\JIB4OR!5BF'\/U-%
M[R=P!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@
MA_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/
MR"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR
M@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NM
MK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1
M?<DV'D@72#LX@L;)#MI@TJ2L:=/625LMVZPON-/-^9XPMI;L+/X^I['SYLQE
MY^3B11H[M;!C:SNVTM3@V9,I"D.3["!C'&.^E!4_9O'1?7#T#GPVF#$E33#!
MIRJ!H8<>F#R`Y+<<S=*MOP```/__`P!02P,$%``&``@````A`+D$CJOS`@``
MI`D``!D```!X;"]W;W)K<VAE971S+W-H965T-3$N>&ULE)9=;YLP%(;O)^T_
M(-^7KP#Y4$C5I.I6:9.F:1_7#IA@%3"RG:;]]SNV28I)1M.;$,)[7C]^CXVS
MO'VI*^>9<$%9DZ+`]9%#FHSEM-FEZ/>OAYL9<H3$38XKUI`4O1*!;E>?/RT/
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M3AFK```^G9JJI0&)X!=]/=!<EBF:)&X\]2<!R)TM$?*!*DOD9'LA6?W7B(+.
MRIB$G0E<.Y,@=J,PGLX^XC+I7.!Z=$FN=O',O'1,]UCBU9*S@P-K#\A%B]5*
M#A;@K/*90,J7\X%@5,V=*M*EH!;0U.=5'$^7WC,T(NLTZW--8"LVYXHXGITT
M'@">*"&YCU.J(ILR'$)>D)P`]%0W8PH+$<+K(XX'J,00-')Z`<[MD==&$_4U
MMF(SIK#8P*3/=EV355&*8/YOC(EO$ZR-9J:7`+S9!H\WYC%\OEF<#"Q`V$M]
MP/'PE'@(-EA;:Z.Y/+)IK%$D!CWJH5M@B0UV77*J:`@8GB:NAU\;3:2'G_5&
M-W#'I^\&-[7YQH-38ILK"@<M6QO-6'!C"BL[=8;V7BWC;$K\WHXPFC&V,87%
M-K?9KNNK*K+SBY/)H*]&,\9H%&;A3>->ZRU`.!0_D)Y6#]&B`5HG^N]N[9Y?
M9C=PYIPU!TB+=^0[YCO:"*<B!6QQWYW"KN+FE#4WDK7Z%;QE$DY'_;6$?T,$
M3A'?!7'!F#S>J'/\]/]J]0\``/__`P!02P,$%``&``@````A``5&;IN]`@``
M+`@``!D```!X;"]W;W)K<VAE971S+W-H965T-3`N>&ULE%7+;MLP$+P7Z#\0
MO$=/4TX,RT%L(6V`%BB*/LZT1%E$)%$@Z3CY^RY)6['LU(^+*9JSPYW9U6IZ
M_]K4Z(5)Q46;XM`+,&)M+@K>KE+\^]?CS2U&2M.VH+5H68K?F,+WL\^?IALA
MGU7%F$;`T*H45UIW$]]7><4:JCS1L19.2B$;JF$K5[[J)*.%#6IJ/PJ"Q&\H
M;[%CF,A+.$19\IQE(E\WK-6.1+*::LA?5;Q3.[8FOX2NH?)YW=WDHNF`8LEK
MKM\L*49-/GE:M4+290VZ7\,1S7?<=G-$W_!<"B5*[0&=[Q(]UGSGW_G`-)L6
M'!08VY%D98H?PDF68'\VM?[\X6RC]IZ1JL3FB^3%-]XR,!O*9`JP%.+90)\*
M\Q<$^T?1C[8`/R0J6$G7M?XI-E\97U4:JDU`D-$U*=XRIG(P%&B\B!BF7-20
M`/RBAIO.`$/HJUTWO-!5BN/$(^,@#@&.EDSI1VXH,<K72HOFKP.%6RI'$FU)
M8-V2A,0;161\>PU+O&6!=<>27,\RVK+`NF.)+A7D.W.LUQG5=#:58H.@?T&^
MZJAY&\()$!N38RC5QR:#NR;FP0394$`K:(R7&2'AU'^!:N9;S/P8<X!8'",(
MB88LV0YC&@4R[M.&>ER?M@D:IAV-A_?-/X`,$8NSB.P804C<LPQD0$-<+\,$
M094PZMV/QW<]OZW0W&&@H#V&#!&+LXCL%&*@`J[95W&Z=PPXQ>#1>V9D-,QM
M[C"GLC^+R!SBUG9G1(*@OV*0.DR"_=0O:W\3="CAP-ZYPYR2<!:1.41B)<3!
M_R0D0PFGW3?@P]23WAK7.P[CG!OOW6I/%_NG8.N[K_88/@CF@H]U.^?=P'=#
MJ*,K]IW*%6\5JED)+1%X8Y`MW;AW&RTZ^]8NA88Q;1\K^"HSF$2!!^!2"+W;
MF#G1?^=G_P```/__`P!02P,$%``&``@````A`)[G)69K!@``WB0``!D```!X
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M[^,TWBSB4T2C3?/$9N`E2;XS=+IA(:I<5VJ[Q0SXJ;:)ML'K(?\K>9]$\6Z?
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M,&9#')>5RD@]\B&Q5@G+_%`1W$@I]3?<R&HQ-Y:7E<T#G6M@*`<<.3"2`ZX<
M&//`K44L.=U,[C'2A3%]@)D]P,P?8!;WF*XXQ=X]IB<RRSN,*66AU0.,_P"S
MKF8$N]`]5+%+ZY?/-V7R8K7H2>;F6K=,*9O;G*&_UWP@98PA)!Q(C"#A0F(,
MB0DDII"806(.B04D/$@L(;&"A`^)=14A&)"\)ABP^J[)Z(%.Z?##5*9TG[8Y
M0PWX8,1K<0@)!Q(C2+B<Z!;/@$:GUVA(=X8QE)C<2O0ZBL(4*LP@,8?$XK85
M75I_2OWPH,(2$BM(^)!85Q&"YV@=]0G/,5KVG)3*;,Y4>0X2#B1&D'`A,8;$
MY`YARHN".XQXC<T@,8?$X@XA/R1[=QBQ)4M(K"#A0V)=10CFH^?Y3YB/T:+Y
MNG*^XTB[R#,MLRT]G`QOBRVK*]VFG=MBH]'K2LX>">6=IBG)N[R\POEC2$P@
M,15:T:!,*,[Q#"K,;Q5:EI+$%E#!@\02$BM(^)!85Q&"T]@>I+RC@1>FK);D
M.,D3-D=:?'>C*?EQ>%MJR$M)AY=RMQI*\:BRLEN6_O+6/H;$!!)32,P@,8?$
M`A(>)):<X(.IWIA7I0#;A5*N&;^Z\KJL?&^L!9OU?LMFK)9H,TO.+39G*G++
M$!(.)$:0<"$QAL0$$E-(S"`QA\0"$AXDEI!80<*'Q+HDF'M;-QE?,)]!&VU"
MDJM>/Q2X;#MIJ6Y?H"K?8<3!R`@C+D;&&)E@9(J1V06YI!M:T(@WX3F66&#$
MP\@2(RN,^!A95R*B#]GN\.W-%OB0;R8+"]FF-)ZVP:%*'T+$P2HCC+@8&6-D
M@I$I1F88F6-D@1'O@O`EO$D/C:+AEUABA1$?(^M*1/0AVRK^A`_YSK+H0VE;
MTF;G=72O[C2*!SXZZ!2'87@IK_"I`R1&6,+%R!@C$XQ,,3+#R!PC"XQX&%EB
M9(41'R/K2D0T(=N`OC4A.TO%*P]V'"P_$S8EL]D7J,)L0XPX&!EAQ,7(^()<
MKQUI^3S!$E.,S#`RQ\@"(QY&EAA98<3'"'OM@]GEOA.X'_EK'?R8_QBENV@8
M'0Z9%B:O[)6-#N6S:Y2_3N*:?3JVHE,P*6X;?3J25^..T:=S=S5NFWTZ0E/C
M0[-/)VEJW#'[=*"FQD=FG\[5*%Z_-HC>+CD'N\@+TEU\RK1#M*6N-&H=VOU,
M^?LI_$N>G(OSY9<DI_=*BG_W]!Y11"\"-&H$;Y,D+[^P'[B^F?3\/P```/__
M`P!02P,$%``&``@````A`+#$6:`H`P``EPD``!D```!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&ULC)9;;YLP&(;O)^T_6+XOQY"30JJ2JMND39JF':X=,,$J
M8&0[3?OO]]E.2$PZEEZD`5Z_?KZ#^;*Z?VUJ]$*%9+Q-<>@%&-$VYP5K=RG^
M]?/I;HZ15*0M2,U;FN(W*O']^N.'U8&+9UE1JA`XM#+%E5+=TO=E7M&&2(]W
MM(4G)1<-47`I=K[L!"6%6=34?A0$4[\AK,7682EN\>!ER7+ZR/-]0UME302M
MB0)^6;%.GMR:_!:[AHCG?7>7\Z8#BRVKF7HSIA@U^?++KN6";&N(^S6<D/SD
M;2ZN[!N6"RYYJ3RP\RWH=<P+?^&#TWI5,(A`IQT)6J;X(5QNP@#[ZY5)T&]&
M#_+B.Y(5/WP2K/C*6@K9ACKI"FPY?];2+X6^!8O]J]5/I@+?!2IH2?:U^L$/
MGRG;50K*G4!$.K!E\?9(90X9!1LO2K13SFL`@$_4,-T:D!'R:OX?6*&J%,=3
M+YD%<0ARM*52/3%MB5&^EXHW?ZPH/%I9D^AH$@/]\7GB3:)D-K_!Q;=$)L!'
MHLAZ)?@!0=?`GK(CN@?#)3B?(K,<?:S_"A5BU"8/VB7%,XP@"@GU>5DG<;SR
M7R"G^5&360U\]II).'4UFVM-V"M\(.ZQ(1F7V.\7XD2GQ9I.%T;C9O;&)<H\
MZO<QDLVUY*QP2"!IMY-H,13_(@?Q=.'NG%G-Y$*3N(K-F,)A`Y/;V;0XQ1!W
M7Y\DGK@[9U8SQF85<],#\);2?[V'PP:-?\FF&R^&@SE>2;UHR#C(3F8UL\`@
M!%X83N<]@:VM5;P?A<,X=1G'V;1XR#;H[\QJSFS1N;TMFA7<@`9G[3)]XVA:
M/$2;N4G)K,;9.1XF[AU-[^(D3@^^P5OE_\75BX:4P\-A-0YE3V`S:!534_TP
M&6G`A<LXGD$M'K!-SHUM=LZL9HS-*MXMOY,^F&5._L;9C'H(-VBL["@:HSM*
M[-F-)TET3KZEL_/1CH^&BAW=T+J6*.=[/?M"2'E_MY_+#Y&9K/T#&(L=V=%O
M1.Q8*U%-2U@:>#,XD\(.5GNA>&>&TY8K&(CF:P4_@"B\O@,/Q"7GZG2A1W?_
MDVK]%P``__\#`%!+`P04``8`"````"$`O/",;K@"```/!P``&0```'AL+W=O
M<FMS:&5E=',O<VAE970T."YX;6R45<MNVS`0O!?H/Q"\1V_+#U@.X@9I`S1`
M4?1QIBE*(B**`DG'R=]W2=JR[+2)>[$L<3BSLT.MEM?/HD5/3&DNNP+'0801
MZZ@L>5<7^.>/NZL91MJ0KB2M[%B!7YC&UZN/'Y8[J1YUPYA!P-#I`C?&](LP
MU+1A@NA`]JR#E4HJ00S<JCK4O6*D=)M$&R91E(>"\`Y[AH6ZA$-6%:?L5M*M
M8)WQ)(JUQ$#]NN&]/K`)>@F=(.IQVU]1*7J@V/"6FQ='BI&@B_NZDXIL6O#]
M'&>$'KC=S2MZP:F26E8F`+K0%_K:\SR<A\"T6I8<'-BV(\6J`M_$B_4,AZNE
MZ\\OSG9Z]!_I1NX^*UY^Y1V#9D-,-H"-E(\6>E_:1[`Y?+7[S@7P3:&2563;
MFN]R]X7QNC&0]@0,65^+\N66:0H-!9H@F5@F*ELH`'Z1X/9D0$/(L[ON>&F:
M`J=Y,)E&:0QPM&':W'%+B1'=:B/%;P^*]U2>)-F3P'5/$B=!,IO$D_Q]EM!7
MY`S>$D-62R5W"`X-:.J>V",8+X#9.LO^Z0PLV3TW=I/;"F@-:3RM)EFR#)^@
MA72/67O,%*,!<T2$(#Y4`*KG%:20T-][>ZC`;CJM()F>%>`A4Q?L6"\]U7M;
MQX(AK9&+-)^?"7E,-L),!L2)4X",G;ZM;,$%!A/'_LVC@=?EL/:8F4L@SM)A
M]405TKQ<U8*MJLTTB>)LH/2"?CGSD4_C8?5$,/\?00L>"1X[YP7]\CN"<,@N
M=VC!(\%\\.`%_;(73.?'U1.'=JR/7IJW@[3@LR#S<YL>LP\RGYTWU@\F_]X*
MIFKVB;6M1E1N[=")(8[AJ9^':YB'B3OYPP+,HY[4[(&HFG<:M:R"K5$PA4B5
MGVC^QLC>O5@;:6`2N;\-?'@8O/=1`.!*2G.XL3-S^)2M_@```/__`P!02P,$
M%``&``@````A`&O<64_G`P``V`X``!D```!X;"]W;W)K<VAE971S+W-H965T
M-#DN>&ULE)?;CJ,X$(;O1]IW0-PW9PB)DHPF'&9&VI56JSU<$W`2U("1[72Z
MWW[*.*1CTXVSN4@"_OSC^JOP8?WUM6V,%T1HC;N-Z5J.::"NQ%7='3?F/W_G
M3[%I4%9T5='@#FW,-T3-K]O?OJPOF#S3$T+,`(6.;LP38_W*MFEY0FU!+=RC
M#EH.F+0%@TMRM&E/4%$-G=K&]APGLMNB[DRAL"*/:.##H2Y1BLMSBSHF1`AJ
M"@;CIZ>ZIZ-:6SXBUQ;D^=P_E;CM06)?-S5[&T1-HRU7/X\=)L6^@;A?W:`H
M1^WA8B+?UB7!%!^8!7*V&.@TYJ6]M$%INZYJB(#;;A!TV)C?W%7NNJ:]70\&
M_5NC"[W[;]`3OGPG=?5[W2%P&_+$,[#'^)FC/RM^"SK;D][YD($_B5&A0W%N
MV%_X\@/5QQ.#=(<0$0]L5;VEB);@*,A87LB52MS``.#;:&M>&N!(\3K\7NJ*
MG3:F'UGAPO%=P(T]HBRON:1IE&?*</N?@(:(;B+>501^KR)N:`5>N(C_CXI_
M58G>53S+BT,WC/1CL45<@TUIP8KMFN"+`;4'(Z=]P2O978'RZ(^(YN;89X:!
M4USD&U<9M,`+"EE^V8:!O[9?(#/EE=E-F<"-9"81S,(T;CJQ*R/IB/!<\6=G
MXXWW/DJ7?"1XH4#8M]@A'VKL/E38Q[4QALH[R:'&CCS$W10)PE!FDBGCR40Z
M)6(%R::(0N13XDY$,@/*Z]Z,>1,X#*_"79[\12"/?R>8X(Y1/=`2J9;(M$0^
M1T@.P%`?=X##&Q/LO55J&*@.""8:WH<HBJ,H5"HE$01\OZO(+J9:(KM_BNM%
M#O_((OF<B&0!S&F/6\!AU0(EQ3O!!(,%RFN9C&V?!Z\E,BV1SQ%2[##[/1X[
MA]78E<EL)YA8Q+X(U:PDHGTN^5HBTQ+Y'"'%#[/NX_%S6(U_(5?=3C`B]XZE
M5$8RMGZ>?2V1:8E\CI"BYQL^91W4KP6\D^I"K+@@&#$)^'[@^Y[JA"#FZD!+
M9%HBGR,D)Y:R$_,+`8=5!Y:*`X(1=>!;D;)$)6/SYX6@)3(MD<\14O@N[`#N
M*V$^_H&6#5BJ[\&5F4EP\@'B*S:F5T;,)T^!HTRGF=3N1<HH<JE9ZBZ'SS=+
M=R^")GRQM9*60761V\'^GA?)<I@(/2M2WI#DVC[C3ZI',CW"#QI\(!\_2+@@
M#A)BA]PB<D0):AIJE/C,#PD>A'"[*PXPB;N"+2GL+)7[&3_8#$>36P.<*_KB
MB/XHR+'NJ-&@`T@ZU@)6*").)N*"X7[88.XQ@Q/%\/<$)T@$FUV81DWC@#$;
M+_B6]G8FW?X"``#__P,`4$L#!!0`!@`(````(0!=^6E2BP,``%,,```8````
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&ULE)==;YLP%(;O)^T_(-\W8/+51"%5
M0]5MTB9-^[QVP$FL`F:VT[3_?L>8$&Q"16_"U\M['A_[F)/5W4N>><]42,:+
M".%1@#Q:)#QEQ3Y"OW\]WMPB3RI2I"3C!8W0*Y7H;OWQP^K$Q9,\4*H\<"AD
MA`Y*E4O?E\F!YD2.>$D+>++C(B<*+L7>EZ6@)*U>RC,_#(*9GQ-6(..P%$,\
M^&['$OK`DV-."V5,!,V(`GYY8*4\N^7)$+N<B*=C>9/PO`2++<N8>JU,D9<G
MRR_[@@NRS6#<+WA"DK-W==&QSUDBN.0[-0([WX!VQ[SP%SXXK5<I@Q'HM'N"
M[B)TCY<QGB!_O:H2](?1DVR=>_+`3Y\$2[^R@D*V89X4V?ZD&4T436'FD*=G
M9,OYDW[U"]P*((BL!#J(_'<.<Q_J*'X3IGU^#OE83=MWX:5T1XZ9^L%/GRG;
M'Q1$FD(:=#:6Z>L#E0E,`\0:A5/MFO`,+.#7RYE>3Y!&\F+H6*H.$1K/1M-Y
M,,8@][94JD>F+9&7'*7B^5\CPK65,0EK$SB>ZN?O-QG7)G`\FX#?VP2^&4V5
MJ`>BR'HE^,F#90J\LB1ZT>,E&%[/!J1!:^^U.$)SF*\(29B2YW6P\I\AZ4FM
MV!@%_#8*;"OBLT+/&S`T(#"$X2!:K$'T-&FRC;G1CALZ<;N*<:.P0"`+;1"]
M3L:P1-_.C'X)=*UQ3QIW0V@4DY9B:BOBMQ06(9BT"=\FT^((P>B;&9G9<3=&
MT2:;VXJXJ[BP6V10"</)M-@FN[7C;HRB3;:P%7%7T4,V>P^9%MMDV%WH1C*M
MBF""IQ,W9>9Y&[T'#*II>,JTV`%SZFMC).W`V"V%KJ2'37\P!V\.6NRP72K,
MU("16&Q.F<1=20_;XCUL6NRP76P-FY%8;$ZAQ%W)Q<0J`PS[Q?#$56J'SEE.
MFUICX3G5$E_1]/'I37CPQ&*S9;>W$.S4X:;6M/E"IV3B*YH^/KU9#^<S6WN;
M+W2K`AN-Q>>6Q15-'Y_>JH?SF8W=XG,K`W<W_]`MC2N:/CX89YMOV#<,6C:W
M2L)+`%,EM::=1T>B.S]M,ZNVQC"XG>)@/KZL%U,HIF4SG4A.Q9[&-,NDE_"C
M;L$PO-O<;7K*NMEK'D!W5I(]_4;$GA72R^@.7@U&<_@F"-/?F0O%RZK/V7(%
M?5EU>H#FG4+?$(Q`O.-<G2]T5]+\'5C_!P``__\#`%!+`P04``8`"````"$`
MM!#)PV8"```6!@``&0```'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6R45-F.
MVR`4?:_4?T"\CXD=9[-BCR:*TH[42E75Y9E@'*,88P%9YN][,8FS34?)2VSB
M<\]RN3!]WLL*;;DV0M4I#H,>1KQF*A?U*L6_?RV>QA@92^N<5JKF*7[C!C]G
MGS]-=TJO3<FY1<!0FQ27UC8)(8:57%(3J(;7\*506E(+2[TBIM&<YFV1K$C4
MZPV)I*+&GB'1]W"HHA",SQ7;2%Y;3Z)Y12WX-Z5HS)%-LGOH)-7K3?/$E&R`
M8BDJ8=]:4HPD2UY7M=)T64'N?1A3=N1N%S?T4C"MC"IL`'3$&[W-/"$3`DS9
M-!>0P+4=:5ZD^"5,9D-,LFG;GS^"[\S9.S*EVGW1(O\F:@[-AFUR&[!4:NV@
MK[G["XK)3?6BW8`?&N6\H)O*_E2[KURL2@N[/8!`+E>2O\VY8=!0H`FB@6-B
MJ@(#\(ND<),!#:'[]KD3N2U3W!\&@U&O'P(<+;FQ"^$H,6(;8Y7\ZT'A@<J3
M1`<2>!Y(PD$01X/1^`X6XAVU`>?4TFRJU0[!T("F::@;P3`!9I>L#_UY/QE$
M<C4OKJ@M!;2!W=AF<32>DBVTD!TPLW<PX;##$)#O/(#NXQY<T:6':-31MS9G
MMY`X/&$N+/0O+7P<WX&A31AU\</QB==K>TQ\AAET[BZ4`?)X>%>48LAW<C")
M.G[OP&/&?GO"27SZ?J$/`WBN_W%R![[6C:]T/29N=:/_B`X?$77@:]%3,WU8
MC^G"#D^F?%A_M/WD-W3%OU.]$K5!%2^@A;U@!*ZU/]A^85733M=263B0[6L)
M]R^'\>\%`"Z4LL>%NSJZ&SW[!P``__\#`%!+`P04``8`"````"$`M/JA[A8#
M``"D"0``&0```'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6R<EEUOFS`4AN\G
M[3]8OB]@$LB'DE1-2+=*FS1-^[AVP`2K@)'M-.V_WS$.#,B:M+M)8O.<-W[/
ML7U8W#X7.7IB4G%1+C%Q/(Q8&8N$E_LE_OGC_F:*D=*T3&@N2K;$+TSAV]7'
M#XNCD(\J8TPC4"C5$F=:5W/757'&"JH<4;$2GJ1"%E3#4.Y=54E&DSJHR%W?
M\T*WH+S$5F$NWZ(ATI3'+!+QH6"EMB*2Y53#^E7&*]6H%?%;Y`HJ'P_532R*
M"B1V/.?ZI1;%J(CG#_M22+K+P?<S&=.XT:X'9_(%CZ50(M4.R+EVH>>>9^[,
M!:75(N'@P*0=298N\1V9;R?872WJ_/SB[*@ZOY'*Q/&3Y,D77C)(-I3)%&`G
MQ*-!'Q(S!<'N6?1]78!O$B4LI8=<?Q?'SXSO,PW5#L"0\35/7B*F8D@HR#A^
M8)1BD<,"X!,5W.P,2`A]KK^//-'9$H]")YAX(P(XVC&E[[F1Q"@^*"V*WQ8B
M)RDKXI]$(.(D0GS'GP8D"*^KN'9%M<&(:KI:2'%$L&G@/U5%S18D<U!NG-EU
MM%Y?LPH>C<B=4:FUP(6"\CRMQH0LW"?(:7QBUI:98-0RTP&R:1"30:,;-1-_
M8P8AVX8PY0-+K2_(UM#7".K^[XHU-DQ0W\;4&[@X1_P^L3DGI@,D.D<&Q/:<
MZ(CTC([^QZ@)@DW8J04)ATXM,^XPP<#I52*Z2FPO$3V?L)#W%]0$+3$DL]US
M8S)(]=HREWQ>)2)+A/7.)SX))N%HW$_6MH_,`@*GMD5Z3N$8OM^I"1HZ';7Z
M]6E:6^:24TM,:Q_08OKQT=7X;3<^[,3W_(5]?Y>/I(&'O@:I75OFDJ^K1'25
MV#:$N=VFKWF#ZZU;N\O>#-SW1KQ)/^=KR]B*!-ZL_W1CGW:=CP9(=%$`FJ99
MPBL"MFJV*]JF43"Y9QN6YPK%XF`ZG@][I9VUS7A-YG"3PX4\F(^@2=?S;OL`
MFF1%]^PKE7M>*I2S%"0]9P+[2-HV:P=:5/6]O!,:VF/],X.W(08]PG,`3H70
MS<!T@O;]:O4'``#__P,`4$L#!!0`!@`(````(0!VP;`$&@P``#U!```9````
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;*S<6W.BRA8'\/=3=;Z#Y?N.`363
M6$EVC2+>%>^7-\>0Q)HH*74F,]]^KX9>--U_-\%SYF6;^;E8#?2B@1;V_=^_
M=F^YG_[AN`WV#WGKZCJ?\_>;X&F[?WG(3R?N7[?YW/&TWC^MWX*]_Y#_[1_S
M?S_^]S_W'\'A^_'5]T\YRK`_/N1?3Z?W2J%PW+SZN_7Q*GCW]_3-<W#8K4_T
MS\-+X?A^\-=/X4*[MX)]?7U3V*VW^WR4H7+(DB-X?MYN?"?8_-CY^U.4Y."_
MK4^T_L?7[?N1L^TV6=+MUH?O/][_V@2[=TKQ;?NV/?T.D^9SNTVE];(/#NMO
M;[3=OZS2>L.YPW]`^MUV<PB.P?/IBM(5HA7%;;XKW!4HT^/]TY:V0.SVW,%_
M?LA_M2HK^S9?>+P/=]!LZW\<$W_GCJ_!1^.P?>IN]S[M;>HGT0/?@N"["&T]
M":*%"["T&_:`=\@]^<_K'V^G4?#1]+<OKR?J[C)MD=BPRM-OQS]N:(]2FBN[
M+#)M@C=:`?IO;K<5I4%[9/TK_/S8/IU>'_+%XE7YRW71HO#<-_]X<K<B93ZW
M^7$\!;MY%&3)5%$26R:A3TYR<W&2HDQ"GS*)1?E26BW)!>A3+E"^LDK7-V+%
M4Q:C;\,MID]NYS;+<C=R.?J4RZ6OWA<93Y_<3OH"=$B&*T:?W,!5R2Y_N0V[
M(F6+[N2"]"D7O%5[/V4YBZHMZGSJWFSK*+HD6H3^N&PM+>Y@\<=EZ\D]+0H[
MXWIR;UF)[LJV-RWN./''9>O)/6BIGOBDAFWN`O''9?O3YD-7_''1>MK<B;;J
MB<_6D[O`5D>;G6U_BL,Q+!GQQV7KR9UHJTX\OYZ%:%0+!TEG?5H_WA^"CQR=
M>6C7'-_7XCQF5406'AZCHR(>,/]MO*2!4F3Y*M(\Y*D>:"@\TB#_\]&ZN;LO
M_*2!>2-CJF=B](@:1XA16*1U3*B;X)K0,*%I0LN$M@D=$[HF]$SHFS`PP3-A
M:,+(A+$)$Q.F)LQ,F)NP,&%IPBH!!2J3N%;HJ/@3M2+2B%KA7JXRJ.*QC<+@
M"%[$,:%N@FM"PX2F"2T3VB9T3.B:T#.A;\+`!,^$H0DC$\8F3$R8FC`S86["
MPH2E":L$:(5!H^2?*`R1ABZO$H.(7;3T2JA&,1:=2.*1IJR'U.*0N%I`ZB`N
M2`.D"=(":8-T0+H@/9`^R`#$`QF"C$#&(!.0*<@,9`ZR`%F"K)*B%1&=-_]$
M$8DT=#*C4HT+!$]%,BBMBN*0N(I`ZB`N2`.D"=(":8-T0+H@/9`^R`#$`QF"
MC$#&(!.0*<@,9`ZR`%F"K)*B51%=0FE5=/XVCR];1'18+-S)U4C$Q69</G;1
M/!W%0;R8`U('<4$:($V0%D@;I`/2!>F!]$$&(![($&0$,@:9@$Q!9B!SD`7(
M$F25%*TVZ/+V@MH0T7IM2+F+KUQJ(`Y('<0%:8`T05H@;9`.2!>D!]('&8!X
M($.0$<@89`(R!9F!S$$6($N055*T0J#[E`L*043KA2"%;F(3@T31N`R)@^)!
M`J0.XH(T0)H@+9`V2`>D"](#Z8,,0#R0(<@(9`PR`9F"S$#F(`N0)<@J*5IM
MT#7!!;4AHO7:D)(8)$`<D#J("](`:8*T0-H@'9`N2`^D#S(`\4"&(".0,<@$
M9`HR`YF#+$"6(*ND:(5`1[=6"-',R-47.KV<7K>;[]6`#GZZ53YSA5&D&9!H
M7D0DT>M#2CAI'<;40)Q(2G2IG!A?2OKX4H^#>'QQ01H@39`62!ND`](%Z8'T
M(Z%)5%[#`8@7+Y7<5...;A@'<:(1R!AD`C(%F8',018@2Y!5)-&F:E4DII#_
M_S(*L^AU)*E$`UFB2&[T(JEQ5/@#BYQ3$VOTD"^I$:K.4;05B5Q?]%PN1ZE<
M#:0FDTK?4I1,?ZNG;W.42M]!ZC*I]#U%R?3&[&.?HU3Z`9+'I-(/%273&SMG
MQ%$J_1AIPJ323Q4ETQL[9\91*OT<:<&DTB\5)=,;.V?%46%ZO7[%9*`Y06R+
MHLL\!EK1?"+=DO/A6Y54UFZS2M=Z1=1D%+7&"SI,-&K'E6K=&9=>=8[2ZKED
M3"6Y''43IV\PJ1:;3*DMMF14V0KGONWBG6442)OSJ-8Z3*JU+E-J:SV.2MV^
M/D>I%@=,JD6/*;7%(4>EMCCB*-7BF$FU.&%*;7$JH^0>+=IW)>.L,.,\JK4Y
MDVIMP93:VI*C4K=OQ5%AB_IA(J9&S</$*E]XM2!FK8S+!4GB5Z6XX.V2.2'!
M4<6XE!U)Q>0A=N9(B5HLT2&:2`]'2A1%*\$'8@-;;&9JL<51*4<*M-;!UKJ<
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MO=$$.PWQ7/-5\=R1&(W5C4<-R4&J([E(#:0F4@NIC=1!ZB+UD/I(`R0/:8@T
M0AHC39"F2#.D.=(":8FTTDBO'3&9GJR=,]->R=.SG'M/UD@\'9\\/1L7]37Q
M.)I>20Y2'<E%:B`UD5I(;:0.4A>IA]1'&B!Y2$.D$=(8:8(T19HAS9$62$ND
ME49ZV8AY]@O*1D[+)\M&4G)H`7+$HXAZV=217*0&4A.IA=1&ZB!UD7I(?:0!
MDH<T1!HAC9$F2%.D&=(<:8&T1%III-<(W9I?4B,BW)@+E:3?O<-<:!S%YRU'
M/$=DE@V0BU$-I"92"ZF-U$'J(O60^D@#)`]IB#1"&B--D*9(,Z0YT@)IB;32
M2"\;ZNU+RD:$&V43$3WMRP51$P\F4U2"'*0ZDHO40&HBM9#:2!VD+E(/J8\T
M0/*0AD@CI#'2!&F*-$.:(RV0ED@KC;0:$<_Q7%`C8;A>(Y(2!5&35(K>%@F?
M4V;2IQZ,*_.ZBN)Z<YG"7/JJFQ/OZ1=<-DZR2])6/8K25EV2ONK&[P]UF:ND
M#A67Z<RJB^FF["=]6D'SR)2DK7H4I:VZ)/I(3/@8OVW492YMU9.Y]+W^V>Q4
MIND$F@Z`+9)S3&H'UF24MD51E/[+;]GX7:3."ZI;1Y?I3&>8$R2?U!'.A(@I
M$#$FTKJIW5PVYHAK*HJ+VV&BY>,%<0I:1A7%W-Z9^UE79:'$>F=]=C^;K;/P
M=I9N9,(MIGN1>,7MLCGISE%J-LMA4C_3U9GHQ)+(9<Q*NAREM7BM9IOT[1;W
M2,GCZW]Z-$&\[6&<$"49/:W6(GI>046IGHYR?3+G)1=,GX%R.3W.7XB?'5.W
M.]O\19C&&.6CVP=MO`%RY(*)J#J2B]1`:B*UD-I(':0N4@^ICS1`\I"&2".D
M,=($:8HT0YHC+9"62"N-]&-&7-8GCYE/AD%Y%Z"&ZRJ]I!H>+_J!;,Y?J"AU
M<,0+,M4QRD5J(#616DAMI`Y2%ZF'U$<:('E(0Z01TAAI@C1%FB'-D19(2R3Q
M_K'LVO@4$[U/'+TJM_,/+W[-?WL[YC;!#_&N,(U1C_<Q1R\R5ZV;BI@)H13P
MS1?Z)CQ-P#>W]$UXMH!O[NB;<-+#_,:F;%3H9]JQ*1MM"WY#+UE_#4O9S$4O
M7X=O*IMN4Z(S>:K%"KW`<29_B?*?:[A:JM"S^KA`M5RAY[3/..W#L[N0MOGL
M)M,6GVO7N:O0`VF8W[NKT--;Z%7[NE*E\QY^0Y?[%7&IAM\X](VXIC_WC47?
MG-NQCFW3-^=VK6,7Z9MS[=!-0D5<X&$[-.]._1==\\4]2"^OOZ]?_-[Z\++=
M'W-O_C,5['7X),(A>OT]^L=)_L[Z+3C1:^MT/J27/^E_4^#3>Y?75W0!]!P$
M)_X'-5V(_\<'C_\```#__P,`4$L#!!0`!@`(````(0`Q4+216`H``$0S```9
M````>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;*R;6W/BN!:%WZ=J_@/%^P1L
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M?SC9]<9H!_^`_'Z[.?HG__5\1W(I=:+8YT*JD"*EY\>7+?5`#GOBZ+T^)853
M%`TGFTP]/P8C--MZGZ?(<>+T[G_6C]N7SO;@T7"34=*"+[[_588V7R2BRBFH
M70LL&!P3+][K^MON//(_&][V[?U,?N>H2[)GQ9>?%>^TH2$EF3LW)Y4V_HY.
M@/XF]EN9&S0DZQ_!Y^?VY?S^E'2=N]Q].N-0>.*+=SK7ME(RF=A\.YW]_5P%
M.5I*B;A:A#ZMR$,NE\T_W-^NDM4J]*E5,G=.-IV7)W*E<2H->D"?NEKASK9]
MI2+-@:`B?>J*^;M[)UW(R'.^4J^@Z]&GKN>XM[7HF(&2!Z:N<TLGG8QN5!Z$
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ML.!@R<&*`Q'::XP1H9DA`?,$N"?`/@'^"3"0+KPZN:BM%*5MF+LT:_Y$[DH9
MF;NF*R4#;#*[+%%-A*E2X:#*08V#.@<-#IH<M#AH<]#AH,M!CX,^!P,.AAR,
M.!AS,.%@RL&,@SD'"PZ6'*PX$`)(:*:Q2I0A!MP38)\`_P08**(.QA*55ND_
MD:A2YBE)?\-%ULWQ15;%.'05"X-R+'G#$#,D%2!5(#4@=2`-($T@+2!M(!T@
M72`]('T@`R!#(",@8R`3(%,@,R!S(`L@2R`K($(@*B$J(T)?!1HKT%F!UHJ8
MM['DIIN&/Y'<4H9N0FARAHF+MQ`ZZ%IVAR%A=@.I`JD!J0-I`&D":0%I`^D`
MZ0+I`>D#&0`9`AD!&0.9`)D"F0&9`UD`60)9`1$"40E1&5$%$1HKT%F!UHJ8
MM['LIJ\2L>R^_(7<W`;+Z"")3?*5%)'?G\*TIF][;$4.@TRU"I`JD!J0.I`&
MD":0%I`VD`Z0+I`>D#Z0`9`AD!&0,9`)D"F0&9`YD`60)9`5$"$06:.-AZ*,
M4>BK0&,%.BO06A'S-I:SM$'P&SDKH^,YJPCEK.E*&4@%2!5(#4@=2`-($T@+
M2!M(!T@72`]('\@`R!#(",@8R`3(%,@,R!S(`L@2R`J($(A*B-!6@;X*-%:@
MLP*M%3%O8PE*^P2_D:`R.IZ@FM"&2V11?6"+:AADLK@"I`JD!J0.I`&D":0%
MI`VD`Z0+I`>D#V0`9`AD!&0,9`)D"F0&9`YD`60)9`5$"$0E1&5$Z*M`8P4Z
M*]!:$?,VEK-TS_D;.2NCXSFK2<$NJD`J0*I`:D#J0!I`FD!:0-I`.D"Z0'I`
M^D`&0(9`1D#&0"9`ID!F0.9`%D"60%9`A$!40E1&A+X*-%:@LP*M%3%O8PE*
MJV$L0=5.[IU\"G)^WVZ^EGQ:+&DK[<(=;(9V;-4^KA2)YZTBM$-MEM$RD(HB
MN7RP\9MU<EEV@UL-`XQ(#4@=2`-($T@+2!M(!T@72`]('\@`R!#(2)'(<(V!
M3,):<I\\Z[CWV?BE:QH&F.&:`9D#60!9`ED!$0)1"9$VG2PVIR2LZR%"GP4:
M+=!IH:U6PQ;+:H>^.?WWM`Y4XGEMD-WW+2.J:)2E[YJ16XU"W*^JC3)#44.M
M.J*&K1B1SZ?C\DT;9>1;J-5&U+$5H_).7+YKHXQ\#[7ZB`:V8E2>[94/;921
M'Z'6&-'$5HS(Y]C83VV4D9^AUAS1PE:,R/.Q7]HH([]"+7I`(M.4$LQF$STB
M42R>.WDV^L)D'869%NC)"<J9)(LV8;*,-<$<H$<JX9F$39C44W+Q*2>?MT2?
M"5ZX8M"S5G/)<-3C&=JY,^(EC7*T)6EG33X3S[NRCG(S8<6*1;:B4V`5JR9*
MG@,]:'3NV0YWS018Y3JBAD57&FOJJ(QJ+)]F_K6LBNE^&U''HBMM=6U;-LK-
MLA9[5LNTV$<TL,AJP5`.390>RGO^T'9D`NQ0CA%-++K2V-1$_<JWF0FPC<T1
M+2RZTMA21VG?LFFV;JRLBAE%FL4JE2,92;,X9%=:HUFLPJ@Y&P;6T<0.U<)6
MPW2VO:;'HF&<E0/W:&+K,#VBN0=V)T'/3D,A:C`^S>5SL.@T_[]N&.6&/;MC
MU"A'BTYD]K,S*^LHUZZ8%5/1KH15@YQ@JKNNDV&WEC74J2-J&!TKW311!777
M&E^<6J;4GEX;40=ENR:*[J%L[W$.JV&+]+YO*MH6!R@_-"@<$"X]0ITQHHG1
ML0,R-4A)9YQ,EMV(S%!GCFAA=*STTD2IL7;9BK8RQ;;K-!=AA&@N*I:SRC3Q
M=-S5\::)AW(FN2(FT,3#)DP^Y<*!@8NXR2\E%9]F\KG<?Y]F^NE>]"*K$"U6
MD43+LTMA6;YH1O,SLJ15-,I%ERI86ZHZ*J,3+4-O$L:G2`VEZX@:-[76U%%9
MU5H^S;K10N$VHLY-;75M6Y&!X].HA_)]1(.;6ASJJ'`L"PY;Q48H/48TN:FU
M:;RUC)MSV&C.4'J.:'%3:TL=I9W+9MB:L4)AFMN0E#2W%;N>E33=51@U=\4\
MFN[8@LGHR%2@Z7Y3JR:OM8$9MY!E0TH7VFB+\15`/JB\M@),_(]?[<Q$[[/U
M\\[H$J!0]$D-O:0<S'?[\*:"J(JHAJB.J(&HB:B%J(VH@ZB+J(>HCVB`:(AH
MA&B,:()HBFB&:(YH@6B):(6(Y@@827,$6?D"N^`XO7J'=2]X3K>4&!=W7>6V
M>I-=O4JZ]XYO7MG;[4Z)C?]-OJ7NRG4\Q.H=>CK[\"5Z5B1?KP_2FO%2\-J]
M_'K("UR2NE@C0P7!C32K(:AQZMH%*7E6%PMR5!"\:\^D2GDJ"#;">,$]%03W
M,+S@@0H>+C1>*11I#Q%/:E(HRFTR+*"=@:+<"<`2^D)?E#M%6$+;0$6YR8,E
MM(-3E/LS6$*;+T6YM8(EM&]2E+LB6$+YF2X&^QD7RFBK@KJDZJ7"X:&?,'RL
MW[SN^OBV/9P2.^^5DB<=[%D?U8\@U#]GO4)^\<_TXX5@L7RG7ZMX](YP^H[N
M8UY]_VS^H<93X>]?GO\'``#__P,`4$L#!!0`!@`(````(0"[*'HF$`P``*4Z
M```9````>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;*R;V7+;.A*&[Z=JWD&E
M^R.)U,ZR?2KBOM;4U)F9:T6F;54LT24IV]N?!@$0R\\H5C(W4?RQT2!^-,!N
MB+K[\]OA=?"E/IWWS?%^Z(PFPT%]W#6/^^/S_?`_?T5_K(:#\V5[?-R^-L?Z
M?OB]/@__?/CG/^Z^-J=/YY>ZO@S(P_%\/WRY7-Z\\?B\>ZD/V_.H>:N/=.6I
M.1VV%_KS]#P^OYWJ[6/;Z/`Z=B>3Q?BPW1^'W(-W>H^/YNEIOZN#9O?Y4!\O
MW,FI?MU>Z/[/+_NWL_1VV+W'W6%[^O3Y[8]=<W@C%Q_WK_O+]];I<'#8>>GS
ML3EM/[[2N+\YL^U.^F[_`/>'_>[4G)NGRXC<C?F-XIC7X_68/#W</>YI!$SV
MP:E^NA]^<+QJ-AF.'^Y:@?Z[K[^>M?\/SB_-U_BT?RSVQYK4IGEB,_"Q:3XQ
MT_21(6H\AM91.P/_.@T>ZZ?MY]?+OYNO2;U_?KG0=,]I1&Q@WN/WH#[O2%%R
M,W+GS-.N>:4;H'\'AST+#5)D^^U^Z%+'^\?+R_UPNAC-EY.I0^:#C_7Y$NV9
MR^%@]_E\:0[_XT:.<,6=3(43^A1.G-7(F4T6S,>5=C/1CCY%N]EHZ4S6T^7U
M=G2UO6GZE/W-1^YJ[LQ_UN-"M%RJEN^Z4UHN;8_T*7J<OV>`:]&,/N6-+D:K
M^7RV6/UDB`Y%0MLC^X]H2_)>$=.14\G^(WM[U^`<FGS>EQ8%*@BN]2EGWM&F
MWAG-W/ERU0;0M;9R]ATU_5?#9LQ#MUT)P?:R?;@[-5\'M+W0>,]O6[99.1YS
M)M<`[[Q;%3]:%+0:F)</S,W]D"*#XOU,*_G+@[M8W(V_T.K;"9L-VCBFA2\M
MV%)C;@,;A#:(;!#;(+%!:H/,!KD-"AN4-J@T,"9I.WTI*OX?^C(W3%^IS$8"
M37!+3&DAFP0V"&T0V2"V06*#U`:9#7(;%#8H;5!IP!"3%@J(.:4UWK]AR]AD
MK6AK-F)S:8JUX38.;5%=`,]-$[\SZ00%$@*)@,1`$B`ID`Q(#J0`4@*I=&)H
M2VL?M&4/PQLW`N:&]A*:P4Y(W`F$T36U.Y-.;2`AD`A(#"0!D@+)@.1`"B`E
MD$HGAMHDK*'V]0AFUJVH4HP-)S/ZT&1>61';&<EF`9`02`0D!I(`28%D0'(@
M!9`22*430T/*1V[0D%F;&G)"&DIY?"`!D!!(!"0&D@!)@61`<B`%D!)(I1-#
M,'H\WR`8LS8%X\2E1UT7=#/7BKG.1HH:``F!1$!B(`F0%$@&)`=2`"F!5#HQ
M)*0MZP8)F;4I(2=ZS`$)@(1`(B`QD`1("B0#D@,I@)1`*IT8@E'V?H-@S-H4
MC!/7?)ZLK:#KC+J@`Q("B8#$0!(@*9`,2`ZD`%("J71B:,C*F!M$;,U-%04B
M&:5"/J(`48@H0A0C2A"EB#)$.:("48FH,I"I'TO.]2+G^M.6U8!6%`IDZ,>M
MM*4<"*N9$:SNQ`S64%G)N8@0Q8@21"FB3*+VL6;*P-)J709>ZXU8-7UYV>\^
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MQXGTHARG$E&V=4V];B@0<2RO_7WU>'9LJ"<29OI0-[:TEJ9/6V`;HVI$@4!3
MRGVZACUKFC><KUM!YW3^:STV(NE:A5HLD>HM>5=OJ;`2O?7L()ETW?9FQB=+
MA*\I_%?S]J-GK+[`>3YM2,R1MB'Z[+C*WB,%4J$5"JNIJG,CV5!9Q1+I`0B^
M4O25R88]^QM+:'4M?O*HX/FO,68])6X7BN\`"A"%B")$,:($48HH0Y0C*A"5
MB"H#&;'DWI;VM^9F8B:04;&[RYF96?C*2CY-`D0AH@A1C"A!E"+*$.6("D0E
MHLI`IJ2W50),.):Z:<]9@;3$UD<4(`H118AB1`FB%%&&*$=4("H1508R]6/9
M^?N7-"O;;?TX8E>Z#=]=VF?MHJ%6402(0D01HAA1@BA%E"'*$16(2D25@4Q)
M61)_@Z0BY]=#DB/J0JY?GYX2[9-!H0!1B"A"%"-*$*6(,D0YH@)1B:@RD*D?
MR_=OT(^7!\:2%A6#$LMG:2`%KK;*`XG,P+6^XPR5E9R+2"+U_(T1)1*9[JVO
MJ5)E)=UG$BGW.:)"(M.]E=:7RDJZKR3"@IF5*8;POW2<T'JQMEA1RNCSP9$Q
M'P*IA"44OO2S`XF4.C&B1"+E*T642:1\Y8@*B6@%:AN<E:^6RDHIK8_1#'&6
MT-\0XCS_-T*\*PFTFUK9-3<K'JU\4B*5*88"Z?DD6L42*4D3B92O%'UE:)5+
MI'P5$BE?)?JJ#"M34E91W"`I+T`,244Q0YJI>5[9!;<KK%01$DBD-\221UB)
M&MQQYFLK;8N4'QE"L42JMT2BJ[VELC<C:%=6]9OU^7(GUGWETDK=1"'1U9LH
MY4WP8P?'F:VM[:]2?FC(YGRR6D6?SU_;C'C%8TQS5P3ITVQ7MJZP4A$:"*2?
M"PBTF+1E[&R]M@2.I!L5U;%$RG."GE.)Z#:T8+1F)I.^Z.&FK'#^8"R%=*^F
MM!2H&\O$>I94JC.8*[LN_+6YPG+1%;6A'F;T9IM=[@@K-9A`-/S)*82P$N<"
MSF*^LI[^D;H!M22AM^1=O:7"BMY_U";+[C%3/6I6.*5P$\6[;J(45MV09Q-+
MS4K=@#W-[,6<JTOR?4<AK1LS01!(3W@1!8A"1!&B&%&"*$64(<H1%8A*1)6!
MC*UN:M>P[;'Q?$3IPXWOZK2>+&E%Q4L!H[:(E;4/^[+ANJLX`D0AH@A1C"A!
ME"+*$.6("D0EHLI`IMJ4,1M1?/T0:\K,+4DY,J(54"`::E8AH@A1C"A!E"+*
M$.6("D0EHLI`IGZL$OWM!_.4U[/Z@UF@!06L%JG64\B7#=579(%`5"7H#:T$
M/516<BN/#%_F(%FYJ`_R)T'"JTMC-!RQ:DN-9FTGZ)0-V@FZ1'I#S":%%>7L
M[:NY2RM-C907V,5957+#T'@18PR-(\K%V[XGCI66^'17[:BT![)$ZC@_%(CN
ME+EQ)BO+362T,:>'$H);QL#,K37,$4V/&(/U&/2GPD"E:8%$*ID+)>+3T#>&
MKA^8A]L*EBD6+`*I>;"R%U\:Z//0%3ER%83"ZLH\Z&W,>6"9Y0VQQ!-1(Y9$
M;MK-`SR9('D-IET;-0:!?CP/>AMS#"R5NF$,//,RQB"2L6X]P)XE#/1YZ-JH
M,7!T91[T-L886$YYPQA:<W,]"*0]K7Q$`:(0480H1I0@2A%EB')$!:(2$?OE
M4;LMM<=07#_^2R+^^XE#?7JN_?KU]3S8-9_9KX2HP<-=A_E/F#;NU&.'ES1M
M]I7IQ&-97M\5^MT3921]5URZTMZ0[6U&WN@&>MJL/7JSK(<[U(+>F>J[0DWH
M:ZF>*RZUH6]7^J[0/=/W!GU7Z)YYH%CW3#_O^M`[%G+5[XD<]?5`$O<I_&'F
M?>B79$9:]3F:>_2V<<\0%AZ]5-O#EQZ]*=K#5QZ]$(F<SFH]=HJ(5^C(UF.'
MB7B%3FX]=B[;=V5.5_K:T*$M*=5WA9(?CZ4VZ&U#;3:];>@PW/-[K]"9N,<.
M7=$;'7I[4>\5.OOVV!$LMJ$C<(\=N^*5C>-X&[Z%6B'DTQ6_]PJ]C.>QU^/0
M6^"X=*4OD.C=.8^](=;7AG2CEZ+P"KU>1=[:*^/NYNA'@F_;Y[K<GI[WQ_/@
MM7ZB[6'2OJ1RXC\SY']<Q,L`'YL+_3R0MECZ_17]'+2FGSY-6#WWU#07^0=U
M/>Y^8/KP-P```/__`P!02P,$%``&``@````A`+R9GPWO`@``A@@``!D```!X
M;"]W;W)K<VAE971S+W-H965T,34N>&ULE%;;;J,P$'U?:?\!^;W<<BLHI$JW
MZFZEK;1:[>79`0-6`2/;:=J_WQF;4&BR+7TA87)\SIP9>YSUU5-=.8],*BZ:
MA`2N3QS6I"+C39&0W[]N+RZ)HS1M,EJ)AB7DF2ERM?G\:7T0\D&5C&D'&!J5
MD%+K-O8\E9:LILH5+6O@EUS(FFIXE86G6LEH9A;5E1?Z_M*K*6^(98CE%`Z1
MYSQE-R+=UZS1ED2RBFK(7Y6\54>V.IU"5U/YL&\O4E&W0+'C%=?/AI0X=1K?
M%8V0=%>![Z=@3M,CMWDYH:]Y*H42N7:!SK.)GGJ.O,@#ILTZX^``R^Y(EB=D
M&\3704B\S=H4Z`]G!S7X[JA2'+Y*GGWG#8-J0Y^P`SLA'A!ZEV$(%GLGJV]-
M!WY()V,YW5?ZISA\8[PH-;1[`8[06)P]WS"50D6!Q@T7R)2*"A*`IU-SW!I0
M$?ID/@\\TV5"PDMW%?C1;`4L.Z;T+4=*XJ1[I47]UX*"CLJ2A!T)?'8DLZ6[
M6/FS`#3?(?%L0L;?#=5TLY;BX,"F`4G54MR"00S$YPV!$\1N$9R0%7$@5P5=
M>-R$4;#V'J%R:8>YMAAX]I@7A`>BO3*H35=&,"IC:3&5:QL8RH1](B.9V4=D
M$)P0>/;)A]$+KU6VF/D`LSBO#)#I!A$,/0!;`^F7REEI"YH@#?MANC2"C71?
MW"X"QV20S.R\R^5'I!`\ENHBIK.COL$N&UK`$Q=!0F]O4%PTYN\BHXT2S<];
MP6D]^2P@>"S51<RA'5F)QKQH9>Y'+EA_VPVN&TMTD;&;_VR_`*HUW8Y!C\6.
MH5-#`20PI#;CT`]='&9O6S(K7\D@&83&II;G6X0'9*C\CEHW)<S-8(^0(3!J
M.._-/+)3WT[%FLF"?6%5I9Q4['&BAS#G^FA_VVP-Y>OX/-X"/Q+WO\`MT-*"
MW5-9\$8Y%<N!TS>5DO8>L2]:M)`5C'&A8?Z;KR7<]PQFG>]"67,A]/$%!?I_
M$)M_````__\#`%!+`P04``8`"````"$`IP"]-JX0``#T70``&0```'AL+W=O
M<FMS:&5E=',O<VAE970Q,2YX;6RLG-MRVS@2AN^W:M_!Y?NQ31T<6Y5X*A+/
M9[)F=Z\56TE4L2V7I"0S;[_=!$`<?EJ6,G,3.1\;30`_`*);$-___N?3X]F/
MU7:WWCQ_./<NKL[/5L_WFX?U\Y</Y__Y(_SMYOQLMU\^/RP?-\^K#^=_K7;G
MO]_]^U_O?VZVWW9?5ZO]&7EXWGTX_[K?O\PN+W?W7U=/R]W%YF7U3%<^;[9/
MRSW]=_OE<O>R72T?ND)/CY>CJZOKRZ?E^OE<>)AMC_&Q^?QY?;_R-_??GU;/
M>^%DNWI<[JG^NZ_KEYWR]G1_C+NGY?;;]Y??[C=/+^3BT_IQO?^K<WI^]G0_
M2[X\;[;+3X_4[C^]R?)>^>[^`^Z?UO?;S6[S>7]![BY%1;'-MY>WE^3I[OW#
MFEK`W7ZV77W^</[1F[73F_/+N_==!_UWO?JY,_X^VWW=_(RVZX=\_;RBWB:=
M6(%/F\TW-DT>&%'A2R@==@K4V[.'U>?E]\=]N_D9K]9?ONY)[BFUB!LV>_C+
M7^WNJ4?)S<5HRI[N-X]4`?KW[&G-0X-Z9/EG]_ES_;#_^N%\/+F8OKL:>V1^
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M9M$_H1&[88U4[\X5T**-'$&4A2KBNR!P0>B"R`6Q"Q(7I"[(7)"[H'!!Z8+*
M!;4+&A>T!K`$H;7IGQ"$W=`3VYHT[VP%YL*&9V8_LZ:VR:(WZ54"$@`)@41`
M8B`)D!1(!B0'4@`I@51`:B`-D-8DEFCT4/@G1&,WM%C2T.@%\6YN;$GFTNB0
M:KU)KQJ0`$@()`(2`TF`I$`R(#F0`D@)I`)2`VF`M":Q5*,'LJ7:\,Y8/8;8
MNA-'=>I<DMM^U5L`\8$$0$(@$9`82`(D!9(!R8$40$H@%9`:2`.D-8G5\;2?
M.:'CV=KN>$$FY-^8)[?V/%GT1DHO'T@`)`02`8F!)$!2(!F0'$@!I`12`:F!
M-$!:DUA:T+[J!"W8VM9"$F,2`/&!!$!"(!&0&$@")`62`<F!%$!*(!60&D@#
MI#6)U?&T@%L=S[OC\0W'XC+(.WJ#S)YL4029D.AZ@MQ>.1.D-^HG")``2`@D
M`A(#28"D0#(@.9`"2`FD`E(#:8"T)K%THJC8TNGP4X*M;2TD,28($!](`"0$
M$@&)@21`4B`9D!Q(`:0$4@&I@31`6I-8'<_I!:OG?WV&=*YL621RYHCGS!%M
MU4\21`&B$%&$*$:4($H198AR1`6B$E&%J$;4(&HM9$O'X:89^A^>-)P.<F:-
M0L:T0>0C"A"%B")$,:($48HH0Y0C*A"5B"I$-:(&46LA6PN.-$TM>!J-KKL'
MS1NRB!B5XA$U^.<<FY!2(XJ$C">+&]IK*U705X@VXT;!L3W=`F4U[=(\$^]V
MXK@.E<6$ZV2WDZ,SMYT>9:YXF_AU??]MOJ$[TT@;:/28[B>333+&,]LLT,A^
MFD[LJB\XJ<@]HW,@OD)=DK]S'RATVS5P!*WK;P6MXRCF[[=.QD)FZP1R%'7S
M`)SV%+IK104:TRI]2%%IY2E%KYV."Y7K`44Y@#C4YC\V+Z\I2MNH7E)VXRS^
M`HUT/RPX/<LMU,A'%"`*$46(8D0)HA11ABA'5"`J$56(:D0-HM9"]JSCP,+4
M:&!VF5J(.(1FL1I'<\YNLSRT#S#&D9/@76@K5=!'%"`*$46(8D0)HA11ABA'
M5"`J$56(:D0-HM9"MCP<?IP@CXQ63'G,`*9;Q!;\I8)03&L!*$"K$%&$*$:4
M($H198AR1`6B$E&%J$;4(&HM9&O!(<8)6HB(Q)HJ$ME3Q4GK+CBAZ\H#*$"K
M$%&$*$:4($H198AR1`6B$E&%J$;4(&HM9,O#@<@)\LBXQ9PJ$IE[5D`^+W2V
M/`&B$%&$*$:4($H198AR1`6B$E&%J$;4(&HM9&DQ<D._PT^5SMQ^PBNDMV,+
M1+Y$8WMKYV3<`VVEUKO0\F57_;309X2ACT0CVCGU#\2QF[Q11N/^0>HK9);S
M;MTMMK(26^SQU=1YTH;*`/=CM#<Z989TYHXJ,GRP^]O-W,J"YE9:H>N^N8%$
M8]Z[_[B[OG(:&EI%;(EXEWW\3.>M,4]88Z9+9$GD><ZX62@K4R.YP>\Z5X0$
MRDH(0L=:W*!`&0P(PIOK$QHB]N)60P2R8ALZI^7$-MQ.Z@%+D+Z@FA.!M)*"
M>-=.#!$J+YV&MB#N1O^-Z8X;>LZ:<@VI5OV<&5VYV1QE90K2%]3MD$@*<CV^
M<?HC5'X&%.'-[`F*R+VO.;0$HK[6+7&CX`7KY0HBD3E#!!I/1+`Y'=TZ(S14
M?@8DX0W="0V1^S^S(0(YDCB#>\'MY):8DO0%M20"C4D90UZ8\7U!TTK'F_:8
MXRW1"0V4.RBS@0(Y<\<9]8N1M-(/(E\A4RIA17/'K#HLS8-W?*V!O,\XH8%R
M6V(V4"!'07>[.9)6IH)]0:V@0(Z",![[@F8WO-)`SCQ8#13GBTY,^'1>[-5=
M(DM8]S&Y4$:&K@H9^1Z%J%W&P'4>>*&RHOEJ6+W6;'>#\6O-QGW'6"!^W/2U
M\&[=\:RME+:^1-P*HZ`S.P-E]7HF2+G&977L[CS<-A^7">K<.%K+'8D>]@MI
M1?L'W4*P"M`J1!0ABA$EB%)$&:(<48&H1%0AJA$UB%H+60LJKUTP':<TIDX\
M[M?Y<402NR:.%_H!-O*<I_)"%=3AEX\H0!0BBA#%B!)$*:(,48ZH0%0BJA#5
MB!I$K85LW7@G=_QS@G83_,`V-Y$2&1-F@<A'%"`*$46(8D0)HA11ABA'5"`J
M$56(:D0-HM9"MA:\]32UZ+ZKF5X0/G46B4VL)9-$]BQR]\C\A&9]S5D$*$"K
M$%&$*$:4($H198AR1`6B$E&%J$;4(&HM9"O'>VU3N<,A#&<<W%DDD>[XA;+2
MR$<4(`H118AB1`FB%%&&*$=4("H158AJ1`VBUD*V%AP'G*"%"!NLJ2*1/57<
MV&7<6^F-`J``K4)$$:(848(H190ARA$5B$I$%:(:48.HM9`M#T<Q)\@C@AY+
M'HGTO%B,`?F(`D0AH@A1C"A!E"+*$.6("D0EH@I1C:A!U%K(UH)&^"E:L+GS
M\)?(GBK.YG\Q[JWT5`$4H%6(*$(4(TH0I8@R1#FB`E&)J$)4(VH0M1:RY)FX
M(>[AITIG;LNCD#%5$/F(`D0AH@A1C"A!E"+*$.6("D0EH@I1C:A!U%K(UF(H
M[A[]RMYL@K&W0O8LTAD`\<6KMNIG$:(`48@H0A0C2A"EB#)$.:("48FH0E0C
M:A"U%K*5<[,';\PB$>R;#YR)1.8L`N2C58`H1!0ABA$EB%)$&:(<48&H1%0A
MJA$UB%H+V5H,90GDL><W9)%)`)V6F4\D$C]?YE_U+332J0+OG;-S\Y65E7#S
M=*K+KO)I`?($`V2)S``9D8\H0!0BBA#%B!)$*:(,48ZH0%0BJA#5B!I$K85L
M+3@4-?>..D!^8_3(&-8</1*9HZ='!T>/M+)'CT[6VS7FL,ZL\1OUE%&@64^!
MK-$#R.>#S+0U,ZP"1"&B"%&,*$&4(LH0Y8@*1"6B"E&-J$'46LC6@J,S4XNC
M1X\,ZTQ5)#)'3X\.CAYI17H9R4S]K8I=X]-BI0G&2A(9XV*!R$<4(`H118AB
M1`FB%%&&*$=4("H158AJ1`VBUD*V%ARPF*/GC9DLXQMSS`A$F0NU?UM,!*('
MID*^1N8`<;XJ"[25*A@BBA#%B!)$*:(,4:Z14=61DY@OM)6J:HFH0E0C:A"U
M%K(4F[KAD_NUT5%'PCLO=E0ED2FD1*:0"M$NQ9CISI=_@;92O1,BBA#%B!)$
MJ4)Z@&6(<H4.5K705JJJ):(*48VH0=0JU%75%G(H]CKY;#]_&>5D+R2B;[54
MBQ8*&5_L2D3;$CYJ1.=*G/1&H`V4FQ#=1(AB75!Z=G:JB390GE-TDR'*=<'A
M.A?:0'DNT4V%J-8%A^O<:`/EN;7<V-*>%IQ-,3A32`NV0.1+Q%GC?C)Z[H&8
M0%NIJH>((D0QH@11BBA#E",J$)6(*D0UH@91*Q&=7:9FV_)PB&4^]'YM"96!
MFIYF\ZE`UFF#T<C]-DI;*3U\B=XX;:"LY&F#FVMGV0V59WT2+U)(GV2)E9N#
M1QL2925N=CURX\U4>=8WRQ32-\N5FX,W*Y25N)E'/Y+2<6N7)BJ5:WVW2B%]
MMUKY.7BW1EG)N]U.W9.HK7*-IS:F;N#<C1UZ_Q=-0?Y!ECJT<?ROLSJ/SJ-8
MA-O681T/3C#*@N8)1HDX^6HL"+"R"_><%NRM1O"[+>7>7%Q&5T[Z+E)6>J&*
MCZI$(JV<2CA5397[@Y7(E)6N1'Y4)8KA2CAM+)7[@Y6HE)6N1'U4)9KA2C@3
MH%7N7ZN$O<)Q-`\KW-\:I3(_8*YV`EE'Z3PXGSJ55GJ6^A*]M=J)@IP"-4:I
MSDATZT*HW-.0UE8X2J$2\5&52*254PD=V':52(^J1*:L=$_D1U6B&*Z$$SR5
MROW!GJB4E:Y$?50EFN%*.$^@5KE_K1+V**6QC*/4^'6K6DP/!Z53=N,LH`(9
M2^-"6AG(5TB'KH%$=+)(/9M#M(H4TE,]5DC[2M!7BE:90MI7KI#V5:"O$JTJ
MA;2O6B'MJT%?K65E:\29'7,E>4,+F0@REPF)C.\9IH!\1`&B$%&$*$:4($H1
M98AR1`6B$E&%J$;4(&HM9&MQ6N*,7L0*\T(B<W\P<G<_"U50*^8C"A"%B")$
M,:($48HH0Y0C*A"5B"I$-:(&$;_>MNO5KG.$/.)UM>(UD4^K[9?58O7XN#N[
MWWSG5]%2*N?N?8_%>W+GDYL99^5HD7&O3-_1*W2["0Q7J`S=?:#,^';&7[@/
M7)E<T7VZ=^JZWB;TJEYZK`V5&=&5;@)#F0E=Z?;$<.6:KG1KC'O%H_:(&`RN
M4'OHIXL#-?"H/>*PGEMF3'43B0VX,J8KW;(-5ZC6=#QQX#Y4@<'[T^T'>].C
MWJ07A`QX\J@WZ7450U>F=*5+J+OU\JC/Z%?.6(;B^AE'M'B%WJ_\<8C/^?8#
M]G/JKD%[[JP!^X^3V<?A(<;*#Q284^L&&T=M&VK:G$;#T."F1.R,<WC89,K'
MSCA#.G!E>D7=-%2&TJ=4K:$K_M2;<68+O5'::L:9*;Q"::<99Y;P"J6-J`9#
M5^A7F#/^C266F5/=YH-UH[SY;#%XA=+G,TYHHS>?^H`SI'B%LMTS3I3BE?F8
M1*-3GT-72#:1`'8'ZYB$H^-O0V5H%M%A++IRV1>B=VZ_++^LBN7VR_IY=_:X
M^DP+X57W*Y:M>&NW^,]>ONSBTV9/;]NF/1R]4)?>KKZB;[VO.*3^O-GLU7_X
M!OW[VN_^+P````#__P,`4$L#!!0`!@`(````(0!7$RVK*@@``/HE```9````
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;*Q:VV[C.!)]7V#^P?#[Q-;%EP1)
M!K&)GAU@!Q@,=F>>U;:2"&U;AJ1TNO]^3XFD6$6R?<GN2Z=]6"P>'18/J<O]
M+]_VN]'7LFFK^O`P3FZFXU%YV-3;ZO#R,/[/OS_]O!R/VJXX;(M=?2@?QM_+
M=OS+XT__N'^OFR_M:UEV(V0XM`_CUZX[WDTF[>:UW!?M37TL#VAYKIM]T>%G
M\S)ICTU9;/M.^]TDG4[GDWU1'<8ZPUUS28[Z^;G:E*K>O.W+0Z>3-.6NZ,"_
M?:V.K<VVWUR2;E\T7]Z./V_J_1$I/E>[JOO>)QV/]IN[WUX.=5-\WN&ZOR5Y
ML;&Y^Q]!^GVU:>JV?NYND&ZBB8;7?#NYG2#3X_VVPA60[*.F?'X8/R5W:C8=
M3Q[O>X'^JLKWEOU_U+[6[[\VU?9?U:&$VI@GFH'/=?V%0G_;$H3.DZ#WIWX&
M_FA&V_*Y>-MU?];O_RRKE]<.TSW#%=&%W6V_J[+=0%&DN4EGE&E3[T``_X[V
M%94&%"F^]7_?JVWW^C#.YC>SQ31+$#[Z7+;=IXI2CD>;M[:K]W_KH,2DTDE2
MDP1_39)D=K-(IK?9`DE.=,Q,1_PU'=.;/)TMEOWH)SKFIB/^7DU[HB7H%55%
M5SS>-_7["&6*BVR/!15]<H?$5DI-8Q#W1]I"5$KR1%D>QHOQ"+*U*(BOC\GL
M]G[R%9.X,3&K2(R,6-L(FC%*JQ@P`=^!-#3_/Y"F+$3:#K>R@+N*U&-H(VP7
MQ0#!$)/K,\Q0Y_$*M2I2)]0B5W$^E0Q6.B:!E0U2SV3(>@@96')$T,2,^S1I
M(5TY^Y0%]0,M!D[A])N@4\2'D($X1P1QD.3$3^M*P3T_FW=ED-MA[M<!HC@B
MQIY?,S8%R[$UDJ(:G%KSQ)O#(<A25AP1=+#J+I>"@B4=C8".'6D=((HC8FS:
M49E[G)X&"I9C:R3%,F=2^&MN"+($%4<$G=MKZ%"PI&,05A4!HC@BQDXPH5P+
M<M)TAB*Z<C'U>20O"V%LIE/FE8R+&H02D&1+UGKQS"7:B+'";>J5A9A8(:0$
M)`F0<S(")-<"N_#U>FD+%MP,)/7*?;V&*'M1BBR,:J*_*$F7+)31/5WIB3%<
MKI>!N%X!I&S'"`&R0D:@WZ@7RX\(9DR5DS.0%,S?5Y(AR@G&(2D8V2?C>T8P
M8[:<DX&X8`&D:+?ZP8R183(")-CRE@Z$5Z](;;VBP@PD!9O[%39$.<$X)`4C
MDV5\SPBF+5EP,A`7+(!4PB%)@&SU<@+:A`6!P9>Y32U\488H)PJ')"<(?`4G
MBO:LTT!<E`!26/`_J"+:ICF!CU=1GTF2LQ!&9[Z^]`1S48-@`A*"T5[*^9ZN
MHC[:XV2LG@EFHQRD!"0)D(5>7$6I,5RV[@U$(S!1O)N)M8MRHNA<Z`A(<KK*
MO-/0O"WD%%B'D!*0)$`VR42A*LJ6'_&BU!@N%VSP8";8PKMO6-N.[A*4@"1?
M<E7&]TP5&0_FG+@M]_=R:S+>P:GU[9V`)`&R24;@?UAVQG`YN<&#N6#^"3P=
MHER%<4CR)5=E?,\(9CR8<^*V;`0+()5R2!(@"V4$6(6=X:*]E_MX:B#]Z(1N
MQ-<.XI)Y)W5EHR"36[H+=TZ5C,ES/<9F?S[#V)@U5\]`G/$`<2X!8Q,E&;N3
MHF!,-_`^XW1&)[#3A/M^TF4MQ`@[Z!1A&R4)NY.:)'S59I`9YV>Z&@AF:]?`
M.H24@"2!JS:#+-P,#"0W@X5_SG)1EJ82D.1TU6:0A9N!@?0^HY=J""D!20*1
MS>!C!],LW`PLA+IF2]`_@[DH)]BPBP"2?,FXV4(]4^S&YEW)K++`^=<AI`0D
M"9#M,@+D;?/LQCUFO?@Q94:9O)5H("F8?P:S'=GN*2#)EUR:\3TCF/%T+ABW
M>5-A`:0R#DD"D<T@3>8?4BS<'C(#2<7\`YJ+<B4V=`Q*C&SX<L4HVIM%`[GY
M66<!I`0D%,L]:S\]97VT)&`@:51+_Q#FH@91!"0Y7>7>>>C>!N)&%4)*0)*`
MY]X?/X3EH;-;"+/DC&KI'\)<E!/,Y.JG6O*]RMGST-DMQ*HHA)2`)`'/V<]4
M4>C>N8:\*O(.+6L7Y409.OI+*[_*O?MHK[)#][913B<E("E*Q+T_]*`O#\W;
M0K*(W(%3>Z>+<GH-KA_H1:YZL17EQH.9>5O(B;,.(24@J9=GWF>**/3G7$->
M$;DSK1%EB'*B<$AR(B^]7!3CO%P4`W%1`DCE'!($\#99$"`K2I+\(SM:GTJ6
MN(4P//,B=ZC6BKFH03$!:<+ZI;5^Q;HOFY=R7>YV[6A3O]$+:5SAX_T`Z[?E
MJWQYIS!IR!JTW**EU\QOF4WM*W:_)4_1IY<^:,G0DD7'R=&21UMF:.GO4H)L
M<[3,HWT6:.E?J_I],O3!N2ERI1GZX$`3:X$Z.$S$6J`.MO1(2PYUL+'&6O!I
M`G:\2$L*!KB_CK1DZ(-[G%@+M,:=1JP%6N,6(-8"K7'^CK5`:YR"(RTI&.AM
MW%<T!0-]>Q:T@`&>2,6R@0&>_<1:P``/96(MF#D\$8FT).B#I_"Q%O1)XGV@
M-1Y$Q_I@MO%R.]:"V=8O9H(KQ6SCB6BD#[I$ZR-!#[P;B_1(H#1>6L5:H+1^
M2N*/GT!IO+B)]8'2>&L2MN`+F:=HW=#PD?@537,,IS*+X$_YW1/,*1QX12L]
MAF,6HY.(.8Q.(68P.H&8OW[Z)H-*^/+F6+R4OQ?-2W5H1[OR&48X[:V[T=_N
MZ!]=?80MX_N;NL,W-_U_7_&-58GG3U-ZR/)<UYW]@0N;#%]M/?X7``#__P,`
M4$L#!!0`!@`(````(0#P6!DGOP(``+`'```8````>&PO=V]R:W-H965T<R]S
M:&5E=#DN>&ULE%5=;YLP%'V?M/]@^;T8:$@:%%*EJ[I-VJ1IVL>S8PQ8Q1C9
M3M/^^UUC0J&-.OK"Q^7XG'NNKR^;ZT=9HP>NC5!-AJ,@Q(@W3.6B*3/\^]?=
MQ15&QM(FI[5J>(:?N,'7VX\?-D>E[TW%N47`T)@,5]:V*2&&55Q2$ZB6-_"E
M4%I2"Z^Z)*;5G.;=(EF3.`R71%+18,^0ZCD<JB@$X[>*'21OK"?1O*86\C>5
M:,V)3;(Y=)+J^T-[P91L@6(O:F&?.E*,)$N_EHW2=%^#[\=H0=F)NWMY12\%
MT\JHP@9`1WRBKSVOR9H`TW:3"W#@RHXT+S*\B]*;*,1DN^D*]$?PHQD](U.I
MXV<M\F^BX5!MV">W`WNE[AWT:^Y"L)B\6GW7[<`/C7)>T$-M?ZKC%R[*RL)V
M)^#(&4OSIUMN&%04:((X<4Q,U9``7)$4KC6@(O2QNQ]%;JL,QX"\2J)D"7BT
MY\;>"<>)$3L8J^1?CXIZ+L\2]RQP[UDNET&R"B^C_Y,0GU%G\)9:NMUH=430
M-2!I6NIZ,$J!^+PCL.*P.P?.\`HCR-7`-CQLHV2Q(0]0.M9C;CP&KL^8`4%`
M=%`&M?G*#NR476U=*C<^,):)S\M<OD?&@3,,U^?DDV3@]<H>LQAAGA$3@P"9
M;]"!80_`UDCZ96T]:(8T--5\:0?NI(?B]A$X)Z-DED,=)BZ7[Y%RX*E4'_'G
M;]P>T&5C"^[(K2&AMQO4+9KR]Y%QHT3)ZKP5-ZYGGP4'GDKUD>[03DJTGO)V
MTV,-._VV%[=J*M!'IEZNSGN!<?@.,QUZ*G8*C>SX^>C'A^2ZY)]X71O$U,'-
MOA@&PA`=YO(N=F?V97R1[OR\)L,7F)<M+?EWJDO1&%3S`CC#8`6]J/W$]2]6
MM9`H#$UE85!VCQ7\&3D,A3``<*&4/;V`,AG^M=M_````__\#`%!+`P04``8`
M"````"$`'W^$;X,#```Z"P``&````'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;)R676^;,!2&[R?M/R#N&S`D(8F25.6CVZ1-FJ9]7#O@)%8!(]MIVG^_8QP(
M=MJFVTT;.(]?_)[78"]OGZK2>21<4%:O7#3R78?4.2MHO5NYOW[>W\Q<1TA<
M%[AD-5FYST2XM^N/'Y9'QA_$GA#I@$(M5NY>RF;A>2+?DPJ+$6M(#94MXQ66
M<,EWGF@XP44[J"J]P/>G7H5I[6J%!7^/!MMN:4Y2EA\J4DLMPDF))<Q?[&DC
M.K4J?X]<A?G#H;G)6=6`Q(:65#ZWHJY3Y8LONYIQO"G!]Q,:X[S3;B\NY"N:
M<R;85HY`SM,3O?0\]^8>**V7!04'JNT.)]N5>X<6V=SUULNV/[\I.8K!;T?L
MV?$3I\576A-H-L2D`M@P]J#0+X6Z!8.]B]'W;0#?N5.0+3Z4\@<[?B9TMY>0
M]@0,*5^+XCDE(H>&@LPHF"BEG)4P`?CK5%2M#&@(?FK_'VDA]RLWG(XFD1\B
MP)T-$?*>*DG7R0]"LNJ/AM!)2HL$)Q$8<1)!P2B83=!D>EW%TS-J#:98XO62
MLZ,#BP:>*1JLEB!:@'+G3,^C]_J:5?"H1.Z42JL%+@3$\[A&?KCT'J&G^8F)
M-1.Y3L_,D(DD':(ZJ'33[L9YC#4DZP@5'UCJ?4&W;%\AY/YR8IT--<BT$43F
M%.,7$)-(+HE98"+I)6(1V24Q$#&,AO]C5`V"13C(`OEC<Y*Q9L8#9F(2R54B
MO4ID;Q&&3YC(,-"W@U3PRH4F]FL-^;XY^U@SLW:UWJ!):`.)`40!LI9":M3#
M:![,S2=D!A#XX^B<LF$-WKOW6U.P'9T53*P9>'QOWR*2JT1ZE<C>(@Q_4].?
M^L9<?Q?5(#O"J=G@6#-C'6%H?7"2875N#4V'1119:S\;5B&X_K&&+?B4O3\V
M!=MVK`45:T;;F?C6:DJZZCG4T$+2#E$?X`N!K*N^*&`X4\>6P:;P]KNF8-O9
MK.]8^QV/-:.=C2,KBV18O0AJ6)S.K(RS8?75H.;_8D?!MAVKS[%FND_'>!:<
M5TCK-S&`"`76KI4:]3`*QE9+X#"C9G%Z0N`'TW-'=5+ZK**W\HKP'4E(60HG
M9P=U#@G@E>COZB-2C!:PO\(V:=U/X>C4WO?Z`AQ=&KPCWS#?T5HX)=F"I#^*
MX(7G^O"C+R1KVMURPR0<6MJ?>SBC$MBY_1'`6\9D=Z'VY_[4N_X+``#__P,`
M4$L#!!0`!@`(````(0!%1[;B%P<``/L?```8````>&PO=V]R:W-H965T<R]S
M:&5E=#8N>&ULG%G;CMLV$'TOT'\0]&Y;)'6Q%[L;1`K2%FB!HNCE66O+:R&V
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MO11-^[G4*7UO_=:TU>$_!`F3"I-(DT0!>Q.7<[F,1!3?SK)`1MT"/^5M_OQ8
M5^\>3`U\9W/*]0R*!\A\7AGRN*SUVE)AC3K)1YVERP6K:*`_7Y^%"!X77Z&F
M:X-)$9/XGL501'9&Z%8`O0M'6#GGJ*"'P]4_4](/44HRH=^7#D`H(NLCEO("
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MV\J*%VY4&H\"VWA:,.8*-PJ&0DZ(V<1FXA"#$S<3L62`3!_F8),C<^%X,25V
MEQ6(OA<(87MAF+ER'SNZ92KFAF<RL16EQ)@?3/-1,60,5CD-0009$9&LY9G)
M85JNKK:46<.-EO8](>P5[JSZ>@_,Q(KQSH0;7P:6-RT<<X0;O`:L0/*SD7#5
M'H[X7'4QC*,HKQ*3=[E!AZ9N(*2=%>RD`9E-H%2PXD9*$2)<)5882=GD7:;0
MH=F!33+12@UH3')'(92?%OG)TB8UFE>/]2TU(%.],.FI+@5(&=@54F[,#J;M
M5=FW!<%5+#4@W(Q+MH*,1)6C1)0><X6)]/KN`*^V=/13B2`LH0H4%V$3=T?`
M$43*DEG$1)9]JQ#.<<QL$]<KI(H5V^"9?MF&<3$[.')>CBC%N\Q"#IA%_WT5
M068&19A$O1)21)3$=@HHNQ]R##G@&)(KLP$ART0JID,9B<]$!.NX#`KE>)=I
M2!1\V">75S[!WTM3`W)'C$UI-@JA_.XR#SE@'GRV4@,R=MIOK^LMLY6=3,)+
MOW--5[\.S=2/]RPUH(O-\Z+1N..)E-A=MJ$&WB5Z1V$#PF$3861+@@<H$T?B
ML1.FQ.[R"]7WBSXOQ)B"\2U@,IAH$EDCIK0&K"($]1D_I:@!JU!6!E#E#,C4
M32[CB!^@"$+&*T?.*4FMZH[73I-BA5X`5;*[E1M":D"&I%AQM3-Q+&-H%T#Y
M:;F^GQ^*/.7'ICY5KA,(.%"%K,P90<#?>B(KEI0D,XN)11PP#><]WG0:05@D
M_BZ>J7/4]N&:YZH?LHSN*2XO5O`-1_05T^@@@DI>+,'L8Q<Q4RJ^MF689TPL
M)'H'[;9ME2&)($,R4;U7#D4`H;CV,J28;TSD..0?=N8-1P2=M[4,5[V))(@@
MN?;7@9"9R#22W5/LJ!\R34X-:,R$1R%DYX3,4R;R'/"6D*ETVJ4^'_1"D!][
MHL>A-`!W(=<V3ZC]@*G0;2GOGF*;A[-(#<BH8,#V5F;"9B14;$6,UG'`:[2K
MCWM-..`U7`13`[I2)E-*3(2+N'JF#K5KL"I.(*F?XE5D`I-VJ?5?@`:%T)#$
M1$C2W?^TDC]D.'H8@"24P1IB:'N%V]N`7)(,DHU"*$_F.3<Z/>`UH15APP]!
M>#$DG&.@J=\$L\$[6+RB/!3U:Y$5^WWCK:LW?;\JX(+B\EN\^TWA[K>[*%U<
M`G#U>LI?BS_R^K4\-MZ^V,*CP3R!$M=X>8L?VNK4W1"^5"U<NG8_[N"2O8`;
MS6`.X&U5M></^D[R<FW__#\```#__P,`4$L#!!0`!@`(````(0"]]^\F>`(`
M`.P%```8````>&PO=V]R:W-H965T<R]S:&5E=#<N>&ULE)1=;]HP%(;O)^T_
M6+YOG(3P442H"JA;I4V:IGU<&\=)+.(XLDUI__V.;4A)Z;;V!G#\GH?W?&5Q
M\R@;],"U$:K-<1+%&/&6J4*T58Y__KB[FF%D+&T+VJB6Y_B)&WRS_/AA<5!Z
M9VK.+0)":W)<6]O-"3&LYI*:2'6\A9M2:4DM''5%3*<Y+7R0;$@:QQ,BJ6AQ
M(,SU6QBJ+`7C&\7VDK<V0#1OJ`7_IA:=.=$D>PM.4KW;=U=,R0X06]$(^^2A
M&$DVOZ]:I>FV@;P?DXRR$]L?+O!2,*V,*FT$.!*,7N9\3:X)D):+0D`&KNQ(
M\S+'M\E\G6&R7/CZ_!+\8,Y^(U.KPR<MBB^BY5!L:)-KP%:IG9/>%^X1!).+
MZ#O?@&\:%;RD^\9^5X?/7%2UA6Z/(2&7U[QXVG##H*"`B=*Q(S'5@`'X1%*X
MR8""T$?_?1"%K7,\FD3C:3Q*0(ZVW-@[X9`8L;VQ2OX.HN2("I#T"!F!^^-]
M&J6S<3*>_)]"@B.?X(9:NEQH=4`P-/"?IJ-N!),YD$^9!1]]KG]+%7)TD%M'
M\2S(PD!['I9)-EV0!Z@I.VI603/%Z%DS5*Q/"M<*L-=[A,Q?>AQ!#U^O_LF2
M"QI:2E\Z>D7RPM&E8I;VDH%'J-W[/;H@F(7SDF2SGN]+NPJ:[$PS'BK6_U(,
M/`+D_1Y=4(ZA$,]MRZZ'#E9!,_.-GR1Q/+R&S72(<)V=W09S8>O"4$JN*[[F
M36,04WNW40E`^Z=AV5>P['XU2'\!R];1BG^ENA*M00TO(32.IK!=.JQK.%C5
M^9G8*@MKYG_6\%;E,,-Q!.)2*7LZN"GLW]/+/P```/__`P!02P,$%``&``@`
M```A``CC):R/`@``BP8``!@```!X;"]W;W)K<VAE971S+W-H965T."YX;6R4
M5=N.FS`0?:_4?[#\OAA(2'91R"IIE':EKE15O3P[QH`5C)'M7/;O.\8LRU[:
M9E\@'H[/F3.><1:W9UFC(]=&J";#41!BQ!NF<M&4&?[Y8WMUC9&QM,EIK1J>
MX0=N\.WRXX?%2>F]J3BW"!@:D^'*VC8EQ+"*2VH"U?(&OA1*2VIAJ4MB6LUI
MWFV2-8G#<$8D%0WV#*F^A$,5A6!\H]A!\L9Z$LUK:B%_4XG6/+))=@F=I'I_
M:*^8DBU0[$0M[$-'BI%DZ5W9*$UW-?@^1U/*'KF[Q2MZ*9A61A4V`#KB$WWM
M^8;<$&!:+G(!#ES9D>9%AE=1NIYCLEQT]?DE^,F,?B-3J=-G+?*OHN%0;#@F
M=P`[I?8.>I>[$&PFKW9ONP/XIE'."WJH[7=U^L)%65DX[00,.5]I_K#AAD%!
M@2:($\?$5`T)P!-)X3H#"D+/W?LD<EME.(Z"ZR29SJ[G0+/CQFZ%X\2('8Q5
M\K='13V79XE[%GCW+)-9D,S#202B_R$A/J/.X(9:NEQH=4+0-"!I6NI:,$J!
M^&U'8,5A5PZ<X3E&D*N!4S@NHR1<D".4CO68M<?`\PDS(`B(#LJ@=KFR`SME
M5UN7RMH'QC+QVS*3]\@X<(;A^91\$@V\7MECIB-,,B">&03(Y08=&,X`;(VD
M7];6@RZ0AGZX7-J!.^FAN'T$YF24S%_J.WN/E`,_E^HC?O[&[0%=-K;@1VX2
MN'GY=Y.ZC<\U^LBX6:)D\N+0_/#[V9!<E_P3KVN#F#JXP8ZAVX?H<.>L8M>0
M+^/3=-4U*AD^P%W0TI+?4UV*QJ":%T`9=EZTOTW\PJH6,H=95A8N@>YG!9<^
MAX8/`S!>*&4?%R!,AK^1Y1\```#__P,`4$L#!!0`!@`(````(0!8Z^WB*P4`
M`"07```9````>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;)286X^R.!C'[S?9
M[T"X'[$5/!#US2OGY-UDL]G#-8-5R0@UP(PSWWZ?4D!:E(YS(>/#KW_;?Y\>
MUS\^L[/V08HRI?E&1Y.IKI$\H?LT/V[T?_[V7Y:Z5E9QOH_/-"<;_8N4^H_M
M[[^MK[1X*T^$5!HHY.5&/U75Q3:,,CF1+"XG]$)R>'.@1197\+4X&N6E(/&^
M+I2=#3R=SHTL3G.=*]C%=S3HX9`FQ*7)>T;RBHL4Y!Q74/_RE%[*5BU+OB.7
MQ<7;^^4EH=D%)%[3<UI]U:*ZEB5V=,QI$;^>H=V?R(R35KO^,I#/TJ2@)3U4
M$Y`S>$6';5X9*P.4MNM]"BU@MFL%.6STG\B.T$PWMNO:H']3<BU[_VOEB5Z#
M(MW_2G,";D,_L1YXI?2-H=&>A:"P,2CMUSWP9Z'MR2%^/U=_T6M(TN.I@NZV
MH$6L8?;^RR5E`HZ"S`1;3"FA9Z@`?&I9RE(#'(D_Z^<UW5>GC3Z;3ZS%=(8`
MUUY)6?DID]2UY+VL:/8?AU`CQ45P(P+/1@19$Q-;B^4S*K-&97Y3P1.\M)`U
M?Z(NBT8%GDU=,'J^+C`\:EO@V;9H];0MJT8$GC>1I669\^5"::[!.ZKN=S>N
MXNVZH%<-!A-T17F)V=!$-BBW'<Z[ITN!1QD`7<]$?C*56@LZMX2T_=B:R%H;
M'Y!J2</L[C%SD7$X`V9W.DLD(FZ+L.1CO^VU@5L9J8C?$FV1@`?@L_L9$TE5
M"=M"-T:2C5J"#2APL[,4\E:V=`8C\?X8:AUDA40'EU.QY3N.],TQT4)DG"&#
M1<(=$DL)\8:(1/A#0A8).-+W6!()E40T1@B6PV#O6SYN-8.9U6TZ['A@T04<
M.>#*`4\.^'(@X(%^^TVT%/LBO,>L1":ZP^!;9@@NF,^XP&"8GOMC`$L9ON,,
M?';C1!K4CI)PE82G)'PE$2B)4$E$8X3@,\RV_6QC<Z9Z@+-"&QTRNO/2Q-*(
MV'%F7D^@L$Y-V9^8#@Y'H*J=C-0EKI+PE(2O)`(E$2J):(P0#(<U_'G#62'1
M<+22#>?,LEFQ5J;TWN'OQ]Q6$IZ2\)5$H"1")1&-$8+;L,+TW1Z?3!DLNVR*
M.;OCC%F[+.>\T[Y\G-!*PE,2OI((E$2H)*(Q0K"8G9>D79=Z!F&%1*M-/).L
MYLQ(PCI*PE42GI+PE42@),(A86(IM:)[S&U"%#R'W6W?\_&T9K#LM60U1_AD
MC2V\DA9WA[\?Z0I727A*PE<2@9((E40T1@@F(]CH?M_EFA9MQH--2`.-&.DT
M".\+<SF5IG%7>&\MYK<,:8X0K-8;O5EX,9I+VVI?$$`+"TG+<M!5LC[[R*MV
MV+U^.,M%HXCH,3MX]&:/\4Q&_)C2WW@@N7Z[!AKUF.MPCUZ0-9-%W$:D(198
M/IQX(C!;K+"TV?5%`D_-A=25@4@@2ZY%V``C38E&$=%J=@+YOM7\O-*WVL32
MN7*'.#12/T>-N&K$:Y`FJ0?=Y:LE`C42JI%H%!'M9H>=GMUL9VW"+E&1X?R(
M)-HNC>`=W)JQ(3YJ.T?X;A"MY,QRU1)>@SR2\-42@1H)U0B[)'S<7.XYOP3D
MET$9*8[$(>=SJ27TG5WPL29T47[YZ"`;;E_@U"S%/63#%<LP'K++RCOQ';;A
MR#WD'6S#R7L8=[$-!_!AW,,VG,.'<1_;<!R'N-%5%.XH+_&1_!$7QS0OM3,Y
M0!.G$W9O5O!;3OZEHI?Z$N:55G`[6?][@MMH`O=,TPG`!TJK]@O[@>Y^>_L_
M````__\#`%!+`P04``8`"````"$`XV*2_$X:``"4E```&0```'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6RLG=MR&SF2AN\W8M]!H?N15#R+87NB5>?S(69W
MK]4R;2O:$AV2NMW]]I,H()D`_EJ:]+0O3/M#(A-``BAD5K'X[I]_/GV]^&/W
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M'C]6C\\[&FWRD_+`K_O];THT_Z@05;Z&VLGH@>[EXN/NT_WO7]^&_?=L]_CY
MRQNY>TD]4AW;?OPKVKT^T(B2FJO94FEZV'^E!M#?%T^/:FK0B-S_.7Y^?_SX
M]N7]Y9QJ_[I[?4L>E:K+BX??7]_V3_^G"P.C0E>>F<KTR9575\OUS3P@6Z<J
MF1LE],E*YE?!XF:E=!PQOC#UZ-/46UVM@YO;^?IX/2H=>TR?;,]J]!&#*U.1
M/DW%VZO99ADL?]32M:E(GVSQI![2&AU;2I]G]?#6U*-/MG=:#P.:?GHVJ'FH
M/7YB'X/#1*)_L-63>AGP+%+_.*N?`4\=]0^V>6)/>?8$,GU.[2E/(+7,V.II
M/>49%,@4.FW.!CR%U#_8YHD]Y5D4R#0ZWM-KO46,.TYT_W;_X=W+_OL%;>/D
MV==O]^JB$&R5-MYK])HY[#[_W^9#NX[2\HM2\_Z2.D+[RROMF']\F-VNWUW_
M0;O<@Y&Y0YG`E0A90FUI2FWD@]@'B0]2'V0^R'U0^*#T0>6#V@>-#UH?=#[H
M?3!8X)K<<_`1K:&_PT=*C?(1C^X=`\MIGD-8@JM$/HA]D/@@]4'F@]P'A0]*
M'U0^J'W0^*#U0>>#W@>#!1R'T-;T=SA$J:%KL[-H-JX'[K2,6IF'E;5T1<*#
MR,%+0&(@"9`42`8D!U(`*8%40&H@#9`62`>D!S+8Q'$:713^#J<I-;19TM0X
M.`2W.B-TS&L'D8/7@,1`$B`ID`Q(#J0`4@*I@-1`&B`MD`Y(#V2PB>,UNAX[
M7IL^`_-E2$F/SN%!O=-D1F<?RUVWW@HZ"'&U"$@,)`&2`LF`Y$`*("60"D@-
MI`'2`NF`]$`&FSB^H!/.&;Y0TJXO-"%?\#"'0"(@,9`$2`HD`Y(#*8"40"H@
M-9`&2`ND`](#&6SB##R=J\X8>"7M#KPF,SI?'!;!_.;&6P0'(?9.!"0&D@!)
M@61`<B`%D!)(!:0&T@!I@71`>B"#31Q?T)Y^AB^4M.L+3>Q%`"0"$@-)@*1`
M,B`YD`)(":0"4@-I@+1`.B`]D,$FSL!3Y.L,O(I4YAN5`3$9A9.#%:7)=8HA
M]&$M$#\Z.0@=%@B0&$@")`62`<F!%$!*(!60&D@#I`72`>F!##9Q_*02#HZC
MCE^R1W'7&XQNY4*!*$(4(TH0I8@R1#FB`E&)J$)4(VH0M8@Z1#VBP4&N+U1(
M:8?W/_"%CD#I<,M3_$[E@-1B(7=;2V/F73M$BBM&B&)$":(4488H1U0@*A%5
MB&I$#:(648>H1S0XR'6/"C#/<(^.1QWW:+1:'3P6JM"$/&:A"%&,*$&4(LH0
MY8@*1"6B"E&-J$'4(NH0]8@&![F^4('C&;XP<::]5#1:T='!6BIS?ZD<I&2I
M`(I5]E,Y4;(U":(4488H1U0@*A%5B&I$#:(648>H1S0XR'6/BA#/<(\)*&WW
M:&2MBU`EBOVE`BA&J011BBA#E",J$)6(*D0UH@91BZA#U",:'.3Z0D6(9_A"
M!Y2T]'C&WZDT.PW\C+8J:ZDL_*5RD.**D51D%"-*$*6(,D0YH@)1B:A"5"-J
M$+6(.D0]HL%!KGM4''F&>W38Z;C'1*+BL5#=WM`>XX&/$,6($D0IH@Q1CJA`
M5"*J$-6(&D0MH@Y1CVAPD.L+%4?:OM#W5Z[4_<RW+X\/O]WM:0'0&6OB8#:G
M^RCF[HJ.1AT7&207B%#=1R(7T6E07*31@JXFUCKS$LBQJ4A27#%!E"+*$.6(
M"H.L=I6(*JEH-W7E;@FU2'%3&T0MH@Y1CV@P2#?5=:2*2_]S1^KHUG&D1G-[
MK1DDOHW4#0#R[8*N3I8CO11.+%(\.HE!<]&5(LJDHJW>NX&7BQ2K+U!7B:B2
MBK9ZK_6U2+'Z!G6UB#JI:*OW6M^+%*L?'%VNNU5X:[M[8GU2YN&P0$TT+$Z\
M4Q&3VC#=I>?=W@E%BAL5,1H?,!G7?\Q(&?SCPVVPF&]FWB).6$:JI8QD76>,
M['D4W'IGU-Q(T5,CREYPM?'&LA`UW.R2D1BK&$F3:D9:\RP(;OT\9,,B4JME
M)+H[1D<[TALITY'%U>WBQO[C'3@&44K=<N:#NH%PQGP8Q=VDAD$SVI&M%>S?
MB1`I'MB(D81XL4'SQ>B?11"LE_XP)E@M921[0<:(KNZ'5N%\8'OJBJ3FPZT7
M_Q>BAIM=,A)C%2/I22V:Q?YLX67>&JS8,A+U':.C?>E/LCB(+I@)YZ545-)=
M792MG<$@=V<(O-TP%"D>THB1K(S8(/5\U\%_\\`;OT0JBM3LQIO]*4O)*LL8
M'5UEN31B?/#C:N;-ZD+4<%]*1F*L8B3=JT6SU7"<'GJ,9U*Q95VBOF-TM"_]
M218'T0730V5?[`O'3QWX5&#DSQJ-W/TC\!9B:"J2%(]TQ&AS0#$C)ZD7>%>!
MA*7L]30Q:P[M8HL95Z0SRV%23FPJIN*MV536WGPL6(UL%R4CZ5[%2+I7,W*[
MYZEO6.IH]UJ6$HL=HZ/=ZUE*=V]Q=>-=L`<6&+OG7FQ4\N<_GT,ZA>3L/!IY
M.X_7L%`5ZY,+>S0R:"ZA1<PHT.XC_ZZ"I;>)):Q*5F;*2%9FQJKLF_03\T4W
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M1HAB1`FB%%&&*$=4("H158AJ1`VB%E&'J$<T.,AUFTJEV6[[P3:H,V_.,<H@
M^U(T#[R@)YP=I'C/BQ#%B!)$*:(,48ZH0%0BJA#5B!I$+:(.48]H<)#K'AK5
M<]RCQ+U=T"`YAH0S0!&B&%&"*$64(<H1%8A*1!6B&E&#J$74(>H1#0YR?$'G
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MH?.R?[$S2*4,Y*CH[T>A2''[(D%2$9(NL9$ZW`GR<Z^)J&'-*:),T!%CN6_L
MAFX.67^\K'8A2METB:@2=,1T#::]6=F(&C;6(NH$'3'6N\9NZ!O.[EWN0=20
M,7?NJ*C?GCL_F#`Z2>"L?Y,WH.#!FC!>"T*ZM33&%A(N18AB@U1S+5W>T"52
MT9;RLD"I2/$`9XARL:A6XLW5DFY\V7^\"+40%4=LER+%MBM$M=BV=7D6&ZEH
M2WF];46*+7:(^FF+7KYVD(K3%MT)Y">'?C"!,`FD[C6IL--UNI\>%"GN8(0H
M-H@^1G>ZRR"1"M,=&V^.IR+%EC)$N4'T,6&ID`I'+)4BQ98J1+5!]#%AJ9$*
M1RRU(L66.D2]0?0Q86F0"M.6W&FALCUG["LZ.>3L*QJIN-O:"_S<$YUT8%\!
M%!LI;U_Q\A^)Z+(M>BLM%2D>R@Q1/FW1"^D+J7C$8BE2;+%"5$]:G'N!1",5
MCUAL18HM=HCZ:8O>SC](Q6F+[K11*:@SIHW.6#G31B-W-YE[EY"0'E\R>PYW
M,$(4&V36PX(.5/Z&`FI25),ARD&SM^L76*=$5"&J1;,UW'-O$C=8L474(>JG
MU7NM'YR*KH//2Y;-,5EFD+LOS#W/A"(E#M:ZJ"*CV$C1OJ`VO!F]H,/3DX@>
M:SAGWG"F(L6J,T3Y#ZT54NF(M5*DV%J%J!9KEJZY=UEMI*(EY?>O%2FVV"'J
M3[(X2,5IB^YT.2]YIV[F><D[1E;R#E&$*$:4($H198AR1`6B$E&%J$;4(&H1
M=8AZ1(.#'%_0K4-W;U89A)_[PN2HRDWL,2(/RN5^[E_N18HG8H0H1I0@2A%E
MB')$!:(2486H1M0@:A%UB'I$@X-<U_E9O..'='J2P%]&C*QEA"A"%"-*$*6(
M,D0YH@)1B:A"5"-J$+6(.D0]HL%!KB_\1-P/?($9-Y76IEW._5[8W#O-AB(E
M2^50D5&,4@FB%%&&*$=4("H158AJ1`VB%E&'J$<T.,AUCTJ)G7X"59EI[XIC
MD/V],$01HAA1@BA%E"'*$16(2D05HAI1@ZA%U"'J$0T.<GWA)Z?4%6>V5$\G
MG?DZ,?4]!]]-!KD7'"]""[FB['L1HAA1@BA%E"'*$16(2D05HAI1@ZA%U"'J
M$0T.<CUW7E9H@5DA1C+P(:((48PH090BRA#EB`I$):(*48VH0=0BZA#UB`8'
MN;Y0^9`S=C2=/K%CZH5!SE)9>*F%4*3XZA(ABA$EB%)$&:(<48&H1%0AJA$U
MB%I$':(>T>`@USTJAW"&>W3*P7&/0?92`10M`,6($D0IH@Q1CJA`5"*J$-6(
M&D0MH@Y1CVAPD.N+\[(3"\Q.&&0]0Q4BB@Q2IY!#L(//)X@4+ZC$06[35>A[
MQC12XEX$II'3=$#10B.OZ=YE,Q8I:?JA(B&GZ<NIP#)8GOF=UE&+VR-&DO$)
M$44&K>2QM]@@2E6,>2&X6YTX==S.^*'6>&8YY6;L$J,N@]QDIG_+-!0I'NQ(
MD$PPO!EKI#C??[7V8HA$U(#/5"AQ^G1;ZLC#WK4,<O-X,R]['(J4]$WKLO-X
M1LKD\6[@"?A$U,AXS*TTE^O"\T*`)88`!KE^FWFYMU"DI&]:%U5D%!LI=I*7
M@18=IW3,/T\?#SV7>&@VR'.:GZ41*>Y%A"@VR#AM>7,%LT_;]XQ)[M5UVGDG
MSB6>.`URG09W#D1*^J9U.4[3B)UVY:>5'2UN/\X[K2WQM&:0.VR0(!<IZ8?6
MY2PLC=A'_N0[5#AE\JGSQQD[ACFNR*Y\MX033(@H0A0C2A"EB#)$.:("48FH
M0E0C:A"UB#I$/:+!0>XD.^^<L\1SCD'J>XN'$\Q\X=]F$RF99%H75604HU2"
M*$64(<H1%8A*1!6B&E&#J$74(>H1#0YRW:..2F<L%7VR<BZN!EDA`7WQ8CSQ
M"8H0Q8@21"FB#%&.J$!4(JH0U8@:1"VB#E&/:'"0XXN5?S@]?LT<Q=U3*",:
M?VNIR&5L?.HD%"E>%Q&B&%&"*$64(<H1%8A*1!6B&E&#J$74(>H1#0YRW>,?
MMW_@'CQCKPR2=1$BBA#%B!)$*:(,48ZH0%0BJA#5B!I$+:(.48]H<)#KB_-B
M`@JX_!"4D;M4O*<+0I&2I6)TB1-CE$H0I8@R1#FB`E&)J$)4(VH0M8@Z1#VB
MP4&N>\X+:U88UC"240X118AB1`FB%%&&*$=4("H158AJ1`VB%E&'J$<T.,CU
MQ7F1V`HC,8/HZ2I>!*%!E)IA%"&*$26(4D29(/LZYL5^N4AQ(PH'N<-P7M"V
MPJ#-(&<8M)0S#(!B4]&22A"EB#)!,@RSE7?RS45*AL%NA#L,*HXZ_;Q'=Q9A
MXS1QFCT;-+(Z&)F*%HH1)8A21)E!Y%ON8(ZH<"JZ?3XO'%0WN[U\I4&.Z[64
MU<'(2!$2=\T77CP>BQ3W)D&4(LH,<H9!-\)"A5/1'08_$ONIK^6L,$`SR!D=
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M]MW'T]YNLU9JO.$TR`J76$I0A"A&E"!*$66(<D0%HA)1A:A&U"!J$76(>D2#
M@UP?J:.S[:/C61[U,F3?%QJY;T!9^DDX4]&Z!1XABA$EB%)$&:(<48&H1%0A
MJA$UB%I$':(>T>`@USTJU#C#/3HRL?/5:XVL@0\118AB1`FB%%&&*$=4("H1
M58AJ1`VB%E&'J$<T.,CUA8H^SO"%#E8<7VAD1PYKC>S(09#LR_@(BTCQA2%!
ME"+*$.6("D0EHDJ0U53_*^VU2'%3&T0MH@Y1CVAPD.LQ%4K9'ONY(Y(.R!Q'
M:N0X4B/'D0;1%?1P@<57;*P/4CPZ":(4488H1U0PDG"M1%0Q.MK46J2XJ0VB
M%E&'J$<T,!J;ZCIR*EJU3Q(GO9M_C9&K0?0&".Y1R$A.GI%!]%#N]$-+L0BP
MF@35I(@RJ6@T>T?"7`18<X%J2D255)QN<RT"K+E!-2VB3BI.M[D7`=8\.&H<
MUV[."Z-'<?<P:)`3!F[\*)J%)$R+&!T-TV(C93($\\#+X"2BA3N;,A);&:.C
MMG+7%FP5A6AA6R4CL54Q.FJK=FUM_!=!-Z*%;;6,Q%;'Z*BMWK6U\K]0,X@6
MLN7.#C])\%,[^`9S!P8Y0>ZM_]PU"UE;`2,KQF6D7YPZ7WAY^X3+K>B6D2C.
M&(GBG)%6/(.W+G.Y*"X9B>**D2BN&6G%MTLO9]MPN2AN&8GBCI$H[@VBAQO5
MUA#<^%^2'[@.QMT;%;?_Q]?J48NW/9B$@#U%YTLOJ1B:BE9\'!FDWN!UN'Q#
MOB$V4B8^7JV\P"=AQ58LSDC647:2K=RUM?!_#*)@Q6*K9"2VJI-LU2QE7+G>
M>"/6L&8QUC(28QVK.3J(/4L98ZN5ESL>6/-HS-TA5'[BV+PY+<FPT6D.^Y#'
M2#(*(:((48PH090BRA#EB`I$):(*48VH0=0BZA#UB`8'N3ZBM>?XZ'B28:/$
MO45LD)W5F_O[5L@5Q6,1HAA1@BA%E"'*$16(2D05HAI1@ZA%U"'J$0T.TNZY
M?OVRV[U%]V_W']X][5X^[\+=UZ^O%P_[WY]IQ[M5[VXXX(N7W:?WEW>;^58Y
MFJ[34+*@DG%]^B6K8*N>;9FHLYI1R7CVACIDA[*E$W769(?R65,E2RH9;XCY
MVM8K*AFO.7[)@DKH&T03VA9K*ADO=WZ=)970$Z`3=98;*AFOAU#GEDK&>>F7
MK&ZHIV-ZUR]94`E]\WS"SH)&E*XX4R4THCH&!6TTHOH^(Y30B%)L,Z6-1I2^
M_C91$E`)_:[=5`F-*/W*VD3)C,9-/P+MMV!&XT;OF9VJ0^-&;SV=*)E3";U2
M8:*$"B9Y0..I?R_,MQ_0>-)OOT[H"F@\]44!ZM!XTH]@3M6A\:2?9,227X+M
M+Y.S79F?D+\CXY/R9'K*\B^+[2_32U!Y>,H`>7'2B>3#21>2!R<G/OEORGV4
M,]JJ=`,.!:6.MBJ9,U6RH9*I.I3I(?-3)12A;U40CMHHPMZJ(!I+*$+>JB`8
M2RC"I19,E=`#-UMU4QWKW%';[B;;%E)).%D248G*O:&V:+VADBD[E)C;JIS.
M1)W59JN>)\`2>@IIFTR6T,-(6_5T`=:A9Y*VZHFCJ9(EE4S-&GIRA4JFY@T]
MS$$E4SVE!QFH9*H%=XO-]HZ^[88MH._];</)$OKZWU9]DP_KT+?KJ&1*VQWU
M]&ZR!?38US:<+*&GOVBLIT8G6BVI9&ITZ!DA*ID:'7J2ADJF1H?>8;Q5;Q7&
M_M!+<:ED:M.@5P[3[C!50J^*W:JWP:(V>M7K5KW-%4OH5:U;]396+*%7K5(+
MIDKNJ`5WDRV@-TIOU<N(41N]6)I:,-53>E,QE4S5H?=`;]4KA%$;O0YZJ]XD
MC"510#.1?CL22^AG+;?JAR:QA'[2<:M^L!%+Z-<82=M4"?V0XE;]3"+6H=]`
M)#MCR?7AFO+ZX=VW^\^[^O[E\^/SZ\77W2<Z@-'K1NG>VLOC9Y7TT/]Y,[\:
M\^O^[6W_1&?DRXLON_N/NQ<E0,*?]OLW_@^9OOZ^?_EM/.1]^+<`````__\#
M`%!+`P04``8`"````"$`\H>C*2$%``"A$@``&0```'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6RL6%V/JS80?:_4_X!XOR&&A"0HR=42H+U2*U75;?O,$B=!
M"S@"=K/[[SOC#V+CW"AJ]V593F;&<V;&,S;KK^]UY;S1MBM9LW')9.HZM"G8
MOFR.&_>O[]F7I>MT?=[L\XHU=.-^T,[]NOWYI_6%M2_=B=+>`0M-MW%/?7^.
M/*\K3K3.NPD[TP9^.;"VSGMX;8]>=VYION=*=>7YTVGHU7G9N,)"U#YB@QT.
M94$35KS6M.F%D996>0_^=Z?RW"EK=?&(N3IO7U[/7PI6G\'$<UF5_0<WZCIU
M$7T[-JS-GRO@_4YF>:%L\Q?+?%T6+>O8H9^`.4\X:G->>2L/+&W7^Q(88-B=
MEAXV[A.),K)PO>V:!^CODEXZ[7^G.['++VVY_ZUL*$0;\H09>&;L!46_[1$"
M9<_2SG@&_FB=/3WDKU7_)[O\2LOCJ8=TSX$1$HOV'PGM"H@HF)GX<[14L`H<
M@+].76)I0$3R=_Z\E/O^M'']8.(OYV0>@KSS3+L^*]&FZQ2O7<_J?X04D;:$
M%5]:@:>T$H23^6(:$#1R1S&0BO!4BK,)F4WYXG?T9E(/GE(OG"SG\UFX7-Q?
M$'[E?.$I%<GRD05#J0?/1QSU1)AYUI*\S[?KEET<V`H0Q^Z<X\8B$=A2Z1)4
MAP3^*'^0.#3RA%8V[L)U(#,=%-W;-@B7:^\-"J60,K$M0TR)G9+`JD"SR1A(
MQT"F`1XP&FA!XC^!%EI!6LJA6`%7GOZ(@Y)0*LD82,=`I@$&!ZC!3^"`5C8N
M_-52LS*=CH4,@1X\",U-D=T@,A"SD-1",ATQN,$^^01N:`4*%P(X^&W7G12Z
M1VX0&<A92&HAF8X8Y&`OZ^1NMSZU=5"8<U!KQP+QH?5>62VFHWP,0DHML9#4
M0C(=,5R&K?^XRRALNBP0<%EYL[.0Q$)2"\ETQ/`/6HON'[:I!71TU<L?;E1H
MQW1=(BLCVN/.-`@I?HF%I!:2Z8C!!@\[6M.]7R`H;+HLD=4UVA:26$AJ(9F.
M&/Y!,![W#X5-_R1BAG3<*`>A(:06DEI(IB.&RP2VR^,^<VG3:05I4;6AQ(92
M&\H,R'03!Y:6>C%O)WA(Z$]E\1(SJ&R0N5$2`<Q5.6W%U(.^IV(7$P&%\!B:
MAK\<C>"=E`+WE&*B%*$6-,71@$BO4DHQ,VR9''&@:1QO<(%3V$!&C#^#C(!\
M:+!7GU;C#HAM'PK/#S0R-Q3)*C!;9RH5`_3A;4MFH]\S97B&ADUF.,\>9R:G
MGYXF`?DA7]J?DIGIVXY(@>N9(U%0./!,)11@2;QMYXM1N\H,%9,!#JW'&<@1
MIS,0$.0&EP8&XX,"D0)Z6@8=53VIE)(YN,%`5S$9X`S3&/RW'20&H5%T`KJF
M)ARG1@KHJ9'04DN-A%8\/L%J9"7#NQ!6+<^F20R'W_\F)B:H04P.55[.O('L
MB(3T'`DHT$\=-[:.E"*<'0F75N7IBYGT<!K>H?>=G7_4^?1N(6>J7I$"T@\?
M<,'E0=;[G`6EMA3>C*^*PGUQTQ5WIIJV1[JC5=4Y!7O%6RS4\78]P.**'2\C
M&*U0ZF-\%<'\NH&3*=S)N:]C#;)0M_71+]"W(^S*MC6XX#_QZ(PT8KSXWY"/
M_0AN(+:=.(C@^&[C3[/H27Q`&"\PB^!(;"O$\PC.G3?P,(+SW@T<./,]Y@T+
MP`>"<WZDO^?ML6PZIZ('"/V43\U6?&(0+[VLH6?6PY<!7DXG^!1$X2XYQ</B
M@;%>O<#"WO!Q:?LO````__\#`%!+`P04``8`"````"$`*@U!4B()``!P*@``
M&0```'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6RLFEEOXSH2A=\'F/]@^/W&
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M*[?;:^W@'Y`_'?87S_=>KP\DEPD/%/M<SI0SI/3\^'*@'LAA3UW<UZ>TL"JB
M;5GIS/-C,$++@_OIQ[93_KOWV;H<7OJ'LTO#3862)?CF>=]E:.=%(FJ<@=;-
MH`3C2^K%?=W].%ZGWF?;/;R]7ZG>>>J2[%GEY7?=]?<TI"3S8.>ETMX[T@'0
MW]3I(+U!0[+[%?Q^'EZN[T]II_"0+V8=B\)3WUS_VCQ(R71J_\._>J=5&!3T
MR(C82H1^E8AM/93R^5RA5+Q?):=4Z%<?RH.5RQ;D@=Q(3GN#'M"O:E:.Y;[1
MD.9`T)!^5</"0]'*EAUYS#?:E54[^E7M+/N^C)8>*+FAVUKW=-)R5%*Y8;J9
ML_/%4E"H&X=K%713VE!-[;MR%G5#VE`-"_=UU"8?!V,K-U13YYZ<MO:CW##]
MC*QTHY^V]H_<,(=[3T&EP<*CC3QT;TEM[2*YH;):=Y74UCZ2&Z:K=Y74T3Z2
M&ZKI725UM(WDAAFC6\.;"=>+8/FI[ZZ[Y\>+]YFB19WJXW_LY"G"JC@TXGKA
M"2MDEJ+_MA+1$B15A)1Y2I/!:)'Q:?W\^>R4"X^9G[3D[55,%6.L9$1-1\CU
M3<K6.6APT.2@Q4&;@PX'70YZ'/0Y&'`PY&#$P9B#"0=3#F8<S#E8<+#D8,7!
MFH,-!UL.A"FO+HPPQ30$BB>@>@+*)Z!^`@I()UYE+LJ5(=L:[]*L^1/>E3+2
MN[HK50TB,]O,J#I"-ZEST."@R4&+@S8''0ZZ'/0XZ',PX&#(P8B#,0<3#J8<
MS#B8<[#@8,G!BH,U!QL.MAP(`<044Y=*U"`&JB>@?`+J)Z"`(E[!A%%IE?X3
M1I4R=&$76V3M/%]DPQB+SF)F)<XS\YH0/21U(`T@32`M(&T@'2!=(#T@?2`#
M($,@(R!C(!,@4R`S(',@"R!+("L@:R`;(%L@0B"J(JHAPKH*+*S`R@HLK4C4
M-F%NNFCX$^:6,G010I/3&-<I%Y/6K:J@6^XV(<;=0!I`FD!:0-I`.D"Z0'I`
M^D`&0(9`1D#&0"9`ID!F0.9`%D"60%9`UD`V0+9`A$`4E5G74-0PJHX("RNP
ML@)+*Q*U3;B;;B42[O[ZAEQ?!LOHP,3ZP*N*T+V!L;6=+R5M73-!NED=2`-(
M$T@+2!M(!T@72`]('\@`R!#(",@8R`3(%,@,R!S(`L@2R`K(&L@&R!:($(BB
M0NL:"BRKP+H*+*S`R@HLK4C4-N%9>D#P#SPKHY.>5:1LKHAK0.I`&D":0%I`
MVD`Z0+I`>D#Z0`9`AD!&0,9`)D"F0&9`YD`60)9`5D#60#9`MD"$0%1%A&45
M6%>!A15868&E%8G:)@Q*SPD2!@T?.CS(!W;7]\/^>]6CQ9+N^KY8;!UZN!`^
M<I`B2=^&A!ZFZ"E8`U(/2;X0/*/(6?D<N\1HF``MT@32`M(&T@'2!=(#T@<R
M`#($,@(R!C(!,@U);+AF0.:FE7RDD[/L8BYYZEJ8`#U<2R`K(&L@&R!;($(@
MJB)21:<2ZT,24=4-PCH+++3`2@M5ZG#8$JZFJ]+_W]52).EJ1:+G$S4@]9#D
MZ(HH=I513I:J88+T(#1!J`6D;5K%I`O9I'3'!&GI+@CU@/1-J[@T>R8X,$%:
M>@A"(R!CTRHNS9[B3$R0EIZ"T`S(W+2*2>?96"],D)9>@M`*R-JTBDGSL=Z8
M("V]!2$A$%5-N[@X&VVAO$5.TNI"F<N*#"B4E>)(>2EIP0(;<:'\%9=7!@NU
M$O.)KID3\^F+LP$]\M>G`QF=G#@AR=-]<30I"D[2N;4PR'9,?^N&1,VL,FO6
M4$$R_<]GRRJR9RQ-(Z*'L06D;<B-1)TPR`D3%;*L7EVCH?/T@/0-N9%G8/)$
M07:.91L:)9UM!&1L2"0$PS=106KXBD7V%&MJ1'2B&9"Y(3<2+9*)H$Y+(Z(3
MK8"L#;F1:!,&J3KELFP]V!H-G4<(1%6#;F02RK*4*HJ"4HG(QB:C-FWD=1'Y
M--*":@GM756N?(E=!(C(RI0L,8<M>G&8F,3_TZ5>H)*<W`KE23\VN]F!U524
M':U===TP6N$:&EG!;+9MRV$7A4W4:2%J:YU(NJ.CRN'U9G+QZ>J]T>'U$/51
M=J"CR#!1[V&ZZJA(?H1HC/(3C<R`<.DIZLP0S;5.-"`+C4)IQW)R[%IBB3HK
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M\:S:P[?=22^^0SE50,<NY]B0!I^@!>M5<`H/5X#PD[+PFXZ3>WES:^[QZ*?V
MW@_YN1B]"'Q^-#CZF"UX1L)X-?C(35X(\QTV??WV90N'=@3'PEJ(7$6._Q=2
MM(,>MG^Q(T\[@B_;F%2U0#N">WFVHUZL3(*UG/%YL2+OVS%%O52A&Q?D[5*%
M;F"1]TL5NOM$/BY5Z-81^;Q4H?L^Y.M2A6[:D(MJJ2)ON+[8TZ0]=*]$>S*F
M=_2YW\?NS1WL+F^'LY\ZNJ]4WVRPQ%_"#P;#?Z[>!]6=/OKSKO2A7[#Y3E]V
MNO0]3?:!EN-7S[OJ?V0"\ZWH\W\```#__P,`4$L#!!0`!@`(````(0#4FM</
M.0H``-4M```9````>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;*R:66_C.!+'
MWQ?8[V#X?6Q+EB\AR2#6+1]8+&9GGAU'28RVK<!V^OCV6Q19/*K43M(S+YW.
M3U5_BL4B661T\_OWP[[SM3J==_7QMNOU!MU.==S6C[OC\VWW?W^DOTV[G?-E
M<WS<[.MC==O]49V[O]_]^U\WW^K3E_-+55TZH'`\WW9?+I?7L-\_;U^JP^;<
MJU^K(SQYJD^'S05^/3WWSZ^G:O/8.!WV?7\P&/</F]VQ*Q7"TT<TZJ>GW;:*
MZ^W;H3I>I,BIVF\N\/[GE]WK&=4.VX_('3:G+V^OOVWKPRM(/.SVN\N/1K3;
M.6S#XOE8GS8/>^CW=R_8;%&[^87)'W;;4WVNGRX]D.O+%^5]GO5G?5"ZNWG<
M00]$V#NGZNFV>^^%ZZ'7[=_=-`'Z<U=].UO_[YQ?ZF_9:?>XW!TKB#:,DQB!
MA[K^(DR+1X'`N<^\TV8$_G/J/%9/F[?]Y;_UM[S:/;]<8+A'T"/1L?#Q1UR=
MMQ!1D.GY(Z&TK??P`O!OY[`3J0$1V7R_[?K0\.[Q\G+;'8Y[H\E@Z(%YYZ$Z
M7]*=D.QVMF_G2WWX2QHU/=(B@1*!GTHDZ$U'HV`\G8#(%4=XVK0./Y6C-^IY
MP6`L&K_B!]G;^,%/Y3?J!?YH,FW>^HKC3#G"3VS0ZNX51P]&IFE2_`==/QTH
M#\(L54R\_8]TV!NB(_Q'-3^YVN6^'.@F;^+-97-W<ZJ_=6`RPE">7S=B:GNA
M!R.&&2,[KW/H9RD$N2-4[H7,;7?2[4!VG"'OO]X-9].;_E?(U:VRF7,;S[6(
MT$(DII"-*4@H2"G(*,@I*"@H*5A0L*1@1<':`GT(K8XOC.P_$5\A(^*+D9DC
M,`'W23#1`EUB"A(*4@HR"G(*"@I*"A84+"E84;"V@!-,R'86S"',P/;E#7-3
M>,%"9N6F/YZXP9I+&P]6$)W`(]<DTB8ZH(PDC*2,9(SDC!2,E(PL&%DRLF)D
M;1,GMC#W66S%UO')A4#(P%H"(Z@#.9S-W%#.E=&U:&L3'6U&$D921C)&<D8*
M1DI&%HPL&5DQLK:)$VT(K!/MZQDLK)N@8C#FDOB^7A`B1F)&$D921C)&<D8*
M1DI&%HPL&5DQLK:)$[#QIP(FK-V`26('3))`ED'-;J.(G;N^/W!S-]%&.!8I
M(QDC.2,%(Z4BS0LY?8=MU4D6N4?W1#5U>=EMO\QK69.U)-$0]F*Y0PL1-R22
MV"&1Q`Z)(K!JZ.GL>V0Z)]I(AX21C)&<D8*14A$>$E@Z_GY(A(@;$D7,/ALI
MTI3=LB:1)`B:*L<?>$.2(/JYC@;3R!C)M9>HG4"5[.:%?HZJI:WAI`M4LTYL
M6M(""FK,"V'M!D$2']8N,^83,@TB9334"U#<XN;-:'"4D6@>2L2A%Y`2,-4J
MV,^,M91K&_."K*7BO99*K0(M.?$3-;T30#'?_+$X,;U3:32>;C`5\F%R6]$D
MO8[0RB1>C&BL(YPH-%2I-_)IB9URIPR1D<X1&>D"I9V)3@>G=!S=F(GZEY\C
M/KE&>;**ANH!1W^N$,E&,CLBM++24:&1Z7>":"JSCR[M*:H$NOD,D1'.4<4(
M%XA@2II!YM&3O8.NL(P3!>_?CYXLFYWH2>3#.FI>;$(F922J-5@#P`K#'BLT
MA$FB'=D<2Y35:-8$=`3G>[(UI"AM4BU#9%K+/]1:X;;6LGB4*-VTYN:GJ'NO
M1?B/^A4F[KL37)7/=H)*Y)L,B<3Q7,33H!B12:U$H:$I0%)NE2$R6CDBHU5P
MK=*Q<F,AJE([%M<W"'$K0'8(A>S2@:.8HX2CE*.,HYRC@J.2HP5'2XY6'*T=
MY,9/%*EV_'[USD06NR)I]1P+!F2CG8LSF`B_O;;0HZFQ,1-8NR%*N%7*4<91
MSE'!4<G1@J,E1RN.U@YR@R^J9#OX[R2O+*HAQAB&N2>1D[P2V86OL@KLP?$G
M8U+K&2N43Q&9:9UQE"-RY<FM1&&L4+Y$9.07'"T1N?+D0FYEK%!^C8A7W)ZH
MQ>W`_](II%$A%9(L\IWQL.M^=1.HD%D'$Z45&)0B,M').,H1&<>"HQ*1T5IP
MM$0$2[Z>Q/Z$;(,K8V4B;??137%1V=N1?B?%U4'`3G&)W*)I2E:62"PI=)O2
MCOB>B;)RMBEFE7&M')&]34E'2ZOD5@M$9GB6B(S62B%+:^U8N2$5Q?XG0BK/
M!LZJH8X+L%*8<9ZR.EY9F=HF]EH<6RHI::5*>\\;S0)WJ4F-#@Y-ALBTEB.R
M7Y.U5BBKH9.T4U)4EVU:_H"\UP*MS$LL$5U]B16^A#S->%XP(\O?VNA`EYWQ
M]-N.:/#'HL]=B30J[F*D$)DYM&!&*Y.AL4+V<4.A\:"ICH/9C`0X11F3U1DB
MHYQSY0(13"<K&<G(E*CE'.39^*&5:7&)\F9(5PKIO@S(7K)&F:8O[EC](T=#
MGQ\-%7*/UE-:&Z&5Z4RLT#N'&V6E#C?>>#0ENW^*TM;A!I%I+?]0:X6R"B"Q
MK2$E+98H;\\L/B71RKS$\D,OL5)6NLO!@$1SC=+\A`7[M[O$TOK@8R>L1H;,
M2:$,QRFSP47*RD(Q1PE'*4<91SE'!4<E1PN.EARM.%H[R)T^XC!I;UV_>-J`
MTZ@ZQID$"P9D`YNCE;VRD!R(C`WN1#%'"4<I1QE'.4<%1R5'"XZ6'*TX6CO(
M#3X]*M.D_M#5N]A-R`E:H3&L:M9T)XMJA([6[;-"4/3:CJ3>3(P5#E'J:+F=
MI.?9Z_6FN`:EO9%(-&%Z,Z/UIG*$:.-+Q8AL1U:N),H*2KWF<GQ"DC8U*JQ.
M@(72F3SO=$V8D\5'(MADU,4\V64CL?V(U<DLMC$BLR\D"F%]-Y@2F=3Q<8='
M'!3L!>"=/LASA5V[BNL_\8KZ3Q9L1BL#>V2T#PY6@C)R&+R6/M@^;A]$X?^)
M/LAS@M,'B2!,:AS(UACYRL`>!^UC^B#1E7&P?=P^B!+]$WV0%;W3!W44T.-`
M"M[(5P;V.&@?TP>%?CX.MH_3!_&QQ"?ZT)B[\T$A,PYTS4(#:QP06?-!H9^/
M@^/C]H'6D]?G`WQN1^>T0K#G8DPCCF*.$HY2CC*.<HX*CDJ.%APM.5IQ)+XR
M;.9\TT<9/_G5H/SZZU"=GJNHVN_/G6W])KX(A,/@W8W&^+GB*+R782)/X%HR
M%+=T$$#ZQ/=#4<[P)_?^,+R']^)/H.P`GR;KJ=I0?S%)GL"GE/=MK<S!H;T-
M:**M;6BZK>7[(+R'.^"6EPU"^*ZCA4-$6@/B@4.K$ESFA>*:B6O!G5XH;IOX
M$[C:"\7%7=N3"3QI\X%;/7B#MB>Q'X2B6.!J<$T:SEM](G@2M3Z)X8FXE>-J
M<"L:BLLY_@0N1T-Q1\>?P!UI*.[E^),YO%H;C^#%VG@,0FT1BR<A?'/`]4L8
MEC8>3\-DVF*?3T/X^SSH]'6.PD>UKYOG:K4Y/>^.Y\Z^>H(I-FCN)T[RLUSY
MRT7]V>FAOL#GM+#4PA>8\/ET!1\_#GI053W5]05_$0WH#[+O_@\``/__`P!0
M2P,$%``&``@````A`(R"%?1L%@``9G4``!D```!X;"]W;W)K<VAE971S+W-H
M965T,C<N>&ULK)U9<QLYDL??-V*_@T+O0Y$LDI(8MB?,NB_6$;.[SVJ9MA4M
MB0Y)?7W[250A*POYKZ$D;_=#2_XA#P`)H("L0Q_^^>?#_=GOAZ?GN^/CQ_/%
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M*4XF`K\<C[\:T?2+0:1\`=I1%X'ZZ>S+X>O-;_<O[?&/Y'#W[?L+A7M-+3(-
MVW[Y*S@\WU*/DIG9LJO&[?&>*D#_/WNX,T.#>N3FSX_G2W)\]^7E^\=S;S-;
M7\Z]!8F?_7)X?HGNC,GSL]O?GE^.#__7"RU,I08CGC5"/ZV1Q6)VM5ZO-E>7
M9.6$YLIJTD^KN9RMENO+J\[]"44RV]6;?K++U6RQFF],M4_H;:P>_;1ZWFQY
MM5ZL7U.\M(KTDQV^L8TTU;JJTD^KN7I;YUQ;1?II%9=7;]-<T#CJ?)I?WM?.
M!8\(\\L[6[J@4=2[E>'TQG@N>`R97]CMFR*ZX#%D?GEG6WD4F1G#3M\8U06/
M)/.+U:4*G!AZ"QY"YA>KL?1FEXOYM??*-%GP&#*_O*F-%_T\[Y:-X.;EYM.'
MI^,?9[064U2??]R8E7VQ-=9XP>@K/BPA_VD%H5EOK'PV9CZ>4T-H<7BF9>_W
M3ZOY\L/%[[14W5J9'<HL7`F?)<QB8LP&&H0:1!K$&B0:I!ID&N0:%!J4&NPU
MJ#2H-6@T:$?@@L(SQ(AFS]\1(V/&Q(A[=\=`@J9"YK,$JP0:A!I$&L0:)!JD
M&F0:Y!H4&I0:[#6H-*@U:#1H1\`)"*U)$)`5K1G35UF>(T:+KJ?.'/'<&;#K
M9<Q$'";2VA7Q!Y$A*$!"(!&0&$@")`62`<F!%$!*('L@%9`:2`.D'1,G1K3X
M0HS,NO[.A<V8H;611L(0D-5\Y89D9X5.16T0&:(&)`02`8F!)$!2(!F0'$@!
MI`2R!U(!J8$T0-HQ<:)&`9J(VLQ<#U^^W]W^NCOVN\^)F>;19:>_&!DC7<RX
MKW>6R-KG6]+MIOMK34]6-*"&2'MS-?G"08A-1T!B(`F0%$C6$]J@L>4<2#%H
MC:NX<0=C.0BQH3V0"D@-I`'2]J2OHA,UVO+\_Z-FC+A1ZXFW'+K$MT3B&/1D
M10-J%+6YVR7A(,1=$H&A&$@R:(U-7[JFTT&(36=@*`=2#%ICTZK6Y2#$IO=@
MJ`)2#UICTZK6S2#$IMNQ(2>VM*=S8CLQ\^B,Q5//2+M![,G2G597;B_Z@Q#7
M)[!D-<0^M,3X^OW3]6+E72W5[(Q`*0;#R2`C_;.X5I?AM!?R>E]T`E#]EPU&
MN+XY."I`IK2DM[I<+*[G*N1[T*G`;CW(G&A`TPO9!JQFUZOY^#]U_6H'D]0<
M)_AT17M'\(VT&_R>+,G^:'9>J^`/0MR9@24;"7Y/O%5_M%@L+M>Z[R)0BL%P
M,LA(?3#XUI>YGOS^:3&[5IOB;##"]<W!40$RY6!57"]7Z@"T![4*3->#C!B"
M-C1O\=8.EG38*</PCK`;:3?L/7'G_$*-=7\0XFX,+!G-^9[0,):V>@O5:=&@
M)D)+O46+P5LRH0;]F`X5,&-A.5NJL9L-1K@1.3@J0*8<K(YJ#&,!U"HP70\R
M8@C:T+S%6SM8TF/!I(R<P=!G"-ZY)>NLN(/$(G=Q6*C)YHL4]W#`Z$J6!T;4
M"EEH%FI5CUB*KG6#%(X4EI)-1L*()LR@"/V<LM2U73@NU3*;L8"L:SDC<58P
MDN:5C-SF*?-[ECK9O(JEQ&/-Z&3S&I;JF[>:Z;UQRP)=\YS+B,D=_@UCJ,^/
MT%F,A\*N,TS9:F=WL5#;`E^D6#&PR)/M=LAHT8>/XKM9K-6B%;$I6:-B1MY0
MK81-T=0Y-5[Z]JRLP]F5VA5E;%F<Y8S$62'.N'4E(VOYZ@H:LF=#8KMB)+9K
M-G2R(8V5L@U9S_3BV[+ESID[,DR*!?*/=,N!>LZ<]_YU_$&KAOW'FPY_YJBN
M+D<6J95&G9M\D>)^#"SRKH?0AA:M[2S8K"ZO+F&=Z:NPE'D>H_%$C)\<)+VM
MU;P;E<N97B`SMBS.<D8RQ0MQQHTK+;(M64P.$FA(A;9KL7VB(8V5L@V9&B1C
M9^X@,4D>&"1KN03Q*#E]-C&W$O3(Z!&M']PMOI4:H8"1S)70(MJ9L&*$4C$C
M,9\P$ELIVLI0*F<DM@I&8JM$6WN4JAB)K9J1V&K05NM(N3$R*1T=HV[&O3EM
M8V[8Z/CT2,U<=1KSK2))<3`"BYR9V]NRXWVSVBQ6U^H2&K$EF4PQ(S&>,!*I
ME/U)CV8HE3,26P4CL56BK3U*58S$5LU(;#5HJW6DW!B:!(^.X>+]\\SFB<;7
MZ1XM:8H/%T1OH:YWODG/T@`@*8DCH!"E(D0QH@11BBA#E",J$)6(]H@J1#6B
M!E'K(#=L)G>#87MWJMO<N>SGGP1II7=Y.Y8:;Q9APV4MR18V$#6.;8@H0A0C
M2A"EB#)$.:("48EHCZA"5"-J$+4.<@-I\C#C0+YR/>O3-G1AY2[=F5O))H3N
M04$=6GV18L4`48@H0A0C2A"EB#)$.:("48EHCZA"5"-J$+4.<L-C\B7O"(\1
M5T=>BV0_Z9M;?7W$)!:`0I2*$,6($D0IH@Q1CJA`5"+:(ZH0U8@:1*V#W%B8
M?,4[8F'$52QZY,G%TC?3AJ1&*+!H-;YP+?6%*Q0I#F*$*$:4($H191:-ZI4C
M*D11EN_E4AU@2Y'BJNX158AJ1`VBUJ*^JD[$EG]+'JFSX@;2HE'O^(@"BYS;
M>\N%6AE#D>+>B1#%B!)$*:+,HE%5<T2%*(X"J:M:BA17=8^H0E0C:A"U%DT%
M\F])YBPQF6/1^'X?HL`BNN/7I63G.LL7B@!W3(1F8D2)*%K+*A>9B@!;SM!,
MCJ@0Q>DZER+`EO=HID)4B^)TG1L18,NM8\:=H^8(/EY53:YWN3&/BK[R;(O9
MV:L%UB(W-Z?7(U^DN'Z!(!G_D&T-K=1PCT[GSR,QPY9C1(F@$\Y2[6Q.M^Y&
M_ZD[$ID89=<YHD+0"=<EN%:C<B]FV%F%J!9TPEGC.IO3PXCNO;I6S)`S=^SH
M),WIS:L9%GK`V&2,<[=PJ6K@6\7Q81]1:)%')N7`N51=%XGB6$JE\V*1X@Y.
M$*7BT<S$^6Q-=RC'_ZE40R8F3OC.18I]%XA*\3VVI3SN17$LI5I;B11[K!$U
MTQ[5.;`5Q6F/[@#2&:17!A!FBY8V6^0&7>=Y18H;&"`*+;++B]I%1:(PW;#N
MB:)8I-A3@B@]Z2D3A1.><I%B3P6B\J2GO2B<\%2)%'NJ$34G/;6B,.W)'18F
M`S2^)KTR+/J$T?A0;*Y>M-2X2<2E3B**%#<L0!1:I-85E<B*1'&Z@79X#/5B
MCXDH,DJG/:J-:R:*)SSF(L7F"T3EI$=/38&]*)[P6(D4>ZP1-=,>U<K?BN*T
M1W?8Z*38*\-FR'UQ/7=T^Z8;-LYJXJE+B"]2K!@@"BVRJ\F*-E3N=35"G1A1
M@B@%RVK5SU`G1U0@*L7RJ+L]=;G8HV*%J$;43)M7M6\=13?`[TN6F=FO]QL]
M<M<%3T7&MXKT0P(\*#(*K12M"]T^W)OIF]"1V!EUYU)U9RQ2;#I!E+[J+1.E
M$]YRD6)O!:)2O(UL>>JRNA?%D91N7R52[+%&U+S)8RN*TQ[=X6*2:N^XC-@<
MW"BWNH2TG(\H0!0BBA#%B!)$*:(,48ZH0%0BVB.J$-6(&D2M@]Q8Z.3=3[YT
MM!RR>C(`Z)4_=VG=L12%;S@*P"2WED8W+$2-1VJ(*$(4(TH0I8@R1#FB`E&)
M:(^H0E0C:A"U#G("28_/O&=2=>)N\LXB<ZP<@N.MU:KHBQ3'(D`4(HH0Q8@2
M1"FB#%&.J$!4(MHCJA#5B!I$K8/<\.A,W>D]D(<I.8LH/-SQ/J(`48@H0A0C
M2A"EB#)$.:("48EHCZA"5"-J$+4.<F.A4VNOQ`+S:907-3N84?+8MXCN3G!X
M`D$RH?"&A4BQ8H0H1I0@2A%EB')$A:!1576"L!0IKNH>486H1M0@:AWD1LRD
MH\8[AI]Z\-6<%-6^TR(GD+V4$TB+Z,>P,N(-"VN+;FMP[T2(8D0)HA11QD@&
M6(ZH8'2RJJ5(<57WB"I$-:(&4<NHJZH;2)U8^KE`8KZ)7D?H9J3TCL]H=%JP
MZ#_?L!`![I@(S<2($E&<3OZG(L"6,S23(RI$T5I65^12!-CR'LU4B&I1G*YS
M(P)LN77,N*%]7W*(SM\P&6T2AD(Y3+,KE5WQK1ZE,[E.`:.Q'MZDL%+TP[36
M6ZB]:216V'#,2'PEC$[Z2JT4_>AZ5M\PS,0*^\H9B:^"T4E?I96B'\;7E7XM
M8B]6V%?%2'S5C$[Z:JP4_3"^-IY*MK5BA7RYHT/G@'YNXF-JB)9N,XY,<F(8
M--<J0>:ST'@IL'IRS`A9JG^>V%NIM&3$Y?*80LQ(#">,Q'#*J#>\A)<1N%P,
MYXS$<,%(#)>,>L/7:W66VG.Y&*X8B>&:D1AN+%K;I];G.N78LDYGV8VT3@;]
M7*0Q1^395,]XB'IKE:7R64K&=F"1V9P/0V1B?>C-VR?G-QNUS$9L6)[*C1F)
MK^1-OE(K97VM]#N/&1L67SDC\56\R5?)4C:4EU>JQ_9L69Q5C,19S69.=F+#
M4M;99@,KQ!!$6"%T5DB/F[<]6>YAMHC1Z%$O1`&B$%&$*$:4($H198AR1`6B
M$M$>486H1M0@:AWDSNV_*5M$SX+;B[_,R-5<K;<[ECJ5+1(9OKH%B$)$$:(8
M48(H190ARA$5B$I$>T05HAI1@ZAUD!-(>O7#/5"=/@)WXFZVB!%%<EA4O95:
M6WR1&L*#*$04(8H1)8A21!FB'%&!J$2T1U0AJA$UB%H'N>%Y7[:(KB-Z+\UH
MM.8A"A"%B")$,:($48HH0Y0C*A"5B/:(*D0UH@91ZR`W%N_+%IG'4U62P2+:
M,O$D\"T:)QD0A8@B1#&B1-!X<JKU-14IKE?F(+<;3`YDG()Y9<7H4R;C>__F
M>4^5-+.(O'(-`D0AH@A1C"@1)-VPW*C;QJE(<24R![G=0+O/]W2#$5<+9X^<
MT=`CIQL`A>;#*F1K)!4ABA$E%FUD@Y<BRAQ%M\WO.]F;KV_I-O?(:7./1JT)
MK"(A"9>W4F>:4*0X7!&B&%%BD=,-?25&*',4W6XP)\;Q#-`;U#>]$[OJSYW.
MQ.B1TSL]<GK'HG%FSUNI+$9HS=,`EMX!6S%+R;Q++.H_B-H]%),BRAQ%MW?,
MQE[WSIN>5UWU1P*G1WJT<=NJSA*^51RG@AC)4`\9V;R/YWEJDQ*QA"C%C*0;
M$T8T"X<-#YPB4RME,R2+F:?R5YF8H0"Y/:@/0*^LL'C06?7(R85X*U4#GZ4D
M`Q`PDBM4:)%)Y0[-A8^D1*@8,Q+S"2,:B(.MB:[K:W_:8R:VH/_TX>25_AO.
M(#Q3=JL>F6?BAGIZ^KL#/DO)V`@8R0@*+3(9L<'61/\-'KD2,=L2\PFC<;TF
M^J^W==IC)K9T_ZWUF>"GUK?.BGO%L\@=EFOU2)G/4C)N`D:2F`H945M/="M+
MR7B.&8GYA!&-N\$6=BM+G?28L13FPRB'-K$PT@+WCH_HX?Z^L_KQW%TAUVIK
MXUNI\0II$27#>,2%C/JD#2V0L$*R'1G?,:/1,&4[)U-$J96B#;?)(4^LD&RY
M<^:LD&N]%3<CU*-'X\TD&W^BXO3,[\Q0RG@4]M5<75QV5LB\]C8,#K45\46&
M^S)`%"**$,6($D0IH@Q1CJA`5"+:(ZH0U8@:1*V#W#":@X#>*IA]URMA,VJO
M?;1UW0N=#ML@(V$#%(HEEHH0Q8@21"FB#%&.J$!4(MHCJA#5B!I$K8/<L)GS
MAPZ;>17^G9]Q71L[W15"9A:^V\Y2)^>?M237AT#4.&HAH@A1C"A!E"+*$.6(
M"D0EHCVB"E&-J$'4.L@-),7,">0K\\Z(JRNZ1>-KHK?2=]W6@Q3'(D`4(HH0
MQ8@21"FB#%&.J$!4(MHCJA#5B!I$K8/<\)CSVGB>O1*>_G@W/CZM+1HE_Q`%
MB$)$$:(848(H190ARA$5B$I$>T05HAI1@ZAUD!L+?:I])19XE%WW:/S8'J+`
M(B?U@8^*B11/J,A!;M7-<>H=P\B(JUG>(Z?J@()UCU35U:$S%"FI^J!(R*VZ
M.<F,J_YS)Q%C1;7((CD$^/0-HDY*4&#11K(CH45T9ZQ[H`/>=(X<':<QFZEC
MU9L2(YVFVP"+S,M\PZ[4TZ_;^B+%G1T($D4XZX16RF8O:&.M=L61F-$QV^AC
MSNF9THFKMO6G'/,J@;0-WCFUBB0E;1L4&856BG())EYS^`Q>)&;&SN2>OQM"
M?>YXI6U&7+6M1V[<EBIYY].(,XKCXQJBT"(.DON(?20*;VF8V?:.)]HK#;.[
M9)D8.W,`-55V@Z;N-/@BQ1$*$(46V:"MYS,8?9/._E/0]';UE;8-NU*NXH[2
MPC8<HZZ$M\Y$BA4#1*%%'+29.DI&CHH[^,:[-;JPO](,W*Q12A=#!.]6B90T
M8U!D%%HI#I$>>X/"J,-&[QWU[>K_8%;_EV\>#D_?#O[A_O[Y[/;XF_EC6)=F
MB1UP_Y>ZZ#"^->=)J@:4>%32Y2!4R>?U:ONYSV:KDAV5F-WQE+4UE73?$02=
M#95TR1U5\GEYO?U,UX4):U1B7MB8*/'F6_.NP%0)_5$R>G)]JN2*2J;\?/:H
M!I0TF=*A&M!#`!,E*ZH!W7^>*J$:4')FJH0*IOB">HW.@:CQ>;'9?J9WC["$
M/EU&.E/]2=_-HI)N=5<]O5M0#]#!?L+:DDHF_=`-S:VY:3&AL[[<[FA7@B4^
ME?B3);1-VYH=%^K0+HA*IJS17YG[/#ERJ9LG>YF&^J0\#?3)<4[#?++SZ5;Q
M-IIL.MTQWII;0-@,NG&\-;>%ITH\*IFJ`-U>I)*I@4%WW*AD:F#0W28JF:K!
MCFJPFRRA>^9;?[(DH!)SKQQK37>3J62JU@'5VMQ1G=)94\E4K0.JM;G!ACKT
M_L36O-$P5>)1R50-Z'4'BNA42>!1W>A!:[1&CYEOS9/D6$*/B6_-D^!80H]Y
M4PVF2G94@]UD#>AMEJT_64(OM5`-IEH:>#1")G7H'92M>7T!ZT:OHFS-6PQ8
M0I_0VIJ/6DV4+.=;\Y4D+*$O7M'<F2JA+Q5MS<>(4(>^-+1-)TOH2T%;\S$@
MU*$O_5`-IDIV5(/=9`WH@V9;\RTLM$;?-=N:+XU-E%!+S:>KL(0^0[8U7[#"
M$OH:V=9\R`I+`IJ,4Z.Z6&^;*1[08)\:ZPE-W2E>;+;T9U+0;[W9-AV_&-9S
M^BN7/VZ^'<J;IV]WC\]G]X>O=.'OT_A/_=_)M#E]^\7I7XXO]/<M:4=-?Q./
M_I[I@?X<'7W4Y?SLZ_'XPO\@QQ?#7TC]]&\!````__\#`%!+`P04``8`"```
M`"$`?V6J:90$``!]#P``&0```'AL+W=O<FMS:&5E=',O<VAE970R."YX;6RL
M5]^OJD80?F_2_X'P?H$%1"'JC0BT-VF3IKEMGQ%7)0=8`ZCG_/>=_2D+UIKV
MO(A\S'P[W\[L[.[RZWM=&5?<=B5I5B:R'-/`34'V97-<F7]\S[XL3*/K\V:?
M5Z3!*_,#=^;7]8\_+&^D?>M.&/<&,#3=RCSU_3FR[:XXX3KO+'+&#7PYD+;.
M>WAMCW9W;G&^9TYU9;N.$]AU7C8F9XC:5SC(X5`6."'%I<9-STE:7.4]Q-^=
MRG,GV>KB%;HZ;]\NYR\%J<]`L2NKLO]@I*91%]&W8T/:?%>![G?DYX7D9B\3
M^KHL6M*10V\!G<T#G6H.[=`&IO5R7X(".NU&BP\K<X.B#'FFO5ZR"?JSQ+=N
M\-_H3N3V4UON?RD;#+,->:(9V!'R1DV_[2D$SO;$.V,9^*TU]OB07ZK^=W+[
M&9?'4P_IGH$B*BS:?R2X*V!&@<9R9Y2I(!4$`+]&7=+2@!G)W]GS5N[[T\KT
M`FLV=SP$YL8.=WU64DK3*"Y=3^J_N!$25)S$%23P?$#RQ-$3CO`4CN["\MW9
M?,&&?^+I"T]X"L^9-4=.Z,TA["=^\)7IA:?P0S,+^4Y`Y3[Q"X0?/%^+U.83
MS?*6Y'V^7K;D9L!B@*GLSCE=6B@"-IDP/K9*X3]E$%)'23:4967.30.2TT'9
M7=>^$R[M*Y1*(6SBJ0W2+;;2@M8%I4W&0#H&L@%@@R(E"W+_";(H"Y4E`XHE
M<-?ICC1("^F2C(%T#&0#0-,`9?@)&B@++*-!:KQ@G!IN@Z`+J_S-1KJ4B1(V
M0=()D@T131LLE$_01EF@<&$"5=P^<O3(8V'T3)PR4>(F2#I!LB&BB8.U.Q;G
MSBRUHE]>592'R9-AQ0()!X*]^;@$E9%T2R9(.D&R(:*I@:XP5/.XE<M&0(WU
MD`42JD6TG2#)!$DG2#9$M/B@ZPSCXQW,HHVW/Y7%6TSXAO$@;@\Z%>]?E$,/
MFR,!]!=56NYBH9?65KBQ/9%W+.$V+#9W,5INJ3*2"<J&1)HX>C`:M.<'(F"G
MD"JHL:Z"(RY4ZEU%.%H@6V'$C@5<Q0,W%'JZ^)0;>73XZQKYH\^9X@"1FB0H
MWM<E46-=$D?<@`WK.LC7P]J*[_>FG2@/.=TI1SR:_^MZ-A_M0]G000L=P8'H
M]=B9M1Z\@"`A=&2(?MQFI<$@&1+RU0I*!23F?BI`<]$5T`US4%#_:;4@ONM"
MWY4S&@OHGI9@E!9I,,B+A!:*)I50R.;'"T<LF?P>4!==&-U%_[<POA5KPC@$
M&9-:MW2_@:)TASGBD`?UH1;:=,4(1P\Q=2A8C`M/,K/!='ET)WTB[SLY0Z7]
MZS%-[,?#Q''(O?>P+5P0F+X[E$RA=`K1F\7=D8?/;PK\Q%GC]HBWN*HZHR`7
M>@N`.ETO%<RO*,D\@@8)DSW"X>JR87&/\)A>:1[8QVX$)ZLI3^Q%<"R9XAL_
MVH"`Z8?8CV"K?X#/(M@T'^!!!)O5`QS!R'P$6VF`R\\Y/^)?\_98-IU1X0-,
MB\-VKY9?G_A++_*[(SU<>UBJ3W#-Q7!*=NC)XD!(+U]@:%M=G-=_`P``__\#
M`%!+`P04``8`"````"$`<]9Z&K$#``!=#0``&0```'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6R<5]MNVS`,?1^P?S#\WOB62Q,D*=H5W0ILP##L\JS82B+4
MM@Q):=J_'RG9KF4[B=N7(&:H<WA(D6:6-R]9ZCQ3(1G/5VXP\EV'YC%/6+Y;
MN7]^/UQ=NXY4)$](RG.Z<E^I=&_6GS\MCUP\R3VER@&$7*[<O5+%PO-DO*<9
MD2->T!Q^V7*1$06/8N?)0E"2Z$-9ZH6^/_4RPG+7("S$$`R^W;*8WO/XD-%<
M&1!!4Z(@?KEGA:S0LG@(7$;$TZ&XBGE6`,2&I4R]:E#7R>+%XR[G@FQ2T/T2
MC$E<8>N'#GS&8L$EWZH1P'DFT*[FN3?W`&F]3!@HP+0[@FY7[FVPN`O'KK=>
MZ@3]9?0H&]\=N>?'KX(EWUE.(=M0)ZS`AO,G='U,T`2'O<[I!UV!G\))Z)8<
M4O6+'[]1MMLK*/<$%*&P1?)Z3V4,&06843A!I)BG$`!\.AG#JP$9(2\K-P1B
MEJC]RHVFH\G,CP)P=S94J@>&D*X3'Z3BV3_C%.B@#)8.[9XHLEX*?G2@WN`M
M"X*W)U@`<!630:BC/!4D1(<@MXBR<F>N`_P2,ON\CB;3I?<,V8A+GSOC`Y^U
M3U![>!!-'1*$T0RI/ST5,SHC,Z8+0[DSAB9-V$\3V32H/(*:GJ?#0^#7$!%-
M9C6^B<#XC!L^D]K#$@HNPX6B,Q0)Y-7YZ^;8.`V@A@LSG!J=-76=Y-)BKE:S
M=E,;%Y,:3O$Z7\@KGK,I2HN=ZNO^1,+%&ZX&G6VJTA+I1FFJP<G;:HX0G,]?
M$3QDXY>69EFBR;Q?RMRF/$^%SC95:>D6)H"KW=8R]N<C2/-Y#GW0)JE,S2:+
MIGZ_H`#[OI'$"VSHW6(K33V:6I-"M_!U-."Z81NU:4J3+>K$B`JPQX>+,A,!
M2.L&T@"@LT<4]G`#6K?0Q4L7F,ZW*$J3=>VF)X8AOH>:K!>JU)T(&J!?4,],
M"&;S(57J3H6@--E5BDY</6SL1BHOB"K'0+-*I:FG2A\:#4%W-E0FNTKC$X+>
M-1V"[GBH3%U!X4?G@SYH=VQELHMTXB488GL/+I+V;K$A0._-"WOFP^7YK4^U
M*,K98!?I;<&QWNKANV:#]FZQE>.BITC8THU<X6P8-,1AK6W/N\ID%^EMES&:
MS#)K-L:,BAW]0M-4.C$_X*(:PJI76^LE^E9W4-L^7MR:Y=JK?X'EMB`[^H.(
M'<NED](M8/JC&4P78=9C\Z!X`1F"%9<K6&OUUSW\C:&P[ODC<-YRKJH'F+!>
M_<=H_1\``/__`P!02P,$%``&``@````A`"9HFDQN"@``]C0``!D```!X;"]W
M;W)K<VAE971S+W-H965T,C0N>&ULK)M;<^(X$X;OMVK_`\7]AMA`$J@D6^%@
MSN<S=PQQ$FH"3@%S^O=?RY(LJU^&-?GF)B:/6V]+<DN6VO;]OS^W[ZGO_OZP
M"78/:>?J.IWR=^O@>;-[?4A/QMX_=^G4X;C:/:_>@YW_D/[E']+_/O[]U_V/
M8/_U\.;[QQ0I[`X/Z;?C\:.8R1S6;_YV=;@*/OP=G7D)]MO5D?[=OV8.'WM_
M]1P6VKYGW.OKF\QVM=FEI4)QGT0C>'G9K/U*L/ZV]7='*;+WWU='JO_A;?-Q
MT&K;=1*Y[6K_]=O'/^M@^T$27S;OF^.O4#2=VJZ+C===L%]]>:=V_W1RJ[76
M#O\!^>UFO0\.P<OQBN0RLJ+8YD*FD"&EQ_OG#;5`='MJ[[\\I)^<XM+-IC./
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M%7V52QJ8X'%98&@+7:3"094#CX,:!W4.&APT.6AQT.:@PT&7@QX'?0X&'`PY
M&'$PYF#"P92#&0=S#A8<+&/`"@RZ;_R)P!`RM(B(32)NEDT1)6GCT+TWFFGR
M+%@BDRA:@%2!>$!J0.I`&D":0%I`VD`Z0+I`>D#Z0`9`AD!&0,9`)D"F0&9`
MYD`60)9Q8@41W1S_1!`)&;J94:A&`9(MY.P0*2FC<U$4F411!*0*Q`-2`U('
MT@#2!-("T@;2`=(%T@/2!S(`,@0R`C(&,@$R!3(#,@>R`+*,$RN*:&UD1='I
MS8Q>M@CK,%CT12XI0LOR*'S<+%O)E",C7:P"I`K$`U(#4@?2`-($T@+2!M(!
MT@72`](',@`R!#(",@8R`3(%,@,R![(`LHP3*S9H>7M!;`AK.S84*40KES*0
M"I`J$`](#4@=2`-($T@+2!M(!T@72`]('\@`R!#(",@8R`3(%,@,R!S(`L@R
M3JQ`H'V*%0ARTW,EMN_'M\WZ:RF@P4^KX!.31Y8V-W++(T3L^%`DS+J$-F4@
M%4ER=!>,S2_L]E2-C/3\X@&I`:D#:0!I`FD!:0/I`.E*XIBF]H#THU+QIK+%
MVB`RTDT=`AD!&0.9`)D"F0&9`UD`64HBFVI%$:T>_O\H$B)V%$F2([>Q"+FQ
M%S!E970734451<SD5(U(7.C6%O)`J`:D'@GI:]2(2%SZSI9N@E`+2#L2TM*=
MB,2E"[9T%X1Z0/J1D)8>1"0NS3ID"$(C(.-(2$M/(A*79ATR!:$9D'DDI*47
M$8E+LPY9QH6L(*6%#`2I*V(K\3PG%.P(E21/J343H;EK^Q*5I1&YT@VI*$)5
MC8HY/$E4549TB(S<'-L$>LKH)M*N*6*\U14YZZTAC?).F+%RLP6'14,3/+7`
M4SN)IXXRHL/OV]551J9=/45,N_J*G&W70!G1X??>ALK(>!LI8KR-%3GK;2*-
M5"]FW4*.3?)3\#0#3_,DGA;*B`Z_;]=2&87MLL8"S>$X&)S\A??]4,4>$`J)
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M/`X2>1QJ>>-QI)'Q.$[D<9+(XU3+&X\SC8S'>2*/"^-1/`MU;]BZ<JF%0U_V
M6!$)\G-C)>'4J_+L%.?1FB%;8`NSDGCT+X94?'W';,K&)EK)(ZHB\A#5$-41
M-1`U$;40M1%U$'41]1#U$0T0#1&-$(T131!-$<T0S1$M$"TM9,>72)W'X^M$
MDBM^"U>9=C=:598<A>Q5.,]0&"L3-E%!C:IHY2&J(:HC:B!J(FHA:B/J(.HB
MZB'J(QH@&B(:(1HCFB":(IHAFB-:(%I:R`X;D56_(&Q4$CX>-A*Y!I7%VV8T
M_<10!5$5D8>HAJB.J(&HB:B%J(VH@ZB+J(>HCVB`:(AHA&B,:()HBFB&:(YH
M@6AI(3M&1,+]@AA1^7D3$"7Q[I@=$&6%<O(-1/E6D+3*Q>]M;H[=8JNZH)'W
M-`JU[*J++.\%55=)8:-=$B^N\:I+9%5=(;OJ+%%855K40#U1>AJ=J#K=O"^I
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MHAFB.:(%(O%Q@KGER3$C/S:0;QAO_?VK7_;?WP^I=?!-?$A`E_?Q/L+Z*X=L
M\8F4*!38&=J=%L5&YM29')T)0Q;*Y.E,."_S,RZIG?1#WUD\A:'(2]#W%^''
M"IR[)'2J5N3@5&V?<L4G>7/B0M2*DXV@-IQLPDV1WFG`[JC<%ND1/?+^;9&>
M9R.G9591W"+Q#*VVBN639RIT1BRIL$S%N:4SI_Q4G#LZ$\[.K.45IT!G3M6`
MUFA%<7\E/YFH$'UU\K%Z]3NK_>MF=TB]^R\43-=A-GHOOUN1_QQ55OI+<*3O
M36C2H??9Z?LBGUXEO[ZBO<9+$!SU/\)!],72X_\```#__P,`4$L#!!0`!@`(
M````(0"P.8`_E`@``%8G```9````>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM
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M^PD\/3UL&ZR`9!^=ZN?'\3I9B?Q^/'EZD`+]U=3OG?/_4??:OO_SU&Q_:PXU
MU$:<*`*?V_8+F?ZZ)0B3)\'L3S("_SF-MO5S];;K?V_?_U4W+Z\]PCW#BFAA
MJ^UW47<;*`HW=^F,/&W:'0C@W]&^H=2`(M4W^?O>;/O7QW$VOYLMIED"\]'G
MNNL_->1R/-J\=7V[_Z\R2K0KY2353O"KG22SNT4RO<\6<')F8J8GXE=/3._R
M=+98RJN?F9CKB?B]FO9$22`5%55?/3V<VO<1TA2+[(X5)7VR@F,CI:(QB/LC
M;2$J.5F3E\?Q8CR";!T2XNM3MIP_3+XBB!MM4X0V";<HC05%C-P*!YB`[T`:
MFO\-I,D+D3:7*PQ@5Y%Z#(V%F2(<@#%$<'V&&?(\GJ%&19J$7'143.93SJ!0
M-@E*V2#UC)N4@\G`TD48343<ITD;Z<KHDQ?D#[08."5S3[I"&YTC/I@,Q%V$
M$0=)E_AY7<E8\C-^"X6DR*\?,RX'(S--N`BC,[^&#AES.AJ1)5-F?AD@PD78
MM;'K7"EH!Z<S,+TRB.2&L]+(/1,I\Y)M,!I$<A%&E-JO4VK.QXR,.1V-."(%
MB'`1=FTLPKTVB;1`S;]:)?+#:6F$JY1[*@U&@THNPI@F*!,NU?,R26M.R$".
M4"$D&,0)4-5UXB1;PF)Y@UB)JM\H#&;9A8&X7'X%LU9FHF`0YTLUV.%[03!5
ML1DG#;F"!9"@\D:AEU:<`)57AP`)MKRGH\>U>S#1A=H53$-<,*^WEF:B78)@
M$.=+5=7C>T/53W1QABY.$5WPS"^,%7;F8!6$VRWSNO.[$&=/1=AA?R'<9.WM
M#P5YQ=_C79(@F`@KFX(NQ#E1<?XX)UW*W2B[U5UU@"2`!(,X`2JZ#H'_(P5U
M^7;)#17=AC"9+WF@RV2PLH*Y$.=+A=KC>TL*ZGK/4_">,ROHL$0Y<#8%!QO+
MWH4X>RK>#OL+*:A+O:NH@KP4]'B7*#5!"KH0XY1>U3:D-=\6!K(EI`PAP2!.
M(-(VLN4M59!D\?:L@;#\H8HD"^]L7%JK(8@,XGRIGG\XB*FN_DX0#>0*IJTL
M))@5)_"WM8TT;!L&XH+Y-US6R@HV]!M`G*_7-LYG?3IT!^.Z,)!5IPPAP2!.
M@.JO$S$J<CK#+G!1A=OM^=2<*<?4XP&ZV2PMY.:8=QLCC!6JLY.)]E3,&5,-
M]QCKD\$%QKKXN^FF(9?Q`+E<`L;:"C\.8WM"Y8RI9'N,TQF=_2X0UJ7>):PA
ME_``N50"PMJ*$[:'!DZ8JK1'^(9.DNIBSSK)PCMF%<8*QH.4EI?JV];&)+Y@
M$&=/]=QA?T%D5?U9'BN(RMS`*/%YE^E@93FY$.-$SRD^SDE:\TZB(7`R5RM#
M2#"($XATDMO.TUG820R$Y3N"^:<_:V66(!C$^5[52;*PDQC(*8PA)!C$"40Z
MR3R[L\\A/_P<+PL[B8&X8/[ISUI9P7[82;*K.HFT]C),-Q=7L``29J*TXH)%
M.DF:S&]2+.PMF8:X8O[ISEI9Q8:)@#AAJN%.G9#WY+"^\AE/IEL!JW)+[QA5
M&*MS5<[:6/;:^9*V/6=/!=UA?[[*9;K\.ZU$0[S*^;Q+:V4Y*5^J%'%.7M^X
MP&EH#\9UD2F(5;D`$LR*$Z`"[(AR^RU;1IZ\#:(AEH)+__AG)MIM)!C$^.9>
M6[@Q!:4;2=:IOTOO"%`8*P@Z5&F_T5H;$Q/!(,[>ZRGGPYV'?4-#7@IZO$MK
M93DI7Y$4S*_J&]*:1]E`-GYE"`D&<5$B?>.FIZ)YV#8,Q#/0GI/58<E:6;U^
MV#;RJ]J&M/;T"GI$::RLA()!7"^JS]Z6O>&LF>LRSZNP/9!+:0IC=78+:$^R
MY,IIPDZ#HIR]UT,N;(&A59C(%+F"O"W@\2ZME9DH&,0Y7=49\K`S&,C&KPPA
MP2!.@$JV'](DO^4DD*OJ[Y[.#<0W05#(]$2[!F$G!E&DRNX0OA!%LO8V@8;L
MU4J\JY=6%J+7]Q92BJG7\>KE\;X^O=1EO=MUHTW[1J_:9SE>^PZP^@Z@R'-\
M")#3><`;6>>SU5I](N"-(.\Q1]XS!B-SC,PCWHI\@1'Y(C>8L\2(W![!R#U&
MY(J]D74V7ZW1!T/6.!FM!$X^L1$PP/DC-@(&.`7$1L`@>IUU/H4Z,=W0&,%:
M?AWAL2YR^NA"WG(%(RE&Y&DJ&,DPDD6XK=,E-(A&`2-T0QM93XKUX$XS,I*!
M->[W8B-@C3NKV`A8XY8G-@+6N-^(C2#?<.J/C2"KHNM9)UAI&HT<1@0>&D>\
M)5BI>A'D*YIBI7A&&IF38J7J$!#,P4KQF#`V!RO%,[K8"%:*)V61$5"+QB`!
M,[STB\Q(P`ROUV(C8*;JF<\Y`3.\80KGK)-\M<:[@'`$KX(P)\HY0734H[C@
M.MAQ>.T1\X8=%[T.OCY:1]6D9<8\D?PQG-(L@J]I@;&!@JI=9$*!U46W$M86
M71I6%A40^2C3<3*HA*^:CM5+_>_J]-(<NM&N?D8IGLKN=5+?1:D_^O:(+H!O
MF]H>WS/)_[[B^[4:SSVG]'#ON6U[\P>TG@Q?Q#W]#P``__\#`%!+`P04``8`
M"````"$`IG3W\,$"``"S!P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6R455UOFS`4?9^T_V#YO9B/D#0HI$I7=:NT2=.TCV?'&+`*&-E.T_[[76."
MH,DZ^@+AYOB<>^Z]7#8WSW6%GKC20C8I#CP?(]XPF8FF2/&OG_=7UQAI0YN,
M5K+A*7[A&M]L/W[8'*5ZU"7G!@%#HU-<&M,FA&A6\IIJ3[:\@7]RJ6IJX%$5
M1+>*TZP[5%<D]/TEJ:EHL&-(U!P.F>>"\3O)#C5OC"-1O*(&\M>E:/6)K69S
MZ&JJ'@_M%9-U"Q1[40GSTI%B5+/DH6BDHOL*?#\'"\I.W-W#&7TMF)):YL8#
M.N(2/?>\)FL"3-M-)L"!+3M2/$_Q+DAN`Q^3[:8KT&_!CWKT&^E2'C\KD7T5
M#8=J0Y]L!_92/EKH0V9#<)B<G;[O.O!=H8SG]%"9'_+XA8NB--#N&!Q98TGV
M<L<U@XH"C1?&EHG)"A*`*ZJ%'0VH"'WN[D>1F3+%8>R%UW$0+P&/]ER;>V$Y
M,6(';63]QZ&"GLNQA#T+W'N6:.G%*S\*_D]"7$:=P3MJZ':CY!'!U("D;JF=
MP2`!XLN.P(K%[BPXQ2N,(%<-;7C:1JMH0YZ@=*S'W#H,7`=,,"`(B`[*H#9?
MV8*MLJVM3>76!<8RX669Z#TR%IQBN`[)1ZO%P.N4'68QPL0#8F(0(/,-6C#T
M`&R-I%_7UH%F2,-0S9>VX$YZ*&X?F=;A'RZ7[Y&RX*E4'XFZ]V\\'C!E8PON
ME8N\%>3V]I#:@U.-/C(>EFBUO-PTN[)GOP\6/)7J(]V+.QF&]937VEG#'GK;
MBCTTY7>1)=Q&8[*Z;`4VXCN\=.BIV"DT<N-6I-L@-5<%_\2K2B,F#W;]A;`3
MANBPFG>A;>[K^"+9N95-AG]@9;:TX-^H*D2C4<5SX/2[EBNW=-V#D2TD"GM3
M&MB5W<\2/HX<]H+OP7SD4IK3`RB3X7.[_0L``/__`P!02P,$%``&``@````A
M`"T0UC*2`@``<`8``!D```!X;"]W;W)K<VAE971S+W-H965T,C`N>&ULC%5=
M;YLP%'V?M/]@^;V80/-1%%*EJ[I56J5IVL>S8PQ8Q1C93M/^^]V+$T2:KLU+
MA"_'YYYS/\CR^EDWY$E:ITR;TTD44R);80K55CG]_>ON8D&)\[PM>&-:F=,7
MZ>CUZO.GY<[81U=+Z0DPM"ZGM?==QI@3M=3<1::3+;PIC=7<P]%6S'56\J*_
MI!N6Q/&,::Y:&A@R>PZ'*4LEY*T16RU;'TBL;+@'_:Y6G3NP:7$.G>;V<=M=
M"*,[H-BH1OF7GI02+;+[JC66;QKP_3RYY.+`W1].Z+42UCA3^@CH6!!ZZOF*
M73%@6BT+!0ZP[,3*,J?K278SIVRU[.OS1\F=&ST35YO=5ZN*[ZJ54&QH$S9@
M8\PC0N\+#,%E=G+[KF_`#TL*6?)MXW^:W3>IJMI#MZ=@"'UEQ<NM=`(*"C11
M,D4F81H0`+]$*YP,*`A_SFD"B57AZYRFLV@ZC],)P,E&.G^GD)(2L77>Z+\!
M-.E%!:Y>VBWW?+6T9D>@W8!V'<?AF61`?-`4&`:5_Q,)ZI!DC2PYG5,"^1T4
M]FF5SA=+]@35$'O,3<#`[X"9#`@&:@9)(&,LZ>WR'#(C&#-CN5#*30B,TR1O
MITF/TZ#S%'KZ?CJ\!+B1B71^-?`'!0%S.<),!\2148"<;Q3!T"2P-]3OM,8!
M=$9J&)AQ:C2?S'#L/O"/]WH50[WWD:.2+.*W#<^.L[Y?:@0?I]I'TGZ@QQ,#
M@W?J9A%]Z`;O':?81\;CDRY>SVG8\+!&6MI*?I%-XX@P6]S>!.9_B`X?EG6"
MJE_'+[-U/[IL>`$+W_%*/G!;J=:11I9`&4=S\&+#)R,<O.E`.:R]\;#J_6,-
M7W8)*Q"C\=(8?SA`8C;\5ZS^`0``__\#`%!+`P04``8`"````"$`X1#(FT4-
M```+0P``&0```'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6RLG%USXL@.AN]/
MU?D/%/<;L$U(H))L!;#Y_JP]YUPSA$RH"2$%S,SNOS^2N^5VZW4([,Y-2!ZK
MU5)+W5:W3>Y^_W/[6OJQWA\VN[?[<G!5+9?6;ZO=T^;MZWWY/W\DO]V62X?C
M\NUI^;I[6]^7_UH?RK\__/M?=S]W^V^'E_7Z6"(-;X?[\LOQ^-ZL5`ZKE_5V
M>;C:O:_?Z,KS;K]='NG/_=?*X7V_7CZEC;:OE;!:K5>VR\U;V6AH[L_1L7M^
MWJS6G=WJ^W;]=C1*]NO7Y9'L/[QLW@^B;;LZ1]UVN?_V_?VWU6[[3BJ^;%XW
MQ[]2I>72=M7L?WW;[9=?7LGO/X/:<B6ZTS]`_7:SVN\.N^?C%:FK&$/1YT:E
M42%-#W=/&_*`A[VT7S_?EQ^#YJ(6EBL/=^D`_7>S_GG(_5XZO.Q^=O>;I]'F
M;4VC37'B"'S9[;ZQ:/^)$36N0.LDC<!L7WI:/R^_OQX7NY^]]>;KRY'"?4T>
ML6/-I[\ZZ\.*1I347(77K&FU>R4#Z&=IN^'4H!%9_GE?#JGCS=/QY;X<U:^N
M;ZI10.*E+^O#,=FPRG)I]?UPW&W_9X0"J\HHB:P2^K1*@JN;H-J(;DC'B78U
MVXX^_W[GU$7J`7U:)3=7X>UU<%UG#T[T7K<-Z?,BJV]L._J4=M6SW*4YEUI*
MG[9A>!74JI_9V;#-Z-,VJY_G8$#9E';(OXBI9UD:2%KP+]+R/"<#RB33J4NI
ML]P,)(OX%]OGF9$,))'X%S'W/$<E>WC.2,LS'97\"5P"G>>H)%#@,NA<1R6%
M`I=#)Z=:Q4SW=/7H+(_+A[O][F>)EF2*Z^%]R0M\T&1ELFZ8^9*M)!\M)+2"
ML)9'5G-?)C]HC3C0ZO?C(;J]N:O\H!5K965:*!/X$FV1X.6)U78TB#5(-.AJ
MT-.@K\%`@Z$&(PW&&DPTF&HPTV"NP2('*A2>+$8T@7Y%C%@-QTA&MR7`!2U4
M`1$):=+1(-8@T:"K04^#O@8##88:C#08:S#18*K!3(.Y!HL<\`)""].O"`BK
MH?ML;M($,&F,#,_,;&9=JR!E(EF4@,1`$B!=(#T@?2`#($,@(R!C(!,@4R`S
M(',@BSSQ@D:WA%\1-%9#BR6E1A:0Z/;6#TG+"IV*6B:210U(#"0!T@72`]('
M,@`R!#(",@8R`3(%,@,R![+($R]J=#OVHE9<S\IMB*73X,B@MBRAFBD7KH8?
MKG8F),TZ0&(@"9`ND!Z0/I`!D"&0$9`QD`F0*9`9D#F019YXL:#ZYH)8L+0?
M"TL:V1VH#:0#)`:2`.D"Z0'I`QD`&0(9`1D#F0"9`ID!F0-9Y(DW\%17>0//
M15I(Q3]%ZO1\X(9^#`P):97,YD/0T+?]3"B;#Y;0-,TUB_QI%%NAZ[3^JP6-
MFM*;9%I(K^<@+93@8'!]Q=O&X\MF]:VUHVZI/"KP-J+>3`W*2GQG#0EI7'-6
MUWRKVU;(U44=2VZS/(TM::2>A=JMK!OM%JTZ_]PM5N*[98B*H:X*,J$LAH9$
MM`?,C8:.H14*)(9U-5R)U5OCP?%BR)O+D][^L7O_*(B4R1+%5(WOKT5A>GR2
MQKJ-J(,H1I0@ZB+J(>HC&B`:(AHA&B.:()HBFB&:(UIXR(\1;S%^Q7;/;%7\
M*JA1]6=6BP\-.'5I?F09I]/4R61YBBA&E"#J(NHAZB,:(!HB&B$:(YH@FB*:
M(9HC6GC(#R1O3?*!+%@9\Y/*[&0H7C+*+8X=!\>M>VU$'8LB?PE5Y6[LI$1]
MXNGR3><*_0+3;4&?-]V@,'\WBE3RM?GTB/RC55)LZ@C*MPL:>@44*7,;BZK7
M=3^M$Q$H6`*YC+W`-1972YU!ZI:EZU4^WF+?7.PZ@NJ9N[%%$=\A?SS4J\K1
MQ&OBAXA+P`O\L!5C/D0&>2$*`I4W;3YLTS'*&DK88I$R`:'C9'W_%8&"@'!)
M=8$CM@++.V*0%Q!ZM.&G1)N/_G1`LH;.$8-L0(*Z6@L3T9+&T`\(5TX7^&$*
M+9J#TG>+SQC90LJ<;"T.JW``9Z7RDR9K*+IBT64#4H]NU7@D(E$0$2Z6+O#$
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MQSXF2"X-HX:ZE;=$BFYQV92!5+6:W'SLN&82VQA1@JB+J(>HCVB`:(AHA&B,
M:()HBFB&:(YHX2$_D%S'Z4"&UU<TFA<^-N455,\WB_(+8J1+WK8T=&>I'40Q
MH@11%U$/41_1`-$0T0C1&-$$T131#-$<T<)#?N2XF,U'[I-;OJE]O7N`16[@
MV[0-2X/H4`=1C"A!U$740]1'-$`T1#1"-$8T031%-$,T1[3PD!\++K[SL>#;
M='1[QJDVU0\P:RPRKS;QNP-MD:)9F2V`P8TJKSLBY546@5LH?9.Y?LZ;_$GZ
MF'+;2Q^#<K?.=@BH@RA&E"#J(NHAZB,:(!HB&B$:(YH@FB*:(9HC6GC(BP47
M4UXLTH<BZ2)\.BII0[^>%93+'H=.98](^=GC=B6^Q9?M-R+<;UB4SQY$'40Q
MH@11%U$/41_1`-$0T0C1&-$$T131#-$<T<)#?BR*MD;F%OY)]N!N*+(HGST9
M.ID]5LK/'K=]]"WF/<3Y:P]OE%5E89&7/7:ODJOD42I&E"#J(NHAZB,:(!HB
M&B$:(YH@FB*:(9HC6GC(CX7>;7V2,[BKHB,G#@^=JTN9W;;(O"1L7G]SR*51
MJ$]18R<ENA)$740]1'U$`T1#1".'<J:&ZEQP[*3$U`FB*:(9HCFBA8?\B/%.
M)S][_M:9`!_.Z$EED!=(@[Q`6D33+:M%PD"=<L16?<T=%"6(NHAZB/J(!H+<
M9!\B&@DZ:>K82;E`9CX*FJ+4#-$<T4)0:JH?2-X>_?-`LA95`QA$B[F8W^:G
M7CQ)<R=8%M7LB7$U4`]58B<@:A)4TT74<PWY:0T=S:M*M>\$1/,`U0P1C5Q#
MJUG9/'8"HGF":J:(9JYAL<US)R":%YX:/[27;<XH+!!#BUS`VB+E4,<B-B2;
MC($^^8^=E)B>(.HBZB'J(QH@&B(:(1HCFB":(IHAFB-:6&0>"_OA*=JO7?R2
M3H1[-XOX<#.+1QBJ\ZRVDY)X="SB(CQKB,]S1<H>J][6U;*;B&9W&-\5Y%;B
MGJ@YV5E?I$QG]5#O-P>BV74V%.0Z&XF:DYV-1<IT%M`;5V[?FA80$U'M>IL*
M<KW-1,_)WN8B97MK7.M'[@M1C<?3D=XXI[=?^H(118[?[Y+3Z?-?]DHUJA7<
M;J2]>0V/:FU#.I=P>60:\I53>62D:OE1"N%=,%&?-R*LNB<5:5RZ(N6,Z%ET
MVHB^E5)&J`5](.I/&C$4*6?$R"+^^'@DQE9*&:%\G(CZDT9,1<H9,;.(/SXV
M8FZEE!%J`BQ$_4=&>"L<Z\+:XI]D::K1SU*+^#&!\PX>Q(N4FZ4=BSY9[:Q4
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M4417TIFLVM#&J<E;!FQ#7VY_+/2&AZ9`OD7#7"C/71?(/]::C_12,W;<HA$N
M&N`6C6+A(-(8%@YA4"5+BWJ@LZXF'Y-@WW3D1<-1U#N=H="5HC9T0D4>%EWI
M1/4F'QY@/W0RT.3-/UZAG7V3-^]XA7;F9$'1%7JCM\GOZV*;%MG6*K2-CB:;
M[<(K';K"9X:HK4-CP(=0>(4.%)M\%D57*EF&T;\B>%]^78^7^Z^;MT/I=?U,
M4Y2^?TT;A+WY9P;FCZ/]#L&7W9'^"0%55O2-9?JG$VMZX%?EW<3S;G>4/[B#
M[-]8//P?``#__P,`4$L#!!0`!@`(````(0"*;B#FB@(``%<&```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;(Q5R6[;,!2\%^@_$+Q'U.(M@N7`:>`V
M0`L419<S35$2$5$42'K[^SZ*CBK90>J+(3X-9]Z\15X^'&6-]EP;H9H,1T&(
M$6^8RD539OC7S\W=`B-C:9/36C4\PR=N\,/JXX?E0>D74W%N$3`T)L.5M6U*
MB&$5E]0$JN4-O"F4EM3"49?$M)K3O+LD:Q*'X8Q(*AKL&5)]"X<J"L'XDV([
MR1OK232OJ87\325:\\HFV2UTDNJ777O'E&R!8BMJ84\=*4:2I<]EHS3=UN#[
M&$TH>^7N#E?T4C"MC"IL`'3$)WKM^9[<$V!:+7,!#ES9D>9%AM=1^CC'9+7L
MZO-;\(,9/"-3J<-G+?*OHN%0;&B3:\!6J1<'?<Y=""Z3J]N;K@'?-<IY07>U
M_:$.7[@H*PO=GH(AYRO-3T_<,"@HT`3QU#$Q54,"\(ND<),!!:''#,<@+');
M93B9!=-YF$0`1UMN[$8X2HS8SE@E_WA0U"7EN;K4GJBEJZ56!P3M!K1IJ1N>
M*`7BMW.!)!QV[<`9GF,$,@;JMU\EBWA)]F":G3&/'@._/2;J$01$>V50NUW9
M@9VRJXI+Y=$'AC+_$AG))&,95_0$6O>^47<)<`,3R2+I;?@,/&8RP$Q[Q"@#
M@-QNU(&A%V"OK]]UC3WH!FF8BZ&T,Q_/W'3]Q[^[UV71U_L<&9=D\K;AV5CU
M_5([\%CJ'$FZN1U.#`S>I9M)>!\`_GT)=V\L<8X,QR=97+;/+[+?%LEUR3_Q
MNC:(J9U;TACFOX_VWX]U[+*^C$_2=3>ZI'\!>]W2DG^CNA2-034O@#(,YE!F
M[;\,_F!5"YG#=BL+&]T]5O`!Y[`"80#@0BG[>@!ATO\EK/X"``#__P,`4$L#
M!!0`!@`(````(0!`Q#^`,0$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@
MH@0!**```0``````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````"<D4%+PS`8
MAN^"_Z'DWJ9I422T&:CLY$!PHNP6DV];L$E#$FW[[\VZKD[TY#&\;YX\WY=J
MT>LF^03G56MJ1+(<)6!$*Y79U>AYO4QO4.(#-Y(WK8$:#>#1@EU>5,)2T3IX
M=*T%%Q3X))*,I\+6:!^"I1A[L0?-?18;)H;;UFD>XM'ML.7BG>\`%WE^C34$
M+GG@^`!,[4Q$$U**&6D_7#,"I,#0@`83/"89P=_=`$[[/R^,R5E3JS#8.-.D
M>\Z6XAC.[=ZKN=AU7=:5HT;T)_AU]?`TCIHJ<]B5`,0.^VFX#ZNXRJT">3NP
M_LTUB??["O_.*BE&.RH<\``RB>_1H]TI>2GO[M=+Q(J<E"DA*2G6!:&DI.1J
M4^%3:[K/9J">!/Y-/`'8Z/WSS]D7````__\#`%!+`P04``8`"````"$`&4SY
M7)`#``!>#```$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0``````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````"<5UUOHS@4?5]I_T/$^Y2TTUFM*L*(
MIF2251*B0MM'RS$WQ"JQL[9AFOGU<X%I"CL&M?N&[?MQ[KW')X[W]>60CTI0
MFDLQ<2XOQLX(!),I%]G$>4AFG_YV1MI0D=)<"I@X)]#.5__//[R-DD=0AH,>
M80BA)\[>F..-ZVJVAP/5%W@L\&0GU8$:7*K,E;L=9W`G67$`8=RK\?@O%UX,
MB!323\=S0*>)>%.:_QLTE:S"IQ^3TQ$!^UYP/.:<48-5^BO.E-1R9T;A"X/<
M<]N''J*+@16*FY,_]MSVTHL9S6&*@?T=S35X[MN&-P=:-6U#N=*^5YJ;$IB1
M:J3Y#VS;E3/:4@T5G(E34L6I,`BK,FL6]7=^U$;Y3U(]ZSV`T9Z+!LUF_=FV
M;7_S:__+96V!7UW+*D*#!`^Z&!-N<M#1;D.5L4#^<MG&7*-H$#>`7J=(D!LD
M%`;[11:BF3:7;>3G&FZ#9;">AB2>AV$2O\.$(#0DRAX,S@X'=8Y4-:Z!$2=!
M$J["=1*3:$:B37@?)(MH;8_>-9Y&J\U].`_7\>(Q),OH'?&G03PGLV7T]*[X
M9^.F#FO\2&54\!\U,^T&>,OJTPX;WNHO#@>J3D3N2,PSP?&"(;5(P)@LA+%&
M#-B_!=>\N@N5VT(S*61)27!K-9\AH\DCS0L@*Z"Z4%!=7CN:A2A!F_[S;U*F
MWWF>UZ2)<+`*.8/JDO%M#L2:/C:2/>]EGJ)&D1"1FU._W2W>L91,Y0&U1_?W
M]"$FWR2*GJB0DB!34-=$_I$<U];P:VE`XQQ/%)%:+9ZH4E7KEYQN>=X'<T5%
ML:/,H,"(C"SI5N)T)0ZPND9V"JZH-MBH&%2)ZJE;>+]SL[=BB0=9T4C%+UTY
M,ZF?%B2A6VN:'FI4]J@L5I<60X;,AHEB+Z!FRN\,&$K3F>J0X7!#KZRE#C1T
M3=5'76)F'_5`%G2Q=VK`YT%0*[*^43?['W*Y!Q0<9G5IL^,.#.6YG47#]+"/
M8]CGLQ7/L,^UU<<B6&2HEC[:(D=0&OI36)C>L/1#+H'6Q>'X(9<FBYU9?<4T
M^]8TPV)L3].]MTVG>`F_^FQ-TW4),A3]C!H@LP*U^)V*/CC'866WUS$L[1V?
MSD/N/T^W)1?/^N&8R#NLZ/5MVMWTXCV^I5)\M;V>OVUX<WR6JKP*,MWCCS&D
MKS:_'U0OZ<?F[X)_>7TQ_CS&1W)KSW/?_ACX/P$``/__`P!02P$"+0`4``8`
M"````"$`">/%7!("``!*'P``$P``````````````````````6T-O;G1E;G1?
M5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C]0```$P"```+````````
M`````````$L$``!?<F5L<R\N<F5L<U!+`0(M`!0`!@`(````(0`V*V)W/0(`
M`)L>```:`````````````````'$'``!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+`0(M`!0`!@`(````(0!MUMXS?00``'P/```/````````````````
M`.X*``!X;"]W;W)K8F]O:RYX;6Q02P$"+0`4``8`"````"$`#VV,)IT%``"!
M%@``&`````````````````"8#P``>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L!`BT`%``&``@````A`%!:5\H3`P``?0D``!D`````````````````:Q4`
M`'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"+0`4``8`"````"$`2:*S
MTEP$```G$0``&0````````````````"U&```>&PO=V]R:W-H965T<R]S:&5E
M=#0P+GAM;%!+`0(M`!0`!@`(````(0`U=XRCP04```\<```9````````````
M`````$@=``!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L!`BT`%``&``@`
M```A`*ZD+\JL!```A1,``!D`````````````````0",``'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"+0`4``8`"````"$`:VZ\(E<#```>"P``&0``
M```````````````C*```>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+`0(M
M`!0`!@`(````(0"-)&AQV@(``+L'```9`````````````````+$K``!X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L!`BT`%``&``@````A`!#9P';J`P``
M'`\``!D`````````````````PBX``'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"+0`4``8`"````"$`5KY-:$P#```%"@``&0````````````````#C
M,@``>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+`0(M`!0`!@`(````(0!Q
MR]Z'"`,``*8(```9`````````````````&8V``!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L!`BT`%``&``@````A`&>A_P`/!```(Q$``!D`````````
M````````I3D``'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"+0`4``8`
M"````"$`I!9<:WT"``"/!@``&0````````````````#K/0``>&PO=V]R:W-H
M965T<R]S:&5E=#,U+GAM;%!+`0(M`!0`!@`(````(0!`<M_,/`8``$H>```9
M`````````````````)]```!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L!
M`BT`%``&``@````A`&.E'T`@`P``20H``!D`````````````````$D<``'AL
M+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"+0`4``8`"````"$`J;UF,7L#
M```N#```&0````````````````!I2@``>&PO=V]R:W-H965T<R]S:&5E=#0U
M+GAM;%!+`0(M`!0`!@`(````(0`BY'#N/PP``*-O```-````````````````
M`!M.``!X;"]S='EL97,N>&UL4$L!`BT`%``&``@````A`*0POTD,2P``I^\`
M`!0`````````````````A5H``'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!`BT`
M%``&``@````A`,7VT045`P``T0D``!@`````````````````PZ4``'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+`0(M`!0`!@`(````(0#?EWCGL08``'L=
M```8``````````````````ZI``!X;"]W;W)K<VAE971S+W-H965T,BYX;6Q0
M2P$"+0`4``8`"````"$`^V*E;90&``"G&P``$P````````````````#UKP``
M>&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0"Y!(ZK\P(``*0)
M```9`````````````````+JV``!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL
M4$L!`BT`%``&``@````A``5&;IN]`@``+`@``!D`````````````````Y+D`
M`'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"+0`4``8`"````"$`GN<E
M9FL&``#>)```&0````````````````#8O```>&PO=V]R:W-H965T<R]S:&5E
M=#0V+GAM;%!+`0(M`!0`!@`(````(0"PQ%F@*`,``)<)```9````````````
M`````'K#``!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L!`BT`%``&``@`
M```A`+SPC&ZX`@``#P<``!D`````````````````V<8``'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"+0`4``8`"````"$`:]Q93^<#``#8#@``&0``
M``````````````#(R0``>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+`0(M
M`!0`!@`(````(0!=^6E2BP,``%,,```8`````````````````.;-``!X;"]W
M;W)K<VAE971S+W-H965T,2YX;6Q02P$"+0`4``8`"````"$`M!#)PV8"```6
M!@``&0````````````````"GT0``>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM
M;%!+`0(M`!0`!@`(````(0"T^J'N%@,``*0)```9`````````````````$34
M``!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L!`BT`%``&``@````A`';!
ML`0:#```/4$``!D`````````````````D=<``'AL+W=O<FMS:&5E=',O<VAE
M970Q,BYX;6Q02P$"+0`4``8`"````"$`,5"TD5@*``!$,P``&0``````````
M``````#BXP``>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+`0(M`!0`!@`(
M````(0"[*'HF$`P``*4Z```9`````````````````''N``!X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L!`BT`%``&``@````A`+R9GPWO`@``A@@``!D`
M````````````````N/H``'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M+0`4``8`"````"$`IP"]-JX0``#T70``&0````````````````#>_0``>&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+`0(M`!0`!@`(````(0!7$RVK*@@`
M`/HE```9`````````````````,,.`0!X;"]W;W)K<VAE971S+W-H965T,3`N
M>&UL4$L!`BT`%``&``@````A`/!8&2>_`@``L`<``!@`````````````````
M)!<!`'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+`0(M`!0`!@`(````(0`?
M?X1O@P,``#H+```8`````````````````!D:`0!X;"]W;W)K<VAE971S+W-H
M965T-2YX;6Q02P$"+0`4``8`"````"$`14>VXA<'``#['P``&```````````
M``````#2'0$`>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!`BT`%``&``@`
M```A`+WW[R9X`@``[`4``!@`````````````````'R4!`'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+`0(M`!0`!@`(````(0`(XR6LCP(``(L&```8````
M`````````````,TG`0!X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"+0`4
M``8`"````"$`6.OMXBL%```D%P``&0````````````````"2*@$`>&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+`0(M`!0`!@`(````(0#C8I+\3AH``)24
M```9`````````````````/0O`0!X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L!`BT`%``&``@````A`/*'HRDA!0``H1(``!D`````````````````>4H!
M`'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"+0`4``8`"````"$`*@U!
M4B()``!P*@``&0````````````````#13P$`>&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+`0(M`!0`!@`(````(0#4FM</.0H``-4M```9````````````
M`````"I9`0!X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L!`BT`%``&``@`
M```A`(R"%?1L%@``9G4``!D`````````````````FF,!`'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"+0`4``8`"````"$`?V6J:90$``!]#P``&0``
M```````````````]>@$`>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+`0(M
M`!0`!@`(````(0!SUGH:L0,``%T-```9``````````````````A_`0!X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L!`BT`%``&``@````A`"9HFDQN"@``
M]C0``!D`````````````````\((!`'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"+0`4``8`"````"$`L#F`/Y0(``!6)P``&0````````````````"5
MC0$`>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+`0(M`!0`!@`(````(0"F
M=/?PP0(``+,'```9`````````````````&"6`0!X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L!`BT`%``&``@````A`"T0UC*2`@``<`8``!D`````````
M````````6)D!`'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"+0`4``8`
M"````"$`X1#(FT4-```+0P``&0`````````````````AG`$`>&PO=V]R:W-H
M965T<R]S:&5E=#(S+GAM;%!+`0(M`!0`!@`(````(0"*;B#FB@(``%<&```9
M`````````````````)VI`0!X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L!
M`BT`%``&``@````A`$#$/X`Q`0``0`(``!$`````````````````7JP!`&1O
M8U!R;W!S+V-O<F4N>&UL4$L!`BT`%``&``@````A`!E,^5R0`P``7@P``!``
M````````````````QJX!`&1O8U!R;W!S+V%P<"YX;6Q02P4&`````#P`/`!6
)$```C+,!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EROAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>STATEMENTS OF OPERATIONS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Government contracts</a></td>
        <td class="nump">$ 4,268<span></span></td>
        <td class="nump">$ 5,583<span></span></td>
        <td class="nump">$ 10,985<span></span></td>
        <td class="nump">$ 17,328<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ResearchAndDevelopmentCollaboration', window );">Research and development collaborations</a></td>
        <td class="nump">534<span></span></td>
        <td class="nump">182<span></span></td>
        <td class="nump">1,182<span></span></td>
        <td class="nump">182<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
        <td class="nump">4,802<span></span></td>
        <td class="nump">5,765<span></span></td>
        <td class="nump">12,167<span></span></td>
        <td class="nump">17,510<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractRevenueCost', window );">Cost of government contracts revenue</a></td>
        <td class="nump">2,276<span></span></td>
        <td class="nump">3,838<span></span></td>
        <td class="nump">5,619<span></span></td>
        <td class="nump">12,740<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">13,948<span></span></td>
        <td class="nump">6,642<span></span></td>
        <td class="nump">33,989<span></span></td>
        <td class="nump">17,270<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">3,857<span></span></td>
        <td class="nump">2,134<span></span></td>
        <td class="nump">10,740<span></span></td>
        <td class="nump">7,670<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
        <td class="nump">20,081<span></span></td>
        <td class="nump">12,614<span></span></td>
        <td class="nump">50,348<span></span></td>
        <td class="nump">37,680<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(15,279)<span></span></td>
        <td class="num">(6,849)<span></span></td>
        <td class="num">(38,181)<span></span></td>
        <td class="num">(20,170)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
        <td class="nump">53<span></span></td>
        <td class="nump">39<span></span></td>
        <td class="nump">149<span></span></td>
        <td class="nump">111<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(64)<span></span></td>
        <td class="num">(6)<span></span></td>
        <td class="num">(132)<span></span></td>
        <td class="num">(12)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
        <td class="num">(10)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(10)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of warrant liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(401)<span></span></td>
        <td class="nump">267<span></span></td>
        <td class="num">(401)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss from operations before income tax</a></td>
        <td class="num">(15,300)<span></span></td>
        <td class="num">(7,217)<span></span></td>
        <td class="num">(37,907)<span></span></td>
        <td class="num">(20,472)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">22<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (15,300)<span></span></td>
        <td class="num">$ (7,217)<span></span></td>
        <td class="num">$ (37,929)<span></span></td>
        <td class="num">$ (20,472)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
        <td class="num">$ (0.09)<span></span></td>
        <td class="num">$ (0.05)<span></span></td>
        <td class="num">$ (0.24)<span></span></td>
        <td class="num">$ (0.16)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average number of common shares outstanding</a></td>
        <td class="nump">168,537<span></span></td>
        <td class="nump">134,178<span></span></td>
        <td class="nump">156,555<span></span></td>
        <td class="nump">127,246<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ResearchAndDevelopmentCollaboration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research And Development Collaboration</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_ResearchAndDevelopmentCollaboration</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractRevenueCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Costs incurred and are directly related to generating contract revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ContractRevenueCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ContractsRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs of sales and operating expenses for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5618551-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDerivativeInstrumentsNetPretax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(a),(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> Note 3 - Summary of Significant Accounting Policies</p> <p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> <strong><em>Basis of Presentation</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The consolidated balance sheet as of September 30, 2013, consolidated statements of operations and consolidated statements of comprehensive loss for the three and nine months ended September 30, 2013 and 2012 and the consolidated statements of cash flows for the nine months ended September 30, 2013 and 2012 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, operating results, comprehensive loss and cash flows, respectively, for the periods presented. Although the Company believes that the disclosures in these consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted under the rules and regulations of the United States Securities and Exchange Commission ("SEC").</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> As discussed in more detail in Note 4, the Company acquired Swedish-based Isconova AB ("Isconova") on July 31, 2013. Isconova was subsequently renamed Novavax AB. The consolidated financial statements include the accounts of Novavax, Inc. and its subsidiary, Novavax AB. All intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The accompanying consolidated financial statements are presented in U.S. dollars. The translation of assets and liabilities to U.S. dollars is made at the exchange rate in effect at the consolidated balance sheet date, while equity accounts are translated at historical rates. The translation of statement of operations data is made at the average exchange rate in effect for the period. The translation of operating cash flow data is made at the average exchange rate in effect for the period, and investing and financing cash flow data is translated at the exchange rate in effect at the date of the underlying transaction. Translation gains and losses are recognized as a component of accumulated other comprehensive income in the accompanying consolidated balance sheets. The foreign currency translation adjustment balance included in accumulated other comprehensive income was $0.5 million at September 30, 2013.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#39;s Annual Report on Form 10-K for the year ended December 31, 2012. Results for this or any interim period are not necessarily indicative of results for any future interim period or for the entire year. The Company operates in one business segment: developing recombinant vaccines.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> <strong><em>Use of Estimates</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these estimates.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> <strong><em>Fair Value Measurements</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Company applies Accounting Standards Codification ("ASC") Topic 820, <em>Fair Value Measurements and Disclosures</em>, for financial and non-financial assets and liabilities.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> ASC 820 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). The statement utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">&middot;</td> <td style="TEXT-ALIGN: justify">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</td> </tr> </table> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">&middot;</td> <td style="TEXT-ALIGN: justify">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</td> </tr> </table> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">&middot;</td> <td style="TEXT-ALIGN: justify">Level 3: Unobservable inputs that reflect the reporting entity&#39;s own assumptions.</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> <strong><em>Investments</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: bold italic 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Investments consist of commercial paper, corporate notes and an investment in one auction rate security. Classification of marketable securities between current and non-current is dependent upon the original maturity date at purchase. Those securities purchased with original maturities greater than 90 days, but less than one year are classified as current and those with greater than one year are classified as non-current.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Interest and dividend income is recorded when earned and included in interest income. Premiums and discounts, if any, on investments are amortized or accreted to maturity and included in interest income. The specific identification method is used in computing realized gains and losses on the sale of the Company&#39;s securities.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Company has classified its investments as available-for-sale since the Company may need to liquidate these securities within the next year. The available-for-sale securities are carried at fair value and unrealized gains and losses on these securities, if determined to be temporary, are included in accumulated other comprehensive income (loss) in stockholders&#39; equity. Investments are evaluated periodically to determine whether a decline in value is "other-than-temporary." The term "other-than-temporary" is not intended to indicate a permanent decline in value. Rather, it means that the prospects for a near term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. Management reviews criteria, such as the magnitude and duration of the decline, as well as the Company&#39;s ability to hold the securities until market recovery, to predict whether the loss in value is other-than-temporary. If a decline in value is determined to be other-than-temporary, the value of the security is reduced and the impairment is recorded in the statement of operations.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: bold italic 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> Restricted Cash</p> <p style="TEXT-ALIGN: justify; FONT: bold italic 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Company&#39;s restricted cash includes payments received under the PATH agreement (See Note 10) until such time as the Company has paid for the work performed under the agreement. In addition, the Company&#39;s non-current restricted cash with respect to its manufacturing, laboratory and office space in Gaithersburg, Maryland functions as collateral for letters of credit, which serve as security deposits for the duration of the leases.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> <strong><em>Net Loss per Share</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Net loss per share is computed using the weighted average number of shares of common stock outstanding. All outstanding warrants, stock options and unvested restricted stock awards totaling 12,157,634 shares and 12,951,625 shares at September 30, 2013 and 2012, respectively, are excluded from the computation, as their effect is antidilutive.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> <strong><em>Reclassifications</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Overhead expenses relating to supply chain management of $0.2 million and $0.6 million for the three and nine months ended September 30, 2012, respectively, have been reclassified from general and administrative expenses to research and development expenses. Also, within the September 30, 2012 statement of cash flows, restricted cash received of $0.8 million recorded in financing activities has been reclassified and is included in operating activities. These reclassifications have been made to conform to current year presentation.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value Hierarchy</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px; TEXT-ALIGN: justify; TEXT-INDENT: 0.5in"> The following table represents the Company&#39;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis (in thousands):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px; TEXT-ALIGN: justify; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="10">Fair Value at September 30, 2013</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="10">Fair Value at December 31, 2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-DECORATION: underline; TEXT-INDENT: 0px"> Assets</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> <strong>Level 1</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"> <font style="FONT-SIZE: 10pt"><strong>Level 2</strong></font> </td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> <strong>Level 3</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> <strong>Level 1</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> <strong>Level 2</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> <strong>Level 3</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.125in; WIDTH: 28%; TEXT-INDENT: -0.125in"> Corporate debt securities and auction rate securities</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> 23,917</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> 32,945</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Total investments</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 23,917</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 32,945</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-LEFT: 0px; TEXT-DECORATION: underline; TEXT-INDENT: 0px"> Liabilities</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Warrant liabilities</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 267</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Level 3 Assets and Liabilities</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table provides a reconciliation of the beginning and ending balance of Level 3 assets and liabilities measured on a recurring basis for the nine months ended September 30, 2013 (in thousands):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 75%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Fair&nbsp;Value&nbsp;Measurements&nbsp;of</strong></p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Warrants&nbsp;Using Significant</strong></p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Unobservable&nbsp;Inputs&nbsp;</strong></p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>(Level&nbsp;3)</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; WIDTH: 77%">Balance at December 31, 2012</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 20%">267</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Change in fair value of Warrant liability</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (267</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"> Balance at September 30, 2013</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Notes Payable<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> Note 11 - Notes Payable</p> <p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In September 2012, the Company entered into a master security agreement with General Electric Capital Corporation ("GE"), whereby the Company could borrow up to $2.0 million to finance the purchases of equipment through June 2013 (each, an "Equipment Loan"). Each Equipment Loan bears interest at the three-year U.S. Government treasury rate plus 11.68%, provided that the rate shall not be less than 12.1%, and is to be repaid over forty-two (42) months. GE will maintain a security interest in all equipment financed under the Equipment Loan. During the nine months ended September 30, 2013, the Company financed $1.5 million at interest rates of 12.1% with monthly principal payments totaling $34,529 ("2013 Funding"). Interest accrues on the outstanding balance until paid in full. As of September 30, 2013, the Company has financed $2.0 million in total under the Equipment Loan.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Aggregate future minimum principal payments on the GE notes payable, including the 2013 Funding, at September 30, 2013 are as follows (in thousands):</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Year</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold" colspan="2">Amount</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 13%"> 2013 (remainder)</td> <td style="FONT-SIZE: 10pt; WIDTH: 74%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 2%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">143</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> 2014</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">571</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> 2015</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">571</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> 2016</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 396</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,681</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Notes Payable (Aggregate Future Minimum Principal Payments on Equipment Loan) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear', window );">2013 (remainder)</a></td>
        <td class="nump">$ 143<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_LoanAgreementFutureMinimumPaymentsNextTwelveMonths', window );">2014</a></td>
        <td class="nump">571<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_LoanAgreementFutureMinimumPaymentsDueInYearTwo', window );">2015</a></td>
        <td class="nump">571<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_LoanAgreementFutureMinimumPaymentsDueInYearThree', window );">2016</a></td>
        <td class="nump">396<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_LoanAgreementFutureMinimumPaymentsDue', window );">Total</a></td>
        <td class="nump">$ 1,681<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LoanAgreementFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum loan payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_LoanAgreementFutureMinimumPaymentsDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LoanAgreementFutureMinimumPaymentsDueInYearThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum loan payments maturing in the third fiscal year following the latest fiscal year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_LoanAgreementFutureMinimumPaymentsDueInYearThree</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LoanAgreementFutureMinimumPaymentsDueInYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum loan payments maturing in the second fiscal year following the latest fiscal year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_LoanAgreementFutureMinimumPaymentsDueInYearTwo</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LoanAgreementFutureMinimumPaymentsNextTwelveMonths">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum loan payments maturing in the next fiscal year following the latest fiscal year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_LoanAgreementFutureMinimumPaymentsNextTwelveMonths</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum loan payments maturing in the remainder of the fiscal year following the latest fiscal year ended.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6DAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Identifiable Intangible Assets) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
        <td class="nump">$ 16,586<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
        <td class="num">(181)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets, Net</a></td>
        <td class="nump">16,405<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Proprietary adjuvant technology [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
        <td class="nump">11,594<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
        <td class="num">(97)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets, Net</a></td>
        <td class="nump">11,497<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Collaboration agreements [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
        <td class="nump">4,992<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
        <td class="num">(84)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible Assets, Net</a></td>
        <td class="nump">$ 4,908<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6">2005 Stock Incentive Plan</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6">1995 Stock Option Plan</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"><strong>Stock Options</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"><strong>Weighted-Average Exercise Price</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"><strong>Stock Options</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"><strong>Weighted-Average Exercise Price</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; WIDTH: 44%; TEXT-INDENT: 0px"> Outstanding at January 1, 2013</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 9,143,825</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1.87</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 211,900</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 4.94</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Granted</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"><font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"> 4,117,500</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt"><font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"> 1.92</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"><font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Exercised</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"><font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"> (522,292</td> <td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2.29</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Canceled</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (802,883</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1.74</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (23,750</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 4.05</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Outstanding at September 30, 2013</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 11,936,150</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1.88</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 188,150</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5.04</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Shares exercisable at September 30, 2013</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,647,873</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2.12</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 188,150</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5.04</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Shares available for grant at September 30, 2013</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="BORDER-BOTTOM: black 2.5pt double; FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"> 6,461,494</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> <font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;&nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions used to Estimate Grant Date Fair Value of Stock Options granted using Black-Scholes Option-Pricing Model</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The fair value of stock options granted was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid" colspan="6"> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Three Months Ended</strong></p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>September 30,</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid" colspan="6"> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Nine Months Ended</strong></p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>September 30,</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>2013</strong></td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>2012</strong></td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>2013</strong></td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>2012</strong></td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"> <td style="FONT-SIZE: 10pt; WIDTH: 44%">Weighted-average fair value of stock options granted</td> <td style="WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1.41</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1.09</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1.02</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 0.71</td> <td style="WIDTH: 1%">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Risk-free interest rate</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.12%-1.36</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.55</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.54%-1.36</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.55%-1.54</td> <td style="FONT-SIZE: 10pt">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"> <td style="FONT-SIZE: 10pt">Dividend yield</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0</td> <td style="FONT-SIZE: 10pt">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Volatility</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">56.75%-62.51</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">76.60%-76.71</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">55.81%-73.72</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">75.47%-80.48</td> <td style="FONT-SIZE: 10pt">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"> <td style="FONT-SIZE: 10pt">Expected term (in years)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">4.25</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">4.24</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">3.98-7.05</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">3.34-7.09</td> <td>&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Expected forfeiture rate</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">23.15</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">23.15</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0%-23.15</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0%-23.15</td> <td style="FONT-SIZE: 10pt">%</td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Three Months Ended</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>September 30,</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Nine Months Ended</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>September 30,</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2013</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2013</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 44%; TEXT-INDENT: 0px"> Research and development</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">316</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">219</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">829</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">638</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> General and administrative</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 347</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 274</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 955</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,030</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Total stock-based compensation expense</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 663</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 493</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,784</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,668</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock', window );">Summary of Restricted Stock Awards Activity</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following is a summary of restricted stock awards activity for the nine months ended September 30, 2013:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>&nbsp;</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>&nbsp;</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>&nbsp;</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Number of</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Shares</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Per Share Weighted-Average Grant-Date</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Fair Value</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 72%"> Outstanding and Unvested at January 1, 2013</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 33,334</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1.39</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Restricted stock granted</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Restricted stock vested</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Restricted stock forfeited</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Outstanding and Unvested at September 30, 2013</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 33,334</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1.39</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Employee Stock Purchase Plan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions used to Estimate Grant Date Fair Value of Stock Options granted using Black-Scholes Option-Pricing Model</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The ESPP is considered compensatory for financial reporting purposes. As such, the fair value of ESPP shares was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 75%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="3"><font style="FONT-SIZE: 10pt"><strong>Three Months Ended</strong></font> <br /> <font style="FONT-SIZE: 10pt"><strong>September 30,</strong></font></td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center"> <strong>2013</strong></td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"> <td style="FONT-SIZE: 10pt; WIDTH: 77%">Weighted-average fair value of ESPP shares granted</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 20%"> 0.78</td> <td style="WIDTH: 1%">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Risk-free interest rate</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.04</td> <td style="FONT-SIZE: 10pt">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"> <td style="FONT-SIZE: 10pt">Dividend yield</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0</td> <td style="FONT-SIZE: 10pt">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Volatility</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">50.80</td> <td style="FONT-SIZE: 10pt">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"> <td style="FONT-SIZE: 10pt">Expected term (in years)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.5</td> <td>&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Expected forfeiture rate</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">5</td> <td style="FONT-SIZE: 10pt">%</td> </tr> </table> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule Of Share Based Compensation, Restricted Stock Awards, Activity</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_ScheduleOfShareBasedCompensationRestrictedStockAwardsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Other Intangible Assets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Nine Months Ended</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>September 30,</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2013</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 72%; TEXT-INDENT: 0px"> Beginning balance</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 33,141</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 33,141</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Goodwill resulting from acquisition of business</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">25,298</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Currency translation</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 320</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Ending balance</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 58,759</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 33,141</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Identifiable Intangible Assets</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"><strong>Gross Carrying Amount</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Accumulated Amortization</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Intangible</strong></p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Assets, Net</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Finite-lived intangible assets:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 58%; TEXT-INDENT: 0px"> Proprietary adjuvant technology</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 11,594</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">(97</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">)</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 11,497</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Collaboration agreements</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 4,992</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (84</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 4,908</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Total identifiable intangible assets</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 16,586</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (181</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 16,405</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Amortization Expense</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Year</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">Amount</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 13%"> 2013 (remainder)</td> <td style="FONT-SIZE: 10pt; WIDTH: 74%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 2%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">271</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> 2014</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,084</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> 2015</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,084</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> 2016</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"><font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"> 1,084</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"><font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> 2017</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"><font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"> 1,084</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> 2018</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"><font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"> 1,084</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13854-109267<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfGoodwillTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZDAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>U.S. Government Agreement, Joint Venture and Collaborations (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">19 Months Ended</th>
        <th class="th" colspan="1">32 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">15 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Cadila [Member]</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2011

</div>
          <div>HHS BARDA Contract [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>HHS BARDA Contract [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>HHS BARDA Contract [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>HHS BARDA Contract [Member]</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2011

</div>
          <div>HHS BARDA Option for Additional Period [Member]</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2011

</div>
          <div>License Agreement with LG Life Sciences, Ltd. [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012

</div>
          <div>PATH Vaccine Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>PATH Vaccine Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>PATH Vaccine Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Aug. 31, 2013

</div>
          <div>PATH Vaccine Solutions [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Contract receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 179,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 97,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 82,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ContractTerm', window );">Contract term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Government contracts</a></td>
        <td class="nump">4,268<span></span></td>
        <td class="nump">5,583<span></span></td>
        <td class="nump">10,985<span></span></td>
        <td class="nump">17,328<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,700<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">45,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ResearchAndDevelopmentCollaboration', window );">Research and development collaborations</a></td>
        <td class="nump">534<span></span></td>
        <td class="nump">182<span></span></td>
        <td class="nump">1,182<span></span></td>
        <td class="nump">182<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,000<span></span></td>
        <td class="nump">700<span></span></td>
        <td class="nump">2,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ResearchAndDevelopmentCollaborationIncrease', window );">Research and development collaboration increase</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">400<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ClinicalTrialCostsIncurred', window );">Trial costs incurred</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,900<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_UpfrontLicensePayment', window );">Upfront license payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
        <td class="nump">20.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_JointVenturePercentageOwnedByOthers', window );">Joint Venture Percentage Owned By Others</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">80.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ClinicalTrialCostsIncurred">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total clinical trial costs incurred.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_ClinicalTrialCostsIncurred</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ContractTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contract Term</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_ContractTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_JointVenturePercentageOwnedByOthers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage of the joint venture owned by others.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_JointVenturePercentageOwnedByOthers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ResearchAndDevelopmentCollaboration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research And Development Collaboration</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_ResearchAndDevelopmentCollaboration</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ResearchAndDevelopmentCollaborationIncrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research And Development Collaboration Increase</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_ResearchAndDevelopmentCollaborationIncrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_UpfrontLicensePayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Upfront License Payment</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_UpfrontLicensePayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ContractsRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityMethodInvestmentOwnershipPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of receivables that are derived from government contracts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 912<br><br> -SubTopic 310<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6471842&amp;loc=d3e55295-109406<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GovernmentContractReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E42AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Fair Value Measurements (Fair Value Hierarchy) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Corporate debt and auction rate securities</a></td>
        <td class="nump">$ 23,917<span></span></td>
        <td class="nump">$ 32,945<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Corporate debt and auction rate securities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrant liabilities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Corporate debt and auction rate securities</a></td>
        <td class="nump">23,917<span></span></td>
        <td class="nump">32,945<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
        <td class="nump">23,917<span></span></td>
        <td class="nump">32,945<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrant liabilities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Corporate debt and auction rate securities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total investments</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrant liabilities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 267<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (aa)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26610-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Available-for-Sale Securities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Trading Securities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Subparagraph a, f, g<br><br> -Article 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27723805&amp;loc=d3e24584-111560<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesFairValueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of other liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1VAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2008</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Second Public Offering [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Minimum [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Maximum [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement', window );">Common stock authorized for issuance under prior shelf registration statement with SEC, dollar amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 50,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">300,000,000<span></span></td>
        <td class="nump">200,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sales per share price range</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3.14<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold</a></td>
        <td class="nump">6,686,650<span></span></td>
        <td class="nump">12,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,846,950<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from shares sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 34,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 94,700<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock issued upon exercise in full over-allotment granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,153,950<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Sales per share price range</a></td>
        <td class="nump">$ 2.68<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.06<span></span></td>
        <td class="nump">$ 3.38<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock authorized for issuance under prior shelf registration statement with SEC, dollar amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuancePerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityIssuancePerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsidiarySaleOfStockLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ERRAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrant Liability (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2008</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_WarrantLiabilityAbstract', window );"><strong>Warrant Liability [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Units issued in direct offering</a></td>
        <td class="nump">6,686,650<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_CommonSharesPerUnit', window );">Common shares per unit</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from direct offering</a></td>
        <td class="nump">$ 17,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Shares entitled per warrant</a></td>
        <td class="nump">0.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate shares common stock callable by warrants</a></td>
        <td class="nump">3,343,325<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrants</a></td>
        <td class="nump">3.62<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of warrant liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">$ (401)<span></span></td>
        <td class="nump">$ 267<span></span></td>
        <td class="num">$ (401)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Equity issuance, price per share</a></td>
        <td class="nump">$ 2.68<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CommonSharesPerUnit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares included in each equity unit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_CommonSharesPerUnit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_WarrantLiabilityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_WarrantLiabilityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuancePerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityIssuancePerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5618551-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDerivativeInstrumentsNetPretax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisition of Isconova AB (Schedule of Purchase Price) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Acquisition Of Isconova AB [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Value of shares of Novavax Common Stock issued</a></td>
        <td class="nump">$ 41,942<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to Isconova warrant holders</a></td>
        <td class="nump">22<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase price</a></td>
        <td class="nump">$ 41,964<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationConsiderationTransferred1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireBusinessesGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZNBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Assumptions Used in Estimation of Fair Value of Stock Options Granted) (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of stock options granted</a></td>
        <td class="nump">$ 1.41<span></span></td>
        <td class="nump">$ 1.09<span></span></td>
        <td class="nump">$ 1.02<span></span></td>
        <td class="nump">$ 0.71<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
        <td class="nump">1.12%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.54%<span></span></td>
        <td class="nump">0.55%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.55%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
        <td class="nump">1.36%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.36%<span></span></td>
        <td class="nump">1.54%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
        <td class="nump">56.75%<span></span></td>
        <td class="nump">76.60%<span></span></td>
        <td class="nump">55.81%<span></span></td>
        <td class="nump">75.47%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
        <td class="nump">62.51%<span></span></td>
        <td class="nump">76.71%<span></span></td>
        <td class="nump">73.72%<span></span></td>
        <td class="nump">80.48%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
        <td class="text">4 years 3 months<span></span></td>
        <td class="text">4 years 2 months 27 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate', window );">Expected forfeiture rate</a></td>
        <td class="nump">23.15%<span></span></td>
        <td class="nump">23.15%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Employee Stock Purchase Plan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of stock options granted</a></td>
        <td class="nump">$ 0.78<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump">0.04%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
        <td class="nump">50.80%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
        <td class="text">6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate', window );">Expected forfeiture rate</a></td>
        <td class="nump">5.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years 11 months 23 days<span></span></td>
        <td class="text">3 years 4 months 2 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate', window );">Expected forfeiture rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years 18 days<span></span></td>
        <td class="text">7 years 1 month 2 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate', window );">Expected forfeiture rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">23.15%<span></span></td>
        <td class="nump">23.15%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Estimated rate of forfeitures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Investments (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Investments Classified as Available-For-Sale</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Investments classified as available-for-sale as of September 30, 2013 and December 31, 2012 were comprised of (in thousands):</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="14"><strong>September 30, 2013</strong></td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="14"><strong>December 31, 2012</strong></td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>Amortized Cost</strong></td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>Gross Unrealized Gains</strong></td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>Gross Unrealized Losses</strong></td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>Fair Value</strong></td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>Amortized Cost</strong></td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>Gross Unrealized Gains</strong></td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>Gross Unrealized Losses</strong></td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>Fair Value</strong></td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 9pt; TEXT-INDENT: -9pt; WIDTH: 20%"> Auction rate securities</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"> 1,175</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%">601</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%">-</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"> 1,776</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"> 1,175</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%">409</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%">-</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"> 1,584</td> <td style="WIDTH: 1%">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 9pt; TEXT-INDENT: -9pt"> Corporate debt securities</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 22,137</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 4</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 22,141</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 31,340</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 21</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 31,361</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">Total</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 23,312</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 605</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; TEXT-ALIGN: right"> <font style="FONT-SIZE: 10pt">-</font> </td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 23,917</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 32,515</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 430</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 32,945</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27337-111563<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27198-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5CBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (37,929)<span></span></td>
        <td class="num">$ (20,472)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of warrant liability</a></td>
        <td class="num">(267)<span></span></td>
        <td class="nump">401<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">1,636<span></span></td>
        <td class="nump">1,216<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of net premiums on investments</a></td>
        <td class="nump">326<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of property and equipment</a></td>
        <td class="num">(37)<span></span></td>
        <td class="num">(26)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Deferred rent</a></td>
        <td class="nump">678<span></span></td>
        <td class="nump">436<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
        <td class="nump">1,784<span></span></td>
        <td class="nump">1,668<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Restricted cash</a></td>
        <td class="nump">862<span></span></td>
        <td class="num">(838)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivables</a></td>
        <td class="num">(291)<span></span></td>
        <td class="num">(504)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInUnbilledReceivables', window );">Unbilled receivables</a></td>
        <td class="num">(1,624)<span></span></td>
        <td class="nump">111<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="nump">639<span></span></td>
        <td class="num">(271)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">623<span></span></td>
        <td class="num">(304)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="num">(199)<span></span></td>
        <td class="nump">803<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Lease incentives received</a></td>
        <td class="nump">703<span></span></td>
        <td class="nump">2,803<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(33,096)<span></span></td>
        <td class="num">(14,977)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
        <td class="num">(4,762)<span></span></td>
        <td class="num">(2,202)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
        <td class="nump">83<span></span></td>
        <td class="nump">318<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Net cash received from the Isconova AB acquisition</a></td>
        <td class="nump">3,034<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities of investments</a></td>
        <td class="nump">23,630<span></span></td>
        <td class="nump">2,500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of investments</a></td>
        <td class="num">(14,754)<span></span></td>
        <td class="num">(15,763)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
        <td class="nump">7,231<span></span></td>
        <td class="num">(15,147)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Principal payments of capital leases</a></td>
        <td class="num">(54)<span></span></td>
        <td class="num">(90)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Principal payments of notes payable</a></td>
        <td class="num">(305)<span></span></td>
        <td class="num">(20)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
        <td class="nump">1,450<span></span></td>
        <td class="nump">650<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities', window );">Restricted cash</a></td>
        <td class="num">(1)<span></span></td>
        <td class="num">(756)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sales of common stock, net of offering costs of $6.1 million and $0.4 million, respectively</a></td>
        <td class="nump">128,659<span></span></td>
        <td class="nump">26,925<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
        <td class="nump">1,194<span></span></td>
        <td class="nump">49<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">130,943<span></span></td>
        <td class="nump">26,758<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate on cash and cash equivalents</a></td>
        <td class="nump">16<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
        <td class="nump">105,094<span></span></td>
        <td class="num">(3,366)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump">17,399<span></span></td>
        <td class="nump">14,104<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump">122,493<span></span></td>
        <td class="nump">10,738<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Common stock issued in connection with the Isconova AB acquisition</a></td>
        <td class="nump">41,942<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable and accrued expenses</a></td>
        <td class="nump">407<span></span></td>
        <td class="nump">1,365<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_DepositsForAcquisitionOfPropertyAndEquipment', window );">Deposit applied towards the purchase of laboratory equipment</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_CapitalLeaseObligationEquipmentPurchased', window );">Equipment acquired under a capital lease</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">399<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash payments of interest</a></td>
        <td class="nump">$ 120<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_CapitalLeaseObligationEquipmentPurchased">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Capital Lease Obligation Equipment Purchased</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_CapitalLeaseObligationEquipmentPurchased</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DepositsForAcquisitionOfPropertyAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deposits For Acquisition Of Property And Equipment</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_DepositsForAcquisitionOfPropertyAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalExpendituresIncurredButNotYetPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAcquiredFromAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConversionOfStockAmountConverted1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5618551-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDerivativeInstrumentsNetPretax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestrictedCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInUnbilledReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInUnbilledReceivables</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other income (expense) included in net income that results in no cash inflows or outflows in the period. Includes noncash adjustments to reconcile net income (loss) to cash provided by (used in) operating activities that are not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNoncashIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireAvailableForSaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireProductiveAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromRepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from cash and cash items that are not available for withdrawal or usage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> Note 1 - Organization</p> <p style="FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Novavax, Inc. ("Novavax," and together with its subsidiary, "Novavax AB," the "Company") is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant protein nanoparticle vaccines and adjuvants. The Company&#39;s product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for seasonal influenza, pandemic influenza and respiratory syncytial virus ("RSV").</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NatureOfOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisition of Isconova AB<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Acquisition Of Isconova AB [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_AcquisitionOfIsconovaAbTextBlock', window );">Acquisition Of Isconova AB</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Note 4 - Acquisition of Isconova AB</strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> <font style="COLOR: windowtext">On July 31, 2013 (the "acquisition date"), Novavax announced the acquisition of Isconova (the "Acquisition") pursuant to its public tender offer to acquire all outstanding shares and warrants of the company directly from such holders and its private offer for all of Isconova&#39;s outstanding stock options.</font> As a result of the public offer for shares and warrants and private offer for stock options, Novavax issued approximately 15.6 million shares of its Common Stock valued at $41.9 million and paid cash of approximately $22,000 to acquire 99.5% of the outstanding shares and all of the outstanding stock options and warrants of Is<font style="COLOR: windowtext">conova. On September 6, 2013, Isconova AB was renamed "Nov</font>avax AB" and was delisted as a publicly traded company in Sweden. This transaction has been accounted for using the purchase method of accounting, with Novavax as the acquirer. The results of Novavax AB&#39;s operations have been included in the consolidated financial statements since the acquisition date. <font style="COLOR: windowtext">For the three months ended September 30, 2013, the minority interest in Novavax AB&#39;s net loss and stockholders&#39; equity is immaterial.</font></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> <font style="FONT-SIZE: 10pt; COLOR: windowtext">Novavax AB has focused its recent efforts on the development of saponin-based, immune-modulating adjuvants that work with different types of vaccine antigens to enhance the immunogenic effect of the antigen. Novavax AB has collaborated with several vaccine companies to allow its lead adjuvant, Matrix-M&trade;, to be tested with a number of antigens in development; the Company has recently begun development work pairing the Novavax AB adjuvant with its own pandemic influenza VLP antigen. The Company believes that the Novavax AB adjuvants can be powerful complements to certain of its recombinant vaccine programs and will enable future discovery efforts and potentially reduce vaccine development timeframes and costs both by eliminating the need to in-license third-party adjuvants and related costs and by harmonizing operating and regulatory processes.</font> <font style="FONT-SIZE: 10pt">The total purchase price is summarized as follows (in thousands):</font></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; WIDTH: 86%">Value of shares of Novavax Common Stock issued</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 41,942</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Cash paid to Isconova warrant holders</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 22</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"> Total purchase price</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 41,964</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The value of Novavax Common Stock issued is based on the closing price of Novavax&#39; Common Stock on the acquisition date.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The table below summarizes the preliminary allocation of the purchase price based upon the fair values of assets acquired and liabilities assumed at the acquisition date. The preliminary allocation is based upon information that was available to management at the time the consolidated financial statements were prepared. Accordingly, the allocation may change.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2">(in thousands)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 86%"> Cash and cash equivalents</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 3,056</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Accounts receivable</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">603</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Prepaid expenses and other assets</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,092</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Property and equipment</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">165</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Intangible assets</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">16,380</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px">Goodwill</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">25,298</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Accounts payable and other current liabilities</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(2,784</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Capital leases</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(94</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Notes payable</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(193</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Other non-current liabilities</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (1,559</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"> Total purchase price</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 41,964</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> A substantial portion of the assets acquired from Isconova consisted of intangible assets relating to its proprietary adjuvant technology and collaboration agreements. The preliminary fair values of the proprietary technology and agreements were determined based on estimates of expected future net cash flows. The present value of future net cash flows was then determined utilizing an estimate of the appropriate discount rate, which is consistent with the uncertainties of the cash flows utilized. The fair value measurements are based on significant unobservable inputs that were developed by the Company using publicly available information, market participant assumptions, cost and development assumptions, expected synergies and other cost savings that a market participant would be expected to realize as a result of the combination and certain other high-level assumptions. The proprietary technology is amortized over its estimated remaining useful life based on the Company&#39;s expected future net cash flows. The agreements are amortized over the estimated periods of expected future net cash flows. Amortization expense for intangible assets will be recorded on a straight-line basis over the expected useful lives of the assets, ranging from seven to 20 years. The carrying value and expected lives of the intangible assets may change based upon finalizing the purchase price allocation, and such intangibles will be periodically reviewed to determine if the facts and circumstances suggest that a potential impairment may have occurred. Impairment charges, if any, will be recorded in the period in which the impairment occurs.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Company recorded $25.3 million in goodwill related to the Acquisition representing the purchase price paid in the Acquisition that was in excess of the fair value of the assets acquired and liabilities assumed, which is included in the Company&#39;s vaccine operations because of the anticipated complementary use of Novavax AB adjuvants with its vaccine candidates discussed above. The goodwill generated from the Acquisition is expected to be deductible for U.S. federal income tax purposes.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Company incurred approximately $1.3 million in transaction costs related to the Acquisition, which is included in general and administrative expenses in the Company&#39;s consolidated statement of operations.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> From the acquisition date to September 30, 2013, the Company has recognized revenue of $0.4 million and recorded a net loss of $1.5 million from the operations of Novavax AB.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following unaudited consolidated pro forma financial information is presented as if the Acquisition occurred on January 1, 2012. The unaudited pro forma financial information has been presented for comparative purposes only and is not necessarily indicative of results of operations that would have been achieved had the Company completed the Acquisition during the periods presented, or the future consolidated results of operations of the combined company. The unaudited pro forma financial information combines the historical results of operations of Novavax and Isconova for the periods presented below and reflects the application of the following adjustments:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">&middot;</td> <td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"> Elimination of the historical intangible assets and amortization expense unrelated to the Acquisition;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">&middot;</td> <td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"> Amortization expense related to the fair value of intangible assets acquired; and</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">&middot;</td> <td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"> The exclusion of acquisition-related costs incurred for the Acquisition.</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Three Months Ended</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>September 30,</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Nine Months Ended</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>September 30,</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2013</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2013</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="14">(in thousands)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; WIDTH: 44%"> Revenue</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; WIDTH: 2%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> 4,869</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; WIDTH: 2%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> 6,272</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; WIDTH: 2%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> 14,195</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; WIDTH: 2%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> 19,530</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Net loss</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (15,687</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (8,490</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (40,565</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (25,033</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Basic and diluted net loss per share</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.09</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.06</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.24</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.18</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Novavax AB has an operating lease for its facility that expires in 2017. As of September 30, 2013, the aggregate remaining rental payments due under this operating lease commitment was approximately $1.9 million.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AcquisitionOfIsconovaAbTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Acquisition Of Isconova Ab [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_AcquisitionOfIsconovaAbTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Operations<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_OperationsAbstract', window );"><strong>Operations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_OperationsDisclosureTextBlock', window );">Operations</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> Note 2 - Operations</p> <p style="FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Company&#39;s vaccine candidates, some of which may include an adjuvant, currently under development will require significant additional research and development efforts that include extensive pre-clinical and clinical testing, and regulatory approval prior to commercial use.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> As a clinical-stage biopharmaceutical company, the Company has primarily funded its operations from proceeds through the sale of its common stock in equity offerings and revenue under its contract with the Department of Health and Human Services, Biomedical Advanced Research and Development Authority ("HHS BARDA"). Management regularly reviews the Company&#39;s cash and cash equivalents and investments against its operating budget to ensure the Company will have sufficient working capital, and will continue to draw upon such available sources of capital to meet its product development activities.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_OperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_OperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_OperationsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operations Disclosure [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_OperationsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECJBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Narrative) (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of stock options outstanding</a></td>
        <td class="nump">$ 15,900<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term of stock options outstanding</a></td>
        <td class="text">7 years 7 months 6 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of stock options exercisable</a></td>
        <td class="nump">5,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term of stock options exercisable</a></td>
        <td class="text">5 years 10 months 24 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
        <td class="nump">300<span></span></td>
        <td class="nump">100<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
        <td class="nump">$ 4,700<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, recognition period</a></td>
        <td class="text">1 year 6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2005 Stock Incentive Plan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance</a></td>
        <td class="nump">22,312,192<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm', window );">Maximum term of options</a></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent', window );">Minimum grant price, percent of common stock fair value</a></td>
        <td class="nump">100.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2005 Stock Incentive Plan [Member] | Scenario, Forecast [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares available for issuance approved at the 2013 annual stockholders' meeting</a></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2005 Stock Incentive Plan [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant', window );">Exercise period</a></td>
        <td class="text">6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2005 Stock Incentive Plan [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant', window );">Exercise period</a></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">1995 Stock Option Plan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance</a></td>
        <td class="nump">5,746,468<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm', window );">Maximum term of options</a></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent', window );">Minimum grant price, percent of common stock fair value</a></td>
        <td class="nump">100.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">1995 Stock Option Plan [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant', window );">Exercise period</a></td>
        <td class="text">6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">1995 Stock Option Plan [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant', window );">Exercise period</a></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Employee Stock Purchase Plan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance</a></td>
        <td class="nump">2,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period of time incentive stock options are exercisable, from the date of grant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodFromDateOfGrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The minimum grant-date exercise price of incentive stock options granted as a percent of the common stock share price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateExercisePriceMinimumPercent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum term of incentive stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Minimum Principal Payments</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Aggregate future minimum principal payments on the GE notes payable, including the 2013 Funding, at September 30, 2013 are as follows (in thousands):</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Year</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold" colspan="2">Amount</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 13%"> 2013 (remainder)</td> <td style="FONT-SIZE: 10pt; WIDTH: 74%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 2%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">143</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> 2014</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">571</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> 2015</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">571</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> 2016</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 396</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,681</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Acquisition of Isconova AB (Schedule of Assets Acquired and Liabilities Assumed) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Jul. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Acquisition Of Isconova AB [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 3,056<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
        <td class="nump">603<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="nump">1,092<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
        <td class="nump">165<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
        <td class="nump">16,380<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill', window );">Goodwill</a></td>
        <td class="nump">25,298<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and other current liabilities</a></td>
        <td class="num">(2,784)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Capital leases</a></td>
        <td class="num">(94)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt', window );">Notes payable</a></td>
        <td class="num">(193)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other non-current liabilities</a></td>
        <td class="num">(1,559)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total purchase price</a></td>
        <td class="nump">$ 41,964<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Goodwill</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of capital lease obligation, assumed at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of property, plant, and equipment recognized as of the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 37<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25498275&amp;loc=d3e2207-128464<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Goodwill) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Other Intangible Assets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
        <td class="nump">$ 33,141<span></span></td>
        <td class="nump">$ 33,141<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill resulting from acquisition of business</a></td>
        <td class="nump">25,298<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillTranslationAdjustments', window );">Currency translation</a></td>
        <td class="nump">320<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
        <td class="nump">$ 58,759<span></span></td>
        <td class="nump">$ 33,141<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Goodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAcquiredDuringPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillTranslationAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) from foreign currency translation adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillTranslationAdjustments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>38
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S
M8V(P9C<P,#1B-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C0Y
M.#9C9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W,#`T8C<T+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0D%,04Y#15]32$5%
M5%,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"04Q!
M3D-%7U-(14544U]087)E;G1H971I8V%L/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`S+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4U1!5$5-14Y44U]/1E]/4$52051)3TY3/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U1!5$5-14Y4
M4U]/1E]#3TU04D5(14Y3259%7TQ//"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`U+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4U1!5$5-14Y44U]/1E]#05-(7T9,3U=3/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U1!5$5-14Y44U]/
M1E]#05-(7T9,3U=37U!A<F5N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^3W)G86YI>F%T:6]N/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^3W!E<F%T:6]N<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P.2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?
M06-C;W5N=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/D%C<75I<VET:6]N7V]F7TES8V]N;W9A7T%"/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$Q+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^1F%I<E]686QU95]-96%S=7)E;65N=',\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);G9E<W1M
M96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D=O
M;V1W:6QL7V%N9%]/=&AE<E]);G1A;F=I8FQE7SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-"YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I='D\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,34N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D
M7T-O;7!E;G-A=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-BYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E537T=O=F5R;FUE;G1?06=R965M96YT7TIO:6YT7SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5S7U!A>6%B;&4\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y787)R86YT
M7TQI86)I;&ET>3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q.2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/DUA;G5F86-T=7)I;F=?3&%B;W)A=&]R>5]A;F1?3SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970R,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DUA<W1E<E]397)V:6-E<U]!
M9W)E96UE;G1?=VET:#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C;W5N=#$\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,C(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!8W%U:7-I=&EO;E]O
M9E])<V-O;F]V85]!0E]486(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C,N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y&86ER7U9A;'5E7TUE87-U<F5M96YT<U]486)L97,\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,C0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);G9E<W1M96YT
M<U]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,C4N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y';V]D=VEL;%]A;F1?3W1H97)?26YT86YG:6)L95\Q/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#(V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM"87-E9%]#;VUP96YS
M871I;VY?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(W+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^3F]T97-?4&%Y86)L95]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C@N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C
M8V]U;G0R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#(Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M06-Q=6ES:71I;VY?;V9?27-C;VYO=F%?04)?3F%R/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,P
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^06-Q=6ES:71I;VY?;V9?27-C;VYO
M=F%?04)?4V-H/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#,Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^06-Q=6ES:71I;VY?;V9?27-C;VYO=F%?04)?4V-H,3PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970S,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D%C<75I<VET:6]N7V]F7TES
M8V]N;W9A7T%"7U5N83PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,RYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/D9A:7)?5F%L=65?365A<W5R96UE;G1S7T9A:7)?5CPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970S-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D9A:7)?5F%L=65?365A
M<W5R96UE;G1S7U)E8V]N8SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/DEN=F5S=&UE;G1S7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S8N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y';V]D=VEL;%]A;F1?3W1H97)?26YT
M86YG:6)L95\R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#,W+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^1V]O9'=I;&Q?86YD7T]T:&5R7TEN=&%N9VEB;&5?,SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970S."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D=O;V1W:6QL7V%N9%]/=&AE
M<E]);G1A;F=I8FQE7S0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,SDN:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y3=&]C:VAO;&1E<G-?17%U:71Y7T1E=&%I;',\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T-#`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O;7!E
M;G-A=&EO;E].87)R870\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#$N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y3=&]C:T)A<V5D7T-O;7!E;G-A=&EO;E]3=6UM87(\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T-#(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O
M;7!E;G-A=&EO;E]!<W-U;7`\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#,N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O;7!E;G-A=&EO;E]3=6UM87(Q/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#0T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM"87-E
M9%]#;VUP96YS871I;VY?4W1O8VM"/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0U+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^55-?1V]V97)N;65N=%]!9W)E96UE;G1?2F]I;G1?
M,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970T-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5S
M7U!A>6%B;&5?3F%R<F%T:79E7T1E=&%I;#PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T-RYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/DYO=&5S7U!A>6%B;&5?06=G<F5G871E7T9U
M='5R93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970T."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E=A
M<G)A;G1?3&EA8FEL:71Y7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#DN:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y-86YU9F%C='5R:6YG7TQA8F]R871O<GE?86YD
M7T\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#4P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^36%S
M=&5R7U-E<G9I8V5S7T%G<F5E;65N=%]W:71H,3PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970U,2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O
M<FMS:&5E=',^#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS1")7;W)K<VAE971S
M+W)E<&]R="YC<W,B+SX-"B`@/'@Z06-T:79E4VAE970^,#PO>#I!8W1I=F53
M:&5E=#X-"B`@/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS93PO>#I0<F]T96-T
M4W1R=6-T=7)E/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&86QS93PO>#I0<F]T
M96-T5VEN9&]W<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N
M9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S
M:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE
M=V5R+CPO<#X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R-#DX-F-F,U\Q-3DP7S0U,C%?
M8F5C95\S8V(P9C<P,#1B-S0O5V]R:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%4$-!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$;V-U;65N="!A
M;F0@16YT:71Y($EN9F]R;6%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^3V-T+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN
M9F]R;6%T:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG,3`M43QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&;&%G/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG9F%L<V4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N
M="!097)I;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/E-E<"`S,"P-"@D),C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R86YT($YA;64\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=.3U9!5D%8($E.0SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5N=&ET>2!#96YT<F%L($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)S`P,#$P,#`V.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%D:6YG(%-Y;6)O;#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)TY605@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I
M<V-A;"!996%R($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG+2TQ,BTS,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,C`Q,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT
M($9I<V-A;"!097)I;V0@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B=1,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5N=&ET>2!&:6QE<B!#871E9V]R>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)T%C8V5L97)A=&5D($9I;&5R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT
M:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`X+#4Q,"PW,SD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S(T.3@V8V8S7S$U.3!?
M-#4R,5]B96-E7S-C8C!F-S`P-&(W-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0O
M5V]R:W-H965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%435!1SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#$^/'-T<F]N9SY"04Q!3D-%(%-(14544R`H55-$("0I/&)R/DEN
M(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0W5R<F5N="!A<W-E=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,C(L-#DS/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-RPS
M.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-H;W)T+71E<FT@:6YV97-T;65N=',@879A:6QA8FQE+69O<BUS86QE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPY,3<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-BPW,3(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E<W1R:6-T960@8V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.3@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PY,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`Q,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YB:6QL960@<F5C96EV
M86)L97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,3DT/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU
M-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R97!A:60@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L,#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPU-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-C4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R
M96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34U
M+#`R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4P+#0P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^26YV97-T;65N=',@879A:6QA8FQE+69O<BUS86QE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPR
M,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3,L.38Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L-#4V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1A;F=I8FQE<RP@
M;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPT,#4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y';V]D=VEL;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3@L-S4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S,L,30Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D(&-A<V@\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<U-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@;F]N+6-U<G)E
M;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(T-2PP-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,#(L,S0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@;&EA8FEL:71I
M97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06-C;W5N=',@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,RPS,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#(R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!E>'!E;G-E<R!A;F0@;W1H97(@
M8W5R<F5N="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.2PU-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW+#(W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3DP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT('!O<G1I;VX@
M;V8@8V%P:71A;"!L96%S97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#=7)R96YT('!O<G1I;VX@;V8@;F]T97,@<&%Y86)L93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3DW/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT
M(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!L:6%B:6QI
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30L,C8P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L
M-C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM8W5R<F5N="!P;W)T:6]N(&]F(&-A
M<&ET86P@;&5A<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYO;BUC=7)R96YT('!O<G1I;VX@;V8@;F]T97,@<&%Y86)L93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV-3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R
M<F5D(')E;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,C@W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-BPY-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]T:&5R(&YO;BUC=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4W.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C@L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C(L,3`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM:71M96YT<R!A;F0@8V]N=&EN9V5N8VEE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!E<75I='DZ
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')E9F5R<F5D('-T;V-K+"`D,"XP,2!P87(@=F%L=64L(#(L,#`P+#`P,"!S
M:&%R97,@875T:&]R:7IE9#L@;F\@<VAA<F5S(&ES<W5E9"!A;F0@;W5T<W1A
M;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL("0P+C`Q('!A<B!V
M86QU92P@,S`P+#`P,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960@870@4V5P=&5M
M8F5R(#,P+"`R,#$S(&%N9"`R,#`L,#`P+#`P,"!S:&%R97,@875T:&]R:7IE
M9"!A="!$96-E;6)E<B`S,2P@,C`Q,CL@86YD(#(P."PY-C4L,38Y('-H87)E
M<R!I<W-U960@86YD(#(P."PU,#DL-S,Y('-H87)E<R!O=71S=&%N9&EN9R!A
M="!397!T96UB97(@,S`L(#(P,3,@86YD(#$T."PS.3@L-S0W('-H87)E<R!I
M<W-U960@86YD(#$T-RPY-#,L,S$W('-H87)E<R!O=71S=&%N9&EN9R!A="!$
M96-E;6)E<B`S,2P@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPP.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#0X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P86ED+6EN(&-A<&ET86P\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Q,2PY,3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,S@L.3,Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8V-U;75L871E9"!D969I8VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@S.38L,#DR*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#,U."PQ-C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F5A<W5R>2!S=&]C:RP@-#4U+#0S
M,"!S:&%R97,L(&-O<W0@8F%S:7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(L-#4P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(L-#4P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@;W1H97(@8V]M<')E
M:&5N<VEV92!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,3$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&]T86P@<W1O8VMH;VQD97)S)R!E<75I='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q-BPU-S0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,"PR-#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!L:6%B:6QI=&EE<R!A;F0@<W1O8VMH;VQD97)S)R!E<75I='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C0U+#`W-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`R+#,T-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,C0Y.#9C
M9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W,#`T8C<T#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F
M-S`P-&(W-"]7;W)K<VAE971S+U-H965T,#,N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!04%%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D)!3$%.0T4@4TA%1513("A087)E
M;G1H971I8V%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY"04Q!3D-%(%-(1454
M4R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!P87(@;W(@<W1A=&5D('9A
M;'5E('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!A=71H;W)I
M>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C
M:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64@<&5R('-H87)E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,P,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UO;B!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C`X+#DV-2PQ-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#@L,SDX+#<T-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(P."PU,#DL-S,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,30W+#DT,RPS,3<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R96%S=7)Y('-T
M;V-K+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U
M-2PT,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-34L-#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C0Y.#9C9C-?,34Y,%\T
M-3(Q7V)E8V5?,V-B,&8W,#`T8C<T+U=O<FMS:&5E=',O4VAE970P-"YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P15)/04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U1!5$5-
M14Y44R!/1B!/4$52051)3TY3("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E
M>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4U1!5$5-14Y44R!/1B!/4$52051)3TY3(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D=O=F5R;FUE;G0@8V]N=')A8W1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#0L,C8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#4X,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`L.3@U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-RPS,C@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!C;VQL86)O<F%T:6]N<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3,T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ.#(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M+#@P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4L-S8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3(L,38W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3<L-3$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O<W1S(&%N9"!E>'!E
M;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O<W0@;V8@9V]V97)N;65N="!C;VYT<F%C=',@<F5V96YU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR-S8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#@S.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-C$Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3(L-S0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$S+#DT.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-C0R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,L.3@Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L,C<P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'
M96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPX-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#$S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#<T,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L-C<P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8V]S
M=',@86YD(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR,"PP.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,BPV,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,"PS-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS-RPV.#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&9R;VT@;W!E<F%T
M:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,34L,C<Y*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L
M.#0Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#,X+#$X,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R,"PQ-S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R(&EN8V]M92`H97AP
M96YS92DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G1E<F5S="!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(&5X<&5N<V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8T*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3,R*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$R*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@
M97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!F86ER('9A
M;'5E(&]F('=A<G)A;G0@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#`Q*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0P,2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&9R
M;VT@;W!E<F%T:6]N<R!B969O<F4@:6YC;VUE('1A>#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,34L,S`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<L,C$W*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,W+#DP-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,"PT-S(I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y);F-O;64@=&%X(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,34L,S`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H-RPR,3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@S-RPY,CDI/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R,"PT-S(I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-I8R!A
M;F0@9&EL=71E9"!N970@;&]S<R!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,"XP.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,#4I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C(T*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XQ-BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)A<VEC(&%N9"!D:6QU=&5D('=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F
M(&-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$V."PU,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,S0L,3<X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34V+#4U-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-RPR-#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S(T.3@V8V8S
M7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S8V(P9C<P
M,#1B-S0O5V]R:W-H965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%441!13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY35$%414U%3E13($]&($-/35!214A%
M3E-)5D4@3$]34R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T
M:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4U1!5$5-14Y44R!/
M1B!#3TU04D5(14Y3259%($Q/4U,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,34L,S`P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-RPR,3<I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@S-RPY,CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@R,"PT-S(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R(&-O;7!R96AE;G-I
M=F4@:6YC;VUE("AL;W-S*3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!U;G)E86QI>F5D(&=A:6YS("AL;W-S
M97,I(&]N(&EN=F5S=&UE;G1S(&%V86EL86)L92UF;W(M<V%L93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S,I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.38\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9O<F5I9VX@
M8W5R<F5N8WD@861J=7-T;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4P.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE
M<B!C;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-C@S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<')E:&5N<VEV92!L
M;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$T+#@R-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#<L,3(Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,S<L,C0V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,C`L,C8X*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E8V5?
M,V-B,&8W,#`T8C<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S(T
M.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-"]7;W)K<VAE971S
M+U-H965T,#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$4U0T)'/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-4051%345.5%,@3T8@0T%32"!&3$]74R`H55-$("0I/&)R/DEN
M(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T
M:6YG($%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,S<L.3(Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,C`L-#<R*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296-O;F-I
M;&EA=&EO;B!O9B!N970@;&]S<R!T;R!N970@8V%S:"!U<V5D(&EN(&]P97)A
M=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-H86YG92!I;B!F86ER('9A;'5E(&]F('=A<G)A
M;G0@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M-C<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV,S8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(Q-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T
M:6]N(&]F(&YE="!P<F5M:75M<R!O;B!I;G9E<W1M96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S(V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V%I;B!O
M;B!D:7-P;W-A;"!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0S-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]N+6-A
M<V@@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#<X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L-C8X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H86YG97,@:6X@
M;W!E<F%T:6YG(&%S<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')I8W1E9"!C
M87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X,S@I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8V-O=6YT<R!R96-E:79A8FQE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,CDQ*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#4P-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E5N8FEL;&5D(')E8V5I=F%B;&5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#8R-"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP
M96YS97,@86YD(&]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,C<Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5E
M9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C(S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,S`T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5F97)R960@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,3DY*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@P,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&5A<V4@:6YC96YT:79E<R!R96-E:79E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX,#,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@S,RPP.38I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,30L.3<W*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY)
M;G9E<W1I;F<@06-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87!I=&%L(&5X<&5N9&ET=7)E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PW-C(I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPR,#(I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C
M965D<R!F<F]M(&1I<W!O<V%L(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S
M:"!R96-E:79E9"!F<F]M('1H92!)<V-O;F]V82!!0B!A8W%U:7-I=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP,S0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]C965D<R!F<F]M(&UA='5R:71I97,@;V8@:6YV97-T;65N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+#8S,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-3`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M=7)C:&%S97,@;V8@:6YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$T+#<U-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q-2PW-C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@<')O=FED960@
M8GD@*'5S960@:6XI(&EN=F5S=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW+#(S,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$U+#$T-RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1FEN
M86YC:6YG($%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')I;F-I<&%L('!A>6UE;G1S(&]F(&-A<&ET
M86P@;&5A<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R:6YC:7!A;"!P87EM96YT<R!O9B!N;W1E<R!P87EA8FQE/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,#4I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F
M<F]M(&YO=&5S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L-#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D(&-A<V@\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-S4V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T('!R;V-E961S(&9R;VT@<V%L
M97,@;V8@8V]M;6]N('-T;V-K+"!N970@;V8@;V9F97)I;F<@8V]S=',@;V8@
M)#8N,2!M:6QL:6]N(&%N9"`D,"XT(&UI;&QI;VXL(')E<W!E8W1I=F5L>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(X+#8U.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V+#DR-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O8V5E9',@9G)O;2!T:&4@97AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ.30\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C
M87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I=FET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S`L.30S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L-S4X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%9F9E8W0@
M;V8@97AC:&%N9V4@<F%T92!O;B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@:6YC<F5A<V4@*&1E8W)E87-E*2!I;B!C87-H(&%N9"!C87-H
M(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,#4L,#DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,RPS-C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S(&%T(&)E
M9VEN;FEN9R!O9B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$W+#,Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$T+#$P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<R!A
M="!E;F0@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,C(L-#DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`L-S,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U<'!L96UE;G1A;"!D:7-C;&]S
M=7)E(&]F(&YO;BUC87-H(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E
M9"!I;B!C;VYN96-T:6]N('=I=&@@=&AE($ES8V]N;W9A($%"(&%C<75I<VET
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,2PY-#(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT('!U<F-H87-E<R!I
M;F-L=61E9"!I;B!A8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&5X<&5N
M<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,V-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5P;W-I="!A<'!L:65D('1O=V%R9',@=&AE('!U<F-H87-E(&]F(&QA8F]R
M871O<GD@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I<&UE;G0@86-Q=6ER960@=6YD97(@
M82!C87!I=&%L(&QE87-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,SDY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U<'!L96UE;G1A;"!D:7-C
M;&]S=7)E(&]F(&-A<V@@9FQO=R!I;F9O<FUA=&EO;CH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!A>6UE;G1S
M(&]F(&EN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P
M-&(W-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R-#DX-F-F,U\Q
M-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0O5V]R:W-H965T<R]3:&5E=#`W
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%1T@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U1!
M5$5-14Y44R!/1B!#05-(($9,3U=3("A087)E;G1H971I8V%L*2`H55-$("0I
M/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4U1!5$5-14Y44R!/1B!#05-(($9,3U=3(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@<')O8V5E
M9',@9G)O;2!S86QE<R!O9B!C;VUM;VX@<W1O8VLL(&]F9F5R:6YG(&-O<W1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L,3`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S(T.3@V
M8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-`T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S8V(P
M9C<P,#1B-S0O5V]R:W-H965T<R]3:&5E=#`X+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^3W)G86YI>F%T:6]N/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W)G86YI
M>F%T:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]R9V%N:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7
M,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W
M=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD
M=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@<W1Y
M;&4],T0G1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P:6XG/B!.
M;W1E(#$@+2!/<F=A;FEZ871I;VX\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(&)O
M;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,&EN)SX@)FYB<W`[/"]P/B`\<"!S
M='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%
M6%0M24Y$14Y4.B`P+C5I;B<^($YO=F%V87@L($EN8RX@*").;W9A=F%X+"(@
M86YD('1O9V5T:&5R('=I=&@@:71S('-U8G-I9&EA<GDL(").;W9A=F%X($%"
M+"(@=&AE(")#;VUP86YY(BD@:7,@82!C;&EN:6-A;"US=&%G92!B:6]P:&%R
M;6%C975T:6-A;"!C;VUP86YY(&9O8W5S960@;VX@=&AE(&1I<V-O=F5R>2P@
M9&5V96QO<&UE;G0@86YD(&-O;6UE<F-I86QI>F%T:6]N(&]F(')E8V]M8FEN
M86YT('!R;W1E:6X@;F%N;W!A<G1I8VQE('9A8V-I;F5S(&%N9"!A9&IU=F%N
M=',N(%1H92!#;VUP86YY)B,S.3MS('!R;V1U8W0@<&EP96QI;F4@=&%R9V5T
M<R!A('9A<FEE='D@;V8@:6YF96-T:6]U<R!D:7-E87-E<R!W:71H('9A8V-I
M;F4@8V%N9&ED871E<R!C=7)R96YT;'D@:6X@8VQI;FEC86P@9&5V96QO<&UE
M;G0@9F]R('-E87-O;F%L(&EN9FQU96YZ82P@<&%N9&5M:6,@:6YF;'5E;GIA
M(&%N9"!R97-P:7)A=&]R>2!S>6YC>71I86P@=FER=7,@*")24U8B*2X\+W`^
M(#PA+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S(T.3@V8V8S7S$U.3!?-#4R
M,5]B96-E7S-C8C!F-S`P-&(W-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0O5V]R
M:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^3W!E<F%T:6]N<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EO;G,@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SPA
M+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@
M5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL
M,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^
M/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@<W1Y;&4],T0G1D].5#H@8F]L9"`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P
M="`P<'@[(%1%6%0M24Y$14Y4.B`P:6XG/B!.;W1E(#(@+2!/<&5R871I;VYS
M/"]P/B`\<"!S='EL93TS1"=&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%
M3E0Z(#!I;B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B!4
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M8VEA;"!U<V4N/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^("9N8G-P.SPO
M<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@
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M+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T
M(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB<W`[/"]P/B`\(2TM16YD
M1G)A9VUE;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S
M8V(P9C<P,#1B-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C0Y
M.#9C9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W,#`T8C<T+U=O<FMS:&5E=',O
M4VAE970Q,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE
M<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE
M<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@
M4&]L:6-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\(2TM
M1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R
M86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O
M1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X\9&EV/B`\9&EV/CPA
M+2U3=&%R=$9R86=M96YT+2T^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU
M<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB
M<W`[/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4
M.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!
M4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#!I;B<^($YO=&4@,R`M(%-U
M;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SPO<#X@
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@8F]L9"`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P
M="`P<'@[(%1%6%0M24Y$14Y4.B`P:6XG/B`F;F)S<#L\+W`^(#QP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XR
M-6EN)SX@/'-T<F]N9SX\96T^0F%S:7,@;V8@4')E<V5N=&%T:6]N/"]E;3X\
M+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!
M4D=)3CH@,'!T(#!P>"`P<'0@,"XR-6EN)SX@)FYB<W`[/"]P/B`\<"!S='EL
M93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M
M24Y$14Y4.B`P+C5I;B<^(%1H92!A8V-O;7!A;GEI;F<@=6YA=61I=&5D(&-O
M;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!H879E(&)E96X@<')E
M<&%R960@:6X@86-C;W)D86YC92!W:71H(&%C8V]U;G1I;F<@<')I;F-I<&QE
M<R!G96YE<F%L;'D@86-C97!T960@:6X@=&AE(%5N:71E9"!3=&%T97,@;V8@
M06UE<FEC82`H(E4N4RX@1T%!4"(I(&9O<B!I;G1E<FEM(&9I;F%N8VEA;"!I
M;F9O<FUA=&EO;B!A;F0@=&AE(&EN<W1R=6-T:6]N<R!T;R!&;W)M(#$P+5$@
M86YD($%R=&EC;&4@,3`@;V8@4F5G=6QA=&EO;B!3+5@N(%1H92!C;VYS;VQI
M9&%T960@8F%L86YC92!S:&5E="!A<R!O9B!397!T96UB97(@,S`L(#(P,3,L
M(&-O;G-O;&ED871E9"!S=&%T96UE;G1S(&]F(&]P97)A=&EO;G,@86YD(&-O
M;G-O;&ED871E9"!S=&%T96UE;G1S(&]F(&-O;7!R96AE;G-I=F4@;&]S<R!F
M;W(@=&AE('1H<F5E(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@
M,S`L(#(P,3,@86YD(#(P,3(@86YD('1H92!C;VYS;VQI9&%T960@<W1A=&5M
M96YT<R!O9B!C87-H(&9L;W=S(&9O<B!T:&4@;FEN92!M;VYT:',@96YD960@
M4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"`R,#$R(&%R92!U;F%U9&ET960L(&)U
M="!I;F-L=61E(&%L;"!A9&IU<W1M96YT<R`H8V]N<VES=&EN9R!O9B!N;W)M
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M+E,N($=!05`@:&%V92!B965N(&-O;F1E;G-E9"!O<B!O;6ET=&5D(&%S('!E
M<FUI='1E9"!U;F1E<B!T:&4@<G5L97,@86YD(')E9W5L871I;VYS(&]F('1H
M92!5;FET960@4W1A=&5S(%-E8W5R:71I97,@86YD($5X8VAA;F=E($-O;6UI
M<W-I;VX@*")314,B*2X\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU
M<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB
M<W`[/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ
M(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^($%S(&1I<V-U<W-E9"!I
M;B!M;W)E(&1E=&%I;"!I;B!.;W1E(#0L('1H92!#;VUP86YY(&%C<75I<F5D
M(%-W961I<V@M8F%S960@27-C;VYO=F$@04(@*"))<V-O;F]V82(I(&]N($IU
M;'D@,S$L(#(P,3,N($ES8V]N;W9A('=A<R!S=6)S97%U96YT;'D@<F5N86UE
M9"!.;W9A=F%X($%"+B!4:&4@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T
M96UE;G1S(&EN8VQU9&4@=&AE(&%C8V]U;G1S(&]F($YO=F%V87@L($EN8RX@
M86YD(&ET<R!S=6)S:61I87)Y+"!.;W9A=F%X($%"+B!!;&P@:6YT97)C;VUP
M86YY(&%C8V]U;G1S(&%N9"!T<F%N<V%C=&EO;G,@:&%V92!B965N(&5L:6UI
M;F%T960@:6X@8V]N<V]L:61A=&EO;BX\+W`^(#QP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N
M-6EN)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T
M:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^(%1H92!A
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M;7!R96AE;G-I=F4@:6YC;VUE('=A<R`D,"XU(&UI;&QI;VX@870@4V5P=&5M
M8F5R(#,P+"`R,#$S+CPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S
M=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B`F;F)S
M<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@
M,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE(&%C8V]M<&%N>6EN
M9R!U;F%U9&ET960@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S
M('-H;W5L9"!B92!R96%D(&EN(&-O;FIU;F-T:6]N('=I=&@@=&AE(&9I;F%N
M8VEA;"!S=&%T96UE;G1S(&%N9"!N;W1E<R!T:&5R971O(&EN8VQU9&5D(&EN
M('1H92!#;VUP86YY)B,S.3MS($%N;G5A;"!297!O<G0@;VX@1F]R;2`Q,"U+
M(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,BX@4F5S=6QT
M<R!F;W(@=&AI<R!O<B!A;GD@:6YT97)I;2!P97)I;V0@87)E(&YO="!N96-E
M<W-A<FEL>2!I;F1I8V%T:79E(&]F(')E<W5L=',@9F]R(&%N>2!F=71U<F4@
M:6YT97)I;2!P97)I;V0@;W(@9F]R('1H92!E;G1I<F4@>65A<BX@5&AE($-O
M;7!A;GD@;W!E<F%T97,@:6X@;VYE(&)U<VEN97-S('-E9VUE;G0Z(&1E=F5L
M;W!I;F<@<F5C;VUB:6YA;G0@=F%C8VEN97,N/"]P/B`\<"!S='EL93TS1"=4
M15A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4
M.B`P+C5I;B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE..B`P<'0@,'!X(#!P="`P+C(U:6XG/B`\<W1R;VYG/CQE
M;3Y5<V4@;V8@17-T:6UA=&5S/"]E;3X\+W-T<F]N9SX\+W`^(#QP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XR
M-6EN)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T
M:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^(%1H92!P
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M<FEA;&QY(&9R;VT@=&AE<V4@97-T:6UA=&5S+CPO<#X@/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.
M5#H@,"XU:6XG/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XR-6EN)SX@/'-T<F]N9SX\
M96T^1F%I<B!686QU92!-96%S=7)E;65N=',\+V5M/CPO<W1R;VYG/CPO<#X@
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X
M(#!P="`P+C(U:6XG/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN
M)SX@5&AE($-O;7!A;GD@87!P;&EE<R!!8V-O=6YT:6YG(%-T86YD87)D<R!#
M;V1I9FEC871I;VX@*")!4T,B*2!4;W!I8R`X,C`L(#QE;3Y&86ER(%9A;'5E
M($UE87-U<F5M96YT<R!A;F0@1&ES8VQO<W5R97,\+V5M/BP@9F]R(&9I;F%N
M8VEA;"!A;F0@;F]N+69I;F%N8VEA;"!A<W-E=',@86YD(&QI86)I;&ET:65S
M+CPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P
M<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B`F;F)S<#L\+W`^(#QP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$58
M5"U)3D1%3E0Z(#`N-6EN)SX@05-#(#@R,"!D:7-C=7-S97,@=F%L=6%T:6]N
M('1E8VAN:7%U97,L('-U8V@@87,@=&AE(&UA<FME="!A<'!R;V%C:"`H8V]M
M<&%R86)L92!M87)K970@<')I8V5S*2P@=&AE(&EN8V]M92!A<'!R;V%C:"`H
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M97-C<FEP=&EO;B!O9B!T:&]S92!T:')E92!L979E;',Z/"]P/B`\<"!S='EL
M93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M
M24Y$14Y4.B`P+C5I;B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE.+51/4#H@,'!T)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$
M)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N
M,C5I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)W=I9'1H.B`P+C(U:6X[
M)SXF;6ED9&]T.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T
M:69Y)SY,979E;"`Q.B!/8G-E<G9A8FQE(&EN<'5T<R!S=6-H(&%S('%U;W1E
M9"!P<FEC97,@*'5N861J=7-T960I(&EN(&%C=&EV92!M87)K971S(&9O<B!I
M9&5N=&EC86P@87-S971S(&]R(&QI86)I;&ET:65S+CPO=&0^(#PO='(^(#PO
M=&%B;&4^(#QT86)L92!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3BU43U`Z(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P
M)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=W:61T:#H@,"XR-6EN.R<^)FUI9&1O=#L\+W1D/B`\=&0@
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M;F]T(&%C=&EV92X\+W1D/B`\+W1R/B`\+W1A8FQE/B`\=&%B;&4@<W1Y;&4]
M,T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM5$]0.B`P<'0G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y
M;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=72414
M2#H@,"XR-6EN)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G=VED=&@Z(#`N
M,C5I;CLG/B9M:61D;W0[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&IU<W1I9GDG/DQE=F5L(#,Z(%5N;V)S97)V86)L92!I;G!U=',@=&AA="!R
M969L96-T('1H92!R97!O<G1I;F<@96YT:71Y)B,S.3MS(&]W;B!A<W-U;7!T
M:6]N<RX\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[($U!4D=)3BU43U`Z(#!P="<^("9N8G-P.SPO<#X@/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!415A4
M+4E.1$5.5#H@,"XU:6XG/B`\<W1R;VYG/CQE;3Y);G9E<W1M96YT<SPO96T^
M/"]S=')O;F<^/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y
M.R!&3TY4.B!B;VQD(&ET86QI8R`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N,C5I;B<^("9N8G-P
M.SPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P
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M(&=R96%T97(@=&AA;B`Y,"!D87ES+"!B=70@;&5S<R!T:&%N(&]N92!Y96%R
M(&%R92!C;&%S<VEF:65D(&%S(&-U<G)E;G0@86YD('1H;W-E('=I=&@@9W)E
M871E<B!T:&%N(&]N92!Y96%R(&%R92!C;&%S<VEF:65D(&%S(&YO;BUC=7)R
M96YT+CPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B`F;F)S<#L\+W`^(#QP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@
M5$585"U)3D1%3E0Z(#`N-6EN)SX@26YT97)E<W0@86YD(&1I=FED96YD(&EN
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M86QE(&]F('1H92!#;VUP86YY)B,S.3MS('-E8W5R:71I97,N/"]P/B`\<"!S
M='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%
M6%0M24Y$14Y4.B`P+C5I;B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@
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M<W1A=&5M96YT(&]F(&]P97)A=&EO;G,N/"]P/B`\<"!S='EL93TS1"=415A4
M+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P
M+C5I;B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S
M=&EF>3L@1D].5#H@8F]L9"!I=&%L:6,@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`P+C(U:6XG/B!2
M97-T<FEC=&5D($-A<V@\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU
M<W1I9GD[($9/3E0Z(&)O;&0@:71A;&EC(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XR-6EN)SX@
M)FYB<W`[/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^(%1H92!#;VUP86YY
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M=&AE(&1U<F%T:6]N(&]F('1H92!L96%S97,N/"]P/B`\<"!S='EL93TS1"=4
M15A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4
M.B`P+C5I;B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE..B`P<'0@,'!X(#!P="`P+C(U:6XG/B`\<W1R;VYG/CQE
M;3Y.970@3&]S<R!P97(@4VAA<F4\+V5M/CPO<W1R;VYG/CPO<#X@/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!415A4
M+4E.1$5.5#H@,"XU:6XG/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N
M-6EN)SX@3F5T(&QO<W,@<&5R('-H87)E(&ES(&-O;7!U=&5D('5S:6YG('1H
M92!W96EG:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!S:&%R97,@;V8@8V]M;6]N
M('-T;V-K(&]U='-T86YD:6YG+B!!;&P@;W5T<W1A;F1I;F<@=V%R<F%N=',L
M('-T;V-K(&]P=&EO;G,@86YD('5N=F5S=&5D(')E<W1R:6-T960@<W1O8VL@
M87=A<F1S('1O=&%L:6YG(#$R+#$U-RPV,S0@<VAA<F5S(&%N9"`Q,BPY-3$L
M-C(U('-H87)E<R!A="!397!T96UB97(@,S`L(#(P,3,@86YD(#(P,3(L(')E
M<W!E8W1I=F5L>2P@87)E(&5X8VQU9&5D(&9R;VT@=&AE(&-O;7!U=&%T:6]N
M+"!A<R!T:&5I<B!E9F9E8W0@:7,@86YT:61I;'5T:79E+CPO<#X@/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!415A4
M+4E.1$5.5#H@,"XU:6XG/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N
M,C5I;B<^(#QS=')O;F<^/&5M/E)E8VQA<W-I9FEC871I;VYS/"]E;3X\+W-T
M<F]N9SX\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^("9N8G-P.SPO<#X@
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X
M.R!415A4+4E.1$5.5#H@,"XU:6XG/B!/=F5R:&5A9"!E>'!E;G-E<R!R96QA
M=&EN9R!T;R!S=7!P;'D@8VAA:6X@;6%N86=E;65N="!O9B`D,"XR(&UI;&QI
M;VX@86YD("0P+C8@;6EL;&EO;B!F;W(@=&AE('1H<F5E(&%N9"!N:6YE(&UO
M;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3(L(')E<W!E8W1I=F5L>2P@
M:&%V92!B965N(')E8VQA<W-I9FEE9"!F<F]M(&=E;F5R86P@86YD(&%D;6EN
M:7-T<F%T:79E(&5X<&5N<V5S('1O(')E<V5A<F-H(&%N9"!D979E;&]P;65N
M="!E>'!E;G-E<RX@06QS;RP@=VET:&EN('1H92!397!T96UB97(@,S`L(#(P
M,3(@<W1A=&5M96YT(&]F(&-A<V@@9FQO=W,L(')E<W1R:6-T960@8V%S:"!R
M96-E:79E9"!O9B`D,"XX(&UI;&QI;VX@<F5C;W)D960@:6X@9FEN86YC:6YG
M(&%C=&EV:71I97,@:&%S(&)E96X@<F5C;&%S<VEF:65D(&%N9"!I<R!I;F-L
M=61E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<RX@5&AE<V4@<F5C;&%S<VEF
M:6-A=&EO;G,@:&%V92!B965N(&UA9&4@=&\@8V]N9F]R;2!T;R!C=7)R96YT
M('EE87(@<')E<V5N=&%T:6]N+CPO<#X@/"$M+45N9$9R86=M96YT+2T^/"]D
M:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W,#`T8C<T#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S(T.3@V8V8S7S$U.3!?-#4R
M,5]B96-E7S-C8C!F-S`P-&(W-"]7;W)K<VAE971S+U-H965T,3$N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY!8W%U:7-I=&EO
M;B!O9B!)<V-O;F]V82!!0CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D%C<75I<VET:6]N($]F($ES8V]N;W9A($%"
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C<75I<VET:6]N($]F($ES8V]N;W9A($%"/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/"$M+41/0U194$4@:'1M;"!054),
M24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B
M:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I
M=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM
M/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P
M<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4]
M,T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M34%21TE..B`P<'0@,'!X)SX@/'-T<F]N9SY.;W1E(#0@+2!!8W%U:7-I=&EO
M;B!O9B!)<V-O;F]V82!!0CPO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X)SX@)FYB<W`[/"]P/B`\
M<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[
M(%1%6%0M24Y$14Y4.B`P+C5I;B<^(#QF;VYT('-T>6QE/3-$)T-/3$]2.B!W
M:6YD;W=T97AT)SY/;B!*=6QY(#,Q+"`R,#$S("AT:&4@(F%C<75I<VET:6]N
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M<W1O8VL@;W!T:6]N<RP@3F]V879A>"!I<W-U960@87!P<F]X:6UA=&5L>2`Q
M-2XV(&UI;&QI;VX@<VAA<F5S(&]F(&ET<R!#;VUM;VX@4W1O8VL@=F%L=65D
M(&%T("0T,2XY(&UI;&QI;VX@86YD('!A:60@8V%S:"!O9B!A<'!R;WAI;6%T
M96QY("0R,BPP,#`@=&\@86-Q=6ER92`Y.2XU)2!O9B!T:&4@;W5T<W1A;F1I
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M;F-E('1H92!A8W%U:7-I=&EO;B!D871E+B`\9F]N="!S='EL93TS1"=#3TQ/
M4CH@=VEN9&]W=&5X="<^1F]R('1H92!T:')E92!M;VYT:',@96YD960@4V5P
M=&5M8F5R(#,P+"`R,#$S+"!T:&4@;6EN;W)I='D@:6YT97)E<W0@:6X@3F]V
M879A>"!!0B8C,SD[<R!N970@;&]S<R!A;F0@<W1O8VMH;VQD97)S)B,S.3L@
M97%U:71Y(&ES(&EM;6%T97)I86PN/"]F;VYT/CPO<#X@/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X)SX@)FYB<W`[/"]P
M/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P
M<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^(#QF;VYT('-T>6QE/3-$)T9/3E0M
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M(&]P97)A=&EN9R!A;F0@<F5G=6QA=&]R>2!P<F]C97-S97,N/"]F;VYT/B`\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/E1H92!T;W1A;"!P=7)C
M:&%S92!P<FEC92!I<R!S=6UM87)I>F5D(&%S(&9O;&QO=W,@*&EN('1H;W5S
M86YD<RDZ/"]F;VYT/CPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S
M=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B`F;F)S
M<#L\+W`^(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA
M<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XM3$5&5#H@,"XU:6X[(%=)1%1(.B`Y,"4G(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR
M,#0I)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU,
M1494.B`P<'@[(%=)1%1(.B`X-B4G/E9A;'5E(&]F('-H87)E<R!O9B!.;W9A
M=F%X($-O;6UO;B!3=&]C:R!I<W-U960\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!724142#H@,B4G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(
M.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%
M6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SX@-#$L.30R/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@
M5TE$5$@Z(#$E)SX@)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E
M)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@G
M/B!#87-H('!A:60@=&\@27-C;VYO=F$@=V%R<F%N="!H;VQD97)S/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ
M(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=.
M.B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!R:6=H="<^(#(R/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^
M("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I
M)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T.R!0041$24Y'+4Q%1E0Z(#!P>"<^(%1O=&%L('!U<F-H87-E
M('!R:6-E/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#0Q+#DV-#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P
M=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#PO='(^(#PO=&%B
M;&4^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"<^("9N8G-P.SPO<#X@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!4
M15A4+4E.1$5.5#H@,"XU:6XG/B!4:&4@=F%L=64@;V8@3F]V879A>"!#;VUM
M;VX@4W1O8VL@:7-S=65D(&ES(&)A<V5D(&]N('1H92!C;&]S:6YG('!R:6-E
M(&]F($YO=F%V87@F(S,Y.R!#;VUM;VX@4W1O8VL@;VX@=&AE(&%C<75I<VET
M:6]N(&1A=&4N/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XZ(#!P="`P<'@G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N
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M8VAA;F=E+CPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B`F;F)S<#L\+W`^
M(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XM3$5&5#H@,"XU:6X[(%=)1%1(.B`Y,"4G(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.
M1RU,1494.B`P<'@G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(^*&EN('1H
M;W5S86YD<RD\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF
M;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M3$5&5#H@,'!X.R!724142#H@.#8E)SX@0V%S:"!A;F0@
M8V%S:"!E<75I=F%L96YT<SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%=)1%1(.B`R)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'
M3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B`S+#`U-CPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q
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M04Q)1TXZ(')I9VAT)SXV,#,\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\
M='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.
M1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@
M,'!X)SX@4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@87-S971S/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58
M5"U!3$E'3CH@<FEG:'0G/C$L,#DR/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T
M<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'
M4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@G/B!0
M<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/C$V
M-3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T
M+#(U-2PR,#0I)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@G/B!);G1A;F=I8FQE
M(&%S<V5T<SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M
M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXQ-BPS.#`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4G/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4Q%1E0Z(#!P>"<^1V]O9'=I
M;&P\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!415A4+4%,24=..B!R:6=H="<^,C4L,CDX/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
M/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T.R!0
M041$24Y'+4Q%1E0Z(#!P>"<^($%C8V]U;G1S('!A>6%B;&4@86YD(&]T:&5R
M(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^*#(L
M-S@T/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!
M3$E'3CH@;&5F="<^*3PO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!W:&ET92<^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q
M<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@0V%P
M:71A;"!L96%S97,\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!4
M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^*#DT/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^
M*3PO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I)SX@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU,1494.B`P<'@G/B!.;W1E<R!P87EA8FQE/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'
M3CH@<FEG:'0G/B@Q.3,\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!415A4+4%,24=..B!L969T)SXI/"]T9#X@/"]T<CX@/'1R('-T>6QE
M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z
M('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.
M1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494
M.B`P<'@G/B!/=&AE<B!N;VXM8W5R<F5N="!L:6%B:6QI=&EE<SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q
M<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@
M;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0G/B`H,2PU-3D\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T
M)SX@*3PO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I)SX@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T.R!0041$24Y'+4Q%1E0Z(#!P>"<^(%1O=&%L('!U<F-H87-E('!R
M:6-E/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.
M1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U
M8FQE.R!415A4+4%,24=..B!R:6=H="<^(#0Q+#DV-#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@
M5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#PO='(^(#PO=&%B;&4^
M(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"<^("9N8G-P.SPO<#X@/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!415A4
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M+"!R86YG:6YG(&9R;VT@<V5V96X@=&\@,C`@>65A<G,N(%1H92!C87)R>6EN
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M:&4@<&5R:6]D(&EN('=H:6-H('1H92!I;7!A:7)M96YT(&]C8W5R<RX\+W`^
M(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN
M)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^(%1H92!#;VUP
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M92!F;W(@52Y3+B!F961E<F%L(&EN8V]M92!T87@@<'5R<&]S97,N/"]P/B`\
M<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G
M/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!
M4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE($-O;7!A
M;GD@:6YC=7)R960@87!P<F]X:6UA=&5L>2`D,2XS(&UI;&QI;VX@:6X@=')A
M;G-A8W1I;VX@8V]S=',@<F5L871E9"!T;R!T:&4@06-Q=6ES:71I;VXL('=H
M:6-H(&ES(&EN8VQU9&5D(&EN(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E
M(&5X<&5N<V5S(&EN('1H92!#;VUP86YY)B,S.3MS(&-O;G-O;&ED871E9"!S
M=&%T96UE;G0@;V8@;W!E<F%T:6]N<RX\+W`^(#QP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"<^("9N8G-P.SPO<#X@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!4
M15A4+4E.1$5.5#H@,"XU:6XG/B!&<F]M('1H92!A8W%U:7-I=&EO;B!D871E
M('1O(%-E<'1E;6)E<B`S,"P@,C`Q,RP@=&AE($-O;7!A;GD@:&%S(')E8V]G
M;FEZ960@<F5V96YU92!O9B`D,"XT(&UI;&QI;VX@86YD(')E8V]R9&5D(&$@
M;F5T(&QO<W,@;V8@)#$N-2!M:6QL:6]N(&9R;VT@=&AE(&]P97)A=&EO;G,@
M;V8@3F]V879A>"!!0BX\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU
M<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3CH@,'!T(#!P>"<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.
M5#H@,"XU:6XG/B!4:&4@9F]L;&]W:6YG('5N875D:71E9"!C;VYS;VQI9&%T
M960@<')O(&9O<FUA(&9I;F%N8VEA;"!I;F9O<FUA=&EO;B!I<R!P<F5S96YT
M960@87,@:68@=&AE($%C<75I<VET:6]N(&]C8W5R<F5D(&]N($IA;G5A<GD@
M,2P@,C`Q,BX@5&AE('5N875D:71E9"!P<F\@9F]R;6$@9FEN86YC:6%L(&EN
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M96YT<SH\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3CH@,'!T(#!P>"<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE.+51/4#H@,'!T)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%
M4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I
M;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)W=I9'1H.B`P+C(U:6X[)SXF
M;6ED9&]T.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(%1%6%0M04Q)1TXZ(&IU<W1I9GDG
M/B!%;&EM:6YA=&EO;B!O9B!T:&4@:&ES=&]R:6-A;"!I;G1A;F=I8FQE(&%S
M<V5T<R!A;F0@86UO<G1I>F%T:6]N(&5X<&5N<V4@=6YR96QA=&5D('1O('1H
M92!!8W%U:7-I=&EO;CL\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU43U`Z(#!P="<^("9N8G-P.SPO
M<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+51/
M4#H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)W=I9'1H.B`P+C(U:6X[)SXF;6ED9&]T.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(%1%6%0M04Q)1TXZ(&IU<W1I9GDG/B!!;6]R=&EZ871I;VX@97AP96YS
M92!R96QA=&5D('1O('1H92!F86ER('9A;'5E(&]F(&EN=&%N9VEB;&4@87-S
M971S(&%C<75I<F5D.R!A;F0\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL
M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU43U`Z(#!P="<^("9N8G-P
M.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M+51/4#H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G
M/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)W=I9'1H.B`P+C(U:6X[)SXF;6ED9&]T.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(%1%6%0M04Q)1TXZ(&IU<W1I9GDG/B!4:&4@97AC;'5S:6]N(&]F
M(&%C<75I<VET:6]N+7)E;&%T960@8V]S=',@:6YC=7)R960@9F]R('1H92!!
M8W%U:7-I=&EO;BX\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XZ(#!P="`P<'@G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"="3U)$
M15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM3$5&5#H@,"XU:6X[(%=)1%1(
M.B`Y,"4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S
M='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!0041$24Y'+4Q%1E0Z(#!P>"<^("9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=.
M.B!C96YT97([($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)R!C;VQS<&%N/3-$-CX@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!415A4+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU43U`Z(#!P="<^(#QS=')O;F<^
M5&AR964@36]N=&AS($5N9&5D/"]S=')O;F<^/"]P/B`\<"!S='EL93TS1"=-
M05)'24XM0D]45$]-.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+51/
M4#H@,'!T)SX@/'-T<F]N9SY397!T96UB97(@,S`L/"]S=')O;F<^/"]P/B`\
M+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B!B
M;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0Z(&)O;&0@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@8V]L<W!A;CTS1#8^(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XM5$]0.B`P<'0G/B`\<W1R;VYG/DYI;F4@36]N=&AS($5N9&5D
M/"]S=')O;F<^/"]P/B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[
M(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@34%21TE.+51/4#H@,'!T)SX@/'-T<F]N9SY3
M97!T96UB97(@,S`L/"]S=')O;F<^/"]P/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F
M;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@4$%$1$E.1RU,1494.B`P<'@G/B`F;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R
M)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@
M8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,CXR,#$S/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E
M<B<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4
M+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P
M86X],T0R/C(P,3(\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$58
M5"U!3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]4
M5$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L
M86-K(#%P="!S;VQI9#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ
M(&-E;G1E<B<@8V]L<W!A;CTS1#(^,C`Q,SPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/
M5%1/33H@,7!T.R!415A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R)SX@
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L
M9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,CXR,#$R/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^
M("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$
M1$E.1RU,1494.B`P<'@G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#$T/BAI
M;B!T:&]U<V%N9',I/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P
M-"DG/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/
M5%1/33H@,BXU<'0[(%!!1$1)3D<M3$5&5#H@,'!X.R!724142#H@-#0E)SX@
M4F5V96YU93PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!
M1$1)3D<M0D]45$]-.B`R+C5P=#L@5TE$5$@Z(#(E)SX@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!724142#H@
M,24G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]2
M1$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R
M:6=H=#L@5TE$5$@Z(#$P)2<^(#0L.#8Y/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,
M24=..B!L969T.R!724142#H@,24G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%=)
M1%1(.B`R)2<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)#PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B`V+#(W
M,CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M
M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T.R!724142#H@,B4G/B`F;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B
M;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q
M)2<^("0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!724142#H@,3`E)SX@,30L,3DU/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,
M24=..B!L969T.R!724142#H@,24G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%=)
M1%1(.B`R)2<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)#PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B`Q.2PU
M,S`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'
M+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^
M("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!W:&ET92<^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@G/B!.970@;&]S
M<SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M
M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0G/B`H,34L-C@W/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!4
M15A4+4%,24=..B!L969T)SX@*3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`H."PT
M.3`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'
M+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`I/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N
M-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,
M24=..B!R:6=H="<^("@T,"PU-C4\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ
M(&QE9G0G/B`I/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P
M="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^("@R-2PP,S,\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@
M,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`I/"]T9#X@/"]T<CX@/'1R('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],
M3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@0F%S:6,@86YD(&1I;'5T960@;F5T
M(&QO<W,@<&5R('-H87)E/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R+C5P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`D/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`H,"XP.3PO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`I/"]T
M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B`H,"XP-CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`I/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R+C5P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`H,"XR-#PO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B`I/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P
M=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`D/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$58
M5"U!3$E'3CH@<FEG:'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B`H,"XQ.#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`I/"]T9#X@/"]T<CX@
M/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5
M3D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@4$%$1$E.1RU,1494.B`P<'@G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I
M9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D
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M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S
M='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@3F]V879A>"!!0B!H
M87,@86X@;W!E<F%T:6YG(&QE87-E(&9O<B!I=',@9F%C:6QI='D@=&AA="!E
M>'!I<F5S(&EN(#(P,3<N($%S(&]F(%-E<'1E;6)E<B`S,"P@,C`Q,RP@=&AE
M(&%G9W)E9V%T92!R96UA:6YI;F<@<F5N=&%L('!A>6UE;G1S(&1U92!U;F1E
M<B!T:&ES(&]P97)A=&EN9R!L96%S92!C;VUM:71M96YT('=A<R!A<'!R;WAI
M;6%T96QY("0Q+CD@;6EL;&EO;BX\+W`^(#PA+2U%;F1&<F%G;65N="TM/CPO
M9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-`T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R-#DX-F-F,U\Q-3DP7S0U
M,C%?8F5C95\S8V(P9C<P,#1B-S0O5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1F%I<B!686QU
M92!-96%S=7)E;65N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E($UE87-U<F5M96YT<R!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y&86ER(%9A;'5E($UE87-U<F5M96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7
M,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W
M=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD
M=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X)SX@/'-T
M<F]N9SY.;W1E(#4@+2!&86ER(%9A;'5E($UE87-U<F5M96YT<SPO<W1R;VYG
M/CPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P
M<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B`F;F)S<#L\+W`^(#QP('-T
M>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($9/3E0M5T5)1TA4.B!N;W)M86P[($U!4D=)3CH@,'!T(#!P>#L@5$58
M5"U!3$E'3CH@:G5S=&EF>3L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE(&9O
M;&QO=VEN9R!T86)L92!R97!R97-E;G1S('1H92!#;VUP86YY)B,S.3MS(&9A
M:7(@=F%L=64@:&EE<F%R8VAY(&9O<B!I=',@9FEN86YC:6%L(&%S<V5T<R!A
M;F0@;&EA8FEL:71I97,@;65A<W5R960@870@9F%I<B!V86QU92!O;B!A(')E
M8W5R<FEN9R!B87-I<R`H:6X@=&AO=7-A;F1S*3H\+W`^(#QP('-T>6QE/3-$
M)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($9/
M3E0M5T5)1TA4.B!N;W)M86P[($U!4D=)3CH@,'!T(#!P>#L@5$585"U!3$E'
M3CH@:G5S=&EF>3L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB<W`[/"]P/B`\
M=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@5TE$5$@Z
M(#$P,"4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S
M='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M
M3$5&5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C96YT97(G
M(&-O;'-P86X],T0Q,#Y&86ER(%9A;'5E(&%T(%-E<'1E;6)E<B`S,"P@,C`Q
M,SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)SX@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C96YT
M97(G(&-O;'-P86X],T0Q,#Y&86ER(%9A;'5E(&%T($1E8V5M8F5R(#,Q+"`R
M,#$R/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B`F;F)S<#L\+W1D
M/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$
M24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T.R!0041$24Y'+4Q%
M1E0Z(#!P>#L@5$585"U$14-/4D%424]..B!U;F1E<FQI;F4[(%1%6%0M24Y$
M14Y4.B`P<'@G/B!!<W-E=',\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P
M=#L@5$585"U!3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R
M)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#%P="!S;VQI9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)SX@/'-T<F]N9SY,979E;"`Q/"]S
M=')O;F<^/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@
M,7!T.R!415A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C96YT
M97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M5T5)1TA4
M.B!B;VQD.R!415A4+4%,24=..B!C96YT97(G/B`\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0G/CQS=')O;F<^3&5V96P@,CPO<W1R;VYG/CPO9F]N
M=#X@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ
M(&-E;G1E<B<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T
M.R!415A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C96YT97(G
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B
M;VQD.R!415A4+4%,24=..B!C96YT97(G/B`\<W1R;VYG/DQE=F5L(#,\+W-T
M<F]N9SX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'
M3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q
M<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^("9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E
M<B<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^(#QS=')O;F<^3&5V96P@,3PO
M<W1R;VYG/CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,
M24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ
M(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N
M=&5R)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)SX@/'-T<F]N9SY,979E;"`R
M/"]S=')O;F<^/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M
M04Q)1TXZ(&-E;G1E<B<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/
M33H@,7!T.R!415A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C
M96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R!415A4+4%,24=..B!C96YT97(G/B`\<W1R;VYG/DQE=F5L
M(#,\+W-T<F]N9SX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$58
M5"U!3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE
M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z
M('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P+C$R-6EN.R!724142#H@,C@E
M.R!415A4+4E.1$5.5#H@+3`N,3(U:6XG/B!#;W)P;W)A=&4@9&5B="!S96-U
M<FET:65S(&%N9"!A=6-T:6]N(')A=&4@<V5C=7)I=&EE<SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!724142#H@,B4G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!7
M24142#H@,24G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(%=)1%1(.B`X)2<^
M("T\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@5TE$5$@Z(#$E
M)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(%=)1%1(.B`R)2<^("9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(%=)1%1(.B`Q)2<^("0\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!R:6=H=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@5TE$5$@Z(#@E)SX@,C,L.3$W/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!724142#H@,B4G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!7
M24142#H@,24G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(%=)1%1(.B`X)2<^
M("T\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@5TE$5$@Z(#$E
M)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(%=)1%1(.B`R)2<^("9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(%=)1%1(.B`Q)2<^("0\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!R:6=H=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@5TE$5$@Z(#@E)SX@+3PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!724142#H@,24G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M5TE$5$@Z(#(E)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@5TE$5$@Z
M(#$E)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!724142#H@."4G/B`S,BPY
M-#4\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@5TE$5$@Z(#$E
M)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(%=)1%1(.B`R)2<^("9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(%=)1%1(.B`Q)2<^("0\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!R:6=H=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@5TE$5$@Z(#@E)SX@+3PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!724142#H@,24G/B`F;F)S<#L\+W1D/B`\+W1R/B`\='(@
M<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#
M3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU,1494.B`P<'@[(%1%6%0M24Y$14Y4.B`P<'@G/B!4
M;W1A;"!I;G9E<W1M96YT<SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`M/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=.
M.B!R:6=H="<^(#(S+#DQ-SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F
M="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`M/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T
M.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G
M/B`D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M="<^("T\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$
M24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/
M5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@
M5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(')I9VAT)SX@,S(L.30U/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4
M+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^("T\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/
M5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\
M+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#
M2T=23U5.1"U#3TQ/4CH@=VAI=&4G/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU,1494.B`P<'@[
M(%1%6%0M1$5#3U)!5$E/3CH@=6YD97)L:6YE.R!415A4+4E.1$5.5#H@,'!X
M)SX@3&EA8FEL:71I97,\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@
M;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
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M+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!
M3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
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M(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S
M<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@[(%1%
M6%0M24Y$14Y4.B`P<'@G/B!787)R86YT(&QI86)I;&ET:65S/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N
M-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,
M24=..B!R:6=H="<^("T\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0G
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0
M041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P
M="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@+3PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@
M5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@
M)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G
M/B`M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.
M1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H="<^("T\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ
M(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C
M:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@+3PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]2
M1$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L
M969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0G/B`R-C<\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F
M;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!&3TY4+5=%24=(
M5#H@;F]R;6%L.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M04Q)1TXZ(&IU<W1I
M9GD[(%1%6%0M24Y$14Y4.B`P+C5I;B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4]
M,T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M1D].5"U714E'2%0Z(&YO<FUA;#L@34%21TE..B`P<'0@,'!X.R!415A4+4%,
M24=..B!J=7-T:69Y.R!415A4+4E.1$5.5#H@,"XU:6XG/B!$=7)I;F<@=&AE
M(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,RP@=&AE($-O
M;7!A;GD@9&ED(&YO="!H879E(&%N>2!T<F%N<V9E<G,@8F5T=V5E;B!L979E
M;',N/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ
M(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^("9N8G-P.SPO<#X@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!4
M15A4+4E.1$5.5#H@,"XU:6XG/B!4:&4@9F]L;&]W:6YG('1A8FQE('!R;W9I
M9&5S(&$@<F5C;VYC:6QI871I;VX@;V8@=&AE(&)E9VEN;FEN9R!A;F0@96YD
M:6YG(&)A;&%N8V4@;V8@3&5V96P@,R!A<W-E=',@86YD(&QI86)I;&ET:65S
M(&UE87-U<F5D(&]N(&$@<F5C=7)R:6YG(&)A<VES(&9O<B!T:&4@;FEN92!M
M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S("AI;B!T:&]U<V%N9',I
M.CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@
M,"XU:6XG/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"="3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!724142#H@-S4E)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M
M0D]45$]-.B`Q<'0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0Z(&)O;&0@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5#H@8F]L9"`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!C;VQS<&%N/3-$,CX@/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G/B`\<W1R
M;VYG/D9A:7(F;F)S<#M686QU929N8G-P.TUE87-U<F5M96YT<R9N8G-P.V]F
M/"]S=')O;F<^/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!
M4D=)3CH@,'!T(#!P>"<^(#QS=')O;F<^5V%R<F%N=',F;F)S<#M5<VEN9R!3
M:6=N:69I8V%N=#PO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G/B`\<W1R;VYG/E5N;V)S97)V86)L
M929N8G-P.TEN<'5T<R9N8G-P.SPO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G/B`\<W1R;VYG/BA,
M979E;"9N8G-P.S,I/"]S=')O;F<^/"]P/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]T9#X@/"]T<CX@/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M
M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!0041$24Y'+4Q%1E0Z(#!P>#L@5TE$5$@Z(#<W)2<^0F%L
M86YC92!A="!$96-E;6)E<B`S,2P@,C`Q,CPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$
M5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`R,"4G/C(V-SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`Q)2<^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!W:&ET92<^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@
M0VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@5V%R<F%N="!L:6%B:6QI='D\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/
M33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(')I9VAT)SX@*#(V-SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE
M9G0G/B`I/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/
M33H@,BXU<'0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@0F%L86YC92!A="!397!T
M96UB97(@,S`L(#(P,3,\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C
M:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@+3PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#PO='(^(#PO
M=&%B;&4^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z
M(#`N-6EN)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J
M=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^(%1H
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M92X\+W`^(#PA+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S(T.3@V8V8S7S$U
M.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B
M-S0O5V]R:W-H965T<R]3:&5E=#$S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^26YV97-T;65N=',\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY);G9E<W1M96YT<R!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G9E<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!8
M2%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G
M+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD
M:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X)SX@/'-T<F]N9SY.;W1E
M(#8@+2!);G9E<W1M96YT<SPO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X)SX@/'-T<F]N9SXF;F)S
M<#L\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I
M9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@26YV97-T
M;65N=',@8VQA<W-I9FEE9"!A<R!A=F%I;&%B;&4M9F]R+7-A;&4@87,@;V8@
M4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"!$96-E;6)E<B`S,2P@,C`Q,B!W97)E
M(&-O;7!R:7-E9"!O9B`H:6X@=&AO=7-A;F1S*3H\+W`^(#QP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%
M3E0Z(#`N-6EN)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G0D]21$52
M+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@5TE$5$@Z(#$P,"4G(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[
M(%1%6%0M04Q)1TXZ(&-E;G1E<B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!C96YT97(G
M(&-O;'-P86X],T0Q-#X\<W1R;VYG/E-E<'1E;6)E<B`S,"P@,C`Q,SPO<W1R
M;VYG/CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!4
M15A4+4%,24=..B!C96YT97(G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!C96YT97(G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60[($9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!C
M;VQS<&%N/3-$,30^/'-T<F]N9SY$96-E;6)E<B`S,2P@,C`Q,CPO<W1R;VYG
M/CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!415A4
M+4%,24=..B!C96YT97(G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5-)6D4Z(#$P<'0[
M(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(^/'-T<F]N9SY!;6]R
M=&EZ960@0V]S=#PO<W1R;VYG/CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U325I%.B`Q,'!T.R!4
M15A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R/CQS=')O;F<^1W)O<W,@
M56YR96%L:7IE9"!'86EN<SPO<W1R;VYG/CPO=&0^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U325I%.B`Q
M,'!T.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R/CQS=')O;F<^
M1W)O<W,@56YR96%L:7IE9"!,;W-S97,\+W-T<F]N9SX\+W1D/B`\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M
M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,CX\
M<W1R;VYG/D9A:7(@5F%L=64\+W-T<F]N9SX\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M4TE:13H@
M,3!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,CX\<W1R;VYG
M/D%M;W)T:7IE9"!#;W-T/"]S=')O;F<^/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5-)6D4Z(#$P
M<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(^/'-T<F]N9SY'
M<F]S<R!5;G)E86QI>F5D($=A:6YS/"]S=')O;F<^/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5-)
M6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(^/'-T
M<F]N9SY'<F]S<R!5;G)E86QI>F5D($QO<W-E<SPO<W1R;VYG/CPO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@
M1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X]
M,T0R/CQS=')O;F<^1F%I<B!686QU93PO<W1R;VYG/CPO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\
M='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.
M1"U#3TQ/4CH@(V-C9F9C8R<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%!!1$1)3D<M3$5&5#H@.7!T.R!415A4+4E.1$5.5#H@+3EP=#L@5TE$
M5$@Z(#(P)2<^($%U8W1I;VX@<F%T92!S96-U<FET:65S/"]T9#X@/'1D('-T
M>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`W
M)2<^(#$L,3<U/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#$E)SXD/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG
M:'0[(%=)1%1(.B`W)2<^-C`Q/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q
M)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#$E
M)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!
M3$E'3CH@<FEG:'0[(%=)1%1(.B`W)2<^+3PO=&0^(#QT9"!S='EL93TS1"=7
M24142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)
M1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@-R4G/B`Q+#<W-CPO=&0^(#QT
M9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[(%=)1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@-R4G/B`Q
M+#$W-3PO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`Q)2<^)#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R!7
M24142#H@-R4G/C0P.3PO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`Q)2<^)#PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ
M(')I9VAT.R!724142#H@-R4G/BT\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z
M(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!724142#H@
M,24G/B0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4
M+4%,24=..B!R:6=H=#L@5TE$5$@Z(#<E)SX@,2PU.#0\+W1D/B`\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4]
M,T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@
M=VAI=&4G/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'
M+4Q%1E0Z(#EP=#L@5$585"U)3D1%3E0Z("TY<'0G/B!#;W)P;W)A=&4@9&5B
M="!S96-U<FET:65S/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M4TE:13H@,3!P
M=#L@5$585"U!3$E'3CH@<FEG:'0G/B`R,BPQ,S<\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[($9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/B`T/"]T
M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ
M(')I9VAT)SX@+3PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U325I%.B`Q,'!T
M.R!415A4+4%,24=..B!R:6=H="<^(#(R+#$T,3PO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9#L@1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^(#,Q+#,T
M,#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U325I%.B`Q,'!T.R!415A4+4%,
M24=..B!R:6=H="<^(#(Q/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5-)6D4Z
M(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SX@+3PO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9#L@1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^(#,Q+#,V
M,3PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S
M<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C9F9C8R<^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^5&]T
M86P\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXR-7!T(&1O=6)L93L@1D].5"U325I%.B`Q,'!T)SX@)#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!&
M3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,C,L,S$R/"]T
M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N
M,C5P="!D;W5B;&4[($9/3E0M4TE:13H@,3!P="<^("0\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXR-7!T(&1O=6)L93L@1D].
M5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^(#8P-3PO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE.R!&3TY4+5-)6D4Z(#$P<'0G/B`D/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N,C5P="!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(')I9VAT)SX@/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXM
M/"]F;VYT/B`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N
M-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXR-7!T(&1O=6)L93L@1D].5"U325I%.B`Q,'!T)SX@)#PO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE.R!&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SX@
M,C,L.3$W/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N,C5P="!D;W5B;&4[($9/3E0M4TE:13H@,3!P="<^("0\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXR-7!T(&1O
M=6)L93L@1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^(#,R
M+#4Q-3PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU
M<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE.R!&3TY4+5-)6D4Z(#$P<'0G/B`D/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4[($9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/B`T,S`\
M+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXR-7!T(&1O=6)L93L@1D].5"U325I%.B`Q,'!T)SX@)#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!&
M3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SX@+3PO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE.R!&3TY4+5-)6D4Z(#$P<'0G/B`D/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N,C5P="!D;W5B;&4[($9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/B`S,BPY-#4\+W1D/B`\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\
M+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XZ(#!P="`P<'@G/B`\<W1R;VYG/B9N8G-P.SPO<W1R;VYG/CPO<#X@
M/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,C0Y.#9C9C-?,34Y,%\T-3(Q
M7V)E8V5?,V-B,&8W,#`T8C<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-"]7;W)K
M<VAE971S+U-H965T,30N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY';V]D=VEL;"!A;F0@3W1H97(@26YT86YG:6)L92!!<W-E
M=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY';V]D=VEL;"!A;F0@3W1H97(@26YT86YG:6)L92!!<W-E=',@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1V]O9'=I;&P@86YD($]T:&5R($EN=&%N9VEB;&4@07-S971S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/"$M+41/0U194$4@:'1M
M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO
M+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M
M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G
M;65N="TM/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G/B`\<W1R;VYG/DYO
M=&4@-R`M($=O;V1W:6QL(&%N9"!/=&AE<B!);G1A;F=I8FQE($%S<V5T<SPO
M<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X)SX@/'-T<F]N
M9SXF;F)S<#L\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XR-6EN)SX@/'-T<F]N9SX\
M96T^1V]O9'=I;&P\+V5M/CPO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X)SX@/'-T<F]N9SXF;F)S<#L\+W-T<F]N9SX\+W`^(#QP('-T
M>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE
M(&-H86YG97,@:6X@=&AE(&-A<G)Y:6YG(&%M;W5N=',@;V8@9V]O9'=I;&P@
M9F]R('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,@
M86YD(#(P,3(@=V5R92!A<R!F;VQL;W=I;F<@*&EN('1H;W5S86YD<RDZ/"]P
M/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G/B`F;F)S<#L\+W`^(#QT86)L
M92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM3$5&
M5#H@,"XU:6X[(%=)1%1(.B`Y,"4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M
M)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@4$%$1$E.1RU,1494.B`P<'@[(%1%6%0M24Y$14Y4.B`P<'@G
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
M=#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B!B
M;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&-O;'-P
M86X],T0V/B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE.+51/4#H@,'!T)SX@/'-T<F]N9SY.:6YE($UO
M;G1H<R!%;F1E9#PO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!415A4+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU43U`Z(#!P="<^
M(#QS=')O;F<^4V5P=&5M8F5R(#,P+#PO<W1R;VYG/CPO<#X@/"]T9#X@/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0Z(&)O;&0@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO=&0^
M(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU,1494.B`P
M<'@[(%1%6%0M24Y$14Y4.B`P<'@G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.
M1RU"3U143TTZ(#%P="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@
M1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A
M;CTS1#(^,C`Q,SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)SX@)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B`F;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,
M24=..B!C96YT97(G(&-O;'-P86X],T0R/C(P,3(\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.
M1RU"3U143TTZ(#%P="<^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R
M9V(H,C`T+#(U-2PR,#0I)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@[(%=)1%1(
M.B`W,B4[(%1%6%0M24Y$14Y4.B`P<'@G/B!"96=I;FYI;F<@8F%L86YC93PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`R)2<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58
M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q
M,"4G/B`S,RPQ-#$\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!415A4+4%,24=..B!L969T.R!724142#H@,24G/B`F;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!724142#H@,B4G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)
M1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SX@
M,S,L,30Q/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58
M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB<W`[/"]T9#X@/"]T<CX@
M/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5
M3D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@[(%1%6%0M
M24Y$14Y4.B`P<'@G/B!';V]D=VEL;"!R97-U;'1I;F<@9G)O;2!A8W%U:7-I
M=&EO;B!O9B!B=7-I;F5S<SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXR-2PR.3@\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^+3PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I
M)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@[
M(%1%6%0M24Y$14Y4.B`P<'@G/B!#=7)R96YC>2!T<F%N<VQA=&EO;CPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!
M3$E'3CH@<FEG:'0G/B`S,C`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T
M)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^("T\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4
M+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$
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M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#4X
M+#<U.3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)
M3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]4
M5$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!4
M15A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@
M5$585"U!3$E'3CH@<FEG:'0G/B`S,RPQ-#$\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M
M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B
M*#(P-"PR-34L,C`T*2<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%!!1$1)3D<M3$5&5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@
M;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
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M(%1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D
M/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3CH@,'!T(#!P>"`P<'0@,"XR-6EN)SX@/'-T<F]N9SX\96T^261E;G1I9FEA
M8FQE($EN=&%N9VEB;&4@07-S971S/"]E;3X\+W-T<F]N9SX\+W`^(#QP('-T
M>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3CH@,'!T(#!P>"<^(#QS=')O;F<^)FYB<W`[/"]S=')O;F<^
M/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P
M+C5I;B<^($ED96YT:69I86)L92!I;G1A;F=I8FQE(&%S<V5T<R!C;VYS:7-T
M960@;V8@=&AE(&9O;&QO=VEN9R!A<R!O9B!397!T96UB97(@,S`L(#(P,3,@
M*&EN('1H;W5S86YD<RDZ/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G
M/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z
M(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XM3$5&5#H@,"XU:6X[(%=)1%1(.B`Y,"4G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(%!!1$1)3D<M3$5&5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B`F;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4
M+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R/CQS=')O;F<^1W)O<W,@0V%R
M<GEI;F<@06UO=6YT/"]S=')O;F<^/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M(&-O;'-P86X],T0R/B`\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!
M4D=)3CH@,'!T(#!P>"<^(#QS=')O;F<^06-C=6UU;&%T960@06UO<G1I>F%T
M:6]N/"]S=')O;F<^/"]P/B`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P=#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)R!C;VQS<&%N/3-$,CX@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XZ(#!P="`P<'@G/B`\<W1R;VYG/DEN=&%N9VEB;&4\+W-T
M<F]N9SX\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X)SX@/'-T<F]N9SY!<W-E=',L($YE=#PO<W1R;VYG/CPO<#X@
M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0Z
M(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N
M8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I)SX@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU,1494.B`P<'@[(%1%6%0M24Y$14Y4.B`P<'@G/B!&:6YI
M=&4M;&EV960@:6YT86YG:6)L92!A<W-E=',Z/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@
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M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!4
M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58
M5"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$
M)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H
M:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@[(%=)1%1(.B`U."4[(%1%6%0M
M24Y$14Y4.B`P<'@G/B!0<F]P<FEE=&%R>2!A9&IU=F%N="!T96-H;F]L;V=Y
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!4
M15A4+4%,24=..B!L969T.R!724142#H@,24G/B0\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z
M(#$P)2<^(#$Q+#4Y-#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`R)2<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G
M/B@Y-SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M
M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^*3PO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`R)2<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$
M5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B`Q,2PT.3<\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T
M.R!724142#H@,24G/B`F;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B
M*#(P-"PR-34L,C`T*2<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M3$5&5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@0V]L;&%B;W)A=&EO
M;B!A9W)E96UE;G1S/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#0L.3DR/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P
M=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G
M/B`H.#0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$
M24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T)SX@*3PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q
M<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@
M;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0G/B`T+#DP.#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE9G0G
M/B`F;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4G/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[
M(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@,'!X.R!415A4+4E.
M1$5.5#H@,'!X)SX@5&]T86P@:61E;G1I9FEA8FQE(&EN=&%N9VEB;&4@87-S
M971S/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.
M1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U
M8FQE.R!415A4+4%,24=..B!R:6=H="<^(#$V+#4X-CPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@
M5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@
M)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G
M/B`H,3@Q/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@*3PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-
M.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4
M+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$58
M5"U!3$E'3CH@<FEG:'0G/B`Q-BPT,#4\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL
M93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XZ(#!P="`P<'@G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z
M(#`N-6EN)SX@06UO<G1I>F%T:6]N(&5X<&5N<V4@9F]R('1H92!N:6YE(&UO
M;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,@=V%S("0P+C(@;6EL;&EO
M;BX@17-T:6UA=&5D(&%M;W)T:7IA=&EO;B!E>'!E;G-E(&9O<B!E>&ES=&EN
M9R!I;G1A;F=I8FQE(&%S<V5T<R!F;W(@=&AE(')E;6%I;F1E<B!O9B`R,#$S
M(&%N9"!F;W(@96%C:"!O9B!T:&4@9FEV92!S=6-C965D:6YG('EE87)S(&5N
M9&EN9R!$96-E;6)E<B`S,2QW:6QL(&)E(&%S(&9O;&QO=W,@*&EN('1H;W5S
M86YD<RDZ/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G/B`F;F)S<#L\
M+W`^(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!7
M24142#H@,3`P)2<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@
M/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!L969T
M.R!0041$24Y'+4Q%1E0Z(#!P>"<^(%EE87(\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"
M3U143TTZ(#%P="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].
M5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS
M1#(^06UO=6YT/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B`F;F)S
M<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M3$5&5#H@,'!X.R!724142#H@,3,E)SX@,C`Q,R`H<F5M86EN
M9&5R*3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(
M.B`W-"4G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`R)2<^)#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R!7
M24142#H@,3`E)SXR-S$\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!415A4+4%,24=..B!L969T.R!724142#H@,24G/B`F;F)S<#L\+W1D
M/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4G/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!415A4+4%,24=..B!L969T.R!0041$24Y'+4Q%1E0Z(#!P
M>"<^(#(P,30\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^,2PP.#0\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@,C`Q-3PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I
M9VAT)SXQ+#`X-#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2
M.B!W:&ET92<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@,C`Q-CPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86P[($9/3E0M4U193$4Z
M(&YO<FUA;"<^)FYB<W`[/"]F;VYT/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M5T5)1TA4
M.B!N;W)M86P[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,2PP.#0\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SX\
M9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L.R!&3TY4+5-464Q%
M.B!N;W)M86PG/B9N8G-P.SPO9F]N=#X@/"]T9#X@/"]T<CX@/'1R('-T>6QE
M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z
M(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!415A4+4%,24=..B!L969T.R!0041$24Y'+4Q%1E0Z(#!P>"<^(#(P
M,3<\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=.
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M3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU,1494.B`P<'@G/B`R,#$X/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U714E'2%0Z(&YO<FUA;#L@1D].5"U35%E,13H@;F]R;6%L)SXF
M;F)S<#L\+V9O;G0^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U714E'2%0Z(&YO<FUA;#L@
M5$585"U!3$E'3CH@<FEG:'0G/B`Q+#`X-#PO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^
M(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"<^("9N
M8G-P.SPO<#X@/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,C0Y.#9C9C-?
M,34Y,%\T-3(Q7V)E8V5?,V-B,&8W,#`T8C<T#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P
M-&(W-"]7;W)K<VAE971S+U-H965T,34N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T
M;V-K:&]L9&5R<R<@17%U:71Y(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K:&]L9&5R<R<@17%U
M:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/"$M+41/0U19
M4$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET
M:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X
M:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A
M<G1&<F%G;65N="TM/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G/B`\<W1R
M;VYG/DYO=&4@."`M(%-T;V-K:&]L9&5R<R8C,SD[($5Q=6ET>3PO<W1R;VYG
M/CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X)SX@)FYB<W`[/"]P/B`\
M<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[
M(%1%6%0M24Y$14Y4.B`P+C5I;B<^($]N($IU;F4@,3,L(#(P,3,L('1H92!#
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M9G)O;2`R,#`L,#`P+#`P,"!S:&%R97,@=&\@,S`P+#`P,"PP,#`@<VAA<F5S
M+CPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P
M<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B`F;F)S<#L\+W`^(#QP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$58
M5"U)3D1%3E0Z(#`N-6EN)SX@26X@3V-T;V)E<B`R,#$R+"!T:&4@0V]M<&%N
M>2!E;G1E<F5D(&EN=&\@86X@070@36%R:V5T($ES<W5A;F-E(%-A;&5S($%G
M<F5E;65N="`H(C(P,3(@4V%L97,@06=R965M96YT(BDL('5N9&5R('=H:6-H
M('1H92!";V%R9"!O9B!$:7)E8W1O<G,@;V8@=&AE($-O;7!A;GD@*'1H92`B
M0F]A<F0B*2!A<'!R;W9E9"!T:&4@0V]M<&%N>28C,SD[<R!S86QE(&]F('5P
M('1O(&%N(&%G9W)E9V%T92!O9B`D-3`@;6EL;&EO;B!I;B!G<F]S<R!P<F]C
M965D<R!O9B!I=',@8V]M;6]N('-T;V-K+B!4:&4@<VAA<F5S(&]F(&-O;6UO
M;B!S=&]C:R!A<F4@8F5I;F<@;V9F97)E9"!P=7)S=6%N="!T;R!A('-H96QF
M(')E9VES=')A=&EO;B!S=&%T96UE;G0@9FEL960@=VET:"!T:&4@4T5#(&EN
M($UA<F-H(#(P,3,L('=H:6-H(')E<&QA8V5D('1H92!P<F5V:6]U<R!S:&5L
M9B!R96=I<W1R871I;VX@<W1A=&5M96YT(&9I;&5D(&EN(#(P,3`N(%1H92!"
M;V%R9"8C,SD[<R!S=&%N9&EN9R!&:6YA;F-E($-O;6UI='1E92`H=&AE(")#
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M=&AE(&-O;6UO;B!S=&]C:R!S;VQD('!U<G-U86YT('1O('1H92`R,#$R(%-A
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M<B`S,"P@,C`Q,RP@=&AE($-O;7!A;GD@<V]L9"`Q,BXV(&UI;&QI;VX@<VAA
M<F5S(&%T('-A;&5S('!R:6-E<R!R86YG:6YG(&9R;VT@)#(N,#8@=&\@)#,N
M,S@@<&5R('-H87)E+"!R97-U;'1I;F<@:6X@)#,T+C`@;6EL;&EO;B!I;B!N
M970@<')O8V5E9',N(%1H92!M;W-T(')E8V5N="!S86QE<R!T;R!O8V-U<B!U
M;F1E<B!T:&4@,C`Q,B!386QE<R!!9W)E96UE;G0@=V5R92!O;B!397!T96UB
M97(@,3`L(#(P,3,N/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T
M:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^("9N8G-P
M.SPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P
M<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B!);B!397!T96UB97(@,C`Q
M,RP@=&AE($-O;7!A;GD@8V]M<&QE=&5D(&$@<'5B;&EC(&]F9F5R:6YG(&]F
M(#,Q+#@T-BPY-3`@<VAA<F5S(&]F(&ET<R!C;VUM;VX@<W1O8VLL(&EN8VQU
M9&EN9R`T+#$U,RPY-3`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!T:&%T('=E
M<F4@:7-S=65D('5P;VX@=&AE(&5X97)C:7-E(&EN(&9U;&P@;V8@=&AE(&]V
M97(M86QL;W1M96YT(&=R86YT960@=&\@=&AE('5N9&5R=W)I=&5R<RP@870@
M82!P<FEC92!O9B`D,RXQ-"!P97(@<VAA<F4@<F5S=6QT:6YG(&EN(&YE="!P
M<F]C965D<R!O9B!A<'!R;WAI;6%T96QY("0Y-"XW(&UI;&QI;VXN/"]P/B`\
M<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[
M(%1%6%0M24Y$14Y4.B`P+C5I;B<^("9N8G-P.SPO<#X@/"$M+45N9$9R86=M
M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W
M,#`T8C<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S(T.3@V8V8S
M7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-"]7;W)K<VAE971S+U-H965T
M,38N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M=&]C:RU"87-E9"!#;VUP96YS871I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS
M871I;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/"$M+41/0U194$4@:'1M;"!0
M54),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.
M(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A
M;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N
M="TM/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P
M="`P<'@G/B`\<W1R;VYG/DYO=&4@.2`M(%-T;V-K+4)A<V5D($-O;7!E;G-A
M=&EO;CPO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S
M=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@34%21TE..B`P<'0@,'!X)SX@/'-T<F]N9SXF;F)S<#L\+W-T<F]N9SX\
M+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T
M(#!P>"`P<'0@,"XR-6EN)SX@/'-T<F]N9SX\96T^4W1O8VL@3W!T:6]N<SPO
M96T^/"]S=')O;F<^/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T
M:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XZ(#!P="`P<'@G/B`\<W1R;VYG/B9N8G-P.SPO<W1R;VYG/CPO
M<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@
M,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B!4:&4@0V]M<&%N>2!H87,@9W)A
M;G1E9"!E<75I='D@87=A<F1S('5N9&5R('-E=F5R86P@<&QA;G,L('1W;R!O
M9B!W:&EC:"!R96UA:6X@86-T:79E+B!5;F1E<B!T:&4@,C`P-2!3=&]C:R!)
M;F-E;G1I=F4@4&QA;B`H=&AE("(R,#`U(%!L86XB*2P@97%U:71Y(&%W87)D
M<R!M87D@8F4@9W)A;G1E9"!T;R!O9F9I8V5R<RP@9&ER96-T;W)S+"!E;7!L
M;WEE97,L(&-O;G-U;'1A;G1S(&%N9"!A9'9I<V]R<R!T;R!T:&4@0V]M<&%N
M>2!A;F0@86YY('!R97-E;G0@;W(@9G5T=7)E('-U8G-I9&EA<GDN(%1H92`R
M,#`U(%!L86XL(&%P<')O=F5D(&EN($UA>2`R,#`U(&%N9"!A;65N9&5D(&EN
M($IU;F4@,C`P-RP@2G5N92`R,#$Q+"!*=6YE(#(P,3(@86YD($IU;F4@,C`Q
M,R!B>2!T:&4@0V]M<&%N>28C,SD[<R!S=&]C:VAO;&1E<G,L(&-U<G)E;G1L
M>2!A=71H;W)I>F5S('1H92!G<F%N="!O9B!E<75I='D@87=A<F1S(&9O<B!U
M<"!T;R`R,BPS,3(L,3DR('-H87)E<R!O9B!C;VUM;VX@<W1O8VLL('=H:6-H
M(&EN8VQU9&5D+"!A="!T:&4@=&EM92!O9B!A<'!R;W9A;"!O9B!T:&4@,C`P
M-2!0;&%N+"!A(&UA>&EM=6T@-2PW-#8L-#8X('-H87)E<R!O9B!C;VUM;VX@
M<W1O8VL@<W5B:F5C="!T;R!S=&]C:R!O<'1I;VYS(&]U='-T86YD:6YG('5N
M9&5R('1H92!#;VUP86YY)B,S.3MS(#$Y.34@4W1O8VL@3W!T:6]N(%!L86X@
M*'1H92`B,3DY-2!0;&%N(BD@=&AA="!M87D@<F5V97)T('1O(&%N9"!B96-O
M;64@:7-S=6%B;&4@=6YD97(@=&AE(#(P,#4@4&QA;B!I9B!S=6-H(&]P=&EO
M;G,@97AP:7)E(&]R(&]T:&5R=VES92!T97)M:6YA=&4@=6YE>&5R8VES960N
M(%1H92!#;VUP86YY(')E8V5I=F5D(&%P<')O=F%L(&%T(&ET<R`R,#$S(&%N
M;G5A;"!M965T:6YG(&]F('-T;V-K:&]L9&5R<R!T;R!I;F-R96%S92!T:&4@
M;G5M8F5R(&]F('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@879A:6QA8FQE(&9O
M<B!I<W-U86YC92!U;F1E<B!T:&4@,C`P-2!0;&%N(&)Y(#0L,#`P+#`P,"!S
M:&%R97,N(%1H92!T97)M(&]F('1H92!#;VUP86YY)B,S.3MS(#$Y.34@4&QA
M;B!H87,@97AP:7)E9"!A;F0@;F\@;F5W(&%W87)D<R!W:6QL(&)E(&UA9&4@
M=6YD97(@=&AE(#$Y.34@4&QA;CL@:&]W979E<BP@;W5T<W1A;F1I;F<@<W1O
M8VL@;W!T:6]N<R!R96UA:6X@:6X@97AI<W1E;F-E(&EN(&%C8V]R9&%N8V4@
M=VET:"!T:&5I<B!T97)M<RX\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@
M)FYB<W`[/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^(%5N9&5R('1H92`R
M,#`U(%!L86X@86YD('1H92`Q.3DU(%!L86XL(&EN8V5N=&EV92!S=&]C:R!O
M<'1I;VYS+"!H879I;F<@82!M87AI;75M('1E<FT@;V8@,3`@>65A<G,L(&-A
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M('!R:6-E(&9O<B!N;VXM<W1A='5T;W)Y('-T;V-K(&]P=&EO;G,N/"]P/B`\
M<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N,C5I;CL@5$585"U)3D1%
M3E0Z(#!I;B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X
M(#!P="`P+C(U:6X[(%1%6%0M24Y$14Y4.B`P:6XG/B`\<W1R;VYG/CQE;3Y3
M=&]C:R!/<'1I;VYS($%W87)D<SPO96T^/"]S=')O;F<^/"]P/B`\<"!S='EL
M93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N,C5I;CL@5$585"U)3D1%3E0Z(#!I
M;B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!415A4
M+4E.1$5.5#H@,"XU:6XG/B!4:&4@9F]L;&]W:6YG(&ES(&$@<W5M;6%R>2!O
M9B!O<'1I;VX@86-T:79I='D@=6YD97(@=&AE(#(P,#4@4&QA;B!A;F0@=&AE
M(#$Y.34@4&QA;B!F;W(@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E
M<B`S,"P@,C`Q,SH\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$58
M5"U)3D1%3E0Z(#`N-6EN)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G
M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@5TE$5$@Z(#$P,"4G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@4$%$1$E.1RU,1494.B`P<'@[(%1%6%0M24Y$14Y4.B`P<'@G/B`F;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P="<^("9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#8^,C`P-2!3=&]C:R!);F-E;G1I=F4@
M4&QA;CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)SX@)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z
M(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B`F;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C
M96YT97(G(&-O;'-P86X],T0V/C$Y.34@4W1O8VL@3W!T:6]N(%!L86X\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P="<^("9N8G-P.SPO=&0^(#PO='(^
M(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@
M5$585"U!3$E'3CH@8V5N=&5R.R!0041$24Y'+4Q%1E0Z(#!P>"<^("9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!C
M96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R/CQS
M=')O;F<^4W1O8VL@3W!T:6]N<SPO<W1R;VYG/CPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'
M+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R
M)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#%P="!S;VQI9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,CX\<W1R;VYG
M/E=E:6=H=&5D+4%V97)A9V4@17AE<F-I<V4@4')I8V4\+W-T<F]N9SX\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R
M)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M
M04Q)1TXZ(&-E;G1E<B<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A
M;CTS1#(^/'-T<F]N9SY3=&]C:R!/<'1I;VYS/"]S=')O;F<^/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^("9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=.
M.B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
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M.B!C96YT97(G/B`F;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P
M-"PR-34L,C`T*2<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!
M1$1)3D<M3$5&5#H@,'!X.R!724142#H@-#0E.R!415A4+4E.1$5.5#H@,'!X
M)SX@3W5T<W1A;F1I;F<@870@2F%N=6%R>2`Q+"`R,#$S/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L
M969T.R!724142#H@,24G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$P)2<^
M(#DL,30S+#@R-3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`R)2<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'
M3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B`Q
M+C@W/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T
M.R!724142#H@,24G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$P)2<^(#(Q
M,2PY,#`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4
M+4%,24=..B!L969T.R!724142#H@,24G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!724142#H@,B4G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE
M9G0[(%=)1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SX@-"XY-#PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ
M(&QE9G0[(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2
M.B!W:&ET92<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)
M3D<M3$5&5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@1W)A;G1E9#PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-
M.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&YO<FUA;#L@1D].5"U35%E,13H@;F]R;6%L)SXF;F)S<#L\+V9O
M;G0^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U714E'2%0Z(&YO<FUA;#L@5$585"U!3$E'
M3CH@<FEG:'0G/B`T+#$Q-RPU,#`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
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M5$585"U!3$E'3CH@<FEG:'0G/B`Q+CDR/"]T9#X@/'1D('-T>6QE/3-$)T9/
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M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!
M3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@
M/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!
M0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4Q%1E0Z(#!P>#L@5$585"U)
M3D1%3E0Z(#!P>"<^($5X97)C:7-E9#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@
M;&5F="<^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;#L@1D].
M5"U35%E,13H@;F]R;6%L)SXF;F)S<#L\+V9O;G0^(#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].
M5"U714E'2%0Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0G/B`H-3(R+#(Y
M,CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4U19
M3$4Z(&YO<FUA;#L@1D].5"U714E'2%0Z(&YO<FUA;#L@5$585"U!3$E'3CH@
M;&5F="<^("D\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4
M+4%,24=..B!L969T)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/C(N,CD\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!415A4+4%,24=..B!R:6=H="<^+3PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B0\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=.
M.B!R:6=H="<^+3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2
M.B!W:&ET92<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)
M3D<M0D]45$]-.B`Q<'0[(%!!1$1)3D<M3$5&5#H@,'!X.R!415A4+4E.1$5.
M5#H@,'!X)SX@0V%N8V5L960\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@*#@P,BPX.#,\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/
M5%1/33H@,7!T.R!415A4+4%,24=..B!L969T)SX@*3PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^
M("0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@
M,2XW-#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)
M3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/
M33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(')I9VAT)SX@*#(S+#<U,#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ
M(&QE9G0G/B`I/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9#L@5$585"U!3$E'3CH@<FEG:'0G/B`T+C`U/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!
M3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R9V(H
M,C`T+#(U-2PR,#0I)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!0041$24Y'+4Q%1E0Z(#!P>#L@5$58
M5"U)3D1%3E0Z(#!P>"<^($]U='-T86YD:6YG(&%T(%-E<'1E;6)E<B`S,"P@
M,C`Q,SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)
M3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U
M8FQE.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#$Q+#DS-BPQ-3`\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/
M33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU
M<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'
M3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(')I9VAT)SX@,2XX.#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F
M="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#$X."PQ-3`\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/
M5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@
M,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!
M3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(')I9VAT)SX@-2XP-#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@
M;&5F="<^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!W:&ET92<^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P=#L@4$%$1$E.1RU,1494.B`P<'@[(%1%6%0M24Y$14Y4.B`P<'@G/B!3
M:&%R97,@97AE<F-I<V%B;&4@870@4V5P=&5M8F5R(#,P+"`R,#$S/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(')I9VAT)SX@-"PV-#<L.#<S/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!4
M15A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^
M(#(N,3(\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$
M24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/
M5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@
M5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`Q.#@L,34P/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T
M.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G
M/B`D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M="<^(#4N,#0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0
M041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S
M<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M3$5&5#H@,'!X
M.R!415A4+4E.1$5.5#H@,'!X)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@
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M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!4
M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58
M5"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T
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M92!F;W(@9W)A;G0@870@4V5P=&5M8F5R(#,P+"`R,#$S/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0G/B`\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L.R!&
M3TY4+5-464Q%.B!N;W)M86PG/B9N8G-P.SPO9F]N=#X@/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M5T5)1TA4
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M1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4
M+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=.
M.B!R:6=H="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F
M="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!4
M15A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,
M24=..B!R:6=H="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@
M;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T
M.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4
M+4%,24=..B!R:6=H="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'
M3CH@;&5F="<^("9N8G-P.SPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE
M/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB<W`[
M)FYB<W`[/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^(%1H92!F86ER('9A
M;'5E(&]F('-T;V-K(&]P=&EO;G,@9W)A;G1E9"!W87,@97-T:6UA=&5D(&%T
M('1H92!D871E(&]F(&=R86YT('5S:6YG('1H92!";&%C:RU38VAO;&5S(&]P
M=&EO;BUP<FEC:6YG(&UO9&5L('=I=&@@=&AE(&9O;&QO=VEN9R!A<W-U;7!T
M:6]N<SH\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB<W`[/"]P/B`\
M=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@5TE$5$@Z
M(#$P,"4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S
M='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%
M6%0M04Q)1TXZ(&-E;G1E<B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<@8V]L<W!A;CTS1#8^(#QP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X)SX@
M/'-T<F]N9SY4:')E92!-;VYT:',@16YD960\+W-T<F]N9SX\+W`^(#QP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X)SX@/'-T
M<F]N9SY397!T96UB97(@,S`L/"]S=')O;F<^/"]P/B`\+W1D/B`\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
M=#L@5$585"U!3$E'3CH@8V5N=&5R)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)R!C;VQS<&%N/3-$
M-CX@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P
M<'@G/B`\<W1R;VYG/DYI;F4@36]N=&AS($5N9&5D/"]S=')O;F<^/"]P/B`\
M<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"<^
M(#QS=')O;F<^4V5P=&5M8F5R(#,P+#PO<W1R;VYG/CPO<#X@/"]T9#X@/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E
M;G1E<B<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5-)
M6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(^/'-T
M<F]N9SXR,#$S/"]S=')O;F<^/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ
M(&-E;G1E<B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U325I%.B`Q,'!T.R!415A4+4%,
M24=..B!C96YT97(G(&-O;'-P86X],T0R/CQS=')O;F<^,C`Q,CPO<W1R;VYG
M/CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!415A4
M+4%,24=..B!C96YT97(G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!C96YT97(G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[($9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS
M<&%N/3-$,CX\<W1R;VYG/C(P,3,\+W-T<F]N9SX\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@
M5$585"U!3$E'3CH@8V5N=&5R)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5-)6D4Z(#$P
M<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(^/'-T<F]N9SXR
M,#$R/"]S=')O;F<^/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^)FYB<W`[/"]T9#X@/"]T<CX@
M/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5
M3D0M0T],3U(Z("-C8V9F8V,G/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!724142#H@-#0E)SY796EG:'1E9"UA=F5R86=E(&9A:7(@=F%L=64@
M;V8@<W1O8VL@;W!T:6]N<R!G<F%N=&5D/"]T9#X@/'1D('-T>6QE/3-$)U=)
M1%1(.B`R)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B`Q+C0Q
M/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U=)1%1(.B`R)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(
M.B`Q,"4G/B`Q+C`Y/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`R)2<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#$E)SXD/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@
M<FEG:'0[(%=)1%1(.B`Q,"4G/B`Q+C`R/"]T9#X@/'1D('-T>6QE/3-$)U=)
M1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`R)2<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$
M5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B`P+C<Q/"]T9#X@/'1D
M('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],
M3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^4FES
M:RUF<F5E(&EN=&5R97-T(')A=&4\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%
M6%0M04Q)1TXZ(')I9VAT)SXQ+C$R)2TQ+C,V/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P="<^)3PO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58
M5"U!3$E'3CH@<FEG:'0G/C`N-34\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T)SXE/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=.
M.B!R:6=H="<^,"XU-"4M,2XS-CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0G/B4\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ
M(')I9VAT)SXP+C4U)2TQ+C4T/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P="<^)3PO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-F9F-C)SX@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^1&EV:61E;F0@>6EE;&0\+W1D
M/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXP/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)3PO=&0^(#QT9#XF;F)S
M<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/C`\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T)SXE/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT
M9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!4
M15A4+4%,24=..B!R:6=H="<^,#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0G/B4\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ
M(')I9VAT)SXP/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^
M)3PO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!W:&ET92<^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0G/E9O;&%T:6QI='D\+W1D/B`\=&0^)FYB<W`[/"]T
M9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXU-BXW-24M-C(N-3$\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXE/"]T9#X@/'1D/B9N8G-P.SPO
M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!415A4+4%,24=..B!R:6=H="<^-S8N-C`E+3<V+C<Q/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)3PO=&0^(#QT9#XF;F)S<#L\
M+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/C4U+C@Q)2TW,RXW,CPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B4\+W1D/B`\=&0^)FYB<W`[
M/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXW-2XT-R4M.#`N-#@\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXE/"]T9#X@/"]T<CX@/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M
M0T],3U(Z("-C8V9F8V,G/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M)SY%>'!E8W1E9"!T97)M("AI;B!Y96%R<RD\+W1D/B`\=&0^)FYB<W`[/"]T
M9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXT+C(U/"]T9#X@/'1D/B9N8G-P.SPO
M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/C0N,C0\
M+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9#XF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,
M24=..B!R:6=H="<^,RXY."TW+C`U/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT
M9#XF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/C,N,S0M-RXP.3PO
M=&0^(#QT9#XF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4G/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SY%>'!E8W1E9"!F;W)F96ET
M=7)E(')A=&4\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I
M9VAT)SXR,RXQ-3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G
M/B4\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXR
M,RXQ-3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B4\+W1D
M/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXP)2TR,RXQ
M-3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B4\+W1D/B`\
M=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXP)2TR,RXQ-3PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B4\+W1D/B`\+W1R
M/B`\+W1A8FQE/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^("9N8G-P.SPO<#X@
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X
M.R!415A4+4E.1$5.5#H@,"XU:6XG/B!4:&4@86=G<F5G871E(&EN=')I;G-I
M8R!V86QU92!A;F0@=V5I9VAT960M879E<F%G92!R96UA:6YI;F<@8V]N=')A
M8W1U86P@=&5R;2!O9B!S=&]C:R!O<'1I;VYS(&]U='-T86YD:6YG(&%S(&]F
M(%-E<'1E;6)E<B`S,"P@,C`Q,R!W87,@87!P<F]X:6UA=&5L>2`D,34N.2!M
M:6QL:6]N(&%N9"`W+C8@>65A<G,L(')E<W!E8W1I=F5L>2X@5&AE(&%G9W)E
M9V%T92!I;G1R:6YS:6,@=F%L=64@86YD('=E:6=H=&5D+6%V97)A9V4@<F5M
M86EN:6YG(&-O;G1R86-T=6%L('1E<FT@;V8@<W1O8VL@;W!T:6]N<R!E>&5R
M8VES86)L92!A<R!O9B!397!T96UB97(@,S`L(#(P,3,@=V%S(&%P<')O>&EM
M871E;'D@)#4N-2!M:6QL:6]N(&%N9"`U+CD@>65A<G,L(')E<W!E8W1I=F5L
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M97)S(&5X97)C:7-E9"!T:&5I<B!O<'1I;VYS(&]N(%-E<'1E;6)E<B`S,"P@
M,C`Q,RX@5&AI<R!A;6]U;G0@:7,@<W5B:F5C="!T;R!C:&%N9V4@8F%S960@
M;VX@8VAA;F=E<R!T;R!T:&4@9F%I<B!V86QU92!O9B!T:&4@0V]M<&%N>28C
M,SD[<R!C;VUM;VX@<W1O8VLN(%1H92!A9V=R96=A=&4@:6YT<FEN<VEC('9A
M;'5E(&]F(&]P=&EO;G,@97AE<F-I<V5D(&9O<B!T:&4@;FEN92!M;VYT:',@
M96YD960@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"`R,#$R('=A<R`D,"XS(&UI
M;&QI;VX@86YD(&QE<W,@=&AA;B`D,"XQ(&UI;&QI;VXL(')E<W!E8W1I=F5L
M>2X\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@
M,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB<W`[/"]P/B`\<"!S
M='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N,C5I;B<^(#QS=')O;F<^/&5M
M/D5M<&QO>65E(%-T;V-K(%!U<F-H87-E(%!L86X\+V5M/CPO<W1R;VYG/CPO
M<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`P+C(U:6XG/B`F;F)S
M<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@
M,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE($-O;7!A;GD@<F5C
M96EV960@87!P<F]V86P@870@:71S(#(P,3,@86YN=6%L(&UE971I;F<@;V8@
M<W1O8VMH;VQD97)S('1O(&%D;W!T(&%N($5M<&QO>65E(%-T;V-K(%!U<F-H
M87-E(%!L86X@*'1H92`B15-04"(I+"!W:&EC:"!C=7)R96YT;'D@875T:&]R
M:7IE<R!A;B!A9V=R96=A=&4@;V8@,BPP,#`L,#`P('-H87)E<R!O9B!#;VUM
M;VX@4W1O8VL@=&\@8F4@<'5R8VAA<V5D+B!4:&4@15-04"!A;&QO=W,@96UP
M;&]Y965S('1O('!U<F-H87-E('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@;V8@
M=&AE($-O;7!A;GD@870@96%C:"!P=7)C:&%S92!D871E('1H<F]U9V@@<&%Y
M<F]L;"!D961U8W1I;VYS(&]F('5P('1O(&$@;6%X:6UU;2!O9B`Q-24@;V8@
M=&AE:7(@8V]M<&5N<V%T:6]N+"!A="`X-24@;V8@=&AE(&QE<W-E<B!O9B!T
M:&4@;6%R:V5T('!R:6-E(&]F('1H92!S:&%R97,@870@=&AE('1I;64@;V8@
M<'5R8VAA<V4@;W(@=&AE(&UA<FME="!P<FEC92!O;B!T:&4@8F5G:6YN:6YG
M(&1A=&4@;V8@86X@;W!T:6]N('!E<FEO9"`H;W(L(&EF(&QA=&5R+"!T:&4@
M9&%T92!D=7)I;F<@=&AE(&]P=&EO;B!P97)I;V0@=VAE;B!T:&4@96UP;&]Y
M964@=V%S(&9I<G-T(&5L:6=I8FQE('1O('!A<G1I8VEP871E*2X@5&AE(&9I
M<G-T(&]P=&EO;B!P97)I;V0@=6YD97(@=&AE($534%`@8V]M;65N8V5D(&]N
M($%U9W5S="`Q+"`R,#$S+CPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE($534%`@:7,@
M8V]N<VED97)E9"!C;VUP96YS871O<GD@9F]R(&9I;F%N8VEA;"!R97!O<G1I
M;F<@<'5R<&]S97,N($%S('-U8V@L('1H92!F86ER('9A;'5E(&]F($534%`@
M<VAA<F5S('=A<R!E<W1I;6%T960@870@=&AE(&1A=&4@;V8@9W)A;G0@=7-I
M;F<@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N+7!R:6-I;F<@;6]D96P@=VET
M:"!T:&4@9F]L;&]W:6YG(&%S<W5M<'1I;VYS.CPO<#X@/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.
M5#H@,"XU:6XG/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"="3U)$15(M
M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!724142#H@-S4E)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<^(#QT9#XF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#,^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SX\<W1R;VYG/E1H<F5E($UO
M;G1H<R!%;F1E9#PO<W1R;VYG/CPO9F]N=#X@/&)R("\^(#QF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P="<^/'-T<F]N9SY397!T96UB97(@,S`L/"]S
M=')O;F<^/"]F;VYT/CPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97(G/B`\
M<W1R;VYG/C(P,3,\+W-T<F]N9SX\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97(G
M/B`F;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C9F9C8R<^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`W-R4G/E=E:6=H=&5D
M+6%V97)A9V4@9F%I<B!V86QU92!O9B!%4U!0('-H87)E<R!G<F%N=&5D/"]T
M9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[
M(%=)1%1(.B`R,"4G/B`P+C<X/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q
M)2<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^4FES:RUF<F5E(&EN=&5R97-T(')A
M=&4\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXP
M+C`T/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)3PO=&0^
M(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M04-+1U)/54Y$+4-/3$]2.B`C8V-F9F-C)SX@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P="<^1&EV:61E;F0@>6EE;&0\+W1D/B`\=&0^)FYB<W`[/"]T
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M/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXU,"XX,#PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B4\+W1D/B`\+W1R
M/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V-C9F9C8R<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0G/D5X<&5C=&5D('1E<FT@*&EN('EE87)S*3PO=&0^(#QT9#XF;F)S
M<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/C`N-3PO=&0^(#QT9#XF;F)S
M<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4G/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T)SY%>'!E8W1E9"!F;W)F96ET=7)E(')A=&4\+W1D
M/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXU/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)3PO=&0^(#PO='(^(#PO
M=&%B;&4^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@
M,'!T(#!P>"`P<'0@,"XR-6EN.R!415A4+4E.1$5.5#H@,&EN)SX@)FYB<W`[
M/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P
M="`P<'@@,'!T(#`N,C5I;CL@5$585"U)3D1%3E0Z(#!I;B<^(#QS=')O;F<^
M/&5M/E)E<W1R:6-T960@4W1O8VL@07=A<F1S/"]E;3X\+W-T<F]N9SX\+W`^
M(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P
M>"`P<'0@,"XR-6EN.R!415A4+4E.1$5.5#H@,&EN)SX@)FYB<W`[/"]P/B`\
M<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[
M(%1%6%0M24Y$14Y4.B`P+C5I;B<^(%5N9&5R('1H92`R,#`U(%!L86XL('1H
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M871E9"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS92X\+W`^(#QP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@
M5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=4
M15A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4
M.B`P+C5I;B<^(%1H92!F;VQL;W=I;F<@:7,@82!S=6UM87)Y(&]F(')E<W1R
M:6-T960@<W1O8VL@87=A<F1S(&%C=&EV:71Y(&9O<B!T:&4@;FEN92!M;VYT
M:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S.CPO<#X@/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.
M5#H@,"XU:6XG/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"="3U)$15(M
M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!724142#H@.#`E)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)
M3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@4$%$1$E.1RU,
M1494.B`P<'@G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B!B;VQD(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED
M.R!415A4+4%,24=..B!C96YT97([($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<@8V]L<W!A;CTS1#(^(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XM5$]0.B`P<'0G/B`\<W1R;VYG/B9N8G-P.SPO<W1R;VYG/CPO<#X@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!415A4+4%,24=..B!C96YT
M97([($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3BU43U`Z(#!P="<^(#QS=')O;F<^)FYB<W`[/"]S=')O;F<^/"]P
M/B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[(%1%6%0M04Q)1TXZ
M(&-E;G1E<CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE.+51/4#H@,'!T)SX@/'-T<F]N9SXF;F)S<#L\+W-T<F]N
M9SX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!-05)'24XM5$]0.B`P<'0G/B`\<W1R;VYG/DYU;6)E<B!O
M9CPO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T
M.R!415A4+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU43U`Z(#!P="<^(#QS=')O;F<^
M4VAA<F5S/"]S=')O;F<^/"]P/B`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B!B;VQD
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<@8V]L<W!A;CTS1#(^(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM5$]0.B`P<'0G/B`\<W1R
M;VYG/E!E<B!3:&%R92!796EG:'1E9"U!=F5R86=E($=R86YT+41A=&4\+W-T
M<F]N9SX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XM5$]0.B`P<'0G/B`\<W1R;VYG/D9A:7(@
M5F%L=64\+W-T<F]N9SX\+W`^(#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!C96YT97([($9/3E0Z(&)O;&0@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO
M=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I)SX@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@,'!X.R!724142#H@-S(E
M)SX@3W5T<W1A;F1I;F<@86YD(%5N=F5S=&5D(&%T($IA;G5A<GD@,2P@,C`Q
M,SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`R
M)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[
M(%=)1%1(.B`Q,"4G/B`S,RPS,S0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!415A4+4%,24=..B!L969T.R!724142#H@,24G/B`F;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!724142#H@
M,B4G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R!72414
M2#H@,3`E)SX@,2XS.3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^
M(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M04-+1U)/54Y$+4-/3$]2.B!W:&ET92<^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@,'!X
M)SX@4F5S=')I8W1E9"!S=&]C:R!G<F%N=&5D/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG
M:'0G/BT\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXD/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/BT\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T
M*2<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@4F5S=')I8W1E9"!S=&]C:R!V
M97-T960\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,
M24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^+3PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE
M9G0G/B0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4
M+4%,24=..B!R:6=H="<^+3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT
M<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$
M+4-/3$]2.B!W:&ET92<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M3$5&5#H@,'!X)SX@4F5S=')I8W1E9"!S=&]C:R!F;W)F96ET960\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/
M33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(')I9VAT)SX@+3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE9G0G
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0
M041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED
M.R!415A4+4%,24=..B!R:6=H="<^("T\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=.
M.B!L969T)SX@)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L
M,C4U+#(P-"DG/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,
M24=..B!L969T.R!0041$24Y'+4Q%1E0Z(#!P>"<^($]U='-T86YD:6YG(&%N
M9"!5;G9E<W1E9"!A="!397!T96UB97(@,S`L(#(P,3,\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!
M3$E'3CH@<FEG:'0G/B`S,RPS,S0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ
M(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C
M:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,2XS.3PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-
M.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#PO='(^
M(#PO=&%B;&4^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB<W`[/"]P/B`\
M<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^
M(%1H92!#;VUP86YY(')E8V]R9&5D('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO
M;B!E>'!E;G-E(&EN('1H92!C;VYS;VQI9&%T960@<W1A=&5M96YT<R!O9B!O
M<&5R871I;VYS(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ/"]P/B`\<"!S
M='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^("9N
M8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3BU,1494.B`P+C5I;CL@5TE$5$@Z(#DP)2<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R('-T>6QE/3-$)U9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!C96YT97([(%!!
M1$1)3D<M3$5&5#H@,'!X)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5#H@
M8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B!B;VQD(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&-O;'-P86X],T0V/B`\
M<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[(%1%6%0M04Q)1TXZ(&-E
M;G1E<CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@34%21TE.+51/4#H@,'!T)SX@/'-T<F]N9SY4:')E92!-;VYT:',@16YD
M960\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P
M=#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM5$]0.B`P<'0G/B`\<W1R;VYG
M/E-E<'1E;6)E<B`S,"P\+W-T<F]N9SX\+W`^(#PO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!C96YT97([($9/
M3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M.R!415A4+4%,24=..B!C96YT97([($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)R!C;VQS<&%N/3-$-CX@/'`@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!415A4+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU43U`Z(#!P
M="<^(#QS=')O;F<^3FEN92!-;VYT:',@16YD960\+W-T<F]N9SX\+W`^(#QP
M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XM5$]0.B`P<'0G/B`\<W1R;VYG/E-E<'1E;6)E<B`S,"P\+W-T
M<F]N9SX\+W`^(#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
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M5%1/33H@,7!T.R!415A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=.
M.B!C96YT97(G(&-O;'-P86X],T0R/C(P,3,\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"
M3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^
M("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U714E'2%0Z(&)O
M;&0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(^,C`Q,CPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B
M;VQD.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!C96YT97(G
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!
M3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&
M3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N
M/3-$,CXR,#$S/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M
M04Q)1TXZ(&-E;G1E<B<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/
M33H@,7!T.R!415A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C
M96YT97(G(&-O;'-P86X],T0R/C(P,3(\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@/"]T
M<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'
M4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T.R!0041$24Y'+4Q%
M1E0Z(#!P>#L@5TE$5$@Z(#0T)3L@5$585"U)3D1%3E0Z(#!P>"<^(%)E<V5A
M<F-H(&%N9"!D979E;&]P;65N=#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[(%=)1%1(.B`R)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E
M)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!
M3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/C,Q-CPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q
M)2<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%=)1%1(.B`R)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG
M:'0[(%=)1%1(.B`Q,"4G/C(Q.3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^("9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`R
M)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(
M.B`Q,"4G/C@R.3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`R)2<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'
M3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/C8S
M.#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)
M1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S
M='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/
M3$]2.B!W:&ET92<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!
M1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M3$5&5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@1V5N97)A;"!A;F0@861M
M:6YI<W1R871I=F4\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,S0W/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@
M5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`R
M-S0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'
M+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ
M(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=.
M.B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!R:6=H="<^(#DU-3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE9G0G
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0
M041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,2PP,S`\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T.R!4
M15A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE
M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z
M(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M3$5&5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@5&]T86P@
M<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(')I9VAT)SX@-C8S/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#0Y,SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@
M5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@
M)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G
M/B`Q+#<X-#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!
M1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M
M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0G/B`Q+#8V.#PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$58
M5"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#PO='(^(#PO=&%B;&4^(#QP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@
M5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=4
M15A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4
M.B`P+C5I;B<^($%S(&]F(%-E<'1E;6)E<B`S,"P@,C`Q,RP@=&AE<F4@=V%S
M(&%P<')O>&EM871E;'D@)#0N-R!M:6QL:6]N(&]F('1O=&%L('5N<F5C;V=N
M:7IE9"!C;VUP96YS871I;VX@97AP96YS92`H;F5T(&]F(&5S=&EM871E9"!F
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M8F4@;6%D92!D=7)I;F<@9G5T=7)E('!E<FEO9',N/"]P/B`\(2TM16YD1G)A
M9VUE;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S8V(P
M9C<P,#1B-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C0Y.#9C
M9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W,#`T8C<T+U=O<FMS:&5E=',O4VAE
M970Q-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/E4N4RX@1V]V97)N;65N="!!9W)E96UE;G0L($IO:6YT(%9E;G1U<F4@86YD
M($-O;&QA8F]R871I;VYS/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^52Y3+B!';W9E<FYM96YT($%G<F5E;65N="P@
M2F]I;G0@5F5N='5R92!A;F0@0V]L;&%B;W)A=&EO;G,@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^52Y3
M+B!';W9E<FYM96YT($%G<F5E;65N="P@2F]I;G0@5F5N='5R92!A;F0@0V]L
M;&%B;W)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP
M(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M
M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X\9&EV/B`\9&EV
M/CPA+2U3=&%R=$9R86=M96YT+2T^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@
M)FYB<W`[/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&
M3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#!I;B<^($YO=&4@,3`@
M+2!5+E,N($=O=F5R;FUE;G0@06=R965M96YT+"!*;VEN="!696YT=7)E(&%N
M9"!#;VQL86)O<F%T:6]N<SPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>3L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P:6XG
M/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!
M4D=)3CH@,'!T(#!P>"`P<'0@,"XR-6EN.R!415A4+4E.1$5.5#H@,&EN)SX@
M/'-T<F]N9SX\96T^2$A3($)!4D1!($-O;G1R86-T(&9O<B!296-O;6)I;F%N
M="!);F9L=65N>F$@5F%C8VEN97,\+V5M/CPO<W1R;VYG/CPO<#X@/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`P
M+C(U:6X[(%1%6%0M24Y$14Y4.B`P:6XG/B`F;F)S<#L\+W`^(#QP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)
M3D1%3E0Z(#`N-6EN)SX@26X@1F5B<G5A<GD@,C`Q,2P@=&AE($-O;7!A;GD@
M=V%S(&%W87)D960@82!C;VYT<F%C="!F<F]M($A(4R!"05)$02!V86QU960@
M870@)#DW(&UI;&QI;VX@9F]R('1H92!F:7)S="!T:')E92UY96%R(&)A<V4M
M<&5R:6]D+"!W:71H(&%N($A(4R!"05)$02!O<'1I;VX@9F]R(&%N(&%D9&ET
M:6]N86P@='=O+7EE87(@<&5R:6]D('9A;'5E9"!A="`D.#(@;6EL;&EO;BP@
M9F]R(&$@=&]T86P@8V]N=')A8W0@=F%L=64@;V8@=7`@=&\@)#$W.2!M:6QL
M:6]N+B!4:&4@2$A3($)!4D1!(&-O;G1R86-T(&%W87)D('!R;W9I9&5S('-I
M9VYI9FEC86YT(&9U;F1I;F<@9F]R('1H92!#;VUP86YY)B,S.3MS(&]N9V]I
M;F<@8VQI;FEC86P@9&5V96QO<&UE;G0@86YD('!R;V1U8W0@<V-A;&4M=7`@
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M:6YA;&QY(&1I<F5C=&5D('1H92!#;VUP86YY('1O(&1E=F5L;W`@:71S(&UO
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M="!B>2!T:&4@52Y3+B!G;W9E<FYM96YT(&]F(&9I<V-A;"!Y96%R<R`R,#$Q
M(&%N9"`R,#$R(&AA<R!B965N(&EN:71I871E9"P@8G5T(&AA<R!N;W0@8F5E
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M:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S+"!A;F0@
M:&%S(')E8V]G;FEZ960@87!P<F]X:6UA=&5L>2`D-#4@;6EL;&EO;B!I;B!R
M979E;G5E('-I;F-E('1H92!I;F-E<'1I;VX@;V8@=&AE(&-O;G1R86-T+CPO
M<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@
M,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B`F;F)S<#L\+W`^(#QP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)
M3D1%3E0Z(#`N-6EN)SX@56YD97(@8V5R=&%I;B!C:7)C=6US=&%N8V5S+"!(
M2%,@0D%21$$@<F5I;6)U<G-E;65N=',@;6%Y(&)E(&1E;&%Y960@;W(@979E
M;B!P;W1E;G1I86QL>2!W:71H:&5L9"X@26X@36%R8V@@,C`Q,BP@=&AE($-O
M;7!A;GD@9&5C:61E9"!T;R!C;VYD=6-T(&$@4&AA<V4@,B!C;&EN:6-A;"!T
M<FEA;"!O9B!I=',@<75A9')I=F%L96YT('-E87-O;F%L(&EN9FQU96YZ82!V
M86-C:6YE(&-A;F1I9&%T92`H(C(P-2!4<FEA;"(I('5N9&5R(&ET<R!E>&ES
M=&EN9R!5+E,N(&EN=F5S=&EG871I;VYA;"!N97<@9')U9R!A<'!L:6-A=&EO
M;B`H(DE.1"(I(&9O<B!I=',@=')I=F%L96YT('-E87-O;F%L(&EN9FQU96YZ
M82!V86-C:6YE(&-A;F1I9&%T92!A<R!O<'!O<V5D('1O('=A:71I;F<@=&\@
M8V]N9'5C="!T:&ES(&-L:6YI8V%L('1R:6%L('5N9&5R(&$@;F5W($E.1"!F
M;W(@:71S('%U861R:79A;&5N="!V86-C:6YE(&-A;F1I9&%T92`H(E%U861R
M:79A;&5N="!)3D0B*2X@0F%S960@;VX@=&AE($-O;7!A;GDF(S,Y.W,@9&ES
M8W5S<VEO;G,@=VET:"!(2%,@0D%21$$@:6X@,C`Q,BP@=&AE(&]U='-I9&4@
M8VQI;FEC86P@=')I86P@8V]S=',@9F]R('1H92`R,#4@5')I86P@;6%Y(&]N
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M92!#;VUP86YY(&EN:71I871E<R!T:&4@;F5X="!0:&%S92`R(&1O<V4M8V]N
M9FER;6%T;W)Y(&-L:6YI8V%L('1R:6%L+"!W:&EC:"!I<R!C=7)R96YT;'D@
M97AP96-T960@:6X@=&AE(&9I<G-T('%U87)T97(@;V8@,C`Q-"X@5&AE(&]U
M='-I9&4@8VQI;FEC86P@=')I86P@8V]S=',@;V8@=&AE(#(P-2!4<FEA;"!C
M;VYD=6-T960@;&%S="!Y96%R('1O=&%L("0R+CD@;6EL;&EO;BP@=VAI8V@@
M=V%S(&EN8W5R<F5D(&9R;VT@=&AE(&EN8V5P=&EO;B!O9B!T:&4@8VQI;FEC
M86P@=')I86P@=&AR;W5G:"!397!T96UB97(@,S`L(#(P,3,N(%1H97-E(&-O
M<W1S(&AA=F4@8F5E;B!R96-O<F1E9"!A<R!A;B!E>'!E;G-E(&%N9"!A<F4@
M:6YC;'5D960@:6X@8V]S="!O9B!G;W9E<FYM96YT(&-O;G1R86-T<R!R979E
M;G5E+CPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B`F;F)S<#L\+W`^(#QP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@
M5$585"U)3D1%3E0Z(#`N,C5I;B<^(#QS=')O;F<^/&5M/D-03"!":6]L;V=I
M8V%L<R!0<FEV871E($QI;6ET960@*")#4$Q"(BD@2F]I;G0@5F5N='5R93PO
M96T^/"]S=')O;F<^/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T
M:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/B`F;F)S
M<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@
M,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@26X@,C`P.2P@=&AE($-O
M;7!A;GD@9F]R;65D(&$@:F]I;G0@=F5N='5R92!W:71H($-A9&EL82!0:&%R
M;6%C975T:6-A;',@3&EM:71E9"`H(D-A9&EL82(I(&YA;65D($-03"!":6]L
M;V=I8V%L<R!0<FEV871E($QI;6ET960@*")#4$Q"(BD@=&\@9&5V96QO<"!A
M;F0@;6%N=69A8W1U<F4@=F%C8VEN97,L(&)I;VQO9VEC86P@=&AE<F%P975T
M:6-S(&%N9"!D:6%G;F]S=&EC<R!I;B!);F1I82X@0U!,0B!I<R!O=VYE9"`R
M,"4@8GD@=&AE($-O;7!A;GD@86YD(#@P)2!B>2!#861I;&$N(%1H92!#;VUP
M86YY(&%C8V]U;G1S(&9O<B!I=',@:6YV97-T;65N="!I;B!#4$Q"('5S:6YG
M('1H92!E<75I='D@;65T:&]D+B!3:6YC92!T:&4@8V%R<GEI;F<@=F%L=64@
M;V8@=&AE($-O;7!A;GDF(S,Y.W,@:6YI=&EA;"!I;G9E<W1M96YT('=A<R!N
M;VUI;F%L(&%N9"!T:&5R92!I<R!N;R!G=6%R86YT964@;W(@8V]M;6ET;65N
M="!T;R!P<F]V:61E(&9U='5R92!F=6YD:6YG+"!T:&4@0V]M<&%N>2!H87,@
M;F]T(')E8V]R9&5D(&%N>2!L;W-S97,@<F5L871E9"!T;R!T:&ES(&EN=F5S
M=&UE;G0N/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^("9N8G-P.SPO<#X@
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X
M.R!415A4+4E.1$5.5#H@,"XR-6EN)SX@/'-T<F]N9SX\96T^3$<@3&EF92!3
M8VEE;F-E<RP@3'1D+B`H(DQ'3%,B*2!,:6-E;G-E($%G<F5E;65N=#PO96T^
M/"]S=')O;F<^/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C(U:6XG/B`F;F)S<#L\
M+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T
M(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@26X@1F5B<G5A<GD@,C`Q,2P@
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M96QO<&UE;G0@;V8@=&AE(&EN9FQU96YZ82!63%`@=F%C8VEN97,@86YD(&$@
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M;F-L=61E(&%N('5P9G)O;G0@<&%Y;65N="!O9B`D,BXU(&UI;&QI;VXL(')E
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M+CPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P
M<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B`F;F)S<#L\+W`^(#QP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$58
M5"U)3D1%3E0Z(#`N,C5I;B<^(#QS=')O;F<^/&5M/E!!5$@@5F%C8VEN92!3
M;VQU=&EO;G,@*")0051((BD@0VQI;FEC86P@1&5V96QO<&UE;G0@06=R965M
M96YT/"]E;3X\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N,C5I;B<^
M("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B!);B!*=6QY(#(P
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M;7!A;GD@=V%S(&%W87)D960@87!P<F]X:6UA=&5L>2`D,BXP(&UI;&QI;VX@
M8GD@4$%42"!F;W(@:6YI=&EA;"!F=6YD:6YG('5N9&5R('1H92!A9W)E96UE
M;G0@=&\@<&%R=&EA;&QY('-U<'!O<G0@:71S(&EN:71I86P@4&AA<V4@,B!D
M;W-E+7)A;F=I;F<@8VQI;FEC86P@=')I86P@:6X@=V]M96X@;V8@8VAI;&1B
M96%R:6YG(&%G92P@=VAI8V@@=V%S(&QA=6YC:&5D(&EN($]C=&]B97(@,C`Q
M,BX@5&AE(&9U;F1I;F<@=6YD97(@=&AE(&%G<F5E;65N="!W87,@:6YC<F5A
M<V5D(&)Y("0P+C0@;6EL;&EO;B!A;F0@=&AE('1E<FT@97AT96YD960@=&\@
M07!R:6P@,C`Q-"!T;R!S=7!P;W)T('1H92!#;VUP86YY)B,S.3MS(')E<')O
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M97AT96YT(%!!5$@@96QE8W1S('1O(&-O;G1I;G5E('1O(&9U;F0@-3`E(&]F
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M96YD960@4V5P=&5M8F5R(#,P+"`R,#$S+"!A;F0@:&%S(')E8V]G;FEZ960@
M87!P<F]X:6UA=&5L>2`D,BXP(&UI;&QI;VX@:6X@<F5V96YU92!S:6YC92!T
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M+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W,#`T
M8C<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S(T.3@V8V8S7S$U
M.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-"]7;W)K<VAE971S+U-H965T,3@N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E
M<R!087EA8FQE/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3F]T97,@4&%Y86)L92!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;W1E<R!087EA
M8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/"$M+41/0U19
M4$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET
M:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X
M:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A
M<G1&<F%G;65N="TM/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y
M.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#!I;B<^($YO=&4@
M,3$@+2!.;W1E<R!087EA8FQE/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=.
M.B!J=7-T:69Y.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#!I
M;B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF
M>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B!);B!397!T
M96UB97(@,C`Q,BP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@;6%S=&5R
M('-E8W5R:71Y(&%G<F5E;65N="!W:71H($=E;F5R86P@16QE8W1R:6,@0V%P
M:71A;"!#;W)P;W)A=&EO;B`H(D=%(BDL('=H97)E8GD@=&AE($-O;7!A;GD@
M8V]U;&0@8F]R<F]W('5P('1O("0R+C`@;6EL;&EO;B!T;R!F:6YA;F-E('1H
M92!P=7)C:&%S97,@;V8@97%U:7!M96YT('1H<F]U9V@@2G5N92`R,#$S("AE
M86-H+"!A;B`B17%U:7!M96YT($QO86XB*2X@16%C:"!%<75I<&UE;G0@3&]A
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M<FEN9R!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$S
M+"!T:&4@0V]M<&%N>2!F:6YA;F-E9"`D,2XU(&UI;&QI;VX@870@:6YT97)E
M<W0@<F%T97,@;V8@,3(N,24@=VET:"!M;VYT:&QY('!R:6YC:7!A;"!P87EM
M96YT<R!T;W1A;&EN9R`D,S0L-3(Y("@B,C`Q,R!&=6YD:6YG(BDN($EN=&5R
M97-T(&%C8W)U97,@;VX@=&AE(&]U='-T86YD:6YG(&)A;&%N8V4@=6YT:6P@
M<&%I9"!I;B!F=6QL+B!!<R!O9B!397!T96UB97(@,S`L(#(P,3,L('1H92!#
M;VUP86YY(&AA<R!F:6YA;F-E9"`D,BXP(&UI;&QI;VX@:6X@=&]T86P@=6YD
M97(@=&AE($5Q=6EP;65N="!,;V%N+CPO<#X@/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU
M:6XG/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I
M9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@06=G<F5G
M871E(&9U='5R92!M:6YI;75M('!R:6YC:7!A;"!P87EM96YT<R!O;B!T:&4@
M1T4@;F]T97,@<&%Y86)L92P@:6YC;'5D:6YG('1H92`R,#$S($9U;F1I;F<L
M(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,R!A<F4@87,@9F]L;&]W<R`H:6X@=&AO
M=7-A;F1S*3H\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!
M4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB<W`[/"]P
M/B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@5TE$
M5$@Z(#$P,"4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT
M<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU,1494.B`P<'@G/B!996%R/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]4
M5$]-.B`Q<'0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M
M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CY!;6]U;G0\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$
M1$E.1RU"3U143TTZ(#%P="<^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2
M.B!R9V(H,C`T+#(U-2PR,#0I)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@[(%=)
M1%1(.B`Q,R4G/B`R,#$S("AR96UA:6YD97(I/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#<T)2<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@
M5TE$5$@Z(#(E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/C$T,SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[
M(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!W:&ET
M92<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@,C`Q-#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ
M(')I9VAT)SXU-S$\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y
M;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/
M4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@
M,C`Q-3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXU-S$\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\
M+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4G/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4Q%1E0Z(#!P>"<^(#(P,38\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT)SX@,SDV/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P
M.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I)SX@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N
M-7!T.R!415A4+4%,24=..B!L969T.R!0041$24Y'+4Q%1E0Z(#!P>"<^("9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)
M3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U
M8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`Q+#8X,3PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@
M5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#PO='(^(#PO=&%B;&4^
M(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(&)O;&0@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P
M<'0@,'!X.R!415A4+4E.1$5.5#H@,&EN)SX@)FYB<W`[/"]P/B`\(2TM16YD
M1G)A9VUE;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S
M8V(P9C<P,#1B-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C0Y
M.#9C9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W,#`T8C<T+U=O<FMS:&5E=',O
M4VAE970Q.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E=A<G)A;G0@3&EA8FEL:71Y/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5V%R<F%N="!,:6%B:6QI='D@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5V%R<F%N="!,:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$
M5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S
M+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M
M+3X\9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^(#QP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!415A4
M+4E.1$5.5#H@,&EN)SX@3F]T92`Q,B`M(%=A<G)A;G0@3&EA8FEL:71Y/"]P
M/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B!B;VQD
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@
M,'!T(#!P>#L@5$585"U)3D1%3E0Z(#!I;B<^("9N8G-P.SPO<#X@/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!415A4
M+4E.1$5.5#H@,"XU-6EN)SX@26X@2G5L>2`R,#`X+"!T:&4@0V]M<&%N>2!C
M;VUP;&5T960@82!R96=I<W1E<F5D(&1I<F5C="!O9F9E<FEN9R!O9B`V+#8X
M-BPV-3`@=6YI=',L(')A:7-I;F<@87!P<F]X:6UA=&5L>2`D,3<N-2!M:6QL
M:6]N(&EN(&YE="!P<F]C965D<RX@16%C:"!U;FET(&-O;G-I<W1E9"!O9B!O
M;F4@<VAA<F4@;V8@8V]M;6]N('-T;V-K(&%N9"!A('=A<G)A;G0@=&\@<'5R
M8VAA<V4@,"XU('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@*'1H92`B5V%R<F%N
M=',B*2!A="!A('!R:6-E(&]F("0R+C8X('!E<B!U;FET+B!4:&4@5V%R<F%N
M=',@<F5P<F5S96YT('1H92!R:6=H="!T;R!A8W%U:7)E(&%N(&%G9W)E9V%T
M92!O9B`S+#,T,RPS,C4@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A="!A;B!E
M>&5R8VES92!P<FEC92!O9B`D,RXV,B!P97(@<VAA<F4@86YD('=E<F4@97AE
M<F-I<V%B;&4@8F5T=V5E;B!*86YU87)Y(#,Q+"`R,#`Y(&%N9"!*=6QY(#,Q
M+"`R,#$S+CPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU-6EN)SX@)FYB<W`[/"]P
M/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P
M<'@[(%1%6%0M24Y$14Y4.B`P+C4U:6XG/B`\9F]N="!S='EL93TS1"=#3TQ/
M4CH@8FQA8VLG/D1U<FEN9R!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M
M8F5R(#,P+"`R,#$S(&%N9"`R,#$R+"!T:&4@0V]M<&%N>2!R96-O<F1E9"!A
M<R!O=&AE<B!I;F-O;64@*&5X<&5N<V4I/"]F;VYT/B!I;B!I=',@8V]N<V]L
M:61A=&5D('-T871E;65N=',@;V8@;W!E<F%T:6]N<R`\9F]N="!S='EL93TS
M1"=#3TQ/4CH@8FQA8VLG/F$@8VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@=V%R
M<F%N="!L:6%B:6QI='D@;V8@)#`N,R!M:6QL:6]N(&%N9"`H)#`N-"D@;6EL
M;&EO;BP@<F5S<&5C=&EV96QY+B!!;&P@5V%R<F%N=',@97AP:7)E9"!U;F5X
M97)C:7-E9"!O;B!*=6QY(#,Q+"`R,#$S+CPO9F]N=#X\+W`^(#QP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)
M3D1%3E0Z(#`N-35I;B<^("9N8G-P.SPO<#X@/"$M+45N9$9R86=M96YT+2T^
M/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W,#`T8C<T
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S(T.3@V8V8S7S$U.3!?
M-#4R,5]B96-E7S-C8C!F-S`P-&(W-"]7;W)K<VAE971S+U-H965T,C`N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY-86YU9F%C
M='5R:6YG+"!,86)O<F%T;W)Y(&%N9"!/9F9I8V4@1F%C:6QI='D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY-86YU
M9F%C='5R:6YG($QA8F]R871O<GD@86YD($]F9FEC92!&86-I;&ET>2!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y-86YU9F%C='5R:6YG+"!,86)O<F%T;W)Y(&%N9"!/9F9I8V4@1F%C
M:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\(2TM1$]#
M5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS
M:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$
M+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X\9&EV/B`\9&EV/CPA+2U3
M=&%R=$9R86=M96YT+2T^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I
M9GD[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,&EN)SX@3F]T
M92`Q,R`M($UA;G5F86-T=7)I;F<L($QA8F]R871O<GD@86YD($]F9FEC92!&
M86-I;&ET>3PO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@
M1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P:6XG/B`F;F)S<#L\
M+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T
M(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE($-O;7!A;GD@;&5A<V5S
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M86P@<F5N="!P87EM96YT<R`H8V]L;&5C=&EV96QY+"!T:&4@(DEM<')O=F5M
M96YT($%L;&]W86YC92(I+B!4:&4@0V]M<&%N>2!H87,@8F5E;B!F=6YD960@
M)#`N-R!M:6QL:6]N(&EN('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB
M97(@,S`L(#(P,3,L(&%N9"!H87,@8F5E;B!F=6YD960@)#4N,"!M:6QL:6]N
M(&EN('1O=&%L('5N9&5R('1H92!);7!R;W9E;65N="!!;&QO=V%N8V4N(%1H
M92!);7!R;W9E;65N="!!;&QO=V%N8V4@:7,@8F5I;F<@86UO<G1I>F5D(&]N
M(&$@<W1R86EG:'0M;&EN92!B87-I<R!O=F5R('1H92!R96UA:6YI;F<@=&5R
M;2!O9B!T:&4@;&5A<V4N/"]P/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E
M8V5?,V-B,&8W,#`T8C<T+U=O<FMS:&5E=',O4VAE970R,2YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DUA<W1E<B!397)V:6-E
M<R!!9W)E96UE;G0@=VET:"!#861I;&$\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY-87-T97(@4V5R=FEC97,@06=R
M965M96YT('=I=&@@0V%D:6QA(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA<W1E<B!397)V:6-E<R!!
M9W)E96UE;G0@=VET:"!#861I;&$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@
M6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R
M9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X\
M9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^(#QP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.
M1$5.5#H@,&EN)SX@3F]T92`Q-"`\9F]N="!S='EL93TS1"=&3TY4+5=%24=(
M5#H@;F]R;6%L)SXM/"]F;VYT/B!-87-T97(@4V5R=FEC97,@06=R965M96YT
M('=I=&@@0V%D:6QA/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T
M:69Y.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#!I;B<^("9N
M8G-P.SPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B!);B!C;VYN96-T:6]N
M('=I=&@@=&AE($I6('=I=&@@0V%D:6QA+"!T:&4@0V]M<&%N>2!E;G1E<F5D
M(&EN=&\@82!M87-T97(@<V5R=FEC97,@86=R965M96YT+"!W:&EC:"!T:&4@
M0V]M<&%N>2!A;F0@0V%D:6QA(&%M96YD960@:6X@2G5L>2`R,#$Q+"!A;F0@
M<W5B<V5Q=65N=&QY(&EN($UA<F-H(#(P,3,L(&EN(&5A8V@@8V%S92!T;R!E
M>'1E;F0@=&AE('1E<FT@8GD@;VYE('EE87(@9F]R('=H:6-H('-E<G9I8V5S
M(&-A;B!B92!P<F]V:61E9"!B>2!#861I;&$@=6YD97(@=&AI<R!A9W)E96UE
M;G0N(%5N9&5R('1H92!R979I<V5D('1E<FUS+"!I9B!B>2!-87)C:"`R,#$T
M+"!T:&4@86UO=6YT(&]F('-E<G9I8V5S('!R;W9I9&5D(&)Y($-A9&EL82!U
M;F1E<B!T:&4@;6%S=&5R('-E<G9I8V5S(&%G<F5E;65N="!I<R!L97-S('1H
M86X@)#<N-2!M:6QL:6]N+"!T:&4@0V]M<&%N>2!W:6QL('!A>2!#861I;&$@
M=&AE('!O<G1I;VX@;V8@=&AE('-H;W)T9F%L;"!A;6]U;G0@=&AA="!I<R!L
M97-S('1H86X@;W(@97%U86P@=&\@)#(N,"!M:6QL:6]N(&%N9"`U,"4@;V8@
M=&AE('!O<G1I;VX@;V8@=&AE('-H;W)T9F%L;"!A;6]U;G0@=&AA="!E>&-E
M961S("0R+C`@;6EL;&EO;BX@5&AR;W5G:"!397!T96UB97(@,S`L(#(P,3,L
M('1H92!#;VUP86YY(&AA<R!P=7)C:&%S960@)#(N-"!M:6QL:6]N(&EN('-E
M<G9I8V5S(&9R;VT@0V%D:6QA('!U<G-U86YT('1O('1H:7,@86=R965M96YT
M+"!W:&EC:"!I;F-L=61E<R`D,"XX(&UI;&QI;VX@;V8@<V5R=FEC97,@<')O
M=FED960L('-I;F-E('1H92!B96=I;FYI;F<@;V8@,C`Q,RP@8GD@0U!,0B!T
M;R!T:&4@0V]M<&%N>2!O;B!B96AA;&8@;V8@0V%D:6QA('!U<G-U86YT('1O
M(&%N($]C=&]B97(@,C`Q,R!A;65N9&UE;G0@875T:&]R:7II;F<@<W5C:"!#
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M:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W,#`T8C<T#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S(T.3@V8V8S7S$U.3!?-#4R
M,5]B96-E7S-C8C!F-S`P-&(W-"]7;W)K<VAE971S+U-H965T,C(N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5(1D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@
M;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H4&]L:6-Y*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y"87-I<R!O9B!0<F5S96YT871I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O
M5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O
M=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN
M9'1D(B`M+3X\9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^(#QP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@
M,"XR-6EN)SX@/'-T<F]N9SX\96T^0F%S:7,@;V8@4')E<V5N=&%T:6]N/"]E
M;3X\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I
M9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XR-6EN)SX@)FYB<W`[/"]P/B`\<"!S
M='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%
M6%0M24Y$14Y4.B`P+C5I;B<^(%1H92!A8V-O;7!A;GEI;F<@=6YA=61I=&5D
M(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!H879E(&)E96X@
M<')E<&%R960@:6X@86-C;W)D86YC92!W:71H(&%C8V]U;G1I;F<@<')I;F-I
M<&QE<R!G96YE<F%L;'D@86-C97!T960@:6X@=&AE(%5N:71E9"!3=&%T97,@
M;V8@06UE<FEC82`H(E4N4RX@1T%!4"(I(&9O<B!I;G1E<FEM(&9I;F%N8VEA
M;"!I;F9O<FUA=&EO;B!A;F0@=&AE(&EN<W1R=6-T:6]N<R!T;R!&;W)M(#$P
M+5$@86YD($%R=&EC;&4@,3`@;V8@4F5G=6QA=&EO;B!3+5@N(%1H92!C;VYS
M;VQI9&%T960@8F%L86YC92!S:&5E="!A<R!O9B!397!T96UB97(@,S`L(#(P
M,3,L(&-O;G-O;&ED871E9"!S=&%T96UE;G1S(&]F(&]P97)A=&EO;G,@86YD
M(&-O;G-O;&ED871E9"!S=&%T96UE;G1S(&]F(&-O;7!R96AE;G-I=F4@;&]S
M<R!F;W(@=&AE('1H<F5E(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB
M97(@,S`L(#(P,3,@86YD(#(P,3(@86YD('1H92!C;VYS;VQI9&%T960@<W1A
M=&5M96YT<R!O9B!C87-H(&9L;W=S(&9O<B!T:&4@;FEN92!M;VYT:',@96YD
M960@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"`R,#$R(&%R92!U;F%U9&ET960L
M(&)U="!I;F-L=61E(&%L;"!A9&IU<W1M96YT<R`H8V]N<VES=&EN9R!O9B!N
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M:"!5+E,N($=!05`@:&%V92!B965N(&-O;F1E;G-E9"!O<B!O;6ET=&5D(&%S
M('!E<FUI='1E9"!U;F1E<B!T:&4@<G5L97,@86YD(')E9W5L871I;VYS(&]F
M('1H92!5;FET960@4W1A=&5S(%-E8W5R:71I97,@86YD($5X8VAA;F=E($-O
M;6UI<W-I;VX@*")314,B*2X\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@
M)FYB<W`[/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^($%S(&1I<V-U<W-E
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M:6UI;F%T960@:6X@8V]N<V]L:61A=&EO;BX\+W`^(#QP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z
M(#`N-6EN)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J
M=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^(%1H
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M(&-O;7!R96AE;G-I=F4@:6YC;VUE('=A<R`D,"XU(&UI;&QI;VX@870@4V5P
M=&5M8F5R(#,P+"`R,#$S+CPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE(&%C8V]M<&%N
M>6EN9R!U;F%U9&ET960@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE
M;G1S('-H;W5L9"!B92!R96%D(&EN(&-O;FIU;F-T:6]N('=I=&@@=&AE(&9I
M;F%N8VEA;"!S=&%T96UE;G1S(&%N9"!N;W1E<R!T:&5R971O(&EN8VQU9&5D
M(&EN('1H92!#;VUP86YY)B,S.3MS($%N;G5A;"!297!O<G0@;VX@1F]R;2`Q
M,"U+(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,BX@4F5S
M=6QT<R!F;W(@=&AI<R!O<B!A;GD@:6YT97)I;2!P97)I;V0@87)E(&YO="!N
M96-E<W-A<FEL>2!I;F1I8V%T:79E(&]F(')E<W5L=',@9F]R(&%N>2!F=71U
M<F4@:6YT97)I;2!P97)I;V0@;W(@9F]R('1H92!E;G1I<F4@>65A<BX@5&AE
M($-O;7!A;GD@;W!E<F%T97,@:6X@;VYE(&)U<VEN97-S('-E9VUE;G0Z(&1E
M=F5L;W!I;F<@<F5C;VUB:6YA;G0@=F%C8VEN97,N/"]P/B`\(2TM16YD1G)A
M9VUE;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5<V4@;V8@17-T:6UA=&5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/"$M+41/0U194$4@:'1M;"!0
M54),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.
M(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A
M;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N
M="TM/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P
M="`P<'@@,'!T(#`N,C5I;B<^(#QS=')O;F<^/&5M/E5S92!O9B!%<W1I;6%T
M97,\+V5M/CPO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE..B`P<'0@,'!X(#!P="`P+C(U:6XG/B`F;F)S<#L\+W`^
M(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P
M>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@5&AE('!R97!A<F%T:6]N(&]F(&-O
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M92!E<W1I;6%T97,N/"]P/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y&86ER(%9A;'5E($UE87-U<F5M96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7
M,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W
M=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD
M=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`P
M+C(U:6XG/B`\<W1R;VYG/CQE;3Y&86ER(%9A;'5E($UE87-U<F5M96YT<SPO
M96T^/"]S=')O;F<^/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T
M:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N,C5I;B<^("9N8G-P.SPO<#X@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!4
M15A4+4E.1$5.5#H@,"XU:6XG/B!4:&4@0V]M<&%N>2!A<'!L:65S($%C8V]U
M;G1I;F<@4W1A;F1A<F1S($-O9&EF:6-A=&EO;B`H(D%30R(I(%1O<&EC(#@R
M,"P@/&5M/D9A:7(@5F%L=64@365A<W5R96UE;G1S(&%N9"!$:7-C;&]S=7)E
M<SPO96T^+"!F;W(@9FEN86YC:6%L(&%N9"!N;VXM9FEN86YC:6%L(&%S<V5T
M<R!A;F0@;&EA8FEL:71I97,N/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=.
M.B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^
M("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B!!4T,@.#(P(&1I
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M=F5L<SH\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB<W`[/"]P/B`\
M=&%B;&4@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM5$]0.B`P
M<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q
M,#`E/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S
M='EL93TS1"=724142#H@,"XR-6EN)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#`N,C5I;CLG/B9M:61D;W0[/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&IU<W1I9GDG/DQE=F5L(#$Z($]B<V5R=F%B;&4@:6YP
M=71S('-U8V@@87,@<75O=&5D('!R:6-E<R`H=6YA9&IU<W1E9"D@:6X@86-T
M:79E(&UA<FME=',@9F]R(&ED96YT:6-A;"!A<W-E=',@;W(@;&EA8FEL:71I
M97,N/"]T9#X@/"]T<CX@/"]T86)L93X@/'1A8FQE('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE.+51/4#H@,'!T)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%
M4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I
M;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)W=I9'1H.B`P+C(U:6X[)SXF
M;6ED9&]T.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y
M)SY,979E;"`R.B!);G!U=',@;W1H97(@=&AA;B!Q=6]T960@<')I8V5S('1H
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M;&4^(#QT86)L92!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU4
M3U`Z(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@
M/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=W:61T:#H@,"XR-6EN.R<^)FUI9&1O=#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>2<^3&5V96P@,SH@56YO8G-E<G9A
M8FQE(&EN<'5T<R!T:&%T(')E9FQE8W0@=&AE(')E<&]R=&EN9R!E;G1I='DF
M(S,Y.W,@;W=N(&%S<W5M<'1I;VYS+CPO=&0^(#PO='(^(#PO=&%B;&4^(#PA
M+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5S=&UE;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/"$M+41/0U194$4@:'1M
M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO
M+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M
M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G
M;65N="TM/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ
M(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^(#QS=')O;F<^/&5M/DEN
M=F5S=&UE;G1S/"]E;3X\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(&)O;&0@:71A;&EC(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@
M,"XR-6EN)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J
M=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^($EN
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M960@87,@;F]N+6-U<G)E;G0N/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=.
M.B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^
M("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B!);G1E<F5S="!A
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M=&EE<RX\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB<W`[/"]P/B`\
M<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[
M(%1%6%0M24Y$14Y4.B`P+C5I;B<^(%1H92!#;VUP86YY(&AA<R!C;&%S<VEF
M:65D(&ET<R!I;G9E<W1M96YT<R!A<R!A=F%I;&%B;&4M9F]R+7-A;&4@<VEN
M8V4@=&AE($-O;7!A;GD@;6%Y(&YE960@=&\@;&EQ=6ED871E('1H97-E('-E
M8W5R:71I97,@=VET:&EN('1H92!N97AT('EE87(N(%1H92!A=F%I;&%B;&4M
M9F]R+7-A;&4@<V5C=7)I=&EE<R!A<F4@8V%R<FEE9"!A="!F86ER('9A;'5E
M(&%N9"!U;G)E86QI>F5D(&=A:6YS(&%N9"!L;W-S97,@;VX@=&AE<V4@<V5C
M=7)I=&EE<RP@:68@9&5T97)M:6YE9"!T;R!B92!T96UP;W)A<GDL(&%R92!I
M;F-L=61E9"!I;B!A8V-U;75L871E9"!O=&AE<B!C;VUP<F5H96YS:79E(&EN
M8V]M92`H;&]S<RD@:6X@<W1O8VMH;VQD97)S)B,S.3L@97%U:71Y+B!);G9E
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M8V]R9&5D(&EN('1H92!S=&%T96UE;G0@;V8@;W!E<F%T:6]N<RX\+W`^(#PA
M+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@0V%S
M:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SPA+2U$3T-465!%
M(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO
M;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT
M;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T
M1G)A9VUE;G0M+3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@
M1D].5#H@8F]L9"!I=&%L:6,@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`P+C(U:6XG/B!297-T<FEC
M=&5D($-A<V@\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[
M($9/3E0Z(&)O;&0@:71A;&EC(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XR-6EN)SX@)FYB<W`[
M/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P
M="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^(%1H92!#;VUP86YY)B,S.3MS
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M<F%T:6]N(&]F('1H92!L96%S97,N/"]P/B`\(2TM16YD1G)A9VUE;G0M+3X\
M+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@3&]S<R!P97(@4VAA<F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B
M+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P
M.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N
M86PN9'1D(B`M+3X\9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^(#QP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P
M<'0@,"XR-6EN)SX@/'-T<F]N9SX\96T^3F5T($QO<W,@<&5R(%-H87)E/"]E
M;3X\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I
M9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB<W`[
M/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P
M="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^($YE="!L;W-S('!E<B!S:&%R
M92!I<R!C;VUP=71E9"!U<VEN9R!T:&4@=V5I9VAT960@879E<F%G92!N=6UB
M97(@;V8@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!O=71S=&%N9&EN9RX@06QL
M(&]U='-T86YD:6YG('=A<G)A;G1S+"!S=&]C:R!O<'1I;VYS(&%N9"!U;G9E
M<W1E9"!R97-T<FEC=&5D('-T;V-K(&%W87)D<R!T;W1A;&EN9R`Q,BPQ-3<L
M-C,T('-H87)E<R!A;F0@,3(L.34Q+#8R-2!S:&%R97,@870@4V5P=&5M8F5R
M(#,P+"`R,#$S(&%N9"`R,#$R+"!R97-P96-T:79E;'DL(&%R92!E>&-L=61E
M9"!F<F]M('1H92!C;VUP=71A=&EO;BP@87,@=&AE:7(@969F96-T(&ES(&%N
M=&ED:6QU=&EV92X\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I
M9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB<W`[
M/"]P/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-L87-S
M:69I8V%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SPA
M+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@
M5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL
M,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^
M/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XR-6EN)SX@
M/'-T<F]N9SX\96T^4F5C;&%S<VEF:6-A=&EO;G,\+V5M/CPO<W1R;VYG/CPO
M<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@
M,'!X.R!415A4+4E.1$5.5#H@,"XR-6EN)SX@)FYB<W`[/"]P/B`\<"!S='EL
M93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M
M24Y$14Y4.B`P+C5I;B<^($]V97)H96%D(&5X<&5N<V5S(')E;&%T:6YG('1O
M('-U<'!L>2!C:&%I;B!M86YA9V5M96YT(&]F("0P+C(@;6EL;&EO;B!A;F0@
M)#`N-B!M:6QL:6]N(&9O<B!T:&4@=&AR964@86YD(&YI;F4@;6]N=&AS(&5N
M9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,BP@<F5S<&5C=&EV96QY+"!H879E(&)E
M96X@<F5C;&%S<VEF:65D(&9R;VT@9V5N97)A;"!A;F0@861M:6YI<W1R871I
M=F4@97AP96YS97,@=&\@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N
M<V5S+B!!;'-O+"!W:71H:6X@=&AE(%-E<'1E;6)E<B`S,"P@,C`Q,B!S=&%T
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M<F5S96YT871I;VXN/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T
M:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^("9N8G-P
M.SPO<#X@/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,C0Y.#9C9C-?,34Y
M,%\T-3(Q7V)E8V5?,V-B,&8W,#`T8C<T#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W
M-"]7;W)K<VAE971S+U-H965T,C,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5+2#X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY!8W%U:7-I=&EO;B!O9B!)<V-O;F]V82!!0B`H
M5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D%C<75I<VET:6]N($]F($ES8V]N;W9A($%"(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-C:&5D=6QE(&]F(%!U<F-H87-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S
M0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W
M=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T
M9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\<"!S='EL
M93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M
M24Y$14Y4.B`P+C5I;B<^(#QF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M="<^5&AE('1O=&%L('!U<F-H87-E('!R:6-E(&ES('-U;6UA<FEZ960@87,@
M9F]L;&]W<R`H:6X@=&AO=7-A;F1S*3H\+V9O;G0^/"]P/B`\<"!S='EL93TS
M1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$
M14Y4.B`P+C5I;B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)T)/4D1%
M4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU,1494.B`P+C5I;CL@5TE$5$@Z
M(#DP)2<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],
M3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!0041$24Y'+4Q%1E0Z(#!P>#L@5TE$5$@Z(#@V)2<^5F%L=64@
M;V8@<VAA<F5S(&]F($YO=F%V87@@0V]M;6]N(%-T;V-K(&ES<W5E9#PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`R)2<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G
M/B`T,2PY-#(\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!4
M15A4+4%,24=..B!L969T.R!724142#H@,24G/B`F;F)S<#L\+W1D/B`\+W1R
M/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=2
M3U5.1"U#3TQ/4CH@=VAI=&4G/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T.R!0
M041$24Y'+4Q%1E0Z(#!P>"<^($-A<V@@<&%I9"!T;R!)<V-O;F]V82!W87)R
M86YT(&AO;&1E<G,\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,C(\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T.R!4
M15A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE
M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z
M(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%!!1$1)3D<M3$5&5#H@,'!X
M)SX@5&]T86P@<'5R8VAA<V4@<')I8V4\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U14
M3TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@
M-#$L.38T/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[
M/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X
M)SX@)FYB<W`[/"]P/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y38VAE9'5L92!O9B!!<W-E=',@06-Q=6ER960@86YD($QI86)I;&ET:65S
M($%S<W5M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\(2TM
M1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R
M86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O
M1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X\9&EV/B`\9&EV/CPA
M+2U3=&%R=$9R86=M96YT+2T^(#QT86)L92!S='EL93TS1"="3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XM3$5&5#H@,"XU:6X[(%=)1%1(.B`Y,"4G
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@4$%$1$E.1RU,1494.B`P<'@G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@
M8V]L<W!A;CTS1#(^*&EN('1H;W5S86YD<RD\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4]
M,T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@
M<F=B*#(P-"PR-34L,C`T*2<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@,'!X.R!72414
M2#H@.#8E)SX@0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`R)2<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@
M;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B`S+#`U
M-CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)
M1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S
M='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/
M3$]2.B!W:&ET92<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@06-C;W5N=',@
M<F5C96EV86)L93PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXV,#,\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@4')E<&%I9"!E>'!E;G-E<R!A;F0@
M;W1H97(@87-S971S/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/C$L,#DR/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F
M="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU,1494.B`P<'@G/B!0<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58
M5"U!3$E'3CH@<FEG:'0G/C$V-3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^
M(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/
M54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I)SX@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494
M.B`P<'@G/B!);G1A;F=I8FQE(&%S<V5T<SPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT
M)SXQ-BPS.#`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!4
M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4]
M,T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@
M=VAI=&4G/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'
M+4Q%1E0Z(#!P>"<^1V]O9'=I;&P\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^,C4L
M,CDX/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!
M3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R
M,#0L,C4U+#(P-"DG/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4Q%1E0Z(#!P>"<^($%C8V]U;G1S
M('!A>6%B;&4@86YD(&]T:&5R(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4
M+4%,24=..B!R:6=H="<^*#(L-S@T/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^*3PO=&0^(#PO='(^(#QT
M<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$
M+4-/3$]2.B!W:&ET92<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M3$5&5#H@,'!X)SX@0V%P:71A;"!L96%S97,\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R
M:6=H="<^*#DT/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M5$585"U!3$E'3CH@;&5F="<^*3PO=&0^(#PO='(^(#QT<B!S='EL93TS1"=6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R9V(H
M,C`T+#(U-2PR,#0I)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@G/B!.;W1E<R!P
M87EA8FQE/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!
M3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/B@Q.3,\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXI/"]T
M9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU,1494.B`P<'@G/B!/=&AE<B!N;VXM8W5R<F5N="!L
M:6%B:6QI=&EE<SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`H,2PU-3D\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T
M.R!415A4+4%,24=..B!L969T)SX@*3PO=&0^(#PO='(^(#QT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R
M9V(H,C`T+#(U-2PR,#0I)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!0041$24Y'+4Q%1E0Z(#!P>"<^
M(%1O=&%L('!U<F-H87-E('!R:6-E/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#0Q
M+#DV-#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)
M3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO
M=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"<^
M("9N8G-P.SPO<#X@/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M56YA=61I=&5D(%!R;R!&;W)M82!&:6YA;F-I86P@26YF;W)M871I;VX@;V8@
M3W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SPA
M+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@
M5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL
M,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^
M/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B!4
M:&4@=6YA=61I=&5D('!R;R!F;W)M82!F:6YA;F-I86P@:6YF;W)M871I;VX@
M8V]M8FEN97,@=&AE(&AI<W1O<FEC86P@<F5S=6QT<R!O9B!O<&5R871I;VYS
M(&]F($YO=F%V87@@86YD($ES8V]N;W9A(&9O<B!T:&4@<&5R:6]D<R!P<F5S
M96YT960@8F5L;W<@86YD(')E9FQE8W1S('1H92!A<'!L:6-A=&EO;B!O9B!T
M:&4@9F]L;&]W:6YG(&%D:G5S=&UE;G1S.CPO<#X@/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X)SX@)FYB<W`[/"]P/B`\
M=&%B;&4@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM5$]0.B`P
M<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q
M,#`E/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S
M='EL93TS1"=724142#H@,"XR-6EN)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#`N,C5I;CLG/B9M:61D;W0[/"]T9#X@/'1D('-T>6QE/3-$
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M+51/4#H@,'!T)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!-05)'24XM5$]0.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G5D52
M5$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XR-6EN
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G=VED=&@Z(#`N,C5I;CLG/B9M
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M1TE.+51/4#H@,'!T)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XM5$]0.B`P<'0G(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G
M5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XR
M-6EN)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G=VED=&@Z(#`N,C5I;CLG
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M3BU,1494.B`P+C5I;CL@5TE$5$@Z(#DP)2<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'
M+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!C96YT97([(%!!1$1)3D<M3$5&
M5#H@,'!X)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5#H@8F]L9"`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G(&-O;'-P86X],T0V/B`\<"!S='EL93TS
M1"=-05)'24XM0D]45$]-.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M+51/4#H@,'!T)SX@/'-T<F]N9SY4:')E92!-;VYT:',@16YD960\+W-T<F]N
M9SX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!-05)'24XM5$]0.B`P<'0G/B`\<W1R;VYG/E-E<'1E;6)E
M<B`S,"P\+W-T<F]N9SX\+W`^(#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
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M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)R!C;VQS<&%N/3-$-CX@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@
M,'!T.R!415A4+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU43U`Z(#!P="<^(#QS=')O
M;F<^3FEN92!-;VYT:',@16YD960\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM
M5$]0.B`P<'0G/B`\<W1R;VYG/E-E<'1E;6)E<B`S,"P\+W-T<F]N9SX\+W`^
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M.R!415A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C96YT97(G
M(&-O;'-P86X],T0R/C(P,3,\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P
M=#L@5$585"U!3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)
M3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^("9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M
M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(^,C`Q,CPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$
M24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N
M=&5R)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(
M5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,CXR,#$S
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'
M2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E
M;G1E<B<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T.R!4
M15A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C96YT97(G(&-O
M;'-P86X],T0R/C(P,3(\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@
M5$585"U!3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4Q%1E0Z(#!P>"<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@8V5N
M=&5R)R!C;VQS<&%N/3-$,30^*&EN('1H;W5S86YD<RD\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@
M<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#
M3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@4$%$1$E.1RU,1494
M.B`P<'@[(%=)1%1(.B`T-"4G/B!2979E;G5E/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!72414
M2#H@,B4G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^("0\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SX@-"PX-CD\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/
M5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^("9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)
M3D<M0D]45$]-.B`R+C5P=#L@5TE$5$@Z(#(E)SX@)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!724142#H@,24G
M/B`D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M=#L@5TE$5$@Z(#$P)2<^(#8L,C<R/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=.
M.B!L969T.R!724142#H@,24G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%=)1%1(
M.B`R)2<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B`Q-"PQ.34\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/
M5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^("9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)
M3D<M0D]45$]-.B`R+C5P=#L@5TE$5$@Z(#(E)SX@)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!724142#H@,24G
M/B`D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M=#L@5TE$5$@Z(#$P)2<^(#$Y+#4S,#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'
M3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T
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M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^("@Q
M-2PV.#<\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$
M24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`I/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4
M+4%,24=..B!R:6=H="<^("@X+#0Y,#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'
M3CH@;&5F="<^("D\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R
M+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@*#0P+#4V-3PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-
M.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^("D\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%
M4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F
M="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT)SX@*#(U+#`S,SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^
M("D\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@G/B!"
M87-I8R!A;F0@9&EL=71E9"!N970@;&]S<R!P97(@<VAA<F4\+W1D/B`\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@
M5$585"U!3$E'3CH@;&5F=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("@P
M+C`Y/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@
M5$585"U!3$E'3CH@;&5F=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^("D\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#(N-7!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("0\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^("@P+C`V/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F=#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("D\
M+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^("0\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=.
M.B!R:6=H=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^("@P+C(T/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F=#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^("D\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'
M3CH@;&5F=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("@P+C$X/"]T9#X@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'
M3CH@;&5F=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^("D\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4G/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4Q%1E0Z(#!P>"<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'
M3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
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M<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L
M969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!415A4+4%,24=..B!R:6=H="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M5$585"U!3$E'3CH@<FEG:'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^
M(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I
M9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3CH@,'!T(#!P>"<^("9N8G-P.SPO<#X@/"$M+45N9$9R86=M96YT
M+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W,#`T
M8C<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S(T.3@V8V8S7S$U
M.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-"]7;W)K<VAE971S+U-H965T,C0N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4R1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY&86ER
M(%9A;'5E($UE87-U<F5M96YT<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64@365A
M<W5R96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@2&EE<F%R8VAY/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/"$M+41/0U194$4@:'1M;"!0
M54),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.
M(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A
M;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N
M="TM/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!&3TY4+5=%24=(5#H@;F]R;6%L.R!-05)'24XZ(#!P
M="`P<'@[(%1%6%0M04Q)1TXZ(&IU<W1I9GD[(%1%6%0M24Y$14Y4.B`P+C5I
M;B<^(%1H92!F;VQL;W=I;F<@=&%B;&4@<F5P<F5S96YT<R!T:&4@0V]M<&%N
M>28C,SD[<R!F86ER('9A;'5E(&AI97)A<F-H>2!F;W(@:71S(&9I;F%N8VEA
M;"!A<W-E=',@86YD(&QI86)I;&ET:65S(&UE87-U<F5D(&%T(&9A:7(@=F%L
M=64@;VX@82!R96-U<G)I;F<@8F%S:7,@*&EN('1H;W5S86YD<RDZ/"]P/B`\
M<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!&3TY4+5=%24=(5#H@;F]R;6%L.R!-05)'24XZ(#!P="`P<'@[
M(%1%6%0M04Q)1TXZ(&IU<W1I9GD[(%1%6%0M24Y$14Y4.B`P+C5I;B<^("9N
M8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(%=)1%1(.B`Q,#`E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD
M.R!0041$24Y'+4Q%1E0Z(#!P>#L@5$585"U)3D1%3E0Z(#!P>"<^("9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)
M1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)SX@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'
M3CH@8V5N=&5R)R!C;VQS<&%N/3-$,3`^1F%I<B!686QU92!A="!397!T96UB
M97(@,S`L(#(P,3,\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P="<^("9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)SX@)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!
M3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,3`^1F%I<B!686QU92!A="!$96-E
M;6)E<B`S,2P@,C`Q,CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)SX@
M)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU,1494.B`P<'@[(%1%6%0M1$5#3U)!5$E/3CH@=6YD97)L:6YE
M.R!415A4+4E.1$5.5#H@,'!X)SX@07-S971S/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M
M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^("9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^(#QS=')O;F<^
M3&5V96P@,3PO<W1R;VYG/CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T
M.R!415A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.
M1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!
M3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&
M3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)SX@/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SX\<W1R;VYG/DQE=F5L(#(\+W-T
M<F]N9SX\+V9O;G0^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T.R!4
M15A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"
M3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'
M3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)SX@/'-T<F]N9SY,
M979E;"`S/"]S=')O;F<^/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[
M(%1%6%0M04Q)1TXZ(&-E;G1E<B<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'
M+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,
M24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C96YT97(G/B`\<W1R;VYG
M/DQE=F5L(#$\+W-T<F]N9SX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P
M=#L@5$585"U!3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)
M3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^("9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M
M04Q)1TXZ(&-E;G1E<B<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^(#QS=')O
M;F<^3&5V96P@,CPO<W1R;VYG/CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@
M,7!T.R!415A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$
M1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R)SX@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$58
M5"U!3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)SX@/'-T
M<F]N9SY,979E;"`S/"]S=')O;F<^/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^("9N8G-P.SPO=&0^(#PO='(^
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M+W1D/B`\=&0@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@5TE$5$@Z(#(E)SX@)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!
M3$E'3CH@;&5F=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@5TE$5$@Z(#$E)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!7
M24142#H@."4G/B`M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!724142#H@,B4G
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!724142#H@,24G/B`D/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(%=)1%1(.B`X)2<^(#(S+#DQ-SPO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!724142#H@,24G/B`F;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@5TE$5$@Z(#(E)SX@)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!
M3$E'3CH@;&5F=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@5TE$5$@Z(#$E)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!7
M24142#H@."4G/B`M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!724142#H@,B4G
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!724142#H@,24G/B`D/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(%=)1%1(.B`X)2<^("T\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@5TE$5$@Z(#$E)SX@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(%=)1%1(.B`R)2<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ
M(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(%=)1%1(.B`Q)2<^("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@5TE$5$@Z
M(#@E)SX@,S(L.30U/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!724142#H@,B4G
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!724142#H@,24G/B`D/"]T
M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9#L@5$585"U!3$E'3CH@<FEG:'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(%=)1%1(.B`X)2<^("T\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@5TE$5$@Z(#$E)SX@)FYB<W`[/"]T9#X@
M/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!
M0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@,'!X.R!415A4+4E.1$5.
M5#H@,'!X)SX@5&]T86P@:6YV97-T;65N=',\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^
M("0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M)SX@+3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)
M3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]4
M5$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!4
M15A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@
M5$585"U!3$E'3CH@<FEG:'0G/B`R,RPY,3<\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M
M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@+3PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]4
M5$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,
M24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!
M3$E'3CH@<FEG:'0G/B`M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T
M)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P
M="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#,R+#DT-3PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]2
M1$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L
M969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0G/B`M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB
M<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M
M3$5&5#H@,'!X.R!415A4+41%0T]2051)3TXZ('5N9&5R;&EN93L@5$585"U)
M3D1%3E0Z(#!P>"<^($QI86)I;&ET:65S/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D
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M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!
M3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
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M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@
M;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U
M+#(P-"DG/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'
M+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&
M5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@5V%R<F%N="!L:6%B:6QI=&EE
M<SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M
M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0G/B`M/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,
M24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B
M;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^("T\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/
M33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU
M<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'
M3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(')I9VAT)SX@+3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^
M("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!
M1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`M/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!4
M15A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^
M("T\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'
M+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/
M33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(')I9VAT)SX@,C8W/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=.
M.B!L969T)SX@)FYB<W`[/"]T9#X@/"]T<CX@/"]T86)L93X@/"$M+45N9$9R
M86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;VYC:6QI871I;VX@;V8@3&5V
M96P@,R!!<W-E=',@86YD($QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S
M0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W
M=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T
M9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\<"!S='EL
M93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M
M24Y$14Y4.B`P+C5I;B<^(%1H92!F;VQL;W=I;F<@=&%B;&4@<')O=FED97,@
M82!R96-O;F-I;&EA=&EO;B!O9B!T:&4@8F5G:6YN:6YG(&%N9"!E;F1I;F<@
M8F%L86YC92!O9B!,979E;"`S(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@;65A
M<W5R960@;VX@82!R96-U<G)I;F<@8F%S:7,@9F]R('1H92!N:6YE(&UO;G1H
M<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,@*&EN('1H;W5S86YD<RDZ/"]P
M/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I
M;B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!3
M13H@8V]L;&%P<V4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(%=)1%1(.B`W-24G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M
M)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@4$%$1$E.1RU,1494.B`P<'@G/B`F;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5#H@8F]L9"`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G(&-O;'-P86X],T0R/B`\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"<^(#QS=')O;F<^
M1F%I<B9N8G-P.U9A;'5E)FYB<W`[365A<W5R96UE;G1S)FYB<W`[;V8\+W-T
M<F]N9SX\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X)SX@/'-T<F]N9SY787)R86YT<R9N8G-P.U5S:6YG(%-I9VYI
M9FEC86YT/"]S=')O;F<^/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3CH@,'!T(#!P>"<^(#QS=')O;F<^56YO8G-E<G9A8FQE)FYB
M<W`[26YP=71S)FYB<W`[/"]S=')O;F<^/"]P/B`\<"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"<^(#QS=')O;F<^*$QE=F5L
M)FYB<W`[,RD\+W-T<F]N9SX\+W`^(#PO=&0^(#QT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,7!T.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y
M;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/
M4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%!!1$1)3D<M3$5&5#H@,'!X.R!724142#H@-S<E)SY"86QA;F-E
M(&%T($1E8V5M8F5R(#,Q+"`R,#$R/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T.R!724142#H@
M,24G/B0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4
M+4%,24=..B!R:6=H=#L@5TE$5$@Z(#(P)2<^,C8W/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z
M(#$E)SX@)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P
M=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@G/B!#:&%N
M9V4@:6X@9F%I<B!V86QU92!O9B!787)R86YT(&QI86)I;&ET>3PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q
M<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@
M;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0G/B`H,C8W/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^
M("D\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P=#L@4$%$1$E.1RU,1494.B`P<'@G/B!"86QA;F-E(&%T(%-E<'1E;6)E
M<B`S,"P@,C`Q,SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`M/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T
M.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/"]T<CX@/"]T86)L
M93X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU
M:6XG/B`F;F)S<#L\+W`^(#PA+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S(T
M.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-`T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S
M8V(P9C<P,#1B-S0O5V]R:W-H965T<R]3:&5E=#(U+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YV97-T;65N=',@*%1A8FQE
M<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY);G9E<W1M96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E<W1M96YT<R!#;&%S<VEF
M:65D(&%S($%V86EL86)L92U&;W(M4V%L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O
M+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N
M=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B
M("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!415A4+4E.
M1$5.5#H@,"XU:6XG/B!);G9E<W1M96YT<R!C;&%S<VEF:65D(&%S(&%V86EL
M86)L92UF;W(M<V%L92!A<R!O9B!397!T96UB97(@,S`L(#(P,3,@86YD($1E
M8V5M8F5R(#,Q+"`R,#$R('=E<F4@8V]M<')I<V5D(&]F("AI;B!T:&]U<V%N
M9',I.CPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B`F;F)S<#L\+W`^(#QT
M86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!724142#H@
M,3`P)2<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@5$58
M5"U!3$E'3CH@8V5N=&5R)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5-)6D4Z(#$P<'0[
M(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#$T/CQS=')O;F<^4V5P
M=&5M8F5R(#,P+"`R,#$S/"]S=')O;F<^/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M
M04Q)1TXZ(&-E;G1E<B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U325I%.B`Q,'!T.R!4
M15A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0Q-#X\<W1R;VYG/D1E8V5M
M8F5R(#,Q+"`R,#$R/"]S=')O;F<^/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^)FYB<W`[/"]T
M9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[($9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS
M<&%N/3-$,CX\<W1R;VYG/D%M;W)T:7IE9"!#;W-T/"]S=')O;F<^/"]T9#X@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED
M.R!&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A
M;CTS1#(^/'-T<F]N9SY'<F]S<R!5;G)E86QI>F5D($=A:6YS/"]S=')O;F<^
M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@
M8V]L<W!A;CTS1#(^/'-T<F]N9SY'<F]S<R!5;G)E86QI>F5D($QO<W-E<SPO
M<W1R;VYG/CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#%P="!S;VQI9#L@1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!C
M96YT97(G(&-O;'-P86X],T0R/CQS=')O;F<^1F%I<B!686QU93PO<W1R;VYG
M/CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!C96YT97(G
M(&-O;'-P86X],T0R/CQS=')O;F<^06UO<G1I>F5D($-O<W0\+W-T<F]N9SX\
M+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60[($9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!C
M;VQS<&%N/3-$,CX\<W1R;VYG/D=R;W-S(%5N<F5A;&EZ960@1V%I;G,\+W-T
M<F]N9SX\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[($9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@8V5N
M=&5R)R!C;VQS<&%N/3-$,CX\<W1R;VYG/D=R;W-S(%5N<F5A;&EZ960@3&]S
M<V5S/"]S=')O;F<^/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(^/'-T<F]N9SY&86ER(%9A;'5E/"]S
M=')O;F<^/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G
M/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-F9F-C)SX@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU,1494.B`Y<'0[(%1%
M6%0M24Y$14Y4.B`M.7!T.R!724142#H@,C`E)SX@075C=&EO;B!R871E('-E
M8W5R:71I97,\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!724142#H@,24G
M/B0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,
M24=..B!R:6=H=#L@5TE$5$@Z(#<E)SX@,2PQ-S4\+W1D/B`\=&0@<W1Y;&4]
M,T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z
M(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!724142#H@,24G/B0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#<E)SXV,#$\+W1D/B`\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!724142#H@,24G/B0\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#<E)SXM
M/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(
M.B`W)2<^(#$L-S<V/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#$E)SXD/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@
M<FEG:'0[(%=)1%1(.B`W)2<^(#$L,3<U/"]T9#X@/'1D('-T>6QE/3-$)U=)
M1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$
M5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`W)2<^-#`Y/"]T9#X@/'1D('-T
M>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)
M1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`W)2<^+3PO=&0^
M(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%=)1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@-R4G
M/B`Q+#4X-#PO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO
M=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"04-+1U)/54Y$+4-/3$]2.B!W:&ET92<^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%!!1$1)3D<M3$5&5#H@.7!T.R!415A4+4E.1$5.5#H@
M+3EP="<^($-O<G!O<F%T92!D96)T('-E8W5R:71I97,\+W1D/B`\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9#L@1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^(#(R
M+#$S-SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9"<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U325I%.B`Q,'!T.R!415A4
M+4%,24=..B!R:6=H="<^(#0\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/B`M/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED.R!&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,C(L
M,30Q/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M
M04Q)1TXZ(')I9VAT)SX@,S$L,S0P/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4
M+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,C$\+W1D/B`\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[($9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G
M/B`M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M
M04Q)1TXZ(')I9VAT)SX@,S$L,S8Q/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C
M8V-F9F-C)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.
M1RU"3U143TTZ(#(N-7!T)SY4;W1A;#PO=&0^(#QT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!&3TY4+5-)6D4Z
M(#$P<'0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N,C5P="!D;W5B;&4[($9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'
M3CH@<FEG:'0G/B`R,RPS,3(\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,BXR-7!T(&1O=6)L93L@1D].5"U325I%.B`Q
M,'!T)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE.R!&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ
M(')I9VAT)SX@-C`U/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N,C5P="!D;W5B;&4[($9/3E0M4TE:13H@,3!P="<^
M("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXR
M-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0G/BT\+V9O;G0^(#PO=&0^(#QT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!&
M3TY4+5-)6D4Z(#$P<'0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N,C5P="!D;W5B;&4[($9/3E0M4TE:13H@,3!P=#L@
M5$585"U!3$E'3CH@<FEG:'0G/B`R,RPY,3<\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXR-7!T(&1O=6)L93L@1D].
M5"U325I%.B`Q,'!T)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!&3TY4+5-)6D4Z(#$P<'0[(%1%
M6%0M04Q)1TXZ(')I9VAT)SX@,S(L-3$U/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N,C5P="!D;W5B;&4[($9/3E0M
M4TE:13H@,3!P="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXR-7!T(&1O=6)L93L@1D].5"U325I%.B`Q,'!T.R!415A4
M+4%,24=..B!R:6=H="<^(#0S,#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!&3TY4+5-)6D4Z
M(#$P<'0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N,C5P="!D;W5B;&4[($9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'
M3CH@<FEG:'0G/B`M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#(N,C5P="!D;W5B;&4[($9/3E0M4TE:13H@,3!P="<^
M("0\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXR
M-7!T(&1O=6)L93L@1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H
M="<^(#,R+#DT-3PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,BXU<'0G/B9N8G-P.SPO=&0^(#PO='(^(#PO=&%B;&4^(#PA+2U%;F1&<F%G
M;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F
M-S`P-&(W-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R-#DX-F-F
M,U\Q-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0O5V]R:W-H965T<R]3:&5E
M=#(V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%2T@^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M1V]O9'=I;&P@86YD($]T:&5R($EN=&%N9VEB;&4@07-S971S("A486)L97,I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^1V]O9'=I;&P@86YD($]T:&5R($EN=&%N9VEB;&4@07-S971S(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-C:&5D=6QE(&]F($=O;V1W:6QL/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O
M1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW
M,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@
M+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\<"!S='EL93TS
M1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XZ(#!P="`P<'@G/B`F;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"="
M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM3$5&5#H@,"XU:6X[(%=)
M1%1(.B`Y,"4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT
M<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@4$%$
M1$E.1RU,1494.B`P<'@[(%1%6%0M24Y$14Y4.B`P<'@G/B`F;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5#H@8F]L
M9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B!B;VQD(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&-O;'-P86X],T0V/B`\<"!S
M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M34%21TE.+51/4#H@,'!T)SX@/'-T<F]N9SY.:6YE($UO;G1H<R!%;F1E9#PO
M<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!4
M15A4+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3BU43U`Z(#!P="<^(#QS=')O;F<^4V5P
M=&5M8F5R(#,P+#PO<W1R;VYG/CPO<#X@/"]T9#X@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S
M='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU,1494.B`P<'@[(%1%6%0M24Y$
M14Y4.B`P<'@G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P
M="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U714E'2%0Z
M(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(^,C`Q,SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4
M.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)SX@)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C96YT97(G
M(&-O;'-P86X],T0R/C(P,3(\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P
M="<^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR
M,#0I)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@[(%=)1%1(.B`W,B4[(%1%6%0M
M24Y$14Y4.B`P<'@G/B!"96=I;FYI;F<@8F%L86YC93PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`R)2<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F
M=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B`S,RPQ-#$\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=.
M.B!L969T.R!724142#H@,24G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!724142#H@,B4G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SX@,S,L,30Q/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F
M=#L@5TE$5$@Z(#$E)SX@)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$
M)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H
M:71E)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@[(%1%6%0M24Y$14Y4.B`P<'@G
M/B!';V]D=VEL;"!R97-U;'1I;F<@9G)O;2!A8W%U:7-I=&EO;B!O9B!B=7-I
M;F5S<SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXR-2PR.3@\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=.
M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!415A4+4%,24=..B!R:6=H="<^+3PO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^
M(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I)SX@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@[(%1%6%0M24Y$14Y4
M.B`P<'@G/B!#=7)R96YC>2!T<F%N<VQA=&EO;CPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G
M/B`S,C`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$
M24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14
M3TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4
M+4%,24=..B!R:6=H="<^("T\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T
M)SX@)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T
M.R!0041$24Y'+4Q%1E0Z(#!P>#L@5$585"U)3D1%3E0Z(#!P>"<^($5N9&EN
M9R!B86QA;F-E/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P
M="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#4X+#<U.3PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]2
M1$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L
M969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0G/B`S,RPQ-#$\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0G
M/B`F;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T
M*2<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M3$5&
M5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
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M(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\+W1A
M8FQE/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G/B`F;F)S<#L\+W`^(#PA
M+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($ED
M96YT:69I86)L92!);G1A;F=I8FQE($%S<V5T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7
M,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W
M=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD
M=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'1A8FQE
M('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU,1494
M.B`P+C5I;CL@5TE$5$@Z(#DP)2<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,#X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@4$%$1$E.1RU,1494
M.B`P<'@[(%1%6%0M24Y$14Y4.B`P<'@G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$
M1$E.1RU"3U143TTZ(#%P="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M4TE:13H@,3!P
M=#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L
M<W!A;CTS1#(^/'-T<F]N9SY'<F]S<R!#87)R>6EN9R!!;6]U;G0\+W-T<F]N
M9SX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P="<^("9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4.B!B;VQD
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0Z(&)O;&0@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@8V]L<W!A;CTS1#(^(#QP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X)SX@/'-T
M<F]N9SY!8V-U;75L871E9"!!;6]R=&EZ871I;VX\+W-T<F]N9SX\+W`^(#PO
M=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4.B!B
M;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B!B;VQD(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&-O;'-P86X],T0R
M/B`\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P
M>"<^(#QS=')O;F<^26YT86YG:6)L93PO<W1R;VYG/CPO<#X@/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G/B`\<W1R;VYG
M/D%S<V5T<RP@3F5T/"]S=')O;F<^/"]P/B`\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]T9#X@/"]T<CX@/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M
M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!415A4+4%,24=..B!L969T.R!0041$24Y'+4Q%1E0Z(#!P
M>#L@5$585"U)3D1%3E0Z(#!P>"<^($9I;FET92UL:79E9"!I;G1A;F=I8FQE
M(&%S<V5T<SH\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!
M3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
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M(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S
M<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4G/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T.R!0041$24Y'+4Q%
M1E0Z(#!P>#L@5TE$5$@Z(#4X)3L@5$585"U)3D1%3E0Z(#!P>"<^(%!R;W!R
M:65T87)Y(&%D:G5V86YT('1E8VAN;VQO9WD\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!724142#H@,B4G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)
M1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SX@,3$L-3DT/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F
M=#L@5TE$5$@Z(#$E)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@5TE$5$@Z(#(E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T.R!724142#H@
M,24G/B0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4
M+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$P)2<^*#DW/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z
M(#$E)SXI/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$
M5$@Z(#(E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!415A4+4%,24=..B!L969T.R!724142#H@,24G/B0\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H=#L@
M5TE$5$@Z(#$P)2<^(#$Q+#0Y-SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^("9N8G-P
M.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I)SX@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P
M=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@[(%1%6%0M
M24Y$14Y4.B`P<'@G/B!#;VQL86)O<F%T:6]N(&%G<F5E;65N=',\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@
M,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ
M(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(')I9VAT)SX@-"PY.3(\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T
M)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^("@X-#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%
M6%0M04Q)1TXZ(&QE9G0G/B`I/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#0L.3`X/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#PO='(^
M(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/
M54Y$+4-/3$]2.B!W:&ET92<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU,1494.B`P<'@[(%1%6%0M24Y$14Y4.B`P<'@G/B!4;W1A;"!I
M9&5N=&EF:6%B;&4@:6YT86YG:6)L92!A<W-E=',\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%
M4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F
M="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT)SX@,38L-3@V/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^("@Q.#$\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[
M(%1%6%0M04Q)1TXZ(&QE9G0G/B`I/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^(#$V
M+#0P-3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)
M3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO
M=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"<^
M("9N8G-P.SPO<#X@/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4V-H961U;&4@;V8@17-T:6UA=&5D($%M;W)T:7IA=&EO;B!%>'!E;G-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/"$M+41/0U194$4@:'1M
M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO
M+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M
M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G
M;65N="TM/B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S93L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@5TE$5$@Z(#$P,"4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU,1494.B`P<'@G/B!996%R/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P
M86X],T0R/D%M;W5N=#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)SX@
M)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L
M969T.R!0041$24Y'+4Q%1E0Z(#!P>#L@5TE$5$@Z(#$S)2<^(#(P,3,@*')E
M;6%I;F1E<BD\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!7
M24142#H@-S0E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!415A4+4%,24=..B!L969T.R!724142#H@,B4G/B0\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H
M=#L@5TE$5$@Z(#$P)2<^,C<Q/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB<W`[
M/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494
M.B`P<'@G/B`R,#$T/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/C$L,#@T/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F
M="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P
M-"DG/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4Q%1E0Z(#!P>"<^(#(P,34\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=.
M.B!R:6=H="<^,2PP.#0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@
M<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#
M3TQ/4CH@=VAI=&4G/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4Q%1E0Z(#!P>"<^(#(P,38\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T
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M3$]2.B!R9V(H,C`T+#(U-2PR,#0I)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P<'@G
M/B`R,#$W/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!
M3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA
M;#L@1D].5"U35%E,13H@;F]R;6%L)SXF;F)S<#L\+V9O;G0^(#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4U193$4Z(&YO<FUA
M;#L@1D].5"U714E'2%0Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0G/B`Q
M+#`X-#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M
M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!W:&ET
M92<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@,C`Q.#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/CQF;VYT('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86P[($9/3E0M4U193$4Z(&YO<FUA
M;"<^)FYB<W`[/"]F;VYT/B`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M5T5)1TA4.B!N;W)M
M86P[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,2PP.#0\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\
M+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G
M/B`F;F)S<#L\+W`^(#PA+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S(T.3@V
M8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-`T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S8V(P
M9C<P,#1B-S0O5V]R:W-H965T<R]3:&5E=#(W+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5D=!
M0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS
M871I;VX@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY$969E<G)E9"!#;VUP96YS871I;VX@07)R86YG
M96UE;G0@=VET:"!);F1I=FED=6%L+"!3:&%R92UB87-E9"!087EM96YT<R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-U;6UA<GD@;V8@3W!T:6]N($%C=&EV:71Y/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/"$M+41/0U194$4@:'1M;"!054),
M24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B
M:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I
M=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM
M/B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@5TE$
M5$@Z(#$P,"4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT
M<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU,1494.B`P<'@[(%1%6%0M
M24Y$14Y4.B`P<'@G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ
M(#%P="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U714E'
M2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#8^,C`P
M-2!3=&]C:R!);F-E;G1I=F4@4&QA;CPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/
M33H@,7!T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B
M;VQD.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0V/C$Y.34@4W1O
M8VL@3W!T:6]N(%!L86X\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
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M,7!T.R!415A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y
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M96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@
M5$585"U!3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C
M;VQS<&%N/3-$,CX\<W1R;VYG/E=E:6=H=&5D+4%V97)A9V4@17AE<F-I<V4@
M4')I8V4\+W-T<F]N9SX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@
M5$585"U!3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M
M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^("9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(^/'-T<F]N9SY3=&]C:R!/<'1I;VYS
M/"]S=')O;F<^/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M
M04Q)1TXZ(&-E;G1E<B<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/
M33H@,7!T.R!415A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@
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M33H@,7!T.R!415A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\+W1R
M/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=2
M3U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M3$5&5#H@,'!X.R!724142#H@-#0E
M.R!415A4+4E.1$5.5#H@,'!X)SX@3W5T<W1A;F1I;F<@870@2F%N=6%R>2`Q
M+"`R,#$S/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$
M5$@Z(#(E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!415A4+4%,24=..B!L969T.R!724142#H@,24G/B`F;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R
M:6=H=#L@5TE$5$@Z(#$P)2<^(#DL,30S+#@R-3PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q
M)2<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%=)1%1(.B`R)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG
M:'0[(%=)1%1(.B`Q,"4G/B`Q+C@W/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SX@)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z
M(#(E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!415A4+4%,24=..B!L969T.R!724142#H@,24G/B`F;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H
M=#L@5TE$5$@Z(#$P)2<^(#(Q,2PY,#`\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T.R!724142#H@,24G/B`F
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!72414
M2#H@,B4G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R!7
M24142#H@,3`E)SX@-"XY-#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^("9N8G-P.SPO
M=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"04-+1U)/54Y$+4-/3$]2.B!W:&ET92<^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%!!1$1)3D<M3$5&5#H@,'!X.R!415A4+4E.1$5.5#H@
M,'!X)SX@1W)A;G1E9#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;#L@1D].5"U35%E,13H@
M;F]R;6%L)SXF;F)S<#L\+V9O;G0^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U714E'2%0Z
M(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0G/B`T+#$Q-RPU,#`\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SX\
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M5"U714E'2%0Z(&YO<FUA;#L@5$585"U!3$E'3CH@<FEG:'0G/B`Q+CDR/"]T
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M5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@
M;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U
M+#(P-"DG/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'
M+4Q%1E0Z(#!P>#L@5$585"U)3D1%3E0Z(#!P>"<^($5X97)C:7-E9#PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-
M.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@5$585"U!3$E'3CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&YO<FUA;#L@1D].5"U35%E,13H@;F]R;6%L)SXF;F)S<#L\+V9O
M;G0^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M4U193$4Z(&YO<FUA;#L@1D].5"U714E'2%0Z(&YO<FUA;#L@5$585"U!3$E'
M3CH@<FEG:'0G/B`H-3(R+#(Y,CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M4U193$4Z(&YO<FUA;#L@1D].5"U714E'2%0Z(&YO
M<FUA;#L@5$585"U!3$E'3CH@;&5F="<^("D\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXD/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/C(N
M,CD\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,
M24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^+3PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE
M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%
M6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^+3PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"04-+1U)/54Y$+4-/3$]2.B!W:&ET92<^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%!!1$1)3D<M3$5&
M5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@0V%N8V5L960\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ
M(')I9VAT)SX@*#@P,BPX.#,\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T
M)SX@*3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@
M5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(')I9VAT)SX@,2XW-#PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ
M(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@*#(S+#<U,#PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`I/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)#PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`T+C`U
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"
M3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#PO
M='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I)SX@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!0041$
M24Y'+4Q%1E0Z(#!P>#L@5$585"U)3D1%3E0Z(#!P>"<^($]U='-T86YD:6YG
M(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,SPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/
M33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M="<^(#$Q+#DS-BPQ-3`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0G
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0
M041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P
M="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,2XX.#PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P
M=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T
M)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=.
M.B!R:6=H="<^(#$X."PQ-3`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE
M9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R
M+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@-2XP-#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#PO='(^(#QT
M<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$
M+4-/3$]2.B!W:&ET92<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@4$%$1$E.1RU,1494.B`P<'@[(%1%
M6%0M24Y$14Y4.B`P<'@G/B!3:&%R97,@97AE<F-I<V%B;&4@870@4V5P=&5M
M8F5R(#,P+"`R,#$S/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R
M+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B
M;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@-"PV-#<L
M.#<S/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.
M1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H="<^(#(N,3(\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U14
M3TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`Q
M.#@L,34P/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"
M3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!415A4+4%,24=..B!R:6=H="<^(#4N,#0\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M
M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B
M*#(P-"PR-34L,C`T*2<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%!!1$1)3D<M3$5&5#H@,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@
M;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
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M(%1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!4
M15A4+4%,24=..B!R:6=H="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58
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M+"`R,#$S/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`\9F]N="!S='EL93TS1"=&3TY4
M+5=%24=(5#H@;F]R;6%L.R!&3TY4+5-464Q%.B!N;W)M86PG/B9N8G-P.SPO
M9F]N=#X@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+5-464Q%.B!N
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M3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"
M3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T.R!415A4+4%,24=..B!R:6=H="<^("9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P
M=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.
M1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T.R!415A4+4%,24=..B!R:6=H="<^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"
M3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!R:6=H="<^("9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-
M.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#PO='(^
M(#PO=&%B;&4^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%
M3E0Z(#`N-6EN)SX@)FYB<W`[)FYB<W`[/"]P/B`\(2TM16YD1G)A9VUE;G0M
M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!<W-U;7!T:6]N<R!U<V5D('1O($5S=&EM871E
M($=R86YT($1A=&4@1F%I<B!686QU92!O9B!3=&]C:R!/<'1I;VYS(&=R86YT
M960@=7-I;F<@0FQA8VLM4V-H;VQE<R!/<'1I;VXM4')I8VEN9R!-;V1E;#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SPA+2U$3T-465!%(&AT
M;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L
M+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ
M+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A
M9VUE;G0M+3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B!4:&4@9F%I<B!V86QU
M92!O9B!S=&]C:R!O<'1I;VYS(&=R86YT960@=V%S(&5S=&EM871E9"!A="!T
M:&4@9&%T92!O9B!G<F%N="!U<VEN9R!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I
M;VXM<')I8VEN9R!M;V1E;"!W:71H('1H92!F;VQL;W=I;F<@87-S=6UP=&EO
M;G,Z/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ
M(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^("9N8G-P.SPO<#X@/'1A
M8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(%=)1%1(.B`Q
M,#`E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\='(@<W1Y
M;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!C96YT97(G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!415A4
M+4%,24=..B!C96YT97(G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60G(&-O;'-P86X],T0V/B`\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"<^(#QS
M=')O;F<^5&AR964@36]N=&AS($5N9&5D/"]S=')O;F<^/"]P/B`\<"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"<^(#QS=')O
M;F<^4V5P=&5M8F5R(#,P+#PO<W1R;VYG/CPO<#X@/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[
M(%1%6%0M04Q)1TXZ(&-E;G1E<B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9"<@8V]L<W!A;CTS1#8^
M(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X
M)SX@/'-T<F]N9SY.:6YE($UO;G1H<R!%;F1E9#PO<W1R;VYG/CPO<#X@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@G/B`\
M<W1R;VYG/E-E<'1E;6)E<B`S,"P\+W-T<F]N9SX\+W`^(#PO=&0^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!C96YT
M97(G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q
M<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U325I%
M.B`Q,'!T.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R/CQS=')O
M;F<^,C`Q,SPO<W1R;VYG/CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T.R!415A4+4%,24=..B!C96YT97(G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!C
M96YT97(G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'
M3CH@8V5N=&5R)R!C;VQS<&%N/3-$,CX\<W1R;VYG/C(P,3(\+W-T<F]N9SX\
M+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!
M3$E'3CH@8V5N=&5R)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED
M.R!&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A
M;CTS1#(^/'-T<F]N9SXR,#$S/"]S=')O;F<^/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%
M6%0M04Q)1TXZ(&-E;G1E<B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U325I%.B`Q,'!T
M.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R/CQS=')O;F<^,C`Q
M,CPO<W1R;VYG/CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T.R!415A4+4%,24=..B!C96YT97(G/B9N8G-P.SPO=&0^(#PO='(^(#QT
M<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$
M+4-/3$]2.B`C8V-F9F-C)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@5TE$5$@Z(#0T)2<^5V5I9VAT960M879E<F%G92!F86ER('9A;'5E(&]F
M('-T;V-K(&]P=&EO;G,@9W)A;G1E9#PO=&0^(#QT9"!S='EL93TS1"=72414
M2#H@,B4G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%=)1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SX@,2XT,3PO
M=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=724142#H@,B4G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@
M,3`E)SX@,2XP.3PO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,B4G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`Q)2<^)#PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!724142#H@,3`E)SX@,2XP,CPO=&0^(#QT9"!S='EL93TS1"=72414
M2#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,B4G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(
M.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%
M6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SX@,"XW,3PO=&0^(#QT9"!S
M='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2
M.B!W:&ET92<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/E)I<VLM
M9G)E92!I;G1E<F5S="!R871E/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9#XF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4
M+4%,24=..B!R:6=H="<^,2XQ,B4M,2XS-CPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0G/B4\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M
M04Q)1TXZ(')I9VAT)SXP+C4U/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P="<^)3PO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@
M<FEG:'0G/C`N-30E+3$N,S8\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T)SXE/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R
M:6=H="<^,"XU-24M,2XU-#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0G/B4\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C9F9C8R<^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/D1I=FED96YD('EI96QD/"]T9#X@
M/'1D/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^,#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B4\+W1D/B`\=&0^)FYB<W`[
M/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXP/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P="<^)3PO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58
M5"U!3$E'3CH@<FEG:'0G/C`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T)SXE/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R
M:6=H="<^,#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B4\
M+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4G/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T)SY6;VQA=&EL:71Y/"]T9#X@/'1D/B9N8G-P.SPO=&0^
M(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!415A4+4%,24=..B!R:6=H="<^-38N-S4E+38R+C4Q/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)3PO=&0^(#QT9#XF;F)S<#L\+W1D
M/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@5$585"U!3$E'3CH@<FEG:'0G/C<V+C8P)2TW-BXW,3PO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B4\+W1D/B`\=&0^)FYB<W`[/"]T
M9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXU-2XX,24M-S,N-S(\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXE/"]T9#X@/'1D/B9N8G-P.SPO
M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!415A4+4%,24=..B!R:6=H="<^-S4N-#<E+3@P+C0X/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)3PO=&0^(#PO='(^(#QT<B!S
M='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/
M3$]2.B`C8V-F9F-C)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^
M17AP96-T960@=&5R;2`H:6X@>65A<G,I/"]T9#X@/'1D/B9N8G-P.SPO=&0^
M(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!415A4+4%,24=..B!R:6=H="<^-"XR-3PO=&0^(#QT9#XF;F)S<#L\+W1D
M/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXT+C(T/"]T
M9#X@/'1D/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'
M3CH@<FEG:'0G/C,N.3@M-RXP-3PO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0^
M)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXS+C,T+3<N,#D\+W1D
M/B`\=&0^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^17AP96-T960@9F]R9F5I='5R
M92!R871E/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H
M="<^,C,N,34\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXE
M/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^,C,N
M,34\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXE/"]T9#X@
M/'1D/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^,"4M,C,N,34\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXE/"]T9#X@/'1D
M/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^,"4M,C,N,34\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXE/"]T9#X@/"]T<CX@
M/"]T86)L93X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B`F;F)S<#L\+W`^(#PA
M+2U%;F1&<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+4)A<V5D($-O
M;7!E;G-A=&EO;B!%>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(
M5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O
M5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I
M=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\<"!S='EL93TS1"=&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ
M(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^(%1H92!#;VUP86YY(')E
M8V]R9&5D('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&EN('1H
M92!C;VYS;VQI9&%T960@<W1A=&5M96YT<R!O9B!O<&5R871I;VYS(&%S(&9O
M;&QO=W,@*&EN('1H;W5S86YD<RDZ/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P
M="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^("9N8G-P.SPO<#X@/'1A8FQE
M('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU,1494
M.B`P+C5I;CL@5TE$5$@Z(#DP)2<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,#X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/
M33H@,7!T.R!415A4+4%,24=..B!C96YT97([(%!!1$1)3D<M3$5&5#H@,'!X
M)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q
M<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5#H@8F]L9"`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G(&-O;'-P86X],T0V/B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+51/4#H@
M,'!T)SX@/'-T<F]N9SY4:')E92!-;VYT:',@16YD960\+W-T<F]N9SX\+W`^
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XM5$]0.B`P<'0G/B`\<W1R;VYG/E-E<'1E;6)E<B`S,"P\
M+W-T<F]N9SX\+W`^(#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
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M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!C
M;VQS<&%N/3-$-CX@/'`@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!4
M15A4+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3BU43U`Z(#!P="<^(#QS=')O;F<^3FEN
M92!-;VYT:',@16YD960\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)TU!4D=)
M3BU"3U143TTZ(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM5$]0.B`P
M<'0G/B`\<W1R;VYG/E-E<'1E;6)E<B`S,"P\+W-T<F]N9SX\+W`^(#PO=&0^
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M+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P
M86X],T0R/C(P,3,\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$58
M5"U!3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]4
M5$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L
M86-K(#%P="!S;VQI9#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ
M(&-E;G1E<B<@8V]L<W!A;CTS1#(^,C`Q,CPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/
M5%1/33H@,7!T.R!415A4+4%,24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R)SX@
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L
M9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,CXR,#$S/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^
M("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,
M24=..B!C96YT97(G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/
M3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X]
M,T0R/C(P,3(\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!
M3$E'3CH@8V5N=&5R)SX@)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$
M)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G
M8B@R,#0L,C4U+#(P-"DG/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!415A4+4%,24=..B!L969T.R!0041$24Y'+4Q%1E0Z(#!P>#L@5TE$5$@Z
M(#0T)3L@5$585"U)3D1%3E0Z(#!P>"<^(%)E<V5A<F-H(&%N9"!D979E;&]P
M;65N=#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(
M.B`R)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)
M1%1(.B`Q,"4G/C,Q-CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`R)2<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!
M3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G
M/C(Q.3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M
M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`R)2<^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F
M=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/C@R.3PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE
M9G0[(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%=)1%1(.B`R)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z
M(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58
M5"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/C8S.#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(
M.B`Q)2<^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!W:&ET92<^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q
M<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@,'!X.R!415A4
M+4E.1$5.5#H@,'!X)SX@1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/
M33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(')I9VAT)SX@,S0W/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F
M="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`R-S0\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T.R!4
M15A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/
M33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^(#DU
M-3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M
M0D]45$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@
M,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ
M(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(')I9VAT)SX@,2PP,S`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T
M)SX@)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P
M-"DG/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/
M5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@
M,'!X.R!415A4+4E.1$5.5#H@,'!X)SX@5&]T86P@<W1O8VLM8F%S960@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B
M;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@-C8S/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U143TTZ(#(N
M-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,
M24=..B!R:6=H="<^(#0Y,SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F
M="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`Q+#<X-#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]2
M1$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L
M969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0G/B`Q+#8V.#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^
M("9N8G-P.SPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N
M-6EN)SX@)FYB<W`[/"]P/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=6UM87)Y(&]F(%)E<W1R:6-T960@4W1O8VL@07=A<F1S($%C=&EV
M:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/"$M+41/0U19
M4$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET
M:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X
M:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A
M<G1&<F%G;65N="TM/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T:69Y
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^(%1H92!F;VQL
M;W=I;F<@:7,@82!S=6UM87)Y(&]F(')E<W1R:6-T960@<W1O8VL@87=A<F1S
M(&%C=&EV:71Y(&9O<B!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R
M(#,P+"`R,#$S.CPO<#X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF
M>3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M34%21TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,"XU:6XG/B`F;F)S<#L\
M+W`^(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!7
M24142#H@.#`E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/B`\
M='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@4$%$1$E.1RU,1494.B`P<'@G/B`F;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<@8V]L<W!A;CTS1#(^(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ
M(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM5$]0.B`P<'0G/B`\<W1R
M;VYG/B9N8G-P.SPO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G34%21TE.+4)/
M5%1/33H@,'!T.R!415A4+4%,24=..B!C96YT97([($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU43U`Z(#!P="<^
M(#QS=')O;F<^)FYB<W`[/"]S=')O;F<^/"]P/B`\<"!S='EL93TS1"=-05)'
M24XM0D]45$]-.B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+51/4#H@
M,'!T)SX@/'-T<F]N9SXF;F)S<#L\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$
M)TU!4D=)3BU"3U143TTZ(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM
M5$]0.B`P<'0G/B`\<W1R;VYG/DYU;6)E<B!O9CPO<W1R;VYG/CPO<#X@/'`@
M<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!415A4+4%,24=..B!C96YT
M97([($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3BU43U`Z(#!P="<^(#QS=')O;F<^4VAA<F5S/"]S=')O;F<^/"]P
M/B`\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0Z(&)O;&0@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<@8V]L<W!A;CTS1#(^
M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5$585"U!3$E'3CH@
M8V5N=&5R.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XM5$]0.B`P<'0G/B`\<W1R;VYG/E!E<B!3:&%R92!796EG
M:'1E9"U!=F5R86=E($=R86YT+41A=&4\+W-T<F]N9SX\+W`^(#QP('-T>6QE
M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XM5$]0.B`P<'0G/B`\<W1R;VYG/D9A:7(@5F%L=64\+W-T<F]N9SX\+W`^
M(#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!415A4
M+4%,24=..B!C96YT97([($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2
M.B!R9V(H,C`T+#(U-2PR,#0I)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M3$5&5#H@,'!X.R!724142#H@-S(E)SX@3W5T<W1A;F1I;F<@86YD
M(%5N=F5S=&5D(&%T($IA;G5A<GD@,2P@,C`Q,SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[(%=)1%1(.B`R)2<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@
M5TE$5$@Z(#$E)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B`S,RPS
M,S0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,
M24=..B!L969T.R!724142#H@,24G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!724142#H@,B4G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[
M(%=)1%1(.B`Q)2<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[(%1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SX@,2XS.3PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE
M9G0[(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!W
M:&ET92<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@4F5S=')I8W1E9"!S=&]C
M:R!G<F%N=&5D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$58
M5"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/BT\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=.
M.B!L969T)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M5$585"U!3$E'3CH@<FEG:'0G/BT\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R
M/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=2
M3U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&
M5#H@,'!X)SX@4F5S=')I8W1E9"!S=&]C:R!V97-T960\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=.
M.B!R:6=H="<^+3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H="<^+3PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ
M(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!W:&ET92<^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`Q
M<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@4F5S
M=')I8W1E9"!S=&]C:R!F;W)F96ET960\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@+3PO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]4
M5$]-.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!"
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H
M="<^("T\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$
M24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T
M9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T.R!0041$24Y'
M+4Q%1E0Z(#!P>"<^($]U='-T86YD:6YG(&%N9"!5;G9E<W1E9"!A="!397!T
M96UB97(@,S`L(#(P,3,\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`S,RPS
M,S0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'
M+4)/5%1/33H@,BXU<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/
M33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(')I9VAT)SX@,2XS.3PO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'
M3CH@;&5F="<^("9N8G-P.SPO=&0^(#PO='(^(#PO=&%B;&4^(#PA+2U%;F1&
M<F%G;65N="TM/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E(%-T;V-K(%!U<F-H
M87-E(%!L86X@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1&5F97)R960@0V]M<&5N<V%T:6]N($%R<F%N9V5M
M96YT('=I=&@@26YD:79I9'5A;"P@4VAA<F4M8F%S960@4&%Y;65N=',@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!<W-U;7!T:6]N<R!U<V5D('1O($5S=&EM871E($=R86YT($1A
M=&4@1F%I<B!686QU92!O9B!3=&]C:R!/<'1I;VYS(&=R86YT960@=7-I;F<@
M0FQA8VLM4V-H;VQE<R!/<'1I;VXM4')I8VEN9R!-;V1E;#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SPA+2U$3T-465!%(&AT;6P@4%5"3$E#
M("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT
M='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I
M;VYA;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@:G5S=&EF>3L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X
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M;W=I;F<@87-S=6UP=&EO;G,Z/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=.
M.B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(%1%6%0M24Y$14Y4.B`P+C5I;B<^
M("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@
M8V]L;&%P<V4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(%=)1%1(.B`W-24G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@
M/'1D/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0G/CQS=')O;F<^5&AR964@36]N=&AS($5N9&5D
M/"]S=')O;F<^/"]F;VYT/B`\8G(@+SX@/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T)SX\<W1R;VYG/E-E<'1E;6)E<B`S,"P\+W-T<F]N9SX\+V9O
M;G0^/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^
M("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^(#QS=')O;F<^,C`Q
M,SPO<W1R;VYG/CPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^("9N8G-P.SPO
M=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-F9F-C)SX@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#<W)2<^5V5I9VAT960M879E<F%G92!F
M86ER('9A;'5E(&]F($534%`@<VAA<F5S(&=R86YT960\+W1D/B`\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!724142#H@,24G/B0\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#(P
M)2<^(#`N-S@\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S<#L\
M+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4G/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T)SY2:7-K+69R964@:6YT97)E<W0@<F%T93PO=&0^(#QT
M9#XF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/C`N,#0\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SXE/"]T9#X@/"]T<CX@/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M
M0T],3U(Z("-C8V9F8V,G/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M)SY$:79I9&5N9"!Y:65L9#PO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!
M3$E'3CH@<FEG:'0G/C`\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T)SXE/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P="<^5F]L871I;&ET>3PO=&0^(#QT9#XF;F)S
M<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/C4P+C@P/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)3PO=&0^(#PO='(^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2
M.B`C8V-F9F-C)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^17AP
M96-T960@=&5R;2`H:6X@>65A<G,I/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT
M9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!4
M15A4+4%,24=..B!R:6=H="<^,"XU/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#PO
M='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$+4-/3$]2.B!W:&ET92<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0G/D5X<&5C=&5D(&9O<F9E:71U<F4@<F%T93PO=&0^(#QT9#XF;F)S
M<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0G/C4\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T)SXE/"]T9#X@/"]T<CX@/"]T86)L93X@/"$M
M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E
M8V5?,V-B,&8W,#`T8C<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-"]7;W)K<VAE
M971S+U-H965T,C@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY.;W1E<R!087EA8FQE("A486)L97,I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]T97,@4&%Y86)L
M92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!&=71U<F4@36EN:6UU;2!0<FEN8VEP
M86P@4&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP
M(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M
M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X\9&EV/B`\9&EV
M/CPA+2U3=&%R=$9R86=M96YT+2T^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&IU<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@
M06=G<F5G871E(&9U='5R92!M:6YI;75M('!R:6YC:7!A;"!P87EM96YT<R!O
M;B!T:&4@1T4@;F]T97,@<&%Y86)L92P@:6YC;'5D:6YG('1H92`R,#$S($9U
M;F1I;F<L(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,R!A<F4@87,@9F]L;&]W<R`H
M:6X@=&AO=7-A;F1S*3H\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU
M<W1I9GD[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3CH@,'!T(#!P>#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB
M<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S93L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@5TE$5$@Z(#$P,"4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU,1494.B`P<'@G/B!996%R/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CY!;6]U;G0\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L
M9#L@4$%$1$E.1RU"3U143TTZ(#%P="<^("9N8G-P.SPO=&0^(#PO='(^(#QT
M<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$
M+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I)SX@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`P
M<'@[(%=)1%1(.B`Q,R4G/B`R,#$S("AR96UA:6YD97(I/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#<T)2<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5$585"U!3$E'3CH@
M;&5F=#L@5TE$5$@Z(#(E)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/C$T,SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ
M(&QE9G0[(%=)1%1(.B`Q)2<^("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2
M.B!W:&ET92<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@,'!X)SX@,C`Q-#PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N
M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%6%0M
M04Q)1TXZ(')I9VAT)SXU-S$\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\
M='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.
M1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@
M,'!X)SX@,C`Q-3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)SXU-S$\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!415A4+4%,24=..B!L969T)SXF
M;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4G/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4
M+4%,24=..B!L969T.R!0041$24Y'+4Q%1E0Z(#!P>"<^(#(P,38\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!0041$24Y'+4)/5%1/33H@
M,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ
M(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!"3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(')I9VAT)SX@,SDV/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^
M("9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I
M)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T.R!415A4+4%,24=..B!L969T.R!0041$24Y'+4Q%1E0Z(#!P
M>"<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($)/4D1%4BU"3U143TTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/B`Q+#8X,3PO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[(%!!1$1)3D<M0D]45$]-.B`R
M+C5P=#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#PO='(^(#PO
M=&%B;&4^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU<W1I9GD[($9/3E0Z
M(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE..B`P<'0@,'!X.R!415A4+4E.1$5.5#H@,&EN)SX@)FYB<W`[/"]P/B`\
M(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R-#DX-F-F,U\Q-3DP7S0U,C%?
M8F5C95\S8V(P9C<P,#1B-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W,#`T8C<T+U=O<FMS
M:&5E=',O4VAE970R.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14)/04,^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG
M(%!O;&EC:65S("A.87)R871I=F4I("A$971A:6QS*2`H55-$("0I/&)R/DEN
M(%1H;W5S86YD<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I
M<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF
M:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@
M;V8@<VAA<F5S(&5X8VQU9&5D(&9R;VT@=&AE(&-O;7!U=&%T:6]N(&]F(&YE
M="!L;W-S('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,BPQ-3<L-C,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3(L.34Q+#8R-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;&%S<VEF:6-A=&EO;B!O
M9B!G96YE<F%L(&%N9"!A9&UI;FES=')A=&EV92!E>'!E;G-E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-L87-S
M:69I8V%T:6]N(&]F(')E<W1R:6-T960@8V%S:#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)E:6=N(&-U<G)E;F-Y(&%D:G5S
M=&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3`Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-3`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E
M8V5?,V-B,&8W,#`T8C<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-"]7;W)K<VAE
M971S+U-H965T,S`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5$2D%'/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D%C<75I<VET:6]N(&]F($ES8V]N;W9A($%"("A.87)R871I
M=F4I("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T
M(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CY.;W9A=F%X($%"(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^36EN:6UU;2!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$S/&)R/DUA>&EM=6T@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0G5S:6YE<W,@06-Q=6ES:71I;VX@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F]V879A>"!S:&%R97,@:7-S=65D(&9O<B!)
M<V-O;F]V82!!0B!S:&%R97,@86-Q=6ER960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$U+#8P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y686QU92!O9B!S:&%R
M97,@;V8@3F]V879A>"!#;VUM;VX@4W1O8VL@:7-S=65D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#0Q+#DT,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%I
M9"!T;R!)<V-O;F]V82!W87)R86YT(&AO;&1E<G,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-Q=6ER960@9FEN:71E+6QI
M=F5D(&EN=&%N9VEB;&4@87-S971S+"!W96EG:'1E9"UA=F5R86=E('5S969U
M;"!L:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M-R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<R,"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1V]O9'=I;&P\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(U+#(Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#@P,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-S8U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L,38W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L-3$P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,34L,S`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#<L,C$W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#,W+#DR.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,"PT-S(I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PU,#`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R86YS
M86-T:6]N(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#,P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!R96UA:6YI;F<@<F5N=&%L('!A>6UE
M;G1S(&1U92!U;F1E<B!O<&5R871I;F<@;&5A<V4@8V]M;6ET;65N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L.3`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PY,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R
M-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E8V5?
M,V-B,&8W,#`T8C<T+U=O<FMS:&5E=',O4VAE970S,2YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M155(/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%C<75I<VET:6]N(&]F($ES
M8V]N;W9A($%"("A38VAE9'5L92!O9B!0=7)C:&%S92!0<FEC92D@*$1E=&%I
M;',I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^06-Q=6ES:71I;VX@3V8@27-C;VYO=F$@04(@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5F%L=64@;V8@<VAA<F5S(&]F($YO=F%V87@@0V]M;6]N(%-T;V-K(&ES<W5E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,2PY-#(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A
M<V@@<&%I9"!T;R!)<V-O;F]V82!W87)R86YT(&AO;&1E<G,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<'5R8VAA<V4@<')I
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#$L.38T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R-#DX-F-F
M,U\Q-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W
M,#`T8C<T+U=O<FMS:&5E=',O4VAE970S,BYH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14I,04,^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0Q/CQS=')O;F<^06-Q=6ES:71I;VX@;V8@27-C;VYO
M=F$@04(@*%-C:&5D=6QE(&]F($%S<V5T<R!!8W%U:7)E9"!A;F0@3&EA8FEL
M:71I97,@07-S=6UE9"D@*$1E=&%I;',I("A54T0@)"D\8G(^26X@5&AO=7-A
M;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,S$L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-Q=6ES
M:71I;VX@3V8@27-C;VYO=F$@04(@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E
M<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S
M+#`U-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C;W5N=',@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-C`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!A
M<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#DR/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DEN=&%N9VEB;&4@87-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-BPS.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=O;V1W:6QL/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR-2PR.3@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4@
M86YD(&]T:&5R(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(L-S@T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%P:71A;"!L96%S97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DT*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]T97,@<&%Y86)L93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3DS*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@;F]N
M+6-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$L-34Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L('!U<F-H87-E('!R:6-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0Q+#DV-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,C0Y.#9C9C-?,34Y,%\T-3(Q
M7V)E8V5?,V-B,&8W,#`T8C<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-"]7;W)K
M<VAE971S+U-H965T,S,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,34%#/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D%C<75I<VET:6]N(&]F($ES8V]N;W9A($%"("A5;F%U
M9&ET960@4')O($9O<FUA($9I;F%N8VEA;"!);F9O<FUA=&EO;B!O9B!/<&5R
M871I;VYS*2`H1&5T86EL<RD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X
M8V5P="!097(@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I
M960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^06-Q=6ES:71I;VX@3V8@27-C;VYO=F$@04(@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`T+#@V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-BPR-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$T+#$Y-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3DL-3,P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q-2PV.#<I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@X
M+#0Y,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#0P+#4V-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#(U+#`S,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VEC(&%N9"!D:6QU=&5D(&YE
M="!L;W-S('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@P+C`Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,"XP-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#`N,C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C$X*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,C0Y.#9C9C-?,34Y,%\T-3(Q
M7V)E8V5?,V-B,&8W,#`T8C<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-"]7;W)K
M<VAE971S+U-H965T,S0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4T,D%%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,3X\<W1R;VYG/D9A:7(@5F%L=64@365A<W5R96UE;G1S("A&86ER(%9A
M;'5E($AI97)A<F-H>2D@*$1E=&%I;',I("A54T0@)"D\8G(^26X@5&AO=7-A
M;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!<W-E
M=',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;W)P;W)A=&4@9&5B="!A;F0@875C=&EO;B!R871E('-E8W5R:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C,L.3$W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,BPY
M-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DQE=F5L(#$@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D%S<V5T<SPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O<G!O<F%T92!D96)T(&%N9"!A
M=6-T:6]N(')A=&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&EN
M=F5S=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6%B:6QI=&EE<SH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M87)R86YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5V96P@,B!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^07-S971S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]R<&]R871E(&1E8G0@86YD(&%U8W1I;VX@<F%T92!S96-U
M<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPY,3<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,BPY-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L(&EN=F5S=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,RPY,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS,BPY-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EA8FEL:71I97,Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V%R<F%N="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE=F5L(#,@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D%S<V5T<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O<G!O<F%T92!D96)T(&%N9"!A=6-T:6]N(')A=&4@<V5C
M=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&EN=F5S=&UE;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY,:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(&QI86)I;&ET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`R-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R-#DX-F-F,U\Q-3DP7S0U,C%?
M8F5C95\S8V(P9C<P,#1B-S0O5V]R:W-H965T<R]3:&5E=#,U+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%3$5!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY&86ER(%9A;'5E
M($UE87-U<F5M96YT<R`H4F5C;VYC:6QI871I;VX@;V8@3&5V96P@,R!!<W-E
M=',@86YD($QI86)I;&ET:65S*2`H1&5T86EL<RD@*%=A<G)A;G1S(%-E='1L
M96%B;&4@26X@0V%S:"!;365M8F5R72P@55-$("0I/&)R/DEN(%1H;W5S86YD
M<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!3971T;&5A8FQE($EN($-A
M<V@@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^1F%I<B!686QU92P@3&EA8FEL:71I97,@365A<W5R960@;VX@
M4F5C=7)R:6YG($)A<VES+"!5;F]B<V5R=F%B;&4@26YP=70@4F5C;VYC:6QI
M871I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T($1E8V5M8F5R(#,Q+"`R,#$R
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(V-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E
M(&EN(&9A:7(@=F%L=64@;V8@5V%R<F%N="!L:6%B:6QI='D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#(V-RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@870@4V5P=&5M
M8F5R(#,P+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C0Y.#9C9C-?,34Y,%\T
M-3(Q7V)E8V5?,V-B,&8W,#`T8C<T+U=O<FMS:&5E=',O4VAE970S-BYH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P15E4044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YV97-T
M;65N=',@*$1E=&%I;',I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE
M<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O
M9B!!=F%I;&%B;&4M9F]R+7-A;&4@4V5C=7)I=&EE<R!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M;6]R=&EZ960@0V]S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R,RPS,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#,R+#4Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1W)O<W,@56YR96%L:7IE9"!'86EN<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S<R!5;G)E
M86QI>F5D($QO<W-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+#DQ-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,R+#DT-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^075C=&EO
M;B!2871E(%-E8W5R:71I97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-C:&5D=6QE(&]F($%V86EL86)L
M92UF;W(M<V%L92!396-U<FET:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IE9"!#
M;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$W-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,3<U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y'<F]S<R!5;G)E86QI>F5D($=A:6YS/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S(%5N<F5A;&EZ960@3&]S<V5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1F%I<B!686QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PW-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#4X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]R<&]R871E($1E8G0@4V5C=7)I=&EE
M<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4V-H961U;&4@;V8@079A:6QA8FQE+69O<BUS86QE(%-E8W5R
M:71I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F5D($-O<W0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(R+#$S-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q+#,T,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)O<W,@56YR96%L
M:7IE9"!'86EN<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y'<F]S<R!5;G)E86QI>F5D($QO<W-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@
M5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C(L,30Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`S,2PS-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R-#DX-F-F,U\Q-3DP7S0U,C%?
M8F5C95\S8V(P9C<P,#1B-S0O5V]R:W-H965T<R]3:&5E=#,W+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%2$9!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY';V]D=VEL;"!A
M;F0@3W1H97(@26YT86YG:6)L92!!<W-E=',@*%-C:&5D=6QE(&]F($=O;V1W
M:6QL*2`H1&5T86EL<RD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S
M<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D=O;V1W:6QL(&%N9"!/=&AE<B!);G1A
M;F=I8FQE($%S<V5T<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG(&)A;&%N8V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S,L,30Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,RPQ-#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=O;V1W:6QL(')E<W5L=&EN9R!F<F]M(&%C<75I<VET:6]N(&]F(&)U<VEN
M97-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PR.3@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#=7)R96YC>2!T<F%N<VQA=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG(&)A
M;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3@L-S4Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`S,RPQ-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-`T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R-#DX-F-F,U\Q-3DP7S0U,C%?
M8F5C95\S8V(P9C<P,#1B-S0O5V]R:W-H965T<R]3:&5E=#,X+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%-D1!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY';V]D=VEL;"!A
M;F0@3W1H97(@26YT86YG:6)L92!!<W-E=',@*%-C:&5D=6QE(&]F($ED96YT
M:69I86)L92!);G1A;F=I8FQE($%S<V5T<RD@*$1E=&%I;',I("A54T0@)"D\
M8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^06-Q=6ER960@1FEN:71E+4QI=F5D($EN=&%N9VEB;&4@07-S971S
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1W)O<W,@0V%R<GEI;F<@06UO=6YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$V+#4X-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@06UO
M<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.#$I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YT86YG:6)L92!!<W-E=',L($YE=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,38L-#`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P<FEE=&%R>2!A9&IU=F%N="!T96-H
M;F]L;V=Y(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D%C<75I<F5D($9I;FET92U,:79E9"!);G1A;F=I8FQE
M($%S<V5T<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S($-A<G)Y:6YG($%M;W5N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L-3DT/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E
M9"!!;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#DW*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN=&%N9VEB;&4@07-S971S+"!.970\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$Q+#0Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]L;&%B;W)A=&EO;B!A9W)E96UE
M;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D%C<75I<F5D($9I;FET92U,:79E9"!);G1A;F=I8FQE($%S
M<V5T<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D=R;W-S($-A<G)Y:6YG($%M;W5N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PY.3(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D($%M
M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#0I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YT86YG:6)L92!!<W-E=',L($YE=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`T+#DP.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W
M,#`T8C<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S(T.3@V8V8S
M7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-"]7;W)K<VAE971S+U-H965T
M,SDN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5(3$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D=O;V1W:6QL(&%N9"!/=&AE<B!);G1A;F=I8FQE($%S<V5T<R`H4V-H961U
M;&4@;V8@17-T:6UA=&5D($%M;W)T:7IA=&EO;B!%>'!E;G-E*2`H1&5T86EL
M<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1V]O9'=I;&P@86YD($]T:&5R($EN=&%N9VEB;&4@
M07-S971S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#XR,#$S("AR96UA:6YD97(I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(W,2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`X-"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$U/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`X-"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$V/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`X-"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$W
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`X-"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR
M,#$X/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`X-"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!;6]R=&EZ871I;VX@97AP96YS92!R96QA=&5D('1O(&EN=&%N9VEB;&4@
M87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-`T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C
M95\S8V(P9C<P,#1B-S0O5V]R:W-H965T<R]3:&5E=#0P+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%,59!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:VAO;&1E<G,G
M($5Q=6ET>2`H1&5T86EL<RD@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X
M8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;"X@,S$L(#(P,#@\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^4V5C;VYD(%!U
M8FQI8R!/9F9E<FEN9R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/DUI;FEM=6T@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CY-87AI;75M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U8G-I9&EA<GDL(%-A;&4@;V8@4W1O
M8VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!A=71H;W)I>F5D(&9O
M<B!I<W-U86YC92!U;F1E<B!P<FEO<B!S:&5L9B!R96=I<W1R871I;VX@<W1A
M=&5M96YT('=I=&@@4T5#+"!D;VQL87(@86UO=6YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL
M('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V%L97,@<&5R('-H
M87)E('!R:6-E(')A;F=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#,N,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VAA<F5S('-O;&0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8L-C@V+#8U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#8P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$L.#0V+#DU,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F]C965D<R!F<F]M('-H87)E<R!S;VQD/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`S-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y-"PW,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K(&ES<W5E9"!U<&]N(&5X97)C:7-E(&EN(&9U;&P@;W9E<BUA;&QO=&UE
M;G0@9W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-"PQ-3,L.34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-A;&5S('!E<B!S:&%R92!P<FEC92!R86YG93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C8X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C`V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S
M+C,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R
M-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E8V5?
M,V-B,&8W,#`T8C<T+U=O<FMS:&5E=',O4VAE970T,2YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14-*0D<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VLM0F%S960@0V]M
M<&5N<V%T:6]N("A.87)R871I=F4I("A$971A:6QS*2`H55-$("0I/&)R/DEN
M(%1H;W5S86YD<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I
M<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E
M;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%G9W)E9V%T92!I;G1R:6YS:6,@=F%L=64@;V8@<W1O8VL@;W!T:6]N<R!O
M=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M-2PY,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y796EG:'1E9"UA=F5R86=E(')E;6%I;FEN9R!C;VYT<F%C='5A
M;"!T97)M(&]F('-T;V-K(&]P=&EO;G,@;W5T<W1A;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<W('EE87)S(#<@;6]N=&AS(#8@9&%Y
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%G9W)E9V%T92!I;G1R:6YS:6,@=F%L=64@;V8@<W1O8VL@;W!T:6]N
M<R!E>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y796EG:'1E9"UA=F5R86=E(')E;6%I;FEN9R!C;VYT<F%C='5A
M;"!T97)M(&]F('-T;V-K(&]P=&EO;G,@97AE<F-I<V%B;&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S(#$P(&UO;G1H<R`R-"!D
M87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06=G<F5G871E(&EN=')I;G-I8R!V86QU92!O9B!S=&]C:R!O<'1I
M;VYS(&5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y5;G)E8V]G;FEZ960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PW,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E8V]G
M;FEZ960@8V]M<&5N<V%T:6]N(&5X<&5N<V4L(')E8V]G;FET:6]N('!E<FEO
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$@>65A<B`V(&UO
M;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/C(P,#4@4W1O8VL@26YC96YT:79E(%!L86X@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E
M+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E
M9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!R97-E
M<G9E9"!F;W(@:7-S=6%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(R+#,Q,BPQ.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M('1E<FT@;V8@;W!T:6]N<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$P('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EN:6UU
M;2!G<F%N="!P<FEC92P@<&5R8V5N="!O9B!C;VUM;VX@<W1O8VL@9F%I<B!V
M86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/C(P,#4@4W1O8VL@26YC96YT:79E(%!L86X@6TUE;6)E<ET@?"!38V5N87)I
M;RP@1F]R96-A<W0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!
M<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN8W)E87-E(&EN('-H87)E<R!A=F%I;&%B;&4@9F]R(&ES<W5A
M;F-E(&%P<')O=F5D(&%T('1H92`R,#$S(&%N;G5A;"!S=&]C:VAO;&1E<G,G
M(&UE971I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/C(P,#4@4W1O8VL@26YC96YT:79E(%!L86X@6TUE;6)E<ET@?"!-
M:6YI;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG
M96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>&5R8VES92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<V(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/C(P,#4@4W1O8VL@26YC96YT:79E(%!L86X@6TUE
M;6)E<ET@?"!-87AI;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I
M;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%>&5R8VES92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<T('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,3DY-2!3=&]C:R!/<'1I;VX@4&QA
M;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT
M(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N('-T;V-K(')E<V5R=F5D(&9O<B!I<W-U86YC93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-2PW-#8L-#8X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU;2!T97)M(&]F
M(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"!Y
M96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DUI;FEM=6T@9W)A;G0@<')I8V4L('!E<F-E;G0@;V8@8V]M;6]N
M('-T;V-K(&9A:7(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#XQ.3DU(%-T;V-K($]P=&EO;B!0;&%N(%M-96UB97)=
M('P@36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R
M<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AE<F-I<V4@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG-B!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#XQ.3DU(%-T;V-K($]P=&EO;B!0;&%N(%M-
M96UB97)=('P@36%X:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T
M:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17AE<F-I<V4@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG-"!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E(%-T;V-K(%!U<F-H
M87-E(%!L86X@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A
M;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!S=&]C:R!R97-E<G9E9"!F;W(@:7-S=6%N8V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S(T.3@V8V8S7S$U.3!?
M-#4R,5]B96-E7S-C8C!F-S`P-&(W-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0O
M5V]R:W-H965T<R]3:&5E=#0R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3D%!1SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS871I;VX@*%-U
M;6UA<GD@;V8@3W!T:6]N($%C=&EV:71Y*2`H1&5T86EL<RD@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#`U(%-T
M;V-K($EN8V5N=&EV92!0;&%N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K($]P=&EO;G,\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-T86YD
M:6YG(&%T($IA;G5A<GD@,2P@,C`Q,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.2PQ-#,L.#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT+#$Q-RPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-3(R+#(Y,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A;F-E;&5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X,#(L.#@S*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I
M;F<@870@4V5P=&5M8F5R(#,P+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,2PY,S8L,34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@97AE<F-I<V%B;&4@870@
M4V5P=&5M8F5R(#,P+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT+#8T-RPX-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!A=F%I;&%B;&4@9F]R(&=R86YT(&%T
M(%-E<'1E;6)E<B`S,"P@,C`Q,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-BPT-C$L-#DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E=E:6=H=&5D+4%V97)A9V4@17AE
M<F-I<V4@4')I8V4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]U='-T86YD:6YG(&%T($IA;G5A<GD@,2P@,C`Q,SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C@W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N=&5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N.3(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C(Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#86YC
M96QE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C<T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M=71S=&%N9&EN9R!A="!397!T96UB97(@,S`L(#(P,3,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,2XX.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!E>&5R8VES86)L
M92P@4V5P=&5M8F5R(#,P+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(N,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/C$Y.34@4W1O8VL@3W!T:6]N(%!L86X@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4W1O8VL@3W!T:6]N<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@870@2F%N=6%R>2`Q+"`R,#$S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3$L.3`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N=&5D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-A;F-E;&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R,RPW-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!A="!397!T96UB97(@,S`L
M(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X."PQ-3`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H87)E<R!E>&5R8VES86)L92!A="!397!T96UB97(@,S`L(#(P,3,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X."PQ-3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M5V5I9VAT960M079E<F%G92!%>&5R8VES92!0<FEC93PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@870@
M2F%N=6%R>2`Q+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#0N.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%N8V5L960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"XP-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@
M870@4V5P=&5M8F5R(#,P+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#4N,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@97AE<F-I<V%B;&4L(%-E<'1E;6)E
M<B`S,"P@,C`Q,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U
M+C`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R
M-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E8V5?
M,V-B,&8W,#`T8C<T+U=O<FMS:&5E=',O4VAE970T,RYH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M15I.0D<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VLM0F%S960@0V]M
M<&5N<V%T:6]N("A!<W-U;7!T:6]N<R!5<V5D(&EN($5S=&EM871I;VX@;V8@
M1F%I<B!686QU92!O9B!3=&]C:R!/<'1I;VYS($=R86YT960I("A$971A:6QS
M*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP
M96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!
M=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D+6%V97)A9V4@9F%I<B!V86QU
M92!O9B!S=&]C:R!O<'1I;VYS(&=R86YT960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,2XT,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,2XP.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XP,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XW,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4FES:RUF
M<F5E(&EN=&5R97-T(')A=&4L(&UI;FEM=6T\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$N,3(E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`N-30E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XU-24\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VLM9G)E92!I;G1E
M<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XU
M-24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4FES:RUF<F5E(&EN=&5R97-T(')A=&4L(&UA>&EM=6T\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,S8E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,S8E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XU-"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1I
M=FED96YD('EI96QD/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5F]L871I;&ET>2P@;6EN:6UU;3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-38N-S4E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S8N-C`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-34N.#$E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-S4N-#<E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y6;VQA=&EL:71Y+"!M87AI;75M/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV,BXU,24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW-BXW,24\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,RXW,B4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,"XT."4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C
M=&5D('1E<FT@*&EN('EE87)S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)S0@>65A<G,@,R!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-"!Y96%R<R`R(&UO;G1H<R`R-R!D
M87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X<&5C=&5D(&9O<F9E:71U<F4@<F%T93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C,N,34E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,N,34E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E(%-T
M;V-K(%!U<F-H87-E(%!L86X@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N
M<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A
M<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"UA=F5R86=E(&9A:7(@=F%L=64@
M;V8@<W1O8VL@;W!T:6]N<R!G<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`N-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VLM9G)E92!I;G1E<F5S="!R871E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`T)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&EV
M:61E;F0@>6EE;&0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y6;VQA=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,"XX,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('1E<FT@*&EN('EE87)S*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S8@;6]N=&AS/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E
M8W1E9"!F;W)F96ET=7)E(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D
M($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM
M96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@=&5R;2`H:6X@>65A
M<G,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<S('EE87)S
M(#$Q(&UO;G1H<R`R,R!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)S,@>65A<G,@-"!M;VYT:',@,B!D87ES/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M>'!E8W1E9"!F;W)F96ET=7)E(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU;2!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:&%R
M92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S
M960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('1E<FT@
M*&EN('EE87)S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M-R!Y96%R<R`Q."!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)S<@>65A<G,@,2!M;VYT:"`R(&1A>7,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C
M=&5D(&9O<F9E:71U<F4@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,RXQ-24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,RXQ-24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F
M-S`P-&(W-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R-#DX-F-F
M,U\Q-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0O5V]R:W-H965T<R]3:&5E
M=#0T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%,TQ!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY3=&]C:RU"87-E9"!#;VUP96YS871I;VX@*%-U;6UA<GD@;V8@4F5S=')I
M8W1E9"!3=&]C:R!!=V%R9',@06-T:79I='DI("A$971A:6QS*2`H55-$("0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^3G5M8F5R(&]F(%-H87)E<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@86YD(%5N=F5S=&5D(&%T
M($IA;G5A<GD@,2P@,C`Q,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S,L,S,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y297-T<FEC=&5D('-T;V-K(&=R86YT960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T
M960@<W1O8VL@=F5S=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D('-T;V-K(&9O<F9E:71E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W5T<W1A;F1I;F<@86YD(%5N=F5S=&5D(&%T(%-E<'1E;6)E<B`S,"P@,C`Q
M,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,L,S,T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E!E<B!3:&%R92!796EG:'1E9"U!=F5R86=E($=R86YT+41A=&4@1F%I
M<B!686QU93PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W5T<W1A;F1I;F<@86YD(%5N=F5S=&5D(&%T($IA;G5A<GD@,2P@
M,C`Q,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C,Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M97-T<FEC=&5D('-T;V-K(&=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@<W1O8VL@=F5S
M=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y297-T<FEC=&5D('-T;V-K(&9O<F9E:71E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@
M86YD(%5N=F5S=&5D(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C,Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C
M95\S8V(P9C<P,#1B-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W,#`T8C<T+U=O<FMS:&5E
M=',O4VAE970T-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15=/044^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N("A3=&]C:RU"87-E
M9"!#;VUP96YS871I;VX@17AP96YS92D@*$1E=&%I;',I("A54T0@)"D\8G(^
M26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY%;7!L;WEE92!397)V:6-E(%-H87)E+6)A<V5D($-O;7!E
M;G-A=&EO;BP@06QL;V-A=&EO;B!O9B!296-O9VYI>F5D(%!E<FEO9"!#;W-T
M<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E
M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8V,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#DS
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q+#<X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2PV-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY%;7!L;WEE92!397)V:6-E(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO
M;BP@06QL;V-A=&EO;B!O9B!296-O9VYI>F5D(%!E<FEO9"!#;W-T<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,38\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,CD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,S@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=E
M;F5R86P@86YD(&%D;6EN:7-T<F%T:79E(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5M<&QO>65E(%-E
M<G9I8V4@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!!;&QO8V%T:6]N(&]F
M(%)E8V]G;FEZ960@4&5R:6]D($-O<W1S(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM
M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,S0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DU-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PP,S`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S(T.3@V8V8S7S$U.3!?
M-#4R,5]B96-E7S-C8C!F-S`P-&(W-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0O
M5V]R:W-H965T<R]3:&5E=#0V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%6D1!23X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY5+E,N($=O=F5R;FUE;G0@06=R965M96YT+"!*
M;VEN="!696YT=7)E(&%N9"!#;VQL86)O<F%T:6]N<R`H1&5T86EL<RD@*%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XS,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ-2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y&96(N
M(#(X+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3,\8G(^0V%D:6QA(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@,C@L(#(P,3$\8G(^2$A3($)!4D1!
M($-O;G1R86-T(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^2$A3($)!4D1!($-O;G1R86-T(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^2$A3($)!4D1!($-O;G1R86-T(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M2$A3($)!4D1!($-O;G1R86-T(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D9E8BX@,C@L(#(P,3$\8G(^2$A3($)!4D1!($]P
M=&EO;B!F;W(@061D:71I;VYA;"!097)I;V0@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B+B`R."P@,C`Q,3QB<CY,:6-E
M;G-E($%G<F5E;65N="!W:71H($Q'($QI9F4@4V-I96YC97,L($QT9"X@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`S
M,2P@,C`Q,CQB<CY0051((%9A8V-I;F4@4V]L=71I;VYS(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\
M8G(^4$%42"!686-C:6YE(%-O;'5T:6]N<R!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/E!!5$@@
M5F%C8VEN92!3;VQU=&EO;G,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^075G+B`S,2P@,C`Q,SQB<CY0051((%9A8V-I;F4@
M4V]L=71I;VYS(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-O;&QA8F]R871I=F4@07)R86YG96UE;G1S
M(&%N9"!.;VXM8V]L;&%B;W)A=&EV92!!<G)A;F=E;65N="!4<F%N<V%C=&EO
M;G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYT<F%C="!R96-E:79A
M8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-SDL
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@.3<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`X,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=')A8W0@=&5R;3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S,@>65A<G,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG,B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y';W9E<FYM96YT(&-O;G1R86-T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PR-C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#4X,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#DX-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#,R
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P+#<P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P
M;65N="!C;VQL86)O<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PQ.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M97-E87)C:"!A;F0@9&5V96QO<&UE;G0@8V]L;&%B;W)A=&EO;B!I;F-R96%S
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4<FEA;"!C;W-T<R!I;F-U<G)E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DP,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5P9G)O;G0@
M;&EC96YS92!P87EM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,BPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=VYE<G-H:7`@<&5R8V5N=&%G
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DIO:6YT(%9E;G1U<F4@4&5R8V5N=&%G92!/=VYE
M9"!">2!/=&AE<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W
M,#`T8C<T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S(T.3@V8V8S
M7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-"]7;W)K<VAE971S+U-H965T
M-#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$523$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/DYO=&5S(%!A>6%B;&4@*$YA<G)A=&EV92D@*$1E=&%I;',I("A54T0@)"D\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^3F]T97,@4&%Y86)L92!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F]R<F]W
M:6YG(&QI;6ET(&]F(&QO86X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^26YT97)E<W0@<F%T92!I;B!A9&1I=&EO;B!T
M;R!T:')E92UY96%R(%4N4RX@1V]V97)N;65N="!T<F5A<W5R>2!R871E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2XV."4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M
M(&EN=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$R+C$P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E<&%Y;65N="!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG-#(@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5B="!I;G-T<G5M96YT+"!I;F-R
M96%S92!I;B!B;W)R;W=I;F=S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!R871E(&1U<FEN9R!P97)I;V0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BXQ,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUO;G1H
M;'D@<')I;F-I<&%L('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`S-"PU,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P
M-&(W-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R-#DX-F-F,U\Q
M-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0O5V]R:W-H965T<R]3:&5E=#0X
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%4$-!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY.
M;W1E<R!087EA8FQE("A!9V=R96=A=&4@1G5T=7)E($UI;FEM=6T@4')I;F-I
M<&%L(%!A>6UE;G1S(&]N($5Q=6EP;65N="!,;V%N*2`H1&5T86EL<RD@*%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY.;W1E<R!087EA8FQE(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3,@*')E;6%I
M;F1E<BD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,30S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR
M,#$T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-S$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,34\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4W,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q-CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDV/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PV.#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S(T.3@V8V8S7S$U.3!?-#4R
M,5]B96-E7S-C8C!F-S`P-&(W-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\R-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0O5V]R
M:W-H965T<R]3:&5E=#0Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4E)!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY787)R86YT($QI86)I;&ET>2`H1&5T86EL<RD@*%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!3:&%R92!D871A+"!U;FQE
M<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN(#,Q+"`R,#`X/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^5V%R<F%N="!,:6%B:6QI='D@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N:71S(&ES
M<W5E9"!I;B!D:7)E8W0@;V9F97)I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8L-C@V+#8U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L-C`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S:&%R
M97,@<&5R('5N:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]C965D<R!F<F]M(&1I<F5C="!O9F9E<FEN9SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-RPU,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@96YT
M:71L960@<&5R('=A<G)A;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!S:&%R97,@8V]M;6]N('-T;V-K(&-A
M;&QA8FQE(&)Y('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#,T,RPS,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC92!O9B!W87)R86YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RXV,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-H
M86YG92!I;B!F86ER('9A;'5E(&]F('=A<G)A;G0@;&EA8FEL:71Y/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-#`Q
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,C8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@T,#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%<75I='D@:7-S=6%N8V4L('!R:6-E('!E<B!S:&%R
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C8X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,C0Y.#9C
M9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W,#`T8C<T#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F
M-S`P-&(W-"]7;W)K<VAE971S+U-H965T-3`N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$561T%#
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DUA;G5F86-T=7)I;F<L($QA8F]R
M871O<GD@86YD($]F9FEC92!&86-I;&ET>2`H1&5T86EL<RD@*%531"`D*3QB
M<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XR,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DYO=BX@
M,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^36%N=69A8W1U<FEN9R!,86)O<F%T;W)Y(&%N9"!/9F9I8V4@
M1F%C:6QI='D@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y496YA;G0@:6UP<F]V96UE;G0@86QL;W=A
M;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPU,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%D9&ET:6]N86P@=&5N86YT(&EM<')O=F5M96YT(&%L;&]W86YC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO=6YT(&9U
M;F1E9"!F<F]M('1E;F%N="!A;&QO=V%N8V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S(T.3@V8V8S7S$U.3!?-#4R,5]B96-E
M7S-C8C!F-S`P-&(W-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\R
M-#DX-F-F,U\Q-3DP7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0O5V]R:W-H965T
M<R]3:&5E=#4Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%5E!!0SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY-87-T97(@4V5R=FEC97,@06=R965M96YT('=I=&@@0V%D:6QA
M("A$971A:6QS*2`H0V%D:6QA(%M-96UB97)=+"!54T0@)"D\8G(^26X@5&AO
M=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^-30@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VES
M(&QI;6ET(&9O<B`U,"4@<&%Y;65N="!O9B!T:&4@<&]R=&EO;B!O9B!T:&4@
M<VAO<G1F86QL/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4V5R=FEC97,@<'5R8VAA<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPT,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-E<G9I8V5S('!R;W9I9&5D(&)Y($-03$(@
M;VX@8F5H86QF(&]F($-A9&EL83PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^36%X:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N
M<V%C=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!A;6]U;G0@;V8@<V5R=FEC97,@
M=&\@8F4@<')O=FED960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4&%Y;65N="!F;W(@<&]R=&EO;B!O9B!S:&]R=&9A;&P\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R-#DX-F-F,U\Q-3DP
M7S0U,C%?8F5C95\S8V(P9C<P,#1B-S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO,C0Y.#9C9C-?,34Y,%\T-3(Q7V)E8V5?,V-B,&8W,#`T8C<T
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M;&4@2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P."YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3(N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#$S+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970Q-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,34N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$V+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970Q-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,3@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Y
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,"YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,C$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#(R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R
M,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C0N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(U+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970R-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,C<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(X+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970R.2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,S`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#,Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,BYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S,N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#,T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970S-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S8N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,W+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970S."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,SDN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0P+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T,2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T-#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#0S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T-"YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#4N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#0V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970T-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#@N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0Y+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970U,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T-3$N:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T7S(T
F.3@V8V8S7S$U.3!?-#4R,5]B96-E7S-C8C!F-S`P-&(W-"TM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>83</ContextCount>
  <ElementCount>272</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>25</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StatementsOfComprehensiveLoss</Role>
      <ShortName>STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Statement - STATEMENTS OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StatementsOfCashFlowsParenthetical</Role>
      <ShortName>STATEMENTS OF CASH FLOWS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>102 - Disclosure - Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Operations</Role>
      <ShortName>Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>103 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>104 - Disclosure - Acquisition of Isconova AB</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/AcquisitionOfIsconovaAb</Role>
      <ShortName>Acquisition of Isconova AB</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>106 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>107 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/GoodwillAndOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>108 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>109 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>110 - Disclosure - U.S. Government Agreement, Joint Venture and Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/UsGovernmentAgreementJointVentureAndCollaborations</Role>
      <ShortName>U.S. Government Agreement, Joint Venture and Collaborations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>111 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.novavax.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>112 - Disclosure - Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/WarrantLiability</Role>
      <ShortName>Warrant Liability</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>113 - Disclosure - Manufacturing, Laboratory and Office Facility</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/ManufacturingLaboratoryAndOfficeFacility</Role>
      <ShortName>Manufacturing, Laboratory and Office Facility</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>114 - Disclosure - Master Services Agreement with Cadila</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/MasterServicesAgreementWithCadila</Role>
      <ShortName>Master Services Agreement with Cadila</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>203 - Disclosure - Summary of Significant Accounting Policies (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryOfSignificantAccountingPoliciesPolicy</Role>
      <ShortName>Summary of Significant Accounting Policies (Policy)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>304 - Disclosure - Acquisition of Isconova AB (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/AcquisitionOfIsconovaAbTables</Role>
      <ShortName>Acquisition of Isconova AB (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>305 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>306 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>307 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>309 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>311 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.novavax.com/role/NotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Acquisition of Isconova AB (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/AcquisitionOfIsconovaAbNarrativeDetails</Role>
      <ShortName>Acquisition of Isconova AB (Narrative) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Acquisition of Isconova AB (Schedule of Purchase Price) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/AcquisitionOfIsconovaAbScheduleOfPurchasePriceDetails</Role>
      <ShortName>Acquisition of Isconova AB (Schedule of Purchase Price) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Acquisition of Isconova AB (Schedule of Assets Acquired and Liabilities Assumed) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/AcquisitionOfIsconovaAbScheduleOfAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisition of Isconova AB (Schedule of Assets Acquired and Liabilities Assumed) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40404 - Disclosure - Acquisition of Isconova AB (Unaudited Pro Forma Financial Information of Operations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/AcquisitionOfIsconovaAbUnauditedProFormaFinancialInformationOfOperationsDetails</Role>
      <ShortName>Acquisition of Isconova AB (Unaudited Pro Forma Financial Information of Operations) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Fair Value Measurements (Fair Value Hierarchy) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/FairValueMeasurementsFairValueHierarchyDetails</Role>
      <ShortName>Fair Value Measurements (Fair Value Hierarchy) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Fair Value Measurements (Reconciliation of Level 3 Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/FairValueMeasurementsReconciliationOfLevelThreeAssetsAndLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements (Reconciliation of Level 3 Assets and Liabilities) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/InvestmentsDetails</Role>
      <ShortName>Investments (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfGoodwillDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Goodwill) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Identifiable Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIdentifiableIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Identifiable Intangible Assets) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Estimated Amortization Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfEstimatedAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Estimated Amortization Expense) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Stock-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockbasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation (Narrative) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Stock-Based Compensation (Summary of Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockbasedCompensationSummaryOfOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation (Summary of Option Activity) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Stock-Based Compensation (Assumptions Used in Estimation of Fair Value of Stock Options Granted) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockbasedCompensationAssumptionsUsedInEstimationOfFairValueOfStockOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Compensation (Assumptions Used in Estimation of Fair Value of Stock Options Granted) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Stock-Based Compensation (Summary of Restricted Stock Awards Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockbasedCompensationSummaryOfRestrictedStockAwardsActivityDetails</Role>
      <ShortName>Stock-Based Compensation (Summary of Restricted Stock Awards Activity) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40905 - Disclosure - Stock-Based Compensation (Stock-Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation (Stock-Based Compensation Expense) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>41001 - Disclosure - U.S. Government Agreement, Joint Venture and Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/UsGovernmentAgreementJointVentureAndCollaborationsDetails</Role>
      <ShortName>U.S. Government Agreement, Joint Venture and Collaborations (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Notes Payable (Narrative) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.novavax.com/role/NotesPayableNarrativeDetails</Role>
      <ShortName>Notes Payable (Narrative) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Notes Payable (Aggregate Future Minimum Principal Payments on Equipment Loan) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.novavax.com/role/NotesPayableAggregateFutureMinimumPrincipalPaymentsOnEquipmentLoanDetails</Role>
      <ShortName>Notes Payable (Aggregate Future Minimum Principal Payments on Equipment Loan) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/WarrantLiabilityDetails</Role>
      <ShortName>Warrant Liability (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Manufacturing, Laboratory and Office Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/ManufacturingLaboratoryAndOfficeFacilityDetails</Role>
      <ShortName>Manufacturing, Laboratory and Office Facility (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Master Services Agreement with Cadila (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novavax.com/role/MasterServicesAgreementWithCadilaDetails</Role>
      <ShortName>Master Services Agreement with Cadila (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">'Monetary' elements on report '40703 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Estimated Amortization Expense) (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '41101 - Disclosure - Notes Payable (Narrative) (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - BALANCE SHEETS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">Process Flow-Through: 005 - Statement - STATEMENTS OF COMPREHENSIVE LOSS</Log>
    <Log type="Info">Process Flow-Through: 006 - Statement - STATEMENTS OF CASH FLOWS</Log>
    <Log type="Info">Process Flow-Through: 007 - Statement - STATEMENTS OF CASH FLOWS (Parenthetical)</Log>
  </Logs>
  <InputFiles>
    <File>nvax-20130930.xml</File>
    <File>nvax-20130930.xsd</File>
    <File>nvax-20130930_cal.xml</File>
    <File>nvax-20130930_def.xml</File>
    <File>nvax-20130930_lab.xml</File>
    <File>nvax-20130930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Manufacturing, Laboratory and Office Facility (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">23 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Nov. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ManufacturingLaboratoryAndOfficeFacilityAbstract', window );"><strong>Manufacturing Laboratory and Office Facility [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_TenantImprovementAllowance', window );">Tenant improvement allowance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2,500<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_AdditionalTenantImprovementAllowance', window );">Additional tenant improvement allowance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Amount funded from tenant allowance</a></td>
        <td class="nump">$ 700<span></span></td>
        <td class="nump">$ 5,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AdditionalTenantImprovementAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional tenant improvement allowance</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_AdditionalTenantImprovementAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ManufacturingLaboratoryAndOfficeFacilityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_ManufacturingLaboratoryAndOfficeFacilityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_TenantImprovementAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tenant Improvement Allowance</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_TenantImprovementAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForProceedsFromTenantAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWOAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Stock-Based Compensation Expense) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump">$ 663<span></span></td>
        <td class="nump">$ 493<span></span></td>
        <td class="nump">$ 1,784<span></span></td>
        <td class="nump">$ 1,668<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and development [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump">316<span></span></td>
        <td class="nump">219<span></span></td>
        <td class="nump">829<span></span></td>
        <td class="nump">638<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">General and administrative [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump">$ 347<span></span></td>
        <td class="nump">$ 274<span></span></td>
        <td class="nump">$ 955<span></span></td>
        <td class="nump">$ 1,030<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>BALANCE SHEETS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">2,000,000<span></span></td>
        <td class="nump">2,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">300,000,000<span></span></td>
        <td class="nump">200,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">208,965,169<span></span></td>
        <td class="nump">148,398,747<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">208,509,739<span></span></td>
        <td class="nump">147,943,317<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
        <td class="nump">455,430<span></span></td>
        <td class="nump">455,430<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Other Intangible Assets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Note 7 - Goodwill and Other Intangible Assets</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> <strong><em>Goodwill</em></strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The changes in the carrying amounts of goodwill for the nine months ended September 30, 2013 and 2012 were as following (in thousands):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Nine Months Ended</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>September 30,</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2013</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 72%; TEXT-INDENT: 0px"> Beginning balance</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 33,141</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 33,141</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Goodwill resulting from acquisition of business</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">25,298</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Currency translation</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 320</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Ending balance</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 58,759</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 33,141</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> <strong><em>Identifiable Intangible Assets</em></strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Identifiable intangible assets consisted of the following as of September 30, 2013 (in thousands):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"><strong>Gross Carrying Amount</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Accumulated Amortization</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Intangible</strong></p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Assets, Net</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Finite-lived intangible assets:</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 58%; TEXT-INDENT: 0px"> Proprietary adjuvant technology</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 11,594</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">(97</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">)</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 11,497</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Collaboration agreements</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 4,992</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (84</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 4,908</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Total identifiable intangible assets</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 16,586</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (181</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 16,405</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Amortization expense for the nine months ended September 30, 2013 was $0.2 million. Estimated amortization expense for existing intangible assets for the remainder of 2013 and for each of the five succeeding years ending December 31,will be as follows (in thousands):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Year</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">Amount</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 13%"> 2013 (remainder)</td> <td style="FONT-SIZE: 10pt; WIDTH: 74%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 2%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">271</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> 2014</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,084</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> 2015</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,084</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> 2016</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"><font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"> 1,084</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"><font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> 2017</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"><font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"> 1,084</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> 2018</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"><font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"> 1,084</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13854-109267<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQDAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STATEMENTS OF COMPREHENSIVE LOSS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>STATEMENTS OF COMPREHENSIVE LOSS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (15,300)<span></span></td>
        <td class="num">$ (7,217)<span></span></td>
        <td class="num">$ (37,929)<span></span></td>
        <td class="num">$ (20,472)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gains (losses) on investments available-for-sale</a></td>
        <td class="num">(33)<span></span></td>
        <td class="nump">96<span></span></td>
        <td class="nump">174<span></span></td>
        <td class="nump">204<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency adjustment</a></td>
        <td class="nump">509<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">509<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
        <td class="nump">476<span></span></td>
        <td class="nump">96<span></span></td>
        <td class="nump">683<span></span></td>
        <td class="nump">204<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num">$ (14,824)<span></span></td>
        <td class="num">$ (7,121)<span></span></td>
        <td class="num">$ (37,246)<span></span></td>
        <td class="num">$ (20,268)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16317811<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTaxAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569643-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (c)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569643-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (c)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=SL7669646-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQ5AG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>BALANCE SHEETS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 122,493<span></span></td>
        <td class="nump">$ 17,399<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Short-term investments available-for-sale</a></td>
        <td class="nump">23,917<span></span></td>
        <td class="nump">26,712<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
        <td class="nump">124<span></span></td>
        <td class="nump">986<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
        <td class="nump">1,911<span></span></td>
        <td class="nump">1,011<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivableUnbilledAmounts', window );">Unbilled receivables</a></td>
        <td class="nump">3,194<span></span></td>
        <td class="nump">1,570<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">3,016<span></span></td>
        <td class="nump">2,559<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
        <td class="nump">365<span></span></td>
        <td class="nump">171<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">155,020<span></span></td>
        <td class="nump">50,408<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Investments available-for-sale</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">6,233<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">13,969<span></span></td>
        <td class="nump">11,456<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
        <td class="nump">16,405<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump">58,759<span></span></td>
        <td class="nump">33,141<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
        <td class="nump">757<span></span></td>
        <td class="nump">756<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
        <td class="nump">164<span></span></td>
        <td class="nump">351<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">245,074<span></span></td>
        <td class="nump">102,345<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">3,339<span></span></td>
        <td class="nump">3,228<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
        <td class="nump">9,553<span></span></td>
        <td class="nump">7,275<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump">190<span></span></td>
        <td class="nump">258<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Current portion of capital leases</a></td>
        <td class="nump">115<span></span></td>
        <td class="nump">58<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
        <td class="nump">597<span></span></td>
        <td class="nump">157<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">267<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
        <td class="nump">466<span></span></td>
        <td class="nump">432<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">14,260<span></span></td>
        <td class="nump">11,675<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue</a></td>
        <td class="nump">2,500<span></span></td>
        <td class="nump">2,500<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Non-current portion of capital leases</a></td>
        <td class="nump">222<span></span></td>
        <td class="nump">237<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current portion of notes payable</a></td>
        <td class="nump">1,653<span></span></td>
        <td class="nump">753<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
        <td class="nump">8,287<span></span></td>
        <td class="nump">6,940<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
        <td class="nump">1,578<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">28,500<span></span></td>
        <td class="nump">22,105<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 2,000,000 shares authorized; no shares issued and outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 300,000,000 shares authorized at September 30, 2013 and 200,000,000 shares authorized at December 31, 2012; and 208,965,169 shares issued and 208,509,739 shares outstanding at September 30, 2013 and 148,398,747 shares issued and 147,943,317 shares outstanding at December 31, 2012</a></td>
        <td class="nump">2,090<span></span></td>
        <td class="nump">1,484<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">611,913<span></span></td>
        <td class="nump">438,939<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(396,092)<span></span></td>
        <td class="num">(358,163)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, 455,430 shares, cost basis</a></td>
        <td class="num">(2,450)<span></span></td>
        <td class="num">(2,450)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
        <td class="nump">1,113<span></span></td>
        <td class="nump">430<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">216,574<span></span></td>
        <td class="nump">80,240<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 245,074<span></span></td>
        <td class="nump">$ 102,345<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=SL7669686-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Available-for-Sale Securities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCreditCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCreditNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=20225523&amp;loc=SL20225862-175312<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Goodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivableUnbilledAmounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unbilled amounts (net of unliquidated progress payments) of government contract receivables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 912<br><br><br><br> -SubTopic 310<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6471842&amp;loc=d3e55376-109406<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GovernmentContractReceivableUnbilledAmounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph ((a)(1),(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsNetExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386993&amp;loc=d3e5879-108316<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Master Services Agreement with Cadila (Details) (Cadila [Member], USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">54 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_HalfPaymentForPortionOfShortfallExceedingTwoMillion', window );">Basis limit for 50% payment of the portion of the shortfall</a></td>
        <td class="nump">$ 2,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ServicesPurchased', window );">Services purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,400<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ServicesProvidedDuringThePeriod', window );">Services provided by CPLB on behalf of Cadila</a></td>
        <td class="nump">800<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_MasterServiceAgreement', window );">Total amount of services to be provided</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_PaymentToRelatedPartyPortionOfShortfall', window );">Payment for portion of shortfall</a></td>
        <td class="nump">$ 2,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_HalfPaymentForPortionOfShortfallExceedingTwoMillion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Half Payment For Portion Of Shortfall Exceeding Two Million</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_HalfPaymentForPortionOfShortfallExceedingTwoMillion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_MasterServiceAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Master Service Agreement</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_MasterServiceAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_PaymentToRelatedPartyPortionOfShortfall">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payment To Related Party Portion Of Shortfall</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_PaymentToRelatedPartyPortionOfShortfall</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ServicesProvidedDuringThePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Services Provided During The Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_ServicesProvidedDuringThePeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ServicesPurchased">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Services Purchased</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_ServicesPurchased</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Narrative) (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of shares excluded from the computation of net loss per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,157,634<span></span></td>
        <td class="nump">12,951,625<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses', window );">Reclassification of general and administrative expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 200<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 600<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities', window );">Reclassification of restricted cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">800<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency adjustment</a></td>
        <td class="nump">$ 509<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 509<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reclassification of general and administrative expenses relating to supply chain management expenses to research and development expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>"Reclassification of restricted cash from financing activities to operating activities</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_ReclassificationOfRestrictedCashFromFinancingActivitiesToOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569643-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (c)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisition of Isconova AB (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Acquisition Of Isconova AB [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ScheduleOfPurchasePriceTableTextBlock', window );">Schedule of Purchase Price</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> <font style="FONT-SIZE: 10pt">The total purchase price is summarized as follows (in thousands):</font></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; WIDTH: 86%">Value of shares of Novavax Common Stock issued</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 41,942</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Cash paid to Isconova warrant holders</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 22</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"> Total purchase price</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 41,964</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Assets Acquired and Liabilities Assumed</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2">(in thousands)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 86%"> Cash and cash equivalents</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 3,056</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Accounts receivable</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">603</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Prepaid expenses and other assets</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1,092</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Property and equipment</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">165</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Intangible assets</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">16,380</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px">Goodwill</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">25,298</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Accounts payable and other current liabilities</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(2,784</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Capital leases</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(94</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Notes payable</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">(193</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Other non-current liabilities</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (1,559</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"> Total purchase price</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 41,964</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Unaudited Pro Forma Financial Information of Operations</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The unaudited pro forma financial information combines the historical results of operations of Novavax and Isconova for the periods presented below and reflects the application of the following adjustments:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">&middot;</td> <td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"> Elimination of the historical intangible assets and amortization expense unrelated to the Acquisition;</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">&middot;</td> <td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"> Amortization expense related to the fair value of intangible assets acquired; and</td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">&middot;</td> <td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"> The exclusion of acquisition-related costs incurred for the Acquisition.</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Three Months Ended</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>September 30,</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Nine Months Ended</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>September 30,</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2013</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2013</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="14">(in thousands)</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; WIDTH: 44%"> Revenue</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; WIDTH: 2%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> 4,869</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; WIDTH: 2%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> 6,272</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; WIDTH: 2%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> 14,195</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; WIDTH: 2%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> 19,530</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Net loss</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (15,687</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (8,490</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (40,565</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (25,033</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Basic and diluted net loss per share</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.09</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.06</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.24</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> (0.18</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ScheduleOfPurchasePriceTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule Of Purchase Price [Table Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_ScheduleOfPurchasePriceTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(2)-(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionProFormaInformationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6910749&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3LAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Summary of Restricted Stock Awards Activity) (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and Unvested at January 1, 2013</a></td>
        <td class="nump">33,334<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock vested</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock forfeited</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and Unvested at September 30, 2013</a></td>
        <td class="nump">33,334<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Per Share Weighted-Average Grant-Date Fair Value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and Unvested at January 1, 2013</a></td>
        <td class="nump">$ 1.39<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock granted</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock vested</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Restricted stock forfeited</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and Unvested at September 30, 2013</a></td>
        <td class="nump">$ 1.39<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Estimated Amortization Expense) (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Other Intangible Assets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2013 (remainder)</a></td>
        <td class="nump">$ 271,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2014</a></td>
        <td class="nump">1,084,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2015</a></td>
        <td class="nump">1,084,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2016</a></td>
        <td class="nump">1,084,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2017</a></td>
        <td class="nump">1,084,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2018</a></td>
        <td class="nump">1,084,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to intangible assets</a></td>
        <td class="nump">$ 200,000<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the next fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized in the remainder of the fiscal year following the latest fiscal year ended for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the fifth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the fourth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the third fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the second fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements (Reconciliation of Level 3 Assets and Liabilities) (Details) (Warrants Settleable In Cash [Member], USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants Settleable In Cash [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2012</a></td>
        <td class="nump">$ 267<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value of Warrant liability</a></td>
        <td class="num">(267)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at September 30, 2013</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EYTAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Investments (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump">$ 23,312<span></span></td>
        <td class="nump">$ 32,515<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains', window );">Gross Unrealized Gains</a></td>
        <td class="nump">605<span></span></td>
        <td class="nump">430<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
        <td class="nump">23,917<span></span></td>
        <td class="nump">32,945<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Auction Rate Securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump">1,175<span></span></td>
        <td class="nump">1,175<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains', window );">Gross Unrealized Gains</a></td>
        <td class="nump">601<span></span></td>
        <td class="nump">409<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
        <td class="nump">1,776<span></span></td>
        <td class="nump">1,584<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Corporate Debt Securities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
        <td class="nump">22,137<span></span></td>
        <td class="nump">31,340<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains', window );">Gross Unrealized Gains</a></td>
        <td class="nump">4<span></span></td>
        <td class="nump">21<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
        <td class="nump">$ 22,141<span></span></td>
        <td class="nump">$ 31,361<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (aa)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26610-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesAmortizedCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of unrealized gain before deducting unrealized loss on investments in debt and equity securities classified as available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGains</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of unrealized loss before deducting unrealized gain on investments in available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesGrossUnrealizedLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Investments<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Note 6 - Investments</strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Investments classified as available-for-sale as of September 30, 2013 and December 31, 2012 were comprised of (in thousands):</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="14"><strong>September 30, 2013</strong></td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="14"><strong>December 31, 2012</strong></td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>Amortized Cost</strong></td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>Gross Unrealized Gains</strong></td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>Gross Unrealized Losses</strong></td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>Fair Value</strong></td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>Amortized Cost</strong></td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>Gross Unrealized Gains</strong></td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>Gross Unrealized Losses</strong></td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>Fair Value</strong></td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 9pt; TEXT-INDENT: -9pt; WIDTH: 20%"> Auction rate securities</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"> 1,175</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%">601</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%">-</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"> 1,776</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"> 1,175</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%">409</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%">-</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 7%"> 1,584</td> <td style="WIDTH: 1%">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 9pt; TEXT-INDENT: -9pt"> Corporate debt securities</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 22,137</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 4</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 22,141</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 31,340</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 21</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 31,361</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">Total</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 23,312</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 605</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; TEXT-ALIGN: right"> <font style="FONT-SIZE: 10pt">-</font> </td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 23,917</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 32,515</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 430</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt"> $</td> <td style="BORDER-BOTTOM: black 2.25pt double; FONT-SIZE: 10pt; TEXT-ALIGN: right"> 32,945</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for  investments in certain debt and equity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27357-111563<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -Glossary Debt Security<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6379141&amp;loc=d3e15032-111544<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27232-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27161-111563<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27405-111563<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -Glossary Equity Security<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6511694<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDJAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisition of Isconova AB (Narrative) (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Novavax AB [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Minimum [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Maximum [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_NovavaxSharesIssued', window );">Novavax shares issued for Isconova AB shares acquired</a></td>
        <td class="nump">15,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Value of shares of Novavax Common Stock issued</a></td>
        <td class="nump">$ 41,942<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid to Isconova warrant holders</a></td>
        <td class="nump">22<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired finite-lived intangible assets, weighted-average useful life</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">20 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill', window );">Goodwill</a></td>
        <td class="nump">25,298<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,802<span></span></td>
        <td class="nump">5,765<span></span></td>
        <td class="nump">12,167<span></span></td>
        <td class="nump">17,510<span></span></td>
        <td class="nump">400<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(15,300)<span></span></td>
        <td class="num">(7,217)<span></span></td>
        <td class="num">(37,929)<span></span></td>
        <td class="num">(20,472)<span></span></td>
        <td class="num">(1,500)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_AcquisitionTransactionCosts', window );">Transaction costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,300<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable', window );">Aggregate remaining rental payments due under operating lease commitments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,900<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,900<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_AcquisitionTransactionCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Acquisition Transaction Costs</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_AcquisitionTransactionCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Goodwill</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NovavaxSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Novavax Shares Issued</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_NovavaxSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Future minimum rental payments in aggregate as of the balance sheet date under operating leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6454179&amp;loc=d3e41551-112718<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireBusinessesGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENAAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Summary of Option Activity) (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2005 Stock Incentive Plan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at January 1, 2013</a></td>
        <td class="nump">9,143,825<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
        <td class="nump">4,117,500<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="num">(522,292)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled</a></td>
        <td class="num">(802,883)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at September 30, 2013</a></td>
        <td class="nump">11,936,150<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable at September 30, 2013</a></td>
        <td class="nump">4,647,873<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant at September 30, 2013</a></td>
        <td class="nump">6,461,494<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at January 1, 2013</a></td>
        <td class="nump">$ 1.87<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
        <td class="nump">$ 1.92<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
        <td class="nump">$ 2.29<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled</a></td>
        <td class="nump">$ 1.74<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at September 30, 2013</a></td>
        <td class="nump">$ 1.88<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, September 30, 2013</a></td>
        <td class="nump">$ 2.12<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">1995 Stock Option Plan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at January 1, 2013</a></td>
        <td class="nump">211,900<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled</a></td>
        <td class="num">(23,750)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at September 30, 2013</a></td>
        <td class="nump">188,150<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares exercisable at September 30, 2013</a></td>
        <td class="nump">188,150<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at January 1, 2013</a></td>
        <td class="nump">$ 4.94<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled</a></td>
        <td class="nump">$ 4.05<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at September 30, 2013</a></td>
        <td class="nump">$ 5.04<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, September 30, 2013</a></td>
        <td class="nump">$ 5.04<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Note 9 - Stock-Based Compensation</strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> <strong><em>Stock Options</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Company has granted equity awards under several plans, two of which remain active. Under the 2005 Stock Incentive Plan (the "2005 Plan"), equity awards may be granted to officers, directors, employees, consultants and advisors to the Company and any present or future subsidiary. The 2005 Plan, approved in May 2005 and amended in June 2007, June 2011, June 2012 and June 2013 by the Company&#39;s stockholders, currently authorizes the grant of equity awards for up to 22,312,192 shares of common stock, which included, at the time of approval of the 2005 Plan, a maximum 5,746,468 shares of common stock subject to stock options outstanding under the Company&#39;s 1995 Stock Option Plan (the "1995 Plan") that may revert to and become issuable under the 2005 Plan if such options expire or otherwise terminate unexercised. The Company received approval at its 2013 annual meeting of stockholders to increase the number of shares of common stock available for issuance under the 2005 Plan by 4,000,000 shares. The term of the Company&#39;s 1995 Plan has expired and no new awards will be made under the 1995 Plan; however, outstanding stock options remain in existence in accordance with their terms.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Under the 2005 Plan and the 1995 Plan, incentive stock options, having a maximum term of 10 years, can be or were granted at no less than 100% of the fair value of the Company&#39;s common stock at the time of grant and are generally exercisable over periods ranging from six months to four years. There is no minimum exercise price for non-statutory stock options.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; TEXT-INDENT: 0in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; TEXT-INDENT: 0in"> <strong><em>Stock Options Awards</em></strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; TEXT-INDENT: 0in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following is a summary of option activity under the 2005 Plan and the 1995 Plan for the nine months ended September 30, 2013:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6">2005 Stock Incentive Plan</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="6">1995 Stock Option Plan</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"><strong>Stock Options</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"><strong>Weighted-Average Exercise Price</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"><strong>Stock Options</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"><strong>Weighted-Average Exercise Price</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; WIDTH: 44%; TEXT-INDENT: 0px"> Outstanding at January 1, 2013</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 9,143,825</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1.87</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 211,900</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 4.94</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Granted</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"><font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"> 4,117,500</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt"><font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"> 1.92</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"><font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Exercised</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left"><font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"> (522,292</td> <td style="FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">2.29</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Canceled</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (802,883</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1.74</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (23,750</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 4.05</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Outstanding at September 30, 2013</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 11,936,150</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1.88</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 188,150</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5.04</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Shares exercisable at September 30, 2013</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,647,873</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2.12</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 188,150</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5.04</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Shares available for grant at September 30, 2013</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> <font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="BORDER-BOTTOM: black 2.5pt double; FONT-SIZE: 10pt; FONT-STYLE: normal; FONT-WEIGHT: normal; TEXT-ALIGN: right"> 6,461,494</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> <font style="FONT-WEIGHT: normal; FONT-STYLE: normal">&nbsp;</font> </td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;&nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The fair value of stock options granted was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid" colspan="6"> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Three Months Ended</strong></p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>September 30,</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid" colspan="6"> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Nine Months Ended</strong></p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>September 30,</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>2013</strong></td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>2012</strong></td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>2013</strong></td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; TEXT-ALIGN: center" colspan="2"><strong>2012</strong></td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"> <td style="FONT-SIZE: 10pt; WIDTH: 44%">Weighted-average fair value of stock options granted</td> <td style="WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1.41</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1.09</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1.02</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 0.71</td> <td style="WIDTH: 1%">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Risk-free interest rate</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">1.12%-1.36</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.55</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.54%-1.36</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.55%-1.54</td> <td style="FONT-SIZE: 10pt">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"> <td style="FONT-SIZE: 10pt">Dividend yield</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0</td> <td style="FONT-SIZE: 10pt">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Volatility</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">56.75%-62.51</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">76.60%-76.71</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">55.81%-73.72</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">75.47%-80.48</td> <td style="FONT-SIZE: 10pt">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"> <td style="FONT-SIZE: 10pt">Expected term (in years)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">4.25</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">4.24</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">3.98-7.05</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">3.34-7.09</td> <td>&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Expected forfeiture rate</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">23.15</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">23.15</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0%-23.15</td> <td style="FONT-SIZE: 10pt">%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0%-23.15</td> <td style="FONT-SIZE: 10pt">%</td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The aggregate intrinsic value and weighted-average remaining contractual term of stock options outstanding as of September 30, 2013 was approximately $15.9 million and 7.6 years, respectively. The aggregate intrinsic value and weighted-average remaining contractual term of stock options exercisable as of September 30, 2013 was approximately $5.5 million and 5.9 years, respectively. The aggregate intrinsic value represents the total intrinsic value (the difference between the Company&#39;s closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on September 30, 2013. This amount is subject to change based on changes to the fair value of the Company&#39;s common stock. The aggregate intrinsic value of options exercised for the nine months ended September 30, 2013 and 2012 was $0.3 million and less than $0.1 million, respectively.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> <strong><em>Employee Stock Purchase Plan</em></strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Company received approval at its 2013 annual meeting of stockholders to adopt an Employee Stock Purchase Plan (the "ESPP"), which currently authorizes an aggregate of 2,000,000 shares of Common Stock to be purchased. The ESPP allows employees to purchase shares of Common Stock of the Company at each purchase date through payroll deductions of up to a maximum of 15% of their compensation, at 85% of the lesser of the market price of the shares at the time of purchase or the market price on the beginning date of an option period (or, if later, the date during the option period when the employee was first eligible to participate). The first option period under the ESPP commenced on August 1, 2013.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The ESPP is considered compensatory for financial reporting purposes. As such, the fair value of ESPP shares was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 75%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="3"><font style="FONT-SIZE: 10pt"><strong>Three Months Ended</strong></font> <br /> <font style="FONT-SIZE: 10pt"><strong>September 30,</strong></font></td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center"> <strong>2013</strong></td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"> <td style="FONT-SIZE: 10pt; WIDTH: 77%">Weighted-average fair value of ESPP shares granted</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 20%"> 0.78</td> <td style="WIDTH: 1%">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Risk-free interest rate</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.04</td> <td style="FONT-SIZE: 10pt">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"> <td style="FONT-SIZE: 10pt">Dividend yield</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0</td> <td style="FONT-SIZE: 10pt">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Volatility</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">50.80</td> <td style="FONT-SIZE: 10pt">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ccffcc"> <td style="FONT-SIZE: 10pt">Expected term (in years)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">0.5</td> <td>&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt">Expected forfeiture rate</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">5</td> <td style="FONT-SIZE: 10pt">%</td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; TEXT-INDENT: 0in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; TEXT-INDENT: 0in"> <strong><em>Restricted Stock Awards</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in; TEXT-INDENT: 0in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Under the 2005 Plan, the Company has granted restricted stock awards subject to certain performance-based and/or time-based vesting conditions which, if not met, would result in forfeiture of the shares and reversal of any previously recognized related stock-based compensation expense.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following is a summary of restricted stock awards activity for the nine months ended September 30, 2013:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 80%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>&nbsp;</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>&nbsp;</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>&nbsp;</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Number of</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Shares</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Per Share Weighted-Average Grant-Date</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Fair Value</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 72%"> Outstanding and Unvested at January 1, 2013</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 33,334</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%"> 1.39</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Restricted stock granted</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Restricted stock vested</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">-</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Restricted stock forfeited</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Outstanding and Unvested at September 30, 2013</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 33,334</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1.39</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Company recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; WIDTH: 90%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Three Months Ended</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>September 30,</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="6"> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>Nine Months Ended</strong></p> <p style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt"> <strong>September 30,</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: center; PADDING-LEFT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2013</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2013</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; WIDTH: 44%; TEXT-INDENT: 0px"> Research and development</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">316</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">219</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">829</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 2%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 10%">638</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> General and administrative</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 347</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 274</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 955</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,030</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Total stock-based compensation expense</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 663</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 493</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,784</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,668</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> As of September 30, 2013, there was approximately $4.7 million of total unrecognized compensation expense (net of estimated forfeitures) related to unvested options and restricted stock awards. This unrecognized compensation expense is expected to be recognized over a weighted-average period of 1.5 years. This estimate does not include the impact of other possible stock-based awards that may be made during future periods.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Note 5 - Fair Value Measurements</strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px; TEXT-ALIGN: justify; TEXT-INDENT: 0.5in"> The following table represents the Company&#39;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis (in thousands):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px; TEXT-ALIGN: justify; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 100%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="10">Fair Value at September 30, 2013</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="10">Fair Value at December 31, 2012</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-DECORATION: underline; TEXT-INDENT: 0px"> Assets</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> <strong>Level 1</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"> <font style="FONT-SIZE: 10pt"><strong>Level 2</strong></font> </td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> <strong>Level 3</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> <strong>Level 1</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> <strong>Level 2</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-ALIGN: center"> <strong>Level 3</strong></td> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt; TEXT-ALIGN: center"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; PADDING-LEFT: 0.125in; WIDTH: 28%; TEXT-INDENT: -0.125in"> Corporate debt securities and auction rate securities</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> 23,917</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> 32,945</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> <td style="FONT: 10pt Times New Roman, Times, Serif; WIDTH: 2%"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 8%"> -</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Total investments</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 23,917</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 32,945</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; FONT-WEIGHT: bold; PADDING-LEFT: 0px; TEXT-DECORATION: underline; TEXT-INDENT: 0px"> Liabilities</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 0px; TEXT-INDENT: 0px"> Warrant liabilities</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 267</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px; TEXT-ALIGN: justify; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; FONT-WEIGHT: normal; MARGIN: 0pt 0px; TEXT-ALIGN: justify; TEXT-INDENT: 0.5in"> During the nine months ended September 30, 2013, the Company did not have any transfers between levels.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table provides a reconciliation of the beginning and ending balance of Level 3 assets and liabilities measured on a recurring basis for the nine months ended September 30, 2013 (in thousands):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 75%" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0px"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: bold 10pt Times New Roman, Times, Serif" colspan="2"> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Fair&nbsp;Value&nbsp;Measurements&nbsp;of</strong></p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Warrants&nbsp;Using Significant</strong></p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Unobservable&nbsp;Inputs&nbsp;</strong></p> <p style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>(Level&nbsp;3)</strong></p> </td> <td style="PADDING-BOTTOM: 1pt; FONT: bold 10pt Times New Roman, Times, Serif"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-LEFT: 0px; WIDTH: 77%">Balance at December 31, 2012</td> <td style="FONT-SIZE: 10pt; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: right; WIDTH: 20%">267</td> <td style="FONT-SIZE: 10pt; TEXT-ALIGN: left; WIDTH: 1%"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0px"> Change in fair value of Warrant liability</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (267</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"> )</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0px"> Balance at September 30, 2013</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="FONT-SIZE: 10pt; BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="FONT-SIZE: 10pt; PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"> &nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The amounts in the Company&#39;s consolidated balance sheet for accounts receivables, unbilled receivables and accounts payable approximate fair value due to their short-term nature. Based on borrowing rates available to the Company, the fair value of capital leases and notes payable approximates their carrying value.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>STATEMENTS OF CASH FLOWS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net proceeds from sales of common stock, offering costs</a></td>
        <td class="nump">$ 6,100<span></span></td>
        <td class="nump">$ 400<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfCashFlowsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ERLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Notes Payable (Narrative) (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Borrowing limit of loan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate in addition to three-year U.S. Government treasury rate</a></td>
        <td class="nump">11.68%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum', window );">Minimum interest rate</a></td>
        <td class="nump">12.10%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Repayment term</a></td>
        <td class="text">42 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Debt instrument, increase in borrowings</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate during period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12.10%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Monthly principal payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 34,529<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average effective interest rate during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateDuringPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the required periodic payments including both interest and principal payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 470<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentPeriodicPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELMAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisition of Isconova AB (Unaudited Pro Forma Financial Information of Operations) (Details) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Acquisition Of Isconova AB [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenue</a></td>
        <td class="nump">$ 4,869<span></span></td>
        <td class="nump">$ 6,272<span></span></td>
        <td class="nump">$ 14,195<span></span></td>
        <td class="nump">$ 19,530<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (15,687)<span></span></td>
        <td class="num">$ (8,490)<span></span></td>
        <td class="num">$ (40,565)<span></span></td>
        <td class="num">$ (25,033)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
        <td class="num">$ (0.09)<span></span></td>
        <td class="num">$ (0.06)<span></span></td>
        <td class="num">$ (0.24)<span></span></td>
        <td class="num">$ (0.18)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(2)-(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(2)-(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionsProFormaRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrant Liability<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_WarrantLiabilityAbstract', window );"><strong>Warrant Liability [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_StockWarrantsTextBlock', window );">Warrant Liability</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> Note 12 - Warrant Liability</p> <p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.55in"> In July 2008, the Company completed a registered direct offering of 6,686,650 units, raising approximately $17.5 million in net proceeds. Each unit consisted of one share of common stock and a warrant to purchase 0.5 shares of common stock (the "Warrants") at a price of $2.68 per unit. The Warrants represent the right to acquire an aggregate of 3,343,325 shares of common stock at an exercise price of $3.62 per share and were exercisable between January 31, 2009 and July 31, 2013.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.55in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.55in"> <font style="COLOR: black">During the nine months ended September 30, 2013 and 2012, the Company recorded as other income (expense)</font> in its consolidated statements of operations <font style="COLOR: black">a change in fair value of warrant liability of $0.3 million and ($0.4) million, respectively. All Warrants expired unexercised on July 31, 2013.</font></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.55in"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_StockWarrantsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Warrant Disclosure</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_StockWarrantsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_WarrantLiabilityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_WarrantLiabilityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>Note 8 - Stockholders&#39; Equity</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> On June 13, 2013, the Company&#39;s stockholders of record as of April 16, 2013 approved the amendment of the Company&#39;s certificate of incorporation to increase the total number of shares of Common Stock that the Company is authorized to issue from 200,000,000 shares to 300,000,000 shares.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In October 2012, the Company entered into an At Market Issuance Sales Agreement ("2012 Sales Agreement"), under which the Board of Directors of the Company (the "Board") approved the Company&#39;s sale of up to an aggregate of $50 million in gross proceeds of its common stock. The shares of common stock are being offered pursuant to a shelf registration statement filed with the SEC in March 2013, which replaced the previous shelf registration statement filed in 2010. The Board&#39;s standing Finance Committee (the "Committee") assists with its responsibilities to monitor, provide advice to senior management of the Company and approve all capital raising activities. The Committee has been authorized by the Board, absent any action by the Board to the contrary, to take any additional actions necessary to carry out the Board&#39;s authorization of the issuance and sale of the common stock sold pursuant to the 2012 Sales Agreement. In doing so, the Committee is authorized to set the amount of shares to be sold, the period of time during which such sales may occur and the minimum sales price per share. During the nine months ended September 30, 2013, the Company sold 12.6 million shares at sales prices ranging from $2.06 to $3.38 per share, resulting in $34.0 million in net proceeds. The most recent sales to occur under the 2012 Sales Agreement were on September 10, 2013.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In September 2013, the Company completed a public offering of 31,846,950 shares of its common stock, including 4,153,950 shares of common stock that were issued upon the exercise in full of the over-allotment granted to the underwriters, at a price of $3.14 per share resulting in net proceeds of approximately $94.7 million.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policy)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> <strong><em>Basis of Presentation</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The consolidated balance sheet as of September 30, 2013, consolidated statements of operations and consolidated statements of comprehensive loss for the three and nine months ended September 30, 2013 and 2012 and the consolidated statements of cash flows for the nine months ended September 30, 2013 and 2012 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, operating results, comprehensive loss and cash flows, respectively, for the periods presented. Although the Company believes that the disclosures in these consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted under the rules and regulations of the United States Securities and Exchange Commission ("SEC").</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> As discussed in more detail in Note 4, the Company acquired Swedish-based Isconova AB ("Isconova") on July 31, 2013. Isconova was subsequently renamed Novavax AB. The consolidated financial statements include the accounts of Novavax, Inc. and its subsidiary, Novavax AB. All intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The accompanying consolidated financial statements are presented in U.S. dollars. The translation of assets and liabilities to U.S. dollars is made at the exchange rate in effect at the consolidated balance sheet date, while equity accounts are translated at historical rates. The translation of statement of operations data is made at the average exchange rate in effect for the period. The translation of operating cash flow data is made at the average exchange rate in effect for the period, and investing and financing cash flow data is translated at the exchange rate in effect at the date of the underlying transaction. Translation gains and losses are recognized as a component of accumulated other comprehensive income in the accompanying consolidated balance sheets. The foreign currency translation adjustment balance included in accumulated other comprehensive income was $0.5 million at September 30, 2013.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#39;s Annual Report on Form 10-K for the year ended December 31, 2012. Results for this or any interim period are not necessarily indicative of results for any future interim period or for the entire year. The Company operates in one business segment: developing recombinant vaccines.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> <strong><em>Use of Estimates</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these estimates.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> <strong><em>Fair Value Measurements</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Company applies Accounting Standards Codification ("ASC") Topic 820, <em>Fair Value Measurements and Disclosures</em>, for financial and non-financial assets and liabilities.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> ASC 820 discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). The statement utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">&middot;</td> <td style="TEXT-ALIGN: justify">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</td> </tr> </table> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">&middot;</td> <td style="TEXT-ALIGN: justify">Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</td> </tr> </table> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td style="FONT-FAMILY: Symbol; WIDTH: 0.25in">&middot;</td> <td style="TEXT-ALIGN: justify">Level 3: Unobservable inputs that reflect the reporting entity&#39;s own assumptions.</td> </tr> </table> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> <strong><em>Investments</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: bold italic 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Investments consist of commercial paper, corporate notes and an investment in one auction rate security. Classification of marketable securities between current and non-current is dependent upon the original maturity date at purchase. Those securities purchased with original maturities greater than 90 days, but less than one year are classified as current and those with greater than one year are classified as non-current.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Interest and dividend income is recorded when earned and included in interest income. Premiums and discounts, if any, on investments are amortized or accreted to maturity and included in interest income. The specific identification method is used in computing realized gains and losses on the sale of the Company&#39;s securities.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Company has classified its investments as available-for-sale since the Company may need to liquidate these securities within the next year. The available-for-sale securities are carried at fair value and unrealized gains and losses on these securities, if determined to be temporary, are included in accumulated other comprehensive income (loss) in stockholders&#39; equity. Investments are evaluated periodically to determine whether a decline in value is "other-than-temporary." The term "other-than-temporary" is not intended to indicate a permanent decline in value. Rather, it means that the prospects for a near term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. Management reviews criteria, such as the magnitude and duration of the decline, as well as the Company&#39;s ability to hold the securities until market recovery, to predict whether the loss in value is other-than-temporary. If a decline in value is determined to be other-than-temporary, the value of the security is reduced and the impairment is recorded in the statement of operations.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: bold italic 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> Restricted Cash</p> <p style="TEXT-ALIGN: justify; FONT: bold italic 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Company&#39;s restricted cash includes payments received under the PATH agreement (See Note 10) until such time as the Company has paid for the work performed under the agreement. In addition, the Company&#39;s non-current restricted cash with respect to its manufacturing, laboratory and office space in Gaithersburg, Maryland functions as collateral for letters of credit, which serve as security deposits for the duration of the leases.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.25in"> <strong><em>Net Loss per Share</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Net loss per share is computed using the weighted average number of shares of common stock outstanding. All outstanding warrants, stock options and unvested restricted stock awards totaling 12,157,634 shares and 12,951,625 shares at September 30, 2013 and 2012, respectively, are excluded from the computation, as their effect is antidilutive.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> <strong><em>Reclassifications</em></strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.25in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Overhead expenses relating to supply chain management of $0.2 million and $0.6 million for the three and nine months ended September 30, 2012, respectively, have been reclassified from general and administrative expenses to research and development expenses. Also, within the September 30, 2012 statement of cash flows, restricted cash received of $0.8 million recorded in financing activities has been reclassified and is included in operating activities. These reclassifications have been made to conform to current year presentation.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Subparagraph a<br><br> -Article 9<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section M<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.2,12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 2, 12<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PriorPeriodReclassificationAdjustmentDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Manufacturing, Laboratory and Office Facility<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_ManufacturingLaboratoryAndOfficeFacilityAbstract', window );"><strong>Manufacturing Laboratory and Office Facility [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_NewFacilityLeaseDisclosureTextBlock', window );">Manufacturing, Laboratory and Office Facility</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> Note 13 - Manufacturing, Laboratory and Office Facility</p> <p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Company leases its new manufacturing, laboratory and office space in Gaithersburg, Maryland with rent payments for such space to the landlord commencing April 1, 2014. Under the terms of one lease agreement, the landlord provided the Company with a tenant improvement allowance of $2.5 million and an additional tenant improvement allowance of $3 million, such additional tenant improvement allowance is to be paid back to the landlord during the remainder of the term of such lease agreement through additional rent payments (collectively, the "Improvement Allowance"). The Company has been funded $0.7 million in the nine months ended September 30, 2013, and has been funded $5.0 million in total under the Improvement Allowance. The Improvement Allowance is being amortized on a straight-line basis over the remaining term of the lease.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_ManufacturingLaboratoryAndOfficeFacilityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_ManufacturingLaboratoryAndOfficeFacilityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_NewFacilityLeaseDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>New Facility Lease Disclosure</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_NewFacilityLeaseDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">NOVAVAX INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001000694<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">NVAX<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">208,510,739<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001144204-13-060509-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-13-060509-xbrl.zip
M4$L#!!0````(`.V`;$/H\!@LM:8``(#D!P`1`!P`;G9A>"TR,#$S,#DS,"YX
M;6Q55`D``XV8@E*-F()2=7@+``$$)0X```0Y`0``[#UI<^.XL=]?5?X#HLRF
M9JMTD+ILV3N3)U\SVOB*K9G=>5]2$`E)R)*$PL.V]M>_;@"\)$JF;'G&XW&R
MFU@DT#<:#:`;_.4?=ZY#;I@?<.&]JYAUHT*89PF;>Y-WE4_7M?[UX6!0(4%(
M/9LZPF/O*IZH_./]7_[GE[_6:H<^HR&SR6A./G,OI!-&3K@#?0/RMO+YI/)S
MK:9;SGQA1Q8T%1YI&F:K9IHULTG^EW3W.@;IGZF&=R/?(4"1%^Q9(O)"?_ZN
M,@W#V5ZC@:_J`;/J$W'3T"\;`*E9,\Q:RZSH;H#\CZ3/[>UM7?83_@3:&JT&
MOA[1@,7-O1MZEVONB1L*S^J6<!%ZR^BUC+@Q@N)K@',/Q60EP.^FH>ODVM^V
M9&NSU^LUY-NDZ1+=N:;X-FYJ,UXL%'@A2<X+)`IJ$TIG29<Q#482LGY1T(4'
MHMTT=]9QJEKH#F5$`MHEY!?D8R^PILRE5VQ,)%][X7P&5A5P=^:@Z.2SJ<_&
M8&F@B5JLA?I=8%=(0P$"7O?Z+O-L^#<\<>B$</M=)?>DWNQV6W4C_6^%6,(+
MV5UXA;#'OG!K,>_P3RCTKUX-<"WVA=[OQ]0)V"^-)=0I18>1[^-#'EC4^<*H
M?^S91S!`)'&K7FZ=SAH,+-"FHG05UI3H(V%%;M+DDOE<V"?P+)!4KWR[=;+_
MU5(4K\2XBF3D:A7!R;NMDXNOBPA.,"Z3JWC)VD3AFR<A5;W.$YS#NDSN$,9E
MCDI\L'7B3*/VKSQ9B":EYM@+>3@_A.<^=0:>S>[^R>:2K,(W6Z?/,`P3_NWV
MVHK*0JQ+Y`K7%=YU**P_KJ?49\%%%,HI%*;&+.UKFM5;W6YS-2,TJ(FQHATD
MV#*7FF.'R..J=2"A5XC-+.Z"&WM7D6:QVS&-G58OQ]@:DA:YA*F>^8=@.Q/A
M9U62>[YUA?0MBP%\&7=(3%GR<Z@7Z;UB$QZ`VKSPG+HL0W#^Q=8I/K_XW/_<
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MN<?[Y*Q_]6$`7;&I,;O;)Q+>X/SH&"$8]0[W*@HI=6?[WBB82<H:LV5*'HRT
MDL`"6Q;>!'^>"YC?VJ1&,C9!Q)C$5D'Z!Y*.M,<JLK8KH++"^&IJ`:1C&`,Q
MWL.+TXNK/7++/5O<XLB0S2X\\FODS$G+K,JE$WD;3AFIT(QL;?!XE9^KY%RM
M7@CU/%@AX7(+F](56E!P,CJJ_$QFD1]$X))(*`@/`_@]<KA%0HAWF0^]Q_"_
M\$J"]`&TXQ"1F=O41`/X;7)+??1M`:)$1+"BFE%O3FSH9X7`#XYX$D36E$R%
M`]!5-XG4YS<8(BET8^$K/"GI4H5_:_7V@SQVG+:(F"$O05UJ%\4K9=T'\`1H
MBYPPIDCSEF(IHAY_+-.3PY3*G0=!!$*G,UCNWL%,&S+@T^S4N\3ECH/RURB`
M`F14S;9$3K?DACJR<TC>M,UZ+^DB*:#<)A8-IM@S#_Y-LUF%`"6KE5ZOWODI
MYG*%>K1$EUID&5O2XR`H9[)*2W4"IGO-9B%S1R"WKC+?:M8-`/0`M.+!!&B3
M"H@QIS0IT_Y!1=,10/SBP)2)0D)M*OV!",`[V_`PMC`.6&^9S;PZ&4YY0*3S
MII:T_RGT'#$&4K7D)@)T0WU&`3*OC,*WH!$C+@NGPI;R5DVA1148#:?I,`O2
M\>4S']$Q;6-27'$[<'<9@YUA\"+%.Z4W3%'#/<N)D`>@70T6+Q`.MV64,^8>
MK*$Y=7`;!H3)4!M`L,66AC=VJ)?T*R?`-_8/8;$-[$+[:4!PG-L9I;6,6&O8
MU.6>\"%T`3)#!HR&2&\AEQX+B2,"94+2J/0@3]H0!F0C*%BWN6C+/G"8'[2O
MLT(\-=>N!_]WK/#LDV)UIFJ01C[&-2A3_A0<+M@,86,P=;1,96,VNV&.F*$Y
MH;$&="8\[M5P>\RNHDXBC]5<84<.1=LGU/Y/=",]03@%)W4K_#_4<+`Y^D4$
M@ULYTO)O8,QP#VP3ALV$@:F#=V+>E,8V*Z$+>`/^%\B""2%V1KI'G2SP8PG'
MH2.AXGZ)-@#Z80V6X%+#GS.)#-R;N)7,.XS:">U5<D9#G]_5SJ2^I>/8KV*'
M$1#&@@0X)5XD!P"._Y@),/:,T/8EO8?:Z4QI+&=P2",VB7)ME;3`B_NQG\FP
M%Q.G,"/-XM:#QC`479`/]\8P,7A_4O+Y]#*5SS"#?`1^$9!IS:P`#S*D'O(Y
M$[?,'T>.E)BC_0F(P&)^2+D73T[`C7!'Z'O"1,8P\4Q\ZNJ9`28HT"H=.8R,
MHS""F<?FX-M!+?/$V.3L!?$@D`TZF0-4W`=.`&9E%,)X&0-T/4-9(H#^(P$R
M&0$\AX/W49:(#'H,HQL(4KP:3`*@'30L[MNU&<3<\PS3",IGCK0;!1*?C%!C
M/C@]_B="U$X9K5PVGZ#1XZH6&+98$+#%<.*>02I')&HH%"&8:#*I0"0!S(/+
M"R+P>3[_4\UE8X'F&I"WTOV+*``J@I_WOH$S?,`:(I0&H*DYN+@Z.KZJ@8LZ
M[5]>@S3DN)T%;'.::J?')S$)^^2WP='PXQ[I&3_!NI$Y3C"CECRD,-3O&;5M
M_3NES(_)^GQ\-1P<]D]C08%5A<+=)P?]PW]^N+KX='Y4TU[5GXS>-HUVM=GI
M5.'_?\Y`LU=ZY,O^T='@_$-,,8I1T[O;_4E"^(S!G72S20`8#]%<$*@B2"GA
MT"Z#6N-I*C0+2BH'(FM!#ANG0$T%],T#8?E\,LT`,Q0TTC:KO79SB_0MFF8&
M:B/T'V4-MU,.*ZM-3.#@8CB\.(.GQ90O68H"?HBAO0SRP:4E\;$.O>/UT08B
M*Z#FX?:AQW0,:^10,%2`2&2(NLSE?4K9$BII7@I7<Q-S*J6IIS:L1[F9F/)F
MO5/H?12P8<'4\P@Q261;-B()D]@"%G)LE0XV\3X;(LE8$#JE;ONQXGF<'37D
M3+K]O;EGL[+!@.@FG@C73'\8(,EE2+Q4L6`IB<&9"I_2SNEB,@=%]UI:&/^8
MZTD9ALH8#98)L"A*0D^U>S'S=6@-T2ZNFBP:;Q3FMD.4Z)56HIF6\!@6-$JC
M,J*A$"AC?*WV0VP92SN<CK@#2L"H'K3KJBVNXHV+X6IZ$I.0R&%-)'Q7O5&K
M4=P1NJ'<D8S")`H2HQ.YMHG1X?*BY.8*K(\D(;"68':=]"U+^!A=.G.U#Y*A
MRZ5S`A+R)E_+O'ZH"/UAT?=#9ZGMA-"X!\!\/-U"$7CO*DT)-[^VVQ9-WR0.
M*1'6+BV`5(@KU_7X!V[^@>/`T?:B%SNMJM'IOK2U3NEE35_MG*N=,=`WAC=?
M=S`F,=BC(:7!8M=H/1TUSW5`*SB7."?"*I7=S7#+3>VE"9@2?3WYOP#UFE6C
M]YCMB2=6\!,,TTL?]S]QUQ2TB9Y9[L>^!%5V.\]7D4\[4@=>"$$IQ\#OY8S,
M;K6U:SQ?C6Z^6YA7V@<A;#Q4>0&J:H)-]W:?KZJ>=O`E<<^,SN7:*YTF+960
MG5T7OP!UOVU6=W8WV3XK)&AI5?3];-_/.&ZV.HP&+T.?O>>GS*<=LIBSF(S7
MEZ!!L_?H5<IW.QXOI*OUA%=[C+O]X8[1WIK53J?W./FLXN-YN(/7$[3M(GD]
M0?NZ6_Q]$D0C3-;%;"HR$W[VK&;Q^$4F6"?)!'CJH9)G,;]K<76H4J1D<I5.
M_/8%V#L+Y3%,G*`6,FOJ"4=,YCI#*\[)DWG*$Y^I\Y/E@YR%@R)U[I0B6(";
M0E(G,38+F0^0L-(X/A9D(&3,&I7P<#O*DJ<Y*@T-LT_E-O,8TZH2<@(F4]GT
M`61A6WF0!.1Y6:11"%/'GRH[+$&<2'VF.,%',OT-`G^":8I5G.ZL*9Y<Q;*/
M<_RP'^;GRWP[>306)\FGA"BD>/PTS)VT$1>"3"!<R8?Z+)5)P"<>'W,+515Y
M8A0P7^ZY@KIG49*WJ20JT^Y4Z78VC5$E0B>9U>F16N;$K4I<ZO\!8L-4.V[Q
M&>*39WMQ/CSFV4E-9M/[<BT2C05SC_D3GMM*E-T#>B,+R271M`CEK8@<&Q,:
M$V!@NSZC*#:5(9[/]]?IC&&<5)_D.TJD4W!E-0?IS5(:VTZAK8)FJ8MC$-/X
M,.U1CIS80#"/T`7X*-`H8)APZ?`QRY]L:[EG,J?+V')F@*`!+!"!<%,B9K+*
ML]0PZ2LX2D)ZBU>FQR^["YG[.6(R2=2W%3^48#D;S@@U!W,[@5&04$I2C#T1
MQDUJ^`IL%08.X`&!J>(0T(:'2FT:9,ZHK[FWJ._/L9$:#W+3,H:=`[I,=GI:
MFSU-QC-@/<`+SKS3P]ZJRF;'DI44="H+)6D8?BK/]8:S6V63B2LA?*S/S2V=
MAVIQWXI<522/6:&3"6;5:YM/\F8)=S%W6`XC9$$6#@A+!K?@(`;I6R#<G^#,
MPC%O>5Y=5I2N,%#$XB_EI516=@)'`@]6'FE_DQJUKYDP$?O#1&QOFIUZ*ZG)
M`;%-]&9=DEP,BD8A9FO>?*9GG16F)<]2M$*R_9*4!H[C$!.08Y/.S`,K9OT5
M21>9V6BQV&39!\79V9E:E1&S*`S<;)H^NN%0U]VH-'+TC[I180)ZDN">Y.QC
MV9$MIW&<.Z,`QR2$%#<Z&201\H1YNN97>H9%@?$@-PF,<(:S(RN48Q\]V*?Z
M=9V,F2TK!D```G-!@#Q0R$PDZ=T_9&[085(VI?S)8GV9F;?[;#65RJ=?/0!6
M&)U2IJ-B/1L<HZR##L%UIP>+*VTSE[V3Y.R@R:76^H-J\R0>&HN95:B:535=
M"P4L`D+(/V7L`G.O\C)OC'H[5XV8.$6:UGEA.[/>2=HEPS3C0W)NX0?5D0SF
M9;F'C`L]&ME<.=&,6</X(S+<SJ2G95/>>!`O9U3]B`XK<N76.CK`P.Q7ZD7H
MFE4!<5.YUA3U?=B2FLD4)[I466^EAVWL1@&;H]9P0*(G0K`/G+VHSQUT,!@<
MR?9@"9DZR8R)Z-(R#.S3ZDAJ3;&\"1_9.9M5,T^HZYRS[-M14FD5!\`)]56B
M*Q]U&)P3?3%9N15$6FJZJ21U?Y5X.06O)WP,%U<C30NZ[70E/];D+S&F$SS5
M$!T[S`J#>(GJ\'Q>9VJ".#L'H5Q,[#V+(9G+5M2)AO$>D=PXVCA-<7AQ*;O>
MFY<(`8H=3M]53"/.WUJ_.QF*6=&VHT[9,NK->-B7WO`[Z9\-3K_L$74'1Y+]
MM0C*Y;8MPK+`[I%2@7855\=QS5UJ-QFC75Y=R?F\:`T9>:MCA`=MZ&W7+%[M
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MW=')Q&<3K,U+;PG`FXKP6@\Z5[7]=H2E$[:LG^?!$AV6<%T>JL]+(:6+99O)
M)P072^W^6JL=>W;^PZ2R2?93IO&/7QJEO@%;_+G885HL>JB2H_-?BEU\O^V/
MQ*:?0/YT?93]_G&M57EOM@S\SS*#BU1E>;-M_1G8(<,O8PU<$/J-+$'M8T65
M_,*99+)$0Z!XIU/B&\]F#?Z1#.:;W\>@XB]AL`1%&4X/\"H0%@09N5SZX@1K
MV8ZIC_8:7#)??B1:;F?T/?M(;V8@_P_O_J0V\&\80_^6^RM9834K[VNXHM"2
M>CCMST5^W?OEU\S)KYG*K_M0^9F[+T9^.Z7L;Z?0_G8>*C^C]V+DMUO*_G8*
M[6_WP?+K/H7\#M-;@ZZ2\OB!C9=ZC#D&2'U96-;7=64`ZS2]?:.O+M^(+_;-
M27:;@.NM[LZ:,9_,)-)H6^92\_MFDF:GV=M-IY*G8"$C>GV=ZBE&.1<CAT\D
MAN/X8O)+?8F*,M2RC0NFE;N`[WG<>5<)_8AM-]*X<QTOV`,$[PH^,=\T#+/Q
M^]GIM36%V*_&/77_3X4TOH80GFQN6`H_>KW49,I2F)6``V&Q!>$*?AE8!F*#
MN+1.\KSR-5"ZVZPW6[UFK]YI[7;O9;95I&(`810"63M0>MF0:S6)63;EIZND
M-T*W]`F@*_Z6GV,$N"8TBH>YL:N'^6+S'/7J2Y19!@R(B6/*EY$ODXP?VY(?
MMNQ'X53(KYE^PN7*I<\%N%?FC*_81-_M@LWCNUHRW#T0A!J!K1:PUVYU.^L5
MO'8,%\!8I]^.D8NI'\=%3J(>O+7"(?-=+9_T`1ICL2D6L0N\-E-VY:_FK@)1
M".3]9>M+PDZ*=&/B0*:/)VX1R/O+YCW$';&9@#D^@.D]MT:-/VH!DT[B923Q
MFW3XWB:-)Q?&5YL\.MEAM@F5&6E\I,[X4FVF0,]+=5OJQ?@:AF@XIHYS?&<Q
MAL7'PUMQ%M]P!4)Y0#_MD,Q6IUEO=]KWKQW6>*0"(&NGG)Q'>@#M&8G]*K@7
M?H:^D<_`[6.^/YVPBUN/V0=S>:NVVL(IT0[9:4M_LU-O[S9+1*:Q$-K:3RWV
M2X0PB_+AOUEY;]3CQ6<)TC(,GPKJ]>/;-$_D?4!G,&>[D:N%&!Q%:D.G5,N8
M_`VY+3TJS.ZNF>JZ%$F;,COPOC#JJQKKTGQG.CVU"%J][H82R!#W0&'<BHU%
M<2N>6A"=G4U-(2%M(S&<`\7#6^;<,%V/7$X4B]V>F3@6R=M()%=RRQX"O(OQ
M"0\@P$>YEI1+8=\G]QOMUB;"*:0Q(Z$S&H3,OV;^#;=8`DH*H/A5O0V+DDRL
MG9_C"B=)8!369:W%25(",M:`6B>&G5Q444SJ*C:#I,5O/)P>4IL[-#G]6&9]
M;?-M;W&_UZ<Z1Q>'PR^7QV0:N@ZY_'1P.C@DE5JC\5OKL-$X&AZ1WS\.STZ)
M63>(/./0YP&-QO%YA13$G,.KQAW",K&S_K,69GK6[="ND/0$*7N`I/_6I,&B
MQP_S1TZES_=*UOO?>\B7'O&%C)AMB7\,<L\=GL:%H1YN%SJR0TV>AV%+V5WI
MF<2*)ND`D/?;*ET_X!ASVVP^GS/5`5Y]Z'E,W1J;7('_Z^>LQ/+7D<I*4WE=
M;"CD]>]2YD$L\^0&]&KF_NJX+R;6*IB$0AM]Z^ROD3/'`U@SOL9[%+#_1@!"
M7DT)6O4!C#J@Q6N7*?RR\)@5\,/`!##J*]*X!A[-B?"8O)-<G@8K$A+B+.K)
M^\!]<<-M=<>^)B=SFIMP4">?]%,F;PW'/3W$HB[QAKX)96U]=.S*;PR(<8IQ
M#2JV6G9X2:>#ETN'4Z#XS4YZ?6M>%W+K>D83T/+RR?RW)X)X?1%3)\_$<_!!
M3B!OZJ!`WS3!!66OE.T8/R4?AB@#F<EE3)`#A+=Q^B*:3$O==3M+-E`!1GJ_
M+:@^$92\PU;S#,W_O[UW;6[<2!)%O]^(^Q]P-/:)[@B230!\ML\X0JU6M[6K
M;NE*LCT^7S8@L"AB!@0X>$C-^?4W,PMO`B1``B`H8=<>BR10E:_*RLS*RK1=
MZH%A)O@7%#GF%8YMK)<["<9+XU)'L#4\)T:0'MF39M#I/SS)(44>WEY_\BO:
M^4";*%0+<._PR12H@,0WJF,BUC@.%WW>><&+2N$L5+V>AO?!ZL6J0*]T!<NP
MHLRO=--BT14JO"AK^BTH3(_%7F<S"WFL425H/Y4AK']J!L%>9/0'E(+(:L*>
M[%XI>J]DZ^9R5JD<K-</@R.0#CNN.X_&H+ZI\KF%,9*.L#!?V#.S.EQX8'!8
MUVP.2S?2R@`&QEJU<U?O"5?S&`1S1=,)<8,]F0ZU^E#\/@)T]1WEP<+>!9Y$
MQ#09%2;W2MMJ3C"?1QA>NM!>(4F4J/`C0</^&VI6^VSB1[@V_>24<-E$)3H0
M^C)20O+;.Q&;"C:3+U[>#)T%?`;[4C>QH4G<F,KQ7&M%-<"*DH4N;%"&BRTM
M:`%WA&O>$\BT^$Y\,Y]CKP.?FZUAE%%_GS>/I,5KP,#+.%'U.%%-3E0LID@J
MZ*NB46CKT;7@8;`8UCH^1LJ;&N`%266H(+@.I7>]30:?!G5/E:WA.:S0*)RO
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M;VC;3.E:%#85`L6/C7Y`3W"O`GMG>6X:WTQX8Z*.WY4;W!FNTJ)]Z[PF3Y3"
M%&NQ%]/A-B,O/=GTSG<RN/'O34T.D$U],RS65;TD$6[=^Q\<[."&&S_OYO#D
MZM[FCUG>SY@ECKD%N#'1CFV1K^5NZL':>=,<*3G'%H`^0;LV'@,*CYJY`CVX
M!-,''$HDM-?*(R5`8(%&I<8EWAZ(EEFD/0=%!X`9/!#A;^P4L@#/S/?@5,H0
M`=1)FQKDN3EKM-^81?T-.7]YLQTN?/PUGNP0!LL^,^Q]Z/<Z^HTINL/%[3<7
MB!1$(SO")PUDGMK0">>S9]QL9\)=5#X_1^332U@!B-Z=_?;;O?#I_.[S.9H6
M8-,KW)OUI,\*FMK969V9,EU4:@AC/#.OSPC80PKF+T0I"GOZHSM[8A3*@-6!
MC5DV8E#4$L9VT?;5:&F:UK_P394GE_'%0D\B_30D*;;?LY07WNB/FX&!3VV;
MX`[S=H'>"/CXDC'';X&*/<3B32S1,J/TQ>8NM'U,GZU[?,1:\$Z('LP[7O/^
M%F1RO9EE0'9#SF>3N5PYSH;RIG05.1N*IU'DA#U"F3NFZHIMT^:`3V$SKJ^\
MT=EYK,?9I=?B#,?FJS*R("^#_F=`P'*'K#5])V:`EHO'J=&\LESX=`FNF^8W
M<WC/L33LO7@!BA\G^L*CO\;3>:`N'\P;7]&'7Z92_)`!:Y7QR39Z'X)%C-J<
M)WA%(63+1:SQ-B?BSN?JO5LG3J0H<79"5QW.M<E#<U"N[/K21M*-/&@(RK5I
MV>9P6<8LR<$P1];UUC6=-LC6))JXVCL>`2;Y";#!>B^R-MF'`'%+\:@4&.Y)
M@<@MEV'S*'!EJ!;%S7-2PG\>T1GLI$@TF6[BB<%@#R(,"M+`AS)""\SEG[DZ
MNYG[]Y]NL2_X`WJG\1ALKB?;6.P1O?&T7+)$51$,6_*#DT0?>,T6;'>)T:;_
M\(:^O#VK+<0+ZW^,Y:$U-OYPNGWE2B\0N=DN8#+B=9?_\%M4\A.<:+-??JE,
MN.<A0SJO*5#P)5XRNY2:,<F:T44JB>:I^B]VIH,BA>1/LJ;U1DN1K15"T67D
MY\^.&79^?J$D(T=8F/J,68>4NQ9++T&;T9$M+-U:^521*K32(7T)4CE5M6!5
MVJS$.S5+V7H.(-/KKF.,2FFTI<3D866,#RO`556MK7T.#G(9IJDFKU]_@\WP
MC(<9ME='PH^:T?YW#BIO9GNAL?56P_C@\5KS^;@G^MSHQ?,\3*?U+&(\*L7C
M=8^)WD&J0FST3^/60:OE/`E.']^0X>P;G6WSY1-O3"N=;<KK47J])@C3T(ZT
M+90EMB)V27V:\R8#R9,;MT/83"UR[/G?I!:[Q?N;*#+"GPQM?C;KGC\S"S/$
MOJ*'W?VL.*S)\OY%T2R!8DBG(_-'<9%W=)3-",($EM/8;SUWXSI8<&=&*>O&
M3/B=TMDP6NL(_Z48+EJJ_*I$D=XW-03K]HN[Y`C;R7)'EHMXR-5`>GKQ3K$G
M%VER>A+1SMR!S;ND*_>$^K9`A+NY]=F[1X"E9&H<).E5$^$H^\?^@LWWAU:N
M6[FN6*[K.I/:D/"Y:<V95D3(W]Q!5!&Q*>4<JMFD/_CLIH$4;XI;<VA3RFT>
MSF84_0`J'^O@L([9(H)8V#\JZ03Q!#A1SQ%N03^K^@/<P\Y7#S[?C)[">K<%
M;[WR#)^IGL'#`BNF8BT>.EG=_LP1*][&+E[L`#,-Z5CI_(UOO5J%^1#;4:6P
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M,\T"ISVH]XJW&4>=T03^'?9IOP$H+$6S*>L":_O"<H+-`:;X28PTY,'2L09S
M@GJS/>$2&Q3A`+A0;(TR-;R2_%12@JJ:1HO/4@7]H(0`=@WQ;X(#@I$R%+&7
MWE$!>G^YGKW'9!#%JUK"2_2/)MC`A2#A]=[]AX$**ZR+3%7O&3^8ISXUO!L\
M%6!^>@)284P(QI([\@#^E3)AP:D-@7G;9@0(N3>2"`B..!6!!>+[C]*MRD?F
MO&`]>S]77Z9D_?Z4GB:6RE[Z_M$*NS:HA')F61LO9XFR,.B)SV$GA#R7;XG<
M&""-+QY8(Z8UX[5O3&QD@;6RL73W.\8K4+XG2@0MV&`U>%62*1E,X3F)7EMM
MWIHB+-2\$X=H+Y\Y7JQY]HNS^*M%][4AR5N_%[26('S>P3>#]V&W"1#>E=_"
MH8<]#\(U`>AHJ!9<PY=CZGN0(H#'+O-339WA]-T_8CD\4&>.2,^(2,L(L!ZR
M?\8^"<-L"R)P`\0N_$-&0_SQG;D9L=Z1V7!$</E]!7:+X5R#G@(1]HPG0B/U
M%P1I2DW0Y3SER\+FZ?!6/_6]_/BD`L11<>WNDZ*L/IZK*O9?L^%'U*@7O&0^
MH9/^4^6=@&5Y2AALA[`$+/+(E=2%?ZB:W*B07,F2--D;BSNF,NT9'_O.G#1<
MTAZHO-GL5!13,4H#IF2\JN24V#\$+XN18\6[W7@E@K'6.HUP;LQN+;;4W*5]
M%:F3[V&\QZNU%OOMRM(H29@]8&X`R1*U@G_8VD=#T_]^YE@N*[=T\(^E;M@?
M88*_IWB98)B*'_[Q[1J3/Y=*%WLE4,LGX<,FC5PV\WTUC=F)M9+^:]4*8#H<
MRAORD`I):>A4N>['$O6-W@<==^E2^X`;M&G1V+78@K=^N2+[]MJT;=`9-_,'
MY8>/9)%W*E?EHKC!R2+P'84@5<H"]5$OCQ[D"<^^:#`CNX8W9E<&K/0G#;:2
M<]MFCNV7)_"J$_QNL[FK7VMSYA%G_P&J3`C\]7;\5Y1&^T/90()5D<WUZZW4
MKX9B08^J6T6#02Z\/C=$C/3?JM8I(Q$,Q(1628>D%%2JU0:3:=('R84*.(LJ
MZHSTZ+O7=8-CENM1+EF#(<B5-!I*!\AFRAA;KV)("?1S@5L#-49YJ;'5@"M(
MC9$\:28UQ@5D(SL/KB`U9''43&I,"LA&]@6&@M20Q(:N%$!B,!X=JC=2QMCA
M(C23&J.\U-BJ-PI20^PGS<JFD&-<0#BR%4=!<LB#<3.I,2D@'-F*HR`UI/&@
MF=2HKYG4>-)0$M376PI$IYDDJ*W7%`A-,RE06^NIP;0$"L1"HDFODF.^]9%:
M5[[?TC`?]!5@6LL"YW?M]L+1<+29IKMXUGS/5->B:.3E#^HS39F[*!"NXPUV
MJ5@&-AV^91:)#$SE^M'5,D:J3C9X2D@R)5,2A^.1/(C0K@PL&D_B:H0R@\33
MH3B2AM62.+(B@Y5790A*&@S[2:LJ;76EP57M":,D#X8YX8J=C42_J?Q0`'PW
MJ9\"9?HIR&Y@JR3IL#_H3W+#ZK<&_V):]XH>D6\.>.;/G(8B<*\GRZ)<C/`I
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M51J-<\MS03R_6J9M_VY83-%1%+XJ8!GL0#KM%1Y`W[&[Y0K!%]SJ\GK]:4#7
M3Z.QF)=&R1BZ+SAC<0^C*&](JQE$`C'8OCOFDJ-B6^6H?UHT`C'(1Z.M<E2,
M1H/^]*1H5-])\:B?=\]M!F7&XF[*;!6<W)39N+)0!V7PTD,QPN`;F5M8CHM8
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M$Z](_\:<"^`0=AV)-5(*9X+3"0&/)PYARRLA"!G+0F@M"Q0B:0FS21CT(UA+
M&><7;.0A4">/EABM0FD52JM03D&A'-K3^F^J.I^K:J&F]+P=]30@BN\_=>DK
MSY^1P)VA0<]=%7U@P<+JP7;@XV<3P7>(?MZ_WW%\B")-C#<Z%`>#C3U\Q(XX
M'I8)?;/Q'?7%MX/LEI;TKPU5D./Q>/2F\'U3ZW;0W])2_;4A^[;6[7`R.!SZ
M0PV'EX7FL-+,!C[0A6FM3+(39NS1R64L5&<"UF-)$H\Y]I+4$>7QJ5G*M9-I
MB^RW%*)1MVC#ED+!4AMLL6M;,M&HLMB1!_V63+NDJ96D5B65L=9&I0K2,4)#
M/G12;^C!]V`ZBIX?K?#%O8DO]2080YB9[J/.-AC`T=EBDN\Q9K9FD#NR=TQ:
M`?:OFW:C_A9O_2T2+H-..%"T:5;:U%S]!DVY6KKNN9BG8@'_K*5=9'>3.D.Q
M7<][T6X@%S#!6\+M972V9(NMU>F@Y+4:M44_4`YE\+%@<\("6<;QM.1/BJW9
M-W.O%9AF/-V"@:ZN^?_&,Y/S/=HF)P=/592?R_\+4AQM<AH_1V=+_(L8AFG$
MM[R/+96T)+GAO].?B0/XRK.+-Z$_>K=8'Q+L_JNH*N_IBEUA74-Q9QHV9XUU
M:IUKAF*HFJ(+D9ZM"^49N_0R0UA9;*5@DU3-H.&L&;7_?-&<!7WFBP?[_\(@
M*QU`?V(&LQ1=7^/OF(Q+[V*#V=\-FOX>YR%6GB\!*541WIW]WKOO"5_/SV_/
MW@MS$SO..O#3,@*=9L#W2^(Z99SC@'@?P^*Y!S9V,P8]L00J=O\_>N+<<C15
M9_`%SG7'GK`U%+Y^W_T'[XX<(\2CHA-J]H(Q)S/;O9.SSRT"L.5)-=J:2M`Q
MOP;11J2<A<5XW^1"/7P#HFR;5;$7PEPW7\+9"LYAL5"..L*CZV!O8"PV*P#'
M!66&$LVG>^=UPO;Z;!O(/!U["[L6-2F.//L>(%&<1`-O>'G&+%LPF,IL&[M$
M(\@*[PF\BN@`'!U?#45E97*UU_$9`M/!"ZZ._;U3*$^\"D@3;QG<"2@%0VGF
MS/;G9C/L)HSW&9X6,=`?F:ZQ9Q#P`*F99JLPD8M]M/E2L%F.14CMLV?LWRZ>
MEH%T+Y5_,4_LPZ400`,4=H2E9NM,P:L$@"BS'`5[,R<6SMPT'0-;S$=_X.R!
M->NQD];L;A"W:8=@24>T"8PXPS+H,P&(:BXUQ^'738"VW@<7'N#TMES4)@BQ
M%2Q=VV=V7)5$ZH_A\Y<_O!;2P!*@B(T(OCN[O[PX>W^T?N+-VR#.;1),U[8Y
M_Y:FA8>R(#.H;(7O*"*#>&=PKUL\T/V%P;N+[B.6N1>N;."K^:P(YY^`SOXG
MT.0;S;3#1U^`Z[;[:(-X@R3IV'7<4)8PV'?X]5GY`6.EZ.A4(?0UD./M>*ZG
M[;R1.L*5H?9(,+!-.4ZJS310*)W87-@9G'8=-4#6&XH4*]I2BK?3A/(,2WT)
M(#G)]0*/M9*6;8KDTWVA:@/:DC:9X=TKR^:"02S1@RU`X?7!D5EZV`L4]6;T
M50%LR*6"VQ57S<Q7%922`/.P^1Q4O__S%@,!O^M@B@18&"#$V(X^E!@K!`\5
MG",L8"<TT=;1::9T%`+\$[8$3*4D`5=XJ\%,!.*[5NITX>88;'XE3-7A*XUN
M%M(^;P0L3ITI3J<</$'"^]L`[18ZR51DA?:XT^1A^D1U04@N*&V9N`-VB/ED
M4#(SWG8DJ\`T/-(K81]1P<1&H@FC0:-6HKY5FRW9,8'Q6`[$8MH3Z`JZ5JNN
M8TP);:+@W>A^G!,N5*T_P?(#:T#7:5@GQ:AK]5,YKI(-%J`.O$:94OQMX)^N
MP3.BR1**6Z=1+6>0V4:V(K,8Z*HHNR,[+]'J;_+T%ULX-PP71KEC*]-R<(?U
MG9[_#A;BFBF69\QOW.?KP9MD"7M/HT\-9K6Q#EPNOHQIE:!)Z=O?&AF',U!A
M:!CC,K$B`^$`<]<!$S<Y#OSHPP4X@_5`X/'%X-L57!-QZQA6(?@5-K@E8)G;
MC,(0'\$N`6/<7'%+'CCUB.1TA&=@&SZ9%.8]`T[Y@D*I,:=H5.+<F-W#&M?F
M0"S#28RV<4?^D`':^-2)ZJ]'$W1&">#XP)"U+@M=X=Y=+M%9QN!%*$)"*$."
M+T0-@+KN+:`--C9Q!VV#C6VPL0TVML'&-MC8*!.E#3:VP<83E+0VV-@&&]M@
M8QML/!G]U`8;3SS8^.J%.7?8Y'>;>'4)$RZ1Q&W$9*L:X`Y-L$7F,3[Q(72D
MT`)(.#X6(WL9MU,#=E!2[+XCQWR.D!8`Z\5=KKQ`!OJ-"M_SR!&BI8X[U3*P
M;3.L'?P<>IL>!K@-X\Q9[VQNJSGL,R_8D`:;!6O5<'D(@_U8H;\'-HQ+7G_X
M#D6-/./D7'5<"@YPA:*21IUI0`)+0!I9&OFF&#OWO.>`>NW*SUKY82$DX1M3
M4!Z(=:T"V*H``E=WM=)Q=42B]/<.2+1BS6QX:$91?(='%L[O+\#9?8#M214F
M$MA7.YG`"_2&8:$(4WC`*5QTW$8PNI%O4M?QFUL(6R(;]Q?(AR"\88.=H+N<
M6PY3%X;V;Q?'M5UU@>8_*J6E8OT+P[ZKE64J\/4[,@<MJCOL_;8"_XW9[SM>
M#(YL[?!YSUNEJ4B1!N80/0@\#7R?]Y%8K1V?TZ8-`C2DKJ@\HF$SZQGFA;>Q
M0+%#QTB*P84`1_6>I;T%WW_/3:O0EW0=#4O$V7[LE`.XT,#DLM3%FF\W@)N)
M$;3_<%L4H%ZY#GG/::037`S[X$[&93HZ,)A_IA?#?@2T0$;1=`N\'QWPQ\6D
M(3R/EL;F8-O9JJ6MPEBN:?M1</[NB=2EYL,%%S3HLD=18+H/-[?TZLZBU&!K
MS)S%W\^H@G4(4.:-8\=<I=TI]@K71!1R[M([7\Z_75W_]5&X7R\?33VHF),<
M:JG-9N:V\GLI7*2WKY'Y@OA1N'G$14"D]N327[G_=DTT/OC*%-Z!WT8>-)N]
MY_XRN2I\^7(_19NA$Z*&6A2^VU"B^6[0M+ROG/?21^&*,YR'.T!5&0F><V,9
M;=U02'Q_,]"1/H?7'8%I--(,S'(5P\YTUNA_(B5E!T&7Q%0XK*TM-1V\ZU3I
M29$Y5/2;HX12F&=(?ZP`573+^3RMO#9*7N6/PN^&N:&MB'$6F^MQCPZW090#
M)QK>,5^,J#-8A,&K:IC;,.,NR]V)-,XHU<6A!!O-470P[E^7NQ-K-<(/Z[W4
MA"6S^$&Z`AXZ'IG[!>)XL)("%H87XR<;TXO;*2E%9T&I7GA]3-0@KL)5&E=(
MX=GM(W->Z)38Z\[CNSY!MQX;;,45!C;1K%V9/$0*=NL3^$8Z1@IH0A[*0*/6
M!0-7L1FJ=;0I(U/Y/\UXR"8Y!C[R9#$,/?!-9PK>A+*V><J#CJ%)^AJ1IF@K
MJN5XNY8H$MRDI9EBHVYY/8)WZ]E%1!9HQVS'"W0]XT8Z"\YC;(H-6QCW?EG@
MZ:QB&4A-_D@05]?\0?A[/<PH6VKN,@R?42BK(VCH:8'-8$9EW<O+""JU8_!;
M52WF>!Z1+X0[9R4O;<547!B>11`LD24#D9DA1J[MGRTO82_A\6^OY/?&P9:W
M(*@UD!?)VSP_"!=!*U>ID9^%$NN\I%&0-\+]U$Y,MF9X_KH_S%)9"P;C0J&#
MUTS15"]Z&5%$J!2\LQZ#_7`BAR-ILT3R7%!C*):E\7/3B`..`N$:NZ0D!@6)
M^@Q$V%IJ!@?Y$6!E2U3[F"BA6'N=1+[#*<D5LQU3_=<"ME)FV8$P>N?FO=A.
MA%,Q'G1`HYDBQ&@J@ZT.8`5`X@JGB15LI:;C-S"-%X*PA3."JHM:MAO@T3OC
MQ^`P0OH#9_@J6M>X6.G\C([DZ-`+"$MI2@J=$B?G[`EW"@X(E'0P*F)$TK]6
MEDGY9-Y)&?`9-#X!@>KJF?'48(]Y*:=N<^79I$!41R#'A@]K,1Y#H9H3\#XC
M9:A2IICMKNAT,)0*&VD-^YMCTB#178C'LU"6Z.PSB%_QX)._AW\+3S`LF(J]
MP"*!7S`TGPRD/1F:0QF!J$W=\#"%3ADXW3KX]`O#E$$[0T]Y'ANB@W(3!0?E
M'V.RNA^9\^G8P:=!#(%A3B`@^"*E^47E(U4\A*MYACAMK(VT]SDA4^G']Z:9
MJWK;$878`&/-6GJ&3;!S><H@(Q?DM'5VV;;T'6@-\*I145PH]J(!$#5R2XNL
M*BND&(6C/:4.!K&RYOH7!)&!"H]F8MZ>/_PF**`SN$"^NV>,IP>*_??>0B0-
MX&A+EEC0M)N"G,^"H,R+:?T+%2D>F<9F"2;`_4#`X`'/X4U7#U&_((D4&=I>
M$B]I<(=.8-VYHCIT#-D!K?F('HUI<4/-G,\QQHXA#%KX7Q4*$]F/K@4/?X/%
MK5,>DY?6058`=1UT,-6=<-.9XV"^,GI0J($<2@X#JF`T@,@2*`-P8C!#.4S"
M3FI)G8%K<N)KO<JCS>^@\ZEW+\B1<+^`3?/8IYK-(6(V)$@UW:>:O5"X!<$=
M"UR)MG]`_\*P+!5N55[FG^%2#A&F*.)K_@V&I>D9=H+I.MB&%^-]/),V\H7P
M`J:%0@Z5]_`JO"+ADN7'9M$US)]27NBHU<%"ICB**'7$X;@SD@<^$/@^?#L=
MBIV1-`R^34MV"VXP))/[R=K\X1FV?GZ!1Q.%ZQ^NT,"0\M(0T>H"G3?3=#<,
MP;YE`=N]7N^8&@L!'3T)81L.QR9G`,D-K+X%YA0&2306TWG"KF?C@W.@+A0Z
M(@BL<UB:/P$^8?(G2#Y\,0J^V.N>T<;""7/@+1;QEFD)>3?`>)QP!F:S!OSE
M:8,!*G3*;3,\@N:.`D_P(Q3\AU"5V."P1'SD3<#BEG+B&D_,+`@L&TZB24"1
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MC;ODE^B2YPR3'`7:F%.^'=!FRMBQYW^3,OX=HTZMB%<J8D6:D>7:<4K>7#;&
MIR_^O+SZ^IM'A-R;W`&3YFHF%P<J9?YPB4D$"T:@FH[YZR+WEI9OS<#\=9&[
ME>XW*-VE[RCIN\<>I-_WO1WT%P<T\#LZ@#)=6S%F]ONR@#JT6:CU]/A.Z@\Z
MTG#8@?^^W\MKI$Y2*8P('-O!X&<_WXIN]A<@;<9<WL#2SV4O-!H_M7>CSN;A
MQ.+/.WM['3H?M?8*)_1#3(/.9#0]G(`[,=N+I"VW$MP:=:1Q$;W;<NN8W!('
M'7&ZI85>RZYFL6O:&6YKLED#NP[=?U\6FL,.V70W8<_PIOWDO4/)M;^5M(>0
MU2-9?)9WXK`SFFQI%+PO2_CP^4V^-T?X26<PK6`9MW3?0?=!OS,<5;#=M83?
M07AIV.G+1:(?AQ&^24YB[OT*TPM5[T*M3OGEQD;Z>?YHN3=[WI#^@2<ONRRG
M8F`4[Q^]PXXJ-OV[?J^_Q>',S>=BLV[1'BUO2^7MJ.7M:^6M-&AY^UIY*TZ.
MS]OZO=^&!/D#8^O@D4*S\*A`'1^"EBPM64Z#+'GR46N]#;+O!:YB5ZAVWMFR
M_;>_,^>*ZK?0%>N,VUKI3Y=]3TMP#8V_^OO]YS,LS:$M%=W^^UE7/ONU.^@/
M1\-^O[^5)NF`UD:-T6YJ2#%J2"$U1H6H(0W[LMQP:HQSR<8X53;&A:@A#D>3
M<<.I,<DE&^-4V9@4HL9D,.U730PO.6`G&;SG:E45XD"<YM<4'H25HEZ;7@#$
MY?R\KP/UVI3`8#*:-@KSVA;\2!I+Y6!^P7OMX`L77D].;E?@I>8YPUM`8HP$
M>5X`?,;[2,&X*V^^NU,*Q.EHD$J,/*#N395+JFWG%ZRTKVS;9;-S8X9_\.+`
MQ8BV:[RZ:3I(%[`2,-E)\KN@>=N55S837SNGVX_GWN5'&.\Z+*-]CA65V>Q"
M66&MKVLLKW3SJ&M/_)YE!B=*GJ8GC\9;M+YB=\UYE"?)QW?Q9+I3R$M&J$H^
MV0OX`07E6=%YGZ72>92<HFK^R."M5,BA)#H5<H=7)N%/WF+#+&UVR:\JP_,W
M6#B-_U8^T_+.7#4OQ?YTI_JK'LN:6'Q'=7/PS8HY&IFH:@:.^NFN<I4X5<ZN
MZ`]>*]I;9;W-V*ANQJH9*(TG%>YWN["KCI5703D'_C`M]X>%8GPUS=F+ADVJ
M2V;ESADK5Z8C>9+NH=:"7G6\_&X:ZH8D79O&TP.SEI_9HU,Z+W?.6#DOI]7I
MU9W(U<Q)DJ1Z6$A35<Z[X3`]7%(M6M5Q[=;"4F/.^E;'<G;<.N85!LMF6N9,
MU>O.]+!FI4B5PC%?_:9+"SN(1[O&KIHKN4).92`2YX3GII.O,-.P^Z1]Y57J
M^>0ZWTWG+^;<8BUN)&W>AVN-TP_Z\3.;O$#61(?Z@O9R8ET?1(A$W,:^\/LI
MA>AG/(*`#_(M%!_/02$\Q50T,Z"I`+EA#N2D+OQ#0=+XX[N0&T[*QBW<1+>A
M%SY5-?LD2<J#8@A095A6R4=)3E5*^;&T%[X^_P):(G($X^&7^7NMNE?NRX,$
MGIF`E8IA0JO^L+6/AJ;__<RQ7%:NDOVQU`W[(TSP]Y3:O2#*XH=_?+N^5Q=L
MJ70U`PO8JP#!AQ1L#8JX1L*MY\Z%UT&'=_L.\-[U9.4J5I(&":<L%UR5(UWE
MDA7'\G3:0)RG.7`60YRGA7`>B/V4!7QLG,?]7'SVA3O^^.XX_%A.[K(EX7Q+
MI:?!R+)0SW]F_+];4$]_H=XTE_ZP/\TC`^FPUDR6^E+C9'DTJI0J82.JC)&Q
M@OYZ"Y7R#="6P2^4JMNV&VO;C;7MQO9M-[9G6OHA^BVA:K%=RLW\3]X^ZL:Z
MPVL"ES^P-[7-;F$T%OQH>[_R`^I]7D338XMJ]2V5_B3,F-JZ-?\/R-S_>)-$
M]R,)'*W>2(K0:P]@<]#I.[7LNIG?!RTS+Q1=9[-/ZTM%7<2?S29:D5%*I2!O
MYA4EG'CV*ZB;'70K`N]!1,PO=_G'J)B`L-W+\D"6I?V)N$,.44.1G@.%?HY/
M\I94GS5;U4W;M5B\!U"!YUO#YW@[^^$=7TL`)^AAR.T`H2O\WKOO"5^Q[:]!
M9L*YOY]WA/\R-?CB#_C;M7B'LXBH^=WGCHO'$5MK9H*DIS?O^^VW>^'3^=WG
M<Z"B`;(,1@X:$GA\16=90.HK8PY>M?$?1?A#454\Z"*LCMC@+P^^C;&=P?[\
MPAXM%^P^;&DGQHQ0X04[SF,S3&PY1VJ/\P`[[86\H7XPU`K^I^EXH]??7+-L
MAW?\ZU)#N4>P^+J\NQ;OKP?+)#(:;]')^Y6'QC'V#W\Q^0#\W>BTDZ#G8,=K
M=$Z].T.(@Y8U[@K-Y)_$\=1_@W>\#^</WB'$L>D8=C<'FS9L3X?6,;47]7'<
M--I!XDQ\`OMY4S^G:)-!5`LP[LR%66SXD74!+`#NT01BH+5L@U5,.-.3\#]L
M"5Z;%HCZ,Q=U\`$`CAF8YM3I#QL"VL0GV^FN=-@;Y]H/-NO.&0NQ`I.?&^LA
MQI3:93%M"3Z`S6("0,3$7F:4R3?3+/0S@K$2'5EPRLC3V+S>>][VVU<)(43`
M22/L.3YW+4IIB9().PRA/^/JCF>KQPFSI(9M]'TVC8`R$=FRM"=0&[J^]G!A
MLQBZ(!H>`'SF7!.`.Z=@Q)YWHWGWV_"[^%[`KI,:R!;F8!H.=:TT7V!HJQ,!
M!SW&ZN`8?Y_Z</C](M$CI;:XN.H2$R[-&2@9KP=M*"S.@CK$DX?YBV`@"O"(
MSFP[RU]%`@02"F+^9"E+&&&)P($$/&M<EJ*,7JU,RT'[<1WQDGTH>L(G7*G&
MDYWR(W7118T"GJV!K?A@N3)OU=I<;P1R^,B'$2Q<,+[/"LIDJ3G4AQ-06Z/0
MS=%QQNZ8!IMKV#O8]+NA(AGS=!@U3.PDJC)&6D(%DB$3L-^;$_3D#,`B<`@/
MVWW\I^?(4\]#X7$=%5Z#%*)AN##[([;0[`GG1O@DDH4LDZ?0,D%L-%0QU,O3
M)A4?-"0.>XL"$HZ&398ZPJ/KT/>(`OV&#8G!XT=-:_M>.ZH<_C<(QUS3J??R
MGPOFK65<8L!@!TD;;W`7:@>N%+B67_-.HP$XV)(4>ZCR2VX([J,O`4ME#<]X
M;141)A7[I\)/.NR/P1*+]*1]9+H&7V*H1G&",7%>O\'C!M6C+5>#YJS*DI)P
M^3"\=?/*6[@F0F0Q1<>$&MAA3,,C`1\.X;>9X^A>R"<2KJ(9>").`!IVOT(Q
M_@&^D\-`4_TD]GOAMNKIRQQ]<^4.38W81*9)C#T81D?V8;!!I_.-`/]813D8
MK,IC6R[-L:%^)ZWDKW)5LU1WR0]P[:BV#W98'GWT)'G&=&6-VLL2D/C""KP,
M`Q8C[E&HID'7SBA,^(WZ%?-^R%'5C5[VC(LA\(9L"D6X7>#)B!2:'XZ%W5*]
M'?7?KC*S-K;4+>:%\.Y,Z@_!#X5!SMY[:AA'8C]`^Z&.(\6C44=U+RD!1C2`
MM#/+?8JU2'UW!B2$07`)XA!.,4A0"<%V87.,7Q3-;TKM(T\Z*8$W!U@A@&#V
M8.X8(=*P_O^B#Q#</2POR'>;].UO!OK6M6V*G=(^&TH`2$?(/VQ3#XQ+@AKJ
M17PHH#J)BVGH)#.@L6`G<;PF>#&Y0DJ$$_)>M9X2(SW`U[>W6_@BI,P=XJ<W
M,`]K)^`"@BBD!\%4(]\V21JNV&@$VXXHC.1S:(<$NM->P,9/2`$F<=/3WY,X
M-`;[X012/0/V=[%?M8:51C"R'0?6W]M1$'C@'*8(YO0M3O)+0`(L1!Z`!=8,
M.!);6>.A%7+&$SP865=LKVDV=S]^DGK3T#'A,*%+%?8P1$<J7<W&IP;WR72?
M%BE*WC<G.'"QUN@!VY6PGR=9+1:+=0['5W'>B-W@:_E`9%IU'SGYRHA67-Q>
M@ZEJZN83<LX6;E'L08U<H]T'I'YW!D]\`M47"Q(=.URQ#=%CTSP:II#Z_6E\
MY_/.U13AGT3/9R_H1DKW0IEI.NV#H")4YCJ<)1%6T`/`#$/!07+S+N*:D0\:
M'+:QP!$#(SH8"0&VE!4!8'LU:94G`U8<?H;%=P6;C=+#^3^AOC)?T"F6^C]O
MZ&AX=<*_YJ#'#4G%NR06;&U\+^8W#@P^/.:!/]&@C*[!"TOF+$RP+NX#<T_U
M4E7"@$GZ)L>5LQZ=Y86<AJ7F>^>(.$.4#%-X`BVK&`YX_0`=.!1`4W^S\N(K
M_J[B15;BC/;]D5"GP9=8SY?9\0;%6A3O5F7M5EG77T'"YTRX5S7&[=5K!P3B
MW=GUU^M[D/9K3:5M(XAPM]KJX*`JH^H3N/.BQRGH'HG#K`-28,@`S]E$G]GV
MOC!A%;.,1>DP=6&@XEDGM10N.3S5):_"9GJ*B6W[#9B?T2\$E7$/5M!"^&\P
MRQ0:`],0$H_X+H])H3L,$6ESC3HU@RJR-(R]G3NDC4"MD9G1X6AX(24LTH&Q
M`-19?D@UB(&F1DX]A11"_\?U;20`1B'&6/Z#`'_AU96UIVO`4F,\A<,W]^.H
M]CQOCG(3DIR)\Q&U-4_!YNK'UV2$(?%0"VOA>9L%<%[#[2715CVZB_B)$7SR
M(%`,8NA/`(S@P67X@B(7D7`'M_B?7)W;Q;9+H35/"+B#%#<M;=\I3)$(9*U%
MU#`!56+U%_0J*,I&VC\,.N%FA`&?!/P1L8[:_8BW%QUBW"V2QCWAUL_,\<CB
M4]K-9HEOR**-ZZ[`GJ88Z=H7%K#`AZ$%GO#`,7_%D^"LZ#Q9U9UHRE",;XJZ
MP."2/YL_&DP(>Y#IBZ1EKA4=)#`8Q:/;0@.+'O=D"JT_49H,.@0H0)%E[>V,
MX1H6;`7K(2#?4M<!9T:2&D%4:\9X+1R"C6+_%+X*(D0O?AQO!;:_9KJVCI:"
M@5*,?F]XZ\#'(V0&!3'A1QO5@._QH.>*N[>I@M?C)5&1$4+92/1G5'`BR5&!
M/*""B!`U)9,J#1%<=3P`_K1PNCHN=@J;4CR77N=1:;**(A"`:F(4;"%S+2(9
MWL$31?@2K">5$H"(@=FUQW<M/\#`(7XJTIHNNTT72M7SSGQ!@^LNE\EW9_@#
MF"X7OIK['.%@:\<4M&/^R]77*4''A`V3?LH9-VB(7XF#K<V0&]]''=S5_..L
MN_L_@O@'[:`4(EPN75@T7A$M`[R!ERZL6].U5!;:'\([!/H,1XBE88![1\=2
M&,Z+>E&Q\^YXH%SJ]8-(.?A@A`WY6IXGY-LO:4L=D5(L+ZCK;\E\S^4OQP);
MF(P4.SKF(2`\N#5A.-IH%IH^>P1=@<_!UA\-+NF*:Z@+'MFY41T3@T7(0([I
M-C"]T!1EGL\0R9_ZO4&`M.?3<4W)?CC\U`%0.U]9H-$Q>H:??/32352+>3LK
M'I<Y0%Z5VZNVX\ZT\%`.]Q&#@3]BHPGM!0<UQS=ADO%=VHE@MWJBC!"B4O*8
MQ:'3QR?=?(27+)XW1T%C?U,%!>QM>GSG]X].\"R*SM2C3NM2^1=_VA=@90X@
MSNA@BXS09P4\='X(GB&:`""W(8B4#A<HIC/5!PSV20S5PM_(,V$(OG^F.XYC
MT+)(78CQD'+F8N!G?[&C!=,[RPR@B0R;R!0Q79WDPQ">T-7W,JD!=I#Y+J5%
M^[:;EZ:,</CDBW@N"*9+QZ,)CN(WM,MFTK/HN5J%QVI1;9'O7"UB]OC5/?TU
MBDD=88HBVM&/C,ZQP^G#Y0Q@X/KC!S!>\CD>17G!'H(]3+T(G_9-VJSD#GPX
M,IH'-:6X4X8XT-WR#&.*?>-!T))LY?B(/>!1;.`HEH$J0CT!5ACN(GBRBL="
MN)J6\"?8PK[1E8FK!QWFHX/0^?0*4O'+2C?/GT2:S%;UE8F-Z>BTN)Z8H6I>
ME;,MOZ=<V=QR:76/&YSEW%,]#,%A<03SW]8L#4'3N'>`M;>*=6/=.RCJ=,'O
MEEGW"SIB\1#=\5S9EW`I^Y]2L!.Y__"D&!7>G9!5BG*95W!K0)E^M<]=T*$6
M:=P$JLG?2^5J>D)]W_N_5`23\)2*6&F\2T5,*A,Q7N$W'2G^6_6<DOJ3Z6@H
MCJ9;$.*PE(),M=P1!Q-Y.AD/QH<B<^,ZJ%S)&TG%*/)`+3P:]J=C>1N/(@"5
MC%O5+!M/![(L;F-9'MPB%_`37U9>[*4_S50(:;?J\\)<:1V(0:)*Z$Z8P>0%
M_PF/5W@/C._,N9D_*#]\\+-^K[?SC3R6!J,D8EF@E8ICC?UL^M)H<A0<:^Q2
M,YA(&P):"X[U]9X9BY*X+XK<:?5\<?19/=0VOJ]U^0U'8J*XS"9`!V%27YTY
M:3Q(*O5R4:EM+4G2.*D1R\6DMA4C3Y(U;?)B8D=[TB2_K+D2S70R3$7"3FTW
MDQN#^I;&6);2V7`@!O6U/]K</TM!H+:%,!Q.Y"H0D'N2/)6FO:$\&>UD1/9B
M2!MD1[&J#9>Z#'PF8FY\`!DI#1\8HC@^@^%FB&`'/L_,PK3TFSE9X.=TG8=_
M[?A]I'8^56]!VHU&1SOAJPSI4ZN3B$<,6#;:OY#'$8U_6:_=UI<'28T8!V=/
M#&K;E.3Q:))<<J5@4)^9UN]/DNY`*1C4MBN)TDA,^FS;,,#.!%DE4#)^:\N=
M-*#(B"ATZ2];\)J^O,&R(5O3DL)3^9VY24O%Q@M>04FR1%K25^\Z]R6F7EB:
M*G@EEF$X:^5G2+P[^WIY]AZS4V#DQ,4,E3(?'DW+,E_\\A+1XW],X,!2)=[!
M_\JU5,SVH?Q-%G2%\!.<_LLU&&49".^8HBXPUT`X"YM'7)N*@4E+6%)*B'\M
M/-(-;\WK;8AU,2A=)RR\D2Q;XUATG+ZF&^B\>H,H]D:3GX-4XQG/0*>D2'S&
M7BBZ[ET-%[`&`/YN"*+4$W_N^$4&_/O0E/1!J99STW+67>?%%-X-I/=>?@6`
M<LF3(#$'D_)FE9!+`1KX-3P34LHC9C3G(4Z(GO"9IW[G3^B(W2KRQ_])#'.'
MD9H!2/S"/K"/\.9B1%/H:R"<9JC:"O,1PF1F++H(\/PD#SI#:4J7:8'!7W@J
M%K+S*F":JH)%9?NW2\W(.<*CHI,0\01:(B[0!O-K>L(Y@;,+,TQ9";%+I*CP
MK(U,FAY[S3='^YP_@0+!I'\_,1M+0"S=91KK/3:"H!NDS5=<FW>\K'5?2*/B
MT$%1V^0DI<0A_TQ^&^0=)2R9K@W28;__>&RB9++'H;P=#YI/-W>?+^^Z%S?7
MU^>W]Y<?>6')E<V*P/3GU>>'W_#1_L]@FC!=QU*60#@\ZJ+/*ZP9Q#^'8%@^
M#']<WCU<79Q?^U1Y-!W'7$:>G/E/(DC=^ZO_>\GA^D7PP/]T\_!P\PW>U!4P
MI42`V#9U;<9QZ/YY>?7U-V_[]>CES:2S.0QR>_[Y\]7WK]WKRR](PM4//O5?
MH*")=,XL#R@I4_D#^^`!8*F\R3=!85S13$16&)AX@3-P-[)VG#XX5FZN`YKG
M%__]]>[F]^^?42IO[CX*UM/C.ZD_Z$C#80?^^SZ79.1@<RBX\L]\3+[+\RL(
MH'7?%R"5-]1XP(?:B\.;,'NC2GS0G_8<BY)K(\N4CR8.Y#)@$W^NFO\O"\UA
M93$]8/0@-_+E,;2<D8B=--1P+%8'35.7;<#!8<O!:CF8?^&E[`K%>#DJ0(6L
M+:B27365Y-5LX.D2(LC3`XE3'(FC+/TDY%)O6$B*]N))ZJ0E2Q.-*<Q,%^SN
M+%X4V=H+3A(1);$SFA31-SE94D2</I#[T<RPV9Z7#C+"MIMQWRO#=BP7Q_Z$
MEU[O5Q939C?&'XI%!1COP(,5@T!PGH>QZ'>^2/<T+=(]SHYTK]QXYO8`,[=%
M<32)HYT'R&UT^**HC'LE*7B'/U:?S)@XNLP"9!LN?L0(D>;A+MY!)@6SK$>K
M._]*\E,F?DIB%LI9$.8E`$_DAW>PUJKR1))PA[=QOGFAF>U$V?5Z?8)?A%"[
MH-Y&/$Y>3?4NV*?0)_%$;6>E>+%A,)2F611(P+4-26S-G8(9?ETV1W^]'4C?
MLD#&"9-P\@H,=_#K!750B78.S?RU:L4T2'2JR@2D-&RJS+\>R%(YV"1Z@FY[
MH&H.3:3)>`=26:U`#\:K2EZ-IH/DEE@<+YZ@F(I1]*?*FUY.LU")0E$"$I7V
MG4TT$-X#B4SQ2OQ:N;DUW#"W,B`I#9UJ.;,O.F`NJQJ=9Y\;,[`P+2>HGT$(
M9?Y>;_;N2$[N0IF`E8IAC8GOXMX84E5*[9E=@\>#9<VP05),*K,?.(V;XP>C
M6.G:&R5WWVQ8$F@%'OO-'(_CF6$3?^]X/3'*XJ*+>%1<VJ][E4C8.FR,-K&K
MZN/QM'I5E,\U%;H"I=9V>>WP*/>.4GTJM;)6/%!UQ*Y)V^M^$2&%FU783NN(
M9;P:2,A<?5(I%X@*]8`X>M6`J?"57ZO.QD8:F,JBP\+K8.\ES##BU9GXD;6@
M4!6G:,%,4/)#+NC"E8%A":SR=`LC>'6XZ'?\C+ET\5F];@@^2%APDAJ56C`Y
M[Y-BXI]LN=+--4/L07G9KNY@3T"O%\NS9L-#R>*1])N!F5F\H`S5&J7$'=M]
MM+69IEAK7CPH`*\3-I+1L/'"FO]$(RUY%IEF^*EZ_7$GR-H3PS\E>CQ,YXMG
M#49J-]E(KX6ISPC7L%Z]XI<XX`7P>54E+V<PI!N52Z*D0TGJR*+4$:>2P&^!
M4Z$PNG/,YPBJXGNEWSM!BB`VL_7+(SWS-A%.@A[`H!\42AMVQH-19S":9,P2
M;:?"O^`-O>Q8,EN89[9)$'$Z]:6(K_*H"-&/7(1X;B(*CD5=B:B!"_:*P>YP
M6'G:=BGYR(W+)PVF>14;?=C8CY5F475JJF7[HMDL4J`4F.@U19UME)GB'80#
MTBF\L!M/V>*M>I:,48\*K!(9X375P?*JK?%41>I]28^E4S:L*D:%YQ`_GA"X
MB1](VZ`#M@K^ZPVW6:(U@_0T`.H'3I295_V7FF=X4N?7KJ3B:.'\P>N15CQ1
MKL?EP5,CFL&[B&#]:<KVI(X^A)G?IDJS".Z--L'-27,[4L^9.-/]"GT!&RC/
MT%/#,=IWL%$$U0X,UK4O&&*?MXKJ8%%&Y#&(V@M6<O=5,T@X"$,D^;<?5J:;
M*\"J':7CXR(=UT!<R?D]*KQ.6]2[@Y8?R3YE%/N]F_Q:B50WU]9^^*F^F'1M
MNA9'A20_J$7OIVOZ2QKS-E6^I+#$-0BKX_+:R5&*98K><=M$'J,I9\P`$\Y)
M(Q2WPTZ4;MNM*YZ=2U5?L-6=[2Z7"N\IYW6U))LIWN9NR_H-:C;FR6+/S`%N
MTWWW2_=-2>&,T^.@7)#F9?#&4RU4ND83R>H=$2R9)GZ34#]1VJ8;OHW.H"XG
M7X_3H]Q<JWRT2.5+[DESB<$.H+;*!<^DCV_$F_&/Q&;;'/J\':;\R3#OC<VZ
MYQ@V>6+"I6]=WJ)UV;*I&6QJUTX#F7*":^>H*<N;5XH&@Y^S;--H)4IPMO]+
M,:@KE<A]A@+$C%\.*O?&T>Y;/0?=/1*F'7$@=R92_CL<50%;`Q7+O;<EB+W)
M^"V0K3+ADT2Q,^WWCP[JZ8G>H#?-?V_N1"X-Y@XJ?.7AU@+XEWR[)/WZ%[PS
MQZYBT;?\+=;`]@NZ;R4\_'5]Z7^7!@4.$V%`_AT]-G)BE_>_S+B2,NB(XK@S
M/&@U[DO1DZ7??O>&#F65V)M*)RVMS;T&VCV:])=&C8-VFJJ)T!3O('UC\;VK
M=FLI55^]&TI21RJDLP[4QOD+1C1N\4D]:7KZ2JA5R6]&)1]8G""W<K[`O!?]
M(-W\R@L4O)OTI<YD4B1T5:!*09$B/`T@_,$7^7?36^R-BSCAI52$:#;1:Y5V
M2>Z,AT7<U5;8#R#WH-<O$B-^=>5/<N]3B6.%S6RDXSD7>U=%J6.VJ&(5.U-Y
MU!$/6MU[UD@Y`6[45*.F-YFTY&_`8IA,VI5PU)4P[/4/L?-**-94KU]6=,?C
M;1)CF>CMQK>7I`TZH\&X,QD?3*IVM>_-`ZDG%HE4OAWRM_M>8UC1[GO'.B(Z
M?C"YQ-#Z48$Z/@0M65JRG`99*O,%,G0VPLM!W74'K:B3$+^H[5UJ?2W.@E[G
M,7T.,$L_R<?J!F)G4"CWL)A94"L)JY:D(QFDF>P[)21:JK=4/U6JYZFSGG^+
MW>?J>6.*<3QLE+Z(5SKQ2V>\8%$5`&.I>(4T\&[_#"O,!+4O7-MO"O8)][KN
MO;HP=:P%0T-UL58%/K`T9TP/ZJ-$Z@XHMNTN^;1M4[`*J@04N4"69W66/=[V
M@^^-*^?9@N'?R=Y;+L+QP\M[#]B,4OC&"UE<8B$+PJ18B;1*((O9YMN!JH>1
M;TLPOF.!DU8N*JO)<#*"F.+/%;Y0''C6>6X-G_:Z+8E<4DNN5KI>C70=&DC\
MFZK.YZJ:ZTPEO(%/CP>U#!2OED$.MR";'"5<V:WX;OA@2X.O^-1YH&\^OOTM
MUU9>);Y;L@1>'[[]WK8&F7GQK2NGB1ZYT^Q_=>?H5<7:TV]BL8OB>W,D/30E
M]D3IYZ[8D_.WDZ3W?CXZY/W>L&"OUT;`/#A=:B/DPX(=DC<@KV_3IT<^:\_:
MC!DS8:TQ/64+KYN,)\?W%N"&`USK-O:'J2L.-E!9'YUNPU%O#"II)/6&^;O7
M-H3GXU%OU/^Y"_\IT.F[(;`/A[V)"+#+O7'^U-2&P#X>]@;CG[N3?F^0_SI)
M(_:QRQ\KIE+'#:S__DXS>,GTE*N!-9-TT$LKUW8H$.4#F6*W-`Q(N3>==,>I
M-QL;!ZD\0$A3G.SM,]6Z5P5+9FY:<Z91*YE&^%R2W!-/SG4Y2:!ACWW+<.=)
M_3AZDL%1LD"4IR>+/6%&AV8XEF;8FNI%?[&YPTLR.LQ;X&#>!K;BLQ35P89!
M?BN6[/9)"C4'VLPGI0P3ZD7T@Y),]+7PDSCL386EINO4?P*@&/=&?HL7B]FH
MR[1G>+)7-0*QJW,%$!CVAC'X$9\]X+>8UP&,]]-R3`<@33Y$3:9FVGS.+.I'
M],B<%\:,K%8VNFF'?8UX'QF3/ZPKMB,`08A=,V7M]\/AC6N"5A_Q)C0=8>GJ
MCK;2-=A=O(9A85<HS>C"%]VE:;"U3U2O"=:+Z>HS[.F#$`.X05\J;Q"O^XC?
M>6JA``2ZGOPZ:'+E]5P*),](X122&YN<+$T7.W/:T;Y?Z@+[T`N/U.P0WN:?
M@\YL1;L$[>)LT%XEBD*1UBG$#NK9AN+W4[\GQP0N['4$/XG^3PGI.[;VV:T'
M]YXT=VO&2Z\[G]?$XM:U@/-VI#]([1V"FKA'E-4\3IF!U,-SPC:R>VWS+N]O
M;['I(N\`F-ID$!L0!4L,II,2_>/PNPN^*OD\`,(C*"YO-J\S'DZ$NL5\L<-F
MC?BH_US6:'%-@*1@"H`:O$9IDL[",MTG^%996R8H,%C.KNHIJ;G7!S%L:8;=
MS(9^;S)0.6JD[2HU/YP$O](:YVH6/RT5ZU_,\34Z_\Z#.]&Q+(#/4S?Q-_E>
M\,B>-,/@&P&G+=#:T[W>?O#.M#K8E!`[^<)?05[HS+7\?-#X"R\+;U?RB4RJ
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M>^[W)L>FW6LY0`1KLN@<[3$2">')G0Z4TA*Z?I`RHFAWL`^"KX:BP4,C^[;8
M?O5$SO8??]]LK]V)Q9<62G@MUPH)[G6E)X+'(MK,<A2-XB5S+,9@J*S+P]N*
M,?N`L1^`T_OF&?UT?B(RTWAPBL)N%.`Q3$=8,J?CA>QA:E=WP/R):H%$P,G`
MQ\!^M16=QX[6P@J^T$S7UBF*:#X9VG\(#UT)D/"`B<:\!/8#_V9M#"=GT_8L
MP0BZN)?2G_WH5*\LIC(Y6L_V*EM-YYZ#TPL;C^8@6I5!@:*@)&]TQ>65"UPP
M?\:UL.(BW'VXN:7A4K?'.&%V;WXME"<.Y7?_X+O)0/*"7]LA;*86.?;\;U*+
MW8)`D\@(&TVOJ=]G][/O`#94WK]@_/0/C)^>CLP?I=9JK*;;9F-TWI\VNZ/W
MV+LC&6^T`9[`[P:Z%_P(\&TV\Y;ECBS7U!?XN"0L_3:O?$C3O4:V4\ZQIO@X
M=TE7;N=Y3^IQ9AEL+F>DMG=@740XROZQOV#S_:&5ZU:N&W+4F[-/6GX)]T*E
M;9?,[$9V1<3F#;1LK*%U8.T4;XI;D[.<;.;RWN;AO(Z*Z37,%A'$PO[1R55A
M;GA'F8)^5HWEF(]^TE1E8>C$U0K3FN4X"L635SS`P_QM5._>^2G\9TDWQ>AJ
M$;,4?HR+&?8FO]OPCEXT71M4EOT^\VSOM(_QO("@I[![=/+O!0&F[='>B0?%
MT^K\'B6FO'=1Z..<^-14$+@]^'E-,KYO?>M6Q*LYYRD<@RMA<]G'F=I6`+>:
M@,*.@ZN,FK\%7;.C8/ZZR%VD?6M+[E:Z3XO<S9#NII[\1,N.)QW%2-2<*9:Z
MH)C:C#TSW5RA3UN`L"=WQ"V+^>O?MGD!'M$DL::L@-=$M(G4$JTPT49R_N*8
M)Y)_LN_)9I;6_LH,9F$E&%#:RFRI&1JX7@J6&#H@HOS*SSKEP?@PXKRVT\XZ
MB2^-#SEJ:HE_$/&G!3H5M,0OF?ABIR_GOZM]RH?^^Y_P9VUS#U1\<=?AW`'$
M?=TGS*/1P7D0[?G^WM0?3%OJ'S&[HC.>M-DMQZ3_:%3$C7N3Z2UU07*>44:9
M:AU8+*V:\J`W%OSBMEAH@'9BUXB4$4C-DWEG,`>?#VL0A@4+[/=!Z0''A+&\
M_#V_)B\O8)!ZD]XK(KQ[>LVF/U5OCD<6K7M@/@/JRF9Q:J^X)98![0UY61IO
M0A\+$';@@V%B!095=V>,DH&TY4I1"5L3R2BL3-O6>&Y-:+!XI0"H_/)262-(
M2V465.R<NU3*@8-@)RLN_*]N]]*8?0$H,23;[9*RP$=FVG,HYMZ'__/!M;M/
MBK+Z^%FSL>0T#'PSOXB0Z8Y3_\*T'9NN%WY"$&^5-24Q/;`?SB<=(/_U__U_
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M@7;O*)835\95;N>YRZE_ARWW&O8>W$7XM7':%HY8`^H4;"*DFNY3C188+]"\
M7-&Z#ZLD^_:"X-L+8:N%L$9YM`]!M`5'3SC'!@J1NPM@#^"54H`XWO8"S9_`
M)LJJ*$1F&(XB2AUQ..Z,Y$&T_A-\.QV"Y2T-(V7(M_0QB/<FZ`A(!/:#+!PP
MW&`)>TG/2!._'+KM54EG\SD6O<):2(:CS5#-P"C-K1FUIRVU0PTF]"K1Y&9^
M^8.WLK@#<^O&N%#L!6AB_,_EOUWM6=$I9YR4;($7*K6BHIM+5S[[51SU^_T(
M%0K`63-)$C;6#UO[:&CZW\\<RV5EFEPP]%(W[(\PP=]3]AFIWQ<__./;];VZ
M8$NEJQFXX%6`X$."'EX=?I#K9TUEH1D>-=2_FYXBX"7]*`P:_1TM^.^F\Q<#
MZ`+WAHA7U>A(GD&V\"EVUYPGY&U01-X&XWX_+G%585(3.V[)H_MB6MY7^)Q8
M+8]2IRS=3KL5_QI]JX%/J=@DF`>:P%E?V;:+2\W7T.=>JR$D]98'`+FQM),P
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M8FL57&FM@(3UU[`5^[7?=-V2T+XSLZ+"NP,-NB<@<I)'M-*AQ2(J)\'KH/%G
MIGHDYD4'R[^GT<@,J'VNF&Q/B?I\>7%S=_YP=0-/4O<]73-8UJ(^)^5>.JD;
M>1DH]_RYIBM0DC.[?]8UWIX1Q#1CI\'L>`LR4.G\>M'V=EQ.I#0YB770:S(#
MWX+4U*TY\C??:P8[6AEH=X]6!LJ7@=2=H<'L:&7@C>P%#:K7W1.E:)DQ:9*\
MX-[U'N'379C6RK0HDY,]`M,PI,4C7W2#DC>'I[9ZD=^VT[Q0=$@J<(&WZ)6F
M?8)5/^],!2]\VVF?OD\>&%MJHI:(;%XUTS*V-,9*<F<J;KEUVW+WE+G;+MN6
ML2UC3XFQLM29#K;<!6^Y>\K</?:R?567SK4@9:7(@<K;NN-Y2"^#]G[M8;3?
M95JW#&B%OZ5]2_O2:;_+AFP9\/J$O[[`;X&<MD*I,==ALF-N\NTO0:GT+;'E
MW5&!.CX$+5E:LK1D:<GRVLCR2@(H?_(;[M$+!JTQUQQCKJ5]2_N6]BWM6]JW
MM']3M)=&1XB7YRE(F?\L+A8>J?BJ9#/`^\SK).*E5P.;XRUY<SR&S?&R*EH&
M_5UGVHRJ-BZ49R;@%W3#>LXL6WADS@MC!O#PF>D;A1<;>"6Y+DC2;A^O+/-9
MFV&V)-73-%0PZWGA32P-"B\\LB?-,/S6W(Q7NGI4="QT@,]X2:T[KQ^G7CC&
M6\QY^?\V&NYZ1_+C82.:ZY;=2)?3X:0;BDIGVQ?POOTXMU9AP"NX(2'H+F[X
M,5:.(?C6G!.]BI5FJ`1X+V@0@>UWJL!WKST9VEQ3%:\E60-`_=TP'VUF/=-F
M'H![9:S<*/A-@?8=Z=X0+OG]=LB.M5"/&OS:;)DW'O-\IT_>)G;@I?9X$E6#
MFW!)?KNW0L;R+M@:<;:X[U5\[PH)52,4P+R(%DB9;T0[UP?X&*^\%<Z[PSRP
M+9UPWC=*FR1<Q@R!BFB6@TJ2O"TG_LC9#X>[\"?J$BI4ILX6R+U**T`%;B&M
M?NKOX+M^]H(QAQPX157Y`.#=,8UL)X#$-4!GZE3P./B67\GS'U\I:W*?(NTI
MH@IX!O\ZIE>2V%Z8EM,%$VHI&`KV5>@)5(H2W<I'T[*X2XNW_&"29T73:63^
MNH\1#R#$5;RJK#3,"=;!AO;@,TP<)`4XOSRR"MO"&J>C44IJ[+"U]%U&';U(
MYHOG`\QNC#O?Q<8R\7;4H"4S]B[FY&>4WRMQX+9J7QOO:>,];;RGC?>T\9XV
MWM/&>]IX3QOO:>,];;RGC?>T\9XVWG-HL*!$1STCQA`Q-GE_I+2&<KF?;J,!
M54<#<K>6VU;/_XC]Y3;A;U2LU$\_4E8K'<,=YSR82>X-MH&C5FX7YHS\'`JK
MO#L[O[\X>R\\F"M-%282[`H[F4!1E4@@,,*4#L50(E7_*6)I='?U`6C3H,*6
MR?<7R`=A!@1V;0S[H@7(N>4P=6%H_W9Q7-M5%UY3/&&I6/]B#H\&*_#U.^R<
MIU@4#O)^6UF:RNSW/,JL&?``BSSO]7@(C4VO/;#WH(EA97LAS'7SY3WQCK?G
ML^-SPD?'Q(X1L,OR3L4V;\Z$@6Q%!9,5AU8,+@0XJO<LBA4-][Y'<FP[BL._
M=!V0D/]00#"UT02U-P;<3*R<]Q\>!`>HT4-&6-)()[@V;]+L!0.C`VL&!>4M
MQH1'0&OF9^DE@I78>Q`>T-A<F#%;M;15&*,T;>:-P-_-C`P>7;1CX4(^7&#!
M]$.W.S\PW8>;6WIU9[!0>-%FS@)K^/=_CEB\F?:S8Z[2#&//]XLHY-R6Z)?S
M;U?7?WT4[M?+1U,/W,CD4$MM-C.W5<%,X2*][575_2C<!/:-+Y?^ROVW:^*1
M%5^9PCO74&8X`IN]1^=/H>:8WO+EL6EM!DL"-'>@1>&[#26:SYYL>5\Y[Z6/
M`@_5>5W:0549"9Z3]L+>IZ$1'!Q"!#HR\/<[`M-HI)EF,=71U_BK9OB?2$G9
M+.@4'Y\*A[6UI:8K5KKTI,@<*OK-44(IS#.D/U:`*J9%\WE:>6V4O,H?A:@W
M%NRBR#B+S75LNHN""7NV:9%-B7+@1(_BS1?:V]TE;RU<A,&'^IJ[?+O=#N2?
ML+@VW%$[[H_&G5??OUWSEI%7AFKA0?UGQO^;Z7R6/A-W/B5Y.AKU!N/^^`#_
M-6V0;?U3N])H'.N?6@O"Y7#3SIB3NSR'<&_KR+R]81JAM_00SNJ1N)M?I70/
M/D$2#W<NB("F4A?^H>ZJU&FSZ!HH:PEL12G!#PW@8=>PB\+:`)8]:3`F;\,$
M3K^[='5,ASI?HJ;^#_>`B-B%7^-R)HNR/`6ZB&*Q#IYI[VVCY&00)V1A<(]*
MI>JZ5(L3\90)(\/_[B4^*>]M(]-T7!N5(B]=_L!^TNP[8//PPO1G]HVG#NVB
MV.XA*A>K?H$%MQO<0ZAW!]N/AL6T;N9?-!N\B[^88NU!PM1QJJ:C-,Z_/'."
M?`@M\?TOZ,@5)Y__:L,ESP?S8"J9[CY"YK]Z"E0",`^ET@.%,_<C$[U[`G0B
M.`\FU(NY+YE>S%,@THN9FT1?+=/>N0?20_7:"*(XG.:F`\%7'<HU6=6#Z51J
M!L852O=H.!E5@^1WYNQ"$1ZI6XH'^8U=@*X:9&N3W_[DV+A6*;F#_G!O]+Z"
MZ7@-TGQC?&:6]JQ@8/W*L!W+I;-Z>/[68H[R@Q#-^W#9B3"%HB=Y@:R)#J/=
M=)!B=)!".HR*T*$[Z(M-)L0XCLJ66&5$/L:I\C'>3I=2(I:5T6&22R#&J0(Q
M.:I`W"LZNYG?6N:*6<[Z5E<,Y_+?KK:B3(LX&;8]6JMVD+.4PS8(:R!`;6I!
M&AU.`&8P2]'/C=GY;`E["T@,R8YGV7/,MS]3*\_%_A@M]"C6VZ&K!-W:.#RF
M#?#(V(YS,7<O=9Y8T)/A^.C8UJ;#)5$>'("M:<Y>-%WG:'D?JK9'AY/Q<!J'
MV9LY)W##',`E3MSR2X\L#L1#@)OF`$X,@9O6"=RXGXMR/EOCCY<-W+D*FXG%
M9KP.(C^&CP&<]D"]CL-0FDY2,4H#K60L$[M##FMXW\VB'&O81\?8<"G#3.[X
MM8EBK[1W)TJ\JY-V-^*[Z3!A+'2%0'M@>MX-)02&_!$X@W)>CB@5P(-N)-=X
MM<2G7_&[),<E5T5W1E2Z;AK4UPG*Q_AU=\RY\.1+7*$"&2B>J.B$%V9A.FLD
M?[[JVAFUU\GP<DJ]BY=(X"!+<]IO9NV,K"8:;[F:QBBEFD9:LG$9M13"!.0T
M98\+S$LCN<0%EE-''`78V-K?#N@IU'S8MY[#_LMI8_18.?-X,[KD#?YJ[M6G
M`+`I1AME:`K>)Z\<R],E8Y&*'^5@>90Z!KEZ/?EU4J2?L];8IZ`HF%<)K`#U
MX@W>&UPO1?1OG\AR!SSY$N';3_9;PC6CV,P!_=("3])BMJO3E1[TTP4%8Q[<
M'T;S_]&UP1RQ7T/_4@F4TW1R!(":2Y(B=4Y.L:U@WN)+68ODPK4L9JA>"Q>=
M4N(*D.R-55Z2I?YAQ*FTS=0K)_XA)8OV(OWQ2JIE5;S*6L67L4JQ!]#I=1>]
M&DXZX^'T4/*TK>+V9D!A&[6"TF/'+(I96A"EN097V^>Z$7VN2R^P=YQ"4KF/
MO:ZH;,=<H[./]`/#MWT8%B.0%A+(*VV";28TK,[CEZ(/C[,4.B4[0HWX-W7.
MM>64(`_HIQ6QSQ59W@%`CE!S?!7RVSP7_@GP.9T`IRW(X]#DM9XZ'J6&?^0"
MO!"][;==_QZ?,:T0E"@$H1F0<]NM7BQIL^W`&#NZ,)S"27*]YV3INQF_2];5
M\3+9IE7SL74<6G^J)4O#SCU*/OSS#/3A)/,`'2\161IS%&LM8!'29^PS015S
M3=U\*M)HXO1.A46Q,YP.2H3OC1RGOYN6V;=EHZ_&:R(5RMB@5'(US4`I_=`5
M8Q./IL5+CRE/%HO4_V_/_E(.#@:=Z;1(UEA[]%HJ^=]-BFPAAS0<:FD>$?E^
MD5R>UW'D?8!6?3"QF;"V-<Y]`#U?]\FL..H,)Z-#R=,>C>_-@'?BI+*#\4.T
M[.NF.HC]H#^L7^Q?X5'MEIX_T4*[S"ME4.BRW8MB"S_U>Y*PU'0=Z^X*EP#N
MDL+[2M;H[(=F4];OYFFG/[GEUR;%$\[@6A^]C$U__*-0+#9JNZK*&*59K9EB
MV7YW[F@W4\HV?HS<!K1?WQEIX/S5?O'OP.LH6[N28OG'`EJ@[+._LG'-.`^-
M''FVEV\BL4-1]N(./*TAT`I[A&W&@RKB-E(5<1MI_!9OBP2,SN_1-C?<+W;Z
MA3SS4[CA4(2'^2VWEH>-6GSY/<VR&0?OS,':C+WE[W"&:2T5W4\_>OCK^M+_
M+@T*'"9"YOP;:FSDQ";K?YGEKY0B+#70H/&J(_]Y12N!Y4O@B:FK_''85EB.
M)"QU1U'V[.A7K.Q8>I6SA_"JYCGU5.5]JZ-5S=(?J;>TK=1/K5Z7#EH%F)Y<
M#;MG9AD(_06`9BDJ3*`RS>M621AG/X#U$K'F_%2:]H;R9)3.X$@)R+[4E2;\
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MGEC+H3VQG.S#R[U6=EE86DRQV6?&_WMEG*LJ&;^WRAI-8NQMH:H`_,SO8*ZQ
M0$?N\6JM:W@DR<E%O`?(#:!8?8:<W!_42+)$E"#/@_5N`E,Q)S6RX@>EXUZ;
M*`QS2T)^W#^S.;,L-KMCS\QPLQ!//%6O=RI.ISO03H!7&<ZU<7K2WZ4F"Z),
MC2R^FX9*Y1:=W7HP^X5:F3_>28AL0&NF27TMZW9+Q_Y$N;782M%FOGAYYA1L
M*30D/RC*($^>5^O5'"-YE^;(`W,#2%:?;(UW;:]E4.P.'%!+4QTVNU#L109M
MX@_5*SB3T8:ON16ZBA"N;[^1)Z7BZX?M0SLD:P6D/%EO,\R1M,NH2@&Q<OSK
M<R]$<=>*SX'_1A?MRQ^J[F(:?JP97YX'Z^\'G@>JBA%.G+=MB5'L<?Q64EB"
MAQ:CG4`3W]6[;N6DAH[!LA?PM2TZL7S8:SN$&"75Y>&PUQ9L'Q4'_19LG1C<
M^$6]DBXECWQ"0`K"?')A;?^D@H=W07MZ:&U\7R]'!DFW8@.>@Q"I3P]M[/WE
M(E*;4AHF'>)R\:A-06WXJ[GQN#5U35W'6\QF_MIVDSW>962<-+6`='@L2YF[
MA:I%;P&>"C-JC@("L`\BFP6P&W.M.YHBX)6/QAO3L%"6S%(U11=6RHI9'?C&
M6F&Q(R88I@-3XQUKQ1"TX'WLSFH:3%!<E6YQT[,V4UT\5.\)%[IBV]I<4Q6_
M9]-2L?[%O+O-_#&,&CXRYX4Q0_"B;C2/81I=_[-FPW)?X25S^."N3-X2UK2T
M)PUD&09U:$)AAM,KCK!R+74!+EA/>%B8=FPJ_Z>9\*(YBXTQ\)$G<-]@^X<Y
M`-=I'T9=`Y$?74<`!\[F7R/2>)M<4"PFJ!Z:>*?=CB'AT/0T4VS4+:]'\.X=
M6U":)++<(".J@H+"8C%8-Q25.XJ'Q4!6L0;!RP+D""AK(#7Y(^`U4HU1+"?`
M!^'O]81;BRTU=VE[H]K\#*@C:'/X9MT!-D5DW29F>44+L-PZ<$\%5Q]+&3AF
M*(0[9\7NQO8*MB]8&$'5&V^)+"G3!#%R;?XZO+-RJ1H"")!.,S\I8/G1/+H)
MWK$M>`O"5F!9>:4/+N`UP($X^#=Y^HL=602M7,4Z37ND$A:X>,.UJ&'P.<I]
M^.=9T7147MVY:76)W#9PE44I#H*P%@S&A4+7_NUJI)7@B;@B0J7@];8VP'X@
M=<!E(VV6\#W2&(IED;IPA+FB6<*SHKN,!,(U=DE)#`H2]1F(L+74#`[R(\#*
MEJCV+5@!.%M4F)5(>6Z3>KRC?%H,5IV-Q3:\%?D.IWR/+]@.F$T+V$J990?"
M*#!*J^K%=B*<BB$F-#CL/YHY@V6AZVL$*P`25SA-K*`)J.,W,`VG`"R;,X*J
MBUJV&^#1.R/"X@CI#YSAJ[#'T6*E6B8PI6;@_+BC(#0@9:C5DW/VA#L%!P1*
M.K!ZP<)"#>\07U>6B>O<*UNB`)]!XQ,0J*Z>F;7&U>HQSZ)-%IY189-1+`W0
MGBO/`!T(0D>@LB=\6(OP5`2J+`'O,U*&*(2F8+LK0"@J%3;2&O8WQZ1!HKM0
M)]Y8G</AJ8]P#_^F&,H353D$J)\U]@*+!'X!]B@=K*VRP(6!KRR5)S#005"X
M-G6M8-/'7SVZ=?#I%Z;K_EN;>HJ?N!'346ZBX*#\@X;6=,^.".C8P:=!#(%A
M3B`@^"+*84P^4L5#N)IGB-/&VDA[GQ,RE7Y\;YJYJK<=X6\:8*Q92\^P"78N
M3QF`2^]P<L-09I"ZF-39>]YBR_1LLMPC^PO`^@>B%MYR2_A(:8_PZ+(DRI.>
M.)U.0G<I3X0V$:%.&:72F,D!*`_W13D1E#XAE(G+TP2P.=F:?&WK`:L\W<CW
MW09;5=S-A>HF.XN@*DO30?*DI694D:M2$N:]UN[&*$T5Y.&^*&\PNV:4,:?I
M$5/7OP7.-4];OP]V3?CQ@ED.6(0/EH)G:)D7EY/$*G7P-GQ6M:>3%BK[;H(-
M.Q*Z0C)2=E!X[%@=UHX2)(M%:%+\L\Q.:VCS10L-XK<2&,#HQ*'CI-F\<5O.
M:H-'=]!/N"SASC++7NV]O'5`RAZO<&NUK74#Q4%0AB1<4YL"FK;H:L'V!*FW
ML8YK)EZ1"CLY%\`A[#H2:](:!)X'0=D+T\[?&?#U$H1W3/P]#`9^Q6!@2YA-
MPEQ3;+2ES"_H%0GD%K7$:!5*JU!:A7(*"N70JH-_4]7Y7%4+-3[A50:G`5%\
M_ZD[C78!\WMLG:>D1FAL2S^3>'7F0YJVE=HT;.SW#.N(XRW5>XM#WVQ\1_TM
MM;9?&[+=MX,JR/%XO*68\2O$]TVMVT%_^G:0?5OK=KBM,FU>Z.OOE[;-;.`#
M703IEC/VZ.0R%JHS`>NQ)",EAR6I(\I;BGLWTU*NG4Q;9+^E$(VZ11NV%`J6
MVF"+7=N2B4:5Q8X\Z+=DVB5-K22U*JF,M38J59".$1K:[+U)O6WSHU6L:6=&
M^TPIVC\SK<W%MAZ=>XR9K1GDCBQNZ?Y]&/:OFW:C;=U-WR+A,NB$`VTT6DE,
MS=5OCCXJ;Y&N!1;S=%OSI99V6W8WJ3/<UO.NI=T6AU<N8(*WA-O+Z&S)%ENK
MTT'):S5/OZOFY-H>?+>HW*SQ>.)[LMIDHIADE16PI,DPT44@LS[D#BBK;!,C
M26*B3E<>*($=]Y&KFIQ;2=!3'ZJ<ZH-A?SS(0B@5I(JPK+2Y3U^2!YEL*X;E
MA5\V(8Z7]W7E=>(&TBASE7@P'`!ZI4P01^-,'J2##AKT@5E+O&/AEQ'GP*?\
M4'V%OD0YGS0@#H2_2O*/"X/_'8LNL)MYV.*#@-_\NKUYM&EP1,K<E'!YQ+\Z
M0K>-1*$KW%A/BJ']A^B?,#`J!J$YY26^F\_*L_*C(UP9:D]X=^9_/N.7P<TG
M?E.="L1@O0G;?;2UF49WROV'A?-/\#Q>#3_S+LN?O><5`/"Z.E9(Z-J.\L2$
M1\U<+11KJ:C,=?![NF*$)2GFIDKE1+PZ(53IA%^;G[%GIINKI5^P)JP!Y'$.
M+R?A%?7EHV8H\-#*`OYJA@`?S!4(F*;J>/5=537#+Q`T^Z?[K&`[H&AUC<@%
M?QABYJHPE+9B=.$>!/4)2STK,)"E,8?*(FC&G&'FG&LCO%A0E=?,\"<35)B,
M:FL$)7?T-15,\:@2PPT+,.`@N(1P:-UEQG^4C@"@S=@2Z[#XWQ$.%K-7&J@.
MTUH+]MI0UPY617K6+(#FW=G=_1]G[TNZD+^IJA(:CCE8-_C6,K',P^S3^G=@
MY)7Q!;F!UZ3.@4;/H9V9__&:BX[VIX.X<L\/:8T$J:]<.!@:DRKIP9VQW/1(
M>;S>=@62+.8A1PJ<-9*CQN+20W$PKI(@GK[)2Y"4QVONM`D:9)2'("F0UDB0
M&B5D,!WGDI`\!`F;WODXA]_TY-%4[,G2N"_WP#O:R>WI)K=IA'[:&#L602+<
M$H.K&!)UMX65IB5"?LSFIX=!?LP6GX=!?L1&EML`C[C"T5A)RO=51QN&TP34
MFR`<!'OUK;0+P!XHT838I'Q?LZJ9B).XY90"TD&XU*E\Q$2'\[)QJ5,=2>-I
MI;C4IZ!&D\&^J%R3X_[%12?W&_CE2W<)RXS.B!)-`XN]4GDH==K/D,1<X"6H
M$39XBNJ]S:^KQDH>Q:/;FQ`<`'BE^CK17:L`X&$SMR3LX2]UM,[)`#\$XF`,
MJF2`/,QDP%8,+J+58;FV^&):3'LR.-_4-87%%;HC>V[,Z)-.@;#S&49F<6&!
M/70S?U!^W.*E?/C!<2SMT:53Y0?S5HE3IJX9:]WFA_WI)OGKPO3-L?7$NKV\
M`8[4UP^E76@ULO7$.LQGT0?MWT-IG'.,6G>=T43.M1ARPMY(8M9WXM-/L0%?
M&3%K4].#\>C5$[,V_WYZ!%J&!9-^,W5JZJEH!LYP8T121"W-AI\^PT?CZ98:
M0O@`;"7RH8/7>S0^SJ<7#D7JE?"E<?JZY<N/>B.K<CZCI.7+CR;N(A6P)9*C
MFU7]/\=SI]>QI&3D3ZMW216<+Z7?Q8Y.'TU$/K6OR7Z</SWD3ZO3206<WP"[
ME"8G&^F.F[O#=O"VXYUV)I+Z<^5'.\/Q9"MJ6X]']L4H<=2SQUK=@F!Y@HI`
M*_:"[_S17O:9O]:;/#%*XUT:6*7A5E\RQ4!.,<CRXV;ZY]UIJ"5_K-=A[J?B
ME82I)+1.\2QH'SQK\]_J9=^)G3#XF21?3.O6,E7&9O87@.N!X=V;<UTW7_`U
MPCK?H_4F\2=R9O*!6#T%QCFTKM@54RDP+J1U><)R222XF=.=WRO;=O$A[$1@
MQQ!/>Z#>`R(Q`]TTR$I&LK:=='`PC@_FN?IO5[/8N=\Y#,3A7M%9&/&(H9SC
M^7IWW,%X.$BE00Y(:R5);4(!9O](KH@DGUP;+U/:S.;-)5+ID'@(-=4^6_B8
MNP3C0ENX)&W'/`';#G1O^750[9GQ?+)T?)-/U;H`!N/1#I23X%6&<WWG'U+_
M,)PM-F?@L/+"%;>*=6/=8VOK&?GYM\RZ7RA>L"+?HV5[\O\#YN+_V#AR%'7I
M[%=X4HR@G0NX&G`O,[VS-MSI`?O<=1:F1>UQ-G%./E(JGPE'.XID'X_VDEOZ
M5H`JP*\T7M:#']HX6W#C/U?/MQT8<3!*Q*9:+I6$S8WKH#.)1VF9*$6>.3J7
M(K!4@MQ1F983.5*?*0C1]RD<VN,X8LL^7TZDHAA"S0]8`^`K19MYL:/H=9?4
M7RJ_JM,71TD=O@G%P2A46HAN.)P61T$S+7[B?\?\MMMJ(KOX,[-52UM1>1J.
M7;&7RO8=7D,QJ(HK(DEA:_%X24KXQ);X5Y)SO.D-_VU[N<HCX-"8`E,WS\Q:
M,&4F,+ZH;,%B.@7!!<<4;'>UTM>"NE`T0X!IE"=&U9#,N?`3X",L-5W'180E
MC^"+4?`%EDO"2E'.PF*,?C:PY-(25LG"%I@Q`_MIHYFXU*&Z28Q<0GW=$1;*
M,Q,>&3.P@I3'7'@1UY?PQ`QF*;I7,6JI&1KP5\$W0U0``QB0*9:ZH.>B!9W\
MAWK"N6Z;'2H-I?'R5IN``5?`:_%1QQ,P8:Z;+S8![%B:"BX-_]JB*YQ8*HM(
M-`DH@C6P+$0;)IG[-7D$):P5LE#L%%P1;`W<>T/57>_MX)@B\C:5RK)9Y%UO
M$41HN%1F#$D"J@K8LZ0_/16_!AH)*Z25X=![R>)4M<MEY@K9LTQ6416?W%7"
MT+L?K[V97YA+$&BR4[QM9,=3]09=I<EH8__<`6!E6-=8%VLJ#<M'&JL1;\$6
M?ZZ7N<G*-MEPY4"/PLLW\T@UV]V/8=!7VHEN?Q(-&/-//&`L%4)WG`O?&(#9
M>&_4*LWZL>9#DF$VBMD53/=&K+8E.3H8KSLP^_TSLZTX9CU8<TF5?K8&RH*P
M8N3KK,%2$>YW@:6%1<JRRC7N_7:](B+F(M).H!M#N?KD:SQ,AC5*IQWN(M1Z
MP,'SUO7-?-<9\W[OUBIQDDS'S1F$*P!U(\A6GSFYS>XHC6HW<_@&O#IG?:MC
M6H\Q0Q.&^ZEIE-KR?*U"E;C>70#,6NE1F[3(XJ0"@J"/<D-.J7WY`VMKV\'A
MTXZGZK5?Q>D@&_LT\"K#N;[4KFS_.A_&Z<+PG05RGOE`Y?<2Y.EH`[M,:$I&
MK-H>'8--$R(G8E$#PV\N<:&L-$?1J:S;S:.N/47Z2!1XOM:UFLC&*P!FK?2H
M;1U/^V71@T>;08@^A['F:*[YUB=JE0%9GDZF";2WP%8ZHO6E6HZE<9*_=2):
MW\T(>3J8'!'1VJZ*PU8F'8!GQ"_$)G+P']3XSV"@P8H_=RX4RUJ#JQCF)!1\
MI_*M64JJ[T+@'84>5>[HT\FH/GHDKEGF?[QJJ1@G2E+GAZQ&`E3;_:N8&&03
M`)M*LMFE8AD@(_:YJKI+5\>TU<]LKJF:C_BNQZKF>!=,]/XTJ0EW054ALE5R
MMRL/)V+BRD1Q9)^9X3+?%N4?:CZ4%4?)9<K!R`EIC5;34$Q:384@K:^6VZ2?
M7`.%`*W-;!F.$^6SBP!ZK"8JR=MKZ3#SZ!;%/+Z[F#H#'R)9R%=&I.8GX57D
M!1_WT5CL#25I<!#RFX-L3]@=B$-Y.HP0H`CDF42ZA8TI?H\CZT>^*^Q"/FLO
MV8KOMGL<<D\<I.(<`RZ!G[I@,Y=.X)<KW5PS=L^L9WB<GOT$CO,,"SJ!3<[S
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M%.H+FW]^CVO^](^Z`LH)@!!(.,L`!>4`6&;\_6QTMBFN'L/]^?O;T2\@0@\W
MMS1<6HKU`^7P?N.INY>8NILSG?HHT,:2=[<#VDP9._;\;U+&OV-V>BOBE8K8
M!\<J=\<I>7/9&)^^^//RZNMO'A%R;W('3+IK^:4`E3)_N,0D@@4MUJ9C_KK(
M+34=\]=%[E:ZWZ!T%]E1@!CG%__]]>[F]^^?T>VZN?LH6$^/[Z3^H",-AQWX
M[_O"NX[.YD[*GA-X88/!STE'T=^1[C(NIA4@K#>)]#.-N)>`;"+C#2KR07_:
M<RQ+>UI$!NOST61Q5")L^RV)DR.:)$Y;HA4EVD1JB5:8:"-Y4@_1#M7;+PO-
M8>4$I3(U>+K6_IIYZ[@`Y5*`VE]$BKCKB&R%UL2&A/&YY,'X,.*4BL0;([XT
M'K3$/Q;QI\-A2_QC$5_L].5^W>0_BD>2A%SJ#0_<YAY,!S:Y78=S!Q"70"Q9
M^FA,86:ZCSK+XEP1@ZG@)!'1&XV*A"-RLJ_$E?^ZJ3^8MM0_'O7%SGARB,G1
MTO]0^H]&1=RXDN@?W?@^4*9#\/'D:P=5EGF4E3X5=#/B=9'/C5FDD<\WIF![
MH]F-<8?7B['#'8"@V0_41#4C9:J$$=LTJ4V)SB^\L2"X85I+1<^2Z.0*V990
MQ=.=J%H;91=9S*OB95/:E)=O10OB;_+T%UN8@R`(SW238Z$Q"R/0:ZK6IL$K
M7ETRC&_PJN(8YM!#01&6GJ0(BA,="2O`84X7EQWA$86G_`RL"DA88ZY6$&NK
M/3%KR_G+3D>@PJ.N!AUKB9SDJ"0%?LL)Y'NC"F#Y1XQOGL:?F>J16.2%%FNG
MP%$<]GU.1+=[\)\O+V[NSA^N;N!)UY@Q2]<,EK6HN0U0.JD;>7:=>_Y<T^T@
M2N;\>C1]ZQH/>P610$DD;C68'6]!!BJ='V::@[V<,=>9+P-).9'2Y`0'BJBP
MYC+P+4A-W9I#;C7'FY>!=O=H92!U9V@P.UH9>"-[07WI/3L=I)XH16_%29-D
M/F;7>X1/=V%:*]-2'";,L."W'1:LI(0?E]]?I@?"W[;3O%!T2"J0;U;T!'Z?
M8-7/.T\N"A_.[P'&Q`.CFPU&B<CF53,M8TMCK"1WIN*6)+&6NZ?,W7;9MHQM
M&7M*C)6ESG2P)76QY>XI<_?8R_95Y4AJQC/CS:.*'*B\K92D+0+7IH-53/M=
MIG7+@%;X6]JWM"^=]KMLR)8!KT_XZPO\%LAI*Y0:$\F*S4V^_24HE;X'CQ3*
MP%&!.CX$+5E:LK1D:<GRVLCR2@(H?RJ6I1A.]()!:\PUQYAK:=_2OJ5]2_N6
M]BWMWQ3MI=$1XN5;[D\??&NYA,N_Z3>5S?D7S=`<=JT]8^,+1S&>-'B+3_/%
M=6#<\Z5I.=I_Z#JTUX]MRT7E,@9L[RF'8ON*;K$>F,B;X9OPJ?]BBE5@R>?+
MG#UZTG*R;"NL'+=0?=%R\&Q\D591]M,000\([RRV5#2,$[\O0"IOJ/&@BF*/
M4B5E1<=B&;`UJ=AC[O4.C,Y?HJ:YL2:QTR]4:N<4PDQ%>)C_=+'E8:,67_XJ
MT&4S3D^YA)LL*<*'>OCK^M+_+@V*O:_@QD;.J&J2X9F4(RPUT*#QJB._A]=*
M8/D2>&+J*G\YM598CB0L627G\GNVB4)2J59M:97DRHAS9!:/RQYY>XFXO.^U
M`98*`RS';.F8>OTW/^BG552LHIO:R:`+3AI>S_YJF;8M7"B6M<9">9&(3(57
MN//39(L`G'2;0>EL<V?('G__W2+&ZT@S>B&JS-/8O5?#OHH8TPI!B4(0[J3;
MV5ZC6-*.WH$Q4A7/\26QJ;YCUF[&[::NCH:3H`7\]DJH?GP%,:HVU:\E2[/(
MTJ@X06"@#S>JRP1*XM8R5Y;&P(U8"\KLG^XS)CXZ3%T8IFX^K0M0ZN2ZB@FB
MV!E.#XD#O-%V;.^F1?)0=L&VQVGFZ9`*96Q0*KF:9J"4W<CN`F,3CUCK"BM:
M*4\68X=>8G_E_:0&G>FT2'WJMIU7J>1_=U!7F2W$+Z(8WQC-0>3[A_22.4H+
MM?V;@Y96$V0&FE2;:Q0<WO`(#Z#GZ\Z[%4>=X:1(@^@V\;E<!KP3)T5RP@J1
M_Q`M^[JI#F(_Z!^A4,()'Y\6.*S,.B7]:IJS%TW7LTY#-WYO3SWK$X_7=:R:
MSTPJ]?3TM9[AC%+.<#S6^O-O>/?[GJ)T'VYN:;BT4Y3OFL&$;[#^%[8`FHS-
MB#Z[CW>.`FRLD]5V0$_AT*?0&CN-9(3"#MM^R0AM$[.RR/A&&I45.?T82YFG
M'Y_8DV88O#6DKAAJD<[AIQ>+EN6..*CI<DU+N-=P*REKW?A.B&`QV]4=7$#H
M9PB*^F]7X_:\8,Z%1]<&<\1^#17+)%!.TR(AQ]=_GEZD%,`IW/`J_23+M2QF
MJ&N!G%P]S+%K0_HIT299ZM<=T&^)7T95C],\2\F]BL&)WL\^?%O!XN&D,QY.
MZP\6MPQP]K11&U):]Z"MNHH@2G,-KC:OLQ%YG2=W)K5Q9)1U]O1-<;S6@3?S
M:]-X>F#6\C-[=+9>S\OW4GM*M2DP41G\IVL[VGQ]P)V*I`KL!<TCSY^>+/:$
MO2'G=(-36&J&MG27PLK2#%5;*;JP4M:492>`X^XLF/#U4C!,!V:''Y"/'0&>
MU%TRA?!WJDCSQ27;J",HCA`+Y?.?%0LS2X2YJ>OFBRV\TW!HT[458V:__Y@0
M\MJ)4N,97UN;RFEB2+VM0Y4S@/XVZU")@R)'4J\EXALP^C74H1H>5$JLB3'*
MMU:%JM$<W#\(E3>T'/#RD.S35QZ[E*<'$N?$8A[%D\+;&%K>C-?.J+I$X\."
M"UO<HIR93CM]HYV>T<&!B'RA@JSHQ!U3S2=#^P^;77GW&-C,*QR-Q\X6?(H5
MD(;?W"6;;0U>E#)F&]NHT'EN9()L7+4>+9J:D086C[24!5-3[=VPC?3(<[4N
M%'LA`.Z"BG\P6,?/BE[P#ND))BEU^L,BEM#K\EC/516#-[9@,94!O_W"-J?M
M_HSZA\0@3G1!\W%N+;92M)G`>(E!FQ:TZ2R85?2Z8G/9*W;ZA6YN-]:_+<!5
M<\4L9TW<1,V\0@/B-;!R5.2FW*M:J5=[7R1N,CL[\J1(0EICEV8ZT_PCX5?`
MJJHS<YN]^`*[QSNHC6R3*N6?[M?&LKGL?B=UQH<7;][PBDXE%GRAK#0LY:`S
MQ7X=_#RH`E<US*QVR7Z/)E:\!@Z*TX.]E)-=CS>D:@W3Z!ZB;M_<H<T[L3,\
M*%VX2-VD)AW79(@1K\^S<BUU`7H=$[/:7//LZD]B9SHZI.C66RQ,4LI)1];1
MS/U"L=@GD-S9A;G$>`U==KIWX)6;%?X)DSC:L^:LMY[&[#M,>P`3KH)7E+W8
MEDJ('>[P&B-2OS\4:$D(5P8^HSTSX597BEPMK!SU$Z6M.)WZM.7ZYCB$K:SF
M2*;QY%=W*3-U)!\M4OF2>]*C]$J)"@@W\2OLD7(8?=X.4_YD:!^R6??\F<&N
MR(3+'\Q2-;"E;P-;NF73T=G4KIT&,N4$UTY3;IUZQO%@D%EBZ,9U;$?AE\@5
M1_@OQ7"QUX+(+TD5(&8-&2G[K8L<N2G3CCB0.Q/ID#/2MUI\2.Q-:NH?\$J%
M3Q+%SK1_R&'NR="P9-$;].IJCW+$\_#,&E>6`CO1['A1V/1S&_VD.^\..J(X
M[@P/6HV'Y=R>(/WVBZ\?RBJQ5T)NVC&IW=P3TPHKI]5%C8-VFJJ)T!3O(*.B
ME.==M5M+J?KJW5"2.E(AG76@-B[M:D7]BT_J245.WQNJA%J5_&94\H'Y//F+
M=F*5/_T@W?S:4W<F?:DSF10)7;W>IF<')[SLIK?8&U?48*ZMC)I#VB6Y,QY6
M5)JV%?:-^$#OH(Y3)U_-(?<^E3A6V"R_=CSG8N_LP3IFBRI6L3.51QWQH-7=
MEJT]D`F]R2&-/%\O^>M>#)-)NQ*.NA*&O?Z1<YJ;78B=DH-M@?'H&;_KUFY\
M>^7/=T:#<6<R/IA4[6K?FP=2KU"KKK=#_G;?:PPKVGVO;5MP(O7Y6[*T9&G)
MTM0SF@R=C?!R4'?=02OJ)"C/BJ:3BS`W+>$),[E>C[.@UWE,GP/,TD_R1YW!
M2.P,"N4>%C,+:B5AU9)T)(,TDWVGA$1+]9;JITKU2LL1)#?8U,8YE14KV+<0
MP.[Z!+>\T='YBV+-HN/]H>@N34)U#_AW.6L5[#]D6[=@4V*CJZ#*_D\/"S`.
M%<T2GH%-#+M5VW0WT>2,XD8CFPDOBBTP`&.IX"<P(K']U0R;:<$KW++$+M>\
M+=8G-(^Z("2F#D#RH;I8S`4?6)HSI@LOFK.@9WE?+#J_#>6C;8M506&)(G<.
M\RCTLL?;GBNQ4:4@6S#\:_Q[RT4X?GC?\V%A,29\`[VTL+$;KI<;E[@0ND-D
M*X$LYLYM!ZH>1KXMP?BN&:U<E!1.25-;)R.(*2&`PG?0@V!,GHOFI[UN2R*7
MU)*KE:Y7(UV'QI[_IJKSN:KF.H8+BS;0XT'Y"\4K?Y'#+<@F1PFWO"LN)["M
M2WQ\ZCS0-Q_?_I:;3J\2WRV)):\/WWYO6XO(O/C6E09'C]QI]K^Z<_2J--2,
MS'8$2W%2ZKWNHOC>'$F/9HH]4?JY*_;D_&V$Z+V?CPYYOS<LV.VT$3`/3I?:
M"/FP8(_@#<CKV_3ID<_:LS9CQDQ8:TQ/V<+K)N/)\;T%N.$`U[J-_6'JBH/5
MHM='I]MPU!N#2AI)O6'^_JT-X?EXU!OU?^["?PKTNFX([,-A;R("[')OG#^;
MN2&PCX>]P?CG[J3?&^2_@=2(?>SRQXJI>!H%QN-2P&Z?:Z98:9T^:R;IH)=6
MX>]0(,H',L5N:1B0<F\ZZ8Y3+\,V#E)Y@)"F.-G;9ZIUKPJ6S-RTYDQS7(LU
MP^>2Y)YX<J[+20(->^Q;AOO`)O/U)!F4F#BT?U;.2281B9/^J"?*4_&`5*+-
M,=J$HF()19?WM[>"9B/I;6W&+-AP5#^!S;36E(T^UPS%4#5%%RRV,BT',X!6
MKK4R;6;WA'-;L%UUT>$I0K&#"!K<Y@GN;5:2IP2KRDH"=[*:I*2R=H^MAWIR
M<*BWD>:>O.RB%\_UB>6\/UK"A^!#L=EVYFGX$QUB.A:A_98CS=).9S-.1DOI
M#I`YMK[W87CYZ!SAI'<\SG72&U6P><]Y"YRDU7(N)D7.Q;:$-=ISL4+G'05N
M*#<B0O3*3CK>;%B[WRO0A+X1DM?8V"18DT7G:"-4)(35!1Z:Z.ZGWCSB;GOJ
M3V7?X1%<0^.O_G[_^4R8,16</-W^^UE7/OM5'$\&_7X_0HI4F$I`:;0;)2F&
MDA2B-"J$TF@T*0FE<PN,MB>&<O!IG2X:E_]V0;%?&6#ZNOBE3?V['Q:*X<G+
M%[[ZV.S*N`6'T)QMH5,E\Z7(TP];^VAH^M_/8!!6FGAQ0Q=&7^K@X<,<?T\)
MU$C]OOCA']^N<<DME:YF8-%)%8#X4#-#0!W:OOGNM2FC!BV?045^`2O^#S+B
M:^%5+E!J8R,LJ?]9,>M_B)V-YR81RJYI;<4G:Q?6-NH<>VT5A*9=7JE4_&X:
MS^`VL]EWE^)JU?(L,1L2<I!M-BAVUYPGZ#[8N8A"8Z%_]JL,_S?892E4@-F;
M8=\P!_ND+OPCBQN/M^P+ICVV,LT/2*EK-J$K0]Y+8.;WY&FMK-^)>BL56Z6B
M-%702D4:1'\0.#49PO')6D-X&W6.O4H+0O,V#>$`_4A4SP^@^F<?=Y@-<1"O
M\LY270APY<95)AA1.R-E)2+V:KE5372SY58UW!KG6EOCU+4U;KE5,[<FN=;6
M.'5M35INU;ZV\F>.9J^PE#$:S+G'W=,]%IGN@5E+,619)<.7K0=_O1W\)7]+
M\*$2R%\1`\I4;<@`Z9LT_MSRH!`/Y)XLC^7>0`Y##GN8VYMC_'H[_DN<M-PH
MQHU17FYL-:<SN/%-:ME1=(>H9C?_]7;4[A7%]=1$.EQ/)<?X]5;^2X2E(;=K
MH[BJRL60':HJC2&#XZFJLFWG,/VU6D<D/L]Q7!$97)'>L#^IV!V)HUH[#[\I
M/[2ENZR+E=YT]05%!\C%L3R6:F6CA^8;XF8]05/BYJ0_J'=1OCUNUA-4)6Z.
MI*'8<K-2;M83=.6:=C1^(]S4C%JYR:>K>=\<#B<U<Y.C^8:X6>.^.1X.QBTW
M*^5FC?OF<#0>MMRLE)OU[)LRWS='KXR9>%_[B\78E7=;NYJ`0=HLQPD7T*+L
M]_MEY##GQ?35LJ]&B[7?'U:E1QO`LLJ<CBV3U6RDPKM5Z<XM2+X1/M9HGO;%
M89VZ\VWQL4;#]&VLQZJ,TBV3U:U7^_6NQZ-8I,?B8YUZM5X#YVWQL5:]*E9U
MB%4]'_E=RYOY^6SF%?&DY^QSUUF8EO8?=N`MI]WC<PTHR=.1U!OT9;$W&`^G
MO:$('_=3I=E#;;_HBC5:<M0T*07IDKE7#<_2.#6(DC=U>67=/DU[;SM#)$D6
M)7%:QN+*0NFT^3#8DP\;[VWGPW`\&`U&91SMOD8VC*?C_CYL2'EOQW(H73_5
MPX9G1=.Q=M<7TZ*;D*5R(SEXW3H*%H8XF)9AC^]`K*2<OAL_^,PL5;-Q`K`M
M+,VP-96,CP-S^G8.7W;I@F1ALN$P;9%4@DI)JV5SGC+JB&2-6O?Z@)UC/!G+
M):R/+(Q.FPTU;>'B9"(.R]@Z:N="XBZ]]PN[M33UP'./8G-5N'"VU=J0>J4X
ME\5P?3O,+'_Y;6/FL%?**>3!S"QG.TQ,>L>6BF9HQM,%D-!25,=5]!)N">P_
M;]EAV5]OAW^)_6_2H(Q+`_NC5<GB9$$1OP?34?2XI5/FRMPZ4:U5>>6RO*D"
M"+YRWM57?OCD>1>I2EM..:GL<8,`Z];-+F]HM:#A*<GC,NW.%/1.GR];+<JB
M(>^<?)GTI<FD1+>L<L;$2\U^M4S;+H4Q*>,>E3$#48054^*224'P]#FSH84.
M+9^62[,=MWS:,2I`[U_GN?I$SVV>%O91JFH)U56-\K3X79G=OJ4,:;_$T$C+
MX]T\KLR^W[:.R[CHU/*X@-[.LXZ+)LYL7\>#EL>U\KB:+/X=NKJ,DM%-X/&-
MZZ!EA^UD*PBU9(Y>]<&I.)R6'%3)1*4R?I1X8K<Q:MT'IZ(XE4>EGMEMH'2R
M?!CFYT.BV'UQ/DS%@3R1RDC4?75L..4#[-?#A6%^+FPNAJ+17-!*%6T1%7.A
M\I/GG',=*8U`[$U*C(?DQ/5-,+.BO6@',\NH%]$R\_7EA+3,3*S,\C?&;<P<
M]$I)!3Z8F8_[9Z1D3YJ5D2*5DN"SQ[SE)_B,_QI_&Y68WK,'4@67IETTL^'P
M%5KJE'6=M6[/L92*!*=*Q?^MLKO>`]RCM,':1;B4E(GJN55PTB8L3[$W+K*I
MEDR!M\STBA/&MEM2_2(QMV8S?>MY107\SC]?,]9WH2N^Y2'_]KC\"G9=QU3_
MM3#U&;-LWI63$W/CZZK/RR1Q-!P/X@=F&T`<`'N9G7R3L$_ZTJ!_(.C?38=]
MUFQ5-VW0J@\`VR<=GLG`*./ITCVX_ZT[O_RO;O?SS<7#7[>7PL)9ZL+M[Y^N
MKRZ$L^Z'#W_*%Q\^?'[X+/SCMX=OUP((K?``J\CVJC1\^'#Y_4Q(D<Z'NP\_
M<"P17_;^[#J1-WLS9W8F=+O_^\GY!6&8:<_XIQ#YVP/MWE$LYPLL45S._`5Z
M:B78SEIG?S_[<O/]X:,@]E>.\*`MF2U\9R_"G;E4C`[_HB/<PXJ?_R)\.[_[
M>O7]HX"/]E<_SH*Q;,<RC2?\B'07)D)7B++D?RO+U2]_DZ>_")PY^,J'\!WZ
MN"H?,)S5>+17F1,\7/[CH7M^??457OVG:SO:?/V+L/>LOP@TWM7WSY<X0K\W
MU`P.R8TA_)=K,$&4.P+*4T=P%DQ`+:P8ZX`X-H`5TDPPYX+%5-.:"0I].%]9
MFBZ((SZ$H*Q6EOG,9C24`KR=(7_QP?2Q568!?IJ*U1OA(<V`H5>F17N`X)CX
MA<5`\=/K#MY&$`Q^D`1/\[,9_`L&7L(+Q%UX5'&BTPF:+2AA$00<U;9=)N"R
M`JC[G3[_UQ\/'I`WONT=FUO-D9LK0[A1'1.9@,HW)C8"HQ(],V`<D%$QA'-'
M^*98_V*.<`5$Q[U,N%=T@./\R6*TOPOOSG"8Y-=G[SN@O$'FA)>%IBYHDD\F
M;/O([\\:"*%C<GF,3O\./YS1<V?OX]*8(M@P(P[@K@0.K/($LS]YLOC3L"\L
M-5U'2=0,X8D2NF$\E;$9S:LY(+]<\&B)](0'F"84RNAO`GPI/#+->()?YD2A
ME6LA01R:&UYC.BZM)PTT$!=_V/H=3J&YIL,++YK#R7!_>8$0`5V!+GSE<AI9
M;*4KJH?ORF+/FNG:>8:&T6"</L>`J!=;_SQT)WS1#&(@KC;-<1CSR!U\1I+;
M-DQC<V"10D",%5AIVB/6]M7X\@*R:,"]#I(3FUT*RNP9[4'XR6:&9EH"R*?"
MS;\DAP$6GZ^"HNN"JJPT5`N6HMD(I*(ZVC/-Q+$)@5V`QGIDS(@J@\=U*%@=
M07FT<4::1B5"17]'\/"#2J%*:]VA+Y1_,?Y"4.3(>]<6#*8RVX8G\4%5L>`/
MTW7"`2,T]D'B[/%0UOP5@SC[PLHAB$B6#9HY)DSX1-J*ZN'*G9E()-L,5JU'
MG`T=:3/'4^*FR[D0JL='1K/R,5;\=A""!OI$F+D6SL`%TG;Q?PB,I0+8JZIK
M$3;XXM*KB<9_7Y%'`(/Q>7K"9SX0/FEHL$T!QL["!@4S`P#OV0H$&%60W$_9
MO3A11*DW"I:P!SUL#9'Y0#S!S<!I:#/X2>KU1XC@3W)/GH3`=%"*7=W!!V&I
M_"2#B1S5#0;0RM<,7.J6INW@1HGBQ.>#43GZ7*EE,4EX`>4@X%X68"AZ&+9;
M4'0+"NFSR7U8'RN=@1<(BG7E/NJ:RK4N5[^"+'8F@U%G.NQ'M'52FW?0]M!=
M4GR#CCB4$\_'UB"9',0Y,BUFL*6@_0(@,<\!13&9NZ"OO"4,ZLOJ@OXR'>+Z
M$SJQ+%`Q)",OE@9[*5`'QE:\]8'[DMP3!Z%LQD4S*HGX,&G*'^#S.$Q?"S]-
M![VQ+[C-%2=P#RZ-6=PYH$>B[H3_89OSEN%NI?AT5\0VKG)X((%B#C9@23_9
MH4.W\]'JKH&DIX1)HV3&:BXPJZ?"6-I)A?XDFF#-/Y$G'W\W1P&JT02\_\81
M01Y-Q9X,Z(B]H20-=DK$=%,B:(A^ZB#;22*+H.6FE=*$?DP<@,UVTR?UM:->
M-P6Z2K'P:V'PCTVU4[X*FHXU)<GG6G7Q)^LMG[%9+C4/C-42H":MDT*.Z6!\
M.#D>,.3C6FMZE<L^(9_R?:GA[53-,!@.!W($GQ0@#H*^M`!W!="']WDVOZ[\
M8&$PC`O2)@@'0%[EL4)AR'^WV<W\$@QM--.YL,2_:L\'JO92^'][4NB<Q,X/
M\!-;XE_`&/2K`M:0*\)_RGE^4#7@C7'2'W@0<J58050+I-8V=6VFH*\[IW"B
MINAA.-)&'Q8>FIO6$L\%*8KX>^^^)WP]/[\%5Q?<.HN"24%X$,.)&(-CP?JA
M"&%8/)X[YPKX_RJ/:`%(ID7!`0IM<3_9MIG#7]4U)8A5XN=9X$!Z&*"O36'"
MC'?X+#,OC.Q%#'>@[<?$TF"SV#,S7!X%9#_PB!QFF871,?X.?N*AN)YP3GF4
M7F0`PQJNCGA@"$1`&EDPN[[F,2\8P8Y0+QD5V-,7C^NON+I+'-''"OY&,D4_
M*;:FGANSSYKN.IY]O-^K=3ODP]$PVM)B/Z`;0+-JZAQD!#'&TF#T"FA63=V`
M=)J-)D-Y_`IH5LT]_'2:R0,Q6A+G$)K]>+1T[2/.1_A[\]%OP:]+LOS8K_P3
M?^3_?(C_1H-]"$=+'1WMS/2A-=L<2.+X(SRQ[\B1]*3X'*#7M1GSOHN]"I0"
MBCFF%?Q8%#!ZX\.V$2/3?6:&N82-<^N$NXB<G'%S4/_7"-X[Z4?-<+9Q'1\X
MB#-_*I@-YYPT;XQGY<='#Y'*>>-I$")BSC#'N"_WQL.(BQ2C-9@^?BY8Y%L`
MP\#L%3R*P1`7BP7!;*;VGLSG#Q=7_WWV*_B#6*QSA/>BDB\GA[49V5I)6LX`
MC!\K75,UYQL_^)J!70ZNE6G\_<S79Y]<6S.8;9^K8"ESK^O\AQ8&ZFB<`$S\
MZ$?J1A_XCV><5=_-9P7^>_[(Y_H_'U)!V&!='';_VQCY/"Q787'$*.[H]F'5
MDE]#E@5C![\E7F*@F*.O8,`C_DL<G,C4_E>>Q!PH1!NQLA.5HGOWT=9FFF*M
M\70:MD,,7.PG1_<,Z#B[I4/8&^\,MA6I64YK<#`<R_#W4#IUB;HR5'/)[GV'
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MW(!>(KF!_0^TTV`X>,OBH_S(+SZ%P&(Z9C+<@C"L*2_(N_#T:1W]9;]XX84R
MTW2E%?GB(O^V564166_EII]0D"<M.*TV:HQ4M?'D4XPGGY2$R=/1J#<8]\>G
M+F(4(XY=5[S0%;MX3".:66'?,\?1&?;1O3(N%'O1"E81P?*N.PW&PVEO*(ZD
M4Q:O6UTQOBO+XB85R=/#B_E_F47_?@$UQ2_Q&'B='3[AT.5[%8&RO8=I%.#Q
MWLK6'^"+:3%5L9UV$>RQ"&(QF'81U+0(VH#1\>0]XDBW\GX:\MYZ_7O+^XE;
MSXV0]%:D>)F`86\H3T:G+E(\02>2T[.?;-TJSN(/154U@]V;NDNQJ%:<BHA3
M:X'ZLG1CL.\:_S?04SS/JY';<6M^'B#L;][\/#%A;VW/O87]Q`V%XXMY*T\D
M3]*T-3Q#P?IM87]2K)GBM]*B)@FM/.65I_:FPENZJ7!2DBG)@S:E>X>$77B-
M`Q@.W"9U%Y>R4[^CT3!:2[&KXF'%DG&R8LG)T5HJ?H=:JIS6J?>\)GX7VS9`
MV=P`I=2XJVQ;BPVU=U].[.[+'O)5J[I*R%>;0GER*90G)F&G;GPTG=;>Q>=)
M>SKZ*HT/J=J[W3"\G&K+2FW,L_DQ3X][S3)F8Q5:_9KF8[&M%7"2M0*DXJ$.
MC^M'$;$V>'F2P<L3D[)3MVD;3NM86>\V`G)Z$9#B\E6K41*3K[;Z1T.RZ4Y.
M;MI2"(U(3#LQN6DCKJ<8<3TE"7M[UFFEM!:[8FH:P_CD:>UAUJ#P$8`CI88C
MQ38<V?QPI,>]QLH3?9(F*$]]+D\@7*T\;<@3SYC\8EKGLYG72I&W43TMV?+8
M?2S9:G75*]-5U<H39KG)73FY]PWZ_4FOK35Y@--9"*Q77-W-%[#F;,\[1+ZM
M&=A*U3Y2-8FFR/!/_.A&.G&'S<>L`*U]],NF=:3ANMA'\LJCT2F25S.PZ:;S
M:XA),+CW2XF4BK6F;Y,A3B(9(B8@,;55M8"T#?X:V>#OJ`(QFH)G*9[\G=$O
MFJ$Y[%I[9K,K`VCVI#WJ[)P:W']:DT(YH#CIK66N+(W!WK@^G_W3?0:6/#!U
M89BZ^;1^,[(BRG(K*[NM9U/7E4?,A<*3JR>+483CS6PQTG@Z[K=%,N+WQ6]=
M2UTH]A$*LQU1$-HZU\VM<WU<L6B+Z#2N@.-1!:*MJM2PJDI'E09IW!M,I)./
MT-X#'#,7?5.^9WQCSL($>_.9V0YEU6Y\R]@!YD;*:"!1;T9L1'!-Q.ET<NI2
M\T71K#\4W66?UL&?O\$<F)6]OL:<[+TC7\%X5\;*=6P:3'I#`C)I!:2X@(AO
M1T"D5H/L(2#R6Q&0]AK@J5P#/)Z,G/119>64FGAE)7ROKRTKT:BR$G%AF%1\
M;CWF)_PGF?$>I]2X2DJ%MX3I5EA[PG]J)_R)>\Y5"T@;=3^-J/L1Q*(-LC8Y
MZEZ_0+11]^9&W>N6AC9\>F+AT_H%I`V?GE3XM'8!:<.GIQ4^K5E`VO#I"89/
M:Y:1$XX#54^IH$9$_]0I56V@60QE:GK:E!(KEBFJU<%EZL17GX=)A93R;^*/
MI]QYEN7V\"+THJ\U%>LI!=GNV*'K^NE:F[-[56.&RNQKI^:;^3'IB%VRKT,Z
MVAH@S:T!<E3):"MXI$G&$2MX'$\:3GJ_K912T0OVI]C8+:14\J[\'I3BW\`?
M_S]02P,$%`````@`[8!L0W@,:FVL$P``W@,!`!4`'`!N=F%X+3(P,3,P.3,P
M7V-A;"YX;6Q55`D``XV8@E*-F()2=7@+``$$)0X```0Y`0``[5U+<^,XDKYO
MQ/P'CN?2?;`L6B^KHGMG57Y4:<.V%+:K>O<T`9.0A%D*T/`AV_/K-P&2$B61
M(D@3-%'5?6B7)9B9^642R$PD$K_]_77I&&OL>H31WT_,5OO$P-1B-J'SWT^^
M/9Z.'B_'XQ/#\Q&UD<,H_OV$LI.__^=?_N.WOYZ>7KH8^=@VGM^,[X3Z:(Z-
M&^+`WWK&+R??;TY^/3V-1JY<9@<6#&74.&^;G5/3/#7/C?\R^I]Z;6-T%PZ$
M/_V_3_Q_S\C#!K!&O4]TC5Y_/UGX_NK3V=G+RTN+LC6"SUH66Y[Q1[6''>`Z
M'/SZ[#JVOQG.?VTQ=P[CVKVS\,O-4$YGY\$O'3'6'`Z'9^+;S5"/I`V$AYIG
M_W-W^V@M\!*=$LI1LC#\E4<^>>+#6V8A7T";^/,D5YVSC;B9(_AOI_&P4_X1
M0'?:,5NOGAVS>"!,.I$30-DP0IQ=YN`'/#/XSV\/XTR,^?=GGY'#97M<8.Q[
M0%0\8>'B&=@###R-%<%Y^IOXY'DSS'];@=EX9+ER`)RS2EB8(A=3?X%]8B%'
MDI]5Q0P]^F#\2V##F\PND;>X<=B+'#8>LV85,W/%K(#S,J+V-?6)_S:F,^8N
MA?5)\60C3"KFZ081]SMR`GR'D1>X(592S,S6RSIXV7SXE6`7N=;B[0K[B#C2
M3,[6"[L.1A^PQ:@%4ZO0YV1VB]?8>0+N\,CSX'4`K=\2]`P#?(*]@D(`682<
M6N1X0L\.EF;,KYBE,5UCSY>WPJK?AP3](BHB5:LFP4<!A9"JU7&':#!#EA^X
MX#'<HF?F(I^Y;V#+D]F,6/@&<8OWWZ2X6SJ(53VGRC)81)F"SZH5>L]\#$OB
M&U>F%!>TZK4PR<%H/G?Q'-;&FP"@PW>$DF6PG`*(%EDA!T:%BR:]_E=`5OS?
MMPS1(B#2%9HM5RN&*Y^UDG+<(Q<43M:X&&M4)4\%WE>ZJOJ%G;AS1,F_Y7T*
M5C4#*^P*ZG((,+-RCX]9PH^V+]ERA:DG#X5GU<(+N`/!<B4@^@9?C>FUYY-E
MY#5LEN3)3/SU)!SXQ444HK@B5NY9*""8S=;,8_.J[3U=LE)OHV=5_C:F<Y?^
MZ?4K_V=!CCT(D^OA.5@ND?LVF85V,+(`W8*K&7#+&*J9W0=P7EQB@<F*@:,7
MY-I>6>Y=#]7$?X&IV[.JGKIW8E5@RL4+X`O>IEOF2<>LCD*F"D[M8'95,Q.;
MUR.94P+N'4R*(\MB`433=#YE#K&(K/J8ARI/-DBQ5VZ2Y.Q6/T]*,2Q^RGGX
M@LU:<CC%DTL\H5,U:]^\+VR-72JR.N!1"S;_FQ'J?X=_@&,-<<@E<YPP+I%^
M<X(Y^N<:5>V-%&>VB(5&/%=MHG_PMP6BCRAS(F>&+U7/@OM<%`'FI?(`2*Q=
M"^;8V/5X?":)BH<KYF-D`7&/A([KV+,8'S%ZEF(&,8*4PU)HAJW<H\N`I]3\
MS^&J?/K_PIC]0AR')TM@*G7'U$=T3GAZ0&0LI3B;*]#D'?)\[#YB=TTL[&WF
MJC^(O[A$-G&0%&=+#[U4/8?F05;`@13`5>U#9MA<`;94<)6KST+9.:[6NE\%
MOG]H!PY$Y?'((BP+52N(PN6Y'MN`-WAXW`[V1Y60A)#*`S)Y6:)T";9'2^;Z
M4:ZK1!@?R8)173/_5H1IX%H+"#ZG$",77@<\MEK5SG&TA\6'N8#\SEZ62&@5
M2TZ%<B"$G,H-*4.4;Q0%-@&KF;KLAN^ZWA"*J$60D]B%3<:X1<4)5K,9`2/.
M%P<B%BMP!)5;^#T>3WP'_J#=/C=.C4W,`__^/+H=W5]>&X]?KZ^?'N/'<UE+
MU`.$7.%7'U,;[%YP%?/E,"L:!3$`=GX_@0_^$2J^U6_W!BVSV^KOXI$LXI@A
M[UF4,P0>O%MH)2H_SK#C>_$G`KG3MAD51OPM^O@?N^Y&R*+#RS*8&R-WE$=0
M*:C-?YLZ*-Q=CS<M[K'?,GOGIJF,]6.DI01*&,/(C66;N6QY''Z?%12=N>`7
MB_(A_M^)\8+)?.&''YP8*Y<P%SQFL+\3(_"`7282CMO8&KG6@<GM%K!$(\X\
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MVW`D3V:]XI!T;V'D7R+7?0,S%:4ZK?Y%MZ-,I5(LU*CBPI#H-3]GKSX;9(#F
M!RS"];_,A:#0+7B-=\(O&?5=9/D/V,)@S"#M-_H,"X](+P=@V3P8[*GSN@IP
M4J/JR^*C5["<B"$NMP%$3]U<?DBP1IWF2*M7K)L7T.^O1Q#5GZMSNPIR4Z/2
MWX.39@%T6+CF;2<JB"=B?'K]?D_=FGV$<IW+M20`<135UD.OB8W&S;1U;IZK
M6Y$/"9;?F4J>"]E.NMV.N@VI%(I5V*"4%F)+S)-:KQ@0WBLWP'8*`KU!7UT"
M/9-L[>J4`D"OW$P\5^X9::^O<J,QE>9':#-'=+T"]BL\PR""_8#7F`8;>0;#
MCKJ"A72:M:LR7W2]HO)+M"(^<FXQ\O#DV2'SL!)GX_GT%=:@'*==NVKEH=`K
MY-Z:+/4OX2?QMU;;4^<599+]P'?V"`!ZQ>)7V(5X@Y>TIR!QT>VJRY8>H_P!
MFI6#0=_X:T3MPT,6')&.NN`ZCWSYV"Q-E$&GK<ZC+\F\O(W*ZB>VV!P$]`K3
M+MER2<*.*>(@FSC#B"D_P=@:``;J/(=LPA^L7TE(]`K=$GAPT?NU)((^6)%9
M,C<V4I.'(D6'*5*GK;YZ34][L5JBE`G\/I4>4@;9BBWZB!JE)&^L)1<)5)/U
M:7V%53ZYY.M3;B$D],I&W#(Z?\+N,IG-!B0&"G>2TDC6I\M<@75/->Q,/::Z
M;?YCE#]BWCTNOU[)!E'%D``@6?S=;9OJ5M)LPO6I5%)XO1SZ!W[0DF+[&KF4
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MO?$4`]+@]EA<7?@*AS];_0N5/D,!3MY1ZHE]3F'JLC4!A#Z_A<V=HX8R=!YU
MOQ4!7N=<8>&@/"-5O*3O4_.F8K0<>'K%/1E"AE<]'`C953==RS/2>`O)`T\O
MESQ#R*A5U;Z0"@\JR3/2>`O)`T\OA_]Z-L,6^*?7K]8"T3E^@"5[0M,!;`U-
MA4GN(IPTQTC*XJ=73B:^O^6)11W[LH_R@GP=A;Y7`4ZJ,))W+;&;%$%)]+*\
MD8^+,?*ZYED8V]X-H,>E@A?@#O&+E/RWR>R8R+VVT@X6I;AJCO%4@*I>2]+!
MZS(5%XGR0MBH`PR\).UA?5/,/OWFV$8AI+)R3II,)Y-99F]*;NS#^J:0(YPT
MQS1*HJ=7?"/\K*B',)<TT:N7=XQ163&52;@Q)B`)CF:>:,*NQYX7\([$XGJC
M>!.-6[/"X]"Y]!6J7RYL3YL!\I'2JVAG9W9+7&MW_8I=BP!87#:%5;"Y]!MI
M!?E(Z97_3,KV@%?Q':.SW1XEJ7AUAPK/Y93FJY%64QY9?5>6W8K57KLF8ZFZ
M3+=R6\C$12^W,<N\=\7K#L_K64&R6&BD"4CAI5?"(2E27+.><0X!C/["5)=Z
M*,!)8XRC+'J:I2,`JVU)C]@T5G=L8X>60D7+U1(D]L,R$-#+;;S"*Q=;)`2+
M[MSZU+KH=-6]W4<(-T;)DN#$&M=$Y8\+Y.+/^[<SM\S^4&'KW72BC=&T!":Q
MEC7QX+\@0OG<-*$I&<]$NK/=5]A"1(Z)QEA!"<QBJSAP]ANZ<N]OYH_I7LLR
M/L\=M*1KF6:GK:YDJAQ3C3&;"C"-S4B3(.%0XKAO];8_*A>P.U"7?);BH<$V
MDH=85MBHS<0275<1GY2-KJV(KR"-]V3-KL)[LLHQU6"C*8RI9H'EH<1[#2[X
MK-FM<U+9H]]@VSB&E%X[6H>R"?/>'LC>7T;5E=@58:7!MB&)GUY-Z3="`6!A
M,B::#\5-=>I.6F;2;8P!R"$3:?M"D[6!N]!8P);(PTQF5\0+G6U8!6%Y7))@
MZ86U(2(/V^KUATI/99;@J3%V\GY((QL::F)#VPA_VU!T3#W?#81D`"K(ZZ-7
MB/%[`X7W[DJRT1A#*85;'-0>]&)MJ'$<+IN[6_S<L59XM#"/?&.,H1!.674/
MVMC`X<TO(-^YPO[W,BPTV!9R\,HJCM#UK'C7--OGQJG!UTR'>8&+X1=1"V!$
MV3_CE]%\[N(Y\K%Q$_A\Q!VA9!DLC:E+J$56R#'BZG6#46.3:39N&:*_&K]<
M\89%CO=K+$+^:?-D,<*&>D@\HKTA'5.>T`U=3C:BN8M:@1/J_!DC("S.O.]2
MC@A>08QZWAFFGH^B((UX/]K#3EN\'?P3N8=*O1LE>7[`2U@)P8(GLQM0.'+^
M%R-72)%67EU:BE0R5;SS9;6R[6+X?H3TVB"70FQ,N91/+TP(FK8TO,>@-T_7
MPP(R\="K+JZ(H*#C$+.T2+,"U?/GZZ;\`TSTJH/+%_4>5L.G%^RL\1VC_L)K
M@9,T3*N#*FT`^Q3T,(&CN#2N#/J]G8)ZQSL%3>ZF#]=?K^\?Q]^OC=O)8]F.
M0<EN6H>%<$4Z!QWVY=KTY!J80W6U($<(E_?8M"Y$+*2*'ZWP4*9)W)0G)0$[
MWW?)<^#S8.:)35'4DM<TU>T#OI.[#[..*E%MW%1=RIZ^41<CA_P;VU^98Q,Z
M3Q1Y;1H$C%SBP5=7\"N=AUU/-EB;G8NAXKTD!6Q788'5OZ)Y9EJILGZ,^?"&
MN<`W#>]HL=Z>7$0]9$45R>*W2('V/X-P?T9.->VANMKN6F71T]+5J[5QT_=[
M/>WN44][,KU^&#V-)_<E/>PH[7UPF*B0:^V)+=-HK]UK#;H#=5O/^]3*.]%?
M,`79'5ZE:B\AEO-\5VSP;6H&VGV%DT4.]6I<J3S%;/8Y"T"AU_KR@#T,8WDG
MMBN\Q@X3F?Z-7+V+"W6AWU':]2I8'H;&S9\Y<P\%4[7\^+9J`*0U.%=8^9)"
ML%Y-YDBL5[)YZV[P8\7A99(!N+?;5>DSGH'+$(X#+P![=X0*$<;4QR[V>!>C
MW:>$7;WOL+_@/1RWU3NFV1ZHRY+4*$GY%6^SQ[V32ND-U15WI%"LXG7Y6+O9
M.+DY<.JU4OZ$-6+-,*/W%)EI,\^':&T<#K/?4UF\OD/MQ[&48S!J=VXJ%GB3
MXP5Q+H8JK>*`XH]D&<?AU.NNF;B.G\4+[+:,?WBA.'^70O;',1,I8#4K76WV
M7NB1L`>4','_&5,\X]<OFBJON<N@6E%-[5$=),IF<P5OKOE5"D+]4T%CPY&\
M70JIJ'6;'\G.I&C63#]*\8"T?;.O,DT9DJED1ZF0KE(%U"NRB=-Q7GS\>-!I
MJZO/V*=6A<J.6-E^SC%-R,;.*@6V`RZ9`V-8./OR(L#4ML$9]8P2CZQ)346%
M:URJ_YU'4MJ#PR,I7QBS7XCC&(C:AG!_#5A$$9T3?D0E[!QA_/)H+;`=P`=L
M9HQM`(W,B#C#<C"VU+&4F(FX8<7VJ>%#8_*369+X_JCW'DVY(130OR5K?MQI
M]]$B7&R#QZ)LYCI.O+PK?>2Y7URQ^K0[;7475N61K^+-+ZRW>#XHA(U>\_@1
MT1(W\NYT+N0XJ4M;%V>HJ:8A@U_S8K3W+AW=PZ4C<5>&6!<\B_&9W1A]WETP
MI@&LN<C#_%BCA4LM$`E2L`9$A$;/VW4AIB%(O'<A^!QXA&+/NV3+9T(%).#A
M><2.XD]1AQ4VU3%;_>Y`71EH$4[*KQ$'5R3%9'$\#W8[G1KODMHC7\5$\#Z5
M9MXE=0PHO1:,`@"%N90XU>+Q>U-@*J2VN$"%G^ON=Q161E?(:',,2Q'Z/UP`
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M4LK7ZVH`!7`EO]B]MX?#I&X[I%91_GPWBB@[ZQZ$AM9'5IO]2KNM%,!1>&94
M/?]_FG^N6C6[#:)*<%(O1HFO[[W"SZ"C[KD>"T&N*#_]FU!(V9I=;Z$<)^%#
M\NV0QFT5%I3AS]=`2KT-O,(CL[0@^H+_[QE6.?CD_P%02P,$%`````@`[8!L
M0S[.M4]H(@``<S\"`!4`'`!N=F%X+3(P,3,P.3,P7V1E9BYX;6Q55`D``XV8
M@E*-F()2=7@+``$$)0X```0Y`0``[3UI<^,VEM^W:O^#UO-ADZJU6H=UI:9W
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M=FUG2=_KC3[X7T:OLGGV!GX9\G?[L]GL`_\V>I4822_20?L?_OOVYE%;X34Z
M-RQ&)0W37Q'C%\(?WM@:<CEI8S^/0S7\$*&;^@;[=!Z^=LX>4=*=#_O='T0/
M03Q")GF2,TKE3L>GLV.;^`$O.NS_WQ^N4VG,OO_P"9D,M\<5QBZAD_(15@Y>
M4'F@+YZ'C&`P_84_>8Y><U\W5&R(L=Z8E#@?I(!PCQQLN2OL&AHR!>'92`;H
MT:7"OZ9@D+O%)2*K*]-^$:,-L;6%9&`^VYK'8)E;^A?+-=S7:VMA.VLN?4(P
MZ0@;DF&Z0H;S&S(]?(L1\1R?5D+`++;K.F")'OYJ8`<YVNKU,W:180H#N=BN
M]#H`?<":;6E4M7)^WBUN\!:;3Q0Z/">$+@?*]1L#/=,77`.3@DC0:1$R:\'C
M"3V;6!@P5S)(U]86$U=<"F6OA]C\15ADR&9-#(X"##%DL^,66=X"::[G4(OA
M!CW;#G)MYY7*\MUB86CX"C&)=U^%H%N;R):M4T4!+,),#J=LAGZS74RWQ%?&
M3"$H+-E[81R"^7+IX"7=&Z\\2CI\:UC&VEO?4R)JQ@:9]"U_T[2^_,,S-NSO
M&QM918AH;=!BO=G86+K6BN/Q#3F4X<86%P/-@H2IP'JU-K(7[)VS1);Q3W&;
MPI8-P`8[?'8Q"MA]Z1:?K7$[6K^TUQML$7%2$*T66*@YX*TWG$3?Z5?7UA?B
M&NO`:HBVY+L%__6=_^)7!UGT%%=$RHF&/`/;BZU-[*5L>4_&K-1J))KTU9@,
M7?+3+S_8GP4A)O287`_,WGJ-G->[A2\'<XU2M^!N1J&U;50SN`_4>'$,C8HL
M?W'^@AR=E(7>(:@F^`NH;J+)5MU[9U4*E(-7%"ZZFFYL(GQF-0&!*JC:J=C)
M!B84KT=C:1G4O*-*<:YIMD=/T];RWC8-S1!EGTV0=&>#$'CEE"0#5[Z>%`*8
M_U_,PN=@UN+#*>Y<8@X=V:!])U_M+78L[M6A%C4'\^^V8;F_T3^H84W/(9>V
M:?KG$N&5XRW1'ULDVQHI#FP1"0U@EBVBO[/50D\?@>=$3`Q?9&O!0RB*$.9%
M^@&([UTKV]2Q0]CY3)`J!$N&8Z[1R8GA&Z[71+/9&_-G(6"0;2!PLA32L-(M
MNA3RE-+_C%S2U?]7V]9?#--DSA*J2IUKRT76TF#N`>ZQ%()L"<#)6T1<[#QB
M9VMHF$2ZZG?#75TBW3"1$&1K@EYDZ]`\DA4P(#GA9-N0*3)7`"P(J'+Y6<@[
MQ]A:]U)@\4/=,^FI/'RS",B<U0"G<'&HKW5*;VKA,3DX?*L$)H8A_4`FCDO@
M+L'Z?&T[;N#K*G&,#W#!J"[-OT/AWG.T%3U\WM,S<N%]@-B;3>T0!S$L]II#
M*;\7R^(.K6+.*1\/A)`I79!24/EN(4\WJ-3<._85B[I>&1:R-`.9L2AL_(Q;
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MCV>#;H_]<];9.(;MT$/[QS/ZP2,4<IO'/';NO6`9E]1(/C7H*T+<G6^IT#-K
MF=H*C\C$CUCS'&[M=,?]Z0!,7E.G;9*I0L0(^-GO3B<C]?@989V4C!4H0/W.
M>F"8L502^L(WVW+"CY\0,?S#?9=+\`B&_=*@+*_6(A`^O1[O!3RG;?[#((P*
M4W`J9((@84'`"46X<@I3,UI%\K5BK@U;>"T)(#567D2R4<RQC;ABZ@YZXQXX
MIB*0R%P3Q9A[)/`%"0<H]]D'(0BAG[X;H8?&5$&AGTH1^BFT"9Q]1*W3;*('
M7GSMXC6AF(_ZW9FZIE,$J80U),>D4)A8XG8FO!&6+F)'2U0B7P[W+-]-]`L[
M5&']XYGK>'CWT+9<_,/]8G+E\/&,X"7[0^J:/W+S-KC*@<[']:_RVH4WZ?PM
M?G`/9'*HIE<E1IPL;(:]\01*@L1`:(UH%*9H("`7:@I("4L*6M-(,T&S$;ZV
M-IY+N*W9O^44[`[Z0S#'>,:\,F6_%!N/]NQ,VD">'"4*=`R'P0Z'69W\';2`
MO\>T43M.D(3#,,)A4"M_ARW@[S%MU+98>"Y2]B;;I:IH"F;Q"@`@@>$E#;.0
MTP6IU+C*_NN'`YI00^O/`M'Z@7"T?K\K0,=>=/@RZ`P[OEG809;>B5%.7B2_
M4C^"PE'^F`?M<84<O)>'?6DB0B)E,0*S[46!*&^N!84`Y!&[5!C\;$I6DQ)J
MM>%LG!#T3\X:RQE,KENS&%/"=2V.;DMVZ>PC&#]S?;?L9X*=K8\MW;CV%Y+O
M!*+FR1`\_"D)V/+2GB(TW!=^,>E-H"B0,:_,50$E#.'J$2-?JR*^U4D6<VGT
MAQ?@#FZ)`$LXY$N5./5))SU$`"E^1Z<6^<QZ>P$#Z0R!M@S5T@<Q>YT50QW-
M?&#$DX<#[W!0CLK'ZL[&%_#N0ID0*ZT9LOP90&QKB0U=$/L4Y.\QQ4Z_MC2'
M#H<_8___W=EL!*\$(#%X+T)=EJUJN_MR37:@++^J)QX)/AGX3,WJ/IGL=5.$
M>0D)NJ(T4CY5,9<.0%E["@@Q?.9EXT*<E7\H3B,E4@^KN>''QT5SL>JC,G[T
M].:OA?WAM^@/VWFBOR)WB\_XF?=\YNS8U<YPE@Z'_2&4ZA6$H?S:%)@@$#R*
MYJA!-*6MSK)L#5=J&8HIO]\4(@J0AE9-UIM#LQE93]B5RE!,B6U)IAP`'67E
MRD$BHI>VLV&-X#`;?S=L$/KK#^"<=9DSUR/8*2P,15N4-HTG.F37.'L:/\E3
M/(YP&%^`%:]G3*L$<X7(HK:O+M:W)[5TVP].7$S&([`PKB@4H+OR;H\"0E.F
MZ9%S-BS-U@)[\@&]VA">%J'+SA-Z,>V![<N%("DO]NF#!SW16%MKXG;'@QY8
M!JH@##6)?3I[\YM8I-%,[=V[!%6`,@9J$OJ"VJ]!9&7E/51C<92&5()N@>B/
M6I^I\!;[^$#KP^.F/G2`D8(J,!V%KXY-R'?+P<ADBOTKG8FB-8"KQR@&2@N$
M((>"T?EGI.+>*(P6NUJ#8D6-W:;E(G[)1WO$XH!^47'IL*$>8-4B2K/>\#"B
MQ)O*GW]B%\5TXC?%='Z*7>/48?<X=0RKL[O)B55ZQ(I"Z"<^4B>XSZD37.A4
MJMP#^EJIPL&NSWB!'><`'%8YL(S22:XMW=@:NH=,'J'D!`UOF?OTRDZD[$":
M,`SONS*<]:$\ZL"PES=WT\<-_%>CX6P`196\R25HJKJ%)M1M!>A:3^2M2C2B
M%B("Q6U;OO*`J/)65EY"\+L`7>N)`U:(>3\P:OE).<,Q6+@WFJ6\,/,A@N@%
M!74,"JJT*$XZ>4-A2L9+?8U]@!F0%H$0'$A0H00G00LEX]4.A1,'&^C`6I0=
MR6$Y_S[I`-SA$,[1MC>3+/E)(7,41$O!3NUXP2WZL0?U!,SGL3=373Q)P:XM
M<?J=F95BE9$@MS=NBO%K=0/7_70*%N"6!F7%S6BGUH$0+;9KBCKB9+-V;R,[
MH$D;HO6U'#^`)$2%,VO3<E<?_R)IEA]DD)=[DD?E-"+OO/"CWF0`%JZN#)Z,
M@+T4400/Z->QNPD4_\@5IN,L`'G,>#/]#&31'2JKK,E%7';N>(B)7%M^8?#O
MV%BNV-6=6^R@)>9??D8NCN)3W?YX-@%K8U`S,@IIA(0C4X.<5?Q45I8P\9;/
M82SVP2!_7CF8W;J+'4Q<EE8>.!`812[`&D?6A<4;%?(*O&Q!BP-(BO"%#I=A
M#0W^.Y?G./?4[A4/O[1]GR*C2`_,WUX7%N]<K!-X>9CC_(:E^\N/#=98HA?S
MRF!+#Q?ZJ!UBG03^.Y+G/.X%@CQ^1X+\FVW285C#J7T;;#H#JTJN#X]W*-JY
M_`QD?/)N99S;9>IYF,01>/=2'>=@(,[3=RO..WML.FNS5+\_ZUJ8GX&,SQ26
M\>,BBB.:/!>AR1-VUGU*@_X,K-`,#NX6R#`XO\*(5N\=">V5[2RPX7H.YKO4
M8#@;)7CO4NXPJ0&B=RB7Z2P)!531)$.Q%'\@U2BE="(1K2_KC6F_8ARKG0M[
M/4WA7(.ILTI8$849%<J[""D:3X2M6@9ZU%@TO0ST&[LBR36V6&(I9S1FU<+,
M>Q/1P=8XX.E%#ZX`?G^J"L57+_;_8H?_>T4IP`ET;6E4:])/;)+8W5,)FB1E
MFQ(<5<+"RB%Y5`M5',W&5U7V18D6_F;X_T8(^>IA'YL+<::)#%D?QXHBJ':.
MPYX:O_<<;4654!R1R6R2<+=R"J=R1JN/20704CM*'^+KYW?WAF#U[_&)RFOM
M)/8``RRM'#:3U*%@I2*H?L7A,7Y`E7QPH@0,,*`H)10@IB+8CAK$4]'SJ>CY
M5/2LLN"<BIY/1<^GHN=3T;.B1\]'#5N(0O3=(ANL&0L#ZZ$I-!DGG#EEE7FE
MS%JEOLT?\LIVL(:(&W)K,H*+_B5.*2-"(LR474%9#O9J:X93Z7W!\]CN3`.$
M:^'C8].%T"F4:4,-_JF?0L%^"BI7H+O(Y7B'&IGC,.J/!V!:*6G&5O`XCU81
MO^7WNSYU'#AU'#AU'#AU'#AU'(`BS3>/'0<"<2-SSUU1-O\3ZSSQ&NS@+QU<
MA5:US%QB$>XH[KBHV#`A<->PI%.>TI?0YB(KRU+.S&]4NK))K':L7THC#M9K
MX\L/:F$:!-\[AA864=W31_1]3HU);0(G`M+;EL2B3'FCM?9W86)S0`3>*^:*
M,I"1YF[!J<3)D!#;`9+-3%C>ME`*L^&-UL8'9+CS7.(B2S>LY;7E.@8]C&M!
MCZ))KZ=>1YX\L-^VT`IQJP4U\&6*1(Y)<-!GZP$SX.CS2WK:=9#F>LADUL^`
MFM6#OGI5:.41:H&0-\?A%I3'5R!.L&TQ7]"^!O!K]Q+,6C6D/!WNMRW,8OQJ
M00V\'!H(+N@^7]!M$&91A-Z-E)?A<`O*XR6<-*+^H$^VB\Q#^VV<6&2BAK4M
M@D$+!+Q&'BI>/!_5!F%G:V@XF3K?;&N+"5O*C!"$8QS_GET1_\UV_P>[#UBS
MEQ;W8,\&?;!(#!C4:LMN'<Q2O)8>C`2!]\=V@D?LO3ZC"UCOM'I1>:>2G<?6
M4-S?6G0M#"S.==WPP4\(,4YGZG4DS@=<;4FNB6.AW*H:O4M/*0,J'BJ??E<F
M'Q\*B4KY^#DR+\22PT3V+/SK*;&K4"F5@3)0[6.]4@B%1#-2F%#:*8)_/?5Z
M.86>57OKC,1[ZZ1^P_ID641FRYWDI\$\5=OP")E\<Y-+&?WK;G%HU#%SC^PV
MY/ZT-X)*3I4,JXQ<7CD@A:FD?3#2@4`L01%!B]]QPB\,Q]Y,\B\(0YH\NM>A
M#X(YL)X,0J"JNZ,97-1;#`155VS"":XP3=5.T+VVZ"Z/([OK)B`/M[L&XQ&8
M*9PQ;WEY3QDT,`H'XPE82ZC,F25(=Q$VA9(J2@WU>Z'D8@]TX&Y*2.M%ISXA
M3?`DB%)#^;XK`H@`;;'5V9J(T`,FF"*_FEOZ9[S%IKUAHP?[6]BY8`17)"0P
M/YS,IK`MJGLN1!NUNSI\Q19VD$E1F>MK2BGB^HUT][$97$S`6@D)0=`8KXO2
M1VU[#_#`"=[/HVX703E;!(@,56T1T38"D&*1L^D?T%"11A)5G;>#`LY;;[U&
MSFO'7G3\?*+.7*.JAN(LTVWK3W*W\*<(9SCU33_U33_U36]UWW0(37GJRWWJ
MRZV.(^C4E_O4EUM2\L>IE^&IE^&[[64HL;[XH(YGKW7#@VV:"]MA/Z2FR5B]
M=-+2Z%3(T:@'5E9D`M=-NR8DFLSEE2?I`$7]HIQ7^QQ77C''&\9$I58Y1)E.
MF],_\A!Y9TL"1@(4=]%7)<I1$6*>NDARE"BR,@KA<EH<<N2@Y;W?\NBRNRI8
M7'/`MH6I$9O3&I$E"^^B_5Q"JX9CM0';@`,>B7>V)N1S_HWVOKLY=7\_=7^7
MM=#3A>G4_?W4_;V1[N_'>P_;7ZZB_:5!CTDID!5:WK#^OV0V*>/6>`LD+FZ%
MM?S4+$X:OQ<%L_]FRK8B.P)7+1L_2\\""/,QQUH>&2CD%O[JV(0PY'O->7&*
M`_S^!#:':\IL;\DBR],J"?&P_MES*,5\+/PN/;$,OL@KJW?[D\$8K']8<7A:
M*'"5:/ZV]^L$QR9;3$F)S&JHP`2`6RB1L%Q[-R[GG<$"J"%E@_O^Q#638V_4
M*7QP*=L6&2;#GY+:OQ*&44`].S,'ZG<DN@7XU_@-*55JSX:]F7CE&7<;5Z\M
M\X<I74/V&2^PXZ1R]'?#75U3`=D:NA?TOXQS-]Z\93B9004C9`$I(VA3$98P
M6#"$BVU)!56"E@(3L>,@CF3FO)E(CEP6`&VT*JUR22795"`^T7?^I#L<8#,'
M,+"56_Q)1DD=/%/\$)@3Q(Z[9<+:<Z[JXK@.AW"1Q\KPM4L097!!<<]K`JYQ
M@S^.*[N`Q:<V(=[:?W:,]Q@NK"45UK9*HASN*.Z_S5F!#YBXCJ&Q1I*,`OZE
M%2E+D=TRF^`&2[OL5][,;14P"816VWM5D:J?7I_H="E'%%;.VA_.P-HT`,->
MWN).'S>H;Q\-9V`-4?,F;WXI%A::J`&-.%W5;T%1"Q&!FD2T?.4!4>6MK+R$
M_AP%Z-JBCAWR'&O@;3MJ\WHVIZN`:*B"KA+M,`(BD.$:KH^);>A<(J;1@$[O
M4G:*1+0B=^'N-!RT>>M/>V"^VM19):R.PHPZNNPQ@Q2-9Z]6:@K:[_7ZAZ'9
M[]W';N>KO<6.Q99M9[YT,%_?_]'YNTUA[/Q&_V:O(HO%;DTJ.[;#R4G*M`;]
M3G9S15/QB8)YYI:^/TO5_J#QXB4Z^#?*G-V3)_H701J?*&#V$*ZS>$%0RJ_J
M7U?D$W)T%-YISGT/N_:-21U24WPZ&2-)6*L5>1.N7$%T&U^\0CSS-<^5[>QN
MW/0#,SN$A@ENXAS^Y8RJ'B\+D$'M*,&-H;%V[9&R8W;3S?+&6.!'S<"6ALF-
M&T<J0?ND\+;`R.KPMR0YU/:YWR-W]1O2-,/"C[;IQ<G`NN4FQ!136)H^D#H<
M%$-6[6!QS,38XF.Z:"E?QXD4"Q#T+BZ@\IAD`BHC)40"/%&+_AY\\I<L<"6L
M/E"1.XY)`3#JS22"R6<%T(%!C=6_.[&%!O8#UK"QY>+1[TU&4[`+>C)F5G))
M)EWC(T@]M2V<$';R@+?8\G!W,NR!72QV.%E;6)U!)+6C^NQ**9:H<$F_,#1D
M/CD&,GDB(#\_)ZSO%/LU?:"V\%",%`$[)VJR\_N&$LUR@Z-6X)#GUZR('RX3
MQV@+$W,)$/!OJB;_'NQ79+JO823E'COLTIR[Q97'/*3WCJU[FON(3,QE<I2@
MAU.8*CYP6SA=CE0!^V=JLO_>=BD.5.U0\+>&CO4KCU>GW2V^_'"I+4'U4:"<
M8G=`<A45H,_/X0G!FS2G0]7YVB(L4@D;GH84=3N&ML@3=M9\YQ)7_?&?MH6U
M:>B&7%+4Z9]\G^M>`(SK+7&'O\"(;>%I0>(H[G$\LB>O+<UC(6J&0U\\(I<^
M4%OX*D:*QFN@LT],__`H++?87=GZM;7%Q&5TN'NQL$-6QB;8+]`2=V?#`9A_
M2!B*MHA&&;*&*KZGIJ1D^7^HW#L8$=P=3'I3<8--9,BV<+PH>=0.]L8S67;"
MRN17__1ZYZZH&/.HIOB136#$MK"Z(''"0UI[3;>=_$Y[(_'E76#DMK"^)+&B
MQ3X>C-23@./-"N/8I93]Z03,0YX]=85TT(1Q[RP<RZ5*N'(AS1><-98$P2U(
M_G03(P5%M=/%'MA"]&^`'(Y'4,5AT2SE18H/$5"7@CH&!56:<*63-U)IB7BI
M7T=V@!E0;1.$X$"""B4X";51R7@I7P9U!#;0UE:4'8G`WE(.K;UUF,@VA+N1
M=&\F6?*30N90@M*P4WO'ND4_]J"&R[/?FZDNGJ1@I_9Y%2I?#+R^L=;$/I%]
M%`CC8ONH:-T@&+/W]K@#XD3:::1ZE5\,98[#:#@=0S$X<<9V,3N/:!'CV2%>
M4<;'&J@ENJ#3#IN^C$\'-:B\XH"U2XPDL2"2MLE;EC:@0S2XM)5VI`$A+,&1
M)KJ`)+`ZRX>52##UW1'5Z0/D%E!W*0`AW(*ED.!-$2:8\@Z6##,*M/57&=LS
M$8$R]85`F$%4VHNTG<CC7BBUI4FEOD+/(`1H'ZU&Q1@(,Z7$.$'YEB:5"LJX
M4BN5WO2XE0IO'+.R38H:^?>.OS&5Z9$2'\<?I6H/E%.P\!0L/`4+E1><4[#P
M%"P\!0M/P4)5@X6(-SMGU@D[8=\M8A9><-R^F`P3$L0D.61RIR^O`J[O[\($
ML-D$[`J0:!89SI3BS`BE+PE9M;7!(]9L2[_WGDU#NULL,+MR-UP\@W%2FF7:
M%06I`S7+$C$$%5</WC,Q=`,YKS%"^,?'P>`"+&*1-FMY92#*1RB,Y.BY'%D5
M9E8DHD6HHO[))H<`4$&%YJ05"B,%I#7AW%2(*LH?IW;XWSE)`8\8MI]>CU\.
M7_/C[Y1D8.E*,@%]5ZE9D`P62LI2N/5ZSNH'%^4RJEH!=HN0K0TY>8EXW$0E
M9Q29"5@CR<RI*^S9TOD/3H":]'D).R!=%(Y7@E1ROYE^F")DA7+J`*VP2WN]
M#FX;Y5>3D+E'.>ZP:VZ[DSYDQ\[4>6N2_\3F."+$4+L!90SA>\?06`$YQZ7;
M'P^&8`[[M%F;XZ4('=1N-LEAOR;$P_IGCSFZ_+[^OF1^PR_\*]+M3P9P]=-B
M,#3(Y<(T4KM=3@H^[-Y=O(?.%.[^;1$0E.-X.H74;D$:][]X;)C@EESBHWAM
MQ?PQ3'6-ZU#AN9`HH=8+T4OM3I;SY=+!2^3BKXY-R+UC:QCK)(9K=]@?CL1;
M2N2.UQP#"Z&J>*NZG;G(U<_.6OQN4;CO&;"/*VPN'O#2(*[?ON71I;CS-KLL
M8"7>K[#:9$K8U!6)I'94+S@"4RV$K)VU.5_;'L5B-DQJ*RJS'"%YXN;8+DB.
MQOM+5TMNO3A.;IUK%'/"?]&Q%YUKHMDL<;4S_]3YZ1O+^F5U?S^727>-C7RW
M",>=/T>#5DU^_>01RE9"8O-P+^AD!%9&ES)E>7=&TH#L3P>'A2Z3"5A>;^[D
M$I:C()/"95B`'NJ'HK-P!XK:-B2@-6)3IX`FQ)\+T$/YZ',"+KN-<C*>004?
MLN:M$'N)JA`3QB>?7F.?PGKU'AB*18&!$>14;AZ7YA>FV9L)DN32#<@.AED%
M@3+2[SR7N(C?@N#[&WBOW0(G\K1QZI#4I&.X"%YJG[B^^09RW/W#>J).$CQD
M*4Q)&*$A=N3@HG;(Z;M%;-/0#!?K3^RPX?#,7/\NJ/YD"K?D,R9NB(^"I%#;
MKY495(EO:,S-/F@F]A0'HR%>ER*3VB''D`R7]OK9L+@K[I(B8%"8^0?N7*<"
M33>.,.7#Q11;-]!9<TOG+A]FVHR',[!L"(EP-B0\,)16.[@97C[V9`?61T@$
M3'@PH-N_&`[!-HN\V1L2A")$43N4&9J45XQ"^,;8LG`<M2V7!A72.47();]C
M8[FB>^-\2\5\B;\3O/!,=J=]=S3M@7G(JP#6L'E>D9:-N]>+[C8/6+.7%HL.
M7>OL"KJ%@2*$0YI0U7=#'QLF)27=:*D67&/]JVWK+X9ILNCAA?@]K!`@J+.C
M2*6FVA'TX"9AJB['_7%"5%52*4,P2T,L3D)2\5N=OF'WVM+L-;[A>]EP,`9+
M7-J;JJES?!JZBM^O&,.1'U8OO;5G\J@BW4WZ8.LI?=HF]]T\.BA^HVG<R;Q+
MAO)]$,/!I)>0TYWEM$P>J7G^9.$6<DA1A]G=AI_RK.4-N\B)^'<P!_U'PO/`
M[G:W+LN'`C..B\'2$-O+$RR4!$5=;6+AS_HB)B7"P5F^^?ESU)QADG2^R_;+
MA[\&BDIGTOG`,9^$B-JM0$ZM[$ZM[&0(SJF5W:F5W:F5W:F5W:F5W;ML95<J
MH0G\BA>)26`B>V`;&J-4953;FY]DY9T"\:]*<G!-W,RE"J#Z*<+:2F48_80R
MC%M$7.QT'K&S-31,.O,E/>HQ/T'GQ7!7G4ND&R8J4X7A#QR.&PW[.QW5'_34
M@[Q-]O?IX*:`X)P.;J>#F^C![3T?$A0]N#U@$[E8OT>.^QJ+RMQ$7OV+T7`*
M51F2-WEY4=L982ES4$-L[YO`$J-,`Z^"*0"1#-$MRN#C>IAR)'PS13%B%`3+
M6H%:(GO&<&0+\PX.XKW&DP>I36P3U7`>6FI[;8*0Z),=I\"][3"(6+\4^M<"
M^=E=(_&HG."H33*N!.)JE]:$Y\Q[S]%6B"H]#GI"1#BUC__![YOD3B8R:A=&
M_(K,12!<5[9S+%%??K`V-H:U?'JQ;PW3I-]RY,1S;4K,T"0O*Q)$\0*H4%`=
M>VOH87G/TPK[%3X<D81C4MX:3!Y-B169CZC:I25BYJ5_>A]=@/4S$0>C@O<D
M-E+8H7]T,:@#)6E-(BJP:Y<+G4&&%CCK"E(`RD76H,#6@%)C`IOD'<PB@_I.
MPA3H:SBR5LU%],,RH4^-[FCB#0+B/Y4L12E$C-KFI0"MMB>P@K\'/&=`MLM,
MBEJ'RBR0J]9%@]55F)ZD)H4IV(8$A3;GE$AA;'IB2:NS#WJ3WN`P^R"LG^P@
M2^_<N2OL=';ENQV_`+/S4TA?WB<R5J!Y_&ZI?I$A$'-+YR`<%A#OV!N?_/"M
MJND,`I7,L7/J!"Q.5`0.&3&CC'F"=3*9PEU'(PR&!#51A</'@:("='LST:'"
M%&RN48*$-9(Q>M#QHC>$:P:1-WL3"R+!_B]")+6#41F8S#7-KZ_%^GS-7,C_
MY&T+&&X#L*-E<7C4%PD!0JH=Y\K`[1MV.1Y@>4G9<ZO/_`,"J1U:R<#C%OUA
M.Y<F(H3=1!OX1P;#'EA'J(*PE-_QGK"VLFS37KZR7EX;9G@$GIW1L`>FZ%)G
ME2#25=D8BK4(9=1V>5W:)OUD^UW;HEP1LO/<)74T2[WC(V,LA;@FC+/:ELF]
M8U.`Z/G6>9WK?WA;9+D[>8SJO<=)_4O34F3R1U2(C07Q![P#%W9C^?2Z(PMW
M0`V&_3Y4O+0`'"!'J'0)J!_ATKMH:?G/9;6`/95#0?5CRX7I`Q2)57<IU(^P
M*DLA(3!=GH+*1ZV+NA7!@Y!2W+%R%CT0KK(7O6B(JC"#!<0_@W"*1!S3(E?!
M<_:?9T0P??+_4$L#!!0````(`.V`;$.]VMLY3Z4``"*)"@`5`!P`;G9A>"TR
M,#$S,#DS,%]L86(N>&UL550)``.-F()2C9B"4G5X"P`!!"4.```$.0$``.W]
M>W/D.)8O"/Z_9OL=L+5WK3/-%"KGF]YSFS.*5Y5F(D/:D+)J>]/6KE'NE,0N
M%ZDFZ8I0??K%@R]WO@`0`.&*&IO;%2G'XW?`WSDX``X._N?__N-I!UZB+(_3
MY#_^9)RO_@2B9)-NX^3A/_[T^\V[BYL/EY=_`GD1)MMPER;1?_PI2?_TOP?_
M]__;__Q_O'OW(8O"(MJ"NU?PMS@IPH<(?(YWL&X.?OG3WS[_Z==W[\J2SUFZ
MW6]@T30!YLJPWAG&.\,$_P=P_]U9@8O?2$%8]1__CO[/79A'`$)+\G__<9?M
MML5__.FQ*)[__<]_1O]YGF8/?S97*^?/Y,<_5451U;KD]^_?S[];N*RQ7J__
MC'^MB^9Q7T'8J/'G_\]O7VXVC]%3^"Y.D.";"-;*XW_/\1^_I)NPP*/5JMY&
M9?VYEF"P!/JO=U6Q=^A/<#3>6<;YCWQ;0>P(T]_)G^#``4"&+DMWT;?H'J#_
M_?W;95W[/LSO<,U]_NXA#)__C`K\>1?>1;L_AS_B_&-T'^YW:!QQ,X]9='\X
MX)T&T#?\<[0K<O07U%K^#G_6E5%*\?_L:;=X?8;\R>.GYQT<TC_/!+YY#).'
MZ`OZ-^S:%`I^H&VQ`MQGX<-3E!0?T\T>_2^FE5`Q1GN0(PP>,RE"'+0LDTJ6
M1"I9_`(<FX`UD6`;/6?1!IGAX:$_J+K+LN.:R`*MD04R7(QYH$T)F#_"_R,#
M=Z==8=B3Z(%GL,MJQXC[6A,-]3K*XG3[*1&,N;]9.>!OBC`;,2W\\+L-BQ;@
M-BW"G5CHW29%@_X:"1[MXP:%CS)T89D-R<0H=YH4")IC>(LN3MHQQ;/<%_BO
MLB1J<<2U)#,C\99;+4<_BBC91EOB<=9MIYNR%.[E/_X$__"_+C:;=)\4^77X
M&M[MH@_[+(,S^+GC^O:Y89Q[O#,L^LOQ!%O^>:#/0Q%VR'E/LVIT#L;G(JL$
MN<_2)S8YBA26#^^&RAN.;[K^N;GR5Z[_)Y!FVRB#JZT_@6=H@[*X>/V//\&%
MUSZ'"--GY*.%]4<-L\W$URI+_'F3PI7*<_%NU^4$+-(K\M&'HQ:`GD7%@!)E
M49[N,[RR>MI!`&BY&27O?K_Y$XBW#%""JA1X)L7^YY\;D6;SU'TC/'4I>6J;
M!AE8[Q1)VD;/8.=$DK,%H6%F6>8,E*7X*/HMVD3Q"VH(SJ7-!W8=Z0:UKV<Q
M=*63Z9BTO;4,SS;L%1Y\;W42[*410ZFAI0#4D#JK"^<2^"S5\"[$YT$CW%O+
M6I-!=]>G2^:V#*H,\A20AL%-R3,`R_*;YVP/%_!Q>!?OXB*.\OJ[>ZXITS;W
M=SN;R+32M%@\4`5[:FMB.DS=64PG@RI[3(4F*`N"Z,=SE.11#L)D"]+B,<K`
MAM0`NZ81T;R69:.7X76?=1ZJXI3SH7&BI&X+H,`N3Z.HF=PJQF^/]T_['=K`
MN4*:\"%]>LZB1Z@?\4MTF6S2I^A+FN?0X%_=WX8_X/?W79E6F@7,;([/D[S%
M?*:&H%5R3)-\2UMWE9@CF2KK/P-CT*I>307M!D",6U"C4[)F"/UUJF\V86K(
MM<I/:KTIA6J+I6#FX<5VH$6X,CBH#4AU\`MJX%>\?`#I/8"M,"K6=AN3[W<=
MQMO+Y$/X'!?A[MSQ#8F34G^G,Q6%5I):(08J(!?7(]N[GJLW]^DD4#-I4&$)
MFF+@&99[%R=@0TJ*Y:T<P[\$;[N&?*""ZUEDF)V3)&T;OG3#/(VAS514"+HM
MX`,74_,\*O)S=^5X\HB)^YC)PP&<->W([X9AV62,-#^AZ8$KG5;=/@/RMUF4
M69\(9=9#E$%[1@X9$<W/GGL!,\R?`V$Q#-PYZ#K`<38@Y.;0Q5U>9.&F.'?-
ME63K4W4E@E*#L`^951<SC%4Y9IJ?58S`5F.<>OLNC13XH_KU_R>":W*6#M*Y
MUETG'`T<U%"'N`F^YL>\H\#5K`K&(`07-S>?;F]XN%;MX+HKF6$R[:Y$4&T0
M]2'5ZK,6PRS'2O-M_F'4:HQ:7]>E3>/=P^_]7A(=,8DL&W#+VB=Z#CG1\S4_
M(QW#K=!)ZT=0^FK5L2>_SU8VW\Q+,G<T^GH42,)!(7JYV,P3JW4YKIIO/D^C
M5VH!>R$<6\*9;M[`EY7H[:FCYX#OUQE=I/ADB>]K?MQ(@U^A)SB.)/AP8#S_
MG9&>+V&\0\%4G]/L)MQ%-Q&TQ0?G_=##E[@*GNI^)F_9I:M)/%G5,'UR\N1K
MOG?,)HETV\L$)ZB+O[M/LW<YK`":&KR.*C4MY!AH74C?M=S3W\;Q;;]<+VA^
MSL<JBQJ+SH@JN'E,L^(=[/$)Q,E+E!?H3G4.PHY:B%*!KW#P:YY8$KUH"@2R
M%&%,QFE=:-4VK&HBUOQ@AUF8Y::!`413,T%33:(F*)X/%M$$AEFA5=M>.X9+
M(D-]S<^K.,19>&X8!!9<"IP3RI/Z+U&81U=WN_@!YQUIO`:7G%A*T8'QON>Q
MGU6NBO<3]5`$IT$<U;7>9QIL@BCA.A.D>HG[#'TA6`P%[94!4&"'6F#<,J0D
MA!2W1P.B=UR=J8^Q+N]A^7H?%+.((=N]8<`2E&4!+@Q:I3F7MP-]MZ=ZU_55
MFW)1O@R'=!,\;SN<R.ZXQ.[H?:[#+,N29GT050!_>;=18MU["*+2P*NG/ZV9
M;W^<]9HD0ECK?7C.*,E"QGX`SIB]YUW$?@CSQXMDB_[GTW_OXQ?H^\,5P47Q
M(<RRUSAY^%NXVT?GKF];$LT^!82YW.>2LN$_375\ND*BO-9ZGU-QR:-H&F!'
M%J#2^"KT!OTC:NK)5`5)4X!FJM`S%=!4-PW?(Y]'[X@"#FGD3PFLD!K^XW^T
M:IV!L`!518!K,JI$^O04DTTBA"E-"MA0E&SB*#_W#-.0-R<,=SR3_BP2U:0?
MJ81O7)&]YK7>YUH,4JBQ]=1X@E918NC;A<536HYM7Y+273L^4LETO=*XZ!V?
M0"V#=)M-":3#XP_S>)PF-T6Z^0>9$CQT#TJF/6[W-I^QX]C;-#THB0U#.:!Z
MGQ9-05=F8T=`!.1WD*,"9^!_K,Y7!G@.,_"""I\!:[4Z6Y'_!_+',$,IA_;%
M(QSH?T9;Y%S<P&&*GNZB#!8]PP\]8%Z;4_4^1INRFH&KF?];6<\_6[O.F>&N
MJWIQGJ-$,=6OSFI]YEGUK^F^P$]5(/]F&(YA^V?6VC_S;*^G6</VSM:V=689
MWD"S';2"5%7:/*-`57MGE(.2IF>1K>JUWB$.X\!5S!V#O5?Z>4/T\V]$*R\Q
M=]DX^#&ZC[(LVGZ#<\\'^+]QG2O/6SOR_/C!;N>QDD&:BI[#50S+M\CM/&.E
M]W$LM0Q*YA9:-$%5$+!O3TY_:"DV=#':=JSJ<!7+=TBBC[7>AZN4$LBVLW0P
M&JZB<H`4Y#Q-[?;8VM?WUH:\'?6QGD4S>$RF81(?G^OYQ%CH?7+*(L9"%G@0
MD%@CW//1%=EAI42FL,:M6I9O6&2X]3X#I1="O4T>0#)@EGD//9M^7Z)D'S63
ML"4O3K&_3U$D'I>C2]^#\MA2&&2L]3ZXI!-`L>T=@=*VNKB84)Y*-KG*>#IB
M9@_*6VM_1496[U-%&OCJ3.L@AK91Q85F^[FXE8-YU)%W&6ZP6Z%<'9-F@*YM
M'\Q=V;9)!ESOPT%J&98PKH-HQ-K7GF^MPL2J8^Z4H6U[7VNW]+[T/@.DE$"Q
MN1V`T6-Q^5W8+'X)B_@EZLFT[]NV3+L[W/-<`K/(U'!XI);A&997NF-Z'Q>R
MB*'(!E,#"OX>9EG8>GWD50*9)9GB1<G<8Y!':MGURD+O`S5Z(>2;94HD05-2
MP)LD?TG3[?=XMSN'35ORWH2JNIE'U!&P%2N;(G!U6Q[L&'H?E0U!5F(Z!SH/
MJK_/99,44RB+31T;5Q?QUD9Y2*CW"58_8-FVJ[=7;@J]1%F"XLY0Q!G*!=4\
MAO=[`JW=+MI>/.%G\M"'<^2E+&!`,I>(<T1NN,K0B@.G=3*C&'H?9,V02I']
MY,475#_SOU?*11Q)%EEG7>FQZ_2M>&O')=],[[,R;IGDSPY\P(*F(JAJ'KR,
M6BM069M->2Z3`J*-84LD`^'7J/CT8[/;HTC*QC4P'$_>DHX&PCQUX12RTA.J
MZFM'\YNT#%+(U@5Z*$%3%%1Y6M%;7K_4Y4%5X5>9Q)?B6NE&_(XS15?=LBU[
M?6YZIJ/Y832/.$K<)PY@+<6`*I%$C!L>K2V3<\,T7'D^4:NG>5P>AUQ1]J#4
MRK!)/)6A]_GS,&C9EGBPY^`+[[O4O=])RM,`<JG5>1?@H!2ZE4..B0R]C=X(
M:@;;QO\FP'#_Y8L`W`^@MUJ^2+;XQL5CNH,?(D<WJHM7]"DM1X5AZ^U>&"5I
MA>OAZ4#5E;$NUQ=ZGQ4S2J+06%+`:5M0?&V-%)+%<=D6=E&.C]GB@:K0U/CE
M+I/>@3RLHJBVVC2@NJ8<,SYOU?LWG.=%-/_KEQ*LE1H?=A2%7'48EI56*UKO
MGQC5/*SWR32G1$O/!/VP!F8$[@=GF`DC91=#4^7H;&;0?S/TQF@YC>L=@L0K
MDI)-#4YPP9?+B_>77RYO+S_=@(NO'\'-[=6'_^NO5U\^?OIV\V_@T__[]\O;
M_^36DSH<RC1,)?.%D-`D*@%Z>%X77JW6-AE@O0_N)[$K-.R]`-HFG#/6:.QC
MRG;BI;-QS%%OW;@QRU!$4^^8I&GPJIWQ?AA';RN*V%$I.VI/J_).`(?[%<W4
M87F&"=MVYFR/C+G>1WW4,J@WI_U`>LVJ"+]XZ+/+]H15TWC,V^V,//*WRJ'7
M.^R)7@C5'NTXG/H5BY8E9GRM\4N:/-Q&V=/7M(CRZ_`5Q7K`:=9S)6YH]W0Y
MD[AT0M2<[2T._2^R.#`U/\2;1B_=W$Y""/!/H/R-_S;3^)>58UT5T[-K4GN+
MH^OCI>)K?A!(`5^-&9T&,O181(+9^TSJL#&VW5N3]LJVY.6DZNEQ'E_I1*CH
MVEO:-"QR%]?4^^1O&KQL6SJ)X-B4<FT&C'Y2*694+2L[1K2W-%K,DBP'IMYG
M=13HE9C0:1Q]#ZG-L)Y7Q6.4';Q1CG(&.O(2274[G,=2*@$JDO85-AVSW&_1
M^\1L$KMLPSD%(,`%ZFA>+K,Y]C6E6$V5=.S8S+["Z.GHTJO7^XQJ&KP2BSD)
MHZ1EY72&N"@W*P]>-O9-><FC>_L4QLU1,7KHV2YONJO2G]?[S(D&OD*;.83A
MR&SR+MPG/JYLXZF(HV,F]"CCYHJ<[5EZGT11X5=M2`>1E%Q-6HMX;GO:VG1M
M]V>O#'GG4<,="V`MK4`'U!VH9#F6WNOX:?!*3.L8@I*L!R=0LZSKQ`>69V(7
M8FR_L1T:<AL..KG$=,+,/1!"G=FE@=-C>[GC`:ZS,OU9^ST:V_7E)3/MZ7$>
M@>E$J)C;7WIEDFT52^]3_VGPLFWM)(*@+B'@A9313RO%RJIE9\>N]I9&NWYD
M$6OI?9A/@5Z))9W&T6+IT#M;YO!K6?\;M+T]CU:U7JABIOES&&\__7B.DKS9
M[;4]B2^;]_8YF^I48K3(WEO>-,F2V-([&H`&O@)S/(4A*,N`LA#G?NS$QY5E
MC!5SM,\@]Y5'CUV3B]26WB$!5/A5&>5))#57(U**V9E-GZ.L>+V&`(J+9(MN
M(3RCM#I?(]23:<B+!!CK>BYCF81JB#M6S5Z7#WEHOKG`((5\4TL+):B*G@%<
MN+X(AHOC[#8R>"W)!"_+ZQZ#/%K--]UR*:)WF`&+&(K,,S6@FM^8V%%#;.8<
M-=^BO,CB31%M/X3Y(WJG&?X/ZAGZX!%ZN;GX$&;9*W2H*R=^;<IS-QC1S*/_
M?-$KC6!OR;=]DKW4TOM@>:9D2O1F'L:@J0XVL*(B]9'B`IV&^G0<)8Z6RFL`
MEMYA0O,$D^U.S4+75AM4#T]$^!^M%C@7NE/`#HY$UQ)3R=,#D:M*HP+3:M'Q
M03+9B;/U/I+G%TJ+J6<0GMQ9IX\OBTPX2RH(\S1SV$B94<32.ZZ*6Z:E)Y<A
M8)3S"F_LP+>H".,DVGX*LP1.;/G%9K-_VN]"V-W'Z#[>Q/@M-4?F"F<*P%Q-
MX1"PT9#IRN@09TW,F-Y'8>S"*)HR&&$%K1)@2XK(([VD:4(?TO=,"Q25#;N<
MNO6.3F"61?XTP`8HJ"J`J@;XI<W_LA)C&O*;`E9&&V17]Y_C)$PV<;B[3O,8
M?:OZ=KEC>/(.)V@0S-,!/ADK):"JC4^*R-4\6^^#81YQ9*L"!Z;@_<67BZ\?
M/H&;OW[Z='O#G:NC+[6D9ZU,:=F01"<QI1*@X7)_(DVR>V[K?=PV#9[!2^'/
MAC0)H\R&-#_YZ-BGE62*U7&SQ\YV"_LKLW3V]`YDF,0NWX*.`PAN#MA8)OZ\
M*.!Z\FY?H/NXH$C!=<B^;!Q)K.@8:WFQD+(2?;+(,TS=@UG+(R<JMMX[\O1"
M*%D,4L,YHC8QM(S9CB@^NB*#JXS$%/:W&7!_5>9&L?4.7*"60;T][@?"8I>Y
M?=S;+`KS??;:#CCV/$->_MENA_/H3"5`Q>.^PKY;K:/UCBF8Q"Z;MU,`@JK`
MP?T)<71TS%/G8R/!,"%M$Y]YE?=2;+W/46C@4]!R36B91`]HMXK/)Z"`TA"T
MO#IA.\Z9;57W),[`)LT+<!?F,6/X[H?TZ2E-<,_0'%]E>,]BBT%<1]D-:OW<
M,R2F\Z(`,(_57!)6)*>I;'KEN[N.WB?KS++(MLJL@`)2H;+1L`X<;D!J$8L-
M8#V`*\K3`BG+/JVTH+,0I*CLD=TBX@$Z>I^9\(BC9''(`:S2B7):J._2@6>H
M"?DL3<#]Y1?U#3S(#UM>QIV1CH4Q?UJB'L9W*D&31/;K';V/PZEE4&CG1X$<
MV7=2%C2%Q3-9MBU7S^0QVWU<J;0EY":8H_?Y'HL8JFWU%*`C&]VYVCR3U^22
M/YJ]Y6U]#'0JF,]#D@QRN:Q@>A9)DN3H?9Y"A5^Y->X!T6N)^=))3'UD-298
M!5VG32^I4)H'<HCEZ'TX32O",B:W'TR_N8U%</>JR38!/[NKT(=H]2R8Q:,R
M#5*Y70L-_YIL53EZ'P:RB+$,I8<!]=.:._\)%0_4^!)JN3WM5;1KF="Q)E]`
M[R-">B&4^Q=#2`:<C*L9&7U:&8@&=[D,VY6;XH<"Q#R:<PO:G_%JI(%5M8C1
M^WR12Q[9>L`#JIO(3>`F-RMM%.1ZTT,_)C+"#3>`W$YRC\G1^["33R`E'A`7
MM&XJN6>B)SG1DUE;X(>(.CMMANVM9.8T&NM<I%Y0"-:O#ST55R:9U5V]3T"9
MY%`[/XR#Z<X+,S?'::F@8`Y8AN,3-K];$=F?\GOH?;K))L@"-GX"4M>VS]PP
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M`.G<T<DY"'JQV6013A#RA%Z8_F>(_GUU_S'.-^D>I>A,MM!4/\7[I_PR>8GR
M`N47R<\==RWQHAD?J'DT%S80E29P-@B_L;O&W]@T]-X=$2,@A3:)N/,F!&S0
MKHR?8H\*^%U(-0#_%#=5E:JA%/_F!+6PXR1QMF?;/OGF>F^]"Y!.MILU'V)0
M-P%^:3?R*U+`NAV<Q;-JZ0Q<<BOB]K_V9<7;]%N$/E.\B[Y&Q66R29^B+VD.
M_XZRA5YGZ4N\C;;O7W_/H^UE<O4<91!7\G"Q*>(7_$ICDRQB)2^#M`S`,W58
MQ1#6"BZC,VCU+:NT^GKO>JD07XF_JT"0H&HV/IB_=[!IE!T$_1LERD;?=0MG
M<I!6+8.P;IHQ(8Y,59`SY_]4UJ3K+LCHS#-=0D&]SXBDRR[=U9`L0-#J`!F,
MN@OTV!<@G8!?4#>_HI]Q2O&J*W#W"G[YG1B67T'=(6AZY$Y+]"%\CHMPA]_<
MV\;%'IVED=3EV_?[XFM:_&=47(?Q]MQU?4O>!1)*%#,#[KEEK8/O:5M`*S_/
M(-]>[[U47I&4S.N<X`:>'P//L+O',$<GP,EFM]^2F3K<E(N`Y_`5)_M"E>`?
M,_1J+]\SD\Q,DW-U14^MZEYIH?[*:]LCWUCO$S8^@63/<%RH@K(6:%<#53UP
MMR\`K`E>X1R&ZG*IR9<(ZN35W2Y^P*YU_:[@=:FNVW-SO;;[@BN2E_`'9O]J
M;:TP]]%?J-L50GP>]$?,IV@"O6UU$J2GET41WZD!U53'-4!3I7F9%=259!/=
M,$^:Z4;G0(.V#<,DW^,DO"86:>CIODTW>]0*;E,:[1MH6A'?.VG>#ZT8)IOP
MR,?0^WR;71B5JP1Z6$'#ZW`#_XD\F7T"AQV$8%/JP@ZUQDKV_/&B;.\S)!'^
M-WE`X]SU;7G7>$<ZGJL`#!(UE!^N9%J:OU`T#5Z^VS*!(,![0U41@+X6:!42
MSUE)6SX+<K;'3(\,NK^R?;V#*6C@*S+%DT""K]51219MHOBEHG#Q&('+'`Y'
M^A*"B_?$,G-3>O*U8$@%O!MAK*2Q6^[[UKQB'E">YC%RB^0\-`W=G1,.>>B5
MXCF"`F]OBC`K9J@&([Z@?F(4*TS4U`-A`>ZBASA!C]"APTB"3ZJF&#^'IA@S
M-,4B7T[O!"1<\K!JRJ>$,]:.!]VXGD3P[T(UY!JW=)EL4`AM]#$B_PL99-G2
MGJQC02)#76AE'E>:@5;PUR3'-Z;>21GFB,7@@?&_C#<#(/;,XK(,^&5;EOH5
M'9)MAA1,@3[)6S/KJT_]JVK:5DS3+@.7],[TPR^4DE4X#[)F*NJ^"D^J@\M:
MQ:H6&-\+1BU_WJ7?T2OS\)\D7!5%H"3;\NG6=C0*BG+=I?D^B^JXE+7,A.(S
MP<U7-J%#T]:_60UC6TO.54W]=Q-$BJILYT$@Z.!F__R\P^\AASNPK8OCN,\T
M>4?F0][(3E$LE38SGKX"]TZ@LQHVRX=,3%/_+6QQ@JJ8:(6A)9,O:NX,E`V"
MND4\*==MMH,GFU;YXRA3V$V6X^LI^-;EQ1,**B-_+J(MG%$LJ2\>3'0_4RG9
MI6OR%4]5M0Q?\_T22A&DJPH=CJ`IAV:K\OXY*0OJPK+H+2G!O";T[DDU/U45
MI49<K<]-SW0TOP[$+(L:QXX1U4'F^3+5$][!2),DVN"PEN]Q\2CNO.EC])S"
M>OGG-&L==UW=5T'(<":KXPW.36MM.O21C"QMS].!F5)4^L#4#(K:=LE535/O
MZRUSQ)(]+<S`%E1U`:S<#B(`5_>@#J*'#3218"IT@S+X47?EZ`9!LG^J-?E4
M>H?^SA&+7COFA47.P*BIEM!%2NJN)!V/BOE#>2ORH?1VKN:(I<3/F@&P4A`0
M/C_O8NAN%>GW,-OFV,>J+EVAM0CL)\T0J5Z;6UG,JI)%&W('&R)JIW0X]RU[
M+6T),M+Q;+6AEZBE)(.5T$:F46Z)Z!VRPR"%*A6@Q!.TBY(+@ZW"XBDM9=-H
M44KWK1P&*]GVNCREUOM:"+4,"M8$5$`.>'P&X'_MHIK2[5IX/_4Y2[?[#3O#
M/]W?PY7WU?VG'W`F2!ZB;V$1727]1ZSG:\.0=R66!<D\'9@G<Z443*TXGN;O
M<W)((UM1V"$%I`IR9ZI*`-5"&=P&S_X5Z(L4KT=S?>GX14RM&)9MKTRR;ZCW
M]M,<L91X3C,`MO0IJO0I*_5)4-397\(X09E5KI*/40:;*.*7Z#+)BPSO)^1?
MH^(ZBXKPQ[FQ<CQ37F926ASS-&F.M)4>T;>!4ER6;K'>L6:\(E'HCX@4HYSP
M@@]$8^($W(=Q5KXE!W4)+L"S,"G`+@[OXAW\$+)51HJ_IJO&=!PUZB8\UR77
M.TR]#[WY!)+MKG&A"E"M*K<6G%6:JJ!5]PPEXCH#I#ZOLMS`Z:G9,KN&,A2M
M3;.5VYO%1+2JC($0I2B,@G;59+0!S[/(YJ*E]VT`'G'4J0@UIF,%0171'%*?
M;>"ZO*<;K*21[7OIHQYC?M=8"[9)MB/)"96E=S@BKTC*_2XF>$1EH*YLX_PY
MS<,=OF'6FW:.35N.+Q=<)A=E?KIKDIX.;>>1Y'1?2M<N1F]J&-9*7OP5'ZAY
MRB1L("K=XFT0?G?R;(9IZ;U+($9`)?L%0J`&%^(S-\YEG137[A35K^/Z<3;H
M^T;II^A]:4:$>+)=0P$8@Y[+:VCSH5;%ZY8JEFV!5F.BM/$;SAV">H)D,RUY
M[[310)"E::-"3NM5J[KO^:79U#M*AEV8Y71F`-&DAC3U9"J#G%64;MK074'1
MU"^]>9,<@UMZ'YKR":1H]<0%KO';LKK0[(GA8_DBZ+?H)4I0@A`#9390MR`Z
MZE^T$DR+-ZP`G;KH:Y"'"2R]`\2895EH\3*.*JA^AGS'OTOCNB(/:"FN4_@^
MQW7AS$S.`2R](\<8)5'O]8S!&7)Y:MY_$\/[^N63,N-K<P?8DWCYD!Z':$6@
MEW=8(0;;P#:J7-?I?7+/+]1"TP$EO/+L/C]Z+BS/H_)%PEVS;F9,,,'!)45S
MAS:Z0S&9#+;A^T[Y%?4^Q.<52?WT0H5K:)YI7L2J,MGSIG'H`58\1AG*)8$>
M/$F*X[U.>7F46*`(5QX6H4?T9Z09QW=]<@]5\XS@<\1::OZA!1B0%Q]B.$P)
MBH?)ZYS,*M1&U8RCE=K03#O#S4"OFVRCV'H'QO`+M<#40X=L</)!U4%37^1I
MQW46/8?QMEI'?2)'FA?)%G=Z@3U%2"K;DA>!R0=*M&9Q#L2PCE$UZ/MEH*U]
M:F>/[.*IUSMFC$,:6#8$RA;PTHEH)6E$K1:J.GC17PUI#F=H6JP.$$BZ;_O4
M@G#X1%SL`(<+;E#I8!5U@Y4PQ4H8"E'";Q%<T,4;*"BZ3H1(YBI5M\/^12O6
MM'3#*G14UUX[1IGAQSZUD\UQ4193B5%80?,KOJ8FB^B*O+ME>$[AL1U57:]6
M).3"/K6(EC%!U'MA(VB&_*T6X3\((/SO"5PN[=#)4AT,@(CA&2K->P\(T=RG
ME'-8`WH;0)FJRC7JJ9WE4\BSF,F?QA94141&L8QR1-$,L+0J4,P%??77JS)*
MU3ZUD_Y):=3/"E.0AJ:&6B>^\>M$$4'(Y4OTAN=X$D]8FJ[F,GP4=$/D=C'T
MWD`YU^I^_CX,6]$)QR``DO'].7S%=WC1):RX+"R"=I(LKES:]=C/5K&U8Y4;
M:KH?70^!EF\-!WH.JE\`^HF-7U^C`C'U.DM?XFVT??_Z>QYM+Y.>)P[.#<MT
MY&7`H@<RCYNS!*Z8R]*(X:U)Q*6C]]$8MTRR><\+##\;A\UP517<O8)?4&UH
MC'_M?7)#OO)(>8119^7IO,#(T@B<4RVRLG'TCL;@%XK!4^%_?9$;7O,J]G-+
MB>YKU0FEJTX=<679:WDY1]GQJ-*D8?G9%:H)^#0\EQR2.'H?(<^639_9J1\@
MSRS%'48X@W525KHGI'6=13//AT>FE:3J</0^+9XOG)(%^&R809]Z,<:T#X!H
M7HP[<(IL>4'M]$"D:!&=P!/JT]N(X7FE5Z_WF1JW3`M-4I/`IB:GY@U#P4NH
M42ZI7$)IH3RT2ZC>1I"]L\D'U3OL@E^H)9=0T_#ZEU"_["LEBIN'0*4K4>/6
M.*:\E(_L>%3IU+#\[*K5\N=]FYQ`.7H?\<V639]YJA\@SWPE>C%%PSJ5BRD=
MM8YV,37ZX9&1)=%NCMX1)O.%6W(Q10\SZ%,O,8NI^B;EH7LD,0*1'H@4+:(3
M>$)]>ALQ?*_<W=7[H)5;IH4FJ4E@4Y-3<UM8\&)JE$LJ%U-:*`_M8JJW$63O
MRM6QWK$Q_$(MN9B:AM<LILKU4SM#A72U:3LR\D(?V?&HTJ)A^=F5Z<"#)RE[
MW).,D*"739^9J1\@SPPE>OE$PSJ5RR<=M8YV^332ED?L*HDA<T\RMH)%NB47
M4`PX@SX-8UQ!U6D#()3+9),^1>552>@"^::\\-'!?N>I"8LXE3J,U#&=\AZ1
MJ_=1$JT(LJ<42AQ!DVT"31^D)/BE+/NK<`;+N7ZU'(6[UZQ&*J&'ULHY6^\3
M'6H9*%@LXCH5+9YV8E36=U*NRY#_VQ2_5I]%%R]AO$,73CZG&7K*Y2;:[+-R
M:6.C8R)9!ID!R3Q^SQ.Y(CQ3*Y;CE).FWB<N_$+)-NS<R(*J)BA24-8%=>5W
M]VGV+D?O=#7U%2B0G/E`;PWJSAD,S9!,&:Y??E:]#U!FR:5H;IF#,;B&C3^&
M*#T)OBB&3E&>V)\3[D"`*Y'M'JTCHBH%CFVMY,503_8O6$DHQ!O4C&Y=:.-(
MR(:K][D(JRC*)Y)Q/+W31U.%*S46`S,4312+,9]B4CBN7)FC\A/I?:[!(<U2
M$\`DLJ#*"HR34VWC8I\Q.TM9NHFB;?X9<N4RS_<A'.*K^P_ITU.:W!3IYA^P
MRY4E[ZABLO^9Q.<0K^;]=%W;L<G!DJ?WP0.K*-)-/AN>H"H/T)<%50WDZY`Z
M`%>2QGPIQP7Z,+]S&D!3U[?*9Y8]O??^F651LM//B@H?K#T?:`%:(V-W?T-4
M($?5SD`""\(_IO?W48:.`39I3M)'_`_WW`!/\6X'OP9.8O@_5N=V]8<S`$$_
M1WBRV;WR*]+7M(BJ-Q<1P5;RXJN&NA6G-A/"]&G+817;,<@&MZ?W-BNE!"IG
MA6$81Y,!+E@]SBF:N-(-OTKBCIKYHRJ^[Y>V1_/M44H1E!OU$3!'!$XP@9_G
M$OA;5.4*NKH_4IZUQ)L:-!#$$9M!R#Z2CU2W7')XXVF^D<DNC4JK30?I2`%^
M:6I!/^57419]FBO2K;L."C%J]8>K.[[KD>UE3_/=3`YQE,\&E,"@8L3))GX.
M=P>)WR3,$(?)<7NSN-AK1<X[$RXYJL,S'%/Z1-.F[91&4?,]4T$B+C45,>*<
MF)^.LD2?"<@#)H"72B<S_=64>MJC:!/9:++\]$]GFW>6C(M.D*QHY[U3T$:!
M3MDODNUO88$.VE^O[L>B*)R5ZRN9'QE0B5.[>4/1IW1,+=J.35+L^*>SN\PO
MH,IYD1OET:R(BN)MY*HEY*F*C.*:2T;I$^+IZ.7H9,C6HN_ZY%C.USOMGR`)
ME4^$_%B/]/.)M!#/#0D[PG9U#__R'&7%ZS64I8!0/_WW/GY&+2.^K=5-B2-(
MQ*H;F\A#*C;:BNV6"5-]O;/Z\0NE>HJC1M8WK4&%J6J?`5S_#$]U=1,*=$C)
M]*67#DU.4^.M^)9%DJ+Z>M_,FB'5(M,1/;XC7=K&^7,*G4"D3\]E$UB/(@%Z
MA*(=KO"'S#_]B+)-G$?H"8V5H^:LJ[=_@3I#*5ZOIO37M=UU:?1.)QB!1A2E
M,\LTGN/Y!-4`9150UY%&?/G3QJ+$'Y\B!NKZKD="9OW3"6:@DD7]=$"!ZD@!
MBL<(1&51-!'@,#5`1IIQ+=+>)/R2)@^W4?941D!_00]U7=WMXH<0-XPP&?(N
MJC`@F:<:\T2NE(2UE7)"USL4@E\HV3,&-[+@X*0)H+KOH.8^@2K.'U<'K?H*
M%$C.A1>]-:A["8:Q&=<O'0*]@R=F2$6A1"(NQ?`C'`BFV)2JM$.U&?7GYC',
MHO>PWO9#^H3N_>..SPUWO9*WZNCO=)Y24`M2T7^H@F>OR+&YKW<$`Q5^V?,"
M#8@`%WIWATJ!=C&Q3)6R3%B"J9T%07\%DB?)()EFUWJ?XE-*H,3YI\,2?$V3
M=SAO#_;N2_9N^-E;P`D#6>RK>QP"L$N_-SG,'$/BN?M8SS.)S"13S>:Q6O@C
MD/.?M=['Y"QB2+?"]%B"F]N+VT^_??IZ>P.N/H,/%S=_!9^_7/W]ACMGX<W^
M^7F'>P]W5>^7R7V:/6$U:0AA.HX\.TT'8B;?>26MJ4_9`'XVF>P^K/4^/>.4
M2(VAY\(6M*NA_?[-+LWW640<;3@?W,-F0-RTPYB*D)5$<N8$'=6E.U/0?D#?
M7)7?3^\(#CZ!I,\>/*@.U03GQT7U0*LB]XQR`5O=HI8_[\('%,<\H0=YM#E_
M2%_^O(UBH@+P'\?,AW\Z;'<>M\<A5@0^+(5]RY7F#TX-099-PH%^@_KO`/W`
MQJ,/^PSE*OP,;7BX^\\HS#XEVX_04X(6?\JTTE)JJ(MY[*(&7A%ML(*Y(B.I
M]RD1#7S9!*3`$)1E`"D$4"D`BP%4CHV:']/-'K$:11XD!?P6?0;7M-9FW\N8
MR4OX`Y-QM;96F(KH+U1MSN,E)^J*I535\8:U1X9<[],:'G%DLY@#4U#5(?%@
MN):0:;QJEVC+=02_W_8S_%L.>YYZ\)76_@[V(8;HT]"/N=VM89@6&6J]STWH
M!%#%WU$4#6-+0TS*`5QP#D>10:\^LR@/8:`'D?P<AMW/SJ:\89ID4/4^ZJ"!
MKY:9O1@ZO,0.P@Q6$E[7SI\[E;..E9,'[8MAY#CD8SX>EB:YH5::OW@SB5T5
M$X<`-#0L[>(\%_46XCHWC:G38%;NH6;%4*X7X#'3<"&+J*KF3[L,05;%JZ-^
M&SJA']@X1+S)#[!R%NXNDVWTX_^*7L\-7Y3[U]O^/%;10:[H-5!Z99#1TWL[
M<AJ\;,I-(@C*]4A9!.`R`!;BXF&3BQ`?`N=7^R(OX*HG3A[.C;4H"S?=F1"&
ML@AS1-?1JN0!FY6K]\$3HR2*B$P)IV9U*]/K&2!50*L.#\D_Q[LH^P!G^X<T
M0W;+$LKJ@]9%T'@<[B%O#\NNR2:QYF]632!7P\NA[BL>XM]!58"'==^BAQAM
M$B7%U_`)^OV^J.5S7_,B>#<!^)!XQX57I:^M]U'.)'8UY!L&4-&O*0%0$3;^
MW68A,I4WKT]WZ>[<\$2YE@?MSF/<.,2*:H>EW'*4]#ZX&<0LFUI#'0?E#X#\
MPD:ESV&<_2W<[:./==1'$T9EKIRIJ90_'F.LYWG<8Y.IXN)H+7OM&`8^/G`T
M#Y%F$4,V8QFP!*@LP(7!;U&(BI)8?]Z3F+Z^;Z,?Q?L=2LN^]FQYH?ZC78NG
M]HA48]QNJKD6>:/!T3RBFD&*)9C=#Z5-[%9A\`<J#G!Y*<R6$G*Z.+,[X:6C
MU3QB9'SR+?3>`643A)[?,X))F2`-&7!.;E\FS_LB_Q*]1#OCM^CI+LK.3<.2
MEU)EI&-!O*:1"+%ZK()A&X9IX)$W<5BBN]*7U>R"2&<U,Z0`%P$&^(.48C35
METV^KAYE@I]^O7:E47J\\WFL9A8,,7NB$AYYGXR\OH<(;$)(9S03G.`V19'+
MW%GDR/MU/?W43KV[DG>I:[+W>91F%ZX.>9ZL:1C6FGP$O4\8&"61[66SP0E(
M\3/0ZW'S1^;3\D**$=>%]!W'>[(F<1#-\O/H?6+!+HP2!YP95L#S:NY(:E+7
M\.4]'B$KSRZ+/#6;1]*SZIX481*[=#,]`2`0F$^Z5@;"](MD^R4.[^(=;JI<
M=VZODF^H>?1P(BSP-4VRZC_?AWF<?XF3Z+*(GG#LJ+PW<85"%;0(E3-JG<T8
M(=VX*"4EMF\>L6]Z7XV0+[RR34U9$K3VB,[*!][Q!8Q6-]7>T1:D":A[PJ7:
M?0'<&?@#=0=P?[R;J#-DO25O/Y5+76UMR.W\M\HDCI9(VT&Z<-'=:DP\@Q!/
M[TLH<@4_!9LQB'YH3_ELS#+\@9OC-0?O7^M__C6.,O@9'U_Q'N#%CSA'[)6W
MOT&'09`B,\K9T=+Q^BY<EY-O:9)OJ;<'/4,J9?K%#.U@LJVK@#]0>5[M&#G#
MD*L22YS*#)._IY+KD@!NUSB1,_0I&901>P+(`8U)V3,P[U2FKVNS^?AKI8>,
MIBPZ#THT1N>J$E0!TR^G8X=\"GV/9/B$47N$3@NK/'`T)5);F:561FTJ2VW6
MQJ4:;7V/SIED6,)2]P$9L=0BZ6S5']]4:ZDM670>E&B,SE8[;,$D5L0EGT+O
MLQ9V81:SU*.P2DMM2:2V,DNMC-I4EKJJY#IKBXRVWJ?FU#(L8:G[@(Q8ZMET
M;N_3=%>L'].G,$Y01AD%X=<T4`11GD_JCA)0->.:Z](6E1]4[RM9\X53IC:\
M"`_TZ7"CLK6#V=J#(4U)"B:4HE0Z!!-V]&:BXMKWRD^D]XTR%C%DZP(#EJ!5
M=B#HBHW@K9.#L8@D:^5ZTGA.AV$>WWGEK&A/6=]8&3Z)##+T/CGGDD>V(O"`
M"EJ51(<A,I)&RJI80^7HK)5IOYL%31D)3##T/A_F$TC)FID+6EM)&//(7Q6/
M43;>*=I5]>7%=%$@F$=_/A$K\E/5-KWJ=$7O4UEV863/"<R(`EP#3$\+$O5`
MRDR@EQYT)@&:VF@)1Q((NJ;>9[8<TB@Q_^RX@K^'&<YYLFMJ"0]6EW,/8[E@
M]0-V3^/Y7[N[W;GM6VORF+7KZ7MPRR>,=&YSP0H^I-ESFH5%!+;1'4DL'NXW
M.)LX_FL^-^+]_2O.EO:8[N#'S#_]]QYE7]N%>5YO+SKRUL6T*(2%IS'*VA.@
M-MZ":SGDY-(\D6-@)H&4;9FRH&J'<]Z]@G;%?P.D*L!U.3=(:U#C(:@XYO3W
M)+W+H^P%J3<^`8$_P\\%:^$'`+XTEQT,:^HM'@%:)1"Q(`V4.H8=;179F^MZ
M)>7TG?G4"*_,"LB2X.!@9?J6".[H#+2[(L>;X+`S$?=&YHM,PMZA;BC(L28(
MK3:V96#L)-B5\G*"NR:[O.:)A")($?R$[$D7O31;,NN^2>NT^.]Q\=B1*C_L
M[7`,*BE>R:,'E\DF@\U%'R/RO^?KM6/+#Y&3*8+X\`P%HSP6UB&^>\/QUSXY
ME#5/+Q)$^GBH#1Y4*%GPX1%"B4"<@'MDV5[PNBJ]!\=[;(S)K=4JC;((L)_:
M-%%%G(GOWG6=<NOW1$*2U8W&$C%M<D4:"H(#WV&W/7Y4?N1(G76=K[K[L^I9
MIPH!^*7"\*L:ZY8/#`QNZWSMVOC*8'-Q3@=S-HIY&?/%.HQS[=5X?WA")3OX
MIMXA4DKDI[=)SU@;;XHP*]0Z3"SR!.]#V/<F`F$!H+7`4>W`,LX`5#-3*ZMA
M_,MJ"!U&!5:#9(@U]0X=4R(_J]7XE&RULQFU-&V;<0/'OS0:*VPT+)V,AE8+
MIY.U&<(61N/=N>@!'$PQO6\B*)!>UX4/O0AS%SKYV$J'M,MF:`9.X'%B&-M;
MR0L*&>EXGM(S252I[E@EP[6<TC'4.^B57@C9BD2-)!@+Y.#(-E3N7^8W45'L
M(J*O'\+\L;I*;*W=OGMNR4OX`Q-UM;96F*;H+Q.MS:,I,]**JA,5<=`D2>1D
MZ1V:RB:(;,HRH:EB47/0%(<&&Z`*G)>@:?G0I)_1GKH-5!;NDD,*2^_(.C9!
MZ+F[+=\.QY.]%`[7J$8Y7-98+KZE>;T)@I5_#BT0L3YQ+L-C*"/6I>X-KHI]
MPR!O.YW(DD6B^&K/D.4)$AR%KJ3W==:/_FS,&MD.[>/C3L!V2(V3:UX_=!V3
M,.Y$PE&D"7]*\7*]$LB-F0/<3V#>;!ZC[7X77=W70T"9?[I).-TRDJYERKLJ
M*13KS&T5R<-6[\2([0?.8:LUH:3>YRU2Y5;BA,B4H'W]I\Z%I(7>R]D<??-Z
MW]V!%=R/8UN$/'H'9\@46_HNKSSL0=4V6F>T'0FFEU_*AUYF.@RM5%4?H[L"
M"D>VJ9LKO76V$K-_>UEX&K4)'/,T?HZ\/=G5IMK`3T&7AE[O2W?\0LG61&YD
M[3QLW.FE6FU<)F7_OX79/Z("*5X'2;+]$&5%&">W6;A%S[I@E6[R/K1,`HJV
M4J%/0F$+TS[9@]FCK&*[7/MNN7^D]\TW-0.@T`C(D^+`8,0)^%CEJVAZJDYQ
MF[[`+ZA$V1TH^RNG\E\/$MR)F*0EJ8WL=]9_*AO46?;+ZK)\Y79%^*OW51)E
M8Z!D.T"5-&V+Q)@/BJ38^186K?0\5<IS6YXC/]+O/+UE$:A^O7BD#AQE\L:,
M38)<+;W]<U919$_(C'B"LCQ`%=JS)U]`"45V,%\*NY?+=N9WR#U8QR>YM_3V
M2VG@TY/X)<KN4N[GY*>AM/9H13'UXBG-BOB?T?9#FA?GKKF2][0))0A9')Z0
M=)K0APT8ED5B+*U39?B(/-+M-@>H\7?JST!=$Z"J9&=2KI8H3F6YH)9T%A/4
M']!V_#5Y^]0NOZ3>*X1Y@BEQ^V=!#`[51)2"_"5+\_SW)(O"'6K[+W"5`9T&
M4^)#66Q89*D+G=S36M/;CF&Y>E^'X))GN;EE&-34W()K@J8J0'65Z([B.48;
MW6&8<7K;P1[SJ4XUHQ(M/,>,80MZ]428%W;4]1?X7Y`OAKP`5"8HBM2D7VIF
M+<'-&)9]JHN787&TF5\:3,S3"ZJJ0FN6G5V6TAK^N04W@XV=WL'3?`+I-;.T
MH74G%O0KZPV(^@T`=%;2LU\L,97X:-?S=(!1JHKSX]4LN'@D*T=RF\W6^Z(K
MNS"R9PEF1*T7*O")_^S3B=_"_TJS6X@WO[H?"EE"M\4M2Z('10EBG@9P2UKI
M`FT#AF$:Y'#4(GORMMYW:&?))5M#YH`+<&6`:Z/XU3I&IAL8PY/C@`):^8`&
MI)2SI/*(>-9EAK0,"E0V`;^FN2)?D^3^MO4^\9XIF09*-`*/18VXWGQIXM>'
MW;XO]=L2MK^2ITQ,4$1=Z."2NGM?@Z89PW77I4]!DKYJOK07()ULY9H/\>"2
MQ>@FP(Q'3VA@D@<7;,]=5L$$/%,R0UH6Q2)-&*ZS7A.C25[(M?7>4IXIF0X*
M-0R/19EX7OT8P=1<OS9<>7<2*0#(VBX;D7!ZDZP=?;QV2=3HJ1Y<#LBRW*9R
M/Z#Q'>79%_)8B*)X#WD!56#8+S[*[4)V=U9Z;YYQ2+/P3O$0KH.K,SC%87P?
M1UL0YJWY`K;V#C7'NB60[._#3;%'UUZA/&BG+LU>X7KKZOX^WD2?PPW.$-I<
MW+365E_TRT`V.=;VYR[Y9TO3+/T9FX*?S'-Q#A-+^^VS>:+)7_S/PA<<U`=-
M`W@+@#0!JC:XKZ[R4XTR#^.I:$XW5^/7Z'M5_`M^N*6^BG/XQ2SRQ?3>*&,7
MAEX]YN5L9$86P!H-\7&=@RN4G)HPC*.9SR!;[!7]K$'1Y#RZ\V&>)OC!#.ZY
M-AEZO7>L.*21/0.P0YKB-O>2@8DIE*9=+WJS&/"CX7?(\.L=-,(AS?(F?`C:
M.,\E4ML[069W%KC4X^V2\=9[5Y1#&B4+7'9<AR[[V83/SKCGL]W&Y#/=1DF8
M%)=/SUGZ@M_.N-CMTN_HX1U$&8,AO3]-FS/W<?A0USLY--4-9^TY>`9U/+W3
M+?.((WUKDQU3T-0!I!)HU0)U-9D$IW11=&-XUTFA'W^'C+_>Z?QXQ%'EIG!@
M:U.](%2/6U0/55"=SF71C>G=77F*ZAX9?G*.XNF=KY9+'C4[\QS(Y!`=^TW;
MRN&Y^>]]F$6?T[0('S!3K+[<=@/\'FEJ'JW9,%9L'JN%1M;VR,CJ?=#*((5L
M/X0>2D"*-LM'4AB4I24PE-+96):B7==B=$@]VW#(D/IZGW\R2*'*D:"'A.[S
M[Z']3.]!3EAZ3\JAO^P(C^]Q.[OBE?&U(2I6T#D/RS*WXRJ,U"KG+9(GV=?[
M@))%#"6.`0.@RLC>5T;VD+YL3+T.7_&A_^<TN\[2311M\\^0(L0[:;G>MFG(
M"]^B`S&/[MR"5LRG;<"RW/)3Z7WLR"6/;%>#!U1058(:D(%?JGH`??M?JUT0
MSIT/5M9(">G243TZ$P-M`\B4^>33Z7UHR2>0DLF""UKE[]SODRV:/6"%:CG)
MN80\ZN\R@2)%>8%21.*'-AF.XT>:FL=K-HP5F<=J&9YA^63#U=?[](9!"MEV
MG1Y*<&RP0548YQZ5P%#*)>2R%.TN(2>'E.R4^GH?G3-(H6H)20])`E>'=FY[
M+T^,,E7\+C,3PD.:#N_GDUS9OMZG@_1"J#&D%$@J;@HX_J/Y[DQ&=!EJ#IG0
MX<$D+TOX>A_KT0NAUH!2(%+,4;H-MR4IVEE539X2D2=-?;W/XQBD4+)^HL=3
M,53`@1M*$=`70&TY\FX6]_<YC\>T<E04'BH/#0#)X6.9>K.73@#9$S\5BN!K
M6D0YN`Y?\2U&WGC[P[Z:D#K/]>4]>3;0J4BRCDC2S]:F`F3WBHRRWL?&5/C5
M<K4?1(!3I@@)H)_ZR%(V91>A:\<_&*C@$;M`[BY8>A\BTXJ@Q#.@!'-H9QG/
MAM,PN7C((NQ,?-X7L)_?XB1^VC]5V[H?]^0$%J<?7%,YK52-SCPOYL1=ITT,
MG^,BW.'#RWRH_AKY7^::^%^.WF?(?`(QT#A%K7/1F`M:<(LZE$IFRG@R[<C<
MC3&CJH_&M]PM=/0^#.:21[8;P0,J0)5`70N0:J"L!^JCXH^L#T$Q,H8V+DT[
MJO?$JE%_AC79?73T/MCEDD?5WAD/N%8DVU/)\QW2@N>R!FOP&@V$R^0_HS"[
MA>0FW&&XVL3:O@+ZCTO#I`@'3:'OH_?N,;=,6AC_'F`,$P"X3`"J#W`#JI1$
MY,R@@99PSA?MMI`U\TA<KJ/W5N!<T;2:189Q3DTHX"DL4]_$"2@>(_C_XFP+
M[N'".=R!5Z12]RG:)4=%T.^[L$"'XJT"RN8DRBCK$]&V;CPV8U,>^=0D*LS1
M>R]SMFQ*MHSFH@P@&UUYVO`]Q>SQY/AGWU-UFM`K"8\>H(;@V+MZ[XMR2J23
M7];`XO+*OJ=JU$*"1[:47LSSQF!+V#:18$Q7[^W7>8+IZ(EU4#+[87D$AU8;
M1ZQ-3/%NV%(J-LL%^YZ6TS_9L'3?P*[PL&3:N5]=C,CY<D1KP-?H1W'[/=J]
M1+^E2?&8GULF>N!`H`-VW(-L3:"0B%X;.HV9_LK5/$Q]AE3+.V1#T&B=,E0?
MD`8`:4&=Q@CSS?11&1X?[;@UPR0?4>^P^5ERZ>.A#8-D=M`2I$J+NF?#O!3E
MHNFC:1RNVG%C'OG4IWZ(,RR6)D[:($#DH=FBE>!;A)YD@]_SZOXSUC7D'F(7
MWQ?IIO5V(UL=:&6CUXG^%I$C7=XN=D_]P)]*PN4=.1J8M$Y=W1:XN@>D-;SM
MIEC5A/EW.NH:CZ<W_(W=<E]([TOG@B34Q_NC@<OL!V:U]L$JZ`\L/B&(4`8'
MX9[A!)E%N8<Z*BJ'H]C;(ME>(EFG'??4MS3H1-3$@:0"BYQ)"_Q2:]^O[!=-
M+I.\R+#!>1_F<7[SG$7A]BKY6YC%Z"X`NO</^>0Z\EZ&IT4Q_RH*GZSMNRE4
M+5CN6N^C6$9)9#N*;'#(1:NF_!G`-0"I`M($5)4XDE8PLT3:72P--:+WMA95
M"^A5/LVSB3/+HF2>8$45U`E;,OAGY)V%9;)E4*30_8(SSCOL<OU^?G,._I*^
M1%F"EU4%;#3?9Z^XWAR=^1QN(N(]0M[8<N\K]O4J4B?&9.G7@58-.%.[Y,EB
MQ]([+HU6A`48/P@F>)]F&5E4[.*G&"]5T!)%,'45.#S*J#OAT+1J6.C);3S0
M>H<OTPF@UGT90-'U6E!!0$K.(6T[G=='O":_CN!WVIY[GMOW#)4,"@]A$$EH
M>CG[Z3U8']D5FUP:U?S903Z!%K#:E-".G)4MV5%ZQD6EJH0"JZZ%2DQ8_,'Z
MENL2PZ7Y2[,\XJB=#:@P=>>&@[2+@%0$UT(5XZ:`_V<+V]R@O>8'O(SX!@6J
M]J$0B?HNG,A6EBE<LA2(?3RFE6JR36P/R;U7S9\$%2?DPO,1(]R@.FB,VW.5
M<B54/&-IKX0,,]MDFY9KDF6EYH^7BA)QN1F0">?$K'@&2&N@:8[,EKC!LRI`
M8(ZFD@DWWI1',I!\EKQ'$4:[%JEODU+UJ]1Q-6PFR9L5]BGM[$[(L<#L-(XH
MP/%CNU<TKLDF?@YW]2F\#&XKF&@6X/;$='%<S7(M<J/"UCL>F4$*M49_#$K7
MKE>EJV"N.;R^C;(GE%ZP[WZP##*C_D0RN!]_/VUQ60M2_(1(VL*LEI)-QUT"
MHM^$D4Z!=R"5=!-^`"Z+3QM/R38>H%Y@CF_W'WR+RAD<%,S$:[^/=)GG>Y2W
M^^H>=79NV+[$[<WACN<QD4F@^G&NT4IKO0WB-'C9EG$207#PZ!RHRJ!#5E1*
M/&7EO#.W(&6[[\F-5/)-9VT1\Z#W@2N]$$IL+#4<,N7'K2D?KJ50Q`L.D;FK
M0@D85U0WF\=HN]_!+G_#X=!%'.57]U_2Y`&9>]3E+0K0:=)>&Z[ER0LK8(4S
M3PD$"%^I!D=3[@JO)RS-%V@S)9,]#\R#%U35T;30-(#^"S7Q#CDW>+H`?^!F
M`'="?'ZN29E73D71.G,0<U/VVC&K#Z[W)M]<T93,5S-!'BC<\3VX>G?PFFMW
M\"L"!(%=/4<9OGF4GQN6T9OE0XP2=3N<IR94`E2*T%?8\"Q\_\E<ZSVG3&*7
M/6M,`0A(`432ILB,YU#&OJP4^ZZ2FAT;W2U,'NLP/#*^>IMA"O1*+.TTCN`J
M>PB3^)_X5S9"MFM^@$VGNWB+_^,BV5Y#<-7E371S*X%KDCC<X;-*;);KEZXL
MSY!WM"\$XCS62QJE2D_$-(\YX1!.Z+WTEB*O[*E"!N@#Q>5^$JXQ#'4WIK6V
M^VXY#MP,[K8P4U]H$-7L[Q;&H[0FHZ3W?9-I\-)Y.84@:'LN$BA&F29")<>Z
MR1T&1LG$M\VLE=YW7*?!TY-L7DJ&221BR=;WWA[ZR`P/5HTV)HJ!=#B[7.RK
MA\?3)>.I]^$/DQSJS.`TF#9)A;QR2<D$9DNY%&7'[.?@\/ID>/6^=\0DAWJK
M.@UJ*>[2I9A9GKJ=38CIP;7(P[<KO2\(,<FA9&."!5&+MHS127735_<?TJ?G
M*,EQ,]\BE'QI^R'-B_SF,<RBNS"/MM6&<>.=N+W/:PB*9)J%;6;4D^!QJ2.D
M9K:+OCIYB]?4VWL1*ZAL]T8HVN"F@!KZ[CTJ"MJM\;]*3POO?1M>8RQ\;RTQ
M*=,\<(KTE'9DF!5UH&%G13:0+5/O>4^HG-JH*078H.7>I?>'>EJV!W"#9P`W
M^0ZK?I-%E-\E%,59.>'#;T&;NX')\QHF)T+D8H)EZKT$$RVJ$E]7,.C!&9@U
M=/\^RC+4?=/"19:A6X.H_[_'Q>-ELHU?XNT^W'7AO7^]A?*C*,.>9G[$Z&AW
M+?,FE53P<R\5*![9YH:"W(ZMM>;K7#4#(-T14"%%@`J10'92[-B9AR59IWY%
MO)=TL^A?%J7OSI/<CDW/=#1_A$/5$*AQ1=0((\&X?'IZWJ6O482=GRM,B=^B
MI[LH.S?\E;P`HL%NYRDT@S25*@Y7<7Q?[XP=4]!E3Z@3_0?5[P`7`*0$^(.4
M$<Y3_TWQU*?G*3(.FF<$GP9/S]67*+M+>0WU))!CTE[#!A_11:YKV!XG=W\+
M?Z`@^K(CR_+D[<0<=#6/HQ.H*UX>%C/LM6OC0WU;\W1'H[B5.`UC"(+R1U[&
MD6L;];?SY=U6.NAJ)N/&4=>,.RAFV-[:M<BXZ7VS8A2W&L:-(*@ST?$Q#J?%
MPKZJ;;GR[D[4W<QCV@C:BF5-$31.SIJ,D]Y!W(.8E;!KJ/<`_\"U.B'9VPA=
MX9>2ES"TU9$`9@TA/N!66PMQ3(;MZ.W$C:!6QZ_>_BN&?4S10T7<MW^;A?G`
M.AXNU#N+]XOO8;;%]RK/;=^7Y]D)@SF/WQ)'JWN->&X7AF.[:^)3.7H?P$F3
M68EFRD)_<".Y?:!^L.W5;AW<O?:=O`/<19DH8''[(#D]QQNS#R/Y/&:SS?77
MY22B]P&<+)%E[Q!*PJV'79B2:$B@SV&<_2W<[:.+/-\_86+EGWX\1YLBVGY$
M9P11LD6IAJ',:T>>RRL=_TQ#LL#PUA9&?M^6;?CE/*=W9G[E8Z'&8U$L55#]
M!E[C:,?XRH9"59#CFOS+TAP/KT)+XSDKG]!0[PUYU4,AW?=1*T]`XP>-ND'H
MS;@X`[AKT.K[#%2]@]J*L3]]V]R$&!^..Y;A^)QF]U&,<K'@`3&MM=.74FK@
M9IP"2`(LD_(Q.[!-DGLWG+5!WN2P';U/;Q88#2462JE(0=/>L(UZ7]JHOI5:
MOX5J#%33N^XFBO+B^;]L5/^@J392Y)Z`[>@=5+G`:-`;J7D7\M6+%GS*B_@)
MW^G"#XBF]^"^+I^?:VQ;Z!(#_,NT](Z90LOB$<:5/KS>L05+#(>ZK2"U@@6U
MO](8%(Z''Z4@1ZF"X43K&NNUW`TA*<`U-#A#`RK5SE2=6JY!2*=WRCYE8W"2
M2ZH>093L]K"_6Z5"@>0=AOVD%DF-YX,[)1-A&>;LZAWNIG`43M?/Z96G<6_P
M&QV_Q`EXC<(L_U6#8Z^_I3O8S`X2K3J9D?F2AWP)-#SZFAQBJ8=?Q[VC8UB;
M,%/S&!_UHW&Z1^VC<@7-KQI;G-,Y:C]9BZ/FN/VX=\]9F82*>F?;4S\8)WGD
M/B:1DF58`X#W3$OND)17%7&(YDG[4J4@VANXX0%7:.=J$#9<1I);A.Y/&&!$
M-2AOQ<_J%Z_E;IV!)U)$?R-UJN[7R1JI)9RQ&H1G&^6DK?D]L*7&Y`VX9KV"
M+>&AG8'?=+6"Y(X_5LJ^)P1.QPH20?2W@H,#KM(*5B#0M%UJQ@D$6RXR*&_&
M5>L5[]!5(T7T-U(GZZJ=JI%:Q%6K0,#9FX3@N3_AQ3B:,7D+KEJ?8`NY:HM;
MP6]Q_H_/611=)G!*B?*BWL.6ET9).GZ-;![E\$HQ=?U]H\/R\K#J!&(^58[%
MZ7E?%%(%J,R[>U@(Q&4IWF!/-3JAO[]UTB9'KG?5W[?GK$CLH'L"%U@4#L5)
M^5+3\LATH5#O`'4/JOZ7/H[L&X]FVWF].I'<*2-B:&[3A@=;F6EK'TGYY(*%
M=P)QI0L,R=OPK?J%&W*Q=#B/I%*<TW2Y3M1*J7?`6D=3U;K@!"[DJ!^1DW?'
M>L5:P"O3X0BR=WSJK>:U+>_1*55BZ&[X!@=;G>%K'4.5V="\GR@,GV%(WHA[
MUBO<B'NFY>Y[1W%.U#T[32NU@'O6'$=5I/V)0O?I1^3TW;,^L99QSY0:OB]Q
M$ET6T5-^[JQTO'U4XUO(5HV,SVPCU+0-6>>0'-;>&XU"'9)56\,Q`'B^20!_
MH*8!;EM58G'RGEW^%UBPR"^3ZPCR:OOW*'YX+*+MQ4N4A0\1_O$C-$&UR<0'
M4[Y^:S$^:18R(,*&?K:YX46"CJQ+_K_1N"LQ(Z/W.DV(C$%5X5U(:H![Y-Z\
M8/<FO0<Y?ADS+7-O/J#F(E4IS><JFEY^ST]EX\2Y5+Q(/,<@M]:\-WI34<C`
M:.NLB9!.Q&+OJEK=$20@3@#!<@8J-*"$0XH`!*BU1F2SE<-OPY/W[LX=2^*5
MQJG>YQDC=MDJXS%9TUC;AM[++%H19"LD)8X`E4/S?U7R0'_.P,5N!U"1G/,A
M1FHN2%FG:,+SSD)@LB9ZN-S7.XZ86@8ESC4M&ME\K]^BC[*7>!/U3XM?T^0E
MRM'\AN:>_#8MPEW[]P]I7GQ-B_^,BF_1)GU(XG]&V_.U:<A3%&FPYVF8PM&L
M5%->EX:[,E=X@]K2/%!$V1@H,0VJI`E^3[+Z-[!INZ'1#_1O1A=1/OFE^)8_
MK2GI>+/RNG3<E4=HI[>/H&@$9/O2:L0(JFY`V<_@*ZAGH.Z,+%_ALA7W=[CX
M13W"D@5XC0K0=*J)%2*KZ\]I5OX)E3.0,LG+8:%6%DWM%>6X2S=B_3C0E&K@
M$'!+\W"-90?FM#TG&A&GW:DSD#75P3-N\R2,VVGY76_'N*GST/IQ.,[:)O36
M^S;3DL-RLK[<M&RJ'+RS\N0"/40$6F@X;2,Z&+Z&H_H(85[#,?TM>KJ+LG/3
M6WLK^G=9)YH39$^HL78LP%!-VUZ9>@>WTXJ@3+/&<;2T`(<<5"4!*@K^((5Y
M=UVGOC_E`YUZD+7[,.9$590A$0VRWB=D]$+0,W;>,Y34B&1P]RJ)OL;D_WV.
M7P@&<AC=YH2UMONV[`;X2]/F/!)SHJZ(3%7=<-8K9TUF3[U-,(\XLLTQ!Z8`
MU@&H`OD_J%I)=%)1'<TI[;1N/.]:;.JOX)KD*^AMNWG$467%.;`%QGKM+$1Q
MNO=\=6-X9W^0IKI'AMTBPZYWF!Z7/$IVXWB0B24XJOHU?(HN?L3YN;VRY%VC
M;/<TC][CF"L6'Y0RH&D@IS*:1\V/H);M70QW'6""H=_`'^A73HZ583O0[9;W
M9/%A7V)X-H3[F&E5%![TNTK_2^_LW:.X5;&MK_,VW[A"MFXV41+"X?Z<9M$F
MS(MRRK,]1^)CV;U]SKP#0"E'':G?7]YPG95#!E?SM((T^&4SDP9$4!4Z`U4Q
MS@FX:NCW)'^.-O%]'&TK>^.Y?9NQ8MG:Z58,82FD.>9LMPH:\7*G7>^8&%H1
M5#%W`D>+O*V2O*:6]Y;(USW2EJO[B^TV)E\/E\LO]L4C_+PD&,]?:YCI=AKY
M0C>_N(9T]BTOFEX]VRR]2;W#9-4-@G1;H$H2$3>U2)\HAK_IE93/0=.OAH9)
MKZOX;\(PB;MB/]VK=^ZL_)5/-@]]O2,X5`Z#DLTOA0(%E\DFB]"I7IR`G-B5
M\"6,(8Q=A&,JXCS?A_`K@?#Y.4M?H(D*"U`\1@#I*`B39`\M$KY0_YCN($?R
M?P-/453$R8-BJ]2C.&O/TM<6:6:!*(9/F-WI]F4Y3D5*O4\_I<M^&A9F0HH`
M-OL$'1V2:`.6C#)D.=KV1!OKH.<2ZF2L@_CE4H]7[9CDE,?7.TQ>MNC:+XW&
M\8M=$(E8!=U-RWHWD,3CTX\HV\0Y\I,NDR*+DSS>X-P8*+;?6'MR38L4X`)L
MC*H!/3`VLCJURF@A7^\X%65CH,3\*!!$:`J=5J=GH.Z6)TV.0/&/<@I]B]#^
M-5R2?4@AP'!3P#7;;90]H7$Q#4_N&DFM1-K8L!F?0()QHT?CK&V[U!2]`T(T
M&!UU:[5%Y>RF4\RJFF#35`50R*=N>L6HZ?^$[*'NKMM/8`]E.GL,:"R7!#?X
M>L=R+C\X)^0>\DDHSV_L9%VL$8$6)(`PJ4U36Z*,R@N?T#"@3)!7]S@K)(J4
M=OI>?QN([Y8*9J$-,LYQ$I5!=KQ?-(U;)+K%USOB4NDX:+N-QB$,L4G@_;A-
M>E_:I++<8:+_LM?*(D75C6K4,4G\>G5/TL!J:7LHKT_]R_AT+VS))ZI='@EI
M'EVK<ASHK<^\*V(JA0I*DP$7?T7\A(()-K`U=*7R<"V(3%#4=GR0$N!H@BVR
M,[`Z3L9_KJ6AH;O$]B\[(_PID-%^/4+%\I!)\W!HI0.A=R0!CTA![:+P),`2
M!;7.W(^SU!R>-.!S\95^04<,(NAA8Q@'6;2I&>\>DM(Q,"G7;S0T<L9PG)39
M81`LN'AXR*('Y*?$]3'?P)-"I8^C^E$A-N71*_#IC5HH:3L^X]U[CE%N$;S1
M:R7\HW$JNS_T(LG8EXX.7@4B^?CF1S?,&);Z7:3:8\SB3?4>+L2)%IQX#=)W
M?"=IK4:#:5ECQ3EJ0A\XF^H>3;/D?2MK_4;C.V<,A^[FBD,F@7O6K=?)FNUK
M!*!ZGQJ4$'0V5HIVL-^:M1*_GUWW?Q/N!GE<9N-8O]%[*IQ#<2J[VHQR!;>/
M$7@J30G>FWZ'=ZJC>B,*&QNX`!S:\BY?EP5A#D*T;85*X7URV/"F?4LFQ\8.
MMZ=X_YM-[=1L@[\U8R7G?>P1(I.]4XL<T:Q/(()=Y5B<Q!X5JU3!;VT[12S)
M6=OD')B;YD5LM<;FM_`'`HE"F;!V]#UJ+<FFM+I>UG2,CX$H"]'N!3+%LLCK
M;>L3B&.4([7N2ZEAZ`)73&4G"\02]K)>T=I';]47OY(YHI*]*CW:$[C2(4?J
M4UF?#(L05)I;7;,86'$H7CST$EK-&D%OI1;N\;=Z(:Z?4;I^;SNT=TSLD_#C
M1P3HZ'2IPVI5^&I?Y$68;./DH7/,M%H9VD:S#.)>UAJP#*<HVS#2)XJ@(E=8
MUF\[.HYZ#$[":M!*PQ*6DC9M:F=AM(Q&.5T+(WPW8:Q/QR%)+]=O.\R?=@AT
MWV>@E$-H6$FKSX739+204%X#-?&=Y+6V:3(X)%KV6KB83R#J6C@7&C0'X^TY
M>W4"(<#+CHXZ?VM1.>>ER9CGFRVEC%JFR?BY[*'P-!E\:"R7O&:_/H&`XT4'
M1XEWN*2$\OQ&>6DR"KA^1OU7#X#@I[X<J&/RC%Q?ES/-$)T4M9WH+6YX/OF4
M]DKS8%P*^-)U;1I#_:8,UPMQM]_3_V^4X?]7OX-X69W['+Y9V<O5@9,7RF;G
MT9$?>\50VA;0.Y`D79F]TCLLDU,BV3SF@Q7`:@#5(?^G]81R77?."YS,_*&,
M)="3_-T8`):/XCCDH^@=Y\<ID:JS>SYX`>S>693W=*?M>M*^LYM#V0)Y_)=L
M5MHKO4/:>$52LF_""4XXZ^<N6VC2AVNY>WO*^=@/M%=FAVBCK>2>OB%LZ@9`
MNF50)@I'5@7V3,(7.ZP\T;;_Y.S3#_3/Z-Q92]S4I,,P3^5YY:SF7LKZOF.2
MSZ=WX!F'-++76>R0@KH*&-Q6*ZM)U0DI4Z>&.M'Q1^GJ$_?(7I'/IG<8!*=$
M2KQ1/FP!]D-+U=BT52/B48U/3\^[]#6*;J+L)=Y$`^$6!"G\U]7]MVB3/B3H
M#2*2,.-#FA?YESB)+HOH*3\W_)6\QYH%@YVG;-)'KM)*T1TYSKI<T.L=(RE5
M;MFSGTSP0=4X*%L?G"[/0-,%\C&;3JK$Q[@;\`?J".">&)>R?XF2*`MW%\GV
M8HONCN=%%J+E<6F]JBT0V^O+G2[&*E!!F*?KG%)6&DQ7W?,]$E]AZ!UEPR&-
M;&UCAQ2454"8;,%AI<K'Y-S<8>.*%%]3.XWH>)I4U4O7AZP/#+U/:/D$4N)G
M<D$[T(_P4#_X].(R@=YJ5)\B?RFG)7R*;+J.O.B#D8[GZ0"31!7SQRKYOJ5W
M1-$T>-F6?A)!0$J`N@BHRG`%)0ST]S%%P3CP*WOR+G2,=BV%N4-237"WK.:O
M-=\DHX&_$'_;&,883,HQ<OA;E$=PE![A#/`Q>HEVZ3-J]7"FMAV)+X13`)C'
M9RX)*U;35#8<WR?K+T/OH!MV860SGAE14-7`OD>KSDS'G(4D4MQRK=2@XY)3
M5"Z=1(-\*;WC;WC$4>*.<P`[U(AM2R,XXP\VC]%VOXNN[L5L4]VB8\ISVS?D
M;?U*@3PSZ$#-*-8AS%*Z,US/(O&[AK[!!JK$EST5*I`AJ/I`V[WB]XEQCSS1
M3CQ7>+_ND6V[NL>_YA<O8;Q#W7].L_)=+G?MXH-,7XK%D01;0*23FL&<?9M^
MNLN5;9'H&$/O8V150T!O@%ZB["Y5GJ^#31QR.2H'854.W*=9F;$S+*!1>BZP
M]P*LU1E`6JB;7=$K3\>)VQ5Q63HFN_0<HYP0]=Z04C0"TMT:)6*(N&I).D0>
M3FF:+@Y,TW(/_R((!!Q6&!O?DC&T,C]#@!>R.RSC)_@]JG9G<)V^+B<\O8]N
MI,M.;V7(@Y:?DJUB[X52DLIM:85@+^JN3#-=+S_EY`R%K'?KVGW!F:PDF-Y!
M=[)%U]87H<,OX_DY\CHXZ6TQDW*4_N+@G0^D*;;D2V7RI=#&_#`.M02C-([`
MLDV2B=LV]8ZY6FA$E)P2+2-;4+V<$+5-DT:>#YWNZ.X/O2$S)=-W&D?@.2L2
MS6OJ'2Z]S("<D)]%+Y4\[ZN3;>OPA4VU]NYSFMU'<;'/FG>1\6(%!Y0ZIH[&
MK0?RLH:,<@Q%6:W>[ISURK,)=_6.E5$@/84]6A-[E.`;\@OM#4U+$GP(X8CO
MHJU&-D%+?^>T3()P/Z:W-\^Q2%"7J7<4J7SA=?=/)B40ZHNT>@-Q4L;<+/`P
M;BWK7[(TSY%VK"2G@A>+>%D#0S>$0A_%/>[-LHVU12BJ>3B??.E/8I]F6HX`
M%U'M;XQR64M_X[3,@7!_H[<WS[9)_(2I=]9`^<+K[F],2B#4WR"]-:X&^@OL
M<;&'LIH3V?4*AVZL=+0P'<#+VA>J\9/P)%8K:,(C!Z/F&XW>I96=-?3EI@BS
M8AE_8TJ6H%4`1;W\GV&R#[-78"QQ\#/&<"V#XT[(0@@/CNMGED\R2IAO.^IE
M4O:3"8Z;DN38/BQ]-CQ"<2U7*:=C(62^JMF$5E4SSQL-U*<47??5R01^>:\@
M+1$5UP+P+=WM/J<9^O'<6?D2KS=+P:R-;1D=1PGVI=T?9*I93E]O.T*?2OX3
MLC2#0L@R-^`/U"4H^U1URYE.6[0\@3E!JR/\&*:_/^_<7CNF1[(V6V\[0(UR
M!$[B.(9.%I*#N[(AB]F)J0A-WSR)O51]HV%GC+4$\S(.`>WBD3ANZVW'EG".
MR&GNT3)(J.O.+:7FZ+Z?^Y:LE,R]WTG&^B2RP7K;(;&<(W**^\0,\FF\>TRG
M.KIO_KPA*R5S?VCJRHE#PKVMMWW_D6]`3F@'B5XJ>3O86MTLHAP;M/2]KS=.
MW)/8@**4YR2,X.CX*S:';2R&9[DNB4BSWG9X\?S!.;7M+CXQ@ZK:NQ,W;Z?L
MV+T%\[:4MW=(;=LJ]WC?=KCT[+%Y(S[@H("+N8-RCR!SNDOYS96WR1P0YG*N
MH5!A)-M-V0-/;30%`T')8TAV!NO$0\"E#HP>OJ!,$8/J1]'7U"1ISC+NWK],
M%H>?)QB(9_LD;M$Z\9!3F>.RN'\G43@JWRYGS"(4'5RF4[OG-S56/:D,)G35
M]Q>\]2]8G(7-Y/S!%V8HF:&@\()RAC_QR%G)0W,:_MT\(67E/9*F0'JZ>#^)
M]1+OYC%#\>PRKZEUXG</Y8Z,]J[>+/'$.GN]:9IT<_<.,TE,JNN"A[OB)%G8
M3,X:<F$6D@4%VKPA#^[:)Q[C(F]43L.KXY9/4EXI&;JBIROWILV3>`>.!85G
MEW'M]HE?G9(V*-J[;;R2B?78NHFNQ#IKZ![899[OH^W'?18G#Z07C"S'/Q[M
M5Z)S9I.\.B0ID3<SHIG&2<@(U$:&HS6T2T&N!MN:7RF8+1R%T@M)HCT7*/=I
MX`PRR?$13DB;NC,V3V-KG\1$VYI?(IPKF_3Y<R9`&4]=+)!<^M-_[R%M+I.\
MR/9XXKXJ'J/L]C%,#G=WHFT[);OIZA=QSB[)0K&80H9\=A0F#PIG;93G#=Z)
M1Q/)&Q4]-B6DR1=\BV#=>(,<]!PG6;BO:IR`Q=(KB/RGL%CBXL9Y4'BV0>ZV
M>B<>3"1M4!;?IY`EF0@'C6``+1``HP`%A-$Y=H+U=77?T(G8T18/WGGY"!>A
MG\,X^UNXV^,@0%/#NX1"A=3<A/)^*&76E1;@RBH/>;T3#TU:9,#>AA?)(_KI
M.)B,JGJ:ON=/:%/5>ZR4`#W;+=7DQ`.FEABOD_=S.816[P(CD#U'>!@H0$@!
M@@HP5EW,^>%!*#YA-T[0"3X40U>3/#G8\HWN,02TOT4N%OLG'FHE:4A.W!D=
M%:[K;CY(B;H2KC`GYDZ>MG52Z!(>0_`@2PE93SS22LZ(G*Y;-R:60L?M.`!+
M3[M'LWSS??ODW;:376K/_URJ32L%1N0IE#JI>>2:KF/VIEQ'5NE/S+=D4-J3
M=CY_/AN[F/M*M5]EE`JC>4"CID/V5AQ@1KD7])!/;7_S:YJ\P(DHVM8/2/I:
M/N+-*HBN9IIBO.7;X0X(Z)F466']GS44:F),Z"WI<@_0S)3Q\'F'9`M^+TLO
M]Q[-#'72ZT6:MV^^Q+U*PT7C\CE;_XTF-I\[)JSF2_W+-#,E'#5>BSU4PZ]/
M)[:(/G7SI7`1W,'@V0ZY0>&_T;SE,X?D=!>QHW(I7*36.!0_R4X_0(>/_<J\
M$ZQ4%NWMX.BX*[2%AZ^%6VL2I>;_K!<)*<;E#5C%0>&6-(T@O2?-YLL\*#]/
M=T_L?/O-V$R%!]5].#R4'<QPR]70SQH`3C4R)W[H3"-C<&S)M#-=5!<N\*[2
MZ9Y#G.Q)\KROI-``TH5<E#<>UC]KA"3_<+VM,P]6\4_Z.(1%=4_UI.3G,K!+
MG*]0QK21$\3USWH_AG^XWM*I#*OPIWY@PZ"[I[J1^5,9V"5V/>G"VLH3@Y\U
M4P;W:+V!'5)&D9?9-SW1@,?)L3W<Y_-.\=HWE["G;]5'OYQ.]OW@!`2Y1^7J
M\V>]4"1DY-[*#N^,,0BNH<'&_=?6^=V!=7[W)JWSFW6TW[QUUM+[/CR?MFWB
M9ZU_UJM((@;N9_#)!Z77V3W7--CA;UB(=LZ-M7>"?OBA&+J:\,G!EF^<CR$@
MKX:\JK#^62/[QX?DQ)W=4>&Z5^2)3=/=.)V8&WK:QDFAYW@,P;/=DJL_:^#^
MZ(B<KJ\W)I9")X[`T"_[TN'P4)VQN-;)>VTG>QHV_W.I-JV49\GD-8?USWI)
M8.:8O2G/D57ZTW(M&73VI'W/G\_$+N:]TIPL.P9Y$W3]L^8$F3=D;\7_991[
M00=93BS"Q^@^RK+!4?Y[7#Q>)MOX)=[NPUUGQ/,O<1)=%M%3?FY8WEJ:C1:%
M<IZ)E3=6E8$4UH/ENWHOVP5+*ML<B84;5,T-FY#OL$70-'G69U!R\`=J&."6
M&4\UA'-9RO+WC>I]9^TIK`?3,QW-@RF%RZIDK2<:M08FX&;S&&WWN^CJ?J9P
MM^'=+CJW?<N4MT@3BG7F2DORN-6K);']&)YMZNT3R!%8^DI%!NJ@:A7=<Q9F
M*G`/>E@).;OE;]]*=+>MQ?:#IR?-MT3D2*QFRU@*=AVMQ:>GYUWZ&D4W4?82
M;Z*!_9P=5BOXKZO[;]$F?4CB?T(9\7['AS2'8D8_BO>PS#_.#=?V7`660S!N
M449$_G!V#8KP/AW?-QRTE6;9>J]1E(V!8J,C5YK@!ATVO7O?W1S]]`/]FS40
M7S[Y):]5?C9;,K*$$=^GY]B$>)IGA%(T!.J6.5+E.'!EJIY`V=6!H]+N[0PT
M_:&*38_EX0G`?98^#4!]`]PYMWO3+W5S\(Y-(3[PR2\V!?2TBE?<=R.V::V=
MOE2@R4OX`YN6U=I:8<."_B*R:U%V1,88="W'_%[P+(6OCUF.YHF2Y$FMSCZ(
MAMZ8A*LRYQOH<3%:,2^X`W+:FH.J"SUUWS#_I?RM09"E_>:*D$GSVVWRI*;7
M_FVZP4$)N,?%K4`C`I45.!LR`V>U'=!`Z;U_Z?S8MH,@YIB$.9HG[I(GM>*M
M!='X@YO]TQ/*0HC=^?&Y7:Q.XR[*,*PAJ*YE.0HV(WD!RE5XK@&BU7.:QI%[
MZ!&BG,J)IBAAM=!J9MAM92;U--!=R9M_IZ^[S(MRJL8=IUS9:9X'2+2L2R_`
M60$?[,0-;[R1";F.6I:ZW&['>;?%07'/9-<QS_=/Y&]=4KLKI3,V/UCQ%D#H
MP(U9@SD=H1G#)^P[E0`$&8(O-L,+$R%H%40?;`N*%'S*B_@)W53HS]"";$S;
MDH`'5`Q6W><HA^[[7;CYQSN(&LJ=EV7>7<,U`?KQMW0;[?2P+LI\BK=F7:A\
MC5D=.6N+$%3S7"LRY5["!Q$%?M`?.;I>=>20U-V`ME6:ZYT@'RB+'J$;%+]$
ME\DF?8J^1L75_6WXX]PSR+.;:QFV8*3C>8K-)%&EI&.5X)Q@D=@0<Z6WRC%(
MP3`YIT6XXYN<Z?$$!T7!+LT9GT.B^>I2YK1%>=R9;,8JF:5G8Z[TWFNBED'V
M)$`+Y(B\I"3XY0LD\:]G`%9!AAY6@HO*HLCBNWV!;3;T):^A\4\*84R_N,N+
M+-P4D!JF+VV-2`%`&O.'):30@*:RXSM6:7OTSDO"(8V291<[KH!<#=\<J$I<
MJ@JR][_^NSP]4&WYU>L!RTQ05S;+G6USI?<^!;,L"\X,O8#FSA#@CZI91O<>
M*UT/VL]I%L4/R8=]!IO?O-YF89+#UM$B)MGB_]J1)<WVO_9Y@58EE7S7:89_
M:.&\30G*<\->K>7E3E`JRSS-77K8*R.@&(?E:I[F:Y'QD&V,EA"JG,U'S5K9
M/Z@`@!8"_)98"P-H0!S:PQ**$,]Y(:V4XH3_RQA2#_LRQM`V7==:G3N&9?@V
M=`96MJ]W!)<.PZ-D[:*!H$%E&S>5;0SK1L78-&2#Z=3%D/C\X4QT<NP._]!,
M61+JEBW/U'O%)4C"I5P?-I@TSHQJGX29I%(.:=Z&_G9.>^:VC+(5K/2^K2E*
M1"7G1(+`3F\QBM'-WY,L"G?H4N9?TQUZ&?DO89P@K%?)301G]+B(H_PBBU'`
MQT?XG\D#N;O9G'U9,M^@D`5;CC9+&,PI-9_?I>G[-MG;.TTK('@$EIKFQ8I!
MXP8T/8*R2X#Z+'\'T"EH.@9ESX!T76>_;5P)W<R1TIV*MVZ.J/<?YG>)0BE,
M0F.]T]&H&H)%]Q$$"Q,@>[%O[,X#;"TG_DQ$3$Z,7Q$DR:["ES#>(>?HW7V:
MO<O#'6NNFB(L<'*MJWLBS46R[9&Q/N5R#$]BO"@;F)D!H7,EKP,^&1O"GQM?
M#S8-S;,ZS)-,>M#F+'C!S>W%[:??/GV]O0%7G\&'J]^NOWWZZZ>O-Y=_^P2^
M7-W<<!_"?D@37.U;]!(E^PAE<#GWS+6\)'`]'<Z-1*"0H(D\Z!9&<?4>/@XW
M7+VG*`KTBB)LIG`$Z&_(DWQ(7Z(LP:'#F[)6#C)23QQ3)<70*&1J3XQ,M["Y
M7MMDA/5>VDUBEQ\#,PX@J`J`L@1.7<7'Q[QLXMRS5O).*XY[$\/$8>S'-*Q+
M6JL5?HX:>A@GP<%^X*H(V-M[S;Z\HI\@YDF=L"4S;W"JKDIZ9(IQR"CJ?5X]
MB5WI-#V$(OA+S^3,2L6\R*$K6^8>S<^],DNEI'LYA[W-I>(4]H:*1R5Q^/"*
MC*/>-^RGH"LY0YD`$=RBIB$%4?9(%'P5E>4$<5'2A*R$BST3\E%)R_1+C=8[
M\=HX</D3\DCOP8>:>I^$4*]9QIN.O#B[H5[%4G%8EB%*'MRR,'TRRKK?3J03
M0=&\306FQ=K*8#)?4YGXU$HLIR+:3EK2NH9E>FLRR+I?1J010+5E[4718V&Y
MMRP_A5D2)P_Y=915%^#C#03P,=[MBVA[OEYY\BX83G0^C\/,DE54GJJ(=I-7
MY<?0^Q8$HR1*[#$;I@#_C*F^)05`$A7XVCAXCC*0HR;D,%Z*N=:"\1WC/571
ML8W2O=,[F)5)#MFFG`5,4!5&L2,D5<@9:*A?5F'C>7,8_3'*XI>PP.=B]0O.
M7Z/B.HL*=`J]<CQY+YS1PIA'_1G"5DI`WP1:;UODT^E]=,`KDI*)@!-<\.$1
M/0N&7AF_1\FX7JID7-_##.?IVL7A7;QCSM/YERB)LG`'%?1B^Q0G,?*F$*32
MPX+$<27>\IKH?:9R,(M6Z\143;2&(I.UK_<)!J,D:C2`"5-0%L<S0GA001+3
MI7A`>C"]XP)-U?1\K]QBU3NJ@4D.V2X0"Y@#>A\6YWN,K;E9\!GR`QW?Q,D>
M^EA7<-V`K_?E[Z/[-"MCA6[#'U'^6YS@KWF90*V.\@("/VSETW_OX<^_1<5C
M"G^I@_$@HU:>(^VD1J$D\]1OV2&O5%DI"K1:)9N(OMXG!@N.BI)CL>7D"U!Q
M@+0`I'5GX`[W5MU**ECO`"RB2E(F_']9+ZHA7\)Z^;9?LECO")#%QD2V@[24
M8,'!;2=BNYK>P57'C)%&`6D5M)H]JRY.87!GT%6#3AND4IR@QS,NB^@)_O$K
M)`$*B4EW.]1\!9W'(M:AWTWZ+=>6MUH9Z%2$H:&0Y-`F="O`><A<&^2CZATY
M0RF!&GV;@G%T0>#J^M.WB]O+JZ_\%P-J_2U7,N_A6N<^1DG]#*OO@361Y.WT
M*H*\-*(<LK>G!AIT$L?IZQW00"F!DDTC.BR5@8=^9Q7/()BQ$LVM:L8.V-MN
M#=^QRA'6.Y:!"K\:6SL.(FB<AVJ3!_Q2%F3,X5`Y%?56G^&2=QN;QT3%,O6@
MN[D,G<3>4/.H*#H<,<EXZAV,,(&<@HYK0L<D>H#S]Y;7?(ZA"*J?>8WFP'>4
M9"Q54+#'.!Z67)L^V<3U]0X.&,4MWQ@.=]Z0CG.?NUJ,U?F)X7?SUS+]RDZ/
M<\E'(T)#P)[2EKVVRJ,RO0]H*-`K\B.G<#2\))N8`FDIR1ZJI&6/7>R67GME
MC(^O=Z#()';Y]G$<0-`4*#><<'H=-DK""LU6&22[Z<H[LSOH:QX-IV!7!#PJ
MA]:#Y`KY6N_0C%'<2LZ.QA#@K"SLSQ1]39/R,"AY(&V7DWL3T>VL36FV<++[
MF91DEZYFZ615PURYY?#K?2S!*HIL(\J()VB7K_.?E55^Y=[KI.>&%.=4&^9W
M_%:*SX/.E4E>A;7>T03,LBCQ:5E1E8D`J\RAY9J?]7VBJ\,NRUE:IG7OZ7$>
MJ^E$J//;]94V+;<<5[U/HJ;!RS;3DPB"JXY5_L*1U';LF\I)(JV4EMUDSWVE
MD2]'8L?7>N_94Z!7X@M/X^B-=^+(<-JVUO6VH[7V)3\LU=/M3);2"W.0(;2_
MBK/2>[4V!5VZ]1SOOYS2#UQ;KFW5Z:\JYV!I*8YVCYJ&ZMC0_'J&9Z]Q.G;-
M$V70"Z'H`(H:4,EDKH.H;U$>P3%Z1-<-HY=HESZCG;,/Z0Z628G%/C>MM=.7
MT35Y"7]@<J[6U@I3$_V%ILEY%.7#7)&5IC8<7\LC9WUKO0-..*21;7?9(055
M%7"![K`VE<!!+8G,-LP3I+;1,<340U^Z:'J?PW)(0\_M;;K!UT=[/II(CM?0
MEN>X=X(4[VR-4=3VR,B7BV2]0UUXQ%&R0<8!K&$X3L+18OBF78UQ`=@/I!64
MX_>16XR'/=JW#"T8%FN<_P<Q2N4'T3NX@4F.!1G?CVB0ZE*X+66'8WEN4WKF
MK7K5;*IWB`2+&,OXXKU8#CG==E"X=D7*Y+?YN>$:[DK:3G+5S5S&#H)MR%D5
M09.>0YYBT?O4>0BRDMWA@<[+I+-<3Q'\/8H?'HMH>_$29>%#]'7_=!=E5_<X
M"=+5OL@+2-PX>>CD"?-7EKQ\+'R@YM%5V$!4Y.9M$)V1NN33ZGV6)T9`)7Z(
M$*@]V?"^E^V"D#0,$MPR2HBT29^>TH2DR,M!VG2B5C^E^#FGJ)\=SXBWP;5I
M6X02>N^]"Y%/MB\E`F10-0+*5L#76@MOB/JUFIJ=V>]BLTGWZ++VPW6ZBS=Q
M*TVL;<B+KQ[N=IY>,8A3:<Y(%>S]XCUH:Z7WB3^]$+)U@!I)<+-_>D(7^Q&Q
MXX<DOH\W*.=>TP"H6N".'T3*D5_=7T/<U48NU+M6;UVTM]&/XCVL^X]SUS+E
MA5W-039/1<2.2:5%LUHU;,<CM-#[*$V<D+*U4!A2[";F2$?;;>'Y9E)I48L`
M-[F$VDI9RYVXVG:6=?-X@NRY19BB]SFA2#&5+/$$`F:89QE=1U@9+QWCEZAY
MH_C3C\UNOXVV)`G1T_.>H+^Z/\YA??&$NC]W5X:\MX"$0)SID<H9I=I[%=*\
ML5KA_3?+T?LP5(*TTOUAX9"#=I.@:1-4C58YN.IFD>KW984GC2^I]5(FZ3>G
M]9UI6Q"IG'7YE+7EZ'U@)D5>)1.Y#.1!LR-4;LA&!YI?/$9HP[:M_7,?.JFV
MLB[V&]3DM[!H27.9D-XODW:.0--:VWW/[@Y$%;'W,$]#A4A47\=C;PQ_4N*D
M.7H'8LP73O8<.QMAI5%7]Z!L`Z!&VI-KU0S\1SMGI3HUH@Q`/24]ZH:G\GY)
M''=CN7I?=YDO'+TBS0M>G8VT-45IJU!TT:ZGI$_=:^+,C7GD0Y+%AJMW](H`
MZ93X@/-QMM0I+-4I0^J4U\VPAEYM=F&>XZT@U!KR0\O]H/PZ?`WO=M%M^B4*
M<Y0M&@*"SFL.ZT3P?[>8;GVOV@V&B_/W-3=F2ZB439S7C&:=E;\J=]==O4_<
M18HI/XA1&-;@N"V`&JMV2W-0-@=N4X`;!$V+H&IR"66DOI]TVMK8=Z-I[K?W
MR;?7^X1?I)BJW$B!F+MJB>;"[38F'P7LL"[&C2YFT09]S2UZW"^LE/>Y5%[\
M[-EFD^VCYHEN4*2]K1`T2Z@T[76LT];HG@LL,UGCDITR5^^`4Y%B*G%C!0)F
MU>;YVE<]']?W=EQ^FU8W&[I7(,CRJB_ZE$$?^7L7KZ%"1V),9V=TA&T_V9US
M]0X)DBOX$GZS,/0#GG3U-F/_NXPY<JSK>T8]=XPTL04SW.VW9@SH7/*YM"KW
M0O2.3Y`K^))NNS`I>J?^A\'GB!OW/(MV)`43]-/S_?/S[A5L'D/HW3^%2?B`
MWV`Z\.6SH;OF52$!/KT(]>'W\M^:(:%:"<PEHDN(J'>\HES!%ULM"!.!UXC,
MT_BK>XBPR.)-$6T_A/DC$NESG(3)!IJEBPWL"6_%WZ9UWL/FC^>6Z;HS=LWG
M]"U6VP6/PI"NS^K&]%>V=UK+?R'RJEXOB`#=U>6K>]`T"U"[9.50MPR:5M!R
MH4EQV_Q=!TWG7".\-56?7A_,Z<<P"9%.:_=>D,1+K0C$P`_^U#>-9XWJ;Y#J
MXY#&^UKUPT;UH9/?)&8-M5)]/J?^K6G^I$,_IQN/T.BTM@?%"+R(`R\$>J_C
M?J3Q7'<%C^Y#O9+_>W`#SI)]F7<"@Y#[?\QR'MWTFZIOV.69ZTKOG38><61[
MQQR8FNNU3:TS<A_O%?Q1_N_<>[2TG)%Y8U8GW1BZ!3M1WR.)Z<@FQ$KO"S.<
M$BF96/BP]5]$9],'-&U=)'CV^O3?^_@EW*%@R\-IK?L[`7;N^E9?V+`8+9F#
M;)[NB!V32J-FM8H_/,D38N@=T2]23"6Z)Q!P<+1'LX`J2G'F3EP5.X[?K%9-
M8[TF%ECO.VKBA)3M)`I#&N"-4738@?_1*GS6V3[M+R7*S3R^M'KL=ZU7$C-P
M3W0^3R.9):N4;JHB-J4D',[0^QH`HR1*9C$V3/C5W2_5Y><;]LO/M"R0,AUI
MP>_.I#)5T;%-<J/"T/L*&9,<LJ<&%C!!7SX/40;]<QAG?PMW^^BW*,SW&8ZM
MZ5]2K]U5WWZW&.I3PYBG!#.DK=2!O@ELFL@U64/O(RMNF91,`;SH`E01X)J@
M597QT(B=,E+F!FT5I#-?T#?AFN4M<D/O^`U.B63/(7RP!K1"W(S2W&WNJ*?A
MKQUI4\A@O_,T@D6<2@6&Z]AK!]8BWT+ON$1J&93,`;1H`N[T$A3?68IA7XZV
M'<L]7&?MF>40ZWT&3RF!;,M,!Z/%57'6]QI]$KA.B-/M\?G[Q?:_]J2[CU&^
MR6+\J<X-VW?DN2VL<.:17H#PE2YP-&61S/Z6H?=Q^DS)9.O./'B=H!,=-$N*
MNW,JFC49&!8FV^?6,2^>T-<D:L+0^^2=49)%0KG&,774A=%I^CV/KNX_Y47\
M%!;X=2_?E_>XUF%G\_@\";QBZW%!M,-`+KB9>I]7CP-7PL51"`'\%2<KKGX7
MPSPI7HP*YG4\D.."T&LOISF]SV='<<OV'L8Z[S!.H&\0ON(EY]7]30%K7^;Y
M/H1#^2'-4;I$VW+E'1J-=3USSF<3JO:<1ZM9S@H?;)AKO;?$&:20[A%30PFJ
MHO@!"%085*4!+BZ#U7*\VX59W?$#QJLYOF>8Y"OHO4'"(H82'X$!$#[<?\[2
M311M<W)7*`]W4=Y^M!*U<0;_<`^7*LD#_#,SZ5NOVK]$%UD&0>,-\H]QOMFE
M:+N\V<WQ5FM/7IPH/9"9L6AS)*Y#SQ@:09_5)C$;IM[J,D,J)=K#CR_X_?SF
M'/PE?8FR!*?*N'C(HO(DZ/],8_B'O\%_PP9(0%G3#_,:D8=><J(]=5:H;BPG
M0R.F6Y[OF7H[5=PRR7:Q>($%!Q5!JR9HJLYX'>_WO-'06D%1R.B!/M:O;IK6
MVK49KJ.S-3]WW3M7E"G-R)LA/WR'E)RXF'J?M\Z0BEX[YET-YX<XK"?Y@:+4
M;[\R)FSB)1==@I934).>[2.FAO#W(OO"IM[G5_,$D[\!-0/='*>,^^'DMC)"
MH%_AIVW^<@O_E8?X&8+\MP@]3'!N>?)N5S-BF:=J<P6O7VAC;,?T]3[6XI)'
MME[Q@`H.YAFD,K#:NU8]T*X(_OB8/H5QPJ@^'^`?XDVXN\WB<(>W+2Z3S3[+
M2-YK@R&;\'!+,Y<C+`AK)VNXDN'9AH-=8'NM-Y/IA9"^P*!%$E0E`2Y*MFU!
M55@\-2E7"DMRLV<%,#J:KFN1T=3[G(Q>"&7^/2VBX#8M(#<W%54+3%6\V8HR
MN9,JXKE*EVEI2:IVMT4'*WE$\?%YN+/2.Y:`00HUVY[4>(+;'FJ*V;\LW9#-
MP,]MU^)+G$271?24GQLKNV_A*7>#DP>IG!U0,6,VN1'$TXOIKM:$-7I?TI4G
M]%*;K+.1C^TN55[_9G"C]G`-@'H`N`O6=4":X-7W;90]H0FA-P?9T)35JCM7
M\491-)K3+H9&4?>#@QZ\\OG:[32H_@C07T4PA-8!ETR1OFWV5CG#75FN3T9!
M]R/;8=CJ-LH',8@G$*57+)D_/0$!33&/#$)IL'4_AQG!K>A0?QA!0Y^"F3XH
M(4SQ^EM4/*9;<O4HBKZ&3Q'9]CHW?$]>IJ7QON<1DE6N.K'%>#W'MW#HD6OK
M;?!8Q)`]93)@"4A90`J#JO090.4Y]V+[NK]*HFI+&-JJONB2`8LYVIAXQH[A
M'&-L4P^]FT%N0KFVWC:628XE.#L$9H"T`)8'?Y`:<BA+Z24NS]FN'TDQOC89
M7[T/$YCD4.5ILH`:(V]900IWZ1S4Y:G;S>PV/;@.&5R](R:8Y%#BXK(@"CZ$
MVW@7"K.O2-FNOB<0_&/\?!UEZ.'9\"$Z7UNFO*U9:ABBF4XM[3#IAYIP5[[F
M&=\815'O:8SBZ;77)!BHK@.:2K+UHKDV^E,H1B,NLV:8*SBIN"M7[SU5'G'H
M->0YS6.TU2YJ?IC$%C0Z\<RK$S^>(YR7=W=\O(B=!(8G_89;FDEC%H0U;X<K
M&<[:L6RRN:2Y#T,MA'0K3HLDJ$J"OI@>\=2D72,NR,V>U>'$:'ID-#5?&E(+
MH6Q=2(NH#.6)*JKVQ?0P+@N;^.5JL_I;M(GBE_!N%YT;*T]BNJFQKN>QFU&H
MBMZCU;RU:Y#OH'>D&KT0LFTO-9*@%41?'YDT96406LHEX*4)W=D3&:N&WO%9
MVVMB6S1_SH5)#B5[(BR(FF/`3`*G+Y--%H5Y=&YZ*]^E]WIIVI1'VA'4-.1M
MJENNK_F;\4QR+&F3C\%,F&50E9?)94HW63<R=UUGFOHH>P8:>KT7=XR2J'*B
MV6#IP&VZHQ;=J,WD9%35/3+N>B\,V019W,WH0`JJO\"%X$R'XZ^/^?LPVX95
MKQ??X7^UCN`8+LJ--#6/MFP8*[:.U<)N&PG^T_QY'`8I9'L4]%`"6!3@LHW)
MQ:4Y3PNI"$#I0"S+TJZ[,#FJ),A0\S?*&*10Y2;00PK^^M<;\/[BV\<+A72E
M\PF696O'`QBIA=?"#GGSS='\Y1@6,93,_@R`^L@ZCZ97^&-\3K.+[38FWX6D
M%&_H8/4E2IV@[$2S8NC+COV8RE,MX-$G&YB:/Q?&*9$JMX$-5LN%(!4!K`F:
MJH#4545]1N="+^X/.QU4WX2<G&K^Q`RG1*J=$39XQ-9KHP1L+HM>.C#HRDRT
M4$Z_Y=)&[_UG7I&4NCB,X%KN3JD"]P)5`&?O*I-W-=%+*&1I^_[UJGB$XF(*
M&7V1=@/\IVAS'O<Y05?$IZIN.X;F%TI9Q*`G^+SX.`9,P6'BN*8T#B+=@O>O
M@%202&@Z?UXO/G?\>)K:Z(F3=7G%3>^8#@YI9/OO[)!TX#:EPZX7N;N..O7@
MXPG3=?3>S.:01I6#S@XMN'V,6C'-Z+D#6`S\%^;^2\G]%!/^[A6DI`DVQG^)
M8>-Y5*<;_7M</'YY^!+?1S>;.((?)/]2M#U=AMPF#$W/4X!Y,E1ZP-(*<B"-
M<@VE]P'[#*ED6WU^:$%9M<F2"U!E\.4!H.J@J@]@`YQN.Q>G*&<$O16C.T,P
M?RB2A$WS-QQG2*5JQN"'V*,AW[&&_.500\Z0BIRKU!&Z'1Z]5:2ST\/0"ME]
M,%SRI?1>*LP12\F.SPR`2C3D6_H:[HK7ZJFKTNN[NO^\QTY@EF[WF^(&/66%
MR.48]`I"W_(\_9@E0:4>O\7P]R)-(I3PC[Y%\LE<<BZI^:.KHD14HC:"P`9E
M5?!<UCVK%BNLKPT6CW\+-YLXB6[2W?X@F;NUMAWZ)<=P2_.T@`EA\W#@8"5L
MBDA,OZGW>II>"-G+!6HD`2H)RJ*@+LMIPFD^/:7?OR0[NU[]Q'B:I9KK'11&
M+X0JGYT:47!]<?M7I32E\RR69&G/XZM#E<AD9))H#E/O8#`&*93,__1X!),T
M+:!>Q>$.>A4O\3;:?MXGVSAYN+K_]`.*`S]0=6OY8_02[=)G$JR>UUX)9@K#
MO;39'<ZDO`1Y:\V8W39VYLHOK7?8F7!9I?LJ@@$'=8.@:A&438*K>U`UVJ2;
M:#5;/B1SS>69BR,PK8_T9C2VQ^.:SPKTQ(5%6*%W[(1P697Y;X*!DS,\='>J
M/L-[KI7YN5+F^SW69?AC5.ERG8]CV])EGJP<`CE-Z4&^&1WN^J-SVR[W4,@V
MI.8/TXH75HUW*QIV:_:]+R==.D45G^F),J/J@HF>.BKS+<HCR+G'BV3;&N_6
M.RQHT_YS!+4@W#575'%RHKH_U`7Y*G:Y?M;[X$2:S$H42!;Z)BT:AW;T@SIX
M";>Y7^ZO'(95(D/3,P]39LDPKE`#K:!04+UG&1YQ9*_?.#`%51T`*QVMOUK5
M.)-!<#&'<LFE-_V[RRB&9E".#O1Y]([1XA-(U8*("YV&VD!YKJZU,E`Z5[VM
M>.3;Z!V4Q27/@D[1.+)&"]!CA(?+@[86Q'Q:P!&:0>D0:1Q<TG6'Z!M![JB#
M[Q`XEM[A)/Q"27>->)'5T2)5U6I+&NU@D]J@K`YP??G:0.L@::P./>X1XP<B
M.4HLO<-0^(52YB;Q(NQ$48$0_O]5)!7::;HGRO%<*D>.&V'3CIO-8[3=[Z*K
M>P%O\=[B3+&V;_2E[!"3_58\WGFJJ6+\*@66T)?A>D9IB/6.YY$NN^SI4;8`
M0=4!,@P"7[_&73&&<S2R]K_:,?0FY,6/.(?T-U68#W9DH@R%B#'IF@2.5B%_
M/(]<*3P5Y9\MI3HUGPMUXC545(%1+6^A$%?W+57'G3I6;T)O,?K6V^4\1:*4
MHM*0_N+&VM9\[V\4MVP6CW4>H!_1)-.>,ZI9)1R<1SCX^OLS_.I)4=['*1UH
MM,)Q&2X;]S8RCX&TN"H*]I?'1V#DYJJE=Y0J%7[9E*0!$92%0'6%JRPFE':4
M>P/J>===\8^,&;D48>D=WDF%7]4ZG@:,$@+2G5>HYU_G#**W?'GV7^YRZ!VK
M2">`DE,&*B@U_78E_9YYZ'=3I)M__!W/Y$5^&_THWL.__@/O+#)D9.]O9>8:
MBA99O3SJKV`XOD>4UM)\>Y-.`.F+&AH4`2X%JF+@#U00X)*LVP<3GYER!EZ"
M@=TY>&SL?#)V>GM_=`*HFH6IT!Q2$7R,\\TNS?<9XSGJU,>FFXB7H&%G*AX;
MMC49-LVW@*@$4#(54T$)*O)]B<.[>`>'DHU[9?6Z]L5=CO.M8W>+X>+[4#OS
M^,>`KF+@8!4\;@X9-[V7([0BR)Z.*7%T*0C^J(HRSLC3WYMR3EZ*CMUY>7P0
M73*(>B]/:$50-3=3XA'(RP^[,,^O[LL&K[)O\<-C\>E'E&UBN$C*X"JH_C$O
M?\W/O97E27N=E0?1//*+&8-*+;A:@ZM0UR?1_)H_*RA"/"5.A@"@054<?88-
MWK+_7M90J&52CI5.3,LZSA!7:Z9CD9MGFC]%.U\XV0[4;(0!;@%I5#67I1G`
MY<Y`K777E=;56R)5(1'Z]W6/\FQ<W=]$FSW\_'&4?PAW.Y0Q^%.X>3PLBXCH
MJU5&%G@2-'/>Z(RJ*5/3IFOK'5<O2L1%5)8=YYCBDM;0;TU[@#2(LFBC)CNU
MEE)D=;[K*2HRG5?+QA[#LWR]SPK$";F<A\L#-[AY#&%_`-W$+Y"R/D,M+CU=
MJ?K9Y^_)"Z6:"4ZI;DZ/#*=F]GEEY+TF[TTIY[B<FDVVHV!GS+B*_>9!TNHP
MV>JISG,GVN.&<4"#ZY7DT?M$2K2H.DZZ4Z"#BX>'+'H(BPCD9!+>I$]/:0)R
M?`"["=$=@UV$E)ESZPDW1R;XZRC[/8GQIG[O#8&!(X>>)F8J#Q6F6B/Z2J/1
MT_O4?PRV].EGN.^`_`9*EP_^"M#/`DE%>9"EEE7=XZN^XD@W71*+Z.E]DDJ!
M7M6AU324:GT1)YO='N7DBQ,0H<V`B%S0V*,J`AE(%U:BEH#=B;Y;NIP<R/F#
MI_?1*0U\-1/R-)#*YI4S+%K=[IEM'KE,=)GG^Q`.'^P)=WGQE.Z3XGQMF7V1
MQ6(<W;&>YS&63::*N6.URJ$G=[!<O2G,)(<2+K,@JFZWQ67IL_*0$K$;$YTQ
ME6F6;J)HFW^&Y*@`7&7H5GUU$>_<L->N*6UW9AK`/*YS"5@G)Z6I[/AK\G'T
M/EUDED6VM\H***@J`/1U054%;7*@2F@WA%23IP%2[+Q.&M!-STM1&3E]%OE*
M>@>QL`NCQ/PSPSK2A&V<11N4U^0^RN+D@2-6&_4:;3_N474X_<3IECA67Z/O
M^*?\W/!,K^\Q-4'9!:A`"`C]YA'T(!2<H@'TJ0SRJ?3.J<LGD!*5X((6H$5`
MCCTCLMB<KQB/Z0Y^OIQHX=>TB.K03`?**2_;QFC?`O2`0:X#^@_7,RUWY>@=
MLD$I@6R_APY&T"[V;Z5GPQWOV]]G<[^G=1O#LV1FH:+%(8/C=.*.\[VW#72;
M[P29/R++,CHP#*A?&U"=UB6UN3<GV0@CSQ'24C_ZW2&J-AS;]=$%+V383L`C
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MKNF9GJLW6^F%D.[PTB)IQ7_BHJ`^T<%'F9#)N+@TXM)ZO-HPM\?GG:J,?#,T
MVIK[#`QB*/-ZZ3$M361*MU<;'G<=WZFZ'AEJO6/Z&:10X_I2XVD1^`$3^+DL
MS!68BIK^6[C;1Q?[XA%^HG]&V]\3^-6NT0>[>8QV]]^BAQBY)>ASW4#]Q"F?
MSRT3Q2VRAN9S]B8DW%6<I$>1L;P-F_[*]D_B;L!<"65[,6)@UC<.\(T6W!!H
M6@*X*8#;`K@QT&X-U,TMHX9LEQE.6@\'KTAPMHQ\`\2`D[A(,5]&53Z9*,!U
M4#Q6R[!1R'NHB%50,=AC[<1?#>18.[.V=N95N^![7#R"FT\?SL`6O8N3@9!$
MD2^CMDPW0$Y::X?NE7`V[!%ZZ!VX+TI$)1ZH(+!JU%7"E1@IV[P+7XGIN*RC
MM1Q_5=[:T'LJI!="MN-)C:2Z!%,5/<,76G%I<"&+T?X;9+3/PFC_W#$='^5)
MA)]"\_S_3'+0\_HERNY2&=>\CC$%^&'3YE97><L+/Q+%QNW+ZZO?(I2GX-Q<
M>WT)L,40N>YF'FM'T%84;8H8*]/7.^2X@U6V"3WN,(!_`'^0/S&>@W4_A920
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M?K_;@12">Q?N=BE^[1T\H)R'T99;E?`;`M46"V*0I62R.>A6F(I,"=.C#D=5
MO)7F87!3T!5.#GW]'T\$Y(F*>M-9-$UE6W>E-!VSVH=5',N!_Q\Q'GI'\M"*
MH-XVC\$1MZE\$\%AW)*MH6IGJ-PW0D?4!L-SQX,MS>0E"\*:F<.5\'FLYM[#
M-'KI9G020D"*`$';BA1?F?;5XP6)V//Z\6"M*I1'\XP3-/CIV3CS[6,*,()Y
MR9AL2EZR%<VR:O6G6:%I8%WEP-1\8Y!''NEFF0-4^19XN<-!J@%2[ZS<_C@#
ML"XIP1@N/P`(1TH=L,:7=V)-A4&*=DR*.:$<Q_5]N$8Y1:7HEV,A9>@%,ZH$
MN,8,'=C?Y?$V#K/7JXR$AOP6%8_I]C)YB?(BBEI._?O7;N&JV"UZ*.+<,4V)
MFB(0Z4R%DCIFM=J)[,7P?5/SO1<)XDI78O&8@Z88RBE<AAB29D%5X0P<[`2A
M!UIZJU7EP1^X"U;W40;-Y9PTOVW3T#V]%MD+WI;YB6Q#):^:$W$)R+4T$2U!
M+G[$.>*NK<`5..I6E/).2M/5Q.,JT)P;>@?W36)7-WWV`V@1_9C.?Z!BPLDJ
M>7)23-:1:>.X"K8LFN_E38)7;-`'8*@@[9<XB2Z+Z`E_:XGAJJ-]2Z#OB%RC
M'&[J0<-AZ9TGB$Z`14SO,8HQ*J.R`!>60VAUIE@MH>F,<E,/6Q7-P^SH)%C.
M/'>PR"$VXR&$G/`*#4];.J$7;&#/K?4*A=[A;Z?W]8-Y@BD*TY@%LGI-,T]W
MK&%Q;*<0*K5CP<,65MTX:@=_G!7Y.'JG39@EEQZ:,8KQZ#6LG%=-<"K1+-I^
MCI.XB+[$+RBHM8!HX[M==)'G49'_/4*O>4?;"RAL^!#]GD?W^]V7^#Y"M]/E
MI3V8@VR>3HD=DX-DS[RMNK;>.Z;SA9.]`IF-,*A:`*2)=SO4!F@:`:25,U"U
M`\J&`&D)H*;XM/-J7^2PFRVT#61"A&9@Y;,^/='7D!A-H<%WK`<]=2S7]_1>
M>TR#5\7C000-3UM%RM@5X>QC>41B$?H-/!O15PF%Q:$AU#L(FP8^/0<%/!0Q
MCD4I&QF>@UB$C/T/0/35\<CXZ;W\I$"O9!-F&D?PZ<=SM$%3<MIB83MO?NE`
MAV53W`^6?$CS(O^P?]KOH$J]('=0XL."P_T*H#*E/#UOF1S7<34_[I^"KF1*
M'^[_X+D'7.`,-$6$,U7*3OB"3!U[=>>X#DZ/K7=4*05Z=49W%$?03JZP066X
MN=IJ"7=V;L$YM2_>8_H%J..FA/&/`F,/`SNU<"HTO??6:.`KM)E#&`[L9IN+
M'R1QD?U%O07(./J.WG$U<E/(LT[&)(X(H'11-(5&.3>97\I;@)IC,_5Q+8^,
MI-XQ1%3X5<_6@TCFSM?5TV6MOLJ5650F8_(DIN*<['T>@=F%.WX6;[BFX1EZ
M\YA6!-F3/B6.H"H'6@7/0%64,]%77^<H#L]SY"WP!_H43^4^0<8(C(-FG;7>
M?NHX\"7(6O?>2U&N@,V>;K[4\4>>NU;)S2]B0MN81!IA:5/)<#5_Y8$"_0)\
M/8(P0-HOO!%L/6^=?DB3/(9?*:P]E?LHRZ)M=3T%ND`1=$Q(L,1%LL5YQ=%=
M%==:RPM,%@A4C&9(&;&1=WRY.S%<S5/FBQ=6E9X*0]RH=:O),W#0*&BU>M;<
MY2H;KJZ*A\D65&TO;PJDA/2]:5/0B0X4V0G:%=;\KH0,<>G-P:Q80@G0`_)\
M87I?'8["?WU-7\*7\`<X>.:0I+B<K?#?HDWZD*!WGBZW45+$]W%8AV951[P0
MYA?XYW@'?8\HA[_MGZ+M7])T^SW>[="#L[9/?RH@`X-PI98Q*B/J/;\[Q![-
MT_9+E7N!^5\8^%Y7`#3-@W;[9;QCM:^R!;`+T.H#E)V`JA>=+`3E6<W/9B*Z
MIT,R^BM?4E^=QII<DN2JSJ/DBO'S6`RZ$[2?S6!TSNQD=$?>K=<\W9M<P96<
M$DH5(>!3ZM_"'_'3_JE*'FMY\FX<'70U3^DF4%?*<EC,,&QC=>ZL?-.Q44)*
MV]9[@J1`+]L9GH80E$4X<]K^%B<'']*7]Z+"05<SZ3>.NJ;?03$X>DXY>A89
M/;U/I2G02Z??)(2@+,))OZ]1<9ELTJ?H2YKGYX9ENO(B*`[ZFL>_*=@5`8_*
M&3ZZX`K'S]7[%M@8;-F4&^D[@+\!\B/X!?W\*[@HBBR^VQ?8^RY2<!UF$>L[
MT0,?4TJ<N'P.=AS6HW*.;\%2>$3UO@@VBEN)NSB&`'-Q!__.R#6ROWQQ5S\6
MX/5>,1]8?1U5GTF@22PUA8Y*XH`ZS4W8`&3IYJN_WZ`Z6+BXXYTIA[X6Y4Z?
M&NIT]]>.BE8APIK;GD'0JG:U!A$T3'HOFDET.T!JB-2=Q@Y+EE&]>I_##&)6
M,WT-]"Z,0>V7`G'C?6O'<1:UFQ#"I`E,1VPZ+&T[YFG8I5[8BF:VOKYK1AT\
MH"J04VQSG")2#<YU[>+(<*-!.@E#-0!<\9S7CT(ZQYAF/T44&YH%VZ4],D)Z
M;Z6.XE8Y&_8BJ+E5!@*5;]K>IYFX'`I7SSA2*7GX$H5YE'_>%_LL*C?/KL-7
MI#7YMV@3Q2\D<M%R))X$L(&91_#9@E?<9VW(]#5?H_())'N>YT(5U+4`J78&
M2$50[0]754%35XT"2=G'.P4%ZDP>C`WA-`=Z'Y%P2J1DPN'#%EP\/&310UA$
M((O0+3ZD4FA/.]R!YTJ%MOL([!/X54!:J]T.]0(VZ=-3C!];9]R8K!#=IN6I
M=W56'N5_R?#VIVU9\BY;374_3X,XA*MTAJ*JL=)[T4@K@NR)A1)'4,\415I%
M4H&FZ!G`A66Q6\JE"EW8W;G_,%D56253[V=WJ&6@Y_>LFPJT>((/8?X(;7J\
M142OUQG?PRP+DP(\ICLXY(P\_X8>?<>W<&U+XDEZW<T\XHZ@K0C:%#$<8^V3
MX`.#!!_H3<L)Y+*-[7CW`?Z9ZSXVKEGNUL//YLHEF8@SAE'$!T2KXES@B*W)
MB)EXQ#3/[S>)70G91@!4=./*2_$M>HD2G.3?-5QYJ2BJ;F9R;1ALS;2FB+7"
M#W/#X=>;7_V(I;.JM]N@^C/C<QF;QVB[1T_8].0!R-^_MA,(X?68[:_D+7=8
MT<PCY7S9Z\>56%LR/,O5^^B#5R39[.?$%53UT&W6OGP6<`%U]WJ8X(+KI=*Q
MUV[:W:&W64Q#GB;1XIBI0C/$K96'O@W?-?7>NF:61;JZ,`(*R-7N,K$#J0)(
MG;/RB/'L0&VDJX><%_JT58_NPWW4;9B&:SIE[G.]CSVY95*R0\V+KGJTK'5,
M"D?^!>U9I_?W4<:F*K\G>;J+-W$1;6\CM*E]A=H@J3,-SY>8X6NDYWGJP"92
MI0"CM=:NYKE`*=#+G@.F(02M(H"4`;@03UY:JJ\LQ:HO2]R.Y1ZI5=H,O=>W
M5/B56&0:)`$A;)&"#=I`3O=%M6?,^>#,K&?@I)R7S$$V3P'$CLGQ(Y2S6C=M
MT]8\OY10.14=UXC$W#P&==]^0B]NGM`+RR?TOI=-O0O+)_3VY`F]'?,3>M2)
MFZ6FBULZ*_6@RDVW8)N685OGCF'9MG\.5R>NH[>G-5<TQ8K%"7.1)-?*=$1V
MDFLF?<`GL.@;F.0;K,DW\$]6"X8%TH#[@^#4YLQ61?6Z8^%\'Q:)@O1-9<M=
M.Y:#OP74'?PM](XLF"'5\O2?0"@Z!7<WQ$0*[Z4%Q`Q2NE44VI(U'D=GA6W)
MVM?[[(!6!,5DG8`C.&1&'@UEA<R,4[$JC(;.Q4-GK,C0Z1T<2R_$$G0<`S0K
MJ*8_?Y<44DK/.G9`S-Y>_]?N;G=N.[Z#WN%:KVQ/7]>6&K\".M)BD9*"3`X7
M9:<@Z^=BNV@S?A8:/T_CAUNH\:ODX@26F?G(NO%[4@YP9`4;>GWTJXKAT3)\
MQU[IZQ^.8I9^!#/6>Q5WR,:G*B<H>G[@:#?Y8YQO=FF^SZ*+N[S(PDUQ;MIK
M>?'43%#F$7.FU)6#R=B,9SJ>WLXFGT"RC\VY4-79;O&C.%?%8Y2!IG:5"/N/
MJAJC&::"=!O]*-[#TO\X-U!>FV45IP:C0'/&!&?2G:8AW_3TWO3BDD<+S3D"
M=:@X795I*H(_4%6`ZRK2'RG.SBGH3Z_CQ-88=A:P==0WX%V`9,J<,'Z,5',3
MZWY)#L6YB;*7>!/E%P]9%*%+GG^/B\</X3;>A?7\:!F6V?=2XT`^(>J&Y^Z<
M\.-ODKG3MH&_@[[K6CYA9$\FS(@"4@-454!=!WR'E0"IQ>V#<5"&,DV;OISO
MIG2C;H0\&>-X>C_BP2,./?'GI7_CP#:B`G]7H0*-)X$HQ/`T'WW+DG5@3`)J
M'6@:P=]%[_`I#FD6-_T=2+3$YUY!\!!'E/E?D/L<$T#=2F66]#U<XI9'FRF@
M!YR6JD"73%1G3>C<\J!OQ".?1N\-)1YQI*]].8'1K03X$B:D]R,1\22IW<53
MFA7Q/['*?_KQ'"5YA*^4M_997*EWP`5"G:=HD@?M.`V#F&Z\E>;9J66(*]NE
MDX#Y(+4#:?4=;K:[N55G7VVW#<K&RX0/@'M"E,-R.???W[AIZ-ZB%]J-9=NV
MBV<9C<-49(NM9-:7*,"!W?B4%_%3B*X_]YD&WIQ*(Y@[S+4M>7G-.1")T>IY
M0]!-K\30FF?9>J\X9TBE:I9FA\8P&0N;;[E()G5:/0T]&YPD&5KSB%$E2R[_
M-/SE.>(IG?1F`#W0P_83WG-/?!MLU6ERFUF.(7\YV].S*"6B$:FK+#VU/%OS
M`R\*].HFF2$(!R2N@Q?$31LCGUOR]+`$@WMC>49JUE&^EKY49A5#690.):!>
MAL^^U'R=I9_3["F\3.[1_^!<F#4?7&LM+ULP(YAYK)\M>67*61LR7%/OS-=\
M`LDV^%RH!O)=P(H`UP2MJK.G!EY&29DM3D*7.FL(YH]LFX;M$+=5[RQ.,R53
MLG*8AS'X/0GW6YP$L-$ON`0)DTT<[@XT#4Y7Y4-.[#E@ZZGQ&DKS&.;1=19O
MCO?JT(%K7XK+@2-CJD9%.5ELN+L+AK'Z^%/H/;NP":)N&4&!IO&WKNY!51[@
M"@+7%53\H(P*TH_8W5@@J@;*R!3-DW"PBJ(J`H@1ET8\IPOYT8_F([NC(_7+
M#3B][ULR2J)XSY,&T\&Z^9#?O&3^%FW2AR3^9[2MMDNC+=D@K;)77B3;+W%X
M%^^@7Q7E\#>HS]O.YKJU4K$%*@2M*'V2-71=S1/4DV=H?!E-HL3J?#&1L`^4
MO6D8-"U7)XIUGEETP:W5.BB;%SCW">:\Y/WFMVPN1B9J03WYKNF>RHPN5F3%
M4[]0\`=F@])`L%D#$C]<I3HR+,>DW[!HUYVG6!,H*JTX*(;>6M7X6&<0K^P)
MK*_3H+HIP94YJ?_K4"[^99.DNY1OER/+24_S!U8&$*M:F/=W/X\S?PUW]^5S
MR9_3[!K%(Z;)U?W-(_S7?;C;??JQB:)MG#S<?D]_BW<[^"O^IGVY7@:8Q='%
M/`**D:FB*4]KZ-/8>N\^S1%+MFF<@2U`=4%9&1TK@+(ZVIVJ&P!U"P`V`<HV
M%&H.I5$^+=7IFGB.YDK#9NOM!,\33-6$,0OEB6@2W9[O:2E29YG)T9I'OJ/>
M>T^SY%*R8)R#,'@?YG$.=O%37.`G&IW5_PL\EPH%%XK%8P2>2YTJ_S.OVIUQ
M/[J^>8H)U;=#3',7NFYEGAY0(^N]X]Q4P,ZNWG/"!'+93M-X]T?WDYOKR6*)
MQI-_0A'3)O)*U#6JE97>EG,2NRH?8PJ((N)Q9'M0Q+OQ+`YU!3)K6'K?\9R"
MKF1*G@`1W*9%N`/A4[HGTVQ>I60H4G`'9]PL?8FWK/NOI0]PFWZ+=NCNYG68
M%:]==P!_]K[+E0.$I&QV'D/YL5>4I6T!?P*]DXZPBB)[VF;$$U0+LML4E#4`
MKM*[.I/,<<K97D^2=_T!RB:J);+>(<3LPJCR&)B1:<5Y.D=#3\IW7!'*%LH5
MK=ZAPLRR*'%66%'57$?[!:W-`<Z-@7:OU5.OCMUW=BSJ597C_N91G`9_1>:>
MLH9KN7H?/0^#ENUX#/8<'-I8OM?-VJW?9F&2AQLTSE_JMR=MQ^I+UBJ>AGV]
MBR,EG6Q]%.VM";^`K?<2D%8$E?0=P7%$YE;).4^:]O>=OW]M_T(>LG1L>5=@
MZ7%((3R5O!/4[VL#?CG-W_]E%V8A=1A&=&SE.1Y5;0?3T?2.8^?.;=]3D7V*
M`9*X8-,9H]`744K?G.$YAM[N^2RY9&O/''!'(>,#LTU^!NY>CWXF$>*L2E?N
M9EZ7VY@?]QDZ?7R,KB/XR;=XL=?W@MW09:CQYF:J!C/66@LF:N+5DN8YURA%
MD,YM.AQ!G;FX*@A(20"+`E)6$E-IKZ=J0=6>*ZGC5:M]++T]&GHA5&T34B-:
MD+F4%TZU(&[W[LIX3;(EY>B]RTTM@Y+-/EHT#6.KPTCD''RX_O(>P'7I7?2(
M(N^@-\&5-+["4-Y4)0QP.#R"J@%!_!S!TV%D71:KN-X;(L.@E<WLQSVW+&+U
MDS`2L4[6TEDT,B%7A:NY0N^MX#'8RB?=+@:9I&*<1Z5S:GBNK,J6!S9ZWU<:
M0:UV/NSTWYH!^<A4)3#$[\>2"V:K0Q*)?3EW'M7&T!X_%XWS3JSUWLSI8*6G
MTS-VA6Z*,"OX2'7<=_`^>HB3!/G[=R&LP9J6H^?;&"?%)&.<27I?0^M@9672
MIV0K@D?FGP+8TFP259>^B>=?+L'@I[+[\LL)?MN[IVLQ7*,4JO/N?5\UWUJ=
MAFD;02_;KY^&4#^O?=:D&2CW/'CV.^@^M-R7Z1=B;\?3&ZM&<D*M];Z&0B>`
M$O^/"DKS5#QL<;\K$(G15P1ADU@4;8;<E?E&^:B-CV)V>%%TL?VO?5Z@-5*.
M9]&^TQ*QY.[O7`R]J04[)OA`1=_4/"4H%7Y5)GH,1,M(MXJ!5CDY5/;?*I5]
M-BK[Q,+H?8^+5@1Z0K]$V5TZUV)/P`D^[+,L2C:OH&@*LK&YFA-&GIWYT@34
M>?)B!5F`S./Y+)$KSC,UXFJ^0<4NC&S#SHPHJ!WPJ2?(OO"&&WY(=_"_4I(!
MO;[PEC<9EBR&[.6CC<WC-RO..A'4:#UH<ES-;W[3"2";NE0H@H-2S6W<G#?G
M&-TWITU"MC@Y>]*4C54DQR.NYI?%:450=<I$B6<AKM(=1BU/U<[6Q6@]CXRJ
MWF?IE!(HV;R@PW+$T7`N1T?\CHL-U+D]#B!M/QP,UT>6*>]&%SN@>>07,@"5
M1G`TYKFFWL:<6R;9_@<OL&#<<49;W'7M@R>SU6F68_[LJN5T_"+VUM"]3=LQ
MT,4'W_0MO;<918A'H7%KHG%)](":XYNI!$`-I.O8^]??PO]*LP^[,,_Q-233
MDOB`+P,0:3HU+3&%*G4:\73WX=B%67!BZD<T,2.A8%U<#>!Z7'?G1C#])4MS
MM.MMK>3=DYOJ7II2#`E'H0JDJN>L];Y)02G!@J1OP9CTO7!96=26$E&@"[4[
MR_.IJMZY8=DKSR5+2[WO73#+HF3)SHHJP'\%'\(L>T5A!Q<X9YPPMC=3R]?P
M*2IS;)C62EXL&",8::I`)SF%8O0V!.=HO8,:^01:<$881C4Y0;0=(529,U_,
M"+BO48'7H?+B=,8[EZ8E_8)1:`6JZ+FFWO>?J?`OR/D:Q"3%84DY9%Z_53*O
M&<F,Y^.3W0]J2\#@YZ`TM<+]G!:60`25K[,4?HJH"+-7%`CT$B;%;;1Y3-)=
M^O!:G4B9KLL0@4#1Y#R6\F&N<R)2U#;]E>WI'5K#(H9L*\R`)6B5!55AT)3F
M/%9CH@1M6ENM>-R3SG:Z.CIK1^.NMR?!)HBJ(`8F5#K0FC)SK5:L[F:LG:[M
MD4'7>Y>020XEFR<LB`[H'%9T+N;2N4G#->+AE/G3/+\OIX7H+')3..:IPAQY
MN_GB)MLP/-/7VVEA%T:VZ\*,Z"`=W%1(,$\"N$8I/_WW/GY&$UAI-1UK)2\.
M:+#;>2K`($W%^.$JQGJE^>'H)';9?)X"$+1\DKH$ISF?_K92KBHMQM3._:3!
M*CY9H^N]BTV!GIZMLVXE32.1Y)"T(V&N[H_-_KFS]N4E=Q[O>QZ76>6J+Q^-
MUUMKGN20!KYL`TR!(6B706Y$QW.0PF(II_$:L+BSAARO1PZ)UR8.C?/TOGC$
M*(F2=20;ID.N1S^>HR2/0%;F22Y2$#?<#SFX/Q8;V>KY$^GX:_2CN/T>[5ZB
MW]*D>,31'!+S]\\#)R\8F&M@:.*"*1KV7$=OG1,BWX+GGM0@I^/RVZI;-H6.
MF'X4@+0&2',R-?9;A((-(%G0`CW?A+O_C,(,L;/W%<8EU+87H4K=I1TB/@7N
M;]US7;W/%,0)J9<JCR#EU.>Z1;*AA=H$J-$%M5IUW.@):C5+]"E]ZW#.]RV2
M!$3O?38)TBIQGL7C#A#=P2]95?17F7J+^O\,R^(H:'DI6_A`J=3.D8'@4\BZ
M0<]=Z9W&>I9<>DVFA^`XYT_4"$"MJ%4\#>9(/11OYDS8-&C;1IF;8G6RES,8
M!-1POAN`BJ8X7[IV05'PKL<RJ1:&02G7KOZ!F*%=J$'/==Z21WDDEX;36@UN
MUK0&6U&K>+I,:XLKGHAI#35H^_YZ;9+5@MZG=V($U'5:ZT)%TYHG6[MNH1YA
M9\E8Y'K5&"K5^C4T%/P*1EKT7..M36UMP?2;VUKHYDQNN!G%^J?)]*:#_@F8
MX$B+R*KZ:V)5W]*AQ*"$FDYQ?5C1'.=*U['O*?:;=#D1+#$IUZ_>89BA7;`]
MN()X:[N1C5@:SFP5MEGSVO=4J<;I,J<MK'$BYC/8'K:?92)^O2]S")%/U[FL
M@Q3-9,XRL6D:*)B>L6D'*B=&L/^UN]O!+V\[3KE.UW?ZDR>P=*64!AUIJ<VF
MI>_+=Z<^I$]W<8+[^Y`F>0R_.?X/_%3*?91ET=9`+T)XTKQ,%B3S%'">S-4$
MQ]2*X=EZ+\XXI)'M0+)#"JHJH%7G#!S4`JUJ"E1%2A(<S56EDQ^'J15\"5O?
M>8=;'H9IA3]W#@^RX!;U5S]5C8:;]8'8GFZ_19OT(8G_">>V;904\7T<-K-;
M^:C01;+]`O\<[^(BCG+XV_XIVGX(GV,D?P2Q7-WMX@>2J]NU/'E7XN7C%ZZ&
MTL=W1'E%]VWH'G.B;`P6F%.E"#(P$S=]@79G5<:`^K&Q,-F"5H>@[!%.Y:1/
M@#L%3:_:FBLY;RO\RU[U#+!"@X5"LS2/)U`X"A1&2\1#$.HD"BHSLT._,][P
M$@LS?X0_H+P`+^$.OQ?K6A)3`\G%KI--F1Y7.>:DTZ^A>_R$$OE/R^_I%T*>
MSY,_XE];/6IIDJ3LU/_+)'7/UB3WBV=!O9^)4S0"2L[GU,@2U&9D@_X1:6%+
M\#OK!2EYG47/8;PM3SM@^:OB,<K(;U`5''G/:2TBDD:6A_\K2#%(U'`,Q]4[
M1F#)83DICXI--FF.%H%11QF52*H`(UP1@^'*4[6LRNKOF_T,AE.N)T<-![L$
M/]&JDWE@3L_O8Q4QJ(Q;F90LQ]8MQ=8MU,FZP58BZ*G"FDB-W!/T`EL2:&J[
M1L=8NJEJ]VXXFF>V5S@*)^O!=411Y;"U.M;8>IV6*W::UDN=H]7NW?0,W_M)
M_:J^<3AM-ZI'(O20/'I$-0=9_>/BEJ;]0PGO.GS%CS;`=8>\YUB5BJ*=[6$9
M=8E&:`0&G'I/+HQ2^G"<H%,U)9-L[ZKUXQFH#6`)X12LWPG$8+U%\R<Y,FL*
M![D6XVI^*7ZI(3G%F"UZ\1H_[9G\U-K=VI1F;=>TLYP1.[[WA7?J;A_#Y"]I
MNOT>[W;GKFW)R\FF5!1];!C'J,LP8=,P#-?_>0+C:8?CE%PX2IEDN7`]J1/(
M`68!(8`*PRF8/^TWS=ZD^9.ZC38-`\_F/\\:EGY`3FYCC5JTH&6RECZ'_`H)
MTO$YOZ3)PVV4/7V,[@JH)^9I[*]-BJ*/=>(8=1G6:1J&X?Y$^VNTPW%*SAFE
M3+*<LZ;[PRTVA.`=M-M/`&$X!?.G_P;;F[1_<C?8IG'`*=O[B2YNTP_("6ZN
M40L7?$V+J-Y7T\PZ8;<2W9N1]ZJE&ADT-T<#XZS,#)'^#7?U\P1;3([#R7M>
M+6%4NURX:ZUMV8FZ6*=GS!9PJ@@`/+\:_[)GS4B\%3?J0*J`;,`G:?).JY/(
MZRQ]CK+B]1J.45%>(7U^@DV<NXYMGX0[-2B"/@:(891EF)_A[@W?^GD")::&
MX91<J0E99'E25;?P7ZCCLSI!!>Y;9S.F_4GBFS!C4D\.QSCOFO[/LRB<'HB3
M.RF<%"FH2F"3$RDU.=5I9;_O%T'ZNZ9V6T]3H!<Q*^PC.=.03'9HK&WK+1H.
M2L$U]7GHT,_S<L[J2*BSD:VC2#,3HRJS^-LW,33YRH5TB+<`?DXC4XG.X(\(
MS8(N4@B!"=-QUWF,$$*WYG.:/86?PBR)DX?\.LIN'L,L>A_F\09"^ACO]D6T
M/;<,R^GS,9*7\`=6Z]7:6F&E1G^9T9,8I14BX;%B<C2*OIUY&DGM9DBG:A;G
MA]A,U:TVT'8"P*V`JAD`VP&X(8!;`K`I4+:E7M<,\\TKFS%X\,'>JF&2SWT:
M*_%9\M%KW#;=[-%*M2>_NE3-:\`&MX]HMDK!/5:U.ZQ7R./=DI(@B0H0)YOT
M"1:#ZI=C]8.%08C^.TZW(,Q!?`\*V,Y=I<>;9I:%7[O]GSEX#+?@+HH2]-?G
M783Z"`M2/7J($P0;I/=U\^?J-=M[\XH]N!7'WJA'F'0:8:]SQ%.Z;38#:/"^
M5X=W*=3+6H-G*U5>P8).\"4V#U]@!^>N[<I/13\)0[B"T4H[HDX#31@GJ#JC
MHBS@;H[AZ?4MSUK.):P#2"7P"ZKVJVS5D'K8I)UJT,PT0]_/<0W3(6;M-'9(
MF&5::DZA0A=\+:<-<1KQ+7J)DGT$V>'(?S5T!(`\+1B4D(;_567#.Y$'0*:%
M6'(Z.$`R.1&4I>617;GA5TYV)F-??QW+\?QR/6J>/NL/I5G<P/?C"H;(WO[#
M%_@O^,?J3_#_W(5Y!/_R_P=02P,$%`````@`[8!L0Z6M)+DY1@``2ZH$`!4`
M'`!N=F%X+3(P,3,P.3,P7W!R92YX;6Q55`D``XV8@E*-F()2=7@+``$$)0X`
M``0Y`0``[%W==^HXDG_?<_9_8#,OW>=L",9@H$_WSG)SD^[L)B$GR>W>>=JC
MV()XQMB,/TCHOWY+LC$&_"$9R3:^.P_3]W)!JOK5AZI*4NGGOWXNK<X:NY[I
MV+]<*-W>10?;NF.8]N*7BV\OE].7Z[N[BX[G(]M`EF/C7RYLY^*O__&O__+S
MOUU>7KL8^=CHO&TZOYNVCQ:X<VM:\%NO\\/%[[<7/UY>1M]<N8X1Z/!5Q^[T
M>XIZJ2B72K_SGQWMIV&O,WT(OP@__<=/Y/_>D(<[0)KM_62OT><O%^^^O_KI
MZNKCXZ-K.VL$GW5U9WE%ANI-5*`Z_/+GFVL9?OQU\M>NXR[@>[WA5?B/\5?)
M/'L#?ZCTN\ID,KFB_QI_U3/3O@B#*E?_\W#_HK_C);HT;8*2CN%7GOF31S^\
M=W3D4V@3/T]2I5[%[&9^@_SM<ONU2_(10'>I*MU/S]B2>,1,^B07@'*G$^+L
M.A9^QO,.^>^WY[M,C,F_7WU!%N'MY1UCWX-)Z0CO+IZ#/L`7+[>"(#3]A7[R
M%G_-WZQ`;3QSN;(`G"LA)#PA%]O^._9-'5F,]*P$$_3B@_(O@0QO-K]&WONM
MY7RP8>,Y^EPP,5\=/2"T3&WCQO9-?W-GSQUW2;6/B28#85,P3;?(=']'5H`?
M,/("-\2*B9CY>ED%+?&'OYG81:[^OOF*?61:S$3.U^]&%80^8]VQ=7"M5)ZS
M^3U>8^L5J,-3SP-S`*G?F^@-ON";V.-D`J9%R*J$CU?T9F%FPGS!)-W9:^SY
M[%HHVAX2\_.(R!0MF@0='`(Q18OC`=G!'.E^X$+$<(_>'!?YCKL!79[-YZ:.
M;Q'1>'_#1-W20HYHG\I*((\P*9VB!?KH^!B6Q`T1)A,5MNBU,$G!=+%P\0+6
MQML`H,,/IFTN@^43@*B;*V3!M\)%T[[Y9V"NR)_O'63S@&BOT'RY6CE8N-=*
M\O&(7!"XN<9\I-DR:>*P5WLEVF!G[@+9YI_L,84CFH`5=NGL;`@XBO"(S]%I
M'&U<.\L5MCUV*#R]$EH@'`B6*PK1-_BG._O&\\UE%#7$2_)L3G\]"[_XJXML
MR.)XM-S346!B9[YV/&<A6M_3.2MEC9XNW!K3J4O_].:3_)&38@_2Y&IH#I9+
MY&YF\U`/ICJ@R[F:`;6.@RHF]QF"%]?4067I%Z<?R#6\LM2['JJ(?@[7[>FB
M7?=>K@I$N?@=Z`)KNG<\YIS5DD@4IVL'M1--S%:]7LR%;4)X!TYQJNM.`-FT
MO7AR+%,W6<7G>$AXL8&)O').DI`KWD\R$4S_RQ;A4S(KJ>'P%Y=(04<T:=^\
M7YTU=FU:U8&(FI+Y7XYI^[_#'R"PACSDVK&L,"]AMIQ@@?Z^1J*C$7YB>30T
MHEFTBOY!K`6RCZARPJ:&'Z*]X"$5/,!\"$^`Z-KU[E@&=CV2GS&BXF'!=$QU
MF-PSP\#USM,=\HWI&Q,QR#&1=%BX/*SPB"X#GE+^G\`EW/W_ZCC&AVE9I%@"
MKM2]LWUD+TQ2'J`52R;*%A(D^8`\'[LOV%V;.O9B7_6'Z;]?(\.T$!-E2P]]
MB/:A19!Q!)`4.-$Q9(;.<9`E@ZI">7)5YXA8JS8%LG]H!!9DY=MO\I!,12TA
M"V>G^LX`O"'"(WIP^*T2G)BF\(2,G9>H7(*-Z=)Q_:C652*-CWC!J"K/OV/A
M*7#U=T@^GR!'YEX'/&>UJISB:`^+?,T%Y/?VLFA!BZ\X%?*!$+*$*U(&*]]L
M%!@F:,V3Z]R27==;TT:V;B(KL0N;S'%YV0E6\[D)2ES,#F3V'I@CG>8>/MC^
MP/0M^$6OU^]<=N*D!_[\97H_?;R^Z;S\=G/S^K(=GS!;XD!`2!;^]+%M@.)3
MLK:$68X>?0N2`&S]<@$?_&\H^>O`)0G7],WS7:3[74W1NDJ_.]J')WFF8XZ\
M-WJZ(?#`U-"*'@2YPI;O;3^A0%[VE.B<Q%^BC]-GW*??(H<V''>+:RX#)&<D
MJ0W\AX2%:V217'+J7T,@MH$\EY9;N]IXH$KCB(D$)@Z3NC-UM]S.76?)(RW?
M*0F-XT)T30\AD?]==%:NZ;@0:8/:7G0"#^AV:*%REY,C5S_2U/V#+]$WKE8T
MI;_4W\W#C`F^0:;"<PQL&?>A:#/'HX-!O.%A^DTF'7ER\0J91K2*1/!UE<%(
M&TM3BM0Y:U""8MXCJ0_:)O5<G"9GX-KVANMJO?&@&LKE:^GD4$LS68V4<]A\
MY71\9'$HYQK"#Q*O0[3R`H[Y!>N!2^.M&`086]XB7#1]#9Z*"Y)XJ1HV72_X
MG-:NB'OMV!2O9ZQC6+L!EV\VQ.06S8P"6,B[2F\TE!>G<5!2@[*4Q2G2FW[;
M](9FU?M>5%''0WE![_&$-6A!`==Q9-,R8>_VW]E"?&4XZ<N+=#FIJ4%-3L$K
M7FA&PU;I4+03[.W<YB/VMT8TU+2AO-@C9^8ZP@Y&(.*5H]\R10AK?S%,?8E1
MY]Y4`F6=27UJ?I&B$NVM?#@K[/J;)PN%-U.V!WY!Q\'-]15%8@$D>^HJ1<\,
M06S@+=.!=)PDEA%$53ZZ6F\XDDRK1$W,*'(DN6IK=6.[W4=2+[4O,44-IZG2
MG:2RUM:LLBAP?G1L?9MW#2<2)<U.2)6Z4!*>6%M:EE(DLO$DY^JX/ZBB#%&/
M#A0S'8M[/&Z5N+/KM0D@M+XJ<2N9@8)*LPQ.1-I:Q#X\W0.1]LVG;@6DJ<5N
M_52&(WFI)@L)5:H&-R1M+3<D3A8=IN-J3Y.G$-GSGI"F1*6CZ&KHKF@TEK?@
MI<\I1)5Y1'-8/<N&H*VE%>#<#;!Q#%IW.-+D1<*9T]:I`L5`M+6XDKP:OMN"
M&JCRZFHI,]8F^B+N(ZFK;9,Z`U92:E8R%K$4NU7Z2E_>*:GZ7-=11:Z`]_,Y
M&<=7GOL:C?U,CD_`?\UXOVLT&<KS7)G3UN:_F("(G5C+LK1KM#*)VF#DX=F;
M92["D_'Q82LM+%-+.C*=-W=M^L`.25LKOCN+6&,[P#MS4.4I0_J<#7`*61"T
M-3?_BEUS36^OIBR,X\%`7G:>-W.-BL`&1[Q`M$P=DI?`;./X`G8207E%7E8J
M1*L))\O9(66:HK6U*,*-G^P,XW25*>*39`S5\%*/AN<E37N\GT^RSY<M73O+
MI1DVZZ0]5&C['&R3YCG=$0`@+TC.GK@ASHX1FO/)H_F\70YD0V4B+V!N_"+(
M!LSYG'X2NP@2KZD.:UO]FK>,%*,4J8K6?%4I6XFCN6;BF,!H,I29;F5,VQ#_
MP01+6V]FW#OVXA6[R^3F"K`\DG@E(VW*AJA"(1IQ,49MU_&JX]KTGADH\J[V
MY<W<$*U@!2=6#FW2*N7(*%0GCYEI$IM;%$[?$#7A@FEW1$%KE:[0$ZH)+)/'
M5`<]15Z4D3UQ0]2#$9G=`=[!L$V*$7>AFLWC=EE/3MA<*Y&OC>15.%@H$*(K
MY5C=O[B3<L:S!65<N<B5L=&V'A5[V@Y.88ANF@^TL;PZ4<J,@JR)O>Z5Z$.5
MRWT+3"FS>AR]3A$R/5)4>:>##V>K3=QY;+?5P*>&889T/R'3N+.CZ+,[',ML
MIY@^:6V"9P#A?#:*>&]+^LBTL7&#7)L\P3K5]6`96(@^[3,W=1/"2JTWE-F)
MI8B`VM2"$YOO>,=(RIZ`C#WPM)+]2.WU*V2B*G4^VKPHX/U\=K;XMBL8H!KV
MST5_7UWZ+NHF&9".1N$J)8>+XQFK4N`=/UL-+N*^^;W3)J$*V_2E2X/KXM9V
MZ:$%H+W7N.YLW5G2-[D>,:2\K^BS.QR-)89O?,34%]:5!RW6I//;I_OYZ@C0
M>_B`H]N[FMOMO?/#WDM7/VY9..*^Q%OLW*W@6U0.9*B_`&8SETYH4._WA-V7
M=\"1%"7DM@5G(*(!-<\2:+4UK]^'@O+M30/_'9C[$QNDEWI/9ANUO,D;IRBY
MZ+0U\4^#X,[S`LJ^-I%7[LN>N*&*D8)*6U/]-/9G@>_YR"9-/XAA2-Q[+9B]
MH>J1A<_YY-.E-P<R5]B1(K&9``,!#5`53IC.Y[!H:6TY6F9'RJ"27:4&!B",
ML$1:,6J]5D1K+!B$O+)%QJ1-U(9C.")-&+=>$Y++Z4C1*G00S0HU6(&)%&/2
M-L78J_6&")!B;T_>R9.4&1N@!T4X;,^@],Y0`4XO56H'I<J7U^GKS</-X^M+
M9W;;N9Z^_-:YO9_]P?%$93R:-YN3UKBWEO-QPE.5QM\#+[QL^.H\8]T!Z=/'
M&G;EYU>'3//D.FL3QORR^>9AX\Z.7OVT%U/=-]?A8;185WH26[5)(+A\^?,K
M!@4`>Z&F8N\]K]L=JX.)Q.L$F1,+\0F5Z,7NX@$3BFUM#T.=YA<$\)$-(&Q[
M(><*N5XA;UL@==+STQT&\-I:#).)LYR]^F8Y[U^1:9,I9S;I*SV;[SUJ$K]H
MTE5Z6MB51@XF;%0TWC"/#T.4@3?>S-#4AIIJV0,2`#$)E/%7'/XW`6ITFC-&
MM#^26&1@IZ/Q*I?2#[P,QFVM7.SL;]=SZ\X&_@,J#I#!DXM]2"V4WG`DT>FS
MTM%X?<MS<3P0-_]6Q@FGP(!?(II$"#^;?S6]L*$Y!/<`R-(,EMZ=O<:1H+I#
M;2+Q@&`YHLY0&P6@W_RN>V55DQZP(W=1`>T0_9M/DBY@^JR,Q%.VF1.?H88Q
M@AAKT5AIF19M"VXQ!L2,"(BV$95.DX`2R[,<+W!Q#.U$YH[BB<2=5`8C]6+O
MUG&G.D3V8>UX%_(G7XCL]M5)/ZWKBKU&GY2UWD3M4<;()UQC"S$IX3).E+G*
MH=3:DQIA4$Y]B&'Z`=E8#)L%&%\"_]'Q_P8!%#*-KJ:-Y75F8:6BV<I5!LLS
M/D1>HI%+;%M/@:N_DXIAMS^9I/9?SG!%K..>A:;PH=/>XS^`J^M1/TQW,"%V
MAE@Y_!A"`Z4[4J4>^2B8ON&JQ(->\R\_E7V8C[OJ)"?3$%S:8V1V^U@9)!_8
M7(>=Y)2^*C&C8J%!B-V<)-GLHF018LU_P5)<$?S@J3NR^WOT\AF@H_:JK(BS
M$%67@C$4O;DQ;>O;R<?0?+,!`(NT.-R:'D%B$!YMJLI;I1#19'=5B%GSKZB)
M\U=/+EY!%K5ME1F5O\#$$D]6$W14B1LJY:AJLHKQH]K\LT`"-XJW5=>PC>*A
M%Y=74.0AI<'K(2-^L4I!UMM,E1*U"AYT`B<H#.1=ARJ<O\&JDX=4HH-IR_7E
M&0-RI@YNC%02B"/6*EW>]N=O\D*6AU1[M_T?L9^VQ9A26]JU)AU,Y!V.YJ>G
M?$$$)M$Q-KQ;4"UR*XHT$)G-$Y=CNLJP)_&R:>'\0LQ%A(1W=Y1Y$(OWOL;M
M>HG@!$2E](&KTF;8Y^HJ:G^H-H#INJWHJ%E>20S/9Q^'KXE>TJD\0S*YB6Y(
M[;]P,ICT97:'*":A;C7*=<9,N,7^N&4OPR2!V&=^V)-XG2UKVD8K2B8^L7(T
MMBISNG(DK60_W$_UO8-)1=K#15>CU:L\PK'^M6PC(XD.#9%GE`WOYA.[NDG.
M:H`52GS:KG#^1NM3,6*QWK2L]'<"HG)J.U5F&4DWLGWP+N/M*E"&L2*1;0Y2
MZK:DXRI7:1QCJVK=98(,?'<'JU+P'88A=)5Y;`X]PI/WE+E(XCF0]X@[.R$R
M;8I+Y@7)>Q&&;4W>3X"VTF5*BCT]1<[UU:&7`EP,LQH!F0!O-[X':D_BXE1(
M0-WF<[PD<6+6_`80-2Q$5>Z\R#&<9(B/Z#FW!^0'1+"S^72-3(O4)VX=E_SC
M"];)OU"/.NQ)[45>BJJZ;2P_@2J);FO+08?N)P^/@1J^T5:1\VZNBC&X<58<
MFU_G*>O0#\WNH&W*WA5!,+5)=8XLAY*Z-:O0>;&BV-X+<=Y[9&(&P21Q_;2K
MC0<RWS3/G+AQ2L,(TFX#3.D/6Z0C&5#F]0D`*.4=;.&GYZ2:QJY?`DFYM;0+
MZL+XVLTETPBX))>H3&0@T?SC:R<_RRT22,F-KYI_YZ)R+U1ED5&6%V*<BQJF
MO#=!V0FIVW^Q5E:+,#R?1Y1XWQ:-6WO'O:(3+;TEUD'R9A:B-7RL\>M'FHO_
M#M9`H;`RQN$M6,PJA97Q1,3Y.#7>][X9L)3T6/:)3BT[.[?I`2=2EE@CBT2-
M3QC$91Q>,8%,-"R#2>&/AY+JG/C1(E\6L.:7#26N\DKOW"UB"L[0=3?@]\*G
MM;7Q0)7'&1,-U1G!CLE\*\@#Z6S.#ZRH*0,NKL]A!<%J95$<D;7%\<Z>.^X2
M[;]DTQ_*J^XP$E%C!%P"IO@)IY;MX[$9GM):ORF%LZ;Y3>5$OZF<T2N'H=^\
ML=,W'.7X$X'-Y>)._"WS,S?S.=8!U9M/_1W9"_P,.,_L=#WL3A1%7J]3'DIJ
M7*/*`M;6`R=W-OP`S(HV<%64T5#>(X/)J<1H0-FP;-=E(8/Y,Z[&G?ZPH-*Y
M['QU]"!Z5S#^([*-SHT-7]MT$BAO63CB_NAYP>U`Y(P$'29E%.Y7!O,&W?79
M4"=]>M)9V]?KK+[@#&.6CZ2VH[_"+[O]\,UT+=O>/*QW%\[ZRL!F:&KPAT,+
M@X_VAA5B7261C5N2I[-9HV6QO#("%!N$ZEL+D2?M!X*$LS=N$Z23Q6B-]7(.
MTWG:!J-?8?7N*IHBV(;VQF^"N(H8K[$>SQ*D4HZ?\<(DC-K^(UH"\>.A(*FE
M#=\$H16P7>/5`6:97<,H+K+N8#'^_&^\`>K3EM'R0CL8OSE2RV:\QA<S6,HT
M82/"6\B%D?4WC-S85PQ%F5O6%$T0'@/[-5:J.5:X'0>W\(G7[?=$B2]CAB9(
MKYCY&LMEW,(+U^HM!Z+\9N8<S1-@.@`UOHG)O.S=FA9VK\%O+!R7^'Y5Z**W
M-WH3Q);/=+Q%TV"!)5K\T5>[O5G@>SZR#=.&[&8B*L<NGJPYXF2$9)N/]YHI
MWE<7$8)?-LLWQ^HJ(U%N=&_<)@@MB]$:Z\YBZHE*;TB*B/'F#/SE%IENA^Z%
M=1XP(A_NO8M:7$DD`]#?I_V<NX08C[8C<K>1`+&'O#V3O)G+%QC31GT%/+Y8
MI`/J9)3Z+ID\AN*IA9@9G["VUL4,R7=<^!_TAF'IG\%4.S\D_N$W$[O`P?OF
MQ\X/7[&/3,O[\41;CC^,QXX&+FWD8?.&%#V(E4?KR3NR7CA[>6M/O+><,GY7
M4283F0\<Y4TNQ.#Y!;?;W6-&I@7'Q-.U/OO6NZ:,Y76/E-PJH+Q.L`$2KP)C
M<IRW/>H0(Q8""*%JXL62R/\:,_N9@.*&!VT>'=O=_O4+\DSO-6S-&ME.3B@N
M((HXE4P!,=27S?%:=(_7V)I^FAZ!82P?AEP:Q$95XA7C*`1C1K396\4B((,@
M#-_Y>$E+G$6;F/7:4TSJV>F;:/DT>XN<-9QVELBT25FVJ#8F0.U82!&K5IQ>
M^TAG>,'['EV5W`)"JUQ5#GAQ8,H1TK;U]F4"V#P@U)XF[Y`J&PWGI%G\J#:_
MJ>6)Z4]>[5#N4EBVT"ND+"HE1CH*P\YD+>1:XN6N=<+BHWR.[^Q5X'LT#%(>
M\/(-N]V^HLHK>N9,+%;GRXGRR`CR\3GCG0%N]>COV)?WE&+.Q$U7CQ1\VEI!
M3F-?C=GO5ZL>ZGFH1PH^;0W9Z0/8^1%F%WSH6%[&R$"!$'TIFYQL%847J3->
M;T3L1/>9=Z*W'1!-.EK'F7>H$7;43AC5TGMK">#%[5+OSSR;TWE?0;E3X^E3
M=[#/.'O)YR<_YZ!)QC?;>?.PNR:Y!G6T^]"'.0BLQA5@((C:)F1]$H`_D^+X
MEPT]$_GN6$"N1ZY\^YMK"WE>O-R'5X%E[^OE4E'>M/Y`+KEPY+U@'QQJ*#MR
M07H;EZ@3C>,Z;/YHH@OWG(+9*C4'R\W6T0S^Z<;%8-23IY8Y$XN5L31_'_<A
M8H/P3`I5I\.5*!(K:M&5YD8LD9*V<*1KGFRA-=MU2>5>3BN^VG26N3C]A^F_
M'\U\D'IXSP>;0B$OF[#?U$0;2&S3*(7FIIE]GCKF'1X0*[RS*0F4:K(H55QR
M2Y1G[3PRU"^CY^UD,JP`4)DL--^W9!>9JQ)MZW<SI"P)4II>ML/),"YR<A'\
MSB*4H_:D\H5W-MM<)[8SY:G1I!R`9ZYQU5ZB.'4K1V6^_=OY@>;6)V_*A*/\
M_V7@;3E1?\=&0-ZIY#WLM3O=M;LIJVBJQ'?YA-):XVUC>9B?30987UR6N-8]
MUBJP5H$4UZBRL@5P-H&!^-,,2D\[7`(3-Y/95[N4'W&O;HDQON*W[6O%_F9W
M#7:G*M&&F>Q[XP5TE%_Y$G/<V=$L#\C]!_:)XA[-9QO7V/4A_HHZL80>>R>V
MA$,&IN1=G99%MA#G<HK^I%S+ER>7,RY@G'YZ2CONXY$`O<SQISVYGW:,J80*
M2=FMK,(%[0+![+X#X8[B8*05-7@4$5<7D%&7CSC>P2\#7.W)<JXN/*"_.RYI
MAN[-YEFXD/J!JBKR3K$Q$E%>XQDFB*H<P*<\C6<F0XC&EQ;M5MU+H=9L=;]V
MW)7C(A\3?G9L1,>QE+[$<RBY4U<E\"PMCSL5L^+3[",?TT"G&TW`R!$3VD#>
MZITS;U,DS`9-8ZRXL.9=/I;A<'.'?K(Q\)2.[W8;,X-Q81-ON3$>W_Y?!0I1
M&K]F.\5R;$DNJ8M2B_1E('/PZ=)Q??-/;%P[GM_5^CUY-P89B:A,^7-$7-R.
M+A.WMFX!E$-TW$JCB7L12F%/<G/&$P7)T:EQ?$;OKJ^Q^^:(:=WYJ^MXWC?;
MQ<@B#N)7B$(!D[[$N]A\M)R'@RU",0XQ6O;@)S,B]_`W`$3BD[%<I)RE5AUB
M&'=64L^NL>SI)X'RMD%+G/Y)_/K$,S_?TZYH3JX6;Z1IT<."%1M]\[8J.<$Z
MX]#\Y$,.BGIHW0_(#N8`;T`.COQ[!Z8C]4['W="&#+/YW-1QYQ;I]"@IN]GO
M#;L;%.0;#GDX(K<W8)T@^:A+:INDC.O4O..7M_5'_+$=[)Z>]$_9-`?B4]\#
MR2">84A!]=>3A;`U8EX4OF,K'H"XCXX.<-EQF<,%K+(^]>1!>PR;ZK&Q'>_E
MGP&HU:WC^&B!*=%IIY,RB,X9JFF&S,KU&1MP_EMHV$:V?[=<N<Z:GG6?6I;S
M@6R=LI\:LF4(/7NDILF<D><S/NZ5'ZT;AAG2G0^$DI:49`B?9<RFJ0$W#F=\
MWCA7(9[0)FQ4Z+A/KJ-C;'BW`'B(R@X*9=!7Y*5P;$0T38=*0-?61MCE467K
M&%5=)'0@O3L;D("TGQRZH`M$VNL6N8MBZE`UJ_+Q8Z&,7-?^5OWI986C=.31
M\;'7`6-.'E@M3C+HSPY^Q9U!D$)22L]/11W*V\%/G[.\Q>R/MTN!1YK$]^`R
M)A5B5ZQ"B1\I+P;@C#.(TTL`RG'OU3V;Z_PP72Q<O`!GT[D-_/]K[\J:V\:U
M]%_1V_2MFG%I7QX=QTY[RK%4MM-==]X8"9)YAR(]).7$]]</`"ZB1)`$2!P2
M@/70G<22L7QGP<'!6<@WOMNNO3_L>RNLVM;VF^7TDL.VY[D]XG=](__J/7B6
M6ZO\:E9ZT]FCR>.YTZF3F9=N.B^9MJGSP`31)SA<8_"HW7R*7@S:$R(QC9CY
ME]L[/+'E_!-9M'@BLTU`D4NAWC2=*`,9D&BL+1JRRU=2]IS@\?++HY"P^O+4
MYI+LZ(HR1R$`IMX_12`AA;`I*`+."='QE>>+'`BFWBDK0%R8<4!BPE)JCAE[
M:L+2;?#QHA8?GVPW9MZI^LSKA98C4ZT]8EOQY1=RWM%WSPU?@ZO1<+I@F7ZU
MN>!\!D556RD0&OOA95R<RIT5O3\>29'RT'Y'C2]!Z4B7>TVTAWL7CW*@7&NM
MT?7>.[@AOM*/87T:K%D[<VI406#J/>5T[UEGZ#,&&&U6R%\3K'>(_.S)<G>)
M3KN:S0##^>JO2P$6J@NCJ1>?8G2^4H=^5%.5(`'7,))O#8HQ3Q$\,:/,S&:4
M:-_V.K:>,``CN'?9TJD58(L2,&)NF)O-#2_(WY-W!KCVU?GY%*#[^;;3,T+U
MI*U&Q*:U\I[QA-9FZ?YE^3:QVXE&'&`L`.N(\JY"`<;@@\C43*QL%,I]$!S(
M4WY4&.%J,)X#VA'%$W?"$YPXI,$,^K%!X]RIBC"(&ME366="P_0I$UP(Q\3`
M[U88Y_@LMP^>NR.'%YDM7Y5W!N=;$%U.)W+;"#.-G1'-"\+FI'GI[RS7_C?]
M!7X99OV6L/1F![GQW,!S[$W$(NYFE=D'>?YVL6JV+8?Z`Z@S^-CV>,8,098C
M#5*6V""-BG`WYO+E&_*C?@A8)@9,Y[^<_>8GE"+?0)1.\ZS*8?K4`I^+J,J3
MED/<"]A!1-C3(;)1IF/69:3@'2L_0GW!.HY5E)/':C55N3"H0$,N\-)V[]Q[
M^]2"L3@7C.<0X_-?7TBF5^_&V[\A-Q`\%>D(/\D`K-\7MV[3U2VWV0&?D$.\
MXJ0\4T#[N=`IDU?2H_4T909%2;*"&ZVMP8,;[[Q?LO,>V7\^6P#Z/YHM3HXI
M+9EI4O>)/.`_L=H9]Q?]7+F"(L73^^,Z"`Y[BD70^T$^MMW>;1#:^^AS;YMM
M:83_14?")WST&]](6W*TJ?7BSU9EF?60Y=R[Q\5D.LXLM_2WXV7$JV@>+1`1
M[F0YI/'Z+FTF=N]N['=[<\#&8XX1OWR0ZI_$M\,8AE3^'(P6D,\CH(MOD,14
M.&Y<8W8R6L#Y&JIFE^1;:)EQTE0I`6PU5HD7$Z:VP^_(;07,&<0-^[(<>?W+
M\C=Q==OY',Z8D;9,I<T:$&(DTMPW39QIZ$W4:W(TA?-"I=/4%[(H2"@J>8[7
M"N<AS$PDA=%+($YXMF!OIIXA<:A7O.'1"#!9]&0J>>0LXL.T.GW1#HTEJ?7[
M9,,SN&/L9*H625JT0XWCU%NV:H";%;1AU;"1JIJX:-Z'M#SLI!^]9L)`U'A]
M4L0,D*%2XT\J)93I#-$^LFP3Y=R*,>`T4P#:%OT9*<'TBWMJ2P/#7+W;T<!R
ML<FZ>X-[-XJX_AO9NU=\/[]^1[ZU0_3#KZ2`1N(KQC?SQ8Q5X:%C).OM1L[!
M!\"=C4\\"=0U0/W+E9@4ILRSRI,=_.^=CTX*:R6Y3AC,,=P;15O;,%=&FM#3
MV&LA-)A4Q0!V,8->_T4<3BAH:A(GO%*)'$X$S#Z<M[NM;5RD@D5/4POX2`7S
M]O<;6I.`$W(%1NXF43$33:2"M?[/)0Z5%-2G%I`"<O"7Y^!A2'G?4]MSOF"%
M."LL$,R-?$[)J*:IJ34.6H"3VJ,*.O?X=W`1BC,JFEKCH0WEDMJA<\!(T/8V
M<I$--DUC$5D8*2+Y0/8<G#]%X"19Q@,,WV`!U_D8;N%ZB``\S8P-TP3![\[S
MM\@FB;9)LP]FD86"',D6EO0YV;J$+`E_&_?BQIU9,5<V:X6YK]O]F^-]()1)
MGXH#"`?SR`D(LJ'"::5(E#BQ$GGA@D.;5^5WY/_T`-()<Q4]BM,)FQ4!9J<$
MRBL'+"?#`R0DTIQ4(0.":EM*%<I'BT(0HT/UQ5,GSK&P@.]1K*G'_2'<?>=T
MK@8IK;^\_T$^_>\.JR6JM>Y=4C\8_XM,$I\AI%N=0+=BSF&E<'`5[&F&:8VM
M:G->"MJ$2Q<]VM%_*1:1S7`*!+,L>U%A%XXQ6R6X\"9-#2LJ``SD=).EF$[,
MV=7!7[_BTR%+M]EB)M`TM&(X2+[,'8TB6^LPPD>`L:+<A7Y4)1J4K;CS7'F)
MQ5YZ6O*TD*1JFR+YC!(0J@"E'L.M%33U.,<]!7M3FW78Z;4@)&DG@3A'EL(=
M*DX89I(L#&%:20/.$Z9HA\HD"Q;X'9!KX17]<(,WM+:W-MHDY\6,V=A<EA^A
M8-HF'I1HR#O/1VLK"!."S29P!B-[3DE)L=R$.;HMJA!01DDHD!)<9$0I@Q%T
M0N,EI?R24JZD9#*MTPXSE'G$,JEAG>A@NOS)8`HH::PIM1&>*KQ2<K??ON>2
M5MY-6OGC@9@K,=,%UX?P%5/\WVA#XSL!J]_)7J\>T2E@%#+UV:%I0GU\0:1]
MRDCL#JL40EE(E9RIS67."IA-?1^14N>!E'*X_8W\M1V@E6^OTW[<43M6"B2K
M/"L0O_*LR7A&%B;,):&:#62*'ZUD0AK`$5276PHP19"5+PK$VJ6+,9ZG^4EQ
M28!F([@\A$%HN1O;W=V[H6^[@;V."_#,^GT%:\94K=MXGN>C6-IXTD1^KQ,)
MGT?OK`;5$R+></SS&\^E\7P'RR%6'Z;B=#A0,%NG_H[TD)$.J6QTF8`&N,;G
M+?'%<>(ZH+C"M6+H8$?&2T]3*AM=04`.KJ<G=Y1<J(60G"W\,\E"&<W2`^-2
M[Y9Y04L+?[YXH>6<VZW3.,93R9L&SQ;T$(,VZ6AJW8PT7AGY[_8:L7%]]-QW
M%)!CDT`84*RRGY-$HD<O_"<*G]#:V[GTS6,Q',`]X($M6WG.;X5@QM8#`$,O
M]MAY?OPC\KT!@12NM%B[>_F\@E%)6F.K"S1^"+_>;.QHXXPG\?E"P6+%U2M7
M7A#:HEK"]CH_&5?2B2]N[3S"N#0HN?,`6AFU%B;\M18*/R&%6]Q`9@D&]D_C
M>2YE&8K6UB2I(`F%Y#I^KQTZN$V:9)\?L'2-25CD`"ZO#63)4@X%^'(-0$3J
M7*,UM_DK-WT\>`?S/ISA(GFQ]24[G@-MV$N(=>K59`'XE,BW!BFR!\XDB3"*
MXVIJP.B]BT]SE%I8#S&TU,(:3B=PF0$E$]>7EX)!8_-O.)W!Y<^73BU%.H1(
ME7`Z-R)J'Q]\VP#1?\T)R]S1$R8VWOWKM;OYBMZ1X[V1T6/-DR1%3@!3"C@6
M`,FV1:1+\ZO$\#%5/W]#+O(M!Z-PO=G;KDW,3%).Z12((;[9@C$*UQ*Z9!5A
MC$P-LX>RGT`.S"Z,;/ZD0M";M)"WO!Z]-$S5;05R3B.J\T1>&>[!H8![\+#?
M6_Y'S]OVHL?YWO4:JU"\8YF.P6B2Y3::(IGAXA*$=`E*SXZ^5&J]5&J]5&J]
M5&HUQ6B^5&HMJ=3:A0'42J56!0MJBBA252K+?IHBH`J4H[G4`E,J2`G*\P#&
M/W(IH8R#`23%H#C7[Z30P9/G.%O/)[^(L8G*@`WZ2K%I[0TUN'RVLU:2&A!5
MEM4:\FY#&67R.T`R.C_]M;F>O%%?Y7-H^6$G%1F$Z3O06+@TU6<Z0ZZ]/AMT
MK\\&&M7:B/39K;O10INIE>B@HC(KO%YD2WZE*9L5##V?=XBZO)WHKM/$TU.`
MN,#4R(O&>.9RH:M."J8[6A'!$MK,1;;D\<*GK:Y8!>FQ+36_S@*NSM7B=BXB
M)I,?+E4?*ZO:5"HLX+)$\+OX?"(%0'VC*^))3BQ70D;$WKR@[_Z$K^]2ON[R
MIEEKS>;6,.`FE39.^P;%"_0@4(WSX]/>Y9NQO?*/E:(J"AK$J"(*,1P6?2T`
MC!:LFH58SHL`*H5%-VT4?M>OM$QJJ?XLJ+SF4!U`C30'Y"LIBVZ7]U#>QYAO
MOA<$!+Q^AQY,\17KP/4P_9-**'>QL6O1:3)4D>FEGY0T;2<(#FCS]>#C42,N
MHFL(,BD>Z8/2YFHP&T['@`@)KT@'J3]B=>P,VPQY]=_I%I%8NVA'4A_;$VS&
MPPQ1B%$6FIIBS5BRIEP-33OU7\ZZ8OO,Z\G1^(WTA9J7EMR"=6!Y^9>6"KII
M\\#5;1`GBU9S%;E>&5_'69/K=\MV"`_B!45=*@D7+M2#L6+9.NB0N305(D)#
M;;I?O2/_IW=V$Y11RV9<JY;-$PI"WU[CHSSZ?B_J.`!:W.8X)_UB-*-BM6Y`
M?$*=U;JI*X"W_W?`)+EW\0(.="W+\!7Y+Z^6&ZN"M%'%J2*8PK43:7<O*E7-
MD>=::TQ6;1ZIVG*Z\2-Z%D:0MH>_LVR?]O,ZA1RP;*MBF_WLHE:7,2X.<*G:
M33%G`MRIU17HJ1=@KN23L^A&NKV1R>+U%O4<B_Z7IVOYM%4K!NP3Z#%=`3=`
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M96<\`WR5@UJWG&!W,.[+]V6&I)NQ=DM%Q\)L&8PD_8TJI"Q,HQ&@S=%X@=KQ
ML11*:/,((8%ALV9/%B9BND24"H+#/OI9'K)IOU7FK;]8C1E9$H6,=055R'YI
M-O(97L/18L+RS!8T.9<XM<;\*0-LC:]%D!>(+Q\O>*'++7,8T@1[,%K`!5(#
M+[[^=:-XW+A_^F2T@.L=4#6["J(LSCB)A(M@:ZJ==*DQ47;,-F3-I$?["+"[
MA]2UJIVX#D86;0KN-.A,`<S3"9%:5.8&J&1#J,:TIDV]A'%;#2#5V*189,Q]
MI6[1X[W[.XKR0N?]*=B&"J>5<A:)$RL1"2XXM%%!$)7:^OT)?=?"ASK1`N3O
M+]<OM]]O'U^>>\N[WLWR^^KI]L_;Q^?[OVY[#\OG9Y$GKGC4(+(A?/2*"6>_
MHX=<\7B!-ZZ3D>Y=/!MZ1.%R^V+]/IH?@^$<S%KC6$!]`:8/MXP9?K@^LASR
M?/&GYY!*A]\PXQ,<E^XS6A\PO]HHN/;M`'^4+7"=K`PK=<C42ZAE2]$?M3@F
M42&M$,348U8$^84QLDJX()EEY?F4+</0MW\>0NI1]%:4)%>#\2`*90;9>L/5
MM2YY"U[)JP.O/OY:+[0<?@$KPNC.\Y&]<V\.>&)W_?&";P$!!IM`Y6[HOYR(
M:)M_'8*0G-%\B/87<&$AK>Y%W8,%GG1I?,-$=6$0?%E+[,WE-H(2`\8`."7-
M9#`#?`X66TS]4PA3_Z@7L54QG,(%:)S,)2<VLRG-$G$JAL%4XZHN="#61FOL
M7J)SKV:#!=P.2R;N5!)R=A,G0MKDSA6;1*TI%\&#7N,#MKD_:5SJ3UJN;I^N
M7^Z7CS7]2,LWY-.IFSB0@C#`G'#[F_@14>;1:CB!LVZ+9FVB"5TZPA-Z1^X!
MD0FN9L,%7/0Q8T))9C0O08[R6+IU;3RZ@B?^$\81S_**L?J*=^YX;T0J8MBN
M!I/Y',Z>+9V[(S;@Q\-4&_`;<K$^=#``UYN][=H$L1"?42D&_2G@C;UB]HZX
M0@034T/]*U$#,I'EGW&G(U[-XC2-5M;?#@,S#/CB39OJR(R,ZM322T$:3L=P
M_%HP:8,7@<@Z=7<GKHA)]#H-X^7/SRB%:[GID;HS*[:>V&0:',%R.1?DY)7.
MN=&`^#X;*YTO^!#=VN16.QC!U7XIF+45#L[9#3P0)%RL?G]008.AP'T*HK/D
M>Y&%M57Q=A,*:Q!'*J:G'CW7.]71,9^G:"7:&N;IH&KZ;H1>")7C&::?8Z^4
M-\YJ0IST.<UT5_UB!?::7+9MYX"_38+H1G!G7+U%=<-&$@!,7!1]]16/&',=
M%>T=!IBX[FSW@,$XNG*_H*WGH_3\1<%WVZ5;OW?Q7"@(,62GHT0%3[ZC\-7#
MGY`:+-0_C,_J_@SNX&IQ)]T<BUV1*E&L$_45J]BA>VOY+L8O6"$_B;@_40"+
M_@PN4+5B\FXTI0`B"5<LU.<*4>]<]'P1Q.\75[-1'RXM]GRV;NA>MN?TO49?
M.@/@5>WW3E\U],5-X)WKQG/P=[SH(*+9^*S7KH+2!QQ#=B,7HGLU]24K5@O8
M+I@.IG!1/,DTW=A7S$VF%!U.%*<HE,-A,E37XU!PI8F,W?1)<3"-2H/`[.1L
M.BF\6X<ZQVM"R?;3PWRF*CLO(G9VT8ZDL@L\MJ<9/E^1;[_31^5,S<U'%*Y\
M%)+4GOYD!N=)XUU&RVR2?X>O`U?*/?.YHMQ3UPF2W'S3\$$L-O,%Y-M*;L:N
M.:(*A)3XTY%1Q*>I'EG<4L4Y6LP7<.=&T;R='R!\@!QUP6"B)CN4G"1-`VD'
M_5&N^O!AO[?\CYZW[3W;.]?>VFO+#7O7Z[5W()ZZ76_E.?;:/EJW'+&UT9C+
M;6;$XX#GXPG'VN:'2KEC/(#3?<73UK?YB*,J6&Y76;%P-Z6P'6O'34=#.(.@
MR<JDJ`(!*B<:0!::&H?Z-M40X_ZH/ZBO(WI_/%I^%!GYC]X?7[$E9CM"!<RY
M-$<Z1SS!19/@K>#Q-L3=C6$YU@JX_;UV#AB+Z.5E_W8(X\K5YQ[SZSU9T=6T
M/X`+]9>RQ*YTBW1\3?6Y)<_4UP>:7_R$C9@C7MBFHWC=N]E7N^%H,68]512X
M7<5GZ(II&F*A\3E4X99=.U804/U.UD^D)PFP9T77!R]>XM'.IV1$D+$B1@J]
M]C)G[XJU`#$T-7^!!5F,?+"R/J+2!@_("D@H`EXE!B_`OX/PGQL*$.M578#)
M>.=2B:5JX:-//D$S!B(-0))2WS=6\$H`N[-=RUUCV.."W^2.X:5Q[,<?7HV&
MTVD#AFHRMRH,)@V_E.$,>[.^5.+ILA)/#0[OO/Z.CCD$37T6PR9>S=X?]&\?
MTIT4T;`7UT3JECL;^B/Z_XD##JZ'+-\:.G9<"B!DZM7P1T#ZL`6AO<=WY>!J
M,)O/X8ZDT\FZ(G[)EDWU$:5M0;_CVP36V.3`8[/\8MJ'BV7F7D97K%$+)U.O
M[^2&0&HMX3](^/^[Y1"'V>D-(O]Y!-35=#X"#(9NL+*N6$L6FOI4_!+CMG,'
M?D[@^H!U<2HF[XIG!##1^#K"&7)UOGD2<P17)+-PWJYX@0\(4SV!*[*/J/;Z
MN5/K>(7_BH*U;]/]X:OZ?`)GR(@NIRNF:02;QKV8FA=`G)4WU+A^_K-W][#\
M^[GW1^0;>D4A!M81ZAV?::Q!G+&.]RLX&:RV+R-3,C,=.5,?D^D&EUY!-C=S
M?8=&TMUHN:4]8.Z#X&"Y:UHQ$-_?QI`-@<NFEB+58K1*!9L7$8W]%HV#+P?]
M<S?ECZOGJ]XW[QWY+I7KZYV/*/C_V?MOS\8_^`O_G7S5<C>]D_0M@6C,'\%Q
MAG0".GP\.BU@RQI;6-"94^6&/Z8TC193@4[#8J/7%^_,>.\HT^SL2+JCL3/K
M`S;`$5B(%-EO3+YCGFDM!#^Q<A@/^OFXRP;JH4[PI;BB:!Q_>60-DI;\B$E[
M_$GFD2R(&ZR-9G`O!()KJ:]>_GP-OEC^QDJ2UVE_\'B#6*2&`J%,)4/),?$;
MTB?1![Q;UE@!<)$\ZA9XY_G7FXT=;22Z#1VQ&`GDGW,.JR0KB$!AZC/(@[VF
MN4V)KB7=5!]V#_86/>/K-+:?@X<PBP=+^16PAL#02K%'74A,??186>'K7]9Z
M;;OHV2/1YT<(2<0=R^%8P!'%(RG%`)P;-M6Q6&0YQYBN"S[.`OQP[+G<'\-%
MBLA<:7UCZFBQ'MLWD(A4VM6:%`.#\RV532U%I&!Y(<VHYT705..,Q,#3%T_\
M`7%SOOBVY42>*V*;"L3H%H^D$3]PPF'J@6M`&;5V^,3PVFML_^8;1MD-8R,U
M=GI3/YB`:<X<1"/"5X-@JG'VY'U83OB1/';@^^J:/I3<'8AW;.5[F\,Z?+:<
M*)]J(I#2R#^R1HQ2$RY3(XI67HCGQH<IWOF[39*&#[1^\W)[^QL/A?>3'+DG
M-?N"%#EZ`6*E9Q?=^)I.J!&OR077U.BEY,Q^0?Z>6G,"QU;V=S5BC,(MIS:*
M\A42/TV=TY:.I;K%40UCE/P%[]Y=DP0UFLP[$'B&*AY)([;@A".]]RI;B5(A
MQ^.P;Z[GD=V"8/G+Q;B_VF^Q66'MT-5B-`1$@WL=ZLKB$9C4"54+7&TB1-^\
MP"8(\8MGF9<6ZRF?5&6X&L[Z<X'[`<^8ZC*-D".;"5%J`0Z&BI:"K*?*LR$[
M1TDAPK/Y\D$SU.F%.TKA.5=*!;S",::ZK)+7+\(0Q;PR-U"U<-C#1_&9]R<"
M&D9@:'6YI\X%@@E8>I&8FJ5O\H<U0H_6'GWU]I;M7@WF,[@'E/*Y95IW""U=
ME(E98X7]%KT+E@TFA?%%25!L9Q5MT]37WR>B!*Y_V\'5>!3UZYQ"\&DZ37V6
MI$/$E,%KG<*N52)SED"<JE3VWCID.@Z"?+==>W_8)P%-H_D0C"0G4\DC2A$W
M)60IW*'BA+%^GRP["C6#(4QVJA8)4[3##D-E.0CSO'Y%FX.#EEL)EMH+C5`:
MSP=],.K*7Z_\K*1&MBT(:JW[YRIS&EM@NZK4IZ9D4D:P50*;:5ET&'S$(<8O
M^-O+;6:[=/F3T1S.GF-.J9U@50+7X8.NT-'']FT7W>`B[IX/VSCDQ%>F'1?)
M(D.'#>GD>61`V$F"1X:?863(4IDOA`V:VK>?FIDX(,P`D51;Q1V<)VS:V*,V
M7&JS0=UD_C,^:*\6`U1U@I(S`.*\Z=Q0;UZG9'A>B.!O*A)A[\&V?MH.WDPR
M>751@?A7<[\I7"O@?*`30@OD01:-4_]F3DO>Q,-F&HJ1&#*!("KV*%(D1P"Z
M5$:J]Z3QBT#S:AW#?+6.G)#4J<%Q3JJF%3;4E9J5[ZT1V@2DZ4-2+VKIDW2`
MQ*R[&HP74[@.A]4+Z$KX!*$Q-14O+26&-E\//JDS2`M$T-*CP2/Z13\B!;.'
M@`_,?(OH5$V+061J,8T;;[_WW&CG&(4?KDV!&PK$N3.&Z(JP5;M)J6A8AN4-
M*0JZW,:(+?TG>_<:)FWTCKWS;BS'(:%:B842?S&XFO5'<`TL&RZN,UZ2AZFQ
MB5$LB&Y_(W]M!VCEV_C\W;)P`:S]5V-%2C&8`'K:Q&T+<M4WRW8?/`R-^Q4?
MR^_4C7#O8C@/U,GPB,*5C^W[WU>#_F0&9^CR+J,K]JD%DS8!N;`'X*VU?CW]
M+A$LN*(WC9>GE(ZJBZNI_0:CRV5RY3SK7;V`[,]5-G-7+,.+1LP-"PU546-?
M<7^>:[U'KJ2OGH,Q"?ZC=^I(X:E"?_QMEA-&J.K\^5"/7HB.M<PQ+K!>@\*Y
M&[J:<^.RRBH/9J-!V_N#JDLM2LD3[X@P6I_8KSWHC\_%^7J-@0MHA5;23?,^
M6'M$:'O77_B%.C/&<IN,</VSMF1_.02VBX+@QMO_M-VS=[_9',Z2+INXOE`7
MP)-Y=9DMI@+I)E7C29%)(1JD;^TB.]784=GX?:D_S[\OL0[6.D],>:W8])$I
M'X8)(GU`.31P:P7-H<FG);+WIO%Q5B/[!H28[63?Y`A:N$-C2<K,:H$A:2MY
M.WF2%NU0X\.N_,)"'ZWID4-B*9?;3.Q4'%@YG@&ZT:OGKW^8W*^62:+L8@;8
M^C&91LY=J@9!TIZ/K`V;JHP$@(()RP?DW&>$3>_-ZO#3L=?++<;0=G>)3AI.
MF<'A15%KA2.US:WY,$^^378>K_GYG%B'GX&]L2W_8^FS@NXS1/_RD?]R\K4H
M\G8R',*I7IDK[=83!@2YL69+"D$&F2B/8#B$ZZE1.*T<YN'?5,HW0M:"`:8`
M/X80NJLXK]4,=/EE[2'-@<8@`5X/2N>6+'60',,/H@$J6V'(S]6IJ9TPXOA4
MLN4H2/7Z@!'V[7^CS=5L`-IVJG!BN$.R1!N=!>Q6`=)AWK`*2GRNJ!*O\@#0
M(,8D`N1J,!V.AG#;*9BV3?:>EQB"Q5AH<[2\(_^G!YF*`L,8[:6BU&83<9RT
MR5Z2Q31_6<X!G6`QG[3-,Z=K4)%E2E#2IKV4.,=DKMM):"H5G0B?>S=S_2::
M=]K**52Y%%5.)C',M.DS)<Q&U[N=CW96B+[Y7A`DV:09H*Y&@]%$)**H:L!.
M36^Q[7Z"&QG5G<?[QP\7[WA%MOG\BISM$]K9Q%],-OF,J4%+6M`G$?%4R9JS
MJ7)3:PI4RDM&5O2NB'P'.7;`\P#J'C.\D&B3(<DZ59K'+8[S<8O%$<2]/QY)
M5@;)]_I'G4C&@G#2=-"F<8U)C&MF'NK?FT6]P4`$H&#.^EX,UH#DKSY**IO-
M9G#WC\K9I08C5Q$J$6813+1Y=A$V$QDH'!7A;,JJ703&%!+<=3_<P'/LM1VB
MS0N1<)\&?42=RP>S.>!^2F:&8N]B0J5MFCGAT,;_(FC#Q`*]61["(+1H,]CH
M7DA[0(FF4[`&ZHZV?'O31G/)K`N4P9%ZC88=E0;*KJ,[1JD'E38.-D'&>8P,
MR*Q[B#1H8I9>*%`&C"&ZHV[5?K1YCQ&D(P]8;5FS$@P71BK=#19)&Q./_H,Z
M,",TDP`%#!@B'6HIS:_=#;V7DFB%Z6@!]]`J<:&M"4VA[2\9;7.]R2OK@]9A
M>?%BLR-!$`74X7HU&(]&<#)7-7UWG"0$C-9^(2Y#^\YV\67CP7XGCR[8*MW9
M6$2N,1IA\#<B%52P[.#!K1WZ$:#MP7FPM^AJ,N_#.1.;K*P[MI*%IS95M6H[
M+C(J_`FMO9U+G/CW&[PR>VM;*5H)H%AS)^5?;&S]8B6^1YMOGK?Y93L.>2,:
ML^HF%1B"$&OHSI($1]34<ET9E*EKY>:P/SC4^8Q%$;``2_&\'7LE*K%(O!+&
MN266;]2"='</I/-O<'<@S:7C'.[$5#AV)+\B3])P^<UBB^F.9QJ`EC"2<9[+
M)_2.7!KT-!U,X51(,DUWQ&=N5.-J:N7.)Q3>NVMOCQ[HU6`T!*R4<C)7A_ZI
MPBTGLMLWC<H9?#)Q9]&KRV@XZ[,2(ZK+.)T/I<097[J_A,"?P??(?CINZ^6T
MQG-ZF7/\^F>:(S_KL^R3<L=X\NM@S_KE6)]YQIF;,?59C*<B&TBE"IBJ>,<N
M70PV"+Y\9#51W(.KOX"KQB&X&JG\ST71?'<S<=S4[FB7SXH&\1H"E9F#6RMH
MF;F<>[)@;]IH56%O([L,&P@YVRDTER-IX0X-)BJS$!L,45LI-9<G:M$.M8D*
M$$^?JGOTP610=6$R-(>@N`:)*0JA/0RKXY*-$,9.`<WY+'3/*6Y>Q'UVGH*1
M/,GU+'?36X:OR.\=GY1[T9L>?]I%,MJUNZ%CG;].U\ZWR`Q\/N9Q.\?&'>,%
M7/UFH:74ORAP39-I4]"?C>!*JX@M1LIQU9#B:0>I^C!J<Z(!='L8Y+H]?+<"
M/$_O&?GO]AH%O;3/>N^7';[V;JR-[5C\FB(:+ADM'>QO/-;I4,*JHG+DE&E&
M@Q&S@%B!'Y-[X/I"7SG%D5/)X@6"4OA'EB*]38APO*;4`N,3B^VHWOG>^X/:
M5B+YE54'?33@Y;BOX=-.)LP<2M/)`#!7I7AFE0YR7H`T%G].!BF)_J1BE\5E
M/((+)*JQ(C49JAZ@VMS/:S*:5X9+%(UUO??\T/XWI=3M[S?D!B@'&&B:G<2E
MJLB:TDF@C?<#PC82:&!7PR(J:F#6S!`RK)_=4>?F8\C1AB."/,?;HWX;EI&4
MU;;V\%]RU,F'76.5(AK-M?*].\_?6_?NEOQ!G=(I)M/1`BX@5W`QW7%:`]1,
M32T_"M_JX*]?K0#1,KEG(D4\&*PR)$7-=7@&54'A\.Y98VNZ<6FL`:,T%I>[
MM4YEK$JOFOR6GR!A=T"Q6'!K!8W%RL7Z%>Q-[3`^=F`*"$G:";W)D:5PAVH3
MY@DY5H@V*\L//S+!_0_I`_MX,F(]1LA*1RJ?7=)[2ZH+:5%8UK6"YVTE'44.
M4PD#SWP]86_-5%=IG!WXXF716Q$_";F;/[_BOVVM*`MY(I#'P#ELQW2OLWF-
MC:]21OC3<K8Q'O@*D@?A]C>I!VV[NY=?WG?;<?"G%!>!5*P:4W3,($U!,?7"
MGYC$R8UE0W?-2M@J;'AZ-D#'A"[?D+'7[637OO=N;Y+B=B^O**IO1S%@O197
M$94]G"HDYMBL-F6HA'/BF>@%7SZRGT2WI<FX#W?)XUY'@QMK9J2DR>9D#)>_
MEY\/DN&Y2':L$%`&A=K7J<C1DEP"L8RR*%C47B'SN]*)4<13:8.$HH6KC7?V
M_8.'\Y)0<T#_0ZTE2<X#:00&2P[Y95D9?FD;+9;G3NT^\]S629NGJICO1PV1
M8"+6X6U*1CQR/HR7[Q23&TL-$(U<DCQ?DT<Z5WG-6[C,\N]4?/'%"7@DS";Y
MC5I]7:KBCO-1HDV?L^J%=`WZ&L<BIV4:23;,$'X['8;>'3=VGC!TNGEM7.5O
M417_$*L@_BOTYPNW3Z>)HYZR+1`(Y<=P+6'*IE8I")4;(E-?#^KA"%(PH&6I
MH%:-$S'8YE^'(*3%-JE&A-\C>_(.)2.7:BX`DS:/)<(5-6J>MP,#Q"-C&H!N
MITN[:,!A%PTT>D6*[*);=R,W=`]?B8;-KT39,NKY[P)?E+*3YSBDX>6)HV%!
MQBLR@PLA$EE(?051,GK<]J,_8E;.E+/)JNFEZ)-&)$V4B1!0VMR]:K8A%$%R
M,C12.J[7ZZ@C`-ID$]H(&PR'</L67U%G(G0$@$.&N.!4_]JVB,3*13NR$UC!
M6A@I5X\HI$2?@FVQ?/+.Q&4A("WG(&ES9PN]T'+XQ:($@N_6OSS_QK&"X-':
M)Q6TAR/`$HB"BZDO'2]H_>IZCK?[(#W[WL@5/8Y?F(SZ</5:"Z>5(A*-29F(
M!1<ZVAA@PDZ,NCBV;;[+%8D;S\'_\J*FENEK:'`,ZQD)9"*6#M8IL^=N'?S[
M5M\VJID9X7MX*_A2[W\0C^6[Y89'#9`V1)A.!>C/,:1:7""*0:K])F;Q0@F@
M7SZ.D-)@I>$HJJ\$$N(CL!`0([F4?=K><6U-WT!^JLG-8457H=AY^`O`:P8(
M<[1><*ZJ_!6Y4\'E<?.OH\/GD))H,!'TE)$!_H!(<>;@T!5E"D<9C*2YED#$
M1KIKJ0V6J(E>Y_'1,IX)1\V?"6^#T-X35V@OZ]7MQ67?@)\)T\D9%>>ZB;'4
M.?ZLS'F?Q_<)$6L*"P$1OF!M.?]$ED]\ELST=?BW$<X5JA3-)AMP;7QB\FZ%
M#)P>L9"__$+.._KNN>$K?;<=PY5!:[8X?=FQ%&93?55B$!$!??GE461448KQ
MFO3E.Q:H^KR.@;,;YBQ$L!G`F2,U5Z4YR^6`U2;,$)SI[KP#-43&<*5_ZRU*
M;Y;+P6IJM8P:T.#OTG@\N.C,>HO2G./.88TY;FH:QV7WO]R>HW,U6<SA+@SE
M<ZO$0/PHQ7PRTY!/FOO1QOEP^[(J_EGO65(&JT=+$=?REA74^"^H=MS4*\93
M>1DD=@FF]G]<<RYX\6(W<#(-2F*^QW$`!LBFJJ:7H@R$2'96L9$/&&VN7\*Q
M6`SL;C!\-MYO5#2>9-M%"R"Q:N$'5I((TR,,[H/@0!L7D+_0%XCI:#%K4SSJ
M+K0[I@-"6QMGE`SVS*$,$F$-HXT%Z#^XFHYGLS;W5[B2UN0E%S]>%R]]/!>Y
M8'(9UEKNU9/76HO?/Y,78_I(FNE+TXL;T\"8<1P=<=HP[C1J[,08-=]JR,HD
M*)5`>V,%K_@#<NR\6PY-J9^.YJQ"O&"(2%Q[:RJKL!<//$VT.?5K]H"2@N#!
M)QN)OHE'01A(TAH.XSB%:V'6Q@X,X7`.^FAS^5*%SU<^>K/L3>SV3(*,8I_6
ME-UD0W'&+]N2@9+`2T%][-SN1(-DGB#2C<.Q,+S1:4I3[JZFDS&KYX1ZHE"X
M!3-8GXM"ICX-R@3R_`&#:HV75\M-RPA-QZ-6+SEP6S&#]84H9NI;)0\58$J1
M:'`MC\R"[`?KM7?`5\&5]1'[@2>+5A&"VTMK,IVOZ](=S6*IGJLKU74KPLAU
MA;S9Q%6*K``M?SKV+JJM,QW-)IHP/W,#IG!\-75B-E]<V+P,R$?/7>>TQX/G
M[EZ0O_^*?F*3>#S41-U7[L40YA>C69+"TK\(@C"HU#HF+O"^QA)`-V$RZ^>I
ME/"\PGE;$GG>L``%'N;(A&,RF`1A#3@=]MN$0L:BE0I[D$V%1"0U>#T4J[<G
M4[VE3IC18#1F!>(75&>"6(,9_BXFHI\\MGHL$JWSP[4.&YM4(UCY7N_.\_=6
M[PY3Q5W;EM.[=[?D)\EO+M_B.*EZU<P+(G;2)>`5T`6D\V>F7VZ/DU^B=IC;
MR<`;)%`^H7?D'A"^,4QFX-LJ64#WVH83'=.#8%@PX*/\WL52BAY(G/IT/(6/
MTJI<AIH,4XB4Z3$E&3`2+&XMW[7=7;!"_O,K7N(7*[#7^)#^:CN',&Y3S\H)
MJ[!QQ&=2BE7JH*-QU$6QO1)_0O[WTPH0_LG_`U!+`P04````"`#M@&Q#TUBN
M)XH0```RP```$0`<`&YV87@M,C`Q,S`Y,S`N>'-D550)``.-F()2C9B"4G5X
M"P`!!"4.```$.0$``.U=W7/CMA%_[TS_!U0OO<Q4MG3.)?%-+JULRW?JV);&
MDB]M7S(0"4IH*(`!0,GJ7]\%^"%2I&3*IB.XY8/O*'(7V%W\L%A\__C7QX6/
MED1(RMFG5O>DTT*$.=RE;/:I]3!N]\:7@T$+2869BWW.R*<6XZV__O3'/_SX
MIW;[4A"LB(NF:_25,H5G!%U3'W@E>M?Z>MWZIMV.*0/!W=`!4L[0^T[WK-WM
MMKOOT=_0=Q\_=%#O-B)\E.Y'Z<S)`B.%Q8RH.[P@,L`.9#M7*OAX>KI:K4X8
M7^(E?CQQ^.)4)]8Y/]-R^V1!F+KF8G%%/!SZZE/KMQ#[U*/$;2%0E,F/#/@J
MI!41/TZ%3W/4^LT)%S,@[9R=4J;MXI`T<<Y8N"AG<)4X5>N`G`)1&ZB(H$[*
M]S13G@'LE&-8G25"=4__<7LS-B9L@441,C;%C'&%%92Q>9>\#0+*/!Z_@I=0
M<K]^U/],L23WQ$./YHW@/MEC!?WYU,&^$_HFBYM-`JTXA;D@'@`'[-Q.;/P+
M<)R`-@F)5O-32])%X)/D'19.(>]8U>[Y^?FIH3H%:`5$*$KD:2)[:B?]8C][
M0EJ@S"NY2?FT%GNYQ*.,'F`N8/@_-I>/I\2O:"F@_3^V5""(!"]X2$T$EO\)
M@VD))R`\T@\/]X.=?MX8JN?\%E)IJN#0&TB':XK>M(6H&QL(<XH/%2H5*1%J
M4]%_ZG:^16UT1:7C<QD*`C\R0B#NH40,U+OX\72;?3OE4!)WR'XRSUON-V:.
M*?8QYOU0=;YMF%7G3*MR=1;`+!$0EI#=;/';!`*O@8P[+`3HNR171&'JRRVD
M,+=.K'S;^;;3K8X6]"Z5[AOT+A;PFP9#MF%(1V9NZ).AUY.2*&G(!'%[S+VA
M>`JQL_:>\`WB/;<<9Y)CC'U<.]K.#D%;HH?^$&F"$E40U`2440;%VC2X?!.X
M'(7"F0->1M#=V.'I)`^"VN'W_KGP2P1&1N(&91:C;(*G/ME&DZH326>'A%CH
M7210@Q3KD/+`<.A21=R1X'I`!U]3AIE#L3]@GOX=,0RANV$>9;FG"@//HYS7
M[JP.`EFJ"W@HCHPV*%4'9?31G!N-&D]F`SXO(-2"S,9S`C%.!EU362>F.J;Y
M&X,)S1`F/%_T;GIWEWTT_M+O3\8-`.P`P`A#SFI.%`4;Y]`0U`N'L[UP0.]R
M@C3^X7CPN.).J,L(.G!]IJA:9_QY!B`N)K1>A)C!@3CS[*/N?4629)N6!B%'
M0\@UIN(K]D-R2[".%G0I95L2;[FH=Y#QPW9PHB5`1@24E:'!A%V82%]^H1`#
M0J=V70QJ`2S><EYS//NA.-*X`S+H7>9#*F83J5J+J7L"'1&'^C3N,-V0)?$G
M<T%(//Z8&W<LQ1LDCK%?.^0*XST[(9?707>2C!;H+!EYW!IP;.!H+1P+`T"`
MKYK'?ZJV?LW@S_$Q\IES=T5]'[S0$#HS8@!ZLAF%8HEJ=@8HL_HG8[_?1DHB
MCG$H1B"TD2AV-@U:K$7+9@ZC+Q5=Z(5IO047BO['F*/_&!`F2Z8T9M&<!L&D
MYD;N^^*<6A6(Y:<W4EU05AD4:].T=6\+F0GE3A3.:L=@(;8_'(,)1X.VMX6V
M@0LVH![5@<XVU4X$4EKWVH+OB\'^X1C,ZE*D;9#Y%I!9"/]GKS`!_*RPKND-
M'!\]`[8D4FT/C]8Z;-[M?+>-CDRN3=G;4/;%AHG6W!Y]5XR),ODW+8E=>"@T
M&K3F!F.?2VC:A>-CX1:ST,.."@5ELQL\Y0(K+M8ZR/`\ZI!KK`>'U3H#D86/
MN5=KP]$M=.5S8OT%;02+X@PC&DID:^!C/7R*[8Y!4;UM3_>LV/8<!*2F=;("
M4E(1,29B"44C>S-!S)S"SU3-+[%+?9P%D<0KIUY75%A]&,F#$H%0*A%:@4@H
MDJG!B[UX*?$]&C8U^YZ2'465D-/X'`LP=,<5D2.\UN%H!B>LUH6'W6X!(29?
M%&?<E+\5Y=^;036=846N0X@:R"T8:Q$N1A`_.#3`/E"9SLN0]7\+::"?;SAF
M12?#`NPM@H"3FI=W=+O%$=\<CM"[5`44Z8!B)5"J!4K4T$=&I(H@K4DSVFL;
M(O?LC65!S3MC`5W[O52S&=9BI!2&<UA0[WC.$TU8,Z)S?#P,Q0RS>"5#!@F\
MWJ'^`@ZRV3:E?[S23[>X9<N^6V_A%^*/3:Y-T1^MZ,>*.Z;TW$N^T`N8MEV`
MK'>HI'.^#0,C0?M"BX"R,C2@L`P4YM2(P%38!_@T8/%".+.,/5U<//0,]S`B
M_"PP4V7G9D@'AY1P;\GK7V%U7ESEMPMDT.W9:(6T6H@RM%%,KW/)+%>&7R8E
M%*N'8OV:H-9>V.[I"$FG[B."SHLQSF[H-7VB-P"?\K<[ERY+1SIUKUH^+VZA
MV`VJG5^:]<GV8RU<++!8ZU,T3(/K@',HG0<%E'%>]Z+0\V*(O@=FD:C1`1GF
M52)M`[`W`+![(I6@#H0NAK"WPL*5^_$F)*X?<86)TTJ(VT@?AV.1_`T$WP`$
M"Z.-TJEY]5CE'F8S\&@)2.;<=XF0>DHIMVAL<UAM'<CH=GXH14:<^Y]1E'\#
M!HO`4-(4U1U=_["CR[8%BZ9)L0(@\0%,<NA=8CF_]ODJ!P[NU+K(M&.6(F>/
M?1I/>I/^;?]N,D;#:W39&W]!US?#GYOSP"P#Q:YSP31":CX9[/N*$&G."+,3
M,A`1"C*'H)`NR0V76_[$KQ<L'_:#97@[NN]_Z=^-!U_[Z&8X;OR*'2`IG2&5
MO-;Y\8[I#>\&QW#4O^]-!L.[!A1'!$4R@C*F,T8]<.1,]1R'ATQ1-AMQGSHT
MW[WE$M>[(K1D=FLS-)(1"VWD0HE@#7(L1\Z^V2J-I+HGK$IVOU1'4S.%]28Q
M9OY?;R.K5B?U_B5."@)E(V&#I.,AZ4%^YDLBF#E)-]F"\G=.F?H*#U"B/>9>
M<M^/ML9M!4;A#/][B6O>8]79!M3#R?@$;:3<[)3Y"S*"HEA2LVDO+VL#K#<$
MK&)+&..KYD7LG6)3^`*(->VA!6#[68<G3"5'D6;;O%6M'?MNMS!W'N>=GH/:
M3"S8@X.B2UG5O>'J?=&;%!#1^(A:L?'CZ?8=NO&;_%V[YJ9=N@BX4(B5WF:\
MZT[AZ"+D&^Z8Q/:PZ%_MA*^M7[6[[]MGW1/(.KDE\U`Q4MP=*$;"]RPQ3'J2
M."<SOCQU"347,K<[74ADIQRE//JAO6$^4()8HP_FEZLJFR!AT+I_>*;QRZ^)
MKB)`EO,N8M2"G.M"Z'[W8G&>)\H+Y,@5+#5'\AR,APQ;_/PL5'A83HUBH6S/
M,`XJRU'*>$I\)9,W+Y9'VUG6))!)Z_GU)K&Z$PKM4=<Z\?>'%%>.,?W5WB3S
M7(%TGU^L#X9/EB_Y\7+S2!4(G63W$%%2)O/4WK`_W\F?1]$*,]NPW6HUVQ<B
MQ[6O9A,_FEG0DGQJ)=>##D.E&RJ7LMEXCD5V]/J7/32,ZNZ.OH%:B5`OU`&)
MZ,<`O`MW)^;":C<4\6XB&4ZEHBK4OSX+'@:?6A$Y56310M']UM$;:9(?P'N=
MR%/BE]QH2![5A<^=7[>UV$M:NS+@\L'5?E1)%H<I-($X46)'/UYRJ0HELHNJ
M7(UI=&$6Z$"FYJBV>DIJP1E$KV)=1377-1)C?T(8A,"#12"@5VW&`'R?KZ+P
M:J-C)?(GE'4`MN7:1H&9>C5EDX,4($DI1X([A+ARC/UD;U16TZ=I;2W3BU!2
M1J3,`#*Y&K*/!0-/(4=$&&]Q@25U>LR]HGYH'%NJ_TL2J;_.0H4-XMP.,,`E
M7TPI,QGIBU%FC/Z'N-G#D2M<+)V<B%MBFGJ3?RZ:7KG.1,<:W9+%E(B,#?*O
MMV7'((D`_U>WTW;Y`E-62>J`*NS?$.A>#:<^G45[@Y*349)[D-V<1E59GNW>
M7KOB7T*/4B]@F@B*?=/P#)B)#'-Z[B&R5[/L"&XZUBN+L-Q/9Q].^0*L$`5N
MX$X?F#9O1IN2KT\[U^=XA,K!72R3;@'-SMM>J.9<:,_WP%PB1B`&^&GB>_=D
M1K5U=>;ITIFB<L].R-;6]Y(S@ZD)$8N<NMG7KQ2B)TP5Q+PB`8=F74*+G@O"
MH9$',90^\S/U?1DU#F.SUI_LNXJT%SN%K-:5R%_=N\155>G#3RLHV5\$/E\3
M8NI8TGZ-P/8%M_DDI76.,UKZ?TO`9[C1&=2$#!DI:K:?SCZ]'@.BM\\56^FL
M4GN(;.U[;>9J$T\(,3.AR^B^%1#+#*"G*E8CMS1F_H)]+SZ1#_SD2%]%I7WD
M&-HWY6'?[S_JSB14XLF*WX(*-'NNRR_/XK;6TWZ9RPLL7)P4H]D06JBF>ZFL
MJZ2)M-'^:MT4IL,B(R/%3OV>Y+!.U^P"$!#5T9.-,S)<,>)>K,T-,5G/5(FZ
M[@@V'AW0F550R'3PW.2,\/%O(02^UYQK.3.*[*5ZI>@-3$=F1%31@3KZQ(C<
MZ<@WLQOJD;%#]02MO%%%$![$91T0]6&FJ>CYPUSCPT^OPEP)5J.WM;VL)/Z`
M_9-@8>XH/E3S'.O_@A%6_)DFT(QOUP!WY%%-5L1?DEMH.^?R(",4F=^N(>Z)
M=B0N$4/OFDJ(BG7A'F2-'2G8:I*JEW64]&</9[6M;YN[)B`MUIR*Y036!LI/
M7GQ06HZ5>:PNP#+1RZ:+#V&R8>+XCJR2JF0"RLVBPS+M*E%;H5:TBK,W+828
MA2_6A9&QA-&@^D#*,#<Y4OKUV.LI[D)MRZ'7"\V*@GNLR)@XX+OU/.*`.7[H
MZD,_2^^$_.4YS*\SQ5"]>S-DY(Y&?]=T23+'EI:.7E8CMPZ)FYW+)9Z][*-M
M+GPCXWZ_]@2=#1YMA-7\*W8<@-"8^R;YXN3B/B+KT!4'M1-^3WR]^FR$A5H7
M!Q-SZE7DL#:$&G&E%U]@?R3XDH)?NP[-PKBAUW^$N(%A/QDQOR)+XO,@&E^6
M2L9C55EKO#RMXXYSZ1DY08WI>NZ_PR7D,R'.G'&?S]9%;%>AM@[D]\3QL91F
MQZH96!5\$6];3>_0X":6@I9.%R<T<M$\0J[5?UDRMDY$EVGUF3#PQ7[/70!V
MHTGU)8G/GY6ZYDOH\CKS#*23CT^8ZR4)OQ4#9@_G-,<9@=[7E(&4X!?B$RZI
MUC9N\+(O]YCO9<G::[RHQ/6ZP*R#S*S/R=FD`K6U[4X%Z4NF.`_BLG2F\YZO
ML0]10CR"%C=]0R\:7X-&Q85NAUXTFZL`!S`=MPT=.W/BAGK);[HH`NII="]3
M6:1;D=Z&B'<C:K*&-W\:[-YSB"L8H(94K3`3<3AS1^'4I\[0\XCN&A6"IWU$
MUL5,R>A9$M=>F4'@R9Q$$]$YM9Z@M+7M204O6>9;\LW:=L74H>)M+WJO\LS0
M7:PW)+$[-54JO?,E<X=*LFCHF@N/4.UI]5A0UC*_1VZOM36@JD,O]4I%'2^V
M=1PF:D%65,8U0$=J5Z#6T#.WS6S;\O7R.?[RT9<J:!31.J6:ZH8RF9`K],9_
MG^R.'&R\4,=;_*BUV5IW7&NJ%N!.APWQ<0VR-`+906!#,!'MF4LWR@V8(@("
MHBT_O)?JR/ZSTB;!M[@U<++B_R+"_*5S".E@3^FL0V4.ZR+`A\`37)^Y8I:#
MQ74^H]F.[[867>FY586SJDKF6`YEM&W^9?OLG!(5=Y-8JHP<$Z5\$BWSUJ-A
MA7KW%.$QJUMTJDUT.`#\_"]02P$"'@,4````"`#M@&Q#Z/`8++6F``"`Y`<`
M$0`8```````!````I($`````;G9A>"TR,#$S,#DS,"YX;6Q55`4``XV8@E)U
M>`L``00E#@``!#D!``!02P$"'@,4````"`#M@&Q#>`QJ;:P3``#>`P$`%0`8
M```````!````I($`IP``;G9A>"TR,#$S,#DS,%]C86PN>&UL550%``.-F()2
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`[8!L0S[.M4]H(@``<S\"`!4`
M&````````0```*2!^[H``&YV87@M,C`Q,S`Y,S!?9&5F+GAM;%54!0`#C9B"
M4G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`.V`;$.]VMLY3Z4``"*)"@`5
M`!@```````$```"D@;+=``!N=F%X+3(P,3,P.3,P7VQA8BYX;6Q55`4``XV8
M@E)U>`L``00E#@``!#D!``!02P$"'@,4````"`#M@&Q#I:TDN3E&``!+J@0`
M%0`8```````!````I(%0@P$`;G9A>"TR,#$S,#DS,%]P<F4N>&UL550%``.-
MF()2=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`[8!L0]-8KB>*$```,L``
M`!$`&````````0```*2!V,D!`&YV87@M,C`Q,S`Y,S`N>'-D550%``.-F()2
E=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``*W:`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Master Services Agreement with Cadila<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_MasterServicesAgreementWithCadilaAbstract', window );"><strong>Master Services Agreement with Cadila [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nvax_MasterServicesAgreementWithCadilaTextBlock', window );">Master Services Agreement with Cadila</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> Note 14 <font style="FONT-WEIGHT: normal">-</font> Master Services Agreement with Cadila</p> <p style="TEXT-ALIGN: justify; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In connection with the JV with Cadila, the Company entered into a master services agreement, which the Company and Cadila amended in July 2011, and subsequently in March 2013, in each case to extend the term by one year for which services can be provided by Cadila under this agreement. Under the revised terms, if by March 2014, the amount of services provided by Cadila under the master services agreement is less than $7.5 million, the Company will pay Cadila the portion of the shortfall amount that is less than or equal to $2.0 million and 50% of the portion of the shortfall amount that exceeds $2.0 million. Through September 30, 2013, the Company has purchased $2.4 million in services from Cadila pursuant to this agreement, which includes $0.8 million of services provided, since the beginning of 2013, by CPLB to the Company on behalf of Cadila pursuant to an October 2013 amendment authorizing such CPLB services. The Company plans to explore with Cadila ways to potentially address its remaining financial obligation and/or extend the time period during which the Company could utilize such services. The Company can provide no assurance, however, that these efforts will be successful. If the Company fails to negotiate a change in this arrangement, the Company expects that it will be obligated to spend a portion of its available cash and cash equivalents to pay Cadila for its shortfall in services purchased.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_MasterServicesAgreementWithCadilaAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_MasterServicesAgreementWithCadilaAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvax_MasterServicesAgreementWithCadilaTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Master Services Agreement With Cadila [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>nvax_MasterServicesAgreementWithCadilaTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>nvax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
